Torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
during	during	O
low	low	O
dose	dose	O
intermittent	intermittent	O
dobutamine	dobutamine	B-Chemical
treatment	treatment	O
in	in	O
a	a	O
patient	patient	O
with	with	O
dilated	dilated	B-Disease
cardiomyopathy	cardiomyopathy	B-Disease
and	and	O
congestive	congestive	B-Disease
heart	heart	B-Disease
failure	failure	I-Disease
.	.	O

The	the	O
authors	authors	O
describe	describe	O
the	the	O
case	case	O
of	of	O
a	a	O
56-year-old	56-year-old	O
woman	woman	O
with	with	O
chronic	chronic	O
,	,	O
severe	severe	O
heart	heart	B-Disease
failure	failure	I-Disease
secondary	secondary	O
to	to	O
dilated	dilated	B-Disease
cardiomyopathy	cardiomyopathy	B-Disease
and	and	O
absence	absence	O
of	of	O
significant	significant	O
ventricular	ventricular	B-Disease
arrhythmias	arrhythmias	B-Disease
who	who	O
developed	developed	O
QT	qt	O
prolongation	prolongation	O
and	and	O
torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
during	during	O
one	one	O
cycle	cycle	O
of	of	O
intermittent	intermittent	O
low	low	O
dose	dose	O
(	(	O
2.5	2.5	O
mcg/kg	mcg/kg	O
per	per	O
min	min	O
)	)	O
dobutamine	dobutamine	B-Chemical
.	.	O

This	this	O
report	report	O
of	of	O
torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
during	during	O
intermittent	intermittent	O
dobutamine	dobutamine	B-Chemical
supports	supports	O
the	the	O
hypothesis	hypothesis	O
that	that	O
unpredictable	unpredictable	O
fatal	fatal	O
arrhythmias	arrhythmias	B-Disease
may	may	O
occur	occur	O
even	even	O
with	with	O
low	low	O
doses	doses	O
and	and	O
in	in	O
patients	patients	O
with	with	O
no	no	O
history	history	O
of	of	O
significant	significant	O
rhythm	rhythm	O
disturbances	disturbances	O
.	.	O

The	the	O
mechanisms	mechanisms	O
of	of	O
proarrhythmic	proarrhythmic	O
effects	effects	O
of	of	O
Dubutamine	dubutamine	O
are	are	O
discussed	discussed	O
.	.	O

Positive	positive	O
skin	skin	O
tests	tests	O
in	in	O
late	late	O
reactions	reactions	O
to	to	O
radiographic	radiographic	O
contrast	contrast	B-Chemical
media	media	I-Chemical
.	.	O

In	in	O
the	the	O
last	last	O
few	few	O
years	years	O
delayed	delayed	O
reactions	reactions	O
several	several	O
hours	hours	O
after	after	O
the	the	O
injection	injection	O
of	of	O
radiographic	radiographic	O
and	and	O
contrast	contrast	B-Chemical
materials	materials	I-Chemical
(	(	O
PRC	prc	O
)	)	O
have	have	O
been	been	O
described	described	O
with	with	O
increasing	increasing	O
frequency	frequency	O
.	.	O

The	the	O
authors	authors	O
report	report	O
two	two	O
observations	observations	O
on	on	O
patients	patients	O
with	with	O
delayed	delayed	O
reactions	reactions	O
in	in	O
whom	whom	O
intradermoreactions	intradermoreactions	O
(	(	O
IDR	idr	O
)	)	O
and	and	O
patch	patch	O
tests	tests	O
to	to	O
a	a	O
series	series	O
of	of	O
ionic	ionic	O
and	and	O
non	non	O
ionic	ionic	O
PRC	prc	O
were	were	O
studied	studied	O
.	.	O

After	after	O
angiography	angiography	O
by	by	O
the	the	O
venous	venous	O
route	route	O
in	in	O
patient	patient	O
n	n	O
degree	degree	O
1	1	O
a	a	O
biphasic	biphasic	O
reaction	reaction	O
with	with	O
an	an	O
immediate	immediate	O
reaction	reaction	O
(	(	O
dyspnea	dyspnea	O
,	,	O
loss	loss	O
of	of	O
consciousness	consciousness	O
)	)	O
and	and	O
delayed	delayed	O
macro-papular	macro-papular	O
rash	rash	B-Disease
appeared	appeared	O
,	,	O
whilst	whilst	O
patient	patient	O
n	n	O
degree	degree	O
2	2	O
developed	developed	O
a	a	O
generalised	generalised	O
sensation	sensation	O
of	of	O
heat	heat	O
,	,	O
persistent	persistent	O
pain	pain	B-Disease
at	at	O
the	the	O
site	site	O
of	of	O
injection	injection	O
immediately	immediately	O
and	and	O
a	a	O
generalised	generalised	O
macro-papular	macro-papular	O
reaction	reaction	O
after	after	O
24	24	O
hours	hours	O
.	.	O

The	the	O
skin	skin	O
tests	tests	O
revealed	revealed	O
positive	positive	O
delayed	delayed	O
reactions	reactions	O
of	of	O
24	24	O
hours	hours	O
and	and	O
48	48	O
hours	hours	O
by	by	O
IDR	idr	O
and	and	O
patch	patch	O
tests	tests	O
to	to	O
only	only	O
some	some	O
PRC	prc	O
with	with	O
common	common	O
chains	chains	O
in	in	O
their	their	O
structures	structures	O
.	.	O

The	the	O
positive	positive	O
skin	skin	O
tests	tests	O
are	are	O
in	in	O
favour	favour	O
of	of	O
immunological	immunological	O
reactions	reactions	O
and	and	O
may	may	O
help	help	O
in	in	O
diagnosis	diagnosis	O
of	of	O
allergy	allergy	O
in	in	O
the	the	O
patients	patients	O
.	.	O

Risk	risk	O
of	of	O
transient	transient	O
hyperammonemic	hyperammonemic	O
encephalopathy	encephalopathy	B-Disease
in	in	O
cancer	cancer	B-Disease
patients	patients	O
who	who	O
received	received	O
continuous	continuous	O
infusion	infusion	O
of	of	O
5-fluorouracil	5-fluorouracil	B-Chemical
with	with	O
the	the	O
complication	complication	O
of	of	O
dehydration	dehydration	B-Disease
and	and	O
infection	infection	B-Disease
.	.	O

From	from	O
1986	1986	O
to	to	O
1998	1998	O
,	,	O
29	29	O
cancer	cancer	B-Disease
patients	patients	O
who	who	O
had	had	O
32	32	O
episodes	episodes	O
of	of	O
transient	transient	O
hyperammonemic	hyperammonemic	O
encephalopathy	encephalopathy	B-Disease
related	related	O
to	to	O
continuous	continuous	O
infusion	infusion	O
of	of	O
5-fluorouracil	5-fluorouracil	B-Chemical
(	(	O
5-FU	5-fu	B-Chemical
)	)	O
were	were	O
identified	identified	O
.	.	O

None	none	O
of	of	O
the	the	O
patients	patients	O
had	had	O
decompensated	decompensated	O
liver	liver	B-Disease
disease	disease	I-Disease
.	.	O

Onset	onset	O
of	of	O
hyperammonemic	hyperammonemic	O
encephalopathy	encephalopathy	B-Disease
varied	varied	O
from	from	O
0.5	0.5	O
to	to	O
5	5	O
days	days	O
(	(	O
mean	mean	O
:	:	O
2.6	2.6	O
+	+	O
/-	/-	O

1.3	1.3	O
days	days	O
)	)	O
after	after	O
the	the	O
initiation	initiation	O
of	of	O
chemotherapy	chemotherapy	O
.	.	O

Plasma	plasma	O
ammonium	ammonium	O
level	level	O
ranged	ranged	O
from	from	O
248	248	O
to	to	O
2387	2387	O
microg%	microg%	O
(	(	O
mean	mean	O
:	:	O
626	626	O
+	+	O
/-	/-	O
431	431	O
microg%	microg%	O
)	)	O
.	.	O

Among	among	O
the	the	O
32	32	O
episodes	episodes	O
,	,	O
26	26	O
(	(	O
81	81	O
%	%	O
)	)	O
had	had	O
various	various	O
degrees	degrees	O
of	of	O
azotemia	azotemia	O
,	,	O
18	18	O
(	(	O
56	56	O
%	%	O
)	)	O
occurred	occurred	O
during	during	O
bacterial	bacterial	B-Disease
infections	infections	B-Disease
and	and	O
14	14	O
(	(	O
44	44	O
%	%	O
)	)	O
without	without	O
infection	infection	B-Disease
occurred	occurred	O
during	during	O
periods	periods	O
of	of	O
dehydration	dehydration	B-Disease
.	.	O

Higher	higher	O
plasma	plasma	O
ammonium	ammonium	O
levels	levels	O
and	and	O
more	more	O
rapid	rapid	O
onset	onset	O
of	of	O
hyperammonemia	hyperammonemia	B-Disease
were	were	O
seen	seen	O
in	in	O
18	18	O
patients	patients	O
with	with	O
bacterial	bacterial	B-Disease
infections	infections	B-Disease
(	(	O
p=0.003	p=0.003	O
and	and	O
0.0006	0.0006	O
,	,	O
respectively	respectively	O
)	)	O
and	and	O
in	in	O
nine	nine	O
patients	patients	O
receiving	receiving	O
high	high	O
daily	daily	O
doses	doses	O
(	(	O
2600	2600	O
or	or	O
1800	1800	O
mg/m2	mg/m2	O
)	)	O
of	of	O
5-FU	5-fu	B-Chemical
(	(	O
p=0.0001	p=0.0001	O
and	and	O
<	<	O
0.0001	0.0001	O
,	,	O
respectively	respectively	O
)	)	O
.	.	O

In	in	O
25	25	O
out	out	O
of	of	O
32	32	O
episodes	episodes	O
(	(	O
78	78	O
%	%	O
)	)	O
,	,	O
plasma	plasma	O
ammonium	ammonium	O
levels	levels	O
and	and	O
mental	mental	O
status	status	O
returned	returned	O
to	to	O
normal	normal	O
within	within	O
2	2	O
days	days	O
after	after	O
adequate	adequate	O
management	management	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
hyperammonemic	hyperammonemic	O
encephalopathy	encephalopathy	B-Disease
can	can	O
occur	occur	O
in	in	O
patients	patients	O
receiving	receiving	O
continuous	continuous	O
infusion	infusion	O
of	of	O
5-FU	5-fu	B-Chemical
.	.	O

Azotemia	azotemia	O
,	,	O
body	body	O
fluid	fluid	O
insufficiency	insufficiency	O
and	and	O
bacterial	bacterial	B-Disease
infections	infections	B-Disease
were	were	O
frequently	frequently	O
found	found	O
in	in	O
these	these	O
patients	patients	O
.	.	O

It	it	O
is	is	O
therefore	therefore	O
important	important	O
to	to	O
recognize	recognize	O
this	this	O
condition	condition	O
in	in	O
patients	patients	O
receiving	receiving	O
continuous	continuous	O
infusion	infusion	O
of	of	O
5-FU	5-fu	B-Chemical
.	.	O

The	the	O
effects	effects	O
of	of	O
quinine	quinine	B-Chemical
and	and	O
4-aminopyridine	4-aminopyridine	O
on	on	O
conditioned	conditioned	O
place	place	O
preference	preference	O
and	and	O
changes	changes	O
in	in	O
motor	motor	O
activity	activity	O
induced	induced	O
by	by	O
morphine	morphine	B-Chemical
in	in	O
rats.1	rats.1	O
.	.	O

The	the	O
effects	effects	O
of	of	O
two	two	O
unselective	unselective	O
potassium	potassium	B-Chemical
(	(	O
K(+)-	k(+)-	O
)	)	O
channel	channel	O
blockers	blockers	O
,	,	O
quinine	quinine	B-Chemical
(	(	O
12.5	12.5	O
,	,	O
25	25	O
and	and	O
50	50	O
mg/kg	mg/kg	O
)	)	O
and	and	O
4-aminopyridine	4-aminopyridine	O
(	(	O
1	1	O
and	and	O
2	2	O
mg/kg	mg/kg	O
)	)	O
,	,	O
on	on	O
conditioned	conditioned	O
place	place	O
preference	preference	O
and	and	O
biphasic	biphasic	O
changes	changes	O
in	in	O
motor	motor	O
activity	activity	O
induced	induced	O
by	by	O
morphine	morphine	B-Chemical
(	(	O
10	10	O
mg/kg	mg/kg	O
)	)	O
were	were	O
tested	tested	O
in	in	O
Wistar	wistar	O
rats	rats	O
.	.	O

Quinine	quinine	B-Chemical
is	is	O
known	known	O
to	to	O
block	block	O
voltage-	voltage-	O
,	,	O
calcium-	calcium-	O
and	and	O
ATP-sensitive	atp-sensitive	O
K(+)-channels	k(+)-channels	O
while	while	O
4-aminopyridine	4-aminopyridine	O
is	is	O
known	known	O
to	to	O
block	block	O
voltage-sensitive	voltage-sensitive	O
K(+)-channels	k(+)-channels	O
.	.	O

2	2	O
.	.	O
In	in	O
the	the	O
counterbalanced	counterbalanced	O
method	method	O
,	,	O
quinine	quinine	B-Chemical
attenuated	attenuated	O
morphine-induced	morphine-induced	O
place	place	O
preference	preference	O
,	,	O
whereas	whereas	O
4-aminopyridine	4-aminopyridine	O
was	was	O
ineffective	ineffective	O
.	.	O

In	in	O
the	the	O
motor	motor	O
activity	activity	O
test	test	O
measured	measured	O
with	with	O
an	an	O
Animex-activity	animex-activity	O
meter	meter	O
neither	neither	O
of	of	O
the	the	O
K(+)-channel	k(+)-channel	O
blockers	blockers	O
affected	affected	O
morphine-induced	morphine-induced	O
hypoactivity	hypoactivity	O
,	,	O
but	but	O
both	both	O
K(+)-channel	k(+)-channel	O
blockers	blockers	O
prevented	prevented	O
morphine-induced	morphine-induced	O
secondary	secondary	O
hyperactivity	hyperactivity	B-Disease
.	.	O

3	3	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
the	the	O
involvement	involvement	O
of	of	O
quinine-sensitive	quinine-sensitive	O
but	but	O
not	not	O
4-aminopyridine-sensitive	4-aminopyridine-sensitive	O
K(+)-channels	k(+)-channels	O
in	in	O
morphine	morphine	B-Chemical
reward	reward	O
.	.	O

It	it	O
is	is	O
also	also	O
suggested	suggested	O
that	that	O
the	the	O
blockade	blockade	O
of	of	O
K(+)-channels	k(+)-channels	O
sensitive	sensitive	O
to	to	O
these	these	O
blockers	blockers	O
is	is	O
not	not	O
sufficient	sufficient	O
to	to	O
prevent	prevent	O
morphine-induced	morphine-induced	O
hypoactivity	hypoactivity	O
whereas	whereas	O
morphine-induced	morphine-induced	O
hyperactivity	hyperactivity	B-Disease
seems	seems	O
to	to	O
be	be	O
connected	connected	O
to	to	O
both	both	O
quinine-	quinine-	O
and	and	O
4-aminopyridine-sensitive	4-aminopyridine-sensitive	O
K(+)-channels	k(+)-channels	O
.	.	O

Nociceptin/orphanin	nociceptin/orphanin	O
FQ	fq	O
and	and	O
nocistatin	nocistatin	O
on	on	O
learning	learning	O
and	and	O
memory	memory	B-Disease
impairment	impairment	I-Disease
induced	induced	O
by	by	O
scopolamine	scopolamine	B-Chemical
in	in	O
mice.1	mice.1	O
.	.	O

Nociceptin	nociceptin	O
,	,	O
also	also	O
known	known	O
as	as	O
orphanin	orphanin	O
FQ	fq	O
,	,	O
is	is	O
an	an	O
endogenous	endogenous	O
ligand	ligand	O
for	for	O
the	the	O
orphan	orphan	O
opioid	opioid	O
receptor-like	receptor-like	O
receptor	receptor	O
1	1	O
(	(	O
ORL1	orl1	O
)	)	O
and	and	O
involves	involves	O
in	in	O
various	various	O
functions	functions	O
in	in	O
the	the	O
central	central	O
nervous	nervous	O
system	system	O
(	(	O
CNS	cns	O
)	)	O
.	.	O

On	on	O
the	the	O
other	other	O
hand	hand	O
,	,	O
nocistatin	nocistatin	O
is	is	O
recently	recently	O
isolated	isolated	O
from	from	O
the	the	O
same	same	O
precursor	precursor	O
as	as	O
nociceptin	nociceptin	O
and	and	O
blocks	blocks	O
nociceptin-induced	nociceptin-induced	O
allodynia	allodynia	O
and	and	O
hyperalgesia	hyperalgesia	B-Disease
.	.	O

2	2	O
.	.	O
Although	although	O
ORL1	orl1	O
receptors	receptors	O
which	which	O
display	display	O
a	a	O
high	high	O
degree	degree	O
of	of	O
sequence	sequence	O
homology	homology	O
with	with	O
classical	classical	O
opioid	opioid	O
receptors	receptors	O
are	are	O
abundant	abundant	O
in	in	O
the	the	O
hippocampus	hippocampus	O
,	,	O
little	little	O
is	is	O
known	known	O
regarding	regarding	O
their	their	O
role	role	O
in	in	O
learning	learning	O
and	and	O
memory	memory	O
.	.	O

3	3	O
.	.	O

The	the	O
present	present	O
study	study	O
was	was	O
designed	designed	O
to	to	O
investigate	investigate	O
whether	whether	O
nociceptin/orphanin	nociceptin/orphanin	O
FQ	fq	O
and	and	O
nocistatin	nocistatin	O
could	could	O
modulate	modulate	O
impairment	impairment	O
of	of	O
learning	learning	O
and	and	O
memory	memory	O
induced	induced	O
by	by	O
scopolamine	scopolamine	B-Chemical
,	,	O
a	a	O
muscarinic	muscarinic	O
cholinergic	cholinergic	O
receptor	receptor	O
antagonist	antagonist	O
,	,	O
using	using	O
spontaneous	spontaneous	O
alternation	alternation	O
of	of	O
Y-maze	y-maze	O
and	and	O
step-down	step-down	O
type	type	O
passive	passive	O
avoidance	avoidance	O
tasks	tasks	O
in	in	O
mice	mice	O
.	.	O

4	4	O
.	.	O
While	while	O
nocistatin	nocistatin	O
(	(	O
0.5	0.5	O
-	-	O
5.0	5.0	O
nmol	nmol	O
mouse-1	mouse-1	O
,	,	O
i.c.v	i.c.v	O
.	.	O
)	)	O
administered	administered	O
30	30	O
min	min	O
before	before	O
spontaneous	spontaneous	O
alternation	alternation	O
performance	performance	O
or	or	O
the	the	O
training	training	O
session	session	O
of	of	O
the	the	O
passive	passive	O
avoidance	avoidance	O
task	task	O
,	,	O
had	had	O
no	no	O
effect	effect	O
on	on	O
spontaneous	spontaneous	O
alternation	alternation	O
or	or	O
passive	passive	O
avoidance	avoidance	O
behaviours	behaviours	O
,	,	O
a	a	O
lower	lower	O
per	per	O
cent	cent	O
alternation	alternation	O
and	and	O
shorter	shorter	O
median	median	O
step-down	step-down	O
latency	latency	O
in	in	O
the	the	O
retention	retention	O
test	test	O
were	were	O
obtained	obtained	O
in	in	O
nociceptin	nociceptin	O
(	(	O
1.5	1.5	O
and/or	and/or	O
5.0	5.0	O
nmol	nmol	O
mouse-1	mouse-1	O
,	,	O
i.c.v.)-treated	i.c.v.)-treated	O
normal	normal	O
mice	mice	O
.	.	O

5	5	O
.	.	O

Administration	administration	O
of	of	O
nocistatin	nocistatin	O
(	(	O
1.5	1.5	O
and/or	and/or	O
5.0	5.0	O
nmol	nmol	O
mouse-1	mouse-1	O
,	,	O
i.c.v	i.c.v	O
.	.	O
)	)	O
30	30	O
min	min	O
before	before	O
spontaneous	spontaneous	O
alternation	alternation	O
performance	performance	O
or	or	O
the	the	O
training	training	O
session	session	O
of	of	O
the	the	O
passive	passive	O
avoidance	avoidance	O
task	task	O
,	,	O
attenuated	attenuated	O
the	the	O
scopolamine-induced	scopolamine-induced	O
impairment	impairment	O
of	of	O
spontaneous	spontaneous	O
alternation	alternation	O
and	and	O
passive	passive	O
avoidance	avoidance	O
behaviours	behaviours	O
.	.	O

6	6	O
.	.	O

These	these	O
results	results	O
indicated	indicated	O
that	that	O
nocistatin	nocistatin	O
,	,	O
a	a	O
new	new	O
biologically	biologically	O
active	active	O
peptide	peptide	O
,	,	O
ameliorates	ameliorates	O
impairments	impairments	O
of	of	O
spontaneous	spontaneous	O
alternation	alternation	O
and	and	O
passive	passive	O
avoidance	avoidance	O
induced	induced	O
by	by	O
scopolamine	scopolamine	B-Chemical
,	,	O
and	and	O
suggested	suggested	O
that	that	O
these	these	O
peptides	peptides	O
play	play	O
opposite	opposite	O
roles	roles	O
in	in	O
learning	learning	O
and	and	O
memory	memory	O
.	.	O

Meloxicam-induced	meloxicam-induced	O
liver	liver	O
toxicity	toxicity	B-Disease
.	.	O

We	we	O
report	report	O
the	the	O
case	case	O
of	of	O
a	a	O
female	female	O
patient	patient	O
with	with	O
rheumatoid	rheumatoid	B-Disease
arthritis	arthritis	B-Disease
who	who	O
developed	developed	O
acute	acute	O
cytolytic	cytolytic	O
hepatitis	hepatitis	B-Disease
due	due	O
to	to	O
meloxicam	meloxicam	O
.	.	O

Recently	recently	O
introduced	introduced	O
in	in	O
Belgium	belgium	O
,	,	O
meloxicam	meloxicam	O
is	is	O
the	the	O
first	first	O
nonsteroidal	nonsteroidal	O
antiinflammatory	antiinflammatory	O
drug	drug	O
with	with	O
selective	selective	O
action	action	O
on	on	O
the	the	O
inducible	inducible	O
form	form	O
of	of	O
cyclooxygenase	cyclooxygenase	B-Chemical
2	2	I-Chemical
.	.	O

The	the	O
acute	acute	O
cytolytic	cytolytic	O
hepatitis	hepatitis	B-Disease
occurred	occurred	O
rapidly	rapidly	O
after	after	O
meloxicam	meloxicam	O
administration	administration	O
and	and	O
was	was	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
antinuclear	antinuclear	O
antibodies	antibodies	O
suggesting	suggesting	O
a	a	O
hypersensitivity	hypersensitivity	B-Disease
mechanism	mechanism	O
.	.	O

This	this	O
first	first	O
case	case	O
of	of	O
meloxicam	meloxicam	O
related	related	O
liver	liver	O
toxicity	toxicity	B-Disease
demonstrates	demonstrates	O
the	the	O
potential	potential	O
of	of	O
this	this	O
drug	drug	O
to	to	O
induce	induce	O
hepatic	hepatic	B-Disease
damage	damage	I-Disease
.	.	O

Induction	induction	O
of	of	O
apoptosis	apoptosis	O
by	by	O
remoxipride	remoxipride	O
metabolites	metabolites	O
in	in	O
HL60	hl60	O
and	and	O
CD34+/CD19-	cd34+/cd19-	O
human	human	O
bone	bone	O
marrow	marrow	O
progenitor	progenitor	O
cells	cells	O
:	:	O
potential	potential	O
relevance	relevance	O
to	to	O
remoxipride-induced	remoxipride-induced	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
.	.	O

The	the	O
antipsychotic	antipsychotic	O
agent	agent	O
,	,	O
remoxipride	remoxipride	O
[	[	O
(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	(s)-(-)-3-bromo-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	O
amide	amide	O
]	]	O
has	has	O
been	been	O
associated	associated	O
with	with	O
acquired	acquired	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
.	.	O

We	we	O
have	have	O
examined	examined	O
the	the	O
ability	ability	O
of	of	O
remoxipride	remoxipride	O
,	,	O
three	three	O
pyrrolidine	pyrrolidine	O
ring	ring	O
metabolites	metabolites	O
and	and	O
five	five	O
aromatic	aromatic	O
ring	ring	O
metabolites	metabolites	O
of	of	O
the	the	O
parent	parent	O
compound	compound	O
to	to	O
induce	induce	O
apoptosis	apoptosis	O
in	in	O
HL60	hl60	O
cells	cells	O
and	and	O
human	human	O
bone	bone	O
marrow	marrow	O
progenitor	progenitor	O
(	(	O
HBMP	hbmp	O
)	)	O
cells	cells	O
.	.	O

Cells	cells	O
were	were	O
treated	treated	O
for	for	O
0	0	O
-	-	O
24	24	O
h	h	B-Chemical
with	with	O
each	each	O
compound	compound	O
(	(	O
0	0	O
-	-	O
200	200	O
microM	microm	O
)	)	O
.	.	O

Apoptosis	apoptosis	O
was	was	O
assessed	assessed	O
by	by	O
fluorescence	fluorescence	O
microscopy	microscopy	O
in	in	O
Hoechst	hoechst	O
33342-	33342-	O
and	and	O
propidium	propidium	O
iodide	iodide	O
stained	stained	O
cell	cell	O
samples	samples	O
.	.	O

Results	results	O
were	were	O
confirmed	confirmed	O
by	by	O
determination	determination	O
of	of	O
internucleosomal	internucleosomal	O
DNA	dna	O
fragmentation	fragmentation	O
using	using	O
gel	gel	O
electrophoresis	electrophoresis	O
for	for	O
HL60	hl60	O
cell	cell	O
samples	samples	O
and	and	O
terminal	terminal	O
deoxynucleotidyl	deoxynucleotidyl	O
transferase	transferase	O
assay	assay	O
in	in	O
HBMP	hbmp	O
cells	cells	O
.	.	O

The	the	O
catechol	catechol	O
and	and	O
hydroquinone	hydroquinone	O
metabolites	metabolites	O
,	,	O
NCQ436	ncq436	O
and	and	O
NCQ344	ncq344	O
,	,	O
induced	induced	O
apoptosis	apoptosis	O
in	in	O
HL60	hl60	O
and	and	O
HBMP	hbmp	O
cells	cells	O
in	in	O
a	a	O
time-	time-	O
and	and	O
concentration	concentration	O
dependent	dependent	O
manner	manner	O
,	,	O
while	while	O
the	the	O
phenols	phenols	O
,	,	O
NCR181	ncr181	O
,	,	O
FLA873	fla873	O
,	,	O
and	and	O
FLA797	fla797	O
,	,	O
and	and	O
the	the	O
derivatives	derivatives	O
formed	formed	O
by	by	O
oxidation	oxidation	O
of	of	O
the	the	O
pyrrolidine	pyrrolidine	O
ring	ring	O
,	,	O
FLA838	fla838	O
,	,	O
NCM001	ncm001	O
,	,	O
and	and	O
NCL118	ncl118	O
,	,	O
had	had	O
no	no	O
effect	effect	O
.	.	O

No	no	O
necrosis	necrosis	B-Disease
was	was	O
observed	observed	O
in	in	O
cells	cells	O
treated	treated	O
with	with	O
NCQ436	ncq436	O
but	but	O
NCQ344	ncq344	O
had	had	O
a	a	O
biphasic	biphasic	O
effect	effect	O
in	in	O
both	both	O
cell	cell	O
types	types	O
,	,	O
inducing	inducing	O
apoptosis	apoptosis	O
at	at	O
lower	lower	O
concentrations	concentrations	O
and	and	O
necrosis	necrosis	B-Disease
at	at	O
higher	higher	O
concentrations	concentrations	O
.	.	O

These	these	O
data	data	O
show	show	O
that	that	O
the	the	O
catechol	catechol	O
and	and	O
hydroquinone	hydroquinone	O
metabolites	metabolites	O
of	of	O
remoxipride	remoxipride	O
have	have	O
direct	direct	O
toxic	toxic	O
effects	effects	O
in	in	O
HL60	hl60	O
and	and	O
HBMP	hbmp	O
cells	cells	O
,	,	O
leading	leading	O
to	to	O
apoptosis	apoptosis	O
,	,	O
while	while	O
the	the	O
phenol	phenol	O
metabolites	metabolites	O
were	were	O
inactive	inactive	O
.	.	O

Similarly	similarly	O
,	,	O
benzene-derived	benzene-derived	O
catechol	catechol	O
and	and	O
hydroquinone	hydroquinone	O
,	,	O
but	but	O
not	not	O
phenol	phenol	O
,	,	O
induce	induce	O
apoptosis	apoptosis	O
in	in	O
HBMP	hbmp	O
cells	cells	O
[	[	O
Moran	moran	O
et	et	O
al.	al.	O
,	,	O
Mol	mol	O
.	.	O

Pharmacol	pharmacol	O
.	.	O
,	,	O
50	50	O
(	(	O
1996	1996	O
)	)	O
610	610	O
-	-	O
615	615	O
]	]	O
.	.	O

We	we	O
propose	propose	O
that	that	O
remoxipride	remoxipride	O
and	and	O
benzene	benzene	O
may	may	O
induce	induce	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
via	via	O
production	production	O
of	of	O
similar	similar	O
reactive	reactive	O
metabolites	metabolites	O
and	and	O
that	that	O
the	the	O
ability	ability	O
of	of	O
NCQ436	ncq436	O
and	and	O
NCQ344	ncq344	O
to	to	O
induce	induce	O
apoptosis	apoptosis	O
in	in	O
HBMP	hbmp	O
cells	cells	O
may	may	O
contribute	contribute	O
to	to	O
the	the	O
mechanism	mechanism	O
underlying	underlying	O
acquired	acquired	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
that	that	O
has	has	O
been	been	O
associated	associated	O
with	with	O
remoxipride	remoxipride	O
.	.	O

Synthesis	synthesis	O
and	and	O
preliminary	preliminary	O
pharmacological	pharmacological	O
investigations	investigations	O
of	of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	1-(1,2-dihydro-2-acenaphthylenyl)piperazine	O
derivatives	derivatives	O
as	as	O
potential	potential	O
atypical	atypical	O
antipsychotic	antipsychotic	B-Chemical
agents	agents	I-Chemical
in	in	O
mice	mice	O
.	.	O

In	in	O
research	research	O
towards	towards	O
the	the	O
development	development	O
of	of	O
new	new	O
atypical	atypical	O
antipsychotic	antipsychotic	B-Chemical
agents	agents	I-Chemical
,	,	O
one	one	O
strategy	strategy	O
is	is	O
that	that	O
the	the	O
dopaminergic	dopaminergic	O
system	system	O
can	can	O
be	be	O
modulated	modulated	O
through	through	O
manipulation	manipulation	O
of	of	O
the	the	O
serotonergic	serotonergic	O
system	system	O
.	.	O

The	the	O
synthesis	synthesis	O
and	and	O
preliminary	preliminary	O
pharmacological	pharmacological	O
evaluation	evaluation	O
of	of	O
a	a	O
series	series	O
of	of	O
potential	potential	O
atypical	atypical	O
antipsychotic	antipsychotic	B-Chemical
agents	agents	I-Chemical
based	based	O
on	on	O
the	the	O
structure	structure	O
of	of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	1-(1,2-dihydro-2-acenaphthylenyl)piperazine	O
(	(	O
7	7	O
)	)	O
is	is	O
described	described	O
.	.	O

Compound	compound	O
7e	7e	O
,	,	O
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	O
dro-1H-	dro-1h-	O
indol-2-one	indol-2-one	O
,	,	O
from	from	O
this	this	O
series	series	O
showed	showed	O
significant	significant	O
affinities	affinities	O
at	at	O
the	the	O
5-HT1A	5-ht1a	O
and	and	O
5-HT2A	5-ht2a	O
receptors	receptors	O
and	and	O
moderate	moderate	O
affinity	affinity	O
at	at	O
the	the	O
D2	d2	O
receptor	receptor	O
.	.	O

7e	7e	O
exhibits	exhibits	O
a	a	O
high	high	O
reversal	reversal	O
of	of	O
catalepsy	catalepsy	B-Disease
induced	induced	O
by	by	O
haloperidol	haloperidol	B-Chemical
indicating	indicating	O
its	its	O
atypical	atypical	O
antipsychotic	antipsychotic	O
nature	nature	O
.	.	O

Sub-chronic	sub-chronic	O
inhibition	inhibition	O
of	of	O
nitric-oxide	nitric-oxide	O
synthesis	synthesis	O
modifies	modifies	O
haloperidol-induced	haloperidol-induced	O
catalepsy	catalepsy	B-Disease
and	and	O
the	the	O
number	number	O
of	of	O
NADPH-diaphorase	nadph-diaphorase	O
neurons	neurons	O
in	in	O
mice	mice	O
.	.	O

RATIONALE	rationale	O
:	:	O
NG-nitro-L-arginine	ng-nitro-l-arginine	O
(	(	O
L-NOARG	l-noarg	O
)	)	O
,	,	O
an	an	O
inhibitor	inhibitor	O
of	of	O
nitric-oxide	nitric-oxide	O
synthase	synthase	O
(	(	O
NOS	nos	O
)	)	O
,	,	O
induces	induces	O
catalepsy	catalepsy	B-Disease
in	in	O
mice	mice	O
.	.	O

This	this	O
effect	effect	O
undergoes	undergoes	O
rapid	rapid	O
tolerance	tolerance	O
,	,	O
showing	showing	O
a	a	O
significant	significant	O
decrease	decrease	O
after	after	O
2	2	O
days	days	O
of	of	O
sub-chronic	sub-chronic	O
L-NOARG	l-noarg	O
treatment	treatment	O
.	.	O

Nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
(	(	O
NO	no	O
)	)	O
has	has	O
been	been	O
shown	shown	O
to	to	O
influence	influence	O
dopaminergic	dopaminergic	O
neurotransmission	neurotransmission	O
in	in	O
the	the	O
striatum	striatum	O
.	.	O

Neuroleptic	neuroleptic	B-Chemical
drugs	drugs	I-Chemical
such	such	O
as	as	O
haloperidol	haloperidol	B-Chemical
,	,	O
which	which	O
block	block	O
dopamine	dopamine	B-Chemical
receptors	receptors	O
,	,	O
also	also	O
cause	cause	O
catalepsy	catalepsy	B-Disease
in	in	O
rodents	rodents	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
To	to	O
investigate	investigate	O
the	the	O
effects	effects	O
of	of	O
subchronic	subchronic	O
L-NOARG	l-noarg	O
treatment	treatment	O
in	in	O
haloperidol-induced	haloperidol-induced	O
catalepsy	catalepsy	B-Disease
and	and	O
the	the	O
number	number	O
of	of	O
NOS	nos	O
neurons	neurons	O
in	in	O
areas	areas	O
related	related	O
to	to	O
motor	motor	O
control	control	O
.	.	O

METHODS	methods	O
:	:	O
Male	male	O
albino	albino	O
Swiss	swiss	O
mice	mice	O
were	were	O
treated	treated	O
sub-chronically	sub-chronically	O
(	(	O
twice	twice	O
a	a	O
day	day	O
for	for	O
4	4	O
days	days	O
)	)	O
with	with	O
L-NOARG	l-noarg	O
(	(	O
40	40	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
)	)	O
or	or	O
haloperidol	haloperidol	B-Chemical
(	(	O
1	1	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
)	)	O
.	.	O

Catalepsy	catalepsy	B-Disease
was	was	O
evaluated	evaluated	O
at	at	O
the	the	O
beginning	beginning	O
and	and	O
the	the	O
end	end	O
of	of	O
the	the	O
treatments	treatments	O
.	.	O

Reduced	reduced	O
nicotinamide	nicotinamide	O
adenine	adenine	O
dinucleotide	dinucleotide	O
phosphate-diaphorase	phosphate-diaphorase	O
(	(	O
NADPH-d	nadph-d	O
)	)	O
histochemistry	histochemistry	O
was	was	O
also	also	O
employed	employed	O
to	to	O
visualize	visualize	O
NOS	nos	O
as	as	O
an	an	O
index	index	O
of	of	O
enzyme	enzyme	O
expression	expression	O
in	in	O
mice	mice	O
brain	brain	O
regions	regions	O
related	related	O
to	to	O
motor	motor	O
control	control	O
.	.	O

RESULTS	results	O
:	:	O
L-NOARG	l-noarg	O
sub-chronic	sub-chronic	O
administration	administration	O
produced	produced	O
tolerance	tolerance	O
of	of	O
L-NOARG	l-noarg	O
and	and	O
of	of	O
haloperidol-induced	haloperidol-induced	O
catalepsy	catalepsy	B-Disease
.	.	O

It	it	O
also	also	O
induced	induced	O
an	an	O
increase	increase	O
in	in	O
the	the	O
number	number	O
of	of	O
NADPH-d-positive	nadph-d-positive	O
cells	cells	O
in	in	O
the	the	O
dorsal	dorsal	O
part	part	O
of	of	O
the	the	O
caudate	caudate	O
and	and	O
accumbens	accumbens	O
nuclei	nuclei	O
compared	compared	O
with	with	O
haloperidol	haloperidol	B-Chemical
and	and	O
in	in	O
the	the	O
pedunculopontine	pedunculopontine	O
tegmental	tegmental	O
nucleus	nucleus	O
compared	compared	O
with	with	O
saline	saline	O
.	.	O

In	in	O
contrast	contrast	O
,	,	O
there	there	O
was	was	O
a	a	O
decrease	decrease	O
in	in	O
NADPH-d	nadph-d	O
neuron	neuron	O
number	number	O
in	in	O
the	the	O
substantia	substantia	O
nigra	nigra	O
,	,	O
pars	pars	O
compacta	compacta	O
in	in	O
both	both	O
haloperidol-treated	haloperidol-treated	O
and	and	O
L-NOARG-treated	l-noarg-treated	O
animals	animals	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
results	results	O
give	give	O
further	further	O
support	support	O
to	to	O
the	the	O
hypothesis	hypothesis	O
that	that	O
NO	no	O
plays	plays	O
a	a	O
role	role	O
in	in	O
motor	motor	O
behavior	behavior	O
control	control	O
and	and	O
suggest	suggest	O
that	that	O
it	it	O
may	may	O
take	take	O
part	part	O
in	in	O
the	the	O
synaptic	synaptic	O
changes	changes	O
produced	produced	O
by	by	O
antipsychotic	antipsychotic	O
treatment	treatment	O
.	.	O

Prolonged	prolonged	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
occurs	occurs	O
in	in	O
patients	patients	O
with	with	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
after	after	O
both	both	O
dobutamine	dobutamine	B-Chemical
and	and	O
exercise	exercise	O
induced	induced	O
myocardial	myocardial	O
ischaemia	ischaemia	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
determine	determine	O
whether	whether	O
pharmacological	pharmacological	O
stress	stress	O
leads	leads	O
to	to	O
prolonged	prolonged	O
but	but	O
reversible	reversible	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
patients	patients	O
with	with	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
,	,	O
similar	similar	O
to	to	O
that	that	O
seen	seen	O
after	after	O
exercise	exercise	O
.	.	O

DESIGN	design	O
:	:	O
A	a	O
randomised	randomised	O
crossover	crossover	O
study	study	O
of	of	O
recovery	recovery	O
time	time	O
of	of	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
left	left	O
ventricular	ventricular	O
function	function	O
after	after	O
exercise	exercise	O
and	and	O
dobutamine	dobutamine	B-Chemical
induced	induced	O
ischaemia	ischaemia	O
.	.	O

SUBJECTS	subjects	O
:	:	O
10	10	O
patients	patients	O
with	with	O
stable	stable	O
angina	angina	O
,	,	O
angiographically	angiographically	O
proven	proven	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
,	,	O
and	and	O
normal	normal	O
left	left	O
ventricular	ventricular	O
function	function	O
.	.	O

INTERVENTIONS	interventions	O
:	:	O
Treadmill	treadmill	O
exercise	exercise	O
and	and	O
dobutamine	dobutamine	B-Chemical
stress	stress	O
were	were	O
performed	performed	O
on	on	O
different	different	O
days	days	O
.	.	O

Quantitative	quantitative	O
assessment	assessment	O
of	of	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
left	left	O
ventricular	ventricular	O
function	function	O
was	was	O
performed	performed	O
using	using	O
transthoracic	transthoracic	O
echocardiography	echocardiography	O
at	at	O
baseline	baseline	O
and	and	O
at	at	O
regular	regular	O
intervals	intervals	O
after	after	O
each	each	O
test	test	O
.	.	O

RESULTS	results	O
:	:	O
Both	both	O
forms	forms	O
of	of	O
stress	stress	O
led	led	O
to	to	O
prolonged	prolonged	O
but	but	O
reversible	reversible	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
dysfunction	dysfunction	O
.	.	O

There	there	O
was	was	O
no	no	O
difference	difference	O
in	in	O
the	the	O
maximum	maximum	O
double	double	O
product	product	O
(	(	O
p	p	O
=	=	O
0.53	0.53	O
)	)	O
or	or	O
ST	st	O
depression	depression	B-Disease
(	(	O
p	p	O
=	=	O
0.63	0.63	O
)	)	O
with	with	O
either	either	O
form	form	O
of	of	O
stress	stress	O
.	.	O

After	after	O
exercise	exercise	O
,	,	O
ejection	ejection	O
fraction	fraction	O
was	was	O
reduced	reduced	O
at	at	O
15	15	O
and	and	O
30	30	O
minutes	minutes	O
compared	compared	O
with	with	O
baseline	baseline	O
(	(	O
mean	mean	O
(	(	O
SEM	sem	O
)	)	O
,	,	O
-5.6	-5.6	O
(1.5)%	(1.5)%	O
,	,	O
p	p	O
<	<	O
0.05	0.05	O
;	;	O
and	and	O
-6.1	-6.1	O
(2.2)%	(2.2)%	O
,	,	O
p	p	O
<	<	O
0	0	O
.	.	O
01	01	O
)	)	O
,	,	O
and	and	O
at	at	O
30	30	O
and	and	O
45	45	O
minutes	minutes	O
after	after	O
dobutamine	dobutamine	B-Chemical
(	(	O
-10.8	-10.8	O
(1.8)%	(1.8)%	O
and	and	O
-5	-5	O
.	.	O
5	5	O
(1.8)%	(1.8)%	O
,	,	O
both	both	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

Regional	regional	O
analysis	analysis	O
showed	showed	O
a	a	O
reduction	reduction	O
in	in	O
the	the	O
worst	worst	O
affected	affected	O
segment	segment	O
15	15	O
and	and	O
30	30	O
minutes	minutes	O
after	after	O
exercise	exercise	O
(	(	O
-27.9	-27.9	O
(7.2)%	(7.2)%	O
and	and	O
-28.6	-28.6	O
(5.7)%	(5.7)%	O
,	,	O
both	both	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
,	,	O
and	and	O
at	at	O
30	30	O
minutes	minutes	O
after	after	O
dobutamine	dobutamine	B-Chemical
(	(	O
-32	-32	O
(5.3)%	(5.3)%	O
,	,	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

The	the	O
isovolumic	isovolumic	O
relaxation	relaxation	O
period	period	O
was	was	O
prolonged	prolonged	O
45	45	O
minutes	minutes	O
after	after	O
each	each	O
form	form	O
of	of	O
stress	stress	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
In	in	O
patients	patients	O
with	with	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
,	,	O
dobutamine	dobutamine	B-Chemical
induced	induced	O
ischaemia	ischaemia	O
results	results	O
in	in	O
prolonged	prolonged	O
reversible	reversible	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
,	,	O
presumed	presumed	O
to	to	O
be	be	O
myocardial	myocardial	B-Disease
stunning	stunning	I-Disease
,	,	O
similar	similar	O
to	to	O
that	that	O
seen	seen	O
after	after	O
exercise	exercise	O
.	.	O

Dobutamine	dobutamine	B-Chemical
induced	induced	O
ischaemia	ischaemia	O
could	could	O
therefore	therefore	O
be	be	O
used	used	O
to	to	O
study	study	O
the	the	O
pathophysiology	pathophysiology	O
of	of	O
this	this	O
phenomenon	phenomenon	O
further	further	O
in	in	O
patients	patients	O
with	with	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
.	.	O

Anorexigens	anorexigens	O
and	and	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
in	in	O
the	the	O
United	united	O
States	states	O
:	:	O
results	results	O
from	from	O
the	the	O
surveillance	surveillance	O
of	of	O
North	north	O
American	american	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
.	.	O

BACKGROUND	background	O
:	:	O
The	the	O
use	use	O
of	of	O
appetite	appetite	B-Chemical
suppressants	suppressants	I-Chemical
in	in	O
Europe	europe	O
has	has	O
been	been	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
primary	primary	B-Disease
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
(	(	O
PPH	pph	O
)	)	O
.	.	O

Recently	recently	O
,	,	O
fenfluramine	fenfluramine	O
appetite	appetite	B-Chemical
suppressants	suppressants	I-Chemical
became	became	O
widely	widely	O
used	used	O
in	in	O
the	the	O
United	united	O
States	states	O
but	but	O
were	were	O
withdrawn	withdrawn	O
in	in	O
September	september	O
1997	1997	O
because	because	O
of	of	O
concerns	concerns	O
over	over	O
adverse	adverse	O
effects	effects	O
.	.	O

MATERIALS	materials	O
AND	and	O
METHODS	methods	O
:	:	O
We	we	O
conducted	conducted	O
a	a	O
prospective	prospective	O
surveillance	surveillance	O
study	study	O
on	on	O
patients	patients	O
diagnosed	diagnosed	O
with	with	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
at	at	O
12	12	O
large	large	O
referral	referral	O
centers	centers	O
in	in	O
North	north	O
America	america	O
.	.	O

Data	data	O
collected	collected	O
on	on	O
patients	patients	O
seen	seen	O
from	from	O
September	september	O
1	1	O
,	,	O
1996	1996	O
,	,	O
to	to	O
December	december	O
31	31	O
,	,	O
1997	1997	O
,	,	O
included	included	O
the	the	O
cause	cause	O
of	of	O
the	the	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
and	and	O
its	its	O
severity	severity	O
.	.	O

Patients	patients	O
with	with	O
no	no	O
identifiable	identifiable	O
cause	cause	O
of	of	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
were	were	O
classed	classed	O
as	as	O
PPH	pph	O
.	.	O

A	a	O
history	history	O
of	of	O
drug	drug	O
exposure	exposure	O
also	also	O
was	was	O
taken	taken	O
with	with	O
special	special	O
attention	attention	O
on	on	O
the	the	O
use	use	O
of	of	O
antidepressants	antidepressants	B-Chemical
,	,	O
anorexigens	anorexigens	O
,	,	O
and	and	O
amphetamines	amphetamines	O
.	.	O

RESULTS	results	O
:	:	O
Five	five	O
hundred	hundred	O
seventy-nine	seventy-nine	O
patients	patients	O
were	were	O
studied	studied	O
,	,	O
205	205	O
with	with	O
PPH	pph	O
and	and	O
374	374	O
with	with	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
from	from	O
other	other	O
causes	causes	O
(	(	O
secondary	secondary	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
[	[	O
SPH	sph	O
]	]	O
)	)	O
.	.	O

The	the	O
use	use	O
of	of	O
anorexigens	anorexigens	O
was	was	O
common	common	O
in	in	O
both	both	O
groups	groups	O
.	.	O

However	however	O
,	,	O
of	of	O
the	the	O
medications	medications	O
surveyed	surveyed	O
,	,	O
only	only	O
the	the	O
fenfluramines	fenfluramines	O
had	had	O
a	a	O
significant	significant	O
preferential	preferential	O
association	association	O
with	with	O
PPH	pph	O
as	as	O
compared	compared	O
with	with	O
SPH	sph	O
(	(	O
adjusted	adjusted	O
odds	odds	O
ratio	ratio	O
for	for	O
use	use	O
>	>	O
6	6	O
months	months	O
,	,	O
7.5	7.5	O
;	;	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
,	,	O
1.7	1.7	O
to	to	O
32.4	32.4	O
)	)	O
.	.	O

The	the	O
association	association	O
was	was	O
stronger	stronger	O
with	with	O
longer	longer	O
duration	duration	O
of	of	O
use	use	O
when	when	O
compared	compared	O
to	to	O
shorter	shorter	O
duration	duration	O
of	of	O
use	use	O
and	and	O
was	was	O
more	more	O
pronounced	pronounced	O
in	in	O
recent	recent	O
users	users	O
than	than	O
in	in	O
remote	remote	O
users	users	O
.	.	O

An	an	O
unexpectedly	unexpectedly	O
high	high	O
(	(	O
11.4	11.4	O
%	%	O
)	)	O
number	number	O
of	of	O
patients	patients	O
with	with	O
SPH	sph	O
had	had	O
used	used	O
anorexigens	anorexigens	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
magnitude	magnitude	O
of	of	O
the	the	O
association	association	O
with	with	O
PPH	pph	O
,	,	O
the	the	O
increase	increase	O
of	of	O
association	association	O
with	with	O
increasing	increasing	O
duration	duration	O
of	of	O
use	use	O
,	,	O
and	and	O
the	the	O
specificity	specificity	O
for	for	O
fenfluramines	fenfluramines	O
are	are	O
consistent	consistent	O
with	with	O
previous	previous	O
studies	studies	O
indicating	indicating	O
that	that	O
fenfluramines	fenfluramines	O
are	are	O
causally	causally	O
related	related	O
to	to	O
PPH	pph	O
.	.	O

The	the	O
high	high	O
prevalence	prevalence	O
of	of	O
anorexigen	anorexigen	O
use	use	O
in	in	O
patients	patients	O
with	with	O
SPH	sph	O
also	also	O
raises	raises	O
the	the	O
possibility	possibility	O
that	that	O
these	these	O
drugs	drugs	O
precipitate	precipitate	O
pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
in	in	O
patients	patients	O
with	with	O
underlying	underlying	O
conditions	conditions	O
associated	associated	O
with	with	O
SPH	sph	O
.	.	O

Clinical	clinical	O
aspects	aspects	O
of	of	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
and	and	O
thrombosis	thrombosis	B-Disease
and	and	O
other	other	O
side	side	O
effects	effects	O
of	of	O
heparin	heparin	B-Chemical
therapy	therapy	O
.	.	O

Heparin	heparin	B-Chemical
,	,	O
first	first	O
used	used	O
to	to	O
prevent	prevent	O
the	the	O
clotting	clotting	O
of	of	O
blood	blood	O
in	in	O
vitro	vitro	O
,	,	O
has	has	O
been	been	O
clinically	clinically	O
used	used	O
to	to	O
treat	treat	O
thrombosis	thrombosis	B-Disease
for	for	O
more	more	O
than	than	O
50	50	O
years	years	O
.	.	O

Although	although	O
several	several	O
new	new	O
anticoagulant	anticoagulant	O
drugs	drugs	O
are	are	O
in	in	O
development	development	O
,	,	O
heparin	heparin	B-Chemical
remains	remains	O
the	the	O
anticoagulant	anticoagulant	O
of	of	O
choice	choice	O
to	to	O
treat	treat	O
acute	acute	O
thrombotic	thrombotic	B-Disease
episodes	episodes	O
.	.	O

The	the	O
clinical	clinical	O
effects	effects	O
of	of	O
heparin	heparin	B-Chemical
are	are	O
meritorious	meritorious	O
,	,	O
but	but	O
side	side	O
effects	effects	O
do	do	O
exist	exist	O
.	.	O

Bleeding	bleeding	B-Disease
is	is	O
the	the	O
primary	primary	O
untoward	untoward	O
effect	effect	O
of	of	O
heparin	heparin	B-Chemical
.	.	O

Major	major	O
bleeding	bleeding	B-Disease
is	is	O
of	of	O
primary	primary	O
concern	concern	O
in	in	O
patients	patients	O
receiving	receiving	O
heparin	heparin	B-Chemical
therapy	therapy	O
.	.	O

However	however	O
,	,	O
additional	additional	O
important	important	O
untoward	untoward	O
effects	effects	O
of	of	O
heparin	heparin	B-Chemical
therapy	therapy	O
include	include	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
,	,	O
heparin-associated	heparin-associated	O
osteoporosis	osteoporosis	B-Disease
,	,	O
eosinophilia	eosinophilia	B-Disease
,	,	O
skin	skin	O
reactions	reactions	O
,	,	O
allergic	allergic	B-Disease
reactions	reactions	I-Disease
other	other	O
than	than	O
thrombocytopenia	thrombocytopenia	B-Disease
,	,	O
alopecia	alopecia	O
,	,	O
transaminasemia	transaminasemia	O
,	,	O
hyperkalemia	hyperkalemia	B-Disease
,	,	O
hypoaldosteronism	hypoaldosteronism	O
,	,	O
and	and	O
priapism	priapism	O
.	.	O

These	these	O
side	side	O
effects	effects	O
are	are	O
relatively	relatively	O
rare	rare	O
in	in	O
a	a	O
given	given	O
individual	individual	O
,	,	O
but	but	O
given	given	O
the	the	O
extremely	extremely	O
widespread	widespread	O
use	use	O
of	of	O
heparin	heparin	B-Chemical
,	,	O
some	some	O
are	are	O
quite	quite	O
common	common	O
,	,	O
particularly	particularly	O
HITT	hitt	B-Disease
and	and	O
osteoporosis	osteoporosis	B-Disease
.	.	O

Although	although	O
reasonable	reasonable	O
incidences	incidences	O
of	of	O
many	many	O
of	of	O
these	these	O
side	side	O
effects	effects	O
can	can	O
be	be	O
"	"	O
softly	softly	O
"	"	O
deduced	deduced	O
from	from	O
current	current	O
reports	reports	O
dealing	dealing	O
with	with	O
unfractionated	unfractionated	O
heparin	heparin	B-Chemical
,	,	O
at	at	O
present	present	O
the	the	O
incidences	incidences	O
of	of	O
these	these	O
side	side	O
effects	effects	O
with	with	O
newer	newer	O
low	low	O
molecular	molecular	O
weight	weight	O
heparins	heparins	O
appear	appear	O
to	to	O
be	be	O
much	much	O
less	less	O
common	common	O
.	.	O

However	however	O
,	,	O
only	only	O
longer	longer	O
experience	experience	O
will	will	O
more	more	O
clearly	clearly	O
define	define	O
the	the	O
incidence	incidence	O
of	of	O
each	each	O
side	side	O
effect	effect	O
with	with	O
low	low	O
molecular	molecular	O
weight	weight	O
preparations	preparations	O
.	.	O

A	a	O
case	case	O
of	of	O
bilateral	bilateral	O
optic	optic	O
neuropathy	neuropathy	B-Disease
in	in	O
a	a	O
patient	patient	O
on	on	O
tacrolimus	tacrolimus	B-Chemical
(	(	O
FK506	fk506	B-Chemical
)	)	O
therapy	therapy	O
after	after	O
liver	liver	O
transplantation	transplantation	O
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
report	report	O
a	a	O
case	case	O
of	of	O
bilateral	bilateral	O
optic	optic	O
neuropathy	neuropathy	B-Disease
in	in	O
a	a	O
patient	patient	O
receiving	receiving	O
tacrolimus	tacrolimus	B-Chemical
(	(	O
FK	fk	B-Chemical
506	506	I-Chemical
,	,	O
Prograf	prograf	O
;	;	O
Fujisawa	fujisawa	O
USA	usa	O
,	,	O
Inc	inc	O
,	,	O
Deerfield	deerfield	O
,	,	O
Illinois	illinois	O
)	)	O
for	for	O
immunosuppression	immunosuppression	O
after	after	O
orthotropic	orthotropic	O
liver	liver	O
transplantation	transplantation	O
.	.	O

METHOD	method	O
:	:	O
Case	case	O
report	report	O
.	.	O

In	in	O
a	a	O
58-year-old	58-year-old	O
man	man	O
receiving	receiving	O
tacrolimus	tacrolimus	B-Chemical
after	after	O
orthotropic	orthotropic	O
liver	liver	O
transplantation	transplantation	O
,	,	O
serial	serial	O
neuro-ophthalmologic	neuro-ophthalmologic	O
examinations	examinations	O
and	and	O
laboratory	laboratory	O
studies	studies	O
were	were	O
performed	performed	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
patient	patient	O
had	had	O
episodic	episodic	O
deterioration	deterioration	O
of	of	O
vision	vision	O
in	in	O
both	both	O
eyes	eyes	O
,	,	O
with	with	O
clinical	clinical	O
features	features	O
resembling	resembling	O
ischemic	ischemic	O
optic	optic	O
neuropathies	neuropathies	O
.	.	O

Deterioration	deterioration	O
of	of	O
vision	vision	O
occurred	occurred	O
despite	despite	O
discontinuation	discontinuation	O
of	of	O
the	the	O
tacrolimus	tacrolimus	B-Chemical
.	.	O

CONCLUSION	conclusion	O
:	:	O
Tacrolimus	tacrolimus	B-Chemical
and	and	O
other	other	O
immunosuppressive	immunosuppressive	B-Chemical
agents	agents	I-Chemical
may	may	O
be	be	O
associated	associated	O
with	with	O
optic	optic	O
nerve	nerve	O
toxicity	toxicity	B-Disease
.	.	O

Hypercalcemia	hypercalcemia	B-Disease
,	,	O
arrhythmia	arrhythmia	B-Disease
,	,	O
and	and	O
mood	mood	O
stabilizers	stabilizers	O
.	.	O

Recent	recent	O
findings	findings	O
in	in	O
a	a	O
bipolar	bipolar	B-Disease
patient	patient	O
receiving	receiving	O
maintenance	maintenance	O
lithium	lithium	B-Chemical
therapy	therapy	O
who	who	O
developed	developed	O
hypercalcemia	hypercalcemia	B-Disease
and	and	O
severe	severe	O
bradyarrhythmia	bradyarrhythmia	O
prompted	prompted	O
the	the	O
authors	authors	O
to	to	O
conduct	conduct	O
a	a	O
retrospective	retrospective	O
study	study	O
of	of	O
bipolar	bipolar	B-Disease
patients	patients	O
with	with	O
lithium-associated	lithium-associated	O
hypercalcemia	hypercalcemia	B-Disease
.	.	O

A	a	O
printout	printout	O
of	of	O
all	all	O
cases	cases	O
of	of	O
hypercalcemia	hypercalcemia	B-Disease
that	that	O
presented	presented	O
during	during	O
a	a	O
1-year	1-year	O
period	period	O
was	was	O
generated	generated	O
.	.	O

After	after	O
eliminating	eliminating	O
spurious	spurious	O
hypercalcemias	hypercalcemias	O
or	or	O
those	those	O
associated	associated	O
with	with	O
intravenous	intravenous	O
fluids	fluids	O
,	,	O
the	the	O
authors	authors	O
identified	identified	O
18	18	O
non-lithium-treated	non-lithium-treated	O
patients	patients	O
with	with	O
hypercalcemias	hypercalcemias	O
related	related	O
to	to	O
malignancies	malignancies	B-Disease
and	and	O
other	other	O
medical	medical	O
conditions	conditions	O
(	(	O
group	group	O
A	a	O
)	)	O
and	and	O
12	12	O
patients	patients	O
with	with	O
lithium-associated	lithium-associated	O
hypercalcemia	hypercalcemia	B-Disease
(	(	O
group	group	O
B	b	O
)	)	O
.	.	O

Patients	patients	O
in	in	O
group	group	O
B	b	O
were	were	O
not	not	O
comparable	comparable	O
to	to	O
those	those	O
in	in	O
group	group	O
A	a	O
,	,	O
as	as	O
the	the	O
latter	latter	O
were	were	O
medically	medically	O
compromised	compromised	O
and	and	O
were	were	O
receiving	receiving	O
multiple	multiple	O
pharmacotherapies	pharmacotherapies	O
.	.	O

Thus	thus	O
,	,	O
two	two	O
control	control	O
groups	groups	O
were	were	O
generated	generated	O
:	:	O
group	group	O
C1	c1	O
,	,	O
which	which	O
included	included	O
age-	age-	O
and	and	O
sex-comparable	sex-comparable	O
lithium-treated	lithium-treated	O
bipolar	bipolar	B-Disease
normocalcemic	normocalcemic	O
patients	patients	O
,	,	O
and	and	O
group	group	O
C2	c2	O
,	,	O
which	which	O
included	included	O
bipolar	bipolar	B-Disease
normocalcemic	normocalcemic	O
patients	patients	O
treated	treated	O
with	with	O
anticonvulsant	anticonvulsant	O
mood	mood	O
stabilizers	stabilizers	O
.	.	O

The	the	O
electrocardiographic	electrocardiographic	O
(	(	O
ECG	ecg	O
)	)	O
findings	findings	O
for	for	O
patients	patients	O
in	in	O
group	group	O
B	b	O
were	were	O
compared	compared	O
with	with	O
those	those	O
of	of	O
patients	patients	O
in	in	O
groups	groups	O
C1	c1	O
and	and	O
C2	c2	O
.	.	O

It	it	O
was	was	O
found	found	O
that	that	O
these	these	O
groups	groups	O
did	did	O
not	not	O
differ	differ	O
in	in	O
their	their	O
overall	overall	O
frequency	frequency	O
of	of	O
ECG	ecg	O
abnormalities	abnormalities	O
;	;	O
however	however	O
,	,	O
there	there	O
were	were	O
significant	significant	O
differences	differences	O
in	in	O
the	the	O
frequency	frequency	O
of	of	O
conduction	conduction	O
defects	defects	O
.	.	O

Patients	patients	O
with	with	O
hypercalcemia	hypercalcemia	B-Disease
resulting	resulting	O
from	from	O
medical	medical	O
diseases	diseases	O
and	and	O
bipolar	bipolar	B-Disease
patients	patients	O
with	with	O
lithium-associated	lithium-associated	O
hypercalcemia	hypercalcemia	B-Disease
had	had	O
significantly	significantly	O
higher	higher	O
frequencies	frequencies	O
of	of	O
conduction	conduction	O
defects	defects	O
.	.	O

Patients	patients	O
in	in	O
group	group	O
A	a	O
had	had	O
significant	significant	O
mortality	mortality	O
at	at	O
2-year	2-year	O
follow-up	follow-up	O
(	(	O
28	28	O
%	%	O
)	)	O
,	,	O
in	in	O
contrast	contrast	O
to	to	O
zero	zero	O
mortality	mortality	O
in	in	O
the	the	O
other	other	O
three	three	O
groups	groups	O
.	.	O

The	the	O
clinical	clinical	O
implications	implications	O
of	of	O
these	these	O
findings	findings	O
are	are	O
discussed	discussed	O
.	.	O

Attenuation	attenuation	O
of	of	O
nephrotoxicity	nephrotoxicity	B-Disease
by	by	O
a	a	O
novel	novel	O
lipid	lipid	O
nanosphere	nanosphere	O
(	(	O
NS-718	ns-718	O
)	)	O
incorporating	incorporating	O
amphotericin	amphotericin	B-Chemical
B.NS-718	b.ns-718	O
,	,	O
a	a	O
lipid	lipid	O
nanosphere	nanosphere	O
incorporating	incorporating	O
amphotericin	amphotericin	B-Chemical
B	b	I-Chemical
,	,	O
is	is	O
effective	effective	O
against	against	O
pathogenic	pathogenic	O
fungi	fungi	O
and	and	O
has	has	O
low	low	O
toxicity	toxicity	B-Disease
.	.	O

We	we	O
compared	compared	O
the	the	O
toxicity	toxicity	B-Disease
of	of	O
NS-718	ns-718	O
with	with	O
that	that	O
of	of	O
Fungizone	fungizone	B-Chemical
(	(	O
amphotericin	amphotericin	B-Chemical
B-sodium	b-sodium	O
deoxycholate	deoxycholate	B-Chemical
;	;	O
D-AmB	d-amb	O
)	)	O
in	in	O
vitro	vitro	O
using	using	O
renal	renal	O
cell	cell	O
cultures	cultures	O
and	and	O
in	in	O
vivo	vivo	O
by	by	O
biochemical	biochemical	O
analysis	analysis	O
,	,	O
histopathological	histopathological	O
study	study	O
of	of	O
the	the	O
kidney	kidney	O
and	and	O
pharmacokinetic	pharmacokinetic	O
study	study	O
of	of	O
amphotericin	amphotericin	B-Chemical
B	b	I-Chemical
following	following	O
intravenous	intravenous	O
infusion	infusion	O
of	of	O
the	the	O
formulation	formulation	O
in	in	O
rats	rats	O
.	.	O

Incubation	incubation	O
with	with	O
NS-718	ns-718	O
resulted	resulted	O
in	in	O
significantly	significantly	O
less	less	O
damage	damage	O
of	of	O
cultured	cultured	O
human	human	O
renal	renal	O
proximal	proximal	O
tubular	tubular	O
epithelial	epithelial	O
cells	cells	O
compared	compared	O
with	with	O
D-AmB.	d-amb.	O
Serum	serum	O
blood	blood	O
urea	urea	B-Chemical
and	and	O
creatinine	creatinine	B-Chemical
concentrations	concentrations	O
increased	increased	O
significantly	significantly	O
in	in	O
rats	rats	O
given	given	O
an	an	O
iv	iv	O
infusion	infusion	O
of	of	O
D-AmB	d-amb	O
3	3	O
mg/kg	mg/kg	O
but	but	O
not	not	O
in	in	O
those	those	O
given	given	O
the	the	O
same	same	O
dose	dose	O
of	of	O
NS-718	ns-718	O
.	.	O

Histopathological	histopathological	O
examination	examination	O
of	of	O
the	the	O
kidney	kidney	O
showed	showed	O
tubular	tubular	B-Disease
necrosis	necrosis	B-Disease
in	in	O
D-AmB-treated	d-amb-treated	O
rats	rats	O
but	but	O
no	no	O
change	change	O
in	in	O
NS-718-treated	ns-718-treated	O
rats	rats	O
.	.	O

Amphotericin	amphotericin	B-Chemical
B	b	I-Chemical
concentrations	concentrations	O
in	in	O
the	the	O
kidney	kidney	O
in	in	O
NS-718-treated	ns-718-treated	O
rats	rats	O
were	were	O
higher	higher	O
than	than	O
those	those	O
in	in	O
D-AmB-treated	d-amb-treated	O
rats	rats	O
.	.	O

Our	our	O
in	in	O
vitro	vitro	O
and	and	O
in	in	O
vivo	vivo	O
results	results	O
suggest	suggest	O
that	that	O
incorporation	incorporation	O
of	of	O
amphotericin	amphotericin	B-Chemical
B	b	I-Chemical
into	into	O
lipid	lipid	O
nanospheres	nanospheres	O
of	of	O
NS-718	ns-718	O
attenuates	attenuates	O
the	the	O
nephrotoxicity	nephrotoxicity	B-Disease
of	of	O
amphotericin	amphotericin	B-Chemical
B.	b.	O

Patterns	patterns	O
of	of	O
sulfadiazine	sulfadiazine	O
acute	acute	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

Sulfadiazine	sulfadiazine	O
acute	acute	O
nephrotoxicity	nephrotoxicity	B-Disease
is	is	O
reviving	reviving	O
specially	specially	O
because	because	O
of	of	O
its	its	O
use	use	O
in	in	O
toxoplasmosis	toxoplasmosis	O
in	in	O
HIV-positive	hiv-positive	O
patients	patients	O
.	.	O

We	we	O
report	report	O
4	4	O
cases	cases	O
,	,	O
one	one	O
of	of	O
them	them	O
in	in	O
a	a	O
previously	previously	O
healthy	healthy	O
person	person	O
.	.	O

Under	under	O
treatment	treatment	O
with	with	O
sulfadiazine	sulfadiazine	O
they	they	O
developed	developed	O
oliguria	oliguria	O
,	,	O
abdominal	abdominal	B-Disease
pain	pain	B-Disease
,	,	O
renal	renal	B-Disease
failure	failure	I-Disease
and	and	O
showed	showed	O
multiple	multiple	O
radiolucent	radiolucent	O
renal	renal	O
calculi	calculi	O
in	in	O
echography	echography	O
.	.	O

All	all	O
patients	patients	O
recovered	recovered	O
their	their	O
previous	previous	O
normal	normal	O
renal	renal	O
function	function	O
after	after	O
adequate	adequate	O
hydration	hydration	O
and	and	O
alcalinization	alcalinization	O
.	.	O

A	a	O
nephrostomy	nephrostomy	O
tube	tube	O
had	had	O
to	to	O
be	be	O
placed	placed	O
in	in	O
one	one	O
of	of	O
the	the	O
patients	patients	O
for	for	O
ureteral	ureteral	O
lithiasis	lithiasis	O
in	in	O
a	a	O
single	single	O
functional	functional	O
kidney	kidney	O
.	.	O

None	none	O
of	of	O
them	them	O
needed	needed	O
dialysis	dialysis	O
or	or	O
a	a	O
renal	renal	O
biopsy	biopsy	O
because	because	O
of	of	O
a	a	O
typical	typical	O
benign	benign	O
course	course	O
.	.	O

Treatment	treatment	O
with	with	O
sulfadiazine	sulfadiazine	O
requires	requires	O
exquisite	exquisite	O
control	control	O
of	of	O
renal	renal	O
function	function	O
,	,	O
an	an	O
increase	increase	O
in	in	O
water	water	O
ingestion	ingestion	O
and	and	O
possibly	possibly	O
the	the	O
alcalinization	alcalinization	O
of	of	O
the	the	O
urine	urine	O
.	.	O

We	we	O
communicate	communicate	O
a	a	O
case	case	O
in	in	O
a	a	O
previously	previously	O
healthy	healthy	O
person	person	O
,	,	O
a	a	O
fact	fact	O
not	not	O
found	found	O
in	in	O
the	the	O
recent	recent	O
literature	literature	O
.	.	O

Probably	probably	O
many	many	O
more	more	O
cases	cases	O
are	are	O
not	not	O
detected	detected	O
.	.	O

We	we	O
think	think	O
that	that	O
a	a	O
prospective	prospective	O
study	study	O
would	would	O
be	be	O
useful	useful	O
.	.	O

Downbeat	downbeat	O
nystagmus	nystagmus	O
associated	associated	O
with	with	O
intravenous	intravenous	O
patient-controlled	patient-controlled	O
administration	administration	O
of	of	O
morphine	morphine	B-Chemical
.	.	O

IMPLICATIONS	implications	O
:	:	O
This	this	O
case	case	O
documents	documents	O
a	a	O
patient	patient	O
who	who	O
developed	developed	O
dizziness	dizziness	B-Disease
with	with	O
downbeating	downbeating	O
nystagmus	nystagmus	O
while	while	O
receiving	receiving	O
a	a	O
relatively	relatively	O
large	large	O
dose	dose	O
of	of	O
IV	iv	O
patient-controlled	patient-controlled	O
analgesia	analgesia	O
morphine	morphine	B-Chemical
.	.	O

Although	although	O
there	there	O
have	have	O
been	been	O
case	case	O
reports	reports	O
of	of	O
epidural	epidural	O
morphine	morphine	B-Chemical
with	with	O
these	these	O
symptoms	symptoms	B-Disease
and	and	I-Disease
signs	signs	I-Disease
,	,	O
this	this	O
has	has	O
not	not	O
been	been	O
previously	previously	O
documented	documented	O
with	with	O
IV	iv	O
or	or	O
patient-controlled	patient-controlled	O
analgesia	analgesia	O
morphine	morphine	B-Chemical
.	.	O

Hemodynamic	hemodynamic	O
and	and	O
antiadrenergic	antiadrenergic	O
effects	effects	O
of	of	O
dronedarone	dronedarone	O
and	and	O
amiodarone	amiodarone	B-Chemical
in	in	O
animals	animals	O
with	with	O
a	a	O
healed	healed	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

The	the	O
hemodynamic	hemodynamic	O
and	and	O
antiadrenergic	antiadrenergic	O
effects	effects	O
of	of	O
dronedarone	dronedarone	O
,	,	O
a	a	O
noniodinated	noniodinated	O
compound	compound	O
structurally	structurally	O
related	related	O
to	to	O
amiodarone	amiodarone	B-Chemical
,	,	O
were	were	O
compared	compared	O
with	with	O
those	those	O
of	of	O
amiodarone	amiodarone	B-Chemical
after	after	O
prolonged	prolonged	O
oral	oral	O
administration	administration	O
,	,	O
both	both	O
at	at	O
rest	rest	O
and	and	O
during	during	O
sympathetic	sympathetic	O
stimulation	stimulation	O
in	in	O
conscious	conscious	O
dogs	dogs	O
with	with	O
a	a	O
healed	healed	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

All	all	O
dogs	dogs	O
(	(	O
n	n	O
=	=	O
6	6	O
)	)	O
randomly	randomly	O
received	received	O
orally	orally	O
dronedarone	dronedarone	O
(	(	O
10	10	O
and	and	O
30	30	O
mg/kg	mg/kg	O
)	)	O
,	,	O
amiodarone	amiodarone	B-Chemical
(	(	O
10	10	O
and	and	O
30	30	O
mg/kg	mg/kg	O
)	)	O
,	,	O
and	and	O
placebo	placebo	O
twice	twice	O
daily	daily	O
for	for	O
7	7	O
days	days	O
,	,	O
with	with	O
a	a	O
3-week	3-week	O
washout	washout	O
between	between	O
consecutive	consecutive	O
treatments	treatments	O
.	.	O

Heart	heart	O
rate	rate	O
(	(	O
HR	hr	O
)	)	O
,	,	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
(	(	O
MBP	mbp	O
)	)	O
,	,	O
positive	positive	O
rate	rate	O
of	of	O
increase	increase	O
of	of	O
left	left	O
ventricular	ventricular	O
pressure	pressure	O
(	(	O
+	+	O
LVdP/dt	lvdp/dt	O
)	)	O
,	,	O
echocardiographically	echocardiographically	O
assessed	assessed	O
left	left	O
ventricular	ventricular	O
ejection	ejection	O
fraction	fraction	O
(	(	O
LVEF	lvef	O
)	)	O
,	,	O
and	and	O
fractional	fractional	O
shortening	shortening	O
(	(	O
FS	fs	O
)	)	O
,	,	O
as	as	O
well	well	O
as	as	O
chronotropic	chronotropic	O
response	response	O
to	to	O
isoproterenol	isoproterenol	B-Chemical
and	and	O
exercise-induced	exercise-induced	O
sympathetic	sympathetic	O
stimulation	stimulation	O
were	were	O
evaluated	evaluated	O
under	under	O
baseline	baseline	O
and	and	O
posttreatment	posttreatment	O
conditions	conditions	O
.	.	O

Resting	resting	O
values	values	O
of	of	O
LVEF	lvef	O
,	,	O
FS	fs	O
,	,	O
+	+	O
LVdP/dt	lvdp/dt	O
,	,	O
and	and	O
MBP	mbp	O
remained	remained	O
unchanged	unchanged	O
whatever	whatever	O
the	the	O
drug	drug	O
and	and	O
the	the	O
dosing	dosing	O
regimen	regimen	O
,	,	O
whereas	whereas	O
resting	resting	O
HR	hr	O
was	was	O
significantly	significantly	O
and	and	O
dose-dependently	dose-dependently	O
lowered	lowered	O
after	after	O
dronedarone	dronedarone	O
and	and	O
to	to	O
a	a	O
lesser	lesser	O
extent	extent	O
after	after	O
amiodarone	amiodarone	B-Chemical
.	.	O

Both	both	O
dronedarone	dronedarone	O
and	and	O
amiodarone	amiodarone	B-Chemical
significantly	significantly	O
reduced	reduced	O
the	the	O
exercise-induced	exercise-induced	O
tachycardia	tachycardia	B-Disease
and	and	O
,	,	O
at	at	O
the	the	O
highest	highest	O
dose	dose	O
,	,	O
decreased	decreased	O
the	the	O
isoproterenol-induced	isoproterenol-induced	O
tachycardia	tachycardia	B-Disease
.	.	O

Thus	thus	O
,	,	O
dronedarone	dronedarone	O
and	and	O
amiodarone	amiodarone	B-Chemical
displayed	displayed	O
a	a	O
similar	similar	O
level	level	O
of	of	O
antiadrenergic	antiadrenergic	O
effect	effect	O
and	and	O
did	did	O
not	not	O
impair	impair	O
the	the	O
resting	resting	O
left	left	O
ventricular	ventricular	O
function	function	O
.	.	O

Consequently	consequently	O
,	,	O
dronedarone	dronedarone	O
might	might	O
be	be	O
particularly	particularly	O
suitable	suitable	O
for	for	O
the	the	O
treatment	treatment	O
and	and	O
prevention	prevention	O
of	of	O
various	various	O
clinical	clinical	O
arrhythmias	arrhythmias	B-Disease
,	,	O
without	without	O
compromising	compromising	O
the	the	O
left	left	O
ventricular	ventricular	O
function	function	O
.	.	O

Phase	phase	O
2	2	O
trial	trial	O
of	of	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
(	(	O
40	40	O
mg/m(2	mg/m(2	O
)	)	O
)	)	O
in	in	O
platinum/paclitaxel-refractory	platinum/paclitaxel-refractory	O
ovarian	ovarian	O
and	and	O
fallopian	fallopian	O
tube	tube	O
cancers	cancers	B-Disease
and	and	O
primary	primary	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
peritoneum	peritoneum	O
.	.	O

BACKGROUND	background	O
:	:	O
Several	several	O
studies	studies	O
have	have	O
demonstrated	demonstrated	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
(	(	O
Doxil	doxil	B-Chemical
)	)	O
to	to	O
be	be	O
an	an	O
active	active	O
antineoplastic	antineoplastic	O
agent	agent	O
in	in	O
platinum-resistant	platinum-resistant	O
ovarian	ovarian	B-Disease
cancer	cancer	B-Disease
,	,	O
with	with	O
dose	dose	O
limiting	limiting	O
toxicity	toxicity	B-Disease
of	of	O
the	the	O
standard	standard	O
dosing	dosing	O
regimen	regimen	O
(	(	O
50	50	O
mg/m(2	mg/m(2	O
)	)	O
q	q	O
4	4	O
weeks	weeks	O
)	)	O
being	being	O
severe	severe	O
erythrodysesthesia	erythrodysesthesia	O
(	(	O
"	"	O
hand-foot	hand-foot	O
syndrome	syndrome	O
"	"	O
)	)	O
and	and	O
stomatitis	stomatitis	B-Disease
.	.	O

We	we	O
wished	wished	O
to	to	O
develop	develop	O
a	a	O
more	more	O
tolerable	tolerable	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
treatment	treatment	O
regimen	regimen	O
and	and	O
document	document	O
its	its	O
level	level	O
of	of	O
activity	activity	O
in	in	O
a	a	O
well-defined	well-defined	O
patient	patient	O
population	population	O
with	with	O
platinum/paclitaxel-refractory	platinum/paclitaxel-refractory	O
disease	disease	O
.	.	O

METHODS	methods	O
AND	and	O
MATERIALS	materials	O
:	:	O
Patients	patients	O
with	with	O
ovarian	ovarian	O
or	or	O
fallopian	fallopian	O
tube	tube	O
cancers	cancers	B-Disease
or	or	O
primary	primary	O
peritoneal	peritoneal	O
carcinoma	carcinoma	B-Disease
with	with	O
platinum/paclitaxel-refractory	platinum/paclitaxel-refractory	O
disease	disease	O
(	(	O
stable	stable	O
or	or	O
progressive	progressive	O
disease	disease	O
following	following	O
treatment	treatment	O
with	with	O
these	these	O
agents	agents	O
or	or	O
previous	previous	O
objective	objective	O
response	response	O
<3	<3	O
months	months	O
in	in	O
duration	duration	O
)	)	O
were	were	O
treated	treated	O
with	with	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
at	at	O
a	a	O
dose	dose	O
of	of	O
40	40	O
mg/m(2	mg/m(2	O
)	)	O
q	q	O
4	4	O
weeks	weeks	O
.	.	O

RESULTS	results	O
:	:	O
A	a	O
total	total	O
of	of	O
49	49	O
patients	patients	O
(	(	O
median	median	O
age	age	O
:	:	O
60	60	O
;	;	O
range	range	O
41	41	O
-	-	O
81	81	O
)	)	O
entered	entered	O
this	this	O
phase	phase	O
2	2	O
trial	trial	O
.	.	O

The	the	O
median	median	O
number	number	O
of	of	O
prior	prior	O
regimens	regimens	O
was	was	O
2	2	O
(	(	O
range	range	O
:	:	O
1	1	O
-	-	O
6	6	O
)	)	O
.	.	O

Six	six	O
(	(	O
12	12	O
%	%	O
)	)	O
and	and	O
4	4	O
(	(	O
8	8	O
%	%	O
)	)	O
patients	patients	O
experienced	experienced	O
grade	grade	O
2	2	O
hand-foot	hand-foot	O
syndrome	syndrome	O
and	and	O
stomatitis	stomatitis	B-Disease
,	,	O
respectively	respectively	O
(	(	O
no	no	O
episodes	episodes	O
of	of	O
grade	grade	O
3	3	O
)	)	O
.	.	O

One	one	O
patient	patient	O
developed	developed	O
grade	grade	O
3	3	O
diarrhea	diarrhea	B-Disease
requiring	requiring	O
hospitalization	hospitalization	O
for	for	O
hydration	hydration	O
.	.	O

Six	six	O
(	(	O
12	12	O
%	%	O
)	)	O
individuals	individuals	O
required	required	O
dose	dose	O
reductions	reductions	O
.	.	O

The	the	O
median	median	O
number	number	O
of	of	O
courses	courses	O
of	of	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
administered	administered	O
on	on	O
this	this	O
protocol	protocol	O
was	was	O
2	2	O
(	(	O
range	range	O
:	:	O
1	1	O
-	-	O
12	12	O
)	)	O
.	.	O

Four	four	O
of	of	O
44	44	O
patients	patients	O
(	(	O
9	9	O
%	%	O
)	)	O
evaluable	evaluable	O
for	for	O
response	response	O
exhibited	exhibited	O
objective	objective	O
and	and	O
subjective	subjective	O
evidence	evidence	O
of	of	O
an	an	O
antineoplastic	antineoplastic	O
effect	effect	O
of	of	O
therapy	therapy	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
This	this	O
modified	modified	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
regimen	regimen	O
results	results	O
in	in	O
less	less	O
toxicity	toxicity	B-Disease
(	(	O
stomatitis	stomatitis	B-Disease
,	,	O
hand-foot	hand-foot	O
syndrome	syndrome	O
)	)	O
than	than	O
the	the	O
standard	standard	O
FDA-approved	fda-approved	O
dose	dose	O
schedule	schedule	O
.	.	O

Definite	definite	O
,	,	O
although	although	O
limited	limited	O
,	,	O
antineoplastic	antineoplastic	O
activity	activity	O
is	is	O
observed	observed	O
in	in	O
patients	patients	O
with	with	O
well-defined	well-defined	O
platinum-	platinum-	O
and	and	O
paclitaxel-refractory	paclitaxel-refractory	O
ovarian	ovarian	B-Disease
cancer	cancer	B-Disease
.	.	O

Efficacy	efficacy	O
of	of	O
olanzapine	olanzapine	B-Chemical
in	in	O
acute	acute	O
bipolar	bipolar	B-Disease
mania	mania	B-Disease
:	:	O
a	a	O
double-blind	double-blind	O
,	,	O
placebo-controlled	placebo-controlled	O
study	study	O
.	.	O

The	the	O
Olanzipine	olanzipine	O
HGGW	hggw	O
Study	study	O
Group	group	O
.	.	O

BACKGROUND	background	O
:	:	O
We	we	O
compared	compared	O
the	the	O
efficacy	efficacy	O
and	and	O
safety	safety	O
of	of	O
olanzapine	olanzapine	B-Chemical
vs	vs	O
placebo	placebo	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
acute	acute	O
bipolar	bipolar	B-Disease
mania	mania	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Four-week	four-week	O
,	,	O
randomized	randomized	O
,	,	O
double-blind	double-blind	O
,	,	O
parallel	parallel	O
study	study	O
.	.	O

A	a	O
total	total	O
of	of	O
115	115	O
patients	patients	O
with	with	O
a	a	O
DSM-IV	dsm-iv	O
diagnosis	diagnosis	O
of	of	O
bipolar	bipolar	B-Disease
disorder	disorder	I-Disease
,	,	O
manic	manic	B-Disease
or	or	O
mixed	mixed	O
,	,	O
were	were	O
randomized	randomized	O
to	to	O
olanzapine	olanzapine	B-Chemical
,	,	O
5	5	O
to	to	O
20	20	O
mg/d	mg/d	O
(	(	O
n	n	O
=	=	O
55	55	O
)	)	O
,	,	O
or	or	O
placebo	placebo	O
(	(	O
n	n	O
=	=	O
60	60	O
)	)	O
.	.	O

The	the	O
primary	primary	O
efficacy	efficacy	O
measure	measure	O
was	was	O
the	the	O
Young-Mania	young-mania	O
Rating	rating	O
Scale	scale	O
(	(	O
Y-MRS	y-mrs	O
)	)	O
total	total	O
score	score	O
.	.	O

Response	response	O
and	and	O
euthymia	euthymia	O
were	were	O
defined	defined	O
,	,	O
a	a	O
priori	priori	O
,	,	O
as	as	O
at	at	O
least	least	O
a	a	O
50	50	O
%	%	O
improvement	improvement	O
from	from	O
baseline	baseline	O
to	to	O
end	end	O
point	point	O
and	and	O
as	as	O
a	a	O
score	score	O
of	of	O
no	no	O
less	less	O
than	than	O
12	12	O
at	at	O
end	end	O
point	point	O
in	in	O
the	the	O
Y-MRS	y-mrs	O
total	total	O
score	score	O
,	,	O
respectively	respectively	O
.	.	O

Safety	safety	O
was	was	O
assessed	assessed	O
using	using	O
adverse	adverse	O
events	events	O
,	,	O
Extrapyramidal	extrapyramidal	O
Symptom	symptom	O
(	(	O
EPS	eps	B-Disease
)	)	O
rating	rating	O
scales	scales	O
,	,	O
laboratory	laboratory	O
values	values	O
,	,	O
electrocardiograms	electrocardiograms	O
,	,	O
vital	vital	O
signs	signs	O
,	,	O
and	and	O
weight	weight	O
change	change	O
.	.	O

RESULTS	results	O
:	:	O
Olanzapine-treated	olanzapine-treated	O
patients	patients	O
demonstrated	demonstrated	O
a	a	O
statistically	statistically	O
significant	significant	O
greater	greater	O
mean	mean	O
(	(	O
+	+	O
/-	/-	O
SD	sd	O
)	)	O
improvement	improvement	O
in	in	O
Y-MRS	y-mrs	O
total	total	O
score	score	O
than	than	O
placebo-treated	placebo-treated	O
patients	patients	O
(	(	O
-14.8	-14.8	O
+	+	O
/-	/-	O
12.5	12.5	O
and	and	O
-8.1	-8.1	O
+	+	O
/-	/-	O
12.7	12.7	O
,	,	O
respectively	respectively	O
;	;	O
P<.001	p<.001	O
)	)	O
,	,	O
which	which	O
was	was	O
evident	evident	O
at	at	O
the	the	O
first	first	O
postbaseline	postbaseline	O
observation	observation	O
1	1	O
week	week	O
after	after	O
randomization	randomization	O
and	and	O
was	was	O
maintained	maintained	O
throughout	throughout	O
the	the	O
study	study	O
(	(	O
last	last	O
observation	observation	O
carried	carried	O
forward	forward	O
)	)	O
.	.	O

Olanzapine-treated	olanzapine-treated	O
patients	patients	O
demonstrated	demonstrated	O
a	a	O
higher	higher	O
rate	rate	O
of	of	O
response	response	O
(	(	O
65	65	O
%	%	O
vs	vs	O
43	43	O
%	%	O
,	,	O
respectively	respectively	O
;	;	O
P	p	O
=	=	O
.02	.02	O
)	)	O
and	and	O
euthymia	euthymia	O
(	(	O
61	61	O
%	%	O
vs	vs	O
36	36	O
%	%	O
,	,	O
respectively	respectively	O
;	;	O
P	p	O
=	=	O
.	.	O
01	01	O
)	)	O
than	than	O
placebo-treated	placebo-treated	O
patients	patients	O
.	.	O

There	there	O
were	were	O
no	no	O
statistically	statistically	O
significant	significant	O
differences	differences	O
in	in	O
EPSs	epss	O
between	between	O
groups	groups	O
.	.	O

However	however	O
,	,	O
olanzapine-treated	olanzapine-treated	O
patients	patients	O
had	had	O
a	a	O
statistically	statistically	O
significant	significant	O
greater	greater	O
mean	mean	O
(	(	O
+	+	O
/-	/-	O
SD	sd	O
)	)	O
weight	weight	B-Disease
gain	gain	I-Disease
than	than	O
placebo-treated	placebo-treated	O
patients	patients	O
(	(	O
2.1	2.1	O
+	+	O
/-	/-	O
2.8	2.8	O
vs	vs	O
0.45	0.45	O
+	+	O
/-	/-	O
2.3	2.3	O
kg	kg	O
,	,	O
respectively	respectively	O
)	)	O
and	and	O
also	also	O
experienced	experienced	O
more	more	O
treatment-emergent	treatment-emergent	O
somnolence	somnolence	B-Disease
(	(	O
21	21	O
patients	patients	O
[	[	O
38.2	38.2	O
%	%	O
]	]	O
vs	vs	O
5	5	O
[	[	O
8.3	8.3	O
%	%	O
]	]	O
,	,	O
respectively	respectively	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Olanzapine	olanzapine	B-Chemical
demonstrated	demonstrated	O
greater	greater	O
efficacy	efficacy	O
than	than	O
placebo	placebo	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
acute	acute	O
bipolar	bipolar	B-Disease
mania	mania	B-Disease
and	and	O
was	was	O
generally	generally	O
well	well	O
tolerated	tolerated	O
.	.	O

The	the	O
effect	effect	O
of	of	O
pupil	pupil	O
dilation	dilation	O
with	with	O
tropicamide	tropicamide	O
on	on	O
vision	vision	O
and	and	O
driving	driving	O
simulator	simulator	O
performance	performance	O
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
assess	assess	O
the	the	O
effect	effect	O
of	of	O
pupil	pupil	O
dilation	dilation	O
on	on	O
vision	vision	O
and	and	O
driving	driving	O
ability	ability	O
.	.	O

METHODS	methods	O
:	:	O
A	a	O
series	series	O
of	of	O
tests	tests	O
on	on	O
various	various	O
parameters	parameters	O
of	of	O
visual	visual	O
function	function	O
and	and	O
driving	driving	O
simulator	simulator	O
performance	performance	O
were	were	O
performed	performed	O
on	on	O
12	12	O
healthy	healthy	O
drivers	drivers	O
,	,	O
before	before	O
and	and	O
after	after	O
pupil	pupil	O
dilation	dilation	O
using	using	O
guttae	guttae	O
tropicamide	tropicamide	O
1	1	O
%	%	O
.	.	O

A	a	O
driving	driving	O
simulator	simulator	O
(	(	O
Transport	transport	O
Research	research	O
Laboratory	laboratory	O
)	)	O
was	was	O
used	used	O
to	to	O
measure	measure	O
reaction	reaction	O
time	time	O
(	(	O
RT	rt	O
)	)	O
,	,	O
speed	speed	O
maintenance	maintenance	O
and	and	O
steering	steering	O
accuracy	accuracy	O
.	.	O

Tests	tests	O
of	of	O
basic	basic	O
visual	visual	O
function	function	O
included	included	O
high-	high-	O
and	and	O
low-contrast	low-contrast	O
visual	visual	O
acuity	acuity	O
(	(	O
HCVA	hcva	O
and	and	O
LCVA	lcva	O
)	)	O
,	,	O
Pelli-Robson	pelli-robson	O
contrast	contrast	O
threshold	threshold	O
(	(	O
CT	ct	O
)	)	O
and	and	O
Goldmann	goldmann	O
perimetry	perimetry	O
(	(	O
FIELDS	fields	O
)	)	O
.	.	O

Useful	useful	O
Field	field	O
of	of	O
View	view	O
(	(	O
UFOV	ufov	O
--	--	O
a	a	O
test	test	O
of	of	O
visual	visual	O
attention	attention	O
)	)	O
was	was	O
also	also	O
undertaken	undertaken	O
.	.	O

The	the	O
mean	mean	O
differences	differences	O
in	in	O
the	the	O
pre-	pre-	O
and	and	O
post-dilatation	post-dilatation	O
measurements	measurements	O
were	were	O
tested	tested	O
for	for	O
statistical	statistical	O
significance	significance	O
at	at	O
the	the	O
95	95	O
%	%	O
level	level	O
using	using	O
one-tail	one-tail	O
paired	paired	O
t-tests	t-tests	O
.	.	O

RESULTS	results	O
:	:	O
Pupillary	pupillary	O
dilation	dilation	O
resulted	resulted	O
in	in	O
a	a	O
statistically	statistically	O
significant	significant	O
deterioration	deterioration	O
in	in	O
CT	ct	O
and	and	O
HCVA	hcva	O
only	only	O
.	.	O

Five	five	O
of	of	O
12	12	O
drivers	drivers	O
also	also	O
exhibited	exhibited	O
deterioration	deterioration	O
in	in	O
LCVA	lcva	O
,	,	O
CT	ct	O
and	and	O
RT	rt	O
.	.	O

Little	little	O
evidence	evidence	O
emerged	emerged	O
for	for	O
deterioration	deterioration	O
in	in	O
FIELDS	fields	O
and	and	O
UFOV	ufov	O
.	.	O

Also	also	O
,	,	O
7	7	O
of	of	O
12	12	O
drivers	drivers	O
appeared	appeared	O
to	to	O
adjust	adjust	O
their	their	O
driving	driving	O
behaviour	behaviour	O
by	by	O
reducing	reducing	O
their	their	O
speed	speed	O
on	on	O
the	the	O
driving	driving	O
simulator	simulator	O
,	,	O
leading	leading	O
to	to	O
improved	improved	O
steering	steering	O
accuracy	accuracy	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Pupillary	pupillary	O
dilation	dilation	O
may	may	O
lead	lead	O
to	to	O
a	a	O
decrease	decrease	O
in	in	O
vision	vision	O
and	and	O
daylight	daylight	O
driving	driving	O
performance	performance	O
in	in	O
young	young	O
people	people	O
.	.	O

A	a	O
larger	larger	O
study	study	O
,	,	O
including	including	O
a	a	O
broader	broader	O
spectrum	spectrum	O
of	of	O
subjects	subjects	O
,	,	O
is	is	O
warranted	warranted	O
before	before	O
guidelines	guidelines	O
can	can	O
be	be	O
recommended	recommended	O
.	.	O

A	a	O
case	case	O
of	of	O
isotretinoin	isotretinoin	O
embryopathy	embryopathy	O
with	with	O
bilateral	bilateral	O
anotia	anotia	O
and	and	O
Taussig-Bing	taussig-bing	O
malformation	malformation	O
.	.	O

We	we	O
report	report	O
a	a	O
newborn	newborn	O
infant	infant	O
with	with	O
multiple	multiple	O
congenital	congenital	O
anomalies	anomalies	O
(	(	O
anotia	anotia	O
and	and	O
Taussig-Bing	taussig-bing	O
malformation	malformation	O
)	)	O
due	due	O
to	to	O
exposure	exposure	O
to	to	O
isotretinoin	isotretinoin	O
within	within	O
the	the	O
first	first	O
trimester	trimester	O
.	.	O

In	in	O
this	this	O
paper	paper	O
we	we	O
aim	aim	O
to	to	O
draw	draw	O
to	to	O
the	the	O
fact	fact	O
that	that	O
caution	caution	O
is	is	O
needed	needed	O
when	when	O
prescribing	prescribing	O
vitamin	vitamin	O
A-containing	a-containing	O
drugs	drugs	O
to	to	O
women	women	O
of	of	O
childbearing	childbearing	O
years	years	O
.	.	O

Effect	effect	O
of	of	O
methoxamine	methoxamine	O
on	on	O
maximum	maximum	O
urethral	urethral	O
pressure	pressure	O
in	in	O
women	women	O
with	with	O
genuine	genuine	O
stress	stress	B-Disease
incontinence	incontinence	B-Disease
:	:	O
a	a	O
placebo-controlled	placebo-controlled	O
,	,	O
double-blind	double-blind	O
crossover	crossover	O
study	study	O
.	.	O

The	the	O
aim	aim	O
of	of	O
the	the	O
study	study	O
was	was	O
to	to	O
evaluate	evaluate	O
the	the	O
potential	potential	O
role	role	O
for	for	O
a	a	O
selective	selective	O
alpha1-adrenoceptor	alpha1-adrenoceptor	O
agonist	agonist	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
urinary	urinary	O
stress	stress	B-Disease
incontinence	incontinence	B-Disease
.	.	O

A	a	O
randomised	randomised	O
,	,	O
double-blind	double-blind	O
,	,	O
placebo-controlled	placebo-controlled	O
,	,	O
crossover	crossover	O
study	study	O
design	design	O
was	was	O
employed	employed	O
.	.	O

Half	half	O
log	log	O
incremental	incremental	O
doses	doses	O
of	of	O
intravenous	intravenous	O
methoxamine	methoxamine	O
or	or	O
placebo	placebo	O
(	(	O
saline	saline	O
)	)	O
were	were	O
administered	administered	O
to	to	O
a	a	O
group	group	O
of	of	O
women	women	O
with	with	O
genuine	genuine	O
stress	stress	B-Disease
incontinence	incontinence	B-Disease
while	while	O
measuring	measuring	O
maximum	maximum	O
urethral	urethral	O
pressure	pressure	O
(	(	O
MUP	mup	O
)	)	O
,	,	O
blood	blood	O
pressure	pressure	O
,	,	O
heart	heart	O
rate	rate	O
,	,	O
and	and	O
symptomatic	symptomatic	O
side	side	O
effects	effects	O
.	.	O

Methoxamine	methoxamine	O
evoked	evoked	O
non-significant	non-significant	O
increases	increases	O
in	in	O
MUP	mup	O
and	and	O
diastolic	diastolic	O
blood	blood	O
pressure	pressure	O
but	but	O
caused	caused	O
a	a	O
significant	significant	O
rise	rise	O
in	in	O
systolic	systolic	O
blood	blood	O
pressure	pressure	O
and	and	O
significant	significant	O
fall	fall	O
in	in	O
heart	heart	O
rate	rate	O
at	at	O
maximum	maximum	O
dosage	dosage	O
.	.	O

Systemic	systemic	O
side	side	O
effects	effects	O
including	including	O
piloerection	piloerection	O
,	,	O
headache	headache	B-Disease
,	,	O
and	and	O
cold	cold	O
extremities	extremities	O
were	were	O
experienced	experienced	O
in	in	O
all	all	O
subjects	subjects	O
.	.	O

The	the	O
results	results	O
indicate	indicate	O
that	that	O
the	the	O
clinical	clinical	O
usefulness	usefulness	O
of	of	O
direct	direct	O
,	,	O
peripherally	peripherally	O
acting	acting	O
sub-type-selective	sub-type-selective	O
alpha1-adrenoceptor	alpha1-adrenoceptor	O
agonists	agonists	O
in	in	O
the	the	O
medical	medical	O
treatment	treatment	O
of	of	O
stress	stress	B-Disease
incontinence	incontinence	B-Disease
may	may	O
be	be	O
limited	limited	O
by	by	O
associated	associated	O
piloerection	piloerection	O
and	and	O
cardiovascular	cardiovascular	O
side	side	O
effects	effects	O
.	.	O

Hyperglycemic	hyperglycemic	O
effect	effect	O
of	of	O
amino	amino	O
compounds	compounds	O
structurally	structurally	O
related	related	O
to	to	O
caproate	caproate	O
in	in	O
rats	rats	O
.	.	O

The	the	O
chronic	chronic	O
feeding	feeding	O
of	of	O
small	small	O
amounts	amounts	O
(	(	O
0.3	0.3	O
-	-	O
3	3	O
%	%	O
of	of	O
diet	diet	O
weight	weight	O
)	)	O
of	of	O
certain	certain	O
amino	amino	O
derivatives	derivatives	O
of	of	O
caproate	caproate	O
resulted	resulted	O
in	in	O
hyperglycemia	hyperglycemia	O
,	,	O
an	an	O
elevated	elevated	O
glucose	glucose	B-Chemical
tolerance	tolerance	O
curve	curve	O
and	and	O
,	,	O
occasionally	occasionally	O
,	,	O
glucosuria	glucosuria	O
.	.	O

Effective	effective	O
compounds	compounds	O
included	included	O
norleucine	norleucine	O
,	,	O
norvaline	norvaline	O
,	,	O
glutamate	glutamate	B-Chemical
,	,	O
epsilon-aminocaproate	epsilon-aminocaproate	O
,	,	O
methionine	methionine	O
,	,	O
and	and	O
leucine	leucine	O
.	.	O

Toleration	toleration	O
of	of	O
high	high	O
doses	doses	O
of	of	O
angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	B-Chemical
inhibitors	inhibitors	I-Chemical
in	in	O
patients	patients	O
with	with	O
chronic	chronic	O
heart	heart	B-Disease
failure	failure	I-Disease
:	:	O
results	results	O
from	from	O
the	the	O
ATLAS	atlas	O
trial	trial	O
.	.	O

The	the	O
Assessment	assessment	O
of	of	O
Treatment	treatment	O
with	with	O
Lisinopril	lisinopril	O
and	and	O
Survival	survival	O
.	.	O

BACKGROUND	background	O
:	:	O
Treatment	treatment	O
with	with	O
angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	O
(	(	O
ACE	ace	O
)	)	O
inhibitors	inhibitors	O
reduces	reduces	O
mortality	mortality	O
and	and	O
morbidity	morbidity	O
in	in	O
patients	patients	O
with	with	O
chronic	chronic	O
heart	heart	B-Disease
failure	failure	I-Disease
(	(	O
CHF	chf	B-Disease
)	)	O
,	,	O
but	but	O
most	most	O
affected	affected	O
patients	patients	O
are	are	O
not	not	O
receiving	receiving	O
these	these	O
agents	agents	O
or	or	O
are	are	O
being	being	O
treated	treated	O
with	with	O
doses	doses	O
lower	lower	O
than	than	O
those	those	O
found	found	O
to	to	O
be	be	O
efficacious	efficacious	O
in	in	O
trials	trials	O
,	,	O
primarily	primarily	O
because	because	O
of	of	O
concerns	concerns	O
about	about	O
the	the	O
safety	safety	O
and	and	O
tolerability	tolerability	O
of	of	O
these	these	O
agents	agents	O
,	,	O
especially	especially	O
at	at	O
the	the	O
recommended	recommended	O
doses	doses	O
.	.	O

The	the	O
present	present	O
study	study	O
examines	examines	O
the	the	O
safety	safety	O
and	and	O
tolerability	tolerability	O
of	of	O
high-	high-	O
compared	compared	O
with	with	O
low-dose	low-dose	O
lisinopril	lisinopril	O
in	in	O
CHF	chf	B-Disease
.	.	O

METHODS	methods	O
:	:	O
The	the	O
Assessment	assessment	O
of	of	O
Lisinopril	lisinopril	O
and	and	O
Survival	survival	O
study	study	O
was	was	O
a	a	O
multicenter	multicenter	O
,	,	O
randomized	randomized	O
,	,	O
double-blind	double-blind	O
trial	trial	O
in	in	O
which	which	O
patients	patients	O
with	with	O
or	or	O
without	without	O
previous	previous	O
ACE	ace	B-Chemical
inhibitor	inhibitor	I-Chemical
treatment	treatment	O
were	were	O
stabilized	stabilized	O
receiving	receiving	O
medium-dose	medium-dose	O
lisinopril	lisinopril	O
(	(	O
12.5	12.5	O
or	or	O
15.0	15.0	O
mg	mg	O
once	once	O
daily	daily	O
[	[	O
OD	od	O
]	]	O
)	)	O
for	for	O
2	2	O
to	to	O
4	4	O
weeks	weeks	O
and	and	O
then	then	O
randomized	randomized	O
to	to	O
high-	high-	O
(	(	O
35.0	35.0	O
or	or	O
32.5	32.5	O
mg	mg	O
OD	od	O
)	)	O
or	or	O
low-dose	low-dose	O
(	(	O
5.0	5.0	O
or	or	O
2.5	2.5	O
mg	mg	O
OD	od	O
)	)	O
groups	groups	O
.	.	O

Patients	patients	O
with	with	O
New	new	O
York	york	O
Heart	heart	O
Association	association	O
classes	classes	O
II	ii	O
to	to	O
IV	iv	O
CHF	chf	B-Disease
and	and	O
left	left	O
ventricular	ventricular	O
ejection	ejection	O
fractions	fractions	O
of	of	O
no	no	O
greater	greater	O
than	than	O
0.30	0.30	O
(	(	O
n	n	O
=	=	O
3164	3164	O
)	)	O
were	were	O
randomized	randomized	O
and	and	O
followed	followed	O
up	up	O
for	for	O
a	a	O
median	median	O
of	of	O
46	46	O
months	months	O
.	.	O

We	we	O
examined	examined	O
the	the	O
occurrence	occurrence	O
of	of	O
adverse	adverse	O
events	events	O
and	and	O
the	the	O
need	need	O
for	for	O
discontinuation	discontinuation	O
and	and	O
dose	dose	O
reduction	reduction	O
during	during	O
treatment	treatment	O
,	,	O
with	with	O
a	a	O
focus	focus	O
on	on	O
hypotension	hypotension	B-Disease
and	and	O
renal	renal	B-Disease
dysfunction	dysfunction	I-Disease
.	.	O

RESULTS	results	O
:	:	O
Of	of	O
405	405	O
patients	patients	O
not	not	O
previously	previously	O
receiving	receiving	O
an	an	O
ACE	ace	B-Chemical
inhibitor	inhibitor	I-Chemical
,	,	O
doses	doses	O
in	in	O
only	only	O
4.2	4.2	O
%	%	O
could	could	O
not	not	O
be	be	O
titrated	titrated	O
to	to	O
the	the	O
medium	medium	O
doses	doses	O
required	required	O
for	for	O
randomization	randomization	O
because	because	O
of	of	O
symptoms	symptoms	O
possibly	possibly	O
related	related	O
to	to	O
hypotension	hypotension	B-Disease
(	(	O
2.0	2.0	O
%	%	O
)	)	O
or	or	O
because	because	O
of	of	O
renal	renal	B-Disease
dysfunction	dysfunction	I-Disease
or	or	O
hyperkalemia	hyperkalemia	B-Disease
(	(	O
2.3	2.3	O
%	%	O
)	)	O
.	.	O

Doses	doses	O
in	in	O
more	more	O
than	than	O
90	90	O
%	%	O
of	of	O
randomized	randomized	O
patients	patients	O
in	in	O
the	the	O
high-	high-	O
and	and	O
low-dose	low-dose	O
groups	groups	O
were	were	O
titrated	titrated	O
to	to	O
their	their	O
assigned	assigned	O
target	target	O
,	,	O
and	and	O
the	the	O
mean	mean	O
doses	doses	O
of	of	O
blinded	blinded	O
medication	medication	O
in	in	O
both	both	O
groups	groups	O
remained	remained	O
similar	similar	O
throughout	throughout	O
the	the	O
study	study	O
.	.	O

Withdrawals	withdrawals	O
occurred	occurred	O
in	in	O
27.1	27.1	O
%	%	O
of	of	O
the	the	O
high-	high-	O
and	and	O
30.7	30.7	O
%	%	O
of	of	O
the	the	O
low-dose	low-dose	O
groups	groups	O
.	.	O

Subgroups	subgroups	O
presumed	presumed	O
to	to	O
be	be	O
at	at	O
higher	higher	O
risk	risk	O
for	for	O
ACE	ace	B-Chemical
inhibitor	inhibitor	I-Chemical
intolerance	intolerance	O
(	(	O
blood	blood	O
pressure	pressure	O
,	,	O
<	<	O
120	120	O
mm	mm	O
Hg	hg	O
;	;	O
creatinine	creatinine	B-Chemical
,	,	O
>	>	O
or	or	O
=	=	O
132.6	132.6	O
micromol/L	micromol/l	O
[	[	O
>	>	O
or	or	O
=	=	O
1.5	1.5	O
mg/dL	mg/dl	O
]	]	O
;	;	O
age	age	O
,	,	O
>	>	O
or	or	O
=	=	O
70	70	O
years	years	O
;	;	O
and	and	O
patients	patients	O
with	with	O
diabetes	diabetes	B-Disease
)	)	O
generally	generally	O
tolerated	tolerated	O
the	the	O
high-dose	high-dose	O
strategy	strategy	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
These	these	O
findings	findings	O
demonstrate	demonstrate	O
that	that	O
ACE	ace	B-Chemical
inhibitor	inhibitor	I-Chemical
therapy	therapy	O
in	in	O
most	most	O
patients	patients	O
with	with	O
CHF	chf	B-Disease
can	can	O
be	be	O
successfully	successfully	O
titrated	titrated	O
to	to	O
and	and	O
maintained	maintained	O
at	at	O
high	high	O
doses	doses	O
,	,	O
and	and	O
that	that	O
more	more	O
aggressive	aggressive	O
use	use	O
of	of	O
these	these	O
agents	agents	O
is	is	O
warranted	warranted	O
.	.	O

Cocaine	cocaine	B-Chemical
,	,	O
ethanol	ethanol	B-Chemical
,	,	O
and	and	O
cocaethylene	cocaethylene	O
cardiotoxity	cardiotoxity	O
in	in	O
an	an	O
animal	animal	O
model	model	O
of	of	O
cocaine	cocaine	B-Chemical
and	and	O
ethanol	ethanol	B-Chemical
abuse	abuse	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
Simultaneous	simultaneous	O
abuse	abuse	O
of	of	O
cocaine	cocaine	B-Chemical
and	and	O
ethanol	ethanol	B-Chemical
affects	affects	O
12	12	O
million	million	O
Americans	americans	O
annually	annually	O
.	.	O

In	in	O
combination	combination	O
,	,	O
these	these	O
substances	substances	O
are	are	O
substantially	substantially	O
more	more	O
toxic	toxic	O
than	than	O
either	either	O
drug	drug	O
alone	alone	O
.	.	O

Their	their	O
combined	combined	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
may	may	O
be	be	O
due	due	O
to	to	O
independent	independent	O
effects	effects	O
of	of	O
each	each	O
drug	drug	O
;	;	O
however	however	O
,	,	O
they	they	O
may	may	O
also	also	O
be	be	O
due	due	O
to	to	O
cocaethylene	cocaethylene	O
(	(	O
CE	ce	O
)	)	O
,	,	O
a	a	O
cocaine	cocaine	B-Chemical
metabolite	metabolite	O
formed	formed	O
only	only	O
in	in	O
the	the	O
presence	presence	O
of	of	O
ethanol	ethanol	B-Chemical
.	.	O

The	the	O
purpose	purpose	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
delineate	delineate	O
the	the	O
role	role	O
of	of	O
CE	ce	O
in	in	O
the	the	O
combined	combined	O
cardiotoxicity	cardiotoxicity	B-Disease
of	of	O
cocaine	cocaine	B-Chemical
and	and	O
ethanol	ethanol	B-Chemical
in	in	O
a	a	O
model	model	O
simulating	simulating	O
their	their	O
abuse	abuse	O
.	.	O

METHODS	methods	O
:	:	O
Twenty-three	twenty-three	O
dogs	dogs	O
were	were	O
randomized	randomized	O
to	to	O
receive	receive	O
either	either	O
1	1	O
)	)	O
three	three	O
intravenous	intravenous	O
(	(	O
IV	iv	O
)	)	O
boluses	boluses	O
of	of	O
cocaine	cocaine	B-Chemical
7.5	7.5	O
mg/kg	mg/kg	O
with	with	O
ethanol	ethanol	B-Chemical
(	(	O
1	1	O
g/kg	g/kg	O
)	)	O
as	as	O
an	an	O
IV	iv	O
infusion	infusion	O
(	(	O
C+E	c+e	O
,	,	O
n	n	O
=	=	O
8)	8)	O
,	,	O
2	2	O
)	)	O
three	three	O
cocaine	cocaine	B-Chemical
boluses	boluses	O
only	only	O
(	(	O
C	c	O
,	,	O
n	n	O
=	=	O
6	6	O
)	)	O
,	,	O
3	3	O
)	)	O
ethanol	ethanol	B-Chemical
infusion	infusion	O
only	only	O
(	(	O
E	e	O
,	,	O
n	n	O
=	=	O
5	5	O
)	)	O
,	,	O
or	or	O
4	4	O
)	)	O
placebo	placebo	O
boluses	boluses	O
and	and	O
infusion	infusion	O
(	(	O
n	n	O
=	=	O
4	4	O
)	)	O
.	.	O

Hemodynamic	hemodynamic	O
measurements	measurements	O
,	,	O
electrocardiograms	electrocardiograms	O
,	,	O
and	and	O
serum	serum	O
drug	drug	O
concentrations	concentrations	O
were	were	O
obtained	obtained	O
at	at	O
baseline	baseline	O
,	,	O
and	and	O
then	then	O
at	at	O
fixed	fixed	O
time	time	O
intervals	intervals	O
after	after	O
each	each	O
drug	drug	O
was	was	O
administered	administered	O
.	.	O

RESULTS	results	O
:	:	O
Two	two	O
of	of	O
eight	eight	O
dogs	dogs	O
in	in	O
the	the	O
C+E	c+e	O
group	group	O
experienced	experienced	O
cardiovascular	cardiovascular	O
collapse	collapse	O
.	.	O

The	the	O
most	most	O
dramatic	dramatic	O
hemodynamic	hemodynamic	O
changes	changes	O
occurred	occurred	O
after	after	O
each	each	O
cocaine	cocaine	B-Chemical
bolus	bolus	O
in	in	O
the	the	O
C+E	c+e	O
and	and	O
C	c	O
only	only	O
groups	groups	O
;	;	O
however	however	O
,	,	O
persistent	persistent	O
hemodynamic	hemodynamic	O
changes	changes	O
occurred	occurred	O
in	in	O
the	the	O
C+E	c+e	O
group	group	O
.	.	O

Peak	peak	O
CE	ce	O
levels	levels	O
were	were	O
associated	associated	O
with	with	O
a	a	O
45	45	O
%	%	O
(	(	O
SD	sd	O
+	+	O
/-	/-	O
22	22	O
%	%	O
,	,	O
95	95	O
%	%	O
CI	ci	O
=	=	O
22	22	O
%	%	O
to	to	O
69	69	O
%	%	O
)	)	O
decrease	decrease	O
in	in	O
cardiac	cardiac	O
output	output	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
,	,	O
a	a	O
56	56	O
%	%	O
(	(	O
SD	sd	O
+	+	O
/-	/-	O
23	23	O
%	%	O
,	,	O
95	95	O
%	%	O
CI	ci	O
=	=	O
32	32	O
%	%	O
to	to	O
80	80	O
%	%	O
)	)	O
decrease	decrease	O
in	in	O
dP/dt(max	dp/dt(max	O
)	)	O
(	(	O
p	p	O
<	<	O
.006	.006	O
)	)	O
,	,	O
and	and	O
a	a	O
23	23	O
%	%	O
(	(	O
SD	sd	O
+	+	O
/-	/-	O
15	15	O
%	%	O
,	,	O
95	95	O
%	%	O
CI	ci	O
=	=	O
7	7	O
%	%	O
to	to	O
49	49	O
%	%	O
)	)	O
decrease	decrease	O
in	in	O
SVO(2	svo(2	O
)	)	O
(	(	O
p	p	O
<	<	O
0.025	0.025	O
)	)	O
.	.	O

Ventricular	ventricular	B-Disease
arrhythmias	arrhythmias	B-Disease
were	were	O
primarily	primarily	O
observed	observed	O
in	in	O
the	the	O
C+E	c+e	O
group	group	O
,	,	O
in	in	O
which	which	O
four	four	O
of	of	O
eight	eight	O
dogs	dogs	O
experienced	experienced	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Cocaine	cocaine	B-Chemical
and	and	O
ethanol	ethanol	B-Chemical
in	in	O
combination	combination	O
were	were	O
more	more	O
toxic	toxic	O
than	than	O
either	either	O
substance	substance	O
alone	alone	O
.	.	O

Co-administration	co-administration	O
resulted	resulted	O
in	in	O
prolonged	prolonged	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
and	and	O
was	was	O
dysrhythmogenic	dysrhythmogenic	O
.	.	O

Peak	peak	O
serum	serum	O
cocaethylene	cocaethylene	O
concentrations	concentrations	O
were	were	O
associated	associated	O
with	with	O
prolonged	prolonged	O
myocardial	myocardial	O
depression	depression	B-Disease
.	.	O

Worsening	worsening	O
of	of	O
Parkinsonism	parkinsonism	B-Disease
after	after	O
the	the	O
use	use	O
of	of	O
veralipride	veralipride	O
for	for	O
treatment	treatment	O
of	of	O
menopause	menopause	O
:	:	O
case	case	O
report	report	O
.	.	O

We	we	O
describe	describe	O
a	a	O
female	female	O
patient	patient	O
with	with	O
stable	stable	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
who	who	O
has	has	O
shown	shown	O
a	a	O
marked	marked	O
worsening	worsening	O
of	of	O
her	her	O
motor	motor	O
functions	functions	O
following	following	O
therapy	therapy	O
of	of	O
menopause	menopause	O
related	related	O
symptoms	symptoms	O
with	with	O
veralipride	veralipride	O
,	,	O
as	as	O
well	well	O
as	as	O
the	the	O
improvement	improvement	O
of	of	O
her	her	O
symptoms	symptoms	O
back	back	O
to	to	O
baseline	baseline	O
after	after	O
discontinuation	discontinuation	O
of	of	O
the	the	O
drug	drug	O
.	.	O

We	we	O
emphasize	emphasize	O
the	the	O
anti-dopaminergic	anti-dopaminergic	O
effect	effect	O
of	of	O
veralipride	veralipride	O
.	.	O

Viracept	viracept	O
and	and	O
irregular	irregular	O
heartbeat	heartbeat	O
warning	warning	O
.	.	O

A	a	O
group	group	O
of	of	O
doctors	doctors	O
in	in	O
Boston	boston	O
warn	warn	O
that	that	O
the	the	O
protease	protease	B-Chemical
inhibitor	inhibitor	I-Chemical
Viracept	viracept	O
may	may	O
cause	cause	O
an	an	O
irregular	irregular	O
heart	heart	O
beat	beat	O
,	,	O
known	known	O
as	as	O
bradycardia	bradycardia	B-Disease
,	,	O
in	in	O
people	people	O
with	with	O
HIV	hiv	O
.	.	O

Bradycardia	bradycardia	B-Disease
occurred	occurred	O
in	in	O
a	a	O
45-year-old	45-year-old	O
male	male	O
patient	patient	O
who	who	O
was	was	O
Viracept	viracept	O
in	in	O
combination	combination	O
with	with	O
other	other	O
anti-HIV	anti-hiv	O
drugs	drugs	O
.	.	O

The	the	O
symptoms	symptoms	O
ceased	ceased	O
after	after	O
switching	switching	O
to	to	O
another	another	O
drug	drug	O
combination	combination	O
.	.	O

Frequency	frequency	O
of	of	O
appearance	appearance	O
of	of	O
myeloperoxidase-antineutrophil	myeloperoxidase-antineutrophil	O
cytoplasmic	cytoplasmic	O
antibody	antibody	O
(	(	O
MPO-ANCA	mpo-anca	O
)	)	O
in	in	O
Graves	graves	B-Disease
'	'	I-Disease
disease	disease	I-Disease
patients	patients	O
treated	treated	O
with	with	O
propylthiouracil	propylthiouracil	B-Chemical
and	and	O
the	the	O
relationship	relationship	O
between	between	O
MPO-ANCA	mpo-anca	O
and	and	O
clinical	clinical	O
manifestations	manifestations	O
.	.	O

OBJECTIVE	objective	O
:	:	O
Myeloperoxidase	myeloperoxidase	O
antineutrophil	antineutrophil	O
cytoplasmic	cytoplasmic	O
antibody	antibody	O
(MPO-ANCA)-positive	(mpo-anca)-positive	O
vasculitis	vasculitis	B-Disease
has	has	O
been	been	O
reported	reported	O
in	in	O
patients	patients	O
with	with	O
Graves	graves	B-Disease
'	'	I-Disease
disease	disease	I-Disease
who	who	O
were	were	O
treated	treated	O
with	with	O
propylthiouracil	propylthiouracil	B-Chemical
(	(	O
PTU	ptu	O
)	)	O
.	.	O

The	the	O
appearance	appearance	O
of	of	O
MPO-ANCA	mpo-anca	O
in	in	O
these	these	O
cases	cases	O
was	was	O
suspected	suspected	O
of	of	O
being	being	O
related	related	O
to	to	O
PTU	ptu	O
because	because	O
the	the	O
titres	titres	O
of	of	O
MPO-ANCA	mpo-anca	O
decreased	decreased	O
when	when	O
PTU	ptu	O
was	was	O
stopped	stopped	O
.	.	O

Nevertheless	nevertheless	O
,	,	O
there	there	O
have	have	O
been	been	O
no	no	O
studies	studies	O
on	on	O
the	the	O
temporal	temporal	O
relationship	relationship	O
between	between	O
the	the	O
appearance	appearance	O
of	of	O
MPO-ANCA	mpo-anca	O
and	and	O
vasculitis	vasculitis	B-Disease
during	during	O
PTU	ptu	O
therapy	therapy	O
,	,	O
or	or	O
on	on	O
the	the	O
incidence	incidence	O
of	of	O
MPO-ANCA	mpo-anca	O
in	in	O
untreated	untreated	O
Graves	graves	B-Disease
'	'	I-Disease
disease	disease	I-Disease
patients	patients	O
.	.	O

Therefore	therefore	O
,	,	O
we	we	O
sought	sought	O
to	to	O
address	address	O
these	these	O
parameters	parameters	O
in	in	O
patients	patients	O
with	with	O
Graves	graves	B-Disease
'	'	I-Disease
disease	disease	I-Disease
.	.	O

PATIENTS	patients	O
:	:	O
We	we	O
investigated	investigated	O
102	102	O
untreated	untreated	O
patients	patients	O
with	with	O
hyperthyroidism	hyperthyroidism	B-Disease
due	due	O
to	to	O
Graves	graves	B-Disease
'	'	I-Disease
disease	disease	I-Disease
for	for	O
the	the	O
presence	presence	O
of	of	O
MPO-ANCA	mpo-anca	O
,	,	O
and	and	O
for	for	O
the	the	O
development	development	O
vasculitis	vasculitis	B-Disease
after	after	O
starting	starting	O
PTU	ptu	O
therapy	therapy	O
.	.	O

Twenty-nine	twenty-nine	O
of	of	O
them	them	O
were	were	O
later	later	O
excluded	excluded	O
because	because	O
of	of	O
adverse	adverse	O
effects	effects	O
of	of	O
PTU	ptu	O
or	or	O
because	because	O
the	the	O
observation	observation	O
period	period	O
was	was	O
less	less	O
than	than	O
3	3	O
months	months	O
.	.	O

The	the	O
remaining	remaining	O
73	73	O
patients	patients	O
(	(	O
55	55	O
women	women	O
and	and	O
18	18	O
men	men	O
)	)	O
,	,	O
all	all	O
of	of	O
whom	whom	O
were	were	O
examined	examined	O
for	for	O
more	more	O
than	than	O
3	3	O
months	months	O
,	,	O
were	were	O
adopted	adopted	O
as	as	O
the	the	O
subjects	subjects	O
of	of	O
the	the	O
investigation	investigation	O
.	.	O

The	the	O
median	median	O
observation	observation	O
period	period	O
was	was	O
23.6	23.6	O
months	months	O
(	(	O
range	range	O
:	:	O
3	3	O
-	-	O
37	37	O
months	months	O
)	)	O
.	.	O

MEASUREMENTS	measurements	O
:	:	O
MPO-ANCA	mpo-anca	O
was	was	O
measured	measured	O
at	at	O
intervals	intervals	O
of	of	O
2	2	O
-	-	O
6	6	O
months	months	O
.	.	O

RESULTS	results	O
:	:	O
Before	before	O
treatment	treatment	O
,	,	O
the	the	O
MPO-ANCA	mpo-anca	O
titres	titres	O
of	of	O
all	all	O
102	102	O
untreated	untreated	O
Graves	graves	B-Disease
'	'	I-Disease
disease	disease	I-Disease
patients	patients	O
were	were	O
within	within	O
the	the	O
reference	reference	O
range	range	O
(	(	O
below	below	O
10	10	O
U/ml	u/ml	O
)	)	O
.	.	O

Three	three	O
(	(	O
4.1	4.1	O
%	%	O
)	)	O
of	of	O
the	the	O
73	73	O
patients	patients	O
were	were	O
positive	positive	O
for	for	O
MPO-ANCA	mpo-anca	O
at	at	O
13	13	O
,	,	O
16	16	O
and	and	O
17	17	O
months	months	O
,	,	O
respectively	respectively	O
,	,	O
after	after	O
the	the	O
start	start	O
of	of	O
PTU	ptu	O
therapy	therapy	O
.	.	O

In	in	O
two	two	O
of	of	O
them	them	O
,	,	O
the	the	O
MPO-ANCA	mpo-anca	O
titres	titres	O
transiently	transiently	O
increased	increased	O
to	to	O
12.8	12.8	O
and	and	O
15.0	15.0	O
U/ml	u/ml	O
,	,	O
respectively	respectively	O
,	,	O
despite	despite	O
continued	continued	O
PTU	ptu	O
therapy	therapy	O
,	,	O
but	but	O
no	no	O
vasculitic	vasculitic	O
disorders	disorders	O
developed	developed	O
.	.	O

In	in	O
the	the	O
third	third	O
patient	patient	O
,	,	O
the	the	O
MPO-ANCA	mpo-anca	O
titre	titre	O
increased	increased	O
to	to	O
204	204	O
U/ml	u/ml	O
and	and	O
she	she	O
developed	developed	O
a	a	O
higher	higher	O
fever	fever	B-Disease
,	,	O
oral	oral	O
ulcers	ulcers	O
and	and	O
polyarthralgia	polyarthralgia	O
,	,	O
but	but	O
the	the	O
symptoms	symptoms	O
resolved	resolved	O
2	2	O
weeks	weeks	O
after	after	O
stopping	stopping	O
PTU	ptu	O
therapy	therapy	O
,	,	O
and	and	O
the	the	O
MPO-ANCA	mpo-anca	O
titre	titre	O
decreased	decreased	O
to	to	O
20.7	20.7	O
U/ml	u/ml	O
by	by	O
4	4	O
months	months	O
after	after	O
discontinuing	discontinuing	O
PTU	ptu	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
PTU	ptu	O
therapy	therapy	O
may	may	O
be	be	O
related	related	O
to	to	O
the	the	O
appearance	appearance	O
of	of	O
MPO-ANCA	mpo-anca	O
,	,	O
but	but	O
MPO-ANCA	mpo-anca	O
does	does	O
not	not	O
appear	appear	O
to	to	O
be	be	O
closely	closely	O
related	related	O
to	to	O
vasculitis	vasculitis	B-Disease
.	.	O

Prevalence	prevalence	O
of	of	O
heart	heart	B-Disease
disease	disease	I-Disease
in	in	O
asymptomatic	asymptomatic	O
chronic	chronic	O
cocaine	cocaine	B-Chemical
users	users	O
.	.	O

To	to	O
determine	determine	O
the	the	O
prevalence	prevalence	O
of	of	O
heart	heart	B-Disease
disease	disease	I-Disease
in	in	O
outpatient	outpatient	O
young	young	O
asymptomatic	asymptomatic	O
chronic	chronic	O
cocaine	cocaine	B-Chemical
users	users	O
,	,	O
35	35	O
cocaine	cocaine	B-Chemical
users	users	O
and	and	O
32	32	O
age-matched	age-matched	O
controls	controls	O
underwent	underwent	O
resting	resting	O
and	and	O
exercise	exercise	O
electrocardiography	electrocardiography	O
(	(	O
ECG	ecg	O
)	)	O
and	and	O
Doppler	doppler	O
echocardiography	echocardiography	O
.	.	O

Findings	findings	O
consistent	consistent	O
with	with	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
were	were	O
detected	detected	O
in	in	O
12	12	O
(	(	O
34	34	O
%	%	O
)	)	O
patients	patients	O
and	and	O
3	3	O
(	(	O
9	9	O
%	%	O
)	)	O
controls	controls	O
(	(	O
p	p	O
=	=	O
0.01	0.01	O
)	)	O
.	.	O

Decreased	decreased	O
left	left	O
ventricular	ventricular	O
systolic	systolic	O
function	function	O
was	was	O
demonstrated	demonstrated	O
in	in	O
5	5	O
(	(	O
14	14	O
%	%	O
)	)	O
patients	patients	O
,	,	O
but	but	O
in	in	O
none	none	O
of	of	O
the	the	O
controls	controls	O
(	(	O
p	p	O
=	=	O
0.055	0.055	O
)	)	O
.	.	O

Finally	finally	O
,	,	O
resting	resting	O
and	and	O
peak	peak	O
exercise	exercise	O
abnormal	abnormal	O
left	left	O
ventricular	ventricular	O
filling	filling	O
was	was	O
detected	detected	O
in	in	O
38	38	O
and	and	O
35	35	O
%	%	O
of	of	O
patients	patients	O
as	as	O
compared	compared	O
to	to	O
19	19	O
and	and	O
9	9	O
%	%	O
of	of	O
controls	controls	O
,	,	O
respectively	respectively	O
(	(	O
p	p	O
=	=	O
0.11	0.11	O
and	and	O
0.02	0.02	O
,	,	O
respectively	respectively	O
)	)	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
coronary	coronary	O
artery	artery	O
or	or	O
myocardial	myocardial	O
disease	disease	O
is	is	O
common	common	O
(	(	O
38	38	O
%	%	O
)	)	O
in	in	O
young	young	O
asymptomatic	asymptomatic	O
chronic	chronic	O
cocaine	cocaine	B-Chemical
users	users	O
.	.	O

Therefore	therefore	O
,	,	O
screening	screening	O
ECG	ecg	O
and	and	O
echocardiography	echocardiography	O
may	may	O
be	be	O
warranted	warranted	O
in	in	O
these	these	O
patients	patients	O
.	.	O

Cardioprotective	cardioprotective	O
effects	effects	O
of	of	O
Picrorrhiza	picrorrhiza	O
kurroa	kurroa	O
against	against	O
isoproterenol-induced	isoproterenol-induced	O
myocardial	myocardial	O
stress	stress	O
in	in	O
rats	rats	O
.	.	O

The	the	O
cardioprotective	cardioprotective	O
effect	effect	O
of	of	O
the	the	O
ethanol	ethanol	B-Chemical
extract	extract	O
of	of	O
Picrorrhiza	picrorrhiza	O
kurroa	kurroa	O
rhizomes	rhizomes	O
and	and	O
roots	roots	O
(	(	O
PK	pk	O
)	)	O
on	on	O
isoproterenol-induced	isoproterenol-induced	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
in	in	O
rats	rats	O
with	with	O
respect	respect	O
to	to	O
lipid	lipid	O
metabolism	metabolism	O
in	in	O
serum	serum	O
and	and	O
heart	heart	O
tissue	tissue	O
has	has	O
been	been	O
investigated	investigated	O
.	.	O

Oral	oral	O
pre-treatment	pre-treatment	O
with	with	O
PK	pk	O
(	(	O
80	80	O
mg	mg	O
kg(-1	kg(-1	O
)	)	O
day(-1	day(-1	O
)	)	O
for	for	O
15	15	O
days	days	O
)	)	O
significantly	significantly	O
prevented	prevented	O
the	the	O
isoproterenol-induced	isoproterenol-induced	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
and	and	O
maintained	maintained	O
the	the	O
rats	rats	O
at	at	O
near	near	O
normal	normal	O
status	status	O
.	.	O

Phase	phase	O
2	2	O
early	early	O
afterdepolarization	afterdepolarization	O
as	as	O
a	a	O
trigger	trigger	O
of	of	O
polymorphic	polymorphic	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
in	in	O
acquired	acquired	O
long-QT	long-qt	O
syndrome	syndrome	O
:	:	O
direct	direct	O
evidence	evidence	O
from	from	O
intracellular	intracellular	O
recordings	recordings	O
in	in	O
the	the	O
intact	intact	O
left	left	O
ventricular	ventricular	O
wall	wall	O
.	.	O

BACKGROUND	background	O
:	:	O
This	this	O
study	study	O
examined	examined	O
the	the	O
role	role	O
of	of	O
phase	phase	O
2	2	O
early	early	O
afterdepolarization	afterdepolarization	O
(	(	O
EAD	ead	O
)	)	O
in	in	O
producing	producing	O
a	a	O
trigger	trigger	O
to	to	O
initiate	initiate	O
torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
(	(	O
TdP	tdp	B-Disease
)	)	O
with	with	O
QT	qt	O
prolongation	prolongation	O
induced	induced	O
by	by	O
dl-sotalol	dl-sotalol	O
and	and	O
azimilide	azimilide	O
.	.	O

The	the	O
contribution	contribution	O
of	of	O
transmural	transmural	O
dispersion	dispersion	O
of	of	O
repolarization	repolarization	O
(	(	O
TDR	tdr	O
)	)	O
to	to	O
transmural	transmural	O
propagation	propagation	O
of	of	O
EAD	ead	O
and	and	O
the	the	O
maintenance	maintenance	O
of	of	O
TdP	tdp	B-Disease
was	was	O
also	also	O
evaluated	evaluated	O
.	.	O

METHODS	methods	O
AND	and	O
RESULTS	results	O
:	:	O
Transmembrane	transmembrane	O
action	action	O
potentials	potentials	O
from	from	O
epicardium	epicardium	O
,	,	O
midmyocardium	midmyocardium	O
,	,	O
and	and	O
endocardium	endocardium	O
were	were	O
recorded	recorded	O
simultaneously	simultaneously	O
,	,	O
together	together	O
with	with	O
a	a	O
transmural	transmural	O
ECG	ecg	O
,	,	O
in	in	O
arterially	arterially	O
perfused	perfused	O
canine	canine	O
and	and	O
rabbit	rabbit	O
left	left	O
ventricular	ventricular	O
preparations	preparations	O
.	.	O

dl-Sotalol	dl-sotalol	O
preferentially	preferentially	O
prolonged	prolonged	O
action	action	O
potential	potential	O
duration	duration	O
(	(	O
APD	apd	O
)	)	O
in	in	O
M	m	O
cells	cells	O
dose-dependently	dose-dependently	O
(	(	O
1	1	O
to	to	O
100	100	O
micromol/L	micromol/l	O
)	)	O
,	,	O
leading	leading	O
to	to	O
QT	qt	O
prolongation	prolongation	O
and	and	O
an	an	O
increase	increase	O
in	in	O
TDR	tdr	O
.	.	O

Azimilide	azimilide	O
,	,	O
however	however	O
,	,	O
significantly	significantly	O
prolonged	prolonged	O
APD	apd	O
and	and	O
QT	qt	O
interval	interval	O
at	at	O
concentrations	concentrations	O
from	from	O
0.1	0.1	O
to	to	O
10	10	O
micromol/L	micromol/l	O
but	but	O
shortened	shortened	O
them	them	O
at	at	O
30	30	O
micromol/L.	micromol/l.	O
Unlike	unlike	O
dl-sotalol	dl-sotalol	O
,	,	O
azimilide	azimilide	O
(	(	O
>	>	O
3	3	O
micromol/L	micromol/l	O
)	)	O
increased	increased	O
epicardial	epicardial	O
APD	apd	O
markedly	markedly	O
,	,	O
causing	causing	O
a	a	O
diminished	diminished	O
TDR	tdr	O
.	.	O

Although	although	O
both	both	O
dl-sotalol	dl-sotalol	O
and	and	O
azimilide	azimilide	O
rarely	rarely	O
induced	induced	O
EADs	eads	O
in	in	O
canine	canine	O
left	left	O
ventricles	ventricles	O
,	,	O
they	they	O
produced	produced	O
frequent	frequent	O
EADs	eads	O
in	in	O
rabbits	rabbits	O
,	,	O
in	in	O
which	which	O
more	more	O
pronounced	pronounced	O
QT	qt	O
prolongation	prolongation	O
was	was	O
seen	seen	O
.	.	O

An	an	O
increase	increase	O
in	in	O
TDR	tdr	O
by	by	O
dl-sotalol	dl-sotalol	O
facilitated	facilitated	O
transmural	transmural	O
propagation	propagation	O
of	of	O
EADs	eads	O
that	that	O
initiated	initiated	O
multiple	multiple	O
episodes	episodes	O
of	of	O
spontaneous	spontaneous	O
TdP	tdp	B-Disease
in	in	O
3	3	O
of	of	O
6	6	O
rabbit	rabbit	O
left	left	O
ventricles	ventricles	O
.	.	O

Of	of	O
note	note	O
,	,	O
although	although	O
azimilide	azimilide	O
(	(	O
3	3	O
to	to	O
10	10	O
micromol/L	micromol/l	O
)	)	O
increased	increased	O
APD	apd	O
more	more	O
than	than	O
dl-sotalol	dl-sotalol	O
,	,	O
its	its	O
EADs	eads	O
often	often	O
failed	failed	O
to	to	O
propagate	propagate	O
transmurally	transmurally	O
,	,	O
probably	probably	O
because	because	O
of	of	O
a	a	O
diminished	diminished	O
TDR	tdr	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
This	this	O
study	study	O
provides	provides	O
the	the	O
first	first	O
direct	direct	O
evidence	evidence	O
from	from	O
intracellular	intracellular	O
action	action	O
potential	potential	O
recordings	recordings	O
that	that	O
phase	phase	O
2	2	O
EAD	ead	O
can	can	O
be	be	O
generated	generated	O
from	from	O
intact	intact	O
ventricular	ventricular	O
wall	wall	O
and	and	O
produce	produce	O
a	a	O
trigger	trigger	O
to	to	O
initiate	initiate	O
the	the	O
onset	onset	O
of	of	O
TdP	tdp	B-Disease
under	under	O
QT	qt	O
prolongation	prolongation	O
.	.	O

A	a	O
pilot	pilot	O
study	study	O
to	to	O
assess	assess	O
the	the	O
safety	safety	O
of	of	O
dobutamine	dobutamine	B-Chemical
stress	stress	O
echocardiography	echocardiography	O
in	in	O
the	the	O
emergency	emergency	O
department	department	O
evaluation	evaluation	O
of	of	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
.	.	O

STUDY	study	O
OBJECTIVE	objective	O
:	:	O
Chest	chest	B-Disease
pain	pain	B-Disease
in	in	O
the	the	O
setting	setting	O
of	of	O
cocaine	cocaine	B-Chemical
use	use	O
poses	poses	O
a	a	O
diagnostic	diagnostic	O
dilemma	dilemma	O
.	.	O

Dobutamine	dobutamine	B-Chemical
stress	stress	O
echocardiography	echocardiography	O
(	(	O
DSE	dse	O
)	)	O
is	is	O
a	a	O
widely	widely	O
available	available	O
and	and	O
sensitive	sensitive	O
test	test	O
for	for	O
evaluating	evaluating	O
cardiac	cardiac	O
ischemia	ischemia	B-Disease
.	.	O

Because	because	O
of	of	O
the	the	O
theoretical	theoretical	O
concern	concern	O
regarding	regarding	O
administration	administration	O
of	of	O
dobutamine	dobutamine	B-Chemical
in	in	O
the	the	O
setting	setting	O
of	of	O
cocaine	cocaine	B-Chemical
use	use	O
,	,	O
we	we	O
conducted	conducted	O
a	a	O
pilot	pilot	O
study	study	O
to	to	O
assess	assess	O
the	the	O
safety	safety	O
of	of	O
DSE	dse	O
in	in	O
emergency	emergency	O
department	department	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
.	.	O

METHODS	methods	O
:	:	O
A	a	O
prospective	prospective	O
case	case	O
series	series	O
was	was	O
conducted	conducted	O
in	in	O
the	the	O
intensive	intensive	O
diagnostic	diagnostic	O
and	and	O
treatment	treatment	O
unit	unit	O
in	in	O
the	the	O
ED	ed	O
of	of	O
an	an	O
urban	urban	O
tertiary-care	tertiary-care	O
teaching	teaching	O
hospital	hospital	O
.	.	O

Patients	patients	O
were	were	O
eligible	eligible	O
for	for	O
DSE	dse	O
if	if	O
they	they	O
had	had	O
used	used	O
cocaine	cocaine	B-Chemical
within	within	O
24	24	O
hours	hours	O
preceding	preceding	O
the	the	O
onset	onset	O
of	of	O
chest	chest	B-Disease
pain	pain	B-Disease
and	and	O
had	had	O
a	a	O
normal	normal	O
ECG	ecg	O
and	and	O
tropinin	tropinin	O
I	i	O
level	level	O
.	.	O

Patients	patients	O
exhibiting	exhibiting	O
signs	signs	O
of	of	O
continuing	continuing	O
cocaine	cocaine	B-Chemical
toxicity	toxicity	B-Disease
were	were	O
excluded	excluded	O
from	from	O
the	the	O
study	study	O
.	.	O

All	all	O
patients	patients	O
were	were	O
admitted	admitted	O
to	to	O
the	the	O
hospital	hospital	O
for	for	O
serial	serial	O
testing	testing	O
after	after	O
the	the	O
DSE	dse	O
testing	testing	O
in	in	O
the	the	O
intensive	intensive	O
diagnostic	diagnostic	O
and	and	O
treatment	treatment	O
unit	unit	O
.	.	O

RESULTS	results	O
:	:	O
Twenty-four	twenty-four	O
patients	patients	O
were	were	O
enrolled	enrolled	O
.	.	O

Two	two	O
patients	patients	O
had	had	O
inadequate	inadequate	O
resting	resting	O
images	images	O
,	,	O
one	one	O
DSE	dse	O
was	was	O
terminated	terminated	O
because	because	O
of	of	O
inferior	inferior	O
hypokinesis	hypokinesis	O
,	,	O
another	another	O
DSE	dse	O
was	was	O
terminated	terminated	O
because	because	O
of	of	O
a	a	O
rate-related	rate-related	O
atrial	atrial	O
conduction	conduction	O
deficit	deficit	O
,	,	O
and	and	O
1	1	O
patient	patient	O
did	did	O
not	not	O
reach	reach	O
the	the	O
target	target	O
heart	heart	O
rate	rate	O
.	.	O

Thus	thus	O
,	,	O
19	19	O
patients	patients	O
completed	completed	O
a	a	O
DSE	dse	O
and	and	O
reached	reached	O
their	their	O
target	target	O
heart	heart	O
rates	rates	O
.	.	O

None	none	O
of	of	O
the	the	O
patients	patients	O
experienced	experienced	O
signs	signs	O
of	of	O
exaggerated	exaggerated	O
adrenergic	adrenergic	O
response	response	O
,	,	O
which	which	O
was	was	O
defined	defined	O
as	as	O
a	a	O
systolic	systolic	O
blood	blood	O
pressure	pressure	O
of	of	O
greater	greater	O
than	than	O
200	200	O
mm	mm	O
Hg	hg	O
or	or	O
the	the	O
occurrence	occurrence	O
of	of	O
tachydysrhythmias	tachydysrhythmias	O
(	(	O
excluding	excluding	O
sinus	sinus	O
tachycardia	tachycardia	B-Disease
)	)	O
.	.	O

Further	further	O
suggesting	suggesting	O
lack	lack	O
of	of	O
exaggerated	exaggerated	O
adrenergic	adrenergic	O
response	response	O
,	,	O
13	13	O
(	(	O
65	65	O
%	%	O
)	)	O
of	of	O
20	20	O
patients	patients	O
required	required	O
supplemental	supplemental	O
atropine	atropine	B-Chemical
to	to	O
reach	reach	O
their	their	O
target	target	O
heart	heart	O
rates	rates	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
No	no	O
exaggerated	exaggerated	O
adrenergic	adrenergic	O
response	response	O
was	was	O
detected	detected	O
when	when	O
dobutamine	dobutamine	B-Chemical
was	was	O
administered	administered	O
to	to	O
patients	patients	O
with	with	O
cocaine-related	cocaine-related	O
chest	chest	B-Disease
pain	pain	B-Disease
.	.	O

Prenatal	prenatal	O
cocaine	cocaine	B-Chemical
exposure	exposure	O
and	and	O
cranial	cranial	O
sonographic	sonographic	O
findings	findings	O
in	in	O
preterm	preterm	O
infants	infants	O
.	.	O

PURPOSE	purpose	O
:	:	O
Prenatal	prenatal	O
cocaine	cocaine	B-Chemical
exposure	exposure	O
has	has	O
been	been	O
linked	linked	O
with	with	O
subependymal	subependymal	O
hemorrhage	hemorrhage	B-Disease
and	and	O
the	the	O
formation	formation	O
of	of	O
cysts	cysts	O
that	that	O
are	are	O
detectable	detectable	O
on	on	O
cranial	cranial	O
sonography	sonography	O
in	in	O
neonates	neonates	O
born	born	O
at	at	O
term	term	O
.	.	O

We	we	O
sought	sought	O
to	to	O
determine	determine	O
if	if	O
prenatal	prenatal	O
cocaine	cocaine	B-Chemical
exposure	exposure	O
increases	increases	O
the	the	O
incidence	incidence	O
of	of	O
subependymal	subependymal	O
cysts	cysts	O
in	in	O
preterm	preterm	O
infants	infants	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
retrospectively	retrospectively	O
reviewed	reviewed	O
the	the	O
medical	medical	O
records	records	O
and	and	O
cranial	cranial	O
sonograms	sonograms	O
obtained	obtained	O
during	during	O
a	a	O
1-year	1-year	O
period	period	O
on	on	O
122	122	O
premature	premature	O
(	(	O
<	<	O
36	36	O
weeks	weeks	O
of	of	O
gestation	gestation	O
)	)	O
infants	infants	O
.	.	O

Infants	infants	O
were	were	O
categorized	categorized	O
into	into	O
1	1	O
of	of	O
2	2	O
groups	groups	O
:	:	O
those	those	O
exposed	exposed	O
to	to	O
cocaine	cocaine	B-Chemical
and	and	O
those	those	O
not	not	O
exposed	exposed	O
to	to	O
cocaine	cocaine	B-Chemical
.	.	O

Infants	infants	O
were	were	O
assigned	assigned	O
to	to	O
the	the	O
cocaine-exposed	cocaine-exposed	O
group	group	O
if	if	O
there	there	O
was	was	O
a	a	O
maternal	maternal	O
history	history	O
of	of	O
cocaine	cocaine	B-Chemical
abuse	abuse	I-Disease
during	during	O
pregnancy	pregnancy	O
or	or	O
if	if	O
maternal	maternal	O
or	or	O
neonatal	neonatal	O
urine	urine	O
toxicology	toxicology	O
results	results	O
were	were	O
positive	positive	O
at	at	O
the	the	O
time	time	O
of	of	O
delivery	delivery	O
.	.	O

RESULTS	results	O
:	:	O
Five	five	O
of	of	O
the	the	O
122	122	O
infants	infants	O
were	were	O
excluded	excluded	O
from	from	O
the	the	O
study	study	O
because	because	O
of	of	O
insufficient	insufficient	O
medical	medical	O
and	and	O
drug	drug	O
histories	histories	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
subependymal	subependymal	O
cysts	cysts	O
in	in	O
the	the	O
117	117	O
remaining	remaining	O
infants	infants	O
was	was	O
14	14	O
%	%	O
(	(	O
16	16	O
of	of	O
117	117	O
)	)	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
subependymal	subependymal	O
cysts	cysts	O
in	in	O
infants	infants	O
exposed	exposed	O
to	to	O
cocaine	cocaine	B-Chemical
prenatally	prenatally	O
was	was	O
44	44	O
%	%	O
(	(	O
8	8	O
of	of	O
18	18	O
)	)	O
compared	compared	O
with	with	O
8	8	O
%	%	O
(	(	O
8	8	O
of	of	O
99	99	O
)	)	O
in	in	O
the	the	O
unexposed	unexposed	O
group	group	O
(	(	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
We	we	O
found	found	O
an	an	O
increased	increased	O
incidence	incidence	O
of	of	O
subependymal	subependymal	O
cyst	cyst	O
formation	formation	O
in	in	O
preterm	preterm	O
infants	infants	O
who	who	O
were	were	O
exposed	exposed	O
to	to	O
cocaine	cocaine	B-Chemical
prenatally	prenatally	O
.	.	O

This	this	O
result	result	O
is	is	O
consistent	consistent	O
with	with	O
results	results	O
of	of	O
similar	similar	O
studies	studies	O
in	in	O
term	term	O
infants	infants	O
.	.	O

Thalidomide	thalidomide	B-Chemical
neuropathy	neuropathy	B-Disease
in	in	O
patients	patients	O
treated	treated	O
for	for	O
metastatic	metastatic	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
.	.	O

We	we	O
prospectively	prospectively	O
evaluated	evaluated	O
thalidomide-induced	thalidomide-induced	O
neuropathy	neuropathy	B-Disease
using	using	O
electrodiagnostic	electrodiagnostic	O
studies	studies	O
.	.	O

Sixty-seven	sixty-seven	O
men	men	O
with	with	O
metastatic	metastatic	O
androgen-independent	androgen-independent	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
in	in	O
an	an	O
open-label	open-label	O
trial	trial	O
of	of	O
oral	oral	O
thalidomide	thalidomide	B-Chemical
underwent	underwent	O
neurologic	neurologic	O
examinations	examinations	O
and	and	O
nerve	nerve	O
conduction	conduction	O
studies	studies	O
(	(	O
NCS	ncs	O
)	)	O
prior	prior	O
to	to	O
and	and	O
at	at	O
3-month	3-month	O
intervals	intervals	O
during	during	O
treatment	treatment	O
.	.	O

NCS	ncs	O
included	included	O
recording	recording	O
of	of	O
sensory	sensory	O
nerve	nerve	O
action	action	O
potentials	potentials	O
(	(	O
SNAPs	snaps	O
)	)	O
from	from	O
median	median	O
,	,	O
radial	radial	O
,	,	O
ulnar	ulnar	O
,	,	O
and	and	O
sural	sural	O
nerves	nerves	O
.	.	O

SNAP	snap	O
amplitudes	amplitudes	O
for	for	O
each	each	O
nerve	nerve	O
were	were	O
expressed	expressed	O
as	as	O
the	the	O
percentage	percentage	O
of	of	O
its	its	O
baseline	baseline	O
,	,	O
and	and	O
the	the	O
mean	mean	O
of	of	O
the	the	O
four	four	O
was	was	O
termed	termed	O
the	the	O
SNAP	snap	O
index	index	O
.	.	O

A	a	O
40	40	O
%	%	O
decline	decline	O
in	in	O
the	the	O
SNAP	snap	O
index	index	O
was	was	O
considered	considered	O
clinically	clinically	O
significant	significant	O
.	.	O

Thalidomide	thalidomide	B-Chemical
was	was	O
discontinued	discontinued	O
in	in	O
55	55	O
patients	patients	O
for	for	O
lack	lack	O
of	of	O
therapeutic	therapeutic	O
response	response	O
.	.	O

Of	of	O
67	67	O
patients	patients	O
initially	initially	O
enrolled	enrolled	O
,	,	O
24	24	O
remained	remained	O
on	on	O
thalidomide	thalidomide	B-Chemical
for	for	O
3	3	O
months	months	O
,	,	O
8	8	O
remained	remained	O
at	at	O
6	6	O
months	months	O
,	,	O
and	and	O
3	3	O
remained	remained	O
at	at	O
9	9	O
months	months	O
.	.	O

Six	six	O
patients	patients	O
developed	developed	O
neuropathy	neuropathy	B-Disease
.	.	O

Clinical	clinical	O
symptoms	symptoms	O
and	and	O
a	a	O
decline	decline	O
in	in	O
the	the	O
SNAP	snap	O
index	index	O
occurred	occurred	O
concurrently	concurrently	O
.	.	O

Older	older	O
age	age	O
and	and	O
cumulative	cumulative	O
dose	dose	O
were	were	O
possible	possible	O
contributing	contributing	O
factors	factors	O
.	.	O

Neuropathy	neuropathy	B-Disease
may	may	O
thus	thus	O
be	be	O
a	a	O
common	common	O
complication	complication	O
of	of	O
thalidomide	thalidomide	B-Chemical
in	in	O
older	older	O
patients	patients	O
.	.	O

The	the	O
SNAP	snap	O
index	index	O
can	can	O
be	be	O
used	used	O
to	to	O
monitor	monitor	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
,	,	O
but	but	O
not	not	O
for	for	O
early	early	O
detection	detection	O
.	.	O

Overexpression	overexpression	O
of	of	O
copper/zinc-superoxide	copper/zinc-superoxide	O
dismutase	dismutase	O
protects	protects	O
from	from	O
kanamycin-induced	kanamycin-induced	O
hearing	hearing	B-Disease
loss	loss	I-Disease
.	.	O

The	the	O
participation	participation	O
of	of	O
reactive	reactive	B-Chemical
oxygen	oxygen	B-Chemical
species	species	I-Chemical
in	in	O
aminoglycoside-induced	aminoglycoside-induced	O
ototoxicity	ototoxicity	B-Disease
has	has	O
been	been	O
deduced	deduced	O
from	from	O
observations	observations	O
that	that	O
aminoglycoside-iron	aminoglycoside-iron	O
complexes	complexes	O
catalyze	catalyze	O
the	the	O
formation	formation	O
of	of	O
superoxide	superoxide	B-Chemical
radicals	radicals	O
in	in	O
vitro	vitro	O
and	and	O
that	that	O
antioxidants	antioxidants	O
attenuate	attenuate	O
ototoxicity	ototoxicity	B-Disease
in	in	O
vivo	vivo	O
.	.	O

We	we	O
therefore	therefore	O
hypothesized	hypothesized	O
that	that	O
overexpression	overexpression	O
of	of	O
Cu/Zn-superoxide	cu/zn-superoxide	O
dismutase	dismutase	O
(	(	O
h-SOD1	h-sod1	O
)	)	O
should	should	O
protect	protect	O
transgenic	transgenic	O
mice	mice	O
from	from	O
ototoxicity	ototoxicity	B-Disease
.	.	O

Immunocytochemistry	immunocytochemistry	O
confirmed	confirmed	O
expression	expression	O
of	of	O
h-SOD1	h-sod1	O
in	in	O
inner	inner	O
ear	ear	O
tissues	tissues	O
of	of	O
transgenic	transgenic	O
C57BL/6-TgN[SOD1]3Cje	c57bl/6-tgn[sod1]3cje	O
mice	mice	O
.	.	O

Transgenic	transgenic	O
and	and	O
nontransgenic	nontransgenic	O
littermates	littermates	O
received	received	O
kanamycin	kanamycin	B-Chemical
(	(	O
400	400	O
mg/kg	mg/kg	O
body	body	O
weight/day	weight/day	O
)	)	O
for	for	O
10	10	O
days	days	O
beginning	beginning	O
on	on	O
day	day	O
10	10	O
after	after	O
birth	birth	O
.	.	O

Auditory	auditory	O
thresholds	thresholds	O
were	were	O
tested	tested	O
by	by	O
evoked	evoked	O
auditory	auditory	O
brain	brain	O
stem	stem	O
responses	responses	O
at	at	O
1	1	O
month	month	O
after	after	O
birth	birth	O
.	.	O

In	in	O
nontransgenic	nontransgenic	O
animals	animals	O
,	,	O
the	the	O
threshold	threshold	O
in	in	O
the	the	O
kanamycin-treated	kanamycin-treated	O
group	group	O
was	was	O
45	45	O
-	-	O
50	50	O
dB	db	O
higher	higher	O
than	than	O
in	in	O
saline-injected	saline-injected	O
controls	controls	O
.	.	O

In	in	O
the	the	O
transgenic	transgenic	O
group	group	O
,	,	O
kanamycin	kanamycin	B-Chemical
increased	increased	O
the	the	O
threshold	threshold	O
by	by	O
only	only	O
15	15	O
dB	db	O
over	over	O
the	the	O
respective	respective	O
controls	controls	O
.	.	O

The	the	O
effects	effects	O
were	were	O
similar	similar	O
at	at	O
12	12	O
and	and	O
24	24	O
kHz	khz	O
.	.	O

The	the	O
protection	protection	O
by	by	O
overexpression	overexpression	O
of	of	O
superoxide	superoxide	B-Chemical
dismutase	dismutase	I-Chemical
supports	supports	O
the	the	O
hypothesis	hypothesis	O
that	that	O
oxidant	oxidant	O
stress	stress	O
plays	plays	O
a	a	O
significant	significant	O
role	role	O
in	in	O
aminoglycoside-induced	aminoglycoside-induced	O
ototoxicity	ototoxicity	B-Disease
.	.	O

The	the	O
results	results	O
also	also	O
suggest	suggest	O
transgenic	transgenic	O
animals	animals	O
as	as	O
suitable	suitable	O
models	models	O
to	to	O
investigate	investigate	O
the	the	O
underlying	underlying	O
mechanisms	mechanisms	O
and	and	O
possible	possible	O
strategies	strategies	O
for	for	O
prevention	prevention	O
.	.	O

Fatty	fatty	B-Disease
liver	liver	I-Disease
induced	induced	O
by	by	O
tetracycline	tetracycline	O
in	in	O
the	the	O
rat	rat	O
.	.	O

Dose-response	dose-response	O
relationships	relationships	O
and	and	O
effect	effect	O
of	of	O
sex	sex	O
.	.	O

Dose-response	dose-response	O
relationships	relationships	O
,	,	O
biochemical	biochemical	O
mechanisms	mechanisms	O
,	,	O
and	and	O
sex	sex	O
differences	differences	O
in	in	O
the	the	O
experimental	experimental	O
fatty	fatty	B-Disease
liver	liver	I-Disease
induced	induced	O
by	by	O
tetracycline	tetracycline	O
were	were	O
studied	studied	O
in	in	O
the	the	O
intact	intact	O
rat	rat	O
and	and	O
with	with	O
the	the	O
isolated	isolated	O
perfused	perfused	O
rat	rat	O
liver	liver	O
in	in	O
vitro	vitro	O
.	.	O

In	in	O
the	the	O
intact	intact	O
male	male	O
and	and	O
female	female	O
rat	rat	O
,	,	O
no	no	O
direct	direct	O
relationship	relationship	O
was	was	O
observed	observed	O
between	between	O
dose	dose	O
of	of	O
tetracycline	tetracycline	O
and	and	O
hepatic	hepatic	O
accumulation	accumulation	O
of	of	O
triglyceride	triglyceride	O
.	.	O

With	with	O
provision	provision	O
of	of	O
adequate	adequate	O
oleic	oleic	B-Chemical
acid	acid	I-Chemical
as	as	O
a	a	O
substrate	substrate	O
for	for	O
the	the	O
isolated	isolated	O
perfused	perfused	O
liver	liver	O
,	,	O
a	a	O
direct	direct	O
relationship	relationship	O
was	was	O
observed	observed	O
between	between	O
dose	dose	O
of	of	O
tetracycline	tetracycline	O
and	and	O
both	both	O
accumulation	accumulation	O
of	of	O
triglyceride	triglyceride	O
in	in	O
the	the	O
liver	liver	O
and	and	O
depression	depression	B-Disease
of	of	O
output	output	O
of	of	O
triglyceride	triglyceride	O
by	by	O
livers	livers	O
from	from	O
male	male	O
and	and	O
female	female	O
rats	rats	O
.	.	O

Marked	marked	O
differences	differences	O
were	were	O
observed	observed	O
between	between	O
female	female	O
and	and	O
male	male	O
rats	rats	O
with	with	O
regard	regard	O
to	to	O
base	base	O
line	line	O
(	(	O
control	control	O
)	)	O
hepatic	hepatic	O
concentration	concentration	O
of	of	O
triglyceride	triglyceride	O
and	and	O
output	output	O
of	of	O
triglyceride	triglyceride	O
.	.	O

Accumulation	accumulation	O
of	of	O
hepatic	hepatic	O
triglyceride	triglyceride	O
,	,	O
as	as	O
a	a	O
per	per	O
cent	cent	O
of	of	O
control	control	O
values	values	O
,	,	O
in	in	O
response	response	O
to	to	O
graded	graded	O
doses	doses	O
of	of	O
tetracycline	tetracycline	O
,	,	O
did	did	O
not	not	O
differ	differ	O
significantly	significantly	O
between	between	O
male	male	O
,	,	O
female	female	O
and	and	O
pregnant	pregnant	O
rat	rat	O
livers	livers	O
.	.	O

However	however	O
,	,	O
livers	livers	O
from	from	O
female	female	O
,	,	O
and	and	O
especially	especially	O
pregnant	pregnant	O
female	female	O
rats	rats	O
,	,	O
were	were	O
strikingly	strikingly	O
resistant	resistant	O
to	to	O
the	the	O
effects	effects	O
of	of	O
tetracycline	tetracycline	O
on	on	O
depression	depression	B-Disease
of	of	O
output	output	O
of	of	O
triglyceride	triglyceride	O
under	under	O
these	these	O
experimental	experimental	O
conditions	conditions	O
.	.	O

These	these	O
differences	differences	O
between	between	O
the	the	O
sexes	sexes	O
could	could	O
not	not	O
be	be	O
related	related	O
to	to	O
altered	altered	O
disposition	disposition	O
of	of	O
tetracycline	tetracycline	O
or	or	O
altered	altered	O
uptake	uptake	O
of	of	O
oleic	oleic	B-Chemical
acid	acid	I-Chemical
.	.	O

Depressed	depressed	B-Disease
hepatic	hepatic	O
secretion	secretion	O
of	of	O
triglyceride	triglyceride	O
accounted	accounted	O
only	only	O
for	for	O
30	30	O
to	to	O
50	50	O
%	%	O
of	of	O
accumulated	accumulated	O
hepatic	hepatic	O
triglyceride	triglyceride	O
,	,	O
indicating	indicating	O
that	that	O
additional	additional	O
mechanisms	mechanisms	O
must	must	O
be	be	O
involved	involved	O
in	in	O
the	the	O
production	production	O
of	of	O
the	the	O
triglyceride-rich	triglyceride-rich	O
fatty	fatty	B-Disease
liver	liver	I-Disease
in	in	O
response	response	O
to	to	O
tetracycline	tetracycline	O
.	.	O

Prednisone	prednisone	B-Chemical
induces	induces	O
anxiety	anxiety	B-Disease
and	and	O
glial	glial	O
cerebral	cerebral	O
changes	changes	O
in	in	O
rats	rats	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
assess	assess	O
whether	whether	O
prednisone	prednisone	B-Chemical
(	(	O
PDN	pdn	O
)	)	O
produces	produces	O
anxiety	anxiety	B-Disease
and/or	and/or	O
cerebral	cerebral	O
glial	glial	O
changes	changes	O
in	in	O
rats	rats	O
.	.	O

METHODS	methods	O
:	:	O
Male	male	O
Wistar	wistar	O
rats	rats	O
were	were	O
studied	studied	O
and	and	O
3	3	O
groups	groups	O
were	were	O
formed	formed	O
(	(	O
8	8	O
rats	rats	O
per	per	O
group	group	O
)	)	O
.	.	O

The	the	O
moderate-dose	moderate-dose	O
group	group	O
received	received	O
5	5	O
mg/kg/day	mg/kg/day	O
PDN	pdn	O
released	released	O
from	from	O
a	a	O
subcutaneous	subcutaneous	O
implant	implant	O
.	.	O

In	in	O
the	the	O
high-dose	high-dose	O
group	group	O
,	,	O
implants	implants	O
containing	containing	O
PDN	pdn	O
equivalent	equivalent	O
to	to	O
60	60	O
mg/kg/day	mg/kg/day	O
were	were	O
applied	applied	O
.	.	O

In	in	O
the	the	O
control	control	O
group	group	O
implants	implants	O
contained	contained	O
no	no	O
PDN	pdn	O
.	.	O

Anxiety	anxiety	B-Disease
was	was	O
assessed	assessed	O
using	using	O
an	an	O
open	open	O
field	field	O
and	and	O
elevated	elevated	O
plus-maze	plus-maze	O
devices	devices	O
.	.	O

The	the	O
number	number	O
of	of	O
cells	cells	O
and	and	O
cytoplasmic	cytoplasmic	O
transformation	transformation	O
of	of	O
astrocytes	astrocytes	O
and	and	O
microglia	microglia	O
cells	cells	O
were	were	O
assessed	assessed	O
by	by	O
immunohistochemical	immunohistochemical	O
analyses	analyses	O
.	.	O

RESULTS	results	O
:	:	O
Anxiety	anxiety	B-Disease
was	was	O
documented	documented	O
in	in	O
both	both	O
groups	groups	O
of	of	O
PDN	pdn	O
treated	treated	O
rats	rats	O
compared	compared	O
with	with	O
controls	controls	O
.	.	O

The	the	O
magnitude	magnitude	O
of	of	O
transformation	transformation	O
of	of	O
the	the	O
microglia	microglia	O
assessed	assessed	O
by	by	O
the	the	O
number	number	O
of	of	O
intersections	intersections	O
was	was	O
significantly	significantly	O
higher	higher	O
in	in	O
the	the	O
PDN	pdn	O
groups	groups	O
than	than	O
in	in	O
controls	controls	O
in	in	O
the	the	O
prefrontal	prefrontal	O
cortex	cortex	O
(	(	O
moderate-dose	moderate-dose	O
,	,	O
24.1	24.1	O
;	;	O
high-dose	high-dose	O
,	,	O
23.6	23.6	O
;	;	O
controls	controls	O
18.7	18.7	O
;	;	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
and	and	O
striatum	striatum	O
(	(	O
moderate-dose	moderate-dose	O
25.6	25.6	O
;	;	O
high-dose	high-dose	O
26.3	26.3	O
;	;	O
controls	controls	O
18.9	18.9	O
;	;	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
,	,	O
but	but	O
not	not	O
in	in	O
hippocampus	hippocampus	O
.	.	O

The	the	O
number	number	O
of	of	O
stained	stained	O
microglia	microglia	O
cells	cells	O
was	was	O
significantly	significantly	O
higher	higher	O
in	in	O
the	the	O
PDN	pdn	O
treated	treated	O
groups	groups	O
in	in	O
the	the	O
prefrontal	prefrontal	O
cortex	cortex	O
than	than	O
in	in	O
controls	controls	O
(	(	O
moderate-dose	moderate-dose	O
,	,	O
29.1	29.1	O
;	;	O
high-dose	high-dose	O
,	,	O
28.4	28.4	O
;	;	O
control	control	O
,	,	O
17.7	17.7	O
cells	cells	O
per	per	O
field	field	O
;	;	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

Stained	stained	O
microglia	microglia	O
cells	cells	O
were	were	O
significantly	significantly	O
more	more	O
numerous	numerous	O
striatum	striatum	O
and	and	O
hippocampus	hippocampus	O
in	in	O
the	the	O
high-dose	high-dose	O
group	group	O
compared	compared	O
to	to	O
controls	controls	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Subacute	subacute	O
exposure	exposure	O
to	to	O
PDN	pdn	O
induced	induced	O
anxiety	anxiety	B-Disease
and	and	O
reactivity	reactivity	O
of	of	O
microglia	microglia	O
.	.	O

The	the	O
relevance	relevance	O
of	of	O
these	these	O
features	features	O
for	for	O
patients	patients	O
using	using	O
PDN	pdn	O
remains	remains	O
to	to	O
be	be	O
elucidated	elucidated	O
.	.	O

Phase	phase	O
II	ii	O
study	study	O
of	of	O
carboplatin	carboplatin	B-Chemical
and	and	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
in	in	O
patients	patients	O
with	with	O
recurrent	recurrent	O
squamous	squamous	O
cell	cell	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
cervix	cervix	O
.	.	O

BACKGROUND	background	O
:	:	O
The	the	O
activity	activity	O
of	of	O
the	the	O
combination	combination	O
of	of	O
carboplatin	carboplatin	B-Chemical
and	and	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
was	was	O
tested	tested	O
in	in	O
a	a	O
Phase	phase	O
II	ii	O
study	study	O
of	of	O
patients	patients	O
with	with	O
recurrent	recurrent	O
cervical	cervical	O
carcinoma	carcinoma	B-Disease
.	.	O

METHODS	methods	O
:	:	O
The	the	O
combination	combination	O
of	of	O
carboplatin	carboplatin	B-Chemical
(	(	O
area	area	O
under	under	O
the	the	O
concentration	concentration	O
curve	curve	O
[	[	O
AUC	auc	O
]	]	O
,	,	O
5	5	O
)	)	O
and	and	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
(	(	O
Doxil	doxil	B-Chemical
;	;	O
starting	starting	O
dose	dose	O
,	,	O
40	40	O
mg/m(2	mg/m(2	O
)	)	O
)	)	O
was	was	O
administered	administered	O
intravenously	intravenously	O
every	every	O
28	28	O
days	days	O
to	to	O
37	37	O
patients	patients	O
with	with	O
recurrent	recurrent	O
squamous	squamous	O
cell	cell	O
cervical	cervical	O
carcinoma	carcinoma	B-Disease
to	to	O
determine	determine	O
antitumor	antitumor	O
activity	activity	O
and	and	O
toxicity	toxicity	B-Disease
profile	profile	O
.	.	O

RESULTS	results	O
:	:	O
Twenty-nine	twenty-nine	O
patients	patients	O
were	were	O
assessable	assessable	O
for	for	O
response	response	O
,	,	O
and	and	O
35	35	O
patients	patients	O
were	were	O
assessable	assessable	O
for	for	O
toxicity	toxicity	B-Disease
.	.	O

The	the	O
overall	overall	O
response	response	O
rate	rate	O
was	was	O
38	38	O
%	%	O
,	,	O
the	the	O
median	median	O
time	time	O
to	to	O
response	response	O
was	was	O
10	10	O
weeks	weeks	O
,	,	O
the	the	O
median	median	O
duration	duration	O
of	of	O
response	response	O
was	was	O
26	26	O
weeks	weeks	O
,	,	O
and	and	O
the	the	O
median	median	O
survival	survival	O
was	was	O
37	37	O
weeks	weeks	O
.	.	O

The	the	O
main	main	O
toxic	toxic	O
effect	effect	O
was	was	O
myelosuppression	myelosuppression	B-Disease
,	,	O
with	with	O
Grade	grade	O
3	3	O
and	and	O
4	4	O
neutropenia	neutropenia	B-Disease
in	in	O
16	16	O
patients	patients	O
,	,	O
anemia	anemia	B-Disease
in	in	O
12	12	O
patients	patients	O
,	,	O
thrombocytopenia	thrombocytopenia	B-Disease
in	in	O
11	11	O
patients	patients	O
,	,	O
and	and	O
neutropenic	neutropenic	O
fever	fever	B-Disease
in	in	O
3	3	O
patients	patients	O
.	.	O

Four	four	O
patients	patients	O
had	had	O
five	five	O
infusion-related	infusion-related	O
reactions	reactions	O
during	during	O
the	the	O
infusion	infusion	O
of	of	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
,	,	O
leading	leading	O
to	to	O
treatment	treatment	O
discontinuation	discontinuation	O
in	in	O
three	three	O
patients	patients	O
.	.	O

Grade	grade	O
>	>	O
or	or	O
=	=	O
2	2	O
nonhematologic	nonhematologic	O
toxicity	toxicity	B-Disease
included	included	O
nausea	nausea	B-Disease
in	in	O
17	17	O
patients	patients	O
,	,	O
emesis	emesis	O
in	in	O
14	14	O
patients	patients	O
,	,	O
fatigue	fatigue	B-Disease
in	in	O
9	9	O
patients	patients	O
,	,	O
mucositis	mucositis	B-Disease
and/or	and/or	O
stomatitis	stomatitis	B-Disease
in	in	O
8	8	O
patients	patients	O
,	,	O
constipation	constipation	B-Disease
in	in	O
6	6	O
patients	patients	O
,	,	O
weight	weight	B-Disease
loss	loss	I-Disease
in	in	O
5	5	O
patients	patients	O
,	,	O
hand-foot	hand-foot	O
syndrome	syndrome	O
in	in	O
2	2	O
patients	patients	O
,	,	O
and	and	O
skin	skin	O
reactions	reactions	O
in	in	O
3	3	O
patients	patients	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
combination	combination	O
of	of	O
carboplatin	carboplatin	B-Chemical
and	and	O
liposomal	liposomal	B-Chemical
doxorubicin	doxorubicin	B-Chemical
has	has	O
modest	modest	O
activity	activity	O
in	in	O
patients	patients	O
with	with	O
recurrent	recurrent	O
cervical	cervical	O
carcinoma	carcinoma	B-Disease
.	.	O

Antimicrobial-induced	antimicrobial-induced	O
mania	mania	B-Disease
(	(	O
antibiomania	antibiomania	O
):	):	O
a	a	O
review	review	O
of	of	O
spontaneous	spontaneous	O
reports	reports	O
.	.	O

The	the	O
authors	authors	O
reviewed	reviewed	O
reported	reported	O
cases	cases	O
of	of	O
antibiotic-induced	antibiotic-induced	O
manic	manic	B-Disease
episodes	episodes	O
by	by	O
means	means	O
of	of	O
a	a	O
MEDLINE	medline	O
and	and	O
PsychLit	psychlit	O
search	search	O
for	for	O
reports	reports	O
of	of	O
antibiotic-induced	antibiotic-induced	O
mania	mania	B-Disease
.	.	O

Unpublished	unpublished	O
reports	reports	O
were	were	O
requested	requested	O
from	from	O
the	the	O
World	world	O
Health	health	O
Organization	organization	O
(	(	O
WHO	who	O
)	)	O
and	and	O
the	the	O
Food	food	O
and	and	O
Drug	drug	O
Administration	administration	O
(	(	O
FDA	fda	O
)	)	O
.	.	O

Twenty-one	twenty-one	O
reports	reports	O
of	of	O
antimicrobial-induced	antimicrobial-induced	O
mania	mania	B-Disease
were	were	O
found	found	O
in	in	O
the	the	O
literature	literature	O
.	.	O

There	there	O
were	were	O
6	6	O
cases	cases	O
implicating	implicating	O
clarithromycin	clarithromycin	O
,	,	O
13	13	O
implicating	implicating	O
isoniazid	isoniazid	B-Chemical
,	,	O
and	and	O
1	1	O
case	case	O
each	each	O
implicating	implicating	O
erythromycin	erythromycin	O
and	and	O
amoxicillin	amoxicillin	B-Chemical
.	.	O

The	the	O
WHO	who	O
reported	reported	O
82	82	O
cases	cases	O
.	.	O

Of	of	O
these	these	O
,	,	O
clarithromycin	clarithromycin	O
was	was	O
implicated	implicated	O
in	in	O
23	23	O
(	(	O
27.6	27.6	O
%	%	O
)	)	O
cases	cases	O
,	,	O
ciprofloxacin	ciprofloxacin	B-Chemical
in	in	O
12	12	O
(	(	O
14.4	14.4	O
%	%	O
)	)	O
cases	cases	O
,	,	O
and	and	O
ofloxacin	ofloxacin	O
in	in	O
10	10	O
(	(	O
12	12	O
%	%	O
)	)	O
cases	cases	O
.	.	O

Cotrimoxazole	cotrimoxazole	O
,	,	O
metronidazole	metronidazole	B-Chemical
,	,	O
and	and	O
erythromycin	erythromycin	O
were	were	O
involved	involved	O
in	in	O
15	15	O
reported	reported	O
manic	manic	B-Disease
episodes	episodes	O
.	.	O

Cases	cases	O
reported	reported	O
by	by	O
the	the	O
FDA	fda	O
showed	showed	O
clarithromycin	clarithromycin	O
and	and	O
ciprofloxacin	ciprofloxacin	B-Chemical
to	to	O
be	be	O
the	the	O
most	most	O
frequently	frequently	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
mania	mania	B-Disease
.	.	O

Statistical	statistical	O
analysis	analysis	O
of	of	O
the	the	O
data	data	O
would	would	O
not	not	O
have	have	O
demonstrated	demonstrated	O
a	a	O
significant	significant	O
statistical	statistical	O
correlative	correlative	O
risk	risk	O
and	and	O
was	was	O
therefore	therefore	O
not	not	O
undertaken	undertaken	O
.	.	O

Patients	patients	O
have	have	O
an	an	O
increased	increased	O
risk	risk	O
of	of	O
developing	developing	O
mania	mania	B-Disease
while	while	O
being	being	O
treated	treated	O
with	with	O
antimicrobials	antimicrobials	O
.	.	O

Although	although	O
this	this	O
is	is	O
not	not	O
a	a	O
statistically	statistically	O
significant	significant	O
risk	risk	O
,	,	O
physicians	physicians	O
must	must	O
be	be	O
aware	aware	O
of	of	O
the	the	O
effect	effect	O
and	and	O
reversibility	reversibility	O
.	.	O

Further	further	O
research	research	O
clearly	clearly	O
is	is	O
required	required	O
to	to	O
determine	determine	O
the	the	O
incidence	incidence	O
of	of	O
antimicrobial-induced	antimicrobial-induced	O
mania	mania	B-Disease
,	,	O
the	the	O
relative	relative	O
risk	risk	O
factors	factors	O
of	of	O
developing	developing	O
an	an	O
antimicrobial-induced	antimicrobial-induced	O
manic	manic	B-Disease
episode	episode	O
among	among	O
various	various	O
demographic	demographic	O
populations	populations	O
,	,	O
and	and	O
the	the	O
incidence	incidence	O
of	of	O
patients	patients	O
who	who	O
continue	continue	O
to	to	O
have	have	O
persistent	persistent	O
affective	affective	B-Disease
disorders	disorders	I-Disease
once	once	O
the	the	O
initial	initial	O
episode	episode	O
,	,	O
which	which	O
occurs	occurs	O
while	while	O
the	the	O
patient	patient	O
is	is	O
taking	taking	O
antibiotics	antibiotics	O
,	,	O
subsides	subsides	O
.	.	O

The	the	O
authors	authors	O
elected	elected	O
to	to	O
name	name	O
this	this	O
syndrome	syndrome	O
"	"	O
antibiomania	antibiomania	O
.	.	O
"	"	O

Levodopa-induced	levodopa-induced	O
ocular	ocular	O
dyskinesias	dyskinesias	B-Disease
in	in	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

Levodopa-induced	levodopa-induced	O
ocular	ocular	O
dyskinesias	dyskinesias	B-Disease
are	are	O
very	very	O
uncommon	uncommon	O
.	.	O

Usually	usually	O
they	they	O
occur	occur	O
simultaneously	simultaneously	O
with	with	O
limb	limb	O
peak-dose	peak-dose	O
choreatic	choreatic	O
dyskinesias	dyskinesias	B-Disease
.	.	O

We	we	O
report	report	O
on	on	O
a	a	O
patient	patient	O
with	with	O
leftward	leftward	O
and	and	O
upward	upward	O
deviations	deviations	O
of	of	O
gaze	gaze	O
during	during	O
the	the	O
peak	peak	O
effect	effect	O
of	of	O
levodopa	levodopa	B-Chemical
,	,	O
and	and	O
hypothesize	hypothesize	O
that	that	O
a	a	O
severe	severe	O
dopaminergic	dopaminergic	O
denervation	denervation	O
in	in	O
the	the	O
caudate	caudate	O
nucleus	nucleus	O
is	is	O
needed	needed	O
for	for	O
the	the	O
appearance	appearance	O
of	of	O
these	these	O
levodopa-induce	levodopa-induce	O
ocular	ocular	O
dyskinesias	dyskinesias	B-Disease
.	.	O

A	a	O
comparison	comparison	O
of	of	O
glyceryl	glyceryl	O
trinitrate	trinitrate	O
with	with	O
diclofenac	diclofenac	B-Chemical
for	for	O
the	the	O
treatment	treatment	O
of	of	O
primary	primary	O
dysmenorrhea	dysmenorrhea	O
:	:	O
an	an	O
open	open	O
,	,	O
randomized	randomized	O
,	,	O
cross-over	cross-over	O
trial	trial	O
.	.	O

Primary	primary	O
dysmenorrhea	dysmenorrhea	O
is	is	O
a	a	O
syndrome	syndrome	O
characterized	characterized	O
by	by	O
painful	painful	O
uterine	uterine	O
contractility	contractility	O
caused	caused	O
by	by	O
a	a	O
hypersecretion	hypersecretion	O
of	of	O
endometrial	endometrial	O
prostaglandins	prostaglandins	B-Chemical
;	;	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
are	are	O
the	the	O
first	first	O
choice	choice	O
for	for	O
its	its	O
treatment	treatment	O
.	.	O

However	however	O
,	,	O
in	in	O
vivo	vivo	O
and	and	O
in	in	O
vitro	vitro	O
studies	studies	O
have	have	O
demonstrated	demonstrated	O
that	that	O
myometrial	myometrial	O
cells	cells	O
are	are	O
also	also	O
targets	targets	O
of	of	O
the	the	O
relaxant	relaxant	O
effects	effects	O
of	of	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
(	(	O
NO	no	O
)	)	O
.	.	O

The	the	O
aim	aim	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
determine	determine	O
the	the	O
efficacy	efficacy	O
of	of	O
glyceryl	glyceryl	O
trinitrate	trinitrate	O
(	(	O
GTN	gtn	O
)	)	O
,	,	O
an	an	O
NO	no	O
donor	donor	O
,	,	O
in	in	O
the	the	O
resolution	resolution	O
of	of	O
primary	primary	O
dysmenorrhea	dysmenorrhea	O
in	in	O
comparison	comparison	O
with	with	O
diclofenac	diclofenac	B-Chemical
(	(	O
DCF	dcf	O
)	)	O
.	.	O

A	a	O
total	total	O
of	of	O
24	24	O
patients	patients	O
with	with	O
the	the	O
diagnosis	diagnosis	O
of	of	O
severe	severe	O
primary	primary	O
dysmenorrhea	dysmenorrhea	O
were	were	O
studied	studied	O
during	during	O
two	two	O
consecutive	consecutive	O
menstrual	menstrual	O
cycles	cycles	O
.	.	O

In	in	O
an	an	O
open	open	O
,	,	O
cross-over	cross-over	O
,	,	O
controlled	controlled	O
design	design	O
,	,	O
patients	patients	O
were	were	O
randomized	randomized	O
to	to	O
receive	receive	O
either	either	O
DCF	dcf	O
per	per	O
os	os	O
or	or	O
GTN	gtn	O
patches	patches	O
the	the	O
first	first	O
days	days	O
of	of	O
menses	menses	O
,	,	O
when	when	O
menstrual	menstrual	O
cramps	cramps	O
became	became	O
unendurable	unendurable	O
.	.	O

In	in	O
the	the	O
subsequent	subsequent	O
cycle	cycle	O
the	the	O
other	other	O
treatment	treatment	O
was	was	O
used	used	O
.	.	O

Patients	patients	O
received	received	O
up	up	O
to	to	O
3	3	O
doses/day	doses/day	O
of	of	O
50	50	O
mg	mg	O
DCF	dcf	O
or	or	O
2.5	2.5	O
mg/24	mg/24	O
h	h	B-Chemical
transdermal	transdermal	O
GTN	gtn	O
for	for	O
the	the	O
first	first	O
3	3	O
days	days	O
of	of	O
the	the	O
cycle	cycle	O
,	,	O
according	according	O
to	to	O
their	their	O
needs	needs	O
.	.	O

The	the	O
participants	participants	O
recorded	recorded	O
menstrual	menstrual	O
symptoms	symptoms	O
and	and	O
possible	possible	O
side-effects	side-effects	O
at	at	O
different	different	O
times	times	O
(	(	O
0	0	O
,	,	O
30	30	O
,	,	O
60	60	O
,	,	O
120	120	O
minutes	minutes	O
)	)	O
after	after	O
the	the	O
first	first	O
dose	dose	O
of	of	O
medication	medication	O
on	on	O
the	the	O
first	first	O
day	day	O
of	of	O
the	the	O
cycle	cycle	O
,	,	O
with	with	O
both	both	O
drugs	drugs	O
.	.	O

The	the	O
difference	difference	O
in	in	O
pain	pain	B-Disease
intensity	intensity	O
score	score	O
(	(	O
DPI	dpi	O
)	)	O
was	was	O
the	the	O
main	main	O
outcome	outcome	O
variable	variable	O
.	.	O

Both	both	O
treatments	treatments	O
significantly	significantly	O
reduced	reduced	O
DPI	dpi	O
by	by	O
the	the	O
30th	30th	O
minute	minute	O
(	(	O
GTN	gtn	O
,	,	O
-12.8	-12.8	O
+	+	O
/-	/-	O
17.9	17.9	O
;	;	O
DCF	dcf	O
,	,	O
-18.9	-18.9	O
+	+	O
/-	/-	O
16.6	16.6	O
)	)	O
.	.	O

However	however	O
,	,	O
DCF	dcf	O
continued	continued	O
to	to	O
be	be	O
effective	effective	O
in	in	O
reducing	reducing	O
pelvic	pelvic	B-Disease
pain	pain	B-Disease
for	for	O
two	two	O
hours	hours	O
,	,	O
whereas	whereas	O
GTN	gtn	O
scores	scores	O
remained	remained	O
more	more	O
or	or	O
less	less	O
stable	stable	O
after	after	O
30	30	O
min	min	O
and	and	O
significantly	significantly	O
higher	higher	O
than	than	O
those	those	O
for	for	O
DFC	dfc	O
(	(	O
after	after	O
one	one	O
hour	hour	O
:	:	O
GTN	gtn	O
,	,	O
-12.8	-12.8	O
+	+	O
/-	/-	O
17.9	17.9	O
;	;	O
DFC	dfc	O
,	,	O
-18.9	-18.9	O
+	+	O
/-	/-	O
16.6	16.6	O
and	and	O
after	after	O
two	two	O
hours	hours	O
:	:	O
GTN	gtn	O
,	,	O
-23.7	-23.7	O
+	+	O
/-	/-	O
20.5	20.5	O
;	;	O
DFC	dfc	O
,	,	O
-59.7	-59.7	O
+	+	O
/-	/-	O
17.9	17.9	O
,	,	O
p	p	O
=	=	O
0.0001	0.0001	O
)	)	O
.	.	O

Low	low	B-Disease
back	back	B-Disease
pain	pain	B-Disease
was	was	O
also	also	O
relieved	relieved	O
by	by	O
both	both	O
drugs	drugs	O
.	.	O

Headache	headache	B-Disease
was	was	O
significantly	significantly	O
increased	increased	O
by	by	O
GTN	gtn	O
but	but	O
not	not	O
by	by	O
DCF	dcf	O
.	.	O

Eight	eight	O
patients	patients	O
stopped	stopped	O
using	using	O
GTN	gtn	O
because	because	O
headache	headache	B-Disease
--	--	O
attributed	attributed	O
to	to	O
its	its	O
use	use	O
--	--	O
became	became	O
intolerable	intolerable	O
.	.	O

These	these	O
findings	findings	O
indicate	indicate	O
that	that	O
GTN	gtn	O
has	has	O
a	a	O
reduced	reduced	O
efficacy	efficacy	O
and	and	O
tolerability	tolerability	O
by	by	O
comparison	comparison	O
with	with	O
DCF	dcf	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
primary	primary	O
dysmenorrhea	dysmenorrhea	O
.	.	O

Temocapril	temocapril	O
,	,	O
a	a	O
long-acting	long-acting	O
non-SH	non-sh	O
group	group	O
angiotensin	angiotensin	B-Chemical
converting	converting	O
enzyme	enzyme	O
inhibitor	inhibitor	O
,	,	O
modulates	modulates	O
glomerular	glomerular	O
injury	injury	O
in	in	O
chronic	chronic	O
puromycin	puromycin	B-Chemical
aminonucleoside	aminonucleoside	B-Chemical
nephrosis	nephrosis	B-Disease
.	.	O

The	the	O
purpose	purpose	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
determine	determine	O
whether	whether	O
chronic	chronic	O
administration	administration	O
of	of	O
temocapril	temocapril	O
,	,	O
a	a	O
long-acting	long-acting	O
non-SH	non-sh	O
group	group	O
angiotensin	angiotensin	B-Chemical
converting	converting	O
enzyme	enzyme	O
(	(	O
ACE	ace	O
)	)	O
inhibitor	inhibitor	O
,	,	O
reduced	reduced	O
proteinuria	proteinuria	B-Disease
,	,	O
inhibited	inhibited	O
glomerular	glomerular	O
hypertrophy	hypertrophy	B-Disease
and	and	O
prevented	prevented	O
glomerulosclerosis	glomerulosclerosis	B-Disease
in	in	O
chronic	chronic	O
puromycin	puromycin	B-Chemical
aminonucleoside	aminonucleoside	B-Chemical
(	(	O
PAN	pan	B-Chemical
)	)	O
-	-	O
induced	induced	O
nephrotic	nephrotic	B-Disease
rats	rats	O
.	.	O

Nephrosis	nephrosis	B-Disease
was	was	O
induced	induced	O
by	by	O
injection	injection	O
of	of	O
PAN	pan	B-Chemical
(	(	O
15mg/100	15mg/100	O
g	g	O
body	body	B-Disease
weight	weight	I-Disease
)	)	O
in	in	O
male	male	O
Sprague-Dawley	sprague-dawley	O
(	(	O
SD	sd	O
)	)	O
rats	rats	O
.	.	O

Four	four	O
groups	groups	O
were	were	O
used	used	O
,	,	O
i	i	O
)	)	O
the	the	O
PAN	pan	B-Chemical
group	group	O
(	(	O
14	14	O
)	)	O
,	,	O
ii	ii	O
)	)	O
PAN/temocapril	pan/temocapril	O
(	(	O
13	13	O
)	)	O
,	,	O
iii	iii	O
)	)	O
temocapril	temocapril	O
(	(	O
14	14	O
)	)	O
and	and	O
iv	iv	O
)	)	O
untreated	untreated	O
controls	controls	O
(	(	O
15	15	O
)	)	O
.	.	O

Temocapril	temocapril	O
(	(	O
8	8	O
mg/kg/day	mg/kg/day	O
)	)	O
was	was	O
administered	administered	O
to	to	O
the	the	O
rats	rats	O
which	which	O
were	were	O
killed	killed	O
at	at	O
weeks	weeks	O
4	4	O
,	,	O
14	14	O
or	or	O
20	20	O
.	.	O

At	at	O
each	each	O
time	time	O
point	point	O
,	,	O
systolic	systolic	O
blood	blood	O
pressure	pressure	O
(	(	O
BP	bp	O
)	)	O
,	,	O
urinary	urinary	O
protein	protein	O
excretion	excretion	O
and	and	O
renal	renal	O
histopathological	histopathological	O
findings	findings	O
were	were	O
evaluated	evaluated	O
,	,	O
and	and	O
morphometric	morphometric	O
image	image	O
analysis	analysis	O
was	was	O
done	done	O
.	.	O

Systolic	systolic	O
BP	bp	O
in	in	O
the	the	O
PAN	pan	B-Chemical
group	group	O
was	was	O
significantly	significantly	O
high	high	O
at	at	O
4	4	O
,	,	O
14	14	O
and	and	O
20	20	O
weeks	weeks	O
,	,	O
but	but	O
was	was	O
normal	normal	O
in	in	O
the	the	O
PAN/temocapril	pan/temocapril	O
group	group	O
.	.	O

Urinary	urinary	O
protein	protein	O
excretion	excretion	O
in	in	O
the	the	O
PAN	pan	B-Chemical
group	group	O
increased	increased	O
significantly	significantly	O
,	,	O
peaking	peaking	O
at	at	O
8	8	O
days	days	O
,	,	O
then	then	O
decreased	decreased	O
at	at	O
4	4	O
weeks	weeks	O
,	,	O
but	but	O
rose	rose	O
again	again	O
significantly	significantly	O
at	at	O
14	14	O
and	and	O
20	20	O
weeks	weeks	O
.	.	O

Temocapril	temocapril	O
did	did	O
not	not	O
attenuate	attenuate	O
proteinuria	proteinuria	B-Disease
at	at	O
8	8	O
days	days	O
,	,	O
but	but	O
it	it	O
did	did	O
markedly	markedly	O
lower	lower	O
it	it	O
from	from	O
weeks	weeks	O
4	4	O
to	to	O
20	20	O
.	.	O

The	the	O
glomerulosclerosis	glomerulosclerosis	B-Disease
index	index	O
(	(	O
GSI	gsi	O
)	)	O
was	was	O
6.21	6.21	O
%	%	O
at	at	O
4	4	O
weeks	weeks	O
and	and	O
respectively	respectively	O
25.35	25.35	O
%	%	O
and	and	O
30.49	30.49	O
%	%	O
at	at	O
14	14	O
and	and	O
20	20	O
weeks	weeks	O
in	in	O
the	the	O
PAN	pan	B-Chemical
group	group	O
.	.	O

There	there	O
was	was	O
a	a	O
significant	significant	O
correlation	correlation	O
between	between	O
urinary	urinary	O
protein	protein	O
excretion	excretion	O
and	and	O
GSI	gsi	O
(	(	O
r	r	O
=	=	O
0.808	0.808	O
,	,	O
p	p	O
<	<	O
0.0001	0.0001	O
)	)	O
.	.	O

The	the	O
ratio	ratio	O
of	of	O
glomerular	glomerular	O
tuft	tuft	O
area	area	O
to	to	O
the	the	O
area	area	O
of	of	O
Bowman	bowman	O
's	's	O
capsules	capsules	O
(	(	O
GT/BC	gt/bc	O
)	)	O
in	in	O
the	the	O
PAN	pan	B-Chemical
group	group	O
was	was	O
significantly	significantly	O
increased	increased	O
,	,	O
but	but	O
it	it	O
was	was	O
significantly	significantly	O
lower	lower	O
in	in	O
the	the	O
PAN/temocapril	pan/temocapril	O
group	group	O
.	.	O

It	it	O
appears	appears	O
that	that	O
temocapril	temocapril	O
was	was	O
effective	effective	O
in	in	O
retarding	retarding	O
renal	renal	O
progression	progression	O
and	and	O
protected	protected	O
renal	renal	O
function	function	O
in	in	O
PAN	pan	B-Chemical
neprotic	neprotic	O
rats	rats	O
.	.	O

Pulmonary	pulmonary	B-Disease
hypertension	hypertension	B-Disease
after	after	O
ibuprofen	ibuprofen	B-Chemical
prophylaxis	prophylaxis	O
in	in	O
very	very	O
preterm	preterm	O
infants	infants	O
.	.	O

We	we	O
report	report	O
three	three	O
cases	cases	O
of	of	O
severe	severe	O
hypoxaemia	hypoxaemia	O
after	after	O
ibuprofen	ibuprofen	B-Chemical
administration	administration	O
during	during	O
a	a	O
randomised	randomised	O
controlled	controlled	O
trial	trial	O
of	of	O
prophylactic	prophylactic	O
treatment	treatment	O
of	of	O
patent	patent	O
ductus	ductus	O
arteriosus	arteriosus	O
with	with	O
ibuprofen	ibuprofen	B-Chemical
in	in	O
premature	premature	O
infants	infants	O
born	born	O
at	at	O
less	less	O
than	than	O
28	28	O
weeks	weeks	O
of	of	O
gestation	gestation	O
.	.	O

Echocardiography	echocardiography	O
showed	showed	O
severely	severely	O
decreased	decreased	O
pulmonary	pulmonary	O
blood	blood	O
flow	flow	O
.	.	O

Hypoxaemia	hypoxaemia	O
resolved	resolved	O
quickly	quickly	O
on	on	O
inhaled	inhaled	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
therapy	therapy	O
.	.	O

We	we	O
suggest	suggest	O
that	that	O
investigators	investigators	O
involved	involved	O
in	in	O
similar	similar	O
trials	trials	O
pay	pay	O
close	close	O
attention	attention	O
to	to	O
pulmonary	pulmonary	O
pressure	pressure	O
if	if	O
hypoxaemia	hypoxaemia	O
occurs	occurs	O
after	after	O
prophylactic	prophylactic	O
administration	administration	O
of	of	O
ibuprofen	ibuprofen	B-Chemical
.	.	O

Hyponatremia	hyponatremia	B-Disease
and	and	O
syndrome	syndrome	O
of	of	O
inappropriate	inappropriate	O
anti-diuretic	anti-diuretic	O
hormone	hormone	O
reported	reported	O
with	with	O
the	the	O
use	use	O
of	of	O
Vincristine	vincristine	B-Chemical
:	:	O
an	an	O
over-representation	over-representation	O
of	of	O
Asians?PURPOSE	asians?purpose	O
:	:	O
This	this	O
retrospective	retrospective	O
study	study	O
used	used	O
a	a	O
pharmaceutical	pharmaceutical	O
company	company	O
's	's	O
global	global	O
safety	safety	O
database	database	O
to	to	O
determine	determine	O
the	the	O
reporting	reporting	O
rate	rate	O
of	of	O
hyponatremia	hyponatremia	B-Disease
and/or	and/or	O
syndrome	syndrome	O
of	of	O
inappropriate	inappropriate	O
secretion	secretion	O
of	of	O
anti-diuretic	anti-diuretic	O
hormone	hormone	O
(	(	O
SIADH	siadh	O
)	)	O
among	among	O
vincristine-treated	vincristine-treated	O
patients	patients	O
and	and	O
to	to	O
explore	explore	O
the	the	O
possibility	possibility	O
of	of	O
at-risk	at-risk	O
population	population	O
subgroups	subgroups	O
.	.	O

METHOD	method	O
:	:	O
We	we	O
searched	searched	O
the	the	O
Eli	eli	O
Lilly	lilly	O
and	and	O
Company	company	O
's	's	O
computerized	computerized	O
adverse	adverse	O
event	event	O
database	database	O
for	for	O
all	all	O
reported	reported	O
cases	cases	O
of	of	O
hyponatremia	hyponatremia	B-Disease
and/or	and/or	O
SIADH	siadh	O
as	as	O
of	of	O
1	1	O
November	november	O
1999	1999	O
that	that	O
had	had	O
been	been	O
reported	reported	O
during	during	O
the	the	O
use	use	O
of	of	O
vincristine	vincristine	B-Chemical
.	.	O

RESULTS	results	O
:	:	O
A	a	O
total	total	O
of	of	O
76	76	O
cases	cases	O
of	of	O
hyponatremia	hyponatremia	B-Disease
and/or	and/or	O
SIADH	siadh	O
associated	associated	O
with	with	O
vincristine	vincristine	B-Chemical
use	use	O
were	were	O
identified	identified	O
.	.	O

The	the	O
overall	overall	O
reporting	reporting	O
rate	rate	O
was	was	O
estimated	estimated	O
to	to	O
be	be	O
1.3/100,000	1.3/100,000	O
treated	treated	O
patients	patients	O
.	.	O

The	the	O
average	average	O
age	age	O
of	of	O
patients	patients	O
was	was	O
35.6	35.6	O
+	+	O
/-	/-	O
28.3	28.3	O
years	years	O
,	,	O
and	and	O
62	62	O
%	%	O
were	were	O
males	males	O
.	.	O

Approximately	approximately	O
75	75	O
%	%	O
of	of	O
the	the	O
patients	patients	O
were	were	O
receiving	receiving	O
treatment	treatment	O
for	for	O
leukemia	leukemia	O
or	or	O
lymphoma	lymphoma	O
.	.	O

Among	among	O
the	the	O
39	39	O
reports	reports	O
that	that	O
included	included	O
information	information	O
on	on	O
race	race	O
,	,	O
the	the	O
racial	racial	O
distribution	distribution	O
was	was	O
:	:	O
1	1	O
Black	black	O
,	,	O
3	3	O
Caucasian	caucasian	O
,	,	O
and	and	O
35	35	O
Asian	asian	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Our	our	O
data	data	O
suggest	suggest	O
that	that	O
Asian	asian	O
patients	patients	O
may	may	O
be	be	O
at	at	O
increased	increased	O
risk	risk	O
of	of	O
hyponatremia	hyponatremia	B-Disease
and/or	and/or	O
SIADH	siadh	O
associated	associated	O
with	with	O
vincristine	vincristine	B-Chemical
use	use	O
.	.	O

Although	although	O
the	the	O
overall	overall	O
reported	reported	O
rate	rate	O
of	of	O
SIADH	siadh	O
associated	associated	O
with	with	O
vincristine	vincristine	B-Chemical
is	is	O
very	very	O
low	low	O
,	,	O
physicians	physicians	O
caring	caring	O
for	for	O
Asian	asian	O
oncology	oncology	O
patients	patients	O
should	should	O
be	be	O
aware	aware	O
of	of	O
this	this	O
potential	potential	O
serious	serious	O
but	but	O
reversible	reversible	O
adverse	adverse	O
event	event	O
.	.	O

Delayed	delayed	O
toxicity	toxicity	B-Disease
of	of	O
cyclophosphamide	cyclophosphamide	B-Chemical
on	on	O
the	the	O
bladder	bladder	O
of	of	O
DBA/2	dba/2	O
and	and	O
C57BL/6	c57bl/6	O
female	female	O
mouse	mouse	O
.	.	O

The	the	O
present	present	O
study	study	O
describes	describes	O
the	the	O
delayed	delayed	O
development	development	O
of	of	O
a	a	O
severe	severe	O
bladder	bladder	O
pathology	pathology	O
in	in	O
a	a	O
susceptible	susceptible	O
strain	strain	O
of	of	O
mice	mice	O
(	(	O
DBA/2	dba/2	O
)	)	O
but	but	O
not	not	O
in	in	O
a	a	O
resistant	resistant	O
strain	strain	O
(	(	O
C57BL/6	c57bl/6	O
)	)	O
when	when	O
both	both	O
were	were	O
treated	treated	O
with	with	O
a	a	O
single	single	O
300	300	O
mg/kg	mg/kg	O
dose	dose	O
of	of	O
cyclophosphamide	cyclophosphamide	B-Chemical
(	(	O
CY	cy	B-Chemical
)	)	O
.	.	O

Inbred	inbred	O
DBA/2	dba/2	O
and	and	O
C57BL/6	c57bl/6	O
female	female	O
mice	mice	O
were	were	O
injected	injected	O
with	with	O
CY	cy	B-Chemical
,	,	O
and	and	O
the	the	O
effect	effect	O
of	of	O
the	the	O
drug	drug	O
on	on	O
the	the	O
bladder	bladder	O
was	was	O
assessed	assessed	O
during	during	O
100	100	O
days	days	O
by	by	O
light	light	O
microscopy	microscopy	O
using	using	O
different	different	O
staining	staining	O
procedures	procedures	O
,	,	O
and	and	O
after	after	O
30	30	O
days	days	O
by	by	O
conventional	conventional	O
electron	electron	O
microscopy	microscopy	O
.	.	O

Early	early	O
CY	cy	B-Chemical
toxicity	toxicity	B-Disease
caused	caused	O
a	a	O
typical	typical	O
haemorrhagic	haemorrhagic	O
cystitis	cystitis	B-Disease
in	in	O
both	both	O
strains	strains	O
that	that	O
was	was	O
completely	completely	O
repaired	repaired	O
in	in	O
about	about	O
7	7	O
-	-	O
10	10	O
days	days	O
.	.	O

After	after	O
30	30	O
days	days	O
of	of	O
CY	cy	B-Chemical
injection	injection	O
ulcerous	ulcerous	O
and	and	O
non-ulcerous	non-ulcerous	O
forms	forms	O
of	of	O
chronic	chronic	O
cystitis	cystitis	B-Disease
appeared	appeared	O
in	in	O
86	86	O
%	%	O
of	of	O
DBA/2	dba/2	O
mice	mice	O
but	but	O
only	only	O
in	in	O
4	4	O
%	%	O
of	of	O
C57BL/6	c57bl/6	O
mice	mice	O
.	.	O

Delayed	delayed	O
cystitis	cystitis	B-Disease
was	was	O
characterized	characterized	O
by	by	O
infiltration	infiltration	O
and	and	O
transepithelial	transepithelial	O
passage	passage	O
into	into	O
the	the	O
lumen	lumen	O
of	of	O
inflammatory	inflammatory	O
cells	cells	O
and	and	O
by	by	O
frequent	frequent	O
exfoliation	exfoliation	O
of	of	O
the	the	O
urothelium	urothelium	O
.	.	O

Mast	mast	O
cells	cells	O
appeared	appeared	O
in	in	O
the	the	O
connective	connective	O
and	and	O
muscular	muscular	O
layers	layers	O
of	of	O
the	the	O
bladder	bladder	O
at	at	O
a	a	O
much	much	O
higher	higher	O
number	number	O
in	in	O
DBA/2	dba/2	O
mice	mice	O
than	than	O
in	in	O
C57BL/6	c57bl/6	O
mice	mice	O
or	or	O
untreated	untreated	O
controls	controls	O
.	.	O

Electron	electron	O
microscopy	microscopy	O
disclosed	disclosed	O
the	the	O
absence	absence	O
of	of	O
the	the	O
typical	typical	O
discoidal	discoidal	O
vesicles	vesicles	O
normally	normally	O
present	present	O
in	in	O
the	the	O
cytoplasm	cytoplasm	O
of	of	O
surface	surface	O
cells	cells	O
.	.	O

Instead	instead	O
,	,	O
numerous	numerous	O
abnormal	abnormal	O
vesicles	vesicles	O
containing	containing	O
one	one	O
or	or	O
several	several	O
dark	dark	O
granules	granules	O
were	were	O
observed	observed	O
in	in	O
the	the	O
cytoplasm	cytoplasm	O
of	of	O
cells	cells	O
from	from	O
all	all	O
the	the	O
epithelial	epithelial	O
layers	layers	O
.	.	O

Delayed	delayed	O
cystitis	cystitis	B-Disease
still	still	O
persisted	persisted	O
in	in	O
DBA/2	dba/2	O
mice	mice	O
100	100	O
days	days	O
after	after	O
treatment	treatment	O
.	.	O

These	these	O
results	results	O
indicate	indicate	O
that	that	O
delayed	delayed	O
toxicity	toxicity	B-Disease
of	of	O
CY	cy	B-Chemical
in	in	O
female	female	O
DBA/2	dba/2	O
mice	mice	O
causes	causes	O
a	a	O
bladder	bladder	O
pathology	pathology	O
that	that	O
is	is	O
not	not	O
observed	observed	O
in	in	O
C57BL/6	c57bl/6	O
mice	mice	O
.	.	O

This	this	O
pathology	pathology	O
resembles	resembles	O
interstitial	interstitial	O
cystitis	cystitis	B-Disease
in	in	O
humans	humans	O
and	and	O
could	could	O
perhaps	perhaps	O
be	be	O
used	used	O
as	as	O
an	an	O
animal	animal	O
model	model	O
for	for	O
studies	studies	O
on	on	O
the	the	O
disease	disease	O
.	.	O

High-dose	high-dose	O
5-fluorouracil	5-fluorouracil	B-Chemical
/	/	O
folinic	folinic	B-Chemical
acid	acid	I-Chemical
in	in	O
combination	combination	O
with	with	O
three-weekly	three-weekly	O
mitomycin	mitomycin	O
C	c	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
advanced	advanced	O
gastric	gastric	O
cancer	cancer	B-Disease
.	.	O

A	a	O
phase	phase	O
II	ii	O
study	study	O
.	.	O

BACKGROUND	background	O
:	:	O
The	the	O
24-hour	24-hour	O
continuous	continuous	O
infusion	infusion	O
of	of	O
5-fluorouracil	5-fluorouracil	B-Chemical
(	(	O
5-FU	5-fu	B-Chemical
)	)	O
and	and	O
folinic	folinic	B-Chemical
acid	acid	I-Chemical
(	(	O
FA	fa	O
)	)	O
as	as	O
part	part	O
of	of	O
several	several	O
new	new	O
multidrug	multidrug	O
chemotherapy	chemotherapy	O
regimens	regimens	O
in	in	O
advanced	advanced	O
gastric	gastric	O
cancer	cancer	B-Disease
(	(	O
AGC	agc	O
)	)	O
has	has	O
shown	shown	O
to	to	O
be	be	O
effective	effective	O
,	,	O
with	with	O
low	low	O
toxicity	toxicity	B-Disease
.	.	O

In	in	O
a	a	O
previous	previous	O
phase	phase	O
II	ii	O
study	study	O
with	with	O
3-weekly	3-weekly	O
bolus	bolus	O
5-FU	5-fu	B-Chemical
,	,	O
FA	fa	O
and	and	O
mitomycin	mitomycin	O
C	c	O
(	(	O
MMC	mmc	O
)	)	O
we	we	O
found	found	O
a	a	O
low	low	O
toxicity	toxicity	B-Disease
rate	rate	O
and	and	O
response	response	O
rates	rates	O
comparable	comparable	O
to	to	O
those	those	O
of	of	O
regimens	regimens	O
such	such	O
as	as	O
ELF	elf	O
,	,	O
FAM	fam	O
or	or	O
FAMTX	famtx	O
,	,	O
and	and	O
a	a	O
promising	promising	O
median	median	O
overall	overall	O
survival	survival	O
.	.	O

In	in	O
order	order	O
to	to	O
improve	improve	O
this	this	O
MMC-dependent	mmc-dependent	O
schedule	schedule	O
we	we	O
initiated	initiated	O
a	a	O
phase	phase	O
II	ii	O
study	study	O
with	with	O
high-dose	high-dose	O
5-FU/FA	5-fu/fa	O
and	and	O
3-weekly	3-weekly	O
bolus	bolus	O
MMC	mmc	O
.	.	O

PATIENTS	patients	O
AND	and	O
METHODS	methods	O
:	:	O
From	from	O
February	february	O
,	,	O
1998	1998	O
to	to	O
September	september	O
,	,	O
2000	2000	O
we	we	O
recruited	recruited	O
33	33	O
patients	patients	O
with	with	O
AGC	agc	O
to	to	O
receive	receive	O
weekly	weekly	O
24-hour	24-hour	O
5-FU	5-fu	B-Chemical
2,600	2,600	O
mg/m(2	mg/m(2	O
)	)	O
preceded	preceded	O
by	by	O
2-hour	2-hour	O
FA	fa	O
500	500	O
mg/m(2	mg/m(2	O
)	)	O
for	for	O
6	6	O
weeks	weeks	O
,	,	O
followed	followed	O
by	by	O
a	a	O
2-week	2-week	O
rest	rest	O
period	period	O
.	.	O

Bolus	bolus	O
MMC	mmc	O
10	10	O
mg/m(2	mg/m(2	O
)	)	O
was	was	O
added	added	O
in	in	O
3-weekly	3-weekly	O
intervals	intervals	O
.	.	O

Treatment	treatment	O
given	given	O
on	on	O
an	an	O
outpatient	outpatient	O
basis	basis	O
,	,	O
using	using	O
portable	portable	O
pump	pump	O
systems	systems	O
,	,	O
was	was	O
repeated	repeated	O
on	on	O
day	day	O
57	57	O
.	.	O

Patients	patients	O
'	'	O
characteristics	characteristics	O
were	were	O
:	:	O
male/female	male/female	O
ratio	ratio	O
20/13	20/13	O
;	;	O
median	median	O
age	age	O
57	57	O
(	(	O
27	27	O
-	-	O
75	75	O
)	)	O
years	years	O
;	;	O
median	median	O
WHO	who	O
status	status	O
1	1	O
(	(	O
0	0	O
-	-	O
2	2	O
)	)	O
.	.	O

18	18	O
patients	patients	O
had	had	O
a	a	O
primary	primary	O
AGC	agc	O
,	,	O
and	and	O
15	15	O
showed	showed	O
a	a	O
relapsed	relapsed	O
AGC	agc	O
.	.	O

Median	median	O
follow-up	follow-up	O
was	was	O
11.8	11.8	O
months	months	O
(	(	O
range	range	O
of	of	O
those	those	O
surviving	surviving	O
:	:	O
2.7	2.7	O
-	-	O
11.8	11.8	O
months	months	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
32	32	O
patients	patients	O
were	were	O
evaluable	evaluable	O
for	for	O
response	response	O
-	-	O
complete	complete	O
remission	remission	O
9.1	9.1	O
%	%	O
(	(	O
n	n	O
=	=	O
3	3	O
)	)	O
,	,	O
partial	partial	O
remission	remission	O
45.5	45.5	O
%	%	O
(	(	O
n	n	O
=	=	O
15	15	O
)	)	O
,	,	O
no	no	O
change	change	O
27.3	27.3	O
%	%	O
(	(	O
n	n	O
=	=	O
9	9	O
)	)	O
,	,	O
progressive	progressive	O
disease	disease	O
15.1	15.1	O
%	%	O
(	(	O
n	n	O
=	=	O
5	5	O
)	)	O
.	.	O

Median	median	O
overall	overall	O
survival	survival	O
time	time	O
was	was	O
10.2	10.2	O
months	months	O
[	[	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
(	(	O
CI	ci	O
):	):	O
8.7	8.7	O
-	-	O
11.6	11.6	O
]	]	O
,	,	O
and	and	O
median	median	O
progression-free	progression-free	O
survival	survival	O
time	time	O
was	was	O
7.6	7.6	O
months	months	O
(	(	O
95	95	O
%	%	O
CI	ci	O
:	:	O
4.4	4.4	O
-	-	O
10.9	10.9	O
)	)	O
.	.	O

The	the	O
worst	worst	O
toxicities	toxicities	B-Disease
(	(	O
%	%	O
)	)	O
observed	observed	O
were	were	O
(	(	O
CTC-NCI	ctc-nci	O
1/2/3	1/2/3	O
):	):	O
leukopenia	leukopenia	B-Disease
45.5/18.2/6.1	45.5/18.2/6.1	O
,	,	O
thrombocytopenia	thrombocytopenia	B-Disease
33.3/9.1/6.1	33.3/9.1/6.1	O
,	,	O
vomitus	vomitus	O
24.2/9.1/0	24.2/9.1/0	O
,	,	O
diarrhea	diarrhea	B-Disease
36.4/6.1/3.0	36.4/6.1/3.0	O
,	,	O
stomatitis	stomatitis	B-Disease
18.2/9.1/0	18.2/9.1/0	O
,	,	O
hand-foot	hand-foot	O
syndrome	syndrome	O
12.1/0/0	12.1/0/0	O
.	.	O

Two	two	O
patients	patients	O
developed	developed	O
hemolytic-uremic	hemolytic-uremic	O
syndrome	syndrome	O
(	(	O
HUS	hus	B-Disease
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
High-dose	high-dose	O
5-FU/FA/MMC	5-fu/fa/mmc	O
is	is	O
an	an	O
effective	effective	O
and	and	O
well-tolerated	well-tolerated	O
outpatient	outpatient	O
regimen	regimen	O
for	for	O
AGC	agc	O
(	(	O
objective	objective	O
response	response	O
rate	rate	O
54.6	54.6	O
%	%	O
)	)	O
.	.	O

It	it	O
may	may	O
serve	serve	O
as	as	O
an	an	O
alternative	alternative	O
to	to	O
cisplatin-containing	cisplatin-containing	O
regimens	regimens	O
;	;	O
however	however	O
,	,	O
it	it	O
has	has	O
to	to	O
be	be	O
considered	considered	O
that	that	O
possibly	possibly	O
HUS	hus	B-Disease
may	may	O
occur	occur	O
.	.	O

Persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
is	is	O
associated	associated	O
with	with	O
impaired	impaired	O
renal	renal	O
function	function	O
in	in	O
human	human	O
immunodeficiency	immunodeficiency	O
virus	virus	O
type	type	O
1-infected	1-infected	O
children	children	O
treated	treated	O
with	with	O
indinavir	indinavir	B-Chemical
.	.	O

BACKGROUND	background	O
:	:	O
Prolonged	prolonged	O
administration	administration	O
of	of	O
indinavir	indinavir	B-Chemical
is	is	O
associated	associated	O
with	with	O
the	the	O
occurrence	occurrence	O
of	of	O
a	a	O
variety	variety	O
of	of	O
renal	renal	O
complications	complications	O
in	in	O
adults	adults	O
.	.	O

These	these	O
well-documented	well-documented	O
side	side	O
effects	effects	O
have	have	O
restricted	restricted	O
the	the	O
use	use	O
of	of	O
this	this	O
potent	potent	O
protease	protease	B-Chemical
inhibitor	inhibitor	I-Chemical
in	in	O
children	children	O
.	.	O

DESIGN	design	O
:	:	O
A	a	O
prospective	prospective	O
study	study	O
to	to	O
monitor	monitor	O
indinavir-related	indinavir-related	O
nephrotoxicity	nephrotoxicity	B-Disease
in	in	O
a	a	O
cohort	cohort	O
of	of	O
30	30	O
human	human	O
immunodeficiency	immunodeficiency	O
virus	virus	O
type	type	O
1-infected	1-infected	O
children	children	O
treated	treated	O
with	with	O
indinavir	indinavir	B-Chemical
.	.	O

METHODS	methods	O
:	:	O
Urinary	urinary	O
pH	ph	O
,	,	O
albumin	albumin	O
,	,	O
creatinine	creatinine	B-Chemical
,	,	O
the	the	O
presence	presence	O
of	of	O
erythrocytes	erythrocytes	O
,	,	O
leukocytes	leukocytes	O
,	,	O
bacteria	bacteria	O
and	and	O
crystals	crystals	O
,	,	O
and	and	O
culture	culture	O
were	were	O
analyzed	analyzed	O
every	every	O
3	3	O
months	months	O
for	for	O
96	96	O
weeks	weeks	O
.	.	O

Serum	serum	O
creatinine	creatinine	B-Chemical
levels	levels	O
were	were	O
routinely	routinely	O
determined	determined	O
at	at	O
the	the	O
same	same	O
time	time	O
points	points	O
.	.	O

Steady-state	steady-state	O
pharmacokinetics	pharmacokinetics	O
of	of	O
indinavir	indinavir	B-Chemical
were	were	O
done	done	O
at	at	O
week	week	O
4	4	O
after	after	O
the	the	O
initiation	initiation	O
of	of	O
indinavir	indinavir	B-Chemical
.	.	O

RESULTS	results	O
:	:	O
The	the	O
cumulative	cumulative	O
incidence	incidence	O
of	of	O
persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
(	(	O
>	>	O
or	or	O
=	=	O
75	75	O
cells/	cells/	O
micro	micro	O
L	l	O
in	in	O
at	at	O
least	least	O
2	2	O
consecutive	consecutive	O
visits	visits	O
)	)	O
after	after	O
96	96	O
weeks	weeks	O
was	was	O
53	53	O
%	%	O
.	.	O

Persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
was	was	O
frequently	frequently	O
associated	associated	O
with	with	O
a	a	O
mild	mild	O
increase	increase	O
in	in	O
the	the	O
urine	urine	O
albumin/creatinine	albumin/creatinine	O
ratio	ratio	O
and	and	O
by	by	O
microscopic	microscopic	O
hematuria	hematuria	B-Disease
.	.	O

The	the	O
cumulative	cumulative	O
incidence	incidence	O
of	of	O
serum	serum	O
creatinine	creatinine	B-Chemical
levels	levels	O
>	>	O
50	50	O
%	%	O
above	above	O
normal	normal	O
was	was	O
33	33	O
%	%	O
after	after	O
96	96	O
weeks	weeks	O
.	.	O

Children	children	O
with	with	O
persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
more	more	O
frequently	frequently	O
had	had	O
serum	serum	O
creatinine	creatinine	B-Chemical
levels	levels	O
of	of	O
50	50	O
%	%	O
above	above	O
normal	normal	O
than	than	O
those	those	O
children	children	O
without	without	O
persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
.	.	O

In	in	O
children	children	O
younger	younger	O
than	than	O
5.6	5.6	O
years	years	O
,	,	O
persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
was	was	O
significantly	significantly	O
more	more	O
frequent	frequent	O
than	than	O
in	in	O
older	older	O
children	children	O
.	.	O

A	a	O
higher	higher	O
cumulative	cumulative	O
incidence	incidence	O
of	of	O
persistent	persistent	O
leukocyturia	leukocyturia	O
was	was	O
found	found	O
in	in	O
children	children	O
with	with	O
an	an	O
area	area	O
under	under	O
the	the	O
curve	curve	O
>	>	O
19	19	O
mg/L	mg/l	O
x	x	O
h	h	B-Chemical
or	or	O
a	a	O
peak	peak	O
serum	serum	O
level	level	O
of	of	O
indinavir	indinavir	B-Chemical
>	>	O
12	12	O
mg/L.	mg/l.	O
In	in	O
4	4	O
children	children	O
,	,	O
indinavir	indinavir	B-Chemical
was	was	O
discontinued	discontinued	O
because	because	O
of	of	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

Subsequently	subsequently	O
,	,	O
the	the	O
serum	serum	O
creatinine	creatinine	B-Chemical
levels	levels	O
decreased	decreased	O
,	,	O
the	the	O
urine	urine	O
albumin/creatinine	albumin/creatinine	O
ratios	ratios	O
returned	returned	O
to	to	O
zero	zero	O
,	,	O
and	and	O
the	the	O
leukocyturia	leukocyturia	O
disappeared	disappeared	O
within	within	O
3	3	O
months	months	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Children	children	O
treated	treated	O
with	with	O
indinavir	indinavir	B-Chemical
have	have	O
a	a	O
high	high	O
cumulative	cumulative	O
incidence	incidence	O
of	of	O
persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
.	.	O

Children	children	O
with	with	O
persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
more	more	O
frequently	frequently	O
had	had	O
an	an	O
increase	increase	O
in	in	O
serum	serum	O
creatinine	creatinine	B-Chemical
levels	levels	O
of	of	O
>	>	O
50	50	O
%	%	O
above	above	O
normal	normal	O
.	.	O

Younger	younger	O
children	children	O
have	have	O
an	an	O
additional	additional	O
risk	risk	O
for	for	O
renal	renal	O
complications	complications	O
.	.	O

The	the	O
impairment	impairment	O
of	of	O
the	the	O
renal	renal	O
function	function	O
in	in	O
these	these	O
children	children	O
occurred	occurred	O
in	in	O
the	the	O
absence	absence	O
of	of	O
clinical	clinical	O
symptoms	symptoms	O
of	of	O
nephrolithiasis	nephrolithiasis	B-Disease
.	.	O

Indinavir-associated	indinavir-associated	O
nephrotoxicity	nephrotoxicity	B-Disease
must	must	O
be	be	O
monitored	monitored	O
closely	closely	O
,	,	O
especially	especially	O
in	in	O
children	children	O
with	with	O
risk	risk	O
factors	factors	O
such	such	O
as	as	O
persistent	persistent	O
sterile	sterile	O
leukocyturia	leukocyturia	O
,	,	O
age	age	O
<	<	O
5.6	5.6	O
years	years	O
,	,	O
an	an	O
area	area	O
under	under	O
the	the	O
curve	curve	O
of	of	O
indinavir	indinavir	B-Chemical
>	>	O
19	19	O
mg/L	mg/l	O
x	x	O
h	h	B-Chemical
,	,	O
and	and	O
a	a	O
C(max	c(max	O
)	)	O
>	>	O
12	12	O
mg/L.	mg/l.	O

Utility	utility	O
of	of	O
troponin	troponin	B-Chemical
I	i	I-Chemical
in	in	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
.	.	O

Baseline	baseline	O
electrocardiogram	electrocardiogram	O
abnormalities	abnormalities	O
and	and	O
market	market	O
elevations	elevations	O
not	not	O
associated	associated	O
with	with	O
myocardial	myocardial	O
necrosis	necrosis	B-Disease
make	make	O
accurate	accurate	O
diagnosis	diagnosis	O
of	of	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
(	(	O
MI	mi	O
)	)	O
difficult	difficult	O
in	in	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
.	.	O

Troponin	troponin	O
sampling	sampling	O
may	may	O
offer	offer	O
greater	greater	O
diagnostic	diagnostic	O
utility	utility	O
in	in	O
these	these	O
patients	patients	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
assess	assess	O
outcomes	outcomes	O
based	based	O
on	on	O
troponin	troponin	O
positivity	positivity	O
in	in	O
patients	patients	O
with	with	O
cocaine	cocaine	B-Chemical
chest	chest	B-Disease
pain	pain	B-Disease
admitted	admitted	O
for	for	O
exclusion	exclusion	O
of	of	O
MI	mi	O
.	.	O

METHODS	methods	O
:	:	O
Outcomes	outcomes	O
were	were	O
examined	examined	O
in	in	O
patients	patients	O
admitted	admitted	O
for	for	O
possible	possible	O
MI	mi	O
after	after	O
cocaine	cocaine	B-Chemical
use	use	O
.	.	O

All	all	O
patients	patients	O
underwent	underwent	O
a	a	O
rapid	rapid	O
rule-in	rule-in	O
protocol	protocol	O
that	that	O
included	included	O
serial	serial	O
sampling	sampling	O
of	of	O
creatine	creatine	B-Chemical
kinase	kinase	I-Chemical
(	(	O
CK	ck	O
)	)	O
,	,	O
CK-MB	ck-mb	O
,	,	O
and	and	O
cardiac	cardiac	O
troponin	troponin	B-Chemical
I	i	I-Chemical
(	(	O
cTnI	ctni	O
)	)	O
over	over	O
eight	eight	O
hours	hours	O
.	.	O

Outcomes	outcomes	O
included	included	O
CK-MB	ck-mb	O
MI	mi	O
(	(	O
CK-MB	ck-mb	O
>	>	O
or=	or=	O
8	8	O
ng/mL	ng/ml	O
with	with	O
a	a	O
relative	relative	O
index	index	O
[	[	O
(	(	O
CK-MB	ck-mb	O
x	x	O
100)/total	100)/total	O
CK	ck	O
]	]	O
>	>	O
or=	or=	O
4	4	O
,	,	O
cardiac	cardiac	O
death	death	B-Disease
,	,	O
and	and	O
significant	significant	O
coronary	coronary	B-Disease
disease	disease	I-Disease
(	(	O
>	>	O
or=50	or=50	O
%	%	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
Of	of	O
the	the	O
246	246	O
admitted	admitted	O
patients	patients	O
,	,	O
34	34	O
(	(	O
14	14	O
%	%	O
)	)	O
met	met	O
CK-MB	ck-mb	O
criteria	criteria	O
for	for	O
MI	mi	O
and	and	O
38	38	O
(	(	O
16	16	O
%	%	O
)	)	O
had	had	O
cTnI	ctni	O
elevations	elevations	O
.	.	O

Angiography	angiography	O
was	was	O
performed	performed	O
in	in	O
29	29	O
of	of	O
38	38	O
patients	patients	O
who	who	O
were	were	O
cTnI-positive	ctni-positive	O
,	,	O
with	with	O
significant	significant	O
disease	disease	O
present	present	O
in	in	O
25	25	O
(	(	O
86	86	O
%	%	O
)	)	O
.	.	O

Three	three	O
of	of	O
the	the	O
four	four	O
patients	patients	O
without	without	O
significant	significant	O
disease	disease	O
who	who	O
had	had	O
cTnI	ctni	O
elevations	elevations	O
met	met	O
CK-MB	ck-mb	O
criteria	criteria	O
for	for	O
MI	mi	O
,	,	O
and	and	O
the	the	O
other	other	O
had	had	O
a	a	O
peak	peak	O
CK-MB	ck-mb	O
level	level	O
of	of	O
13	13	O
ng/mL.	ng/ml.	O
Sensitivities	sensitivities	O
,	,	O
specificities	specificities	O
,	,	O
and	and	O
positive	positive	O
and	and	O
negative	negative	O
likelihood	likelihood	O
ratios	ratios	O
for	for	O
predicting	predicting	O
cardiac	cardiac	O
death	death	B-Disease
or	or	O
significant	significant	O
disease	disease	O
were	were	O
high	high	O
for	for	O
both	both	O
CK-MB	ck-mb	O
MI	mi	O
and	and	O
cTnI	ctni	O
and	and	O
were	were	O
not	not	O
significantly	significantly	O
different	different	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Most	most	O
patients	patients	O
with	with	O
cTnI	ctni	O
elevations	elevations	O
meet	meet	O
CK-MB	ck-mb	O
criteria	criteria	O
for	for	O
MI	mi	O
,	,	O
as	as	O
well	well	O
as	as	O
have	have	O
a	a	O
high	high	O
incidence	incidence	O
of	of	O
underlying	underlying	O
significant	significant	O
disease	disease	O
.	.	O

Troponin	troponin	O
appears	appears	O
to	to	O
have	have	O
an	an	O
equivalent	equivalent	O
diagnostic	diagnostic	O
accuracy	accuracy	O
compared	compared	O
with	with	O
CK-MB	ck-mb	O
for	for	O
diagnosing	diagnosing	O
necrosis	necrosis	B-Disease
in	in	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
and	and	O
suspected	suspected	O
MI	mi	O
.	.	O

Acute	acute	O
interstitial	interstitial	B-Disease
nephritis	nephritis	I-Disease
due	due	O
to	to	O
nicergoline	nicergoline	O
(Sermion).We	(sermion).we	O
report	report	O
a	a	O
case	case	O
of	of	O
acute	acute	O
interstitial	interstitial	B-Disease
nephritis	nephritis	I-Disease
(	(	O
AIN	ain	O
)	)	O
due	due	O
to	to	O
nicergoline	nicergoline	O
(	(	O
Sermion	sermion	O
)	)	O
.	.	O

A	a	O
50-year-old	50-year-old	O
patient	patient	O
admitted	admitted	O
to	to	O
our	our	O
hospital	hospital	O
for	for	O
fever	fever	B-Disease
and	and	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
.	.	O

Before	before	O
admission	admission	O
,	,	O
he	he	O
had	had	O
been	been	O
taking	taking	O
nicergoline	nicergoline	O
and	and	O
bendazac	bendazac	B-Chemical
lysine	lysine	I-Chemical
due	due	O
to	to	O
retinal	retinal	B-Disease
vein	vein	I-Disease
occlusion	occlusion	I-Disease
at	at	O
ophthalmologic	ophthalmologic	O
department	department	O
.	.	O

Thereafter	thereafter	O
,	,	O
he	he	O
experienced	experienced	O
intermittent	intermittent	O
fever	fever	B-Disease
and	and	O
skin	skin	O
rash	rash	B-Disease
.	.	O

On	on	O
admission	admission	O
,	,	O
clinical	clinical	O
symptoms	symptoms	O
(	(	O
i.e.	i.e.	O
arthralgia	arthralgia	O
and	and	O
fever	fever	B-Disease
)	)	O
and	and	O
laboratory	laboratory	O
findings	findings	O
(	(	O
i.e.	i.e.	O
eosinophilia	eosinophilia	B-Disease
and	and	O
renal	renal	B-Disease
failure	failure	I-Disease
)	)	O
suggested	suggested	O
AIN	ain	O
,	,	O
and	and	O
which	which	O
was	was	O
confirmed	confirmed	O
by	by	O
pathologic	pathologic	O
findings	findings	O
on	on	O
renal	renal	O
biopsy	biopsy	O
.	.	O

A	a	O
lymphocyte	lymphocyte	O
transformation	transformation	O
test	test	O
demonstrated	demonstrated	O
a	a	O
positive	positive	O
result	result	O
against	against	O
nicergoline	nicergoline	O
.	.	O

Treatment	treatment	O
was	was	O
consisted	consisted	O
of	of	O
withdrawal	withdrawal	O
of	of	O
nicergoline	nicergoline	O
and	and	O
intravenous	intravenous	O
methylprednisolone	methylprednisolone	B-Chemical
,	,	O
and	and	O
his	his	O
renal	renal	O
function	function	O
was	was	O
completely	completely	O
recovered	recovered	O
.	.	O

To	to	O
our	our	O
knowledge	knowledge	O
,	,	O
this	this	O
is	is	O
the	the	O
first	first	O
report	report	O
of	of	O
nicergoline-associated	nicergoline-associated	O
AIN	ain	O
.	.	O

Neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
complicated	complicated	O
by	by	O
massive	massive	O
intestinal	intestinal	O
bleeding	bleeding	B-Disease
in	in	O
a	a	O
patient	patient	O
with	with	O
chronic	chronic	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
.	.	O

A	a	O
patient	patient	O
with	with	O
chronic	chronic	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
(	(	O
CRF	crf	B-Disease
)	)	O
developed	developed	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
(	(	O
NMS	nms	O
)	)	O
after	after	O
administration	administration	O
of	of	O
risperidone	risperidone	B-Chemical
and	and	O
levomepromazine	levomepromazine	O
.	.	O

In	in	O
addition	addition	O
to	to	O
the	the	O
typical	typical	O
symptoms	symptoms	O
of	of	O
NMS	nms	O
,	,	O
massive	massive	O
intestinal	intestinal	O
bleeding	bleeding	B-Disease
was	was	O
observed	observed	O
during	during	O
the	the	O
episode	episode	O
.	.	O

This	this	O
report	report	O
suggests	suggests	O
that	that	O
NMS	nms	O
in	in	O
a	a	O
patient	patient	O
with	with	O
CRF	crf	B-Disease
may	may	O
be	be	O
complicated	complicated	O
by	by	O
intestinal	intestinal	O
bleeding	bleeding	B-Disease
and	and	O
needs	needs	O
special	special	O
caution	caution	O
for	for	O
this	this	O
complication	complication	O
.	.	O

Blood	blood	O
brain	brain	O
barrier	barrier	O
in	in	O
right-	right-	O
and	and	O
left-pawed	left-pawed	O
female	female	O
rats	rats	O
assessed	assessed	O
by	by	O
a	a	O
new	new	O
staining	staining	O
method	method	O
.	.	O

The	the	O
asymmetrical	asymmetrical	O
breakdown	breakdown	O
of	of	O
the	the	O
blood-brain	blood-brain	O
barrier	barrier	O
(	(	O
BBB	bbb	O
)	)	O
was	was	O
studied	studied	O
in	in	O
female	female	O
rats	rats	O
.	.	O

Paw	paw	O
preference	preference	O
was	was	O
assessed	assessed	O
by	by	O
a	a	O
food	food	O
reaching	reaching	O
test	test	O
.	.	O

Adrenaline-induced	adrenaline-induced	O
hypertension	hypertension	B-Disease
was	was	O
used	used	O
to	to	O
destroy	destroy	O
the	the	O
BBB	bbb	O
,	,	O
which	which	O
was	was	O
evaluated	evaluated	O
using	using	O
triphenyltetrazolium	triphenyltetrazolium	O
(	(	O
TTC	ttc	O
)	)	O
staining	staining	O
of	of	O
the	the	O
brain	brain	O
slices	slices	O
just	just	O
after	after	O
giving	giving	O
adrenaline	adrenaline	B-Chemical
for	for	O
30	30	O
s.	s.	O
In	in	O
normal	normal	O
rats	rats	O
,	,	O
the	the	O
whole	whole	O
brain	brain	O
sections	sections	O
exhibited	exhibited	O
complete	complete	O
staining	staining	O
with	with	O
TTC	ttc	O
.	.	O

After	after	O
adrenaline	adrenaline	B-Chemical
infusion	infusion	O
for	for	O
30	30	O
s	s	O
,	,	O
there	there	O
were	were	O
large	large	O
unstained	unstained	O
areas	areas	O
in	in	O
the	the	O
left	left	O
brain	brain	O
in	in	O
right-pawed	right-pawed	O
animals	animals	O
,	,	O
and	and	O
vice	vice	O
versa	versa	O
in	in	O
left-pawed	left-pawed	O
animals	animals	O
.	.	O

Similar	similar	O
results	results	O
were	were	O
obtained	obtained	O
in	in	O
seizure-induced	seizure-induced	O
breakdown	breakdown	O
of	of	O
BBB	bbb	O
.	.	O

These	these	O
results	results	O
were	were	O
explained	explained	O
by	by	O
an	an	O
asymmetric	asymmetric	O
cerebral	cerebral	O
blood	blood	O
flow	flow	O
depending	depending	O
upon	upon	O
the	the	O
paw	paw	O
preference	preference	O
in	in	O
rats	rats	O
.	.	O

It	it	O
was	was	O
suggested	suggested	O
that	that	O
this	this	O
new	new	O
method	method	O
and	and	O
the	the	O
results	results	O
are	are	O
consistent	consistent	O
with	with	O
contralateral	contralateral	O
motor	motor	O
control	control	O
that	that	O
may	may	O
be	be	O
important	important	O
in	in	O
determining	determining	O
the	the	O
dominant	dominant	O
cerebral	cerebral	O
hemisphere	hemisphere	O
in	in	O
animals	animals	O
.	.	O

Carvedilol	carvedilol	O
protects	protects	O
against	against	O
doxorubicin-induced	doxorubicin-induced	O
mitochondrial	mitochondrial	O
cardiomyopathy	cardiomyopathy	B-Disease
.	.	O

Several	several	O
cytopathic	cytopathic	O
mechanisms	mechanisms	O
have	have	O
been	been	O
suggested	suggested	O
to	to	O
mediate	mediate	O
the	the	O
dose-limiting	dose-limiting	O
cumulative	cumulative	O
and	and	O
irreversible	irreversible	O
cardiomyopathy	cardiomyopathy	B-Disease
caused	caused	O
by	by	O
doxorubicin	doxorubicin	B-Chemical
.	.	O

Recent	recent	O
evidence	evidence	O
indicates	indicates	O
that	that	O
oxidative	oxidative	O
stress	stress	O
and	and	O
mitochondrial	mitochondrial	B-Disease
dysfunction	dysfunction	I-Disease
are	are	O
key	key	O
factors	factors	O
in	in	O
the	the	O
pathogenic	pathogenic	O
process	process	O
.	.	O

The	the	O
objective	objective	O
of	of	O
this	this	O
investigation	investigation	O
was	was	O
to	to	O
test	test	O
the	the	O
hypothesis	hypothesis	O
that	that	O
carvedilol	carvedilol	O
,	,	O
a	a	O
nonselective	nonselective	O
beta-adrenergic	beta-adrenergic	O
receptor	receptor	O
antagonist	antagonist	O
with	with	O
potent	potent	O
antioxidant	antioxidant	O
properties	properties	O
,	,	O
protects	protects	O
against	against	O
the	the	O
cardiac	cardiac	O
and	and	O
hepatic	hepatic	O
mitochondrial	mitochondrial	O
bioenergetic	bioenergetic	O
dysfunction	dysfunction	O
associated	associated	O
with	with	O
subchronic	subchronic	O
doxorubicin	doxorubicin	B-Chemical
toxicity	toxicity	B-Disease
.	.	O

Heart	heart	O
and	and	O
liver	liver	O
mitochondria	mitochondria	O
were	were	O
isolated	isolated	O
from	from	O
rats	rats	O
treated	treated	O
for	for	O
7	7	O
weeks	weeks	O
with	with	O
doxorubicin	doxorubicin	B-Chemical
(	(	O
2	2	O
mg/kg	mg/kg	O
sc/week	sc/week	O
)	)	O
,	,	O
carvedilol	carvedilol	O
(	(	O
1	1	O
mg/kg	mg/kg	O
ip/week	ip/week	O
)	)	O
,	,	O
or	or	O
the	the	O
combination	combination	O
of	of	O
the	the	O
two	two	O
drugs	drugs	O
.	.	O

Heart	heart	O
mitochondria	mitochondria	O
isolated	isolated	O
from	from	O
doxorubicin-treated	doxorubicin-treated	O
rats	rats	O
exhibited	exhibited	O
depressed	depressed	B-Disease
rates	rates	O
for	for	O
state	state	O
3	3	O
respiration	respiration	O
(	(	O
336	336	O
+	+	O
/-	/-	O
26	26	O
versus	versus	O
425	425	O
+	+	O
/-	/-	O
53	53	O
natom	natom	O
O/min/mg	o/min/mg	O
protein	protein	O
)	)	O
and	and	O
a	a	O
lower	lower	O
respiratory	respiratory	O
control	control	O
ratio	ratio	O
(	(	O
RCR	rcr	O
)	)	O
(	(	O
4.3	4.3	O
+	+	O
/-	/-	O
0.6	0.6	O
versus	versus	O
5.8	5.8	O
+	+	O
/-	/-	O
0.4	0.4	O
)	)	O
compared	compared	O
with	with	O
cardiac	cardiac	O
mitochondria	mitochondria	O
isolated	isolated	O
from	from	O
saline-treated	saline-treated	O
rats	rats	O
.	.	O

Mitochondrial	mitochondrial	O
calcium-loading	calcium-loading	O
capacity	capacity	O
and	and	O
the	the	O
activity	activity	O
of	of	O
NADH-dehydrogenase	nadh-dehydrogenase	O
were	were	O
also	also	O
suppressed	suppressed	O
in	in	O
cardiac	cardiac	O
mitochondria	mitochondria	O
from	from	O
doxorubicin-treated	doxorubicin-treated	O
rats	rats	O
.	.	O

Doxorubicin	doxorubicin	B-Chemical
treatment	treatment	O
also	also	O
caused	caused	O
a	a	O
decrease	decrease	O
in	in	O
RCR	rcr	O
for	for	O
liver	liver	O
mitochondria	mitochondria	O
(	(	O
3.9	3.9	O
+	+	O
/-	/-	O
0.9	0.9	O
versus	versus	O
5.6	5.6	O
+	+	O
/-	/-	O
0.7	0.7	O
for	for	O
control	control	O
rats	rats	O
)	)	O
and	and	O
inhibition	inhibition	O
of	of	O
hepatic	hepatic	O
cytochrome	cytochrome	O
oxidase	oxidase	O
activity	activity	O
.	.	O

Coadministration	coadministration	O
of	of	O
carvedilol	carvedilol	O
decreased	decreased	O
the	the	O
extent	extent	O
of	of	O
cellular	cellular	O
vacuolization	vacuolization	O
in	in	O
cardiac	cardiac	O
myocytes	myocytes	O
and	and	O
prevented	prevented	O
the	the	O
inhibitory	inhibitory	O
effect	effect	O
of	of	O
doxorubicin	doxorubicin	B-Chemical
on	on	O
mitochondrial	mitochondrial	O
respiration	respiration	O
in	in	O
both	both	O
heart	heart	O
and	and	O
liver	liver	O
.	.	O

Carvedilol	carvedilol	O
also	also	O
prevented	prevented	O
the	the	O
decrease	decrease	O
in	in	O
mitochondrial	mitochondrial	O
Ca(2	ca(2	O
+	+	O
)	)	O
loading	loading	O
capacity	capacity	O
and	and	O
the	the	O
inhibition	inhibition	O
of	of	O
the	the	O
respiratory	respiratory	O
complexes	complexes	O
of	of	O
heart	heart	O
mitochondria	mitochondria	O
caused	caused	O
by	by	O
doxorubicin	doxorubicin	B-Chemical
.	.	O

Carvedilol	carvedilol	O
by	by	O
itself	itself	O
did	did	O
not	not	O
affect	affect	O
any	any	O
of	of	O
the	the	O
parameters	parameters	O
measured	measured	O
for	for	O
heart	heart	O
or	or	O
liver	liver	O
mitochondria	mitochondria	O
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
this	this	O
protection	protection	O
by	by	O
carvedilol	carvedilol	O
against	against	O
both	both	O
the	the	O
structural	structural	O
and	and	O
functional	functional	O
cardiac	cardiac	O
tissue	tissue	O
damage	damage	O
may	may	O
afford	afford	O
significant	significant	O
clinical	clinical	O
advantage	advantage	O
in	in	O
minimizing	minimizing	O
the	the	O
dose-limiting	dose-limiting	O
mitochondrial	mitochondrial	B-Disease
dysfunction	dysfunction	I-Disease
and	and	O
cardiomyopathy	cardiomyopathy	B-Disease
that	that	O
accompanies	accompanies	O
long-term	long-term	O
doxorubicin	doxorubicin	B-Chemical
therapy	therapy	O
in	in	O
cancer	cancer	B-Disease
patients	patients	O
.	.	O

Cocaine-induced	cocaine-induced	O
hyperactivity	hyperactivity	B-Disease
is	is	O
more	more	O
influenced	influenced	O
by	by	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
agonists	agonists	O
than	than	O
amphetamine-induced	amphetamine-induced	O
hyperactivity	hyperactivity	B-Disease
.	.	O

The	the	O
influence	influence	O
of	of	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
agonists	agonists	O
and	and	O
antagonists	antagonists	O
on	on	O
cocaine-and	cocaine-and	O
amphetamine-induced	amphetamine-induced	O
hyperactivity	hyperactivity	B-Disease
was	was	O
examined	examined	O
in	in	O
mice	mice	O
.	.	O

All	all	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
agonists	agonists	O
significantly	significantly	O
decreased	decreased	O
the	the	O
locomotor	locomotor	O
activity	activity	O
in	in	O
mice	mice	O
,	,	O
and	and	O
the	the	O
effects	effects	O
were	were	O
dose-dependent	dose-dependent	O
.	.	O

It	it	O
seems	seems	O
that	that	O
adenosine	adenosine	B-Chemical
A1	a1	O
and	and	O
A2	a2	O
receptors	receptors	O
might	might	O
be	be	O
involved	involved	O
in	in	O
this	this	O
reaction	reaction	O
.	.	O

Moreover	moreover	O
,	,	O
all	all	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
agonists	agonists	O
:	:	O
2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine	2-p-(2-carboxyethyl)phenethylamino-5'-n-ethylcarboxamidoadenosine	O
(	(	O
CGS	cgs	O
21680	21680	O
)	)	O
,	,	O
A2A	a2a	O
receptor	receptor	O
agonist	agonist	O
,	,	O
N6-cyclopentyladenosine	n6-cyclopentyladenosine	O
(	(	O
CPA	cpa	B-Chemical
)	)	O
,	,	O
A1	a1	O
receptor	receptor	O
agonist	agonist	O
,	,	O
and	and	O
5'-N-ethylcarboxamidoadenosine	5'-n-ethylcarboxamidoadenosine	O
(	(	O
NECA	neca	O
)	)	O
,	,	O
A2/A1	a2/a1	O
receptor	receptor	O
agonist	agonist	O
significantly	significantly	O
and	and	O
dose-dependently	dose-dependently	O
decreased	decreased	O
cocaine-induced	cocaine-induced	O
locomotor	locomotor	O
activity	activity	O
.	.	O

CPA	cpa	B-Chemical
reduced	reduced	O
cocaine	cocaine	B-Chemical
action	action	O
at	at	O
the	the	O
doses	doses	O
which	which	O
,	,	O
given	given	O
alone	alone	O
,	,	O
did	did	O
not	not	O
influence	influence	O
motility	motility	O
,	,	O
while	while	O
CGS	cgs	O
21680	21680	O
and	and	O
NECA	neca	O
decreased	decreased	O
the	the	O
action	action	O
of	of	O
cocaine	cocaine	B-Chemical
at	at	O
the	the	O
doses	doses	O
which	which	O
,	,	O
given	given	O
alone	alone	O
,	,	O
decreased	decreased	O
locomotor	locomotor	O
activity	activity	O
in	in	O
animals	animals	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
the	the	O
involvement	involvement	O
of	of	O
both	both	O
adenosine	adenosine	B-Chemical
receptors	receptors	O
in	in	O
the	the	O
action	action	O
of	of	O
cocaine	cocaine	B-Chemical
although	although	O
agonists	agonists	O
of	of	O
A1	a1	O
receptors	receptors	O
seem	seem	O
to	to	O
have	have	O
stronger	stronger	O
influence	influence	O
on	on	O
it	it	O
.	.	O

The	the	O
selective	selective	O
blockade	blockade	O
of	of	O
A2	a2	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
by	by	O
DMPX	dmpx	O
(	(	O
3,7-dimethyl-1-propargylxanthine	3,7-dimethyl-1-propargylxanthine	O
)	)	O
significantly	significantly	O
enhanced	enhanced	O
cocaine-induced	cocaine-induced	O
locomotor	locomotor	O
activity	activity	O
of	of	O
animals	animals	O
.	.	O

Caffeine	caffeine	B-Chemical
had	had	O
similar	similar	O
action	action	O
but	but	O
the	the	O
effect	effect	O
was	was	O
not	not	O
significant	significant	O
.	.	O

CPT	cpt	O
(8-cyclopentyltheophylline)--A1	(8-cyclopentyltheophylline)--a1	O
receptor	receptor	O
antagonist	antagonist	O
,	,	O
did	did	O
not	not	O
show	show	O
any	any	O
influence	influence	O
in	in	O
this	this	O
test	test	O
.	.	O

Similarly	similarly	O
,	,	O
all	all	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
agonists	agonists	O
decreased	decreased	O
amphetamine-induced	amphetamine-induced	O
hyperactivity	hyperactivity	B-Disease
,	,	O
but	but	O
at	at	O
the	the	O
higher	higher	O
doses	doses	O
than	than	O
those	those	O
which	which	O
were	were	O
active	active	O
in	in	O
cocaine-induced	cocaine-induced	O
hyperactivity	hyperactivity	B-Disease
.	.	O

The	the	O
selective	selective	O
blockade	blockade	O
of	of	O
A2	a2	O
adenosine	adenosine	B-Chemical
receptors	receptors	O
(	(	O
DMPX	dmpx	O
)	)	O
and	and	O
non-selective	non-selective	O
blockade	blockade	O
of	of	O
adenosine	adenosine	B-Chemical
receptors	receptors	O
(	(	O
caffeine	caffeine	B-Chemical
)	)	O
significantly	significantly	O
increased	increased	O
the	the	O
action	action	O
of	of	O
amphetamine	amphetamine	B-Chemical
in	in	O
the	the	O
locomotor	locomotor	O
activity	activity	O
test	test	O
.	.	O

Our	our	O
results	results	O
have	have	O
shown	shown	O
that	that	O
all	all	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
agonists	agonists	O
(	(	O
A1	a1	O
and	and	O
A2	a2	O
)	)	O
reduce	reduce	O
cocaine-	cocaine-	O
and	and	O
amphetamine-induced	amphetamine-induced	O
locomotor	locomotor	O
activity	activity	O
and	and	O
indicate	indicate	O
that	that	O
cocaine-induced	cocaine-induced	O
hyperactivity	hyperactivity	B-Disease
is	is	O
more	more	O
influenced	influenced	O
by	by	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
agonists	agonists	O
(	(	O
particularly	particularly	O
A1	a1	O
receptors	receptors	O
)	)	O
than	than	O
amphetamine-induced	amphetamine-induced	O
hyperactivity	hyperactivity	B-Disease
.	.	O

Amiodarone	amiodarone	B-Chemical
and	and	O
the	the	O
risk	risk	O
of	of	O
bradyarrhythmia	bradyarrhythmia	O
requiring	requiring	O
permanent	permanent	O
pacemaker	pacemaker	O
in	in	O
elderly	elderly	O
patients	patients	O
with	with	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
and	and	O
prior	prior	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

OBJECTIVES	objectives	O
:	:	O
The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
determine	determine	O
whether	whether	O
the	the	O
use	use	O
of	of	O
amiodarone	amiodarone	B-Chemical
in	in	O
patients	patients	O
with	with	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
(	(	O
AF	af	O
)	)	O
increases	increases	O
the	the	O
risk	risk	O
of	of	O
bradyarrhythmia	bradyarrhythmia	O
requiring	requiring	O
a	a	O
permanent	permanent	O
pacemaker	pacemaker	O
.	.	O

BACKGROUND	background	O
:	:	O
Reports	reports	O
of	of	O
severe	severe	O
bradyarrhythmia	bradyarrhythmia	O
during	during	O
amiodarone	amiodarone	B-Chemical
therapy	therapy	O
are	are	O
infrequent	infrequent	O
and	and	O
limited	limited	O
to	to	O
studies	studies	O
assessing	assessing	O
the	the	O
therapy	therapy	O
's	's	O
use	use	O
in	in	O
the	the	O
management	management	O
of	of	O
patients	patients	O
with	with	O
ventricular	ventricular	B-Disease
arrhythmias	arrhythmias	B-Disease
.	.	O

METHODS	methods	O
:	:	O
A	a	O
study	study	O
cohort	cohort	O
of	of	O
8,770	8,770	O
patients	patients	O
age	age	O
>	>	O
or	or	O
=	=	O
65	65	O
years	years	O
with	with	O
a	a	O
new	new	O
diagnosis	diagnosis	O
of	of	O
AF	af	O
was	was	O
identified	identified	O
from	from	O
a	a	O
provincewide	provincewide	O
database	database	O
of	of	O
Quebec	quebec	O
residents	residents	O
with	with	O
a	a	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
(	(	O
MI	mi	O
)	)	O
between	between	O
1991	1991	O
and	and	O
1999	1999	O
.	.	O

Using	using	O
a	a	O
nested	nested	O
case-control	case-control	O
design	design	O
,	,	O
477	477	O
cases	cases	O
of	of	O
bradyarrhythmia	bradyarrhythmia	O
requiring	requiring	O
a	a	O
permanent	permanent	O
pacemaker	pacemaker	O
were	were	O
matched	matched	O
(	(	O
1:4	1:4	O
)	)	O
to	to	O
1,908	1,908	O
controls	controls	O
.	.	O

Multivariable	multivariable	O
logistic	logistic	O
regression	regression	O
was	was	O
used	used	O
to	to	O
estimate	estimate	O
the	the	O
odds	odds	O
ratio	ratio	O
(	(	O
OR	or	O
)	)	O
of	of	O
pacemaker	pacemaker	O
insertion	insertion	O
associated	associated	O
with	with	O
amiodarone	amiodarone	B-Chemical
use	use	O
,	,	O
controlling	controlling	O
for	for	O
baseline	baseline	O
risk	risk	O
factors	factors	O
and	and	O
exposure	exposure	O
to	to	O
sotalol	sotalol	O
,	,	O
Class	class	O
I	i	O
antiarrhythmic	antiarrhythmic	O
agents	agents	O
,	,	O
beta-blockers	beta-blockers	O
,	,	O
calcium	calcium	B-Chemical
channel	channel	I-Chemical
blockers	blockers	I-Chemical
,	,	O
and	and	O
digoxin	digoxin	O
.	.	O

RESULTS	results	O
:	:	O
amiodarone	amiodarone	B-Chemical
use	use	O
was	was	O
associated	associated	O
with	with	O
an	an	O
increased	increased	O
risk	risk	O
of	of	O
pacemaker	pacemaker	O
insertion	insertion	O
(	(	O
OR	or	O
:	:	O
2.14	2.14	O
,	,	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
[	[	O
CI	ci	O
]	]	O
:	:	O
1.30	1.30	O
to	to	O
3.54	3.54	O
)	)	O
.	.	O

This	this	O
effect	effect	O
was	was	O
modified	modified	O
by	by	O
gender	gender	O
,	,	O
with	with	O
a	a	O
greater	greater	O
risk	risk	O
in	in	O
women	women	O
versus	versus	O
men	men	O
(	(	O
OR	or	O
:	:	O
3.86	3.86	O
,	,	O
95	95	O
%	%	O
CI	ci	O
:	:	O
1.70	1.70	O
to	to	O
8.75	8.75	O
vs.	vs.	O
OR	or	O
:	:	O
1.52	1.52	O
,	,	O
95	95	O
%	%	O
CI	ci	O
:	:	O
0.80	0.80	O
to	to	O
2.89	2.89	O
)	)	O
.	.	O

Digoxin	digoxin	O
was	was	O
the	the	O
only	only	O
other	other	O
medication	medication	O
associated	associated	O
with	with	O
an	an	O
increased	increased	O
risk	risk	O
of	of	O
pacemaker	pacemaker	O
insertion	insertion	O
(	(	O
OR	or	O
:	:	O
1.78	1.78	O
,	,	O
95	95	O
%	%	O
CI	ci	O
:	:	O
1.37	1.37	O
to	to	O
2.31	2.31	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
This	this	O
study	study	O
suggests	suggests	O
that	that	O
the	the	O
use	use	O
of	of	O
amiodarone	amiodarone	B-Chemical
in	in	O
elderly	elderly	O
patients	patients	O
with	with	O
AF	af	O
and	and	O
a	a	O
previous	previous	O
MI	mi	O
increases	increases	O
the	the	O
risk	risk	O
of	of	O
bradyarrhythmia	bradyarrhythmia	O
requiring	requiring	O
a	a	O
permanent	permanent	O
pacemaker	pacemaker	O
.	.	O

The	the	O
finding	finding	O
of	of	O
an	an	O
augmented	augmented	O
risk	risk	O
of	of	O
pacemaker	pacemaker	O
insertion	insertion	O
in	in	O
elderly	elderly	O
women	women	O
receiving	receiving	O
amiodarone	amiodarone	B-Chemical
requires	requires	O
further	further	O
investigation	investigation	O
.	.	O

Indomethacin-induced	indomethacin-induced	O
morphologic	morphologic	O
changes	changes	O
in	in	O
the	the	O
rat	rat	O
urinary	urinary	O
bladder	bladder	O
epithelium	epithelium	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
To	to	O
evaluate	evaluate	O
the	the	O
morphologic	morphologic	O
changes	changes	O
in	in	O
rat	rat	O
urothelium	urothelium	O
induced	induced	O
by	by	O
indomethacin	indomethacin	B-Chemical
.	.	O

Nonsteroidal	nonsteroidal	O
anti-inflammatory	anti-inflammatory	O
drug-induced	drug-induced	O
cystitis	cystitis	B-Disease
is	is	O
a	a	O
poorly	poorly	O
recognized	recognized	O
and	and	O
under-reported	under-reported	O
condition	condition	O
.	.	O

In	in	O
addition	addition	O
to	to	O
tiaprofenic	tiaprofenic	B-Chemical
acid	acid	I-Chemical
,	,	O
indomethacin	indomethacin	B-Chemical
has	has	O
been	been	O
reported	reported	O
to	to	O
be	be	O
associated	associated	O
with	with	O
this	this	O
condition	condition	O
.	.	O

METHODS	methods	O
:	:	O
Three	three	O
groups	groups	O
were	were	O
established	established	O
:	:	O
a	a	O
control	control	O
group	group	O
(	(	O
n	n	O
=	=	O
10	10	O
)	)	O
,	,	O
a	a	O
high-dose	high-dose	O
group	group	O
(	(	O
n	n	O
=	=	O
10	10	O
)	)	O
,	,	O
treated	treated	O
with	with	O
one	one	O
intraperitoneal	intraperitoneal	O
injection	injection	O
of	of	O
indomethacin	indomethacin	B-Chemical
20	20	O
mg/kg	mg/kg	O
,	,	O
and	and	O
a	a	O
therapeutic	therapeutic	O
dose	dose	O
group	group	O
(	(	O
n	n	O
=	=	O
10	10	O
)	)	O
in	in	O
which	which	O
oral	oral	O
indomethacin	indomethacin	B-Chemical
was	was	O
administered	administered	O
3.25	3.25	O
mg/kg	mg/kg	O
body	body	B-Disease
weight	weight	I-Disease
daily	daily	O
for	for	O
3	3	O
weeks	weeks	O
.	.	O

The	the	O
animals	animals	O
were	were	O
then	then	O
killed	killed	O
and	and	O
the	the	O
bladders	bladders	O
removed	removed	O
for	for	O
light	light	O
and	and	O
electron	electron	O
microscopic	microscopic	O
studies	studies	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
light	light	O
microscopic	microscopic	O
findings	findings	O
showed	showed	O
some	some	O
focal	focal	O
epithelial	epithelial	O
degeneration	degeneration	O
that	that	O
was	was	O
more	more	O
prominent	prominent	O
in	in	O
the	the	O
high-dose	high-dose	O
group	group	O
.	.	O

When	when	O
compared	compared	O
with	with	O
the	the	O
control	control	O
group	group	O
,	,	O
both	both	O
indomethacin	indomethacin	B-Chemical
groups	groups	O
revealed	revealed	O
statistically	statistically	O
increased	increased	O
numbers	numbers	O
of	of	O
mast	mast	O
cells	cells	O
in	in	O
the	the	O
mucosa	mucosa	O
(	(	O
P	p	O
<	<	O
0.0001	0.0001	O
)	)	O
and	and	O
penetration	penetration	O
of	of	O
lanthanum	lanthanum	O
nitrate	nitrate	O
through	through	O
intercellular	intercellular	O
areas	areas	O
of	of	O
the	the	O
epithelium	epithelium	O
.	.	O

Furthermore	furthermore	O
,	,	O
the	the	O
difference	difference	O
in	in	O
mast	mast	O
cell	cell	O
counts	counts	O
between	between	O
the	the	O
high	high	O
and	and	O
therapeutic	therapeutic	O
dose	dose	O
groups	groups	O
was	was	O
also	also	O
statistically	statistically	O
significant	significant	O
(	(	O
P	p	O
<	<	O
0.0001	0.0001	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Indomethacin	indomethacin	B-Chemical
resulted	resulted	O
in	in	O
histopathologic	histopathologic	O
findings	findings	O
typical	typical	O
of	of	O
interstitial	interstitial	O
cystitis	cystitis	B-Disease
,	,	O
such	such	O
as	as	O
leaky	leaky	O
bladder	bladder	O
epithelium	epithelium	O
and	and	O
mucosal	mucosal	O
mastocytosis	mastocytosis	O
.	.	O

The	the	O
true	true	O
incidence	incidence	O
of	of	O
nonsteroidal	nonsteroidal	O
anti-inflammatory	anti-inflammatory	O
drug-induced	drug-induced	O
cystitis	cystitis	B-Disease
in	in	O
humans	humans	O
must	must	O
be	be	O
clarified	clarified	O
by	by	O
prospective	prospective	O
clinical	clinical	O
trials	trials	O
.	.	O

An	an	O
open-label	open-label	O
phase	phase	O
II	ii	O
study	study	O
of	of	O
low-dose	low-dose	O
thalidomide	thalidomide	B-Chemical
in	in	O
androgen-independent	androgen-independent	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
.	.	O

The	the	O
antiangiogenic	antiangiogenic	O
effects	effects	O
of	of	O
thalidomide	thalidomide	B-Chemical
have	have	O
been	been	O
assessed	assessed	O
in	in	O
clinical	clinical	O
trials	trials	O
in	in	O
patients	patients	O
with	with	O
various	various	O
solid	solid	O
and	and	O
haematological	haematological	O
malignancies	malignancies	B-Disease
.	.	O

Thalidomide	thalidomide	B-Chemical
blocks	blocks	O
the	the	O
activity	activity	O
of	of	O
angiogenic	angiogenic	O
agents	agents	O
including	including	O
bFGF	bfgf	O
,	,	O
VEGF	vegf	O
and	and	O
IL-6	il-6	O
.	.	O

We	we	O
undertook	undertook	O
an	an	O
open-label	open-label	O
study	study	O
using	using	O
thalidomide	thalidomide	B-Chemical
100	100	O
mg	mg	O
once	once	O
daily	daily	O
for	for	O
up	up	O
to	to	O
6	6	O
months	months	O
in	in	O
20	20	O
men	men	O
with	with	O
androgen-independent	androgen-independent	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
.	.	O

The	the	O
mean	mean	O
time	time	O
of	of	O
study	study	O
was	was	O
109	109	O
days	days	O
(	(	O
median	median	O
107	107	O
,	,	O
range	range	O
4	4	O
-	-	O
184	184	O
days	days	O
)	)	O
.	.	O

Patients	patients	O
underwent	underwent	O
regular	regular	O
measurement	measurement	O
of	of	O
prostate-specific	prostate-specific	O
antigen	antigen	O
(	(	O
PSA	psa	O
)	)	O
,	,	O
urea	urea	B-Chemical
and	and	O
electrolytes	electrolytes	O
,	,	O
serum	serum	O
bFGF	bfgf	O
and	and	O
VEGF	vegf	O
.	.	O

Three	three	O
men	men	O
(	(	O
15	15	O
%	%	O
)	)	O
showed	showed	O
a	a	O
decline	decline	O
in	in	O
serum	serum	O
PSA	psa	O
of	of	O
at	at	O
least	least	O
50	50	O
%	%	O
,	,	O
sustained	sustained	O
throughout	throughout	O
treatment	treatment	O
.	.	O

Of	of	O
16	16	O
men	men	O
treated	treated	O
for	for	O
at	at	O
least	least	O
2	2	O
months	months	O
,	,	O
six	six	O
(	(	O
37.5	37.5	O
%	%	O
)	)	O
showed	showed	O
a	a	O
fall	fall	O
in	in	O
absolute	absolute	O
PSA	psa	O
by	by	O
a	a	O
median	median	O
of	of	O
48	48	O
%	%	O
.	.	O

Increasing	increasing	O
levels	levels	O
of	of	O
serum	serum	O
bFGF	bfgf	O
and	and	O
VEGF	vegf	O
were	were	O
associated	associated	O
with	with	O
progressive	progressive	O
disease	disease	O
;	;	O
five	five	O
of	of	O
six	six	O
men	men	O
who	who	O
demonstrated	demonstrated	O
a	a	O
fall	fall	O
in	in	O
PSA	psa	O
also	also	O
showed	showed	O
a	a	O
decline	decline	O
in	in	O
bFGF	bfgf	O
and	and	O
VEGF	vegf	O
levels	levels	O
,	,	O
and	and	O
three	three	O
of	of	O
four	four	O
men	men	O
with	with	O
a	a	O
rising	rising	O
PSA	psa	O
showed	showed	O
an	an	O
increase	increase	O
in	in	O
both	both	O
growth	growth	O
factors	factors	O
.	.	O

Adverse	adverse	O
effects	effects	O
included	included	O
constipation	constipation	B-Disease
,	,	O
morning	morning	O
drowsiness	drowsiness	O
,	,	O
dizziness	dizziness	B-Disease
and	and	O
rash	rash	B-Disease
,	,	O
and	and	O
resulted	resulted	O
in	in	O
withdrawal	withdrawal	O
from	from	O
the	the	O
study	study	O
by	by	O
three	three	O
men	men	O
.	.	O

Evidence	evidence	O
of	of	O
peripheral	peripheral	O
sensory	sensory	O
neuropathy	neuropathy	B-Disease
was	was	O
found	found	O
in	in	O
nine	nine	O
of	of	O
13	13	O
men	men	O
before	before	O
treatment	treatment	O
.	.	O

In	in	O
the	the	O
seven	seven	O
men	men	O
who	who	O
completed	completed	O
six	six	O
months	months	O
on	on	O
thalidomide	thalidomide	B-Chemical
,	,	O
subclinical	subclinical	O
evidence	evidence	O
of	of	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
was	was	O
found	found	O
in	in	O
four	four	O
before	before	O
treatment	treatment	O
,	,	O
but	but	O
in	in	O
all	all	O
seven	seven	O
at	at	O
repeat	repeat	O
testing	testing	O
.	.	O

The	the	O
findings	findings	O
indicate	indicate	O
that	that	O
thalidomide	thalidomide	B-Chemical
may	may	O
be	be	O
an	an	O
option	option	O
for	for	O
patients	patients	O
who	who	O
have	have	O
failed	failed	O
other	other	O
forms	forms	O
of	of	O
therapy	therapy	O
,	,	O
provided	provided	O
close	close	O
follow-up	follow-up	O
is	is	O
maintained	maintained	O
for	for	O
development	development	O
of	of	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
.	.	O

Central	central	O
nervous	nervous	O
system	system	O
toxicity	toxicity	B-Disease
following	following	O
the	the	O
administration	administration	O
of	of	O
levobupivacaine	levobupivacaine	O
for	for	O
lumbar	lumbar	O
plexus	plexus	O
block	block	O
:	:	O
A	a	O
report	report	O
of	of	O
two	two	O
cases	cases	O
.	.	O

BACKGROUND	background	O
AND	and	O
OBJECTIVES	objectives	O
:	:	O
Central	central	O
nervous	nervous	O
system	system	O
and	and	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
following	following	O
the	the	O
administration	administration	O
of	of	O
local	local	O
anesthetics	anesthetics	O
is	is	O
a	a	O
recognized	recognized	O
complication	complication	O
of	of	O
regional	regional	O
anesthesia	anesthesia	O
.	.	O

Levobupivacaine	levobupivacaine	O
,	,	O
the	the	O
pure	pure	O
S(-	s(-	O
)	)	O
enantiomer	enantiomer	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
,	,	O
was	was	O
developed	developed	O
to	to	O
improve	improve	O
the	the	O
cardiac	cardiac	O
safety	safety	O
profile	profile	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
.	.	O

We	we	O
describe	describe	O
2	2	O
cases	cases	O
of	of	O
grand	grand	O
mal	mal	O
seizures	seizures	B-Disease
following	following	O
accidental	accidental	O
intravascular	intravascular	O
injection	injection	O
of	of	O
levobupivacaine	levobupivacaine	O
.	.	O

CASE	case	O
REPORT	report	O
:	:	O
Two	two	O
patients	patients	O
presenting	presenting	O
for	for	O
elective	elective	O
orthopedic	orthopedic	O
surgery	surgery	O
of	of	O
the	the	O
lower	lower	O
limb	limb	O
underwent	underwent	O
blockade	blockade	O
of	of	O
the	the	O
lumbar	lumbar	O
plexus	plexus	O
via	via	O
the	the	O
posterior	posterior	O
approach	approach	O
.	.	O

Immediately	immediately	O
after	after	O
the	the	O
administration	administration	O
of	of	O
levobupivacaine	levobupivacaine	O
0.5	0.5	O
%	%	O
with	with	O
epinephrine	epinephrine	B-Chemical
2.5	2.5	O
microgram/mL	microgram/ml	O
,	,	O
the	the	O
patients	patients	O
developed	developed	O
grand	grand	O
mal	mal	O
seizures	seizures	B-Disease
,	,	O
despite	despite	O
negative	negative	O
aspiration	aspiration	O
for	for	O
blood	blood	O
and	and	O
no	no	O
clinical	clinical	O
signs	signs	O
of	of	O
intravenous	intravenous	O
epinephrine	epinephrine	B-Chemical
administration	administration	O
.	.	O

The	the	O
seizures	seizures	B-Disease
were	were	O
successfully	successfully	O
treated	treated	O
with	with	O
sodium	sodium	B-Chemical
thiopental	thiopental	O
in	in	O
addition	addition	O
to	to	O
succinylcholine	succinylcholine	B-Chemical
in	in	O
1	1	O
patient	patient	O
.	.	O

Neither	neither	O
patient	patient	O
developed	developed	O
signs	signs	O
of	of	O
cardiovascular	cardiovascular	O
toxicity	toxicity	B-Disease
.	.	O

Both	both	O
patients	patients	O
were	were	O
treated	treated	O
preoperatively	preoperatively	O
with	with	O
beta-adrenergic	beta-adrenergic	O
antagonist	antagonist	O
medications	medications	O
,	,	O
which	which	O
may	may	O
have	have	O
masked	masked	O
the	the	O
cardiovascular	cardiovascular	O
signs	signs	O
of	of	O
the	the	O
unintentional	unintentional	O
intravascular	intravascular	O
administration	administration	O
of	of	O
levobupivacaine	levobupivacaine	O
with	with	O
epinephrine	epinephrine	B-Chemical
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Although	although	O
levobupivacaine	levobupivacaine	O
may	may	O
have	have	O
a	a	O
safer	safer	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
profile	profile	O
than	than	O
racemic	racemic	O
bupivacaine	bupivacaine	B-Chemical
,	,	O
if	if	O
adequate	adequate	O
amounts	amounts	O
of	of	O
levobupivacaine	levobupivacaine	O
reach	reach	O
the	the	O
circulation	circulation	O
,	,	O
it	it	O
will	will	O
result	result	O
in	in	O
convulsions	convulsions	B-Disease
.	.	O

Plasma	plasma	O
concentrations	concentrations	O
sufficient	sufficient	O
to	to	O
result	result	O
in	in	O
central	central	O
nervous	nervous	O
system	system	O
toxicity	toxicity	B-Disease
did	did	O
not	not	O
produce	produce	O
manifestations	manifestations	O
of	of	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
in	in	O
these	these	O
2	2	O
patients	patients	O
.	.	O

Amiodarone-induced	amiodarone-induced	O
torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
during	during	O
bladder	bladder	O
irrigation	irrigation	O
:	:	O
an	an	O
unusual	unusual	O
presentation	presentation	O
--	--	O
a	a	O
case	case	O
report	report	O
.	.	O

The	the	O
authors	authors	O
present	present	O
a	a	O
case	case	O
of	of	O
early	early	O
(	(	O
within	within	O
4	4	O
days	days	O
)	)	O
development	development	O
of	of	O
torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
(	(	O
TdP	tdp	B-Disease
)	)	O
associated	associated	O
with	with	O
oral	oral	O
amiodarone	amiodarone	B-Chemical
therapy	therapy	O
.	.	O

Consistent	consistent	O
with	with	O
other	other	O
reports	reports	O
this	this	O
case	case	O
of	of	O
TdP	tdp	B-Disease
occurred	occurred	O
in	in	O
the	the	O
context	context	O
of	of	O
multiple	multiple	O
exacerbating	exacerbating	O
factors	factors	O
including	including	O
hypokalemia	hypokalemia	O
and	and	O
digoxin	digoxin	O
excess	excess	O
.	.	O

Transient	transient	O
prolongation	prolongation	O
of	of	O
the	the	O
QT	qt	O
during	during	O
bladder	bladder	O
irrigation	irrigation	O
prompted	prompted	O
the	the	O
episode	episode	O
of	of	O
TdP.	tdp.	O
It	it	O
is	is	O
well	well	O
known	known	O
that	that	O
bradycardia	bradycardia	B-Disease
exacerbates	exacerbates	O
acquired	acquired	O
TdP.	tdp.	O
The	the	O
authors	authors	O
speculate	speculate	O
that	that	O
the	the	O
increased	increased	O
vagal	vagal	O
tone	tone	O
during	during	O
bladder	bladder	O
irrigation	irrigation	O
,	,	O
a	a	O
vagal	vagal	O
maneuver	maneuver	O
,	,	O
in	in	O
the	the	O
context	context	O
of	of	O
amiodarone	amiodarone	B-Chemical
therapy	therapy	O
resulted	resulted	O
in	in	O
amiodarone-induced	amiodarone-induced	O
proarrhythmia	proarrhythmia	O
.	.	O

In	in	O
the	the	O
absence	absence	O
of	of	O
amiodarone	amiodarone	B-Chemical
therapy	therapy	O
,	,	O
a	a	O
second	second	O
bladder	bladder	O
irrigation	irrigation	O
did	did	O
not	not	O
induce	induce	O
TdP	tdp	B-Disease
despite	despite	O
hypokalemia	hypokalemia	O
and	and	O
hypomagnesemia	hypomagnesemia	O
.	.	O

Anaesthetic	anaesthetic	O
complications	complications	O
associated	associated	O
with	with	O
myotonia	myotonia	B-Disease
congenita	congenita	I-Disease
:	:	O
case	case	O
study	study	O
and	and	O
comparison	comparison	O
with	with	O
other	other	O
myotonic	myotonic	B-Disease
disorders	disorders	I-Disease
.	.	O

Myotonia	myotonia	B-Disease
congenita	congenita	I-Disease
(	(	O
MC	mc	O
)	)	O
is	is	O
caused	caused	O
by	by	O
a	a	O
defect	defect	O
in	in	O
the	the	O
skeletal	skeletal	O
muscle	muscle	O
chloride	chloride	O
channel	channel	O
function	function	O
,	,	O
which	which	O
may	may	O
cause	cause	O
sustained	sustained	O
membrane	membrane	O
depolarisation	depolarisation	O
.	.	O

We	we	O
describe	describe	O
a	a	O
previously	previously	O
healthy	healthy	O
32-year-old	32-year-old	O
woman	woman	O
who	who	O
developed	developed	O
a	a	O
life-threatening	life-threatening	O
muscle	muscle	O
spasm	spasm	B-Disease
and	and	O
secondary	secondary	O
ventilation	ventilation	O
difficulties	difficulties	O
following	following	O
a	a	O
preoperative	preoperative	O
injection	injection	O
of	of	O
suxamethonium	suxamethonium	B-Chemical
.	.	O

The	the	O
muscle	muscle	O
spasms	spasms	O
disappeared	disappeared	O
spontaneously	spontaneously	O
and	and	O
the	the	O
surgery	surgery	O
proceeded	proceeded	O
without	without	O
further	further	O
problems	problems	O
.	.	O

When	when	O
subsequently	subsequently	O
questioned	questioned	O
,	,	O
she	she	O
reported	reported	O
minor	minor	O
symptoms	symptoms	O
suggesting	suggesting	O
a	a	O
myotonic	myotonic	O
condition	condition	O
.	.	O

Myotonia	myotonia	O
was	was	O
found	found	O
on	on	O
clinical	clinical	O
examination	examination	O
and	and	O
EMG	emg	O
.	.	O

The	the	O
diagnosis	diagnosis	O
MC	mc	O
was	was	O
confirmed	confirmed	O
genetically	genetically	O
.	.	O

Neither	neither	O
the	the	O
patient	patient	O
nor	nor	O
the	the	O
anaesthetist	anaesthetist	O
were	were	O
aware	aware	O
of	of	O
the	the	O
diagnosis	diagnosis	O
before	before	O
this	this	O
potentially	potentially	O
lethal	lethal	O
complication	complication	O
occurred	occurred	O
.	.	O

We	we	O
give	give	O
a	a	O
brief	brief	O
overview	overview	O
of	of	O
ion	ion	O
channel	channel	O
disorders	disorders	O
including	including	O
malignant	malignant	B-Disease
hyperthermia	hyperthermia	B-Disease
and	and	O
their	their	O
anaesthetic	anaesthetic	O
considerations	considerations	O
.	.	O

Respiratory	respiratory	O
pattern	pattern	O
in	in	O
a	a	O
rat	rat	O
model	model	O
of	of	O
epilepsy	epilepsy	B-Disease
.	.	O

PURPOSE	purpose	O
:	:	O
Apnea	apnea	B-Disease
is	is	O
known	known	O
to	to	O
occur	occur	O
during	during	O
seizures	seizures	B-Disease
,	,	O
but	but	O
systematic	systematic	O
studies	studies	O
of	of	O
ictal	ictal	O
respiratory	respiratory	O
changes	changes	O
in	in	O
adults	adults	O
are	are	O
few	few	O
.	.	O

Data	data	O
regarding	regarding	O
respiratory	respiratory	O
pattern	pattern	O
defects	defects	O
during	during	O
interictal	interictal	O
periods	periods	O
also	also	O
are	are	O
scarce	scarce	O
.	.	O

Here	here	O
we	we	O
sought	sought	O
to	to	O
generate	generate	O
information	information	O
with	with	O
regard	regard	O
to	to	O
the	the	O
interictal	interictal	O
period	period	O
in	in	O
animals	animals	O
with	with	O
pilocarpine-induced	pilocarpine-induced	O
epilepsy	epilepsy	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Twelve	twelve	O
rats	rats	O
(	(	O
six	six	O
chronically	chronically	O
epileptic	epileptic	B-Disease
animals	animals	O
and	and	O
six	six	O
controls	controls	O
)	)	O
were	were	O
anesthetized	anesthetized	O
,	,	O
given	given	O
tracheotomies	tracheotomies	O
,	,	O
and	and	O
subjected	subjected	O
to	to	O
hyperventilation	hyperventilation	O
or	or	O
hypoventilation	hypoventilation	O
conditions	conditions	O
.	.	O

Breathing	breathing	O
movements	movements	O
caused	caused	O
changes	changes	O
in	in	O
thoracic	thoracic	O
volume	volume	O
and	and	O
forced	forced	O
air	air	O
to	to	O
flow	flow	O
tidally	tidally	O
through	through	O
a	a	O
pneumotachograph	pneumotachograph	O
.	.	O

This	this	O
flow	flow	O
was	was	O
measured	measured	O
by	by	O
using	using	O
a	a	O
differential	differential	O
pressure	pressure	O
transducer	transducer	O
,	,	O
passed	passed	O
through	through	O
a	a	O
polygraph	polygraph	O
,	,	O
and	and	O
from	from	O
this	this	O
to	to	O
a	a	O
computer	computer	O
with	with	O
custom	custom	O
software	software	O
that	that	O
derived	derived	O
ventilation	ventilation	O
(	(	O
VE	ve	O
)	)	O
,	,	O
tidal	tidal	O
volume	volume	O
(	(	O
VT	vt	O
)	)	O
,	,	O
inspiratory	inspiratory	O
time	time	O
(	(	O
TI	ti	O
)	)	O
,	,	O
expiratory	expiratory	O
time	time	O
(	(	O
TE	te	O
)	)	O
,	,	O
breathing	breathing	O
frequency	frequency	O
(	(	O
f	f	O
)	)	O
,	,	O
and	and	O
mean	mean	O
inspiratory	inspiratory	O
flow	flow	O
(	(	O
VT/TI	vt/ti	O
)	)	O
on	on	O
a	a	O
breath-by-breath	breath-by-breath	O
basis	basis	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
hyperventilation	hyperventilation	O
maneuver	maneuver	O
caused	caused	O
a	a	O
decrease	decrease	O
in	in	O
spontaneous	spontaneous	O
ventilation	ventilation	O
in	in	O
pilocarpine-treated	pilocarpine-treated	O
and	and	O
control	control	O
rats	rats	O
.	.	O

Although	although	O
VE	ve	O
had	had	O
a	a	O
similar	similar	O
decrease	decrease	O
in	in	O
both	both	O
groups	groups	O
,	,	O
in	in	O
the	the	O
epileptic	epileptic	B-Disease
group	group	O
,	,	O
the	the	O
decrease	decrease	O
in	in	O
VE	ve	O
was	was	O
due	due	O
to	to	O
a	a	O
significant	significant	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
increase	increase	O
in	in	O
TE	te	O
peak	peak	O
in	in	O
relation	relation	O
to	to	O
that	that	O
of	of	O
the	the	O
control	control	O
animals	animals	O
.	.	O

The	the	O
hypoventilation	hypoventilation	O
maneuver	maneuver	O
led	led	O
to	to	O
an	an	O
increase	increase	O
in	in	O
the	the	O
arterial	arterial	O
Paco2	paco2	O
,	,	O
followed	followed	O
by	by	O
an	an	O
increase	increase	O
in	in	O
VE	ve	O
.	.	O

In	in	O
the	the	O
epileptic	epileptic	B-Disease
group	group	O
,	,	O
the	the	O
increase	increase	O
in	in	O
VE	ve	O
was	was	O
mediated	mediated	O
by	by	O
a	a	O
significant	significant	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
decrease	decrease	O
in	in	O
TE	te	O
peak	peak	O
compared	compared	O
with	with	O
the	the	O
control	control	O
group	group	O
.	.	O

Systemic	systemic	O
application	application	O
of	of	O
KCN	kcn	O
,	,	O
to	to	O
evaluate	evaluate	O
the	the	O
effects	effects	O
of	of	O
peripheral	peripheral	O
chemoreception	chemoreception	O
activation	activation	O
on	on	O
ventilation	ventilation	O
,	,	O
led	led	O
to	to	O
a	a	O
similar	similar	O
increase	increase	O
in	in	O
VE	ve	O
for	for	O
both	both	O
groups	groups	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
data	data	O
indicate	indicate	O
that	that	O
pilocarpine-treated	pilocarpine-treated	O
animals	animals	O
have	have	O
an	an	O
altered	altered	O
ability	ability	O
to	to	O
react	react	O
to	to	O
(	(	O
or	or	O
compensate	compensate	O
for	for	O
)	)	O
blood	blood	O
gas	gas	O
changes	changes	O
with	with	O
changes	changes	O
in	in	O
ventilation	ventilation	O
and	and	O
suggest	suggest	O
that	that	O
it	it	O
is	is	O
centrally	centrally	O
determined	determined	O
.	.	O

We	we	O
speculate	speculate	O
on	on	O
the	the	O
possible	possible	O
relation	relation	O
of	of	O
the	the	O
current	current	O
findings	findings	O
on	on	O
treating	treating	O
different	different	O
epilepsy-associated	epilepsy-associated	O
conditions	conditions	O
.	.	O

Fatal	fatal	O
myeloencephalopathy	myeloencephalopathy	O
due	due	O
to	to	O
intrathecal	intrathecal	O
vincristine	vincristine	B-Chemical
administration	administration	O
.	.	O

Vincristine	vincristine	B-Chemical
was	was	O
accidentally	accidentally	O
given	given	O
intrathecally	intrathecally	O
to	to	O
a	a	O
child	child	O
with	with	O
leukaemia	leukaemia	O
,	,	O
producing	producing	O
sensory	sensory	O
and	and	O
motor	motor	O
dysfunction	dysfunction	O
followed	followed	O
by	by	O
encephalopathy	encephalopathy	B-Disease
and	and	O
death	death	B-Disease
.	.	O

Separate	separate	O
times	times	O
for	for	O
administering	administering	O
vincristine	vincristine	B-Chemical
and	and	O
intrathecal	intrathecal	O
therapy	therapy	O
is	is	O
recommended	recommended	O
.	.	O

Progesterone	progesterone	B-Chemical
potentiation	potentiation	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
arrhythmogenicity	arrhythmogenicity	O
in	in	O
pentobarbital-anesthetized	pentobarbital-anesthetized	O
rats	rats	O
and	and	O
beating	beating	O
rat	rat	O
heart	heart	O
cell	cell	O
cultures	cultures	O
.	.	O

The	the	O
effects	effects	O
of	of	O
progesterone	progesterone	B-Chemical
treatment	treatment	O
on	on	O
bupivacaine	bupivacaine	B-Chemical
arrhythmogenicity	arrhythmogenicity	O
in	in	O
beating	beating	O
rat	rat	O
heart	heart	O
myocyte	myocyte	O
cultures	cultures	O
and	and	O
on	on	O
anesthetized	anesthetized	O
rats	rats	O
were	were	O
determined	determined	O
.	.	O

After	after	O
determining	determining	O
the	the	O
bupivacaine	bupivacaine	B-Chemical
AD50	ad50	O
(	(	O
the	the	O
concentration	concentration	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
that	that	O
caused	caused	O
50	50	O
%	%	O
of	of	O
all	all	O
beating	beating	O
rat	rat	O
heart	heart	O
myocyte	myocyte	O
cultures	cultures	O
to	to	O
become	become	O
arrhythmic	arrhythmic	O
)	)	O
,	,	O
we	we	O
determined	determined	O
the	the	O
effect	effect	O
of	of	O
1-hour	1-hour	O
progesterone	progesterone	B-Chemical
HCl	hcl	O
exposure	exposure	O
on	on	O
myocyte	myocyte	O
contractile	contractile	O
rhythm	rhythm	O
.	.	O

Each	each	O
concentration	concentration	O
of	of	O
progesterone	progesterone	B-Chemical
(	(	O
6.25	6.25	O
,	,	O
12.5	12.5	O
,	,	O
25	25	O
,	,	O
and	and	O
50	50	O
micrograms/ml	micrograms/ml	O
)	)	O
caused	caused	O
a	a	O
significant	significant	O
and	and	O
concentration-dependent	concentration-dependent	O
reduction	reduction	O
in	in	O
the	the	O
AD50	ad50	O
for	for	O
bupivacaine	bupivacaine	B-Chemical
.	.	O

Estradiol	estradiol	B-Chemical
treatment	treatment	O
also	also	O
increased	increased	O
the	the	O
arrhythmogenicity	arrhythmogenicity	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
in	in	O
myocyte	myocyte	O
cultures	cultures	O
,	,	O
but	but	O
was	was	O
only	only	O
one	one	O
fourth	fourth	O
as	as	O
potent	potent	O
as	as	O
progesterone	progesterone	B-Chemical
.	.	O

Neither	neither	O
progesterone	progesterone	B-Chemical
nor	nor	O
estradiol	estradiol	B-Chemical
effects	effects	O
on	on	O
bupivacaine	bupivacaine	B-Chemical
arrhythmogenicity	arrhythmogenicity	O
were	were	O
potentiated	potentiated	O
by	by	O
epinephrine	epinephrine	B-Chemical
.	.	O

Chronic	chronic	O
progesterone	progesterone	B-Chemical
pretreatment	pretreatment	O
(	(	O
5	5	O
mg/kg/day	mg/kg/day	O
for	for	O
21	21	O
days	days	O
)	)	O
caused	caused	O
a	a	O
significant	significant	O
increase	increase	O
in	in	O
bupivacaine	bupivacaine	B-Chemical
arrhythmogenicity	arrhythmogenicity	O
in	in	O
intact	intact	O
pentobarbital-anesthetized	pentobarbital-anesthetized	O
rats	rats	O
.	.	O

There	there	O
was	was	O
a	a	O
significant	significant	O
decrease	decrease	O
in	in	O
the	the	O
time	time	O
to	to	O
onset	onset	O
of	of	O
arrhythmia	arrhythmia	B-Disease
as	as	O
compared	compared	O
with	with	O
control	control	O
nonprogesterone-treated	nonprogesterone-treated	O
rats	rats	O
(	(	O
6.2	6.2	O
+	+	O
/-	/-	O
1.3	1.3	O
vs.	vs.	O
30.8	30.8	O
+	+	O
/-	/-	O
2.5	2.5	O
min	min	O
,	,	O
mean	mean	O
+	+	O
/-	/-	O
SE	se	B-Disease
)	)	O
.	.	O

The	the	O
results	results	O
of	of	O
this	this	O
study	study	O
indicate	indicate	O
that	that	O
progesterone	progesterone	B-Chemical
can	can	O
potentiate	potentiate	O
bupivacaine	bupivacaine	B-Chemical
arrhythmogenicity	arrhythmogenicity	O
both	both	O
in	in	O
vivo	vivo	O
and	and	O
in	in	O
vitro	vitro	O
.	.	O

Potentiation	potentiation	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
arrhythmia	arrhythmia	B-Disease
in	in	O
myocyte	myocyte	O
cultures	cultures	O
suggests	suggests	O
that	that	O
this	this	O
effect	effect	O
is	is	O
at	at	O
least	least	O
partly	partly	O
mediated	mediated	O
at	at	O
the	the	O
myocyte	myocyte	O
level	level	O
.	.	O

Increased	increased	O
serum	serum	O
soluble	soluble	O
Fas	fas	O
in	in	O
patients	patients	O
with	with	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
due	due	O
to	to	O
paracetamol	paracetamol	B-Chemical
overdose	overdose	B-Disease
.	.	O

BACKGROUND/AIMS	background/aims	O
:	:	O
Experimental	experimental	O
studies	studies	O
have	have	O
suggested	suggested	O
that	that	O
apoptosis	apoptosis	O
via	via	O
the	the	O
Fas/Fas	fas/fas	O
Ligand	ligand	O
signaling	signaling	O
system	system	O
may	may	O
play	play	O
an	an	O
important	important	O
role	role	O
in	in	O
the	the	O
development	development	O
of	of	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
.	.	O

The	the	O
aim	aim	O
of	of	O
the	the	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
the	the	O
soluble	soluble	O
form	form	O
of	of	O
Fas	fas	O
in	in	O
patients	patients	O
with	with	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
.	.	O

METHODOLOGY	methodology	O
:	:	O
Serum	serum	O
levels	levels	O
of	of	O
sFas	sfas	O
(	(	O
soluble	soluble	O
Fas	fas	O
)	)	O
were	were	O
measured	measured	O
by	by	O
ELISA	elisa	O
in	in	O
24	24	O
patients	patients	O
with	with	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
and	and	O
10	10	O
normal	normal	O
control	control	O
subjects	subjects	O
.	.	O

Serum	serum	O
levels	levels	O
of	of	O
tumor	tumor	B-Disease
necrosis	necrosis	B-Disease
factor-alpha	factor-alpha	O
and	and	O
interferon-gamma	interferon-gamma	O
were	were	O
also	also	O
determined	determined	O
by	by	O
ELISA	elisa	O
.	.	O

RESULTS	results	O
:	:	O
Serum	serum	O
sFas	sfas	O
was	was	O
significantly	significantly	O
increased	increased	O
in	in	O
patients	patients	O
with	with	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
(	(	O
median	median	O
,	,	O
26.8	26.8	O
U/mL	u/ml	O
;	;	O
range	range	O
,	,	O
6.9	6.9	O
-	-	O
52.7	52.7	O
U/mL	u/ml	O
)	)	O
compared	compared	O
to	to	O
the	the	O
normal	normal	O
controls	controls	O
(	(	O
median	median	O
,	,	O
8.6	8.6	O
U/mL	u/ml	O
;	;	O
range	range	O
,	,	O
6.5	6.5	O
-	-	O
12.0	12.0	O
U/mL	u/ml	O
,	,	O
P	p	O
<	<	O
0.0001	0.0001	O
)	)	O
.	.	O

Levels	levels	O
were	were	O
significantly	significantly	O
greater	greater	O
in	in	O
patients	patients	O
with	with	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
due	due	O
to	to	O
paracetamol	paracetamol	B-Chemical
overdose	overdose	B-Disease
(	(	O
median	median	O
,	,	O
28.7	28.7	O
U/mL	u/ml	O
;	;	O
range	range	O
,	,	O
12.8	12.8	O
-	-	O
52.7	52.7	O
U/mL	u/ml	O
,	,	O
n	n	O
=	=	O
17	17	O
)	)	O
than	than	O
those	those	O
due	due	O
to	to	O
non-A	non-a	O
to	to	O
E	e	O
hepatitis	hepatitis	B-Disease
(	(	O
median	median	O
,	,	O
12.5	12.5	O
U/mL	u/ml	O
;	;	O
range	range	O
,	,	O
6.9	6.9	O
-	-	O
46.0	46.0	O
U/mL	u/ml	O
,	,	O
n	n	O
=	=	O
7	7	O
,	,	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

There	there	O
was	was	O
no	no	O
relationship	relationship	O
of	of	O
sFas	sfas	O
to	to	O
eventual	eventual	O
outcome	outcome	O
in	in	O
the	the	O
patients	patients	O
.	.	O

A	a	O
significant	significant	O
correlation	correlation	O
was	was	O
observed	observed	O
between	between	O
serum	serum	O
sFas	sfas	O
levels	levels	O
and	and	O
aspartate	aspartate	B-Chemical
aminotransferase	aminotransferase	O
(	(	O
r	r	O
=	=	O
0.613	0.613	O
,	,	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
increased	increased	O
concentration	concentration	O
of	of	O
sFas	sfas	O
in	in	O
serum	serum	O
of	of	O
patients	patients	O
with	with	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
may	may	O
reflect	reflect	O
activation	activation	O
of	of	O
Fas-mediated	fas-mediated	O
apoptosis	apoptosis	O
in	in	O
the	the	O
liver	liver	O
and	and	O
this	this	O
together	together	O
with	with	O
increased	increased	O
tumor	tumor	B-Disease
necrosis	necrosis	B-Disease
factor-alpha	factor-alpha	O
may	may	O
be	be	O
an	an	O
important	important	O
factor	factor	O
in	in	O
liver	liver	O
cell	cell	O
loss	loss	O
.	.	O

Bilateral	bilateral	O
subthalamic	subthalamic	O
nucleus	nucleus	O
stimulation	stimulation	O
for	for	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

High	high	O
frequency	frequency	O
stimulation	stimulation	O
of	of	O
the	the	O
subthalamic	subthalamic	O
nucleus	nucleus	O
(	(	O
STN	stn	O
)	)	O
is	is	O
known	known	O
to	to	O
ameliorate	ameliorate	O
the	the	O
signs	signs	B-Disease
and	and	I-Disease
symptoms	symptoms	I-Disease
of	of	O
advanced	advanced	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

AIM	aim	O
:	:	O
We	we	O
studied	studied	O
the	the	O
effect	effect	O
of	of	O
high	high	O
frequency	frequency	O
STN	stn	O
stimulation	stimulation	O
in	in	O
23	23	O
patients	patients	O
.	.	O

METHOD	method	O
:	:	O
Twenty-three	twenty-three	O
patients	patients	O
suffering	suffering	O
from	from	O
severe	severe	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
(	(	O
Stages	stages	O
III-V	iii-v	O
on	on	O
Hoehn	hoehn	O
and	and	O
Yahr	yahr	O
scale	scale	O
)	)	O
and	and	O
,	,	O
particularly	particularly	O
bradykinesia	bradykinesia	O
,	,	O
rigidity	rigidity	B-Disease
,	,	O
and	and	O
levodopa-induced	levodopa-induced	O
dyskinesias	dyskinesias	B-Disease
underwent	underwent	O
bilateral	bilateral	O
implantation	implantation	O
of	of	O
electrodes	electrodes	O
in	in	O
the	the	O
STN	stn	O
.	.	O

Preoperative	preoperative	O
and	and	O
postoperative	postoperative	O
assessments	assessments	O
of	of	O
these	these	O
patients	patients	O
at	at	O
1	1	O
,	,	O
3	3	O
,	,	O
6	6	O
and	and	O
12	12	O
months	months	O
follow-up	follow-up	O
,	,	O
in	in	O
"	"	O
on	on	O
"	"	O
and	and	O
"	"	O
off	off	O
"	"	O
drug	drug	O
conditions	conditions	O
,	,	O
was	was	O
carried	carried	O
out	out	O
using	using	O
Unified	unified	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
Disease	disease	I-Disease
Rating	rating	O
Scale	scale	O
,	,	O
Hoehn	hoehn	O
and	and	O
Yahr	yahr	O
staging	staging	O
,	,	O
England	england	O
activities	activities	O
of	of	O
daily	daily	O
living	living	O
score	score	O
and	and	O
video	video	O
recordings	recordings	O
.	.	O

RESULTS	results	O
:	:	O
After	after	O
one	one	O
year	year	O
of	of	O
electrical	electrical	O
stimulation	stimulation	O
of	of	O
the	the	O
STN	stn	O
,	,	O
the	the	O
patients	patients	O
'	'	O
scores	scores	O
for	for	O
activities	activities	O
of	of	O
daily	daily	O
living	living	O
and	and	O
motor	motor	O
examination	examination	O
scores	scores	O
(	(	O
Unified	unified	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
Disease	disease	I-Disease
Rating	rating	O
Scale	scale	O
parts	parts	O
II	ii	O
and	and	O
III	iii	O
)	)	O
off	off	O
medication	medication	O
improved	improved	O
by	by	O
62	62	O
%	%	O
and	and	O
61	61	O
%	%	O
respectively	respectively	O
(	(	O
p<0.0005	p<0.0005	O
)	)	O
.	.	O

The	the	O
subscores	subscores	O
for	for	O
the	the	O
akinesia	akinesia	O
,	,	O
rigidity	rigidity	B-Disease
,	,	O
tremor	tremor	B-Disease
and	and	O
gait	gait	O
also	also	O
improved	improved	O
.	.	O

(	(	O
p<0.0005	p<0.0005	O
)	)	O
.	.	O

The	the	O
average	average	O
levodopa	levodopa	B-Chemical
dose	dose	O
decreased	decreased	O
from	from	O
813	813	O
mg	mg	O
to	to	O
359	359	O
mg	mg	O
.	.	O

The	the	O
cognitive	cognitive	O
functions	functions	O
remained	remained	O
unchanged	unchanged	O
.	.	O

Two	two	O
patients	patients	O
developed	developed	O
device-related	device-related	O
complications	complications	O
and	and	O
two	two	O
patients	patients	O
experienced	experienced	O
abnormal	abnormal	O
weight	weight	B-Disease
gain	gain	I-Disease
.	.	O

CONCLUSION	conclusion	O
:	:	O
Bilateral	bilateral	O
subthalamic	subthalamic	O
nucleus	nucleus	O
stimulation	stimulation	O
is	is	O
an	an	O
effective	effective	O
treatment	treatment	O
for	for	O
advanced	advanced	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

It	it	O
reduces	reduces	O
the	the	O
severity	severity	O
of	of	O
"	"	O
off	off	O
"	"	O
phase	phase	O
symptoms	symptoms	O
,	,	O
improves	improves	O
the	the	O
axial	axial	O
symptoms	symptoms	O
and	and	O
reduces	reduces	O
levodopa	levodopa	B-Chemical
requirements	requirements	O
.	.	O

The	the	O
reduction	reduction	O
in	in	O
the	the	O
levodopa	levodopa	B-Chemical
dose	dose	O
is	is	O
useful	useful	O
in	in	O
controlling	controlling	O
drug-induced	drug-induced	O
dyskinesias	dyskinesias	B-Disease
.	.	O

Acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
occurring	occurring	O
during	during	O
intravenous	intravenous	O
desferrioxamine	desferrioxamine	B-Chemical
therapy	therapy	O
:	:	O
recovery	recovery	O
after	after	O
haemodialysis	haemodialysis	O
.	.	O

A	a	O
patient	patient	O
with	with	O
transfusion-dependent	transfusion-dependent	O
thalassemia	thalassemia	O
was	was	O
undergoing	undergoing	O
home	home	O
intravenous	intravenous	O
desferrioxamine	desferrioxamine	B-Chemical
(	(	O
DFX	dfx	O
)	)	O
treatment	treatment	O
by	by	O
means	means	O
of	of	O
a	a	O
totally	totally	O
implanted	implanted	O
system	system	O
because	because	O
of	of	O
his	his	O
poor	poor	O
compliance	compliance	O
with	with	O
the	the	O
nightly	nightly	O
subcutaneous	subcutaneous	O
therapy	therapy	O
.	.	O

Due	due	O
to	to	O
an	an	O
accidental	accidental	O
malfunctioning	malfunctioning	O
of	of	O
the	the	O
infusion	infusion	O
pump	pump	O
,	,	O
the	the	O
patient	patient	O
was	was	O
inadvertently	inadvertently	O
administered	administered	O
a	a	O
toxic	toxic	O
dosage	dosage	O
of	of	O
the	the	O
drug	drug	O
which	which	O
caused	caused	O
renal	renal	B-Disease
insufficiency	insufficiency	I-Disease
.	.	O

Given	given	O
the	the	O
progressive	progressive	O
deterioration	deterioration	O
of	of	O
the	the	O
symptoms	symptoms	O
and	and	O
of	of	O
the	the	O
laboratory	laboratory	O
values	values	O
,	,	O
despite	despite	O
adequate	adequate	O
medical	medical	O
treatment	treatment	O
,	,	O
a	a	O
decision	decision	O
was	was	O
made	made	O
to	to	O
introduce	introduce	O
haemodialytical	haemodialytical	O
therapy	therapy	O
in	in	O
order	order	O
to	to	O
remove	remove	O
the	the	O
drug	drug	O
and	and	O
therapy	therapy	O
reduce	reduce	O
the	the	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

From	from	O
the	the	O
results	results	O
obtained	obtained	O
,	,	O
haemodialysis	haemodialysis	O
can	can	O
therefore	therefore	O
be	be	O
suggested	suggested	O
as	as	O
a	a	O
useful	useful	O
therapy	therapy	O
in	in	O
rare	rare	O
cases	cases	O
of	of	O
progressive	progressive	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
caused	caused	O
by	by	O
desferrioxamine	desferrioxamine	B-Chemical
.	.	O

Ocular	ocular	O
motility	motility	O
changes	changes	O
after	after	O
subtenon	subtenon	O
carboplatin	carboplatin	B-Chemical
chemotherapy	chemotherapy	O
for	for	O
retinoblastoma	retinoblastoma	O
.	.	O

BACKGROUND	background	O
:	:	O
Focal	focal	O
subtenon	subtenon	O
carboplatin	carboplatin	B-Chemical
injections	injections	O
have	have	O
recently	recently	O
been	been	O
used	used	O
as	as	O
a	a	O
presumably	presumably	O
toxicity-free	toxicity-free	O
adjunct	adjunct	O
to	to	O
systemic	systemic	O
chemotherapy	chemotherapy	O
for	for	O
intraocular	intraocular	O
retinoblastoma	retinoblastoma	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
report	report	O
our	our	O
clinical	clinical	O
experience	experience	O
with	with	O
abnormal	abnormal	O
ocular	ocular	O
motility	motility	O
in	in	O
patients	patients	O
treated	treated	O
with	with	O
subtenon	subtenon	O
carboplatin	carboplatin	B-Chemical
chemotherapy	chemotherapy	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
noted	noted	O
abnormal	abnormal	O
ocular	ocular	O
motility	motility	O
in	in	O
10	10	O
consecutive	consecutive	O
patients	patients	O
with	with	O
retinoblastoma	retinoblastoma	O
who	who	O
had	had	O
received	received	O
subtenon	subtenon	O
carboplatin	carboplatin	B-Chemical
.	.	O

During	during	O
ocular	ocular	O
manipulation	manipulation	O
under	under	O
general	general	O
anesthesia	anesthesia	O
,	,	O
we	we	O
assessed	assessed	O
their	their	O
eyes	eyes	O
by	by	O
forced	forced	O
duction	duction	O
testing	testing	O
,	,	O
comparing	comparing	O
ocular	ocular	O
motility	motility	O
after	after	O
tumor	tumor	B-Disease
control	control	O
with	with	O
ocular	ocular	O
motility	motility	O
at	at	O
diagnosis	diagnosis	O
.	.	O

Eyes	eyes	O
subsequently	subsequently	O
enucleated	enucleated	O
because	because	O
of	of	O
treatment	treatment	O
failure	failure	O
(	(	O
n	n	O
=	=	O
4	4	O
)	)	O
were	were	O
examined	examined	O
histologically	histologically	O
.	.	O

RESULTS	results	O
:	:	O
Limitation	limitation	O
of	of	O
ocular	ocular	O
motility	motility	O
was	was	O
detected	detected	O
in	in	O
all	all	O
12	12	O
eyes	eyes	O
of	of	O
10	10	O
patients	patients	O
treated	treated	O
for	for	O
intraocular	intraocular	O
retinoblastoma	retinoblastoma	O
with	with	O
1	1	O
to	to	O
6	6	O
injections	injections	O
of	of	O
subtenon	subtenon	O
carboplatin	carboplatin	B-Chemical
as	as	O
part	part	O
of	of	O
multimodality	multimodality	O
therapy	therapy	O
.	.	O

Histopathological	histopathological	O
examination	examination	O
revealed	revealed	O
many	many	O
lipophages	lipophages	O
in	in	O
the	the	O
periorbital	periorbital	O
fat	fat	O
surrounding	surrounding	O
the	the	O
optic	optic	O
nerve	nerve	O
in	in	O
1	1	O
eye	eye	O
,	,	O
indicative	indicative	O
of	of	O
phagocytosis	phagocytosis	O
of	of	O
previously	previously	O
existing	existing	O
fat	fat	O
cells	cells	O
and	and	O
suggesting	suggesting	O
prior	prior	O
fat	fat	B-Disease
necrosis	necrosis	B-Disease
.	.	O

The	the	O
enucleations	enucleations	O
were	were	O
technically	technically	O
difficult	difficult	O
and	and	O
hazardous	hazardous	O
for	for	O
globe	globe	O
rupture	rupture	O
because	because	O
of	of	O
extensive	extensive	O
orbital	orbital	O
soft	soft	O
tissue	tissue	B-Disease
adhesions	adhesions	I-Disease
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Subtenon	subtenon	O
carboplatin	carboplatin	B-Chemical
chemotherapy	chemotherapy	O
is	is	O
associated	associated	O
with	with	O
significant	significant	O
fibrosis	fibrosis	B-Disease
of	of	O
orbital	orbital	O
soft	soft	O
tissues	tissues	O
,	,	O
leading	leading	O
to	to	O
mechanical	mechanical	O
restriction	restriction	O
of	of	O
eye	eye	O
movements	movements	O
and	and	O
making	making	O
subsequent	subsequent	O
enucleation	enucleation	O
difficult	difficult	O
.	.	O

Subtenon	subtenon	O
carboplatin	carboplatin	B-Chemical
is	is	O
not	not	O
free	free	O
of	of	O
toxicity	toxicity	B-Disease
,	,	O
and	and	O
its	its	O
use	use	O
is	is	O
best	best	O
restricted	restricted	O
to	to	O
specific	specific	O
indications	indications	O
.	.	O

Ethambutol	ethambutol	O
and	and	O
optic	optic	O
neuropathy	neuropathy	B-Disease
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
demonstrate	demonstrate	O
the	the	O
association	association	O
between	between	O
ethambutol	ethambutol	O
and	and	O
optic	optic	O
neuropathy	neuropathy	B-Disease
.	.	O

METHOD	method	O
:	:	O
Thirteen	thirteen	O
patients	patients	O
who	who	O
developed	developed	O
optic	optic	O
neuropathy	neuropathy	B-Disease
after	after	O
being	being	O
treated	treated	O
with	with	O
ethambutol	ethambutol	O
for	for	O
tuberculosis	tuberculosis	B-Disease
of	of	O
the	the	O
lung	lung	O
or	or	O
lymph	lymph	O
node	node	O
at	at	O
Siriraj	siriraj	O
Hospital	hospital	O
between	between	O
1997	1997	O
and	and	O
2001	2001	O
were	were	O
retrospectively	retrospectively	O
reviewed	reviewed	O
.	.	O

The	the	O
clinical	clinical	O
characteristics	characteristics	O
and	and	O
initial	initial	O
and	and	O
final	final	O
visual	visual	O
acuity	acuity	O
were	were	O
analyzed	analyzed	O
to	to	O
determine	determine	O
visual	visual	O
outcome	outcome	O
.	.	O

RESULTS	results	O
:	:	O
All	all	O
patients	patients	O
had	had	O
optic	optic	O
neuropathy	neuropathy	B-Disease
between	between	O
1	1	O
to	to	O
6	6	O
months	months	O
(	(	O
mean	mean	O
=	=	O
2.9	2.9	O
months	months	O
)	)	O
after	after	O
starting	starting	O
ethambutol	ethambutol	O
therapy	therapy	O
at	at	O
a	a	O
dosage	dosage	O
ranging	ranging	O
from	from	O
13	13	O
to	to	O
20	20	O
mg/kg/day	mg/kg/day	O
(	(	O
mean	mean	O
=	=	O
17	17	O
mg/kg/day	mg/kg/day	O
)	)	O
.	.	O

Seven	seven	O
(	(	O
54	54	O
%	%	O
)	)	O
of	of	O
the	the	O
13	13	O
patients	patients	O
experienced	experienced	O
visual	visual	O
recovery	recovery	O
after	after	O
stopping	stopping	O
the	the	O
drug	drug	O
.	.	O

Of	of	O
6	6	O
patients	patients	O
with	with	O
irreversible	irreversible	O
visual	visual	O
impairment	impairment	O
,	,	O
4	4	O
patients	patients	O
had	had	O
diabetes	diabetes	B-Disease
mellitus	mellitus	I-Disease
,	,	O
glaucoma	glaucoma	B-Disease
and	and	O
a	a	O
history	history	O
of	of	O
heavy	heavy	O
smoking	smoking	B-Chemical
.	.	O

CONCLUSION	conclusion	O
:	:	O
Early	early	O
recognition	recognition	O
of	of	O
optic	optic	O
neuropathy	neuropathy	B-Disease
should	should	O
be	be	O
considered	considered	O
in	in	O
patients	patients	O
with	with	O
ethambutol	ethambutol	O
therapy	therapy	O
.	.	O

A	a	O
low	low	O
dose	dose	O
and	and	O
prompt	prompt	O
discontinuation	discontinuation	O
of	of	O
the	the	O
drug	drug	O
is	is	O
recommended	recommended	O
particularly	particularly	O
in	in	O
individuals	individuals	O
with	with	O
diabetes	diabetes	B-Disease
mellitus	mellitus	I-Disease
,	,	O
glaucoma	glaucoma	B-Disease
or	or	O
who	who	O
are	are	O
heavy	heavy	O
smokers	smokers	O
.	.	O

Treatment	treatment	O
of	of	O
compensatory	compensatory	O
gustatory	gustatory	O
hyperhidrosis	hyperhidrosis	O
with	with	O
topical	topical	O
glycopyrrolate	glycopyrrolate	B-Chemical
.	.	O

Gustatory	gustatory	O
hyperhidrosis	hyperhidrosis	O
is	is	O
facial	facial	O
sweating	sweating	O
usually	usually	O
associated	associated	O
with	with	O
the	the	O
eating	eating	O
of	of	O
hot	hot	O
spicy	spicy	O
food	food	O
or	or	O
even	even	O
smelling	smelling	O
this	this	O
food	food	O
.	.	O

Current	current	O
options	options	O
of	of	O
treatment	treatment	O
include	include	O
oral	oral	O
anticholinergic	anticholinergic	O
drugs	drugs	O
,	,	O
the	the	O
topical	topical	O
application	application	O
of	of	O
anticholinergics	anticholinergics	O
or	or	O
aluminum	aluminum	B-Chemical
chloride	chloride	I-Chemical
,	,	O
and	and	O
the	the	O
injection	injection	O
of	of	O
botulinum	botulinum	O
toxin	toxin	O
.	.	O

Thirteen	thirteen	O
patients	patients	O
have	have	O
been	been	O
treated	treated	O
to	to	O
date	date	O
with	with	O
1.5	1.5	O
%	%	O
or	or	O
2	2	O
%	%	O
topical	topical	O
glycopyrrolate	glycopyrrolate	B-Chemical
.	.	O

All	all	O
patients	patients	O
had	had	O
gustatory	gustatory	O
hyperhidrosis	hyperhidrosis	O
,	,	O
which	which	O
interfered	interfered	O
with	with	O
their	their	O
social	social	O
activities	activities	O
,	,	O
after	after	O
transthroacic	transthroacic	O
endoscopic	endoscopic	O
sympathectomy	sympathectomy	O
,	,	O
and	and	O
which	which	O
was	was	O
associated	associated	O
with	with	O
compensatory	compensatory	O
focal	focal	O
hyperhidrosis	hyperhidrosis	O
.	.	O

After	after	O
applying	applying	O
topical	topical	O
glycopyrrolate	glycopyrrolate	B-Chemical
,	,	O
the	the	O
subjective	subjective	O
effect	effect	O
was	was	O
excellent	excellent	O
(	(	O
no	no	O
sweating	sweating	O
after	after	O
eating	eating	O
hot	hot	O
spicy	spicy	O
food	food	O
)	)	O
in	in	O
10	10	O
patients	patients	O
(	(	O
77	77	O
%	%	O
)	)	O
,	,	O
and	and	O
fair	fair	O
(	(	O
clearly	clearly	O
reduced	reduced	O
sweating	sweating	O
)	)	O
in	in	O
3	3	O
patients	patients	O
(	(	O
23	23	O
%	%	O
)	)	O
.	.	O

All	all	O
had	had	O
reported	reported	O
incidents	incidents	O
of	of	O
being	being	O
very	very	O
embarrassed	embarrassed	O
whilst	whilst	O
eating	eating	O
hot	hot	O
spicy	spicy	O
foods	foods	O
.	.	O

Adverse	adverse	O
effects	effects	O
included	included	O
a	a	O
mildly	mildly	O
dry	dry	B-Disease
mouth	mouth	I-Disease
and	and	O
a	a	O
sore	sore	O
throat	throat	O
in	in	O
2	2	O
patients	patients	O
(	(	O
2	2	O
%	%	O
glycopyrrolate	glycopyrrolate	B-Chemical
)	)	O
,	,	O
a	a	O
light	light	O
headache	headache	B-Disease
in	in	O
1	1	O
patient	patient	O
(	(	O
1.5	1.5	O
%	%	O
glycopyrrolate	glycopyrrolate	B-Chemical
)	)	O
.	.	O

The	the	O
topical	topical	O
application	application	O
of	of	O
a	a	O
glycopyrrolate	glycopyrrolate	B-Chemical
pad	pad	O
appeared	appeared	O
to	to	O
be	be	O
safe	safe	O
,	,	O
efficacious	efficacious	O
,	,	O
well	well	O
tolerated	tolerated	O
,	,	O
and	and	O
a	a	O
convenient	convenient	O
method	method	O
of	of	O
treatment	treatment	O
for	for	O
moderate	moderate	O
to	to	O
severe	severe	O
symptoms	symptoms	O
of	of	O
gustatory	gustatory	O
hyperhidrosis	hyperhidrosis	O
in	in	O
post	post	O
transthoracic	transthoracic	O
endoscopic	endoscopic	O
sympathectomy	sympathectomy	O
or	or	O
sympathicotomy	sympathicotomy	O
patients	patients	O
,	,	O
with	with	O
few	few	O
side	side	O
effects	effects	O
.	.	O

Neuroleptic-associated	neuroleptic-associated	O
hyperprolactinemia	hyperprolactinemia	B-Disease
.	.	O
Can	can	O
it	it	O
be	be	O
treated	treated	O
with	with	O
bromocriptine?Six	bromocriptine?six	O
stable	stable	O
psychiatric	psychiatric	B-Disease
outpatients	outpatients	O
with	with	O
hyperprolactinemia	hyperprolactinemia	B-Disease
and	and	O
amenorrhea/oligomenorrhea	amenorrhea/oligomenorrhea	O
associated	associated	O
with	with	O
their	their	O
neuroleptic	neuroleptic	O
medications	medications	O
were	were	O
treated	treated	O
with	with	O
bromocriptine	bromocriptine	B-Chemical
.	.	O

Daily	daily	O
dosages	dosages	O
of	of	O
5	5	O
-	-	O
10	10	O
mg	mg	O
corrected	corrected	O
the	the	O
hyperprolactinemia	hyperprolactinemia	B-Disease
and	and	O
restored	restored	O
menstruation	menstruation	O
in	in	O
four	four	O
of	of	O
the	the	O
six	six	O
patients	patients	O
.	.	O

One	one	O
woman	woman	O
,	,	O
however	however	O
,	,	O
developed	developed	O
worsened	worsened	O
psychiatric	psychiatric	B-Disease
symptoms	symptoms	O
while	while	O
taking	taking	O
bromocriptine	bromocriptine	B-Chemical
,	,	O
and	and	O
it	it	O
was	was	O
discontinued	discontinued	O
.	.	O

Thus	thus	O
,	,	O
three	three	O
of	of	O
six	six	O
patients	patients	O
had	had	O
their	their	O
menstrual	menstrual	O
irregularity	irregularity	O
successfully	successfully	O
corrected	corrected	O
with	with	O
bromocriptine	bromocriptine	B-Chemical
.	.	O

This	this	O
suggests	suggests	O
that	that	O
bromocriptine	bromocriptine	B-Chemical
should	should	O
be	be	O
further	further	O
evaluated	evaluated	O
as	as	O
potential	potential	O
therapy	therapy	O
for	for	O
neuroleptic-associated	neuroleptic-associated	O
hyperprolactinemia	hyperprolactinemia	B-Disease
and	and	O
amenorrhea/galactorrhea	amenorrhea/galactorrhea	O
.	.	O

Ethacrynic	ethacrynic	O
acid-induced	acid-induced	O
convulsions	convulsions	B-Disease
and	and	O
brain	brain	O
neurotransmitters	neurotransmitters	O
in	in	O
mice	mice	O
.	.	O

Intracerebroventricular	intracerebroventricular	O
injection	injection	O
of	of	O
ethacrynic	ethacrynic	B-Chemical
acid	acid	I-Chemical
(	(	O
50	50	O
%	%	O
convulsive	convulsive	B-Disease
dose	dose	O
;	;	O
50	50	O
micrograms/mouse	micrograms/mouse	O
)	)	O
accelerated	accelerated	O
the	the	O
synthesis/turnover	synthesis/turnover	O
of	of	O
5-hydroxytryptamine	5-hydroxytryptamine	B-Chemical
(	(	O
5-HT	5-ht	B-Chemical
)	)	O
but	but	O
suppressed	suppressed	O
the	the	O
synthesis	synthesis	O
of	of	O
gamma-aminobutyric	gamma-aminobutyric	O
acid	acid	O
and	and	O
acetylcholine	acetylcholine	B-Chemical
in	in	O
mouse	mouse	O
brain	brain	O
.	.	O

These	these	O
effects	effects	O
were	were	O
completely	completely	O
antagonized	antagonized	O
by	by	O
pretreatment	pretreatment	O
with	with	O
a	a	O
glutamate/N-methyl-D-aspartate	glutamate/n-methyl-d-aspartate	O
antagonist	antagonist	O
,	,	O
aminophosphonovaleric	aminophosphonovaleric	O
acid	acid	O
.	.	O

In	in	O
ethacrynic	ethacrynic	O
acid-induced	acid-induced	O
convulsions	convulsions	B-Disease
,	,	O
these	these	O
neurotransmitter	neurotransmitter	O
systems	systems	O
may	may	O
be	be	O
differentially	differentially	O
modulated	modulated	O
,	,	O
probably	probably	O
through	through	O
activation	activation	O
of	of	O
glutaminergic	glutaminergic	O
neurons	neurons	O
in	in	O
the	the	O
brain	brain	O
.	.	O

Pharmacology	pharmacology	O
of	of	O
gamma-aminobutyric	gamma-aminobutyric	O
acidA	acida	O
receptor	receptor	O
complex	complex	O
after	after	O
the	the	O
in	in	O
vivo	vivo	O
administration	administration	O
of	of	O
the	the	O
anxioselective	anxioselective	O
and	and	O
anticonvulsant	anticonvulsant	O
beta-carboline	beta-carboline	O
derivative	derivative	O
abecarnil	abecarnil	O
.	.	O

In	in	O
rodents	rodents	O
,	,	O
the	the	O
effect	effect	O
of	of	O
the	the	O
beta-carboline	beta-carboline	O
derivative	derivative	O
isopropyl-6-	isopropyl-6-	O
benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate	benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate	O
(	(	O
abecarrnil	abecarrnil	O
)	)	O
,	,	O
a	a	O
new	new	O
ligand	ligand	O
for	for	O
benzodiazepine	benzodiazepine	B-Chemical
receptors	receptors	O
possessing	possessing	O
anxiolytic	anxiolytic	O
and	and	O
anticonvulsant	anticonvulsant	O
properties	properties	O
,	,	O
was	was	O
evaluated	evaluated	O
on	on	O
the	the	O
function	function	O
of	of	O
central	central	O
gamma-aminobutyric	gamma-aminobutyric	O
acid	acid	O
(GABA)A	(gaba)a	O
receptor	receptor	O
complex	complex	O
,	,	O
both	both	O
in	in	O
vitro	vitro	O
and	and	O
in	in	O
vivo	vivo	O
.	.	O

Added	added	O
in	in	O
vitro	vitro	O
to	to	O
rat	rat	O
cortical	cortical	O
membrane	membrane	O
preparation	preparation	O
,	,	O
abecarnil	abecarnil	O
increased	increased	O
[3H]GABA	[3h]gaba	O
binding	binding	O
,	,	O
enhanced	enhanced	O
muscimol-stimulated	muscimol-stimulated	O
36Cl-	36cl-	O
uptake	uptake	O
and	and	O
reduced	reduced	O
the	the	O
binding	binding	O
of	of	O
t-[35S]butylbicyclophosphorothionate	t-[35s]butylbicyclophosphorothionate	O
(	(	O
[35S]TBPS	[35s]tbps	O
)	)	O
.	.	O

These	these	O
effects	effects	O
were	were	O
similar	similar	O
to	to	O
those	those	O
induced	induced	O
by	by	O
diazepam	diazepam	B-Chemical
,	,	O
whereas	whereas	O
the	the	O
partial	partial	O
agonist	agonist	O
Ro	ro	O
16	16	O
-	-	O
6028	6028	O
(	(	O
tert-butyl-(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-	tert-butyl-(s)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9h-	O
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	O
)	)	O
showed	showed	O
very	very	O
weak	weak	O
efficacy	efficacy	O
in	in	O
these	these	O
biochemical	biochemical	O
tests	tests	O
.	.	O

After	after	O
i.p	i.p	O
.	.	O

injection	injection	O
to	to	O
rats	rats	O
,	,	O
abecarnil	abecarnil	O
and	and	O
diazepam	diazepam	B-Chemical
decreased	decreased	O
in	in	O
a	a	O
time-dependent	time-dependent	O
and	and	O
dose-related	dose-related	O
(	(	O
0.25	0.25	O
-	-	O
20	20	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
)	)	O
manner	manner	O
[35S]TBPS	[35s]tbps	O
binding	binding	O
measured	measured	O
ex	ex	O
vivo	vivo	O
in	in	O
the	the	O
cerebral	cerebral	O
cortex	cortex	O
.	.	O

Moreover	moreover	O
,	,	O
both	both	O
drugs	drugs	O
at	at	O
the	the	O
dose	dose	O
of	of	O
0.5	0.5	O
mg/kg	mg/kg	O
antagonized	antagonized	O
completely	completely	O
the	the	O
convulsant	convulsant	O
activity	activity	O
and	and	O
the	the	O
increase	increase	O
of	of	O
[35S]TBPS	[35s]tbps	O
binding	binding	O
induced	induced	O
by	by	O
isoniazide	isoniazide	O
(	(	O
350	350	O
mg/kg	mg/kg	O
s.c	s.c	O
.	.	O
)	)	O
as	as	O
well	well	O
as	as	O
the	the	O
increase	increase	O
of	of	O
[35S]TBPS	[35s]tbps	O
binding	binding	O
induced	induced	O
by	by	O
foot-shock	foot-shock	O
stress	stress	O
.	.	O

To	to	O
better	better	O
correlate	correlate	O
the	the	O
biochemical	biochemical	O
and	and	O
the	the	O
pharmacological	pharmacological	O
effects	effects	O
,	,	O
we	we	O
studied	studied	O
the	the	O
action	action	O
of	of	O
abecarnil	abecarnil	O
on	on	O
[35S]TBPS	[35s]tbps	O
binding	binding	O
,	,	O
exploratory	exploratory	O
motility	motility	O
and	and	O
on	on	O
isoniazid-induced	isoniazid-induced	O
biochemical	biochemical	O
and	and	O
pharmacological	pharmacological	O
effects	effects	O
in	in	O
mice	mice	O
.	.	O

In	in	O
these	these	O
animals	animals	O
,	,	O
abecarnil	abecarnil	O
produced	produced	O
a	a	O
paralleled	paralleled	O
dose-dependent	dose-dependent	O
(	(	O
0.05	0.05	O
-	-	O
1	1	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
)	)	O
reduction	reduction	O
of	of	O
both	both	O
motor	motor	O
behavior	behavior	O
and	and	O
cortical	cortical	O
[35S]TBPS	[35s]tbps	O
binding	binding	O
.	.	O

Moreover	moreover	O
,	,	O
0.05	0.05	O
mg/kg	mg/kg	O
of	of	O
this	this	O
beta-carboline	beta-carboline	O
reduced	reduced	O
markedly	markedly	O
the	the	O
increase	increase	O
of	of	O
[35S]TBPS	[35s]tbps	O
binding	binding	O
and	and	O
the	the	O
convulsions	convulsions	B-Disease
induced	induced	O
by	by	O
isoniazid	isoniazid	B-Chemical
(	(	O
200	200	O
mg/kg	mg/kg	O
s.c.).(ABSTRACT	s.c.).(abstract	O
TRUNCATED	truncated	O
AT	at	O
250	250	O
WORDS	words	O
)	)	O

Recurrent	recurrent	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
in	in	O
a	a	O
postpartum	postpartum	O
patient	patient	O
receiving	receiving	O
bromocriptine	bromocriptine	B-Chemical
.	.	O

Myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
in	in	O
puerperium	puerperium	O
is	is	O
infrequently	infrequently	O
reported	reported	O
.	.	O

Spasm	spasm	B-Disease
,	,	O
coronary	coronary	O
dissection	dissection	O
,	,	O
or	or	O
atheromatous	atheromatous	O
etiology	etiology	O
has	has	O
been	been	O
described	described	O
.	.	O

Bromocriptine	bromocriptine	B-Chemical
has	has	O
been	been	O
implicated	implicated	O
in	in	O
several	several	O
previous	previous	O
case	case	O
reports	reports	O
of	of	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
in	in	O
the	the	O
puerperium	puerperium	O
.	.	O

Our	our	O
case	case	O
(	(	O
including	including	O
an	an	O
inadvertent	inadvertent	O
rechallenge	rechallenge	O
)	)	O
suggests	suggests	O
such	such	O
a	a	O
relationship	relationship	O
.	.	O

Although	although	O
generally	generally	O
regarded	regarded	O
as	as	O
"	"	O
safe	safe	O
,	,	O
"	"	O
possible	possible	O
serious	serious	O
cardiac	cardiac	O
effects	effects	O
of	of	O
bromocriptine	bromocriptine	B-Chemical
should	should	O
be	be	O
acknowledged	acknowledged	O
.	.	O

Asterixis	asterixis	B-Disease
induced	induced	O
by	by	O
carbamazepine	carbamazepine	B-Chemical
therapy	therapy	O
.	.	O

There	there	O
are	are	O
very	very	O
few	few	O
reports	reports	O
about	about	O
asterixis	asterixis	B-Disease
as	as	O
a	a	O
side	side	O
effect	effect	O
of	of	O
treatment	treatment	O
with	with	O
psychopharmacologic	psychopharmacologic	O
agents	agents	O
.	.	O

In	in	O
this	this	O
report	report	O
we	we	O
present	present	O
four	four	O
patients	patients	O
treated	treated	O
with	with	O
a	a	O
combination	combination	O
of	of	O
different	different	O
psychotropic	psychotropic	B-Chemical
drugs	drugs	I-Chemical
,	,	O
in	in	O
whom	whom	O
asterixis	asterixis	B-Disease
was	was	O
triggered	triggered	O
either	either	O
by	by	O
adding	adding	O
carbamazepine	carbamazepine	B-Chemical
(	(	O
CBZ	cbz	B-Chemical
)	)	O
to	to	O
a	a	O
treatment	treatment	O
regimen	regimen	O
,	,	O
or	or	O
by	by	O
increasing	increasing	O
its	its	O
dosage	dosage	O
.	.	O

Neither	neither	O
dosage	dosage	O
nor	nor	O
serum	serum	O
levels	levels	O
of	of	O
CBZ	cbz	B-Chemical
were	were	O
in	in	O
a	a	O
higher	higher	O
range	range	O
.	.	O

We	we	O
consider	consider	O
asterixis	asterixis	B-Disease
to	to	O
be	be	O
an	an	O
easily	easily	O
overlooked	overlooked	O
sign	sign	O
of	of	O
neurotoxicity	neurotoxicity	B-Disease
,	,	O
which	which	O
may	may	O
occur	occur	O
even	even	O
at	at	O
low	low	O
or	or	O
moderate	moderate	O
dosage	dosage	O
levels	levels	O
,	,	O
if	if	O
certain	certain	O
drugs	drugs	O
as	as	O
lithium	lithium	B-Chemical
or	or	O
clozapine	clozapine	B-Chemical
are	are	O
used	used	O
in	in	O
combination	combination	O
with	with	O
CBZ	cbz	B-Chemical
.	.	O

Pharmacodynamics	pharmacodynamics	O
of	of	O
the	the	O
hypotensive	hypotensive	B-Disease
effect	effect	O
of	of	O
levodopa	levodopa	B-Chemical
in	in	O
parkinsonian	parkinsonian	B-Disease
patients	patients	O
.	.	O

Blood	blood	O
pressure	pressure	O
effects	effects	O
of	of	O
i.v	i.v	O
.	.	O

levodopa	levodopa	B-Chemical
were	were	O
examined	examined	O
in	in	O
parkinsonian	parkinsonian	B-Disease
patients	patients	O
with	with	O
stable	stable	O
and	and	O
fluctuating	fluctuating	O
responses	responses	O
to	to	O
levodopa	levodopa	B-Chemical
.	.	O

The	the	O
magnitude	magnitude	O
of	of	O
the	the	O
hypotensive	hypotensive	B-Disease
effect	effect	O
of	of	O
levodopa	levodopa	B-Chemical
was	was	O
concentration	concentration	O
dependent	dependent	O
and	and	O
was	was	O
fit	fit	O
to	to	O
an	an	O
Emax	emax	O
model	model	O
in	in	O
fluctuating	fluctuating	O
responders	responders	O
.	.	O

Stable	stable	O
responders	responders	O
demonstrated	demonstrated	O
a	a	O
small	small	O
hypotensive	hypotensive	B-Disease
response	response	O
.	.	O

Baseline	baseline	O
blood	blood	O
pressures	pressures	O
were	were	O
higher	higher	O
in	in	O
fluctuating	fluctuating	O
patients	patients	O
;	;	O
a	a	O
higher	higher	O
baseline	baseline	O
blood	blood	O
pressure	pressure	O
correlated	correlated	O
with	with	O
greater	greater	O
hypotensive	hypotensive	B-Disease
effects	effects	O
.	.	O

Antiparkinsonian	antiparkinsonian	O
effects	effects	O
of	of	O
levodopa	levodopa	B-Chemical
temporally	temporally	O
correlated	correlated	O
with	with	O
blood	blood	O
pressure	pressure	O
changes	changes	O
.	.	O

Phenylalanine	phenylalanine	O
,	,	O
a	a	O
large	large	O
neutral	neutral	O
amino	amino	B-Chemical
acid	acid	I-Chemical
(	(	O
LNAA	lnaa	O
)	)	O
competing	competing	O
with	with	O
levodopa	levodopa	B-Chemical
for	for	O
transport	transport	O
across	across	O
the	the	O
blood-brain	blood-brain	O
barrier	barrier	O
,	,	O
reduced	reduced	O
the	the	O
hypotensive	hypotensive	B-Disease
and	and	O
antiparkinsonian	antiparkinsonian	O
effects	effects	O
of	of	O
levodopa	levodopa	B-Chemical
.	.	O

We	we	O
conclude	conclude	O
that	that	O
levodopa	levodopa	B-Chemical
has	has	O
a	a	O
central	central	O
hypotensive	hypotensive	B-Disease
action	action	O
that	that	O
parallels	parallels	O
the	the	O
motor	motor	O
effects	effects	O
in	in	O
fluctuating	fluctuating	O
patients	patients	O
.	.	O

The	the	O
hypotensive	hypotensive	B-Disease
effect	effect	O
appears	appears	O
to	to	O
be	be	O
related	related	O
to	to	O
the	the	O
higher	higher	O
baseline	baseline	O
blood	blood	O
pressure	pressure	O
we	we	O
observed	observed	O
in	in	O
fluctuating	fluctuating	O
patients	patients	O
relative	relative	O
to	to	O
stable	stable	O
patients	patients	O
.	.	O

Syndrome	syndrome	O
of	of	O
inappropriate	inappropriate	O
secretion	secretion	O
of	of	O
antidiuretic	antidiuretic	O
hormone	hormone	O
after	after	O
infusional	infusional	O
vincristine	vincristine	B-Chemical
.	.	O

A	a	O
77-year-old	77-year-old	O
woman	woman	O
with	with	O
refractory	refractory	O
multiple	multiple	B-Disease
myeloma	myeloma	I-Disease
was	was	O
treated	treated	O
with	with	O
a	a	O
4-day	4-day	O
continuous	continuous	O
intravenous	intravenous	O
infusion	infusion	O
of	of	O
vincristine	vincristine	B-Chemical
and	and	O
doxorubicin	doxorubicin	B-Chemical
and	and	O
4	4	O
days	days	O
of	of	O
oral	oral	O
dexamethasone	dexamethasone	B-Chemical
.	.	O

Nine	nine	O
days	days	O
after	after	O
her	her	O
second	second	O
cycle	cycle	O
she	she	O
presented	presented	O
with	with	O
lethargy	lethargy	O
and	and	O
weakness	weakness	B-Disease
associated	associated	O
with	with	O
hyponatremia	hyponatremia	B-Disease
.	.	O

Evaluation	evaluation	O
revealed	revealed	O
the	the	O
syndrome	syndrome	O
of	of	O
inappropriate	inappropriate	O
secretion	secretion	O
of	of	O
antidiuretic	antidiuretic	O
hormone	hormone	O
,	,	O
which	which	O
was	was	O
attributed	attributed	O
to	to	O
the	the	O
vincristine	vincristine	B-Chemical
infusion	infusion	O
.	.	O

After	after	O
normal	normal	O
serum	serum	O
sodium	sodium	B-Chemical
levels	levels	O
returned	returned	O
,	,	O
further	further	O
doxorubicin	doxorubicin	B-Chemical
and	and	O
dexamethasone	dexamethasone	B-Chemical
chemotherapy	chemotherapy	O
without	without	O
vincristine	vincristine	B-Chemical
did	did	O
not	not	O
produce	produce	O
this	this	O
complication	complication	O
.	.	O

Heart	heart	B-Disease
failure	failure	I-Disease
:	:	O
to	to	O
digitalise	digitalise	O
or	or	O
not	not	O
?	?	O
The	the	O
view	view	O
against	against	O
.	.	O

Despite	despite	O
extensive	extensive	O
clinical	clinical	O
experience	experience	O
the	the	O
role	role	O
of	of	O
digoxin	digoxin	O
is	is	O
still	still	O
not	not	O
well	well	O
defined	defined	O
.	.	O

In	in	O
patients	patients	O
with	with	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
digoxin	digoxin	O
is	is	O
beneficial	beneficial	O
for	for	O
ventricular	ventricular	O
rate	rate	O
control	control	O
.	.	O

For	for	O
patients	patients	O
in	in	O
sinus	sinus	O
rhythm	rhythm	O
and	and	O
heart	heart	B-Disease
failure	failure	I-Disease
the	the	O
situation	situation	O
is	is	O
less	less	O
clear	clear	O
.	.	O

Digoxin	digoxin	O
has	has	O
a	a	O
narrow	narrow	O
therapeutic	therapeutic	O
:	:	O
toxic	toxic	O
ratio	ratio	O
and	and	O
concentrations	concentrations	O
are	are	O
affected	affected	O
by	by	O
a	a	O
number	number	O
of	of	O
drugs	drugs	O
.	.	O

Also	also	O
,	,	O
digoxin	digoxin	O
has	has	O
undesirable	undesirable	O
effects	effects	O
such	such	O
as	as	O
increasing	increasing	O
peripheral	peripheral	O
resistance	resistance	O
and	and	O
myocardial	myocardial	O
demands	demands	O
,	,	O
and	and	O
causing	causing	O
arrhythmias	arrhythmias	B-Disease
.	.	O

There	there	O
is	is	O
a	a	O
paucity	paucity	O
of	of	O
data	data	O
from	from	O
well-designed	well-designed	O
trials	trials	O
.	.	O

The	the	O
trials	trials	O
that	that	O
are	are	O
available	available	O
are	are	O
generally	generally	O
small	small	O
with	with	O
limitations	limitations	O
in	in	O
design	design	O
and	and	O
these	these	O
show	show	O
variation	variation	O
in	in	O
patient	patient	O
benefit	benefit	O
.	.	O

More	more	O
convincing	convincing	O
evidence	evidence	O
is	is	O
required	required	O
showing	showing	O
that	that	O
digoxin	digoxin	O
improves	improves	O
symptoms	symptoms	O
or	or	O
exercise	exercise	O
capacity	capacity	O
.	.	O

Furthermore	furthermore	O
,	,	O
no	no	O
trial	trial	O
has	has	O
had	had	O
sufficient	sufficient	O
power	power	O
to	to	O
evaluate	evaluate	O
mortality	mortality	O
.	.	O

Pooled	pooled	O
analysis	analysis	O
of	of	O
the	the	O
effects	effects	O
of	of	O
other	other	O
inotropic	inotropic	O
drugs	drugs	O
shows	shows	O
an	an	O
excess	excess	O
mortality	mortality	O
and	and	O
there	there	O
is	is	O
a	a	O
possibility	possibility	O
that	that	O
digoxin	digoxin	O
may	may	O
increase	increase	O
mortality	mortality	O
after	after	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
(	(	O
MI	mi	O
)	)	O
.	.	O

Angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	O
(	(	O
ACE	ace	O
)	)	O
inhibitors	inhibitors	O
should	should	O
be	be	O
used	used	O
first	first	O
as	as	O
they	they	O
are	are	O
safer	safer	O
,	,	O
do	do	O
not	not	O
require	require	O
blood	blood	O
level	level	O
monitoring	monitoring	O
,	,	O
modify	modify	O
progression	progression	O
of	of	O
disease	disease	O
,	,	O
relieve	relieve	O
symptoms	symptoms	O
,	,	O
improve	improve	O
exercise	exercise	O
tolerance	tolerance	O
and	and	O
reduce	reduce	O
mortality	mortality	O
.	.	O

Caution	caution	O
should	should	O
be	be	O
exercised	exercised	O
in	in	O
using	using	O
digoxin	digoxin	O
until	until	O
large	large	O
mortality	mortality	O
trials	trials	O
are	are	O
completed	completed	O
showing	showing	O
either	either	O
benefit	benefit	O
or	or	O
harm	harm	O
.	.	O

Until	until	O
then	then	O
digoxin	digoxin	O
should	should	O
be	be	O
considered	considered	O
a	a	O
third-line	third-line	O
therapy	therapy	O
.	.	O

Isradipine	isradipine	O
treatment	treatment	O
for	for	O
hypertension	hypertension	B-Disease
in	in	O
general	general	O
practice	practice	O
in	in	O
Hong	hong	O
Kong	kong	O
.	.	O

A	a	O
6-week	6-week	O
open	open	O
study	study	O
of	of	O
the	the	O
introduction	introduction	O
of	of	O
isradipine	isradipine	O
treatment	treatment	O
was	was	O
conducted	conducted	O
in	in	O
general	general	O
practice	practice	O
in	in	O
Hong	hong	O
Kong	kong	O
.	.	O

303	303	O
Chinese	chinese	O
patients	patients	O
with	with	O
mild	mild	O
to	to	O
moderate	moderate	O
hypertension	hypertension	B-Disease
entered	entered	O
the	the	O
study	study	O
.	.	O

Side	side	O
effects	effects	O
were	were	O
reported	reported	O
in	in	O
21	21	O
%	%	O
of	of	O
patients	patients	O
and	and	O
caused	caused	O
withdrawal	withdrawal	O
from	from	O
the	the	O
study	study	O
in	in	O
3	3	O
patients	patients	O
.	.	O

The	the	O
main	main	O
side-effects	side-effects	O
were	were	O
headache	headache	B-Disease
,	,	O
dizziness	dizziness	B-Disease
,	,	O
palpitation	palpitation	O
and	and	O
flushing	flushing	O
and	and	O
these	these	O
were	were	O
not	not	O
more	more	O
frequent	frequent	O
than	than	O
reported	reported	O
in	in	O
other	other	O
studies	studies	O
with	with	O
isradipine	isradipine	O
or	or	O
with	with	O
placebo	placebo	O
.	.	O

Supine	supine	O
blood	blood	O
pressure	pressure	O
was	was	O
reduced	reduced	O
(	(	O
P	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
from	from	O
170	170	O
+	+	O
/-	/-	O
20/102	20/102	O
+	+	O
/-	/-	O
6	6	O
mmHg	mmhg	O
to	to	O
153	153	O
+	+	O
/-	/-	O
19/92	19/92	O
+	+	O
/-	/-	O
8	8	O
,	,	O
147	147	O
+	+	O
/-	/-	O
18/88	18/88	O
+	+	O
/-	/-	O
7	7	O
and	and	O
144	144	O
+	+	O
/-	/-	O
14/87	14/87	O
+	+	O
/-	/-	O
6	6	O
mmHg	mmhg	O
at	at	O
2	2	O
,	,	O
4	4	O
and	and	O
6	6	O
weeks	weeks	O
respectively	respectively	O
in	in	O
evaluable	evaluable	O
patients	patients	O
.	.	O

Similar	similar	O
reductions	reductions	O
occurred	occurred	O
in	in	O
standing	standing	O
blood	blood	O
pressure	pressure	O
and	and	O
there	there	O
was	was	O
no	no	O
evidence	evidence	O
of	of	O
postural	postural	O
hypotension	hypotension	B-Disease
.	.	O

Normalization	normalization	O
and	and	O
responder	responder	O
rates	rates	O
at	at	O
6	6	O
weeks	weeks	O
were	were	O
86	86	O
%	%	O
and	and	O
69	69	O
%	%	O
respectively	respectively	O
.	.	O

Dosage	dosage	O
was	was	O
increased	increased	O
from	from	O
2.5	2.5	O
mg	mg	O
b.d	b.d	O
.	.	O
to	to	O
5	5	O
mg	mg	O
b.d	b.d	O
.	.	O

at	at	O
4	4	O
weeks	weeks	O
in	in	O
patients	patients	O
with	with	O
diastolic	diastolic	O
blood	blood	O
pressure	pressure	O
greater	greater	O
than	than	O
90	90	O
mmHg	mmhg	O
and	and	O
their	their	O
further	further	O
response	response	O
was	was	O
greater	greater	O
than	than	O
those	those	O
remaining	remaining	O
on	on	O
2.5	2.5	O
mg	mg	O
b.d	b.d	O
.	.	O

Pharmacological	pharmacological	O
characteristics	characteristics	O
and	and	O
side	side	O
effects	effects	O
of	of	O
a	a	O
new	new	O
galenic	galenic	O
formulation	formulation	O
of	of	O
propofol	propofol	B-Chemical
without	without	O
soyabean	soyabean	O
oil	oil	O
.	.	O

We	we	O
compared	compared	O
the	the	O
pharmacokinetics	pharmacokinetics	O
,	,	O
pharmacodynamics	pharmacodynamics	O
and	and	O
safety	safety	O
profile	profile	O
of	of	O
a	a	O
new	new	O
galenic	galenic	O
formulation	formulation	O
of	of	O
propofol	propofol	B-Chemical
(	(	O
AM149	am149	O
1	1	O
%	%	O
)	)	O
,	,	O
which	which	O
does	does	O
not	not	O
contain	contain	O
soyabean	soyabean	O
oil	oil	O
,	,	O
with	with	O
a	a	O
standard	standard	O
formulation	formulation	O
of	of	O
propofol	propofol	B-Chemical
(	(	O
Disoprivan	disoprivan	O
1	1	O
%	%	O
)	)	O
.	.	O

In	in	O
a	a	O
randomised	randomised	O
,	,	O
double-blind	double-blind	O
,	,	O
cross-over	cross-over	O
study	study	O
,	,	O
30	30	O
healthy	healthy	O
volunteers	volunteers	O
received	received	O
a	a	O
single	single	O
intravenous	intravenous	O
bolus	bolus	O
injection	injection	O
of	of	O
2.5	2.5	O
mg.kg-1	mg.kg-1	O
propofol	propofol	B-Chemical
.	.	O

Plasma	plasma	O
propofol	propofol	B-Chemical
levels	levels	O
were	were	O
measured	measured	O
for	for	O
48	48	O
h	h	B-Chemical
following	following	O
drug	drug	O
administration	administration	O
and	and	O
evaluated	evaluated	O
according	according	O
to	to	O
a	a	O
three-compartment	three-compartment	O
model	model	O
.	.	O

The	the	O
pharmacodynamic	pharmacodynamic	O
parameters	parameters	O
assessed	assessed	O
included	included	O
induction	induction	O
and	and	O
emergence	emergence	O
times	times	O
,	,	O
respiratory	respiratory	O
and	and	O
cardiovascular	cardiovascular	O
effects	effects	O
,	,	O
and	and	O
pain	pain	B-Disease
on	on	O
injection	injection	O
.	.	O

Patients	patients	O
were	were	O
monitored	monitored	O
for	for	O
side	side	O
effects	effects	O
over	over	O
48	48	O
h.	h.	O
Owing	owing	O
to	to	O
a	a	O
high	high	O
incidence	incidence	O
of	of	O
thrombophlebitis	thrombophlebitis	O
,	,	O
the	the	O
study	study	O
was	was	O
terminated	terminated	O
prematurely	prematurely	O
and	and	O
only	only	O
the	the	O
data	data	O
of	of	O
the	the	O
two	two	O
parallel	parallel	O
treatment	treatment	O
groups	groups	O
(	(	O
15	15	O
patients	patients	O
in	in	O
each	each	O
group	group	O
)	)	O
were	were	O
analysed	analysed	O
.	.	O

Plasma	plasma	O
concentrations	concentrations	O
did	did	O
not	not	O
differ	differ	O
significantly	significantly	O
between	between	O
the	the	O
two	two	O
formulations	formulations	O
.	.	O

Anaesthesia	anaesthesia	O
induction	induction	O
and	and	O
emergence	emergence	O
times	times	O
,	,	O
respiratory	respiratory	O
and	and	O
cardiovascular	cardiovascular	O
variables	variables	O
showed	showed	O
no	no	O
significant	significant	O
differences	differences	O
between	between	O
the	the	O
two	two	O
treatment	treatment	O
groups	groups	O
.	.	O

Pain	pain	B-Disease
on	on	O
injection	injection	O
(	(	O
80	80	O
vs.	vs.	O
20	20	O
%	%	O
,	,	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
and	and	O
thrombophlebitis	thrombophlebitis	O
(	(	O
93.3	93.3	O
vs.	vs.	O
6.6	6.6	O
%	%	O
,	,	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
occurred	occurred	O
more	more	O
frequently	frequently	O
with	with	O
AM149	am149	O
than	than	O
with	with	O
Disoprivan	disoprivan	O
.	.	O
Although	although	O
both	both	O
formulations	formulations	O
had	had	O
similar	similar	O
pharmacokinetic	pharmacokinetic	O
and	and	O
pharmacodynamic	pharmacodynamic	O
profiles	profiles	O
the	the	O
new	new	O
formulation	formulation	O
is	is	O
not	not	O
suitable	suitable	O
for	for	O
clinical	clinical	O
use	use	O
due	due	O
to	to	O
the	the	O
high	high	O
incidence	incidence	O
of	of	O
thrombophlebitis	thrombophlebitis	O
produced	produced	O
.	.	O

Pure	pure	O
red	red	O
cell	cell	O
aplasia	aplasia	O
,	,	O
toxic	toxic	O
dermatitis	dermatitis	B-Disease
and	and	O
lymphadenopathy	lymphadenopathy	B-Disease
in	in	O
a	a	O
patient	patient	O
taking	taking	O
diphenylhydantoin	diphenylhydantoin	O
.	.	O

A	a	O
patient	patient	O
taking	taking	O
diphenylhydantoin	diphenylhydantoin	O
for	for	O
3	3	O
weeks	weeks	O
developed	developed	O
a	a	O
generalized	generalized	O
skin	skin	O
rash	rash	B-Disease
,	,	O
lymphadenopathy	lymphadenopathy	B-Disease
and	and	O
pure	pure	O
red	red	O
cell	cell	O
aplasia	aplasia	O
.	.	O

After	after	O
withdrawal	withdrawal	O
of	of	O
the	the	O
pharmacon	pharmacon	O
all	all	O
symptoms	symptoms	O
disappeared	disappeared	O
spontaneously	spontaneously	O
.	.	O

Skin	skin	O
rash	rash	B-Disease
is	is	O
a	a	O
well-known	well-known	O
complication	complication	O
of	of	O
diphenylhydantoin	diphenylhydantoin	O
treatment	treatment	O
as	as	O
is	is	O
benign	benign	O
and	and	O
malignant	malignant	O
lymphadenopathy	lymphadenopathy	B-Disease
.	.	O

Pure	pure	O
red	red	O
cell	cell	O
aplasia	aplasia	O
associated	associated	O
with	with	O
diphenylhydantoin	diphenylhydantoin	O
medication	medication	O
has	has	O
been	been	O
reported	reported	O
in	in	O
3	3	O
patients	patients	O
.	.	O

The	the	O
exact	exact	O
mechanism	mechanism	O
by	by	O
which	which	O
diphenylhydantoin	diphenylhydantoin	O
exerts	exerts	O
its	its	O
toxic	toxic	O
effects	effects	O
is	is	O
not	not	O
known	known	O
.	.	O

In	in	O
this	this	O
patient	patient	O
the	the	O
time	time	O
relation	relation	O
between	between	O
the	the	O
ingestion	ingestion	O
of	of	O
diphenylhydantoin	diphenylhydantoin	O
and	and	O
the	the	O
occurrence	occurrence	O
of	of	O
the	the	O
skin	skin	O
rash	rash	B-Disease
,	,	O
lymphadenopathy	lymphadenopathy	B-Disease
and	and	O
pure	pure	O
red	red	O
cell	cell	O
aplasia	aplasia	O
is	is	O
very	very	O
suggestive	suggestive	O
of	of	O
a	a	O
direct	direct	O
connection	connection	O
.	.	O

Vinorelbine-related	vinorelbine-related	O
cardiac	cardiac	O
events	events	O
:	:	O
a	a	O
meta-analysis	meta-analysis	O
of	of	O
randomized	randomized	O
clinical	clinical	O
trials	trials	O
.	.	O

Several	several	O
cases	cases	O
of	of	O
cardiac	cardiac	O
adverse	adverse	O
reactions	reactions	O
related	related	O
to	to	O
vinorelbine	vinorelbine	B-Chemical
(	(	O
VNR	vnr	O
)	)	O
have	have	O
been	been	O
reported	reported	O
in	in	O
the	the	O
literature	literature	O
.	.	O

In	in	O
order	order	O
to	to	O
quantify	quantify	O
the	the	O
incidence	incidence	O
of	of	O
these	these	O
cardiac	cardiac	O
events	events	O
,	,	O
we	we	O
performed	performed	O
a	a	O
meta-analysis	meta-analysis	O
of	of	O
clinical	clinical	O
trials	trials	O
comparing	comparing	O
VNR	vnr	O
with	with	O
other	other	O
chemotherapeutic	chemotherapeutic	O
agents	agents	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
various	various	O
malignancies	malignancies	B-Disease
.	.	O

Randomized	randomized	O
clinical	clinical	O
trials	trials	O
comparing	comparing	O
VNR	vnr	O
with	with	O
other	other	O
drugs	drugs	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
cancer	cancer	B-Disease
were	were	O
searched	searched	O
in	in	O
Medline	medline	O
,	,	O
Embase	embase	O
,	,	O
Evidence-based	evidence-based	O
Medicine	medicine	O
Reviews	reviews	O
databases	databases	O
and	and	O
the	the	O
Cochrane	cochrane	O
library	library	O
from	from	O
1987	1987	O
to	to	O
2002	2002	O
.	.	O

Outcomes	outcomes	O
of	of	O
interest	interest	O
were	were	O
severe	severe	O
cardiac	cardiac	O
events	events	O
,	,	O
toxic	toxic	O
deaths	deaths	B-Disease
and	and	O
cardiac	cardiac	O
event-related	event-related	O
deaths	deaths	B-Disease
reported	reported	O
in	in	O
each	each	O
publication	publication	O
.	.	O

We	we	O
found	found	O
19	19	O
trials	trials	O
,	,	O
involving	involving	O
2441	2441	O
patients	patients	O
treated	treated	O
by	by	O
VNR	vnr	O
and	and	O
2050	2050	O
control	control	O
patients	patients	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
cardiac	cardiac	O
events	events	O
with	with	O
VNR	vnr	O
was	was	O
1.19	1.19	O
%	%	O
[	[	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
(	(	O
CI	ci	O
)	)	O
(	(	O
0.75	0.75	O
;	;	O
1.67	1.67	O
)	)	O
]	]	O
.	.	O

There	there	O
was	was	O
no	no	O
difference	difference	O
in	in	O
the	the	O
risk	risk	O
of	of	O
cardiac	cardiac	O
events	events	O
between	between	O
VNR	vnr	O
and	and	O
other	other	O
drugs	drugs	O
[	[	O
odds	odds	O
ratio	ratio	O
:	:	O
0.92	0.92	O
,	,	O
95	95	O
%	%	O
CI	ci	O
(	(	O
0.54	0.54	O
;	;	O
1.55	1.55	O
)	)	O
]	]	O
.	.	O

The	the	O
risk	risk	O
of	of	O
VNR	vnr	O
cardiac	cardiac	O
events	events	O
was	was	O
similar	similar	O
to	to	O
vindesine	vindesine	O
(	(	O
VDS	vds	O
)	)	O
and	and	O
other	other	O
cardiotoxic	cardiotoxic	B-Disease
drugs	drugs	O
[	[	O
fluorouracil	fluorouracil	O
,	,	O
anthracyclines	anthracyclines	O
,	,	O
gemcitabine	gemcitabine	B-Chemical
(	(	O
GEM	gem	B-Chemical
)	)	O
em	em	O
leader	leader	O
]	]	O
.	.	O

Even	even	O
if	if	O
it	it	O
did	did	O
not	not	O
reach	reach	O
statistical	statistical	O
significance	significance	O
because	because	O
of	of	O
a	a	O
few	few	O
number	number	O
of	of	O
cases	cases	O
,	,	O
the	the	O
risk	risk	O
was	was	O
lower	lower	O
in	in	O
trials	trials	O
excluding	excluding	O
patients	patients	O
with	with	O
cardiac	cardiac	O
history	history	O
,	,	O
and	and	O
seemed	seemed	O
to	to	O
be	be	O
higher	higher	O
in	in	O
trials	trials	O
including	including	O
patients	patients	O
with	with	O
pre-existing	pre-existing	O
cardiac	cardiac	B-Disease
diseases	diseases	I-Disease
.	.	O

Vinorelbine-related	vinorelbine-related	O
cardiac	cardiac	O
events	events	O
concern	concern	O
about	about	O
1	1	O
%	%	O
of	of	O
treated	treated	O
patients	patients	O
in	in	O
clinical	clinical	O
trials	trials	O
.	.	O

However	however	O
,	,	O
the	the	O
risk	risk	O
associated	associated	O
with	with	O
VNR	vnr	O
seems	seems	O
to	to	O
be	be	O
similar	similar	O
to	to	O
that	that	O
of	of	O
other	other	O
chemotherapeutic	chemotherapeutic	O
agents	agents	O
in	in	O
the	the	O
same	same	O
indications	indications	O
.	.	O

MRI	mri	O
findings	findings	O
of	of	O
hypoxic	hypoxic	O
cortical	cortical	O
laminar	laminar	O
necrosis	necrosis	B-Disease
in	in	O
a	a	O
child	child	O
with	with	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
crisis	crisis	O
.	.	O

We	we	O
present	present	O
magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
findings	findings	O
of	of	O
a	a	O
5-year-old	5-year-old	O
girl	girl	O
who	who	O
had	had	O
a	a	O
rapidly	rapidly	O
installing	installing	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
crisis	crisis	O
induced	induced	O
by	by	O
trimethoprim-sulfomethoxazole	trimethoprim-sulfomethoxazole	O
,	,	O
resulting	resulting	O
in	in	O
cerebral	cerebral	O
anoxia	anoxia	O
leading	leading	O
to	to	O
permanent	permanent	O
damage	damage	O
.	.	O

Magnetic	magnetic	O
Resonance	resonance	O
imaging	imaging	O
revealed	revealed	O
cortical	cortical	O
laminar	laminar	O
necrosis	necrosis	B-Disease
in	in	O
arterial	arterial	O
border	border	O
zones	zones	O
in	in	O
both	both	O
cerebral	cerebral	O
hemispheres	hemispheres	O
,	,	O
ischemic	ischemic	O
changes	changes	O
in	in	O
subcortical	subcortical	O
white	white	O
matter	matter	O
of	of	O
left	left	O
cerebral	cerebral	O
hemisphere	hemisphere	O
,	,	O
and	and	O
in	in	O
the	the	O
left	left	O
putamen	putamen	O
.	.	O

Although	although	O
cortical	cortical	O
laminar	laminar	O
necrosis	necrosis	B-Disease
is	is	O
a	a	O
classic	classic	O
entity	entity	O
in	in	O
adulthood	adulthood	O
related	related	O
to	to	O
conditions	conditions	O
of	of	O
energy	energy	O
depletions	depletions	O
,	,	O
there	there	O
are	are	O
few	few	O
reports	reports	O
available	available	O
in	in	O
children	children	O
.	.	O

A	a	O
wide	wide	O
review	review	O
of	of	O
the	the	O
literature	literature	O
is	is	O
also	also	O
presented	presented	O
.	.	O

The	the	O
natural	natural	O
history	history	O
of	of	O
Vigabatrin	vigabatrin	B-Chemical
associated	associated	O
visual	visual	B-Disease
field	field	I-Disease
defects	defects	I-Disease
in	in	O
patients	patients	O
electing	electing	O
to	to	O
continue	continue	O
their	their	O
medication	medication	O
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
determine	determine	O
the	the	O
natural	natural	O
history	history	O
of	of	O
visual	visual	B-Disease
field	field	I-Disease
defects	defects	I-Disease
in	in	O
a	a	O
group	group	O
of	of	O
patients	patients	O
known	known	O
to	to	O
have	have	O
Vigabatrin-associated	vigabatrin-associated	O
changes	changes	O
who	who	O
elected	elected	O
to	to	O
continue	continue	O
the	the	O
medication	medication	O
because	because	O
of	of	O
good	good	O
seizure	seizure	B-Disease
control	control	O
.	.	O

METHODS	methods	O
:	:	O
All	all	O
patients	patients	O
taking	taking	O
Vigabatrin	vigabatrin	B-Chemical
alone	alone	O
or	or	O
in	in	O
combination	combination	O
with	with	O
other	other	O
antiepileptic	antiepileptic	O
drugs	drugs	O
for	for	O
at	at	O
least	least	O
5	5	O
years	years	O
(	(	O
range	range	O
5	5	O
-	-	O
12	12	O
years	years	O
)	)	O
were	were	O
entered	entered	O
into	into	O
a	a	O
visual	visual	O
surveillance	surveillance	O
programme	programme	O
.	.	O

Patients	patients	O
were	were	O
followed	followed	O
up	up	O
at	at	O
6-monthly	6-monthly	O
intervals	intervals	O
for	for	O
not	not	O
less	less	O
than	than	O
18	18	O
months	months	O
(	(	O
range	range	O
18	18	O
-	-	O
43	43	O
months	months	O
)	)	O
.	.	O

In	in	O
all	all	O
,	,	O
16	16	O
patients	patients	O
with	with	O
unequivocal	unequivocal	O
defects	defects	O
continued	continued	O
the	the	O
medication	medication	O
.	.	O

Following	following	O
already	already	O
published	published	O
methodology	methodology	O
(	(	O
Eye	eye	O
2002	2002	O
;	;	O
16;567	16;567	O
-	-	O
571	571	O
)	)	O
monocular	monocular	O
mean	mean	O
radial	radial	O
degrees	degrees	O
(	(	O
MRDs	mrds	O
)	)	O
to	to	O
the	the	O
I/4e	i/4e	O
isopter	isopter	O
on	on	O
Goldmann	goldmann	O
perimetry	perimetry	O
was	was	O
calculated	calculated	O
for	for	O
the	the	O
right	right	O
eye	eye	O
at	at	O
the	the	O
time	time	O
of	of	O
discovery	discovery	O
of	of	O
a	a	O
visual	visual	O
field	field	O
defect	defect	O
and	and	O
again	again	O
after	after	O
not	not	O
less	less	O
than	than	O
18	18	O
months	months	O
follow-up	follow-up	O
.	.	O

RESULTS	results	O
:	:	O
Mean	mean	O
right	right	O
eye	eye	O
MRD	mrd	O
at	at	O
presentation	presentation	O
was	was	O
36.98	36.98	O
degrees	degrees	O
(	(	O
range	range	O
22.25	22.25	O
-	-	O
51.0	51.0	O
)	)	O
,	,	O
compared	compared	O
to	to	O
38.40	38.40	O
degrees	degrees	O
(	(	O
range	range	O
22.5	22.5	O
-	-	O
49.75	49.75	O
)	)	O
after	after	O
follow-up	follow-up	O
;	;	O
P=0.338	p=0.338	O
unpaired	unpaired	O
t-test	t-test	O
.	.	O

Only	only	O
one	one	O
patient	patient	O
demonstrated	demonstrated	O
a	a	O
deterioration	deterioration	O
in	in	O
visual	visual	O
field	field	O
during	during	O
the	the	O
study	study	O
period	period	O
and	and	O
discontinued	discontinued	O
treatment	treatment	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Established	established	O
visual	visual	B-Disease
field	field	I-Disease
defects	defects	I-Disease
presumed	presumed	O
to	to	O
be	be	O
due	due	O
to	to	O
Vigabatrin	vigabatrin	B-Chemical
therapy	therapy	O
did	did	O
not	not	O
usually	usually	O
progress	progress	O
in	in	O
spite	spite	O
of	of	O
continuing	continuing	O
use	use	O
of	of	O
the	the	O
medication	medication	O
.	.	O

These	these	O
data	data	O
give	give	O
support	support	O
to	to	O
the	the	O
hypothesis	hypothesis	O
that	that	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
Vigabatrin-associated	vigabatrin-associated	O
visual	visual	B-Disease
field	field	I-Disease
defects	defects	I-Disease
may	may	O
be	be	O
an	an	O
idiosyncratic	idiosyncratic	O
adverse	adverse	O
drug	drug	O
reaction	reaction	O
rather	rather	O
than	than	O
dose-dependent	dose-dependent	O
toxicity	toxicity	B-Disease
.	.	O

Induction	induction	O
of	of	O
rosaceiform	rosaceiform	O
dermatitis	dermatitis	B-Disease
during	during	O
treatment	treatment	O
of	of	O
facial	facial	O
inflammatory	inflammatory	O
dermatoses	dermatoses	B-Disease
with	with	O
tacrolimus	tacrolimus	B-Chemical
ointment	ointment	O
.	.	O

BACKGROUND	background	O
:	:	O
Tacrolimus	tacrolimus	B-Chemical
ointment	ointment	O
is	is	O
increasingly	increasingly	O
used	used	O
for	for	O
anti-inflammatory	anti-inflammatory	O
treatment	treatment	O
of	of	O
sensitive	sensitive	O
areas	areas	O
such	such	O
as	as	O
the	the	O
face	face	O
,	,	O
and	and	O
recent	recent	O
observations	observations	O
indicate	indicate	O
that	that	O
the	the	O
treatment	treatment	O
is	is	O
effective	effective	O
in	in	O
steroid-aggravated	steroid-aggravated	O
rosacea	rosacea	O
and	and	O
perioral	perioral	O
dermatitis	dermatitis	B-Disease
.	.	O

We	we	O
report	report	O
on	on	O
rosaceiform	rosaceiform	O
dermatitis	dermatitis	B-Disease
as	as	O
a	a	O
complication	complication	O
of	of	O
treatment	treatment	O
with	with	O
tacrolimus	tacrolimus	B-Chemical
ointment	ointment	O
.	.	O

OBSERVATIONS	observations	O
:	:	O
Six	six	O
adult	adult	O
patients	patients	O
with	with	O
inflammatory	inflammatory	O
facial	facial	B-Disease
dermatoses	dermatoses	B-Disease
were	were	O
treated	treated	O
with	with	O
tacrolimus	tacrolimus	B-Chemical
ointment	ointment	O
because	because	O
of	of	O
the	the	O
ineffectiveness	ineffectiveness	O
of	of	O
standard	standard	O
treatments	treatments	O
.	.	O

Within	within	O
2	2	O
to	to	O
3	3	O
weeks	weeks	O
of	of	O
initially	initially	O
effective	effective	O
and	and	O
well-tolerated	well-tolerated	O
treatment	treatment	O
,	,	O
3	3	O
patients	patients	O
with	with	O
a	a	O
history	history	O
of	of	O
rosacea	rosacea	O
and	and	O
1	1	O
with	with	O
a	a	O
history	history	O
of	of	O
acne	acne	B-Disease
experienced	experienced	O
sudden	sudden	O
worsening	worsening	O
with	with	O
pustular	pustular	O
rosaceiform	rosaceiform	O
lesions	lesions	O
.	.	O

Biopsy	biopsy	O
revealed	revealed	O
an	an	O
abundance	abundance	O
of	of	O
Demodex	demodex	O
mites	mites	O
in	in	O
2	2	O
of	of	O
these	these	O
patients	patients	O
.	.	O

In	in	O
1	1	O
patient	patient	O
with	with	O
eyelid	eyelid	O
eczema	eczema	O
,	,	O
rosaceiform	rosaceiform	O
periocular	periocular	O
dermatitis	dermatitis	B-Disease
gradually	gradually	O
appeared	appeared	O
after	after	O
3	3	O
weeks	weeks	O
of	of	O
treatment	treatment	O
.	.	O

In	in	O
1	1	O
patient	patient	O
with	with	O
atopic	atopic	O
dermatitis	dermatitis	B-Disease
,	,	O
telangiectatic	telangiectatic	O
and	and	O
papular	papular	O
rosacea	rosacea	O
insidiously	insidiously	O
appeared	appeared	O
after	after	O
5	5	O
months	months	O
of	of	O
treatment	treatment	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Our	our	O
observations	observations	O
suggest	suggest	O
that	that	O
the	the	O
spectrum	spectrum	O
of	of	O
rosaceiform	rosaceiform	O
dermatitis	dermatitis	B-Disease
as	as	O
a	a	O
complication	complication	O
of	of	O
treatment	treatment	O
with	with	O
tacrolimus	tacrolimus	B-Chemical
ointment	ointment	O
is	is	O
heterogeneous	heterogeneous	O
.	.	O

A	a	O
variety	variety	O
of	of	O
factors	factors	O
,	,	O
such	such	O
as	as	O
vasoactive	vasoactive	O
properties	properties	O
of	of	O
tacrolimus	tacrolimus	B-Chemical
,	,	O
proliferation	proliferation	O
of	of	O
Demodex	demodex	O
due	due	O
to	to	O
local	local	O
immunosuppression	immunosuppression	O
,	,	O
and	and	O
the	the	O
occlusive	occlusive	O
properties	properties	O
of	of	O
the	the	O
ointment	ointment	O
,	,	O
may	may	O
be	be	O
involved	involved	O
in	in	O
the	the	O
observed	observed	O
phenomena	phenomena	O
.	.	O

Future	future	O
studies	studies	O
are	are	O
needed	needed	O
to	to	O
identify	identify	O
individual	individual	O
risk	risk	O
factors	factors	O
.	.	O

Intravascular	intravascular	O
hemolysis	hemolysis	B-Disease
and	and	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
following	following	O
intermittent	intermittent	O
rifampin	rifampin	B-Chemical
therapy	therapy	O
.	.	O

Renal	renal	B-Disease
failure	failure	I-Disease
is	is	O
a	a	O
rare	rare	O
complication	complication	O
associated	associated	O
with	with	O
the	the	O
use	use	O
of	of	O
rifampin	rifampin	B-Chemical
.	.	O

Intravascular	intravascular	O
hemolysis	hemolysis	B-Disease
leading	leading	O
to	to	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
following	following	O
rifampin	rifampin	B-Chemical
therapy	therapy	O
is	is	O
extremely	extremely	O
rare	rare	O
.	.	O

Two	two	O
patients	patients	O
with	with	O
leprosy	leprosy	O
who	who	O
developed	developed	O
hemolysis	hemolysis	B-Disease
and	and	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
following	following	O
rifampin	rifampin	B-Chemical
are	are	O
reported	reported	O
.	.	O

Structural	structural	O
abnormalities	abnormalities	O
in	in	O
the	the	O
brains	brains	O
of	of	O
human	human	O
subjects	subjects	O
who	who	O
use	use	O
methamphetamine	methamphetamine	B-Chemical
.	.	O

We	we	O
visualize	visualize	O
,	,	O
for	for	O
the	the	O
first	first	O
time	time	O
,	,	O
the	the	O
profile	profile	O
of	of	O
structural	structural	O
deficits	deficits	O
in	in	O
the	the	O
human	human	O
brain	brain	O
associated	associated	O
with	with	O
chronic	chronic	O
methamphetamine	methamphetamine	B-Chemical
(	(	O
MA	ma	O
)	)	O
abuse	abuse	O
.	.	O

Studies	studies	O
of	of	O
human	human	O
subjects	subjects	O
who	who	O
have	have	O
used	used	O
MA	ma	O
chronically	chronically	O
have	have	O
revealed	revealed	O
deficits	deficits	O
in	in	O
dopaminergic	dopaminergic	O
and	and	O
serotonergic	serotonergic	O
systems	systems	O
and	and	O
cerebral	cerebral	O
metabolic	metabolic	O
abnormalities	abnormalities	O
.	.	O

Using	using	O
magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
(	(	O
MRI	mri	O
)	)	O
and	and	O
new	new	O
computational	computational	O
brain-mapping	brain-mapping	O
techniques	techniques	O
,	,	O
we	we	O
determined	determined	O
the	the	O
pattern	pattern	O
of	of	O
structural	structural	O
brain	brain	O
alterations	alterations	O
associated	associated	O
with	with	O
chronic	chronic	O
MA	ma	O
abuse	abuse	O
in	in	O
human	human	O
subjects	subjects	O
and	and	O
related	related	O
these	these	O
deficits	deficits	O
to	to	O
cognitive	cognitive	B-Disease
impairment	impairment	I-Disease
.	.	O

We	we	O
used	used	O
high-resolution	high-resolution	O
MRI	mri	O
and	and	O
surface-based	surface-based	O
computational	computational	O
image	image	O
analyses	analyses	O
to	to	O
map	map	O
regional	regional	O
abnormalities	abnormalities	O
in	in	O
the	the	O
cortex	cortex	O
,	,	O
hippocampus	hippocampus	O
,	,	O
white	white	O
matter	matter	O
,	,	O
and	and	O
ventricles	ventricles	O
in	in	O
22	22	O
human	human	O
subjects	subjects	O
who	who	O
used	used	O
MA	ma	O
and	and	O
21	21	O
age-matched	age-matched	O
,	,	O
healthy	healthy	O
controls	controls	O
.	.	O

Cortical	cortical	O
maps	maps	O
revealed	revealed	O
severe	severe	O
gray-matter	gray-matter	O
deficits	deficits	O
in	in	O
the	the	O
cingulate	cingulate	O
,	,	O
limbic	limbic	O
,	,	O
and	and	O
paralimbic	paralimbic	O
cortices	cortices	O
of	of	O
MA	ma	O
abusers	abusers	O
(	(	O
averaging	averaging	O
11.3	11.3	O
%	%	O
below	below	O
control	control	O
;	;	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

On	on	O
average	average	O
,	,	O
MA	ma	O
abusers	abusers	O
had	had	O
7.8	7.8	O
%	%	O
smaller	smaller	O
hippocampal	hippocampal	O
volumes	volumes	O
than	than	O
control	control	O
subjects	subjects	O
(	(	O
p	p	O
<	<	O
0.01	0.01	O
;	;	O
left	left	O
,	,	O
p	p	O
=	=	O
0.01	0.01	O
;	;	O
right	right	O
,	,	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
and	and	O
significant	significant	O
white-matter	white-matter	O
hypertrophy	hypertrophy	B-Disease
(	(	O
7.0	7.0	O
%	%	O
;	;	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

Hippocampal	hippocampal	O
deficits	deficits	O
were	were	O
mapped	mapped	O
and	and	O
correlated	correlated	O
with	with	O
memory	memory	O
performance	performance	O
on	on	O
a	a	O
word-recall	word-recall	O
test	test	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

MRI-based	mri-based	O
maps	maps	O
suggest	suggest	O
that	that	O
chronic	chronic	O
methamphetamine	methamphetamine	B-Chemical
abuse	abuse	O
causes	causes	O
a	a	O
selective	selective	O
pattern	pattern	O
of	of	O
cerebral	cerebral	O
deterioration	deterioration	O
that	that	O
contributes	contributes	O
to	to	O
impaired	impaired	O
memory	memory	O
performance	performance	O
.	.	O

MA	ma	O
may	may	O
selectively	selectively	O
damage	damage	O
the	the	O
medial	medial	O
temporal	temporal	O
lobe	lobe	O
and	and	O
,	,	O
consistent	consistent	O
with	with	O
metabolic	metabolic	O
studies	studies	O
,	,	O
the	the	O
cingulate-limbic	cingulate-limbic	O
cortex	cortex	O
,	,	O
inducing	inducing	O
neuroadaptation	neuroadaptation	O
,	,	O
neuropil	neuropil	O
reduction	reduction	O
,	,	O
or	or	O
cell	cell	O
death	death	B-Disease
.	.	O

Prominent	prominent	O
white-matter	white-matter	O
hypertrophy	hypertrophy	B-Disease
may	may	O
result	result	O
from	from	O
altered	altered	O
myelination	myelination	O
and	and	O
adaptive	adaptive	O
glial	glial	O
changes	changes	O
,	,	O
including	including	O
gliosis	gliosis	O
secondary	secondary	O
to	to	O
neuronal	neuronal	B-Disease
damage	damage	I-Disease
.	.	O

These	these	O
brain	brain	O
substrates	substrates	O
may	may	O
help	help	O
account	account	O
for	for	O
the	the	O
symptoms	symptoms	O
of	of	O
MA	ma	O
abuse	abuse	O
,	,	O
providing	providing	O
therapeutic	therapeutic	O
targets	targets	O
for	for	O
drug-induced	drug-induced	O
brain	brain	O
injury	injury	O
.	.	O

Disruption	disruption	O
of	of	O
hepatic	hepatic	O
lipid	lipid	O
homeostasis	homeostasis	O
in	in	O
mice	mice	O
after	after	O
amiodarone	amiodarone	B-Chemical
treatment	treatment	O
is	is	O
associated	associated	O
with	with	O
peroxisome	peroxisome	O
proliferator-activated	proliferator-activated	O
receptor-alpha	receptor-alpha	O
target	target	O
gene	gene	O
activation	activation	O
.	.	O

Amiodarone	amiodarone	B-Chemical
,	,	O
an	an	O
efficacious	efficacious	O
and	and	O
widely	widely	O
used	used	O
antiarrhythmic	antiarrhythmic	O
agent	agent	O
,	,	O
has	has	O
been	been	O
reported	reported	O
to	to	O
cause	cause	O
hepatotoxicity	hepatotoxicity	B-Disease
in	in	O
some	some	O
patients	patients	O
.	.	O

To	to	O
gain	gain	O
insight	insight	O
into	into	O
the	the	O
mechanism	mechanism	O
of	of	O
this	this	O
unwanted	unwanted	O
effect	effect	O
,	,	O
mice	mice	O
were	were	O
administered	administered	O
various	various	O
doses	doses	O
of	of	O
amiodarone	amiodarone	B-Chemical
and	and	O
examined	examined	O
for	for	O
changes	changes	O
in	in	O
hepatic	hepatic	O
histology	histology	O
and	and	O
gene	gene	O
regulation	regulation	O
.	.	O

Amiodarone	amiodarone	B-Chemical
induced	induced	O
hepatomegaly	hepatomegaly	B-Disease
,	,	O
hepatocyte	hepatocyte	O
microvesicular	microvesicular	O
lipid	lipid	O
accumulation	accumulation	O
,	,	O
and	and	O
a	a	O
significant	significant	O
decrease	decrease	O
in	in	O
serum	serum	O
triglycerides	triglycerides	O
and	and	O
glucose	glucose	B-Chemical
.	.	O

Northern	northern	O
blot	blot	O
analysis	analysis	O
of	of	O
hepatic	hepatic	O
RNA	rna	O
revealed	revealed	O
a	a	O
dose-dependent	dose-dependent	O
increase	increase	O
in	in	O
the	the	O
expression	expression	O
of	of	O
a	a	O
number	number	O
of	of	O
genes	genes	O
critical	critical	O
for	for	O
fatty	fatty	O
acid	acid	O
oxidation	oxidation	O
,	,	O
lipoprotein	lipoprotein	O
assembly	assembly	O
,	,	O
and	and	O
lipid	lipid	O
transport	transport	O
.	.	O

Many	many	O
of	of	O
these	these	O
genes	genes	O
are	are	O
regulated	regulated	O
by	by	O
the	the	O
peroxisome	peroxisome	O
proliferator-activated	proliferator-activated	O
receptor-alpha	receptor-alpha	O
(	(	O
PPARalpha	pparalpha	O
)	)	O
,	,	O
a	a	O
ligand-activated	ligand-activated	O
nuclear	nuclear	O
hormone	hormone	O
receptor	receptor	O
transcription	transcription	O
factor	factor	O
.	.	O

The	the	O
absence	absence	O
of	of	O
induction	induction	O
of	of	O
these	these	O
genes	genes	O
as	as	O
well	well	O
as	as	O
hepatomegaly	hepatomegaly	B-Disease
in	in	O
PPARalpha	pparalpha	O
knockout	knockout	O
[	[	O
PPARalpha-/-	pparalpha-/-	O
]	]	O
mice	mice	O
indicated	indicated	O
that	that	O
the	the	O
effects	effects	O
of	of	O
amiodarone	amiodarone	B-Chemical
were	were	O
dependent	dependent	O
upon	upon	O
the	the	O
presence	presence	O
of	of	O
a	a	O
functional	functional	O
PPARalpha	pparalpha	O
gene	gene	O
.	.	O

Compared	compared	O
to	to	O
wild-type	wild-type	O
mice	mice	O
,	,	O
treatment	treatment	O
of	of	O
PPARalpha-/-	pparalpha-/-	O
mice	mice	O
with	with	O
amiodarone	amiodarone	B-Chemical
resulted	resulted	O
in	in	O
an	an	O
increased	increased	O
rate	rate	O
and	and	O
extent	extent	O
of	of	O
total	total	O
body	body	B-Disease
weight	weight	B-Disease
loss	loss	I-Disease
.	.	O

The	the	O
inability	inability	O
of	of	O
amiodarone	amiodarone	B-Chemical
to	to	O
directly	directly	O
activate	activate	O
either	either	O
human	human	O
or	or	O
mouse	mouse	O
PPARalpha	pparalpha	O
transiently	transiently	O
expressed	expressed	O
in	in	O
human	human	O
HepG2	hepg2	O
hepatoma	hepatoma	O
cells	cells	O
indicates	indicates	O
that	that	O
the	the	O
effects	effects	O
of	of	O
amiodarone	amiodarone	B-Chemical
on	on	O
the	the	O
function	function	O
of	of	O
this	this	O
receptor	receptor	O
were	were	O
indirect	indirect	O
.	.	O

Based	based	O
upon	upon	O
these	these	O
results	results	O
,	,	O
we	we	O
conclude	conclude	O
that	that	O
amiodarone	amiodarone	B-Chemical
disrupts	disrupts	O
hepatic	hepatic	O
lipid	lipid	O
homeostasis	homeostasis	O
and	and	O
that	that	O
the	the	O
increased	increased	O
expression	expression	O
of	of	O
PPARalpha	pparalpha	O
target	target	O
genes	genes	O
is	is	O
secondary	secondary	O
to	to	O
this	this	O
toxic	toxic	O
effect	effect	O
.	.	O

These	these	O
results	results	O
provide	provide	O
important	important	O
new	new	O
mechanistic	mechanistic	O
information	information	O
regarding	regarding	O
the	the	O
hepatotoxic	hepatotoxic	B-Disease
effects	effects	O
of	of	O
amiodarone	amiodarone	B-Chemical
and	and	O
indicate	indicate	O
that	that	O
PPARalpha	pparalpha	O
protects	protects	O
against	against	O
amiodarone-induced	amiodarone-induced	O
hepatotoxicity	hepatotoxicity	B-Disease
.	.	O

Safety	safety	O
and	and	O
compliance	compliance	O
with	with	O
once-daily	once-daily	O
niacin	niacin	O
extended-release/lovastatin	extended-release/lovastatin	O
as	as	O
initial	initial	O
therapy	therapy	O
in	in	O
the	the	O
Impact	impact	O
of	of	O
Medical	medical	O
Subspecialty	subspecialty	O
on	on	O
Patient	patient	O
Compliance	compliance	O
to	to	O
Treatment	treatment	O
(	(	O
IMPACT	impact	O
)	)	O
study	study	O
.	.	O

Niacin	niacin	O
extended-release/lovastatin	extended-release/lovastatin	O
is	is	O
a	a	O
new	new	O
combination	combination	O
product	product	O
approved	approved	O
for	for	O
treatment	treatment	O
of	of	O
primary	primary	O
hypercholesterolemia	hypercholesterolemia	B-Disease
and	and	O
mixed	mixed	O
dyslipidemia	dyslipidemia	O
.	.	O

This	this	O
open-labeled	open-labeled	O
,	,	O
multicenter	multicenter	O
study	study	O
evaluated	evaluated	O
the	the	O
safety	safety	O
of	of	O
bedtime	bedtime	O
niacin	niacin	O
extended-release/lovastatin	extended-release/lovastatin	O
when	when	O
dosed	dosed	O
as	as	O
initial	initial	O
therapy	therapy	O
and	and	O
patient	patient	O
compliance	compliance	O
to	to	O
treatment	treatment	O
in	in	O
various	various	O
clinical	clinical	O
practice	practice	O
settings	settings	O
.	.	O

A	a	O
total	total	O
of	of	O
4,499	4,499	O
patients	patients	O
with	with	O
dyslipidemia	dyslipidemia	O
requiring	requiring	O
drug	drug	O
intervention	intervention	O
was	was	O
enrolled	enrolled	O
at	at	O
1,081	1,081	O
sites	sites	O
.	.	O

Patients	patients	O
were	were	O
treated	treated	O
with	with	O
1	1	O
tablet	tablet	O
(	(	O
500	500	O
mg	mg	O
of	of	O
niacin	niacin	O
extended-release/20	extended-release/20	O
mg	mg	O
of	of	O
lovastatin	lovastatin	B-Chemical
)	)	O
once	once	O
nightly	nightly	O
for	for	O
4	4	O
weeks	weeks	O
and	and	O
then	then	O
2	2	O
tablets	tablets	O
for	for	O
8	8	O
weeks	weeks	O
.	.	O

Patients	patients	O
also	also	O
received	received	O
dietary	dietary	O
counseling	counseling	O
,	,	O
educational	educational	O
materials	materials	O
,	,	O
and	and	O
reminders	reminders	O
to	to	O
call	call	O
a	a	O
toll-free	toll-free	O
number	number	O
that	that	O
provided	provided	O
further	further	O
education	education	O
about	about	O
dyslipidemia	dyslipidemia	O
and	and	O
niacin	niacin	O
extended-release/lovastatin	extended-release/lovastatin	O
.	.	O

Primary	primary	O
end	end	O
points	points	O
were	were	O
study	study	O
compliance	compliance	O
,	,	O
increases	increases	O
in	in	O
liver	liver	O
transaminases	transaminases	O
to	to	O
>	>	O
3	3	O
times	times	O
the	the	O
upper	upper	O
limit	limit	O
of	of	O
normal	normal	O
,	,	O
and	and	O
clinical	clinical	O
myopathy	myopathy	B-Disease
.	.	O

Final	final	O
study	study	O
status	status	O
was	was	O
available	available	O
for	for	O
4,217	4,217	O
patients	patients	O
(	(	O
94	94	O
%	%	O
)	)	O
.	.	O

Compliance	compliance	O
to	to	O
niacin	niacin	O
extended-release/lovastatin	extended-release/lovastatin	O
was	was	O
77	77	O
%	%	O
,	,	O
with	with	O
3,245	3,245	O
patients	patients	O
completing	completing	O
the	the	O
study	study	O
.	.	O

Patients	patients	O
in	in	O
the	the	O
southeast	southeast	O
and	and	O
those	those	O
enrolled	enrolled	O
by	by	O
endocrinologists	endocrinologists	O
had	had	O
the	the	O
lowest	lowest	O
compliance	compliance	O
and	and	O
highest	highest	O
adverse	adverse	O
event	event	O
rates	rates	O
.	.	O

Flushing	flushing	O
was	was	O
the	the	O
most	most	O
common	common	O
adverse	adverse	O
event	event	O
,	,	O
reported	reported	O
by	by	O
18	18	O
%	%	O
of	of	O
patients	patients	O
and	and	O
leading	leading	O
to	to	O
discontinuation	discontinuation	O
by	by	O
6	6	O
%	%	O
.	.	O

Incidence	incidence	O
of	of	O
increased	increased	O
aspartate	aspartate	B-Chemical
aminotransferase	aminotransferase	O
and/or	and/or	O
alanine	alanine	B-Chemical
aminotransferase	aminotransferase	O
>	>	O
3	3	O
times	times	O
the	the	O
upper	upper	O
limit	limit	O
of	of	O
normal	normal	O
was	was	O
<	<	O
0.3	0.3	O
%	%	O
.	.	O

An	an	O
increase	increase	O
of	of	O
creatine	creatine	B-Chemical
phosphokinase	phosphokinase	O
to	to	O
>	>	O
5	5	O
times	times	O
the	the	O
upper	upper	O
limit	limit	O
of	of	O
normal	normal	O
occurred	occurred	O
in	in	O
0.24	0.24	O
%	%	O
of	of	O
patients	patients	O
,	,	O
and	and	O
no	no	O
cases	cases	O
of	of	O
drug-induced	drug-induced	O
myopathy	myopathy	B-Disease
were	were	O
observed	observed	O
.	.	O

Niacin	niacin	O
extended-release/lovastatin	extended-release/lovastatin	O
1,000/40	1,000/40	O
mg	mg	O
,	,	O
dosed	dosed	O
as	as	O
initial	initial	O
therapy	therapy	O
,	,	O
was	was	O
associated	associated	O
with	with	O
good	good	O
compliance	compliance	O
and	and	O
safety	safety	O
and	and	O
had	had	O
very	very	O
low	low	O
incidences	incidences	O
of	of	O
increased	increased	O
liver	liver	O
and	and	O
muscle	muscle	O
enzymes	enzymes	O
.	.	O

Protective	protective	O
effect	effect	O
of	of	O
Terminalia	terminalia	O
chebula	chebula	O
against	against	O
experimental	experimental	O
myocardial	myocardial	B-Disease
injury	injury	I-Disease
induced	induced	O
by	by	O
isoproterenol	isoproterenol	B-Chemical
.	.	O

Cardioprotective	cardioprotective	O
effect	effect	O
of	of	O
ethanolic	ethanolic	O
extract	extract	O
of	of	O
Terminalia	terminalia	O
chebula	chebula	O
fruits	fruits	O
(	(	O
500	500	O
mg/kg	mg/kg	O
body	body	O
wt	wt	O
)	)	O
was	was	O
examined	examined	O
in	in	O
isoproterenol	isoproterenol	B-Chemical
(	(	O
200	200	O
mg/kg	mg/kg	O
body	body	O
wt	wt	O
)	)	O
induced	induced	O
myocardial	myocardial	B-Disease
damage	damage	I-Disease
in	in	O
rats	rats	O
.	.	O

In	in	O
isoproterenol	isoproterenol	B-Chemical
administered	administered	O
rats	rats	O
,	,	O
the	the	O
level	level	O
of	of	O
lipid	lipid	B-Chemical
peroxides	peroxides	I-Chemical
increased	increased	O
significantly	significantly	O
in	in	O
the	the	O
serum	serum	O
and	and	O
heart	heart	O
.	.	O

A	a	O
significant	significant	O
decrease	decrease	O
was	was	O
observed	observed	O
in	in	O
the	the	O
activity	activity	O
of	of	O
the	the	O
myocardial	myocardial	O
marker	marker	O
enzymes	enzymes	O
with	with	O
a	a	O
concomitant	concomitant	O
increase	increase	O
in	in	O
their	their	O
activity	activity	O
in	in	O
serum	serum	O
.	.	O

Histopathological	histopathological	O
examination	examination	O
was	was	O
carried	carried	O
out	out	O
to	to	O
confirm	confirm	O
the	the	O
myocardial	myocardial	O
necrosis	necrosis	B-Disease
.	.	O

T.	t.	O
chebula	chebula	O
extract	extract	O
pretreatment	pretreatment	O
was	was	O
found	found	O
to	to	O
ameliorate	ameliorate	O
the	the	O
effect	effect	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
on	on	O
lipid	lipid	O
peroxide	peroxide	O
formation	formation	O
and	and	O
retained	retained	O
the	the	O
activities	activities	O
of	of	O
the	the	O
diagnostic	diagnostic	O
marker	marker	O
enzymes	enzymes	O
.	.	O

A	a	O
case	case	O
of	of	O
postoperative	postoperative	O
anxiety	anxiety	B-Disease
due	due	O
to	to	O
low	low	O
dose	dose	O
droperidol	droperidol	O
used	used	O
with	with	O
patient-controlled	patient-controlled	O
analgesia	analgesia	O
.	.	O

A	a	O
multiparous	multiparous	O
woman	woman	O
in	in	O
good	good	O
psychological	psychological	O
health	health	O
underwent	underwent	O
urgent	urgent	O
caesarean	caesarean	O
section	section	O
in	in	O
labour	labour	O
.	.	O

Postoperatively	postoperatively	O
,	,	O
she	she	O
was	was	O
given	given	O
a	a	O
patient-controlled	patient-controlled	O
analgesia	analgesia	O
device	device	O
delivering	delivering	O
boluses	boluses	O
of	of	O
diamorphine	diamorphine	O
0.5	0.5	O
mg	mg	O
and	and	O
droperidol	droperidol	O
0.025	0.025	O
mg	mg	O
.	.	O

Whilst	whilst	O
using	using	O
the	the	O
device	device	O
she	she	O
gradually	gradually	O
became	became	O
anxious	anxious	O
,	,	O
the	the	O
feeling	feeling	O
worsening	worsening	O
after	after	O
each	each	O
bolus	bolus	O
.	.	O

The	the	O
diagnosis	diagnosis	O
of	of	O
droperidol-induced	droperidol-induced	O
psychological	psychological	O
disturbance	disturbance	O
was	was	O
not	not	O
made	made	O
straight	straight	O
away	away	O
although	although	O
on	on	O
subsequent	subsequent	O
close	close	O
questioning	questioning	O
the	the	O
patient	patient	O
gave	gave	O
a	a	O
very	very	O
clear	clear	O
history	history	O
.	.	O

After	after	O
she	she	O
had	had	O
received	received	O
a	a	O
total	total	O
of	of	O
only	only	O
0.9	0.9	O
mg	mg	O
droperidol	droperidol	O
,	,	O
a	a	O
syringe	syringe	O
containing	containing	O
diamorphine	diamorphine	O
only	only	O
was	was	O
substituted	substituted	O
and	and	O
her	her	O
unease	unease	O
resolved	resolved	O
completely	completely	O
.	.	O

We	we	O
feel	feel	O
that	that	O
,	,	O
although	although	O
the	the	O
dramatic	dramatic	O
extrapyramidal	extrapyramidal	O
side	side	O
effects	effects	O
of	of	O
dopaminergic	dopaminergic	O
antiemetics	antiemetics	O
are	are	O
well	well	O
known	known	O
,	,	O
more	more	O
subtle	subtle	O
manifestations	manifestations	O
may	may	O
easily	easily	O
be	be	O
overlooked	overlooked	O
.	.	O

Accurate	accurate	O
patient	patient	O
history	history	O
contributes	contributes	O
to	to	O
differentiating	differentiating	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
:	:	O
a	a	O
case	case	O
study	study	O
.	.	O

This	this	O
case	case	O
study	study	O
highlights	highlights	O
the	the	O
important	important	O
contribution	contribution	O
of	of	O
nursing	nursing	O
in	in	O
obtaining	obtaining	O
an	an	O
accurate	accurate	O
health	health	O
history	history	O
.	.	O

The	the	O
case	case	O
discussed	discussed	O
herein	herein	O
initially	initially	O
appeared	appeared	O
to	to	O
be	be	O
neurogenic	neurogenic	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
(	(	O
DI	di	O
)	)	O
secondary	secondary	O
to	to	O
a	a	O
traumatic	traumatic	O
brain	brain	O
injury	injury	O
.	.	O

The	the	O
nursing	nursing	O
staff	staff	O
,	,	O
by	by	O
reviewing	reviewing	O
the	the	O
patient	patient	O
's	's	O
health	health	O
history	history	O
with	with	O
his	his	O
family	family	O
,	,	O
discovered	discovered	O
a	a	O
history	history	O
of	of	O
polydipsia	polydipsia	B-Disease
and	and	O
long-standing	long-standing	O
lithium	lithium	B-Chemical
use	use	O
.	.	O

Lithium	lithium	B-Chemical
is	is	O
implicated	implicated	O
in	in	O
drug-induced	drug-induced	O
nephrogenic	nephrogenic	O
DI	di	O
,	,	O
and	and	O
because	because	O
the	the	O
patient	patient	O
had	had	O
not	not	O
received	received	O
lithium	lithium	B-Chemical
since	since	O
being	being	O
admitted	admitted	O
to	to	O
the	the	O
hospital	hospital	O
,	,	O
his	his	O
treatment	treatment	O
changed	changed	O
to	to	O
focus	focus	O
on	on	O
nephrogenic	nephrogenic	O
DI	di	O
.	.	O

By	by	O
combining	combining	O
information	information	O
from	from	O
the	the	O
patient	patient	O
history	history	O
,	,	O
the	the	O
physical	physical	O
examination	examination	O
,	,	O
and	and	O
radiologic	radiologic	O
and	and	O
laboratory	laboratory	O
studies	studies	O
,	,	O
the	the	O
critical	critical	O
care	care	O
team	team	O
demonstrated	demonstrated	O
that	that	O
the	the	O
patient	patient	O
had	had	O
been	been	O
self-treating	self-treating	O
his	his	O
lithium-induced	lithium-induced	O
nephrogenic	nephrogenic	O
DI	di	O
and	and	O
developed	developed	O
neurogenic	neurogenic	O
DI	di	O
secondary	secondary	O
to	to	O
brain	brain	O
trauma	trauma	O
.	.	O

Thus	thus	O
successful	successful	O
treatment	treatment	O
required	required	O
that	that	O
nephrogenic	nephrogenic	O
and	and	O
neurogenic	neurogenic	O
DI	di	O
be	be	O
treated	treated	O
concomitantly	concomitantly	O
.	.	O

Factors	factors	O
contributing	contributing	O
to	to	O
ribavirin-induced	ribavirin-induced	O
anemia	anemia	B-Disease
.	.	O

BACKGROUND	background	O
AND	and	O
AIM	aim	O
:	:	O
Interferon	interferon	O
and	and	O
ribavirin	ribavirin	B-Chemical
combination	combination	O
therapy	therapy	O
for	for	O
chronic	chronic	B-Disease
hepatitis	hepatitis	B-Disease
C	c	I-Disease
produces	produces	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
.	.	O

This	this	O
study	study	O
was	was	O
conducted	conducted	O
to	to	O
identify	identify	O
the	the	O
factors	factors	O
contributing	contributing	O
to	to	O
ribavirin-induced	ribavirin-induced	O
anemia	anemia	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Eighty-eight	eighty-eight	O
patients	patients	O
with	with	O
chronic	chronic	B-Disease
hepatitis	hepatitis	B-Disease
C	c	I-Disease
who	who	O
received	received	O
interferon-alpha-2b	interferon-alpha-2b	O
at	at	O
a	a	O
dose	dose	O
of	of	O
6	6	O
MU	mu	O
administered	administered	O
intramuscularly	intramuscularly	O
for	for	O
24	24	O
weeks	weeks	O
in	in	O
combination	combination	O
with	with	O
ribavirin	ribavirin	B-Chemical
administered	administered	O
orally	orally	O
at	at	O
a	a	O
dose	dose	O
of	of	O
600	600	O
mg	mg	O
or	or	O
800	800	O
mg	mg	O
participated	participated	O
in	in	O
the	the	O
study	study	O
.	.	O

A	a	O
hemoglobin	hemoglobin	O
concentration	concentration	O
of	of	O
<	<	O
10	10	O
g/dL	g/dl	O
was	was	O
defined	defined	O
as	as	O
ribavirin-induced	ribavirin-induced	O
anemia	anemia	B-Disease
.	.	O

RESULTS	results	O
:	:	O
Ribavirin-induced	ribavirin-induced	O
anemia	anemia	B-Disease
occurred	occurred	O
in	in	O
18	18	O
(	(	O
20.5	20.5	O
%	%	O
)	)	O
patients	patients	O
during	during	O
treatment	treatment	O
.	.	O

A	a	O
2	2	O
g/dL	g/dl	O
decrease	decrease	O
in	in	O
hemoglobin	hemoglobin	O
concentrations	concentrations	O
in	in	O
patients	patients	O
with	with	O
anemia	anemia	B-Disease
was	was	O
observed	observed	O
at	at	O
week	week	O
2	2	O
after	after	O
the	the	O
start	start	O
of	of	O
treatment	treatment	O
.	.	O

The	the	O
hemoglobin	hemoglobin	O
concentration	concentration	O
in	in	O
patients	patients	O
with	with	O
>	>	O
or	or	O
=	=	O
2	2	O
g/dL	g/dl	O
decrease	decrease	O
at	at	O
week	week	O
2	2	O
was	was	O
observed	observed	O
to	to	O
be	be	O
significantly	significantly	O
lower	lower	O
even	even	O
after	after	O
week	week	O
2	2	O
than	than	O
in	in	O
patients	patients	O
with	with	O
<	<	O
2	2	O
g/dL	g/dl	O
decrease	decrease	O
(	(	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

A	a	O
significant	significant	O
relationship	relationship	O
was	was	O
observed	observed	O
between	between	O
the	the	O
rate	rate	O
of	of	O
reduction	reduction	O
of	of	O
hemoglobin	hemoglobin	O
concentrations	concentrations	O
at	at	O
week	week	O
2	2	O
and	and	O
the	the	O
severity	severity	O
of	of	O
anemia	anemia	B-Disease
(	(	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

Such	such	O
factors	factors	O
as	as	O
sex	sex	O
(	(	O
female	female	O
)	)	O
,	,	O
age	age	O
(	(	O
>	>	O
or	or	O
=	=	O
60	60	O
years	years	O
old	old	O
)	)	O
,	,	O
and	and	O
the	the	O
ribavirin	ribavirin	B-Chemical
dose	dose	O
by	by	O
body	body	B-Disease
weight	weight	I-Disease
(	(	O
12	12	O
mg/kg	mg/kg	O
or	or	O
more	more	O
)	)	O
were	were	O
significant	significant	O
by	by	O
univariate	univariate	O
analysis	analysis	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Careful	careful	O
administration	administration	O
is	is	O
necessary	necessary	O
in	in	O
patients	patients	O
>	>	O
or	or	O
=	=	O
60	60	O
years	years	O
old	old	O
,	,	O
in	in	O
female	female	O
patients	patients	O
,	,	O
and	and	O
in	in	O
patients	patients	O
receiving	receiving	O
a	a	O
ribavirin	ribavirin	B-Chemical
dose	dose	O
of	of	O
12	12	O
mg/kg	mg/kg	O
or	or	O
more	more	O
.	.	O

Patients	patients	O
who	who	O
experience	experience	O
a	a	O
fall	fall	O
in	in	O
hemoglobin	hemoglobin	O
concentrations	concentrations	O
of	of	O
2	2	O
g/dL	g/dl	O
or	or	O
more	more	O
at	at	O
week	week	O
2	2	O
after	after	O
the	the	O
start	start	O
of	of	O
treatment	treatment	O
should	should	O
be	be	O
monitored	monitored	O
with	with	O
particular	particular	O
care	care	O
.	.	O

Zidovudine-induced	zidovudine-induced	O
hepatitis	hepatitis	B-Disease
.	.	O

A	a	O
case	case	O
of	of	O
acute	acute	O
hepatitis	hepatitis	B-Disease
induced	induced	O
by	by	O
zidovudine	zidovudine	B-Chemical
in	in	O
a	a	O
38-year-old	38-year-old	O
patient	patient	O
with	with	O
AIDS	aids	B-Disease
is	is	O
presented	presented	O
.	.	O

The	the	O
mechanism	mechanism	O
whereby	whereby	O
the	the	O
hepatitis	hepatitis	B-Disease
was	was	O
induced	induced	O
is	is	O
not	not	O
known	known	O
.	.	O

However	however	O
,	,	O
the	the	O
patient	patient	O
tolerated	tolerated	O
well	well	O
an	an	O
alternative	alternative	O
reverse	reverse	O
transcriptase	transcriptase	O
inhibitor	inhibitor	O
,	,	O
2'3	2'3	O
'	'	O
dideoxyinosine	dideoxyinosine	O
.	.	O

Physicians	physicians	O
caring	caring	O
for	for	O
patients	patients	O
with	with	O
AIDS	aids	B-Disease
should	should	O
be	be	O
aware	aware	O
of	of	O
this	this	O
hitherto	hitherto	O
rarely	rarely	O
reported	reported	O
complication	complication	O
.	.	O

Oxidative	oxidative	O
damage	damage	O
precedes	precedes	O
nitrative	nitrative	O
damage	damage	O
in	in	O
adriamycin-induced	adriamycin-induced	O
cardiac	cardiac	O
mitochondrial	mitochondrial	O
injury	injury	O
.	.	O

The	the	O
purpose	purpose	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
determine	determine	O
if	if	O
elevated	elevated	O
reactive	reactive	O
oxygen	oxygen	B-Chemical
(ROS)/nitrogen	(ros)/nitrogen	O
species	species	O
(	(	O
RNS	rns	O
)	)	O
reported	reported	O
to	to	O
be	be	O
present	present	O
in	in	O
adriamycin	adriamycin	B-Chemical
(ADR)-induced	(adr)-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
actually	actually	O
resulted	resulted	O
in	in	O
cardiomyocyte	cardiomyocyte	O
oxidative/nitrative	oxidative/nitrative	O
damage	damage	O
,	,	O
and	and	O
to	to	O
quantitatively	quantitatively	O
determine	determine	O
the	the	O
time	time	O
course	course	O
and	and	O
subcellular	subcellular	O
localization	localization	O
of	of	O
these	these	O
postulated	postulated	O
damage	damage	O
products	products	O
using	using	O
an	an	O
in	in	O
vivo	vivo	O
approach	approach	O
.	.	O

B6C3	b6c3	O
mice	mice	O
were	were	O
treated	treated	O
with	with	O
a	a	O
single	single	O
dose	dose	O
of	of	O
20	20	O
mg/kg	mg/kg	O
ADR	adr	B-Chemical
.	.	O

Ultrastructural	ultrastructural	O
damage	damage	O
and	and	O
levels	levels	O
of	of	O
4-hydroxy-2-nonenal	4-hydroxy-2-nonenal	O
(4HNE)-protein	(4hne)-protein	O
adducts	adducts	O
and	and	O
3-nitrotyrosine	3-nitrotyrosine	O
(	(	O
3NT	3nt	O
)	)	O
were	were	O
analyzed	analyzed	O
.	.	O

Quantitative	quantitative	O
ultrastructural	ultrastructural	O
damage	damage	O
using	using	O
computerized	computerized	O
image	image	O
techniques	techniques	O
showed	showed	O
cardiomyocyte	cardiomyocyte	O
injury	injury	O
as	as	O
early	early	O
as	as	O
3	3	O
hours	hours	O
,	,	O
with	with	O
mitochondria	mitochondria	O
being	being	O
the	the	O
most	most	O
extensively	extensively	O
and	and	O
progressively	progressively	O
injured	injured	O
subcellular	subcellular	O
organelle	organelle	O
.	.	O

Analysis	analysis	O
of	of	O
4HNE	4hne	O
protein	protein	O
adducts	adducts	O
by	by	O
immunogold	immunogold	O
electron	electron	O
microscopy	microscopy	O
showed	showed	O
appearance	appearance	O
of	of	O
4HNE	4hne	O
protein	protein	O
adducts	adducts	O
in	in	O
mitochondria	mitochondria	O
as	as	O
early	early	O
as	as	O
3	3	O
hours	hours	O
,	,	O
with	with	O
a	a	O
peak	peak	O
at	at	O
6	6	O
hours	hours	O
and	and	O
subsequent	subsequent	O
decline	decline	O
at	at	O
24	24	O
hours	hours	O
.	.	O

3NT	3nt	O
levels	levels	O
were	were	O
significantly	significantly	O
increased	increased	O
in	in	O
all	all	O
subcellular	subcellular	O
compartments	compartments	O
at	at	O
6	6	O
hours	hours	O
and	and	O
subsequently	subsequently	O
declined	declined	O
at	at	O
24	24	O
hours	hours	O
.	.	O

Our	our	O
data	data	O
showed	showed	O
ADR	adr	B-Chemical
induced	induced	O
4HNE-protein	4hne-protein	O
adducts	adducts	O
in	in	O
mitochondria	mitochondria	O
at	at	O
the	the	O
same	same	O
time	time	O
point	point	O
as	as	O
when	when	O
mitochondrial	mitochondrial	O
injury	injury	O
initially	initially	O
appeared	appeared	O
.	.	O

These	these	O
results	results	O
document	document	O
for	for	O
the	the	O
first	first	O
time	time	O
in	in	O
vivo	vivo	O
that	that	O
mitochondrial	mitochondrial	O
oxidative	oxidative	O
damage	damage	O
precedes	precedes	O
nitrative	nitrative	O
damage	damage	O
.	.	O

The	the	O
progressive	progressive	O
nature	nature	O
of	of	O
mitochondrial	mitochondrial	O
injury	injury	O
suggests	suggests	O
that	that	O
mitochondria	mitochondria	O
,	,	O
not	not	O
other	other	O
subcellular	subcellular	O
organelles	organelles	O
,	,	O
are	are	O
the	the	O
major	major	O
site	site	O
of	of	O
intracellular	intracellular	O
injury	injury	O
.	.	O

Sotalol-induced	sotalol-induced	O
coronary	coronary	B-Disease
spasm	spasm	B-Disease
in	in	O
a	a	O
patient	patient	O
with	with	O
dilated	dilated	B-Disease
cardiomyopathy	cardiomyopathy	B-Disease
associated	associated	O
with	with	O
sustained	sustained	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
.	.	O

A	a	O
54-year-old	54-year-old	O
man	man	O
with	with	O
severe	severe	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
due	due	O
to	to	O
dilated	dilated	B-Disease
cardiomyopathy	cardiomyopathy	B-Disease
was	was	O
referred	referred	O
to	to	O
our	our	O
hospital	hospital	O
for	for	O
symptomatic	symptomatic	O
incessant	incessant	O
sustained	sustained	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
(	(	O
VT	vt	O
)	)	O
.	.	O

After	after	O
the	the	O
administration	administration	O
of	of	O
nifekalant	nifekalant	O
hydrochloride	hydrochloride	O
,	,	O
sustained	sustained	O
VT	vt	O
was	was	O
terminated	terminated	O
.	.	O

An	an	O
alternate	alternate	O
class	class	O
III	iii	O
agent	agent	O
,	,	O
sotalol	sotalol	O
,	,	O
was	was	O
also	also	O
effective	effective	O
for	for	O
the	the	O
prevention	prevention	O
of	of	O
VT	vt	O
.	.	O

However	however	O
,	,	O
one	one	O
month	month	O
after	after	O
switching	switching	O
over	over	O
nifekalant	nifekalant	O
to	to	O
sotalol	sotalol	O
,	,	O
a	a	O
short	short	O
duration	duration	O
of	of	O
ST	st	O
elevation	elevation	O
was	was	O
documented	documented	O
in	in	O
ECG	ecg	O
monitoring	monitoring	O
at	at	O
almost	almost	O
the	the	O
same	same	O
time	time	O
for	for	O
three	three	O
consecutive	consecutive	O
days	days	O
.	.	O

ST	st	O
elevation	elevation	O
with	with	O
chest	chest	O
discomfort	discomfort	O
disappeared	disappeared	O
since	since	O
he	he	O
began	began	O
taking	taking	O
long-acting	long-acting	O
diltiazem	diltiazem	B-Chemical
.	.	O

Coronary	coronary	B-Disease
vasospasm	vasospasm	B-Disease
may	may	O
be	be	O
induced	induced	O
by	by	O
the	the	O
non-selective	non-selective	O
beta-blocking	beta-blocking	O
properties	properties	O
of	of	O
sotalol	sotalol	O
.	.	O

Effects	effects	O
of	of	O
the	the	O
antidepressant	antidepressant	B-Chemical
trazodone	trazodone	O
,	,	O
a	a	O
5-HT	5-ht	B-Chemical
2A/2C	2a/2c	O
receptor	receptor	O
antagonist	antagonist	O
,	,	O
on	on	O
dopamine-dependent	dopamine-dependent	O
behaviors	behaviors	O
in	in	O
rats	rats	O
.	.	O

RATIONALE	rationale	O
:	:	O
5-Hydroxytryptamine	5-hydroxytryptamine	B-Chemical
,	,	O
via	via	O
stimulation	stimulation	O
of	of	O
5-HT	5-ht	B-Chemical
2C	2c	O
receptors	receptors	O
,	,	O
exerts	exerts	O
a	a	O
tonic	tonic	O
inhibitory	inhibitory	O
influence	influence	O
on	on	O
dopaminergic	dopaminergic	O
neurotransmission	neurotransmission	O
,	,	O
whereas	whereas	O
activation	activation	O
of	of	O
5-HT	5-ht	B-Chemical
2A	2a	O
receptors	receptors	O
enhances	enhances	O
stimulated	stimulated	O
DAergic	daergic	O
neurotransmission	neurotransmission	O
.	.	O

The	the	O
antidepressant	antidepressant	B-Chemical
trazodone	trazodone	O
is	is	O
a	a	O
5-HT	5-ht	B-Chemical
2A/2C	2a/2c	O
receptor	receptor	O
antagonist	antagonist	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
To	to	O
evaluate	evaluate	O
the	the	O
effect	effect	O
of	of	O
trazodone	trazodone	O
treatment	treatment	O
on	on	O
behaviors	behaviors	O
dependent	dependent	O
on	on	O
the	the	O
functional	functional	O
status	status	O
of	of	O
the	the	O
nigrostriatal	nigrostriatal	O
DAergic	daergic	O
system	system	O
.	.	O

METHODS	methods	O
:	:	O
The	the	O
effect	effect	O
of	of	O
pretreatment	pretreatment	O
with	with	O
trazodone	trazodone	O
on	on	O
dexamphetamine-	dexamphetamine-	O
and	and	O
apomorphine-induced	apomorphine-induced	O
oral	oral	O
stereotypies	stereotypies	O
,	,	O
on	on	O
catalepsy	catalepsy	B-Disease
induced	induced	O
by	by	O
haloperidol	haloperidol	B-Chemical
and	and	O
apomorphine	apomorphine	B-Chemical
(	(	O
0.05	0.05	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
,	,	O
on	on	O
ergometrine-induced	ergometrine-induced	O
wet	wet	O
dog	dog	O
shake	shake	O
(	(	O
WDS	wds	O
)	)	O
behavior	behavior	O
and	and	O
fluoxetine-induced	fluoxetine-induced	O
penile	penile	O
erections	erections	O
was	was	O
studied	studied	O
in	in	O
rats	rats	O
.	.	O

We	we	O
also	also	O
investigated	investigated	O
whether	whether	O
trazodone	trazodone	O
induces	induces	O
catalepsy	catalepsy	B-Disease
in	in	O
rats	rats	O
.	.	O

RESULTS	results	O
:	:	O
Trazodone	trazodone	O
at	at	O
2.5	2.5	O
-	-	O
20	20	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
did	did	O
not	not	O
induce	induce	O
catalepsy	catalepsy	B-Disease
,	,	O
and	and	O
did	did	O
not	not	O
antagonize	antagonize	O
apomorphine	apomorphine	B-Chemical
(	(	O
1.5	1.5	O
and	and	O
3	3	O
mg/kg	mg/kg	O
)	)	O
stereotypy	stereotypy	O
and	and	O
apomorphine	apomorphine	B-Chemical
(	(	O
0.05	0.05	O
mg/kg)-induced	mg/kg)-induced	O
catalepsy	catalepsy	B-Disease
.	.	O

However	however	O
,	,	O
pretreatment	pretreatment	O
with	with	O
5	5	O
,	,	O
10	10	O
and	and	O
20	20	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O

trazodone	trazodone	O
enhanced	enhanced	O
dexamphetamine	dexamphetamine	O
stereotypy	stereotypy	O
,	,	O
and	and	O
antagonized	antagonized	O
haloperidol	haloperidol	B-Chemical
catalepsy	catalepsy	B-Disease
,	,	O
ergometrine-induced	ergometrine-induced	O
WDS	wds	O
behavior	behavior	O
and	and	O
fluoxetine-induced	fluoxetine-induced	O
penile	penile	O
erections	erections	O
.	.	O

Trazodone	trazodone	O
at	at	O
30	30	O
,	,	O
40	40	O
and	and	O
50	50	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
induced	induced	O
catalepsy	catalepsy	B-Disease
and	and	O
antagonized	antagonized	O
apomorphine	apomorphine	B-Chemical
and	and	O
dexamphetamine	dexamphetamine	O
stereotypies	stereotypies	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Our	our	O
results	results	O
indicate	indicate	O
that	that	O
trazodone	trazodone	O
at	at	O
2.5	2.5	O
-	-	O
20	20	O
mg/kg	mg/kg	O
does	does	O
not	not	O
block	block	O
pre-	pre-	O
and	and	O
postsynaptic	postsynaptic	O
striatal	striatal	O
D2	d2	O
DA	da	B-Chemical
receptors	receptors	O
,	,	O
while	while	O
at	at	O
30	30	O
,	,	O
40	40	O
and	and	O
50	50	O
mg/kg	mg/kg	O
it	it	O
blocks	blocks	O
postsynaptic	postsynaptic	O
striatal	striatal	O
D2	d2	O
DA	da	B-Chemical
receptors	receptors	O
.	.	O

Furthermore	furthermore	O
,	,	O
at	at	O
5	5	O
,	,	O
10	10	O
and	and	O
20	20	O
mg/kg	mg/kg	O
,	,	O
trazodone	trazodone	O
blocks	blocks	O
5-HT	5-ht	B-Chemical
2A	2a	O
and	and	O
5-HT	5-ht	B-Chemical
2C	2c	O
receptors	receptors	O
.	.	O

We	we	O
suggest	suggest	O
that	that	O
trazodone	trazodone	O
(	(	O
5	5	O
,	,	O
10	10	O
and	and	O
20	20	O
mg/kg	mg/kg	O
)	)	O
,	,	O
by	by	O
blocking	blocking	O
the	the	O
5-HT	5-ht	B-Chemical
2C	2c	O
receptors	receptors	O
,	,	O
releases	releases	O
the	the	O
nigrostriatal	nigrostriatal	O
DAergic	daergic	O
neurons	neurons	O
from	from	O
tonic	tonic	O
inhibition	inhibition	O
caused	caused	O
by	by	O
5-HT	5-ht	B-Chemical
,	,	O
and	and	O
thereby	thereby	O
potentiates	potentiates	O
dexamphetamine	dexamphetamine	O
stereotypy	stereotypy	O
and	and	O
antagonizes	antagonizes	O
haloperidol	haloperidol	B-Chemical
catalepsy	catalepsy	B-Disease
.	.	O

Swallowing	swallowing	O
abnormalities	abnormalities	O
and	and	O
dyskinesia	dyskinesia	B-Disease
in	in	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

Gastrointestinal	gastrointestinal	O
abnormalities	abnormalities	O
in	in	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
(	(	O
PD	pd	B-Disease
)	)	O
have	have	O
been	been	O
known	known	O
for	for	O
almost	almost	O
two	two	O
centuries	centuries	O
,	,	O
but	but	O
many	many	O
aspects	aspects	O
concerning	concerning	O
their	their	O
pathophysiology	pathophysiology	O
have	have	O
not	not	O
been	been	O
completely	completely	O
clarified	clarified	O
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
characterize	characterize	O
the	the	O
oropharyngeal	oropharyngeal	O
dynamics	dynamics	O
in	in	O
PD	pd	B-Disease
patients	patients	O
with	with	O
and	and	O
without	without	O
levodopa-induced	levodopa-induced	O
dyskinesia	dyskinesia	B-Disease
.	.	O

Fifteen	fifteen	O
dyskinetic	dyskinetic	O
,	,	O
12	12	O
nondyskinetic	nondyskinetic	O
patients	patients	O
,	,	O
and	and	O
a	a	O
control	control	O
group	group	O
were	were	O
included	included	O
.	.	O

Patients	patients	O
were	were	O
asked	asked	O
about	about	O
dysphagia	dysphagia	O
and	and	O
evaluated	evaluated	O
with	with	O
the	the	O
Unified	unified	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
Disease	disease	I-Disease
Rating	rating	O
Scale	scale	O
Parts	parts	O
II	ii	O
and	and	O
III	iii	O
and	and	O
the	the	O
Hoehn	hoehn	O
and	and	O
Yahr	yahr	O
scale	scale	O
.	.	O

Deglutition	deglutition	O
was	was	O
assessed	assessed	O
using	using	O
modified	modified	O
barium	barium	O
swallow	swallow	O
with	with	O
videofluoroscopy	videofluoroscopy	O
.	.	O

Nondyskinetic	nondyskinetic	O
patients	patients	O
,	,	O
but	but	O
not	not	O
the	the	O
dyskinetic	dyskinetic	O
ones	ones	O
,	,	O
showed	showed	O
less	less	O
oropharyngeal	oropharyngeal	O
swallowing	swallowing	O
efficiency	efficiency	O
(	(	O
OPSE	opse	O
)	)	O
for	for	O
liquid	liquid	O
food	food	O
than	than	O
controls	controls	O
(	(	O
Dunnett	dunnett	O
,	,	O
P	p	O
=	=	O
0.02	0.02	O
)	)	O
.	.	O

Dyskinetic	dyskinetic	O
patients	patients	O
tended	tended	O
to	to	O
have	have	O
a	a	O
greater	greater	O
OPSE	opse	O
than	than	O
nondyskinetic	nondyskinetic	O
(	(	O
Dunnett	dunnett	O
,	,	O
P	p	O
=	=	O
0.06	0.06	O
)	)	O
.	.	O

Patients	patients	O
who	who	O
were	were	O
using	using	O
a	a	O
higher	higher	O
dose	dose	O
of	of	O
levodopa	levodopa	B-Chemical
had	had	O
a	a	O
greater	greater	O
OPSE	opse	O
and	and	O
a	a	O
trend	trend	O
toward	toward	O
a	a	O
smaller	smaller	O
oral	oral	O
transit	transit	O
time	time	O
(	(	O
Pearson	pearson	O
's	's	O
correlation	correlation	O
,	,	O
P	p	O
=	=	O
0.01	0.01	O
and	and	O
0.08	0.08	O
,	,	O
respectively	respectively	O
)	)	O
.	.	O

Neither	neither	O
the	the	O
report	report	O
of	of	O
dysphagia	dysphagia	O
nor	nor	O
any	any	O
of	of	O
the	the	O
PD	pd	B-Disease
severity	severity	O
parameters	parameters	O
correlated	correlated	O
to	to	O
the	the	O
videofluoroscopic	videofluoroscopic	O
variables	variables	O
.	.	O

In	in	O
the	the	O
current	current	O
study	study	O
,	,	O
dyskinetic	dyskinetic	O
patients	patients	O
performed	performed	O
better	better	O
in	in	O
swallowing	swallowing	O
function	function	O
,	,	O
which	which	O
could	could	O
be	be	O
explained	explained	O
on	on	O
the	the	O
basis	basis	O
of	of	O
a	a	O
greater	greater	O
levodopa	levodopa	B-Chemical
dose	dose	O
.	.	O

Our	our	O
results	results	O
suggest	suggest	O
a	a	O
role	role	O
for	for	O
levodopa	levodopa	B-Chemical
in	in	O
the	the	O
oral	oral	O
phase	phase	O
of	of	O
deglutition	deglutition	O
and	and	O
confirm	confirm	O
that	that	O
dysphagia	dysphagia	O
is	is	O
not	not	O
a	a	O
good	good	O
predictor	predictor	O
of	of	O
deglutition	deglutition	O
alterations	alterations	O
in	in	O
PD	pd	B-Disease
.	.	O

Inhibition	inhibition	O
of	of	O
nuclear	nuclear	O
factor-kappaB	factor-kappab	O
activation	activation	O
attenuates	attenuates	O
tubulointerstitial	tubulointerstitial	O
nephritis	nephritis	O
induced	induced	O
by	by	O
gentamicin	gentamicin	B-Chemical
.	.	O

BACKGROUND	background	O
:	:	O
Animals	animals	O
treated	treated	O
with	with	O
gentamicin	gentamicin	B-Chemical
can	can	O
show	show	O
residual	residual	O
areas	areas	O
of	of	O
interstitial	interstitial	O
fibrosis	fibrosis	B-Disease
in	in	O
the	the	O
renal	renal	O
cortex	cortex	O
.	.	O

This	this	O
study	study	O
investigated	investigated	O
the	the	O
expression	expression	O
of	of	O
nuclear	nuclear	O
factor-kappaB	factor-kappab	O
(	(	O
NF-kappaB	nf-kappab	O
)	)	O
,	,	O
mitogen-activated	mitogen-activated	O
protein	protein	O
(	(	O
MAP	map	O
)	)	O
kinases	kinases	O
and	and	O
macrophages	macrophages	O
in	in	O
the	the	O
renal	renal	O
cortex	cortex	O
and	and	O
structural	structural	O
and	and	O
functional	functional	O
renal	renal	O
changes	changes	O
of	of	O
rats	rats	O
treated	treated	O
with	with	O
gentamicin	gentamicin	B-Chemical
or	or	O
gentamicin	gentamicin	B-Chemical
+	+	O
pyrrolidine	pyrrolidine	O
dithiocarbamate	dithiocarbamate	O
(	(	O
PDTC	pdtc	B-Chemical
)	)	O
,	,	O
an	an	O
NF-kappaB	nf-kappab	O
inhibitor	inhibitor	O
.	.	O

METHODS	methods	O
:	:	O
38	38	O
female	female	O
Wistar	wistar	O
rats	rats	O
were	were	O
injected	injected	O
with	with	O
gentamicin	gentamicin	B-Chemical
,	,	O
40	40	O
mg/kg	mg/kg	O
,	,	O
twice	twice	O
a	a	O
day	day	O
for	for	O
9	9	O
days	days	O
,	,	O
38	38	O
with	with	O
gentamicin	gentamicin	B-Chemical
+	+	O
PDTC	pdtc	B-Chemical
,	,	O
and	and	O
28	28	O
with	with	O
0.15	0.15	O
M	m	O
NaCl	nacl	B-Chemical
solution	solution	O
.	.	O

The	the	O
animals	animals	O
were	were	O
killed	killed	O
5	5	O
and	and	O
30	30	O
days	days	O
after	after	O
these	these	O
injections	injections	O
and	and	O
the	the	O
kidneys	kidneys	O
were	were	O
removed	removed	O
for	for	O
histological	histological	O
and	and	O
immunohistochemical	immunohistochemical	O
studies	studies	O
.	.	O

The	the	O
results	results	O
of	of	O
the	the	O
immunohistochemical	immunohistochemical	O
studies	studies	O
were	were	O
scored	scored	O
according	according	O
to	to	O
the	the	O
extent	extent	O
of	of	O
staining	staining	O
.	.	O

The	the	O
fractional	fractional	O
interstitial	interstitial	O
area	area	O
was	was	O
determined	determined	O
by	by	O
morphometry	morphometry	O
.	.	O

RESULTS	results	O
:	:	O
Gentamicin-treated	gentamicin-treated	O
rats	rats	O
presented	presented	O
a	a	O
transitory	transitory	O
increase	increase	O
in	in	O
plasma	plasma	O
creatinine	creatinine	B-Chemical
levels	levels	O
.	.	O

Increased	increased	O
ED-1	ed-1	O
,	,	O
MAP	map	O
kinases	kinases	O
and	and	O
NF-kappaB	nf-kappab	O
staining	staining	O
were	were	O
also	also	O
observed	observed	O
in	in	O
the	the	O
renal	renal	O
cortex	cortex	O
from	from	O
all	all	O
gentamicin-treated	gentamicin-treated	O
rats	rats	O
compared	compared	O
to	to	O
control	control	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

The	the	O
animals	animals	O
killed	killed	O
on	on	O
day	day	O
30	30	O
also	also	O
presented	presented	O
fibrosis	fibrosis	B-Disease
in	in	O
the	the	O
renal	renal	O
cortex	cortex	O
despite	despite	O
the	the	O
recovery	recovery	O
of	of	O
renal	renal	O
function	function	O
.	.	O

Treatment	treatment	O
with	with	O
PDTC	pdtc	B-Chemical
reduced	reduced	O
the	the	O
functional	functional	O
and	and	O
structural	structural	O
changes	changes	O
induced	induced	O
by	by	O
gentamicin	gentamicin	B-Chemical
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
These	these	O
data	data	O
show	show	O
that	that	O
inhibition	inhibition	O
of	of	O
NF-kappaB	nf-kappab	O
activation	activation	O
attenuates	attenuates	O
tubulointerstitial	tubulointerstitial	O
nephritis	nephritis	O
induced	induced	O
by	by	O
gentamicin	gentamicin	B-Chemical
.	.	O

Glucose	glucose	B-Chemical
metabolism	metabolism	O
in	in	O
patients	patients	O
with	with	O
schizophrenia	schizophrenia	B-Disease
treated	treated	O
with	with	O
atypical	atypical	O
antipsychotic	antipsychotic	B-Chemical
agents	agents	I-Chemical
:	:	O
a	a	O
frequently	frequently	O
sampled	sampled	O
intravenous	intravenous	O
glucose	glucose	B-Chemical
tolerance	tolerance	O
test	test	O
and	and	O
minimal	minimal	O
model	model	O
analysis	analysis	O
.	.	O

BACKGROUND	background	O
:	:	O
While	while	O
the	the	O
incidence	incidence	O
of	of	O
new-onset	new-onset	O
diabetes	diabetes	B-Disease
mellitus	mellitus	I-Disease
may	may	O
be	be	O
increasing	increasing	O
in	in	O
patients	patients	O
with	with	O
schizophrenia	schizophrenia	B-Disease
treated	treated	O
with	with	O
certain	certain	O
atypical	atypical	O
antipsychotic	antipsychotic	B-Chemical
agents	agents	I-Chemical
,	,	O
it	it	O
remains	remains	O
unclear	unclear	O
whether	whether	O
atypical	atypical	O
agents	agents	O
are	are	O
directly	directly	O
affecting	affecting	O
glucose	glucose	B-Chemical
metabolism	metabolism	O
or	or	O
simply	simply	O
increasing	increasing	O
known	known	O
risk	risk	O
factors	factors	O
for	for	O
diabetes	diabetes	B-Disease
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
study	study	O
the	the	O
2	2	O
drugs	drugs	O
most	most	O
clearly	clearly	O
implicated	implicated	O
(	(	O
clozapine	clozapine	B-Chemical
and	and	O
olanzapine	olanzapine	B-Chemical
)	)	O
and	and	O
risperidone	risperidone	B-Chemical
using	using	O
a	a	O
frequently	frequently	O
sampled	sampled	O
intravenous	intravenous	O
glucose	glucose	B-Chemical
tolerance	tolerance	O
test	test	O
.	.	O

DESIGN	design	O
:	:	O
A	a	O
cross-sectional	cross-sectional	O
design	design	O
in	in	O
stable	stable	O
,	,	O
treated	treated	O
patients	patients	O
with	with	O
schizophrenia	schizophrenia	B-Disease
evaluated	evaluated	O
using	using	O
a	a	O
frequently	frequently	O
sampled	sampled	O
intravenous	intravenous	O
glucose	glucose	B-Chemical
tolerance	tolerance	O
test	test	O
and	and	O
the	the	O
Bergman	bergman	O
minimal	minimal	O
model	model	O
analysis	analysis	O
.	.	O

SETTING	setting	O
:	:	O
Subjects	subjects	O
were	were	O
recruited	recruited	O
from	from	O
an	an	O
urban	urban	O
community	community	O
mental	mental	O
health	health	O
clinic	clinic	O
and	and	O
were	were	O
studied	studied	O
at	at	O
a	a	O
general	general	O
clinical	clinical	O
research	research	O
center	center	O
.	.	O

Patients	patients	O
Fifty	fifty	O
subjects	subjects	O
signed	signed	O
informed	informed	O
consent	consent	O
and	and	O
41	41	O
underwent	underwent	O
the	the	O
frequently	frequently	O
sampled	sampled	O
intravenous	intravenous	O
glucose	glucose	B-Chemical
tolerance	tolerance	O
test	test	O
.	.	O

Thirty-six	thirty-six	O
nonobese	nonobese	O
subjects	subjects	O
with	with	O
schizophrenia	schizophrenia	B-Disease
or	or	O
schizoaffective	schizoaffective	B-Disease
disorder	disorder	I-Disease
,	,	O
matched	matched	O
by	by	O
body	body	O
mass	mass	O
index	index	O
and	and	O
treated	treated	O
with	with	O
either	either	O
clozapine	clozapine	B-Chemical
,	,	O
olanzapine	olanzapine	B-Chemical
,	,	O
or	or	O
risperidone	risperidone	B-Chemical
,	,	O
were	were	O
included	included	O
in	in	O
the	the	O
analysis	analysis	O
.	.	O

MAIN	main	O
OUTCOME	outcome	O
MEASURES	measures	O
:	:	O
Fasting	fasting	O
plasma	plasma	O
glucose	glucose	B-Chemical
and	and	O
fasting	fasting	O
serum	serum	O
insulin	insulin	O
levels	levels	O
,	,	O
insulin	insulin	B-Disease
sensitivity	sensitivity	I-Disease
index	index	O
,	,	O
homeostasis	homeostasis	O
model	model	O
assessment	assessment	O
of	of	O
insulin	insulin	B-Disease
resistance	resistance	I-Disease
,	,	O
and	and	O
glucose	glucose	B-Chemical
effectiveness	effectiveness	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
mean	mean	O
+	+	O
/-	/-	O
SD	sd	O
duration	duration	O
of	of	O
treatment	treatment	O
with	with	O
the	the	O
identified	identified	O
atypical	atypical	O
antipsychotic	antipsychotic	O
agent	agent	O
was	was	O
68.3	68.3	O
+	+	O
/-	/-	O
28.9	28.9	O
months	months	O
(	(	O
clozapine	clozapine	B-Chemical
)	)	O
,	,	O
29.5	29.5	O
+	+	O
/-	/-	O
17.5	17.5	O
months	months	O
(	(	O
olanzapine	olanzapine	B-Chemical
)	)	O
,	,	O
and	and	O
40.9	40.9	O
+	+	O
/-	/-	O
33.7	33.7	O
(	(	O
risperidone	risperidone	B-Chemical
)	)	O
.	.	O

Fasting	fasting	O
serum	serum	O
insulin	insulin	O
concentrations	concentrations	O
differed	differed	O
among	among	O
groups	groups	O
(	(	O
F(33	f(33	O
)	)	O
=	=	O
3.35	3.35	O
;	;	O
P	p	O
=	=	O
.047	.047	O
)	)	O
(	(	O
clozapine	clozapine	B-Chemical
>	>	O
olanzapine	olanzapine	B-Chemical
>	>	O
risperidone	risperidone	B-Chemical
)	)	O
with	with	O
significant	significant	O
differences	differences	O
between	between	O
clozapine	clozapine	B-Chemical
and	and	O
risperidone	risperidone	B-Chemical
(	(	O
t(33	t(33	O
)	)	O
=	=	O
2.32	2.32	O
;	;	O
P	p	O
=	=	O
.03	.03	O
)	)	O
and	and	O
olanzapine	olanzapine	B-Chemical
and	and	O
risperidone	risperidone	B-Chemical
(	(	O
t(33	t(33	O
)	)	O
=	=	O
2.15	2.15	O
;	;	O
P	p	O
=	=	O
.04	.04	O
)	)	O
.	.	O

There	there	O
was	was	O
a	a	O
significant	significant	O
difference	difference	O
in	in	O
insulin	insulin	B-Disease
sensitivity	sensitivity	I-Disease
index	index	O
among	among	O
groups	groups	O
(	(	O
F(33	f(33	O
)	)	O
=	=	O
10.66	10.66	O
;	;	O
P<.001	p<.001	O
)	)	O
(	(	O
clozapine	clozapine	B-Chemical
<	<	O
olanzapine	olanzapine	B-Chemical
<	<	O
risperidone	risperidone	B-Chemical
)	)	O
,	,	O
with	with	O
subjects	subjects	O
who	who	O
received	received	O
clozapine	clozapine	B-Chemical
and	and	O
olanzapine	olanzapine	B-Chemical
exhibiting	exhibiting	O
significant	significant	O
insulin	insulin	B-Disease
resistance	resistance	I-Disease
compared	compared	O
with	with	O
subjects	subjects	O
who	who	O
were	were	O
treated	treated	O
with	with	O
risperidone	risperidone	B-Chemical
(	(	O
clozapine	clozapine	B-Chemical
vs	vs	O
risperidone	risperidone	B-Chemical
,	,	O
t(33	t(33	O
)	)	O
=	=	O
-4.29	-4.29	O
;	;	O
P<.001	p<.001	O
;	;	O
olanzapine	olanzapine	B-Chemical
vs	vs	O
risperidone	risperidone	B-Chemical
,	,	O
t(33	t(33	O
)	)	O
=	=	O
-3.62	-3.62	O
;	;	O
P	p	O
=	=	O
.001	.001	O
[	[	O
P<.001	p<.001	O
]	]	O
)	)	O
.	.	O

The	the	O
homeostasis	homeostasis	O
model	model	O
assessment	assessment	O
of	of	O
insulin	insulin	B-Disease
resistance	resistance	I-Disease
also	also	O
differed	differed	O
significantly	significantly	O
among	among	O
groups	groups	O
(	(	O
F(33	f(33	O
)	)	O
=	=	O
4.92	4.92	O
;	;	O
P	p	O
=	=	O
.01	.01	O
)	)	O
(	(	O
clozapine	clozapine	B-Chemical
>	>	O
olanzapine	olanzapine	B-Chemical
>	>	O
risperidone	risperidone	B-Chemical
)	)	O
(	(	O
clozapine	clozapine	B-Chemical
vs	vs	O
risperidone	risperidone	B-Chemical
,	,	O
t(33	t(33	O
)	)	O
=	=	O
2.94	2.94	O
;	;	O
P	p	O
=	=	O
.006	.006	O
;	;	O
olanzapine	olanzapine	B-Chemical
vs	vs	O
risperidone	risperidone	B-Chemical
,	,	O
t(33	t(33	O
)	)	O
=	=	O
2.42	2.42	O
;	;	O
P	p	O
=	=	O
.02	.02	O
)	)	O
.	.	O

There	there	O
was	was	O
a	a	O
significant	significant	O
difference	difference	O
among	among	O
groups	groups	O
in	in	O
glucose	glucose	B-Chemical
effectiveness	effectiveness	O
(	(	O
F(30	f(30	O
)	)	O
=	=	O
4.18	4.18	O
;	;	O
P	p	O
=	=	O
.02	.02	O
)	)	O
(	(	O
clozapine	clozapine	B-Chemical
<	<	O
olanzapine	olanzapine	B-Chemical
<	<	O
risperidone	risperidone	B-Chemical
)	)	O
with	with	O
significant	significant	O
differences	differences	O
between	between	O
clozapine	clozapine	B-Chemical
and	and	O
risperidone	risperidone	B-Chemical
(	(	O
t(30	t(30	O
)	)	O
=	=	O
-2.59	-2.59	O
;	;	O
P	p	O
=	=	O
.02	.02	O
)	)	O
and	and	O
olanzapine	olanzapine	B-Chemical
and	and	O
risperidone	risperidone	B-Chemical
(	(	O
t(30	t(30	O
)	)	O
=	=	O
-2.34	-2.34	O
,	,	O
P	p	O
=	=	O
.03	.03	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Both	both	O
nonobese	nonobese	O
clozapine-	clozapine-	O
and	and	O
olanzapine-treated	olanzapine-treated	O
groups	groups	O
displayed	displayed	O
significant	significant	O
insulin	insulin	B-Disease
resistance	resistance	I-Disease
and	and	O
impairment	impairment	O
of	of	O
glucose	glucose	B-Chemical
effectiveness	effectiveness	O
compared	compared	O
with	with	O
risperidone-treated	risperidone-treated	O
subjects	subjects	O
.	.	O

Patients	patients	O
taking	taking	O
clozapine	clozapine	B-Chemical
and	and	O
olanzapine	olanzapine	B-Chemical
must	must	O
be	be	O
examined	examined	O
for	for	O
insulin	insulin	B-Disease
resistance	resistance	I-Disease
and	and	O
its	its	O
consequences	consequences	O
.	.	O

Thoracic	thoracic	O
hematomyelia	hematomyelia	O
secondary	secondary	O
to	to	O
coumadin	coumadin	O
anticoagulant	anticoagulant	O
therapy	therapy	O
:	:	O
a	a	O
case	case	O
report	report	O
.	.	O

A	a	O
case	case	O
of	of	O
thoracic	thoracic	O
hematomyelia	hematomyelia	O
secondary	secondary	O
to	to	O
anticoagulant	anticoagulant	O
therapy	therapy	O
is	is	O
presented	presented	O
.	.	O

Clinical	clinical	O
features	features	O
,	,	O
similar	similar	O
to	to	O
2	2	O
other	other	O
previously	previously	O
reported	reported	O
cases	cases	O
,	,	O
are	are	O
discussed	discussed	O
.	.	O

A	a	O
high	high	O
index	index	O
of	of	O
suspicion	suspicion	O
may	may	O
lead	lead	O
to	to	O
a	a	O
quick	quick	O
diagnostic	diagnostic	O
procedure	procedure	O
and	and	O
successful	successful	O
decompressive	decompressive	O
surgery	surgery	O
.	.	O

Mania	mania	B-Disease
associated	associated	O
with	with	O
fluoxetine	fluoxetine	B-Chemical
treatment	treatment	O
in	in	O
adolescents	adolescents	O
.	.	O

Fluoxetine	fluoxetine	B-Chemical
,	,	O
a	a	O
selective	selective	O
serotonin	serotonin	B-Chemical
reuptake	reuptake	O
inhibitor	inhibitor	O
,	,	O
is	is	O
gaining	gaining	O
increased	increased	O
acceptance	acceptance	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
adolescent	adolescent	O
depression	depression	B-Disease
.	.	O

Generally	generally	O
safe	safe	O
and	and	O
well	well	O
tolerated	tolerated	O
by	by	O
adults	adults	O
,	,	O
fluoxetine	fluoxetine	B-Chemical
has	has	O
been	been	O
reported	reported	O
to	to	O
induce	induce	O
mania	mania	B-Disease
.	.	O

The	the	O
cases	cases	O
of	of	O
five	five	O
depressed	depressed	B-Disease
adolescents	adolescents	O
,	,	O
14	14	O
-	-	O
16	16	O
years	years	O
of	of	O
age	age	O
,	,	O
who	who	O
developed	developed	O
mania	mania	B-Disease
during	during	O
pharmacotherapy	pharmacotherapy	O
with	with	O
fluoxetine	fluoxetine	B-Chemical
,	,	O
are	are	O
reported	reported	O
here	here	O
.	.	O

Apparent	apparent	O
risk	risk	O
factors	factors	O
for	for	O
the	the	O
development	development	O
of	of	O
mania	mania	B-Disease
or	or	O
hypomania	hypomania	O
during	during	O
fluoxetine	fluoxetine	B-Chemical
pharmacotherapy	pharmacotherapy	O
in	in	O
this	this	O
population	population	O
were	were	O
the	the	O
combination	combination	O
of	of	O
attention-deficit	attention-deficit	O
hyperactivity	hyperactivity	B-Disease
disorder	disorder	O
and	and	O
affective	affective	O
instability	instability	O
;	;	O
major	major	B-Disease
depression	depression	B-Disease
with	with	O
psychotic	psychotic	O
features	features	O
;	;	O
a	a	O
family	family	O
history	history	O
of	of	O
affective	affective	B-Disease
disorder	disorder	I-Disease
,	,	O
especially	especially	O
bipolar	bipolar	B-Disease
disorder	disorder	I-Disease
;	;	O
and	and	O
a	a	O
diagnosis	diagnosis	O
of	of	O
bipolar	bipolar	B-Disease
disorder	disorder	I-Disease
.	.	O

Further	further	O
study	study	O
is	is	O
needed	needed	O
to	to	O
determine	determine	O
the	the	O
optimal	optimal	O
dosage	dosage	O
and	and	O
to	to	O
identify	identify	O
risk	risk	O
factors	factors	O
that	that	O
increase	increase	O
individual	individual	O
vulnerability	vulnerability	O
to	to	O
fluoxetine	fluoxetine	B-Chemical
induced	induced	O
mania	mania	B-Disease
in	in	O
adolescents	adolescents	O
.	.	O

Acute	acute	B-Disease
renal	renal	B-Disease
insufficiency	insufficiency	I-Disease
after	after	O
high-dose	high-dose	O
melphalan	melphalan	B-Chemical
in	in	O
patients	patients	O
with	with	O
primary	primary	O
systemic	systemic	O
amyloidosis	amyloidosis	O
during	during	O
stem	stem	O
cell	cell	O
transplantation	transplantation	O
.	.	O

BACKGROUND	background	O
:	:	O
Patients	patients	O
with	with	O
primary	primary	O
systemic	systemic	O
amyloidosis	amyloidosis	O
(	(	O
AL	al	O
)	)	O
have	have	O
a	a	O
poor	poor	O
prognosis	prognosis	O
.	.	O

Median	median	O
survival	survival	O
time	time	O
from	from	O
standard	standard	O
treatments	treatments	O
is	is	O
only	only	O
17	17	O
months	months	O
.	.	O

High-dose	high-dose	O
intravenous	intravenous	O
melphalan	melphalan	B-Chemical
followed	followed	O
by	by	O
peripheral	peripheral	O
blood	blood	O
stem	stem	O
cell	cell	O
transplant	transplant	O
(	(	O
PBSCT	pbsct	O
)	)	O
appears	appears	O
to	to	O
be	be	O
the	the	O
most	most	O
promising	promising	O
therapy	therapy	O
,	,	O
but	but	O
treatment	treatment	O
mortality	mortality	O
can	can	O
be	be	O
high	high	O
.	.	O

The	the	O
authors	authors	O
have	have	O
noted	noted	O
the	the	O
development	development	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
insufficiency	insufficiency	I-Disease
immediately	immediately	O
after	after	O
melphalan	melphalan	B-Chemical
conditioning	conditioning	O
.	.	O

This	this	O
study	study	O
was	was	O
undertaken	undertaken	O
to	to	O
further	further	O
examine	examine	O
its	its	O
risk	risk	O
factors	factors	O
and	and	O
impact	impact	O
on	on	O
posttransplant	posttransplant	O
mortality	mortality	O
.	.	O

METHODS	methods	O
:	:	O
Consecutive	consecutive	O
AL	al	O
patients	patients	O
who	who	O
underwent	underwent	O
PBSCT	pbsct	O
were	were	O
studied	studied	O
retrospectively	retrospectively	O
.	.	O

Acute	acute	B-Disease
renal	renal	B-Disease
insufficiency	insufficiency	I-Disease
(	(	O
ARI	ari	O
)	)	O
after	after	O
high-dose	high-dose	O
melphalan	melphalan	B-Chemical
was	was	O
defined	defined	O
by	by	O
a	a	O
minimum	minimum	O
increase	increase	O
of	of	O
0.5	0.5	O
mg/dL	mg/dl	O
(	(	O
44	44	O
micromol/L	micromol/l	O
)	)	O
in	in	O
the	the	O
serum	serum	O
creatinine	creatinine	B-Chemical
level	level	O
that	that	O
is	is	O
greater	greater	O
than	than	O
50	50	O
%	%	O
of	of	O
baseline	baseline	O
immediately	immediately	O
after	after	O
conditioning	conditioning	O
.	.	O

Urine	urine	O
sediment	sediment	O
score	score	O
was	was	O
the	the	O
sum	sum	O
of	of	O
the	the	O
individual	individual	O
types	types	O
of	of	O
sediment	sediment	O
identified	identified	O
on	on	O
urine	urine	O
microscopy	microscopy	O
.	.	O

RESULTS	results	O
:	:	O
Of	of	O
the	the	O
80	80	O
patients	patients	O
studied	studied	O
,	,	O
ARI	ari	O
developed	developed	O
in	in	O
18.8	18.8	O
%	%	O
of	of	O
the	the	O
patients	patients	O
after	after	O
high-dose	high-dose	O
melphalan	melphalan	B-Chemical
.	.	O

Univariate	univariate	O
analysis	analysis	O
identified	identified	O
age	age	O
,	,	O
hypoalbuminemia	hypoalbuminemia	O
,	,	O
heavy	heavy	O
proteinuria	proteinuria	B-Disease
,	,	O
diuretic	diuretic	O
use	use	O
,	,	O
and	and	O
urine	urine	O
sediment	sediment	O
score	score	O
(	(	O
>	>	O
3	3	O
)	)	O
as	as	O
risk	risk	O
factors	factors	O
.	.	O

Age	age	O
and	and	O
urine	urine	O
sediment	sediment	O
score	score	O
remained	remained	O
independently	independently	O
significant	significant	O
risk	risk	O
factors	factors	O
in	in	O
the	the	O
multivariate	multivariate	O
analysis	analysis	O
.	.	O

Patients	patients	O
who	who	O
had	had	O
ARI	ari	O
after	after	O
high-dose	high-dose	O
melphalan	melphalan	B-Chemical
underwent	underwent	O
dialysis	dialysis	O
more	more	O
often	often	O
(	(	O
P	p	O
=	=	O
0.007	0.007	O
)	)	O
,	,	O
and	and	O
had	had	O
a	a	O
worse	worse	O
1-year	1-year	O
survival	survival	O
(	(	O
P	p	O
=	=	O
0.03	0.03	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
timing	timing	O
of	of	O
renal	renal	B-Disease
injury	injury	I-Disease
strongly	strongly	O
suggests	suggests	O
melphalan	melphalan	B-Chemical
as	as	O
the	the	O
causative	causative	O
agent	agent	O
.	.	O

Ongoing	ongoing	O
tubular	tubular	O
injury	injury	O
may	may	O
be	be	O
a	a	O
prerequisite	prerequisite	O
for	for	O
renal	renal	B-Disease
injury	injury	I-Disease
by	by	O
melphalan	melphalan	B-Chemical
as	as	O
evidenced	evidenced	O
by	by	O
the	the	O
active	active	O
urinary	urinary	O
sediment	sediment	O
.	.	O

Development	development	O
of	of	O
ARI	ari	O
adversely	adversely	O
affected	affected	O
the	the	O
outcome	outcome	O
after	after	O
PBSCT	pbsct	O
.	.	O

Effective	effective	O
preventive	preventive	O
measures	measures	O
may	may	O
help	help	O
decrease	decrease	O
the	the	O
treatment	treatment	O
mortality	mortality	O
of	of	O
PBSCT	pbsct	O
in	in	O
AL	al	O
patients	patients	O
.	.	O

Focal	focal	O
cerebral	cerebral	O
ischemia	ischemia	B-Disease
in	in	O
rats	rats	O
:	:	O
effect	effect	O
of	of	O
phenylephrine-induced	phenylephrine-induced	O
hypertension	hypertension	B-Disease
during	during	O
reperfusion	reperfusion	O
.	.	O

After	after	O
180	180	O
min	min	O
of	of	O
temporary	temporary	O
middle	middle	O
cerebral	cerebral	O
artery	artery	O
occlusion	occlusion	O
in	in	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
rats	rats	O
,	,	O
the	the	O
effect	effect	O
of	of	O
phenylephrine-induced	phenylephrine-induced	O
hypertension	hypertension	B-Disease
on	on	O
ischemic	ischemic	O
brain	brain	O
injury	injury	O
and	and	O
blood-brain	blood-brain	O
barrier	barrier	O
permeability	permeability	O
was	was	O
determined	determined	O
.	.	O

Blood	blood	O
pressure	pressure	O
was	was	O
manipulated	manipulated	O
by	by	O
one	one	O
of	of	O
the	the	O
following	following	O
schedules	schedules	O
during	during	O
120	120	O
min	min	O
of	of	O
reperfusion	reperfusion	O
:	:	O
Control	control	O
,	,	O
normotensive	normotensive	O
reperfusion	reperfusion	O
;	;	O
90/hypertension	90/hypertension	O
(	(	O
90/HTN	90/htn	O
)	)	O
,	,	O
blood	blood	O
pressure	pressure	O
was	was	O
increased	increased	O
by	by	O
35	35	O
mm	mm	O
Hg	hg	O
during	during	O
the	the	O
initial	initial	O
90	90	O
min	min	O
of	of	O
reperfusion	reperfusion	O
only	only	O
;	;	O
15/hypertension	15/hypertension	O
(	(	O
15/HTN	15/htn	O
)	)	O
,	,	O
normotensive	normotensive	O
reperfusion	reperfusion	O
for	for	O
30	30	O
min	min	O
followed	followed	O
by	by	O
15	15	O
min	min	O
of	of	O
hypertension	hypertension	B-Disease
and	and	O
75	75	O
min	min	O
of	of	O
normotension	normotension	O
.	.	O

Part	part	O
A	a	O
,	,	O
for	for	O
eight	eight	O
rats	rats	O
in	in	O
each	each	O
group	group	O
brain	brain	O
injury	injury	O
was	was	O
evaluated	evaluated	O
by	by	O
staining	staining	O
tissue	tissue	O
using	using	O
2,3,5-triphenyltetrazolium	2,3,5-triphenyltetrazolium	O
chloride	chloride	O
and	and	O
edema	edema	B-Disease
was	was	O
evaluated	evaluated	O
by	by	O
microgravimetry	microgravimetry	O
.	.	O

Part	part	O
B	b	O
,	,	O
for	for	O
eight	eight	O
different	different	O
rats	rats	O
in	in	O
each	each	O
group	group	O
blood-brain	blood-brain	O
barrier	barrier	O
permeability	permeability	O
was	was	O
evaluated	evaluated	O
by	by	O
measuring	measuring	O
the	the	O
amount	amount	O
and	and	O
extent	extent	O
of	of	O
extravasation	extravasation	O
of	of	O
Evans	evans	B-Chemical
Blue	blue	I-Chemical
dye	dye	O
.	.	O

Brain	brain	O
injury	injury	O
(	(	O
percentage	percentage	O
of	of	O
the	the	O
ischemic	ischemic	O
hemisphere	hemisphere	O
)	)	O
was	was	O
less	less	O
in	in	O
the	the	O
15/HTN	15/htn	O
group	group	O
(	(	O
16	16	O
+	+	O
/-	/-	O
6	6	O
,	,	O
mean	mean	O
+	+	O
/-	/-	O
SD	sd	O
)	)	O
versus	versus	O
the	the	O
90/HTN	90/htn	O
group	group	O
(	(	O
30	30	O
+	+	O
/-	/-	O
6	6	O
)	)	O
,	,	O
which	which	O
was	was	O
in	in	O
turn	turn	O
less	less	O
than	than	O
the	the	O
control	control	O
group	group	O
(	(	O
42	42	O
+	+	O
/-	/-	O
5	5	O
)	)	O
.	.	O

Specific	specific	O
gravity	gravity	O
was	was	O
greater	greater	O
in	in	O
the	the	O
15/HTN	15/htn	O
group	group	O
(	(	O
1.043	1.043	O
+	+	O
/-	/-	O
0.002	0.002	O
)	)	O
versus	versus	O
the	the	O
90/HTN	90/htn	O
(	(	O
1.036	1.036	O
+	+	O
/-	/-	O
0.003	0.003	O
)	)	O
and	and	O
control	control	O
(	(	O
1.037	1.037	O
+	+	O
/-	/-	O
0.003	0.003	O
)	)	O
groups	groups	O
.	.	O

Evans	evans	B-Chemical
Blue	blue	I-Chemical
(	(	O
mug	mug	O
g-1	g-1	O
of	of	O
brain	brain	O
tissue	tissue	O
)	)	O
was	was	O
greater	greater	O
in	in	O
the	the	O
90/HTN	90/htn	O
group	group	O
(	(	O
24.4	24.4	O
+	+	O
/-	/-	O
6.0	6.0	O
)	)	O
versus	versus	O
the	the	O
control	control	O
group	group	O
(	(	O
12.3	12.3	O
+	+	O
/-	/-	O
4.1	4.1	O
)	)	O
,	,	O
which	which	O
was	was	O
in	in	O
turn	turn	O
greater	greater	O
than	than	O
the	the	O
15/HTN	15/htn	O
group	group	O
(	(	O
7.3	7.3	O
+	+	O
/-	/-	O
3.2	3.2	O
)	)	O
.	.	O

This	this	O
study	study	O
supports	supports	O
a	a	O
hypothesis	hypothesis	O
that	that	O
during	during	O
reperfusion	reperfusion	O
,	,	O
a	a	O
short	short	O
interval	interval	O
of	of	O
hypertension	hypertension	B-Disease
decreases	decreases	O
brain	brain	O
injury	injury	O
and	and	O
edema	edema	B-Disease
;	;	O
and	and	O
that	that	O
sustained	sustained	O
hypertension	hypertension	B-Disease
increases	increases	O
the	the	O
risk	risk	O
of	of	O
vasogenic	vasogenic	O
edema	edema	B-Disease
.	.	O

People	people	O
aged	aged	O
over	over	O
75	75	O
in	in	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
on	on	O
warfarin	warfarin	B-Chemical
:	:	O
the	the	O
rate	rate	O
of	of	O
major	major	O
hemorrhage	hemorrhage	B-Disease
and	and	O
stroke	stroke	B-Disease
in	in	O
more	more	O
than	than	O
500	500	O
patient-years	patient-years	O
of	of	O
follow-up	follow-up	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
To	to	O
determine	determine	O
the	the	O
incidence	incidence	O
of	of	O
major	major	O
hemorrhage	hemorrhage	B-Disease
and	and	O
stroke	stroke	B-Disease
in	in	O
people	people	O
aged	aged	O
76	76	O
and	and	O
older	older	O
with	with	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
on	on	O
adjusted-dose	adjusted-dose	O
warfarin	warfarin	B-Chemical
who	who	O
had	had	O
been	been	O
recently	recently	O
been	been	O
admitted	admitted	O
to	to	O
hospital	hospital	O
.	.	O

DESIGN	design	O
:	:	O
A	a	O
retrospective	retrospective	O
observational	observational	O
cohort	cohort	O
study	study	O
.	.	O

SETTING	setting	O
:	:	O
A	a	O
major	major	O
healthcare	healthcare	O
network	network	O
involving	involving	O
four	four	O
tertiary	tertiary	O
hospitals	hospitals	O
.	.	O

PARTICIPANTS	participants	O
:	:	O
Two	two	O
hundred	hundred	O
thirty-five	thirty-five	O
patients	patients	O
aged	aged	O
76	76	O
and	and	O
older	older	O
admitted	admitted	O
to	to	O
a	a	O
major	major	O
healthcare	healthcare	O
network	network	O
between	between	O
July	july	O
1	1	O
,	,	O
2001	2001	O
,	,	O
and	and	O
June	june	O
30	30	O
,	,	O
2002	2002	O
,	,	O
with	with	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
on	on	O
warfarin	warfarin	B-Chemical
were	were	O
enrolled	enrolled	O
.	.	O

MEASUREMENTS	measurements	O
:	:	O
Information	information	O
regarding	regarding	O
major	major	O
bleeding	bleeding	B-Disease
episodes	episodes	O
,	,	O
strokes	strokes	B-Disease
,	,	O
and	and	O
warfarin	warfarin	B-Chemical
use	use	O
was	was	O
obtained	obtained	O
from	from	O
patients	patients	O
,	,	O
relatives	relatives	O
,	,	O
primary	primary	O
physicians	physicians	O
,	,	O
and	and	O
medical	medical	O
records	records	O
.	.	O

RESULTS	results	O
:	:	O
Two	two	O
hundred	hundred	O
twenty-eight	twenty-eight	O
patients	patients	O
(	(	O
42	42	O
%	%	O
men	men	O
)	)	O
with	with	O
a	a	O
mean	mean	O
age	age	O
of	of	O
81.1	81.1	O
(	(	O
range	range	O
76	76	O
-	-	O
94	94	O
)	)	O
were	were	O
included	included	O
in	in	O
the	the	O
analysis	analysis	O
.	.	O

Total	total	O
follow-up	follow-up	O
on	on	O
warfarin	warfarin	B-Chemical
was	was	O
530	530	O
years	years	O
(	(	O
mean	mean	O
28	28	O
months	months	O
)	)	O
.	.	O

There	there	O
were	were	O
53	53	O
major	major	O
hemorrhages	hemorrhages	O
,	,	O
for	for	O
an	an	O
annual	annual	O
rate	rate	O
of	of	O
10.0	10.0	O
%	%	O
,	,	O
including	including	O
24	24	O
(	(	O
45.3	45.3	O
%	%	O
)	)	O
life-threatening	life-threatening	O
and	and	O
five	five	O
(	(	O
9.4	9.4	O
%	%	O
)	)	O
fatal	fatal	O
bleeds	bleeds	O
.	.	O

The	the	O
annual	annual	O
stroke	stroke	B-Disease
rate	rate	O
after	after	O
initiation	initiation	O
of	of	O
warfarin	warfarin	B-Chemical
was	was	O
2.6	2.6	O
%	%	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
rate	rate	O
of	of	O
major	major	O
hemorrhage	hemorrhage	B-Disease
was	was	O
high	high	O
in	in	O
this	this	O
old	old	O
,	,	O
frail	frail	O
group	group	O
,	,	O
but	but	O
excluding	excluding	O
fatalities	fatalities	O
,	,	O
resulted	resulted	O
in	in	O
no	no	O
long-term	long-term	O
sequelae	sequelae	O
,	,	O
and	and	O
the	the	O
stroke	stroke	B-Disease
rate	rate	O
on	on	O
warfarin	warfarin	B-Chemical
was	was	O
low	low	O
,	,	O
demonstrating	demonstrating	O
how	how	O
effective	effective	O
warfarin	warfarin	B-Chemical
treatment	treatment	O
is	is	O
.	.	O

Safety	safety	O
of	of	O
celecoxib	celecoxib	O
in	in	O
patients	patients	O
with	with	O
adverse	adverse	O
skin	skin	O
reactions	reactions	O
to	to	O
acetaminophen	acetaminophen	B-Chemical
(	(	O
paracetamol	paracetamol	B-Chemical
)	)	O
and	and	O
nimesulide	nimesulide	O
associated	associated	O
or	or	O
not	not	O
with	with	O
common	common	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
.	.	O

BACKGROUND	background	O
:	:	O
Acetaminophen	acetaminophen	B-Chemical
(	(	O
paracetamol	paracetamol	B-Chemical
--	--	O
P	p	O
)	)	O
and	and	O
Nimesulide	nimesulide	O
(	(	O
N	n	O
)	)	O
are	are	O
widely	widely	O
used	used	O
analgesic-antipyretic/anti-inflammatory	analgesic-antipyretic/anti-inflammatory	O
drugs	drugs	O
.	.	O

The	the	O
rate	rate	O
of	of	O
adverse	adverse	O
hypersensitivity	hypersensitivity	B-Disease
reactions	reactions	O
to	to	O
these	these	O
agents	agents	O
is	is	O
generally	generally	O
low	low	O
.	.	O

On	on	O
the	the	O
contrary	contrary	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
(	(	O
NSAIDs	nsaids	O
)	)	O
are	are	O
commonly	commonly	O
involved	involved	O
in	in	O
such	such	O
reactions	reactions	O
.	.	O

Celecoxib	celecoxib	O
(	(	O
CE	ce	O
)	)	O
is	is	O
a	a	O
novel	novel	O
drug	drug	O
,	,	O
with	with	O
high	high	O
selectivity	selectivity	O
and	and	O
affinity	affinity	O
for	for	O
COX-2	cox-2	O
enzyme	enzyme	O
.	.	O

OBJECTIVE	objective	O
:	:	O
We	we	O
evaluated	evaluated	O
the	the	O
tolerability	tolerability	O
of	of	O
CE	ce	O
in	in	O
a	a	O
group	group	O
of	of	O
patients	patients	O
with	with	O
documented	documented	O
history	history	O
of	of	O
adverse	adverse	O
cutaneous	cutaneous	O
reactions	reactions	O
to	to	O
P	p	O
and	and	O
N	n	O
associated	associated	O
or	or	O
not	not	O
to	to	O
classic	classic	O
NSAIDs	nsaids	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
studied	studied	O
9	9	O
patients	patients	O
with	with	O
hypersensitivity	hypersensitivity	B-Disease
to	to	O
P	p	O
and	and	O
N	n	O
with	with	O
or	or	O
without	without	O
associated	associated	O
reactions	reactions	O
to	to	O
classic	classic	O
NSAIDs	nsaids	O
.	.	O

The	the	O
diagnosis	diagnosis	O
of	of	O
P	p	O
and	and	O
N-induced	n-induced	O
skin	skin	O
reactions	reactions	O
was	was	O
based	based	O
in	in	O
vivo	vivo	O
challenge	challenge	O
.	.	O

The	the	O
placebo	placebo	O
was	was	O
blindly	blindly	O
administered	administered	O
at	at	O
the	the	O
beginning	beginning	O
of	of	O
each	each	O
challenge	challenge	O
.	.	O

After	after	O
three	three	O
days	days	O
,	,	O
a	a	O
cumulative	cumulative	O
dosage	dosage	O
of	of	O
200	200	O
mg	mg	O
of	of	O
CE	ce	O
in	in	O
refracted	refracted	O
doses	doses	O
were	were	O
given	given	O
.	.	O

After	after	O
2	2	O
-	-	O
3	3	O
days	days	O
,	,	O
a	a	O
single	single	O
dose	dose	O
of	of	O
200	200	O
mg	mg	O
was	was	O
administered	administered	O
.	.	O

All	all	O
patients	patients	O
were	were	O
observed	observed	O
for	for	O
6	6	O
hours	hours	O
after	after	O
each	each	O
challenge	challenge	O
,	,	O
and	and	O
controlled	controlled	O
again	again	O
after	after	O
24	24	O
hours	hours	O
to	to	O
exclude	exclude	O
delayed	delayed	O
reactions	reactions	O
.	.	O

The	the	O
challenge	challenge	O
was	was	O
considered	considered	O
positive	positive	O
if	if	O
one	one	O
or	or	O
more	more	O
of	of	O
the	the	O
following	following	O
appeared	appeared	O
:	:	O
erythema	erythema	O
,	,	O
rush	rush	O
or	or	O
urticaria-angioedema	urticaria-angioedema	O
.	.	O

RESULTS	results	O
:	:	O
No	no	O
reaction	reaction	O
was	was	O
observed	observed	O
with	with	O
placebo	placebo	O
and	and	O
eight	eight	O
patients	patients	O
(	(	O
88.8	88.8	O
%	%	O
)	)	O
tolerated	tolerated	O
CE	ce	O
.	.	O

Only	only	O
one	one	O
patient	patient	O
developed	developed	O
a	a	O
moderate	moderate	O
angioedema	angioedema	B-Disease
of	of	O
the	the	O
lips	lips	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Only	only	O
one	one	O
hypersensitivity	hypersensitivity	B-Disease
reaction	reaction	O
to	to	O
CE	ce	O
was	was	O
documented	documented	O
among	among	O
9	9	O
P	p	O
and	and	O
N-highly	n-highly	O
NSAIDs	nsaids	O
intolerant	intolerant	O
patients	patients	O
.	.	O

Thus	thus	O
,	,	O
we	we	O
conclude	conclude	O
that	that	O
CE	ce	O
is	is	O
a	a	O
reasonably	reasonably	O
safe	safe	O
alternative	alternative	O
to	to	O
be	be	O
used	used	O
in	in	O
subjects	subjects	O
who	who	O
do	do	O
not	not	O
tolerate	tolerate	O
P	p	O
and	and	O
N.	n.	O

Case-control	case-control	O
study	study	O
of	of	O
regular	regular	O
analgesic	analgesic	O
and	and	O
nonsteroidal	nonsteroidal	O
anti-inflammatory	anti-inflammatory	O
use	use	O
and	and	O
end-stage	end-stage	O
renal	renal	O
disease	disease	O
.	.	O

BACKGROUND	background	O
:	:	O
Studies	studies	O
on	on	O
the	the	O
association	association	O
between	between	O
the	the	O
long-term	long-term	O
use	use	O
of	of	O
aspirin	aspirin	B-Chemical
and	and	O
other	other	O
analgesic	analgesic	O
and	and	O
nonsteroidal	nonsteroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
(	(	O
NSAIDs	nsaids	O
)	)	O
and	and	O
end-stage	end-stage	O
renal	renal	O
disease	disease	O
(	(	O
ESRD	esrd	B-Disease
)	)	O
have	have	O
given	given	O
conflicting	conflicting	O
results	results	O
.	.	O

In	in	O
order	order	O
to	to	O
examine	examine	O
this	this	O
association	association	O
,	,	O
a	a	O
case-control	case-control	O
study	study	O
with	with	O
incident	incident	O
cases	cases	O
of	of	O
ESRD	esrd	B-Disease
was	was	O
carried	carried	O
out	out	O
.	.	O

METHODS	methods	O
:	:	O
The	the	O
cases	cases	O
were	were	O
all	all	O
patients	patients	O
entering	entering	O
the	the	O
local	local	O
dialysis	dialysis	O
program	program	O
because	because	O
of	of	O
ESRD	esrd	B-Disease
in	in	O
the	the	O
study	study	O
area	area	O
between	between	O
June	june	O
1	1	O
,	,	O
1995	1995	O
and	and	O
November	november	O
30	30	O
,	,	O
1997	1997	O
.	.	O
They	they	O
were	were	O
classified	classified	O
according	according	O
to	to	O
the	the	O
underlying	underlying	O
disease	disease	O
,	,	O
which	which	O
had	had	O
presumably	presumably	O
led	led	O
them	them	O
to	to	O
ESRD	esrd	B-Disease
.	.	O

Controls	controls	O
were	were	O
patients	patients	O
admitted	admitted	O
to	to	O
the	the	O
same	same	O
hospitals	hospitals	O
from	from	O
where	where	O
the	the	O
cases	cases	O
arose	arose	O
,	,	O
also	also	O
matched	matched	O
by	by	O
age	age	O
and	and	O
sex	sex	O
.	.	O

Odds	odds	O
ratios	ratios	O
were	were	O
calculated	calculated	O
using	using	O
a	a	O
conditional	conditional	O
logistic	logistic	O
model	model	O
,	,	O
including	including	O
potential	potential	O
confounding	confounding	O
factors	factors	O
,	,	O
both	both	O
for	for	O
the	the	O
whole	whole	O
study	study	O
population	population	O
and	and	O
for	for	O
the	the	O
various	various	O
underlying	underlying	O
diseases	diseases	O
.	.	O

RESULTS	results	O
:	:	O
Five	five	O
hundred	hundred	O
and	and	O
eighty-three	eighty-three	O
cases	cases	O
and	and	O
1190	1190	O
controls	controls	O
were	were	O
included	included	O
in	in	O
the	the	O
analysis	analysis	O
.	.	O

Long-term	long-term	O
use	use	O
of	of	O
any	any	O
analgesic	analgesic	O
was	was	O
associated	associated	O
with	with	O
an	an	O
overall	overall	O
odds	odds	O
ratio	ratio	O
of	of	O
1.22	1.22	O
(	(	O
95	95	O
%	%	O
CI	ci	O
,	,	O
0.89	0.89	O
-	-	O
1.66	1.66	O
)	)	O
.	.	O

For	for	O
specific	specific	O
groups	groups	O
of	of	O
drugs	drugs	O
,	,	O
the	the	O
risks	risks	O
were	were	O
1.56	1.56	O
(	(	O
1.05	1.05	O
-	-	O
2.30	2.30	O
)	)	O
for	for	O
aspirin	aspirin	B-Chemical
,	,	O
1.03	1.03	O
(	(	O
0.60	0.60	O
-	-	O
1.76	1.76	O
)	)	O
for	for	O
pyrazolones	pyrazolones	O
,	,	O
0.80	0.80	O
(	(	O
0.39	0.39	O
-	-	O
1.63	1.63	O
)	)	O
for	for	O
paracetamol	paracetamol	B-Chemical
,	,	O
and	and	O
0.94	0.94	O
(	(	O
0.57	0.57	O
-	-	O
1.56	1.56	O
)	)	O
for	for	O
nonaspirin	nonaspirin	O
NSAIDs	nsaids	O
.	.	O

The	the	O
risk	risk	O
of	of	O
ESRD	esrd	B-Disease
associated	associated	O
with	with	O
aspirin	aspirin	B-Chemical
was	was	O
related	related	O
to	to	O
the	the	O
cumulated	cumulated	O
dose	dose	O
and	and	O
duration	duration	O
of	of	O
use	use	O
,	,	O
and	and	O
it	it	O
was	was	O
particularly	particularly	O
high	high	O
among	among	O
the	the	O
subset	subset	O
of	of	O
patients	patients	O
with	with	O
vascular	vascular	O
nephropathy	nephropathy	B-Disease
as	as	O
underlying	underlying	O
disease	disease	O
[	[	O
2.35	2.35	O
(	(	O
1.17	1.17	O
-	-	O
4.72	4.72	O
)	)	O
]	]	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Our	our	O
data	data	O
indicate	indicate	O
that	that	O
long-term	long-term	O
use	use	O
of	of	O
nonaspirin	nonaspirin	O
analgesic	analgesic	O
drugs	drugs	O
and	and	O
NSAIDs	nsaids	O
is	is	O
not	not	O
associated	associated	O
with	with	O
an	an	O
increased	increased	O
risk	risk	O
of	of	O
ESRD	esrd	B-Disease
.	.	O

However	however	O
,	,	O
the	the	O
chronic	chronic	O
use	use	O
of	of	O
aspirin	aspirin	B-Chemical
may	may	O
increase	increase	O
the	the	O
risk	risk	O
of	of	O
ESRD	esrd	B-Disease
.	.	O

Two	two	O
cases	cases	O
of	of	O
amisulpride	amisulpride	O
overdose	overdose	B-Disease
:	:	O
a	a	O
cause	cause	O
for	for	O
prolonged	prolonged	O
QT	qt	O
syndrome	syndrome	O
.	.	O

Two	two	O
cases	cases	O
of	of	O
deliberate	deliberate	O
self-poisoning	self-poisoning	O
with	with	O
5	5	O
g	g	O
and	and	O
3.6	3.6	O
g	g	O
of	of	O
amisulpride	amisulpride	O
,	,	O
respectively	respectively	O
,	,	O
are	are	O
reported	reported	O
.	.	O

In	in	O
both	both	O
cases	cases	O
,	,	O
QT	qt	O
prolongation	prolongation	O
and	and	O
hypocalcaemia	hypocalcaemia	O
were	were	O
noted	noted	O
.	.	O

The	the	O
QT	qt	O
prolongation	prolongation	O
appeared	appeared	O
to	to	O
respond	respond	O
to	to	O
administration	administration	O
of	of	O
i.v	i.v	O
.	.	O
calcium	calcium	B-Chemical
gluconate	gluconate	I-Chemical
.	.	O

Growth-associated	growth-associated	O
protein	protein	O
43	43	O
expression	expression	O
in	in	O
hippocampal	hippocampal	O
molecular	molecular	O
layer	layer	O
of	of	O
chronic	chronic	O
epileptic	epileptic	B-Disease
rats	rats	O
treated	treated	O
with	with	O
cycloheximide	cycloheximide	B-Chemical
.	.	O

PURPOSE	purpose	O
:	:	O
GAP43	gap43	O
has	has	O
been	been	O
thought	thought	O
to	to	O
be	be	O
linked	linked	O
with	with	O
mossy	mossy	O
fiber	fiber	O
sprouting	sprouting	O
(	(	O
MFS	mfs	O
)	)	O
in	in	O
various	various	O
experimental	experimental	O
models	models	O
of	of	O
epilepsy	epilepsy	B-Disease
.	.	O

To	to	O
investigate	investigate	O
how	how	O
GAP43	gap43	O
expression	expression	O
(	(	O
GAP43-ir	gap43-ir	O
)	)	O
correlates	correlates	O
with	with	O
MFS	mfs	O
,	,	O
we	we	O
assessed	assessed	O
the	the	O
intensity	intensity	O
(	(	O
densitometry	densitometry	O
)	)	O
and	and	O
extension	extension	O
(	(	O
width	width	O
)	)	O
of	of	O
GAP43-ir	gap43-ir	O
in	in	O
the	the	O
inner	inner	O
molecular	molecular	O
layer	layer	O
of	of	O
the	the	O
dentate	dentate	O
gyrus	gyrus	O
(	(	O
IML	iml	O
)	)	O
of	of	O
rats	rats	O
subject	subject	O
to	to	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
induced	induced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
(	(	O
Pilo	pilo	O
)	)	O
,	,	O
previously	previously	O
injected	injected	O
or	or	O
not	not	O
with	with	O
cycloheximide	cycloheximide	B-Chemical
(	(	O
CHX	chx	O
)	)	O
,	,	O
which	which	O
has	has	O
been	been	O
shown	shown	O
to	to	O
inhibit	inhibit	O
MFS	mfs	O
.	.	O

METHODS	methods	O
:	:	O
CHX	chx	O
was	was	O
injected	injected	O
before	before	O
the	the	O
Pilo	pilo	O
injection	injection	O
in	in	O
adult	adult	O
Wistar	wistar	O
rats	rats	O
.	.	O

The	the	O
Pilo	pilo	O
group	group	O
was	was	O
injected	injected	O
with	with	O
the	the	O
same	same	O
drugs	drugs	O
,	,	O
except	except	O
for	for	O
CHX	chx	O
.	.	O

Animals	animals	O
were	were	O
killed	killed	O
between	between	O
30	30	O
and	and	O
60	60	O
days	days	O
later	later	O
,	,	O
and	and	O
brain	brain	O
sections	sections	O
were	were	O
processed	processed	O
for	for	O
GAP43	gap43	O
immunohistochemistry	immunohistochemistry	O
.	.	O

RESULTS	results	O
:	:	O
Densitometry	densitometry	O
showed	showed	O
no	no	O
significant	significant	O
difference	difference	O
regarding	regarding	O
GAP43-ir	gap43-ir	O
in	in	O
the	the	O
IML	iml	O
between	between	O
Pilo	pilo	O
,	,	O
CHX+Pilo	chx+pilo	O
,	,	O
and	and	O
control	control	O
groups	groups	O
.	.	O

However	however	O
,	,	O
the	the	O
results	results	O
of	of	O
the	the	O
width	width	O
of	of	O
the	the	O
GAP43-ir	gap43-ir	O
band	band	O
in	in	O
the	the	O
IML	iml	O
showed	showed	O
that	that	O
CHX+Pilo	chx+pilo	O
and	and	O
control	control	O
animals	animals	O
had	had	O
a	a	O
significantly	significantly	O
larger	larger	O
band	band	O
(	(	O
p	p	O
=	=	O
0.03	0.03	O
)	)	O
as	as	O
compared	compared	O
with	with	O
that	that	O
in	in	O
the	the	O
Pilo	pilo	O
group	group	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Our	our	O
current	current	O
finding	finding	O
that	that	O
animals	animals	O
in	in	O
the	the	O
CHX+Pilo	chx+pilo	O
group	group	O
have	have	O
a	a	O
GAP43-ir	gap43-ir	O
band	band	O
in	in	O
the	the	O
IML	iml	O
,	,	O
similar	similar	O
to	to	O
that	that	O
of	of	O
controls	controls	O
,	,	O
reinforces	reinforces	O
prior	prior	O
data	data	O
on	on	O
the	the	O
blockade	blockade	O
of	of	O
MFS	mfs	O
in	in	O
these	these	O
animals	animals	O
.	.	O

The	the	O
change	change	O
in	in	O
GAP43-ir	gap43-ir	O
present	present	O
in	in	O
Pilo-treated	pilo-treated	O
animals	animals	O
was	was	O
a	a	O
thinning	thinning	O
of	of	O
the	the	O
band	band	O
to	to	O
a	a	O
very	very	O
narrow	narrow	O
layer	layer	O
just	just	O
above	above	O
the	the	O
granule	granule	O
cell	cell	O
layer	layer	O
that	that	O
is	is	O
likely	likely	O
to	to	O
be	be	O
associated	associated	O
with	with	O
the	the	O
loss	loss	O
of	of	O
hilar	hilar	O
cell	cell	O
projections	projections	O
that	that	O
express	express	O
GAP-43	gap-43	O
.	.	O

Nicotine	nicotine	B-Chemical
antagonizes	antagonizes	O
caffeine-	caffeine-	O
but	but	O
not	not	O
pentylenetetrazole-induced	pentylenetetrazole-induced	O
anxiogenic	anxiogenic	O
effect	effect	O
in	in	O
mice	mice	O
.	.	O

RATIONALE	rationale	O
:	:	O
Nicotine	nicotine	B-Chemical
and	and	O
caffeine	caffeine	B-Chemical
are	are	O
widely	widely	O
consumed	consumed	O
licit	licit	O
psychoactive	psychoactive	B-Chemical
drugs	drugs	I-Chemical
worldwide	worldwide	O
.	.	O

Epidemiological	epidemiological	O
studies	studies	O
showed	showed	O
that	that	O
they	they	O
were	were	O
generally	generally	O
used	used	O
concurrently	concurrently	O
.	.	O

Although	although	O
some	some	O
studies	studies	O
in	in	O
experimental	experimental	O
animals	animals	O
indicate	indicate	O
clear	clear	O
pharmacological	pharmacological	O
interactions	interactions	O
between	between	O
them	them	O
,	,	O
no	no	O
studies	studies	O
have	have	O
shown	shown	O
a	a	O
specific	specific	O
interaction	interaction	O
on	on	O
anxiety	anxiety	B-Disease
responses	responses	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
The	the	O
present	present	O
study	study	O
investigates	investigates	O
the	the	O
effects	effects	O
of	of	O
nicotine	nicotine	B-Chemical
on	on	O
anxiety	anxiety	B-Disease
induced	induced	O
by	by	O
caffeine	caffeine	B-Chemical
and	and	O
another	another	O
anxiogenic	anxiogenic	O
drug	drug	O
,	,	O
pentylenetetrazole	pentylenetetrazole	O
,	,	O
in	in	O
mice	mice	O
.	.	O

The	the	O
elevated	elevated	O
plus-maze	plus-maze	O
(	(	O
EPM	epm	O
)	)	O
test	test	O
was	was	O
used	used	O
to	to	O
evaluate	evaluate	O
the	the	O
effects	effects	O
of	of	O
drugs	drugs	O
on	on	O
anxiety	anxiety	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Adult	adult	O
male	male	O
Swiss	swiss	O
Webster	webster	O
mice	mice	O
(	(	O
25	25	O
-	-	O
32	32	O
g	g	O
)	)	O
were	were	O
given	given	O
nicotine	nicotine	B-Chemical
(	(	O
0.05	0.05	O
-	-	O
0.25	0.25	O
mg/kg	mg/kg	O
s.c	s.c	O
.	.	O
)	)	O
or	or	O
saline	saline	O
10	10	O
min	min	O
before	before	O
caffeine	caffeine	B-Chemical
(	(	O
70	70	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
)	)	O
or	or	O
pentylenetetrazole	pentylenetetrazole	O
(	(	O
15	15	O
and	and	O
30	30	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
)	)	O
injections	injections	O
.	.	O

After	after	O
15	15	O
min	min	O
,	,	O
mice	mice	O
were	were	O
evaluated	evaluated	O
for	for	O
their	their	O
open-	open-	O
and	and	O
closed-arm	closed-arm	O
time	time	O
and	and	O
entries	entries	O
on	on	O
the	the	O
EPM	epm	O
for	for	O
a	a	O
10-min	10-min	O
session	session	O
.	.	O

Locomotor	locomotor	O
activity	activity	O
was	was	O
recorded	recorded	O
for	for	O
individual	individual	O
groups	groups	O
by	by	O
using	using	O
the	the	O
same	same	O
treatment	treatment	O
protocol	protocol	O
with	with	O
the	the	O
EPM	epm	O
test	test	O
.	.	O

RESULTS	results	O
:	:	O
Nicotine	nicotine	B-Chemical
(	(	O
0.05	0.05	O
-	-	O
0.25	0.25	O
mg/kg	mg/kg	O
)	)	O
itself	itself	O
did	did	O
not	not	O
produce	produce	O
any	any	O
significant	significant	O
effect	effect	O
in	in	O
the	the	O
EPM	epm	O
test	test	O
,	,	O
whereas	whereas	O
caffeine	caffeine	B-Chemical
(	(	O
70	70	O
mg/kg	mg/kg	O
)	)	O
and	and	O
pentylenetetrazole	pentylenetetrazole	O
(	(	O
30	30	O
mg/kg	mg/kg	O
)	)	O
produced	produced	O
an	an	O
anxiogenic	anxiogenic	O
effect	effect	O
,	,	O
apparent	apparent	O
with	with	O
decreases	decreases	O
in	in	O
open-arm	open-arm	O
time	time	O
and	and	O
entry	entry	O
.	.	O

Nicotine	nicotine	B-Chemical
(	(	O
0.25	0.25	O
mg/kg	mg/kg	O
)	)	O
pretreatment	pretreatment	O
blocked	blocked	O
the	the	O
caffeine-	caffeine-	O
but	but	O
not	not	O
pentylenetetrazole-induced	pentylenetetrazole-induced	O
anxiety	anxiety	B-Disease
.	.	O

Administration	administration	O
of	of	O
each	each	O
drug	drug	O
and	and	O
their	their	O
combinations	combinations	O
did	did	O
not	not	O
produce	produce	O
any	any	O
effect	effect	O
on	on	O
locomotor	locomotor	O
activity	activity	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Our	our	O
results	results	O
suggest	suggest	O
that	that	O
the	the	O
antagonistic	antagonistic	O
effect	effect	O
of	of	O
nicotine	nicotine	B-Chemical
on	on	O
caffeine-induced	caffeine-induced	O
anxiety	anxiety	B-Disease
is	is	O
specific	specific	O
to	to	O
caffeine	caffeine	B-Chemical
,	,	O
instead	instead	O
of	of	O
a	a	O
non-specific	non-specific	O
anxiolytic	anxiolytic	O
effect	effect	O
.	.	O

Thus	thus	O
,	,	O
it	it	O
may	may	O
extend	extend	O
the	the	O
current	current	O
findings	findings	O
on	on	O
the	the	O
interaction	interaction	O
between	between	O
nicotine	nicotine	B-Chemical
and	and	O
caffeine	caffeine	B-Chemical
.	.	O

Long	long	O
term	term	O
hormone	hormone	O
therapy	therapy	O
for	for	O
perimenopausal	perimenopausal	O
and	and	O
postmenopausal	postmenopausal	O
women	women	O
.	.	O

BACKGROUND	background	O
:	:	O
Hormone	hormone	O
therapy	therapy	O
(	(	O
HT	ht	O
)	)	O
is	is	O
widely	widely	O
used	used	O
for	for	O
controlling	controlling	O
menopausal	menopausal	O
symptoms	symptoms	O
.	.	O

It	it	O
has	has	O
also	also	O
been	been	O
used	used	O
for	for	O
the	the	O
management	management	O
and	and	O
prevention	prevention	O
of	of	O
cardiovascular	cardiovascular	B-Disease
disease	disease	I-Disease
,	,	O
osteoporosis	osteoporosis	B-Disease
and	and	O
dementia	dementia	B-Disease
in	in	O
older	older	O
women	women	O
but	but	O
the	the	O
evidence	evidence	O
supporting	supporting	O
its	its	O
use	use	O
for	for	O
these	these	O
indications	indications	O
is	is	O
largely	largely	O
observational	observational	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
To	to	O
assess	assess	O
the	the	O
effect	effect	O
of	of	O
long-term	long-term	O
HT	ht	O
on	on	O
mortality	mortality	O
,	,	O
heart	heart	B-Disease
disease	disease	I-Disease
,	,	O
venous	venous	B-Disease
thromboembolism	thromboembolism	I-Disease
,	,	O
stroke	stroke	B-Disease
,	,	O
transient	transient	O
ischaemic	ischaemic	O
attacks	attacks	O
,	,	O
breast	breast	B-Disease
cancer	cancer	B-Disease
,	,	O
colorectal	colorectal	O
cancer	cancer	B-Disease
,	,	O
ovarian	ovarian	B-Disease
cancer	cancer	B-Disease
,	,	O
endometrial	endometrial	B-Disease
cancer	cancer	B-Disease
,	,	O
gallbladder	gallbladder	B-Disease
disease	disease	I-Disease
,	,	O
cognitive	cognitive	O
function	function	O
,	,	O
dementia	dementia	B-Disease
,	,	O
fractures	fractures	B-Disease
and	and	O
quality	quality	O
of	of	O
life	life	O
.	.	O

SEARCH	search	O
STRATEGY	strategy	O
:	:	O
We	we	O
searched	searched	O
the	the	O
following	following	O
databases	databases	O
up	up	O
to	to	O
November	november	O
2004	2004	O
:	:	O
the	the	O
Cochrane	cochrane	O
Menstrual	menstrual	O
Disorders	disorders	O
and	and	O
Subfertility	subfertility	O
Group	group	O
Trials	trials	O
Register	register	O
,	,	O
Cochrane	cochrane	O
Central	central	O
Register	register	O
of	of	O
Controlled	controlled	O
Trials	trials	O
(	(	O
CENTRAL	central	O
)	)	O
,	,	O
MEDLINE	medline	O
,	,	O
EMBASE	embase	O
,	,	O
Biological	biological	O
Abstracts	abstracts	O
.	.	O

Relevant	relevant	O
non-indexed	non-indexed	O
journals	journals	O
and	and	O
conference	conference	O
abstracts	abstracts	O
were	were	O
also	also	O
searched	searched	O
.	.	O

SELECTION	selection	O
CRITERIA	criteria	O
:	:	O
Randomised	randomised	O
double-blind	double-blind	O
trials	trials	O
of	of	O
HT	ht	O
(	(	O
oestrogens	oestrogens	O
with	with	O
or	or	O
without	without	O
progestogens	progestogens	O
)	)	O
versus	versus	O
placebo	placebo	O
,	,	O
taken	taken	O
for	for	O
at	at	O
least	least	O
one	one	O
year	year	O
by	by	O
perimenopausal	perimenopausal	O
or	or	O
postmenopausal	postmenopausal	O
women	women	O
.	.	O

DATA	data	O
COLLECTION	collection	O
AND	and	O
ANALYSIS	analysis	O
:	:	O
Fifteen	fifteen	O
RCTs	rcts	O
were	were	O
included	included	O
.	.	O

Trials	trials	O
were	were	O
assessed	assessed	O
for	for	O
quality	quality	O
and	and	O
two	two	O
review	review	O
authors	authors	O
extracted	extracted	O
data	data	O
independently	independently	O
.	.	O

They	they	O
calculated	calculated	O
risk	risk	O
ratios	ratios	O
for	for	O
dichotomous	dichotomous	O
outcomes	outcomes	O
and	and	O
weighted	weighted	O
mean	mean	O
differences	differences	O
for	for	O
continuous	continuous	O
outcomes	outcomes	O
.	.	O

Clinical	clinical	O
heterogeneity	heterogeneity	O
precluded	precluded	O
meta-analysis	meta-analysis	O
for	for	O
most	most	O
outcomes	outcomes	O
.	.	O

MAIN	main	O
RESULTS	results	O
:	:	O
All	all	O
the	the	O
statistically	statistically	O
significant	significant	O
results	results	O
were	were	O
derived	derived	O
from	from	O
the	the	O
two	two	O
biggest	biggest	O
trials	trials	O
.	.	O

In	in	O
relatively	relatively	O
healthy	healthy	O
women	women	O
,	,	O
combined	combined	O
continuous	continuous	O
HT	ht	O
significantly	significantly	O
increased	increased	O
the	the	O
risk	risk	O
of	of	O
venous	venous	B-Disease
thromboembolism	thromboembolism	I-Disease
or	or	O
coronary	coronary	O
event	event	O
(	(	O
after	after	O
one	one	O
year	year	O
's	's	O
use	use	O
)	)	O
,	,	O
stroke	stroke	B-Disease
(	(	O
after	after	O
3	3	O
years	years	O
)	)	O
,	,	O
breast	breast	B-Disease
cancer	cancer	B-Disease
(	(	O
after	after	O
5	5	O
years	years	O
)	)	O
and	and	O
gallbladder	gallbladder	B-Disease
disease	disease	I-Disease
.	.	O

Long-term	long-term	O
oestrogen-only	oestrogen-only	O
HT	ht	O
also	also	O
significantly	significantly	O
increased	increased	O
the	the	O
risk	risk	O
of	of	O
stroke	stroke	B-Disease
and	and	O
gallbladder	gallbladder	B-Disease
disease	disease	I-Disease
.	.	O

Overall	overall	O
,	,	O
the	the	O
only	only	O
statistically	statistically	O
significant	significant	O
benefits	benefits	O
of	of	O
HT	ht	O
were	were	O
a	a	O
decreased	decreased	O
incidence	incidence	O
of	of	O
fractures	fractures	B-Disease
and	and	O
colon	colon	O
cancer	cancer	B-Disease
with	with	O
long-term	long-term	O
use	use	O
.	.	O

Among	among	O
relatively	relatively	O
healthy	healthy	O
women	women	O
over	over	O
65	65	O
years	years	O
taking	taking	O
continuous	continuous	O
combined	combined	O
HT	ht	O
,	,	O
there	there	O
was	was	O
a	a	O
statistically	statistically	O
significant	significant	O
increase	increase	O
in	in	O
the	the	O
incidence	incidence	O
of	of	O
dementia	dementia	B-Disease
.	.	O

Among	among	O
women	women	O
with	with	O
cardiovascular	cardiovascular	B-Disease
disease	disease	I-Disease
,	,	O
long-term	long-term	O
use	use	O
of	of	O
combined	combined	O
continuous	continuous	O
HT	ht	O
significantly	significantly	O
increased	increased	O
the	the	O
risk	risk	O
of	of	O
venous	venous	B-Disease
thromboembolism	thromboembolism	I-Disease
.	.	O

No	no	O
trials	trials	O
focussed	focussed	O
specifically	specifically	O
on	on	O
younger	younger	O
women	women	O
.	.	O

However	however	O
,	,	O
one	one	O
trial	trial	O
analysed	analysed	O
subgroups	subgroups	O
of	of	O
2839	2839	O
relatively	relatively	O
healthy	healthy	O
50	50	O
to	to	O
59	59	O
year-old	year-old	O
women	women	O
taking	taking	O
combined	combined	O
continuous	continuous	O
HT	ht	O
and	and	O
1637	1637	O
taking	taking	O
oestrogen-only	oestrogen-only	O
HT	ht	O
,	,	O
versus	versus	O
similar-sized	similar-sized	O
placebo	placebo	O
groups	groups	O
.	.	O

The	the	O
only	only	O
significantly	significantly	O
increased	increased	O
risk	risk	O
reported	reported	O
was	was	O
for	for	O
venous	venous	B-Disease
thromboembolism	thromboembolism	I-Disease
in	in	O
women	women	O
taking	taking	O
combined	combined	O
continuous	continuous	O
HT	ht	O
;	;	O
their	their	O
absolute	absolute	O
risk	risk	O
remained	remained	O
very	very	O
low	low	O
.	.	O
AUTHORS	authors	O
'	'	O
CONCLUSIONS	conclusions	O
:	:	O
HT	ht	O
is	is	O
not	not	O
indicated	indicated	O
for	for	O
the	the	O
routine	routine	O
management	management	O
of	of	O
chronic	chronic	B-Disease
disease	disease	I-Disease
.	.	O

We	we	O
need	need	O
more	more	O
evidence	evidence	O
on	on	O
the	the	O
safety	safety	O
of	of	O
HT	ht	O
for	for	O
menopausal	menopausal	O
symptom	symptom	O
control	control	O
,	,	O
though	though	O
short-term	short-term	O
use	use	O
appears	appears	O
to	to	O
be	be	O
relatively	relatively	O
safe	safe	O
for	for	O
healthy	healthy	O
younger	younger	O
women	women	O
.	.	O

Drug-induced	drug-induced	O
liver	liver	B-Disease
injury	injury	I-Disease
:	:	O
an	an	O
analysis	analysis	O
of	of	O
461	461	O
incidences	incidences	O
submitted	submitted	O
to	to	O
the	the	O
Spanish	spanish	O
registry	registry	O
over	over	O
a	a	O
10-year	10-year	O
period	period	O
.	.	O

BACKGROUND	background	O
&	&	O
AIMS	aims	O
:	:	O
Progress	progress	O
in	in	O
the	the	O
understanding	understanding	O
of	of	O
susceptibility	susceptibility	O
factors	factors	O
to	to	O
drug-induced	drug-induced	O
liver	liver	B-Disease
injury	injury	I-Disease
(	(	O
DILI	dili	O
)	)	O
and	and	O
outcome	outcome	O
predictability	predictability	O
are	are	O
hampered	hampered	O
by	by	O
the	the	O
lack	lack	O
of	of	O
systematic	systematic	O
programs	programs	O
to	to	O
detect	detect	O
bona	bona	O
fide	fide	O
cases	cases	O
.	.	O

METHODS	methods	O
:	:	O
A	a	O
cooperative	cooperative	O
network	network	O
was	was	O
created	created	O
in	in	O
1994	1994	O
in	in	O
Spain	spain	O
to	to	O
identify	identify	O
all	all	O
suspicions	suspicions	O
of	of	O
DILI	dili	O
following	following	O
a	a	O
prospective	prospective	O
structured	structured	O
report	report	O
form	form	O
.	.	O

The	the	O
liver	liver	B-Disease
damage	damage	I-Disease
was	was	O
characterized	characterized	O
according	according	O
to	to	O
hepatocellular	hepatocellular	O
,	,	O
cholestatic	cholestatic	O
,	,	O
and	and	O
mixed	mixed	O
laboratory	laboratory	O
criteria	criteria	O
and	and	O
to	to	O
histologic	histologic	O
criteria	criteria	O
when	when	O
available	available	O
.	.	O

Further	further	O
evaluation	evaluation	O
of	of	O
causality	causality	O
assessment	assessment	O
was	was	O
centrally	centrally	O
performed	performed	O
.	.	O

RESULTS	results	O
:	:	O
Since	since	O
April	april	O
1994	1994	O
to	to	O
August	august	O
2004	2004	O
,	,	O
461	461	O
out	out	O
of	of	O
570	570	O
submitted	submitted	O
cases	cases	O
,	,	O
involving	involving	O
505	505	O
drugs	drugs	O
,	,	O
were	were	O
deemed	deemed	O
to	to	O
be	be	O
related	related	O
to	to	O
DILI	dili	O
.	.	O

The	the	O
antiinfective	antiinfective	O
group	group	O
of	of	O
drugs	drugs	O
was	was	O
the	the	O
more	more	O
frequently	frequently	O
incriminated	incriminated	O
,	,	O
amoxicillin-clavulanate	amoxicillin-clavulanate	O
accounting	accounting	O
for	for	O
the	the	O
12.8	12.8	O
%	%	O
of	of	O
the	the	O
whole	whole	O
series	series	O
.	.	O

The	the	O
hepatocellular	hepatocellular	O
pattern	pattern	O
of	of	O
damage	damage	O
was	was	O
the	the	O
most	most	O
common	common	O
(	(	O
58	58	O
%	%	O
)	)	O
,	,	O
was	was	O
inversely	inversely	O
correlated	correlated	O
with	with	O
age	age	O
(	(	O
P	p	O
<	<	O
.0001	.0001	O
)	)	O
,	,	O
and	and	O
had	had	O
the	the	O
worst	worst	O
outcome	outcome	O
(	(	O
Cox	cox	O
regression	regression	O
,	,	O
P	p	O
<	<	O
.034	.034	O
)	)	O
.	.	O

Indeed	indeed	O
,	,	O
the	the	O
incidence	incidence	O
of	of	O
liver	liver	O
transplantation	transplantation	O
and	and	O
death	death	B-Disease
in	in	O
this	this	O
group	group	O
was	was	O
11.7	11.7	O
%	%	O
if	if	O
patients	patients	O
had	had	O
jaundice	jaundice	B-Disease
at	at	O
presentation	presentation	O
,	,	O
whereas	whereas	O
the	the	O
corresponding	corresponding	O
figure	figure	O
was	was	O
3.8	3.8	O
%	%	O
in	in	O
nonjaundiced	nonjaundiced	O
patients	patients	O
(	(	O
P	p	O
<	<	O
.04	.04	O
)	)	O
.	.	O

Factors	factors	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
fulminant	fulminant	B-Disease
hepatic	hepatic	B-Disease
failure	failure	I-Disease
were	were	O
female	female	O
sex	sex	O
(	(	O
OR	or	O
=	=	O
25	25	O
;	;	O
95	95	O
%	%	O
CI	ci	O
:	:	O
4.1	4.1	O
-	-	O
151	151	O
;	;	O
P	p	O
<	<	O
.0001	.0001	O
)	)	O
,	,	O
hepatocellular	hepatocellular	O
damage	damage	O
(	(	O
OR	or	O
=	=	O
7.9	7.9	O
;	;	O
95	95	O
%	%	O
CI	ci	O
:	:	O
1.6	1.6	O
-	-	O
37	37	O
;	;	O
P	p	O
<	<	O
.009	.009	O
)	)	O
,	,	O
and	and	O
higher	higher	O
baseline	baseline	O
plasma	plasma	O
bilirubin	bilirubin	B-Chemical
value	value	O
(	(	O
OR	or	O
=	=	O
1.15	1.15	O
;	;	O
95	95	O
%	%	O
CI	ci	O
:	:	O
1.09	1.09	O
-	-	O
1.22	1.22	O
;	;	O
P	p	O
<	<	O
.0001	.0001	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Patients	patients	O
with	with	O
drug-induced	drug-induced	O
hepatocellular	hepatocellular	O
jaundice	jaundice	B-Disease
have	have	O
11.7	11.7	O
%	%	O
chance	chance	O
of	of	O
progressing	progressing	O
to	to	O
death	death	B-Disease
or	or	O
transplantation	transplantation	O
.	.	O

Amoxicillin-clavulanate	amoxicillin-clavulanate	O
stands	stands	O
out	out	O
as	as	O
the	the	O
most	most	O
common	common	O
drug	drug	O
related	related	O
to	to	O
DILI	dili	O
.	.	O

Morphological	morphological	O
evaluation	evaluation	O
of	of	O
the	the	O
effect	effect	O
of	of	O
d-ribose	d-ribose	O
on	on	O
adriamycin-evoked	adriamycin-evoked	O
cardiotoxicity	cardiotoxicity	B-Disease
in	in	O
rats	rats	O
.	.	O

The	the	O
influence	influence	O
of	of	O
d-ribose	d-ribose	O
on	on	O
adriamycin-induced	adriamycin-induced	O
myocardiopathy	myocardiopathy	O
in	in	O
rats	rats	O
was	was	O
studied	studied	O
.	.	O

Adriamycin	adriamycin	B-Chemical
in	in	O
the	the	O
cumulative	cumulative	O
dose	dose	O
of	of	O
25	25	O
mg/kg	mg/kg	O
evoked	evoked	O
fully	fully	O
developed	developed	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
.	.	O

D-ribose	d-ribose	O
in	in	O
the	the	O
multiple	multiple	O
doses	doses	O
of	of	O
200	200	O
mg/kg	mg/kg	O
did	did	O
not	not	O
influence	influence	O
ADR	adr	B-Chemical
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

In	in	O
vivo	vivo	O
evidences	evidences	O
suggesting	suggesting	O
the	the	O
role	role	O
of	of	O
oxidative	oxidative	O
stress	stress	O
in	in	O
pathogenesis	pathogenesis	O
of	of	O
vancomycin-induced	vancomycin-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
:	:	O
protection	protection	O
by	by	O
erdosteine	erdosteine	O
.	.	O

The	the	O
aims	aims	O
of	of	O
this	this	O
study	study	O
were	were	O
to	to	O
examine	examine	O
vancomycin	vancomycin	B-Chemical
(VCM)-induced	(vcm)-induced	O
oxidative	oxidative	O
stress	stress	O
that	that	O
promotes	promotes	O
production	production	O
of	of	O
reactive	reactive	B-Chemical
oxygen	oxygen	B-Chemical
species	species	I-Chemical
(	(	O
ROS	ros	O
)	)	O
and	and	O
to	to	O
investigate	investigate	O
the	the	O
role	role	O
of	of	O
erdosteine	erdosteine	O
,	,	O
an	an	O
expectorant	expectorant	O
agent	agent	O
,	,	O
which	which	O
has	has	O
also	also	O
antioxidant	antioxidant	O
properties	properties	O
,	,	O
on	on	O
kidney	kidney	O
tissue	tissue	O
against	against	O
the	the	O
possible	possible	O
VCM-induced	vcm-induced	O
renal	renal	O
impairment	impairment	O
in	in	O
rats	rats	O
.	.	O

Rats	rats	O
were	were	O
divided	divided	O
into	into	O
three	three	O
groups	groups	O
:	:	O
sham	sham	O
,	,	O
VCM	vcm	O
and	and	O
VCM	vcm	O
plus	plus	O
erdosteine	erdosteine	O
.	.	O

VCM	vcm	O
was	was	O
administrated	administrated	O
intraperitoneally	intraperitoneally	O
(	(	O
i.p	i.p	O
.	.	O
)	)	O
with	with	O
200mgkg(-1	200mgkg(-1	O
)	)	O
twice	twice	O
daily	daily	O
for	for	O
7	7	O
days	days	O
.	.	O

Erdosteine	erdosteine	O
was	was	O
administered	administered	O
orally	orally	O
.	.	O

VCM	vcm	O
administration	administration	O
to	to	O
control	control	O
rats	rats	O
significantly	significantly	O
increased	increased	O
renal	renal	O
malondialdehyde	malondialdehyde	B-Chemical
(	(	O
MDA	mda	O
)	)	O
and	and	O
urinary	urinary	O
N-acetyl-beta-d-glucosaminidase	n-acetyl-beta-d-glucosaminidase	O
(	(	O
NAG	nag	O
,	,	O
a	a	O
marker	marker	O
of	of	O
renal	renal	O
tubular	tubular	O
injury	injury	O
)	)	O
excretion	excretion	O
but	but	O
decreased	decreased	O
superoxide	superoxide	B-Chemical
dismutase	dismutase	I-Chemical
(	(	O
SOD	sod	O
)	)	O
and	and	O
catalase	catalase	O
(	(	O
CAT	cat	O
)	)	O
activities	activities	O
.	.	O

Erdosteine	erdosteine	O
administration	administration	O
with	with	O
VCM	vcm	O
injections	injections	O
caused	caused	O
significantly	significantly	O
decreased	decreased	O
renal	renal	O
MDA	mda	O
and	and	O
urinary	urinary	O
NAG	nag	O
excretion	excretion	O
,	,	O
and	and	O
increased	increased	O
SOD	sod	O
activity	activity	O
,	,	O
but	but	O
not	not	O
CAT	cat	O
activity	activity	O
in	in	O
renal	renal	O
tissue	tissue	O
when	when	O
compared	compared	O
with	with	O
VCM	vcm	O
alone	alone	O
.	.	O

Erdosteine	erdosteine	O
showed	showed	O
histopathological	histopathological	O
protection	protection	O
against	against	O
VCM-induced	vcm-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

There	there	O
were	were	O
a	a	O
significant	significant	O
dilatation	dilatation	O
of	of	O
tubular	tubular	O
lumens	lumens	O
,	,	O
extensive	extensive	O
epithelial	epithelial	O
cell	cell	O
vacuolization	vacuolization	O
,	,	O
atrophy	atrophy	B-Disease
,	,	O
desquamation	desquamation	O
,	,	O
and	and	O
necrosis	necrosis	B-Disease
in	in	O
VCM-treated	vcm-treated	O
rats	rats	O
more	more	O
than	than	O
those	those	O
of	of	O
the	the	O
control	control	O
and	and	O
the	the	O
erdosteine	erdosteine	O
groups	groups	O
.	.	O

Erdosteine	erdosteine	O
caused	caused	O
a	a	O
marked	marked	O
reduction	reduction	O
in	in	O
the	the	O
extent	extent	O
of	of	O
tubular	tubular	O
damage	damage	O
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
oxidative	oxidative	O
tubular	tubular	O
damage	damage	O
plays	plays	O
an	an	O
important	important	O
role	role	O
in	in	O
the	the	O
VCM-induced	vcm-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
and	and	O
the	the	O
modulation	modulation	O
of	of	O
oxidative	oxidative	O
stress	stress	O
with	with	O
erdosteine	erdosteine	O
reduces	reduces	O
the	the	O
VCM-induced	vcm-induced	O
kidney	kidney	O
damage	damage	O
both	both	O
at	at	O
the	the	O
biochemical	biochemical	O
and	and	O
histological	histological	O
levels	levels	O
.	.	O

Gemfibrozil-lovastatin	gemfibrozil-lovastatin	O
therapy	therapy	O
for	for	O
primary	primary	O
hyperlipoproteinemias	hyperlipoproteinemias	O
.	.	O

The	the	O
specific	specific	O
aim	aim	O
of	of	O
this	this	O
retrospective	retrospective	O
,	,	O
observational	observational	O
study	study	O
was	was	O
to	to	O
assess	assess	O
safety	safety	O
and	and	O
efficacy	efficacy	O
of	of	O
long-term	long-term	O
(	(	O
21	21	O
months/patient	months/patient	O
)	)	O
,	,	O
open-label	open-label	O
,	,	O
gemfibrozil-lovastatin	gemfibrozil-lovastatin	O
treatment	treatment	O
in	in	O
80	80	O
patients	patients	O
with	with	O
primary	primary	O
mixed	mixed	O
hyperlipidemia	hyperlipidemia	O
(	(	O
68	68	O
%	%	O
of	of	O
whom	whom	O
had	had	O
atherosclerotic	atherosclerotic	B-Disease
vascular	vascular	O
disease	disease	O
)	)	O
.	.	O

Because	because	O
ideal	ideal	O
lipid	lipid	O
targets	targets	O
were	were	O
not	not	O
reached	reached	O
(	(	O
low-density	low-density	O
lipoprotein	lipoprotein	O
(	(	O
LDL	ldl	O
)	)	O
cholesterol	cholesterol	B-Chemical
less	less	O
than	than	O
130	130	O
mg/dl	mg/dl	O
,	,	O
high-density	high-density	O
lipoprotein	lipoprotein	O
(	(	O
HDL	hdl	O
)	)	O
cholesterol	cholesterol	B-Chemical
greater	greater	O
than	than	O
35	35	O
mg/dl	mg/dl	O
,	,	O
or	or	O
total	total	O
cholesterol/HDL	cholesterol/hdl	O
cholesterol	cholesterol	B-Chemical
less	less	O
than	than	O
4.5	4.5	O
mg/dl	mg/dl	O
)	)	O
with	with	O
diet	diet	O
plus	plus	O
a	a	O
single	single	O
drug	drug	O
,	,	O
gemfibrozil	gemfibrozil	O
(	(	O
1.2	1.2	O
g/day)-lovastatin	g/day)-lovastatin	O
(	(	O
primarily	primarily	O
20	20	O
or	or	O
40	40	O
mg	mg	O
)	)	O
treatment	treatment	O
was	was	O
given	given	O
.	.	O

Follow-up	follow-up	O
visits	visits	O
were	were	O
scheduled	scheduled	O
with	with	O
2-drug	2-drug	O
therapy	therapy	O
every	every	O
6	6	O
to	to	O
8	8	O
weeks	weeks	O
,	,	O
an	an	O
average	average	O
of	of	O
10.3	10.3	O
visits	visits	O
per	per	O
patient	patient	O
,	,	O
with	with	O
741	741	O
batteries	batteries	O
of	of	O
6	6	O
liver	liver	O
function	function	O
tests	tests	O
and	and	O
714	714	O
creatine	creatine	B-Chemical
phosphokinase	phosphokinase	O
levels	levels	O
measured	measured	O
.	.	O

Only	only	O
1	1	O
of	of	O
the	the	O
4,446	4,446	O
liver	liver	O
function	function	O
tests	tests	O
(	(	O
0.02	0.02	O
%	%	O
)	)	O
,	,	O
a	a	O
gamma	gamma	O
glutamyl	glutamyl	O
transferase	transferase	O
,	,	O
was	was	O
greater	greater	O
than	than	O
or	or	O
equal	equal	O
to	to	O
3	3	O
times	times	O
the	the	O
upper	upper	O
normal	normal	O
limit	limit	O
.	.	O

Of	of	O
the	the	O
714	714	O
creatine	creatine	B-Chemical
phosphokinase	phosphokinase	O
levels	levels	O
,	,	O
9	9	O
%	%	O
were	were	O
high	high	O
;	;	O
only	only	O
1	1	O
(	(	O
0.1	0.1	O
%	%	O
)	)	O
was	was	O
greater	greater	O
than	than	O
or	or	O
equal	equal	O
to	to	O
3	3	O
times	times	O
the	the	O
upper	upper	O
normal	normal	O
limit	limit	O
.	.	O

With	with	O
2-drug	2-drug	O
therapy	therapy	O
,	,	O
mean	mean	O
total	total	O
cholesterol	cholesterol	B-Chemical
decreased	decreased	O
22	22	O
%	%	O
from	from	O
255	255	O
to	to	O
200	200	O
mg/dl	mg/dl	O
,	,	O
triglyceride	triglyceride	O
levels	levels	O
decreased	decreased	O
35	35	O
%	%	O
from	from	O
236	236	O
to	to	O
154	154	O
mg/dl	mg/dl	O
,	,	O
LDL	ldl	O
cholesterol	cholesterol	B-Chemical
decreased	decreased	O
26	26	O
%	%	O
from	from	O
176	176	O
to	to	O
131	131	O
mg/dl	mg/dl	O
,	,	O
and	and	O
the	the	O
total	total	O
cholesterol/HDL	cholesterol/hdl	O
cholesterol	cholesterol	B-Chemical
ratio	ratio	O
decreased	decreased	O
24	24	O
%	%	O
from	from	O
7.1	7.1	O
to	to	O
5.4	5.4	O
,	,	O
all	all	O
p	p	O
less	less	O
than	than	O
or	or	O
equal	equal	O
to	to	O
0.0001	0.0001	O
.	.	O

Myositis	myositis	O
,	,	O
attributable	attributable	O
to	to	O
the	the	O
drug	drug	O
combination	combination	O
and	and	O
symptomatic	symptomatic	O
enough	enough	O
to	to	O
discontinue	discontinue	O
it	it	O
,	,	O
occurred	occurred	O
in	in	O
3	3	O
%	%	O
of	of	O
patients	patients	O
,	,	O
and	and	O
in	in	O
1	1	O
%	%	O
with	with	O
concurrent	concurrent	O
high	high	O
creatine	creatine	B-Chemical
phosphokinase	phosphokinase	O
(	(	O
769	769	O
U/liter	u/liter	O
)	)	O
;	;	O
no	no	O
patients	patients	O
had	had	O
rhabdomyolysis	rhabdomyolysis	B-Disease
or	or	O
myoglobinuria.(ABSTRACT	myoglobinuria.(abstract	O
TRUNCATED	truncated	O
AT	at	O
250	250	O
WORDS	words	O
)	)	O

Does	does	O
domperidone	domperidone	O
potentiate	potentiate	O
mirtazapine-associated	mirtazapine-associated	O
restless	restless	B-Disease
legs	legs	I-Disease
syndrome?There	syndrome?there	O
is	is	O
now	now	O
evidence	evidence	O
to	to	O
suggest	suggest	O
a	a	O
central	central	O
role	role	O
for	for	O
the	the	O
dopaminergic	dopaminergic	O
system	system	O
in	in	O
restless	restless	B-Disease
legs	legs	I-Disease
syndrome	syndrome	I-Disease
(	(	O
RLS	rls	O
)	)	O
.	.	O

For	for	O
example	example	O
,	,	O
the	the	O
symptoms	symptoms	O
of	of	O
RLS	rls	O
can	can	O
be	be	O
dramatically	dramatically	O
improved	improved	O
by	by	O
levodopa	levodopa	B-Chemical
and	and	O
dopamine	dopamine	B-Chemical
agonists	agonists	I-Chemical
,	,	O
whereas	whereas	O
central	central	O
dopamine	dopamine	B-Chemical
D2	d2	I-Chemical
receptor	receptor	I-Chemical
antagonists	antagonists	I-Chemical
can	can	O
induce	induce	O
or	or	O
aggravate	aggravate	O
RLS	rls	O
symptoms	symptoms	O
.	.	O

To	to	O
our	our	O
knowledge	knowledge	O
,	,	O
there	there	O
is	is	O
no	no	O
previous	previous	O
report	report	O
regarding	regarding	O
whether	whether	O
domperidone	domperidone	O
,	,	O
a	a	O
peripheral	peripheral	O
dopamine	dopamine	B-Chemical
D2	d2	O
receptor	receptor	O
antagonist	antagonist	O
,	,	O
can	can	O
also	also	O
induce	induce	O
or	or	O
aggravate	aggravate	O
symptoms	symptoms	O
of	of	O
RLS	rls	O
.	.	O

Mirtazapine	mirtazapine	O
,	,	O
the	the	O
first	first	O
noradrenergic	noradrenergic	O
and	and	O
specific	specific	O
serotonergic	serotonergic	O
antidepressant	antidepressant	B-Chemical
(	(	O
NaSSA	nassa	O
)	)	O
,	,	O
has	has	O
been	been	O
associated	associated	O
with	with	O
RLS	rls	O
in	in	O
several	several	O
recent	recent	O
publications	publications	O
.	.	O

The	the	O
authors	authors	O
report	report	O
here	here	O
a	a	O
depressed	depressed	B-Disease
patient	patient	O
comorbid	comorbid	O
with	with	O
postprandial	postprandial	O
dyspepsia	dyspepsia	O
who	who	O
developed	developed	O
RLS	rls	O
after	after	O
mirtazapine	mirtazapine	O
had	had	O
been	been	O
added	added	O
to	to	O
his	his	O
domperidone	domperidone	O
therapy	therapy	O
.	.	O

Our	our	O
patient	patient	O
started	started	O
to	to	O
have	have	O
symptoms	symptoms	O
of	of	O
RLS	rls	O
only	only	O
after	after	O
he	he	O
had	had	O
been	been	O
treated	treated	O
with	with	O
mirtazapine	mirtazapine	O
,	,	O
and	and	O
his	his	O
RLS	rls	O
symptoms	symptoms	O
resolved	resolved	O
completely	completely	O
upon	upon	O
discontinuation	discontinuation	O
of	of	O
his	his	O
mirtazapine	mirtazapine	O
.	.	O

Such	such	O
a	a	O
temporal	temporal	O
relationship	relationship	O
between	between	O
the	the	O
use	use	O
of	of	O
mirtazapine	mirtazapine	O
and	and	O
the	the	O
symptoms	symptoms	O
of	of	O
RLS	rls	O
in	in	O
our	our	O
patient	patient	O
did	did	O
not	not	O
support	support	O
a	a	O
potentiating	potentiating	O
effect	effect	O
of	of	O
domperione	domperione	O
on	on	O
mirtazapine-associated	mirtazapine-associated	O
RLS	rls	O
.	.	O

However	however	O
,	,	O
physicians	physicians	O
should	should	O
be	be	O
aware	aware	O
of	of	O
the	the	O
possibility	possibility	O
that	that	O
mirtazapine	mirtazapine	O
can	can	O
be	be	O
associated	associated	O
with	with	O
RLS	rls	O
in	in	O
some	some	O
individuals	individuals	O
,	,	O
especially	especially	O
those	those	O
receiving	receiving	O
concomitant	concomitant	O
dopamine	dopamine	B-Chemical
D2	d2	I-Chemical
receptor	receptor	I-Chemical
antagonists	antagonists	I-Chemical
.	.	O

Antiandrogenic	antiandrogenic	O
therapy	therapy	O
can	can	O
cause	cause	O
coronary	coronary	O
arterial	arterial	O
disease	disease	O
.	.	O

AIM	aim	O
:	:	O
To	to	O
study	study	O
the	the	O
change	change	O
of	of	O
lipid	lipid	O
metabolism	metabolism	O
by	by	O
antiandrogen	antiandrogen	O
therapy	therapy	O
in	in	O
patients	patients	O
with	with	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
.	.	O

MATERIALS	materials	O
AND	and	O
METHODS	methods	O
:	:	O
We	we	O
studied	studied	O
with	with	O
a	a	O
2.5	2.5	O
years	years	O
follow-up	follow-up	O
the	the	O
changes	changes	O
in	in	O
plasma	plasma	O
cholesterols	cholesterols	O
(	(	O
C	c	O
)	)	O
,	,	O
triglycerides	triglycerides	O
(	(	O
TG	tg	B-Disease
)	)	O
,	,	O
lipoproteins	lipoproteins	O
(	(	O
LP	lp	O
)	)	O
,	,	O
and	and	O
apolipoproteins	apolipoproteins	O
(	(	O
Apo	apo	O
)	)	O
B-100	b-100	O
,	,	O
A-I	a-i	O
,	,	O
and	and	O
A-II	a-ii	O
pro	pro	O
fi	fi	O
les	les	O
in	in	O
24	24	O
patients	patients	O
of	of	O
mean	mean	O
age	age	O
60	60	O
years	years	O
with	with	O
low	low	O
risk	risk	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
(	(	O
stage	stage	O
:	:	O
T1cN0M0	t1cn0m0	O
,	,	O
Gleason	gleason	O
score	score	O
:	:	O
2	2	O
-	-	O
5	5	O
)	)	O
during	during	O
treatment	treatment	O
with	with	O
cyproterone	cyproterone	B-Chemical
acetate	acetate	I-Chemical
(	(	O
CPA	cpa	B-Chemical
)	)	O
without	without	O
surgical	surgical	O
management	management	O
or	or	O
radiation	radiation	O
therapy	therapy	O
.	.	O

RESULTS	results	O
:	:	O
Significant	significant	O
decreases	decreases	O
of	of	O
HDL-C	hdl-c	O
,	,	O
Apo	apo	O
A-I	a-i	O
and	and	O
Apo	apo	O
A-II	a-ii	O
and	and	O
an	an	O
increase	increase	O
of	of	O
triglyceride	triglyceride	O
levels	levels	O
in	in	O
VLDL	vldl	O
were	were	O
induced	induced	O
by	by	O
CPA	cpa	B-Chemical
.	.	O

After	after	O
a	a	O
period	period	O
of	of	O
2.5	2.5	O
years	years	O
on	on	O
CPA	cpa	B-Chemical
treatment	treatment	O
,	,	O
four	four	O
patients	patients	O
out	out	O
of	of	O
twenty-four	twenty-four	O
were	were	O
found	found	O
to	to	O
be	be	O
affected	affected	O
by	by	O
coronary	coronary	B-Disease
heart	heart	B-Disease
disease	disease	I-Disease
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Ischaemic	ischaemic	O
coronary	coronary	B-Disease
arteriosclerosis	arteriosclerosis	I-Disease
with	with	O
an	an	O
incidence	incidence	O
rate	rate	O
of	of	O
16.6	16.6	O
%	%	O
as	as	O
caused	caused	O
by	by	O
prolonged	prolonged	O
CPA	cpa	B-Chemical
therapy	therapy	O
is	is	O
mediated	mediated	O
through	through	O
changes	changes	O
in	in	O
HDL	hdl	O
cholesterol	cholesterol	B-Chemical
,	,	O
Apo	apo	O
A-I	a-i	O
and	and	O
Apo	apo	O
A-II	a-ii	O
pro	pro	O
fi	fi	O
les	les	O
,	,	O
other	other	O
than	than	O
the	the	O
well-known	well-known	O
hyperglyceridemic	hyperglyceridemic	O
effect	effect	O
caused	caused	O
by	by	O
estrogen	estrogen	B-Chemical
.	.	O

5-Fluorouracil	5-fluorouracil	B-Chemical
cardiotoxicity	cardiotoxicity	B-Disease
induced	induced	O
by	by	O
alpha-fluoro-beta-alanine	alpha-fluoro-beta-alanine	O
.	.	O

Cardiotoxicity	cardiotoxicity	B-Disease
is	is	O
a	a	O
rare	rare	O
complication	complication	O
occurring	occurring	O
during	during	O
5-fluorouracil	5-fluorouracil	B-Chemical
(	(	O
5-FU	5-fu	B-Chemical
)	)	O
treatment	treatment	O
for	for	O
malignancies	malignancies	B-Disease
.	.	O

We	we	O
herein	herein	O
report	report	O
the	the	O
case	case	O
of	of	O
a	a	O
70-year-old	70-year-old	O
man	man	O
with	with	O
5-FU-induced	5-fu-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
,	,	O
in	in	O
whom	whom	O
a	a	O
high	high	O
serum	serum	O
level	level	O
of	of	O
alpha-fluoro-beta-alanine	alpha-fluoro-beta-alanine	O
(	(	O
FBAL	fbal	O
)	)	O
was	was	O
observed	observed	O
.	.	O

The	the	O
patient	patient	O
,	,	O
who	who	O
had	had	O
unresectable	unresectable	O
colon	colon	O
cancer	cancer	B-Disease
metastases	metastases	O
to	to	O
the	the	O
liver	liver	O
and	and	O
lung	lung	O
,	,	O
was	was	O
referred	referred	O
to	to	O
us	us	O
for	for	O
chemotherapy	chemotherapy	O
from	from	O
an	an	O
affiliated	affiliated	O
hospital	hospital	O
;	;	O
he	he	O
had	had	O
no	no	O
cardiac	cardiac	O
history	history	O
.	.	O

After	after	O
admission	admission	O
,	,	O
the	the	O
patient	patient	O
received	received	O
a	a	O
continuous	continuous	O
intravenous	intravenous	O
infusion	infusion	O
of	of	O
5-FU	5-fu	B-Chemical
(	(	O
1000	1000	O
mg/day	mg/day	O
)	)	O
,	,	O
during	during	O
which	which	O
precordial	precordial	O
pain	pain	B-Disease
with	with	O
right	right	O
bundle	bundle	O
branch	branch	O
block	block	O
occurred	occurred	O
concomitantly	concomitantly	O
with	with	O
a	a	O
high	high	O
serum	serum	O
FBAL	fbal	O
concentration	concentration	O
of	of	O
1955	1955	O
ng/ml	ng/ml	O
.	.	O

Both	both	O
the	the	O
precordial	precordial	O
pain	pain	B-Disease
and	and	O
the	the	O
electrocardiographic	electrocardiographic	O
changes	changes	O
disappeared	disappeared	O
spontaneously	spontaneously	O
after	after	O
the	the	O
discontinuation	discontinuation	O
of	of	O
5-FU	5-fu	B-Chemical
.	.	O

As	as	O
the	the	O
precordial	precordial	O
pain	pain	B-Disease
in	in	O
this	this	O
patient	patient	O
was	was	O
considered	considered	O
to	to	O
have	have	O
been	been	O
due	due	O
to	to	O
5-FU-induced	5-fu-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
,	,	O
the	the	O
administration	administration	O
of	of	O
5-FU	5-fu	B-Chemical
was	was	O
abandoned	abandoned	O
.	.	O

Instead	instead	O
,	,	O
oral	oral	O
administration	administration	O
of	of	O
S-1	s-1	O
(	(	O
a	a	O
derivative	derivative	O
of	of	O
5-FU	5-fu	B-Chemical
)	)	O
,	,	O
at	at	O
200	200	O
mg/day	mg/day	O
twice	twice	O
a	a	O
week	week	O
,	,	O
was	was	O
instituted	instituted	O
,	,	O
because	because	O
S-1	s-1	O
has	has	O
a	a	O
strong	strong	O
inhibitory	inhibitory	O
effect	effect	O
on	on	O
dihydropyrimidine	dihydropyrimidine	O
dehydrogenase	dehydrogenase	O
,	,	O
which	which	O
catalyzes	catalyzes	O
the	the	O
degradative	degradative	O
of	of	O
5-FU	5-fu	B-Chemical
into	into	O
FBAL	fbal	O
.	.	O

The	the	O
serum	serum	O
FBAL	fbal	O
concentration	concentration	O
subsequently	subsequently	O
decreased	decreased	O
to	to	O
352	352	O
ng/ml	ng/ml	O
,	,	O
the	the	O
same	same	O
as	as	O
the	the	O
value	value	O
measured	measured	O
on	on	O
the	the	O
first	first	O
day	day	O
of	of	O
S-1	s-1	O
administration	administration	O
.	.	O

Thereafter	thereafter	O
,	,	O
no	no	O
cardiac	cardiac	O
symptoms	symptoms	O
were	were	O
observed	observed	O
.	.	O

The	the	O
patient	patient	O
achieved	achieved	O
a	a	O
partial	partial	O
response	response	O
6	6	O
months	months	O
after	after	O
the	the	O
initiation	initiation	O
of	of	O
the	the	O
S-1	s-1	O
treatment	treatment	O
.	.	O

The	the	O
experience	experience	O
of	of	O
this	this	O
case	case	O
,	,	O
together	together	O
with	with	O
a	a	O
review	review	O
of	of	O
the	the	O
literature	literature	O
,	,	O
suggests	suggests	O
that	that	O
FBAL	fbal	O
is	is	O
related	related	O
to	to	O
5-FU-induced	5-fu-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

S-1	s-1	O
may	may	O
be	be	O
administered	administered	O
safely	safely	O
to	to	O
patients	patients	O
with	with	O
5-FU-induced	5-fu-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

Hepatocellular	hepatocellular	B-Disease
carcinoma	carcinoma	B-Disease
in	in	O
Fanconi	fanconi	O
's	's	O
anemia	anemia	B-Disease
treated	treated	O
with	with	O
androgen	androgen	O
and	and	O
corticosteroid	corticosteroid	O
.	.	O

The	the	O
case	case	O
of	of	O
an	an	O
11-year-old	11-year-old	O
boy	boy	O
is	is	O
reported	reported	O
who	who	O
was	was	O
known	known	O
to	to	O
have	have	O
Fanconi	fanconi	O
's	's	O
anemia	anemia	B-Disease
for	for	O
3	3	O
years	years	O
and	and	O
was	was	O
treated	treated	O
with	with	O
androgens	androgens	O
,	,	O
corticosteroids	corticosteroids	B-Chemical
and	and	O
transfusions	transfusions	O
.	.	O

Two	two	O
weeks	weeks	O
before	before	O
his	his	O
death	death	B-Disease
he	he	O
was	was	O
readmitted	readmitted	O
because	because	O
of	of	O
aplastic	aplastic	O
crisis	crisis	O
with	with	O
septicemia	septicemia	O
and	and	O
marked	marked	O
abnormalities	abnormalities	O
in	in	O
liver	liver	O
function	function	O
and	and	O
died	died	O
of	of	O
hemorrhagic	hemorrhagic	B-Disease
bronchopneumonia	bronchopneumonia	O
.	.	O

At	at	O
autopsy	autopsy	O
peliosis	peliosis	O
and	and	O
multiple	multiple	O
hepatic	hepatic	O
tumors	tumors	B-Disease
were	were	O
found	found	O
which	which	O
histologically	histologically	O
proved	proved	O
to	to	O
be	be	O
well-differentiated	well-differentiated	O
hepatocellular	hepatocellular	B-Disease
carcinoma	carcinoma	B-Disease
.	.	O

This	this	O
case	case	O
contributes	contributes	O
to	to	O
the	the	O
previous	previous	O
observations	observations	O
that	that	O
non-metastasizing	non-metastasizing	O
hepatic	hepatic	B-Disease
neoplasms	neoplasms	I-Disease
and	and	O
peliosis	peliosis	O
can	can	O
develop	develop	O
in	in	O
patients	patients	O
with	with	O
androgen-	androgen-	O
and	and	O
corticosteroid-treated	corticosteroid-treated	O
Fanconi	fanconi	O
's	's	O
anemia	anemia	B-Disease
.	.	O

The	the	O
influence	influence	O
of	of	O
the	the	O
time	time	O
interval	interval	O
between	between	O
monoHER	monoher	O
and	and	O
doxorubicin	doxorubicin	B-Chemical
administration	administration	O
on	on	O
the	the	O
protection	protection	O
against	against	O
doxorubicin-induced	doxorubicin-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
in	in	O
mice	mice	O
.	.	O

PURPOSE	purpose	O
:	:	O
Despite	despite	O
its	its	O
well-known	well-known	O
cardiotoxicity	cardiotoxicity	B-Disease
,	,	O
the	the	O
anthracyclin	anthracyclin	O
doxorubicin	doxorubicin	B-Chemical
(	(	O
DOX	dox	B-Chemical
)	)	O
continues	continues	O
to	to	O
be	be	O
an	an	O
effective	effective	O
and	and	O
widely	widely	O
used	used	O
chemotherapeutic	chemotherapeutic	O
agent	agent	O
.	.	O

DOX-induced	dox-induced	O
cardiac	cardiac	O
damage	damage	O
presumably	presumably	O
results	results	O
from	from	O
the	the	O
formation	formation	O
of	of	O
free	free	B-Chemical
radicals	radicals	I-Chemical
by	by	O
DOX	dox	B-Chemical
.	.	O

Reactive	reactive	B-Chemical
oxygen	oxygen	B-Chemical
species	species	I-Chemical
particularly	particularly	O
affect	affect	O
the	the	O
cardiac	cardiac	O
myocytes	myocytes	O
because	because	O
these	these	O
cells	cells	O
seem	seem	O
to	to	O
have	have	O
a	a	O
relatively	relatively	O
poor	poor	O
antioxidant	antioxidant	O
defense	defense	O
system	system	O
.	.	O

The	the	O
semisynthetic	semisynthetic	O
flavonoid	flavonoid	O
monohydroxyethylrutoside	monohydroxyethylrutoside	O
(	(	O
monoHER	monoher	O
)	)	O
showed	showed	O
cardioprotection	cardioprotection	O
against	against	O
DOX-induced	dox-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
through	through	O
its	its	O
radical	radical	O
scavenging	scavenging	O
and	and	O
iron	iron	B-Chemical
chelating	chelating	O
properties	properties	O
.	.	O

Because	because	O
of	of	O
the	the	O
relatively	relatively	O
short	short	O
final	final	O
half-life	half-life	O
of	of	O
monoHER	monoher	O
(	(	O
about	about	O
30	30	O
min	min	O
)	)	O
,	,	O
it	it	O
is	is	O
expected	expected	O
that	that	O
the	the	O
time	time	O
interval	interval	O
between	between	O
monoHER	monoher	O
and	and	O
DOX	dox	B-Chemical
might	might	O
be	be	O
of	of	O
influence	influence	O
on	on	O
the	the	O
cardioprotective	cardioprotective	O
effect	effect	O
of	of	O
monoHER	monoher	O
.	.	O

Therefore	therefore	O
,	,	O
the	the	O
aim	aim	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
this	this	O
possible	possible	O
effect	effect	O
.	.	O

METHODS	methods	O
:	:	O
Six	six	O
groups	groups	O
of	of	O
6	6	O
BALB/c	balb/c	O
mice	mice	O
were	were	O
treated	treated	O
with	with	O
saline	saline	O
,	,	O
DOX	dox	B-Chemical
alone	alone	O
or	or	O
DOX	dox	B-Chemical
(	(	O
4	4	O
mg/kg	mg/kg	O
i.v	i.v	O
.	.	O
)	)	O
preceded	preceded	O
by	by	O
monoHER	monoher	O
(	(	O
500	500	O
mg/kg	mg/kg	O
i.p	i.p	O
.	.	O
)	)	O
with	with	O
an	an	O
interval	interval	O
of	of	O
10	10	O
,	,	O
30	30	O
,	,	O
60	60	O
or	or	O
120	120	O
min	min	O
.	.	O

After	after	O
a	a	O
6-week	6-week	O
treatment	treatment	O
period	period	O
and	and	O
additional	additional	O
observation	observation	O
for	for	O
2	2	O
weeks	weeks	O
,	,	O
the	the	O
mice	mice	O
were	were	O
sacrificed	sacrificed	O
.	.	O

Their	their	O
cardiac	cardiac	O
tissues	tissues	O
were	were	O
processed	processed	O
for	for	O
light	light	O
microscopy	microscopy	O
,	,	O
after	after	O
which	which	O
cardiomyocyte	cardiomyocyte	O
damage	damage	O
was	was	O
evaluated	evaluated	O
according	according	O
to	to	O
Billingham	billingham	O
(	(	O
in	in	O
Cancer	cancer	B-Disease
Treat	treat	O
Rep	rep	O
62(6):865	62(6):865	O
-	-	O
872	872	O
,	,	O
1978	1978	O
)	)	O
.	.	O

Microscopic	microscopic	O
evaluation	evaluation	O
revealed	revealed	O
that	that	O
treatment	treatment	O
with	with	O
DOX	dox	B-Chemical
alone	alone	O
induced	induced	O
significant	significant	O
cardiac	cardiac	O
damage	damage	O
in	in	O
comparison	comparison	O
to	to	O
the	the	O
saline	saline	O
control	control	O
group	group	O
(	(	O
P<0.001	p<0.001	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
number	number	O
of	of	O
damaged	damaged	O
cardiomyocytes	cardiomyocytes	O
was	was	O
9.6-fold	9.6-fold	O
(	(	O
95	95	O
%	%	O
CI	ci	O
4.4	4.4	O
-	-	O
21.0	21.0	O
)	)	O
higher	higher	O
in	in	O
mice	mice	O
treated	treated	O
with	with	O
DOX	dox	B-Chemical
alone	alone	O
than	than	O
that	that	O
in	in	O
animals	animals	O
of	of	O
the	the	O
control	control	O
group	group	O
.	.	O

The	the	O
ratio	ratio	O
of	of	O
aberrant	aberrant	O
cardiomyocytes	cardiomyocytes	O
in	in	O
mice	mice	O
treated	treated	O
with	with	O
DOX	dox	B-Chemical
preceded	preceded	O
by	by	O
monoHER	monoher	O
and	and	O
those	those	O
in	in	O
mice	mice	O
treated	treated	O
with	with	O
saline	saline	O
ranged	ranged	O
from	from	O
1.6	1.6	O
to	to	O
2.8	2.8	O
(	(	O
mean	mean	O
2.2	2.2	O
,	,	O
95	95	O
%	%	O
CI	ci	O
1.2	1.2	O
-	-	O
4.1	4.1	O
,	,	O
P=0.019	p=0.019	O
)	)	O
.	.	O

The	the	O
mean	mean	O
protective	protective	O
effect	effect	O
by	by	O
adding	adding	O
monoHER	monoher	O
before	before	O
DOX	dox	B-Chemical
led	led	O
to	to	O
a	a	O
significant	significant	O
4.4-fold	4.4-fold	O
reduction	reduction	O
(	(	O
P<0.001	p<0.001	O
,	,	O
95	95	O
%	%	O
CI	ci	O
2.3	2.3	O
-	-	O
8.2	8.2	O
)	)	O
of	of	O
abnormal	abnormal	O
cardiomyocytes	cardiomyocytes	O
.	.	O

This	this	O
protective	protective	O
effect	effect	O
did	did	O
not	not	O
depend	depend	O
on	on	O
the	the	O
time	time	O
interval	interval	O
between	between	O
monoHER	monoher	O
and	and	O
DOX	dox	B-Chemical
administration	administration	O
(	(	O
P=0.345	p=0.345	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
results	results	O
indicate	indicate	O
that	that	O
in	in	O
an	an	O
outpatient	outpatient	O
clinical	clinical	O
setting	setting	O
monoHER	monoher	O
may	may	O
be	be	O
administered	administered	O
shortly	shortly	O
before	before	O
DOX	dox	B-Chemical
.	.	O

Clinical	clinical	O
evaluation	evaluation	O
of	of	O
adverse	adverse	O
effects	effects	O
during	during	O
bepridil	bepridil	B-Chemical
administration	administration	O
for	for	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
and	and	O
flutter	flutter	O
.	.	O

BACKGROUND	background	O
:	:	O
Bepridil	bepridil	B-Chemical
hydrochloride	hydrochloride	O
(	(	O
Bpd	bpd	O
)	)	O
has	has	O
attracted	attracted	O
attention	attention	O
as	as	O
an	an	O
effective	effective	O
drug	drug	O
for	for	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
(	(	O
AF	af	O
)	)	O
and	and	O
atrial	atrial	B-Disease
flutter	flutter	I-Disease
(	(	O
AFL	afl	O
)	)	O
.	.	O

However	however	O
,	,	O
serious	serious	O
adverse	adverse	O
effects	effects	O
,	,	O
including	including	O
torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
(	(	O
Tdp	tdp	B-Disease
)	)	O
,	,	O
have	have	O
been	been	O
reported	reported	O
.	.	O

METHODS	methods	O
AND	and	O
RESULTS	results	O
:	:	O
Adverse	adverse	O
effects	effects	O
of	of	O
Bpd	bpd	O
requiring	requiring	O
discontinuation	discontinuation	O
of	of	O
treatment	treatment	O
were	were	O
evaluated	evaluated	O
.	.	O

Bpd	bpd	O
was	was	O
administered	administered	O
to	to	O
459	459	O
patients	patients	O
(	(	O
361	361	O
males	males	O
,	,	O
63+/-12	63+/-12	O
years	years	O
old	old	O
)	)	O
comprising	comprising	O
378	378	O
AF	af	O
and	and	O
81	81	O
AFL	afl	O
cases	cases	O
.	.	O

Mean	mean	O
left	left	O
ventricular	ventricular	O
ejection	ejection	O
fraction	fraction	O
and	and	O
atrial	atrial	O
dimension	dimension	O
(	(	O
LAD	lad	O
)	)	O
were	were	O
66+/-11	66+/-11	O
%	%	O
and	and	O
40+/-6	40+/-6	O
mm	mm	O
,	,	O
respectively	respectively	O
.	.	O

Adverse	adverse	O
effects	effects	O
were	were	O
observed	observed	O
in	in	O
19	19	O
patients	patients	O
(	(	O
4	4	O
%	%	O
)	)	O
during	during	O
an	an	O
average	average	O
follow-up	follow-up	O
of	of	O
20	20	O
months	months	O
.	.	O

There	there	O
was	was	O
marked	marked	O
QT	qt	O
prolongation	prolongation	O
greater	greater	O
than	than	O
0.55	0.55	O
s	s	O
in	in	O
13	13	O
patients	patients	O
,	,	O
bradycardia	bradycardia	B-Disease
less	less	O
than	than	O
40	40	O
beats/min	beats/min	O
in	in	O
6	6	O
patients	patients	O
,	,	O
dizziness	dizziness	B-Disease
and	and	O
general	general	O
fatigue	fatigue	B-Disease
in	in	O
1	1	O
patient	patient	O
each	each	O
.	.	O

In	in	O
4	4	O
of	of	O
13	13	O
patients	patients	O
with	with	O
QT	qt	O
prolongation	prolongation	O
,	,	O
Tdp	tdp	B-Disease
occurred	occurred	O
.	.	O

The	the	O
major	major	O
triggering	triggering	O
factors	factors	O
of	of	O
Tdp	tdp	B-Disease
were	were	O
hypokalemia	hypokalemia	O
and	and	O
sudden	sudden	O
decrease	decrease	O
in	in	O
heart	heart	O
rate	rate	O
.	.	O

There	there	O
were	were	O
no	no	O
differences	differences	O
in	in	O
the	the	O
clinical	clinical	O
backgrounds	backgrounds	O
of	of	O
the	the	O
patients	patients	O
with	with	O
and	and	O
without	without	O
Tdp	tdp	B-Disease
other	other	O
than	than	O
LAD	lad	O
and	and	O
age	age	O
,	,	O
which	which	O
were	were	O
larger	larger	O
and	and	O
older	older	O
in	in	O
the	the	O
patients	patients	O
with	with	O
Tdp	tdp	B-Disease
.	.	O

CONCLUSION	conclusion	O
:	:	O
Careful	careful	O
observation	observation	O
of	of	O
serum	serum	O
potassium	potassium	B-Chemical
concentration	concentration	O
and	and	O
the	the	O
ECG	ecg	O
should	should	O
always	always	O
be	be	O
done	done	O
during	during	O
Bpd	bpd	O
administration	administration	O
,	,	O
particularly	particularly	O
in	in	O
elderly	elderly	O
patients	patients	O
.	.	O

Enhanced	enhanced	O
isoproterenol-induced	isoproterenol-induced	O
cardiac	cardiac	B-Disease
hypertrophy	hypertrophy	B-Disease
in	in	O
transgenic	transgenic	O
rats	rats	O
with	with	O
low	low	O
brain	brain	O
angiotensinogen	angiotensinogen	O
.	.	O

We	we	O
have	have	O
previously	previously	O
shown	shown	O
that	that	O
a	a	O
permanent	permanent	O
deficiency	deficiency	O
in	in	O
the	the	O
brain	brain	O
renin-angiotensin	renin-angiotensin	O
system	system	O
(	(	O
RAS	ras	O
)	)	O
may	may	O
increase	increase	O
the	the	O
sensitivity	sensitivity	O
of	of	O
the	the	O
baroreflex	baroreflex	O
control	control	O
of	of	O
heart	heart	O
rate	rate	O
.	.	O

In	in	O
this	this	O
study	study	O
we	we	O
aimed	aimed	O
at	at	O
studying	studying	O
the	the	O
involvement	involvement	O
of	of	O
the	the	O
brain	brain	O
RAS	ras	O
in	in	O
the	the	O
cardiac	cardiac	O
reactivity	reactivity	O
to	to	O
the	the	O
beta-adrenoceptor	beta-adrenoceptor	O
(	(	O
beta-AR	beta-ar	O
)	)	O
agonist	agonist	O
isoproterenol	isoproterenol	B-Chemical
(	(	O
Iso	iso	B-Chemical
)	)	O
.	.	O

Transgenic	transgenic	O
rats	rats	O
with	with	O
low	low	O
brain	brain	O
angiotensinogen	angiotensinogen	O
(	(	O
TGR	tgr	O
)	)	O
were	were	O
used	used	O
.	.	O

In	in	O
isolated	isolated	O
hearts	hearts	O
,	,	O
Iso	iso	B-Chemical
induced	induced	O
a	a	O
significantly	significantly	O
greater	greater	O
increase	increase	O
in	in	O
left	left	O
ventricular	ventricular	O
(	(	O
LV	lv	O
)	)	O
pressure	pressure	O
and	and	O
maximal	maximal	O
contraction	contraction	O
(	(	O
+	+	O
dP/dt(max	dp/dt(max	O
)	)	O
)	)	O
in	in	O
the	the	O
TGR	tgr	O
than	than	O
in	in	O
the	the	O
Sprague-Dawley	sprague-dawley	O
(	(	O
SD	sd	O
)	)	O
rats	rats	O
.	.	O

LV	lv	O
hypertrophy	hypertrophy	B-Disease
induced	induced	O
by	by	O
Iso	iso	B-Chemical
treatment	treatment	O
was	was	O
significantly	significantly	O
higher	higher	O
in	in	O
TGR	tgr	O
than	than	O
in	in	O
SD	sd	O
rats	rats	O
(	(	O
in	in	O
g	g	O
LV	lv	O
wt/100	wt/100	O
g	g	O
body	body	O
wt	wt	O
,	,	O
0.28	0.28	O
+	+	O
/-	/-	O
0.004	0.004	O
vs.	vs.	O
0.24	0.24	O
+	+	O
/-	/-	O
0.004	0.004	O
,	,	O
respectively	respectively	O
)	)	O
.	.	O

The	the	O
greater	greater	O
LV	lv	O
hypertrophy	hypertrophy	B-Disease
in	in	O
TGR	tgr	O
rats	rats	O
was	was	O
associated	associated	O
with	with	O
more	more	O
pronounced	pronounced	O
downregulation	downregulation	O
of	of	O
beta-AR	beta-ar	O
and	and	O
upregulation	upregulation	O
of	of	O
LV	lv	O
beta-AR	beta-ar	O
kinase-1	kinase-1	O
mRNA	mrna	O
levels	levels	O
compared	compared	O
with	with	O
those	those	O
in	in	O
SD	sd	O
rats	rats	O
.	.	O

The	the	O
decrease	decrease	O
in	in	O
the	the	O
heart	heart	O
rate	rate	O
(	(	O
HR	hr	O
)	)	O
induced	induced	O
by	by	O
the	the	O
beta-AR	beta-ar	O
antagonist	antagonist	O
metoprolol	metoprolol	B-Chemical
in	in	O
conscious	conscious	O
rats	rats	O
was	was	O
significantly	significantly	O
attenuated	attenuated	O
in	in	O
TGR	tgr	O
compared	compared	O
with	with	O
SD	sd	O
rats	rats	O
(	(	O
-9.9	-9.9	O
+	+	O
/-	/-	O
1.7	1.7	O
%	%	O
vs.	vs.	O
-18.1	-18.1	O
+	+	O
/-	/-	O
1.5	1.5	O
%	%	O
)	)	O
,	,	O
whereas	whereas	O
the	the	O
effect	effect	O
of	of	O
parasympathetic	parasympathetic	O
blockade	blockade	O
by	by	O
atropine	atropine	B-Chemical
on	on	O
HR	hr	O
was	was	O
similar	similar	O
in	in	O
both	both	O
strains	strains	O
.	.	O

These	these	O
results	results	O
indicate	indicate	O
that	that	O
TGR	tgr	O
are	are	O
more	more	O
sensitive	sensitive	O
to	to	O
beta-AR	beta-ar	O
agonist-induced	agonist-induced	O
cardiac	cardiac	O
inotropic	inotropic	O
response	response	O
and	and	O
hypertrophy	hypertrophy	B-Disease
,	,	O
possibly	possibly	O
due	due	O
to	to	O
chronically	chronically	O
low	low	O
sympathetic	sympathetic	O
outflow	outflow	O
directed	directed	O
to	to	O
the	the	O
heart	heart	O
.	.	O

Drug-induced	drug-induced	O
long	long	B-Disease
QT	qt	I-Disease
syndrome	syndrome	I-Disease
in	in	O
injection	injection	O
drug	drug	O
users	users	O
receiving	receiving	O
methadone	methadone	B-Chemical
:	:	O
high	high	O
frequency	frequency	O
in	in	O
hospitalized	hospitalized	O
patients	patients	O
and	and	O
risk	risk	O
factors	factors	O
.	.	O

BACKGROUND	background	O
:	:	O
Drug-induced	drug-induced	O
long	long	B-Disease
QT	qt	I-Disease
syndrome	syndrome	I-Disease
is	is	O
a	a	O
serious	serious	O
adverse	adverse	O
drug	drug	O
reaction	reaction	O
.	.	O

Methadone	methadone	B-Chemical
prolongs	prolongs	O
the	the	O
QT	qt	O
interval	interval	O
in	in	O
vitro	vitro	O
in	in	O
a	a	O
dose-dependent	dose-dependent	O
manner	manner	O
.	.	O

In	in	O
the	the	O
inpatient	inpatient	O
setting	setting	O
,	,	O
the	the	O
frequency	frequency	O
of	of	O
QT	qt	O
interval	interval	O
prolongation	prolongation	O
with	with	O
methadone	methadone	B-Chemical
treatment	treatment	O
,	,	O
its	its	O
dose	dose	O
dependence	dependence	O
,	,	O
and	and	O
the	the	O
importance	importance	O
of	of	O
cofactors	cofactors	O
such	such	O
as	as	O
drug-drug	drug-drug	O
interactions	interactions	O
remain	remain	O
unknown	unknown	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
performed	performed	O
a	a	O
systematic	systematic	O
,	,	O
retrospective	retrospective	O
study	study	O
comparing	comparing	O
active	active	O
or	or	O
former	former	O
intravenous	intravenous	O
drug	drug	O
users	users	O
receiving	receiving	O
methadone	methadone	B-Chemical
and	and	O
those	those	O
not	not	O
receiving	receiving	O
methadone	methadone	B-Chemical
among	among	O
all	all	O
patients	patients	O
hospitalized	hospitalized	O
over	over	O
a	a	O
5-year	5-year	O
period	period	O
in	in	O
a	a	O
tertiary	tertiary	O
care	care	O
hospital	hospital	O
.	.	O

A	a	O
total	total	O
of	of	O
167	167	O
patients	patients	O
receiving	receiving	O
methadone	methadone	B-Chemical
fulfilled	fulfilled	O
the	the	O
inclusion	inclusion	O
criteria	criteria	O
and	and	O
were	were	O
compared	compared	O
with	with	O
a	a	O
control	control	O
group	group	O
of	of	O
80	80	O
injection	injection	O
drug	drug	O
users	users	O
not	not	O
receiving	receiving	O
methadone	methadone	B-Chemical
.	.	O

In	in	O
addition	addition	O
to	to	O
methadone	methadone	B-Chemical
dose	dose	O
,	,	O
15	15	O
demographic	demographic	O
,	,	O
biological	biological	O
,	,	O
and	and	O
pharmacological	pharmacological	O
variables	variables	O
were	were	O
considered	considered	O
as	as	O
potential	potential	O
risk	risk	O
factors	factors	O
for	for	O
QT	qt	O
prolongation	prolongation	O
.	.	O

RESULTS	results	O
:	:	O
Among	among	O
167	167	O
methadone	methadone	B-Chemical
maintenance	maintenance	O
patients	patients	O
,	,	O
the	the	O
prevalence	prevalence	O
of	of	O
QTc	qtc	O
prolongation	prolongation	O
to	to	O
0.50	0.50	O
second((1/2	second((1/2	O
)	)	O
)	)	O
or	or	O
longer	longer	O
was	was	O
16.2	16.2	O
%	%	O
compared	compared	O
with	with	O
0	0	O
%	%	O
in	in	O
80	80	O
control	control	O
subjects	subjects	O
.	.	O

Six	six	O
patients	patients	O
(	(	O
3.6	3.6	O
%	%	O
)	)	O
in	in	O
the	the	O
methadone	methadone	B-Chemical
group	group	O
presented	presented	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
.	.	O

QTc	qtc	O
length	length	O
was	was	O
weakly	weakly	O
but	but	O
significantly	significantly	O
associated	associated	O
with	with	O
methadone	methadone	B-Chemical
daily	daily	O
dose	dose	O
(	(	O
Spearman	spearman	O
rank	rank	O
correlation	correlation	O
coefficient	coefficient	O
,	,	O
0.20	0.20	O
;	;	O
P<.01	p<.01	O
)	)	O
.	.	O

Multivariate	multivariate	O
regression	regression	O
analysis	analysis	O
allowed	allowed	O
attribution	attribution	O
of	of	O
31.8	31.8	O
%	%	O
of	of	O
QTc	qtc	O
variability	variability	O
to	to	O
methadone	methadone	B-Chemical
dose	dose	O
,	,	O
cytochrome	cytochrome	O
P-450	p-450	O
3A4	3a4	O
drug-drug	drug-drug	O
interactions	interactions	O
,	,	O
hypokalemia	hypokalemia	O
,	,	O
and	and	O
altered	altered	O
liver	liver	O
function	function	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
QT	qt	O
interval	interval	O
prolongation	prolongation	O
in	in	O
methadone	methadone	B-Chemical
maintenance	maintenance	O
patients	patients	O
hospitalized	hospitalized	O
in	in	O
a	a	O
tertiary	tertiary	O
care	care	O
center	center	O
is	is	O
a	a	O
frequent	frequent	O
finding	finding	O
.	.	O

Methadone	methadone	B-Chemical
dose	dose	O
,	,	O
presence	presence	O
of	of	O
cytochrome	cytochrome	O
P-450	p-450	O
3A4	3a4	O
inhibitors	inhibitors	O
,	,	O
potassium	potassium	B-Chemical
level	level	O
,	,	O
and	and	O
liver	liver	O
function	function	O
contribute	contribute	O
to	to	O
QT	qt	O
prolongation	prolongation	O
.	.	O

Long	long	B-Disease
QT	qt	I-Disease
syndrome	syndrome	I-Disease
can	can	O
occur	occur	O
with	with	O
low	low	O
doses	doses	O
of	of	O
methadone	methadone	B-Chemical
.	.	O

Mechanisms	mechanisms	O
of	of	O
hypertension	hypertension	B-Disease
induced	induced	O
by	by	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
(	(	O
NO	no	O
)	)	O
deficiency	deficiency	O
:	:	O
focus	focus	O
on	on	O
venous	venous	O
function	function	O
.	.	O

Loss	loss	O
of	of	O
endothelial	endothelial	O
cell-derived	cell-derived	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
(	(	O
NO	no	O
)	)	O
in	in	O
hypertension	hypertension	B-Disease
is	is	O
a	a	O
hallmark	hallmark	O
of	of	O
arterial	arterial	O
dysfunction	dysfunction	O
.	.	O

Experimental	experimental	O
hypertension	hypertension	B-Disease
created	created	O
by	by	O
the	the	O
removal	removal	O
of	of	O
NO	no	O
,	,	O
however	however	O
,	,	O
involves	involves	O
mechanisms	mechanisms	O
in	in	O
addition	addition	O
to	to	O
decreased	decreased	O
arterial	arterial	O
vasodilator	vasodilator	O
activity	activity	O
.	.	O

These	these	O
include	include	O
augmented	augmented	O
endothelin-1	endothelin-1	O
(	(	O
ET-1	et-1	O
)	)	O
release	release	O
,	,	O
increased	increased	O
sympathetic	sympathetic	O
nervous	nervous	O
system	system	O
activity	activity	O
,	,	O
and	and	O
elevated	elevated	O
tissue	tissue	O
oxidative	oxidative	O
stress	stress	O
.	.	O

We	we	O
hypothesized	hypothesized	O
that	that	O
increased	increased	O
venous	venous	O
smooth	smooth	O
muscle	muscle	O
(	(	O
venomotor	venomotor	O
)	)	O
tone	tone	O
plays	plays	O
a	a	O
role	role	O
in	in	O
Nomega-nitro-L-arginine	nomega-nitro-l-arginine	O
(	(	O
LNNA	lnna	O
)	)	O
hypertension	hypertension	B-Disease
through	through	O
these	these	O
mechanisms	mechanisms	O
.	.	O

Rats	rats	O
were	were	O
treated	treated	O
with	with	O
the	the	O
NO	no	O
synthase	synthase	O
inhibitor	inhibitor	O
LNNA	lnna	O
(	(	O
0.5	0.5	O
g/L	g/l	O
in	in	O
drinking	drinking	B-Chemical
water	water	I-Chemical
)	)	O
for	for	O
2	2	O
weeks	weeks	O
.	.	O

Mean	mean	O
arterial	arterial	O
pressure	pressure	O
of	of	O
conscious	conscious	O
rats	rats	O
was	was	O
119	119	O
+	+	O
/-	/-	O
2	2	O
mm	mm	O
Hg	hg	O
in	in	O
control	control	O
and	and	O
194	194	O
+	+	O
/-	/-	O
5	5	O
mm	mm	O
Hg	hg	O
in	in	O
LNNA	lnna	O
rats	rats	O
(	(	O
P<0.05	p<0.05	O
)	)	O
.	.	O

Carotid	carotid	O
arteries	arteries	O
and	and	O
vena	vena	O
cava	cava	O
were	were	O
removed	removed	O
for	for	O
measurement	measurement	O
of	of	O
isometric	isometric	O
contraction	contraction	O
.	.	O

Maximal	maximal	O
contraction	contraction	O
to	to	O
norepinephrine	norepinephrine	B-Chemical
was	was	O
modestly	modestly	O
reduced	reduced	O
in	in	O
arteries	arteries	O
from	from	O
LNNA	lnna	O
compared	compared	O
with	with	O
control	control	O
rats	rats	O
whereas	whereas	O
the	the	O
maximum	maximum	O
contraction	contraction	O
to	to	O
ET-1	et-1	O
was	was	O
significantly	significantly	O
reduced	reduced	O
(	(	O
54	54	O
%	%	O
control	control	O
)	)	O
.	.	O

Maximum	maximum	O
contraction	contraction	O
of	of	O
vena	vena	O
cava	cava	O
to	to	O
norepinephrine	norepinephrine	B-Chemical
(	(	O
37	37	O
%	%	O
control	control	O
)	)	O
also	also	O
was	was	O
reduced	reduced	O
but	but	O
no	no	O
change	change	O
in	in	O
response	response	O
to	to	O
ET-1	et-1	O
was	was	O
observed	observed	O
.	.	O

Mean	mean	O
circulatory	circulatory	O
filling	filling	O
pressure	pressure	O
,	,	O
an	an	O
in	in	O
vivo	vivo	O
measure	measure	O
of	of	O
venomotor	venomotor	O
tone	tone	O
,	,	O
was	was	O
not	not	O
elevated	elevated	O
in	in	O
LNNA	lnna	O
hypertension	hypertension	B-Disease
at	at	O
1	1	O
or	or	O
2	2	O
weeks	weeks	O
after	after	O
LNNA	lnna	O
.	.	O

The	the	O
superoxide	superoxide	B-Chemical
scavenger	scavenger	O
tempol	tempol	O
(	(	O
30	30	O
,	,	O
100	100	O
,	,	O
and	and	O
300	300	O
micromol	micromol	O
kg(-1	kg(-1	O
)	)	O
,	,	O
IV	iv	O
)	)	O
did	did	O
not	not	O
change	change	O
arterial	arterial	O
pressure	pressure	O
in	in	O
control	control	O
rats	rats	O
but	but	O
caused	caused	O
a	a	O
dose-dependent	dose-dependent	O
decrease	decrease	O
in	in	O
LNNA	lnna	O
rats	rats	O
(	(	O
-18	-18	O
+	+	O
/-	/-	O
8	8	O
,	,	O
-26	-26	O
+	+	O
/-	/-	O
15	15	O
,	,	O
and	and	O
-54	-54	O
+	+	O
/-	/-	O
11	11	O
mm	mm	O
Hg	hg	O
)	)	O
.	.	O

Similarly	similarly	O
,	,	O
ganglionic	ganglionic	O
blockade	blockade	O
with	with	O
hexamethonium	hexamethonium	B-Chemical
caused	caused	O
a	a	O
significantly	significantly	O
greater	greater	O
fall	fall	O
in	in	O
LNNA	lnna	O
hypertensive	hypertensive	B-Disease
rats	rats	O
(	(	O
76	76	O
+	+	O
/-	/-	O
9	9	O
mm	mm	O
Hg	hg	O
)	)	O
compared	compared	O
with	with	O
control	control	O
rats	rats	O
(	(	O
35	35	O
+	+	O
/-	/-	O
10	10	O
mm	mm	O
Hg	hg	O
)	)	O
.	.	O

Carotid	carotid	O
arteries	arteries	O
,	,	O
vena	vena	O
cava	cava	O
,	,	O
and	and	O
sympathetic	sympathetic	O
ganglia	ganglia	O
from	from	O
LNNA	lnna	O
rats	rats	O
had	had	O
higher	higher	O
basal	basal	O
levels	levels	O
of	of	O
superoxide	superoxide	B-Chemical
compared	compared	O
with	with	O
those	those	O
from	from	O
control	control	O
rats	rats	O
.	.	O

These	these	O
data	data	O
suggest	suggest	O
that	that	O
while	while	O
NO	no	O
deficiency	deficiency	O
increases	increases	O
oxidative	oxidative	O
stress	stress	O
and	and	O
sympathetic	sympathetic	O
activity	activity	O
in	in	O
both	both	O
arterial	arterial	O
and	and	O
venous	venous	O
vessels	vessels	O
,	,	O
the	the	O
impact	impact	O
on	on	O
veins	veins	O
does	does	O
not	not	O
make	make	O
a	a	O
major	major	O
contribution	contribution	O
to	to	O
this	this	O
form	form	O
of	of	O
hypertension	hypertension	B-Disease
.	.	O

Association	association	O
of	of	O
DRD2	drd2	O
polymorphisms	polymorphisms	O
and	and	O
chlorpromazine-induced	chlorpromazine-induced	O
extrapyramidal	extrapyramidal	O
syndrome	syndrome	O
in	in	O
Chinese	chinese	O
schizophrenic	schizophrenic	B-Disease
patients	patients	O
.	.	O

AIM	aim	O
:	:	O
Extrapyramidal	extrapyramidal	O
syndrome	syndrome	O
(	(	O
EPS	eps	B-Disease
)	)	O
is	is	O
most	most	O
commonly	commonly	O
affected	affected	O
by	by	O
typical	typical	O
antipsychotic	antipsychotic	B-Chemical
drugs	drugs	I-Chemical
that	that	O
have	have	O
a	a	O
high	high	O
affinity	affinity	O
with	with	O
the	the	O
D2	d2	O
receptor	receptor	O
.	.	O

Recently	recently	O
,	,	O
many	many	O
research	research	O
groups	groups	O
have	have	O
reported	reported	O
on	on	O
the	the	O
positive	positive	O
relationship	relationship	O
between	between	O
the	the	O
genetic	genetic	O
variations	variations	O
in	in	O
the	the	O
DRD2	drd2	O
gene	gene	O
and	and	O
the	the	O
therapeutic	therapeutic	O
response	response	O
in	in	O
schizophrenia	schizophrenia	B-Disease
patients	patients	O
as	as	O
a	a	O
result	result	O
of	of	O
the	the	O
role	role	O
of	of	O
variations	variations	O
in	in	O
the	the	O
receptor	receptor	O
in	in	O
modulating	modulating	O
receptor	receptor	O
expression	expression	O
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
we	we	O
evaluate	evaluate	O
the	the	O
role	role	O
DRD2	drd2	O
plays	plays	O
in	in	O
chlorpromazine-induced	chlorpromazine-induced	O
EPS	eps	B-Disease
in	in	O
schizophrenic	schizophrenic	B-Disease
patients	patients	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
identified	identified	O
seven	seven	O
SNP(single	snp(single	O
nucleotide	nucleotide	O
polymorphism	polymorphism	O
)	)	O
(	(	O
-141Cins	-141cins	O
>	>	O
del	del	O
,	,	O
TaqIB	taqib	O
,	,	O
TaqID	taqid	O
,	,	O
Ser311Cys	ser311cys	O
,	,	O
rs6275	rs6275	O
,	,	O
rs6277	rs6277	O
and	and	O
TaqIA	taqia	O
)	)	O
in	in	O
the	the	O
DRD2	drd2	O
gene	gene	O
in	in	O
146	146	O
schizophrenic	schizophrenic	B-Disease
inpatients	inpatients	O
(	(	O
59	59	O
with	with	O
EPS	eps	B-Disease
and	and	O
87	87	O
without	without	O
EPS	eps	B-Disease
according	according	O
to	to	O
the	the	O
Simpson-Angus	simpson-angus	O
Scale	scale	O
)	)	O
treated	treated	O
with	with	O
chlorpromazine	chlorpromazine	B-Chemical
after	after	O
8	8	O
weeks	weeks	O
.	.	O

The	the	O
alleles	alleles	O
of	of	O
all	all	O
loci	loci	O
were	were	O
determined	determined	O
by	by	O
PCR	pcr	O
(	(	O
polymerase	polymerase	O
chain	chain	O
reaction	reaction	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
Polymorphisms	polymorphisms	O
TaqID	taqid	O
,	,	O
Ser311Cys	ser311cys	O
and	and	O
rs6277	rs6277	O
were	were	O
not	not	O
polymorphic	polymorphic	O
in	in	O
the	the	O
population	population	O
recruited	recruited	O
in	in	O
the	the	O
present	present	O
study	study	O
.	.	O

No	no	O
statistical	statistical	O
significance	significance	O
was	was	O
found	found	O
in	in	O
the	the	O
allele	allele	O
distribution	distribution	O
of	of	O
-141Cins	-141cins	O
>	>	O
del	del	O
,	,	O
TaqIB	taqib	O
,	,	O
rs6275	rs6275	O
and	and	O
TaqIA	taqia	O
or	or	O
in	in	O
the	the	O
estimated	estimated	O
haplotypes	haplotypes	O
(	(	O
constituted	constituted	O
by	by	O
TaqIB	taqib	O
,	,	O
rs6275	rs6275	O
and	and	O
TaqIA	taqia	O
)	)	O
in	in	O
linkage	linkage	O
disequilibrium	disequilibrium	O
between	between	O
the	the	O
two	two	O
groups	groups	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Our	our	O
results	results	O
did	did	O
not	not	O
lend	lend	O
strong	strong	O
support	support	O
to	to	O
the	the	O
view	view	O
that	that	O
the	the	O
genetic	genetic	O
variation	variation	O
of	of	O
the	the	O
DRD2	drd2	O
gene	gene	O
plays	plays	O
a	a	O
major	major	O
role	role	O
in	in	O
the	the	O
individually	individually	O
variable	variable	O
adverse	adverse	O
effect	effect	O
induced	induced	O
by	by	O
chlorpromazine	chlorpromazine	B-Chemical
,	,	O
at	at	O
least	least	O
in	in	O
Chinese	chinese	O
patients	patients	O
with	with	O
schizophrenia	schizophrenia	B-Disease
.	.	O

Our	our	O
results	results	O
confirmed	confirmed	O
a	a	O
previous	previous	O
study	study	O
on	on	O
the	the	O
relationship	relationship	O
between	between	O
DRD2	drd2	O
and	and	O
EPS	eps	B-Disease
in	in	O
Caucasians	caucasians	O
.	.	O

Physical	physical	O
training	training	O
decreases	decreases	O
susceptibility	susceptibility	O
to	to	O
subsequent	subsequent	O
pilocarpine-induced	pilocarpine-induced	O
seizures	seizures	B-Disease
in	in	O
the	the	O
rat	rat	O
.	.	O

Regular	regular	O
motor	motor	O
activity	activity	O
has	has	O
many	many	O
benefits	benefits	O
for	for	O
mental	mental	O
and	and	O
physical	physical	O
condition	condition	O
but	but	O
its	its	O
implications	implications	O
for	for	O
epilepsy	epilepsy	B-Disease
are	are	O
still	still	O
controversial	controversial	O
.	.	O

In	in	O
order	order	O
to	to	O
elucidate	elucidate	O
this	this	O
problem	problem	O
,	,	O
we	we	O
have	have	O
studied	studied	O
the	the	O
effect	effect	O
of	of	O
long-term	long-term	O
physical	physical	O
activity	activity	O
on	on	O
susceptibility	susceptibility	O
to	to	O
subsequent	subsequent	O
seizures	seizures	B-Disease
.	.	O

Male	male	O
Wistar	wistar	O
rats	rats	O
were	were	O
subjected	subjected	O
to	to	O
repeated	repeated	O
training	training	O
sessions	sessions	O
in	in	O
a	a	O
treadmill	treadmill	O
and	and	O
swimming	swimming	O
pool	pool	O
.	.	O

Thereafter	thereafter	O
,	,	O
seizures	seizures	B-Disease
were	were	O
induced	induced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
injections	injections	O
in	in	O
trained	trained	O
and	and	O
non-trained	non-trained	O
control	control	O
groups	groups	O
.	.	O

During	during	O
the	the	O
acute	acute	O
period	period	O
of	of	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
,	,	O
we	we	O
measured	measured	O
:	:	O
(	(	O
1	1	O
)	)	O
the	the	O
latency	latency	O
of	of	O
the	the	O
first	first	O
motor	motor	O
sign	sign	O
,	,	O
(	(	O
2	2	O
)	)	O
the	the	O
intensity	intensity	O
of	of	O
seizures	seizures	B-Disease
,	,	O
(	(	O
3	3	O
)	)	O
the	the	O
time	time	O
when	when	O
it	it	O
occurred	occurred	O
within	within	O
the	the	O
6-h	6-h	O
observation	observation	O
period	period	O
,	,	O
and	and	O
(	(	O
4	4	O
)	)	O
the	the	O
time	time	O
when	when	O
the	the	O
acute	acute	O
period	period	O
ended	ended	O
.	.	O

All	all	O
these	these	O
behavioral	behavioral	O
parameters	parameters	O
showed	showed	O
statistically	statistically	O
significant	significant	O
changes	changes	O
suggesting	suggesting	O
that	that	O
regular	regular	O
physical	physical	O
exercises	exercises	O
decrease	decrease	O
susceptibility	susceptibility	O
to	to	O
subsequently	subsequently	O
induced	induced	O
seizures	seizures	B-Disease
and	and	O
ameliorate	ameliorate	O
the	the	O
course	course	O
of	of	O
experimentally	experimentally	O
induced	induced	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
.	.	O

Tonic	tonic	O
dopaminergic	dopaminergic	O
stimulation	stimulation	O
impairs	impairs	O
associative	associative	O
learning	learning	O
in	in	O
healthy	healthy	O
subjects	subjects	O
.	.	O

Endogenous	endogenous	O
dopamine	dopamine	B-Chemical
plays	plays	O
a	a	O
central	central	O
role	role	O
in	in	O
salience	salience	O
coding	coding	O
during	during	O
associative	associative	O
learning	learning	O
.	.	O

Administration	administration	O
of	of	O
the	the	O
dopamine	dopamine	B-Chemical
precursor	precursor	O
levodopa	levodopa	B-Chemical
enhances	enhances	O
learning	learning	O
in	in	O
healthy	healthy	O
subjects	subjects	O
and	and	O
stroke	stroke	B-Disease
patients	patients	O
.	.	O

Because	because	O
levodopa	levodopa	B-Chemical
increases	increases	O
both	both	O
phasic	phasic	O
and	and	O
tonic	tonic	O
dopaminergic	dopaminergic	O
neurotransmission	neurotransmission	O
,	,	O
the	the	O
critical	critical	O
mechanism	mechanism	O
mediating	mediating	O
the	the	O
enhancement	enhancement	O
of	of	O
learning	learning	O
is	is	O
unresolved	unresolved	O
.	.	O

We	we	O
here	here	O
probed	probed	O
how	how	O
selective	selective	O
tonic	tonic	O
dopaminergic	dopaminergic	O
stimulation	stimulation	O
affects	affects	O
associative	associative	O
learning	learning	O
.	.	O

Forty	forty	O
healthy	healthy	O
subjects	subjects	O
were	were	O
trained	trained	O
in	in	O
a	a	O
novel	novel	O
vocabulary	vocabulary	O
of	of	O
45	45	O
concrete	concrete	O
nouns	nouns	O
over	over	O
the	the	O
course	course	O
of	of	O
5	5	O
consecutive	consecutive	O
training	training	O
days	days	O
in	in	O
a	a	O
prospective	prospective	O
,	,	O
randomized	randomized	O
,	,	O
double-blind	double-blind	O
,	,	O
placebo-controlled	placebo-controlled	O
design	design	O
.	.	O

Subjects	subjects	O
received	received	O
the	the	O
tonically	tonically	O
stimulating	stimulating	O
dopamine-receptor	dopamine-receptor	O
agonist	agonist	O
pergolide	pergolide	B-Chemical
(	(	O
0.1	0.1	O
mg	mg	O
)	)	O
vs	vs	O
placebo	placebo	O
120	120	O
min	min	O
before	before	O
training	training	O
on	on	O
each	each	O
training	training	O
day	day	O
.	.	O

The	the	O
dopamine	dopamine	B-Chemical
agonist	agonist	I-Chemical
significantly	significantly	O
impaired	impaired	O
novel	novel	O
word	word	O
learning	learning	O
compared	compared	O
to	to	O
placebo	placebo	O
.	.	O

This	this	O
learning	learning	O
decrement	decrement	O
persisted	persisted	O
up	up	O
to	to	O
the	the	O
last	last	O
follow-up	follow-up	O
4	4	O
weeks	weeks	O
post-training	post-training	O
.	.	O

Subjects	subjects	O
treated	treated	O
with	with	O
pergolide	pergolide	B-Chemical
also	also	O
showed	showed	O
restricted	restricted	O
emotional	emotional	O
responses	responses	O
compared	compared	O
to	to	O
the	the	O
PLACEBO	placebo	O
group	group	O
.	.	O

The	the	O
extent	extent	O
of	of	O
'	'	O
flattened	flattened	O
'	'	O
affect	affect	O
with	with	O
pergolide	pergolide	B-Chemical
was	was	O
related	related	O
to	to	O
the	the	O
degree	degree	O
of	of	O
learning	learning	O
inhibition	inhibition	O
.	.	O

These	these	O
findings	findings	O
suggest	suggest	O
that	that	O
tonic	tonic	O
occupation	occupation	O
of	of	O
dopamine	dopamine	B-Chemical
receptors	receptors	O
impairs	impairs	O
learning	learning	O
by	by	O
competition	competition	O
with	with	O
phasic	phasic	O
dopamine	dopamine	B-Chemical
signals	signals	O
.	.	O

Thus	thus	O
,	,	O
phasic	phasic	O
signaling	signaling	O
seems	seems	O
to	to	O
be	be	O
the	the	O
critical	critical	O
mechanism	mechanism	O
by	by	O
which	which	O
dopamine	dopamine	B-Chemical
enhances	enhances	O
associative	associative	O
learning	learning	O
in	in	O
healthy	healthy	O
subjects	subjects	O
and	and	O
stroke	stroke	B-Disease
patients	patients	O
.	.	O

Minocycline-induced	minocycline-induced	O
vasculitis	vasculitis	B-Disease
fulfilling	fulfilling	O
the	the	O
criteria	criteria	O
of	of	O
polyarteritis	polyarteritis	B-Disease
nodosa	nodosa	I-Disease
.	.	O

A	a	O
47-year-old	47-year-old	O
man	man	O
who	who	O
had	had	O
been	been	O
taking	taking	O
minocycline	minocycline	O
for	for	O
palmoplantar	palmoplantar	O
pustulosis	pustulosis	O
developed	developed	O
fever	fever	B-Disease
,	,	O
myalgias	myalgias	O
,	,	O
polyneuropathy	polyneuropathy	B-Disease
,	,	O
and	and	O
testicular	testicular	O
pain	pain	B-Disease
,	,	O
with	with	O
elevated	elevated	O
C-reactive	c-reactive	O
protein	protein	O
(	(	O
CRP	crp	O
)	)	O
.	.	O

Neither	neither	O
myeloperoxidase-	myeloperoxidase-	O
nor	nor	O
proteinase-3-antineutrophil	proteinase-3-antineutrophil	O
cytoplasmic	cytoplasmic	O
antibody	antibody	O
was	was	O
positive	positive	O
.	.	O

These	these	O
manifestations	manifestations	O
met	met	O
the	the	O
American	american	O
College	college	O
of	of	O
Rheumatology	rheumatology	O
1990	1990	O
criteria	criteria	O
for	for	O
the	the	O
classification	classification	O
of	of	O
polyarteritis	polyarteritis	B-Disease
nodosa	nodosa	I-Disease
.	.	O

Stopping	stopping	O
minocycline	minocycline	O
led	led	O
to	to	O
amelioration	amelioration	O
of	of	O
symptoms	symptoms	O
and	and	O
normalization	normalization	O
of	of	O
CRP	crp	O
level	level	O
.	.	O

To	to	O
our	our	O
knowledge	knowledge	O
,	,	O
this	this	O
is	is	O
the	the	O
second	second	O
case	case	O
of	of	O
minocycline-induced	minocycline-induced	O
vasculitis	vasculitis	B-Disease
satisfying	satisfying	O
the	the	O
criteria	criteria	O
.	.	O

Differential	differential	O
diagnosis	diagnosis	O
for	for	O
drug-induced	drug-induced	O
disease	disease	O
is	is	O
invaluable	invaluable	O
even	even	O
for	for	O
patients	patients	O
with	with	O
classical	classical	O
polyarteritis	polyarteritis	B-Disease
nodosa	nodosa	I-Disease
.	.	O

Intramuscular	intramuscular	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
immune	immune	O
globulin	globulin	O
combined	combined	O
with	with	O
lamivudine	lamivudine	B-Chemical
in	in	O
prevention	prevention	O
of	of	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
recurrence	recurrence	O
after	after	O
liver	liver	O
transplantation	transplantation	O
.	.	O

BACKGROUND	background	O
:	:	O
Combined	combined	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
immune	immune	O
globulin	globulin	O
(	(	O
HBIg	hbig	O
)	)	O
and	and	O
lamivudine	lamivudine	B-Chemical
in	in	O
prophylaxis	prophylaxis	O
of	of	O
the	the	O
recurrence	recurrence	O
of	of	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
after	after	O
liver	liver	O
transplantation	transplantation	O
has	has	O
significantly	significantly	O
improved	improved	O
the	the	O
survival	survival	O
of	of	O
HBsAg	hbsag	B-Chemical
positive	positive	O
patients	patients	O
.	.	O

This	this	O
study	study	O
was	was	O
undertaken	undertaken	O
to	to	O
evaluate	evaluate	O
the	the	O
outcomes	outcomes	O
of	of	O
liver	liver	O
transplantation	transplantation	O
for	for	O
patients	patients	O
with	with	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
virus	virus	O
(	(	O
HBV	hbv	O
)	)	O
.	.	O

METHODS	methods	O
:	:	O
A	a	O
retrospective	retrospective	O
chart	chart	O
analysis	analysis	O
and	and	O
a	a	O
review	review	O
of	of	O
the	the	O
organ	organ	O
transplant	transplant	O
database	database	O
identified	identified	O
51	51	O
patients	patients	O
(	(	O
43	43	O
men	men	O
and	and	O
8	8	O
women	women	O
)	)	O
transplanted	transplanted	O
for	for	O
benign	benign	O
HBV-related	hbv-related	O
cirrhotic	cirrhotic	O
diseases	diseases	O
between	between	O
June	june	O
2002	2002	O
and	and	O
December	december	O
2004	2004	O
who	who	O
had	had	O
survived	survived	O
more	more	O
than	than	O
3	3	O
months	months	O
.	.	O

HBIg	hbig	O
was	was	O
administered	administered	O
intravenously	intravenously	O
during	during	O
the	the	O
first	first	O
week	week	O
and	and	O
intramuscularly	intramuscularly	O
thereafter	thereafter	O
.	.	O

RESULTS	results	O
:	:	O
At	at	O
a	a	O
median	median	O
follow-up	follow-up	O
of	of	O
14.1	14.1	O
months	months	O
,	,	O
the	the	O
overall	overall	O
recurrence	recurrence	O
rate	rate	O
in	in	O
the	the	O
51	51	O
patients	patients	O
was	was	O
3.9	3.9	O
%	%	O
(	(	O
2/51	2/51	O
)	)	O
.	.	O

The	the	O
overall	overall	O
patient	patient	O
survival	survival	O
was	was	O
88.3	88.3	O
%	%	O
,	,	O
and	and	O
82.4	82.4	O
%	%	O
after	after	O
1	1	O
and	and	O
2	2	O
years	years	O
,	,	O
respectively	respectively	O
.	.	O

A	a	O
daily	daily	O
oral	oral	O
dose	dose	O
of	of	O
100	100	O
mg	mg	O
lamivudine	lamivudine	B-Chemical
for	for	O
2	2	O
weeks	weeks	O
before	before	O
transplantation	transplantation	O
for	for	O
10	10	O
patients	patients	O
enabled	enabled	O
57.1	57.1	O
%	%	O
(	(	O
4/7	4/7	O
)	)	O
and	and	O
62.5	62.5	O
%	%	O
(	(	O
5/8	5/8	O
)	)	O
of	of	O
HBV-DNA	hbv-dna	O
and	and	O
HBeAg	hbeag	B-Chemical
positive	positive	O
patients	patients	O
respectively	respectively	O
to	to	O
convert	convert	O
to	to	O
be	be	O
negative	negative	O
.	.	O

Intramuscular	intramuscular	O
HBIg	hbig	O
was	was	O
well	well	O
tolerated	tolerated	O
in	in	O
all	all	O
patients	patients	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Lamivudine	lamivudine	B-Chemical
combined	combined	O
with	with	O
intramuscular	intramuscular	O
HBIg	hbig	O
can	can	O
effectively	effectively	O
prevent	prevent	O
allograft	allograft	O
from	from	O
the	the	O
recurrence	recurrence	O
of	of	O
HBV	hbv	O
after	after	O
liver	liver	O
transplantation	transplantation	O
.	.	O

Anticonvulsant	anticonvulsant	O
effect	effect	O
of	of	O
eslicarbazepine	eslicarbazepine	B-Chemical
acetate	acetate	I-Chemical
(	(	O
BIA	bia	O
2	2	O
-	-	O
093	093	O
)	)	O
on	on	O
seizures	seizures	B-Disease
induced	induced	O
by	by	O
microperfusion	microperfusion	O
of	of	O
picrotoxin	picrotoxin	B-Chemical
in	in	O
the	the	O
hippocampus	hippocampus	O
of	of	O
freely	freely	O
moving	moving	O
rats	rats	O
.	.	O

Eslicarbazepine	eslicarbazepine	B-Chemical
acetate	acetate	I-Chemical
(	(	O
BIA	bia	O
2	2	O
-	-	O
093	093	O
,	,	O
S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b	s-(-)-10-acetoxy-10,11-dihydro-5h-dibenzo/b	O
,	,	O
f/azepine-5-carboxamide	f/azepine-5-carboxamide	O
)	)	O
is	is	O
a	a	O
novel	novel	O
antiepileptic	antiepileptic	O
drug	drug	O
,	,	O
now	now	O
in	in	O
Phase	phase	O
III	iii	O
clinical	clinical	O
trials	trials	O
,	,	O
designed	designed	O
with	with	O
the	the	O
aim	aim	O
of	of	O
improving	improving	O
efficacy	efficacy	O
and	and	O
safety	safety	O
in	in	O
comparison	comparison	O
with	with	O
the	the	O
structurally	structurally	O
related	related	O
drugs	drugs	O
carbamazepine	carbamazepine	B-Chemical
(	(	O
CBZ	cbz	B-Chemical
)	)	O
and	and	O
oxcarbazepine	oxcarbazepine	O
(	(	O
OXC	oxc	O
)	)	O
.	.	O

We	we	O
have	have	O
studied	studied	O
the	the	O
effects	effects	O
of	of	O
oral	oral	O
treatment	treatment	O
with	with	O
eslicarbazepine	eslicarbazepine	B-Chemical
acetate	acetate	I-Chemical
on	on	O
a	a	O
whole-animal	whole-animal	O
model	model	O
in	in	O
which	which	O
partial	partial	O
seizures	seizures	B-Disease
can	can	O
be	be	O
elicited	elicited	O
repeatedly	repeatedly	O
on	on	O
different	different	O
days	days	O
without	without	O
changes	changes	O
in	in	O
threshold	threshold	O
or	or	O
seizure	seizure	B-Disease
patterns	patterns	O
.	.	O

In	in	O
the	the	O
animals	animals	O
treated	treated	O
with	with	O
threshold	threshold	O
doses	doses	O
of	of	O
picrotoxin	picrotoxin	B-Chemical
,	,	O
the	the	O
average	average	O
number	number	O
of	of	O
seizures	seizures	B-Disease
was	was	O
2.3+/-1.2	2.3+/-1.2	O
,	,	O
and	and	O
average	average	O
seizure	seizure	B-Disease
duration	duration	O
was	was	O
39.5+/-8.4s	39.5+/-8.4s	O
.	.	O
Pre-treatment	pre-treatment	O
with	with	O
a	a	O
dose	dose	O
of	of	O
30	30	O
mg/kg	mg/kg	O
2h	2h	O
before	before	O
picrotoxin	picrotoxin	B-Chemical
microperfusion	microperfusion	O
prevented	prevented	O
seizures	seizures	B-Disease
in	in	O
the	the	O
75	75	O
%	%	O
of	of	O
the	the	O
rats	rats	O
.	.	O

Lower	lower	O
doses	doses	O
(	(	O
3	3	O
and	and	O
10mg/kg	10mg/kg	O
)	)	O
did	did	O
not	not	O
suppress	suppress	O
seizures	seizures	B-Disease
,	,	O
however	however	O
,	,	O
after	after	O
administration	administration	O
of	of	O
10mg/kg	10mg/kg	O
,	,	O
significant	significant	O
reductions	reductions	O
in	in	O
seizures	seizures	B-Disease
duration	duration	O
(	(	O
24.3+/-6.8s	24.3+/-6.8s	O
)	)	O
and	and	O
seizure	seizure	B-Disease
number	number	O
(	(	O
1.6+/-0.34	1.6+/-0.34	O
)	)	O
were	were	O
found	found	O
.	.	O

No	no	O
adverse	adverse	O
effects	effects	O
of	of	O
eslicarbazepine	eslicarbazepine	B-Chemical
acetate	acetate	I-Chemical
were	were	O
observed	observed	O
in	in	O
the	the	O
behavioral/EEG	behavioral/eeg	O
patterns	patterns	O
studied	studied	O
,	,	O
including	including	O
sleep/wakefulness	sleep/wakefulness	O
cycle	cycle	O
,	,	O
at	at	O
the	the	O
doses	doses	O
studied	studied	O
.	.	O

Acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
associated	associated	O
with	with	O
prolonged	prolonged	O
intake	intake	O
of	of	O
slimming	slimming	O
pills	pills	O
containing	containing	O
anthraquinones	anthraquinones	O
.	.	O

Chinese	chinese	O
herbal	herbal	O
medicine	medicine	O
preparations	preparations	O
are	are	O
widely	widely	O
available	available	O
and	and	O
often	often	O
regarded	regarded	O
by	by	O
the	the	O
public	public	O
as	as	O
natural	natural	O
and	and	O
safe	safe	O
remedies	remedies	O
for	for	O
a	a	O
variety	variety	O
of	of	O
medical	medical	O
conditions	conditions	O
.	.	O

Nephropathy	nephropathy	B-Disease
caused	caused	O
by	by	O
Chinese	chinese	O
herbs	herbs	O
has	has	O
previously	previously	O
been	been	O
reported	reported	O
,	,	O
usually	usually	O
involving	involving	O
the	the	O
use	use	O
of	of	O
aristolochic	aristolochic	B-Chemical
acids	acids	I-Chemical
.	.	O

We	we	O
report	report	O
a	a	O
23-year-old	23-year-old	O
woman	woman	O
who	who	O
developed	developed	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
following	following	O
prolonged	prolonged	O
use	use	O
of	of	O
a	a	O
proprietary	proprietary	O
Chinese	chinese	O
herbal	herbal	O
slimming	slimming	O
pill	pill	O
that	that	O
contained	contained	O
anthraquinone	anthraquinone	O
derivatives	derivatives	O
,	,	O
extracted	extracted	O
from	from	O
Rhizoma	rhizoma	O
Rhei	rhei	O
(	(	O
rhubarb	rhubarb	O
)	)	O
.	.	O

The	the	O
renal	renal	B-Disease
injury	injury	I-Disease
was	was	O
probably	probably	O
aggravated	aggravated	O
by	by	O
the	the	O
concomitant	concomitant	O
intake	intake	O
of	of	O
a	a	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drug	drug	O
,	,	O
diclofenac	diclofenac	B-Chemical
.	.	O

Renal	renal	O
pathology	pathology	O
was	was	O
that	that	O
of	of	O
hypocellular	hypocellular	O
interstitial	interstitial	O
fibrosis	fibrosis	B-Disease
.	.	O

Spontaneous	spontaneous	O
renal	renal	O
recovery	recovery	O
occurred	occurred	O
upon	upon	O
cessation	cessation	O
of	of	O
the	the	O
slimming	slimming	O
pills	pills	O
,	,	O
but	but	O
mild	mild	O
interstitial	interstitial	O
fibrosis	fibrosis	B-Disease
and	and	O
tubular	tubular	O
atrophy	atrophy	B-Disease
was	was	O
still	still	O
evident	evident	O
histologically	histologically	O
4	4	O
months	months	O
later	later	O
.	.	O

Although	although	O
a	a	O
causal	causal	O
relationship	relationship	O
between	between	O
the	the	O
use	use	O
of	of	O
an	an	O
anthraquinone-containing	anthraquinone-containing	O
herbal	herbal	O
agent	agent	O
and	and	O
renal	renal	B-Disease
injury	injury	I-Disease
remains	remains	O
to	to	O
be	be	O
proven	proven	O
,	,	O
phytotherapy-associated	phytotherapy-associated	O
interstitial	interstitial	O
nephropathy	nephropathy	B-Disease
should	should	O
be	be	O
considered	considered	O
in	in	O
patients	patients	O
who	who	O
present	present	O
with	with	O
unexplained	unexplained	O
renal	renal	B-Disease
failure	failure	I-Disease
.	.	O

Chloroacetaldehyde	chloroacetaldehyde	O
as	as	O
a	a	O
sulfhydryl	sulfhydryl	O
reagent	reagent	O
:	:	O
the	the	O
role	role	O
of	of	O
critical	critical	O
thiol	thiol	O
groups	groups	O
in	in	O
ifosfamide	ifosfamide	B-Chemical
nephropathy	nephropathy	B-Disease
.	.	O

Chloroacetaldehyde	chloroacetaldehyde	O
(	(	O
CAA	caa	B-Disease
)	)	O
is	is	O
a	a	O
metabolite	metabolite	O
of	of	O
the	the	O
alkylating	alkylating	O
agent	agent	O
ifosfamide	ifosfamide	B-Chemical
(	(	O
IFO	ifo	O
)	)	O
and	and	O
putatively	putatively	O
responsible	responsible	O
for	for	O
renal	renal	B-Disease
damage	damage	I-Disease
following	following	O
anti-tumor	anti-tumor	O
therapy	therapy	O
with	with	O
IFO	ifo	O
.	.	O

Depletion	depletion	O
of	of	O
sulfhydryl	sulfhydryl	O
(	(	O
SH	sh	O
)	)	O
groups	groups	O
has	has	O
been	been	O
reported	reported	O
from	from	O
cell	cell	O
culture	culture	O
,	,	O
animal	animal	O
and	and	O
clinical	clinical	O
studies	studies	O
.	.	O

In	in	O
this	this	O
work	work	O
the	the	O
effect	effect	O
of	of	O
CAA	caa	B-Disease
on	on	O
human	human	O
proximal	proximal	O
tubule	tubule	O
cells	cells	O
in	in	O
primary	primary	O
culture	culture	O
(	(	O
hRPTEC	hrptec	O
)	)	O
was	was	O
investigated	investigated	O
.	.	O

Toxicity	toxicity	B-Disease
of	of	O
CAA	caa	B-Disease
was	was	O
determined	determined	O
by	by	O
protein	protein	O
content	content	O
,	,	O
cell	cell	O
number	number	O
,	,	O
LDH	ldh	O
release	release	O
,	,	O
trypan	trypan	B-Chemical
blue	blue	I-Chemical
exclusion	exclusion	O
assay	assay	O
and	and	O
caspase-3	caspase-3	O
activity	activity	O
.	.	O

Free	free	O
thiols	thiols	O
were	were	O
measured	measured	O
by	by	O
the	the	O
method	method	O
of	of	O
Ellman	ellman	O
.	.	O

CAA	caa	B-Disease
reduced	reduced	O
hRPTEC	hrptec	O
cell	cell	O
number	number	O
and	and	O
protein	protein	O
,	,	O
induced	induced	O
a	a	O
loss	loss	O
in	in	O
free	free	O
intracellular	intracellular	O
thiols	thiols	O
and	and	O
an	an	O
increase	increase	O
in	in	O
necrosis	necrosis	B-Disease
markers	markers	O
.	.	O

CAA	caa	B-Disease
but	but	O
not	not	O
acrolein	acrolein	O
inhibited	inhibited	O
the	the	O
cysteine	cysteine	B-Chemical
proteases	proteases	I-Chemical
caspase-3	caspase-3	O
,	,	O
caspase-8	caspase-8	O
and	and	O
cathepsin	cathepsin	O
B.	b.	O
Caspase	caspase	O
activation	activation	O
by	by	O
cisplatin	cisplatin	B-Chemical
was	was	O
inhibited	inhibited	O
by	by	O
CAA	caa	B-Disease
.	.	O

In	in	O
cells	cells	O
stained	stained	O
with	with	O
fluorescent	fluorescent	B-Chemical
dyes	dyes	I-Chemical
targeting	targeting	O
lysosomes	lysosomes	O
,	,	O
CAA	caa	B-Disease
induced	induced	O
an	an	O
increase	increase	O
in	in	O
lysosomal	lysosomal	O
size	size	O
and	and	O
lysosomal	lysosomal	O
leakage	leakage	O
.	.	O

The	the	O
effects	effects	O
of	of	O
CAA	caa	B-Disease
on	on	O
cysteine	cysteine	O
protease	protease	O
activities	activities	O
and	and	O
thiols	thiols	O
could	could	O
be	be	O
reproduced	reproduced	O
in	in	O
cell	cell	O
lysate	lysate	O
.	.	O

Acidification	acidification	O
,	,	O
which	which	O
slowed	slowed	O
the	the	O
reaction	reaction	O
of	of	O
CAA	caa	B-Disease
with	with	O
thiol	thiol	O
donors	donors	O
,	,	O
could	could	O
also	also	O
attenuate	attenuate	O
effects	effects	O
of	of	O
CAA	caa	B-Disease
on	on	O
necrosis	necrosis	B-Disease
markers	markers	O
,	,	O
thiol	thiol	O
depletion	depletion	O
and	and	O
cysteine	cysteine	O
protease	protease	O
inhibition	inhibition	O
in	in	O
living	living	O
cells	cells	O
.	.	O

Thus	thus	O
,	,	O
CAA	caa	B-Disease
directly	directly	O
reacts	reacts	O
with	with	O
cellular	cellular	O
protein	protein	O
and	and	O
non-protein	non-protein	O
thiols	thiols	O
,	,	O
mediating	mediating	O
its	its	O
toxicity	toxicity	B-Disease
on	on	O
hRPTEC	hrptec	O
.	.	O

This	this	O
effect	effect	O
can	can	O
be	be	O
reduced	reduced	O
by	by	O
acidification	acidification	O
.	.	O

Therefore	therefore	O
,	,	O
urinary	urinary	O
acidification	acidification	O
could	could	O
be	be	O
an	an	O
option	option	O
to	to	O
prevent	prevent	O
IFO	ifo	O
nephropathy	nephropathy	B-Disease
in	in	O
patients	patients	O
.	.	O

Stereological	stereological	O
methods	methods	O
reveal	reveal	O
the	the	O
robust	robust	O
size	size	O
and	and	O
stability	stability	O
of	of	O
ectopic	ectopic	O
hilar	hilar	O
granule	granule	O
cells	cells	O
after	after	O
pilocarpine-induced	pilocarpine-induced	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
in	in	O
the	the	O
adult	adult	O
rat	rat	O
.	.	O

Following	following	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
in	in	O
the	the	O
rat	rat	O
,	,	O
dentate	dentate	O
granule	granule	O
cell	cell	O
neurogenesis	neurogenesis	O
increases	increases	O
greatly	greatly	O
,	,	O
and	and	O
many	many	O
of	of	O
the	the	O
new	new	O
neurons	neurons	O
appear	appear	O
to	to	O
develop	develop	O
ectopically	ectopically	O
,	,	O
in	in	O
the	the	O
hilar	hilar	O
region	region	O
of	of	O
the	the	O
hippocampal	hippocampal	O
formation	formation	O
.	.	O

It	it	O
has	has	O
been	been	O
suggested	suggested	O
that	that	O
the	the	O
ectopic	ectopic	O
hilar	hilar	O
granule	granule	O
cells	cells	O
could	could	O
contribute	contribute	O
to	to	O
the	the	O
spontaneous	spontaneous	O
seizures	seizures	B-Disease
that	that	O
ultimately	ultimately	O
develop	develop	O
after	after	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
.	.	O

However	however	O
,	,	O
the	the	O
population	population	O
has	has	O
never	never	O
been	been	O
quantified	quantified	O
,	,	O
so	so	O
it	it	O
is	is	O
unclear	unclear	O
whether	whether	O
it	it	O
is	is	O
substantial	substantial	O
enough	enough	O
to	to	O
have	have	O
a	a	O
strong	strong	O
influence	influence	O
on	on	O
epileptogenesis	epileptogenesis	O
.	.	O

To	to	O
quantify	quantify	O
this	this	O
population	population	O
,	,	O
the	the	O
total	total	O
number	number	O
of	of	O
ectopic	ectopic	O
hilar	hilar	O
granule	granule	O
cells	cells	O
was	was	O
estimated	estimated	O
using	using	O
unbiased	unbiased	O
stereology	stereology	O
at	at	O
different	different	O
times	times	O
after	after	O
pilocarpine-induced	pilocarpine-induced	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
.	.	O

The	the	O
number	number	O
of	of	O
hilar	hilar	O
neurons	neurons	O
immunoreactive	immunoreactive	O
for	for	O
Prox-1	prox-1	O
,	,	O
a	a	O
granule-cell-specific	granule-cell-specific	O
marker	marker	O
,	,	O
was	was	O
estimated	estimated	O
using	using	O
the	the	O
optical	optical	O
fractionator	fractionator	O
method	method	O
.	.	O

The	the	O
results	results	O
indicate	indicate	O
that	that	O
the	the	O
size	size	O
of	of	O
the	the	O
hilar	hilar	O
ectopic	ectopic	O
granule	granule	O
cell	cell	O
population	population	O
after	after	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
is	is	O
substantial	substantial	O
,	,	O
and	and	O
stable	stable	O
over	over	O
time	time	O
.	.	O

Interestingly	interestingly	O
,	,	O
the	the	O
size	size	O
of	of	O
the	the	O
population	population	O
appears	appears	O
to	to	O
be	be	O
correlated	correlated	O
with	with	O
the	the	O
frequency	frequency	O
of	of	O
behavioral	behavioral	O
seizures	seizures	B-Disease
,	,	O
because	because	O
animals	animals	O
with	with	O
more	more	O
ectopic	ectopic	O
granule	granule	O
cells	cells	O
in	in	O
the	the	O
hilus	hilus	O
have	have	O
more	more	O
frequent	frequent	O
behavioral	behavioral	O
seizures	seizures	B-Disease
.	.	O

The	the	O
hilar	hilar	O
ectopic	ectopic	O
granule	granule	O
cell	cell	O
population	population	O
does	does	O
not	not	O
appear	appear	O
to	to	O
vary	vary	O
systematically	systematically	O
across	across	O
the	the	O
septotemporal	septotemporal	O
axis	axis	O
,	,	O
although	although	O
it	it	O
is	is	O
associated	associated	O
with	with	O
an	an	O
increase	increase	O
in	in	O
volume	volume	O
of	of	O
the	the	O
hilus	hilus	O
.	.	O

The	the	O
results	results	O
provide	provide	O
new	new	O
insight	insight	O
into	into	O
the	the	O
potential	potential	O
role	role	O
of	of	O
ectopic	ectopic	O
hilar	hilar	O
granule	granule	O
cells	cells	O
in	in	O
the	the	O
pilocarpine	pilocarpine	B-Chemical
model	model	O
of	of	O
temporal	temporal	B-Disease
lobe	lobe	I-Disease
epilepsy	epilepsy	B-Disease
.	.	O

A	a	O
prospective	prospective	O
,	,	O
open-label	open-label	O
trial	trial	O
of	of	O
galantamine	galantamine	O
in	in	O
autistic	autistic	B-Disease
disorder	disorder	I-Disease
.	.	O

OBJECTIVE	objective	O
:	:	O
Post-mortem	post-mortem	O
studies	studies	O
have	have	O
reported	reported	O
abnormalities	abnormalities	O
of	of	O
the	the	O
cholinergic	cholinergic	O
system	system	O
in	in	O
autism	autism	B-Disease
.	.	O

The	the	O
purpose	purpose	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
assess	assess	O
the	the	O
use	use	O
of	of	O
galantamine	galantamine	O
,	,	O
an	an	O
acetylcholinesterase	acetylcholinesterase	O
inhibitor	inhibitor	O
and	and	O
nicotinic	nicotinic	O
receptor	receptor	O
modulator	modulator	O
,	,	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
interfering	interfering	O
behaviors	behaviors	O
in	in	O
children	children	O
with	with	O
autism	autism	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Thirteen	thirteen	O
medication-free	medication-free	O
children	children	O
with	with	O
autism	autism	B-Disease
(	(	O
mean	mean	O
age	age	O
,	,	O
8.8	8.8	O
+	+	O
/-	/-	O
3.5	3.5	O
years	years	O
)	)	O
participated	participated	O
in	in	O
a	a	O
12-week	12-week	O
,	,	O
open-label	open-label	O
trial	trial	O
of	of	O
galantamine	galantamine	O
.	.	O

Patients	patients	O
were	were	O
rated	rated	O
monthly	monthly	O
by	by	O
parents	parents	O
on	on	O
the	the	O
Aberrant	aberrant	O
Behavior	behavior	O
Checklist	checklist	O
(	(	O
ABC	abc	O
)	)	O
and	and	O
the	the	O
Conners	conners	O
'	'	O
Parent	parent	O
Rating	rating	O
Scale-Revised	scale-revised	O
,	,	O
and	and	O
by	by	O
a	a	O
physician	physician	O
using	using	O
the	the	O
Children	children	O
's	's	O
Psychiatric	psychiatric	B-Disease
Rating	rating	O
Scale	scale	O
and	and	O
the	the	O
Clinical	clinical	O
Global	global	O
Impressions	impressions	O
scale	scale	O
.	.	O

RESULTS	results	O
:	:	O
Patients	patients	O
showed	showed	O
a	a	O
significant	significant	O
reduction	reduction	O
in	in	O
parent-rated	parent-rated	O
irritability	irritability	B-Disease
and	and	O
social	social	O
withdrawal	withdrawal	O
on	on	O
the	the	O
ABC	abc	O
as	as	O
well	well	O
as	as	O
significant	significant	O
improvements	improvements	O
in	in	O
emotional	emotional	O
lability	lability	O
and	and	O
inattention	inattention	O
on	on	O
the	the	O
Conners	conners	O
'	'	O
Parent	parent	O
Rating	rating	O
Scale	scale	O
--	--	O
Revised	revised	O
.	.	O

Similarly	similarly	O
,	,	O
clinician	clinician	O
ratings	ratings	O
showed	showed	O
reductions	reductions	O
in	in	O
the	the	O
anger	anger	O
subscale	subscale	O
of	of	O
the	the	O
Children	children	O
's	's	O
Psychiatric	psychiatric	B-Disease
Rating	rating	O
Scale	scale	O
.	.	O

Eight	eight	O
of	of	O
13	13	O
participants	participants	O
were	were	O
rated	rated	O
as	as	O
responders	responders	O
on	on	O
the	the	O
basis	basis	O
of	of	O
their	their	O
improvement	improvement	O
scores	scores	O
on	on	O
the	the	O
Clinical	clinical	O
Global	global	O
Impressions	impressions	O
scale	scale	O
.	.	O

Overall	overall	O
,	,	O
galantamine	galantamine	O
was	was	O
well-tolerated	well-tolerated	O
,	,	O
with	with	O
no	no	O
significant	significant	O
adverse	adverse	O
effects	effects	O
apart	apart	O
from	from	O
headaches	headaches	O
in	in	O
one	one	O
patient	patient	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
In	in	O
this	this	O
open	open	O
trial	trial	O
,	,	O
galantamine	galantamine	O
was	was	O
well-tolerated	well-tolerated	O
and	and	O
appeared	appeared	O
to	to	O
be	be	O
beneficial	beneficial	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
interfering	interfering	O
behaviors	behaviors	O
in	in	O
children	children	O
with	with	O
autism	autism	B-Disease
,	,	O
particularly	particularly	O
aggression	aggression	B-Disease
,	,	O
behavioral	behavioral	O
dyscontrol	dyscontrol	O
,	,	O
and	and	O
inattention	inattention	O
.	.	O

Further	further	O
controlled	controlled	O
trials	trials	O
are	are	O
warranted	warranted	O
.	.	O

Randomized	randomized	O
comparison	comparison	O
of	of	O
olanzapine	olanzapine	B-Chemical
versus	versus	O
risperidone	risperidone	B-Chemical
for	for	O
the	the	O
treatment	treatment	O
of	of	O
first-episode	first-episode	O
schizophrenia	schizophrenia	B-Disease
:	:	O
4-month	4-month	O
outcomes	outcomes	O
.	.	O

OBJECTIVE	objective	O
:	:	O
The	the	O
authors	authors	O
compared	compared	O
4-month	4-month	O
treatment	treatment	O
outcomes	outcomes	O
for	for	O
olanzapine	olanzapine	B-Chemical
versus	versus	O
risperidone	risperidone	B-Chemical
in	in	O
patients	patients	O
with	with	O
first-episode	first-episode	O
schizophrenia	schizophrenia	B-Disease
spectrum	spectrum	O
disorders	disorders	O
.	.	O

METHOD	method	O
:	:	O
One	one	O
hundred	hundred	O
twelve	twelve	O
subjects	subjects	O
(	(	O
70	70	O
%	%	O
male	male	O
;	;	O
mean	mean	O
age=23.3	age=23.3	O
years	years	O
[	[	O
SD	sd	O
=	=	O
5.1	5.1	O
]	]	O
)	)	O
with	with	O
first-episode	first-episode	O
schizophrenia	schizophrenia	B-Disease
(	(	O
75	75	O
%	%	O
)	)	O
,	,	O
schizophreniform	schizophreniform	B-Disease
disorder	disorder	I-Disease
(	(	O
17	17	O
%	%	O
)	)	O
,	,	O
or	or	O
schizoaffective	schizoaffective	B-Disease
disorder	disorder	I-Disease
(	(	O
8	8	O
%	%	O
)	)	O
were	were	O
randomly	randomly	O
assigned	assigned	O
to	to	O
treatment	treatment	O
with	with	O
olanzapine	olanzapine	B-Chemical
(	(	O
2.5	2.5	O
-	-	O
20	20	O
mg/day	mg/day	O
)	)	O
or	or	O
risperidone	risperidone	B-Chemical
(	(	O
1	1	O
-	-	O
6	6	O
mg/day	mg/day	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
Response	response	O
rates	rates	O
did	did	O
not	not	O
significantly	significantly	O
differ	differ	O
between	between	O
olanzapine	olanzapine	B-Chemical
(	(	O
43.7	43.7	O
%	%	O
,	,	O
95	95	O
%	%	O
CI=28.8%-58.6	ci=28.8%-58.6	O
%	%	O
)	)	O
and	and	O
risperidone	risperidone	B-Chemical
(	(	O
54.3	54.3	O
%	%	O
,	,	O
95	95	O
%	%	O
CI=39.9%-68.7	ci=39.9%-68.7	O
%	%	O
)	)	O
.	.	O

Among	among	O
those	those	O
responding	responding	O
to	to	O
treatment	treatment	O
,	,	O
more	more	O
subjects	subjects	O
in	in	O
the	the	O
olanzapine	olanzapine	B-Chemical
group	group	O
(	(	O
40.9	40.9	O
%	%	O
,	,	O
95	95	O
%	%	O
CI=16.8%-65.0	ci=16.8%-65.0	O
%	%	O
)	)	O
than	than	O
in	in	O
the	the	O
risperidone	risperidone	B-Chemical
group	group	O
(	(	O
18.9	18.9	O
%	%	O
,	,	O
95	95	O
%	%	O
CI=0%-39.2	ci=0%-39.2	O
%	%	O
)	)	O
had	had	O
subsequent	subsequent	O
ratings	ratings	O
not	not	O
meeting	meeting	O
response	response	O
criteria	criteria	O
.	.	O

Negative	negative	O
symptom	symptom	O
outcomes	outcomes	O
and	and	O
measures	measures	O
of	of	O
parkinsonism	parkinsonism	B-Disease
and	and	O
akathisia	akathisia	B-Disease
did	did	O
not	not	O
differ	differ	O
between	between	O
medications	medications	O
.	.	O

Extrapyramidal	extrapyramidal	O
symptom	symptom	O
severity	severity	O
scores	scores	O
were	were	O
1.4	1.4	O
(	(	O
95	95	O
%	%	O
CI=1.2	ci=1.2	O
-	-	O
1.6	1.6	O
)	)	O
with	with	O
risperidone	risperidone	B-Chemical
and	and	O
1.2	1.2	O
(	(	O
95	95	O
%	%	O
CI=1.0	ci=1.0	O
-	-	O
1.4	1.4	O
)	)	O
with	with	O
olanzapine	olanzapine	B-Chemical
.	.	O

Significantly	significantly	O
more	more	O
weight	weight	B-Disease
gain	gain	I-Disease
occurred	occurred	O
with	with	O
olanzapine	olanzapine	B-Chemical
than	than	O
with	with	O
risperidone	risperidone	B-Chemical
:	:	O
the	the	O
increase	increase	O
in	in	O
weight	weight	O
at	at	O
4	4	O
months	months	O
relative	relative	O
to	to	O
baseline	baseline	O
weight	weight	O
was	was	O
17.3	17.3	O
%	%	O
(	(	O
95	95	O
%	%	O
CI=14.2%-20.5	ci=14.2%-20.5	O
%	%	O
)	)	O
with	with	O
olanzapine	olanzapine	B-Chemical
and	and	O
11.3	11.3	O
%	%	O
(	(	O
95	95	O
%	%	O
CI=8.4%-14.3	ci=8.4%-14.3	O
%	%	O
)	)	O
with	with	O
risperidone	risperidone	B-Chemical
.	.	O

Body	body	O
mass	mass	O
index	index	O
at	at	O
baseline	baseline	O
and	and	O
at	at	O
4	4	O
months	months	O
was	was	O
24.3	24.3	O
(	(	O
95	95	O
%	%	O
CI=22.8	ci=22.8	O
-	-	O
25.7	25.7	O
)	)	O
versus	versus	O
28.2	28.2	O
(	(	O
95	95	O
%	%	O
CI=26.7	ci=26.7	O
-	-	O
29.7	29.7	O
)	)	O
with	with	O
olanzapine	olanzapine	B-Chemical
and	and	O
23.9	23.9	O
(	(	O
95	95	O
%	%	O
CI=22.5	ci=22.5	O
-	-	O
25.3	25.3	O
)	)	O
versus	versus	O
26.7	26.7	O
(	(	O
95	95	O
%	%	O
CI=25.2	ci=25.2	O
-	-	O
28.2	28.2	O
)	)	O
with	with	O
risperidone	risperidone	B-Chemical
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Clinical	clinical	O
outcomes	outcomes	O
with	with	O
risperidone	risperidone	B-Chemical
were	were	O
equal	equal	O
to	to	O
those	those	O
with	with	O
olanzapine	olanzapine	B-Chemical
,	,	O
and	and	O
response	response	O
may	may	O
be	be	O
more	more	O
stable	stable	O
.	.	O

Olanzapine	olanzapine	B-Chemical
may	may	O
have	have	O
an	an	O
advantage	advantage	O
for	for	O
motor	motor	O
side	side	O
effects	effects	O
.	.	O

Both	both	O
medications	medications	O
caused	caused	O
substantial	substantial	O
rapid	rapid	O
weight	weight	B-Disease
gain	gain	I-Disease
,	,	O
but	but	O
weight	weight	B-Disease
gain	gain	I-Disease
was	was	O
greater	greater	O
with	with	O
olanzapine	olanzapine	B-Chemical
.	.	O

Early	early	O
paracentral	paracentral	O
visual	visual	O
field	field	O
loss	loss	O
in	in	O
patients	patients	O
taking	taking	O
hydroxychloroquine	hydroxychloroquine	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
review	review	O
the	the	O
natural	natural	O
history	history	O
and	and	O
ocular	ocular	O
and	and	O
systemic	systemic	O
adverse	adverse	O
effects	effects	O
of	of	O
patients	patients	O
taking	taking	O
hydroxychloroquine	hydroxychloroquine	O
sulfate	sulfate	O
who	who	O
attended	attended	O
an	an	O
ophthalmic	ophthalmic	O
screening	screening	O
program	program	O
.	.	O

DESIGN	design	O
:	:	O
Retrospective	retrospective	O
study	study	O
.	.	O

RESULTS	results	O
:	:	O
Records	records	O
of	of	O
262	262	O
patients	patients	O
who	who	O
were	were	O
taking	taking	O
hydroxychloroquine	hydroxychloroquine	O
and	and	O
screened	screened	O
in	in	O
the	the	O
Department	department	O
of	of	O
Ophthalmology	ophthalmology	O
were	were	O
reviewed	reviewed	O
.	.	O

Of	of	O
the	the	O
262	262	O
patients	patients	O
,	,	O
14	14	O
(	(	O
18	18	O
%	%	O
)	)	O
of	of	O
76	76	O
who	who	O
had	had	O
stopped	stopped	O
treatment	treatment	O
at	at	O
the	the	O
time	time	O
of	of	O
the	the	O
study	study	O
experienced	experienced	O
documented	documented	O
adverse	adverse	O
effects	effects	O
.	.	O

Systemic	systemic	O
adverse	adverse	O
effects	effects	O
occurred	occurred	O
in	in	O
8	8	O
patients	patients	O
(	(	O
10.5	10.5	O
%	%	O
)	)	O
and	and	O
ocular	ocular	O
adverse	adverse	O
effects	effects	O
,	,	O
in	in	O
5	5	O
(	(	O
6.5	6.5	O
%	%	O
)	)	O
.	.	O

Thirty-five	thirty-five	O
patients	patients	O
(	(	O
13.4	13.4	O
%	%	O
)	)	O
had	had	O
visual	visual	O
field	field	O
abnormalities	abnormalities	O
,	,	O
which	which	O
were	were	O
attributed	attributed	O
to	to	O
hydroxychloroquine	hydroxychloroquine	O
treatment	treatment	O
in	in	O
4	4	O
patients	patients	O
(	(	O
1.5	1.5	O
%	%	O
)	)	O
.	.	O

Three	three	O
of	of	O
the	the	O
4	4	O
patients	patients	O
were	were	O
taking	taking	O
less	less	O
than	than	O
6.5	6.5	O
mg/kg	mg/kg	O
per	per	O
day	day	O
and	and	O
all	all	O
patients	patients	O
had	had	O
normal	normal	O
renal	renal	O
and	and	O
liver	liver	O
function	function	O
test	test	O
results	results	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
current	current	O
study	study	O
used	used	O
a	a	O
protocol	protocol	O
of	of	O
visual	visual	O
acuity	acuity	O
and	and	O
color	color	O
vision	vision	O
assessment	assessment	O
,	,	O
funduscopy	funduscopy	O
,	,	O
and	and	O
Humphrey	humphrey	O
10	10	O
-	-	O
2	2	O
visual	visual	O
field	field	O
testing	testing	O
and	and	O
shows	shows	O
that	that	O
visual	visual	B-Disease
field	field	I-Disease
defects	defects	I-Disease
appeared	appeared	O
before	before	O
any	any	O
corresponding	corresponding	O
changes	changes	O
in	in	O
any	any	O
other	other	O
tested	tested	O
clinical	clinical	O
parameters	parameters	O
;	;	O
the	the	O
defects	defects	O
were	were	O
reproducible	reproducible	O
and	and	O
the	the	O
test	test	O
parameters	parameters	O
were	were	O
reliable	reliable	O
.	.	O

Patients	patients	O
taking	taking	O
hydroxychloroquine	hydroxychloroquine	O
can	can	O
demonstrate	demonstrate	O
a	a	O
toxic	toxic	O
reaction	reaction	O
in	in	O
the	the	O
retina	retina	O
despite	despite	O
the	the	O
absence	absence	O
of	of	O
known	known	O
risk	risk	O
factors	factors	O
.	.	O

Screening	screening	O
,	,	O
including	including	O
Humphrey	humphrey	O
10	10	O
-	-	O
2	2	O
visual	visual	O
field	field	O
assessment	assessment	O
,	,	O
is	is	O
recommended	recommended	O
2	2	O
years	years	O
after	after	O
the	the	O
initial	initial	O
baseline	baseline	O
and	and	O
yearly	yearly	O
thereafter	thereafter	O
.	.	O

Peri-operative	peri-operative	O
atrioventricular	atrioventricular	B-Disease
block	block	I-Disease
as	as	O
a	a	O
result	result	O
of	of	O
chemotherapy	chemotherapy	O
with	with	O
epirubicin	epirubicin	O
and	and	O
paclitaxel	paclitaxel	B-Chemical
.	.	O

A	a	O
47-year-old	47-year-old	O
woman	woman	O
presented	presented	O
for	for	O
mastectomy	mastectomy	O
and	and	O
immediate	immediate	O
latissimus	latissimus	O
dorsi	dorsi	O
flap	flap	O
reconstruction	reconstruction	O
having	having	O
been	been	O
diagnosed	diagnosed	O
with	with	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
breast	breast	O
6	6	O
months	months	O
previously	previously	O
.	.	O

In	in	O
the	the	O
preceding	preceding	O
months	months	O
she	she	O
had	had	O
received	received	O
neo-adjuvant	neo-adjuvant	O
chemotherapy	chemotherapy	O
with	with	O
epirubicin	epirubicin	O
,	,	O
paclitaxel	paclitaxel	B-Chemical
(	(	O
Taxol	taxol	B-Chemical
)	)	O
and	and	O
cyclophosphamide	cyclophosphamide	B-Chemical
.	.	O

This	this	O
had	had	O
been	been	O
apparently	apparently	O
uncomplicated	uncomplicated	O
and	and	O
she	she	O
had	had	O
maintained	maintained	O
a	a	O
remarkably	remarkably	O
high	high	O
level	level	O
of	of	O
physical	physical	O
activity	activity	O
.	.	O

She	she	O
was	was	O
found	found	O
to	to	O
be	be	O
bradycardic	bradycardic	O
at	at	O
pre-operative	pre-operative	O
assessment	assessment	O
but	but	O
had	had	O
no	no	O
cardiac	cardiac	O
symptoms	symptoms	O
.	.	O

Second	second	O
degree	degree	O
Mobitz	mobitz	O
type	type	O
II	ii	O
atrioventricular	atrioventricular	B-Disease
block	block	I-Disease
was	was	O
diagnosed	diagnosed	O
on	on	O
electrocardiogram	electrocardiogram	O
,	,	O
and	and	O
temporary	temporary	O
transvenous	transvenous	O
ventricular	ventricular	O
pacing	pacing	O
instituted	instituted	O
in	in	O
the	the	O
peri-operative	peri-operative	O
period	period	O
.	.	O

We	we	O
discuss	discuss	O
how	how	O
evidence-based	evidence-based	O
guidelines	guidelines	O
would	would	O
not	not	O
have	have	O
been	been	O
helpful	helpful	O
in	in	O
this	this	O
case	case	O
,	,	O
and	and	O
how	how	O
chemotherapy	chemotherapy	O
can	can	O
exhibit	exhibit	O
substantial	substantial	O
cardiotoxicity	cardiotoxicity	B-Disease
that	that	O
may	may	O
develop	develop	O
over	over	O
many	many	O
years	years	O
.	.	O

We	we	O
suggest	suggest	O
that	that	O
patients	patients	O
who	who	O
have	have	O
received	received	O
chemotherapy	chemotherapy	O
at	at	O
any	any	O
time	time	O
should	should	O
have	have	O
a	a	O
pre-operative	pre-operative	O
electrocardiogram	electrocardiogram	O
even	even	O
if	if	O
they	they	O
are	are	O
asymptomatic	asymptomatic	O
.	.	O

Risks	risks	O
and	and	O
benefits	benefits	O
of	of	O
COX-2	cox-2	O
inhibitors	inhibitors	O
vs	vs	O
non-selective	non-selective	O
NSAIDs	nsaids	O
:	:	O
does	does	O
their	their	O
cardiovascular	cardiovascular	O
risk	risk	O
exceed	exceed	O
their	their	O
gastrointestinal	gastrointestinal	O
benefit	benefit	O
?	?	O
A	a	O
retrospective	retrospective	O
cohort	cohort	O
study	study	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
The	the	O
risk	risk	O
of	of	O
acute	acute	B-Disease
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
(	(	O
AMI	ami	B-Chemical
)	)	O
with	with	O
COX-2	cox-2	O
inhibitors	inhibitors	O
may	may	O
offset	offset	O
their	their	O
gastrointestinal	gastrointestinal	O
(	(	O
GI	gi	O
)	)	O
benefit	benefit	O
compared	compared	O
with	with	O
non-selective	non-selective	O
(	(	O
NS	ns	O
)	)	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
(	(	O
NSAIDs	nsaids	O
)	)	O
.	.	O

We	we	O
aimed	aimed	O
to	to	O
compare	compare	O
the	the	O
risks	risks	O
of	of	O
hospitalization	hospitalization	O
for	for	O
AMI	ami	B-Chemical
and	and	O
GI	gi	O
bleeding	bleeding	B-Disease
among	among	O
elderly	elderly	O
patients	patients	O
using	using	O
COX-2	cox-2	O
inhibitors	inhibitors	O
,	,	O
NS-NSAIDs	ns-nsaids	O
and	and	O
acetaminophen	acetaminophen	B-Chemical
.	.	O

METHODS	methods	O
:	:	O
We	we	O
conducted	conducted	O
a	a	O
retrospective	retrospective	O
cohort	cohort	O
study	study	O
using	using	O
administrative	administrative	O
data	data	O
of	of	O
patients	patients	O
>	>	O
or	or	O
=	=	O
65	65	O
years	years	O
of	of	O
age	age	O
who	who	O
filled	filled	O
a	a	O
prescription	prescription	O
for	for	O
NSAID	nsaid	O
or	or	O
acetaminophen	acetaminophen	B-Chemical
during	during	O
1999	1999	O
-	-	O
2002	2002	O
.	.	O

Outcomes	outcomes	O
were	were	O
compared	compared	O
using	using	O
Cox	cox	O
regression	regression	O
models	models	O
with	with	O
time-dependent	time-dependent	O
exposures	exposures	O
.	.	O

RESULTS	results	O
:	:	O
Person-years	person-years	O
of	of	O
exposure	exposure	O
among	among	O
non-users	non-users	O
of	of	O
aspirin	aspirin	B-Chemical
were	were	O
:	:	O
75,761	75,761	O
to	to	O
acetaminophen	acetaminophen	B-Chemical
,	,	O
42,671	42,671	O
to	to	O
rofecoxib	rofecoxib	O
65,860	65,860	O
to	to	O
celecoxib	celecoxib	O
,	,	O
and	and	O
37,495	37,495	O
to	to	O
NS-NSAIDs	ns-nsaids	O
.	.	O

Among	among	O
users	users	O
of	of	O
aspirin	aspirin	B-Chemical
,	,	O
they	they	O
were	were	O
:	:	O
14,671	14,671	O
to	to	O
rofecoxib	rofecoxib	O
,	,	O
22,875	22,875	O
to	to	O
celecoxib	celecoxib	O
,	,	O
9,832	9,832	O
to	to	O
NS-NSAIDs	ns-nsaids	O
and	and	O
38,048	38,048	O
to	to	O
acetaminophen	acetaminophen	B-Chemical
.	.	O

Among	among	O
non-users	non-users	O
of	of	O
aspirin	aspirin	B-Chemical
,	,	O
the	the	O
adjusted	adjusted	O
hazard	hazard	O
ratios	ratios	O
(	(	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
)	)	O
of	of	O
hospitalization	hospitalization	O
for	for	O
AMI/GI	ami/gi	O
vs	vs	O
the	the	O
acetaminophen	acetaminophen	B-Chemical
(	(	O
with	with	O
no	no	O
aspirin	aspirin	B-Chemical
)	)	O
group	group	O
were	were	O
:	:	O
rofecoxib	rofecoxib	O
1.27	1.27	O
(	(	O
1.13	1.13	O
,	,	O
1.42	1.42	O
)	)	O
,	,	O
celecoxib	celecoxib	O
0.93	0.93	O
(	(	O
0.83	0.83	O
,	,	O
1.03	1.03	O
)	)	O
,	,	O
naproxen	naproxen	O
1.59	1.59	O
(	(	O
1.31	1.31	O
,	,	O
1.93	1.93	O
)	)	O
,	,	O
diclofenac	diclofenac	B-Chemical
1.17	1.17	O
(	(	O
0.99	0.99	O
,	,	O
1.38	1.38	O
)	)	O
and	and	O
ibuprofen	ibuprofen	B-Chemical
1.05	1.05	O
(	(	O
0.74	0.74	O
,	,	O
1.51	1.51	O
)	)	O
.	.	O

Among	among	O
users	users	O
of	of	O
aspirin	aspirin	B-Chemical
,	,	O
they	they	O
were	were	O
:	:	O
rofecoxib	rofecoxib	O
1.73	1.73	O
(	(	O
1.52	1.52	O
,	,	O
1.98	1.98	O
)	)	O
,	,	O
celecoxib	celecoxib	O
1.34	1.34	O
(	(	O
1.19	1.19	O
,	,	O
1.52	1.52	O
)	)	O
,	,	O
ibuprofen	ibuprofen	B-Chemical
1.51	1.51	O
(	(	O
0.95	0.95	O
,	,	O
2.41	2.41	O
)	)	O
,	,	O
diclofenac	diclofenac	B-Chemical
1.69	1.69	O
(	(	O
1.35	1.35	O
,	,	O
2.10	2.10	O
)	)	O
,	,	O
naproxen	naproxen	O
1.35	1.35	O
(	(	O
0.97	0.97	O
,	,	O
1.88	1.88	O
)	)	O
and	and	O
acetaminophen	acetaminophen	B-Chemical
1.29	1.29	O
(	(	O
1.17	1.17	O
,	,	O
1.42	1.42	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Among	among	O
non-users	non-users	O
of	of	O
aspirin	aspirin	B-Chemical
,	,	O
naproxen	naproxen	O
seemed	seemed	O
to	to	O
carry	carry	O
the	the	O
highest	highest	O
risk	risk	O
for	for	O
AMI/GI	ami/gi	O
bleeding	bleeding	B-Disease
.	.	O

The	the	O
AMI/GI	ami/gi	O
toxicity	toxicity	B-Disease
of	of	O
celecoxib	celecoxib	O
was	was	O
similar	similar	O
to	to	O
that	that	O
of	of	O
acetaminophen	acetaminophen	B-Chemical
and	and	O
seemed	seemed	O
to	to	O
be	be	O
better	better	O
than	than	O
those	those	O
of	of	O
rofecoxib	rofecoxib	O
and	and	O
NS-NSAIDs	ns-nsaids	O
.	.	O

Among	among	O
users	users	O
of	of	O
aspirin	aspirin	B-Chemical
,	,	O
both	both	O
celecoxib	celecoxib	O
and	and	O
naproxen	naproxen	O
seemed	seemed	O
to	to	O
be	be	O
the	the	O
least	least	O
toxic	toxic	O
.	.	O

Quinine-induced	quinine-induced	O
arrhythmia	arrhythmia	B-Disease
in	in	O
a	a	O
patient	patient	O
with	with	O
severe	severe	O
malaria	malaria	O
.	.	O

It	it	O
was	was	O
reported	reported	O
that	that	O
there	there	O
was	was	O
a	a	O
case	case	O
of	of	O
severe	severe	O
malaria	malaria	O
patient	patient	O
with	with	O
jaundice	jaundice	B-Disease
who	who	O
presented	presented	O
with	with	O
arrhythmia	arrhythmia	B-Disease
(	(	O
premature	premature	O
ventricular	ventricular	O
contraction	contraction	O
)	)	O
while	while	O
getting	getting	O
quinine	quinine	B-Chemical
infusion	infusion	O
was	was	O
reported	reported	O
.	.	O

A	a	O
man	man	O
,	,	O
25	25	O
years	years	O
old	old	O
,	,	O
was	was	O
admitted	admitted	O
to	to	O
hospital	hospital	O
with	with	O
high	high	O
fever	fever	B-Disease
,	,	O
chill	chill	O
,	,	O
vomiting	vomiting	B-Disease
,	,	O
jaundice	jaundice	B-Disease
.	.	O

The	the	O
patient	patient	O
was	was	O
fully	fully	O
conscious	conscious	O
,	,	O
blood	blood	O
pressure	pressure	O
120/80	120/80	O
mmHg	mmhg	O
,	,	O
pulse	pulse	O
rate	rate	O
100	100	O
x/minute	x/minute	O
,	,	O
regular	regular	O
.	.	O

On	on	O
admission	admission	O
,	,	O
laboratory	laboratory	O
examination	examination	O
showed	showed	O
Plasmodium	plasmodium	O
falciparum	falciparum	O
(	(	O
+	+	O
+	+	O
+	+	O
+	+	O
)	)	O
,	,	O
total	total	O
bilirubin	bilirubin	B-Chemical
8.25	8.25	O
mg/dL	mg/dl	O
,	,	O
conjugated	conjugated	O
bilirubin	bilirubin	B-Chemical
4.36	4.36	O
mg/dL	mg/dl	O
,	,	O
unconjugated	unconjugated	O
bilirubin	bilirubin	B-Chemical
3.89	3.89	O
mg/dL	mg/dl	O
,	,	O
potassium	potassium	B-Chemical
3.52	3.52	O
meq/L	meq/l	O
Patient	patient	O
was	was	O
diagnosed	diagnosed	O
as	as	O
severe	severe	O
malaria	malaria	O
with	with	O
jaundice	jaundice	B-Disease
and	and	O
got	got	O
quinine	quinine	B-Chemical
infusion	infusion	O
in	in	O
dextrose	dextrose	O
5	5	O
%	%	O
500	500	O
mg/8	mg/8	O
hour	hour	O
.	.	O

On	on	O
the	the	O
second	second	O
day	day	O
the	the	O
patient	patient	O
had	had	O
vomitus	vomitus	O
,	,	O
diarrhea	diarrhea	B-Disease
,	,	O
tinnitus	tinnitus	B-Disease
,	,	O
loss	loss	O
of	of	O
hearing	hearing	O
.	.	O

After	after	O
30	30	O
hours	hours	O
of	of	O
quinine	quinine	B-Chemical
infusion	infusion	O
the	the	O
patient	patient	O
felt	felt	O
palpitation	palpitation	O
and	and	O
electrocardiography	electrocardiography	O
(	(	O
ECG	ecg	O
)	)	O
recording	recording	O
showed	showed	O
premature	premature	O
ventricular	ventricular	O
contraction	contraction	O
(	(	O
PVC	pvc	O
)	)	O
>	>	O
5	5	O
x/minute	x/minute	O
,	,	O
trigemini	trigemini	O
,	,	O
constant	constant	O
type	type	O
--	--	O
sinoatrial	sinoatrial	B-Disease
block	block	I-Disease
,	,	O
positive	positive	O
U	u	O
wave	wave	O
.	.	O

He	he	O
was	was	O
treated	treated	O
with	with	O
lidocaine	lidocaine	B-Chemical
50	50	O
mg	mg	O
intravenously	intravenously	O
followed	followed	O
by	by	O
infusion	infusion	O
1500	1500	O
mg	mg	O
in	in	O
dextrose	dextrose	O
5%/24	5%/24	O
hour	hour	O
and	and	O
potassium	potassium	B-Chemical
aspartate	aspartate	B-Chemical
tablet	tablet	O
.	.	O

Quinine	quinine	B-Chemical
infusion	infusion	O
was	was	O
discontinued	discontinued	O
and	and	O
changed	changed	O
with	with	O
sulfate	sulfate	O
quinine	quinine	B-Chemical
tablets	tablets	O
.	.	O

Three	three	O
hours	hours	O
later	later	O
the	the	O
patient	patient	O
felt	felt	O
better	better	O
,	,	O
the	the	O
frequency	frequency	O
of	of	O
PVC	pvc	O
reduced	reduced	O
to	to	O
4	4	O
-	-	O
5	5	O
x/minute	x/minute	O
and	and	O
on	on	O
the	the	O
third	third	O
day	day	O
ECG	ecg	O
was	was	O
normal	normal	O
,	,	O
potassium	potassium	B-Chemical
level	level	O
was	was	O
3.34	3.34	O
meq/L.	meq/l.	O
He	he	O
was	was	O
discharged	discharged	O
on	on	O
7th	7th	O
day	day	O
in	in	O
good	good	O
condition	condition	O
.	.	O

Quinine	quinine	B-Chemical
,	,	O
like	like	O
quinidine	quinidine	O
,	,	O
is	is	O
a	a	O
chincona	chincona	O
alkaloid	alkaloid	O
that	that	O
has	has	O
anti-arrhythmic	anti-arrhythmic	O
property	property	O
,	,	O
although	although	O
it	it	O
also	also	O
pro-arrhythmic	pro-arrhythmic	O
that	that	O
can	can	O
cause	cause	O
various	various	O
arrhythmias	arrhythmias	B-Disease
,	,	O
including	including	O
severe	severe	O
arrhythmia	arrhythmia	B-Disease
such	such	O
as	as	O
multiple	multiple	O
PVC	pvc	O
.	.	O

Administration	administration	O
of	of	O
parenteral	parenteral	O
quinine	quinine	B-Chemical
must	must	O
be	be	O
done	done	O
carefully	carefully	O
and	and	O
with	with	O
good	good	O
observation	observation	O
because	because	O
of	of	O
its	its	O
pro-arrhythmic	pro-arrhythmic	O
effect	effect	O
,	,	O
especially	especially	O
in	in	O
older	older	O
patients	patients	O
who	who	O
have	have	O
heart	heart	B-Disease
diseases	diseases	I-Disease
or	or	O
patients	patients	O
with	with	O
electrolyte	electrolyte	O
disorder	disorder	O
(	(	O
hypokalemia	hypokalemia	O
)	)	O
which	which	O
frequently	frequently	O
occurs	occurs	O
due	due	O
to	to	O
vomiting	vomiting	B-Disease
and	and	O
or	or	O
diarrhea	diarrhea	B-Disease
in	in	O
malaria	malaria	O
cases	cases	O
.	.	O

Penicillamine-related	penicillamine-related	O
lichenoid	lichenoid	O
dermatitis	dermatitis	B-Disease
and	and	O
utility	utility	O
of	of	O
zinc	zinc	B-Chemical
acetate	acetate	I-Chemical
in	in	O
a	a	O
Wilson	wilson	O
disease	disease	O
patient	patient	O
with	with	O
hepatic	hepatic	O
presentation	presentation	O
,	,	O
anxiety	anxiety	B-Disease
and	and	O
SPECT	spect	O
abnormalities	abnormalities	O
.	.	O

Wilson	wilson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
is	is	O
an	an	O
autosomal	autosomal	O
recessive	recessive	O
disorder	disorder	O
of	of	O
hepatic	hepatic	O
copper	copper	O
metabolism	metabolism	O
with	with	O
consequent	consequent	O
copper	copper	O
accumulation	accumulation	O
and	and	O
toxicity	toxicity	B-Disease
in	in	O
many	many	O
tissues	tissues	O
and	and	O
consequent	consequent	O
hepatic	hepatic	O
,	,	O
neurologic	neurologic	O
and	and	O
psychiatric	psychiatric	B-Disease
disorders	disorders	O
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
Wilson	wilson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
with	with	O
chronic	chronic	O
liver	liver	B-Disease
disease	disease	I-Disease
;	;	O
moreover	moreover	O
,	,	O
in	in	O
our	our	O
patient	patient	O
,	,	O
presenting	presenting	O
also	also	O
with	with	O
high	high	O
levels	levels	O
of	of	O
state	state	O
anxiety	anxiety	B-Disease
without	without	O
depression	depression	B-Disease
,	,	O
99mTc-ECD-SPECT	99mtc-ecd-spect	O
showed	showed	O
cortical	cortical	O
hypoperfusion	hypoperfusion	O
in	in	O
frontal	frontal	O
lobes	lobes	O
,	,	O
more	more	O
marked	marked	O
on	on	O
the	the	O
left	left	O
frontal	frontal	O
lobe	lobe	O
.	.	O

During	during	O
the	the	O
follow-up	follow-up	O
of	of	O
our	our	O
patient	patient	O
,	,	O
penicillamine	penicillamine	B-Chemical
was	was	O
interrupted	interrupted	O
after	after	O
the	the	O
appearance	appearance	O
of	of	O
a	a	O
lichenoid	lichenoid	O
dermatitis	dermatitis	B-Disease
,	,	O
and	and	O
zinc	zinc	B-Chemical
acetate	acetate	I-Chemical
permitted	permitted	O
to	to	O
continue	continue	O
the	the	O
successful	successful	O
treatment	treatment	O
of	of	O
the	the	O
patient	patient	O
without	without	O
side-effects	side-effects	O
.	.	O

In	in	O
our	our	O
case	case	O
the	the	O
therapy	therapy	O
with	with	O
zinc	zinc	B-Chemical
acetate	acetate	I-Chemical
represented	represented	O
an	an	O
effective	effective	O
treatment	treatment	O
for	for	O
a	a	O
Wilson	wilson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
patient	patient	O
in	in	O
which	which	O
penicillamine-related	penicillamine-related	O
side	side	O
effects	effects	O
appeared	appeared	O
.	.	O

The	the	O
safety	safety	O
of	of	O
the	the	O
zinc	zinc	B-Chemical
acetate	acetate	I-Chemical
allowed	allowed	O
us	us	O
to	to	O
avoid	avoid	O
other	other	O
potentially	potentially	O
toxic	toxic	O
chelating	chelating	O
drugs	drugs	O
;	;	O
this	this	O
observation	observation	O
is	is	O
in	in	O
line	line	O
with	with	O
the	the	O
growing	growing	O
evidence	evidence	O
on	on	O
the	the	O
efficacy	efficacy	O
of	of	O
the	the	O
drug	drug	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
Wilson	wilson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

Since	since	O
most	most	O
of	of	O
Wilson	wilson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
penicillamine-treated	penicillamine-treated	O
patients	patients	O
do	do	O
not	not	O
seem	seem	O
to	to	O
develop	develop	O
this	this	O
skin	skin	O
lesion	lesion	O
,	,	O
it	it	O
could	could	O
be	be	O
conceivable	conceivable	O
that	that	O
a	a	O
specific	specific	O
genetic	genetic	O
factor	factor	O
is	is	O
involved	involved	O
in	in	O
drug	drug	O
response	response	O
.	.	O

Further	further	O
studies	studies	O
are	are	O
needed	needed	O
for	for	O
a	a	O
better	better	O
clarification	clarification	O
of	of	O
Wilson	wilson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
therapy	therapy	O
,	,	O
and	and	O
in	in	O
particular	particular	O
to	to	O
differentiate	differentiate	O
specific	specific	O
therapies	therapies	O
for	for	O
different	different	O
Wilson	wilson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
phenotypes	phenotypes	O
.	.	O

A	a	O
dramatic	dramatic	O
drop	drop	O
in	in	O
blood	blood	O
pressure	pressure	O
following	following	O
prehospital	prehospital	O
GTN	gtn	O
administration	administration	O
.	.	O

A	a	O
male	male	O
in	in	O
his	his	O
sixties	sixties	O
with	with	O
no	no	O
history	history	O
of	of	O
cardiac	cardiac	O
chest	chest	B-Disease
pain	pain	B-Disease
awoke	awoke	O
with	with	O
chest	chest	B-Disease
pain	pain	B-Disease
following	following	O
an	an	O
afternoon	afternoon	O
sleep	sleep	O
.	.	O

The	the	O
patient	patient	O
did	did	O
not	not	O
self	self	O
medicate	medicate	O
.	.	O

The	the	O
patient	patient	O
's	's	O
observations	observations	O
were	were	O
within	within	O
normal	normal	O
limits	limits	O
,	,	O
he	he	O
was	was	O
administered	administered	O
oxygen	oxygen	B-Chemical
via	via	O
a	a	O
face	face	O
mask	mask	O
and	and	O
glyceryl	glyceryl	O
trinitrate	trinitrate	O
(	(	O
GTN	gtn	O
)	)	O
.	.	O

Several	several	O
minutes	minutes	O
after	after	O
the	the	O
GTN	gtn	O
the	the	O
patient	patient	O
experienced	experienced	O
a	a	O
sudden	sudden	O
drop	drop	O
in	in	O
blood	blood	O
pressure	pressure	O
and	and	O
heart	heart	O
rate	rate	O
,	,	O
this	this	O
was	was	O
rectified	rectified	O
by	by	O
atropine	atropine	B-Chemical
sulphate	sulphate	O
and	and	O
a	a	O
fluid	fluid	O
challenge	challenge	O
.	.	O

There	there	O
was	was	O
no	no	O
further	further	O
deterioration	deterioration	O
in	in	O
the	the	O
patient	patient	O
's	's	O
condition	condition	O
during	during	O
transport	transport	O
to	to	O
hospital	hospital	O
.	.	O

There	there	O
are	are	O
very	very	O
few	few	O
documented	documented	O
case	case	O
like	like	O
this	this	O
in	in	O
the	the	O
prehospital	prehospital	O
scientific	scientific	O
literature	literature	O
.	.	O

The	the	O
cause	cause	O
appears	appears	O
to	to	O
be	be	O
the	the	O
Bezold-Jarish	bezold-jarish	O
reflex	reflex	O
,	,	O
stimulation	stimulation	O
of	of	O
the	the	O
ventricular	ventricular	O
walls	walls	O
which	which	O
in	in	O
turn	turn	O
decreases	decreases	O
sympathetic	sympathetic	O
outflow	outflow	O
from	from	O
the	the	O
vasomotor	vasomotor	O
centre	centre	O
.	.	O

Prehospital	prehospital	O
care	care	O
providers	providers	O
who	who	O
are	are	O
managing	managing	O
any	any	O
patient	patient	O
with	with	O
a	a	O
syncopal	syncopal	O
episode	episode	O
that	that	O
fails	fails	O
to	to	O
recover	recover	O
within	within	O
a	a	O
reasonable	reasonable	O
time	time	O
frame	frame	O
should	should	O
consider	consider	O
the	the	O
Bezold-Jarisch	bezold-jarisch	O
reflex	reflex	O
as	as	O
the	the	O
cause	cause	O
and	and	O
manage	manage	O
the	the	O
patient	patient	O
accordingly	accordingly	O
.	.	O

Chronic	chronic	O
lesion	lesion	O
of	of	O
rostral	rostral	O
ventrolateral	ventrolateral	O
medulla	medulla	O
in	in	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
rats	rats	O
.	.	O

We	we	O
studied	studied	O
the	the	O
effects	effects	O
of	of	O
chronic	chronic	O
selective	selective	O
neuronal	neuronal	O
lesion	lesion	O
of	of	O
rostral	rostral	O
ventrolateral	ventrolateral	O
medulla	medulla	O
on	on	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
,	,	O
heart	heart	O
rate	rate	O
,	,	O
and	and	O
neurogenic	neurogenic	O
tone	tone	O
in	in	O
conscious	conscious	O
,	,	O
unrestrained	unrestrained	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
rats	rats	O
.	.	O

The	the	O
lesions	lesions	O
were	were	O
placed	placed	O
via	via	O
bilateral	bilateral	O
microinjections	microinjections	O
of	of	O
30	30	O
nmol/200	nmol/200	O
nl	nl	O
N-methyl-D-aspartic	n-methyl-d-aspartic	O
acid	acid	O
.	.	O

The	the	O
restimulation	restimulation	O
of	of	O
this	this	O
area	area	O
with	with	O
N-methyl-D-aspartic	n-methyl-d-aspartic	O
acid	acid	O
15	15	O
days	days	O
postlesion	postlesion	O
failed	failed	O
to	to	O
produce	produce	O
a	a	O
pressor	pressor	O
response	response	O
.	.	O

One	one	O
day	day	O
postlesion	postlesion	O
,	,	O
the	the	O
resting	resting	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
was	was	O
significantly	significantly	O
decreased	decreased	O
in	in	O
lesioned	lesioned	O
rats	rats	O
when	when	O
compared	compared	O
with	with	O
sham	sham	O
rats	rats	O
(	(	O
100	100	O
+	+	O
/-	/-	O
7	7	O
versus	versus	O
173	173	O
+	+	O
/-	/-	O
4	4	O
mm	mm	O
Hg	hg	O
,	,	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

Fifteen	fifteen	O
days	days	O
later	later	O
,	,	O
the	the	O
lesioned	lesioned	O
group	group	O
still	still	O
showed	showed	O
values	values	O
significantly	significantly	O
lower	lower	O
than	than	O
the	the	O
sham	sham	O
group	group	O
(	(	O
150	150	O
+	+	O
/-	/-	O
6	6	O
versus	versus	O
167	167	O
+	+	O
/-	/-	O
5	5	O
mm	mm	O
Hg	hg	O
,	,	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

No	no	O
significant	significant	O
heart	heart	O
rate	rate	O
differences	differences	O
were	were	O
observed	observed	O
between	between	O
the	the	O
sham	sham	O
and	and	O
lesioned	lesioned	O
groups	groups	O
.	.	O

The	the	O
ganglionic	ganglionic	O
blocker	blocker	O
trimethaphan	trimethaphan	O
(	(	O
5	5	O
mg/kg	mg/kg	O
i.v	i.v	O
.	.	O
)	)	O
caused	caused	O
similar	similar	O
reductions	reductions	O
in	in	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
in	in	O
both	both	O
lesioned	lesioned	O
and	and	O
sham	sham	O
groups	groups	O
.	.	O

The	the	O
trimethaphan-induced	trimethaphan-induced	O
hypotension	hypotension	B-Disease
was	was	O
accompanied	accompanied	O
by	by	O
a	a	O
significant	significant	O
bradycardia	bradycardia	B-Disease
in	in	O
lesioned	lesioned	O
rats	rats	O
(	(	O
-32	-32	O
+	+	O
/-	/-	O
13	13	O
beats	beats	O
per	per	O
minute	minute	O
)	)	O
but	but	O
a	a	O
tachycardia	tachycardia	B-Disease
in	in	O
sham	sham	O
rats	rats	O
(	(	O
+	+	O
33	33	O
+	+	O
/-	/-	O
12	12	O
beats	beats	O
per	per	O
minute	minute	O
)	)	O
1	1	O
day	day	O
postlesion	postlesion	O
.	.	O

Therefore	therefore	O
,	,	O
rostral	rostral	O
ventrolateral	ventrolateral	O
medulla	medulla	O
neurons	neurons	O
appear	appear	O
to	to	O
play	play	O
a	a	O
significant	significant	O
role	role	O
in	in	O
maintaining	maintaining	O
hypertension	hypertension	B-Disease
in	in	O
conscious	conscious	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
rats	rats	O
.	.	O

Spinal	spinal	O
or	or	O
suprabulbar	suprabulbar	O
structures	structures	O
could	could	O
be	be	O
responsible	responsible	O
for	for	O
the	the	O
gradual	gradual	O
recovery	recovery	O
of	of	O
the	the	O
hypertension	hypertension	B-Disease
in	in	O
the	the	O
lesioned	lesioned	O
rats	rats	O
.	.	O

Acute	acute	O
encephalopathy	encephalopathy	B-Disease
and	and	O
cerebral	cerebral	O
vasospasm	vasospasm	B-Disease
after	after	O
multiagent	multiagent	O
chemotherapy	chemotherapy	O
including	including	O
PEG-asparaginase	peg-asparaginase	O
and	and	O
intrathecal	intrathecal	O
cytarabine	cytarabine	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
acute	acute	B-Disease
lymphoblastic	lymphoblastic	I-Disease
leukemia	leukemia	I-Disease
.	.	O

A	a	O
7-year-old	7-year-old	O
girl	girl	O
with	with	O
an	an	O
unusual	unusual	O
reaction	reaction	O
to	to	O
induction	induction	O
chemotherapy	chemotherapy	O
for	for	O
precursor	precursor	O
B-cell	b-cell	O
acute	acute	B-Disease
lymphoblastic	lymphoblastic	I-Disease
leukemia	leukemia	I-Disease
(	(	O
ALL	all	O
)	)	O
is	is	O
described	described	O
.	.	O

The	the	O
patient	patient	O
developed	developed	O
acute	acute	O
encephalopathy	encephalopathy	B-Disease
evidenced	evidenced	O
by	by	O
behavioral	behavioral	O
changes	changes	O
,	,	O
aphasia	aphasia	O
,	,	O
incontinence	incontinence	B-Disease
,	,	O
visual	visual	B-Disease
hallucinations	hallucinations	B-Disease
,	,	O
and	and	O
right-sided	right-sided	O
weakness	weakness	B-Disease
with	with	O
diffuse	diffuse	O
cerebral	cerebral	O
vasospasm	vasospasm	B-Disease
on	on	O
magnetic	magnetic	O
resonance	resonance	O
angiography	angiography	O
after	after	O
the	the	O
administration	administration	O
of	of	O
intrathecal	intrathecal	O
cytarabine	cytarabine	O
.	.	O

Vincristine	vincristine	B-Chemical
,	,	O
dexamethasone	dexamethasone	B-Chemical
,	,	O
and	and	O
polyethylene	polyethylene	O
glycol-asparaginase	glycol-asparaginase	O
were	were	O
also	also	O
administered	administered	O
before	before	O
the	the	O
episode	episode	O
as	as	O
part	part	O
of	of	O
induction	induction	O
therapy	therapy	O
.	.	O

Neurologic	neurologic	O
status	status	O
returned	returned	O
to	to	O
baseline	baseline	O
within	within	O
10	10	O
days	days	O
of	of	O
the	the	O
acute	acute	O
event	event	O
,	,	O
and	and	O
magnetic	magnetic	O
resonance	resonance	O
angiography	angiography	O
findings	findings	O
returned	returned	O
to	to	O
normal	normal	O
4	4	O
months	months	O
later	later	O
.	.	O

Comparison	comparison	O
of	of	O
valsartan/hydrochlorothiazide	valsartan/hydrochlorothiazide	O
combination	combination	O
therapy	therapy	O
at	at	O
doses	doses	O
up	up	O
to	to	O
320/25	320/25	O
mg	mg	O
versus	versus	O
monotherapy	monotherapy	O
:	:	O
a	a	O
double-blind	double-blind	O
,	,	O
placebo-controlled	placebo-controlled	O
study	study	O
followed	followed	O
by	by	O
long-term	long-term	O
combination	combination	O
therapy	therapy	O
in	in	O
hypertensive	hypertensive	B-Disease
adults	adults	O
.	.	O

BACKGROUND	background	O
:	:	O
One	one	O
third	third	O
of	of	O
patients	patients	O
treated	treated	O
for	for	O
hypertension	hypertension	B-Disease
attain	attain	O
adequate	adequate	O
blood	blood	O
pressure	pressure	O
(	(	O
BP	bp	O
)	)	O
control	control	O
,	,	O
and	and	O
multidrug	multidrug	O
regimens	regimens	O
are	are	O
often	often	O
required	required	O
.	.	O

Given	given	O
the	the	O
lifelong	lifelong	O
nature	nature	O
of	of	O
hypertension	hypertension	B-Disease
,	,	O
there	there	O
is	is	O
a	a	O
need	need	O
to	to	O
evaluate	evaluate	O
the	the	O
long-term	long-term	O
efficacy	efficacy	O
and	and	O
tolerability	tolerability	O
of	of	O
higher	higher	O
doses	doses	O
of	of	O
combination	combination	O
anti-hypertensive	anti-hypertensive	O
therapies	therapies	O
.	.	O

OBJECTIVE	objective	O
:	:	O
This	this	O
study	study	O
investigated	investigated	O
the	the	O
efficacy	efficacy	O
and	and	O
tolerability	tolerability	O
of	of	O
valsartan	valsartan	O
(	(	O
VAL	val	O
)	)	O
or	or	O
hydrochlorothiazide	hydrochlorothiazide	O
(HCTZ)-monotherapy	(hctz)-monotherapy	O
and	and	O
higher-dose	higher-dose	O
combinations	combinations	O
in	in	O
patients	patients	O
with	with	O
essential	essential	B-Disease
hypertension	hypertension	B-Disease
.	.	O

METHODS	methods	O
:	:	O
The	the	O
first	first	O
part	part	O
of	of	O
this	this	O
study	study	O
was	was	O
an	an	O
8-week	8-week	O
,	,	O
multicenter	multicenter	O
,	,	O
randomized	randomized	O
,	,	O
double-blind	double-blind	O
,	,	O
placebo	placebo	O
controlled	controlled	O
,	,	O
parallel-group	parallel-group	O
trial	trial	O
.	.	O

Patients	patients	O
with	with	O
essential	essential	B-Disease
hypertension	hypertension	B-Disease
(	(	O
mean	mean	O
sitting	sitting	O
diastolic	diastolic	O
BP	bp	O
[	[	O
MSDBP	msdbp	O
]	]	O
,	,	O
>	>	O
or	or	O
=	=	O
95	95	O
mm	mm	O
Hg	hg	O
and	and	O
<	<	O
110	110	O
mm	mm	O
Hg	hg	O
)	)	O
were	were	O
randomized	randomized	O
to	to	O
1	1	O
of	of	O
8	8	O
treatment	treatment	O
groups	groups	O
:	:	O
VAL	val	O
160	160	O
or	or	O
320	320	O
mg	mg	O
;	;	O
HCTZ	hctz	O
12.5	12.5	O
or	or	O
25	25	O
mg	mg	O
;	;	O
VAL/HCTZ	val/hctz	O
160/12.5	160/12.5	O
,	,	O
320/12.5	320/12.5	O
,	,	O
or	or	O
320/25	320/25	O
mg	mg	O
;	;	O
or	or	O
placebo	placebo	O
.	.	O

Mean	mean	O
changes	changes	O
in	in	O
MSDBP	msdbp	O
and	and	O
mean	mean	O
sitting	sitting	O
systolic	systolic	O
BP	bp	O
(	(	O
MSSBP	mssbp	O
)	)	O
were	were	O
analyzed	analyzed	O
at	at	O
the	the	O
8-week	8-week	O
core	core	O
study	study	O
end	end	O
point	point	O
.	.	O

VAL/HCTZ	val/hctz	O
320/12.5	320/12.5	O
and	and	O
320/25	320/25	O
mg	mg	O
were	were	O
further	further	O
investigated	investigated	O
in	in	O
a	a	O
54-week	54-week	O
,	,	O
open-label	open-label	O
extension	extension	O
.	.	O

Response	response	O
was	was	O
defined	defined	O
as	as	O
MSDBP	msdbp	O
<	<	O
90	90	O
mm	mm	O
Hg	hg	O
or	or	O
a	a	O
>	>	O
or	or	O
=	=	O
10	10	O
mm	mm	O
Hg	hg	O
decrease	decrease	O
compared	compared	O
to	to	O
baseline	baseline	O
.	.	O

Control	control	O
was	was	O
defined	defined	O
as	as	O
MSDBP	msdbp	O
<	<	O
90	90	O
mm	mm	O
Hg	hg	O
compared	compared	O
with	with	O
baseline	baseline	O
.	.	O

Tolerability	tolerability	O
was	was	O
assessed	assessed	O
by	by	O
monitoring	monitoring	O
adverse	adverse	O
events	events	O
at	at	O
randomization	randomization	O
and	and	O
all	all	O
subsequent	subsequent	O
study	study	O
visits	visits	O
and	and	O
regular	regular	O
evaluation	evaluation	O
of	of	O
hematology	hematology	O
and	and	O
blood	blood	O
chemistry	chemistry	O
.	.	O

RESULTS	results	O
:	:	O
A	a	O
total	total	O
of	of	O
1346	1346	O
patients	patients	O
were	were	O
randomized	randomized	O
into	into	O
the	the	O
8-week	8-week	O
core	core	O
study	study	O
(	(	O
734	734	O
men	men	O
,	,	O
612	612	O
women	women	O
;	;	O
924	924	O
white	white	O
,	,	O
291	291	O
black	black	O
,	,	O
23	23	O
Asian	asian	O
,	,	O
108	108	O
other	other	O
;	;	O
mean	mean	O
age	age	O
,	,	O
52.7	52.7	O
years	years	O
;	;	O
mean	mean	O
weight	weight	O
,	,	O
92.6	92.6	O
kg	kg	O
)	)	O
.	.	O

All	all	O
active	active	O
treatments	treatments	O
were	were	O
associated	associated	O
with	with	O
significantly	significantly	O
reduced	reduced	O
MSSBP	mssbp	O
and	and	O
MSDBP	msdbp	O
during	during	O
the	the	O
core	core	O
8-week	8-week	O
study	study	O
,	,	O
with	with	O
each	each	O
monotherapy	monotherapy	O
significantly	significantly	O
contributing	contributing	O
to	to	O
the	the	O
overall	overall	O
effect	effect	O
of	of	O
combination	combination	O
therapy	therapy	O
(	(	O
VAL	val	O
and	and	O
HCTZ	hctz	O
,	,	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

Each	each	O
combination	combination	O
was	was	O
associated	associated	O
with	with	O
significantly	significantly	O
greater	greater	O
reductions	reductions	O
in	in	O
MSSBP	mssbp	O
and	and	O
MSDBP	msdbp	O
compared	compared	O
with	with	O
the	the	O
monotherapies	monotherapies	O
and	and	O
placebo	placebo	O
(	(	O
all	all	O
,	,	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

The	the	O
mean	mean	O
reduction	reduction	O
in	in	O
MSSBP/MSDBP	mssbp/msdbp	O
with	with	O
VAL/HCTZ	val/hctz	O
320/25	320/25	O
mg	mg	O
was	was	O
24.7/16.6	24.7/16.6	O
mm	mm	O
Hg	hg	O
,	,	O
compared	compared	O
with	with	O
5.9/7.0	5.9/7.0	O
mm	mm	O
Hg	hg	O
with	with	O
placebo	placebo	O
.	.	O

The	the	O
reduction	reduction	O
in	in	O
MSSBP	mssbp	O
was	was	O
significantly	significantly	O
greater	greater	O
with	with	O
VAL/HCTZ	val/hctz	O
320/25	320/25	O
mg	mg	O
compared	compared	O
with	with	O
VAL/HCTZ	val/hctz	O
160/12.5	160/12.5	O
mg	mg	O
(	(	O
P	p	O
<	<	O
0.002	0.002	O
)	)	O
.	.	O

Rates	rates	O
of	of	O
response	response	O
and	and	O
BP	bp	O
control	control	O
were	were	O
significantly	significantly	O
higher	higher	O
in	in	O
the	the	O
groups	groups	O
that	that	O
received	received	O
combination	combination	O
treatment	treatment	O
compared	compared	O
with	with	O
those	those	O
that	that	O
received	received	O
monotherapy	monotherapy	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
hypokalemia	hypokalemia	O
was	was	O
lower	lower	O
with	with	O
VAL/HCTZ	val/hctz	O
combinations	combinations	O
(	(	O
1.8%-6.1	1.8%-6.1	O
%	%	O
)	)	O
than	than	O
with	with	O
HCTZ	hctz	O
monotherapies	monotherapies	O
(	(	O
7.1%-13.3	7.1%-13.3	O
%	%	O
)	)	O
.	.	O

The	the	O
majority	majority	O
of	of	O
adverse	adverse	O
events	events	O
in	in	O
the	the	O
core	core	O
study	study	O
were	were	O
of	of	O
mild	mild	O
to	to	O
moderate	moderate	O
severity	severity	O
.	.	O

The	the	O
efficacy	efficacy	O
and	and	O
tolerability	tolerability	O
of	of	O
VAL/HCTZ	val/hctz	O
combinations	combinations	O
were	were	O
maintained	maintained	O
during	during	O
the	the	O
extension	extension	O
(	(	O
797	797	O
patients	patients	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
In	in	O
this	this	O
study	study	O
population	population	O
,	,	O
combination	combination	O
therapies	therapies	O
with	with	O
VAL/HCTZ	val/hctz	O
were	were	O
associated	associated	O
with	with	O
significantly	significantly	O
greater	greater	O
BP	bp	O
reductions	reductions	O
compared	compared	O
with	with	O
either	either	O
monotherapy	monotherapy	O
,	,	O
were	were	O
well	well	O
tolerated	tolerated	O
,	,	O
and	and	O
were	were	O
associated	associated	O
with	with	O
less	less	O
hypokalemia	hypokalemia	O
than	than	O
HCTZ	hctz	O
alone	alone	O
.	.	O

Succimer	succimer	O
chelation	chelation	O
improves	improves	O
learning	learning	O
,	,	O
attention	attention	O
,	,	O
and	and	O
arousal	arousal	O
regulation	regulation	O
in	in	O
lead-exposed	lead-exposed	O
rats	rats	O
but	but	O
produces	produces	O
lasting	lasting	O
cognitive	cognitive	B-Disease
impairment	impairment	I-Disease
in	in	O
the	the	O
absence	absence	O
of	of	O
lead	lead	O
exposure	exposure	O
.	.	O

BACKGROUND	background	O
:	:	O
There	there	O
is	is	O
growing	growing	O
pressure	pressure	O
for	for	O
clinicians	clinicians	O
to	to	O
prescribe	prescribe	O
chelation	chelation	O
therapy	therapy	O
at	at	O
only	only	O
slightly	slightly	O
elevated	elevated	O
blood	blood	O
lead	lead	O
levels	levels	O
.	.	O

However	however	O
,	,	O
very	very	O
few	few	O
studies	studies	O
have	have	O
evaluated	evaluated	O
whether	whether	O
chelation	chelation	O
improves	improves	O
cognitive	cognitive	O
outcomes	outcomes	O
in	in	O
Pb-exposed	pb-exposed	O
children	children	O
,	,	O
or	or	O
whether	whether	O
these	these	O
agents	agents	O
have	have	O
adverse	adverse	O
effects	effects	O
that	that	O
may	may	O
affect	affect	O
brain	brain	O
development	development	O
in	in	O
the	the	O
absence	absence	O
of	of	O
Pb	pb	O
exposure	exposure	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
The	the	O
present	present	O
study	study	O
was	was	O
designed	designed	O
to	to	O
answer	answer	O
these	these	O
questions	questions	O
,	,	O
using	using	O
a	a	O
rodent	rodent	O
model	model	O
of	of	O
early	early	O
childhood	childhood	O
Pb	pb	O
exposure	exposure	O
and	and	O
treatment	treatment	O
with	with	O
succimer	succimer	O
,	,	O
a	a	O
widely	widely	O
used	used	O
chelating	chelating	O
agent	agent	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
Pb	pb	O
poisoning	poisoning	B-Disease
.	.	O

RESULTS	results	O
:	:	O
Pb	pb	O
exposure	exposure	O
produced	produced	O
lasting	lasting	O
impairments	impairments	O
in	in	O
learning	learning	O
,	,	O
attention	attention	O
,	,	O
inhibitory	inhibitory	O
control	control	O
,	,	O
and	and	O
arousal	arousal	O
regulation	regulation	O
,	,	O
paralleling	paralleling	O
the	the	O
areas	areas	O
of	of	O
dysfunction	dysfunction	O
seen	seen	O
in	in	O
Pb-exposed	pb-exposed	O
children	children	O
.	.	O

Succimer	succimer	O
treatment	treatment	O
of	of	O
the	the	O
Pb-exposed	pb-exposed	O
rats	rats	O
significantly	significantly	O
improved	improved	O
learning	learning	O
,	,	O
attention	attention	O
,	,	O
and	and	O
arousal	arousal	O
regulation	regulation	O
,	,	O
although	although	O
the	the	O
efficacy	efficacy	O
of	of	O
the	the	O
treatment	treatment	O
varied	varied	O
as	as	O
a	a	O
function	function	O
of	of	O
the	the	O
Pb	pb	O
exposure	exposure	O
level	level	O
and	and	O
the	the	O
specific	specific	O
functional	functional	O
deficit	deficit	O
.	.	O

In	in	O
contrast	contrast	O
,	,	O
succimer	succimer	O
treatment	treatment	O
of	of	O
rats	rats	O
not	not	O
previously	previously	O
exposed	exposed	O
to	to	O
Pb	pb	O
produced	produced	O
lasting	lasting	O
and	and	O
pervasive	pervasive	O
cognitive	cognitive	O
and	and	O
affective	affective	O
dysfunction	dysfunction	O
comparable	comparable	O
in	in	O
magnitude	magnitude	O
to	to	O
that	that	O
produced	produced	O
by	by	O
the	the	O
higher	higher	O
Pb	pb	O
exposure	exposure	O
regimen	regimen	O
.	.	O
CONCLUSIONS	conclusions	O
:	:	O
These	these	O
are	are	O
the	the	O
first	first	O
data	data	O
,	,	O
to	to	O
our	our	O
knowledge	knowledge	O
,	,	O
to	to	O
show	show	O
that	that	O
treatment	treatment	O
with	with	O
any	any	O
chelating	chelating	O
agent	agent	O
can	can	O
alleviate	alleviate	O
cognitive	cognitive	B-Disease
deficits	deficits	I-Disease
due	due	O
to	to	O
Pb	pb	O
exposure	exposure	O
.	.	O

These	these	O
findings	findings	O
suggest	suggest	O
that	that	O
it	it	O
may	may	O
be	be	O
possible	possible	O
to	to	O
identify	identify	O
a	a	O
succimer	succimer	O
treatment	treatment	O
protocol	protocol	O
that	that	O
improves	improves	O
cognitive	cognitive	O
outcomes	outcomes	O
in	in	O
Pb-exposed	pb-exposed	O
children	children	O
.	.	O

However	however	O
,	,	O
they	they	O
also	also	O
suggest	suggest	O
that	that	O
succimer	succimer	O
treatment	treatment	O
should	should	O
be	be	O
strongly	strongly	O
discouraged	discouraged	O
for	for	O
children	children	O
who	who	O
do	do	O
not	not	O
have	have	O
elevated	elevated	O
tissue	tissue	O
levels	levels	O
of	of	O
Pb	pb	O
or	or	O
other	other	O
heavy	heavy	O
metals	metals	O
.	.	O

Caffeine	caffeine	B-Chemical
challenge	challenge	O
test	test	O
in	in	O
panic	panic	B-Disease
disorder	disorder	I-Disease
and	and	O
depression	depression	B-Disease
with	with	O
panic	panic	B-Disease
attacks	attacks	I-Disease
.	.	O

Our	our	O
aim	aim	O
was	was	O
to	to	O
observe	observe	O
if	if	O
patients	patients	O
with	with	O
panic	panic	B-Disease
disorder	disorder	I-Disease
(	(	O
PD	pd	B-Disease
)	)	O
and	and	O
patients	patients	O
with	with	O
major	major	B-Disease
depression	depression	B-Disease
with	with	O
panic	panic	B-Disease
attacks	attacks	I-Disease
(	(	O
MDP	mdp	O
)	)	O
(	(	O
Diagnostic	diagnostic	O
and	and	O
Statistical	statistical	O
Manual	manual	O
of	of	O
Mental	mental	B-Disease
Disorders	disorders	I-Disease
,	,	O
Fourth	fourth	O
Edition	edition	O
criteria	criteria	O
)	)	O
respond	respond	O
in	in	O
a	a	O
similar	similar	O
way	way	O
to	to	O
the	the	O
induction	induction	O
of	of	O
panic	panic	B-Disease
attacks	attacks	I-Disease
by	by	O
an	an	O
oral	oral	O
caffeine	caffeine	B-Chemical
challenge	challenge	O
test	test	O
.	.	O

We	we	O
randomly	randomly	O
selected	selected	O
29	29	O
patients	patients	O
with	with	O
PD	pd	B-Disease
,	,	O
27	27	O
with	with	O
MDP	mdp	O
,	,	O
25	25	O
with	with	O
major	major	B-Disease
depression	depression	B-Disease
without	without	O
panic	panic	B-Disease
attacks	attacks	I-Disease
(	(	O
MD	md	O
)	)	O
,	,	O
and	and	O
28	28	O
healthy	healthy	O
volunteers	volunteers	O
.	.	O

The	the	O
patients	patients	O
had	had	O
no	no	O
psychotropic	psychotropic	O
drug	drug	O
for	for	O
at	at	O
least	least	O
a	a	O
4-week	4-week	O
period	period	O
.	.	O

In	in	O
a	a	O
randomized	randomized	O
double-blind	double-blind	O
experiment	experiment	O
performed	performed	O
in	in	O
2	2	O
occasions	occasions	O
7	7	O
days	days	O
apart	apart	O
,	,	O
480	480	O
mg	mg	O
caffeine	caffeine	B-Chemical
and	and	O
a	a	O
caffeine-free	caffeine-free	O
(	(	O
placebo	placebo	O
)	)	O
solution	solution	O
were	were	O
administered	administered	O
in	in	O
a	a	O
coffee	coffee	O
form	form	O
and	and	O
anxiety	anxiety	B-Disease
scales	scales	O
were	were	O
applied	applied	O
before	before	O
and	and	O
after	after	O
each	each	O
test	test	O
.	.	O

A	a	O
total	total	O
of	of	O
58.6	58.6	O
%	%	O
(	(	O
n	n	O
=	=	O
17	17	O
)	)	O
of	of	O
patients	patients	O
with	with	O
PD	pd	B-Disease
,	,	O
44.4	44.4	O
%	%	O
(	(	O
n	n	O
=	=	O
12	12	O
)	)	O
of	of	O
patients	patients	O
with	with	O
MDP	mdp	O
,	,	O
12.0	12.0	O
%	%	O
(	(	O
n	n	O
=	=	O
3	3	O
)	)	O
of	of	O
patients	patients	O
with	with	O
MD	md	O
,	,	O
and	and	O
7.1	7.1	O
%	%	O
(	(	O
n=	n=	O
2	2	O
)	)	O
of	of	O
control	control	O
subjects	subjects	O
had	had	O
a	a	O
panic	panic	B-Disease
attack	attack	I-Disease
after	after	O
the	the	O
480-mg	480-mg	O
caffeine	caffeine	B-Chemical
challenge	challenge	O
test	test	O
(	(	O
chi(2)(3	chi(2)(3	O
)	)	O
=	=	O
16.22	16.22	O
,	,	O
P	p	O
=	=	O
.001	.001	O
)	)	O
.	.	O

The	the	O
patients	patients	O
with	with	O
PD	pd	B-Disease
and	and	O
MDP	mdp	O
were	were	O
more	more	O
sensitive	sensitive	O
to	to	O
caffeine	caffeine	B-Chemical
than	than	O
were	were	O
patients	patients	O
with	with	O
MD	md	O
and	and	O
healthy	healthy	O
volunteers	volunteers	O
.	.	O

No	no	O
panic	panic	B-Disease
attack	attack	I-Disease
was	was	O
observed	observed	O
after	after	O
the	the	O
caffeine-free	caffeine-free	O
solution	solution	O
intake	intake	O
.	.	O

The	the	O
patients	patients	O
with	with	O
MD	md	O
had	had	O
a	a	O
lower	lower	O
heart	heart	O
rate	rate	O
response	response	O
to	to	O
the	the	O
test	test	O
than	than	O
all	all	O
the	the	O
other	other	O
groups	groups	O
(	(	O
2-way	2-way	O
analysis	analysis	O
of	of	O
variance	variance	O
,	,	O
group	group	O
by	by	O
time	time	O
interaction	interaction	O
with	with	O
Greenhouse-Geisser	greenhouse-geisser	O
correction	correction	O
:	:	O
F(3,762	f(3,762	O
)	)	O
=	=	O
2.85	2.85	O
,	,	O
P	p	O
=	=	O
.026	.026	O
)	)	O
.	.	O

Our	our	O
data	data	O
suggest	suggest	O
that	that	O
there	there	O
is	is	O
an	an	O
association	association	O
between	between	O
panic	panic	B-Disease
attacks	attacks	I-Disease
,	,	O
no	no	O
matter	matter	O
if	if	O
associated	associated	O
with	with	O
PD	pd	B-Disease
or	or	O
MDP	mdp	O
,	,	O
and	and	O
hyperreactivity	hyperreactivity	O
to	to	O
an	an	O
oral	oral	O
caffeine	caffeine	B-Chemical
challenge	challenge	O
test	test	O
.	.	O

Mitral	mitral	O
annuloplasty	annuloplasty	O
as	as	O
a	a	O
ventricular	ventricular	O
restoration	restoration	O
method	method	O
for	for	O
the	the	O
failing	failing	O
left	left	O
ventricle	ventricle	O
:	:	O
a	a	O
pilot	pilot	O
study	study	O
.	.	O

BACKGROUND	background	O
AND	and	O
AIM	aim	O
OF	of	O
THE	the	O
STUDY	study	O
:	:	O
Undersized	undersized	O
mitral	mitral	O
annuloplasty	annuloplasty	O
(	(	O
MAP	map	O
)	)	O
is	is	O
effective	effective	O
in	in	O
patients	patients	O
with	with	O
dilated	dilated	B-Disease
cardiomyopathy	cardiomyopathy	B-Disease
and	and	O
functional	functional	O
mitral	mitral	B-Disease
regurgitation	regurgitation	I-Disease
(	(	O
MR	mr	B-Disease
)	)	O
since	since	O
,	,	O
as	as	O
well	well	O
as	as	O
addressing	addressing	O
the	the	O
MR	mr	B-Disease
,	,	O
the	the	O
MAP	map	O
may	may	O
also	also	O
reshape	reshape	O
the	the	O
dilated	dilated	O
left	left	O
ventricular	ventricular	O
(	(	O
LV	lv	O
)	)	O
base	base	O
.	.	O

However	however	O
,	,	O
the	the	O
direct	direct	O
benefits	benefits	O
of	of	O
this	this	O
possible	possible	O
reshaping	reshaping	O
on	on	O
LV	lv	O
function	function	O
in	in	O
the	the	O
absence	absence	O
of	of	O
underlying	underlying	O
MR	mr	B-Disease
remain	remain	O
incompletely	incompletely	O
understood	understood	O
.	.	O

The	the	O
study	study	O
aim	aim	O
was	was	O
to	to	O
identify	identify	O
these	these	O
benefits	benefits	O
in	in	O
a	a	O
canine	canine	O
model	model	O
of	of	O
acute	acute	O
heart	heart	B-Disease
failure	failure	I-Disease
.	.	O

METHODS	methods	O
:	:	O
Six	six	O
dogs	dogs	O
underwent	underwent	O
MAP	map	O
with	with	O
a	a	O
prosthetic	prosthetic	O
band	band	O
on	on	O
the	the	O
posterior	posterior	O
mitral	mitral	O
annulus	annulus	O
,	,	O
using	using	O
four	four	O
mattress	mattress	O
sutures	sutures	O
.	.	O

The	the	O
sutures	sutures	O
were	were	O
passed	passed	O
individually	individually	O
through	through	O
four	four	O
tourniquets	tourniquets	O
and	and	O
exteriorized	exteriorized	O
untied	untied	O
via	via	O
the	the	O
left	left	O
atriotomy	atriotomy	O
.	.	O

Sonomicrometry	sonomicrometry	O
crystals	crystals	O
were	were	O
implanted	implanted	O
around	around	O
the	the	O
mitral	mitral	O
annulus	annulus	O
and	and	O
left	left	O
ventricle	ventricle	O
to	to	O
measure	measure	O
geometry	geometry	O
and	and	O
regional	regional	O
function	function	O
.	.	O

Acute	acute	O
heart	heart	B-Disease
failure	failure	I-Disease
was	was	O
induced	induced	O
by	by	O
propranolol	propranolol	B-Chemical
and	and	O
volume	volume	O
loading	loading	O
after	after	O
weaning	weaning	O
from	from	O
cardiopulmonary	cardiopulmonary	O
bypass	bypass	O
;	;	O
an	an	O
absence	absence	O
of	of	O
MR	mr	B-Disease
was	was	O
confirmed	confirmed	O
by	by	O
echocardiography	echocardiography	O
.	.	O

MAP	map	O
was	was	O
accomplished	accomplished	O
by	by	O
cinching	cinching	O
the	the	O
tourniquets	tourniquets	O
.	.	O

Data	data	O
were	were	O
acquired	acquired	O
at	at	O
baseline	baseline	O
,	,	O
after	after	O
induction	induction	O
of	of	O
acute	acute	O
heart	heart	B-Disease
failure	failure	I-Disease
,	,	O
and	and	O
after	after	O
MAP	map	O
.	.	O

RESULTS	results	O
:	:	O
MAP	map	O
decreased	decreased	O
mitral	mitral	O
annular	annular	O
dimensions	dimensions	O
in	in	O
both	both	O
commissure-commissure	commissure-commissure	O
and	and	O
septal-lateral	septal-lateral	O
directions	directions	O
.	.	O

Concomitantly	concomitantly	O
,	,	O
the	the	O
diastolic	diastolic	O
diameter	diameter	O
of	of	O
the	the	O
LV	lv	O
base	base	O
and	and	O
LV	lv	O
sphericity	sphericity	O
decreased	decreased	O
(	(	O
i.e.	i.e.	O
,	,	O
improved	improved	O
)	)	O
from	from	O
37.4	37.4	O
+	+	O
/-	/-	O
9.3	9.3	O
to	to	O
35.9	35.9	O
+	+	O
/-	/-	O
10	10	O
mm	mm	O
(	(	O
p	p	O
=	=	O
0.063	0.063	O
)	)	O
,	,	O
and	and	O
from	from	O
67.9	67.9	O
+	+	O
/-	/-	O
18.6	18.6	O
%	%	O
to	to	O
65.3	65.3	O
+	+	O
/-	/-	O
18.9	18.9	O
%	%	O
(	(	O
p	p	O
=	=	O
0.016	0.016	O
)	)	O
,	,	O
respectively	respectively	O
.	.	O

Decreases	decreases	O
were	were	O
evident	evident	O
in	in	O
both	both	O
LV	lv	O
end-diastolic	end-diastolic	O
pressure	pressure	O
(	(	O
from	from	O
17	17	O
+	+	O
/-	/-	O
7	7	O
to	to	O
15	15	O
+	+	O
/-	/-	O
6	6	O
mmHg	mmhg	O
,	,	O
p	p	O
=	=	O
0.0480	0.0480	O
and	and	O
Tau	tau	O
(	(	O
from	from	O
48	48	O
+	+	O
/-	/-	O
8	8	O
to	to	O
45	45	O
+	+	O
/-	/-	O
8	8	O
ms	ms	B-Disease
,	,	O
p	p	O
<	<	O
0.01	0.01	O
)	)	O
,	,	O
while	while	O
fractional	fractional	O
shortening	shortening	O
at	at	O
the	the	O
LV	lv	O
base	base	O
increased	increased	O
from	from	O
7.7	7.7	O
+	+	O
/-	/-	O
4.5	4.5	O
%	%	O
to	to	O
9.4	9.4	O
+	+	O
/-	/-	O
4.5	4.5	O
%	%	O
(	(	O
p	p	O
=	=	O
0.045	0.045	O
)	)	O
.	.	O

After	after	O
MAP	map	O
,	,	O
increases	increases	O
were	were	O
identified	identified	O
in	in	O
both	both	O
cardiac	cardiac	O
output	output	O
(	(	O
from	from	O
1.54	1.54	O
+	+	O
/-	/-	O
0.57	0.57	O
to	to	O
1.65	1.65	O
+	+	O
/-	/-	O
0.57	0.57	O
1/min	1/min	O
)	)	O
and	and	O
Emax	emax	O
(	(	O
from	from	O
1.86	1.86	O
+	+	O
/-	/-	O
0.9	0.9	O
to	to	O
2.41	2.41	O
+	+	O
/-	/-	O
1.31	1.31	O
mmHg/ml	mmhg/ml	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
data	data	O
acquired	acquired	O
suggest	suggest	O
that	that	O
isolated	isolated	O
MAP	map	O
may	may	O
have	have	O
certain	certain	O
benefits	benefits	O
on	on	O
LV	lv	O
dimension/function	dimension/function	O
in	in	O
acute	acute	O
heart	heart	B-Disease
failure	failure	I-Disease
,	,	O
even	even	O
in	in	O
the	the	O
absence	absence	O
of	of	O
MR	mr	B-Disease
.	.	O

However	however	O
,	,	O
further	further	O
investigations	investigations	O
are	are	O
warranted	warranted	O
in	in	O
a	a	O
model	model	O
of	of	O
chronic	chronic	O
heart	heart	B-Disease
failure	failure	I-Disease
.	.	O

Piperacillin/tazobactam-induced	piperacillin/tazobactam-induced	O
seizure	seizure	B-Disease
rapidly	rapidly	O
reversed	reversed	O
by	by	O
high	high	O
flux	flux	O
hemodialysis	hemodialysis	O
in	in	O
a	a	O
patient	patient	O
on	on	O
peritoneal	peritoneal	O
dialysis	dialysis	O
.	.	O

Despite	despite	O
popular	popular	O
use	use	O
of	of	O
piperacillin	piperacillin	O
,	,	O
the	the	O
dire	dire	O
neurotoxicity	neurotoxicity	B-Disease
associated	associated	O
with	with	O
piperacillin	piperacillin	O
still	still	O
goes	goes	O
unrecognized	unrecognized	O
,	,	O
leading	leading	O
to	to	O
a	a	O
delay	delay	O
in	in	O
appropriate	appropriate	O
management	management	O
.	.	O

We	we	O
report	report	O
a	a	O
57-year-old	57-year-old	O
woman	woman	O
with	with	O
end-stage	end-stage	O
renal	renal	O
disease	disease	O
receiving	receiving	O
continuous	continuous	O
ambulatory	ambulatory	O
peritoneal	peritoneal	O
dialysis	dialysis	O
(	(	O
CAPD	capd	O
)	)	O
,	,	O
who	who	O
developed	developed	O
slurred	slurred	O
speech	speech	O
,	,	O
tremor	tremor	B-Disease
,	,	O
bizarre	bizarre	O
behavior	behavior	O
,	,	O
progressive	progressive	O
mental	mental	O
confusion	confusion	B-Disease
,	,	O
and	and	O
2	2	O
episodes	episodes	O
of	of	O
generalized	generalized	O
tonic-clonic	tonic-clonic	O
seizure	seizure	B-Disease
(	(	O
GTCS	gtcs	O
)	)	O
after	after	O
5	5	O
doses	doses	O
of	of	O
piperacillin/tazobactam	piperacillin/tazobactam	O
(	(	O
2	2	O
g/250	g/250	O
mg	mg	O
)	)	O
were	were	O
given	given	O
for	for	O
bronchiectasis	bronchiectasis	O
with	with	O
secondary	secondary	O
infection	infection	B-Disease
.	.	O

The	the	O
laboratory	laboratory	O
data	data	O
revealed	revealed	O
normal	normal	O
plasma	plasma	O
electrolyte	electrolyte	O
and	and	O
ammonia	ammonia	O
levels	levels	O
but	but	O
leukocytosis	leukocytosis	O
.	.	O

Neurologic	neurologic	O
examinations	examinations	O
showed	showed	O
dysarthria	dysarthria	O
and	and	O
bilateral	bilateral	O
Babinski	babinski	O
sign	sign	O
.	.	O

Computed	computed	O
tomography	tomography	O
of	of	O
brain	brain	O
and	and	O
electroencephalogram	electroencephalogram	O
were	were	O
unremarkable	unremarkable	O
.	.	O

Despite	despite	O
the	the	O
use	use	O
of	of	O
antiepileptic	antiepileptic	O
agents	agents	O
,	,	O
another	another	O
GTCS	gtcs	O
episode	episode	O
recurred	recurred	O
after	after	O
the	the	O
sixth	sixth	O
dose	dose	O
of	of	O
piperacillin/tazobactam	piperacillin/tazobactam	O
.	.	O

Brain	brain	O
magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
did	did	O
not	not	O
demonstrate	demonstrate	O
acute	acute	O
infarction	infarction	B-Disease
and	and	O
organic	organic	O
brain	brain	O
lesions	lesions	O
.	.	O

Initiation	initiation	O
of	of	O
high-flux	high-flux	O
hemodialysis	hemodialysis	O
rapidly	rapidly	O
reversed	reversed	O
the	the	O
neurologic	neurologic	O
symptoms	symptoms	O
within	within	O
4	4	O
hours	hours	O
.	.	O

Piperacillin-induced	piperacillin-induced	O
encephalopathy	encephalopathy	B-Disease
should	should	O
be	be	O
considered	considered	O
in	in	O
any	any	O
uremic	uremic	O
patients	patients	O
with	with	O
unexplained	unexplained	O
neurological	neurological	O
manifestations	manifestations	O
.	.	O

CAPD	capd	O
is	is	O
inefficient	inefficient	O
in	in	O
removing	removing	O
piperacillin	piperacillin	O
,	,	O
whereas	whereas	O
hemodialysis	hemodialysis	O
can	can	O
rapidly	rapidly	O
terminate	terminate	O
the	the	O
piperacillin-induced	piperacillin-induced	O
encephalopathy	encephalopathy	B-Disease
.	.	O

Frequency	frequency	O
of	of	O
transient	transient	O
ipsilateral	ipsilateral	O
vocal	vocal	B-Disease
cord	cord	I-Disease
paralysis	paralysis	B-Disease
in	in	O
patients	patients	O
undergoing	undergoing	O
carotid	carotid	O
endarterectomy	endarterectomy	O
under	under	O
local	local	O
anesthesia	anesthesia	O
.	.	O

BACKGROUND	background	O
:	:	O
Especially	especially	O
because	because	O
of	of	O
improvements	improvements	O
in	in	O
clinical	clinical	O
neurologic	neurologic	O
monitoring	monitoring	O
,	,	O
carotid	carotid	O
endarterectomy	endarterectomy	O
done	done	O
under	under	O
local	local	O
anesthesia	anesthesia	O
has	has	O
become	become	O
the	the	O
technique	technique	O
of	of	O
choice	choice	O
in	in	O
several	several	O
centers	centers	O
.	.	O

Temporary	temporary	O
ipsilateral	ipsilateral	O
vocal	vocal	O
nerve	nerve	O
palsies	palsies	O
due	due	O
to	to	O
local	local	O
anesthetics	anesthetics	O
have	have	O
been	been	O
described	described	O
,	,	O
however	however	O
.	.	O

Such	such	O
complications	complications	O
are	are	O
most	most	O
important	important	O
in	in	O
situations	situations	O
where	where	O
there	there	O
is	is	O
a	a	O
pre-existing	pre-existing	O
contralateral	contralateral	O
paralysis	paralysis	B-Disease
.	.	O

We	we	O
therefore	therefore	O
examined	examined	O
the	the	O
effect	effect	O
of	of	O
local	local	O
anesthesia	anesthesia	O
on	on	O
vocal	vocal	O
cord	cord	O
function	function	O
to	to	O
better	better	O
understand	understand	O
its	its	O
possible	possible	O
consequences	consequences	O
.	.	O

METHODS	methods	O
:	:	O
This	this	O
prospective	prospective	O
study	study	O
included	included	O
28	28	O
patients	patients	O
undergoing	undergoing	O
carotid	carotid	O
endarterectomy	endarterectomy	O
under	under	O
local	local	O
anesthesia	anesthesia	O
.	.	O

Vocal	vocal	O
cord	cord	O
function	function	O
was	was	O
evaluated	evaluated	O
before	before	O
,	,	O
during	during	O
,	,	O
and	and	O
after	after	O
surgery	surgery	O
(	(	O
postoperative	postoperative	O
day	day	O
1	1	O
)	)	O
using	using	O
flexible	flexible	O
laryngoscopy	laryngoscopy	O
.	.	O

Anesthesia	anesthesia	O
was	was	O
performed	performed	O
by	by	O
injecting	injecting	O
20	20	O
to	to	O
40	40	O
mL	ml	O
of	of	O
a	a	O
mixture	mixture	O
of	of	O
long-acting	long-acting	O
(	(	O
ropivacaine	ropivacaine	O
)	)	O
and	and	O
short-acting	short-acting	O
(	(	O
prilocaine	prilocaine	B-Chemical
)	)	O
anesthetic	anesthetic	O
.	.	O

RESULTS	results	O
:	:	O
All	all	O
patients	patients	O
had	had	O
normal	normal	O
vocal	vocal	O
cord	cord	O
function	function	O
preoperatively	preoperatively	O
.	.	O

Twelve	twelve	O
patients	patients	O
(	(	O
43	43	O
%	%	O
)	)	O
were	were	O
found	found	O
to	to	O
have	have	O
intraoperative	intraoperative	O
ipsilateral	ipsilateral	O
vocal	vocal	B-Disease
cord	cord	I-Disease
paralysis	paralysis	B-Disease
.	.	O

It	it	O
resolved	resolved	O
in	in	O
all	all	O
cases	cases	O
<	<	O
or	or	O
=	=	O
24	24	O
hours	hours	O
.	.	O

There	there	O
were	were	O
no	no	O
significant	significant	O
differences	differences	O
in	in	O
operating	operating	O
time	time	O
or	or	O
volume	volume	O
or	or	O
frequency	frequency	O
of	of	O
anesthetic	anesthetic	O
administration	administration	O
in	in	O
patients	patients	O
with	with	O
temporary	temporary	O
vocal	vocal	B-Disease
cord	cord	I-Disease
paralysis	paralysis	B-Disease
compared	compared	O
with	with	O
those	those	O
without	without	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Local	local	O
anesthesia	anesthesia	O
led	led	O
to	to	O
temporary	temporary	O
ipsilateral	ipsilateral	O
vocal	vocal	B-Disease
cord	cord	I-Disease
paralysis	paralysis	B-Disease
in	in	O
almost	almost	O
half	half	O
of	of	O
these	these	O
patients	patients	O
.	.	O

Because	because	O
pre-existing	pre-existing	O
paralysis	paralysis	B-Disease
is	is	O
of	of	O
a	a	O
relevant	relevant	O
frequency	frequency	O
(	(	O
up	up	O
to	to	O
3	3	O
%	%	O
)	)	O
,	,	O
a	a	O
preoperative	preoperative	O
evaluation	evaluation	O
of	of	O
vocal	vocal	O
cord	cord	O
function	function	O
before	before	O
carotid	carotid	O
endarterectomy	endarterectomy	O
under	under	O
local	local	O
anesthesia	anesthesia	O
is	is	O
recommended	recommended	O
to	to	O
avoid	avoid	O
intraoperative	intraoperative	O
bilateral	bilateral	O
paralysis	paralysis	B-Disease
.	.	O

In	in	O
patients	patients	O
with	with	O
preoperative	preoperative	O
contralateral	contralateral	O
vocal	vocal	B-Disease
cord	cord	I-Disease
paralysis	paralysis	B-Disease
,	,	O
surgery	surgery	O
under	under	O
general	general	O
anesthesia	anesthesia	O
should	should	O
be	be	O
considered	considered	O
.	.	O

Impaired	impaired	O
fear	fear	O
recognition	recognition	O
in	in	O
regular	regular	O
recreational	recreational	O
cocaine	cocaine	B-Chemical
users	users	O
.	.	O

INTRODUCTION	introduction	O
:	:	O
The	the	O
ability	ability	O
to	to	O
read	read	O
facial	facial	O
expressions	expressions	O
is	is	O
essential	essential	O
for	for	O
normal	normal	O
human	human	O
social	social	O
interaction	interaction	O
.	.	O

The	the	O
aim	aim	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
conduct	conduct	O
the	the	O
first	first	O
investigation	investigation	O
of	of	O
facial	facial	O
expression	expression	O
recognition	recognition	O
performance	performance	O
in	in	O
recreational	recreational	O
cocaine	cocaine	B-Chemical
users	users	O
.	.	O

MATERIALS	materials	O
AND	and	O
METHODS	methods	O
:	:	O
Three	three	O
groups	groups	O
,	,	O
comprised	comprised	O
of	of	O
21	21	O
cocaine	cocaine	B-Chemical
naive	naive	O
participants	participants	O
(	(	O
CN	cn	O
)	)	O
,	,	O
_	 	O
30	30	O
occasional	occasional	O
cocaine	cocaine	B-Chemical
(	(	O
OC	oc	B-Chemical
)	)	O
,	,	O
and	and	O
48	48	O
regular	regular	O
recreational	recreational	O
cocaine	cocaine	B-Chemical
(	(	O
RC	rc	O
)	)	O
users	users	O
,	,	O
were	were	O
compared	compared	O
.	.	O

An	an	O
emotional	emotional	O
facial	facial	O
expression	expression	O
(	(	O
EFE	efe	O
)	)	O
task	task	O
consisting	consisting	O
of	of	O
a	a	O
male	male	O
and	and	O
female	female	O
face	face	O
expressing	expressing	O
six	six	O
basic	basic	O
emotions	emotions	O
(	(	O
happiness	happiness	O
,	,	O
surprise	surprise	O
,	,	O
sadness	sadness	O
,	,	O
anger	anger	O
,	,	O
fear	fear	O
,	,	O
and	and	O
disgust	disgust	O
)	)	O
was	was	O
administered	administered	O
.	.	O

Mean	mean	O
percent	percent	O
accuracy	accuracy	O
and	and	O
latencies	latencies	O
for	for	O
correct	correct	O
responses	responses	O
across	across	O
eight	eight	O
presentations	presentations	O
of	of	O
each	each	O
basic	basic	O
emotion	emotion	O
were	were	O
derived	derived	O
.	.	O

Participants	participants	O
were	were	O
also	also	O
assessed	assessed	O
with	with	O
the	the	O
"	"	O
Eyes	eyes	O
task	task	O
"	"	O
to	to	O
investigate	investigate	O
their	their	O
ability	ability	O
to	to	O
recognize	recognize	O
more	more	O
complex	complex	O
emotional	emotional	O
states	states	O
and	and	O
the	the	O
Symptom	symptom	O
CheckList-90-Revised	checklist-90-revised	O
to	to	O
measure	measure	O
psychopathology	psychopathology	O
.	.	O

RESULTS	results	O
:	:	O
There	there	O
were	were	O
no	no	O
group	group	O
differences	differences	O
in	in	O
psychopathology	psychopathology	O
or	or	O
"	"	O
eyes	eyes	O
task	task	O
"	"	O
performance	performance	O
,	,	O
but	but	O
the	the	O
RC	rc	O
group	group	O
,	,	O
who	who	O
otherwise	otherwise	O
had	had	O
similar	similar	O
illicit	illicit	O
substance	substance	O
use	use	O
histories	histories	O
to	to	O
the	the	O
OC	oc	B-Chemical
group	group	O
,	,	O
exhibited	exhibited	O
impaired	impaired	O
fear	fear	O
recognition	recognition	O
accuracy	accuracy	O
compared	compared	O
to	to	O
the	the	O
OC	oc	B-Chemical
and	and	O
CN	cn	O
groups	groups	O
.	.	O

The	the	O
RC	rc	O
group	group	O
also	also	O
correctly	correctly	O
identified	identified	O
anger	anger	O
,	,	O
fear	fear	O
,	,	O
happiness	happiness	O
,	,	O
and	and	O
surprise	surprise	O
,	,	O
more	more	O
slowly	slowly	O
than	than	O
CN	cn	O
,	,	O
but	but	O
not	not	O
OC	oc	B-Chemical
participants	participants	O
.	.	O

The	the	O
OC	oc	B-Chemical
group	group	O
was	was	O
slower	slower	O
than	than	O
CN	cn	O
when	when	O
correctly	correctly	O
identifying	identifying	O
disgust	disgust	O
.	.	O

The	the	O
selective	selective	O
deficit	deficit	O
in	in	O
fear	fear	O
recognition	recognition	O
accuracy	accuracy	O
manifested	manifested	O
by	by	O
the	the	O
RC	rc	O
group	group	O
can	can	O
not	not	O
be	be	O
explained	explained	O
by	by	O
the	the	O
subacute	subacute	O
effects	effects	O
of	of	O
cocaine	cocaine	B-Chemical
,	,	O
or	or	O
ecstasy	ecstasy	B-Chemical
,	,	O
because	because	O
recent	recent	O
and	and	O
less	less	O
recent	recent	O
users	users	O
of	of	O
these	these	O
drugs	drugs	O
within	within	O
this	this	O
group	group	O
were	were	O
similarly	similarly	O
impaired	impaired	O
.	.	O

Possible	possible	O
parallels	parallels	O
between	between	O
RC	rc	O
users	users	O
and	and	O
psychopaths	psychopaths	O
with	with	O
respect	respect	O
to	to	O
impaired	impaired	O
fear	fear	O
recognition	recognition	O
,	,	O
amygdala	amygdala	O
dysfunction	dysfunction	O
,	,	O
and	and	O
etiology	etiology	O
are	are	O
discussed	discussed	O
.	.	O

Damage	damage	O
of	of	O
substantia	substantia	O
nigra	nigra	O
pars	pars	O
reticulata	reticulata	O
during	during	O
pilocarpine-induced	pilocarpine-induced	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
in	in	O
the	the	O
rat	rat	O
:	:	O
immunohistochemical	immunohistochemical	O
study	study	O
of	of	O
neurons	neurons	O
,	,	O
astrocytes	astrocytes	O
and	and	O
serum-protein	serum-protein	O
extravasation	extravasation	O
.	.	O

The	the	O
substantia	substantia	O
nigra	nigra	O
has	has	O
a	a	O
gating	gating	O
function	function	O
controlling	controlling	O
the	the	O
spread	spread	O
of	of	O
epileptic	epileptic	B-Disease
seizure	seizure	B-Disease
activity	activity	O
.	.	O

Additionally	additionally	O
,	,	O
in	in	O
models	models	O
of	of	O
prolonged	prolonged	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
the	the	O
pars	pars	O
reticulata	reticulata	O
of	of	O
substantia	substantia	O
nigra	nigra	O
(	(	O
SNR	snr	O
)	)	O
suffers	suffers	O
from	from	O
a	a	O
massive	massive	O
lesion	lesion	O
which	which	O
may	may	O
arise	arise	O
from	from	O
a	a	O
massive	massive	O
metabolic	metabolic	O
derangement	derangement	O
and	and	O
hyperexcitation	hyperexcitation	O
developing	developing	O
in	in	O
the	the	O
activated	activated	O
SNR	snr	O
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
was	was	O
induced	induced	O
by	by	O
systemic	systemic	O
injection	injection	O
of	of	O
pilocarpine	pilocarpine	B-Chemical
in	in	O
rats	rats	O
.	.	O

The	the	O
neuropathology	neuropathology	O
of	of	O
SNR	snr	O
was	was	O
investigated	investigated	O
using	using	O
immunohistochemical	immunohistochemical	O
techniques	techniques	O
with	with	O
the	the	O
major	major	O
emphasis	emphasis	O
on	on	O
the	the	O
time-course	time-course	O
of	of	O
changes	changes	O
in	in	O
neurons	neurons	O
and	and	O
astrocytes	astrocytes	O
.	.	O

Animals	animals	O
surviving	surviving	O
20	20	O
,	,	O
30	30	O
,	,	O
40	40	O
,	,	O
60	60	O
min	min	O
,	,	O
2	2	O
,	,	O
3	3	O
,	,	O
6	6	O
hours	hours	O
,	,	O
1	1	O
,	,	O
2	2	O
,	,	O
and	and	O
3	3	O
days	days	O
after	after	O
induction	induction	O
of	of	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
were	were	O
perfusion-fixed	perfusion-fixed	O
,	,	O
and	and	O
brains	brains	O
processed	processed	O
for	for	O
immunohistochemical	immunohistochemical	O
staining	staining	O
of	of	O
SNR	snr	O
.	.	O

Nissl-staining	nissl-staining	O
and	and	O
antibodies	antibodies	O
against	against	O
the	the	O
neuron-specific	neuron-specific	O
calcium-binding	calcium-binding	O
protein	protein	O
,	,	O
parvalbumin	parvalbumin	O
,	,	O
served	served	O
to	to	O
detect	detect	O
neuronal	neuronal	B-Disease
damage	damage	I-Disease
in	in	O
SNR	snr	O
.	.	O

Antibodies	antibodies	O
against	against	O
the	the	O
astroglia-specific	astroglia-specific	O
cytoskeletal	cytoskeletal	O
protein	protein	O
,	,	O
glial	glial	B-Chemical
fibrillary	fibrillary	I-Chemical
acidic	acidic	I-Chemical
protein	protein	I-Chemical
(	(	O
GFAP	gfap	O
)	)	O
,	,	O
and	and	O
against	against	O
the	the	O
glial	glial	O
calcium-binding	calcium-binding	O
protein	protein	O
,	,	O
S-100	s-100	O
protein	protein	O
,	,	O
were	were	O
used	used	O
to	to	O
assess	assess	O
the	the	O
status	status	O
of	of	O
astrocytes	astrocytes	O
.	.	O

Immunohistochemical	immunohistochemical	O
staining	staining	O
for	for	O
serum-albumin	serum-albumin	O
and	and	O
immunoglobulins	immunoglobulins	O
in	in	O
brain	brain	O
tissue	tissue	O
was	was	O
taken	taken	O
as	as	O
indicator	indicator	O
of	of	O
blood-brain	blood-brain	O
barrier	barrier	O
disturbances	disturbances	O
and	and	O
vasogenic	vasogenic	O
edema	edema	B-Disease
formation	formation	O
.	.	O

Immunohistochemical	immunohistochemical	O
staining	staining	O
indicated	indicated	O
loss	loss	O
of	of	O
GFAP-staining	gfap-staining	O
already	already	O
at	at	O
30	30	O
min	min	O
after	after	O
induction	induction	O
of	of	O
seizures	seizures	B-Disease
in	in	O
an	an	O
oval	oval	O
focus	focus	O
situated	situated	O
in	in	O
the	the	O
center	center	O
of	of	O
SNR	snr	O
while	while	O
sparing	sparing	O
medial	medial	O
and	and	O
lateral	lateral	O
aspects	aspects	O
.	.	O

At	at	O
1	1	O
h	h	B-Chemical
there	there	O
was	was	O
additional	additional	O
vacuolation	vacuolation	O
in	in	O
S-100	s-100	O
protein	protein	O
staining	staining	O
.	.	O

By	by	O
2	2	O
hours	hours	O
,	,	O
parvalbumin-staining	parvalbumin-staining	O
changed	changed	O
in	in	O
the	the	O
central	central	O
SNR	snr	O
indicating	indicating	O
neuronal	neuronal	B-Disease
damage	damage	I-Disease
,	,	O
and	and	O
Nissl-staining	nissl-staining	O
visualized	visualized	O
some	some	O
neuronal	neuronal	O
distortion	distortion	O
.	.	O

Staining	staining	O
for	for	O
serum-proteins	serum-proteins	O
occurred	occurred	O
in	in	O
a	a	O
patchy	patchy	O
manner	manner	O
throughout	throughout	O
the	the	O
forebrain	forebrain	O
during	during	O
the	the	O
first	first	O
hours	hours	O
.	.	O

By	by	O
6	6	O
h	h	B-Chemical
,	,	O
vasogenic	vasogenic	O
edema	edema	B-Disease
covered	covered	O
the	the	O
lesioned	lesioned	O
SNR	snr	O
.	.	O

By	by	O
24	24	O
h	h	B-Chemical
,	,	O
glial	glial	O
and	and	O
neuronal	neuronal	O
markers	markers	O
indicated	indicated	O
a	a	O
massive	massive	O
lesion	lesion	O
in	in	O
the	the	O
center	center	O
of	of	O
SNR	snr	O
.	.	O

By	by	O
48	48	O
-	-	O
72	72	O
h	h	B-Chemical
,	,	O
astrocytes	astrocytes	O
surrounding	surrounding	O
the	the	O
lesion	lesion	O
increased	increased	O
in	in	O
size	size	O
,	,	O
and	and	O
polymorphic	polymorphic	O
phagocytotic	phagocytotic	O
cells	cells	O
invaded	invaded	O
the	the	O
damaged	damaged	O
area	area	O
.	.	O

In	in	O
a	a	O
further	further	O
group	group	O
of	of	O
animals	animals	O
surviving	surviving	O
1	1	O
to	to	O
5	5	O
days	days	O
,	,	O
conventional	conventional	O
paraffin-sections	paraffin-sections	O
confirmed	confirmed	O
the	the	O
neuronal	neuronal	O
and	and	O
glial	glial	O
damage	damage	O
of	of	O
SNR	snr	O
.	.	O

Additional	additional	O
pathology	pathology	O
of	of	O
similar	similar	O
quality	quality	O
was	was	O
found	found	O
in	in	O
the	the	O
globus	globus	O
pallidus	pallidus	O
.	.	O

Since	since	O
astrocytes	astrocytes	O
were	were	O
always	always	O
damaged	damaged	O
in	in	O
parallel	parallel	O
with	with	O
neurons	neurons	O
in	in	O
SNR	snr	O
it	it	O
is	is	O
proposed	proposed	O
that	that	O
the	the	O
anatomical	anatomical	O
and	and	O
functional	functional	O
interrelationship	interrelationship	O
between	between	O
neurons	neurons	O
and	and	O
astrocytes	astrocytes	O
is	is	O
particularly	particularly	O
tight	tight	O
in	in	O
SNR	snr	O
.	.	O

Both	both	O
cell	cell	O
elements	elements	O
may	may	O
suffer	suffer	O
in	in	O
common	common	O
from	from	O
metabolic	metabolic	O
disturbance	disturbance	O
and	and	O
neurotransmitter	neurotransmitter	O
dysfunction	dysfunction	O
as	as	O
occur	occur	O
during	during	O
massive	massive	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
.	.	O

Neuroprotective	neuroprotective	O
effects	effects	O
of	of	O
melatonin	melatonin	O
upon	upon	O
the	the	O
offspring	offspring	O
cerebellar	cerebellar	O
cortex	cortex	O
in	in	O
the	the	O
rat	rat	O
model	model	O
of	of	O
BCNU-induced	bcnu-induced	O
cortical	cortical	O
dysplasia	dysplasia	O
.	.	O

Cortical	cortical	O
dysplasia	dysplasia	O
is	is	O
a	a	O
malformation	malformation	O
characterized	characterized	O
by	by	O
defects	defects	O
in	in	O
proliferation	proliferation	O
,	,	O
migration	migration	O
and	and	O
maturation	maturation	O
.	.	O

This	this	O
study	study	O
was	was	O
designed	designed	O
to	to	O
evaluate	evaluate	O
the	the	O
alterations	alterations	O
in	in	O
offspring	offspring	O
rat	rat	O
cerebellum	cerebellum	O
induced	induced	O
by	by	O
maternal	maternal	O
exposure	exposure	O
to	to	O
carmustine-[1,3-bis	carmustine-[1,3-bis	O
(2-chloroethyl)-1-nitrosoure	(2-chloroethyl)-1-nitrosoure	O
]	]	O
(	(	O
BCNU	bcnu	B-Chemical
)	)	O
and	and	O
to	to	O
investigate	investigate	O
the	the	O
effects	effects	O
of	of	O
exogenous	exogenous	O
melatonin	melatonin	O
upon	upon	O
cerebellar	cerebellar	O
BCNU-induced	bcnu-induced	O
cortical	cortical	O
dysplasia	dysplasia	O
,	,	O
using	using	O
histological	histological	O
and	and	O
biochemical	biochemical	O
analyses	analyses	O
.	.	O

Pregnant	pregnant	O
Wistar	wistar	O
rats	rats	O
were	were	O
assigned	assigned	O
to	to	O
five	five	O
groups	groups	O
:	:	O
intact-control	intact-control	O
,	,	O
saline-control	saline-control	O
,	,	O
melatonin-treated	melatonin-treated	O
,	,	O
BCNU-exposed	bcnu-exposed	O
and	and	O
BCNU-exposed	bcnu-exposed	O
plus	plus	O
melatonin	melatonin	O
.	.	O

Rats	rats	O
were	were	O
exposed	exposed	O
to	to	O
BCNU	bcnu	B-Chemical
on	on	O
embryonic	embryonic	O
day	day	O
15	15	O
and	and	O
melatonin	melatonin	O
was	was	O
given	given	O
until	until	O
delivery	delivery	O
.	.	O

Immuno/histochemistry	immuno/histochemistry	O
and	and	O
electron	electron	O
microscopy	microscopy	O
were	were	O
carried	carried	O
out	out	O
on	on	O
the	the	O
offspring	offspring	O
cerebellum	cerebellum	O
,	,	O
and	and	O
levels	levels	O
of	of	O
malondialdehyde	malondialdehyde	B-Chemical
and	and	O
superoxide	superoxide	B-Chemical
dismutase	dismutase	I-Chemical
were	were	O
determined	determined	O
.	.	O

Histopathologically	histopathologically	O
,	,	O
typical	typical	O
findings	findings	O
were	were	O
observed	observed	O
in	in	O
the	the	O
cerebella	cerebella	O
from	from	O
the	the	O
control	control	O
groups	groups	O
,	,	O
but	but	O
the	the	O
findings	findings	O
consistent	consistent	O
with	with	O
early	early	O
embryonic	embryonic	O
development	development	O
were	were	O
noted	noted	O
in	in	O
BCNU-exposed	bcnu-exposed	O
cortical	cortical	O
dysplasia	dysplasia	O
group	group	O
.	.	O

There	there	O
was	was	O
a	a	O
marked	marked	O
increase	increase	O
in	in	O
the	the	O
number	number	O
of	of	O
TUNEL	tunel	O
positive	positive	O
cells	cells	O
and	and	O
nestin	nestin	O
positive	positive	O
cells	cells	O
in	in	O
BCNU-exposed	bcnu-exposed	O
group	group	O
,	,	O
but	but	O
a	a	O
decreased	decreased	O
immunoreactivity	immunoreactivity	O
to	to	O
glial	glial	B-Chemical
fibrillary	fibrillary	I-Chemical
acidic	acidic	I-Chemical
protein	protein	I-Chemical
,	,	O
synaptophysin	synaptophysin	O
and	and	O
transforming	transforming	B-Chemical
growth	growth	I-Chemical
factor	factor	I-Chemical
beta1	beta1	I-Chemical
was	was	O
observed	observed	O
,	,	O
indicating	indicating	O
a	a	O
delayed	delayed	O
maturation	maturation	O
,	,	O
and	and	O
melatonin	melatonin	O
significantly	significantly	O
reversed	reversed	O
these	these	O
changes	changes	O
.	.	O

Malondialdehyde	malondialdehyde	B-Chemical
level	level	O
in	in	O
BCNU-exposed	bcnu-exposed	O
group	group	O
was	was	O
higher	higher	O
than	than	O
those	those	O
in	in	O
control	control	O
groups	groups	O
and	and	O
melatonin	melatonin	O
decreased	decreased	O
malondialdehyde	malondialdehyde	B-Chemical
levels	levels	O
in	in	O
BCNU	bcnu	B-Chemical
group	group	O
(	(	O
P<0.01	p<0.01	O
)	)	O
,	,	O
while	while	O
there	there	O
were	were	O
no	no	O
significant	significant	O
differences	differences	O
in	in	O
the	the	O
superoxide	superoxide	B-Chemical
dismutase	dismutase	I-Chemical
levels	levels	O
between	between	O
these	these	O
groups	groups	O
.	.	O

These	these	O
data	data	O
suggest	suggest	O
that	that	O
exposure	exposure	O
of	of	O
animals	animals	O
to	to	O
BCNU	bcnu	B-Chemical
during	during	O
pregnancy	pregnancy	O
leads	leads	O
to	to	O
delayed	delayed	O
maturation	maturation	O
of	of	O
offspring	offspring	O
cerebellum	cerebellum	O
and	and	O
melatonin	melatonin	O
protects	protects	O
the	the	O
cerebellum	cerebellum	O
against	against	O
the	the	O
effects	effects	O
of	of	O
BCNU	bcnu	B-Chemical
.	.	O

Reduced	reduced	O
cardiotoxicity	cardiotoxicity	B-Disease
of	of	O
doxorubicin	doxorubicin	B-Chemical
given	given	O
in	in	O
the	the	O
form	form	O
of	of	O
N-(2-hydroxypropyl)methacrylamide	n-(2-hydroxypropyl)methacrylamide	O
conjugates	conjugates	O
:	:	O
and	and	O
experimental	experimental	O
study	study	O
in	in	O
the	the	O
rat	rat	O
.	.	O

A	a	O
rat	rat	O
model	model	O
was	was	O
used	used	O
to	to	O
evaluate	evaluate	O
the	the	O
general	general	O
acute	acute	O
toxicity	toxicity	B-Disease
and	and	O
the	the	O
late	late	O
cardiotoxicity	cardiotoxicity	B-Disease
of	of	O
4	4	O
mg/kg	mg/kg	O
doxorubicin	doxorubicin	B-Chemical
(	(	O
DOX	dox	B-Chemical
)	)	O
given	given	O
either	either	O
as	as	O
free	free	O
drug	drug	O
or	or	O
in	in	O
the	the	O
form	form	O
of	of	O
three	three	O
N-(2-hydroxypropyl)methacrylamide	n-(2-hydroxypropyl)methacrylamide	O
(	(	O
HPMA	hpma	O
)	)	O
copolymer	copolymer	O
conjugates	conjugates	O
.	.	O

In	in	O
these	these	O
HPMA	hpma	O
copolymers	copolymers	O
,	,	O
DOX	dox	B-Chemical
was	was	O
covalently	covalently	O
bound	bound	O
via	via	O
peptide	peptide	O
linkages	linkages	O
that	that	O
were	were	O
either	either	O
non-biodegradable	non-biodegradable	O
(	(	O
Gly-Gly	gly-gly	O
)	)	O
or	or	O
degradable	degradable	O
by	by	O
lysosomal	lysosomal	O
proteinases	proteinases	O
(	(	O
Gly-Phe-Leu-Gly	gly-phe-leu-gly	O
)	)	O
.	.	O

In	in	O
addition	addition	O
,	,	O
one	one	O
biodegradable	biodegradable	O
conjugate	conjugate	O
containing	containing	O
galactosamine	galactosamine	O
was	was	O
used	used	O
;	;	O
this	this	O
residue	residue	O
was	was	O
targeted	targeted	O
to	to	O
the	the	O
liver	liver	O
.	.	O

Over	over	O
the	the	O
first	first	O
3	3	O
weeks	weeks	O
after	after	O
the	the	O
i.v	i.v	O
.	.	O

administration	administration	O
of	of	O
free	free	O
and	and	O
polymer-bound	polymer-bound	O
DOX	dox	B-Chemical
,	,	O
all	all	O
animals	animals	O
showed	showed	O
a	a	O
transient	transient	O
reduction	reduction	O
in	in	O
body	body	B-Disease
weight	weight	I-Disease
.	.	O

However	however	O
,	,	O
the	the	O
maximal	maximal	O
reduction	reduction	O
in	in	O
body	body	B-Disease
weight	weight	I-Disease
seen	seen	O
in	in	O
animals	animals	O
that	that	O
received	received	O
polymer-bound	polymer-bound	O
DOX	dox	B-Chemical
(	(	O
4	4	O
mg/kg	mg/kg	O
)	)	O
was	was	O
significantly	significantly	O
lower	lower	O
than	than	O
that	that	O
observed	observed	O
in	in	O
those	those	O
that	that	O
received	received	O
free	free	O
DOX	dox	B-Chemical
(	(	O
4	4	O
mg/kg	mg/kg	O
)	)	O
or	or	O
a	a	O
mixture	mixture	O
of	of	O
the	the	O
unmodified	unmodified	O
parent	parent	O
HPMA	hpma	O
copolymer	copolymer	O
and	and	O
free	free	O
DOX	dox	B-Chemical
(	(	O
4	4	O
mg/kg	mg/kg	O
;	;	O
P	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
.	.	O

Throughout	throughout	O
the	the	O
study	study	O
(	(	O
20	20	O
weeks	weeks	O
)	)	O
,	,	O
deaths	deaths	B-Disease
related	related	O
to	to	O
cardiotoxicity	cardiotoxicity	B-Disease
were	were	O
observed	observed	O
only	only	O
in	in	O
animals	animals	O
that	that	O
received	received	O
either	either	O
free	free	O
DOX	dox	B-Chemical
or	or	O
the	the	O
mixture	mixture	O
of	of	O
HPMA	hpma	O
copolymer	copolymer	O
and	and	O
free	free	O
DOX	dox	B-Chemical
;	;	O
in	in	O
these	these	O
cases	cases	O
,	,	O
histological	histological	O
investigations	investigations	O
revealed	revealed	O
marked	marked	O
changes	changes	O
in	in	O
the	the	O
heart	heart	O
that	that	O
were	were	O
consistent	consistent	O
with	with	O
DOX-induced	dox-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

Sequential	sequential	O
measurements	measurements	O
of	of	O
cardiac	cardiac	O
output	output	O
in	in	O
surviving	surviving	O
animals	animals	O
that	that	O
received	received	O
either	either	O
free	free	O
DOX	dox	B-Chemical
or	or	O
the	the	O
mixture	mixture	O
of	of	O
HPMA	hpma	O
copolymer	copolymer	O
and	and	O
free	free	O
DOX	dox	B-Chemical
showed	showed	O
a	a	O
reduction	reduction	O
of	of	O
approximately	approximately	O
30	30	O
%	%	O
in	in	O
function	function	O
beginning	beginning	O
at	at	O
the	the	O
4th	4th	O
week	week	O
after	after	O
drug	drug	O
administration	administration	O
.	.	O

The	the	O
heart	heart	O
rate	rate	O
in	in	O
these	these	O
animals	animals	O
was	was	O
approximately	approximately	O
12	12	O
%	%	O
lower	lower	O
than	than	O
that	that	O
measured	measured	O
in	in	O
age-matched	age-matched	O
control	control	O
rats	rats	O
(	(	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

Animals	animals	O
that	that	O
were	were	O
given	given	O
the	the	O
HPMA	hpma	O
copolymer	copolymer	O
conjugates	conjugates	O
containing	containing	O
DOX	dox	B-Chemical
exhibited	exhibited	O
no	no	O
significant	significant	O
change	change	O
in	in	O
cardiac	cardiac	O
output	output	O
throughout	throughout	O
the	the	O
study	study	O
(	(	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

In	in	O
addition	addition	O
,	,	O
no	no	O
significant	significant	O
histological	histological	O
change	change	O
was	was	O
observed	observed	O
in	in	O
the	the	O
heart	heart	O
of	of	O
animals	animals	O
that	that	O
received	received	O
DOX	dox	B-Chemical
in	in	O
the	the	O
form	form	O
of	of	O
HPMA	hpma	O
copolymer	copolymer	O
conjugates	conjugates	O
and	and	O
were	were	O
killed	killed	O
at	at	O
the	the	O
end	end	O
of	of	O
the	the	O
study	study	O
.	.	O

However	however	O
,	,	O
these	these	O
animals	animals	O
had	had	O
shown	shown	O
a	a	O
significant	significant	O
increase	increase	O
in	in	O
heart	heart	O
rate	rate	O
beginning	beginning	O
at	at	O
8	8	O
weeks	weeks	O
after	after	O
drug	drug	O
administration	administration	O
(	(	O
P	p	O
less	less	O
than	than	O
0.01).(ABSTRACT	0.01).(abstract	O
TRUNCATED	truncated	O
AT	at	O
400	400	O
WORDS	words	O
)	)	O

Corneal	corneal	O
ulcers	ulcers	O
associated	associated	O
with	with	O
aerosolized	aerosolized	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
use	use	O
.	.	O

PURPOSE	purpose	O
:	:	O
We	we	O
report	report	O
4	4	O
cases	cases	O
of	of	O
corneal	corneal	O
ulcers	ulcers	O
associated	associated	O
with	with	O
drug	drug	B-Disease
abuse	abuse	I-Disease
.	.	O

The	the	O
pathogenesis	pathogenesis	O
of	of	O
these	these	O
ulcers	ulcers	O
and	and	O
management	management	O
of	of	O
these	these	O
patients	patients	O
are	are	O
also	also	O
reviewed	reviewed	O
.	.	O

METHODS	methods	O
:	:	O
Review	review	O
of	of	O
all	all	O
cases	cases	O
of	of	O
corneal	corneal	O
ulcers	ulcers	O
associated	associated	O
with	with	O
drug	drug	B-Disease
abuse	abuse	I-Disease
seen	seen	O
at	at	O
our	our	O
institution	institution	O
from	from	O
July	july	O
2006	2006	O
to	to	O
December	december	O
2006	2006	O
.	.	O

RESULTS	results	O
:	:	O
Four	four	O
patients	patients	O
with	with	O
corneal	corneal	O
ulcers	ulcers	O
associated	associated	O
with	with	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
use	use	O
were	were	O
reviewed	reviewed	O
.	.	O

All	all	O
corneal	corneal	O
ulcers	ulcers	O
were	were	O
cultured	cultured	O
,	,	O
and	and	O
the	the	O
patients	patients	O
were	were	O
admitted	admitted	O
to	to	O
the	the	O
hospital	hospital	O
for	for	O
intensive	intensive	O
topical	topical	O
antibiotic	antibiotic	O
treatment	treatment	O
.	.	O

Each	each	O
patient	patient	O
received	received	O
comprehensive	comprehensive	O
health	health	O
care	care	O
,	,	O
including	including	O
medical	medical	O
and	and	O
substance	substance	O
abuse	abuse	O
consultations	consultations	O
.	.	O

Streptococcal	streptococcal	O
organisms	organisms	O
were	were	O
found	found	O
in	in	O
3	3	O
cases	cases	O
and	and	O
Capnocytophaga	capnocytophaga	O
and	and	O
Brevibacterium	brevibacterium	O
casei	casei	O
in	in	O
1	1	O
patient	patient	O
.	.	O

The	the	O
infections	infections	B-Disease
responded	responded	O
to	to	O
antibiotic	antibiotic	O
treatment	treatment	O
.	.	O

Two	two	O
patients	patients	O
needed	needed	O
a	a	O
lateral	lateral	O
tarsorrhaphy	tarsorrhaphy	O
for	for	O
persistent	persistent	O
epithelial	epithelial	O
defects	defects	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Aerosolized	aerosolized	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
use	use	O
can	can	O
be	be	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
corneal	corneal	O
ulcers	ulcers	O
.	.	O

Drug	drug	B-Disease
abuse	abuse	I-Disease
provides	provides	O
additional	additional	O
challenges	challenges	O
for	for	O
management	management	O
.	.	O

Not	not	O
only	only	O
treatment	treatment	O
of	of	O
their	their	O
infections	infections	B-Disease
but	but	O
also	also	O
the	the	O
overall	overall	O
poor	poor	O
health	health	O
of	of	O
the	the	O
patients	patients	O
and	and	O
increased	increased	O
risk	risk	O
of	of	O
noncompliance	noncompliance	O
need	need	O
to	to	O
be	be	O
addressed	addressed	O
.	.	O

Comprehensive	comprehensive	O
care	care	O
may	may	O
provide	provide	O
the	the	O
patient	patient	O
the	the	O
opportunity	opportunity	O
to	to	O
discontinue	discontinue	O
their	their	O
substance	substance	O
abuse	abuse	O
,	,	O
improve	improve	O
their	their	O
overall	overall	O
health	health	O
,	,	O
and	and	O
prevent	prevent	O
future	future	O
corneal	corneal	O
complications	complications	O
.	.	O

Topical	topical	O
0.025	0.025	O
%	%	O
capsaicin	capsaicin	B-Chemical
in	in	O
chronic	chronic	O
post-herpetic	post-herpetic	O
neuralgia	neuralgia	O
:	:	O
efficacy	efficacy	O
,	,	O
predictors	predictors	O
of	of	O
response	response	O
and	and	O
long-term	long-term	O
course	course	O
.	.	O

In	in	O
order	order	O
to	to	O
evaluate	evaluate	O
the	the	O
efficacy	efficacy	O
,	,	O
time-course	time-course	O
of	of	O
action	action	O
and	and	O
predictors	predictors	O
of	of	O
response	response	O
to	to	O
topical	topical	O
capsaicin	capsaicin	B-Chemical
,	,	O
39	39	O
patients	patients	O
with	with	O
chronic	chronic	O
post-herpetic	post-herpetic	O
neuralgia	neuralgia	O
(	(	O
PHN	phn	O
)	)	O
,	,	O
median	median	O
duration	duration	O
24	24	O
months	months	O
,	,	O
were	were	O
treated	treated	O
with	with	O
0.025	0.025	O
%	%	O
capsaicin	capsaicin	B-Chemical
cream	cream	O
for	for	O
8	8	O
weeks	weeks	O
.	.	O

During	during	O
therapy	therapy	O
the	the	O
patients	patients	O
rated	rated	O
their	their	O
pain	pain	B-Disease
on	on	O
a	a	O
visual	visual	O
analogue	analogue	O
scale	scale	O
(	(	O
VAS	vas	O
)	)	O
and	and	O
a	a	O
verbal	verbal	O
outcome	outcome	O
scale	scale	O
.	.	O

A	a	O
follow-up	follow-up	O
investigation	investigation	O
was	was	O
performed	performed	O
10	10	O
-	-	O
12	12	O
months	months	O
after	after	O
study	study	O
onset	onset	O
on	on	O
the	the	O
patients	patients	O
who	who	O
had	had	O
improved	improved	O
.	.	O

Nineteen	nineteen	O
patients	patients	O
(	(	O
48.7	48.7	O
%	%	O
)	)	O
substantially	substantially	O
improved	improved	O
after	after	O
the	the	O
8-week	8-week	O
trial	trial	O
;	;	O
5	5	O
(	(	O
12.8	12.8	O
%	%	O
)	)	O
discontinued	discontinued	O
therapy	therapy	O
due	due	O
to	to	O
side-effects	side-effects	O
such	such	O
as	as	O
intolerable	intolerable	O
capsaicin-induced	capsaicin-induced	O
burning	burning	O
sensations	sensations	O
(	(	O
4	4	O
)	)	O
or	or	O
mastitis	mastitis	O
(	(	O
1	1	O
)	)	O
;	;	O
15	15	O
(	(	O
38.5	38.5	O
%	%	O
)	)	O
reported	reported	O
no	no	O
benefit	benefit	O
.	.	O

The	the	O
decrease	decrease	O
in	in	O
VAS	vas	O
ratings	ratings	O
was	was	O
significant	significant	O
after	after	O
2	2	O
weeks	weeks	O
of	of	O
continuous	continuous	O
application	application	O
.	.	O

Of	of	O
the	the	O
responders	responders	O
72.2	72.2	O
%	%	O
were	were	O
still	still	O
improved	improved	O
at	at	O
the	the	O
follow-up	follow-up	O
;	;	O
only	only	O
one-third	one-third	O
of	of	O
them	them	O
had	had	O
continued	continued	O
application	application	O
irregularly	irregularly	O
.	.	O

Treatment	treatment	O
effect	effect	O
was	was	O
not	not	O
dependent	dependent	O
on	on	O
patient	patient	O
's	's	O
age	age	O
,	,	O
duration	duration	O
or	or	O
localization	localization	O
of	of	O
PHN	phn	O
(	(	O
trigeminal	trigeminal	O
involvement	involvement	O
was	was	O
excluded	excluded	O
)	)	O
,	,	O
sensory	sensory	O
disturbance	disturbance	O
or	or	O
pain	pain	B-Disease
character	character	O
.	.	O

Treatment	treatment	O
response	response	O
was	was	O
not	not	O
correlated	correlated	O
with	with	O
the	the	O
incidence	incidence	O
,	,	O
time-course	time-course	O
or	or	O
severity	severity	O
of	of	O
capsaicin-induced	capsaicin-induced	O
burning	burning	O
.	.	O

If	if	O
confirmed	confirmed	O
in	in	O
controlled	controlled	O
trials	trials	O
,	,	O
the	the	O
long-term	long-term	O
results	results	O
of	of	O
this	this	O
open	open	O
,	,	O
non-randomized	non-randomized	O
study	study	O
might	might	O
indicate	indicate	O
that	that	O
the	the	O
analgesic	analgesic	O
effect	effect	O
of	of	O
capsaicin	capsaicin	B-Chemical
in	in	O
PHN	phn	O
is	is	O
mediated	mediated	O
by	by	O
both	both	O
interference	interference	O
with	with	O
neuropeptide	neuropeptide	O
metabolism	metabolism	O
and	and	O
morphological	morphological	O
changes	changes	O
(	(	O
perhaps	perhaps	O
degeneration	degeneration	O
)	)	O
of	of	O
nociceptive	nociceptive	O
afferents	afferents	O
.	.	O

Myo-inositol-1-phosphate	myo-inositol-1-phosphate	O
(	(	O
MIP	mip	O
)	)	O
synthase	synthase	O
inhibition	inhibition	O
:	:	O
in-vivo	in-vivo	O
study	study	O
in	in	O
rats	rats	O
.	.	O

Lithium	lithium	B-Chemical
and	and	O
valproate	valproate	B-Chemical
are	are	O
the	the	O
prototypic	prototypic	O
mood	mood	O
stabilizers	stabilizers	O
and	and	O
have	have	O
diverse	diverse	O
structures	structures	O
and	and	O
targets	targets	O
.	.	O

Both	both	O
drugs	drugs	O
influence	influence	O
inositol	inositol	O
metabolism	metabolism	O
.	.	O

Lithium	lithium	B-Chemical
inhibits	inhibits	O
IMPase	impase	O
and	and	O
valproate	valproate	B-Chemical
inhibits	inhibits	O
MIP	mip	O
synthase	synthase	O
.	.	O

This	this	O
study	study	O
shows	shows	O
that	that	O
MIP	mip	O
synthase	synthase	O
inhibition	inhibition	O
does	does	O
not	not	O
replicate	replicate	O
or	or	O
augment	augment	O
the	the	O
effects	effects	O
of	of	O
lithium	lithium	B-Chemical
in	in	O
the	the	O
inositol	inositol	O
sensitive	sensitive	O
pilocarpine-induced	pilocarpine-induced	O
seizures	seizures	B-Disease
model	model	O
.	.	O

This	this	O
lack	lack	O
of	of	O
effects	effects	O
may	may	O
stem	stem	O
from	from	O
the	the	O
low	low	O
contribution	contribution	O
of	of	O
de-novo	de-novo	O
synthesis	synthesis	O
to	to	O
cellular	cellular	O
inositol	inositol	O
supply	supply	O
or	or	O
to	to	O
the	the	O
inhibition	inhibition	O
of	of	O
the	the	O
de-novo	de-novo	O
synthesis	synthesis	O
by	by	O
lithium	lithium	B-Chemical
itself	itself	O
.	.	O

Non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs-associated	drugs-associated	O
acute	acute	O
interstitial	interstitial	B-Disease
nephritis	nephritis	I-Disease
with	with	O
granular	granular	O
tubular	tubular	O
basement	basement	O
membrane	membrane	O
deposits	deposits	O
.	.	O

Acute	acute	O
tubulo-interstitial	tubulo-interstitial	O
nephritis	nephritis	O
(	(	O
ATIN	atin	O
)	)	O
is	is	O
an	an	O
important	important	O
cause	cause	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
resulting	resulting	O
from	from	O
a	a	O
variety	variety	O
of	of	O
insults	insults	O
,	,	O
including	including	O
immune	immune	O
complex-mediated	complex-mediated	O
tubulo-interstitial	tubulo-interstitial	O
injury	injury	O
,	,	O
but	but	O
drugs	drugs	O
such	such	O
as	as	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
(	(	O
NSAIDs	nsaids	O
)	)	O
are	are	O
a	a	O
far	far	O
more	more	O
frequent	frequent	O
cause	cause	O
.	.	O

Overall	overall	O
,	,	O
as	as	O
an	an	O
entity	entity	O
,	,	O
ATIN	atin	O
remains	remains	O
under-diagnosed	under-diagnosed	O
,	,	O
as	as	O
symptoms	symptoms	O
resolve	resolve	O
spontaneously	spontaneously	O
if	if	O
the	the	O
medication	medication	O
is	is	O
stopped	stopped	O
.	.	O

We	we	O
report	report	O
on	on	O
a	a	O
14-year-old	14-year-old	O
boy	boy	O
who	who	O
developed	developed	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
2	2	O
weeks	weeks	O
after	after	O
aortic	aortic	O
valve	valve	O
surgery	surgery	O
.	.	O

He	he	O
was	was	O
put	put	O
on	on	O
aspirin	aspirin	B-Chemical
following	following	O
surgery	surgery	O
and	and	O
took	took	O
ibuprofen	ibuprofen	B-Chemical
for	for	O
fever	fever	B-Disease
for	for	O
nearly	nearly	O
a	a	O
week	week	O
prior	prior	O
to	to	O
presentation	presentation	O
.	.	O

He	he	O
then	then	O
presented	presented	O
to	to	O
the	the	O
emergency	emergency	O
department	department	O
feeling	feeling	O
quite	quite	O
ill	ill	O
and	and	O
was	was	O
found	found	O
to	to	O
have	have	O
a	a	O
blood	blood	B-Chemical
urea	urea	B-Chemical
nitrogen	nitrogen	I-Chemical
(	(	O
BUN	bun	O
)	)	O
concentration	concentration	O
of	of	O
of	of	O
147	147	O
mg/dl	mg/dl	O
,	,	O
creatinine	creatinine	B-Chemical
of	of	O
15.3	15.3	O
mg/dl	mg/dl	O
and	and	O
serum	serum	O
potassium	potassium	B-Chemical
of	of	O
8.7	8.7	O
mEq/l	meq/l	O
.	.	O

Dialysis	dialysis	O
was	was	O
immediately	immediately	O
initiated	initiated	O
.	.	O

A	a	O
kidney	kidney	O
biopsy	biopsy	O
showed	showed	O
inflammatory	inflammatory	O
infiltrate	infiltrate	O
consistent	consistent	O
with	with	O
ATIN	atin	O
.	.	O

However	however	O
,	,	O
in	in	O
the	the	O
tubular	tubular	O
basement	basement	O
membrane	membrane	O
(	(	O
TBM	tbm	O
)	)	O
,	,	O
very	very	O
intense	intense	O
granular	granular	O
deposits	deposits	O
of	of	O
polyclonal	polyclonal	O
IgG	igg	O
and	and	O
C3	c3	O
were	were	O
noted	noted	O
.	.	O

He	he	O
needed	needed	O
dialysis	dialysis	O
for	for	O
2	2	O
weeks	weeks	O
and	and	O
was	was	O
treated	treated	O
successfully	successfully	O
with	with	O
steroids	steroids	B-Chemical
for	for	O
6	6	O
months	months	O
.	.	O

His	his	O
renal	renal	O
recovery	recovery	O
and	and	O
disappearance	disappearance	O
of	of	O
proteinuria	proteinuria	B-Disease
took	took	O
a	a	O
year	year	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
this	this	O
is	is	O
a	a	O
first	first	O
report	report	O
of	of	O
NSAIDs-associated	nsaids-associated	O
ATIN	atin	O
,	,	O
showing	showing	O
deposits	deposits	O
of	of	O
granular	granular	O
immune	immune	O
complex	complex	O
present	present	O
only	only	O
in	in	O
the	the	O
TBM	tbm	O
and	and	O
not	not	O
in	in	O
the	the	O
glomeruli	glomeruli	O
.	.	O

Rifampicin-associated	rifampicin-associated	O
segmental	segmental	O
necrotizing	necrotizing	O
glomerulonephritis	glomerulonephritis	B-Disease
in	in	O
staphylococcal	staphylococcal	O
endocarditis	endocarditis	O
.	.	O

Segmental	segmental	O
necrotising	necrotising	O
glomerulonephritis	glomerulonephritis	B-Disease
has	has	O
been	been	O
reported	reported	O
as	as	O
complication	complication	O
of	of	O
rifampicin	rifampicin	O
therapy	therapy	O
in	in	O
patients	patients	O
receiving	receiving	O
treatment	treatment	O
for	for	O
tuberculosis	tuberculosis	B-Disease
.	.	O

Changing	changing	O
epidemiology	epidemiology	O
of	of	O
infections	infections	B-Disease
such	such	O
as	as	O
infective	infective	O
endocarditis	endocarditis	O
(	(	O
IE	ie	O
)	)	O
has	has	O
led	led	O
to	to	O
an	an	O
increase	increase	O
in	in	O
the	the	O
use	use	O
of	of	O
rifampicin	rifampicin	O
for	for	O
Staphylococcal	staphylococcal	B-Disease
infections	infections	B-Disease
.	.	O

We	we	O
describe	describe	O
a	a	O
case	case	O
of	of	O
a	a	O
patient	patient	O
with	with	O
Staphylococcal	staphylococcal	O
IE	ie	O
who	who	O
developed	developed	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
secondary	secondary	O
to	to	O
a	a	O
segmental	segmental	O
necrotising	necrotising	O
glomerulonephritis	glomerulonephritis	B-Disease
while	while	O
being	being	O
treated	treated	O
with	with	O
rifampicin	rifampicin	O
,	,	O
and	and	O
review	review	O
the	the	O
literature	literature	O
regarding	regarding	O
this	this	O
complication	complication	O
of	of	O
rifampicin	rifampicin	O
therapy	therapy	O
.	.	O

Rate	rate	O
of	of	O
YMDD	ymdd	O
motif	motif	O
mutants	mutants	O
in	in	O
lamivudine-untreated	lamivudine-untreated	O
Iranian	iranian	O
patients	patients	O
with	with	O
chronic	chronic	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
virus	virus	I-Disease
infection	infection	B-Disease
.	.	O

BACKGROUND	background	O
:	:	O
Lamivudine	lamivudine	B-Chemical
is	is	O
used	used	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
chronic	chronic	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
patients	patients	O
.	.	O

Recent	recent	O
studies	studies	O
show	show	O
that	that	O
the	the	O
YMDD	ymdd	O
motif	motif	O
mutants	mutants	O
(	(	O
resistant	resistant	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
virus	virus	O
)	)	O
occur	occur	O
as	as	O
natural	natural	O
genome	genome	O
variability	variability	O
in	in	O
lamivudine-untreated	lamivudine-untreated	O
chronic	chronic	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
patients	patients	O
.	.	O

In	in	O
this	this	O
study	study	O
we	we	O
aimed	aimed	O
to	to	O
determine	determine	O
the	the	O
rate	rate	O
of	of	O
YMDD	ymdd	O
motif	motif	O
mutants	mutants	O
in	in	O
lamivudine-untreated	lamivudine-untreated	O
chronic	chronic	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
patients	patients	O
in	in	O
Iran	iran	O
.	.	O

PATIENTS	patients	O
AND	and	O
METHODS	methods	O
:	:	O
A	a	O
total	total	O
of	of	O
77	77	O
chronic	chronic	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
patients	patients	O
who	who	O
had	had	O
not	not	O
been	been	O
treated	treated	O
with	with	O
lamivudine	lamivudine	B-Chemical
were	were	O
included	included	O
in	in	O
the	the	O
study	study	O
.	.	O

Serum	serum	O
samples	samples	O
from	from	O
patients	patients	O
were	were	O
tested	tested	O
by	by	O
polymerase	polymerase	O
chain	chain	O
reaction-restriction	reaction-restriction	O
fragment	fragment	O
length	length	O
polymorphism	polymorphism	O
(	(	O
PCR-RFLP	pcr-rflp	O
)	)	O
for	for	O
detection	detection	O
of	of	O
YMDD	ymdd	O
motif	motif	O
mutants	mutants	O
.	.	O

All	all	O
patients	patients	O
were	were	O
also	also	O
tested	tested	O
for	for	O
liver	liver	O
enzymes	enzymes	O
,	,	O
anti-HCV	anti-hcv	O
,	,	O
HBeAg	hbeag	B-Chemical
,	,	O
and	and	O
anti-HBe	anti-hbe	O
.	.	O

RESULTS	results	O
:	:	O
Of	of	O
the	the	O
77	77	O
patients	patients	O
enrolled	enrolled	O
in	in	O
the	the	O
study	study	O
,	,	O
73	73	O
%	%	O
were	were	O
male	male	O
and	and	O
27	27	O
%	%	O
were	were	O
female	female	O
.	.	O

Mean	mean	O
ALT	alt	O
and	and	O
AST	ast	O
levels	levels	O
were	were	O
124.4+/-73.4	124.4+/-73.4	O
and	and	O
103.1+/-81	103.1+/-81	O
IU/l	iu/l	O
,	,	O
respectively	respectively	O
.	.	O

HBeAg	hbeag	B-Chemical
was	was	O
positive	positive	O
in	in	O
40	40	O
%	%	O
and	and	O
anti-HBe	anti-hbe	O
in	in	O
60	60	O
%	%	O
of	of	O
the	the	O
patients	patients	O
.	.	O

Anti-HCV	anti-hcv	O
was	was	O
negative	negative	O
in	in	O
all	all	O
of	of	O
them	them	O
.	.	O

YMDD	ymdd	O
motif	motif	O
mutants	mutants	O
were	were	O
not	not	O
detected	detected	O
in	in	O
any	any	O
of	of	O
the	the	O
patients	patients	O
despite	despite	O
the	the	O
liver	liver	O
enzyme	enzyme	O
levels	levels	O
and	and	O
the	the	O
presence	presence	O
of	of	O
HBeAg	hbeag	B-Chemical
or	or	O
anti-HBe	anti-hbe	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Although	although	O
the	the	O
natural	natural	O
occurrence	occurrence	O
of	of	O
YMDD	ymdd	O
motif	motif	O
mutants	mutants	O
in	in	O
lamivudine-untreated	lamivudine-untreated	O
patients	patients	O
with	with	O
chronic	chronic	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
has	has	O
been	been	O
reported	reported	O
,	,	O
these	these	O
mutants	mutants	O
were	were	O
not	not	O
detected	detected	O
in	in	O
Iranian	iranian	O
lamivudine-untreated	lamivudine-untreated	O
chronic	chronic	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
patients	patients	O
.	.	O

Branch	branch	O
retinal	retinal	B-Disease
vein	vein	I-Disease
occlusion	occlusion	I-Disease
and	and	O
fluoxetine	fluoxetine	B-Chemical
.	.	O

A	a	O
case	case	O
of	of	O
branch	branch	O
retinal	retinal	B-Disease
vein	vein	I-Disease
occlusion	occlusion	I-Disease
associated	associated	O
with	with	O
fluoxetine-induced	fluoxetine-induced	O
secondary	secondary	O
hypertension	hypertension	B-Disease
is	is	O
described	described	O
.	.	O

Although	although	O
an	an	O
infrequent	infrequent	O
complication	complication	O
of	of	O
selective	selective	O
serotonin	serotonin	B-Chemical
reuptake	reuptake	O
inhibitor	inhibitor	O
therapy	therapy	O
,	,	O
it	it	O
is	is	O
important	important	O
that	that	O
ophthalmologists	ophthalmologists	O
are	are	O
aware	aware	O
that	that	O
these	these	O
agents	agents	O
can	can	O
cause	cause	O
hypertension	hypertension	B-Disease
because	because	O
this	this	O
class	class	O
of	of	O
drugs	drugs	O
is	is	O
widely	widely	O
prescribed	prescribed	O
.	.	O

The	the	O
differential	differential	O
effects	effects	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
and	and	O
lidocaine	lidocaine	B-Chemical
on	on	O
prostaglandin	prostaglandin	O
E2	e2	B-Chemical
release	release	O
,	,	O
cyclooxygenase	cyclooxygenase	O
gene	gene	O
expression	expression	O
and	and	O
pain	pain	B-Disease
in	in	O
a	a	O
clinical	clinical	O
pain	pain	B-Disease
model	model	O
.	.	O

BACKGROUND	background	O
:	:	O
In	in	O
addition	addition	O
to	to	O
blocking	blocking	O
nociceptive	nociceptive	O
input	input	O
from	from	O
surgical	surgical	O
sites	sites	O
,	,	O
long-acting	long-acting	O
local	local	O
anesthetics	anesthetics	O
might	might	O
directly	directly	O
modulate	modulate	O
inflammation	inflammation	B-Disease
.	.	O

In	in	O
the	the	O
present	present	O
study	study	O
,	,	O
we	we	O
describe	describe	O
the	the	O
proinflammatory	proinflammatory	O
effects	effects	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
on	on	O
local	local	O
prostaglandin	prostaglandin	O
E2	e2	B-Chemical
(	(	O
PGE2	pge2	O
)	)	O
production	production	O
and	and	O
cyclooxygenase	cyclooxygenase	O
(	(	O
COX	cox	O
)	)	O
gene	gene	O
expression	expression	O
that	that	O
increases	increases	O
postoperative	postoperative	O
pain	pain	B-Disease
in	in	O
human	human	O
subjects	subjects	O
.	.	O

METHODS	methods	O
:	:	O
Subjects	subjects	O
(	(	O
n	n	O
=	=	O
114	114	O
)	)	O
undergoing	undergoing	O
extraction	extraction	O
of	of	O
impacted	impacted	O
third	third	O
molars	molars	O
received	received	O
either	either	O
2	2	O
%	%	O
lidocaine	lidocaine	B-Chemical
or	or	O
0.5	0.5	O
%	%	O
bupivacaine	bupivacaine	B-Chemical
before	before	O
surgery	surgery	O
and	and	O
either	either	O
rofecoxib	rofecoxib	O
50	50	O
mg	mg	O
or	or	O
placebo	placebo	O
orally	orally	O
90	90	O
min	min	O
before	before	O
surgery	surgery	O
and	and	O
for	for	O
the	the	O
following	following	O
48	48	O
h.	h.	O
Oral	oral	O
mucosal	mucosal	O
biopsies	biopsies	O
were	were	O
taken	taken	O
before	before	O
surgery	surgery	O
and	and	O
48	48	O
h	h	B-Chemical
after	after	O
surgery	surgery	O
.	.	O

After	after	O
extraction	extraction	O
,	,	O
a	a	O
microdialysis	microdialysis	O
probe	probe	O
was	was	O
placed	placed	O
at	at	O
the	the	O
surgical	surgical	O
site	site	O
for	for	O
PGE2	pge2	O
and	and	O
thromboxane	thromboxane	B-Chemical
B2	b2	I-Chemical
(	(	O
TXB2	txb2	O
)	)	O
measurements	measurements	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
bupivacaine/rofecoxib	bupivacaine/rofecoxib	O
group	group	O
reported	reported	O
significantly	significantly	O
less	less	O
pain	pain	B-Disease
,	,	O
as	as	O
assessed	assessed	O
by	by	O
a	a	O
visual	visual	O
analog	analog	O
scale	scale	O
,	,	O
compared	compared	O
with	with	O
the	the	O
other	other	O
three	three	O
treatment	treatment	O
groups	groups	O
over	over	O
the	the	O
first	first	O
4	4	O
h.	h.	O
However	however	O
,	,	O
the	the	O
bupivacaine/placebo	bupivacaine/placebo	O
group	group	O
reported	reported	O
significantly	significantly	O
more	more	O
pain	pain	B-Disease
at	at	O
24	24	O
h	h	B-Chemical
and	and	O
PGE2	pge2	O
levels	levels	O
during	during	O
the	the	O
first	first	O
4	4	O
h	h	B-Chemical
were	were	O
significantly	significantly	O
higher	higher	O
than	than	O
the	the	O
other	other	O
three	three	O
treatment	treatment	O
groups	groups	O
.	.	O

Moreover	moreover	O
,	,	O
bupivacaine	bupivacaine	B-Chemical
significantly	significantly	O
increased	increased	O
COX-2	cox-2	O
gene	gene	O
expression	expression	O
at	at	O
48	48	O
h	h	B-Chemical
as	as	O
compared	compared	O
with	with	O
the	the	O
lidocaine/placebo	lidocaine/placebo	O
group	group	O
.	.	O

Thromboxane	thromboxane	O
levels	levels	O
were	were	O
not	not	O
significantly	significantly	O
affected	affected	O
by	by	O
any	any	O
of	of	O
the	the	O
treatments	treatments	O
,	,	O
indicating	indicating	O
that	that	O
the	the	O
effects	effects	O
seen	seen	O
were	were	O
attributable	attributable	O
to	to	O
inhibition	inhibition	O
of	of	O
COX-2	cox-2	O
,	,	O
but	but	O
not	not	O
COX-1	cox-1	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
These	these	O
results	results	O
suggest	suggest	O
that	that	O
bupivacaine	bupivacaine	B-Chemical
stimulates	stimulates	O
COX-2	cox-2	O
gene	gene	O
expression	expression	O
after	after	O
tissue	tissue	O
injury	injury	O
,	,	O
which	which	O
is	is	O
associated	associated	O
with	with	O
higher	higher	O
PGE2	pge2	O
production	production	O
and	and	O
pain	pain	B-Disease
after	after	O
the	the	O
local	local	O
anesthetic	anesthetic	O
effect	effect	O
dissipates	dissipates	O
.	.	O

p75NTR	p75ntr	O
expression	expression	O
in	in	O
rat	rat	O
urinary	urinary	O
bladder	bladder	O
sensory	sensory	O
neurons	neurons	O
and	and	O
spinal	spinal	O
cord	cord	O
with	with	O
cyclophosphamide-induced	cyclophosphamide-induced	O
cystitis	cystitis	B-Disease
.	.	O

A	a	O
role	role	O
for	for	O
nerve	nerve	B-Chemical
growth	growth	I-Chemical
factor	factor	I-Chemical
(	(	O
NGF	ngf	B-Chemical
)	)	O
in	in	O
contributing	contributing	O
to	to	O
increased	increased	O
voiding	voiding	O
frequency	frequency	O
and	and	O
altered	altered	O
sensation	sensation	O
from	from	O
the	the	O
urinary	urinary	O
bladder	bladder	O
has	has	O
been	been	O
suggested	suggested	O
.	.	O

Previous	previous	O
studies	studies	O
have	have	O
examined	examined	O
the	the	O
expression	expression	O
and	and	O
regulation	regulation	O
of	of	O
tyrosine	tyrosine	B-Chemical
kinase	kinase	O
receptors	receptors	O
(	(	O
Trks	trks	O
)	)	O
in	in	O
micturition	micturition	O
reflexes	reflexes	O
with	with	O
urinary	urinary	O
bladder	bladder	O
inflammation	inflammation	B-Disease
.	.	O

The	the	O
present	present	O
studies	studies	O
examine	examine	O
the	the	O
expression	expression	O
and	and	O
regulation	regulation	O
of	of	O
another	another	O
receptor	receptor	O
known	known	O
to	to	O
bind	bind	O
NGF	ngf	B-Chemical
,	,	O
p75(NTR	p75(ntr	O
)	)	O
,	,	O
after	after	O
various	various	O
durations	durations	O
of	of	O
bladder	bladder	O
inflammation	inflammation	B-Disease
induced	induced	O
by	by	O
cyclophosphamide	cyclophosphamide	B-Chemical
(	(	O
CYP	cyp	O
)	)	O
.	.	O

CYP-induced	cyp-induced	O
cystitis	cystitis	B-Disease
increased	increased	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
0.001	0.001	O
)	)	O
p75(NTR	p75(ntr	O
)	)	O
expression	expression	O
in	in	O
the	the	O
superficial	superficial	O
lateral	lateral	O
and	and	O
medial	medial	O
dorsal	dorsal	O
horn	horn	O
in	in	O
L1-L2	l1-l2	O
and	and	O
L6-S1	l6-s1	O
spinal	spinal	O
segments	segments	O
.	.	O

The	the	O
number	number	O
of	of	O
p75(NTR)-immunoreactive	p75(ntr)-immunoreactive	O
(	(	O
-IR	-ir	O
)	)	O
cells	cells	O
in	in	O
the	the	O
lumbosacral	lumbosacral	O
dorsal	dorsal	O
root	root	O
ganglia	ganglia	O
(	(	O
DRG	drg	O
)	)	O
also	also	O
increased	increased	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
0.05	0.05	O
)	)	O
with	with	O
CYP-induced	cyp-induced	O
cystitis	cystitis	B-Disease
(	(	O
acute	acute	O
,	,	O
intermediate	intermediate	O
,	,	O
and	and	O
chronic	chronic	O
)	)	O
.	.	O

Quantitative	quantitative	O
,	,	O
real-time	real-time	O
polymerase	polymerase	O
chain	chain	O
reaction	reaction	O
also	also	O
demonstrated	demonstrated	O
significant	significant	O
increases	increases	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
0.01	0.01	O
)	)	O
in	in	O
p75(NTR	p75(ntr	O
)	)	O
mRNA	mrna	O
in	in	O
DRG	drg	O
with	with	O
intermediate	intermediate	O
and	and	O
chronic	chronic	O
CYP-induced	cyp-induced	O
cystitis	cystitis	B-Disease
.	.	O

Retrograde	retrograde	O
dye-tracing	dye-tracing	O
techniques	techniques	O
with	with	O
Fastblue	fastblue	O
were	were	O
used	used	O
to	to	O
identify	identify	O
presumptive	presumptive	O
bladder	bladder	O
afferent	afferent	O
cells	cells	O
in	in	O
the	the	O
lumbosacral	lumbosacral	O
DRG	drg	O
.	.	O

In	in	O
bladder	bladder	O
afferent	afferent	O
cells	cells	O
in	in	O
DRG	drg	O
,	,	O
p75(NTR)-IR	p75(ntr)-ir	O
was	was	O
also	also	O
increased	increased	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
0.01	0.01	O
)	)	O
with	with	O
cystitis	cystitis	B-Disease
.	.	O

In	in	O
addition	addition	O
to	to	O
increases	increases	O
in	in	O
p75(NTR)-IR	p75(ntr)-ir	O
in	in	O
DRG	drg	O
cell	cell	O
bodies	bodies	O
,	,	O
increases	increases	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
0.001	0.001	O
)	)	O
in	in	O
pericellular	pericellular	O
(	(	O
encircling	encircling	O
DRG	drg	O
cells	cells	O
)	)	O
p75(NTR)-IR	p75(ntr)-ir	O
in	in	O
DRG	drg	O
also	also	O
increased	increased	O
.	.	O

Confocal	confocal	O
analyses	analyses	O
demonstrated	demonstrated	O
that	that	O
pericellular	pericellular	O
p75(NTR)-IR	p75(ntr)-ir	O
was	was	O
not	not	O
colocalized	colocalized	O
with	with	O
the	the	O
glial	glial	O
marker	marker	O
,	,	O
glial	glial	B-Chemical
fibrillary	fibrillary	I-Chemical
acidic	acidic	I-Chemical
protein	protein	I-Chemical
(	(	O
GFAP	gfap	O
)	)	O
.	.	O

These	these	O
studies	studies	O
demonstrate	demonstrate	O
that	that	O
p75(NTR	p75(ntr	O
)	)	O
expression	expression	O
in	in	O
micturition	micturition	O
reflexes	reflexes	O
is	is	O
present	present	O
constitutively	constitutively	O
and	and	O
modified	modified	O
by	by	O
bladder	bladder	O
inflammation	inflammation	B-Disease
.	.	O

The	the	O
functional	functional	O
significance	significance	O
of	of	O
p75(NTR	p75(ntr	O
)	)	O
expression	expression	O
in	in	O
micturition	micturition	O
reflexes	reflexes	O
remains	remains	O
to	to	O
be	be	O
determined	determined	O
.	.	O

Azathioprine-induced	azathioprine-induced	O
suicidal	suicidal	O
erythrocyte	erythrocyte	O
death	death	B-Disease
.	.	O

BACKGROUND	background	O
:	:	O
Azathioprine	azathioprine	B-Chemical
is	is	O
widely	widely	O
used	used	O
as	as	O
an	an	O
immunosuppressive	immunosuppressive	O
drug	drug	O
.	.	O

The	the	O
side	side	O
effects	effects	O
of	of	O
azathioprine	azathioprine	B-Chemical
include	include	O
anemia	anemia	B-Disease
,	,	O
which	which	O
has	has	O
been	been	O
attributed	attributed	O
to	to	O
bone	bone	B-Disease
marrow	marrow	I-Disease
suppression	suppression	I-Disease
.	.	O

Alternatively	alternatively	O
,	,	O
anemia	anemia	B-Disease
could	could	O
result	result	O
from	from	O
accelerated	accelerated	O
suicidal	suicidal	O
erythrocyte	erythrocyte	O
death	death	B-Disease
or	or	O
eryptosis	eryptosis	O
,	,	O
which	which	O
is	is	O
characterized	characterized	O
by	by	O
exposure	exposure	O
of	of	O
phosphatidylserine	phosphatidylserine	O
(	(	O
PS	ps	O
)	)	O
at	at	O
the	the	O
erythrocyte	erythrocyte	O
surface	surface	O
and	and	O
by	by	O
cell	cell	O
shrinkage	shrinkage	O
.	.	O

METHODS	methods	O
:	:	O
The	the	O
present	present	O
experiments	experiments	O
explored	explored	O
whether	whether	O
azathioprine	azathioprine	B-Chemical
influences	influences	O
eryptosis	eryptosis	O
.	.	O

According	according	O
to	to	O
annexin	annexin	O
V	v	O
binding	binding	O
,	,	O
erythrocytes	erythrocytes	O
from	from	O
patients	patients	O
indeed	indeed	O
showed	showed	O
a	a	O
significant	significant	O
increase	increase	O
of	of	O
PS	ps	O
exposure	exposure	O
within	within	O
1	1	O
week	week	O
of	of	O
treatment	treatment	O
with	with	O
azathioprine	azathioprine	B-Chemical
.	.	O

In	in	O
a	a	O
second	second	O
series	series	O
,	,	O
cytosolic	cytosolic	O
Ca2	ca2	O
+	+	O
activity	activity	O
(	(	O
Fluo3	fluo3	O
fluorescence	fluorescence	O
)	)	O
,	,	O
cell	cell	O
volume	volume	O
(	(	O
forward	forward	O
scatter	scatter	O
)	)	O
,	,	O
and	and	O
PS-exposure	ps-exposure	O
(	(	O
annexin	annexin	O
V	v	O
binding	binding	O
)	)	O
were	were	O
determined	determined	O
by	by	O
FACS	facs	O
analysis	analysis	O
in	in	O
erythrocytes	erythrocytes	O
from	from	O
healthy	healthy	O
volunteers	volunteers	O
.	.	O

RESULTS	results	O
:	:	O
Exposure	exposure	O
to	to	O
azathioprine	azathioprine	B-Chemical
(	(	O
>	>	O
or	or	O
=	=	O
2	2	O
microg/mL	microg/ml	O
)	)	O
for	for	O
48	48	O
hours	hours	O
increased	increased	O
cytosolic	cytosolic	O
Ca2	ca2	O
+	+	O
activity	activity	O
and	and	O
annexin	annexin	O
V	v	O
binding	binding	O
and	and	O
decreased	decreased	O
forward	forward	O
scatter	scatter	O
.	.	O

The	the	O
effect	effect	O
of	of	O
azathioprine	azathioprine	B-Chemical
on	on	O
both	both	O
annexin	annexin	O
V	v	O
binding	binding	O
and	and	O
forward	forward	O
scatter	scatter	O
was	was	O
significantly	significantly	O
blunted	blunted	O
in	in	O
the	the	O
nominal	nominal	O
absence	absence	O
of	of	O
extracellular	extracellular	O
Ca2	ca2	O
+	+	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Azathioprine	azathioprine	B-Chemical
triggers	triggers	O
suicidal	suicidal	O
erythrocyte	erythrocyte	O
death	death	B-Disease
,	,	O
an	an	O
effect	effect	O
presumably	presumably	O
contributing	contributing	O
to	to	O
azathioprine-induced	azathioprine-induced	O
anemia	anemia	B-Disease
.	.	O

Levetiracetam	levetiracetam	B-Chemical
as	as	O
an	an	O
adjunct	adjunct	O
to	to	O
phenobarbital	phenobarbital	B-Chemical
treatment	treatment	O
in	in	O
cats	cats	O
with	with	O
suspected	suspected	O
idiopathic	idiopathic	B-Disease
epilepsy	epilepsy	B-Disease
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
assess	assess	O
pharmacokinetics	pharmacokinetics	O
,	,	O
efficacy	efficacy	O
,	,	O
and	and	O
tolerability	tolerability	O
of	of	O
oral	oral	O
levetiracetam	levetiracetam	B-Chemical
administered	administered	O
as	as	O
an	an	O
adjunct	adjunct	O
to	to	O
phenobarbital	phenobarbital	B-Chemical
treatment	treatment	O
in	in	O
cats	cats	O
with	with	O
poorly	poorly	O
controlled	controlled	O
suspected	suspected	O
idiopathic	idiopathic	B-Disease
epilepsy	epilepsy	B-Disease
.	.	O

DESIGN-Open-label	design-open-label	O
,	,	O
noncomparative	noncomparative	O
clinical	clinical	O
trial	trial	O
.	.	O

ANIMALS	animals	O
:	:	O
12	12	O
cats	cats	O
suspected	suspected	O
to	to	O
have	have	O
idiopathic	idiopathic	B-Disease
epilepsy	epilepsy	B-Disease
that	that	O
was	was	O
poorly	poorly	O
controlled	controlled	O
with	with	O
phenobarbital	phenobarbital	B-Chemical
or	or	O
that	that	O
had	had	O
unacceptable	unacceptable	O
adverse	adverse	O
effects	effects	O
when	when	O
treated	treated	O
with	with	O
phenobarbital	phenobarbital	B-Chemical
.	.	O

PROCEDURES	procedures	O
:	:	O
Cats	cats	O
were	were	O
treated	treated	O
with	with	O
levetiracetam	levetiracetam	B-Chemical
(	(	O
20	20	O
mg/kg	mg/kg	O
[	[	O
9.1	9.1	O
mg/lb	mg/lb	O
]	]	O
,	,	O
PO	po	O
,	,	O
q	q	O
8	8	O
h	h	B-Chemical
)	)	O
.	.	O

After	after	O
a	a	O
minimum	minimum	O
of	of	O
1	1	O
week	week	O
of	of	O
treatment	treatment	O
,	,	O
serum	serum	O
levetiracetam	levetiracetam	B-Chemical
concentrations	concentrations	O
were	were	O
measured	measured	O
before	before	O
and	and	O
2	2	O
,	,	O
4	4	O
,	,	O
and	and	O
6	6	O
hours	hours	O
after	after	O
drug	drug	O
administration	administration	O
,	,	O
and	and	O
maximum	maximum	O
and	and	O
minimum	minimum	O
serum	serum	O
concentrations	concentrations	O
and	and	O
elimination	elimination	O
half-life	half-life	O
were	were	O
calculated	calculated	O
.	.	O

Seizure	seizure	B-Disease
frequencies	frequencies	O
before	before	O
and	and	O
after	after	O
initiation	initiation	O
of	of	O
levetiracetam	levetiracetam	B-Chemical
treatment	treatment	O
were	were	O
compared	compared	O
,	,	O
and	and	O
adverse	adverse	O
effects	effects	O
were	were	O
recorded	recorded	O
.	.	O

RESULTS	results	O
:	:	O
Median	median	O
maximum	maximum	O
serum	serum	O
levetiracetam	levetiracetam	B-Chemical
concentration	concentration	O
was	was	O
25.5	25.5	O
microg/mL	microg/ml	O
,	,	O
median	median	O
minimum	minimum	O
serum	serum	O
levetiracetam	levetiracetam	B-Chemical
concentration	concentration	O
was	was	O
8.3	8.3	O
microg/mL	microg/ml	O
,	,	O
and	and	O
median	median	O
elimination	elimination	O
half-life	half-life	O
was	was	O
2.9	2.9	O
hours	hours	O
.	.	O

Median	median	O
seizure	seizure	B-Disease
frequency	frequency	O
prior	prior	O
to	to	O
treatment	treatment	O
with	with	O
levetiracetam	levetiracetam	B-Chemical
(	(	O
2.1	2.1	O
seizures/mo	seizures/mo	O
)	)	O
was	was	O
significantly	significantly	O
higher	higher	O
than	than	O
median	median	O
seizure	seizure	B-Disease
frequency	frequency	O
after	after	O
initiation	initiation	O
of	of	O
levetiracetam	levetiracetam	B-Chemical
treatment	treatment	O
(	(	O
0.42	0.42	O
seizures/mo	seizures/mo	O
)	)	O
,	,	O
and	and	O
7	7	O
of	of	O
10	10	O
cats	cats	O
were	were	O
classified	classified	O
as	as	O
having	having	O
responded	responded	O
to	to	O
levetiracetam	levetiracetam	B-Chemical
treatment	treatment	O
(	(	O
ie	ie	O
,	,	O
reduction	reduction	O
in	in	O
seizure	seizure	B-Disease
frequency	frequency	O
of	of	O
>	>	O
or=50	or=50	O
%	%	O
)	)	O
.	.	O

Two	two	O
cats	cats	O
had	had	O
transient	transient	O
lethargy	lethargy	O
and	and	O
inappetence	inappetence	O
.	.	O

CONCLUSIONS	conclusions	O
AND	and	O
CLINICAL	clinical	O
RELEVANCE	relevance	O
:	:	O
Results	results	O
suggested	suggested	O
that	that	O
levetiracetam	levetiracetam	B-Chemical
is	is	O
well	well	O
tolerated	tolerated	O
in	in	O
cats	cats	O
and	and	O
may	may	O
be	be	O
useful	useful	O
as	as	O
an	an	O
adjunct	adjunct	O
to	to	O
phenobarbital	phenobarbital	B-Chemical
treatment	treatment	O
in	in	O
cats	cats	O
with	with	O
idiopathic	idiopathic	B-Disease
epilepsy	epilepsy	B-Disease
.	.	O

Serotonin	serotonin	B-Chemical
reuptake	reuptake	O
inhibitors	inhibitors	O
,	,	O
paranoia	paranoia	O
,	,	O
and	and	O
the	the	O
ventral	ventral	O
basal	basal	O
ganglia	ganglia	O
.	.	O

Antidepressants	antidepressants	B-Chemical
have	have	O
previously	previously	O
been	been	O
associated	associated	O
with	with	O
paranoid	paranoid	O
reactions	reactions	O
in	in	O
psychiatric	psychiatric	B-Disease
patients	patients	O
.	.	O

Five	five	O
cases	cases	O
of	of	O
paranoid	paranoid	O
exacerbation	exacerbation	O
with	with	O
the	the	O
serotonin	serotonin	B-Chemical
reuptake	reuptake	O
inhibitors	inhibitors	O
fluoxetine	fluoxetine	B-Chemical
and	and	O
amitriptyline	amitriptyline	B-Chemical
are	are	O
reported	reported	O
here	here	O
.	.	O

Elements	elements	O
common	common	O
to	to	O
these	these	O
cases	cases	O
included	included	O
a	a	O
history	history	O
of	of	O
paranoid	paranoid	O
symptomatology	symptomatology	O
and	and	O
the	the	O
concomitant	concomitant	O
occurrence	occurrence	O
of	of	O
depressive	depressive	B-Disease
and	and	O
psychotic	psychotic	B-Disease
symptoms	symptoms	I-Disease
.	.	O

Complicated	complicated	O
depressive	depressive	B-Disease
disorders	disorders	I-Disease
(	(	O
including	including	O
atypicality	atypicality	O
of	of	O
course	course	O
and	and	O
symptomatology	symptomatology	O
,	,	O
chronicity	chronicity	O
,	,	O
psychosis	psychosis	B-Disease
,	,	O
bipolarity	bipolarity	O
,	,	O
and	and	O
secondary	secondary	O
onset	onset	O
in	in	O
the	the	O
course	course	O
of	of	O
a	a	O
primary	primary	O
psychosis	psychosis	B-Disease
)	)	O
may	may	O
present	present	O
particular	particular	O
vulnerability	vulnerability	O
to	to	O
paranoid	paranoid	O
exacerbations	exacerbations	O
associated	associated	O
with	with	O
serotonin	serotonin	B-Chemical
reuptake	reuptake	O
inhibitors	inhibitors	O
.	.	O

Although	although	O
the	the	O
pharmacology	pharmacology	O
and	and	O
neurobiology	neurobiology	O
of	of	O
paranoia	paranoia	O
remain	remain	O
cryptic	cryptic	O
,	,	O
several	several	O
mechanisms	mechanisms	O
,	,	O
including	including	O
5HT3	5ht3	O
receptor-mediated	receptor-mediated	O
dopamine	dopamine	B-Chemical
release	release	O
,	,	O
beta-noradrenergic	beta-noradrenergic	O
receptor	receptor	O
downregulation	downregulation	O
,	,	O
or	or	O
GABAB	gabab	O
receptor	receptor	O
upregulation	upregulation	O
acting	acting	O
in	in	O
the	the	O
vicinity	vicinity	O
of	of	O
the	the	O
ventral	ventral	O
basal	basal	O
ganglia	ganglia	O
(	(	O
possibly	possibly	O
in	in	O
lateral	lateral	O
orbitofrontal	orbitofrontal	O
or	or	O
anterior	anterior	O
cingulate	cingulate	O
circuits	circuits	O
)	)	O
,	,	O
might	might	O
apply	apply	O
to	to	O
this	this	O
phenomenon	phenomenon	O
.	.	O

These	these	O
cases	cases	O
call	call	O
attention	attention	O
to	to	O
possible	possible	O
paranoid	paranoid	O
exacerbations	exacerbations	O
with	with	O
serotonin	serotonin	B-Chemical
reuptake	reuptake	O
blockers	blockers	O
in	in	O
select	select	O
patients	patients	O
and	and	O
raise	raise	O
neurobiological	neurobiological	O
considerations	considerations	O
regarding	regarding	O
paranoia	paranoia	O
.	.	O

Clinical	clinical	O
comparison	comparison	O
of	of	O
cardiorespiratory	cardiorespiratory	O
effects	effects	O
during	during	O
unilateral	unilateral	O
and	and	O
conventional	conventional	O
spinal	spinal	O
anaesthesia	anaesthesia	O
.	.	O

BACKGROUND	background	O
:	:	O
Spinal	spinal	O
anaesthesia	anaesthesia	O
is	is	O
widely	widely	O
employed	employed	O
in	in	O
clinical	clinical	O
practice	practice	O
but	but	O
has	has	O
the	the	O
main	main	O
drawback	drawback	O
of	of	O
post-spinal	post-spinal	O
block	block	O
hypotension	hypotension	B-Disease
.	.	O

Efforts	efforts	O
must	must	O
therefore	therefore	O
continue	continue	O
to	to	O
be	be	O
made	made	O
to	to	O
obviate	obviate	O
this	this	O
setback	setback	O
OBJECTIVE	objective	O
:	:	O
To	to	O
evaluate	evaluate	O
the	the	O
cardiovascular	cardiovascular	O
and	and	O
respiratory	respiratory	O
changes	changes	O
during	during	O
unilateral	unilateral	O
and	and	O
conventional	conventional	O
spinal	spinal	O
anaesthesia	anaesthesia	O
.	.	O

METHODS	methods	O
:	:	O
With	with	O
ethical	ethical	O
approval	approval	O
,	,	O
we	we	O
studied	studied	O
74	74	O
American	american	O
Society	society	O
of	of	O
Anesthesiologists	anesthesiologists	O
(	(	O
ASA	asa	B-Chemical
)	)	O
,	,	O
physical	physical	O
status	status	O
class	class	O
1	1	O
and	and	O
2	2	O
patients	patients	O
scheduled	scheduled	O
for	for	O
elective	elective	O
unilateral	unilateral	O
lower	lower	O
limb	limb	O
surgery	surgery	O
.	.	O

Patients	patients	O
were	were	O
randomly	randomly	O
allocated	allocated	O
into	into	O
one	one	O
of	of	O
two	two	O
groups	groups	O
:	:	O
lateral	lateral	O
and	and	O
conventional	conventional	O
spinal	spinal	O
anaesthesia	anaesthesia	O
groups	groups	O
.	.	O

In	in	O
the	the	O
lateral	lateral	O
position	position	O
with	with	O
operative	operative	O
side	side	O
down	down	O
,	,	O
patients	patients	O
recived	recived	O
10	10	O
mg	mg	O
(	(	O
2mls	2mls	O
)	)	O
of	of	O
0.5	0.5	O
%	%	O
hyperbaric	hyperbaric	O
bupivacaine	bupivacaine	B-Chemical
through	through	O
a	a	O
25-gauge	25-gauge	O
spinal	spinal	O
needle	needle	O
.	.	O

Patients	patients	O
in	in	O
the	the	O
unilateral	unilateral	O
group	group	O
were	were	O
maintained	maintained	O
in	in	O
the	the	O
lateral	lateral	O
position	position	O
for	for	O
15	15	O
minutes	minutes	O
following	following	O
spinal	spinal	O
injection	injection	O
while	while	O
those	those	O
in	in	O
the	the	O
conventional	conventional	O
group	group	O
were	were	O
turned	turned	O
supine	supine	O
immediately	immediately	O
after	after	O
injection	injection	O
.	.	O

Blood	blood	O
pressure	pressure	O
,	,	O
heart	heart	O
rate	rate	O
,	,	O
respiratory	respiratory	O
rate	rate	O
and	and	O
oxygen	oxygen	B-Chemical
saturation	saturation	O
were	were	O
monitored	monitored	O
over	over	O
1	1	O
hour	hour	O
.	.	O

RESULTS	results	O
:	:	O
Three	three	O
patients	patients	O
(	(	O
8.1	8.1	O
%	%	O
)	)	O
in	in	O
the	the	O
unilateral	unilateral	O
group	group	O
and	and	O
5	5	O
(	(	O
13.5	13.5	O
%	%	O
)	)	O
in	in	O
the	the	O
conventional	conventional	O
group	group	O
developed	developed	O
hypotension	hypotension	B-Disease
,	,	O
P=	p=	O
0.71	0.71	O
.	.	O

Four	four	O
(	(	O
10.8	10.8	O
%	%	O
)	)	O
patients	patients	O
in	in	O
the	the	O
conventional	conventional	O
group	group	O
and	and	O
1	1	O
(	(	O
2.7	2.7	O
%	%	O
)	)	O
in	in	O
the	the	O
unilateral	unilateral	O
group	group	O
,	,	O
P=	p=	O
0.17	0.17	O
required	required	O
epinephrine	epinephrine	B-Chemical
infusion	infusion	O
to	to	O
treat	treat	O
hypotension	hypotension	B-Disease
.	.	O

Patients	patients	O
in	in	O
the	the	O
conventional	conventional	O
group	group	O
had	had	O
statistically	statistically	O
significant	significant	O
greater	greater	O
fall	fall	O
in	in	O
the	the	O
systolic	systolic	O
blood	blood	O
pressures	pressures	O
at	at	O
15	15	O
,	,	O
30	30	O
and	and	O
45	45	O
minutes	minutes	O
when	when	O
compared	compared	O
to	to	O
the	the	O
baseline	baseline	O
(	(	O
P=	p=	O
0.003	0.003	O
,	,	O
0.001	0.001	O
and	and	O
0.004	0.004	O
)	)	O
.	.	O

The	the	O
mean	mean	O
respiratory	respiratory	O
rate	rate	O
and	and	O
oxygen	oxygen	B-Chemical
saturations	saturations	O
in	in	O
the	the	O
two	two	O
groups	groups	O
were	were	O
similar	similar	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Compared	compared	O
to	to	O
conventional	conventional	O
spinal	spinal	O
anaesthesia	anaesthesia	O
,	,	O
unilateral	unilateral	O
spinal	spinal	O
anaesthesia	anaesthesia	O
was	was	O
associated	associated	O
with	with	O
fewer	fewer	O
cardiovascular	cardiovascular	O
perturbations	perturbations	O
.	.	O

Also	also	O
,	,	O
the	the	O
type	type	O
of	of	O
spinal	spinal	O
block	block	O
instituted	instituted	O
affected	affected	O
neither	neither	O
the	the	O
respiratory	respiratory	O
rate	rate	O
nor	nor	O
the	the	O
arterial	arterial	O
oxygen	oxygen	B-Chemical
saturation	saturation	O
.	.	O

Spectrum	spectrum	O
of	of	O
adverse	adverse	O
events	events	O
after	after	O
generic	generic	O
HAART	haart	O
in	in	O
southern	southern	O
Indian	indian	O
HIV-infected	hiv-infected	O
patients	patients	O
.	.	O

To	to	O
determine	determine	O
the	the	O
incidence	incidence	O
of	of	O
clinically	clinically	O
significant	significant	O
adverse	adverse	O
events	events	O
after	after	O
long-term	long-term	O
,	,	O
fixed-dose	fixed-dose	O
,	,	O
generic	generic	O
highly	highly	O
active	active	O
antiretroviral	antiretroviral	O
therapy	therapy	O
(	(	O
HAART	haart	O
)	)	O
use	use	O
among	among	O
HIV-infected	hiv-infected	O
individuals	individuals	O
in	in	O
South	south	O
India	india	O
,	,	O
we	we	O
examined	examined	O
the	the	O
experiences	experiences	O
of	of	O
3154	3154	O
HIV-infected	hiv-infected	O
individuals	individuals	O
who	who	O
received	received	O
a	a	O
minimum	minimum	O
of	of	O
3	3	O
months	months	O
of	of	O
generic	generic	O
HAART	haart	O
between	between	O
February	february	O
1996	1996	O
and	and	O
December	december	O
2006	2006	O
at	at	O
a	a	O
tertiary	tertiary	O
HIV	hiv	O
care	care	O
referral	referral	O
center	center	O
in	in	O
South	south	O
India	india	O
.	.	O

The	the	O
most	most	O
common	common	O
regimens	regimens	O
were	were	O
3TC	3tc	O
+	+	O
d4	d4	O
T	t	O
+	+	O
nevirapine	nevirapine	O
(	(	O
NVP	nvp	O
)	)	O
(	(	O
54.8	54.8	O
%	%	O
)	)	O
,	,	O
zidovudine	zidovudine	B-Chemical
(	(	O
AZT	azt	B-Chemical
)	)	O
+	+	O
3TC	3tc	O
+	+	O
NVP	nvp	O
(	(	O
14.5	14.5	O
%	%	O
)	)	O
,	,	O
3TC	3tc	O
+	+	O
d4	d4	O
T	t	O
+	+	O
efavirenz	efavirenz	O
(	(	O
EFV	efv	O
)	)	O
(	(	O
20.1	20.1	O
%	%	O
)	)	O
,	,	O
and	and	O
AZT	azt	B-Chemical
+	+	O
3TC	3tc	O
+	+	O
EFV	efv	O
(	(	O
5.4	5.4	O
%	%	O
)	)	O
.	.	O

The	the	O
most	most	O
common	common	O
adverse	adverse	O
events	events	O
and	and	O
median	median	O
CD4	cd4	O
at	at	O
time	time	O
of	of	O
event	event	O
were	were	O
rash	rash	B-Disease
(	(	O
15.2	15.2	O
%	%	O
;	;	O
CD4	cd4	O
,	,	O
285	285	O
cells/microL	cells/microl	O
)	)	O
and	and	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
(	(	O
9.0	9.0	O
%	%	O
and	and	O
348	348	O
cells/microL	cells/microl	O
)	)	O
.	.	O

Clinically	clinically	O
significant	significant	O
anemia	anemia	B-Disease
(	(	O
hemoglobin	hemoglobin	O
<	<	O
7	7	O
g/dL	g/dl	O
)	)	O
was	was	O
observed	observed	O
in	in	O
5.4	5.4	O
%	%	O
of	of	O
patients	patients	O
(	(	O
CD4	cd4	O
,	,	O
165	165	O
cells/microL	cells/microl	O
)	)	O
and	and	O
hepatitis	hepatitis	B-Disease
(	(	O
clinical	clinical	O
jaundice	jaundice	B-Disease
with	with	O
alanine	alanine	B-Chemical
aminotransferase	aminotransferase	O
>	>	O
5	5	O
times	times	O
upper	upper	O
limits	limits	O
of	of	O
normal	normal	O
)	)	O
in	in	O
3.5	3.5	O
%	%	O
of	of	O
patients	patients	O
(	(	O
CD4	cd4	O
,	,	O
260	260	O
cells/microL	cells/microl	O
)	)	O
.	.	O

Women	women	O
were	were	O
significantly	significantly	O
more	more	O
likely	likely	O
to	to	O
experience	experience	O
lactic	lactic	O
acidosis	acidosis	B-Disease
,	,	O
while	while	O
men	men	O
were	were	O
significantly	significantly	O
more	more	O
likely	likely	O
to	to	O
experience	experience	O
immune	immune	O
reconstitution	reconstitution	O
syndrome	syndrome	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

Among	among	O
the	the	O
patients	patients	O
with	with	O
1	1	O
year	year	O
of	of	O
follow-up	follow-up	O
,	,	O
NVP	nvp	O
therapy	therapy	O
was	was	O
significantly	significantly	O
associated	associated	O
with	with	O
developing	developing	O
rash	rash	B-Disease
and	and	O
d4	d4	O
T	t	O
therapy	therapy	O
with	with	O
developing	developing	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

Anemia	anemia	B-Disease
and	and	O
hepatitis	hepatitis	B-Disease
often	often	O
occur	occur	O
within	within	O
12	12	O
weeks	weeks	O
of	of	O
initiating	initiating	O
generic	generic	O
HAART	haart	O
.	.	O

Frequent	frequent	O
and	and	O
early	early	O
monitoring	monitoring	O
for	for	O
these	these	O
toxicities	toxicities	B-Disease
is	is	O
warranted	warranted	O
in	in	O
developing	developing	O
countries	countries	O
where	where	O
generic	generic	O
HAART	haart	O
is	is	O
increasingly	increasingly	O
available	available	O
.	.	O

Thalidomide	thalidomide	B-Chemical
and	and	O
sensory	sensory	O
neurotoxicity	neurotoxicity	B-Disease
:	:	O
a	a	O
neurophysiological	neurophysiological	O
study	study	O
.	.	O

BACKGROUND	background	O
:	:	O
Recent	recent	O
studies	studies	O
confirmed	confirmed	O
a	a	O
high	high	O
incidence	incidence	O
of	of	O
sensory	sensory	O
axonal	axonal	O
neuropathy	neuropathy	B-Disease
in	in	O
patients	patients	O
treated	treated	O
with	with	O
different	different	O
doses	doses	O
of	of	O
thalidomide	thalidomide	B-Chemical
.	.	O

The	the	O
study	study	O
's	's	O
aims	aims	O
were	were	O
to	to	O
measure	measure	O
variations	variations	O
in	in	O
sural	sural	O
nerve	nerve	O
sensory	sensory	O
action	action	O
potential	potential	O
(	(	O
SAP	sap	O
)	)	O
amplitude	amplitude	O
in	in	O
patients	patients	O
with	with	O
refractory	refractory	O
cutaneous	cutaneous	O
lupus	lupus	O
erythematosus	erythematosus	O
(	(	O
CLE	cle	O
)	)	O
treated	treated	O
with	with	O
thalidomide	thalidomide	B-Chemical
and	and	O
use	use	O
these	these	O
findings	findings	O
to	to	O
identify	identify	O
the	the	O
neurotoxic	neurotoxic	B-Disease
potential	potential	O
of	of	O
thalidomide	thalidomide	B-Chemical
and	and	O
the	the	O
recovery	recovery	O
capacity	capacity	O
of	of	O
sensory	sensory	O
fibres	fibres	O
after	after	O
discontinuation	discontinuation	O
of	of	O
treatment	treatment	O
.	.	O

PATIENTS	patients	O
AND	and	O
METHODS	methods	O
:	:	O
Clinical	clinical	O
and	and	O
electrophysiological	electrophysiological	O
data	data	O
in	in	O
12	12	O
female	female	O
patients	patients	O
with	with	O
CLE	cle	O
during	during	O
treatment	treatment	O
with	with	O
thalidomide	thalidomide	B-Chemical
and	and	O
up	up	O
to	to	O
47	47	O
months	months	O
after	after	O
discontinuation	discontinuation	O
of	of	O
treatment	treatment	O
were	were	O
analysed	analysed	O
.	.	O

Sural	sural	O
nerve	nerve	O
SAP	sap	O
amplitude	amplitude	O
reduction	reduction	O
>	>	O
or	or	O
=	=	O
40	40	O
%	%	O
was	was	O
the	the	O
criteria	criteria	O
for	for	O
discontinuing	discontinuing	O
therapy	therapy	O
.	.	O

RESULTS	results	O
:	:	O
During	during	O
treatment	treatment	O
,	,	O
11	11	O
patients	patients	O
showed	showed	O
a	a	O
reduction	reduction	O
in	in	O
sural	sural	O
nerve	nerve	O
SAP	sap	O
amplitude	amplitude	O
compared	compared	O
to	to	O
baseline	baseline	O
values	values	O
(	(	O
9	9	O
with	with	O
a	a	O
reduction	reduction	O
>	>	O
or	or	O
=	=	O
50	50	O
%	%	O
and	and	O
2	2	O
<	<	O
50	50	O
%	%	O
)	)	O
.	.	O

One	one	O
patient	patient	O
showed	showed	O
no	no	O
changes	changes	O
in	in	O
SAP	sap	O
amplitude	amplitude	O
.	.	O

Five	five	O
patients	patients	O
complained	complained	O
of	of	O
paresthesias	paresthesias	O
and	and	O
leg	leg	O
cramps	cramps	O
.	.	O

After	after	O
thalidomide	thalidomide	B-Chemical
treatment	treatment	O
,	,	O
sural	sural	O
SAP	sap	O
amplitude	amplitude	O
recovered	recovered	O
in	in	O
3	3	O
patients	patients	O
.	.	O

At	at	O
detection	detection	O
of	of	O
reduction	reduction	O
in	in	O
sural	sural	O
nerve	nerve	O
SAP	sap	O
amplitude	amplitude	O
,	,	O
the	the	O
median	median	O
thalidomide	thalidomide	B-Chemical
cumulative	cumulative	O
dose	dose	O
was	was	O
21.4	21.4	O
g.	g.	O
The	the	O
threshold	threshold	O
neurotoxic	neurotoxic	B-Disease
dosage	dosage	O
is	is	O
lower	lower	O
than	than	O
previously	previously	O
reported	reported	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Sural	sural	O
nerve	nerve	O
SAP	sap	O
amplitude	amplitude	O
reduction	reduction	O
is	is	O
a	a	O
reliable	reliable	O
and	and	O
sensitive	sensitive	O
marker	marker	O
of	of	O
degeneration	degeneration	O
and	and	O
recovery	recovery	O
of	of	O
sensory	sensory	O
fibres	fibres	O
.	.	O

This	this	O
electrophysiological	electrophysiological	O
parameter	parameter	O
provides	provides	O
information	information	O
about	about	O
subclinical	subclinical	O
neurotoxic	neurotoxic	B-Disease
potential	potential	O
of	of	O
thalidomide	thalidomide	B-Chemical
but	but	O
is	is	O
not	not	O
helpful	helpful	O
in	in	O
predicting	predicting	O
the	the	O
appearance	appearance	O
of	of	O
sensory	sensory	O
symptoms	symptoms	O
.	.	O

Five	five	O
cases	cases	O
of	of	O
encephalitis	encephalitis	O
during	during	O
treatment	treatment	O
of	of	O
loiasis	loiasis	O
with	with	O
diethylcarbamazine	diethylcarbamazine	O
.	.	O

Five	five	O
cases	cases	O
of	of	O
encephalitis	encephalitis	O
following	following	O
treatment	treatment	O
with	with	O
diethylcarbamazine	diethylcarbamazine	O
(	(	O
DEC	dec	O
)	)	O
were	were	O
observed	observed	O
in	in	O
Congolese	congolese	O
patients	patients	O
with	with	O
Loa	loa	O
loa	loa	O
filariasis	filariasis	O
.	.	O

Two	two	O
cases	cases	O
had	had	O
a	a	O
fatal	fatal	O
outcome	outcome	O
and	and	O
one	one	O
resulted	resulted	O
in	in	O
severe	severe	O
sequelae	sequelae	O
.	.	O

The	the	O
notable	notable	O
fact	fact	O
was	was	O
that	that	O
this	this	O
complication	complication	O
occurred	occurred	O
in	in	O
three	three	O
patients	patients	O
hospitalized	hospitalized	O
before	before	O
treatment	treatment	O
began	began	O
,	,	O
with	with	O
whom	whom	O
particularly	particularly	O
strict	strict	O
therapeutic	therapeutic	O
precautions	precautions	O
were	were	O
taken	taken	O
,	,	O
i.e.	i.e.	O
,	,	O
initial	initial	O
dose	dose	O
less	less	O
than	than	O
10	10	O
mg	mg	O
of	of	O
DEC	dec	O
,	,	O
very	very	O
gradual	gradual	O
dose	dose	O
increases	increases	O
,	,	O
and	and	O
associated	associated	O
anti-allergic	anti-allergic	O
treatment	treatment	O
.	.	O

This	this	O
type	type	O
of	of	O
drug-induced	drug-induced	O
complication	complication	O
may	may	O
not	not	O
be	be	O
that	that	O
uncommon	uncommon	O
in	in	O
highly	highly	O
endemic	endemic	O
regions	regions	O
.	.	O

It	it	O
occurs	occurs	O
primarily	primarily	O
,	,	O
but	but	O
not	not	O
exclusively	exclusively	O
,	,	O
in	in	O
subjects	subjects	O
presenting	presenting	O
with	with	O
a	a	O
high	high	O
microfilarial	microfilarial	O
load	load	O
.	.	O

The	the	O
relationship	relationship	O
between	between	O
the	the	O
occurrence	occurrence	O
of	of	O
encephalitis	encephalitis	O
and	and	O
the	the	O
decrease	decrease	O
in	in	O
microfilaremia	microfilaremia	O
is	is	O
evident	evident	O
.	.	O

The	the	O
pathophysiological	pathophysiological	O
mechanisms	mechanisms	O
are	are	O
discussed	discussed	O
in	in	O
the	the	O
light	light	O
of	of	O
these	these	O
observations	observations	O
and	and	O
the	the	O
few	few	O
other	other	O
comments	comments	O
on	on	O
this	this	O
subject	subject	O
published	published	O
in	in	O
the	the	O
literature	literature	O
.	.	O

Amiodarone-related	amiodarone-related	O
pulmonary	pulmonary	O
mass	mass	O
and	and	O
unique	unique	O
membranous	membranous	O
glomerulonephritis	glomerulonephritis	B-Disease
in	in	O
a	a	O
patient	patient	O
with	with	O
valvular	valvular	B-Disease
heart	heart	B-Disease
disease	disease	I-Disease
:	:	O
Diagnostic	diagnostic	O
pitfall	pitfall	O
and	and	O
new	new	O
findings	findings	O
.	.	O

Amiodarone	amiodarone	B-Chemical
is	is	O
an	an	O
anti-arrhythmic	anti-arrhythmic	O
drug	drug	O
for	for	O
life-threatening	life-threatening	O
tachycardia	tachycardia	B-Disease
,	,	O
but	but	O
various	various	O
adverse	adverse	O
effects	effects	O
have	have	O
been	been	O
reported	reported	O
.	.	O

Reported	reported	O
herein	herein	O
is	is	O
an	an	O
autopsy	autopsy	O
case	case	O
of	of	O
valvular	valvular	B-Disease
heart	heart	B-Disease
disease	disease	I-Disease
,	,	O
in	in	O
a	a	O
patient	patient	O
who	who	O
developed	developed	O
a	a	O
lung	lung	O
mass	mass	O
(	(	O
1.5	1.5	O
cm	cm	B-Disease
in	in	O
diameter	diameter	O
)	)	O
and	and	O
proteinuria	proteinuria	B-Disease
(	(	O
2.76	2.76	O
g/day	g/day	O
)	)	O
after	after	O
treatment	treatment	O
with	with	O
amiodarone	amiodarone	B-Chemical
for	for	O
a	a	O
long	long	O
time	time	O
.	.	O

The	the	O
lung	lung	O
mass	mass	O
was	was	O
highly	highly	O
suspected	suspected	O
to	to	O
be	be	O
lung	lung	O
cancer	cancer	B-Disease
on	on	O
CT	ct	O
and	and	O
positron	positron	O
emission	emission	O
tomography	tomography	O
,	,	O
but	but	O
histologically	histologically	O
the	the	O
lesion	lesion	O
was	was	O
composed	composed	O
of	of	O
lymphoplasmacytic	lymphoplasmacytic	O
infiltrates	infiltrates	O
in	in	O
alveolar	alveolar	O
walls	walls	O
and	and	O
intra-alveolar	intra-alveolar	O
accumulation	accumulation	O
of	of	O
foamy	foamy	O
macrophages	macrophages	O
containing	containing	O
characteristic	characteristic	O
myelinoid	myelinoid	O
bodies	bodies	O
,	,	O
indicating	indicating	O
that	that	O
it	it	O
was	was	O
an	an	O
amiodarone-related	amiodarone-related	O
lesion	lesion	O
.	.	O

In	in	O
addition	addition	O
,	,	O
the	the	O
lung	lung	O
tissue	tissue	O
had	had	O
unevenly	unevenly	O
distributed	distributed	O
hemosiderin	hemosiderin	O
deposition	deposition	O
,	,	O
and	and	O
abnormally	abnormally	O
tortuous	tortuous	O
capillaries	capillaries	O
were	were	O
seen	seen	O
in	in	O
the	the	O
mass	mass	O
and	and	O
in	in	O
heavily	heavily	O
hemosiderotic	hemosiderotic	O
lung	lung	O
portions	portions	O
outside	outside	O
the	the	O
mass	mass	O
.	.	O

In	in	O
the	the	O
kidneys	kidneys	O
,	,	O
glomeruli	glomeruli	O
had	had	O
membrane	membrane	O
spikes	spikes	O
,	,	O
prominent	prominent	O
swelling	swelling	O
of	of	O
podocytes	podocytes	O
and	and	O
subepithelial	subepithelial	O
deposits	deposits	O
,	,	O
which	which	O
were	were	O
sometimes	sometimes	O
large	large	O
and	and	O
hump-like	hump-like	O
.	.	O

Autoimmune	autoimmune	B-Disease
diseases	diseases	I-Disease
,	,	O
viral	viral	O
hepatitis	hepatitis	B-Disease
,	,	O
malignant	malignant	O
neoplasms	neoplasms	O
or	or	O
other	other	O
diseases	diseases	O
with	with	O
a	a	O
known	known	O
relationship	relationship	O
to	to	O
membranous	membranous	O
glomerulonephritis	glomerulonephritis	B-Disease
were	were	O
not	not	O
found	found	O
.	.	O

The	the	O
present	present	O
case	case	O
highlights	highlights	O
the	the	O
possibility	possibility	O
that	that	O
differential	differential	O
diagnosis	diagnosis	O
between	between	O
an	an	O
amiodarone-related	amiodarone-related	O
pulmonary	pulmonary	O
lesion	lesion	O
and	and	O
a	a	O
neoplasm	neoplasm	O
can	can	O
be	be	O
very	very	O
difficult	difficult	O
radiologically	radiologically	O
,	,	O
and	and	O
suggests	suggests	O
that	that	O
membranous	membranous	O
glomerulonephritis	glomerulonephritis	B-Disease
might	might	O
be	be	O
another	another	O
possible	possible	O
complication	complication	O
of	of	O
amiodarone	amiodarone	B-Chemical
treatment	treatment	O
.	.	O

Risk	risk	O
of	of	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
associated	associated	O
with	with	O
initial	initial	O
sulphonylurea	sulphonylurea	O
treatment	treatment	O
of	of	O
patients	patients	O
with	with	O
type	type	O
2	2	O
diabetes	diabetes	B-Disease
:	:	O
a	a	O
matched	matched	O
case-control	case-control	O
study	study	O
.	.	O

AIMS	aims	O
:	:	O
This	this	O
study	study	O
sought	sought	O
to	to	O
assess	assess	O
the	the	O
risk	risk	O
of	of	O
developing	developing	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
(	(	O
CAD	cad	O
)	)	O
associated	associated	O
with	with	O
initial	initial	O
treatment	treatment	O
of	of	O
type	type	O
2	2	O
diabetes	diabetes	B-Disease
with	with	O
different	different	O
sulphonylureas	sulphonylureas	O
.	.	O

METHODS	methods	O
:	:	O
In	in	O
type	type	O
2	2	O
diabetic	diabetic	B-Disease
patients	patients	O
,	,	O
cases	cases	O
who	who	O
developed	developed	O
CAD	cad	O
were	were	O
compared	compared	O
retrospectively	retrospectively	O
with	with	O
controls	controls	O
that	that	O
did	did	O
not	not	O
.	.	O

The	the	O
20-year	20-year	O
risk	risk	O
of	of	O
CAD	cad	O
at	at	O
diagnosis	diagnosis	O
of	of	O
diabetes	diabetes	B-Disease
,	,	O
using	using	O
the	the	O
UKPDS	ukpds	O
risk	risk	O
engine	engine	O
,	,	O
was	was	O
used	used	O
to	to	O
match	match	O
cases	cases	O
with	with	O
controls	controls	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
76	76	O
cases	cases	O
of	of	O
CAD	cad	O
were	were	O
compared	compared	O
with	with	O
152	152	O
controls	controls	O
.	.	O

The	the	O
hazard	hazard	O
of	of	O
developing	developing	O
CAD	cad	O
(	(	O
95	95	O
%	%	O
CI	ci	O
)	)	O
associated	associated	O
with	with	O
initial	initial	O
treatment	treatment	O
increased	increased	O
by	by	O
2.4-fold	2.4-fold	O
(	(	O
1.3	1.3	O
-	-	O
4.3	4.3	O
,	,	O
P=0.004	p=0.004	O
)	)	O
with	with	O
glibenclamide	glibenclamide	O
;	;	O
2-fold	2-fold	O
(	(	O
0.9	0.9	O
-	-	O
4.6	4.6	O
,	,	O
P=0.099	p=0.099	O
)	)	O
with	with	O
glipizide	glipizide	O
;	;	O
2.9-fold	2.9-fold	O
(	(	O
1.6	1.6	O
-	-	O
5.1	5.1	O
,	,	O
P=0.000	p=0.000	O
)	)	O
with	with	O
either	either	O
,	,	O
and	and	O
was	was	O
unchanged	unchanged	O
with	with	O
metformin	metformin	O
.	.	O

The	the	O
hazard	hazard	O
decreased	decreased	O
0.3-fold	0.3-fold	O
(	(	O
0.7	0.7	O
-	-	O
1.7	1.7	O
,	,	O
P=0.385	p=0.385	O
)	)	O
with	with	O
glimepiride	glimepiride	O
,	,	O
0.4-fold	0.4-fold	O
(	(	O
0.7	0.7	O
-	-	O
1.3	1.3	O
,	,	O
P=0.192	p=0.192	O
)	)	O
with	with	O
gliclazide	gliclazide	O
,	,	O
and	and	O
0.4-fold	0.4-fold	O
(	(	O
0.7	0.7	O
-	-	O
1.1	1.1	O
,	,	O
P=0.09	p=0.09	O
)	)	O
with	with	O
either	either	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Initiating	initiating	O
treatment	treatment	O
of	of	O
type	type	O
2	2	O
diabetes	diabetes	B-Disease
with	with	O
glibenclamide	glibenclamide	O
or	or	O
glipizide	glipizide	O
is	is	O
associated	associated	O
with	with	O
increased	increased	O
risk	risk	O
of	of	O
CAD	cad	O
in	in	O
comparison	comparison	O
to	to	O
gliclazide	gliclazide	O
or	or	O
glimepiride	glimepiride	O
.	.	O

If	if	O
confirmed	confirmed	O
,	,	O
this	this	O
may	may	O
be	be	O
important	important	O
because	because	O
most	most	O
Indian	indian	O
patients	patients	O
receive	receive	O
the	the	O
cheaper	cheaper	O
older	older	O
sulphonylureas	sulphonylureas	O
,	,	O
and	and	O
present	present	O
guidelines	guidelines	O
do	do	O
not	not	O
distinguish	distinguish	O
between	between	O
individual	individual	O
agents	agents	O
.	.	O

Reduced	reduced	O
progression	progression	O
of	of	O
adriamycin	adriamycin	B-Chemical
nephropathy	nephropathy	B-Disease
in	in	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
rats	rats	O
treated	treated	O
by	by	O
losartan	losartan	B-Chemical
.	.	O

BACKGROUND	background	O
:	:	O
The	the	O
aim	aim	O
of	of	O
the	the	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
the	the	O
antihypertensive	antihypertensive	O
effects	effects	O
of	of	O
angiotensin	angiotensin	B-Chemical
II	ii	I-Chemical
type-1	type-1	O
receptor	receptor	O
blocker	blocker	O
,	,	O
losartan	losartan	B-Chemical
,	,	O
and	and	O
its	its	O
potential	potential	O
in	in	O
slowing	slowing	O
down	down	O
renal	renal	O
disease	disease	B-Disease
progression	progression	I-Disease
in	in	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
rats	rats	O
(	(	O
SHR	shr	O
)	)	O
with	with	O
adriamycin	adriamycin	B-Chemical
(	(	O
ADR	adr	B-Chemical
)	)	O
nephropathy	nephropathy	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Six-month-old	six-month-old	O
female	female	O
SHR	shr	O
were	were	O
randomly	randomly	O
selected	selected	O
in	in	O
six	six	O
groups	groups	O
.	.	O

Two	two	O
control	control	O
groups	groups	O
(	(	O
SH(6	sh(6	O
)	)	O
,	,	O
SH(12	sh(12	O
)	)	O
)	)	O
received	received	O
vehicle	vehicle	O
.	.	O

Groups	groups	O
ADR(6	adr(6	O
)	)	O
,	,	O
ADR+LOS(6	adr+los(6	O
)	)	O
and	and	O
ADR(12	adr(12	O
)	)	O
,	,	O
and	and	O
ADR+LOS(12	adr+los(12	O
)	)	O
received	received	O
ADR	adr	B-Chemical
(	(	O
2	2	O
mg/kg/b.w	mg/kg/b.w	O
.	.	O

i.v	i.v	O
.	.	O
)	)	O
twice	twice	O
in	in	O
a	a	O
3-week	3-week	O
interval	interval	O
.	.	O

Group	group	O
ADR+LOS(6	adr+los(6	O
)	)	O
received	received	O
losartan	losartan	B-Chemical
(	(	O
10	10	O
mg/kg/b.w./day	mg/kg/b.w./day	O
by	by	O
gavages	gavages	O
)	)	O
for	for	O
6	6	O
weeks	weeks	O
and	and	O
group	group	O
ADR+LOS(12	adr+los(12	O
)	)	O
for	for	O
12	12	O
weeks	weeks	O
after	after	O
second	second	O
injection	injection	O
of	of	O
ADR	adr	B-Chemical
.	.	O

Animals	animals	O
were	were	O
killed	killed	O
after	after	O
6	6	O
or	or	O
12	12	O
weeks	weeks	O
,	,	O
respectively	respectively	O
.	.	O

Haemodynamic	haemodynamic	O
measurements	measurements	O
were	were	O
performed	performed	O
on	on	O
anaesthetized	anaesthetized	O
animals	animals	O
,	,	O
blood	blood	O
and	and	O
urine	urine	O
samples	samples	O
were	were	O
taken	taken	O
for	for	O
biochemical	biochemical	O
analysis	analysis	O
and	and	O
the	the	O
left	left	O
kidney	kidney	O
was	was	O
processed	processed	O
for	for	O
morphological	morphological	O
studies	studies	O
.	.	O

RESULTS	results	O
:	:	O
Short-term	short-term	O
losartan	losartan	B-Chemical
treatment	treatment	O
,	,	O
besides	besides	O
antihypertensive	antihypertensive	O
effect	effect	O
,	,	O
improved	improved	O
glomerular	glomerular	O
filtration	filtration	O
rate	rate	O
and	and	O
ameliorated	ameliorated	O
glomerulosclerosis	glomerulosclerosis	B-Disease
resulting	resulting	O
in	in	O
decreased	decreased	O
proteinuria	proteinuria	B-Disease
.	.	O

Prolonged	prolonged	O
treatment	treatment	O
with	with	O
losartan	losartan	B-Chemical
showed	showed	O
further	further	O
reduction	reduction	O
of	of	O
glomerulosclerosis	glomerulosclerosis	B-Disease
associated	associated	O
with	with	O
reduced	reduced	O
progression	progression	O
of	of	O
tubular	tubular	O
atrophy	atrophy	B-Disease
and	and	O
interstitial	interstitial	O
fibrosis	fibrosis	B-Disease
,	,	O
thus	thus	O
preventing	preventing	O
heavy	heavy	O
proteinuria	proteinuria	B-Disease
and	and	O
chronic	chronic	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
.	.	O

Losartan	losartan	B-Chemical
reduced	reduced	O
uraemia	uraemia	O
and	and	O
increased	increased	O
urea	urea	B-Chemical
clearance	clearance	O
in	in	O
advanced	advanced	O
ADR	adr	B-Chemical
nephropathy	nephropathy	B-Disease
in	in	O
SHR	shr	O
.	.	O

Histological	histological	O
examination	examination	O
showed	showed	O
that	that	O
losartan	losartan	B-Chemical
could	could	O
prevent	prevent	O
tubular	tubular	O
atrophy	atrophy	B-Disease
,	,	O
interstitial	interstitial	O
infiltration	infiltration	O
and	and	O
fibrosis	fibrosis	B-Disease
in	in	O
ADR	adr	B-Chemical
nephropathy	nephropathy	B-Disease
.	.	O

CONCLUSION	conclusion	O
:	:	O
Losartan	losartan	B-Chemical
reduces	reduces	O
the	the	O
rate	rate	O
of	of	O
progression	progression	O
of	of	O
ADR-induced	adr-induced	O
focal	focal	O
segmental	segmental	B-Disease
glomerulosclerosis	glomerulosclerosis	B-Disease
to	to	O
end-stage	end-stage	O
renal	renal	O
disease	disease	O
in	in	O
SHR	shr	O
.	.	O

The	the	O
risks	risks	O
of	of	O
aprotinin	aprotinin	O
and	and	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
in	in	O
cardiac	cardiac	O
surgery	surgery	O
:	:	O
a	a	O
one-year	one-year	O
follow-up	follow-up	O
of	of	O
1188	1188	O
consecutive	consecutive	O
patients	patients	O
.	.	O

BACKGROUND	background	O
:	:	O
Our	our	O
aim	aim	O
was	was	O
to	to	O
investigate	investigate	O
postoperative	postoperative	B-Disease
complications	complications	I-Disease
and	and	O
mortality	mortality	O
after	after	O
administration	administration	O
of	of	O
aprotinin	aprotinin	O
compared	compared	O
to	to	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
in	in	O
an	an	O
unselected	unselected	O
,	,	O
consecutive	consecutive	O
cohort	cohort	O
.	.	O

METHODS	methods	O
:	:	O
Perioperative	perioperative	O
data	data	O
from	from	O
consecutive	consecutive	O
cardiac	cardiac	O
surgery	surgery	O
patients	patients	O
were	were	O
prospectively	prospectively	O
collected	collected	O
between	between	O
September	september	O
2005	2005	O
and	and	O
June	june	O
2006	2006	O
in	in	O
a	a	O
university-affiliated	university-affiliated	O
clinic	clinic	O
(	(	O
n	n	O
=	=	O
1188	1188	O
)	)	O
.	.	O

During	during	O
the	the	O
first	first	O
5	5	O
mo	mo	O
,	,	O
596	596	O
patients	patients	O
received	received	O
aprotinin	aprotinin	O
(	(	O
Group	group	O
A	a	O
)	)	O
;	;	O
in	in	O
the	the	O
next	next	O
5	5	O
mo	mo	O
,	,	O
592	592	O
patients	patients	O
were	were	O
treated	treated	O
with	with	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
(	(	O
Group	group	O
T	t	O
)	)	O
.	.	O

Except	except	O
for	for	O
antifibrinolytic	antifibrinolytic	O
therapy	therapy	O
,	,	O
the	the	O
anesthetic	anesthetic	O
and	and	O
surgical	surgical	O
protocols	protocols	O
remained	remained	O
unchanged	unchanged	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
pre-	pre-	O
and	and	O
intraoperative	intraoperative	O
variables	variables	O
were	were	O
comparable	comparable	O
between	between	O
the	the	O
treatment	treatment	O
groups	groups	O
.	.	O

Postoperatively	postoperatively	O
,	,	O
a	a	O
significantly	significantly	O
higher	higher	O
incidence	incidence	O
of	of	O
seizures	seizures	B-Disease
was	was	O
found	found	O
in	in	O
Group	group	O
T	t	O
(	(	O
4.6	4.6	O
%	%	O
vs	vs	O
1.2	1.2	O
%	%	O
,	,	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

This	this	O
difference	difference	O
was	was	O
also	also	O
significant	significant	O
in	in	O
the	the	O
primary	primary	O
valve	valve	O
surgery	surgery	O
and	and	O
the	the	O
high	high	O
risk	risk	O
surgery	surgery	O
subgroups	subgroups	O
(	(	O
7.9	7.9	O
%	%	O
vs	vs	O
1.2	1.2	O
%	%	O
,	,	O
P	p	O
=	=	O
0.003	0.003	O
;	;	O
7.3	7.3	O
%	%	O
vs	vs	O
2.4	2.4	O
%	%	O
,	,	O
P	p	O
=	=	O
0.035	0.035	O
,	,	O
respectively	respectively	O
)	)	O
.	.	O

Persistent	persistent	B-Disease
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
(	(	O
7.9	7.9	O
%	%	O
vs	vs	O
2.3	2.3	O
%	%	O
,	,	O
P	p	O
=	=	O
0.020	0.020	O
)	)	O
and	and	O
renal	renal	B-Disease
failure	failure	I-Disease
(	(	O
9.7	9.7	O
%	%	O
vs	vs	O
1.7	1.7	O
%	%	O
,	,	O
P	p	O
=	=	O
0.002	0.002	O
)	)	O
were	were	O
also	also	O
more	more	O
common	common	O
in	in	O
Group	group	O
T	t	O
,	,	O
in	in	O
the	the	O
primary	primary	O
valve	valve	O
surgery	surgery	O
subgroup	subgroup	O
.	.	O

On	on	O
the	the	O
contrary	contrary	O
,	,	O
among	among	O
primary	primary	O
coronary	coronary	O
artery	artery	O
bypass	bypass	O
surgery	surgery	O
patients	patients	O
,	,	O
there	there	O
were	were	O
more	more	O
acute	acute	O
myocardial	myocardial	B-Disease
infarctions	infarctions	I-Disease
and	and	O
renal	renal	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
Group	group	O
A	a	O
(	(	O
5.8	5.8	O
%	%	O
vs	vs	O
2.0	2.0	O
%	%	O
,	,	O
P	p	O
=	=	O
0.027	0.027	O
;	;	O
22.5	22.5	O
%	%	O
vs	vs	O
15.2	15.2	O
%	%	O
,	,	O
P	p	O
=	=	O
0.036	0.036	O
,	,	O
respectively	respectively	O
)	)	O
.	.	O

The	the	O
1-yr	1-yr	O
mortality	mortality	O
was	was	O
significantly	significantly	O
higher	higher	O
after	after	O
aprotinin	aprotinin	O
treatment	treatment	O
in	in	O
the	the	O
high	high	O
risk	risk	O
surgery	surgery	O
group	group	O
(	(	O
17.7	17.7	O
%	%	O
vs	vs	O
9.8	9.8	O
%	%	O
,	,	O
P	p	O
=	=	O
0.034	0.034	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Both	both	O
antifibrinolytic	antifibrinolytic	O
drugs	drugs	O
bear	bear	O
the	the	O
risk	risk	O
of	of	O
adverse	adverse	O
outcome	outcome	O
depending	depending	O
on	on	O
the	the	O
type	type	O
of	of	O
cardiac	cardiac	O
surgery	surgery	O
.	.	O

Administration	administration	O
of	of	O
aprotinin	aprotinin	O
should	should	O
be	be	O
avoided	avoided	O
in	in	O
coronary	coronary	O
artery	artery	O
bypass	bypass	O
graft	graft	O
and	and	O
high	high	O
risk	risk	O
patients	patients	O
,	,	O
whereas	whereas	O
administration	administration	O
of	of	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
is	is	O
not	not	O
recommended	recommended	O
in	in	O
valve	valve	O
surgery	surgery	O
.	.	O

Delirium	delirium	B-Disease
in	in	O
an	an	O
elderly	elderly	O
woman	woman	O
possibly	possibly	O
associated	associated	O
with	with	O
administration	administration	O
of	of	O
misoprostol	misoprostol	O
.	.	O

Misoprostol	misoprostol	O
has	has	O
been	been	O
associated	associated	O
with	with	O
adverse	adverse	O
reactions	reactions	O
,	,	O
including	including	O
gastrointestinal	gastrointestinal	O
symptoms	symptoms	O
,	,	O
gynecologic	gynecologic	O
problems	problems	O
,	,	O
and	and	O
headache	headache	B-Disease
.	.	O

Changes	changes	O
in	in	O
mental	mental	O
status	status	O
,	,	O
however	however	O
,	,	O
have	have	O
not	not	O
been	been	O
reported	reported	O
.	.	O

We	we	O
present	present	O
a	a	O
case	case	O
in	in	O
which	which	O
an	an	O
89-year-old	89-year-old	O
woman	woman	O
in	in	O
a	a	O
long-term	long-term	O
care	care	O
facility	facility	O
became	became	O
confused	confused	O
after	after	O
the	the	O
initiation	initiation	O
of	of	O
misoprostol	misoprostol	O
therapy	therapy	O
.	.	O

The	the	O
patient	patient	O
's	's	O
change	change	O
in	in	O
mental	mental	O
status	status	O
was	was	O
first	first	O
reported	reported	O
nine	nine	O
days	days	O
after	after	O
the	the	O
initiation	initiation	O
of	of	O
therapy	therapy	O
.	.	O

Her	her	O
delirium	delirium	B-Disease
significantly	significantly	O
improved	improved	O
after	after	O
misoprostol	misoprostol	O
was	was	O
discontinued	discontinued	O
and	and	O
her	her	O
mental	mental	O
status	status	O
returned	returned	O
to	to	O
normal	normal	O
within	within	O
a	a	O
week	week	O
.	.	O
Because	because	O
no	no	O
other	other	O
factors	factors	O
related	related	O
to	to	O
this	this	O
patient	patient	O
changed	changed	O
significantly	significantly	O
,	,	O
the	the	O
delirium	delirium	B-Disease
experienced	experienced	O
by	by	O
this	this	O
patient	patient	O
possibly	possibly	O
resulted	resulted	O
from	from	O
misoprostol	misoprostol	O
therapy	therapy	O
.	.	O

The	the	O
biological	biological	O
properties	properties	O
of	of	O
the	the	O
optical	optical	O
isomers	isomers	O
of	of	O
propranolol	propranolol	B-Chemical
and	and	O
their	their	O
effects	effects	O
on	on	O
cardiac	cardiac	O
arrhythmias.1	arrhythmias.1	O
.	.	O

The	the	O
optical	optical	O
isomers	isomers	O
of	of	O
propranolol	propranolol	B-Chemical
have	have	O
been	been	O
compared	compared	O
for	for	O
their	their	O
beta-blocking	beta-blocking	O
and	and	O
antiarrhythmic	antiarrhythmic	O
activities.2	activities.2	O
.	.	O

In	in	O
blocking	blocking	O
the	the	O
positive	positive	O
inotropic	inotropic	O
and	and	O
chronotropic	chronotropic	O
responses	responses	O
to	to	O
isoprenaline	isoprenaline	O
,	,	O
(+)-propranolol	(+)-propranolol	O
had	had	O
less	less	O
than	than	O
one	one	O
hundredth	hundredth	O
the	the	O
potency	potency	O
of	of	O
(-)-propranolol	(-)-propranolol	O
.	.	O

At	at	O
dose	dose	O
levels	levels	O
of	of	O
(+)-propranolol	(+)-propranolol	O
which	which	O
attenuated	attenuated	O
the	the	O
responses	responses	O
to	to	O
isoprenaline	isoprenaline	O
,	,	O
there	there	O
was	was	O
a	a	O
significant	significant	O
prolongation	prolongation	O
of	of	O
the	the	O
PR	pr	O
interval	interval	O
of	of	O
the	the	O
electrocardiogram.3	electrocardiogram.3	O
.	.	O

The	the	O
metabolic	metabolic	O
responses	responses	O
to	to	O
isoprenaline	isoprenaline	O
in	in	O
dogs	dogs	O
(	(	O
an	an	O
increase	increase	O
in	in	O
circulating	circulating	O
glucose	glucose	B-Chemical
,	,	O
lactate	lactate	B-Chemical
and	and	O
free	free	O
fatty	fatty	B-Chemical
acids	acids	I-Chemical
)	)	O
were	were	O
all	all	O
blocked	blocked	O
by	by	O
(-)-propranolol	(-)-propranolol	O
.	.	O

(+)-Propranolol	(+)-propranolol	O
had	had	O
no	no	O
effect	effect	O
on	on	O
fatty	fatty	O
acid	acid	O
mobilization	mobilization	O
but	but	O
significantly	significantly	O
reduced	reduced	O
the	the	O
increments	increments	O
in	in	O
both	both	O
lactate	lactate	B-Chemical
and	and	O
glucose.4	glucose.4	O
.	.	O

Both	both	O
isomers	isomers	O
of	of	O
propranolol	propranolol	B-Chemical
possessed	possessed	O
similar	similar	O
depressant	depressant	O
potency	potency	O
on	on	O
isolated	isolated	O
atrial	atrial	O
muscle	muscle	O
taken	taken	O
from	from	O
guinea-pigs.5	guinea-pigs.5	O
.	.	O

The	the	O
isomers	isomers	O
of	of	O
propranolol	propranolol	B-Chemical
exhibited	exhibited	O
similar	similar	O
local	local	O
anaesthetic	anaesthetic	O
potencies	potencies	O
on	on	O
an	an	O
isolated	isolated	O
frog	frog	O
nerve	nerve	O
preparation	preparation	O
at	at	O
a	a	O
level	level	O
approximately	approximately	O
three	three	O
times	times	O
that	that	O
of	of	O
procaine	procaine	O
.	.	O

The	the	O
racemic	racemic	O
compound	compound	O
was	was	O
significantly	significantly	O
less	less	O
potent	potent	O
than	than	O
either	either	O
isomer.6	isomer.6	O
.	.	O

Both	both	O
isomers	isomers	O
of	of	O
propranolol	propranolol	B-Chemical
were	were	O
capable	capable	O
of	of	O
preventing	preventing	O
adrenaline-induced	adrenaline-induced	O
cardiac	cardiac	B-Disease
arrhythmias	arrhythmias	B-Disease
in	in	O
cats	cats	O
anaesthetized	anaesthetized	O
with	with	O
halothane	halothane	B-Chemical
,	,	O
but	but	O
the	the	O
mean	mean	O
dose	dose	O
of	of	O
(-)-propranolol	(-)-propranolol	O
was	was	O
0.09+/-0.02	0.09+/-0.02	O
mg/kg	mg/kg	O
whereas	whereas	O
that	that	O
of	of	O
(+)-propranolol	(+)-propranolol	O
was	was	O
4.2+/-1.2	4.2+/-1.2	O
mg/kg	mg/kg	O
.	.	O

At	at	O
the	the	O
effective	effective	O
dose	dose	O
level	level	O
of	of	O
(+)-propranolol	(+)-propranolol	O
there	there	O
was	was	O
a	a	O
significant	significant	O
prolongation	prolongation	O
of	of	O
the	the	O
PR	pr	O
interval	interval	O
of	of	O
the	the	O
electrocardiogram	electrocardiogram	O
.	.	O

Blockade	blockade	O
of	of	O
arrhythmias	arrhythmias	B-Disease
with	with	O
both	both	O
isomers	isomers	O
was	was	O
surmountable	surmountable	O
by	by	O
increasing	increasing	O
the	the	O
dose	dose	O
of	of	O
adrenaline.7	adrenaline.7	O
.	.	O

Both	both	O
isomers	isomers	O
of	of	O
propranolol	propranolol	B-Chemical
were	were	O
also	also	O
capable	capable	O
of	of	O
reversing	reversing	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
caused	caused	O
by	by	O
ouabain	ouabain	B-Chemical
in	in	O
anaesthetized	anaesthetized	O
cats	cats	O
and	and	O
dogs	dogs	O
.	.	O

The	the	O
dose	dose	O
of	of	O
(-)-propranolol	(-)-propranolol	O
was	was	O
significantly	significantly	O
smaller	smaller	O
than	than	O
that	that	O
of	of	O
(+)-propranolol	(+)-propranolol	O
in	in	O
both	both	O
species	species	O
but	but	O
much	much	O
higher	higher	O
than	than	O
that	that	O
required	required	O
to	to	O
produce	produce	O
evidence	evidence	O
of	of	O
beta-blockade.8	beta-blockade.8	O
.	.	O

The	the	O
implications	implications	O
of	of	O
these	these	O
results	results	O
are	are	O
discussed	discussed	O
.	.	O

Topotecan	topotecan	O
in	in	O
combination	combination	O
with	with	O
radiotherapy	radiotherapy	O
in	in	O
unresectable	unresectable	O
glioblastoma	glioblastoma	B-Disease
:	:	O
a	a	O
phase	phase	O
2	2	O
study	study	O
.	.	O

Improving	improving	O
glioblastoma	glioblastoma	B-Disease
multiforme	multiforme	O
(	(	O
GBM	gbm	O
)	)	O
treatment	treatment	O
with	with	O
radio-chemotherapy	radio-chemotherapy	O
remains	remains	O
a	a	O
challenge	challenge	O
.	.	O

Topotecan	topotecan	O
is	is	O
an	an	O
attractive	attractive	O
option	option	O
as	as	O
it	it	O
exhibits	exhibits	O
growth	growth	O
inhibition	inhibition	O
of	of	O
human	human	O
glioma	glioma	O
as	as	O
well	well	O
as	as	O
brain	brain	O
penetration	penetration	O
.	.	O

The	the	O
present	present	O
study	study	O
assessed	assessed	O
the	the	O
combination	combination	O
of	of	O
radiotherapy	radiotherapy	O
(	(	O
60	60	O
Gy/30	gy/30	O
fractions/40	fractions/40	O
days	days	O
)	)	O
and	and	O
topotecan	topotecan	O
(	(	O
0.9	0.9	O
mg/m(2)/day	mg/m(2)/day	O
on	on	O
days	days	O
1	1	O
-	-	O
5	5	O
on	on	O
weeks	weeks	O
1	1	O
,	,	O
3	3	O
and	and	O
5	5	O
)	)	O
in	in	O
50	50	O
adults	adults	O
with	with	O
histologically	histologically	O
proven	proven	O
and	and	O
untreated	untreated	O
GBM	gbm	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
non-hematological	non-hematological	O
toxicities	toxicities	B-Disease
was	was	O
low	low	O
and	and	O
grade	grade	O
3	3	O
-	-	O
4	4	O
hematological	hematological	O
toxicities	toxicities	B-Disease
were	were	O
reported	reported	O
in	in	O
20	20	O
patients	patients	O
(	(	O
mainly	mainly	O
lymphopenia	lymphopenia	O
and	and	O
neutropenia	neutropenia	B-Disease
)	)	O
.	.	O

Partial	partial	O
response	response	O
and	and	O
stabilization	stabilization	O
rates	rates	O
were	were	O
2	2	O
%	%	O
and	and	O
32	32	O
%	%	O
,	,	O
respectively	respectively	O
,	,	O
with	with	O
an	an	O
overall	overall	O
time	time	O
to	to	O
progression	progression	O
of	of	O
12	12	O
weeks	weeks	O
.	.	O

One-year	one-year	O
overall	overall	O
survival	survival	O
(	(	O
OS	os	O
)	)	O
rate	rate	O
was	was	O
42	42	O
%	%	O
,	,	O
with	with	O
a	a	O
median	median	O
OS	os	O
of	of	O
40	40	O
weeks	weeks	O
.	.	O

Topotecan	topotecan	O
in	in	O
combination	combination	O
with	with	O
radiotherapy	radiotherapy	O
was	was	O
well	well	O
tolerated	tolerated	O
.	.	O

However	however	O
,	,	O
while	while	O
response	response	O
and	and	O
stabilization	stabilization	O
concerned	concerned	O
one-third	one-third	O
of	of	O
the	the	O
patients	patients	O
,	,	O
the	the	O
study	study	O
did	did	O
not	not	O
show	show	O
increased	increased	O
benefits	benefits	O
in	in	O
terms	terms	O
of	of	O
survival	survival	O
in	in	O
patients	patients	O
with	with	O
unresectable	unresectable	O
GBM	gbm	O
.	.	O

Long-term	long-term	O
lithium	lithium	B-Chemical
therapy	therapy	O
leading	leading	O
to	to	O
hyperparathyroidism	hyperparathyroidism	O
:	:	O
a	a	O
case	case	O
report	report	O
.	.	O

PURPOSE	purpose	O
:	:	O
This	this	O
paper	paper	O
reviews	reviews	O
the	the	O
effect	effect	O
of	of	O
chronic	chronic	O
lithium	lithium	B-Chemical
therapy	therapy	O
on	on	O
serum	serum	O
calcium	calcium	B-Chemical
level	level	O
and	and	O
parathyroid	parathyroid	O
glands	glands	O
,	,	O
its	its	O
pathogenesis	pathogenesis	O
,	,	O
and	and	O
treatment	treatment	O
options	options	O
.	.	O

We	we	O
examined	examined	O
the	the	O
case	case	O
of	of	O
a	a	O
lithium-treated	lithium-treated	O
patient	patient	O
who	who	O
had	had	O
recurrent	recurrent	O
hypercalcemia	hypercalcemia	B-Disease
to	to	O
better	better	O
understand	understand	O
the	the	O
disease	disease	O
process	process	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Primary	primary	O
hyperparathyroidism	hyperparathyroidism	O
is	is	O
a	a	O
rare	rare	O
but	but	O
potentially	potentially	O
life-threatening	life-threatening	O
side	side	O
effect	effect	O
of	of	O
long-term	long-term	O
lithium	lithium	B-Chemical
therapy	therapy	O
.	.	O

Careful	careful	O
patient	patient	O
selection	selection	O
and	and	O
long-term	long-term	O
follow-up	follow-up	O
can	can	O
reduce	reduce	O
morbidity	morbidity	O
.	.	O

PRACTICAL	practical	O
IMPLICATIONS	implications	O
:	:	O
As	as	O
much	much	O
as	as	O
15	15	O
%	%	O
of	of	O
lithium-treated	lithium-treated	O
patients	patients	O
become	become	O
hypercalcemic	hypercalcemic	O
.	.	O

By	by	O
routinely	routinely	O
monitoring	monitoring	O
serum	serum	O
calcium	calcium	B-Chemical
levels	levels	O
,	,	O
healthcare	healthcare	O
providers	providers	O
can	can	O
improve	improve	O
the	the	O
quality	quality	O
of	of	O
life	life	O
of	of	O
this	this	O
patient	patient	O
group	group	O
.	.	O

Comparison	comparison	O
of	of	O
laryngeal	laryngeal	O
mask	mask	O
with	with	O
endotracheal	endotracheal	O
tube	tube	O
for	for	O
anesthesia	anesthesia	O
in	in	O
endoscopic	endoscopic	O
sinus	sinus	O
surgery	surgery	O
.	.	O

BACKGROUND	background	O
:	:	O
The	the	O
purpose	purpose	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
compare	compare	O
surgical	surgical	O
conditions	conditions	O
,	,	O
including	including	O
the	the	O
amount	amount	O
of	of	O
intraoperative	intraoperative	O
bleeding	bleeding	B-Disease
as	as	O
well	well	O
as	as	O
intraoperative	intraoperative	O
blood	blood	O
pressure	pressure	O
,	,	O
during	during	O
functional	functional	O
endoscopic	endoscopic	O
sinus	sinus	O
surgery	surgery	O
(	(	O
FESS	fess	O
)	)	O
using	using	O
flexible	flexible	O
reinforced	reinforced	O
laryngeal	laryngeal	O
mask	mask	O
airway	airway	O
(	(	O
FRLMA	frlma	O
)	)	O
versus	versus	O
endotracheal	endotracheal	O
tube	tube	O
(	(	O
ETT	ett	O
)	)	O
in	in	O
maintaining	maintaining	O
controlled	controlled	O
hypotension	hypotension	B-Disease
anesthesia	anesthesia	O
induced	induced	O
by	by	O
propofol-remifentanil	propofol-remifentanil	O
total	total	O
i.v	i.v	O
.	.	O
anesthesia	anesthesia	O
(	(	O
TIVA	tiva	O
)	)	O
.	.	O

METHODS	methods	O
:	:	O
Sixty	sixty	O
normotensive	normotensive	O
American	american	O
Society	society	O
of	of	O
Anesthesiologists	anesthesiologists	O
I-II	i-ii	O
adult	adult	O
patients	patients	O
undergoing	undergoing	O
FESS	fess	O
under	under	O
controlled	controlled	O
hypotension	hypotension	B-Disease
anesthesia	anesthesia	O
caused	caused	O
by	by	O
propofol-remifentanil-TIVA	propofol-remifentanil-tiva	O
were	were	O
randomly	randomly	O
assigned	assigned	O
into	into	O
two	two	O
groups	groups	O
:	:	O
group	group	O
I	i	O
,	,	O
FRLMA	frlma	O
;	;	O
group	group	O
II	ii	O
,	,	O
ETT	ett	O
.	.	O

Hemorrhage	hemorrhage	B-Disease
was	was	O
measured	measured	O
and	and	O
the	the	O
visibility	visibility	O
of	of	O
the	the	O
operative	operative	O
field	field	O
was	was	O
evaluated	evaluated	O
according	according	O
to	to	O
a	a	O
six-point	six-point	O
scale	scale	O
.	.	O

RESULTS	results	O
:	:	O
Controlled	controlled	O
hypotension	hypotension	B-Disease
was	was	O
achieved	achieved	O
within	within	O
a	a	O
shorter	shorter	O
period	period	O
using	using	O
laryngeal	laryngeal	O
mask	mask	O
using	using	O
lower	lower	O
rates	rates	O
of	of	O
remifentanil	remifentanil	O
infusion	infusion	O
and	and	O
lower	lower	O
total	total	O
dose	dose	O
of	of	O
remifentanil	remifentanil	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
In	in	O
summary	summary	O
,	,	O
our	our	O
results	results	O
indicate	indicate	O
that	that	O
airway	airway	O
management	management	O
using	using	O
FRLMA	frlma	O
during	during	O
controlled	controlled	O
hypotension	hypotension	B-Disease
anesthesia	anesthesia	O
provided	provided	O
better	better	O
surgical	surgical	O
conditions	conditions	O
in	in	O
terms	terms	O
of	of	O
quality	quality	O
of	of	O
operative	operative	O
field	field	O
and	and	O
blood	blood	O
loss	loss	O
and	and	O
allowed	allowed	O
for	for	O
convenient	convenient	O
induced	induced	O
hypotension	hypotension	B-Disease
with	with	O
low	low	O
doses	doses	O
of	of	O
remifentanil	remifentanil	O
during	during	O
TIVA	tiva	O
in	in	O
patients	patients	O
undergoing	undergoing	O
FESS	fess	O
.	.	O

Nonalcoholic	nonalcoholic	O
fatty	fatty	B-Disease
liver	liver	B-Disease
disease	disease	I-Disease
during	during	O
valproate	valproate	B-Chemical
therapy	therapy	O
.	.	O

Valproic	valproic	B-Chemical
acid	acid	I-Chemical
(	(	O
VPA	vpa	B-Chemical
)	)	O
is	is	O
effective	effective	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
many	many	O
types	types	O
of	of	O
epilepsy	epilepsy	B-Disease
,	,	O
but	but	O
its	its	O
use	use	O
can	can	O
be	be	O
associated	associated	O
with	with	O
an	an	O
increase	increase	O
in	in	O
body	body	B-Disease
weight	weight	I-Disease
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
nonalcoholic	nonalcoholic	O
fatty	fatty	B-Disease
liver	liver	B-Disease
disease	disease	I-Disease
(	(	O
NAFLD	nafld	O
)	)	O
arising	arising	O
in	in	O
a	a	O
child	child	O
who	who	O
developed	developed	O
obesity	obesity	O
during	during	O
VPA	vpa	B-Chemical
treatment	treatment	O
.	.	O

Laboratory	laboratory	O
data	data	O
revealed	revealed	O
hyperinsulinemia	hyperinsulinemia	O
with	with	O
insulin	insulin	B-Disease
resistance	resistance	I-Disease
.	.	O

After	after	O
the	the	O
withdrawal	withdrawal	O
of	of	O
VPA	vpa	B-Chemical
therapy	therapy	O
,	,	O
our	our	O
patient	patient	O
showed	showed	O
a	a	O
significant	significant	O
weight	weight	B-Disease
loss	loss	I-Disease
,	,	O
a	a	O
decrease	decrease	O
of	of	O
body	body	O
mass	mass	O
index	index	O
,	,	O
and	and	O
normalization	normalization	O
of	of	O
metabolic	metabolic	O
and	and	O
endocrine	endocrine	O
parameters	parameters	O
;	;	O
moreover	moreover	O
,	,	O
ultrasound	ultrasound	O
measurements	measurements	O
showed	showed	O
a	a	O
complete	complete	O
normalization	normalization	O
.	.	O

The	the	O
present	present	O
case	case	O
suggests	suggests	O
that	that	O
obesity	obesity	O
,	,	O
hyperinsulinemia	hyperinsulinemia	O
,	,	O
insulin	insulin	B-Disease
resistance	resistance	I-Disease
,	,	O
and	and	O
long-term	long-term	O
treatment	treatment	O
with	with	O
VPA	vpa	B-Chemical
may	may	O
be	be	O
all	all	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
NAFLD	nafld	O
;	;	O
this	this	O
side	side	O
effect	effect	O
is	is	O
reversible	reversible	O
after	after	O
VPA	vpa	B-Chemical
withdrawal	withdrawal	O
.	.	O

Carbimazole	carbimazole	B-Chemical
induced	induced	O
ANCA	anca	O
positive	positive	O
vasculitis	vasculitis	B-Disease
.	.	O

Anti-thyroid	anti-thyroid	O
drugs	drugs	O
,	,	O
like	like	O
carbimazole	carbimazole	B-Chemical
and	and	O
propylthiouracil	propylthiouracil	B-Chemical
(	(	O
PTU	ptu	O
)	)	O
are	are	O
commonly	commonly	O
prescribed	prescribed	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
hyperthyroidism	hyperthyroidism	B-Disease
.	.	O

One	one	O
should	should	O
be	be	O
aware	aware	O
of	of	O
the	the	O
side	side	O
effects	effects	O
of	of	O
antithyroid	antithyroid	O
medications	medications	O
.	.	O

Antineutrophil	antineutrophil	O
cytoplasmic	cytoplasmic	O
antibody	antibody	O
(ANCA)--associated	(anca)--associated	O
vasculitis	vasculitis	B-Disease
is	is	O
a	a	O
potentially	potentially	O
life-threatening	life-threatening	O
adverse	adverse	O
effect	effect	O
of	of	O
antithyroidmedications	antithyroidmedications	O
.	.	O

We	we	O
report	report	O
a	a	O
patient	patient	O
with	with	O
Graves	graves	B-Disease
'	'	I-Disease
disease	disease	I-Disease
who	who	O
developed	developed	O
ANCA	anca	O
positive	positive	O
carbimazole	carbimazole	B-Chemical
induced	induced	O
vasculitis	vasculitis	B-Disease
.	.	O

The	the	O
episode	episode	O
was	was	O
characterized	characterized	O
by	by	O
a	a	O
vasculitic	vasculitic	O
skin	skin	O
rash	rash	B-Disease
associated	associated	O
with	with	O
large	large	O
joint	joint	O
arthritis	arthritis	B-Disease
,	,	O
pyrexia	pyrexia	O
and	and	O
parotiditis	parotiditis	O
but	but	O
no	no	O
renal	renal	O
or	or	O
pulmonary	pulmonary	O
involvement	involvement	O
.	.	O

He	he	O
was	was	O
referred	referred	O
to	to	O
us	us	O
for	for	O
neurological	neurological	O
evaluation	evaluation	O
because	because	O
he	he	O
had	had	O
difficulty	difficulty	O
in	in	O
getting	getting	O
up	up	O
from	from	O
squatting	squatting	O
position	position	O
and	and	O
was	was	O
suspected	suspected	O
to	to	O
have	have	O
myositis	myositis	O
.	.	O

Carbimazole	carbimazole	B-Chemical
and	and	O
methimazole	methimazole	O
have	have	O
a	a	O
lower	lower	O
incidence	incidence	O
of	of	O
reported	reported	O
ANCA	anca	O
positive	positive	O
side	side	O
effects	effects	O
than	than	O
PUT	put	O
.	.	O

To	to	O
the	the	O
best	best	O
of	of	O
our	our	O
knowledge	knowledge	O
this	this	O
is	is	O
the	the	O
first	first	O
ANCA	anca	O
positive	positive	O
carbimazole	carbimazole	B-Chemical
induced	induced	O
vasculitis	vasculitis	B-Disease
case	case	O
reported	reported	O
from	from	O
India	india	O
.	.	O

Aspirin	aspirin	B-Chemical
for	for	O
the	the	O
primary	primary	O
prevention	prevention	O
of	of	O
cardiovascular	cardiovascular	O
events	events	O
:	:	O
an	an	O
update	update	O
of	of	O
the	the	O
evidence	evidence	O
for	for	O
the	the	O
U.S.	u.s.	O
Preventive	preventive	O
Services	services	O
Task	task	O
Force	force	O
.	.	O

BACKGROUND	background	O
:	:	O
Coronary	coronary	B-Disease
heart	heart	B-Disease
disease	disease	I-Disease
and	and	O
cerebrovascular	cerebrovascular	O
disease	disease	O
are	are	O
leading	leading	O
causes	causes	O
of	of	O
death	death	B-Disease
in	in	O
the	the	O
United	united	O
States	states	O
.	.	O

In	in	O
2002	2002	O
,	,	O
the	the	O
U.S.	u.s.	O
Preventive	preventive	O
Services	services	O
Task	task	O
Force	force	O
(	(	O
USPSTF	uspstf	O
)	)	O
strongly	strongly	O
recommended	recommended	O
that	that	O
clinicians	clinicians	O
discuss	discuss	O
aspirin	aspirin	B-Chemical
with	with	O
adults	adults	O
who	who	O
are	are	O
at	at	O
increased	increased	O
risk	risk	O
for	for	O
coronary	coronary	B-Disease
heart	heart	B-Disease
disease	disease	I-Disease
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
determine	determine	O
the	the	O
benefits	benefits	O
and	and	O
harms	harms	O
of	of	O
taking	taking	O
aspirin	aspirin	B-Chemical
for	for	O
the	the	O
primary	primary	O
prevention	prevention	O
of	of	O
myocardial	myocardial	B-Disease
infarctions	infarctions	I-Disease
,	,	O
strokes	strokes	B-Disease
,	,	O
and	and	O
death	death	B-Disease
.	.	O

DATA	data	O
SOURCES	sources	O
:	:	O
MEDLINE	medline	O
and	and	O
Cochrane	cochrane	O
Library	library	O
(	(	O
search	search	O
dates	dates	O
,	,	O
1	1	O
January	january	O
2001	2001	O
to	to	O
28	28	O
August	august	O
2008	2008	O
)	)	O
,	,	O
recent	recent	O
systematic	systematic	O
reviews	reviews	O
,	,	O
reference	reference	O
lists	lists	O
of	of	O
retrieved	retrieved	O
articles	articles	O
,	,	O
and	and	O
suggestions	suggestions	O
from	from	O
experts	experts	O
.	.	O

STUDY	study	O
SELECTION	selection	O
:	:	O
English-language	english-language	O
randomized	randomized	O
,	,	O
controlled	controlled	O
trials	trials	O
(	(	O
RCTs	rcts	O
)	)	O
;	;	O
case-control	case-control	O
studies	studies	O
;	;	O
meta-analyses	meta-analyses	O
;	;	O
and	and	O
systematic	systematic	O
reviews	reviews	O
of	of	O
aspirin	aspirin	B-Chemical
versus	versus	O
control	control	O
for	for	O
the	the	O
primary	primary	O
prevention	prevention	O
of	of	O
cardiovascular	cardiovascular	B-Disease
disease	disease	I-Disease
(	(	O
CVD	cvd	O
)	)	O
were	were	O
selected	selected	O
to	to	O
answer	answer	O
the	the	O
following	following	O
questions	questions	O
:	:	O
Does	does	O
aspirin	aspirin	B-Chemical
decrease	decrease	O
coronary	coronary	O
heart	heart	O
events	events	O
,	,	O
strokes	strokes	B-Disease
,	,	O
death	death	B-Disease
from	from	O
coronary	coronary	O
heart	heart	O
events	events	O
or	or	O
stroke	stroke	B-Disease
,	,	O
or	or	O
all-cause	all-cause	O
mortality	mortality	O
in	in	O
adults	adults	O
without	without	O
known	known	O
CVD	cvd	O
?	?	O
Does	does	O
aspirin	aspirin	B-Chemical
increase	increase	O
gastrointestinal	gastrointestinal	O
bleeding	bleeding	B-Disease
or	or	O
hemorrhagic	hemorrhagic	B-Disease
strokes	strokes	B-Disease
?	?	O
DATA	data	O
EXTRACTION	extraction	O
:	:	O
All	all	O
studies	studies	O
were	were	O
reviewed	reviewed	O
,	,	O
abstracted	abstracted	O
,	,	O
and	and	O
rated	rated	O
for	for	O
quality	quality	O
by	by	O
using	using	O
predefined	predefined	O
USPSTF	uspstf	O
criteria	criteria	O
.	.	O

DATA	data	O
SYNTHESIS	synthesis	O
:	:	O
New	new	O
evidence	evidence	O
from	from	O
1	1	O
good-quality	good-quality	O
RCT	rct	O
,	,	O
1	1	O
good-quality	good-quality	O
meta-analysis	meta-analysis	O
,	,	O
and	and	O
2	2	O
fair-quality	fair-quality	O
subanalyses	subanalyses	O
of	of	O
RCTs	rcts	O
demonstrates	demonstrates	O
that	that	O
aspirin	aspirin	B-Chemical
use	use	O
reduces	reduces	O
the	the	O
number	number	O
of	of	O
CVD	cvd	O
events	events	O
in	in	O
patients	patients	O
without	without	O
known	known	O
CVD	cvd	O
.	.	O

Men	men	O
in	in	O
these	these	O
studies	studies	O
experienced	experienced	O
fewer	fewer	O
myocardial	myocardial	B-Disease
infarctions	infarctions	I-Disease
and	and	O
women	women	O
experienced	experienced	O
fewer	fewer	O
ischemic	ischemic	O
strokes	strokes	B-Disease
.	.	O

Aspirin	aspirin	B-Chemical
does	does	O
not	not	O
seem	seem	O
to	to	O
affect	affect	O
CVD	cvd	O
mortality	mortality	O
or	or	O
all-cause	all-cause	O
mortality	mortality	O
in	in	O
either	either	O
men	men	O
or	or	O
women	women	O
.	.	O

The	the	O
use	use	O
of	of	O
aspirin	aspirin	B-Chemical
for	for	O
primary	primary	O
prevention	prevention	O
increases	increases	O
the	the	O
risk	risk	O
for	for	O
major	major	O
bleeding	bleeding	B-Disease
events	events	O
,	,	O
primarily	primarily	O
gastrointestinal	gastrointestinal	O
bleeding	bleeding	B-Disease
events	events	O
,	,	O
in	in	O
both	both	O
men	men	O
and	and	O
women	women	O
.	.	O

Men	men	O
have	have	O
an	an	O
increased	increased	O
risk	risk	O
for	for	O
hemorrhagic	hemorrhagic	B-Disease
strokes	strokes	B-Disease
with	with	O
aspirin	aspirin	B-Chemical
use	use	O
.	.	O

A	a	O
new	new	O
RCT	rct	O
and	and	O
meta-analysis	meta-analysis	O
suggest	suggest	O
that	that	O
the	the	O
risk	risk	O
for	for	O
hemorrhagic	hemorrhagic	B-Disease
strokes	strokes	B-Disease
in	in	O
women	women	O
is	is	O
not	not	O
statistically	statistically	O
significantly	significantly	O
increased	increased	O
.	.	O

LIMITATIONS	limitations	O
:	:	O
New	new	O
evidence	evidence	O
on	on	O
aspirin	aspirin	B-Chemical
for	for	O
the	the	O
primary	primary	O
prevention	prevention	O
of	of	O
CVD	cvd	O
is	is	O
limited	limited	O
.	.	O

The	the	O
dose	dose	O
of	of	O
aspirin	aspirin	B-Chemical
used	used	O
in	in	O
the	the	O
RCTs	rcts	O
varied	varied	O
,	,	O
which	which	O
prevented	prevented	O
the	the	O
estimation	estimation	O
of	of	O
the	the	O
most	most	O
appropriate	appropriate	O
dose	dose	O
for	for	O
primary	primary	O
prevention	prevention	O
.	.	O

Several	several	O
of	of	O
the	the	O
RCTs	rcts	O
were	were	O
conducted	conducted	O
within	within	O
populations	populations	O
of	of	O
health	health	O
professionals	professionals	O
,	,	O
which	which	O
potentially	potentially	O
limits	limits	O
generalizability	generalizability	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Aspirin	aspirin	B-Chemical
reduces	reduces	O
the	the	O
risk	risk	O
for	for	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
in	in	O
men	men	O
and	and	O
strokes	strokes	B-Disease
in	in	O
women	women	O
.	.	O

Aspirin	aspirin	B-Chemical
use	use	O
increases	increases	O
the	the	O
risk	risk	O
for	for	O
serious	serious	O
bleeding	bleeding	B-Disease
events	events	O
.	.	O

Reducing	reducing	O
harm	harm	O
associated	associated	O
with	with	O
anticoagulation	anticoagulation	O
:	:	O
practical	practical	O
considerations	considerations	O
of	of	O
argatroban	argatroban	B-Chemical
therapy	therapy	O
in	in	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
.	.	O

Argatroban	argatroban	B-Chemical
is	is	O
a	a	O
hepatically	hepatically	O
metabolized	metabolized	O
,	,	O
direct	direct	O
thrombin	thrombin	O
inhibitor	inhibitor	O
used	used	O
for	for	O
prophylaxis	prophylaxis	O
or	or	O
treatment	treatment	O
of	of	O
thrombosis	thrombosis	B-Disease
in	in	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
(	(	O
HIT	hit	B-Disease
)	)	O
and	and	O
for	for	O
patients	patients	O
with	with	O
or	or	O
at	at	O
risk	risk	O
of	of	O
HIT	hit	B-Disease
undergoing	undergoing	O
percutaneous	percutaneous	O
coronary	coronary	O
intervention	intervention	O
(	(	O
PCI	pci	O
)	)	O
.	.	O

The	the	O
objective	objective	O
of	of	O
this	this	O
review	review	O
is	is	O
to	to	O
summarize	summarize	O
practical	practical	O
considerations	considerations	O
of	of	O
argatroban	argatroban	B-Chemical
therapy	therapy	O
in	in	O
HIT	hit	B-Disease
.	.	O

The	the	O
US	us	O
FDA-recommended	fda-recommended	O
argatroban	argatroban	B-Chemical
dose	dose	O
in	in	O
HIT	hit	B-Disease
is	is	O
2	2	O
microg/kg/min	microg/kg/min	O
(	(	O
reduced	reduced	O
in	in	O
patients	patients	O
with	with	O
hepatic	hepatic	O
impairment	impairment	O
and	and	O
in	in	O
paediatric	paediatric	O
patients	patients	O
)	)	O
,	,	O
adjusted	adjusted	O
to	to	O
achieve	achieve	O
activated	activated	O
partial	partial	O
thromboplastin	thromboplastin	O
times	times	O
(	(	O
aPTTs	aptts	O
)	)	O
1.5	1.5	O
-	-	O
3	3	O
times	times	O
baseline	baseline	O
(	(	O
not	not	O
>	>	O
100	100	O
seconds	seconds	O
)	)	O
.	.	O

Contemporary	contemporary	O
experiences	experiences	O
indicate	indicate	O
that	that	O
reduced	reduced	O
doses	doses	O
are	are	O
also	also	O
needed	needed	O
in	in	O
patients	patients	O
with	with	O
conditions	conditions	O
associated	associated	O
with	with	O
hepatic	hepatic	O
hypoperfusion	hypoperfusion	O
,	,	O
e.g.	e.g.	O
heart	heart	B-Disease
failure	failure	I-Disease
,	,	O
yet	yet	O
are	are	O
unnecessary	unnecessary	O
for	for	O
renal	renal	B-Disease
dysfunction	dysfunction	I-Disease
,	,	O
adult	adult	O
age	age	O
,	,	O
sex	sex	O
,	,	O
race/ethnicity	race/ethnicity	O
or	or	O
obesity	obesity	O
.	.	O

Argatroban	argatroban	B-Chemical
0.5	0.5	O
-	-	O
1.2	1.2	O
microg/kg/min	microg/kg/min	O
typically	typically	O
supports	supports	O
therapeutic	therapeutic	O
aPTTs	aptts	O
.	.	O

The	the	O
FDA-recommended	fda-recommended	O
dose	dose	O
during	during	O
PCI	pci	O
is	is	O
25	25	O
microg/kg/min	microg/kg/min	O
(	(	O
350	350	O
microg/kg	microg/kg	O
initial	initial	O
bolus	bolus	O
)	)	O
,	,	O
adjusted	adjusted	O
to	to	O
achieve	achieve	O
activated	activated	O
clotting	clotting	O
times	times	O
(	(	O
ACTs	acts	O
)	)	O
of	of	O
300	300	O
-	-	O
450	450	O
sec.	sec.	O
For	for	O
PCI	pci	O
,	,	O
argatroban	argatroban	B-Chemical
has	has	O
not	not	O
been	been	O
investigated	investigated	O
in	in	O
hepatically	hepatically	O
impaired	impaired	O
patients	patients	O
;	;	O
dose	dose	O
adjustment	adjustment	O
is	is	O
unnecessary	unnecessary	O
for	for	O
adult	adult	O
age	age	O
,	,	O
sex	sex	O
,	,	O
race/ethnicity	race/ethnicity	O
or	or	O
obesity	obesity	O
,	,	O
and	and	O
lesser	lesser	O
doses	doses	O
may	may	O
be	be	O
adequate	adequate	O
with	with	O
concurrent	concurrent	O
glycoprotein	glycoprotein	O
IIb/IIIa	iib/iiia	O
inhibition	inhibition	O
.	.	O

Argatroban	argatroban	B-Chemical
prolongs	prolongs	O
the	the	O
International	international	O
Normalized	normalized	O
Ratio	ratio	O
,	,	O
and	and	O
published	published	O
approaches	approaches	O
for	for	O
monitoring	monitoring	O
the	the	O
argatroban-to-warfarin	argatroban-to-warfarin	O
transition	transition	O
should	should	O
be	be	O
followed	followed	O
.	.	O

Major	major	O
bleeding	bleeding	B-Disease
with	with	O
argatroban	argatroban	B-Chemical
is	is	O
0	0	O
-	-	O
10	10	O
%	%	O
in	in	O
the	the	O
non-interventional	non-interventional	O
setting	setting	O
and	and	O
0	0	O
-	-	O
5.8	5.8	O
%	%	O
periprocedurally	periprocedurally	O
.	.	O

Argatroban	argatroban	B-Chemical
has	has	O
no	no	O
specific	specific	O
antidote	antidote	O
,	,	O
and	and	O
if	if	O
excessive	excessive	O
anticoagulation	anticoagulation	O
occurs	occurs	O
,	,	O
argatroban	argatroban	B-Chemical
infusion	infusion	O
should	should	O
be	be	O
stopped	stopped	O
or	or	O
reduced	reduced	O
.	.	O

Improved	improved	O
familiarity	familiarity	O
of	of	O
healthcare	healthcare	O
professionals	professionals	O
with	with	O
argatroban	argatroban	B-Chemical
therapy	therapy	O
in	in	O
HIT	hit	B-Disease
,	,	O
including	including	O
in	in	O
special	special	O
populations	populations	O
and	and	O
during	during	O
PCI	pci	O
,	,	O
may	may	O
facilitate	facilitate	O
reduction	reduction	O
of	of	O
harm	harm	O
associated	associated	O
with	with	O
HIT	hit	B-Disease
(	(	O
e.g.	e.g.	O
fewer	fewer	O
thromboses	thromboses	O
)	)	O
or	or	O
its	its	O
treatment	treatment	O
(	(	O
e.g.	e.g.	O
fewer	fewer	O
argatroban	argatroban	B-Chemical
medication	medication	O
errors	errors	O
)	)	O
.	.	O

Rhabdomyolysis	rhabdomyolysis	B-Disease
and	and	O
brain	brain	O
ischemic	ischemic	B-Disease
stroke	stroke	B-Disease
in	in	O
a	a	O
heroin-dependent	heroin-dependent	O
male	male	O
under	under	O
methadone	methadone	B-Chemical
maintenance	maintenance	O
therapy	therapy	O
.	.	O

OBJECTIVE	objective	O
:	:	O
There	there	O
are	are	O
several	several	O
complications	complications	O
associated	associated	O
with	with	O
heroin	heroin	B-Disease
abuse	abuse	I-Disease
,	,	O
some	some	O
of	of	O
which	which	O
are	are	O
life-threatening	life-threatening	O
.	.	O

Methadone	methadone	B-Chemical
may	may	O
aggravate	aggravate	O
this	this	O
problem	problem	O
.	.	O

METHOD	method	O
:	:	O
A	a	O
clinical	clinical	O
case	case	O
description	description	O
.	.	O

RESULTS	results	O
:	:	O
A	a	O
33-year-old	33-year-old	O
man	man	O
presented	presented	O
with	with	O
rhabdomyolysis	rhabdomyolysis	B-Disease
and	and	O
cerebral	cerebral	O
ischemic	ischemic	B-Disease
stroke	stroke	B-Disease
after	after	O
intravenous	intravenous	O
heroin	heroin	O
.	.	O

He	he	O
had	had	O
used	used	O
heroin	heroin	O
since	since	O
age	age	O
20	20	O
,	,	O
and	and	O
had	had	O
used	used	O
150	150	O
mg	mg	O
methadone	methadone	B-Chemical
daily	daily	O
for	for	O
6	6	O
months	months	O
.	.	O

He	he	O
was	was	O
found	found	O
unconsciousness	unconsciousness	O
at	at	O
home	home	O
and	and	O
was	was	O
sent	sent	O
to	to	O
our	our	O
hospital	hospital	O
.	.	O

In	in	O
the	the	O
ER	er	O
,	,	O
his	his	O
opiate	opiate	O
level	level	O
was	was	O
4497	4497	O
ng/ml	ng/ml	O
.	.	O

In	in	O
the	the	O
ICU	icu	O
,	,	O
we	we	O
found	found	O
rhabdomyolysis	rhabdomyolysis	B-Disease
,	,	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
and	and	O
acute	acute	O
respiratory	respiratory	B-Disease
failure	failure	I-Disease
.	.	O

After	after	O
transfer	transfer	O
to	to	O
an	an	O
internal	internal	O
ward	ward	O
,	,	O
we	we	O
noted	noted	O
aphasia	aphasia	O
and	and	O
weakness	weakness	B-Disease
of	of	O
his	his	O
left	left	O
limbs	limbs	O
.	.	O

After	after	O
MRI	mri	O
,	,	O
we	we	O
found	found	O
cerebral	cerebral	O
ischemic	ischemic	O
infarction	infarction	B-Disease
.	.	O

CONCLUSION	conclusion	O
:	:	O
Those	those	O
using	using	O
methadone	methadone	B-Chemical
and	and	O
heroin	heroin	O
simultaneously	simultaneously	O
may	may	O
increase	increase	O
risk	risk	O
of	of	O
rhabdomyolysis	rhabdomyolysis	B-Disease
and	and	O
ischemic	ischemic	B-Disease
stroke	stroke	B-Disease
.	.	O

Patients	patients	O
under	under	O
methadone	methadone	B-Chemical
maintenance	maintenance	O
therapy	therapy	O
should	should	O
be	be	O
warned	warned	O
regarding	regarding	O
these	these	O
serious	serious	O
adverse	adverse	O
events	events	O
.	.	O

Hypotheses	hypotheses	O
of	of	O
heroin-related	heroin-related	O
rhabdomyolysis	rhabdomyolysis	B-Disease
and	and	O
stroke	stroke	B-Disease
in	in	O
heroin	heroin	O
abusers	abusers	O
are	are	O
discussed	discussed	O
.	.	O

Increased	increased	O
vulnerability	vulnerability	O
to	to	O
6-hydroxydopamine	6-hydroxydopamine	B-Chemical
lesion	lesion	O
and	and	O
reduced	reduced	O
development	development	O
of	of	O
dyskinesias	dyskinesias	B-Disease
in	in	O
mice	mice	O
lacking	lacking	O
CB1	cb1	O
cannabinoid	cannabinoid	O
receptors	receptors	O
.	.	O

Motor	motor	O
impairment	impairment	O
,	,	O
dopamine	dopamine	B-Chemical
(	(	O
DA	da	B-Chemical
)	)	O
neuronal	neuronal	O
activity	activity	O
and	and	O
proenkephalin	proenkephalin	O
(	(	O
PENK	penk	O
)	)	O
gene	gene	O
expression	expression	O
in	in	O
the	the	O
caudate-putamen	caudate-putamen	O
(	(	O
CPu	cpu	O
)	)	O
were	were	O
measured	measured	O
in	in	O
6-OHDA-lesioned	6-ohda-lesioned	O
and	and	O
treated	treated	O
(	(	O
L-DOPA+benserazide	l-dopa+benserazide	O
)	)	O
CB1	cb1	O
KO	ko	O
and	and	O
WT	wt	O
mice	mice	O
.	.	O

A	a	O
lesion	lesion	O
induced	induced	O
by	by	O
6-OHDA	6-ohda	B-Chemical
produced	produced	O
more	more	O
severe	severe	O
motor	motor	O
deterioration	deterioration	O
in	in	O
CB1	cb1	O
KO	ko	O
mice	mice	O
accompanied	accompanied	O
by	by	O
more	more	O
loss	loss	O
of	of	O
DA	da	B-Chemical
neurons	neurons	O
and	and	O
increased	increased	O
PENK	penk	O
gene	gene	O
expression	expression	O
in	in	O
the	the	O
CPu	cpu	O
.	.	O

Oxidative/nitrosative	oxidative/nitrosative	O
and	and	O
neuroinflammatory	neuroinflammatory	O
parameters	parameters	O
were	were	O
estimated	estimated	O
in	in	O
the	the	O
CPu	cpu	O
and	and	O
cingulate	cingulate	O
cortex	cortex	O
(	(	O
Cg	cg	O
)	)	O
.	.	O

CB1	cb1	O
KO	ko	O
mice	mice	O
exhibited	exhibited	O
higher	higher	O
MDA	mda	O
levels	levels	O
and	and	O
iNOS	inos	O
protein	protein	O
expression	expression	O
in	in	O
the	the	O
CPu	cpu	O
and	and	O
Cg	cg	O
compared	compared	O
to	to	O
WT	wt	O
mice	mice	O
.	.	O

Treatment	treatment	O
with	with	O
L-DOPA+benserazide	l-dopa+benserazide	O
(	(	O
12	12	O
weeks	weeks	O
)	)	O
resulted	resulted	O
in	in	O
less	less	O
severe	severe	O
dyskinesias	dyskinesias	B-Disease
in	in	O
CB1	cb1	O
KO	ko	O
than	than	O
in	in	O
WT	wt	O
mice	mice	O
.	.	O

The	the	O
results	results	O
revealed	revealed	O
that	that	O
the	the	O
lack	lack	O
of	of	O
cannabinoid	cannabinoid	O
CB1	cb1	O
receptors	receptors	O
increased	increased	O
the	the	O
severity	severity	O
of	of	O
motor	motor	O
impairment	impairment	O
and	and	O
DA	da	B-Chemical
lesion	lesion	O
,	,	O
and	and	O
reduced	reduced	O
L-DOPA-induced	l-dopa-induced	O
dyskinesias	dyskinesias	B-Disease
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
activation	activation	O
of	of	O
CB1	cb1	O
receptors	receptors	O
offers	offers	O
neuroprotection	neuroprotection	O
against	against	O
dopaminergic	dopaminergic	O
lesion	lesion	O
and	and	O
the	the	O
development	development	O
of	of	O
L-DOPA-induced	l-dopa-induced	O
dyskinesias	dyskinesias	B-Disease
.	.	O

Hepatocellular	hepatocellular	O
oxidant	oxidant	O
stress	stress	O
following	following	O
intestinal	intestinal	O
ischemia-reperfusion	ischemia-reperfusion	O
injury	injury	O
.	.	O

Reperfusion	reperfusion	O
of	of	O
ischemic	ischemic	O
intestine	intestine	O
results	results	O
in	in	O
acute	acute	O
liver	liver	O
dysfunction	dysfunction	O
characterized	characterized	O
by	by	O
hepatocellular	hepatocellular	O
enzyme	enzyme	O
release	release	O
into	into	O
plasma	plasma	O
,	,	O
reduction	reduction	O
in	in	O
bile	bile	O
flow	flow	O
rate	rate	O
,	,	O
and	and	O
neutrophil	neutrophil	O
sequestration	sequestration	O
within	within	O
the	the	O
liver	liver	O
.	.	O

The	the	O
pathophysiology	pathophysiology	O
underlying	underlying	O
this	this	O
acute	acute	O
hepatic	hepatic	B-Disease
injury	injury	I-Disease
is	is	O
unknown	unknown	O
.	.	O

This	this	O
study	study	O
was	was	O
undertaken	undertaken	O
to	to	O
determine	determine	O
whether	whether	O
oxidants	oxidants	O
are	are	O
associated	associated	O
with	with	O
the	the	O
hepatic	hepatic	B-Disease
injury	injury	I-Disease
and	and	O
to	to	O
determine	determine	O
the	the	O
relative	relative	O
value	value	O
of	of	O
several	several	O
indirect	indirect	O
methods	methods	O
of	of	O
assessing	assessing	O
oxidant	oxidant	O
exposure	exposure	O
in	in	O
vivo	vivo	O
.	.	O

Rats	rats	O
were	were	O
subjected	subjected	O
to	to	O
a	a	O
standardized	standardized	O
intestinal	intestinal	O
ischemia-reperfusion	ischemia-reperfusion	O
injury	injury	O
.	.	O

Hepatic	hepatic	O
tissue	tissue	O
was	was	O
assayed	assayed	O
for	for	O
lipid	lipid	O
peroxidation	peroxidation	O
products	products	O
and	and	O
oxidized	oxidized	O
and	and	O
reduced	reduced	O
glutathione	glutathione	B-Chemical
.	.	O

There	there	O
was	was	O
no	no	O
change	change	O
in	in	O
hepatic	hepatic	O
tissue	tissue	O
total	total	O
glutathione	glutathione	B-Chemical
following	following	O
intestinal	intestinal	O
ischemia-reperfusion	ischemia-reperfusion	O
injury	injury	O
.	.	O

Oxidized	oxidized	O
glutathione	glutathione	B-Chemical
(	(	O
GSSG	gssg	O
)	)	O
increased	increased	O
significantly	significantly	O
following	following	O
30	30	O
and	and	O
60	60	O
min	min	O
of	of	O
reperfusion	reperfusion	O
.	.	O

There	there	O
was	was	O
no	no	O
increase	increase	O
in	in	O
any	any	O
of	of	O
the	the	O
products	products	O
of	of	O
lipid	lipid	O
peroxidation	peroxidation	O
associated	associated	O
with	with	O
this	this	O
injury	injury	O
.	.	O

An	an	O
increase	increase	O
in	in	O
GSSG	gssg	O
within	within	O
hepatic	hepatic	O
tissue	tissue	O
during	during	O
intestinal	intestinal	O
reperfusion	reperfusion	O
suggests	suggests	O
exposure	exposure	O
of	of	O
hepatocytes	hepatocytes	O
to	to	O
an	an	O
oxidant	oxidant	O
stress	stress	O
.	.	O

The	the	O
lack	lack	O
of	of	O
a	a	O
significant	significant	O
increase	increase	O
in	in	O
products	products	O
of	of	O
lipid	lipid	O
peroxidation	peroxidation	O
suggests	suggests	O
that	that	O
the	the	O
oxidant	oxidant	O
stress	stress	O
is	is	O
of	of	O
insufficient	insufficient	O
magnitude	magnitude	O
to	to	O
result	result	O
in	in	O
irreversible	irreversible	O
injury	injury	O
to	to	O
hepatocyte	hepatocyte	O
cell	cell	O
membranes	membranes	O
.	.	O

These	these	O
data	data	O
also	also	O
suggest	suggest	O
that	that	O
the	the	O
measurement	measurement	O
of	of	O
tissue	tissue	O
GSSG	gssg	O
may	may	O
be	be	O
a	a	O
more	more	O
sensitive	sensitive	O
indicator	indicator	O
of	of	O
oxidant	oxidant	O
stress	stress	O
than	than	O
measurement	measurement	O
of	of	O
products	products	O
of	of	O
lipid	lipid	O
peroxidation	peroxidation	O
.	.	O

Animal	animal	O
model	model	O
of	of	O
mania	mania	B-Disease
induced	induced	O
by	by	O
ouabain	ouabain	B-Chemical
:	:	O
Evidence	evidence	O
of	of	O
oxidative	oxidative	O
stress	stress	O
in	in	O
submitochondrial	submitochondrial	O
particles	particles	O
of	of	O
the	the	O
rat	rat	O
brain	brain	O
.	.	O

The	the	O
intracerebroventricular	intracerebroventricular	O
(	(	O
ICV	icv	O
)	)	O
administration	administration	O
of	of	O
ouabain	ouabain	B-Chemical
(	(	O
a	a	O
Na(+)/K(+)-ATPase	na(+)/k(+)-atpase	O
inhibitor	inhibitor	O
)	)	O
in	in	O
rats	rats	O
has	has	O
been	been	O
suggested	suggested	O
to	to	O
mimic	mimic	O
some	some	O
symptoms	symptoms	O
of	of	O
human	human	O
bipolar	bipolar	B-Disease
mania	mania	B-Disease
.	.	O

Clinical	clinical	O
studies	studies	O
have	have	O
shown	shown	O
that	that	O
bipolar	bipolar	B-Disease
disorder	disorder	I-Disease
may	may	O
be	be	O
related	related	O
to	to	O
mitochondrial	mitochondrial	B-Disease
dysfunction	dysfunction	I-Disease
.	.	O

Herein	herein	O
,	,	O
we	we	O
investigated	investigated	O
the	the	O
behavioral	behavioral	O
and	and	O
biochemical	biochemical	O
effects	effects	O
induced	induced	O
by	by	O
the	the	O
ICV	icv	O
administration	administration	O
of	of	O
ouabain	ouabain	B-Chemical
in	in	O
rats	rats	O
.	.	O

To	to	O
achieve	achieve	O
this	this	O
aim	aim	O
,	,	O
the	the	O
effects	effects	O
of	of	O
ouabain	ouabain	B-Chemical
injection	injection	O
immediately	immediately	O
after	after	O
and	and	O
7	7	O
days	days	O
following	following	O
a	a	O
single	single	O
ICV	icv	O
administration	administration	O
(	(	O
at	at	O
concentrations	concentrations	O
of	of	O
10(-2	10(-2	O
)	)	O
and	and	O
10(-3)M	10(-3)m	O
)	)	O
on	on	O
locomotion	locomotion	O
was	was	O
measured	measured	O
using	using	O
the	the	O
open-field	open-field	O
test	test	O
.	.	O

Additionally	additionally	O
,	,	O
thiobarbituric	thiobarbituric	B-Chemical
acid	acid	I-Chemical
reactive	reactive	I-Chemical
substances	substances	I-Chemical
(	(	O
TBARSs	tbarss	O
)	)	O
and	and	O
superoxide	superoxide	B-Chemical
production	production	O
were	were	O
measured	measured	O
in	in	O
submitochondrial	submitochondrial	O
particles	particles	O
of	of	O
the	the	O
prefrontal	prefrontal	O
cortex	cortex	O
,	,	O
hippocampus	hippocampus	O
,	,	O
striatum	striatum	O
and	and	O
amygdala	amygdala	O
.	.	O

Our	our	O
findings	findings	O
demonstrated	demonstrated	O
that	that	O
ouabain	ouabain	B-Chemical
at	at	O
10(-2	10(-2	O
)	)	O
and	and	O
10(-3)M	10(-3)m	O
induced	induced	O
hyperlocomotion	hyperlocomotion	O
in	in	O
rats	rats	O
,	,	O
and	and	O
this	this	O
response	response	O
remained	remained	O
up	up	O
to	to	O
7	7	O
days	days	O
following	following	O
a	a	O
single	single	O
ICV	icv	O
injection	injection	O
.	.	O

In	in	O
addition	addition	O
,	,	O
we	we	O
observed	observed	O
that	that	O
the	the	O
persistent	persistent	O
increase	increase	O
in	in	O
the	the	O
rat	rat	O
spontaneous	spontaneous	O
locomotion	locomotion	O
is	is	O
associated	associated	O
with	with	O
increased	increased	O
TBARS	tbars	B-Chemical
levels	levels	O
and	and	O
superoxide	superoxide	B-Chemical
generation	generation	O
in	in	O
submitochondrial	submitochondrial	O
particles	particles	O
in	in	O
the	the	O
prefrontal	prefrontal	O
cortex	cortex	O
,	,	O
striatum	striatum	O
and	and	O
amygdala	amygdala	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
ouabain-induced	ouabain-induced	O
mania-like	mania-like	O
behavior	behavior	O
may	may	O
provide	provide	O
a	a	O
useful	useful	O
animal	animal	O
model	model	O
to	to	O
test	test	O
the	the	O
hypothesis	hypothesis	O
of	of	O
the	the	O
involvement	involvement	O
of	of	O
oxidative	oxidative	O
stress	stress	O
in	in	O
bipolar	bipolar	B-Disease
disorder	disorder	I-Disease
.	.	O

Intraoperative	intraoperative	O
dialysis	dialysis	O
during	during	O
liver	liver	O
transplantation	transplantation	O
with	with	O
citrate	citrate	B-Chemical
dialysate	dialysate	O
.	.	O

Liver	liver	O
transplantation	transplantation	O
for	for	O
acutely	acutely	O
ill	ill	O
patients	patients	O
with	with	O
fulminant	fulminant	O
liver	liver	B-Disease
failure	failure	I-Disease
carries	carries	O
high	high	O
intraoperative	intraoperative	O
and	and	O
immediate	immediate	O
postoperative	postoperative	O
risks	risks	O
.	.	O

These	these	O
are	are	O
increased	increased	O
with	with	O
the	the	O
presence	presence	O
of	of	O
concomitant	concomitant	O
acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
(	(	O
AKI	aki	O
)	)	O
and	and	O
intraoperative	intraoperative	O
dialysis	dialysis	O
is	is	O
sometimes	sometimes	O
required	required	O
to	to	O
allow	allow	O
the	the	O
transplant	transplant	O
to	to	O
proceed	proceed	O
.	.	O

The	the	O
derangements	derangements	O
in	in	O
the	the	O
procoagulant	procoagulant	O
and	and	O
anticoagulant	anticoagulant	O
pathways	pathways	O
during	during	O
fulminant	fulminant	O
liver	liver	B-Disease
failure	failure	I-Disease
can	can	O
lead	lead	O
to	to	O
difficulties	difficulties	O
with	with	O
anticoagulation	anticoagulation	O
during	during	O
dialysis	dialysis	O
,	,	O
especially	especially	O
when	when	O
continued	continued	O
in	in	O
the	the	O
operating	operating	O
room	room	O
.	.	O

Systemic	systemic	O
anticoagulation	anticoagulation	O
is	is	O
unsafe	unsafe	O
and	and	O
regional	regional	O
citrate	citrate	B-Chemical
anticoagulation	anticoagulation	O
in	in	O
the	the	O
absence	absence	O
of	of	O
a	a	O
functional	functional	O
liver	liver	O
carries	carries	O
the	the	O
risk	risk	O
of	of	O
citrate	citrate	B-Chemical
toxicity	toxicity	B-Disease
.	.	O

Citrate	citrate	B-Chemical
dialysate	dialysate	O
,	,	O
a	a	O
new	new	O
dialysate	dialysate	O
with	with	O
citric	citric	B-Chemical
acid	acid	I-Chemical
can	can	O
be	be	O
used	used	O
for	for	O
anticoagulation	anticoagulation	O
in	in	O
patients	patients	O
who	who	O
can	can	O
not	not	O
tolerate	tolerate	O
heparin	heparin	B-Chemical
or	or	O
regional	regional	O
citrate	citrate	B-Chemical
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
a	a	O
40-year-old	40-year-old	O
female	female	O
with	with	O
acetaminophen-induced	acetaminophen-induced	O
fulminant	fulminant	O
liver	liver	B-Disease
failure	failure	I-Disease
with	with	O
associated	associated	O
AKI	aki	O
who	who	O
underwent	underwent	O
intraoperative	intraoperative	O
dialytic	dialytic	O
support	support	O
during	during	O
liver	liver	O
transplantation	transplantation	O
anticoagulated	anticoagulated	O
with	with	O
citrate	citrate	B-Chemical
dialysate	dialysate	O
during	during	O
the	the	O
entire	entire	O
procedure	procedure	O
.	.	O

The	the	O
patient	patient	O
tolerated	tolerated	O
the	the	O
procedure	procedure	O
well	well	O
without	without	O
any	any	O
signs	signs	O
of	of	O
citrate	citrate	B-Chemical
toxicity	toxicity	B-Disease
and	and	O
maintained	maintained	O
adequate	adequate	O
anticoagulation	anticoagulation	O
for	for	O
patency	patency	O
of	of	O
the	the	O
dialysis	dialysis	O
circuit	circuit	O
.	.	O

Citrate	citrate	B-Chemical
dialysate	dialysate	O
is	is	O
a	a	O
safe	safe	O
alternative	alternative	O
for	for	O
intradialytic	intradialytic	O
support	support	O
of	of	O
liver	liver	O
transplantation	transplantation	O
in	in	O
fulminant	fulminant	O
liver	liver	B-Disease
failure	failure	I-Disease
.	.	O

Delirium	delirium	B-Disease
in	in	O
a	a	O
patient	patient	O
with	with	O
toxic	toxic	O
flecainide	flecainide	O
plasma	plasma	O
concentrations	concentrations	O
:	:	O
the	the	O
role	role	O
of	of	O
a	a	O
pharmacokinetic	pharmacokinetic	O
drug	drug	O
interaction	interaction	O
with	with	O
paroxetine	paroxetine	B-Chemical
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
describe	describe	O
a	a	O
case	case	O
of	of	O
flecainide-induced	flecainide-induced	O
delirium	delirium	B-Disease
associated	associated	O
with	with	O
a	a	O
pharmacokinetic	pharmacokinetic	O
drug	drug	O
interaction	interaction	O
with	with	O
paroxetine	paroxetine	B-Chemical
.	.	O

CASE	case	O
SUMMARY	summary	O
:	:	O
A	a	O
69-year-old	69-year-old	O
white	white	O
female	female	O
presented	presented	O
to	to	O
the	the	O
emergency	emergency	O
department	department	O
with	with	O
a	a	O
history	history	O
of	of	O
confusion	confusion	B-Disease
and	and	O
paranoia	paranoia	O
over	over	O
the	the	O
past	past	O
several	several	O
days	days	O
.	.	O

On	on	O
admission	admission	O
the	the	O
patient	patient	O
was	was	O
taking	taking	O
carvedilol	carvedilol	O
12	12	O
mg	mg	O
twice	twice	O
daily	daily	O
,	,	O
warfarin	warfarin	B-Chemical
2	2	O
mg/day	mg/day	O
,	,	O
folic	folic	B-Chemical
acid	acid	I-Chemical
1	1	O
mg/day	mg/day	O
,	,	O
levothyroxine	levothyroxine	O
100	100	O
microg/day	microg/day	O
,	,	O
pantoprazole	pantoprazole	O
40	40	O
mg/day	mg/day	O
,	,	O
paroxetine	paroxetine	B-Chemical
40	40	O
mg/day	mg/day	O
,	,	O
and	and	O
flecainide	flecainide	O
100	100	O
mg	mg	O
twice	twice	O
daily	daily	O
.	.	O

Flecainide	flecainide	O
had	had	O
been	been	O
started	started	O
2	2	O
weeks	weeks	O
prior	prior	O
for	for	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
.	.	O

Laboratory	laboratory	O
test	test	O
findings	findings	O
on	on	O
admission	admission	O
were	were	O
notable	notable	O
only	only	O
for	for	O
a	a	O
flecainide	flecainide	O
plasma	plasma	O
concentration	concentration	O
of	of	O
1360	1360	O
microg/L	microg/l	O
(	(	O
reference	reference	O
range	range	O
200	200	O
-	-	O
1000	1000	O
)	)	O
.	.	O

A	a	O
metabolic	metabolic	O
drug	drug	O
interaction	interaction	O
between	between	O
flecainide	flecainide	O
and	and	O
paroxetine	paroxetine	B-Chemical
,	,	O
which	which	O
the	the	O
patient	patient	O
had	had	O
been	been	O
taking	taking	O
for	for	O
more	more	O
than	than	O
5	5	O
years	years	O
,	,	O
was	was	O
considered	considered	O
.	.	O

Paroxetine	paroxetine	B-Chemical
was	was	O
discontinued	discontinued	O
and	and	O
the	the	O
dose	dose	O
of	of	O
flecainide	flecainide	O
was	was	O
reduced	reduced	O
to	to	O
50	50	O
mg	mg	O
twice	twice	O
daily	daily	O
.	.	O

Her	her	O
delirium	delirium	B-Disease
resolved	resolved	O
3	3	O
days	days	O
later	later	O
.	.	O

DISCUSSION	discussion	O
:	:	O
Flecainide	flecainide	O
and	and	O
pharmacologically	pharmacologically	O
similar	similar	O
agents	agents	O
that	that	O
interact	interact	O
with	with	O
sodium	sodium	B-Chemical
channels	channels	I-Chemical
may	may	O
cause	cause	O
delirium	delirium	B-Disease
in	in	O
susceptible	susceptible	O
patients	patients	O
.	.	O

A	a	O
MEDLINE	medline	O
search	search	O
(	(	O
1966-January	1966-january	O
2009	2009	O
)	)	O
revealed	revealed	O
one	one	O
in	in	O
vivo	vivo	O
pharmacokinetic	pharmacokinetic	O
study	study	O
on	on	O
the	the	O
interaction	interaction	O
between	between	O
flecainide	flecainide	O
,	,	O
a	a	O
CYP2D6	cyp2d6	O
substrate	substrate	O
,	,	O
and	and	O
paroxetine	paroxetine	B-Chemical
,	,	O
a	a	O
CYP2D6	cyp2d6	O
inhibitor	inhibitor	O
,	,	O
as	as	O
well	well	O
as	as	O
3	3	O
case	case	O
reports	reports	O
of	of	O
flecainide-induced	flecainide-induced	O
delirium	delirium	B-Disease
.	.	O

According	according	O
to	to	O
the	the	O
Naranjo	naranjo	O
probability	probability	O
scale	scale	O
,	,	O
flecainide	flecainide	O
was	was	O
the	the	O
probable	probable	O
cause	cause	O
of	of	O
the	the	O
patient	patient	O
's	's	O
delirium	delirium	B-Disease
;	;	O
the	the	O
Horn	horn	O
Drug	drug	O
Interaction	interaction	O
Probability	probability	O
Scale	scale	O
indicates	indicates	O
a	a	O
possible	possible	O
pharmacokinetic	pharmacokinetic	O
drug	drug	O
interaction	interaction	O
between	between	O
flecainide	flecainide	O
and	and	O
paroxetine	paroxetine	B-Chemical
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Supratherapeutic	supratherapeutic	O
flecainide	flecainide	O
plasma	plasma	O
concentrations	concentrations	O
may	may	O
cause	cause	O
delirium	delirium	B-Disease
.	.	O

Because	because	O
toxicity	toxicity	B-Disease
may	may	O
occur	occur	O
when	when	O
flecainide	flecainide	O
is	is	O
prescribed	prescribed	O
with	with	O
paroxetine	paroxetine	B-Chemical
and	and	O
other	other	O
potent	potent	O
CYP2D6	cyp2d6	O
inhibitors	inhibitors	O
,	,	O
flecainide	flecainide	O
plasma	plasma	O
concentrations	concentrations	O
should	should	O
be	be	O
monitored	monitored	O
closely	closely	O
with	with	O
commencement	commencement	O
of	of	O
CYP2D6	cyp2d6	O
inhibitors	inhibitors	O
.	.	O

Efficacy	efficacy	O
of	of	O
everolimus	everolimus	B-Chemical
(	(	O
RAD001	rad001	O
)	)	O
in	in	O
patients	patients	O
with	with	O
advanced	advanced	O
NSCLC	nsclc	B-Disease
previously	previously	O
treated	treated	O
with	with	O
chemotherapy	chemotherapy	O
alone	alone	O
or	or	O
with	with	O
chemotherapy	chemotherapy	O
and	and	O
EGFR	egfr	O
inhibitors	inhibitors	O
.	.	O

BACKGROUND	background	O
:	:	O
Treatment	treatment	O
options	options	O
are	are	O
scarce	scarce	O
in	in	O
pretreated	pretreated	O
advanced	advanced	O
non-small-cell	non-small-cell	O
lung	lung	O
cancer	cancer	B-Disease
(	(	O
NSCLC	nsclc	B-Disease
)	)	O
patients	patients	O
.	.	O

RAD001	rad001	O
,	,	O
an	an	O
oral	oral	O
inhibitor	inhibitor	O
of	of	O
the	the	O
mammalian	mammalian	O
target	target	O
of	of	O
rapamycin	rapamycin	B-Chemical
(	(	O
mTOR	mtor	O
)	)	O
,	,	O
has	has	O
shown	shown	O
phase	phase	O
I	i	O
efficacy	efficacy	O
in	in	O
NSCLC	nsclc	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Stage	stage	O
IIIb	iiib	O
or	or	O
IV	iv	O
NSCLC	nsclc	B-Disease
patients	patients	O
,	,	O
with	with	O
two	two	O
or	or	O
fewer	fewer	O
prior	prior	O
chemotherapy	chemotherapy	O
regimens	regimens	O
,	,	O
one	one	O
platinum	platinum	O
based	based	O
(	(	O
stratum	stratum	O
1	1	O
)	)	O
or	or	O
both	both	O
chemotherapy	chemotherapy	O
and	and	O
epidermal	epidermal	B-Chemical
growth	growth	I-Chemical
factor	factor	I-Chemical
receptor	receptor	O
tyrosine	tyrosine	B-Chemical
kinase	kinase	O
inhibitors	inhibitors	O
(	(	O
stratum	stratum	O
2	2	O
)	)	O
,	,	O
received	received	O
RAD001	rad001	O
10	10	O
mg/day	mg/day	O
until	until	O
progression	progression	O
or	or	O
unacceptable	unacceptable	O
toxicity	toxicity	B-Disease
.	.	O

Primary	primary	O
objective	objective	O
was	was	O
overall	overall	O
response	response	O
rate	rate	O
(	(	O
ORR	orr	O
)	)	O
.	.	O

Analyses	analyses	O
of	of	O
markers	markers	O
associated	associated	O
with	with	O
the	the	O
mTOR	mtor	O
pathway	pathway	O
were	were	O
carried	carried	O
out	out	O
on	on	O
archival	archival	O
tumor	tumor	B-Disease
from	from	O
a	a	O
subgroup	subgroup	O
using	using	O
immunohistochemistry	immunohistochemistry	O
(	(	O
IHC	ihc	O
)	)	O
and	and	O
direct	direct	O
mutation	mutation	O
sequencing	sequencing	O
.	.	O

RESULTS	results	O
:	:	O
Eighty-five	eighty-five	O
patients	patients	O
were	were	O
enrolled	enrolled	O
,	,	O
42	42	O
in	in	O
stratum	stratum	O
1	1	O
and	and	O
43	43	O
in	in	O
stratum	stratum	O
.	.	O

ORR	orr	O
was	was	O
4.7	4.7	O
%	%	O
(	(	O
7.1	7.1	O
%	%	O
stratum	stratum	O
1	1	O
;	;	O
2.3	2.3	O
%	%	O
stratum	stratum	O
2	2	O
)	)	O
.	.	O

Overall	overall	O
disease	disease	O
control	control	O
rate	rate	O
was	was	O
47.1	47.1	O
%	%	O
.	.	O

Median	median	O
progression-free	progression-free	O
survivals	survivals	O
(	(	O
PFSs	pfss	O
)	)	O
were	were	O
2.6	2.6	O
(	(	O
stratum	stratum	O
1	1	O
)	)	O
and	and	O
2.7	2.7	O
months	months	O
(	(	O
stratum	stratum	O
2	2	O
)	)	O
.	.	O

Common	common	O
>	>	O
or	or	O
=	=	O
grade	grade	O
3	3	O
events	events	O
were	were	O
fatigue	fatigue	B-Disease
,	,	O
dyspnea	dyspnea	O
,	,	O
stomatitis	stomatitis	B-Disease
,	,	O
anemia	anemia	B-Disease
,	,	O
and	and	O
thrombocytopenia	thrombocytopenia	B-Disease
.	.	O

Pneumonitis	pneumonitis	O
,	,	O
probably	probably	O
or	or	O
possibly	possibly	O
related	related	O
,	,	O
mainly	mainly	O
grade	grade	O
1/2	1/2	O
,	,	O
occurred	occurred	O
in	in	O
25	25	O
%	%	O
.	.	O

Cox	cox	O
regression	regression	O
analysis	analysis	O
of	of	O
IHC	ihc	O
scores	scores	O
found	found	O
that	that	O
only	only	O
phospho	phospho	O
AKT	akt	O
(	(	O
pAKT	pakt	O
)	)	O
was	was	O
a	a	O
significant	significant	O
independent	independent	O
predictor	predictor	O
of	of	O
worse	worse	O
PFS	pfs	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
RAD001	rad001	O
10	10	O
mg/day	mg/day	O
was	was	O
well	well	O
tolerated	tolerated	O
,	,	O
showing	showing	O
modest	modest	O
clinical	clinical	O
activity	activity	O
in	in	O
pretreated	pretreated	O
NSCLC	nsclc	B-Disease
.	.	O

Evaluation	evaluation	O
of	of	O
RAD001	rad001	O
plus	plus	O
standard	standard	O
therapy	therapy	O
for	for	O
metastatic	metastatic	O
NSCLC	nsclc	B-Disease
continues	continues	O
.	.	O

Posttransplant	posttransplant	O
anemia	anemia	B-Disease
:	:	O
the	the	O
role	role	O
of	of	O
sirolimus	sirolimus	B-Chemical
.	.	O

Posttransplant	posttransplant	O
anemia	anemia	B-Disease
is	is	O
a	a	O
common	common	O
problem	problem	O
that	that	O
may	may	O
hinder	hinder	O
patients	patients	O
'	'	O
quality	quality	O
of	of	O
life	life	O
.	.	O

It	it	O
occurs	occurs	O
in	in	O
12	12	O
to	to	O
76	76	O
%	%	O
of	of	O
patients	patients	O
,	,	O
and	and	O
is	is	O
most	most	O
common	common	O
in	in	O
the	the	O
immediate	immediate	O
posttransplant	posttransplant	O
period	period	O
.	.	O

A	a	O
variety	variety	O
of	of	O
factors	factors	O
have	have	O
been	been	O
identified	identified	O
that	that	O
increase	increase	O
the	the	O
risk	risk	O
of	of	O
posttransplant	posttransplant	O
anemia	anemia	B-Disease
,	,	O
of	of	O
which	which	O
the	the	O
level	level	O
of	of	O
renal	renal	O
function	function	O
is	is	O
most	most	O
important	important	O
.	.	O

Sirolimus	sirolimus	B-Chemical
,	,	O
a	a	O
mammalian	mammalian	O
target	target	O
of	of	O
rapamycin	rapamycin	B-Chemical
inhibitor	inhibitor	O
,	,	O
has	has	O
been	been	O
implicated	implicated	O
as	as	O
playing	playing	O
a	a	O
special	special	O
role	role	O
in	in	O
posttransplant	posttransplant	O
anemia	anemia	B-Disease
.	.	O

This	this	O
review	review	O
considers	considers	O
anemia	anemia	B-Disease
associated	associated	O
with	with	O
sirolimus	sirolimus	B-Chemical
,	,	O
including	including	O
its	its	O
presentation	presentation	O
,	,	O
mechanisms	mechanisms	O
,	,	O
and	and	O
management	management	O
.	.	O

Coronary	coronary	O
computerized	computerized	O
tomography	tomography	O
angiography	angiography	O
for	for	O
rapid	rapid	O
discharge	discharge	O
of	of	O
low-risk	low-risk	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
.	.	O

BACKGROUND	background	O
:	:	O
Most	most	O
patients	patients	O
presenting	presenting	O
to	to	O
emergency	emergency	O
departments	departments	O
(	(	O
EDs	eds	O
)	)	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
are	are	O
admitted	admitted	O
for	for	O
at	at	O
least	least	O
12	12	O
hours	hours	O
and	and	O
receive	receive	O
a	a	O
"	"	O
rule	rule	O
out	out	O
acute	acute	B-Disease
coronary	coronary	I-Disease
syndrome	syndrome	I-Disease
"	"	O
protocol	protocol	O
,	,	O
often	often	O
with	with	O
noninvasive	noninvasive	O
testing	testing	O
prior	prior	O
to	to	O
discharge	discharge	O
.	.	O

In	in	O
patients	patients	O
without	without	O
cocaine	cocaine	B-Chemical
use	use	O
,	,	O
coronary	coronary	O
computerized	computerized	O
tomography	tomography	O
angiography	angiography	O
(	(	O
CTA	cta	O
)	)	O
has	has	O
been	been	O
shown	shown	O
to	to	O
be	be	O
useful	useful	O
for	for	O
identifying	identifying	O
a	a	O
group	group	O
of	of	O
patients	patients	O
at	at	O
low	low	O
risk	risk	O
for	for	O
cardiac	cardiac	O
events	events	O
who	who	O
can	can	O
be	be	O
safely	safely	O
discharged	discharged	O
.	.	O

It	it	O
is	is	O
unclear	unclear	O
whether	whether	O
a	a	O
coronary	coronary	O
CTA	cta	O
strategy	strategy	O
would	would	O
be	be	O
efficacious	efficacious	O
in	in	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
,	,	O
as	as	O
coronary	coronary	B-Disease
vasospasm	vasospasm	B-Disease
may	may	O
account	account	O
for	for	O
some	some	O
of	of	O
the	the	O
ischemia	ischemia	B-Disease
.	.	O

We	we	O
studied	studied	O
whether	whether	O
a	a	O
negative	negative	O
coronary	coronary	O
CTA	cta	O
in	in	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
could	could	O
identify	identify	O
a	a	O
subset	subset	O
safe	safe	O
for	for	O
discharge	discharge	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
prospectively	prospectively	O
evaluated	evaluated	O
the	the	O
safety	safety	O
of	of	O
coronary	coronary	O
CTA	cta	O
for	for	O
low-risk	low-risk	O
patients	patients	O
who	who	O
presented	presented	O
to	to	O
the	the	O
ED	ed	O
with	with	O
cocaineassociated	cocaineassociated	O
chest	chest	B-Disease
pain	pain	B-Disease
(	(	O
self-reported	self-reported	O
or	or	O
positive	positive	O
urine	urine	O
test	test	O
)	)	O
.	.	O

Consecutive	consecutive	O
patients	patients	O
received	received	O
either	either	O
immediate	immediate	O
coronary	coronary	O
CTA	cta	O
in	in	O
the	the	O
ED	ed	O
(	(	O
without	without	O
serial	serial	O
markers	markers	O
)	)	O
or	or	O
underwent	underwent	O
coronary	coronary	O
CTA	cta	O
after	after	O
a	a	O
brief	brief	O
observation	observation	O
period	period	O
with	with	O
serial	serial	O
cardiac	cardiac	O
marker	marker	O
measurements	measurements	O
.	.	O

Patients	patients	O
with	with	O
negative	negative	O
coronary	coronary	O
CTA	cta	O
(	(	O
maximal	maximal	O
stenosis	stenosis	O
less	less	O
than	than	O
50	50	O
%	%	O
)	)	O
were	were	O
discharged	discharged	O
.	.	O

The	the	O
main	main	O
outcome	outcome	O
was	was	O
30-day	30-day	O
cardiovascular	cardiovascular	O
death	death	B-Disease
or	or	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

RESULTS	results	O
:	:	O
A	a	O
total	total	O
of	of	O
59	59	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
chest	chest	B-Disease
pain	pain	B-Disease
were	were	O
evaluated	evaluated	O
.	.	O

Patients	patients	O
had	had	O
a	a	O
mean	mean	O
age	age	O
of	of	O
45.6	45.6	O
+	+	O
/-	/-	O
6.6	6.6	O
yrs	yrs	O
and	and	O
were	were	O
86	86	O
%	%	O
black	black	O
,	,	O
66	66	O
%	%	O
male	male	O
.	.	O

Seventy-nine	seventy-nine	O
percent	percent	O
had	had	O
a	a	O
normal	normal	O
or	or	O
nonspecific	nonspecific	O
ECG	ecg	O
and	and	O
85	85	O
%	%	O
had	had	O
a	a	O
TIMI	timi	O
score	score	O
<	<	O
2	2	O
.	.	O

Twenty	twenty	O
patients	patients	O
received	received	O
coronary	coronary	O
CTA	cta	O
immediately	immediately	O
in	in	O
the	the	O
ED	ed	O
,	,	O
18	18	O
of	of	O
whom	whom	O
were	were	O
discharged	discharged	O
following	following	O
CTA	cta	O
(	(	O
90	90	O
%	%	O
)	)	O
.	.	O

Thirty-nine	thirty-nine	O
received	received	O
coronary	coronary	O
CTA	cta	O
after	after	O
a	a	O
brief	brief	O
observation	observation	O
period	period	O
,	,	O
with	with	O
37	37	O
discharged	discharged	O
home	home	O
following	following	O
CTA	cta	O
(	(	O
95	95	O
%	%	O
)	)	O
.	.	O

Six	six	O
patients	patients	O
had	had	O
coronary	coronary	B-Disease
stenosis	stenosis	I-Disease
>	>	O
or=50	or=50	O
%	%	O
.	.	O

During	during	O
the	the	O
30-day	30-day	O
follow-up	follow-up	O
period	period	O
,	,	O
no	no	O
patients	patients	O
died	died	O
of	of	O
a	a	O
cardiovascular	cardiovascular	O
event	event	O
(	(	O
0	0	O
%	%	O
;	;	O
95	95	O
%	%	O
CI	ci	O
,	,	O
0	0	O
-	-	O
6.1	6.1	O
%	%	O
)	)	O
and	and	O
no	no	O
patient	patient	O
sustained	sustained	O
a	a	O
nonfatal	nonfatal	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
(	(	O
0	0	O
%	%	O
;	;	O
95	95	O
%	%	O
CI	ci	O
,	,	O
0	0	O
-	-	O
6.1	6.1	O
%	%	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Although	although	O
cocaine-associated	cocaine-associated	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
can	can	O
result	result	O
from	from	O
coronary	coronary	O
vasoconstriction	vasoconstriction	O
,	,	O
patients	patients	O
with	with	O
cocaine	cocaine	B-Chemical
associated	associated	O
chest	chest	B-Disease
pain	pain	B-Disease
,	,	O
a	a	O
non-ischemic	non-ischemic	O
ECG	ecg	O
,	,	O
and	and	O
a	a	O
TIMI	timi	O
risk	risk	O
score	score	O
<	<	O
2	2	O
may	may	O
be	be	O
safely	safely	O
discharged	discharged	O
from	from	O
the	the	O
ED	ed	O
after	after	O
a	a	O
negative	negative	O
coronary	coronary	O
CTA	cta	O
with	with	O
a	a	O
low	low	O
risk	risk	O
of	of	O
30-day	30-day	O
adverse	adverse	O
events	events	O
.	.	O

Bilateral	bilateral	O
haemorrhagic	haemorrhagic	O
infarction	infarction	B-Disease
of	of	O
the	the	O
globus	globus	O
pallidus	pallidus	O
after	after	O
cocaine	cocaine	B-Chemical
and	and	O
alcohol	alcohol	B-Chemical
intoxication	intoxication	O
.	.	O

Cocaine	cocaine	B-Chemical
is	is	O
a	a	O
risk	risk	O
factor	factor	O
for	for	O
both	both	O
ischemic	ischemic	O
and	and	O
haemorrhagic	haemorrhagic	O
stroke	stroke	B-Disease
.	.	O

We	we	O
present	present	O
the	the	O
case	case	O
of	of	O
a	a	O
31-year-old	31-year-old	O
man	man	O
with	with	O
bilateral	bilateral	O
ischemia	ischemia	B-Disease
of	of	O
the	the	O
globus	globus	O
pallidus	pallidus	O
after	after	O
excessive	excessive	O
alcohol	alcohol	B-Chemical
and	and	O
intranasal	intranasal	O
cocaine	cocaine	B-Chemical
use	use	O
.	.	O

Drug-related	drug-related	O
globus	globus	O
pallidus	pallidus	O
infarctions	infarctions	O
are	are	O
most	most	O
often	often	O
associated	associated	O
with	with	O
heroin	heroin	O
.	.	O

Bilateral	bilateral	O
basal	basal	O
ganglia	ganglia	O
infarcts	infarcts	O
after	after	O
the	the	O
use	use	O
of	of	O
cocaine	cocaine	B-Chemical
,	,	O
without	without	O
concurrent	concurrent	O
heroin	heroin	O
use	use	O
,	,	O
have	have	O
never	never	O
been	been	O
reported	reported	O
.	.	O

In	in	O
our	our	O
patient	patient	O
,	,	O
transient	transient	O
cardiac	cardiac	O
arrhythmia	arrhythmia	B-Disease
or	or	O
respiratory	respiratory	O
dysfunction	dysfunction	O
related	related	O
to	to	O
cocaine	cocaine	B-Chemical
and/or	and/or	O
ethanol	ethanol	B-Chemical
use	use	O
were	were	O
the	the	O
most	most	O
likely	likely	O
causes	causes	O
of	of	O
cerebral	cerebral	O
hypoperfusion	hypoperfusion	O
.	.	O

Late	late	O
fulminant	fulminant	O
posterior	posterior	O
reversible	reversible	O
encephalopathy	encephalopathy	B-Disease
syndrome	syndrome	O
after	after	O
liver	liver	O
transplant	transplant	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
Posterior	posterior	O
leukoencephalopathy	leukoencephalopathy	B-Disease
due	due	O
to	to	O
calcineurin-inhibitor-related	calcineurin-inhibitor-related	O
neurotoxicity	neurotoxicity	B-Disease
is	is	O
a	a	O
rare	rare	O
but	but	O
severe	severe	O
complication	complication	O
that	that	O
results	results	O
from	from	O
treatment	treatment	O
with	with	O
immunosuppressive	immunosuppressive	B-Chemical
agents	agents	I-Chemical
(	(	O
primarily	primarily	O
those	those	O
administered	administered	O
after	after	O
a	a	O
liver	liver	O
or	or	O
kidney	kidney	O
transplant	transplant	O
)	)	O
.	.	O

The	the	O
pathophysiologic	pathophysiologic	O
mechanisms	mechanisms	O
of	of	O
that	that	O
disorder	disorder	O
remain	remain	O
unknown	unknown	O
.	.	O

CASE	case	O
:	:	O
We	we	O
report	report	O
the	the	O
case	case	O
of	of	O
a	a	O
46-year-old	46-year-old	O
woman	woman	O
who	who	O
received	received	O
a	a	O
liver	liver	O
transplant	transplant	O
in	in	O
our	our	O
center	center	O
as	as	O
treatment	treatment	O
for	for	O
alcoholic	alcoholic	O
cirrhosis	cirrhosis	B-Disease
and	and	O
in	in	O
whom	whom	O
either	either	O
a	a	O
fulminant	fulminant	O
course	course	O
of	of	O
posterior	posterior	O
leukoencephalopathy	leukoencephalopathy	B-Disease
or	or	O
posterior	posterior	O
reversible	reversible	O
encephalopathy	encephalopathy	B-Disease
syndrome	syndrome	O
developed	developed	O
110	110	O
days	days	O
after	after	O
transplant	transplant	O
.	.	O

After	after	O
an	an	O
initially	initially	O
uneventful	uneventful	O
course	course	O
after	after	O
the	the	O
transplant	transplant	O
,	,	O
the	the	O
patient	patient	O
rapidly	rapidly	O
fell	fell	O
into	into	O
deep	deep	O
coma	coma	B-Disease
.	.	O

RESULTS	results	O
:	:	O
Cerebral	cerebral	O
MRI	mri	O
scan	scan	O
showed	showed	O
typical	typical	O
signs	signs	O
of	of	O
enhancement	enhancement	O
in	in	O
the	the	O
pontine	pontine	O
and	and	O
posterior	posterior	O
regions	regions	O
.	.	O

Switching	switching	O
the	the	O
immunosuppressive	immunosuppressive	O
regimen	regimen	O
from	from	O
tacrolimus	tacrolimus	B-Chemical
to	to	O
cyclosporine	cyclosporine	B-Chemical
did	did	O
not	not	O
improve	improve	O
the	the	O
clinical	clinical	O
situation	situation	O
.	.	O

The	the	O
termination	termination	O
of	of	O
treatment	treatment	O
with	with	O
any	any	O
calcineurin	calcineurin	O
inhibitor	inhibitor	O
resulted	resulted	O
in	in	O
a	a	O
complete	complete	O
resolution	resolution	O
of	of	O
that	that	O
complication	complication	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Posterior	posterior	O
reversible	reversible	O
encephalopathy	encephalopathy	B-Disease
syndrome	syndrome	O
after	after	O
liver	liver	O
transplant	transplant	O
is	is	O
rare	rare	O
.	.	O

We	we	O
recommend	recommend	O
a	a	O
complete	complete	O
cessation	cessation	O
of	of	O
any	any	O
calcineurin	calcineurin	O
inhibitor	inhibitor	O
rather	rather	O
than	than	O
a	a	O
dose	dose	O
reduction	reduction	O
.	.	O

Prolonged	prolonged	O
hypothermia	hypothermia	B-Disease
as	as	O
a	a	O
bridge	bridge	O
to	to	O
recovery	recovery	O
for	for	O
cerebral	cerebral	B-Disease
edema	edema	B-Disease
and	and	O
intracranial	intracranial	B-Disease
hypertension	hypertension	B-Disease
associated	associated	O
with	with	O
fulminant	fulminant	B-Disease
hepatic	hepatic	B-Disease
failure	failure	I-Disease
.	.	O

BACKGROUND	background	O
:	:	O
To	to	O
review	review	O
evidence-based	evidence-based	O
treatment	treatment	O
options	options	O
in	in	O
patients	patients	O
with	with	O
cerebral	cerebral	B-Disease
edema	edema	B-Disease
complicating	complicating	O
fulminant	fulminant	B-Disease
hepatic	hepatic	B-Disease
failure	failure	I-Disease
(	(	O
FHF	fhf	O
)	)	O
and	and	O
discuss	discuss	O
the	the	O
potential	potential	O
applications	applications	O
of	of	O
hypothermia	hypothermia	B-Disease
.	.	O

METHOD	method	O
:	:	O
Case-based	case-based	O
observations	observations	O
from	from	O
a	a	O
medical	medical	O
intensive	intensive	O
care	care	O
unit	unit	O
(	(	O
MICU	micu	O
)	)	O
in	in	O
a	a	O
tertiary	tertiary	O
care	care	O
facility	facility	O
in	in	O
a	a	O
27-year-old	27-year-old	O
female	female	O
with	with	O
FHF	fhf	O
from	from	O
acetaminophen	acetaminophen	B-Chemical
and	and	O
resultant	resultant	O
cerebral	cerebral	B-Disease
edema	edema	B-Disease
.	.	O

RESULTS	results	O
:	:	O
Our	our	O
patient	patient	O
was	was	O
admitted	admitted	O
to	to	O
the	the	O
MICU	micu	O
after	after	O
being	being	O
found	found	O
unresponsive	unresponsive	O
with	with	O
presumed	presumed	O
toxicity	toxicity	B-Disease
from	from	O
acetaminophen	acetaminophen	B-Chemical
which	which	O
was	was	O
ingested	ingested	O
over	over	O
a	a	O
2-day	2-day	O
period	period	O
.	.	O

The	the	O
patient	patient	O
had	had	O
depressed	depressed	B-Disease
of	of	O
mental	mental	O
status	status	O
lasting	lasting	O
at	at	O
least	least	O
24	24	O
h	h	B-Chemical
prior	prior	O
to	to	O
admission	admission	O
.	.	O

Initial	initial	O
evaluation	evaluation	O
confirmed	confirmed	O
FHF	fhf	O
from	from	O
acetaminophen	acetaminophen	B-Chemical
and	and	O
cerebral	cerebral	B-Disease
edema	edema	B-Disease
.	.	O

The	the	O
patient	patient	O
was	was	O
treated	treated	O
with	with	O
hyperosmolar	hyperosmolar	O
therapy	therapy	O
,	,	O
hyperventilation	hyperventilation	O
,	,	O
sedation	sedation	O
,	,	O
and	and	O
chemical	chemical	O
paralysis	paralysis	B-Disease
.	.	O

Her	her	O
intracranial	intracranial	O
pressure	pressure	O
remained	remained	O
elevated	elevated	O
despite	despite	O
maximal	maximal	O
medical	medical	O
therapy	therapy	O
.	.	O

We	we	O
then	then	O
initiated	initiated	O
therapeutic	therapeutic	O
hypothermia	hypothermia	B-Disease
which	which	O
was	was	O
continued	continued	O
for	for	O
5	5	O
days	days	O
.	.	O

At	at	O
re-warming	re-warming	O
,	,	O
patient	patient	O
had	had	O
resolution	resolution	O
of	of	O
her	her	O
cerebral	cerebral	B-Disease
edema	edema	B-Disease
and	and	O
intracranial	intracranial	B-Disease
hypertension	hypertension	B-Disease
.	.	O

At	at	O
discharge	discharge	O
,	,	O
she	she	O
had	had	O
complete	complete	O
recovery	recovery	O
of	of	O
neurological	neurological	O
and	and	O
hepatic	hepatic	O
functions	functions	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
In	in	O
patients	patients	O
with	with	O
FHF	fhf	O
and	and	O
cerebral	cerebral	B-Disease
edema	edema	B-Disease
from	from	O
acetaminophen	acetaminophen	B-Chemical
overdose	overdose	B-Disease
,	,	O
prolonged	prolonged	O
therapeutic	therapeutic	O
hypothermia	hypothermia	B-Disease
could	could	O
potentially	potentially	O
be	be	O
used	used	O
as	as	O
a	a	O
life	life	O
saving	saving	O
therapy	therapy	O
and	and	O
a	a	O
bridge	bridge	O
to	to	O
hepatic	hepatic	O
and	and	O
neurological	neurological	O
recovery	recovery	O
.	.	O

A	a	O
clinical	clinical	O
trial	trial	O
of	of	O
hypothermia	hypothermia	B-Disease
in	in	O
patients	patients	O
with	with	O
this	this	O
condition	condition	O
is	is	O
warranted	warranted	O
.	.	O

Binasal	binasal	O
visual	visual	B-Disease
field	field	I-Disease
defects	defects	I-Disease
are	are	O
not	not	O
specific	specific	O
to	to	O
vigabatrin	vigabatrin	B-Chemical
.	.	O

This	this	O
study	study	O
investigated	investigated	O
the	the	O
visual	visual	O
defects	defects	O
associated	associated	O
with	with	O
the	the	O
antiepileptic	antiepileptic	O
drug	drug	O
vigabatrin	vigabatrin	B-Chemical
(	(	O
VGB	vgb	O
)	)	O
.	.	O

Two	two	O
hundred	hundred	O
four	four	O
people	people	O
with	with	O
epilepsy	epilepsy	B-Disease
were	were	O
grouped	grouped	O
on	on	O
the	the	O
basis	basis	O
of	of	O
antiepileptic	antiepileptic	O
drug	drug	O
therapy	therapy	O
(	(	O
current	current	O
,	,	O
previous	previous	O
,	,	O
or	or	O
no	no	O
exposure	exposure	O
to	to	O
VGB	vgb	O
)	)	O
.	.	O

Groups	groups	O
were	were	O
matched	matched	O
with	with	O
respect	respect	O
to	to	O
age	age	O
,	,	O
gender	gender	O
,	,	O
and	and	O
seizure	seizure	B-Disease
frequency	frequency	O
.	.	O

All	all	O
patients	patients	O
underwent	underwent	O
objective	objective	O
assessment	assessment	O
of	of	O
electrophysiological	electrophysiological	O
function	function	O
(	(	O
wide-field	wide-field	O
multifocal	multifocal	O
electroretinography	electroretinography	O
)	)	O
and	and	O
conventional	conventional	O
visual	visual	O
field	field	O
testing	testing	O
(	(	O
static	static	O
perimetry	perimetry	O
)	)	O
.	.	O

Bilateral	bilateral	O
visual	visual	O
field	field	O
constriction	constriction	O
was	was	O
observed	observed	O
in	in	O
59	59	O
%	%	O
of	of	O
patients	patients	O
currently	currently	O
taking	taking	O
VGB	vgb	O
,	,	O
43	43	O
%	%	O
of	of	O
patients	patients	O
who	who	O
previously	previously	O
took	took	O
VGB	vgb	O
,	,	O
and	and	O
24	24	O
%	%	O
of	of	O
patients	patients	O
with	with	O
no	no	O
exposure	exposure	O
to	to	O
VGB	vgb	O
.	.	O

Assessment	assessment	O
of	of	O
retinal	retinal	O
function	function	O
revealed	revealed	O
abnormal	abnormal	O
responses	responses	O
in	in	O
48	48	O
%	%	O
of	of	O
current	current	O
VGB	vgb	O
users	users	O
and	and	O
22	22	O
%	%	O
of	of	O
prior	prior	O
VGB	vgb	O
users	users	O
,	,	O
but	but	O
in	in	O
none	none	O
of	of	O
the	the	O
patients	patients	O
without	without	O
previous	previous	O
exposure	exposure	O
to	to	O
VGB	vgb	O
.	.	O

Bilateral	bilateral	O
visual	visual	O
field	field	O
abnormalities	abnormalities	O
are	are	O
common	common	O
in	in	O
the	the	O
treated	treated	O
epilepsy	epilepsy	B-Disease
population	population	O
,	,	O
irrespective	irrespective	O
of	of	O
drug	drug	O
history	history	O
.	.	O

Assessment	assessment	O
by	by	O
conventional	conventional	O
static	static	O
perimetry	perimetry	O
may	may	O
neither	neither	O
be	be	O
sufficiently	sufficiently	O
sensitive	sensitive	O
nor	nor	O
specific	specific	O
to	to	O
reliably	reliably	O
identify	identify	O
retinal	retinal	O
toxicity	toxicity	B-Disease
associated	associated	O
with	with	O
VGB	vgb	O
.	.	O

Smoking	smoking	B-Chemical
of	of	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
as	as	O
a	a	O
risk	risk	O
factor	factor	O
for	for	O
HIV	hiv	O
infection	infection	B-Disease
among	among	O
people	people	O
who	who	O
use	use	O
injection	injection	O
drugs	drugs	O
.	.	O

BACKGROUND	background	O
:	:	O
Little	little	O
is	is	O
known	known	O
about	about	O
the	the	O
possible	possible	O
role	role	O
that	that	O
smoking	smoking	B-Chemical
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
has	has	O
on	on	O
the	the	O
incidence	incidence	O
of	of	O
HIV	hiv	O
infection	infection	B-Disease
.	.	O

Given	given	O
the	the	O
increasing	increasing	O
use	use	O
of	of	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
,	,	O
we	we	O
sought	sought	O
to	to	O
examine	examine	O
whether	whether	O
use	use	O
of	of	O
this	this	O
illicit	illicit	O
drug	drug	O
has	has	O
become	become	O
a	a	O
risk	risk	O
factor	factor	O
for	for	O
HIV	hiv	O
infection	infection	B-Disease
.	.	O

METHODS	methods	O
:	:	O
We	we	O
included	included	O
data	data	O
from	from	O
people	people	O
participating	participating	O
in	in	O
the	the	O
Vancouver	vancouver	O
Injection	injection	O
Drug	drug	O
Users	users	O
Study	study	O
who	who	O
reported	reported	O
injecting	injecting	O
illicit	illicit	O
drugs	drugs	O
at	at	O
least	least	O
once	once	O
in	in	O
the	the	O
month	month	O
before	before	O
enrolment	enrolment	O
,	,	O
lived	lived	O
in	in	O
the	the	O
greater	greater	O
Vancouver	vancouver	O
area	area	O
,	,	O
were	were	O
HIV-negative	hiv-negative	O
at	at	O
enrolment	enrolment	O
and	and	O
completed	completed	O
at	at	O
least	least	O
1	1	O
follow-up	follow-up	O
study	study	O
visit	visit	O
.	.	O

To	to	O
determine	determine	O
whether	whether	O
the	the	O
risk	risk	O
of	of	O
HIV	hiv	O
seroconversion	seroconversion	O
among	among	O
daily	daily	O
smokers	smokers	O
of	of	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
changed	changed	O
over	over	O
time	time	O
,	,	O
we	we	O
used	used	O
Cox	cox	O
proportional	proportional	O
hazards	hazards	O
regression	regression	O
and	and	O
divided	divided	O
the	the	O
study	study	O
into	into	O
3	3	O
periods	periods	O
:	:	O
May	may	O
1	1	O
,	,	O
1996-Nov	1996-nov	O
.	.	O

30	30	O
,	,	O
1999	1999	O
(	(	O
period	period	O
1	1	O
)	)	O
,	,	O
Dec.	dec.	O
1	1	O
,	,	O
1999-Nov	1999-nov	O
.	.	O

30	30	O
,	,	O
2002	2002	O
(	(	O
period	period	O
2	2	O
)	)	O
,	,	O
and	and	O
Dec.	dec.	O
1	1	O
,	,	O
2002-Dec	2002-dec	O
.	.	O
30	30	O
,	,	O
2005	2005	O
(	(	O
period	period	O
3	3	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
Overall	overall	O
,	,	O
1048	1048	O
eligible	eligible	O
injection	injection	O
drug	drug	O
users	users	O
were	were	O
included	included	O
in	in	O
our	our	O
study	study	O
.	.	O

Of	of	O
these	these	O
,	,	O
137	137	O
acquired	acquired	O
HIV	hiv	O
infection	infection	B-Disease
during	during	O
follow-up	follow-up	O
.	.	O

The	the	O
mean	mean	O
proportion	proportion	O
of	of	O
participants	participants	O
who	who	O
reported	reported	O
daily	daily	O
smoking	smoking	B-Chemical
of	of	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
increased	increased	O
from	from	O
11.6	11.6	O
%	%	O
in	in	O
period	period	O
1	1	O
to	to	O
39.7	39.7	O
%	%	O
in	in	O
period	period	O
3	3	O
.	.	O

After	after	O
adjusting	adjusting	O
for	for	O
potential	potential	O
confounders	confounders	O
,	,	O
we	we	O
found	found	O
that	that	O
the	the	O
risk	risk	O
of	of	O
HIV	hiv	O
seroconversion	seroconversion	O
among	among	O
participants	participants	O
who	who	O
were	were	O
daily	daily	O
smokers	smokers	O
of	of	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
increased	increased	O
over	over	O
time	time	O
(	(	O
period	period	O
1	1	O
:	:	O
hazard	hazard	O
ratio	ratio	O
[	[	O
HR	hr	O
]	]	O
1.03	1.03	O
,	,	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
[	[	O
CI	ci	O
]	]	O
0.57	0.57	O
-	-	O
1.85	1.85	O
;	;	O
period	period	O
2	2	O
:	:	O
HR	hr	O
1.68	1.68	O
,	,	O
95	95	O
%	%	O
CI	ci	O
1.01	1.01	O
-	-	O
2.80	2.80	O
;	;	O
and	and	O
period	period	O
3	3	O
:	:	O
HR	hr	O
2.74	2.74	O
,	,	O
95	95	O
%	%	O
CI	ci	O
1.06	1.06	O
-	-	O
7.11	7.11	O
)	)	O
.	.	O

INTERPRETATION	interpretation	O
:	:	O
Smoking	smoking	B-Chemical
of	of	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
was	was	O
found	found	O
to	to	O
be	be	O
an	an	O
independent	independent	O
risk	risk	O
factor	factor	O
for	for	O
HIV	hiv	O
seroconversion	seroconversion	O
among	among	O
people	people	O
who	who	O
were	were	O
injection	injection	O
drug	drug	O
users	users	O
.	.	O

This	this	O
finding	finding	O
points	points	O
to	to	O
the	the	O
urgent	urgent	O
need	need	O
for	for	O
evidence-based	evidence-based	O
public	public	O
health	health	O
initiatives	initiatives	O
targeted	targeted	O
at	at	O
people	people	O
who	who	O
smoke	smoke	O
crack	crack	B-Chemical
cocaine	cocaine	B-Chemical
.	.	O

Fluoxetine	fluoxetine	B-Chemical
improves	improves	O
the	the	O
memory	memory	O
deficits	deficits	O
caused	caused	O
by	by	O
the	the	O
chemotherapy	chemotherapy	O
agent	agent	O
5-fluorouracil	5-fluorouracil	B-Chemical
.	.	O

Cancer	cancer	B-Disease
patients	patients	O
who	who	O
have	have	O
been	been	O
treated	treated	O
with	with	O
systemic	systemic	O
adjuvant	adjuvant	O
chemotherapy	chemotherapy	O
have	have	O
described	described	O
experiencing	experiencing	O
deteriorations	deteriorations	O
in	in	O
cognition	cognition	O
.	.	O

A	a	O
widely	widely	O
used	used	O
chemotherapeutic	chemotherapeutic	O
agent	agent	O
,	,	O
5-fluorouracil	5-fluorouracil	B-Chemical
(	(	O
5-FU	5-fu	B-Chemical
)	)	O
,	,	O
readily	readily	O
crosses	crosses	O
the	the	O
blood-brain	blood-brain	O
barrier	barrier	O
and	and	O
so	so	O
could	could	O
have	have	O
a	a	O
direct	direct	O
effect	effect	O
on	on	O
brain	brain	O
function	function	O
.	.	O

In	in	O
particular	particular	O
this	this	O
anti	anti	O
mitotic	mitotic	O
drug	drug	O
could	could	O
reduce	reduce	O
cell	cell	O
proliferation	proliferation	O
in	in	O
the	the	O
neurogenic	neurogenic	O
regions	regions	O
of	of	O
the	the	O
adult	adult	O
brain	brain	O
.	.	O

In	in	O
contrast	contrast	O
reports	reports	O
indicate	indicate	O
that	that	O
hippocampal	hippocampal	O
dependent	dependent	O
neurogenesis	neurogenesis	O
and	and	O
cognition	cognition	O
are	are	O
enhanced	enhanced	O
by	by	O
the	the	O
SSRI	ssri	O
antidepressant	antidepressant	B-Chemical
Fluoxetine	fluoxetine	B-Chemical
.	.	O

In	in	O
this	this	O
investigation	investigation	O
the	the	O
behavioural	behavioural	O
effects	effects	O
of	of	O
chronic	chronic	O
(	(	O
two	two	O
week	week	O
)	)	O
treatment	treatment	O
with	with	O
5-FU	5-fu	B-Chemical
and	and	O
(	(	O
three	three	O
weeks	weeks	O
)	)	O
with	with	O
Fluoxetine	fluoxetine	B-Chemical
either	either	O
separately	separately	O
or	or	O
in	in	O
combination	combination	O
with	with	O
5-FU	5-fu	B-Chemical
were	were	O
tested	tested	O
on	on	O
adult	adult	O
Lister	lister	O
hooded	hooded	O
rats	rats	O
.	.	O

Behavioural	behavioural	O
effects	effects	O
were	were	O
tested	tested	O
using	using	O
a	a	O
context	context	O
dependent	dependent	O
conditioned	conditioned	O
emotional	emotional	O
response	response	O
test	test	O
(	(	O
CER	cer	O
)	)	O
which	which	O
showed	showed	O
that	that	O
animals	animals	O
treated	treated	O
with	with	O
5-FU	5-fu	B-Chemical
had	had	O
a	a	O
significant	significant	O
reduction	reduction	O
in	in	O
freezing	freezing	O
time	time	O
compared	compared	O
to	to	O
controls	controls	O
.	.	O

A	a	O
separate	separate	O
group	group	O
of	of	O
animals	animals	O
was	was	O
tested	tested	O
using	using	O
a	a	O
hippocampal	hippocampal	O
dependent	dependent	O
spatial	spatial	O
working	working	O
memory	memory	O
test	test	O
,	,	O
the	the	O
object	object	O
location	location	O
recognition	recognition	O
test	test	O
(	(	O
OLR	olr	O
)	)	O
.	.	O

Animals	animals	O
treated	treated	O
only	only	O
with	with	O
5-FU	5-fu	B-Chemical
showed	showed	O
significant	significant	O
deficits	deficits	O
in	in	O
their	their	O
ability	ability	O
to	to	O
carry	carry	O
out	out	O
the	the	O
OLR	olr	O
task	task	O
but	but	O
co	co	B-Chemical
administration	administration	O
of	of	O
Fluoxetine	fluoxetine	B-Chemical
improved	improved	O
their	their	O
performance	performance	O
.	.	O

5-FU	5-fu	B-Chemical
chemotherapy	chemotherapy	O
caused	caused	O
a	a	O
significant	significant	O
reduction	reduction	O
in	in	O
the	the	O
number	number	O
of	of	O
proliferating	proliferating	O
cells	cells	O
in	in	O
the	the	O
sub	sub	O
granular	granular	O
zone	zone	O
of	of	O
the	the	O
dentate	dentate	O
gyrus	gyrus	O
compared	compared	O
to	to	O
controls	controls	O
.	.	O

This	this	O
reduction	reduction	O
was	was	O
eliminated	eliminated	O
when	when	O
Fluoxetine	fluoxetine	B-Chemical
was	was	O
co	co	B-Chemical
administered	administered	O
with	with	O
5-FU	5-fu	B-Chemical
.	.	O

Fluoxetine	fluoxetine	B-Chemical
on	on	O
its	its	O
own	own	O
had	had	O
no	no	O
effect	effect	O
on	on	O
proliferating	proliferating	O
cell	cell	O
number	number	O
or	or	O
behaviour	behaviour	O
.	.	O

These	these	O
findings	findings	O
suggest	suggest	O
that	that	O
5-FU	5-fu	B-Chemical
can	can	O
negatively	negatively	O
affect	affect	O
both	both	O
cell	cell	O
proliferation	proliferation	O
and	and	O
hippocampal	hippocampal	O
dependent	dependent	O
working	working	O
memory	memory	O
and	and	O
that	that	O
these	these	O
deficits	deficits	O
can	can	O
be	be	O
reversed	reversed	O
by	by	O
the	the	O
simultaneous	simultaneous	O
administration	administration	O
of	of	O
the	the	O
antidepressant	antidepressant	B-Chemical
Fluoxetine	fluoxetine	B-Chemical
.	.	O

Liver-specific	liver-specific	O
ablation	ablation	O
of	of	O
integrin-linked	integrin-linked	O
kinase	kinase	O
in	in	O
mice	mice	O
results	results	O
in	in	O
enhanced	enhanced	O
and	and	O
prolonged	prolonged	O
cell	cell	O
proliferation	proliferation	O
and	and	O
hepatomegaly	hepatomegaly	B-Disease
after	after	O
phenobarbital	phenobarbital	B-Chemical
administration	administration	O
.	.	O

We	we	O
have	have	O
recently	recently	O
demonstrated	demonstrated	O
that	that	O
disruption	disruption	O
of	of	O
extracellular	extracellular	O
matrix	matrix	O
(ECM)/integrin	(ecm)/integrin	O
signaling	signaling	O
via	via	O
elimination	elimination	O
of	of	O
integrin-linked	integrin-linked	O
kinase	kinase	O
(	(	O
ILK	ilk	O
)	)	O
in	in	O
hepatocytes	hepatocytes	O
interferes	interferes	O
with	with	O
signals	signals	O
leading	leading	O
to	to	O
termination	termination	O
of	of	O
liver	liver	O
regeneration	regeneration	O
.	.	O

This	this	O
study	study	O
investigates	investigates	O
the	the	O
role	role	O
of	of	O
ILK	ilk	O
in	in	O
liver	liver	O
enlargement	enlargement	O
induced	induced	O
by	by	O
phenobarbital	phenobarbital	B-Chemical
(	(	O
PB	pb	O
)	)	O
.	.	O

Wild-type	wild-type	O
(	(	O
WT	wt	O
)	)	O
and	and	O
ILK	ilk	O
:	:	O
liver-/-	liver-/-	O
mice	mice	O
were	were	O
given	given	O
PB	pb	O
(	(	O
0.1	0.1	O
%	%	O
in	in	O
drinking	drinking	B-Chemical
water	water	I-Chemical
)	)	O
for	for	O
10	10	O
days	days	O
.	.	O

Livers	livers	O
were	were	O
harvested	harvested	O
on	on	O
2	2	O
,	,	O
5	5	O
,	,	O
and	and	O
10	10	O
days	days	O
during	during	O
PB	pb	O
administration	administration	O
.	.	O

In	in	O
the	the	O
hepatocyte-specific	hepatocyte-specific	O
ILK/liver-/-	ilk/liver-/-	O
mice	mice	O
,	,	O
the	the	O
liver	liver	O
:	:	O
body	body	B-Disease
weight	weight	I-Disease
ratio	ratio	O
was	was	O
more	more	O
than	than	O
double	double	O
as	as	O
compared	compared	O
to	to	O
0	0	O
h	h	B-Chemical
at	at	O
day	day	O
2	2	O
(	(	O
2.5	2.5	O
times	times	O
)	)	O
,	,	O
while	while	O
at	at	O
days	days	O
5	5	O
and	and	O
10	10	O
,	,	O
it	it	O
was	was	O
enlarged	enlarged	O
three	three	O
times	times	O
.	.	O

In	in	O
the	the	O
WT	wt	O
mice	mice	O
,	,	O
the	the	O
increase	increase	O
was	was	O
as	as	O
expected	expected	O
from	from	O
previous	previous	O
literature	literature	O
(	(	O
1.8	1.8	O
times	times	O
)	)	O
and	and	O
seems	seems	O
to	to	O
have	have	O
leveled	leveled	O
off	off	O
after	after	O
day	day	O
2	2	O
.	.	O

There	there	O
were	were	O
slightly	slightly	O
increased	increased	O
proliferating	proliferating	O
cell	cell	O
nuclear	nuclear	O
antigen-positive	antigen-positive	O
cells	cells	O
in	in	O
the	the	O
ILK/liver-/-	ilk/liver-/-	O
animals	animals	O
at	at	O
day	day	O
2	2	O
as	as	O
compared	compared	O
to	to	O
WT	wt	O
after	after	O
PB	pb	O
administration	administration	O
.	.	O

In	in	O
the	the	O
WT	wt	O
animals	animals	O
,	,	O
the	the	O
proliferative	proliferative	O
response	response	O
had	had	O
come	come	O
back	back	O
to	to	O
normal	normal	O
by	by	O
days	days	O
5	5	O
and	and	O
10	10	O
.	.	O

Hepatocytes	hepatocytes	O
of	of	O
the	the	O
ILK/liver-/-	ilk/liver-/-	O
mice	mice	O
continued	continued	O
to	to	O
proliferate	proliferate	O
up	up	O
until	until	O
day	day	O
10	10	O
.	.	O

ILK/liver-/-	ilk/liver-/-	O
mice	mice	O
also	also	O
showed	showed	O
increased	increased	O
expression	expression	O
of	of	O
key	key	O
genes	genes	O
involved	involved	O
in	in	O
hepatocyte	hepatocyte	O
proliferation	proliferation	O
at	at	O
different	different	O
time	time	O
points	points	O
during	during	O
PB	pb	O
administration	administration	O
.	.	O

In	in	O
summary	summary	O
,	,	O
ECM	ecm	O
proteins	proteins	O
communicate	communicate	O
with	with	O
the	the	O
signaling	signaling	O
machinery	machinery	O
of	of	O
dividing	dividing	O
cells	cells	O
via	via	O
ILK	ilk	O
to	to	O
regulate	regulate	O
hepatocyte	hepatocyte	O
proliferation	proliferation	O
and	and	O
termination	termination	O
of	of	O
the	the	O
proliferative	proliferative	O
response	response	O
.	.	O

Lack	lack	O
of	of	O
ILK	ilk	O
in	in	O
the	the	O
hepatocytes	hepatocytes	O
imparts	imparts	O
prolonged	prolonged	O
proliferative	proliferative	O
response	response	O
not	not	O
only	only	O
to	to	O
stimuli	stimuli	O
related	related	O
to	to	O
liver	liver	O
regeneration	regeneration	O
but	but	O
also	also	O
to	to	O
xenobiotic	xenobiotic	O
chemical	chemical	O
mitogens	mitogens	O
,	,	O
such	such	O
as	as	O
PB	pb	O
.	.	O

Decreased	decreased	O
Expression	expression	O
of	of	O
Na/K-ATPase	na/k-atpase	O
,	,	O
NHE3	nhe3	O
,	,	O
NBC1	nbc1	O
,	,	O
AQP1	aqp1	O
and	and	O
OAT	oat	O
in	in	O
Gentamicin-induced	gentamicin-induced	O
Nephropathy	nephropathy	B-Disease
.	.	O

The	the	O
present	present	O
study	study	O
was	was	O
aimed	aimed	O
to	to	O
determine	determine	O
whether	whether	O
there	there	O
is	is	O
an	an	O
altered	altered	O
regulation	regulation	O
of	of	O
tubular	tubular	O
transporters	transporters	O
in	in	O
gentamicin-induced	gentamicin-induced	O
nephropathy	nephropathy	B-Disease
.	.	O

Sprague-Dawley	sprague-dawley	O
male	male	O
rats	rats	O
(	(	O
200~250	200~250	O
g	g	O
)	)	O
were	were	O
subcutaneously	subcutaneously	O
injected	injected	O
with	with	O
gentamicin	gentamicin	B-Chemical
(	(	O
100	100	O
mg/kg	mg/kg	O
per	per	O
day	day	O
)	)	O
for	for	O
7	7	O
days	days	O
,	,	O
and	and	O
the	the	O
expression	expression	O
of	of	O
tubular	tubular	O
transporters	transporters	O
was	was	O
determined	determined	O
by	by	O
immunoblotting	immunoblotting	O
and	and	O
immunohistochemistry	immunohistochemistry	O
.	.	O

The	the	O
mRNA	mrna	O
and	and	O
protein	protein	O
expression	expression	O
of	of	O
OAT	oat	O
was	was	O
also	also	O
determined	determined	O
.	.	O

Gentamicin-treated	gentamicin-treated	O
rats	rats	O
exhibited	exhibited	O
significantly	significantly	O
decreased	decreased	O
creatinine	creatinine	B-Chemical
clearance	clearance	O
along	along	O
with	with	O
increased	increased	O
plasma	plasma	O
creatinine	creatinine	B-Chemical
levels	levels	O
.	.	O

Accordingly	accordingly	O
,	,	O
the	the	O
fractional	fractional	O
excretion	excretion	O
of	of	O
sodium	sodium	B-Chemical
increased	increased	O
.	.	O

Urine	urine	O
volume	volume	O
was	was	O
increased	increased	O
,	,	O
while	while	O
urine	urine	O
osmolality	osmolality	O
and	and	O
free	free	O
water	water	O
reabsorption	reabsorption	O
were	were	O
decreased	decreased	O
.	.	O

Immunoblotting	immunoblotting	O
and	and	O
immunohistochemistry	immunohistochemistry	O
revealed	revealed	O
decreased	decreased	O
expression	expression	O
of	of	O
Na(+)/K(+)-ATPase	na(+)/k(+)-atpase	O
,	,	O
NHE3	nhe3	O
,	,	O
NBC1	nbc1	O
,	,	O
and	and	O
AQP1	aqp1	O
in	in	O
the	the	O
kidney	kidney	O
of	of	O
gentamicin-treated	gentamicin-treated	O
rats	rats	O
.	.	O

The	the	O
expression	expression	O
of	of	O
OAT1	oat1	O
and	and	O
OAT3	oat3	O
was	was	O
also	also	O
decreased	decreased	O
.	.	O

Gentamicin-induced	gentamicin-induced	O
nephropathy	nephropathy	B-Disease
may	may	O
at	at	O
least	least	O
in	in	O
part	part	O
be	be	O
causally	causally	O
related	related	O
with	with	O
a	a	O
decreased	decreased	O
expression	expression	O
of	of	O
Na(+)/K(+)-ATPase	na(+)/k(+)-atpase	O
,	,	O
NHE3	nhe3	O
,	,	O
NBC1	nbc1	O
,	,	O
AQP1	aqp1	O
and	and	O
OAT	oat	O
.	.	O

Acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
after	after	O
high-dose	high-dose	O
methotrexate	methotrexate	B-Chemical
therapy	therapy	O
in	in	O
a	a	O
patient	patient	O
with	with	O
ileostomy	ileostomy	O
.	.	O

High-dose	high-dose	O
methotrexate	methotrexate	B-Chemical
(	(	O
HD-MTX	hd-mtx	O
)	)	O
is	is	O
an	an	O
important	important	O
treatment	treatment	O
for	for	O
Burkitt	burkitt	B-Disease
lymphoma	lymphoma	I-Disease
,	,	O
but	but	O
can	can	O
cause	cause	O
hepatic	hepatic	O
and	and	O
renal	renal	B-Disease
toxicity	toxicity	B-Disease
when	when	O
its	its	O
clearance	clearance	O
is	is	O
delayed	delayed	O
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
after	after	O
HD-MTX	hd-mtx	O
therapy	therapy	O
in	in	O
a	a	O
patient	patient	O
with	with	O
ileostomy	ileostomy	O
,	,	O
The	the	O
patient	patient	O
was	was	O
a	a	O
3-year-old	3-year-old	O
boy	boy	O
who	who	O
had	had	O
received	received	O
a	a	O
living-related	living-related	O
liver	liver	O
transplantation	transplantation	O
for	for	O
congenital	congenital	O
biliary	biliary	B-Disease
atresia	atresia	I-Disease
.	.	O

At	at	O
day	day	O
833	833	O
after	after	O
the	the	O
transplantation	transplantation	O
,	,	O
he	he	O
was	was	O
diagnosed	diagnosed	O
with	with	O
PTLD	ptld	O
(	(	O
post-transplantation	post-transplantation	O
lymphoproliferative	lymphoproliferative	O
disorder	disorder	O
,	,	O
Burkitt-type	burkitt-type	O
malignant	malignant	O
lymphoma	lymphoma	O
)	)	O
.	.	O

During	during	O
induction	induction	O
therapy	therapy	O
,	,	O
he	he	O
suffered	suffered	O
ileal	ileal	O
perforation	perforation	O
and	and	O
ileostomy	ileostomy	O
was	was	O
performed	performed	O
.	.	O

Subsequent	subsequent	O
HD-MTX	hd-mtx	O
therapy	therapy	O
caused	caused	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
that	that	O
required	required	O
continuous	continuous	O
hemodialysis	hemodialysis	O
.	.	O

We	we	O
supposed	supposed	O
that	that	O
intravascular	intravascular	O
hypovolemia	hypovolemia	O
due	due	O
to	to	O
substantial	substantial	O
drainage	drainage	O
from	from	O
the	the	O
ileostoma	ileostoma	O
caused	caused	O
acute	acute	O
prerenal	prerenal	O
failure	failure	O
.	.	O

After	after	O
recovery	recovery	O
of	of	O
his	his	O
renal	renal	O
function	function	O
,	,	O
we	we	O
could	could	O
safely	safely	O
treat	treat	O
the	the	O
patient	patient	O
with	with	O
HD-MTX	hd-mtx	O
therapy	therapy	O
by	by	O
controlling	controlling	O
drainage	drainage	O
from	from	O
ileostoma	ileostoma	O
with	with	O
total	total	O
parenteral	parenteral	O
nutrition	nutrition	O
.	.	O

Longitudinal	longitudinal	O
association	association	O
of	of	O
alcohol	alcohol	B-Chemical
use	use	O
with	with	O
HIV	hiv	O
disease	disease	B-Disease
progression	progression	I-Disease
and	and	O
psychological	psychological	O
health	health	O
of	of	O
women	women	O
with	with	O
HIV.We	hiv.we	O
evaluated	evaluated	O
the	the	O
association	association	O
of	of	O
alcohol	alcohol	B-Chemical
consumption	consumption	O
and	and	O
depression	depression	B-Disease
,	,	O
and	and	O
their	their	O
effects	effects	O
on	on	O
HIV	hiv	O
disease	disease	B-Disease
progression	progression	I-Disease
among	among	O
women	women	O
with	with	O
HIV	hiv	O
.	.	O

The	the	O
study	study	O
included	included	O
871	871	O
women	women	O
with	with	O
HIV	hiv	O
who	who	O
were	were	O
recruited	recruited	O
from	from	O
1993	1993	O
-	-	O
1995	1995	O
in	in	O
four	four	O
US	us	O
cities	cities	O
.	.	O

The	the	O
participants	participants	O
had	had	O
physical	physical	O
examination	examination	O
,	,	O
medical	medical	O
record	record	O
extraction	extraction	O
,	,	O
and	and	O
venipuncture	venipuncture	O
,	,	O
CD4+T-cell	cd4+t-cell	O
counts	counts	O
determination	determination	O
,	,	O
measurement	measurement	O
of	of	O
depression	depression	B-Disease
symptoms	symptoms	O
(	(	O
using	using	O
the	the	O
self-report	self-report	O
Center	center	O
for	for	O
Epidemiological	epidemiological	O
Studies-Depression	studies-depression	O
Scale	scale	O
)	)	O
,	,	O
and	and	O
alcohol	alcohol	B-Chemical
use	use	O
assessment	assessment	O
at	at	O
enrollment	enrollment	O
,	,	O
and	and	O
semiannually	semiannually	O
until	until	O
March	march	O
2000	2000	O
.	.	O

Multilevel	multilevel	O
random	random	O
coefficient	coefficient	O
ordinal	ordinal	O
models	models	O
as	as	O
well	well	O
as	as	O
multilevel	multilevel	O
models	models	O
with	with	O
joint	joint	O
responses	responses	O
were	were	O
used	used	O
in	in	O
the	the	O
analysis	analysis	O
.	.	O

There	there	O
was	was	O
no	no	O
significant	significant	O
association	association	O
between	between	O
level	level	O
of	of	O
alcohol	alcohol	B-Chemical
use	use	O
and	and	O
CD4	cd4	O
+	+	O
T-cell	t-cell	O
counts	counts	O
.	.	O

When	when	O
participants	participants	O
were	were	O
stratified	stratified	O
by	by	O
antiretroviral	antiretroviral	O
therapy	therapy	O
(	(	O
ART	art	O
)	)	O
use	use	O
,	,	O
the	the	O
association	association	O
between	between	O
alcohol	alcohol	B-Chemical
and	and	O
CD4	cd4	O
+	+	O
T-cell	t-cell	O
did	did	O
not	not	O
reach	reach	O
statistical	statistical	O
significance	significance	O
.	.	O

The	the	O
association	association	O
between	between	O
alcohol	alcohol	B-Chemical
consumption	consumption	O
and	and	O
depression	depression	B-Disease
was	was	O
significant	significant	O
(	(	O
p<0.001	p<0.001	O
)	)	O
.	.	O

Depression	depression	B-Disease
had	had	O
a	a	O
significant	significant	O
negative	negative	O
effect	effect	O
on	on	O
CD4	cd4	O
+	+	O
T-cell	t-cell	O
counts	counts	O
over	over	O
time	time	O
regardless	regardless	O
of	of	O
ART	art	O
use	use	O
.	.	O

Our	our	O
findings	findings	O
suggest	suggest	O
that	that	O
alcohol	alcohol	B-Chemical
consumption	consumption	O
has	has	O
a	a	O
direct	direct	O
association	association	O
with	with	O
depression	depression	B-Disease
.	.	O

Moreover	moreover	O
,	,	O
depression	depression	B-Disease
is	is	O
associated	associated	O
with	with	O
HIV	hiv	O
disease	disease	B-Disease
progression	progression	I-Disease
.	.	O

Our	our	O
findings	findings	O
have	have	O
implications	implications	O
for	for	O
the	the	O
provision	provision	O
of	of	O
alcohol	alcohol	B-Chemical
use	use	O
interventions	interventions	O
and	and	O
psychological	psychological	O
resources	resources	O
to	to	O
improve	improve	O
the	the	O
health	health	O
of	of	O
women	women	O
with	with	O
HIV	hiv	O
.	.	O

Chemokine	chemokine	B-Chemical
CCL2	ccl2	I-Chemical
and	and	O
its	its	O
receptor	receptor	O
CCR2	ccr2	O
are	are	O
increased	increased	O
in	in	O
the	the	O
hippocampus	hippocampus	O
following	following	O
pilocarpine-induced	pilocarpine-induced	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
.	.	O

BACKGROUND	background	O
:	:	O
Neuroinflammation	neuroinflammation	O
occurs	occurs	O
after	after	O
seizures	seizures	B-Disease
and	and	O
is	is	O
implicated	implicated	O
in	in	O
epileptogenesis	epileptogenesis	O
.	.	O

CCR2	ccr2	O
is	is	O
a	a	O
chemokine	chemokine	O
receptor	receptor	O
for	for	O
CCL2	ccl2	O
and	and	O
their	their	O
interaction	interaction	O
mediates	mediates	O
monocyte	monocyte	O
infiltration	infiltration	O
in	in	O
the	the	O
neuroinflammatory	neuroinflammatory	O
cascade	cascade	O
triggered	triggered	O
in	in	O
different	different	O
brain	brain	O
pathologies	pathologies	O
.	.	O

In	in	O
this	this	O
work	work	O
CCR2	ccr2	O
and	and	O
CCL2	ccl2	O
expression	expression	O
were	were	O
examined	examined	O
following	following	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
(	(	O
SE	se	B-Disease
)	)	O
induced	induced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
injection	injection	O
.	.	O

METHODS	methods	O
:	:	O
SE	se	B-Disease
was	was	O
induced	induced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
injection	injection	O
.	.	O

Control	control	O
rats	rats	O
were	were	O
injected	injected	O
with	with	O
saline	saline	O
instead	instead	O
of	of	O
pilocarpine	pilocarpine	B-Chemical
.	.	O

Five	five	O
days	days	O
after	after	O
SE	se	B-Disease
,	,	O
CCR2	ccr2	O
staining	staining	O
in	in	O
neurons	neurons	O
and	and	O
glial	glial	O
cells	cells	O
was	was	O
examined	examined	O
using	using	O
imunohistochemical	imunohistochemical	O
analyses	analyses	O
.	.	O

The	the	O
number	number	O
of	of	O
CCR2	ccr2	O
positive	positive	O
cells	cells	O
was	was	O
determined	determined	O
using	using	O
stereology	stereology	O
probes	probes	O
in	in	O
the	the	O
hippocampus	hippocampus	O
.	.	O

CCL2	ccl2	O
expression	expression	O
in	in	O
the	the	O
hippocampus	hippocampus	O
was	was	O
examined	examined	O
by	by	O
molecular	molecular	O
assay	assay	O
.	.	O

RESULTS	results	O
:	:	O
Increased	increased	O
CCR2	ccr2	O
was	was	O
observed	observed	O
in	in	O
the	the	O
hippocampus	hippocampus	O
after	after	O
SE	se	B-Disease
.	.	O

Seizures	seizures	B-Disease
also	also	O
resulted	resulted	O
in	in	O
alterations	alterations	O
to	to	O
the	the	O
cell	cell	O
types	types	O
expressing	expressing	O
CCR2	ccr2	O
.	.	O

Increased	increased	O
numbers	numbers	O
of	of	O
neurons	neurons	O
that	that	O
expressed	expressed	O
CCR2	ccr2	O
was	was	O
observed	observed	O
following	following	O
SE	se	B-Disease
.	.	O

Microglial	microglial	O
cells	cells	O
were	were	O
more	more	O
closely	closely	O
apposed	apposed	O
to	to	O
the	the	O
CCR2-labeled	ccr2-labeled	O
cells	cells	O
in	in	O
SE	se	B-Disease
rats	rats	O
.	.	O

In	in	O
addition	addition	O
,	,	O
rats	rats	O
that	that	O
experienced	experienced	O
SE	se	B-Disease
exhibited	exhibited	O
CCR2-labeling	ccr2-labeling	O
in	in	O
populations	populations	O
of	of	O
hypertrophied	hypertrophied	O
astrocytes	astrocytes	O
,	,	O
especially	especially	O
in	in	O
CA1	ca1	O
and	and	O
dentate	dentate	O
gyrus	gyrus	O
.	.	O

These	these	O
CCR2	ccr2	O
+	+	O
astroctytes	astroctytes	O
were	were	O
not	not	O
observed	observed	O
in	in	O
control	control	O
rats	rats	O
.	.	O

Examination	examination	O
of	of	O
CCL2	ccl2	O
expression	expression	O
showed	showed	O
that	that	O
it	it	O
was	was	O
elevated	elevated	O
in	in	O
the	the	O
hippocampus	hippocampus	O
following	following	O
SE	se	B-Disease
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
data	data	O
show	show	O
that	that	O
CCR2	ccr2	O
and	and	O
CCL2	ccl2	O
are	are	O
up-regulated	up-regulated	O
in	in	O
the	the	O
hippocampus	hippocampus	O
after	after	O
pilocarpine-induced	pilocarpine-induced	O
SE	se	B-Disease
.	.	O

Seizures	seizures	B-Disease
also	also	O
result	result	O
in	in	O
changes	changes	O
to	to	O
CCR2	ccr2	O
receptor	receptor	O
expression	expression	O
in	in	O
neurons	neurons	O
and	and	O
astrocytes	astrocytes	O
.	.	O

These	these	O
changes	changes	O
might	might	O
be	be	O
involved	involved	O
in	in	O
detrimental	detrimental	O
neuroplasticity	neuroplasticity	O
and	and	O
neuroinflammatory	neuroinflammatory	O
changes	changes	O
that	that	O
occur	occur	O
following	following	O
seizures	seizures	B-Disease
.	.	O

Metallothionein	metallothionein	O
induction	induction	O
reduces	reduces	O
caspase-3	caspase-3	O
activity	activity	O
and	and	O
TNFalpha	tnfalpha	O
levels	levels	O
with	with	O
preservation	preservation	O
of	of	O
cognitive	cognitive	O
function	function	O
and	and	O
intact	intact	O
hippocampal	hippocampal	O
neurons	neurons	O
in	in	O
carmustine-treated	carmustine-treated	O
rats	rats	O
.	.	O

Hippocampal	hippocampal	O
integrity	integrity	O
is	is	O
essential	essential	O
for	for	O
cognitive	cognitive	O
functions	functions	O
.	.	O

On	on	O
the	the	O
other	other	O
hand	hand	O
,	,	O
induction	induction	O
of	of	O
metallothionein	metallothionein	O
(	(	O
MT	mt	O
)	)	O
by	by	O
ZnSO(4	znso(4	O
)	)	O
and	and	O
its	its	O
role	role	O
in	in	O
neuroprotection	neuroprotection	O
has	has	O
been	been	O
documented	documented	O
.	.	O

The	the	O
present	present	O
study	study	O
aimed	aimed	O
to	to	O
explore	explore	O
the	the	O
effect	effect	O
of	of	O
MT	mt	O
induction	induction	O
on	on	O
carmustine	carmustine	O
(BCNU)-induced	(bcnu)-induced	O
hippocampal	hippocampal	O
cognitive	cognitive	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
rats	rats	O
.	.	O

A	a	O
total	total	O
of	of	O
60	60	O
male	male	O
Wistar	wistar	O
albino	albino	O
rats	rats	O
were	were	O
randomly	randomly	O
divided	divided	O
into	into	O
four	four	O
groups	groups	O
(	(	O
15/group	15/group	O
):	):	O
The	the	O
control	control	O
group	group	O
injected	injected	O
with	with	O
single	single	O
doses	doses	O
of	of	O
normal	normal	O
saline	saline	O
(	(	O
i.c.v	i.c.v	O
)	)	O
followed	followed	O
24	24	O
h	h	B-Chemical
later	later	O
by	by	O
BCNU	bcnu	B-Chemical
solvent	solvent	O
(	(	O
i.v	i.v	O
)	)	O
.	.	O

The	the	O
second	second	O
group	group	O
administered	administered	O
ZnSO(4	znso(4	O
)	)	O
(	(	O
0.1	0.1	O
micromol/10	micromol/10	O
microl	microl	O
normal	normal	O
saline	saline	O
,	,	O
i.c.v	i.c.v	O
,	,	O
once	once	O
)	)	O
then	then	O
BCNU	bcnu	B-Chemical
solvent	solvent	O
(	(	O
i.v	i.v	O
)	)	O
after	after	O
24	24	O
h.	h.	O
Third	third	O
group	group	O
received	received	O
BCNU	bcnu	B-Chemical
(	(	O
20	20	O
mg/kg	mg/kg	O
,	,	O
i.v	i.v	O
,	,	O
once	once	O
)	)	O
24	24	O
h	h	B-Chemical
after	after	O
injection	injection	O
with	with	O
normal	normal	O
saline	saline	O
(	(	O
i.c.v	i.c.v	O
)	)	O
.	.	O

Fourth	fourth	O
group	group	O
received	received	O
a	a	O
single	single	O
dose	dose	O
of	of	O
ZnSO(4	znso(4	O
)	)	O
(	(	O
0.1	0.1	O
micromol/10	micromol/10	O
microl	microl	O
normal	normal	O
saline	saline	O
,	,	O
i.c.v	i.c.v	O
)	)	O
then	then	O
BCNU	bcnu	B-Chemical
(	(	O
20	20	O
mg/kg	mg/kg	O
,	,	O
i.v	i.v	O
,	,	O
once	once	O
)	)	O
after	after	O
24	24	O
h.	h.	O
The	the	O
obtained	obtained	O
data	data	O
revealed	revealed	O
that	that	O
BCNU	bcnu	B-Chemical
administration	administration	O
resulted	resulted	O
in	in	O
deterioration	deterioration	O
of	of	O
learning	learning	O
and	and	O
short-term	short-term	O
memory	memory	O
(	(	O
STM	stm	O
)	)	O
,	,	O
as	as	O
measured	measured	O
by	by	O
using	using	O
radial	radial	O
arm	arm	O
water	water	O
maze	maze	O
,	,	O
accompanied	accompanied	O
with	with	O
decreased	decreased	O
hippocampal	hippocampal	O
glutathione	glutathione	B-Chemical
reductase	reductase	I-Chemical
(	(	O
GR	gr	O
)	)	O
activity	activity	O
and	and	O
reduced	reduced	O
glutathione	glutathione	B-Chemical
(	(	O
GSH	gsh	B-Chemical
)	)	O
content	content	O
.	.	O

Also	also	O
,	,	O
BCNU	bcnu	B-Chemical
administration	administration	O
increased	increased	O
serum	serum	O
tumor	tumor	B-Disease
necrosis	necrosis	B-Disease
factor-alpha	factor-alpha	O
(	(	O
TNFalpha	tnfalpha	O
)	)	O
,	,	O
hippocampal	hippocampal	O
MT	mt	O
and	and	O
malondialdehyde	malondialdehyde	B-Chemical
(	(	O
MDA	mda	O
)	)	O
contents	contents	O
as	as	O
well	well	O
as	as	O
caspase-3	caspase-3	O
activity	activity	O
in	in	O
addition	addition	O
to	to	O
histological	histological	O
alterations	alterations	O
.	.	O

ZnSO(4	znso(4	O
)	)	O
pretreatment	pretreatment	O
counteracted	counteracted	O
BCNU-induced	bcnu-induced	O
inhibition	inhibition	O
of	of	O
GR	gr	O
and	and	O
depletion	depletion	O
of	of	O
GSH	gsh	B-Chemical
and	and	O
resulted	resulted	O
in	in	O
significant	significant	O
reduction	reduction	O
in	in	O
the	the	O
levels	levels	O
of	of	O
MDA	mda	O
and	and	O
TNFalpha	tnfalpha	O
as	as	O
well	well	O
as	as	O
the	the	O
activity	activity	O
of	of	O
caspase-3	caspase-3	O
.	.	O

The	the	O
histological	histological	O
features	features	O
were	were	O
improved	improved	O
in	in	O
hippocampus	hippocampus	O
of	of	O
rats	rats	O
treated	treated	O
with	with	O
ZnSO(4	znso(4	O
)	)	O
+	+	O
BCNU	bcnu	B-Chemical
compared	compared	O
to	to	O
only	only	O
BCNU-treated	bcnu-treated	O
animals	animals	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
MT	mt	O
induction	induction	O
halts	halts	O
BCNU-induced	bcnu-induced	O
hippocampal	hippocampal	O
toxicity	toxicity	B-Disease
as	as	O
it	it	O
prevented	prevented	O
GR	gr	O
inhibition	inhibition	O
and	and	O
GSH	gsh	B-Chemical
depletion	depletion	O
and	and	O
counteracted	counteracted	O
the	the	O
increased	increased	O
levels	levels	O
of	of	O
TNFalpha	tnfalpha	O
,	,	O
MDA	mda	O
and	and	O
caspase-3	caspase-3	O
activity	activity	O
with	with	O
subsequent	subsequent	O
preservation	preservation	O
of	of	O
cognition	cognition	O
.	.	O

Fatal	fatal	O
carbamazepine	carbamazepine	B-Chemical
induced	induced	O
fulminant	fulminant	O
eosinophilic	eosinophilic	O
(	(	O
hypersensitivity	hypersensitivity	B-Disease
)	)	O
myocarditis	myocarditis	B-Disease
:	:	O
emphasis	emphasis	O
on	on	O
anatomical	anatomical	O
and	and	O
histological	histological	O
characteristics	characteristics	O
,	,	O
mechanisms	mechanisms	O
and	and	O
genetics	genetics	O
of	of	O
drug	drug	B-Disease
hypersensitivity	hypersensitivity	B-Disease
and	and	O
differential	differential	O
diagnosis	diagnosis	O
.	.	O

The	the	O
most	most	O
severe	severe	O
adverse	adverse	O
reactions	reactions	O
to	to	O
carbamazepine	carbamazepine	B-Chemical
have	have	O
been	been	O
observed	observed	O
in	in	O
the	the	O
haemopoietic	haemopoietic	O
system	system	O
,	,	O
the	the	O
liver	liver	O
and	and	O
the	the	O
cardiovascular	cardiovascular	O
system	system	O
.	.	O

A	a	O
frequently	frequently	O
fatal	fatal	O
,	,	O
although	although	O
exceptionally	exceptionally	O
rare	rare	O
side	side	O
effect	effect	O
of	of	O
carbamazepine	carbamazepine	B-Chemical
is	is	O
necrotizing	necrotizing	O
eosinophilic	eosinophilic	O
(	(	O
hypersensitivity	hypersensitivity	B-Disease
)	)	O
myocarditis	myocarditis	B-Disease
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
hypersensitivity	hypersensitivity	B-Disease
myocarditis	myocarditis	B-Disease
secondary	secondary	O
to	to	O
administration	administration	O
of	of	O
carbamazepine	carbamazepine	B-Chemical
.	.	O

Acute	acute	O
hypersensitivity	hypersensitivity	B-Disease
myocarditis	myocarditis	B-Disease
was	was	O
not	not	O
suspected	suspected	O
clinically	clinically	O
,	,	O
and	and	O
the	the	O
diagnosis	diagnosis	O
was	was	O
made	made	O
post-mortem	post-mortem	O
.	.	O

Histology	histology	O
revealed	revealed	O
diffuse	diffuse	O
infiltration	infiltration	O
of	of	O
the	the	O
myocardium	myocardium	O
by	by	O
eosinophils	eosinophils	O
and	and	O
lymphocytes	lymphocytes	O
with	with	O
myocyte	myocyte	O
damage	damage	O
.	.	O

Clinically	clinically	O
,	,	O
death	death	B-Disease
was	was	O
due	due	O
to	to	O
cardiogenic	cardiogenic	O
shock	shock	B-Disease
.	.	O

To	to	O
best	best	O
of	of	O
our	our	O
knowledge	knowledge	O
this	this	O
is	is	O
the	the	O
second	second	O
case	case	O
of	of	O
fatal	fatal	O
carbamazepine	carbamazepine	B-Chemical
induced	induced	O
myocarditis	myocarditis	B-Disease
reported	reported	O
in	in	O
English	english	O
literature	literature	O
.	.	O

Neuropsychiatric	neuropsychiatric	O
behaviors	behaviors	O
in	in	O
the	the	O
MPTP	mptp	B-Chemical
marmoset	marmoset	O
model	model	O
of	of	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

OBJECTIVES	objectives	O
:	:	O
Neuropsychiatric	neuropsychiatric	O
symptoms	symptoms	O
are	are	O
increasingly	increasingly	O
recognised	recognised	O
as	as	O
a	a	O
significant	significant	O
problem	problem	O
in	in	O
patients	patients	O
with	with	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
(	(	O
PD	pd	B-Disease
)	)	O
.	.	O

These	these	O
symptoms	symptoms	O
may	may	O
be	be	O
due	due	O
to	to	O
'	'	O
sensitisation	sensitisation	O
'	'	O
following	following	O
repeated	repeated	O
levodopa	levodopa	B-Chemical
treatment	treatment	O
or	or	O
a	a	O
direct	direct	O
effect	effect	O
of	of	O
dopamine	dopamine	B-Chemical
on	on	O
the	the	O
disease	disease	O
state	state	O
.	.	O

The	the	O
levodopa-treated	levodopa-treated	O
MPTP-lesioned	mptp-lesioned	O
marmoset	marmoset	O
was	was	O
used	used	O
as	as	O
a	a	O
model	model	O
of	of	O
neuropsychiatric	neuropsychiatric	O
symptoms	symptoms	O
in	in	O
PD	pd	B-Disease
patients	patients	O
.	.	O

Here	here	O
we	we	O
compare	compare	O
the	the	O
time	time	O
course	course	O
of	of	O
levodopa-induced	levodopa-induced	O
motor	motor	O
fluctuations	fluctuations	O
and	and	O
neuropsychiatric-like	neuropsychiatric-like	O
behaviors	behaviors	O
to	to	O
determine	determine	O
the	the	O
relationship	relationship	O
between	between	O
duration	duration	O
of	of	O
treatment	treatment	O
and	and	O
onset	onset	O
of	of	O
symptoms	symptoms	O
.	.	O

METHODS	methods	O
:	:	O
Marmosets	marmosets	O
were	were	O
administered	administered	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	O
(	(	O
2.0	2.0	O
mg/kg	mg/kg	O
s.c	s.c	O
.	.	O
)	)	O
for	for	O
five	five	O
days	days	O
,	,	O
resulting	resulting	O
in	in	O
stable	stable	O
parkinsonism	parkinsonism	B-Disease
.	.	O

Levodopa	levodopa	B-Chemical
(	(	O
15	15	O
mg/kg	mg/kg	O
and	and	O
benserazide	benserazide	O
,	,	O
3.75	3.75	O
mg/kg	mg/kg	O
)	)	O
p.o	p.o	O
.	.	O

b.i.d	b.i.d	O
,	,	O
was	was	O
administered	administered	O
for	for	O
30	30	O
days	days	O
.	.	O

Animals	animals	O
were	were	O
evaluated	evaluated	O
for	for	O
parkinsonian	parkinsonian	B-Disease
disability	disability	O
,	,	O
dyskinesia	dyskinesia	B-Disease
and	and	O
on-time	on-time	O
(	(	O
motor	motor	O
fluctuations	fluctuations	O
)	)	O
and	and	O
neuropsychiatric-like	neuropsychiatric-like	O
behaviors	behaviors	O
on	on	O
Day	day	O
0	0	O
(	(	O
prior	prior	O
to	to	O
levodopa	levodopa	B-Chemical
)	)	O
and	and	O
on	on	O
Days	days	O
1	1	O
,	,	O
7	7	O
,	,	O
13	13	O
,	,	O
27	27	O
and	and	O
30	30	O
of	of	O
treatment	treatment	O
using	using	O
post	post	O
hoc	hoc	O
DVD	dvd	O
analysis	analysis	O
by	by	O
a	a	O
trained	trained	O
rater	rater	O
,	,	O
blind	blind	O
to	to	O
the	the	O
treatment	treatment	O
day	day	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
neuropsychiatric-like	neuropsychiatric-like	O
behavior	behavior	O
rating	rating	O
scale	scale	O
demonstrated	demonstrated	O
high	high	O
interrater	interrater	O
reliability	reliability	O
between	between	O
three	three	O
trained	trained	O
raters	raters	O
of	of	O
differing	differing	O
professional	professional	O
backgrounds	backgrounds	O
.	.	O

As	as	O
anticipated	anticipated	O
,	,	O
animals	animals	O
exhibited	exhibited	O
a	a	O
progressive	progressive	O
increase	increase	O
in	in	O
levodopa-induced	levodopa-induced	O
motor	motor	O
fluctuations	fluctuations	O
,	,	O
dyskinesia	dyskinesia	B-Disease
and	and	O
wearing-off	wearing-off	O
,	,	O
that	that	O
correlated	correlated	O
with	with	O
the	the	O
duration	duration	O
of	of	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
.	.	O

In	in	O
contrast	contrast	O
,	,	O
levodopa-induced	levodopa-induced	O
neuropsychiatric-like	neuropsychiatric-like	O
behaviors	behaviors	O
were	were	O
present	present	O
on	on	O
Day	day	O
1	1	O
of	of	O
levodopa	levodopa	B-Chemical
treatment	treatment	O
and	and	O
their	their	O
severity	severity	O
did	did	O
not	not	O
correlate	correlate	O
with	with	O
duration	duration	O
of	of	O
treatment	treatment	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
data	data	O
suggest	suggest	O
that	that	O
neuropsychiatric	neuropsychiatric	O
disorders	disorders	O
in	in	O
PD	pd	B-Disease
are	are	O
more	more	O
likely	likely	O
an	an	O
interaction	interaction	O
between	between	O
levodopa	levodopa	B-Chemical
and	and	O
the	the	O
disease	disease	O
state	state	O
than	than	O
a	a	O
consequence	consequence	O
of	of	O
sensitisation	sensitisation	O
to	to	O
repeated	repeated	O
dopaminergic	dopaminergic	O
therapy	therapy	O
.	.	O

Contrast	contrast	O
medium	medium	O
nephrotoxicity	nephrotoxicity	B-Disease
after	after	O
renal	renal	O
artery	artery	O
and	and	O
coronary	coronary	O
angioplasty	angioplasty	O
.	.	O

BACKGROUND	background	O
:	:	O
Renal	renal	B-Disease
dysfunction	dysfunction	I-Disease
induced	induced	O
by	by	O
iodinated	iodinated	O
contrast	contrast	O
medium	medium	O
(	(	O
CM	cm	B-Disease
)	)	O
administration	administration	O
can	can	O
minimize	minimize	O
the	the	O
benefit	benefit	O
of	of	O
the	the	O
interventional	interventional	O
procedure	procedure	O
in	in	O
patients	patients	O
undergoing	undergoing	O
renal	renal	O
angioplasty	angioplasty	O
(	(	O
PTRA	ptra	O
)	)	O
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
compare	compare	O
the	the	O
susceptibility	susceptibility	O
to	to	O
nephrotoxic	nephrotoxic	B-Disease
effect	effect	O
of	of	O
CM	cm	B-Disease
in	in	O
patients	patients	O
undergoing	undergoing	O
PTRA	ptra	O
with	with	O
that	that	O
of	of	O
patients	patients	O
submitted	submitted	O
to	to	O
percutaneous	percutaneous	O
coronary	coronary	O
intervention	intervention	O
(	(	O
PCI	pci	O
)	)	O
.	.	O

MATERIAL	material	O
AND	and	O
METHODS	methods	O
:	:	O
A	a	O
total	total	O
of	of	O
33	33	O
patients	patients	O
successfully	successfully	O
treated	treated	O
with	with	O
PTRA	ptra	O
(	(	O
PTRA	ptra	O
group	group	O
,	,	O
mean	mean	O
age	age	O
70+/-12	70+/-12	O
years	years	O
,	,	O
23	23	O
female	female	O
,	,	O
basal	basal	O
creatinine	creatinine	B-Chemical
1.46+/-0.79	1.46+/-0.79	O
,	,	O
range	range	O
0.7	0.7	O
-	-	O
4.9	4.9	O
mg/dl	mg/dl	O
)	)	O
were	were	O
compared	compared	O
with	with	O
33	33	O
patients	patients	O
undergoing	undergoing	O
successful	successful	O
PCI	pci	O
(	(	O
PCI	pci	O
group	group	O
)	)	O
,	,	O
matched	matched	O
for	for	O
basal	basal	O
creatinine	creatinine	B-Chemical
(	(	O
1.44+/-0.6	1.44+/-0.6	O
,	,	O
range	range	O
0.7	0.7	O
-	-	O
3.4	3.4	O
mg/dl	mg/dl	O
)	)	O
,	,	O
gender	gender	O
,	,	O
and	and	O
age	age	O
.	.	O

In	in	O
both	both	O
groups	groups	O
postprocedural	postprocedural	O
(	(	O
48	48	O
h	h	B-Chemical
)	)	O
serum	serum	O
creatinine	creatinine	B-Chemical
was	was	O
measured	measured	O
.	.	O

RESULTS	results	O
:	:	O
Postprocedural	postprocedural	O
creatinine	creatinine	B-Chemical
level	level	O
decreased	decreased	O
nonsignificantly	nonsignificantly	O
in	in	O
the	the	O
PTRA	ptra	O
group	group	O
(	(	O
1.46+/-0.8	1.46+/-0.8	O
vs.	vs.	O
1.34+/-0.5	1.34+/-0.5	O
mg/dl	mg/dl	O
,	,	O
P	p	O
=	=	O
NS	ns	O
)	)	O
and	and	O
increased	increased	O
significantly	significantly	O
in	in	O
the	the	O
PCI	pci	O
group	group	O
(	(	O
1.44+/-0.6	1.44+/-0.6	O
vs.	vs.	O
1.57+/-0.7	1.57+/-0.7	O
mg/dl	mg/dl	O
,	,	O
P<0.02	p<0.02	O
)	)	O
.	.	O

Changes	changes	O
in	in	O
serum	serum	O
creatinine	creatinine	B-Chemical
after	after	O
intervention	intervention	O
(	(	O
after-before	after-before	O
)	)	O
were	were	O
significantly	significantly	O
different	different	O
between	between	O
the	the	O
PTRA	ptra	O
and	and	O
PCI	pci	O
groups	groups	O
(	(	O
-0.12+/-0.5	-0.12+/-0.5	O
vs.	vs.	O
0.13+/-0.3	0.13+/-0.3	O
,	,	O
P=0.014	p=0.014	O
)	)	O
.	.	O

This	this	O
difference	difference	O
was	was	O
not	not	O
related	related	O
to	to	O
either	either	O
a	a	O
different	different	O
clinical	clinical	O
risk	risk	O
profile	profile	O
or	or	O
to	to	O
the	the	O
volume	volume	O
of	of	O
CM	cm	B-Disease
administered	administered	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
In	in	O
this	this	O
preliminary	preliminary	O
study	study	O
patients	patients	O
submitted	submitted	O
to	to	O
PTRA	ptra	O
showed	showed	O
a	a	O
lower	lower	O
susceptibility	susceptibility	O
to	to	O
renal	renal	B-Disease
damage	damage	I-Disease
induced	induced	O
by	by	O
CM	cm	B-Disease
administration	administration	O
than	than	O
PCI	pci	O
patients	patients	O
.	.	O

The	the	O
effectiveness	effectiveness	O
of	of	O
PTRA	ptra	O
on	on	O
renal	renal	O
function	function	O
seems	seems	O
to	to	O
be	be	O
barely	barely	O
influenced	influenced	O
by	by	O
CM	cm	B-Disease
toxicity	toxicity	B-Disease
.	.	O

Diphenhydramine	diphenhydramine	O
prevents	prevents	O
the	the	O
haemodynamic	haemodynamic	O
changes	changes	O
of	of	O
cimetidine	cimetidine	B-Chemical
in	in	O
ICU	icu	O
patients	patients	O
.	.	O

Cimetidine	cimetidine	B-Chemical
,	,	O
a	a	O
histamine	histamine	B-Chemical
2	2	O
(	(	O
H2	h2	O
)	)	O
antagonist	antagonist	O
,	,	O
produces	produces	O
a	a	O
decrease	decrease	O
in	in	O
arterial	arterial	O
pressure	pressure	O
due	due	O
to	to	O
vasodilatation	vasodilatation	O
,	,	O
especially	especially	O
in	in	O
critically	critically	O
ill	ill	O
patients	patients	O
.	.	O

This	this	O
may	may	O
be	be	O
because	because	O
cimetidine	cimetidine	B-Chemical
acts	acts	O
as	as	O
a	a	O
histamine	histamine	B-Chemical
agonist	agonist	O
.	.	O

We	we	O
,	,	O
therefore	therefore	O
,	,	O
investigated	investigated	O
the	the	O
effects	effects	O
of	of	O
the	the	O
histamine	histamine	B-Chemical
1(H1	1(h1	O
)	)	O
receptor	receptor	O
antagonist	antagonist	O
,	,	O
diphenhydramine	diphenhydramine	O
,	,	O
on	on	O
the	the	O
haemodynamic	haemodynamic	O
changes	changes	O
observed	observed	O
after	after	O
cimetidine	cimetidine	B-Chemical
in	in	O
ICU	icu	O
patients	patients	O
.	.	O

Each	each	O
patient	patient	O
was	was	O
studied	studied	O
on	on	O
two	two	O
separate	separate	O
days	days	O
.	.	O

In	in	O
a	a	O
random	random	O
fashion	fashion	O
,	,	O
they	they	O
received	received	O
cimetidine	cimetidine	B-Chemical
200	200	O
mg	mg	O
iv	iv	O
on	on	O
one	one	O
day	day	O
,	,	O
and	and	O
on	on	O
the	the	O
other	other	O
,	,	O
a	a	O
pretreatment	pretreatment	O
of	of	O
diphenhydramine	diphenhydramine	O
40	40	O
mg	mg	O
iv	iv	O
with	with	O
cimetidine	cimetidine	B-Chemical
200	200	O
mg	mg	O
iv	iv	O
.	.	O

In	in	O
the	the	O
non-pretreatment	non-pretreatment	O
group	group	O
,	,	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
(	(	O
MAP	map	O
)	)	O
decreased	decreased	O
from	from	O
107.4	107.4	O
+	+	O
/-	/-	O
8.4	8.4	O
mmHg	mmhg	O
to	to	O
86.7	86.7	O
+	+	O
/-	/-	O
11.4	11.4	O
mmHg	mmhg	O
(	(	O
P	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
two	two	O
minutes	minutes	O
after	after	O
cimetidine	cimetidine	B-Chemical
.	.	O

Also	also	O
,	,	O
systemic	systemic	O
vascular	vascular	O
resistance	resistance	O
(	(	O
SVR	svr	O
)	)	O
decreased	decreased	O
during	during	O
the	the	O
eight-minute	eight-minute	O
observation	observation	O
period	period	O
(	(	O
P	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
.	.	O

In	in	O
contrast	contrast	O
,	,	O
in	in	O
the	the	O
pretreatment	pretreatment	O
group	group	O
,	,	O
little	little	O
haemodynamic	haemodynamic	O
change	change	O
was	was	O
seen	seen	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
an	an	O
H1	h1	O
antagonist	antagonist	O
may	may	O
be	be	O
useful	useful	O
in	in	O
preventing	preventing	O
hypotension	hypotension	B-Disease
caused	caused	O
by	by	O
iv	iv	O
cimetidine	cimetidine	B-Chemical
,	,	O
since	since	O
the	the	O
vasodilating	vasodilating	O
activity	activity	O
of	of	O
cimetidine	cimetidine	B-Chemical
is	is	O
mediated	mediated	O
,	,	O
in	in	O
part	part	O
,	,	O
through	through	O
the	the	O
H1	h1	O
receptor	receptor	O
.	.	O

Medical	medical	O
and	and	O
psychiatric	psychiatric	B-Disease
outcomes	outcomes	O
for	for	O
patients	patients	O
transplanted	transplanted	O
for	for	O
acetaminophen-induced	acetaminophen-induced	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
:	:	O
a	a	O
case-control	case-control	O
study	study	O
.	.	O

BACKGROUND	background	O
:	:	O
Acetaminophen-induced	acetaminophen-induced	O
hepatotoxicity	hepatotoxicity	B-Disease
is	is	O
the	the	O
most	most	O
common	common	O
cause	cause	O
of	of	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
(	(	O
ALF	alf	B-Disease
)	)	O
in	in	O
the	the	O
UK	uk	O
.	.	O

Patients	patients	O
often	often	O
consume	consume	O
the	the	O
drug	drug	O
with	with	O
suicidal	suicidal	O
intent	intent	O
or	or	O
with	with	O
a	a	O
background	background	O
of	of	O
substance	substance	O
dependence	dependence	O
.	.	O

AIMS	aims	O
AND	and	O
METHODS	methods	O
:	:	O
We	we	O
compared	compared	O
the	the	O
severity	severity	O
of	of	O
pretransplant	pretransplant	O
illness	illness	O
,	,	O
psychiatric	psychiatric	B-Disease
co-morbidity	co-morbidity	O
,	,	O
medical	medical	O
and	and	O
psychosocial	psychosocial	O
outcomes	outcomes	O
of	of	O
all	all	O
patients	patients	O
who	who	O
had	had	O
undergone	undergone	O
liver	liver	O
transplantation	transplantation	O
(	(	O
LT	lt	O
)	)	O
emergently	emergently	O
between	between	O
1999	1999	O
-	-	O
2004	2004	O
for	for	O
acetaminophen-induced	acetaminophen-induced	O
ALF	alf	B-Disease
(	(	O
n=36	n=36	O
)	)	O
with	with	O
age-	age-	O
and	and	O
sex-matched	sex-matched	O
patients	patients	O
undergoing	undergoing	O
emergent	emergent	O
LT	lt	O
for	for	O
non-acetaminophen-induced	non-acetaminophen-induced	O
ALF	alf	B-Disease
(	(	O
n=35	n=35	O
)	)	O
and	and	O
elective	elective	O
LT	lt	O
for	for	O
chronic	chronic	O
liver	liver	B-Disease
disease	disease	I-Disease
(	(	O
CLD	cld	O
,	,	O
n=34	n=34	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
Acetaminophen-induced	acetaminophen-induced	O
ALF	alf	B-Disease
patients	patients	O
undergoing	undergoing	O
LT	lt	O
had	had	O
a	a	O
greater	greater	O
severity	severity	O
of	of	O
pre-LT	pre-lt	O
illness	illness	O
reflected	reflected	O
by	by	O
higher	higher	O
Acute	acute	O
Physiology	physiology	O
and	and	O
Chronic	chronic	O
Health	health	O
Evaluation	evaluation	O
II	ii	O
scores	scores	O
and	and	O
requirement	requirement	O
for	for	O
organ	organ	O
support	support	O
compared	compared	O
with	with	O
the	the	O
other	other	O
two	two	O
groups	groups	O
.	.	O

Twenty	twenty	O
(	(	O
56	56	O
%	%	O
)	)	O
acetaminophen-induced	acetaminophen-induced	O
ALF	alf	B-Disease
patients	patients	O
had	had	O
a	a	O
formal	formal	O
psychiatric	psychiatric	B-Disease
diagnosis	diagnosis	I-Disease
before	before	O
LT	lt	O
(	(	O
non-acetaminophen-induced	non-acetaminophen-induced	O
ALF=0/35	alf=0/35	O
,	,	O
CLD=2/34	cld=2/34	O
;	;	O
P<0.01	p<0.01	O
for	for	O
all	all	O
)	)	O
and	and	O
nine	nine	O
(	(	O
25	25	O
%	%	O
)	)	O
had	had	O
a	a	O
previous	previous	O
suicide	suicide	O
attempt	attempt	O
.	.	O

During	during	O
follow-up	follow-up	O
(	(	O
median	median	O
5	5	O
years	years	O
)	)	O
,	,	O
there	there	O
were	were	O
no	no	O
significant	significant	O
differences	differences	O
in	in	O
rejection	rejection	O
(	(	O
acute	acute	O
and	and	O
chronic	chronic	O
)	)	O
,	,	O
graft	graft	O
failure	failure	O
or	or	O
survival	survival	O
between	between	O
the	the	O
groups	groups	O
(	(	O
acetaminophen-induced	acetaminophen-induced	O
ALF	alf	B-Disease
1	1	O
year	year	O
87	87	O
%	%	O
,	,	O
5	5	O
years	years	O
75	75	O
%	%	O
;	;	O
non-acetaminophen-induced	non-acetaminophen-induced	O
ALF	alf	B-Disease
88	88	O
%	%	O
,	,	O
78	78	O
%	%	O
;	;	O
CLD	cld	O
93	93	O
%	%	O
,	,	O
82	82	O
%	%	O
:	:	O
P>0.6	p>0.6	O
log	log	O
rank	rank	O
)	)	O
.	.	O

Two	two	O
acetaminophen-induced	acetaminophen-induced	O
ALF	alf	B-Disease
patients	patients	O
reattempted	reattempted	O
suicide	suicide	O
post-LT	post-lt	O
(	(	O
one	one	O
died	died	O
8	8	O
years	years	O
post-LT	post-lt	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Despite	despite	O
a	a	O
high	high	O
prevalence	prevalence	O
of	of	O
psychiatric	psychiatric	B-Disease
disturbance	disturbance	O
,	,	O
outcomes	outcomes	O
for	for	O
patients	patients	O
transplanted	transplanted	O
emergently	emergently	O
for	for	O
acetaminophen-induced	acetaminophen-induced	O
ALF	alf	B-Disease
were	were	O
comparable	comparable	O
to	to	O
those	those	O
transplanted	transplanted	O
for	for	O
non-acetaminophen-induced	non-acetaminophen-induced	O
ALF	alf	B-Disease
and	and	O
electively	electively	O
for	for	O
CLD	cld	O
.	.	O

Multidisciplinary	multidisciplinary	O
approaches	approaches	O
with	with	O
long-term	long-term	O
psychiatric	psychiatric	B-Disease
follow-up	follow-up	O
may	may	O
contribute	contribute	O
to	to	O
low	low	O
post-transplant	post-transplant	O
suicide	suicide	O
rates	rates	O
seen	seen	O
and	and	O
low	low	O
rates	rates	O
of	of	O
graft	graft	O
loss	loss	O
because	because	O
of	of	O
non-compliance	non-compliance	O
.	.	O

Antithrombotic	antithrombotic	O
drug	drug	O
use	use	O
,	,	O
cerebral	cerebral	O
microbleeds	microbleeds	O
,	,	O
and	and	O
intracerebral	intracerebral	B-Disease
hemorrhage	hemorrhage	B-Disease
:	:	O
a	a	O
systematic	systematic	O
review	review	O
of	of	O
published	published	O
and	and	O
unpublished	unpublished	O
studies	studies	O
.	.	O

BACKGROUND	background	O
AND	and	O
PURPOSE	purpose	O
:	:	O
Cerebral	cerebral	O
microbleeds	microbleeds	O
(	(	O
MB	mb	O
)	)	O
are	are	O
potential	potential	O
risk	risk	O
factors	factors	O
for	for	O
intracerebral	intracerebral	B-Disease
hemorrhage	hemorrhage	B-Disease
(	(	O
ICH	ich	B-Disease
)	)	O
,	,	O
but	but	O
it	it	O
is	is	O
unclear	unclear	O
if	if	O
they	they	O
are	are	O
a	a	O
contraindication	contraindication	O
to	to	O
using	using	O
antithrombotic	antithrombotic	O
drugs	drugs	O
.	.	O

Insights	insights	O
could	could	O
be	be	O
gained	gained	O
by	by	O
pooling	pooling	O
data	data	O
on	on	O
MB	mb	O
frequency	frequency	O
stratified	stratified	O
by	by	O
antithrombotic	antithrombotic	O
use	use	O
in	in	O
cohorts	cohorts	O
with	with	O
ICH	ich	B-Disease
and	and	O
ischemic	ischemic	B-Disease
stroke	stroke	B-Disease
(IS)/transient	(is)/transient	O
ischemic	ischemic	O
attack	attack	O
(	(	O
TIA	tia	O
)	)	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
performed	performed	O
a	a	O
systematic	systematic	O
review	review	O
of	of	O
published	published	O
and	and	O
unpublished	unpublished	O
data	data	O
from	from	O
cohorts	cohorts	O
with	with	O
stroke	stroke	B-Disease
or	or	O
TIA	tia	O
to	to	O
compare	compare	O
the	the	O
presence	presence	O
of	of	O
MB	mb	O
in	in	O
:	:	O
(	(	O
1	1	O
)	)	O
antithrombotic	antithrombotic	O
users	users	O
vs	vs	O
nonantithrombotic	nonantithrombotic	O
users	users	O
with	with	O
ICH	ich	B-Disease
;	;	O
(	(	O
2	2	O
)	)	O
antithrombotic	antithrombotic	O
users	users	O
vs	vs	O
nonusers	nonusers	O
with	with	O
IS/TIA	is/tia	O
;	;	O
and	and	O
(	(	O
3	3	O
)	)	O
ICH	ich	B-Disease
vs	vs	O
ischemic	ischemic	O
events	events	O
stratified	stratified	O
by	by	O
antithrombotic	antithrombotic	O
use	use	O
.	.	O

We	we	O
also	also	O
analyzed	analyzed	O
published	published	O
and	and	O
unpublished	unpublished	O
follow-up	follow-up	O
data	data	O
to	to	O
determine	determine	O
the	the	O
risk	risk	O
of	of	O
ICH	ich	B-Disease
in	in	O
antithrombotic	antithrombotic	O
users	users	O
with	with	O
MB	mb	O
.	.	O

RESULTS	results	O
:	:	O
In	in	O
a	a	O
pooled	pooled	O
analysis	analysis	O
of	of	O
1460	1460	O
ICH	ich	B-Disease
and	and	O
3817	3817	O
IS/TIA	is/tia	O
,	,	O
MB	mb	O
were	were	O
more	more	O
frequent	frequent	O
in	in	O
ICH	ich	B-Disease
vs	vs	O
IS/TIA	is/tia	O
in	in	O
all	all	O
treatment	treatment	O
groups	groups	O
,	,	O
but	but	O
the	the	O
excess	excess	O
increased	increased	O
from	from	O
2.8	2.8	O
(	(	O
odds	odds	O
ratio	ratio	O
;	;	O
range	range	O
,	,	O
2.3	2.3	O
-	-	O
3.5	3.5	O
)	)	O
in	in	O
nonantithrombotic	nonantithrombotic	O
users	users	O
to	to	O
5.7	5.7	O
(	(	O
range	range	O
,	,	O
3.4	3.4	O
-	-	O
9.7	9.7	O
)	)	O
in	in	O
antiplatelet	antiplatelet	O
users	users	O
and	and	O
8.0	8.0	O
(	(	O
range	range	O
,	,	O
3.5	3.5	O
-	-	O
17.8	17.8	O
)	)	O
in	in	O
warfarin	warfarin	B-Chemical
users	users	O
(	(	O
P	p	O
difference=0.01	difference=0.01	O
)	)	O
.	.	O

There	there	O
was	was	O
also	also	O
an	an	O
excess	excess	O
of	of	O
MB	mb	O
in	in	O
warfarin	warfarin	B-Chemical
users	users	O
vs	vs	O
nonusers	nonusers	O
with	with	O
ICH	ich	B-Disease
(	(	O
OR	or	O
,	,	O
2.7	2.7	O
;	;	O
95	95	O
%	%	O
CI	ci	O
,	,	O
1.6	1.6	O
-	-	O
4.4	4.4	O
;	;	O
P<0.001	p<0.001	O
)	)	O
but	but	O
none	none	O
in	in	O
warfarin	warfarin	B-Chemical
users	users	O
with	with	O
IS/TIA	is/tia	O
(	(	O
OR	or	O
,	,	O
1.3	1.3	O
;	;	O
95	95	O
%	%	O
CI	ci	O
,	,	O
0.9	0.9	O
-	-	O
1.7	1.7	O
;	;	O
P=0.33	p=0.33	O
;	;	O
P	p	O
difference=0.01	difference=0.01	O
)	)	O
.	.	O

There	there	O
was	was	O
a	a	O
smaller	smaller	O
excess	excess	O
of	of	O
MB	mb	O
in	in	O
antiplatelet	antiplatelet	O
users	users	O
vs	vs	O
nonusers	nonusers	O
with	with	O
ICH	ich	B-Disease
(	(	O
OR	or	O
,	,	O
1.7	1.7	O
;	;	O
95	95	O
%	%	O
CI	ci	O
,	,	O
1.3	1.3	O
-	-	O
2.3	2.3	O
;	;	O
P<0.001	p<0.001	O
)	)	O
,	,	O
but	but	O
findings	findings	O
were	were	O
similar	similar	O
for	for	O
antiplatelet	antiplatelet	O
users	users	O
with	with	O
IS/TIA	is/tia	O
(	(	O
OR	or	O
,	,	O
1.4	1.4	O
;	;	O
95	95	O
%	%	O
CI	ci	O
,	,	O
1.2	1.2	O
-	-	O
1.7	1.7	O
;	;	O
P<0.001	p<0.001	O
;	;	O
P	p	O
difference=0.25	difference=0.25	O
)	)	O
.	.	O

In	in	O
pooled	pooled	O
follow-up	follow-up	O
data	data	O
for	for	O
768	768	O
antithrombotic	antithrombotic	O
users	users	O
,	,	O
presence	presence	O
of	of	O
MB	mb	O
at	at	O
baseline	baseline	O
was	was	O
associated	associated	O
with	with	O
a	a	O
substantially	substantially	O
increased	increased	O
risk	risk	O
of	of	O
subsequent	subsequent	O
ICH	ich	B-Disease
(	(	O
OR	or	O
,	,	O
12.1	12.1	O
;	;	O
95	95	O
%	%	O
CI	ci	O
,	,	O
3.4	3.4	O
-	-	O
42.5	42.5	O
;	;	O
P<0.001	p<0.001	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
excess	excess	O
of	of	O
MB	mb	O
in	in	O
warfarin	warfarin	B-Chemical
users	users	O
with	with	O
ICH	ich	B-Disease
compared	compared	O
to	to	O
other	other	O
groups	groups	O
suggests	suggests	O
that	that	O
MB	mb	O
increase	increase	O
the	the	O
risk	risk	O
of	of	O
warfarin-associated	warfarin-associated	O
ICH	ich	B-Disease
.	.	O

Limited	limited	O
prospective	prospective	O
data	data	O
corroborate	corroborate	O
these	these	O
findings	findings	O
,	,	O
but	but	O
larger	larger	O
prospective	prospective	O
studies	studies	O
are	are	O
urgently	urgently	O
required	required	O
.	.	O

Studies	studies	O
of	of	O
synergy	synergy	O
between	between	O
morphine	morphine	B-Chemical
and	and	O
a	a	O
novel	novel	O
sodium	sodium	B-Chemical
channel	channel	O
blocker	blocker	O
,	,	O
CNSB002	cnsb002	O
,	,	O
in	in	O
rat	rat	O
models	models	O
of	of	O
inflammatory	inflammatory	O
and	and	O
neuropathic	neuropathic	B-Disease
pain	pain	B-Disease
.	.	O

OBJECTIVE	objective	O
:	:	O
This	this	O
study	study	O
determined	determined	O
the	the	O
antihyperalgesic	antihyperalgesic	O
effect	effect	O
of	of	O
CNSB002	cnsb002	O
,	,	O
a	a	O
sodium	sodium	B-Chemical
channel	channel	O
blocker	blocker	O
with	with	O
antioxidant	antioxidant	O
properties	properties	O
given	given	O
alone	alone	O
and	and	O
in	in	O
combinations	combinations	O
with	with	O
morphine	morphine	B-Chemical
in	in	O
rat	rat	O
models	models	O
of	of	O
inflammatory	inflammatory	O
and	and	O
neuropathic	neuropathic	B-Disease
pain	pain	B-Disease
.	.	O

DESIGN	design	O
:	:	O
Dose	dose	O
response	response	O
curves	curves	O
for	for	O
nonsedating	nonsedating	O
doses	doses	O
of	of	O
morphine	morphine	B-Chemical
and	and	O
CNSB002	cnsb002	O
given	given	O
intraperitoneally	intraperitoneally	O
alone	alone	O
and	and	O
together	together	O
in	in	O
combinations	combinations	O
were	were	O
constructed	constructed	O
for	for	O
antihyperalgesic	antihyperalgesic	O
effect	effect	O
using	using	O
paw	paw	O
withdrawal	withdrawal	O
from	from	O
noxious	noxious	O
heat	heat	O
in	in	O
two	two	O
rat	rat	O
pain	pain	B-Disease
models	models	O
:	:	O
carrageenan-induced	carrageenan-induced	O
paw	paw	O
inflammation	inflammation	B-Disease
and	and	O
streptozotocin	streptozotocin	B-Chemical
(STZ)-induced	(stz)-induced	O
diabetic	diabetic	B-Disease
neuropathy	neuropathy	B-Disease
.	.	O

RESULTS	results	O
:	:	O
The	the	O
maximum	maximum	O
nonsedating	nonsedating	O
doses	doses	O
were	were	O
:	:	O
morphine	morphine	B-Chemical
,	,	O
3.2	3.2	O
mg/kg	mg/kg	O
;	;	O
CNSB002	cnsb002	O
10.0	10.0	O
mg/kg	mg/kg	O
;	;	O
5.0	5.0	O
mg/kg	mg/kg	O
CNSB002	cnsb002	O
with	with	O
morphine	morphine	B-Chemical
3.2	3.2	O
mg/kg	mg/kg	O
in	in	O
combination	combination	O
.	.	O

The	the	O
doses	doses	O
calculated	calculated	O
to	to	O
cause	cause	O
50	50	O
%	%	O
reversal	reversal	O
of	of	O
hyperalgesia	hyperalgesia	B-Disease
(	(	O
ED50	ed50	O
)	)	O
were	were	O
7.54	7.54	O
(	(	O
1.81	1.81	O
)	)	O
and	and	O
4.83	4.83	O
(	(	O
1.54	1.54	O
)	)	O
in	in	O
the	the	O
carrageenan	carrageenan	O
model	model	O
and	and	O
44.18	44.18	O
(	(	O
1.37	1.37	O
)	)	O
and	and	O
9.14	9.14	O
(	(	O
1.24	1.24	O
)	)	O
in	in	O
the	the	O
STZ-induced	stz-induced	O
neuropathy	neuropathy	B-Disease
model	model	O
for	for	O
CNSB002	cnsb002	O
and	and	O
morphine	morphine	B-Chemical
,	,	O
respectively	respectively	O
(	(	O
mg/kg	mg/kg	O
;	;	O
mean	mean	O
,	,	O
SEM	sem	O
)	)	O
.	.	O

These	these	O
values	values	O
were	were	O
greater	greater	O
than	than	O
the	the	O
maximum	maximum	O
nonsedating	nonsedating	O
doses	doses	O
.	.	O

The	the	O
ED50	ed50	O
values	values	O
for	for	O
morphine	morphine	B-Chemical
when	when	O
given	given	O
in	in	O
combination	combination	O
with	with	O
CNSB002	cnsb002	O
(	(	O
5	5	O
mg/kg	mg/kg	O
)	)	O
were	were	O
less	less	O
than	than	O
the	the	O
maximum	maximum	O
nonsedating	nonsedating	O
dose	dose	O
:	:	O
0.56	0.56	O
(	(	O
1.55	1.55	O
)	)	O
in	in	O
the	the	O
carrageenan	carrageenan	O
model	model	O
and	and	O
1.37	1.37	O
(	(	O
1.23	1.23	O
)	)	O
in	in	O
the	the	O
neuropathy	neuropathy	B-Disease
model	model	O
(	(	O
mg/kg	mg/kg	O
;	;	O
mean	mean	O
,	,	O
SEM	sem	O
)	)	O
.	.	O

The	the	O
antinociception	antinociception	O
after	after	O
morphine	morphine	B-Chemical
(	(	O
3.2	3.2	O
mg/kg	mg/kg	O
)	)	O
was	was	O
increased	increased	O
by	by	O
co-administration	co-administration	O
with	with	O
CNSB002	cnsb002	O
from	from	O
28.0	28.0	O
and	and	O
31.7	31.7	O
%	%	O
to	to	O
114.6	114.6	O
and	and	O
56.9	56.9	O
%	%	O
reversal	reversal	O
of	of	O
hyperalgesia	hyperalgesia	B-Disease
in	in	O
the	the	O
inflammatory	inflammatory	O
and	and	O
neuropathic	neuropathic	O
models	models	O
,	,	O
respectively	respectively	O
(	(	O
P	p	O
<	<	O
0.01	0.01	O
;	;	O
one-way	one-way	O
analysis	analysis	O
of	of	O
variance-significantly	variance-significantly	O
greater	greater	O
than	than	O
either	either	O
drug	drug	O
given	given	O
alone	alone	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
maximum	maximum	O
antihyperalgesic	antihyperalgesic	O
effect	effect	O
achievable	achievable	O
with	with	O
nonsedating	nonsedating	O
doses	doses	O
of	of	O
morphine	morphine	B-Chemical
may	may	O
be	be	O
increased	increased	O
significantly	significantly	O
when	when	O
the	the	O
drug	drug	O
is	is	O
used	used	O
in	in	O
combination	combination	O
with	with	O
CNSB002	cnsb002	O
.	.	O

Heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
:	:	O
a	a	O
practical	practical	O
review	review	O
.	.	O

Heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
(	(	O
HIT	hit	B-Disease
)	)	O
remains	remains	O
under-recognized	under-recognized	O
despite	despite	O
its	its	O
potentially	potentially	O
devastating	devastating	O
outcomes	outcomes	O
.	.	O

It	it	O
begins	begins	O
when	when	O
heparin	heparin	B-Chemical
exposure	exposure	O
stimulates	stimulates	O
the	the	O
formation	formation	O
of	of	O
heparin-platelet	heparin-platelet	O
factor	factor	O
4	4	O
antibodies	antibodies	O
,	,	O
which	which	O
in	in	O
turn	turn	O
triggers	triggers	O
the	the	O
release	release	O
of	of	O
procoagulant	procoagulant	O
platelet	platelet	O
particles	particles	O
.	.	O

Thrombosis	thrombosis	B-Disease
and	and	O
thrombocytopenia	thrombocytopenia	B-Disease
that	that	O
follow	follow	O
comprise	comprise	O
the	the	O
2	2	O
hallmark	hallmark	O
traits	traits	O
of	of	O
HIT	hit	B-Disease
,	,	O
with	with	O
the	the	O
former	former	O
largely	largely	O
responsible	responsible	O
for	for	O
significant	significant	O
vascular	vascular	O
complications	complications	O
.	.	O

The	the	O
prevalence	prevalence	O
of	of	O
HIT	hit	B-Disease
varies	varies	O
among	among	O
several	several	O
subgroups	subgroups	O
,	,	O
with	with	O
greater	greater	O
incidence	incidence	O
in	in	O
surgical	surgical	O
as	as	O
compared	compared	O
with	with	O
medical	medical	O
populations	populations	O
.	.	O

HIT	hit	B-Disease
must	must	O
be	be	O
acknowledged	acknowledged	O
for	for	O
its	its	O
intense	intense	O
predilection	predilection	O
for	for	O
thrombosis	thrombosis	B-Disease
and	and	O
suspected	suspected	O
whenever	whenever	O
thrombosis	thrombosis	B-Disease
occurs	occurs	O
after	after	O
heparin	heparin	B-Chemical
exposure	exposure	O
.	.	O

Early	early	O
recognition	recognition	O
that	that	O
incorporates	incorporates	O
the	the	O
clinical	clinical	O
and	and	O
serologic	serologic	O
clues	clues	O
is	is	O
paramount	paramount	O
to	to	O
timely	timely	O
institution	institution	O
of	of	O
treatment	treatment	O
,	,	O
as	as	O
its	its	O
delay	delay	O
may	may	O
result	result	O
in	in	O
catastrophic	catastrophic	O
outcomes	outcomes	O
.	.	O

The	the	O
treatment	treatment	O
of	of	O
HIT	hit	B-Disease
mandates	mandates	O
an	an	O
immediate	immediate	O
cessation	cessation	O
of	of	O
all	all	O
heparin	heparin	B-Chemical
exposure	exposure	O
and	and	O
the	the	O
institution	institution	O
of	of	O
an	an	O
antithrombotic	antithrombotic	O
therapy	therapy	O
,	,	O
most	most	O
commonly	commonly	O
using	using	O
a	a	O
direct	direct	O
thrombin	thrombin	O
inhibitor	inhibitor	O
.	.	O

Current	current	O
"	"	O
diagnostic	diagnostic	O
"	"	O
tests	tests	O
,	,	O
which	which	O
primarily	primarily	O
include	include	O
functional	functional	O
and	and	O
antigenic	antigenic	O
assays	assays	O
,	,	O
have	have	O
more	more	O
of	of	O
a	a	O
confirmatory	confirmatory	O
than	than	O
diagnostic	diagnostic	O
role	role	O
in	in	O
the	the	O
management	management	O
of	of	O
HIT	hit	B-Disease
.	.	O

Special	special	O
attention	attention	O
must	must	O
be	be	O
paid	paid	O
to	to	O
cardiac	cardiac	O
patients	patients	O
who	who	O
are	are	O
often	often	O
exposed	exposed	O
to	to	O
heparin	heparin	B-Chemical
multiple	multiple	O
times	times	O
during	during	O
their	their	O
course	course	O
of	of	O
treatment	treatment	O
.	.	O

Direct	direct	O
thrombin	thrombin	O
inhibitors	inhibitors	O
are	are	O
appropriate	appropriate	O
,	,	O
evidence-based	evidence-based	O
alternatives	alternatives	O
to	to	O
heparin	heparin	B-Chemical
in	in	O
patients	patients	O
with	with	O
a	a	O
history	history	O
of	of	O
HIT	hit	B-Disease
,	,	O
who	who	O
need	need	O
to	to	O
undergo	undergo	O
percutaneous	percutaneous	O
coronary	coronary	O
intervention	intervention	O
.	.	O

As	as	O
heparin	heparin	B-Chemical
remains	remains	O
one	one	O
of	of	O
the	the	O
most	most	O
frequently	frequently	O
used	used	O
medications	medications	O
today	today	O
with	with	O
potential	potential	O
for	for	O
HIT	hit	B-Disease
with	with	O
every	every	O
heparin	heparin	B-Chemical
exposure	exposure	O
,	,	O
a	a	O
close	close	O
vigilance	vigilance	O
of	of	O
platelet	platelet	O
counts	counts	O
must	must	O
be	be	O
practiced	practiced	O
whenever	whenever	O
heparin	heparin	B-Chemical
is	is	O
initiated	initiated	O
.	.	O

Abductor	abductor	O
paralysis	paralysis	B-Disease
after	after	O
botox	botox	O
injection	injection	O
for	for	O
adductor	adductor	O
spasmodic	spasmodic	O
dysphonia	dysphonia	O
.	.	O

OBJECTIVES/HYPOTHESIS	objectives/hypothesis	O
:	:	O
Botulinum	botulinum	O
toxin	toxin	O
(	(	O
Botox	botox	O
)	)	O
injections	injections	O
into	into	O
the	the	O
thyroarytenoid	thyroarytenoid	O
muscles	muscles	O
are	are	O
the	the	O
current	current	O
standard	standard	O
of	of	O
care	care	O
for	for	O
adductor	adductor	O
spasmodic	spasmodic	O
dysphonia	dysphonia	O
(	(	O
ADSD	adsd	O
)	)	O
.	.	O

Reported	reported	O
adverse	adverse	O
effects	effects	O
include	include	O
a	a	O
period	period	O
of	of	O
breathiness	breathiness	O
,	,	O
throat	throat	O
pain	pain	B-Disease
,	,	O
and	and	O
difficulty	difficulty	O
with	with	O
swallowing	swallowing	O
liquids	liquids	O
.	.	O

Here	here	O
we	we	O
report	report	O
multiple	multiple	O
cases	cases	O
of	of	O
bilateral	bilateral	O
abductor	abductor	O
paralysis	paralysis	B-Disease
following	following	O
Botox	botox	O
injections	injections	O
for	for	O
ADSD	adsd	O
,	,	O
a	a	O
complication	complication	O
previously	previously	O
unreported	unreported	O
.	.	O

STUDY	study	O
DESIGN	design	O
:	:	O
Retrospective	retrospective	O
case	case	O
series	series	O
.	.	O

METHODS	methods	O
:	:	O
Patients	patients	O
that	that	O
received	received	O
Botox	botox	O
injections	injections	O
for	for	O
spasmodic	spasmodic	O
dysphonia	dysphonia	O
between	between	O
January	january	O
2000	2000	O
and	and	O
October	october	O
2009	2009	O
were	were	O
evaluated	evaluated	O
.	.	O

Patients	patients	O
with	with	O
ADSD	adsd	O
were	were	O
identified	identified	O
.	.	O

The	the	O
number	number	O
of	of	O
treatments	treatments	O
received	received	O
and	and	O
adverse	adverse	O
effects	effects	O
were	were	O
noted	noted	O
.	.	O

For	for	O
patients	patients	O
with	with	O
bilateral	bilateral	O
abductor	abductor	O
paralysis	paralysis	B-Disease
,	,	O
age	age	O
,	,	O
sex	sex	O
,	,	O
paralytic	paralytic	O
Botox	botox	O
dose	dose	O
,	,	O
prior	prior	O
Botox	botox	O
dose	dose	O
,	,	O
and	and	O
course	course	O
following	following	O
paralysis	paralysis	B-Disease
were	were	O
noted	noted	O
.	.	O

RESULTS	results	O
:	:	O
From	from	O
a	a	O
database	database	O
of	of	O
452	452	O
patients	patients	O
receiving	receiving	O
Botox	botox	O
,	,	O
352	352	O
patients	patients	O
had	had	O
been	been	O
diagnosed	diagnosed	O
with	with	O
ADSD	adsd	O
.	.	O

Of	of	O
these	these	O
352	352	O
patients	patients	O
,	,	O
eight	eight	O
patients	patients	O
suffered	suffered	O
bilateral	bilateral	O
abductor	abductor	O
paralysis	paralysis	B-Disease
,	,	O
and	and	O
two	two	O
suffered	suffered	O
this	this	O
complication	complication	O
twice	twice	O
.	.	O

All	all	O
affected	affected	O
patients	patients	O
were	were	O
females	females	O
over	over	O
the	the	O
age	age	O
of	of	O
50	50	O
years	years	O
.	.	O

Most	most	O
patients	patients	O
had	had	O
received	received	O
treatments	treatments	O
prior	prior	O
to	to	O
abductor	abductor	O
paralysis	paralysis	B-Disease
and	and	O
continued	continued	O
receiving	receiving	O
after	after	O
paralysis	paralysis	B-Disease
.	.	O

Seven	seven	O
patients	patients	O
recovered	recovered	O
after	after	O
a	a	O
brief	brief	O
period	period	O
of	of	O
activity	activity	O
restrictions	restrictions	O
,	,	O
and	and	O
one	one	O
underwent	underwent	O
a	a	O
tracheotomy	tracheotomy	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
abductor	abductor	O
paralysis	paralysis	B-Disease
after	after	O
Botox	botox	O
injection	injection	O
for	for	O
ADSD	adsd	O
was	was	O
0.34	0.34	O
%	%	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Bilateral	bilateral	O
abductor	abductor	O
paralysis	paralysis	B-Disease
is	is	O
a	a	O
rare	rare	O
complication	complication	O
of	of	O
Botox	botox	O
injections	injections	O
for	for	O
ADSD	adsd	O
,	,	O
causing	causing	O
difficulty	difficulty	O
with	with	O
breathing	breathing	O
upon	upon	O
exertion	exertion	O
.	.	O

The	the	O
likely	likely	O
mechanism	mechanism	O
of	of	O
paralysis	paralysis	B-Disease
is	is	O
diffusion	diffusion	O
of	of	O
Botox	botox	O
around	around	O
the	the	O
muscular	muscular	O
process	process	O
of	of	O
the	the	O
arytenoid	arytenoid	O
to	to	O
the	the	O
posterior	posterior	O
cricoarytenoid	cricoarytenoid	O
muscles	muscles	O
.	.	O

The	the	O
paralysis	paralysis	B-Disease
is	is	O
temporary	temporary	O
,	,	O
and	and	O
watchful	watchful	O
waiting	waiting	O
with	with	O
restriction	restriction	O
of	of	O
activity	activity	O
is	is	O
the	the	O
recommended	recommended	O
management	management	O
.	.	O

Mitochondrial	mitochondrial	O
impairment	impairment	O
contributes	contributes	O
to	to	O
cocaine-induced	cocaine-induced	O
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
:	:	O
Prevention	prevention	O
by	by	O
the	the	O
targeted	targeted	O
antioxidant	antioxidant	O
MitoQ.The	mitoq.the	O
goal	goal	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
assess	assess	O
mitochondrial	mitochondrial	O
function	function	O
and	and	O
ROS	ros	O
production	production	O
in	in	O
an	an	O
experimental	experimental	O
model	model	O
of	of	O
cocaine-induced	cocaine-induced	O
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
.	.	O

We	we	O
hypothesized	hypothesized	O
that	that	O
cocaine	cocaine	B-Chemical
abuse	abuse	I-Disease
may	may	O
lead	lead	O
to	to	O
altered	altered	O
mitochondrial	mitochondrial	O
function	function	O
that	that	O
in	in	O
turn	turn	O
may	may	O
cause	cause	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
.	.	O

Seven	seven	O
days	days	O
of	of	O
cocaine	cocaine	B-Chemical
administration	administration	O
to	to	O
rats	rats	O
led	led	O
to	to	O
an	an	O
increased	increased	O
oxygen	oxygen	B-Chemical
consumption	consumption	O
detected	detected	O
in	in	O
cardiac	cardiac	O
fibers	fibers	O
,	,	O
specifically	specifically	O
through	through	O
complex	complex	O
I	i	O
and	and	O
complex	complex	O
III	iii	O
.	.	O

ROS	ros	O
levels	levels	O
were	were	O
increased	increased	O
,	,	O
specifically	specifically	O
in	in	O
interfibrillar	interfibrillar	O
mitochondria	mitochondria	O
.	.	O

In	in	O
parallel	parallel	O
there	there	O
was	was	O
a	a	O
decrease	decrease	O
in	in	O
ATP	atp	B-Chemical
synthesis	synthesis	O
,	,	O
whereas	whereas	O
no	no	O
difference	difference	O
was	was	O
observed	observed	O
in	in	O
subsarcolemmal	subsarcolemmal	O
mitochondria	mitochondria	O
.	.	O

This	this	O
uncoupling	uncoupling	O
effect	effect	O
on	on	O
oxidative	oxidative	O
phosphorylation	phosphorylation	O
was	was	O
not	not	O
detectable	detectable	O
after	after	O
short-term	short-term	O
exposure	exposure	O
to	to	O
cocaine	cocaine	B-Chemical
,	,	O
suggesting	suggesting	O
that	that	O
these	these	O
mitochondrial	mitochondrial	O
abnormalities	abnormalities	O
were	were	O
a	a	O
late	late	O
rather	rather	O
than	than	O
a	a	O
primary	primary	O
event	event	O
in	in	O
the	the	O
pathological	pathological	O
response	response	O
to	to	O
cocaine	cocaine	B-Chemical
.	.	O

MitoQ	mitoq	O
,	,	O
a	a	O
mitochondrial-targeted	mitochondrial-targeted	O
antioxidant	antioxidant	O
,	,	O
was	was	O
shown	shown	O
to	to	O
completely	completely	O
prevent	prevent	O
these	these	O
mitochondrial	mitochondrial	O
abnormalities	abnormalities	O
as	as	O
well	well	O
as	as	O
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
characterized	characterized	O
here	here	O
by	by	O
a	a	O
diastolic	diastolic	O
dysfunction	dysfunction	O
studied	studied	O
with	with	O
a	a	O
conductance	conductance	O
catheter	catheter	O
to	to	O
obtain	obtain	O
pressure-volume	pressure-volume	O
data	data	O
.	.	O

Taken	taken	O
together	together	O
,	,	O
these	these	O
results	results	O
extend	extend	O
previous	previous	O
studies	studies	O
and	and	O
demonstrate	demonstrate	O
that	that	O
cocaine-induced	cocaine-induced	O
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
may	may	O
be	be	O
due	due	O
to	to	O
a	a	O
mitochondrial	mitochondrial	O
defect	defect	O
.	.	O

Trimethoprim-induced	trimethoprim-induced	O
immune	immune	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
in	in	O
a	a	O
pediatric	pediatric	O
oncology	oncology	O
patient	patient	O
presenting	presenting	O
as	as	O
an	an	O
acute	acute	B-Disease
hemolytic	hemolytic	B-Disease
transfusion	transfusion	B-Disease
reaction	reaction	I-Disease
.	.	O

A	a	O
10-year-old	10-year-old	O
male	male	O
with	with	O
acute	acute	O
leukemia	leukemia	O
presented	presented	O
with	with	O
post-chemotherapy	post-chemotherapy	O
anemia	anemia	B-Disease
.	.	O

During	during	O
red	red	O
cell	cell	O
transfusion	transfusion	O
,	,	O
he	he	O
developed	developed	O
hemoglobinuria	hemoglobinuria	O
.	.	O

Transfusion	transfusion	B-Disease
reaction	reaction	I-Disease
workup	workup	O
was	was	O
negative	negative	O
.	.	O

Drug-induced	drug-induced	O
immune	immune	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
was	was	O
suspected	suspected	O
because	because	O
of	of	O
positive	positive	O
direct	direct	O
antiglobulin	antiglobulin	O
test	test	O
,	,	O
negative	negative	O
eluate	eluate	O
,	,	O
and	and	O
microspherocytes	microspherocytes	O
on	on	O
smear	smear	O
pre-	pre-	O
and	and	O
post-transfusion	post-transfusion	O
.	.	O

Drug	drug	O
studies	studies	O
using	using	O
the	the	O
indirect	indirect	O
antiglobulin	antiglobulin	O
test	test	O
were	were	O
strongly	strongly	O
positive	positive	O
with	with	O
trimethoprim	trimethoprim	O
and	and	O
trimethoprim-sulfamethoxazole	trimethoprim-sulfamethoxazole	O
but	but	O
negative	negative	O
with	with	O
sulfamethoxazole	sulfamethoxazole	O
.	.	O

The	the	O
patient	patient	O
recovered	recovered	O
after	after	O
discontinuing	discontinuing	O
the	the	O
drug	drug	O
,	,	O
with	with	O
no	no	O
recurrence	recurrence	O
in	in	O
2	2	O
years	years	O
.	.	O

Other	other	O
causes	causes	O
of	of	O
anemia	anemia	B-Disease
should	should	O
be	be	O
considered	considered	O
in	in	O
patients	patients	O
with	with	O
worse-than-expected	worse-than-expected	O
anemia	anemia	B-Disease
after	after	O
chemotherapy	chemotherapy	O
.	.	O

Furthermore	furthermore	O
,	,	O
hemolysis	hemolysis	B-Disease
during	during	O
transfusion	transfusion	O
is	is	O
not	not	O
always	always	O
a	a	O
transfusion	transfusion	B-Disease
reaction	reaction	I-Disease
.	.	O

Verapamil	verapamil	B-Chemical
stimulation	stimulation	O
test	test	O
in	in	O
hyperprolactinemia	hyperprolactinemia	B-Disease
:	:	O
loss	loss	O
of	of	O
prolactin	prolactin	O
response	response	O
in	in	O
anatomic	anatomic	O
or	or	O
functional	functional	O
stalk	stalk	O
effect	effect	O
.	.	O

AIM	aim	O
:	:	O
Verapamil	verapamil	B-Chemical
stimulation	stimulation	O
test	test	O
was	was	O
previously	previously	O
investigated	investigated	O
as	as	O
a	a	O
tool	tool	O
for	for	O
differential	differential	O
diagnosis	diagnosis	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
,	,	O
but	but	O
with	with	O
conflicting	conflicting	O
results	results	O
.	.	O

Macroprolactinemia	macroprolactinemia	O
was	was	O
never	never	O
considered	considered	O
in	in	O
those	those	O
previous	previous	O
studies	studies	O
.	.	O

Here	here	O
,	,	O
we	we	O
aimed	aimed	O
to	to	O
re-investigate	re-investigate	O
the	the	O
diagnostic	diagnostic	O
value	value	O
of	of	O
verapamil	verapamil	B-Chemical
in	in	O
a	a	O
population	population	O
who	who	O
were	were	O
all	all	O
screened	screened	O
for	for	O
macroprolactinemia	macroprolactinemia	O
.	.	O

Prolactin	prolactin	O
responses	responses	O
to	to	O
verapamil	verapamil	B-Chemical
in	in	O
65	65	O
female	female	O
patients	patients	O
(	(	O
age	age	O
:	:	O
29.9	29.9	O
+	+	O
/-	/-	O
8.1	8.1	O
years	years	O
)	)	O
with	with	O
hyperprolactinemia	hyperprolactinemia	B-Disease
were	were	O
tested	tested	O
in	in	O
a	a	O
descriptive	descriptive	O
,	,	O
matched	matched	O
case-control	case-control	O
study	study	O
.	.	O

METHODS	methods	O
:	:	O
Verapamil	verapamil	B-Chemical
80	80	O
mg	mg	O
,	,	O
p.o	p.o	O
.	.	O
was	was	O
administered	administered	O
,	,	O
and	and	O
then	then	O
PRL	prl	O
levels	levels	O
were	were	O
measured	measured	O
at	at	O
8th	8th	O
and	and	O
16th	16th	O
hours	hours	O
,	,	O
by	by	O
immunometric	immunometric	O
chemiluminescence	chemiluminescence	O
.	.	O

Verapamil	verapamil	B-Chemical
responsiveness	responsiveness	O
was	was	O
determined	determined	O
by	by	O
peak	peak	O
percent	percent	O
change	change	O
in	in	O
basal	basal	O
prolactin	prolactin	O
levels	levels	O
(	(	O
PRL	prl	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
Verapamil	verapamil	B-Chemical
significantly	significantly	O
increased	increased	O
PRL	prl	O
levels	levels	O
in	in	O
healthy	healthy	O
controls	controls	O
(	(	O
N.	n.	O
8	8	O
,	,	O
PRL	prl	O
:	:	O
183	183	O
%	%	O
)	)	O
,	,	O
macroprolactinoma	macroprolactinoma	O
(	(	O
N.	n.	O
8	8	O
,	,	O
PRL	prl	O
:	:	O
7	7	O
%	%	O
)	)	O
,	,	O
microprolactinoma	microprolactinoma	O
(	(	O
N.	n.	O
19	19	O
,	,	O
PRL	prl	O
:	:	O
21	21	O
%	%	O
)	)	O
,	,	O
macroprolactinemia	macroprolactinemia	O
(	(	O
N.	n.	O
23	23	O
,	,	O
PRL	prl	O
:	:	O
126	126	O
%	%	O
)	)	O
,	,	O
but	but	O
not	not	O
in	in	O
pseudoprolactinoma	pseudoprolactinoma	O
(	(	O
N.	n.	O
8	8	O
,	,	O
PRL	prl	O
:	:	O
0.8	0.8	O
%	%	O
)	)	O
,	,	O
and	and	O
risperidone-induced	risperidone-induced	O
hyperprolactinemia	hyperprolactinemia	B-Disease
(	(	O
N.	n.	O
7	7	O
,	,	O
PRL	prl	O
:	:	O
3	3	O
%	%	O
)	)	O
.	.	O

ROC	roc	O
curve	curve	O
analysis	analysis	O
revealed	revealed	O
that	that	O
unresponsiveness	unresponsiveness	O
to	to	O
verapamil	verapamil	B-Chemical
defined	defined	O
as	as	O
PRL	prl	O
<	<	O
7	7	O
%	%	O
,	,	O
discriminated	discriminated	O
anatomical	anatomical	O
or	or	O
functional	functional	O
stalk	stalk	O
effect	effect	O
(	(	O
sensitivity	sensitivity	O
:	:	O
74	74	O
%	%	O
,	,	O
specificity	specificity	O
:	:	O
73	73	O
%	%	O
,	,	O
AUC	auc	O
:	:	O
0.855+/-0.04	0.855+/-0.04	O
,	,	O
P	p	O
<	<	O
0.001	0.001	O
,	,	O
CI	ci	O
:	:	O
0.768	0.768	O
-	-	O
0.942	0.942	O
)	)	O
associated	associated	O
with	with	O
pseudoprolactinoma	pseudoprolactinoma	O
or	or	O
risperidone-induced	risperidone-induced	O
hyperprolactinemia	hyperprolactinemia	B-Disease
,	,	O
respectively	respectively	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Verapamil	verapamil	B-Chemical
responsiveness	responsiveness	O
is	is	O
not	not	O
a	a	O
reliable	reliable	O
finding	finding	O
for	for	O
the	the	O
differential	differential	O
diagnosis	diagnosis	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
.	.	O

However	however	O
,	,	O
verapamil	verapamil	B-Chemical
unresponsiveness	unresponsiveness	O
discriminates	discriminates	O
stalk	stalk	O
effect	effect	O
(	(	O
i.e.	i.e.	O
,	,	O
anatomically	anatomically	O
or	or	O
functionally	functionally	O
inhibited	inhibited	O
dopaminergic	dopaminergic	O
tonus	tonus	O
)	)	O
from	from	O
other	other	O
causes	causes	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
with	with	O
varying	varying	O
degrees	degrees	O
of	of	O
responsiveness	responsiveness	O
.	.	O

Blockade	blockade	O
of	of	O
endothelial-mesenchymal	endothelial-mesenchymal	O
transition	transition	O
by	by	O
a	a	O
Smad3	smad3	O
inhibitor	inhibitor	O
delays	delays	O
the	the	O
early	early	O
development	development	O
of	of	O
streptozotocin-induced	streptozotocin-induced	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
.	.	O

OBJECTIVE	objective	O
:	:	O
A	a	O
multicenter	multicenter	O
,	,	O
controlled	controlled	O
trial	trial	O
showed	showed	O
that	that	O
early	early	O
blockade	blockade	O
of	of	O
the	the	O
renin-angiotensin	renin-angiotensin	O
system	system	O
in	in	O
patients	patients	O
with	with	O
type	type	O
1	1	O
diabetes	diabetes	B-Disease
and	and	O
normoalbuminuria	normoalbuminuria	O
did	did	O
not	not	O
retard	retard	O
the	the	O
progression	progression	O
of	of	O
nephropathy	nephropathy	B-Disease
,	,	O
suggesting	suggesting	O
that	that	O
other	other	O
mechanism(s	mechanism(s	O
)	)	O
are	are	O
involved	involved	O
in	in	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
early	early	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
(	(	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
)	)	O
.	.	O

We	we	O
have	have	O
previously	previously	O
demonstrated	demonstrated	O
that	that	O
endothelial-mesenchymal-transition	endothelial-mesenchymal-transition	O
(	(	O
EndoMT	endomt	O
)	)	O
contributes	contributes	O
to	to	O
the	the	O
early	early	O
development	development	O
of	of	O
renal	renal	O
interstitial	interstitial	O
fibrosis	fibrosis	B-Disease
independently	independently	O
of	of	O
microalbuminuria	microalbuminuria	O
in	in	O
mice	mice	O
with	with	O
streptozotocin	streptozotocin	B-Chemical
(STZ)-induced	(stz)-induced	O
diabetes	diabetes	B-Disease
.	.	O

In	in	O
the	the	O
present	present	O
study	study	O
,	,	O
we	we	O
hypothesized	hypothesized	O
that	that	O
blocking	blocking	O
EndoMT	endomt	O
reduces	reduces	O
the	the	O
early	early	O
development	development	O
of	of	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
.	.	O

RESEARCH	research	O
DESIGN	design	O
AND	and	O
METHODS	methods	O
:	:	O
EndoMT	endomt	O
was	was	O
induced	induced	O
in	in	O
a	a	O
mouse	mouse	O
pancreatic	pancreatic	O
microvascular	microvascular	O
endothelial	endothelial	O
cell	cell	O
line	line	O
(	(	O
MMEC	mmec	O
)	)	O
in	in	O
the	the	O
presence	presence	O
of	of	O
advanced	advanced	O
glycation	glycation	O
end	end	O
products	products	O
(	(	O
AGEs	ages	O
)	)	O
and	and	O
in	in	O
the	the	O
endothelial	endothelial	O
lineage-traceble	lineage-traceble	O
mouse	mouse	O
line	line	O
Tie2-Cre;Loxp-EGFP	tie2-cre;loxp-egfp	O
by	by	O
administration	administration	O
of	of	O
AGEs	ages	O
,	,	O
with	with	O
nonglycated	nonglycated	O
mouse	mouse	O
albumin	albumin	O
serving	serving	O
as	as	O
a	a	O
control	control	O
.	.	O

Phosphorylated	phosphorylated	O
Smad3	smad3	O
was	was	O
detected	detected	O
by	by	O
immunoprecipitation/Western	immunoprecipitation/western	O
blotting	blotting	O
and	and	O
confocal	confocal	O
microscopy	microscopy	O
.	.	O

Blocking	blocking	O
studies	studies	O
using	using	O
receptor	receptor	O
for	for	O
AGE	age	O
siRNA	sirna	O
and	and	O
a	a	O
specific	specific	O
inhibitor	inhibitor	O
of	of	O
Smad3	smad3	O
(	(	O
SIS3	sis3	O
)	)	O
were	were	O
performed	performed	O
in	in	O
MMECs	mmecs	O
and	and	O
in	in	O
STZ-induced	stz-induced	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
in	in	O
Tie2-Cre;Loxp-EGFP	tie2-cre;loxp-egfp	O
mice	mice	O
.	.	O

RESULTS	results	O
:	:	O
Confocal	confocal	O
microscopy	microscopy	O
and	and	O
real-time	real-time	O
PCR	pcr	O
demonstrated	demonstrated	O
that	that	O
AGEs	ages	O
induced	induced	O
EndoMT	endomt	O
in	in	O
MMECs	mmecs	O
and	and	O
in	in	O
Tie2-Cre;Loxp-EGFP	tie2-cre;loxp-egfp	O
mice	mice	O
.	.	O

Immunoprecipitation/Western	immunoprecipitation/western	O
blotting	blotting	O
showed	showed	O
that	that	O
Smad3	smad3	O
was	was	O
activated	activated	O
by	by	O
AGEs	ages	O
but	but	O
was	was	O
inhibited	inhibited	O
by	by	O
SIS3	sis3	O
in	in	O
MMECs	mmecs	O
and	and	O
in	in	O
STZ-induced	stz-induced	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
.	.	O

Confocal	confocal	O
microscopy	microscopy	O
and	and	O
real-time	real-time	O
PCR	pcr	O
further	further	O
demonstrated	demonstrated	O
that	that	O
SIS3	sis3	O
abrogated	abrogated	O
EndoMT	endomt	O
,	,	O
reduced	reduced	O
renal	renal	O
fibrosis	fibrosis	B-Disease
,	,	O
and	and	O
retarded	retarded	O
progression	progression	O
of	of	O
nephropathy	nephropathy	B-Disease
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
EndoMT	endomt	O
is	is	O
a	a	O
novel	novel	O
pathway	pathway	O
leading	leading	O
to	to	O
early	early	O
development	development	O
of	of	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
.	.	O

Blockade	blockade	O
of	of	O
EndoMT	endomt	O
by	by	O
SIS3	sis3	O
may	may	O
provide	provide	O
a	a	O
new	new	O
strategy	strategy	O
to	to	O
retard	retard	O
the	the	O
progression	progression	O
of	of	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
and	and	O
other	other	O
diabetes	diabetes	B-Disease
complications	complications	I-Disease
.	.	O

Cytostatic	cytostatic	O
and	and	O
anti-angiogenic	anti-angiogenic	O
effects	effects	O
of	of	O
temsirolimus	temsirolimus	O
in	in	O
refractory	refractory	O
mantle	mantle	O
cell	cell	O
lymphoma	lymphoma	O
.	.	O

Mantle	mantle	O
cell	cell	O
lymphoma	lymphoma	O
(	(	O
MCL	mcl	O
)	)	O
is	is	O
a	a	O
rare	rare	O
and	and	O
aggressive	aggressive	O
type	type	O
of	of	O
B-cell	b-cell	O
non-Hodgkin	non-hodgkin	O
's	's	O
lymphoma	lymphoma	O
.	.	O

Patients	patients	O
become	become	O
progressively	progressively	O
refractory	refractory	O
to	to	O
conventional	conventional	O
chemotherapy	chemotherapy	O
,	,	O
and	and	O
their	their	O
prognosis	prognosis	O
is	is	O
poor	poor	O
.	.	O

However	however	O
,	,	O
a	a	O
38	38	O
%	%	O
remission	remission	O
rate	rate	O
has	has	O
been	been	O
recently	recently	O
reported	reported	O
in	in	O
refractory	refractory	O
MCL	mcl	O
treated	treated	O
with	with	O
temsirolimus	temsirolimus	O
,	,	O
a	a	O
mTOR	mtor	O
inhibitor	inhibitor	O
.	.	O

Here	here	O
we	we	O
had	had	O
the	the	O
opportunity	opportunity	O
to	to	O
study	study	O
a	a	O
case	case	O
of	of	O
refractory	refractory	O
MCL	mcl	O
who	who	O
had	had	O
tumor	tumor	B-Disease
regression	regression	O
two	two	O
months	months	O
after	after	O
temsirolimus	temsirolimus	O
treatment	treatment	O
,	,	O
and	and	O
a	a	O
progression-free	progression-free	O
survival	survival	O
of	of	O
10	10	O
months	months	O
.	.	O

In	in	O
this	this	O
case	case	O
,	,	O
lymph	lymph	O
node	node	O
biopsies	biopsies	O
were	were	O
performed	performed	O
before	before	O
and	and	O
six	six	O
months	months	O
after	after	O
temsirolimus	temsirolimus	O
therapy	therapy	O
.	.	O

Comparison	comparison	O
of	of	O
the	the	O
two	two	O
biopsies	biopsies	O
showed	showed	O
that	that	O
temsirolimus	temsirolimus	O
inhibited	inhibited	O
tumor	tumor	B-Disease
cell	cell	O
proliferation	proliferation	O
through	through	O
cell	cell	O
cycle	cycle	O
arrest	arrest	O
,	,	O
but	but	O
did	did	O
not	not	O
induce	induce	O
any	any	O
change	change	O
in	in	O
the	the	O
number	number	O
of	of	O
apoptotic	apoptotic	O
tumor	tumor	B-Disease
cells	cells	O
.	.	O

Apart	apart	O
from	from	O
this	this	O
cytostatic	cytostatic	O
effect	effect	O
,	,	O
temsirolimus	temsirolimus	O
had	had	O
an	an	O
antiangiogenic	antiangiogenic	O
effect	effect	O
with	with	O
decrease	decrease	O
of	of	O
tumor	tumor	B-Disease
microvessel	microvessel	O
density	density	O
and	and	O
of	of	O
VEGF	vegf	O
expression	expression	O
.	.	O

Moreover	moreover	O
,	,	O
numerous	numerous	O
patchy	patchy	O
,	,	O
well-limited	well-limited	O
fibrotic	fibrotic	O
areas	areas	O
,	,	O
compatible	compatible	O
with	with	O
post-necrotic	post-necrotic	O
tissue	tissue	O
repair	repair	O
,	,	O
were	were	O
found	found	O
after	after	O
6-month	6-month	O
temsirolimus	temsirolimus	O
therapy	therapy	O
.	.	O

Thus	thus	O
,	,	O
temsirolimus	temsirolimus	O
reduced	reduced	O
tumor	tumor	B-Disease
burden	burden	O
through	through	O
associated	associated	O
cytostatic	cytostatic	O
and	and	O
anti-angiogenic	anti-angiogenic	O
effects	effects	O
.	.	O

This	this	O
dual	dual	O
effect	effect	O
of	of	O
temsirolimus	temsirolimus	O
on	on	O
tumor	tumor	B-Disease
tissue	tissue	O
could	could	O
contribute	contribute	O
to	to	O
its	its	O
recently	recently	O
reported	reported	O
efficiency	efficiency	O
in	in	O
refractory	refractory	O
MCL	mcl	O
resistant	resistant	O
to	to	O
conventional	conventional	O
chemotherapy	chemotherapy	O
.	.	O

Acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
due	due	O
to	to	O
rifampicin	rifampicin	O
.	.	O

A	a	O
23-year-old	23-year-old	O
male	male	O
patient	patient	O
with	with	O
bacteriologically	bacteriologically	O
proven	proven	O
pulmonary	pulmonary	O
tuberculosis	tuberculosis	B-Disease
was	was	O
treated	treated	O
with	with	O
the	the	O
various	various	O
regimens	regimens	O
of	of	O
antituberculosis	antituberculosis	O
drugs	drugs	O
for	for	O
nearly	nearly	O
15	15	O
months	months	O
.	.	O

Rifampicin	rifampicin	O
was	was	O
administered	administered	O
thrice	thrice	O
as	as	O
one	one	O
of	of	O
the	the	O
3	3	O
-	-	O
4	4	O
drug	drug	O
regimen	regimen	O
and	and	O
each	each	O
time	time	O
he	he	O
developed	developed	O
untoward	untoward	O
side	side	O
effects	effects	O
like	like	O
nausea	nausea	B-Disease
,	,	O
vomiting	vomiting	B-Disease
and	and	O
fever	fever	B-Disease
with	with	O
chills	chills	O
and	and	O
rigors	rigors	O
.	.	O

The	the	O
last	last	O
such	such	O
episode	episode	O
was	was	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
at	at	O
which	which	O
stage	stage	O
the	the	O
patient	patient	O
was	was	O
seen	seen	O
by	by	O
the	the	O
authors	authors	O
of	of	O
this	this	O
report	report	O
.	.	O

The	the	O
patient	patient	O
,	,	O
however	however	O
,	,	O
made	made	O
a	a	O
full	full	O
recovery	recovery	O
.	.	O

Syncope	syncope	B-Disease
caused	caused	O
by	by	O
hyperkalemia	hyperkalemia	B-Disease
during	during	O
use	use	O
of	of	O
a	a	O
combined	combined	O
therapy	therapy	O
with	with	O
the	the	O
angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	O
inhibitor	inhibitor	O
and	and	O
spironolactone	spironolactone	B-Chemical
.	.	O

A	a	O
76	76	O
year-old	year-old	O
woman	woman	O
with	with	O
a	a	O
history	history	O
of	of	O
coronary	coronary	O
artery	artery	O
bypass	bypass	O
grafting	grafting	O
and	and	O
prior	prior	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
was	was	O
transferred	transferred	O
to	to	O
the	the	O
emergency	emergency	O
room	room	O
with	with	O
loss	loss	O
of	of	O
consciousness	consciousness	O
due	due	O
to	to	O
marked	marked	O
bradycardia	bradycardia	B-Disease
caused	caused	O
by	by	O
hyperkalemia	hyperkalemia	B-Disease
.	.	O

The	the	O
concentration	concentration	O
of	of	O
serum	serum	O
potassium	potassium	B-Chemical
was	was	O
high	high	O
,	,	O
and	and	O
normal	normal	O
sinus	sinus	O
rhythm	rhythm	O
was	was	O
restored	restored	O
after	after	O
correction	correction	O
of	of	O
the	the	O
serum	serum	O
potassium	potassium	B-Chemical
level	level	O
.	.	O

The	the	O
cause	cause	O
of	of	O
hyperkalemia	hyperkalemia	B-Disease
was	was	O
considered	considered	O
to	to	O
be	be	O
several	several	O
doses	doses	O
of	of	O
spiranolactone	spiranolactone	O
,	,	O
an	an	O
aldosterone	aldosterone	B-Chemical
antagonist	antagonist	O
,	,	O
in	in	O
addition	addition	O
to	to	O
the	the	O
long-term	long-term	O
intake	intake	O
of	of	O
ramipril	ramipril	O
,	,	O
an	an	O
ACE	ace	B-Chemical
inhibitor	inhibitor	I-Chemical
.	.	O

This	this	O
case	case	O
is	is	O
a	a	O
good	good	O
example	example	O
of	of	O
electrolyte	electrolyte	O
imbalance	imbalance	O
causing	causing	O
acute	acute	O
life-threatening	life-threatening	O
cardiac	cardiac	O
events	events	O
.	.	O

Clinicians	clinicians	O
should	should	O
be	be	O
alert	alert	O
to	to	O
the	the	O
possibility	possibility	O
of	of	O
hyperkalemia	hyperkalemia	B-Disease
,	,	O
especially	especially	O
in	in	O
elderly	elderly	O
patients	patients	O
using	using	O
ACE/ARB	ace/arb	O
in	in	O
combination	combination	O
with	with	O
potassium	potassium	B-Chemical
sparing	sparing	O
agents	agents	O
and	and	O
who	who	O
have	have	O
mild	mild	O
renal	renal	O
disturbance	disturbance	O
.	.	O

Diffuse	diffuse	O
skeletal	skeletal	O
pain	pain	B-Disease
after	after	O
administration	administration	O
of	of	O
alendronate	alendronate	O
.	.	O

BACKGROUND	background	O
:	:	O
Osteoporosis	osteoporosis	B-Disease
is	is	O
caused	caused	O
by	by	O
bone	bone	B-Disease
resorption	resorption	I-Disease
in	in	O
excess	excess	O
of	of	O
bone	bone	O
formation	formation	O
,	,	O
and	and	O
bisphosphonates	bisphosphonates	O
,	,	O
are	are	O
used	used	O
to	to	O
inhibit	inhibit	O
bone	bone	B-Disease
resorption	resorption	I-Disease
.	.	O

Alendronate	alendronate	O
,	,	O
a	a	O
biphosphonate	biphosphonate	O
,	,	O
is	is	O
effective	effective	O
for	for	O
both	both	O
the	the	O
treatment	treatment	O
and	and	O
prevention	prevention	O
of	of	O
osteoporosis	osteoporosis	B-Disease
in	in	O
postmenopausal	postmenopausal	O
women	women	O
.	.	O

Side	side	O
effects	effects	O
are	are	O
relatively	relatively	O
few	few	O
and	and	O
prominently	prominently	O
gastrointestinal	gastrointestinal	O
.	.	O

Musculoskeletal	musculoskeletal	B-Disease
pain	pain	B-Disease
may	may	O
be	be	O
an	an	O
important	important	O
side	side	O
effect	effect	O
in	in	O
these	these	O
patients	patients	O
.	.	O

We	we	O
presented	presented	O
a	a	O
patient	patient	O
admitted	admitted	O
to	to	O
our	our	O
out-patient	out-patient	O
clinic	clinic	O
with	with	O
diffuse	diffuse	O
skeletal	skeletal	O
pain	pain	B-Disease
after	after	O
three	three	O
consecutive	consecutive	O
administration	administration	O
of	of	O
alendronate	alendronate	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
We	we	O
conclude	conclude	O
that	that	O
patients	patients	O
with	with	O
osteoporosis	osteoporosis	B-Disease
can	can	O
report	report	O
pain	pain	B-Disease
,	,	O
and	and	O
bisphosphonate-related	bisphosphonate-related	O
pain	pain	B-Disease
should	should	O
also	also	O
be	be	O
considered	considered	O
before	before	O
ascribing	ascribing	O
this	this	O
complaint	complaint	O
to	to	O
osteoporosis	osteoporosis	B-Disease
.	.	O

Cerebrospinal	cerebrospinal	O
fluid	fluid	O
penetration	penetration	O
of	of	O
high-dose	high-dose	O
daptomycin	daptomycin	O
in	in	O
suspected	suspected	O
Staphylococcus	staphylococcus	O
aureus	aureus	O
meningitis	meningitis	B-Disease
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
report	report	O
a	a	O
case	case	O
of	of	O
methicillin-sensitive	methicillin-sensitive	O
Staphylococcus	staphylococcus	O
aureus	aureus	O
(	(	O
MSSA	mssa	O
)	)	O
bacteremia	bacteremia	O
with	with	O
suspected	suspected	O
MSSA	mssa	O
meningitis	meningitis	B-Disease
treated	treated	O
with	with	O
high-dose	high-dose	O
daptomycin	daptomycin	O
assessed	assessed	O
with	with	O
concurrent	concurrent	O
serum	serum	O
and	and	O
cerebrospinal	cerebrospinal	O
fluid	fluid	O
(	(	O
CSF	csf	O
)	)	O
concentrations	concentrations	O
.	.	O

CASE	case	O
SUMMARY	summary	O
:	:	O
A	a	O
54-year-old	54-year-old	O
male	male	O
presented	presented	O
to	to	O
the	the	O
emergency	emergency	O
department	department	O
with	with	O
generalized	generalized	O
weakness	weakness	B-Disease
and	and	O
presumed	presumed	O
health-care-associated	health-care-associated	O
pneumonia	pneumonia	O
shown	shown	O
on	on	O
chest	chest	O
radiograph	radiograph	O
.	.	O

Treatment	treatment	O
was	was	O
empirically	empirically	O
initiated	initiated	O
with	with	O
vancomycin	vancomycin	B-Chemical
,	,	O
levofloxacin	levofloxacin	B-Chemical
,	,	O
and	and	O
piperacillin/tazobactam	piperacillin/tazobactam	O
.	.	O

Blood	blood	O
cultures	cultures	O
revealed	revealed	O
S.	s.	O
aureus	aureus	O
susceptible	susceptible	O
to	to	O
oxacillin	oxacillin	O
.	.	O

Empiric	empiric	O
antibiotic	antibiotic	O
treatment	treatment	O
was	was	O
narrowed	narrowed	O
to	to	O
nafcillin	nafcillin	O
on	on	O
day	day	O
4	4	O
.	.	O

On	on	O
day	day	O
8	8	O
,	,	O
the	the	O
patient	patient	O
developed	developed	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
(	(	O
serum	serum	O
creatinine	creatinine	B-Chemical
1.9	1.9	O
mg/dL	mg/dl	O
,	,	O
increased	increased	O
from	from	O
1.2	1.2	O
mg/dL	mg/dl	O
the	the	O
previous	previous	O
day	day	O
and	and	O
0.8	0.8	O
mg/dL	mg/dl	O
on	on	O
admission	admission	O
)	)	O
.	.	O

The	the	O
patient	patient	O
's	's	O
Glasgow	glasgow	O
Coma	coma	B-Disease
Score	score	O
was	was	O
3	3	O
,	,	O
with	with	O
normal	normal	O
findings	findings	O
shown	shown	O
on	on	O
computed	computed	O
tomography	tomography	O
scan	scan	O
of	of	O
the	the	O
head	head	O
72	72	O
hours	hours	O
following	following	O
an	an	O
episode	episode	O
of	of	O
cardiac	cardiac	B-Disease
arrest	arrest	I-Disease
on	on	O
day	day	O
10	10	O
.	.	O

The	the	O
patient	patient	O
experienced	experienced	O
relapsing	relapsing	O
MSSA	mssa	O
bacteremia	bacteremia	O
on	on	O
day	day	O
9	9	O
,	,	O
increasing	increasing	O
the	the	O
suspicion	suspicion	O
for	for	O
a	a	O
central	central	O
nervous	nervous	O
system	system	O
(	(	O
CNS	cns	O
)	)	O
infection	infection	B-Disease
.	.	O

Nafcillin	nafcillin	O
was	was	O
discontinued	discontinued	O
and	and	O
daptomycin	daptomycin	O
9	9	O
mg/kg	mg/kg	O
daily	daily	O
was	was	O
initiated	initiated	O
for	for	O
suspected	suspected	O
meningitis	meningitis	B-Disease
and	and	O
was	was	O
continued	continued	O
until	until	O
the	the	O
patient	patient	O
's	's	O
death	death	B-Disease
on	on	O
day	day	O
16	16	O
.	.	O

Daptomycin	daptomycin	O
serum	serum	O
and	and	O
CSF	csf	O
trough	trough	O
concentrations	concentrations	O
were	were	O
11.21	11.21	O
ug/mL	ug/ml	O
and	and	O
0.52	0.52	O
ug/mL	ug/ml	O
,	,	O
respectively	respectively	O
,	,	O
prior	prior	O
to	to	O
the	the	O
third	third	O
dose	dose	O
.	.	O

Lumbar	lumbar	O
puncture	puncture	O
results	results	O
were	were	O
inconclusive	inconclusive	O
and	and	O
no	no	O
further	further	O
blood	blood	O
cultures	cultures	O
were	were	O
positive	positive	O
for	for	O
MSSA	mssa	O
.	.	O

Creatine	creatine	B-Chemical
kinase	kinase	I-Chemical
levels	levels	O
were	were	O
normal	normal	O
prior	prior	O
to	to	O
daptomycin	daptomycin	O
therapy	therapy	O
and	and	O
were	were	O
not	not	O
reassessed	reassessed	O
.	.	O

DISCUSSION	discussion	O
:	:	O
Daptomycin	daptomycin	O
was	was	O
initiated	initiated	O
in	in	O
our	our	O
patient	patient	O
secondary	secondary	O
to	to	O
possible	possible	O
nafcillin-induced	nafcillin-induced	O
acute	acute	O
interstitial	interstitial	B-Disease
nephritis	nephritis	I-Disease
and	and	O
relapsing	relapsing	O
bacteremia	bacteremia	O
.	.	O

At	at	O
a	a	O
dose	dose	O
of	of	O
9	9	O
mg/kg	mg/kg	O
,	,	O
resultant	resultant	O
penetration	penetration	O
of	of	O
5	5	O
%	%	O
was	was	O
higher	higher	O
than	than	O
in	in	O
previous	previous	O
reports	reports	O
,	,	O
more	more	O
consistent	consistent	O
with	with	O
inflamed	inflamed	O
meninges	meninges	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
High-dose	high-dose	O
daptomycin	daptomycin	O
may	may	O
be	be	O
an	an	O
alternative	alternative	O
option	option	O
for	for	O
MSSA	mssa	O
bacteremia	bacteremia	O
with	with	O
or	or	O
without	without	O
a	a	O
CNS	cns	O
source	source	O
in	in	O
patients	patients	O
who	who	O
have	have	O
failed	failed	O
or	or	O
can	can	O
not	not	O
tolerate	tolerate	O
standard	standard	O
therapy	therapy	O
.	.	O

Further	further	O
clinical	clinical	O
evaluation	evaluation	O
in	in	O
patients	patients	O
with	with	O
confirmed	confirmed	O
meningitis	meningitis	B-Disease
is	is	O
warranted	warranted	O
.	.	O

The	the	O
role	role	O
of	of	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
in	in	O
convulsions	convulsions	B-Disease
induced	induced	O
by	by	O
lindane	lindane	B-Chemical
in	in	O
rats	rats	O
.	.	O

Lindane	lindane	B-Chemical
is	is	O
an	an	O
organochloride	organochloride	O
pesticide	pesticide	O
and	and	O
scabicide	scabicide	O
.	.	O

It	it	O
evokes	evokes	O
convulsions	convulsions	B-Disease
mainly	mainly	O
trough	trough	O
the	the	O
blockage	blockage	O
of	of	O
GABA(A	gaba(a	O
)	)	O
receptors	receptors	O
.	.	O

Nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
(	(	O
NO	no	O
)	)	O
,	,	O
gaseous	gaseous	O
neurotransmitter	neurotransmitter	O
,	,	O
has	has	O
contradictor	contradictor	O
role	role	O
in	in	O
epileptogenesis	epileptogenesis	O
due	due	O
to	to	O
opposite	opposite	O
effects	effects	O
of	of	O
L-arginine	l-arginine	O
,	,	O
precursor	precursor	O
of	of	O
NO	no	O
syntheses	syntheses	O
(	(	O
NOS	nos	O
)	)	O
,	,	O
and	and	O
L-NAME	l-name	O
(	(	O
NOS	nos	O
inhibitor	inhibitor	O
)	)	O
observed	observed	O
in	in	O
different	different	O
epilepsy	epilepsy	B-Disease
models	models	O
.	.	O

The	the	O
aim	aim	O
of	of	O
the	the	O
current	current	O
study	study	O
was	was	O
to	to	O
determine	determine	O
the	the	O
effects	effects	O
of	of	O
NO	no	O
on	on	O
the	the	O
behavioral	behavioral	O
and	and	O
EEG	eeg	O
characteristics	characteristics	O
of	of	O
lindane-induced	lindane-induced	O
epilepsy	epilepsy	B-Disease
in	in	O
male	male	O
Wistar	wistar	O
albino	albino	O
rats	rats	O
.	.	O

The	the	O
administration	administration	O
of	of	O
L-arginine	l-arginine	O
(	(	O
600	600	O
,	,	O
800	800	O
and	and	O
1000	1000	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
in	in	O
dose-dependent	dose-dependent	O
manner	manner	O
significantly	significantly	O
increased	increased	O
convulsion	convulsion	B-Disease
incidence	incidence	O
and	and	O
severity	severity	O
and	and	O
shortened	shortened	O
latency	latency	O
time	time	O
to	to	O
first	first	O
convulsion	convulsion	B-Disease
elicited	elicited	O
by	by	O
lower	lower	O
lindane	lindane	B-Chemical
dose	dose	O
(	(	O
4	4	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
.	.	O

On	on	O
the	the	O
contrary	contrary	O
,	,	O
pretreatment	pretreatment	O
with	with	O
L-NAME	l-name	O
(	(	O
500	500	O
,	,	O
700	700	O
and	and	O
900	900	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
decreased	decreased	O
convulsion	convulsion	B-Disease
incidence	incidence	O
and	and	O
severity	severity	O
and	and	O
prolonged	prolonged	O
latency	latency	O
time	time	O
to	to	O
convulsion	convulsion	B-Disease
following	following	O
injection	injection	O
with	with	O
a	a	O
convulsive	convulsive	B-Disease
dose	dose	O
of	of	O
lindane	lindane	B-Chemical
(	(	O
8	8	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
.	.	O

EEG	eeg	O
analyses	analyses	O
showed	showed	O
increase	increase	O
of	of	O
number	number	O
and	and	O
duration	duration	O
of	of	O
ictal	ictal	O
periods	periods	O
in	in	O
EEG	eeg	O
of	of	O
rats	rats	O
receiving	receiving	O
l-arginine	l-arginine	O
prior	prior	O
to	to	O
lindane	lindane	B-Chemical
and	and	O
decrease	decrease	O
of	of	O
this	this	O
number	number	O
in	in	O
rats	rats	O
pretreated	pretreated	O
with	with	O
L-NAME	l-name	O
.	.	O

These	these	O
results	results	O
support	support	O
the	the	O
conclusion	conclusion	O
that	that	O
NO	no	O
plays	plays	O
a	a	O
role	role	O
of	of	O
endogenous	endogenous	O
convulsant	convulsant	O
in	in	O
rat	rat	O
model	model	O
of	of	O
lindane	lindane	B-Chemical
seizures	seizures	B-Disease
.	.	O

Severe	severe	O
polyneuropathy	polyneuropathy	B-Disease
and	and	O
motor	motor	O
loss	loss	O
after	after	O
intrathecal	intrathecal	O
thiotepa	thiotepa	O
combination	combination	O
chemotherapy	chemotherapy	O
:	:	O
description	description	O
of	of	O
two	two	O
cases	cases	O
.	.	O

Two	two	O
cases	cases	O
of	of	O
severe	severe	O
delayed	delayed	O
neurologic	neurologic	O
toxicity	toxicity	B-Disease
related	related	O
to	to	O
the	the	O
administration	administration	O
of	of	O
intrathecal	intrathecal	O
(	(	O
IT	it	O
)	)	O
combination	combination	O
chemotherapy	chemotherapy	O
including	including	O
thiotepa	thiotepa	O
(	(	O
TSPA	tspa	O
)	)	O
are	are	O
presented	presented	O
.	.	O

Both	both	O
cases	cases	O
developed	developed	O
axonal	axonal	O
neuropathy	neuropathy	B-Disease
with	with	O
motor	motor	O
predominance	predominance	O
in	in	O
the	the	O
lower	lower	O
extremities	extremities	O
1	1	O
and	and	O
6	6	O
months	months	O
after	after	O
IT	it	O
chemotherapy	chemotherapy	O
was	was	O
administered	administered	O
.	.	O

Neurologic	neurologic	O
toxicities	toxicities	B-Disease
have	have	O
been	been	O
described	described	O
with	with	O
IT-methotrexate	it-methotrexate	O
,	,	O
IT-cytosine	it-cytosine	O
arabinoside	arabinoside	O
and	and	O
IT-TSPA	it-tspa	O
.	.	O

To	to	O
our	our	O
knowledge	knowledge	O
,	,	O
however	however	O
,	,	O
axonal	axonal	O
neuropathy	neuropathy	B-Disease
following	following	O
administration	administration	O
of	of	O
these	these	O
three	three	O
agents	agents	O
has	has	O
not	not	O
been	been	O
previously	previously	O
described	described	O
.	.	O

In	in	O
spite	spite	O
of	of	O
the	the	O
fact	fact	O
that	that	O
TSPA	tspa	O
is	is	O
a	a	O
useful	useful	O
IT	it	O
agent	agent	O
,	,	O
its	its	O
combination	combination	O
with	with	O
MTX	mtx	B-Chemical
,	,	O
ara-C	ara-c	O
and	and	O
radiotherapy	radiotherapy	O
could	could	O
cause	cause	O
severe	severe	O
neurotoxicity	neurotoxicity	B-Disease
.	.	O

This	this	O
unexpected	unexpected	O
complication	complication	O
indicates	indicates	O
the	the	O
need	need	O
for	for	O
further	further	O
toxicology	toxicology	O
research	research	O
on	on	O
IT-TSPA	it-tspa	O
.	.	O

Effects	effects	O
of	of	O
cromakalim	cromakalim	O
and	and	O
pinacidil	pinacidil	O
on	on	O
large	large	O
epicardial	epicardial	O
and	and	O
small	small	O
coronary	coronary	O
arteries	arteries	O
in	in	O
conscious	conscious	O
dogs	dogs	O
.	.	O

The	the	O
effects	effects	O
of	of	O
i.v	i.v	O
.	.	O

bolus	bolus	O
administration	administration	O
of	of	O
cromakalim	cromakalim	O
(	(	O
1	1	O
-	-	O
10	10	O
micrograms/kg	micrograms/kg	O
)	)	O
and	and	O
pinacidil	pinacidil	O
(	(	O
3	3	O
-	-	O
100	100	O
micrograms/kg	micrograms/kg	O
)	)	O
on	on	O
large	large	O
(	(	O
circumflex	circumflex	O
artery	artery	O
)	)	O
and	and	O
small	small	O
coronary	coronary	O
arteries	arteries	O
and	and	O
on	on	O
systemic	systemic	O
hemodynamics	hemodynamics	O
were	were	O
investigated	investigated	O
in	in	O
chronically	chronically	O
instrumented	instrumented	O
conscious	conscious	O
dogs	dogs	O
and	and	O
compared	compared	O
to	to	O
those	those	O
of	of	O
nitroglycerin	nitroglycerin	B-Chemical
(	(	O
0.03	0.03	O
-	-	O
10	10	O
micrograms/kg	micrograms/kg	O
)	)	O
.	.	O

Nitroglycerin	nitroglycerin	B-Chemical
,	,	O
up	up	O
to	to	O
0.3	0.3	O
micrograms/kg	micrograms/kg	O
,	,	O
selectively	selectively	O
increased	increased	O
circumflex	circumflex	O
artery	artery	O
diameter	diameter	O
(	(	O
CxAD	cxad	O
)	)	O
without	without	O
simultaneously	simultaneously	O
affecting	affecting	O
any	any	O
other	other	O
cardiac	cardiac	O
or	or	O
systemic	systemic	O
hemodynamic	hemodynamic	O
parameter	parameter	O
.	.	O

In	in	O
contrast	contrast	O
,	,	O
cromakalim	cromakalim	O
and	and	O
pinacidil	pinacidil	O
at	at	O
all	all	O
doses	doses	O
and	and	O
nitroglycerin	nitroglycerin	B-Chemical
at	at	O
doses	doses	O
higher	higher	O
than	than	O
0.3	0.3	O
micrograms/kg	micrograms/kg	O
simultaneously	simultaneously	O
and	and	O
dose-dependently	dose-dependently	O
increased	increased	O
CxAD	cxad	O
,	,	O
coronary	coronary	O
blood	blood	O
flow	flow	O
and	and	O
heart	heart	O
rate	rate	O
and	and	O
decreased	decreased	O
coronary	coronary	O
vascular	vascular	O
resistance	resistance	O
and	and	O
aortic	aortic	O
pressure	pressure	O
.	.	O

Cromakalim	cromakalim	O
was	was	O
approximately	approximately	O
8-	8-	O
to	to	O
9.5-fold	9.5-fold	O
more	more	O
potent	potent	O
than	than	O
pinacidil	pinacidil	O
in	in	O
increasing	increasing	O
CxAD	cxad	O
.	.	O

Vasodilation	vasodilation	O
of	of	O
large	large	O
and	and	O
small	small	O
coronary	coronary	O
vessels	vessels	O
and	and	O
hypotension	hypotension	B-Disease
induced	induced	O
by	by	O
cromakalim	cromakalim	O
and	and	O
pinacidil	pinacidil	O
were	were	O
not	not	O
affected	affected	O
by	by	O
prior	prior	O
combined	combined	O
beta	beta	O
adrenergic	adrenergic	O
and	and	O
muscarinic	muscarinic	O
receptors	receptors	O
blockade	blockade	O
but	but	O
drug-induced	drug-induced	O
tachycardia	tachycardia	B-Disease
was	was	O
abolished	abolished	O
.	.	O

When	when	O
circumflex	circumflex	O
artery	artery	O
blood	blood	O
flow	flow	O
was	was	O
maintained	maintained	O
constant	constant	O
,	,	O
the	the	O
increases	increases	O
in	in	O
CxAD	cxad	O
induced	induced	O
by	by	O
cromakalim	cromakalim	O
(	(	O
10	10	O
micrograms/kg	micrograms/kg	O
)	)	O
,	,	O
pinacidil	pinacidil	O
(	(	O
30	30	O
micrograms/kg	micrograms/kg	O
)	)	O
and	and	O
nitroglycerin	nitroglycerin	B-Chemical
(	(	O
10	10	O
micrograms/kg	micrograms/kg	O
)	)	O
were	were	O
reduced	reduced	O
by	by	O
68	68	O
+	+	O
/-	/-	O
7	7	O
,	,	O
54	54	O
+	+	O
/-	/-	O
9	9	O
and	and	O
1	1	O
+	+	O
/-	/-	O
1	1	O
%	%	O
,	,	O
respectively	respectively	O
.	.	O

Thus	thus	O
,	,	O
whereas	whereas	O
nitroglycerin	nitroglycerin	B-Chemical
preferentially	preferentially	O
and	and	O
flow-independently	flow-independently	O
dilates	dilates	O
large	large	O
coronary	coronary	O
arteries	arteries	O
,	,	O
cromakalim	cromakalim	O
and	and	O
pinacidil	pinacidil	O
dilate	dilate	O
both	both	O
large	large	O
and	and	O
small	small	O
coronary	coronary	O
arteries	arteries	O
and	and	O
this	this	O
effect	effect	O
is	is	O
not	not	O
dependent	dependent	O
upon	upon	O
the	the	O
simultaneous	simultaneous	O
beta	beta	O
adrenoceptors-mediated	adrenoceptors-mediated	O
rise	rise	O
in	in	O
myocardial	myocardial	O
metabolic	metabolic	O
demand	demand	O
.	.	O

Finally	finally	O
,	,	O
two	two	O
mechanisms	mechanisms	O
at	at	O
least	least	O
,	,	O
direct	direct	O
vasodilation	vasodilation	O
and	and	O
flow	flow	O
dependency	dependency	O
,	,	O
are	are	O
involved	involved	O
in	in	O
the	the	O
cromakalim-	cromakalim-	O
and	and	O
pinacidil-induced	pinacidil-induced	O
increase	increase	O
in	in	O
CxAD	cxad	O
.	.	O

Mefenamic	mefenamic	O
acid-induced	acid-induced	O
neutropenia	neutropenia	B-Disease
and	and	O
renal	renal	B-Disease
failure	failure	I-Disease
in	in	O
elderly	elderly	O
females	females	O
with	with	O
hypothyroidism	hypothyroidism	B-Disease
.	.	O

We	we	O
report	report	O
mefenamic	mefenamic	O
acid-induced	acid-induced	O
non-oliguric	non-oliguric	O
renal	renal	B-Disease
failure	failure	I-Disease
and	and	O
severe	severe	O
neutropenia	neutropenia	B-Disease
occurring	occurring	O
simultaneously	simultaneously	O
in	in	O
two	two	O
elderly	elderly	O
females	females	O
.	.	O

The	the	O
neutropenia	neutropenia	B-Disease
was	was	O
due	due	O
to	to	O
maturation	maturation	O
arrest	arrest	O
of	of	O
the	the	O
myeloid	myeloid	O
series	series	O
in	in	O
one	one	O
patient	patient	O
.	.	O

Both	both	O
patients	patients	O
were	were	O
also	also	O
hypothyroid	hypothyroid	B-Disease
,	,	O
but	but	O
it	it	O
is	is	O
not	not	O
clear	clear	O
whether	whether	O
this	this	O
was	was	O
a	a	O
predisposing	predisposing	O
factor	factor	O
to	to	O
the	the	O
development	development	O
of	of	O
these	these	O
adverse	adverse	O
reactions	reactions	O
.	.	O

However	however	O
,	,	O
it	it	O
would	would	O
seem	seem	O
prudent	prudent	O
not	not	O
to	to	O
use	use	O
mefenamic	mefenamic	B-Chemical
acid	acid	I-Chemical
in	in	O
hypothyroid	hypothyroid	B-Disease
patients	patients	O
until	until	O
the	the	O
hypothyroidism	hypothyroidism	B-Disease
has	has	O
been	been	O
corrected	corrected	O
.	.	O

Etiology	etiology	O
of	of	O
hypercalcemia	hypercalcemia	B-Disease
in	in	O
hemodialysis	hemodialysis	O
patients	patients	O
on	on	O
calcium	calcium	B-Chemical
carbonate	carbonate	I-Chemical
therapy	therapy	O
.	.	O

Fourteen	fourteen	O
of	of	O
39	39	O
dialysis	dialysis	O
patients	patients	O
(	(	O
36	36	O
%	%	O
)	)	O
became	became	O
hypercalcemic	hypercalcemic	O
after	after	O
switching	switching	O
to	to	O
calcium	calcium	B-Chemical
carbonate	carbonate	I-Chemical
as	as	O
their	their	O
principal	principal	O
phosphate	phosphate	B-Chemical
binder	binder	O
.	.	O

In	in	O
order	order	O
to	to	O
identify	identify	O
risk	risk	O
factors	factors	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
hypercalcemia	hypercalcemia	B-Disease
,	,	O
indirect	indirect	O
parameters	parameters	O
of	of	O
intestinal	intestinal	O
calcium	calcium	B-Chemical
reabsorption	reabsorption	O
and	and	O
bone	bone	O
turnover	turnover	O
rate	rate	O
in	in	O
these	these	O
14	14	O
patients	patients	O
were	were	O
compared	compared	O
with	with	O
results	results	O
in	in	O
14	14	O
eucalcemic	eucalcemic	O
patients	patients	O
matched	matched	O
for	for	O
age	age	O
,	,	O
sex	sex	O
,	,	O
length	length	O
of	of	O
time	time	O
on	on	O
dialysis	dialysis	O
,	,	O
and	and	O
etiology	etiology	O
of	of	O
renal	renal	O
disease	disease	O
.	.	O

In	in	O
addition	addition	O
to	to	O
experiencing	experiencing	O
hypercalcemic	hypercalcemic	O
episodes	episodes	O
with	with	O
peak	peak	O
calcium	calcium	B-Chemical
values	values	O
of	of	O
2.7	2.7	O
to	to	O
3.8	3.8	O
mmol/L	mmol/l	O
(	(	O
10.7	10.7	O
to	to	O
15.0	15.0	O
mg/dL	mg/dl	O
)	)	O
,	,	O
patients	patients	O
in	in	O
the	the	O
hypercalcemic	hypercalcemic	O
group	group	O
exhibited	exhibited	O
a	a	O
significant	significant	O
increase	increase	O
in	in	O
the	the	O
mean	mean	O
calcium	calcium	B-Chemical
concentration	concentration	O
obtained	obtained	O
during	during	O
6	6	O
months	months	O
before	before	O
the	the	O
switch	switch	O
,	,	O
compared	compared	O
with	with	O
the	the	O
mean	mean	O
value	value	O
obtained	obtained	O
during	during	O
the	the	O
7	7	O
months	months	O
of	of	O
observation	observation	O
after	after	O
the	the	O
switch	switch	O
(	(	O
2.4	2.4	O
+	+	O
/-	/-	O
0.03	0.03	O
to	to	O
2.5	2.5	O
+	+	O
/-	/-	O
0.03	0.03	O
mmol/L	mmol/l	O
[	[	O
9.7	9.7	O
+	+	O
/-	/-	O
0.2	0.2	O
to	to	O
10.2	10.2	O
+	+	O
/-	/-	O
0.1	0.1	O
mg/dL	mg/dl	O
]	]	O
,	,	O
P	p	O
=	=	O
0.006	0.006	O
)	)	O
.	.	O

In	in	O
contrast	contrast	O
,	,	O
eucalcemic	eucalcemic	O
patients	patients	O
exhibited	exhibited	O
no	no	O
change	change	O
in	in	O
mean	mean	O
calcium	calcium	B-Chemical
values	values	O
over	over	O
the	the	O
same	same	O
time	time	O
period	period	O
(	(	O
2.3	2.3	O
+	+	O
/-	/-	O
0.05	0.05	O
to	to	O
2.3	2.3	O
+	+	O
/-	/-	O
0.05	0.05	O
mmol/L	mmol/l	O
[	[	O
9.2	9.2	O
+	+	O
/-	/-	O
0.2	0.2	O
to	to	O
9.2	9.2	O
+	+	O
/-	/-	O
0.2	0.2	O
mg/dL	mg/dl	O
]	]	O
)	)	O
.	.	O

CaCO3	caco3	O
dosage	dosage	O
,	,	O
calculated	calculated	O
dietary	dietary	O
calcium	calcium	B-Chemical
intake	intake	O
,	,	O
and	and	O
circulating	circulating	O
levels	levels	O
of	of	O
vitamin	vitamin	B-Chemical
D	d	I-Chemical
metabolites	metabolites	O
were	were	O
similar	similar	O
in	in	O
both	both	O
groups	groups	O
.	.	O

Physical	physical	O
activity	activity	O
index	index	O
and	and	O
predialysis	predialysis	O
serum	serum	O
bicarbonate	bicarbonate	O
levels	levels	O
also	also	O
were	were	O
similar	similar	O
in	in	O
both	both	O
groups	groups	O
.	.	O

However	however	O
,	,	O
there	there	O
was	was	O
a	a	O
significant	significant	O
difference	difference	O
in	in	O
parameters	parameters	O
reflecting	reflecting	O
bone	bone	O
turnover	turnover	O
rates	rates	O
between	between	O
groups.(ABSTRACT	groups.(abstract	O
TRUNCATED	truncated	O
AT	at	O
250	250	O
WORDS	words	O
)	)	O

Late-onset	late-onset	O
scleroderma	scleroderma	O
renal	renal	O
crisis	crisis	O
induced	induced	O
by	by	O
tacrolimus	tacrolimus	B-Chemical
and	and	O
prednisolone	prednisolone	B-Chemical
:	:	O
a	a	O
case	case	O
report	report	O
.	.	O

Scleroderma	scleroderma	O
renal	renal	O
crisis	crisis	O
(	(	O
SRC	src	O
)	)	O
is	is	O
a	a	O
rare	rare	O
complication	complication	O
of	of	O
systemic	systemic	O
sclerosis	sclerosis	O
(	(	O
SSc	ssc	O
)	)	O
but	but	O
can	can	O
be	be	O
severe	severe	O
enough	enough	O
to	to	O
require	require	O
temporary	temporary	O
or	or	O
permanent	permanent	O
renal	renal	O
replacement	replacement	O
therapy	therapy	O
.	.	O

Moderate	moderate	O
to	to	O
high	high	O
dose	dose	O
corticosteroid	corticosteroid	O
use	use	O
is	is	O
recognized	recognized	O
as	as	O
a	a	O
major	major	O
risk	risk	O
factor	factor	O
for	for	O
SRC	src	O
.	.	O

Furthermore	furthermore	O
,	,	O
there	there	O
have	have	O
been	been	O
reports	reports	O
of	of	O
thrombotic	thrombotic	B-Disease
microangiopathy	microangiopathy	I-Disease
precipitated	precipitated	O
by	by	O
cyclosporine	cyclosporine	B-Chemical
in	in	O
patients	patients	O
with	with	O
SSc	ssc	O
.	.	O

In	in	O
this	this	O
article	article	O
,	,	O
we	we	O
report	report	O
a	a	O
patient	patient	O
with	with	O
SRC	src	O
induced	induced	O
by	by	O
tacrolimus	tacrolimus	B-Chemical
and	and	O
corticosteroids	corticosteroids	B-Chemical
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
work	work	O
is	is	O
to	to	O
call	call	O
attention	attention	O
to	to	O
the	the	O
risk	risk	O
of	of	O
tacrolimus	tacrolimus	B-Chemical
use	use	O
in	in	O
patients	patients	O
with	with	O
SSc	ssc	O
.	.	O

Methyldopa-induced	methyldopa-induced	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
in	in	O
a	a	O
15	15	O
year	year	O
old	old	O
presenting	presenting	O
as	as	O
near-syncope	near-syncope	O
.	.	O

Methyldopa	methyldopa	B-Chemical
is	is	O
an	an	O
antihypertensive	antihypertensive	O
medication	medication	O
which	which	O
is	is	O
available	available	O
generically	generically	O
and	and	O
under	under	O
the	the	O
trade	trade	O
name	name	O
Aldomet	aldomet	O
that	that	O
is	is	O
widely	widely	O
prescribed	prescribed	O
in	in	O
the	the	O
adult	adult	O
population	population	O
and	and	O
infrequently	infrequently	O
used	used	O
in	in	O
children	children	O
.	.	O

Methyldopa	methyldopa	B-Chemical
causes	causes	O
an	an	O
autoimmune	autoimmune	B-Disease
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
in	in	O
a	a	O
small	small	O
percentage	percentage	O
of	of	O
patients	patients	O
who	who	O
take	take	O
the	the	O
drug	drug	O
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
methyldopa-induced	methyldopa-induced	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
in	in	O
a	a	O
15-year-old	15-year-old	O
boy	boy	O
who	who	O
presented	presented	O
to	to	O
the	the	O
emergency	emergency	O
department	department	O
with	with	O
near-syncope	near-syncope	O
.	.	O

The	the	O
boy	boy	O
had	had	O
been	been	O
treated	treated	O
with	with	O
intravenous	intravenous	O
methyldopa	methyldopa	B-Chemical
during	during	O
a	a	O
trauma	trauma	O
admission	admission	O
seven	seven	O
weeks	weeks	O
prior	prior	O
to	to	O
presentation	presentation	O
.	.	O

Evaluation	evaluation	O
revealed	revealed	O
a	a	O
hemoglobin	hemoglobin	O
of	of	O
three	three	O
grams	grams	O
,	,	O
3	3	O
+	+	O
Coombs	coombs	O
'	'	O
test	test	O
with	with	O
polyspecific	polyspecific	O
anti-human	anti-human	O
globulin	globulin	O
and	and	O
monospecific	monospecific	O
IgG	igg	O
reagents	reagents	O
,	,	O
and	and	O
a	a	O
warm	warm	O
reacting	reacting	O
autoantibody	autoantibody	O
.	.	O

Transfusion	transfusion	O
and	and	O
corticosteroid	corticosteroid	O
therapy	therapy	O
resulted	resulted	O
in	in	O
a	a	O
complete	complete	O
recovery	recovery	O
of	of	O
the	the	O
patient	patient	O
.	.	O

Emergency	emergency	O
physicians	physicians	O
treating	treating	O
children	children	O
must	must	O
be	be	O
aware	aware	O
of	of	O
this	this	O
syndrome	syndrome	O
in	in	O
order	order	O
to	to	O
diagnose	diagnose	O
and	and	O
treat	treat	O
it	it	O
correctly	correctly	O
.	.	O

A	a	O
brief	brief	O
review	review	O
of	of	O
autoimmune	autoimmune	O
and	and	O
drug-induced	drug-induced	O
hemolytic	hemolytic	O
anemias	anemias	O
is	is	O
provided	provided	O
.	.	O

The	the	O
risk	risk	O
and	and	O
associated	associated	O
factors	factors	O
of	of	O
methamphetamine	methamphetamine	B-Chemical
psychosis	psychosis	B-Disease
in	in	O
methamphetamine-dependent	methamphetamine-dependent	O
patients	patients	O
in	in	O
Malaysia	malaysia	O
.	.	O

OBJECTIVE	objective	O
:	:	O
The	the	O
objective	objective	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
determine	determine	O
the	the	O
risk	risk	O
of	of	O
lifetime	lifetime	O
and	and	O
current	current	O
methamphetamine-induced	methamphetamine-induced	O
psychosis	psychosis	B-Disease
in	in	O
patients	patients	O
with	with	O
methamphetamine	methamphetamine	B-Chemical
dependence	dependence	O
.	.	O

The	the	O
association	association	O
between	between	O
psychiatric	psychiatric	B-Disease
co-morbidity	co-morbidity	O
and	and	O
methamphetamine-induced	methamphetamine-induced	O
psychosis	psychosis	B-Disease
was	was	O
also	also	O
studied	studied	O
.	.	O

METHODS	methods	O
:	:	O
This	this	O
was	was	O
a	a	O
cross-sectional	cross-sectional	O
study	study	O
conducted	conducted	O
concurrently	concurrently	O
at	at	O
a	a	O
teaching	teaching	O
hospital	hospital	O
and	and	O
a	a	O
drug	drug	O
rehabilitation	rehabilitation	O
center	center	O
in	in	O
Malaysia	malaysia	O
.	.	O

Patients	patients	O
with	with	O
the	the	O
diagnosis	diagnosis	O
of	of	O
methamphetamine	methamphetamine	B-Chemical
based	based	O
on	on	O
DSM-IV	dsm-iv	O
were	were	O
interviewed	interviewed	O
using	using	O
the	the	O
Mini	mini	O
International	international	O
Neuropsychiatric	neuropsychiatric	O
Interview	interview	O
(	(	O
M.I.N.I.	m.i.n.i.	O
)	)	O
for	for	O
methamphetamine-induced	methamphetamine-induced	O
psychosis	psychosis	B-Disease
and	and	O
other	other	O
Axis	axis	O
I	i	O
psychiatric	psychiatric	B-Disease
disorders	disorders	O
.	.	O

The	the	O
information	information	O
on	on	O
sociodemographic	sociodemographic	O
background	background	O
and	and	O
drug	drug	O
use	use	O
history	history	O
was	was	O
obtained	obtained	O
from	from	O
interview	interview	O
or	or	O
medical	medical	O
records	records	O
.	.	O

RESULTS	results	O
:	:	O
Of	of	O
292	292	O
subjects	subjects	O
,	,	O
47.9	47.9	O
%	%	O
of	of	O
the	the	O
subjects	subjects	O
had	had	O
a	a	O
past	past	O
history	history	O
of	of	O
psychotic	psychotic	B-Disease
symptoms	symptoms	I-Disease
and	and	O
13.0	13.0	O
%	%	O
of	of	O
the	the	O
patients	patients	O
were	were	O
having	having	O
current	current	O
psychotic	psychotic	B-Disease
symptoms	symptoms	I-Disease
.	.	O

Co-morbid	co-morbid	O
major	major	O
depressive	depressive	B-Disease
disorder	disorder	I-Disease
(	(	O
OR=7.18	or=7.18	O
,	,	O
95	95	O
CI=2.612	ci=2.612	O
-	-	O
19.708	19.708	O
)	)	O
,	,	O
bipolar	bipolar	B-Disease
disorder	disorder	I-Disease
(	(	O
OR=13.807	or=13.807	O
,	,	O
95	95	O
CI=5.194	ci=5.194	O
-	-	O
36.706	36.706	O
)	)	O
,	,	O
antisocial	antisocial	B-Disease
personality	personality	I-Disease
disorder	disorder	I-Disease
(	(	O
OR=12.619	or=12.619	O
,	,	O
95	95	O
CI=6.702	ci=6.702	O
-	-	O
23.759	23.759	O
)	)	O
and	and	O
heavy	heavy	O
methamphetamine	methamphetamine	B-Chemical
uses	uses	O
were	were	O
significantly	significantly	O
associated	associated	O
with	with	O
lifetime	lifetime	O
methamphetamine-induced	methamphetamine-induced	O
psychosis	psychosis	B-Disease
after	after	O
adjusted	adjusted	O
for	for	O
other	other	O
factors	factors	O
.	.	O

Major	major	O
depressive	depressive	B-Disease
disorder	disorder	I-Disease
(	(	O
OR=2.870	or=2.870	O
,	,	O
CI=1.154	ci=1.154	O
-	-	O
7.142	7.142	O
)	)	O
and	and	O
antisocial	antisocial	B-Disease
personality	personality	I-Disease
disorder	disorder	I-Disease
(	(	O
OR=3.299	or=3.299	O
,	,	O
95	95	O
CI=1.375	ci=1.375	O
-	-	O
7.914	7.914	O
)	)	O
were	were	O
the	the	O
only	only	O
factors	factors	O
associated	associated	O
with	with	O
current	current	O
psychosis	psychosis	B-Disease
.	.	O

CONCLUSION	conclusion	O
:	:	O
There	there	O
was	was	O
a	a	O
high	high	O
risk	risk	O
of	of	O
psychosis	psychosis	B-Disease
in	in	O
patients	patients	O
with	with	O
methamphetamine	methamphetamine	B-Chemical
dependence	dependence	O
.	.	O

It	it	O
was	was	O
associated	associated	O
with	with	O
co-morbid	co-morbid	O
affective	affective	B-Disease
disorder	disorder	I-Disease
,	,	O
antisocial	antisocial	B-Disease
personality	personality	I-Disease
,	,	O
and	and	O
heavy	heavy	O
methamphetamine	methamphetamine	B-Chemical
use	use	O
.	.	O

It	it	O
is	is	O
recommended	recommended	O
that	that	O
all	all	O
cases	cases	O
of	of	O
methamphetamine	methamphetamine	B-Chemical
dependence	dependence	O
should	should	O
be	be	O
screened	screened	O
for	for	O
psychotic	psychotic	B-Disease
symptoms	symptoms	I-Disease
.	.	O

Cerebellar	cerebellar	O
sensory	sensory	O
processing	processing	O
alterations	alterations	O
impact	impact	O
motor	motor	O
cortical	cortical	O
plasticity	plasticity	O
in	in	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
:	:	O
clues	clues	O
from	from	O
dyskinetic	dyskinetic	O
patients	patients	O
.	.	O

The	the	O
plasticity	plasticity	O
of	of	O
primary	primary	O
motor	motor	O
cortex	cortex	O
(	(	O
M1	m1	O
)	)	O
in	in	O
patients	patients	O
with	with	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
(	(	O
PD	pd	B-Disease
)	)	O
and	and	O
levodopa-induced	levodopa-induced	O
dyskinesias	dyskinesias	B-Disease
(	(	O
LIDs	lids	B-Disease
)	)	O
is	is	O
severely	severely	O
impaired	impaired	O
.	.	O

We	we	O
recently	recently	O
reported	reported	O
in	in	O
young	young	O
healthy	healthy	O
subjects	subjects	O
that	that	O
inhibitory	inhibitory	O
cerebellar	cerebellar	O
stimulation	stimulation	O
enhanced	enhanced	O
the	the	O
sensorimotor	sensorimotor	O
plasticity	plasticity	O
of	of	O
M1	m1	O
that	that	O
was	was	O
induced	induced	O
by	by	O
paired	paired	O
associative	associative	O
stimulation	stimulation	O
(	(	O
PAS	pas	O
)	)	O
.	.	O

This	this	O
study	study	O
demonstrates	demonstrates	O
that	that	O
the	the	O
deficient	deficient	O
sensorimotor	sensorimotor	O
M1	m1	O
plasticity	plasticity	O
in	in	O
16	16	O
patients	patients	O
with	with	O
LIDs	lids	B-Disease
could	could	O
be	be	O
reinstated	reinstated	O
by	by	O
a	a	O
single	single	O
session	session	O
of	of	O
real	real	O
inhibitory	inhibitory	O
cerebellar	cerebellar	O
stimulation	stimulation	O
but	but	O
not	not	O
sham	sham	O
stimulation	stimulation	O
.	.	O

This	this	O
was	was	O
evident	evident	O
only	only	O
when	when	O
a	a	O
sensory	sensory	O
component	component	O
was	was	O
involved	involved	O
in	in	O
the	the	O
induction	induction	O
of	of	O
plasticity	plasticity	O
,	,	O
indicating	indicating	O
that	that	O
cerebellar	cerebellar	O
sensory	sensory	O
processing	processing	O
function	function	O
is	is	O
involved	involved	O
in	in	O
the	the	O
resurgence	resurgence	O
of	of	O
M1	m1	O
plasticity	plasticity	O
.	.	O

The	the	O
benefit	benefit	O
of	of	O
inhibitory	inhibitory	O
cerebellar	cerebellar	O
stimulation	stimulation	O
on	on	O
LIDs	lids	B-Disease
is	is	O
known	known	O
.	.	O

To	to	O
explore	explore	O
whether	whether	O
this	this	O
benefit	benefit	O
is	is	O
linked	linked	O
to	to	O
the	the	O
restoration	restoration	O
of	of	O
sensorimotor	sensorimotor	O
plasticity	plasticity	O
of	of	O
M1	m1	O
,	,	O
we	we	O
conducted	conducted	O
an	an	O
additional	additional	O
study	study	O
looking	looking	O
at	at	O
changes	changes	O
in	in	O
LIDs	lids	B-Disease
and	and	O
PAS-induced	pas-induced	O
plasticity	plasticity	O
after	after	O
10	10	O
sessions	sessions	O
of	of	O
either	either	O
bilateral	bilateral	O
,	,	O
real	real	O
inhibitory	inhibitory	O
cerebellar	cerebellar	O
stimulation	stimulation	O
or	or	O
sham	sham	O
stimulation	stimulation	O
.	.	O

Only	only	O
real	real	O
and	and	O
not	not	O
sham	sham	O
stimulation	stimulation	O
had	had	O
an	an	O
antidyskinetic	antidyskinetic	O
effect	effect	O
and	and	O
it	it	O
was	was	O
paralleled	paralleled	O
by	by	O
a	a	O
resurgence	resurgence	O
in	in	O
the	the	O
sensorimotor	sensorimotor	O
plasticity	plasticity	O
of	of	O
M1	m1	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
alterations	alterations	O
in	in	O
cerebellar	cerebellar	O
sensory	sensory	O
processing	processing	O
function	function	O
,	,	O
occurring	occurring	O
secondary	secondary	O
to	to	O
abnormal	abnormal	O
basal	basal	O
ganglia	ganglia	O
signals	signals	O
reaching	reaching	O
it	it	O
,	,	O
may	may	O
be	be	O
an	an	O
important	important	O
element	element	O
contributing	contributing	O
to	to	O
the	the	O
maladaptive	maladaptive	O
sensorimotor	sensorimotor	O
plasticity	plasticity	O
of	of	O
M1	m1	O
and	and	O
the	the	O
emergence	emergence	O
of	of	O
abnormal	abnormal	O
involuntary	involuntary	O
movements	movements	O
.	.	O

The	the	O
long-term	long-term	O
safety	safety	O
of	of	O
danazol	danazol	B-Chemical
in	in	O
women	women	O
with	with	O
hereditary	hereditary	O
angioedema	angioedema	B-Disease
.	.	O

Although	although	O
the	the	O
short-term	short-term	O
safety	safety	O
(	(	O
less	less	O
than	than	O
or	or	O
equal	equal	O
to	to	O
6	6	O
months	months	O
)	)	O
of	of	O
danazol	danazol	B-Chemical
has	has	O
been	been	O
established	established	O
in	in	O
a	a	O
variety	variety	O
of	of	O
settings	settings	O
,	,	O
no	no	O
information	information	O
exists	exists	O
as	as	O
to	to	O
its	its	O
long-term	long-term	O
safety	safety	O
.	.	O

We	we	O
therefore	therefore	O
investigated	investigated	O
the	the	O
long-term	long-term	O
safety	safety	O
of	of	O
danazol	danazol	B-Chemical
by	by	O
performing	performing	O
a	a	O
retrospective	retrospective	O
chart	chart	O
review	review	O
of	of	O
60	60	O
female	female	O
patients	patients	O
with	with	O
hereditary	hereditary	O
angioedema	angioedema	B-Disease
treated	treated	O
with	with	O
danazol	danazol	B-Chemical
for	for	O
a	a	O
continuous	continuous	O
period	period	O
of	of	O
6	6	O
months	months	O
or	or	O
longer	longer	O
.	.	O

The	the	O
mean	mean	O
age	age	O
of	of	O
the	the	O
patients	patients	O
was	was	O
35.2	35.2	O
years	years	O
and	and	O
the	the	O
mean	mean	O
duration	duration	O
of	of	O
therapy	therapy	O
was	was	O
59.7	59.7	O
months	months	O
.	.	O

Virtually	virtually	O
all	all	O
patients	patients	O
experienced	experienced	O
one	one	O
or	or	O
more	more	O
adverse	adverse	O
reactions	reactions	O
.	.	O

Menstrual	menstrual	O
abnormalities	abnormalities	O
(	(	O
79	79	O
%	%	O
)	)	O
,	,	O
weight	weight	B-Disease
gain	gain	I-Disease
(	(	O
60	60	O
%	%	O
)	)	O
,	,	O
muscle	muscle	O
cramps/myalgias	cramps/myalgias	O
(	(	O
40	40	O
%	%	O
)	)	O
,	,	O
and	and	O
transaminase	transaminase	O
elevations	elevations	O
(	(	O
40	40	O
%	%	O
)	)	O
were	were	O
the	the	O
most	most	O
common	common	O
adverse	adverse	O
reactions	reactions	O
.	.	O

The	the	O
drug	drug	O
was	was	O
discontinued	discontinued	O
due	due	O
to	to	O
adverse	adverse	O
reactions	reactions	O
in	in	O
8	8	O
patients	patients	O
.	.	O

No	no	O
patient	patient	O
has	has	O
died	died	O
or	or	O
suffered	suffered	O
any	any	O
apparent	apparent	O
long-term	long-term	O
sequelae	sequelae	O
that	that	O
were	were	O
directly	directly	O
attributable	attributable	O
to	to	O
the	the	O
drug	drug	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
,	,	O
despite	despite	O
a	a	O
relatively	relatively	O
high	high	O
incidence	incidence	O
of	of	O
adverse	adverse	O
reactions	reactions	O
,	,	O
danazol	danazol	B-Chemical
has	has	O
proven	proven	O
to	to	O
be	be	O
remarkably	remarkably	O
safe	safe	O
over	over	O
the	the	O
long-term	long-term	O
in	in	O
this	this	O
group	group	O
of	of	O
patients	patients	O
.	.	O

The	the	O
function	function	O
of	of	O
P2X3	p2x3	O
receptor	receptor	O
and	and	O
NK1	nk1	O
receptor	receptor	O
antagonists	antagonists	O
on	on	O
cyclophosphamide-induced	cyclophosphamide-induced	O
cystitis	cystitis	B-Disease
in	in	O
rats	rats	O
.	.	O

PURPOSE	purpose	O
:	:	O
The	the	O
purpose	purpose	O
of	of	O
the	the	O
study	study	O
is	is	O
to	to	O
explore	explore	O
the	the	O
function	function	O
of	of	O
P2X3	p2x3	O
and	and	O
NK1	nk1	O
receptors	receptors	O
antagonists	antagonists	O
on	on	O
cyclophosphamide	cyclophosphamide	B-Chemical
(CYP)-induced	(cyp)-induced	O
cystitis	cystitis	B-Disease
in	in	O
rats	rats	O
.	.	O

METHODS	methods	O
:	:	O
Sixty	sixty	O
female	female	O
Sprague-Dawley	sprague-dawley	O
(	(	O
SD	sd	O
)	)	O
rats	rats	O
were	were	O
randomly	randomly	O
divided	divided	O
into	into	O
three	three	O
groups	groups	O
.	.	O

The	the	O
rats	rats	O
in	in	O
the	the	O
control	control	O
group	group	O
were	were	O
intraperitoneally	intraperitoneally	O
(	(	O
i.p	i.p	O
.	.	O
)	)	O
injected	injected	O
with	with	O
0.9	0.9	O
%	%	O
saline	saline	O
(	(	O
4	4	O
ml/kg	ml/kg	O
)	)	O
;	;	O
the	the	O
rats	rats	O
in	in	O
the	the	O
model	model	O
group	group	O
were	were	O
i.p	i.p	O
.	.	O
injected	injected	O
with	with	O
CYP	cyp	O
(	(	O
150	150	O
mg/kg	mg/kg	O
)	)	O
;	;	O
and	and	O
the	the	O
rats	rats	O
in	in	O
the	the	O
intervention	intervention	O
group	group	O
were	were	O
i.p	i.p	O
.	.	O
injected	injected	O
with	with	O
CYP	cyp	O
with	with	O
subsequently	subsequently	O
perfusion	perfusion	O
of	of	O
bladder	bladder	O
with	with	O
P2X3	p2x3	O
and	and	O
NK1	nk1	O
receptors	receptors	O
'	'	O
antagonists	antagonists	O
,	,	O
Suramin	suramin	O
and	and	O
GR	gr	B-Chemical
82334	82334	I-Chemical
.	.	O

Spontaneous	spontaneous	O
pain	pain	B-Disease
behaviors	behaviors	O
following	following	O
the	the	O
administration	administration	O
of	of	O
CYP	cyp	O
were	were	O
observed	observed	O
.	.	O

Urodynamic	urodynamic	O
parameters	parameters	O
,	,	O
bladder	bladder	O
pressure-volume	pressure-volume	O
curve	curve	O
,	,	O
maximum	maximum	O
voiding	voiding	O
pressure	pressure	O
(	(	O
MVP	mvp	O
)	)	O
,	,	O
and	and	O
maximum	maximum	O
cystometric	cystometric	O
capacity	capacity	O
(	(	O
MCC	mcc	O
)	)	O
,	,	O
were	were	O
recorded	recorded	O
.	.	O

Pathological	pathological	O
changes	changes	O
in	in	O
bladder	bladder	O
tissue	tissue	O
were	were	O
observed	observed	O
.	.	O

Immunofluorescence	immunofluorescence	O
was	was	O
used	used	O
to	to	O
detect	detect	O
the	the	O
expression	expression	O
of	of	O
P2X3	p2x3	O
and	and	O
NK1	nk1	O
receptors	receptors	O
in	in	O
bladder	bladder	O
.	.	O

RESULTS	results	O
:	:	O
Cyclophosphamide	cyclophosphamide	B-Chemical
treatment	treatment	O
increased	increased	O
the	the	O
spontaneous	spontaneous	O
pain	pain	B-Disease
behaviors	behaviors	O
scores	scores	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
bladder	bladder	O
instability	instability	O
during	during	O
urine	urine	O
storage	storage	O
period	period	O
of	of	O
model	model	O
group	group	O
was	was	O
significantly	significantly	O
higher	higher	O
than	than	O
intervention	intervention	O
group	group	O
(	(	O
X(2	x(2	O
)	)	O
=	=	O
7.619	7.619	O
,	,	O
P	p	O
=	=	O
0.007	0.007	O
)	)	O
and	and	O
control	control	O
group	group	O
(	(	O
X(2	x(2	O
)	)	O
=	=	O
13.755	13.755	O
,	,	O
P	p	O
=	=	O
0.000	0.000	O
)	)	O
.	.	O

MCC	mcc	O
in	in	O
the	the	O
model	model	O
group	group	O
was	was	O
lower	lower	O
than	than	O
the	the	O
control	control	O
and	and	O
intervention	intervention	O
groups	groups	O
(	(	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

Histological	histological	O
changes	changes	O
evident	evident	O
in	in	O
model	model	O
and	and	O
intervention	intervention	O
groups	groups	O
rats	rats	O
'	'	O
bladder	bladder	O
included	included	O
edema	edema	B-Disease
,	,	O
vasodilation	vasodilation	O
,	,	O
and	and	O
infiltration	infiltration	O
of	of	O
inflammatory	inflammatory	O
cells	cells	O
.	.	O

In	in	O
model	model	O
group	group	O
,	,	O
the	the	O
expression	expression	O
of	of	O
P2X3	p2x3	O
receptor	receptor	O
increased	increased	O
in	in	O
urothelium	urothelium	O
and	and	O
suburothelium	suburothelium	O
,	,	O
and	and	O
NK1	nk1	O
receptor	receptor	O
increased	increased	O
in	in	O
suburothelium	suburothelium	O
,	,	O
while	while	O
the	the	O
expression	expression	O
of	of	O
them	them	O
in	in	O
intervention	intervention	O
group	group	O
was	was	O
lower	lower	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
In	in	O
CYP-induced	cyp-induced	O
cystitis	cystitis	B-Disease
,	,	O
the	the	O
expression	expression	O
of	of	O
P2X3	p2x3	O
and	and	O
NK1	nk1	O
receptors	receptors	O
increased	increased	O
in	in	O
urothelium	urothelium	O
and/or	and/or	O
suburothelium	suburothelium	O
.	.	O

Perfusion	perfusion	O
of	of	O
bladder	bladder	O
with	with	O
P2X3	p2x3	O
and	and	O
NK1	nk1	O
receptors	receptors	O
antagonists	antagonists	O
ameliorated	ameliorated	O
the	the	O
bladder	bladder	O
function	function	O
.	.	O

Patient	patient	O
tolerance	tolerance	O
study	study	O
of	of	O
topical	topical	O
chlorhexidine	chlorhexidine	B-Chemical
diphosphanilate	diphosphanilate	I-Chemical
:	:	O
a	a	O
new	new	O
topical	topical	O
agent	agent	O
for	for	O
burns	burns	O
.	.	O

Effective	effective	O
topical	topical	O
antimicrobial	antimicrobial	O
agents	agents	O
decrease	decrease	O
infection	infection	B-Disease
and	and	O
mortality	mortality	O
in	in	O
burn	burn	O
patients	patients	O
.	.	O

Chlorhexidine	chlorhexidine	B-Chemical
phosphanilate	phosphanilate	I-Chemical
(	(	O
CHP	chp	O
)	)	O
,	,	O
a	a	O
new	new	O
broad-spectrum	broad-spectrum	O
antimicrobial	antimicrobial	O
agent	agent	O
,	,	O
has	has	O
been	been	O
evaluated	evaluated	O
as	as	O
a	a	O
topical	topical	O
burn	burn	O
wound	wound	O
dressing	dressing	O
in	in	O
cream	cream	O
form	form	O
,	,	O
but	but	O
preliminary	preliminary	O
clinical	clinical	O
trials	trials	O
reported	reported	O
that	that	O
it	it	O
was	was	O
painful	painful	O
upon	upon	O
application	application	O
.	.	O

This	this	O
study	study	O
compared	compared	O
various	various	O
concentrations	concentrations	O
of	of	O
CHP	chp	O
to	to	O
determine	determine	O
if	if	O
a	a	O
tolerable	tolerable	O
concentration	concentration	O
could	could	O
be	be	O
identified	identified	O
with	with	O
retention	retention	O
of	of	O
antimicrobial	antimicrobial	O
efficacy	efficacy	O
.	.	O

Twenty-nine	twenty-nine	O
burn	burn	O
patients	patients	O
,	,	O
each	each	O
with	with	O
two	two	O
similar	similar	O
burns	burns	O
which	which	O
could	could	O
be	be	O
separately	separately	O
treated	treated	O
,	,	O
were	were	O
given	given	O
pairs	pairs	O
of	of	O
treatments	treatments	O
at	at	O
successive	successive	O
12-h	12-h	O
intervals	intervals	O
over	over	O
a	a	O
3-day	3-day	O
period	period	O
.	.	O

One	one	O
burn	burn	O
site	site	O
was	was	O
treated	treated	O
with	with	O
each	each	O
of	of	O
four	four	O
different	different	O
CHP	chp	O
concentrations	concentrations	O
,	,	O
from	from	O
0.25	0.25	O
per	per	O
cent	cent	O
to	to	O
2	2	O
per	per	O
cent	cent	O
,	,	O
their	their	O
vehicle	vehicle	O
,	,	O
and	and	O
1	1	O
per	per	O
cent	cent	O
silver	silver	O
sulphadiazine	sulphadiazine	O
(	(	O
AgSD	agsd	O
)	)	O
cream	cream	O
,	,	O
an	an	O
antimicrobial	antimicrobial	O
agent	agent	O
frequently	frequently	O
used	used	O
for	for	O
topical	topical	O
treatment	treatment	O
of	of	O
burn	burn	O
wounds	wounds	O
.	.	O

The	the	O
other	other	O
site	site	O
was	was	O
always	always	O
treated	treated	O
with	with	O
AgSD	agsd	O
cream	cream	O
.	.	O

There	there	O
was	was	O
a	a	O
direct	direct	O
relationship	relationship	O
between	between	O
CHP	chp	O
concentration	concentration	O
and	and	O
patients	patients	O
'	'	O
ratings	ratings	O
of	of	O
pain	pain	B-Disease
on	on	O
an	an	O
analogue	analogue	O
scale	scale	O
.	.	O

The	the	O
0.25	0.25	O
per	per	O
cent	cent	O
CHP	chp	O
cream	cream	O
was	was	O
closest	closest	O
to	to	O
AgSD	agsd	O
in	in	O
pain	pain	B-Disease
tolerance	tolerance	O
;	;	O
however	however	O
,	,	O
none	none	O
of	of	O
the	the	O
treatments	treatments	O
differed	differed	O
statistically	statistically	O
from	from	O
AgSD	agsd	O
or	or	O
from	from	O
each	each	O
other	other	O
.	.	O

In	in	O
addition	addition	O
,	,	O
ease	ease	O
of	of	O
application	application	O
of	of	O
CHP	chp	O
creams	creams	O
was	was	O
less	less	O
satisfactory	satisfactory	O
than	than	O
that	that	O
of	of	O
AgSD	agsd	O
.	.	O

It	it	O
was	was	O
concluded	concluded	O
that	that	O
formulations	formulations	O
at	at	O
or	or	O
below	below	O
0.5	0.5	O
per	per	O
cent	cent	O
CHP	chp	O
may	may	O
prove	prove	O
acceptable	acceptable	O
for	for	O
wound	wound	O
care	care	O
,	,	O
but	but	O
the	the	O
vehicle	vehicle	O
system	system	O
needs	needs	O
pharmaceutical	pharmaceutical	O
improvement	improvement	O
to	to	O
render	render	O
it	it	O
more	more	O
tolerable	tolerable	O
and	and	O
easier	easier	O
to	to	O
use	use	O
.	.	O

Acute	acute	O
hepatitis	hepatitis	B-Disease
associated	associated	O
with	with	O
clopidogrel	clopidogrel	B-Chemical
:	:	O
a	a	O
case	case	O
report	report	O
and	and	O
review	review	O
of	of	O
the	the	O
literature	literature	O
.	.	O

Drug-induced	drug-induced	O
hepatotoxicity	hepatotoxicity	B-Disease
is	is	O
a	a	O
common	common	O
cause	cause	O
of	of	O
acute	acute	O
hepatitis	hepatitis	B-Disease
,	,	O
and	and	O
the	the	O
recognition	recognition	O
of	of	O
the	the	O
responsible	responsible	O
drug	drug	O
may	may	O
be	be	O
difficult	difficult	O
.	.	O

We	we	O
describe	describe	O
a	a	O
case	case	O
of	of	O
clopidogrel-related	clopidogrel-related	O
acute	acute	O
hepatitis	hepatitis	B-Disease
.	.	O

The	the	O
diagnosis	diagnosis	O
is	is	O
strongly	strongly	O
suggested	suggested	O
by	by	O
an	an	O
accurate	accurate	O
medical	medical	O
history	history	O
and	and	O
liver	liver	O
biopsy	biopsy	O
.	.	O

Reports	reports	O
about	about	O
cases	cases	O
of	of	O
hepatotoxicity	hepatotoxicity	B-Disease
due	due	O
to	to	O
clopidogrel	clopidogrel	B-Chemical
are	are	O
increasing	increasing	O
in	in	O
the	the	O
last	last	O
few	few	O
years	years	O
,	,	O
after	after	O
the	the	O
increased	increased	O
use	use	O
of	of	O
this	this	O
drug	drug	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
we	we	O
believe	believe	O
that	that	O
physicians	physicians	O
should	should	O
carefully	carefully	O
consider	consider	O
the	the	O
risk	risk	O
of	of	O
drug-induced	drug-induced	O
hepatic	hepatic	B-Disease
injury	injury	I-Disease
when	when	O
clopidogrel	clopidogrel	B-Chemical
is	is	O
prescribed	prescribed	O
.	.	O

Bortezomib	bortezomib	O
and	and	O
dexamethasone	dexamethasone	B-Chemical
as	as	O
salvage	salvage	O
therapy	therapy	O
in	in	O
patients	patients	O
with	with	O
relapsed/refractory	relapsed/refractory	O
multiple	multiple	B-Disease
myeloma	myeloma	I-Disease
:	:	O
analysis	analysis	O
of	of	O
long-term	long-term	O
clinical	clinical	O
outcomes	outcomes	O
.	.	O

Bortezomib	bortezomib	O
(bort)-dexamethasone	(bort)-dexamethasone	O
(	(	O
dex	dex	B-Chemical
)	)	O
is	is	O
an	an	O
effective	effective	O
therapy	therapy	O
for	for	O
relapsed/refractory	relapsed/refractory	O
(	(	O
R/R	r/r	O
)	)	O
multiple	multiple	B-Disease
myeloma	myeloma	I-Disease
(	(	O
MM	mm	O
)	)	O
.	.	O

This	this	O
retrospective	retrospective	O
study	study	O
investigated	investigated	O
the	the	O
combination	combination	O
of	of	O
bort	bort	O
(	(	O
1.3	1.3	O
mg/m(2	mg/m(2	O
)	)	O
on	on	O
days	days	O
1	1	O
,	,	O
4	4	O
,	,	O
8	8	O
,	,	O
and	and	O
11	11	O
every	every	O
3	3	O
weeks	weeks	O
)	)	O
and	and	O
dex	dex	B-Chemical
(	(	O
20	20	O
mg	mg	O
on	on	O
the	the	O
day	day	O
of	of	O
and	and	O
the	the	O
day	day	O
after	after	O
bort	bort	O
)	)	O
as	as	O
salvage	salvage	O
treatment	treatment	O
in	in	O
85	85	O
patients	patients	O
with	with	O
R/R	r/r	O
MM	mm	O
after	after	O
prior	prior	O
autologous	autologous	O
stem	stem	O
cell	cell	O
transplantation	transplantation	O
or	or	O
conventional	conventional	O
chemotherapy	chemotherapy	O
.	.	O

The	the	O
median	median	O
number	number	O
of	of	O
prior	prior	O
lines	lines	O
of	of	O
therapy	therapy	O
was	was	O
2	2	O
.	.	O

Eighty-seven	eighty-seven	O
percent	percent	O
of	of	O
the	the	O
patients	patients	O
had	had	O
received	received	O
immunomodulatory	immunomodulatory	O
drugs	drugs	O
included	included	O
in	in	O
some	some	O
line	line	O
of	of	O
therapy	therapy	O
before	before	O
bort-dex	bort-dex	O
.	.	O

The	the	O
median	median	O
number	number	O
of	of	O
bort-dex	bort-dex	O
cycles	cycles	O
was	was	O
6	6	O
,	,	O
up	up	O
to	to	O
a	a	O
maximum	maximum	O
of	of	O
12	12	O
cycles	cycles	O
.	.	O

On	on	O
an	an	O
intention-to-treat	intention-to-treat	O
basis	basis	O
,	,	O
55	55	O
%	%	O
of	of	O
the	the	O
patients	patients	O
achieved	achieved	O
at	at	O
least	least	O
partial	partial	O
response	response	O
,	,	O
including	including	O
19	19	O
%	%	O
CR	cr	B-Chemical
and	and	O
35	35	O
%	%	O
achieved	achieved	O
at	at	O
least	least	O
very	very	O
good	good	O
partial	partial	O
response	response	O
.	.	O

Median	median	O
durations	durations	O
of	of	O
response	response	O
,	,	O
time	time	O
to	to	O
next	next	O
therapy	therapy	O
and	and	O
treatment-free	treatment-free	O
interval	interval	O
were	were	O
8	8	O
,	,	O
11.2	11.2	O
,	,	O
and	and	O
5.1	5.1	O
months	months	O
,	,	O
respectively	respectively	O
.	.	O

The	the	O
most	most	O
relevant	relevant	O
adverse	adverse	O
event	event	O
was	was	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
,	,	O
which	which	O
occurred	occurred	O
in	in	O
78	78	O
%	%	O
of	of	O
the	the	O
patients	patients	O
(	(	O
grade	grade	O
II	ii	O
,	,	O
38	38	O
%	%	O
;	;	O
grade	grade	O
III	iii	O
,	,	O
21	21	O
%	%	O
)	)	O
and	and	O
led	led	O
to	to	O
treatment	treatment	O
discontinuation	discontinuation	O
in	in	O
6	6	O
%	%	O
.	.	O

With	with	O
a	a	O
median	median	O
follow	follow	O
up	up	O
of	of	O
22	22	O
months	months	O
,	,	O
median	median	O
time	time	O
to	to	O
progression	progression	O
,	,	O
progression-free	progression-free	O
survival	survival	O
(	(	O
PFS	pfs	O
)	)	O
and	and	O
overall	overall	O
survival	survival	O
(	(	O
OS	os	O
)	)	O
were	were	O
8.9	8.9	O
,	,	O
8.7	8.7	O
,	,	O
and	and	O
22	22	O
months	months	O
,	,	O
respectively	respectively	O
.	.	O

Prolonged	prolonged	O
PFS	pfs	O
and	and	O
OS	os	O
were	were	O
observed	observed	O
in	in	O
patients	patients	O
achieving	achieving	O
CR	cr	B-Chemical
and	and	O
receiving	receiving	O
bort-dex	bort-dex	O
a	a	O
single	single	O
line	line	O
of	of	O
prior	prior	O
therapy	therapy	O
.	.	O

Bort-dex	bort-dex	O
was	was	O
an	an	O
effective	effective	O
salvage	salvage	O
treatment	treatment	O
for	for	O
MM	mm	O
patients	patients	O
,	,	O
particularly	particularly	O
for	for	O
those	those	O
in	in	O
first	first	O
relapse	relapse	O
.	.	O

Pubertal	pubertal	O
exposure	exposure	O
to	to	O
Bisphenol	bisphenol	B-Chemical
A	a	I-Chemical
increases	increases	O
anxiety-like	anxiety-like	O
behavior	behavior	O
and	and	O
decreases	decreases	O
acetylcholinesterase	acetylcholinesterase	O
activity	activity	O
of	of	O
hippocampus	hippocampus	O
in	in	O
adult	adult	O
male	male	O
mice	mice	O
.	.	O

The	the	O
negative	negative	O
effects	effects	O
of	of	O
Bisphenol	bisphenol	B-Chemical
A	a	I-Chemical
(	(	O
BPA	bpa	O
)	)	O
on	on	O
neurodevelopment	neurodevelopment	O
and	and	O
behaviors	behaviors	O
have	have	O
been	been	O
well	well	O
established	established	O
.	.	O

Acetylcholinesterase	acetylcholinesterase	O
(	(	O
AChE	ache	O
)	)	O
is	is	O
a	a	O
regulatory	regulatory	O
enzyme	enzyme	O
which	which	O
is	is	O
involved	involved	O
in	in	O
anxiety-like	anxiety-like	O
behavior	behavior	O
.	.	O

This	this	O
study	study	O
investigated	investigated	O
behavioral	behavioral	O
phenotypes	phenotypes	O
and	and	O
AChE	ache	O
activity	activity	O
in	in	O
male	male	O
mice	mice	O
following	following	O
BPA	bpa	O
exposure	exposure	O
during	during	O
puberty	puberty	O
.	.	O

On	on	O
postnatal	postnatal	O
day	day	O
(	(	O
PND	pnd	O
)	)	O
35	35	O
,	,	O
male	male	O
mice	mice	O
were	were	O
exposed	exposed	O
to	to	O
50	50	O
mg	mg	O
BPA/kg	bpa/kg	O
diet	diet	O
per	per	O
day	day	O
for	for	O
a	a	O
period	period	O
of	of	O
35	35	O
days	days	O
.	.	O

On	on	O
PND71	pnd71	O
,	,	O
a	a	O
behavioral	behavioral	O
assay	assay	O
was	was	O
performed	performed	O
using	using	O
the	the	O
elevated	elevated	O
plus	plus	O
maze	maze	O
(	(	O
EPM	epm	O
)	)	O
and	and	O
the	the	O
light/dark	light/dark	O
test	test	O
.	.	O

In	in	O
addition	addition	O
,	,	O
AChE	ache	O
activity	activity	O
was	was	O
measured	measured	O
in	in	O
the	the	O
prefrontal	prefrontal	O
cortex	cortex	O
,	,	O
hypothalamus	hypothalamus	O
,	,	O
cerebellum	cerebellum	O
and	and	O
hippocampus	hippocampus	O
.	.	O

Results	results	O
from	from	O
our	our	O
behavioral	behavioral	O
phenotyping	phenotyping	O
indicated	indicated	O
that	that	O
anxiety-like	anxiety-like	O
behavior	behavior	O
was	was	O
increased	increased	O
in	in	O
mice	mice	O
exposed	exposed	O
to	to	O
BPA	bpa	O
.	.	O

AChE	ache	O
activity	activity	O
was	was	O
significantly	significantly	O
decreased	decreased	O
in	in	O
the	the	O
hippocampus	hippocampus	O
of	of	O
mice	mice	O
with	with	O
BPA	bpa	O
compared	compared	O
to	to	O
control	control	O
mice	mice	O
,	,	O
whereas	whereas	O
no	no	O
difference	difference	O
was	was	O
found	found	O
in	in	O
the	the	O
prefrontal	prefrontal	O
cortex	cortex	O
,	,	O
hypothalamus	hypothalamus	O
and	and	O
cerebellum	cerebellum	O
.	.	O

Our	our	O
findings	findings	O
showed	showed	O
that	that	O
pubertal	pubertal	O
BPA	bpa	O
exposure	exposure	O
increased	increased	O
anxiety-like	anxiety-like	O
behavior	behavior	O
,	,	O
which	which	O
may	may	O
be	be	O
associated	associated	O
with	with	O
decreased	decreased	O
AChE	ache	O
activity	activity	O
of	of	O
the	the	O
hippocampus	hippocampus	O
in	in	O
adult	adult	O
male	male	O
mice	mice	O
.	.	O

Further	further	O
studies	studies	O
are	are	O
necessary	necessary	O
to	to	O
investigate	investigate	O
the	the	O
cholinergic	cholinergic	O
signaling	signaling	O
of	of	O
the	the	O
hippocampus	hippocampus	O
in	in	O
PBE	pbe	O
induced	induced	O
anxiety-like	anxiety-like	O
behaviors	behaviors	O
.	.	O

Biochemical	biochemical	O
effects	effects	O
of	of	O
Solidago	solidago	O
virgaurea	virgaurea	O
extract	extract	O
on	on	O
experimental	experimental	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

Cardiovascular	cardiovascular	B-Disease
diseases	diseases	I-Disease
(	(	O
CVDs	cvds	O
)	)	O
are	are	O
the	the	O
major	major	O
health	health	O
problem	problem	O
of	of	O
advanced	advanced	O
as	as	O
well	well	O
as	as	O
developing	developing	O
countries	countries	O
of	of	O
the	the	O
world	world	O
.	.	O

The	the	O
aim	aim	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
the	the	O
protective	protective	O
effect	effect	O
of	of	O
the	the	O
Solidago	solidago	O
virgaurea	virgaurea	O
extract	extract	O
on	on	O
isoproterenol-induced	isoproterenol-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
in	in	O
rats	rats	O
.	.	O

The	the	O
subcutaneous	subcutaneous	O
injection	injection	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
(	(	O
30	30	O
mg/kg	mg/kg	O
)	)	O
into	into	O
rats	rats	O
twice	twice	O
at	at	O
an	an	O
interval	interval	O
of	of	O
24	24	O
h	h	B-Chemical
,	,	O
for	for	O
two	two	O
consecutive	consecutive	O
days	days	O
,	,	O
led	led	O
to	to	O
a	a	O
significant	significant	O
increase	increase	O
in	in	O
serum	serum	O
lactate	lactate	B-Chemical
dehydrogenase	dehydrogenase	O
,	,	O
creatine	creatine	B-Chemical
phosphokinase	phosphokinase	O
,	,	O
alanine	alanine	B-Chemical
transaminase	transaminase	I-Chemical
,	,	O
aspartate	aspartate	B-Chemical
transaminase	transaminase	O
,	,	O
and	and	O
angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	O
activities	activities	O
,	,	O
total	total	O
cholesterol	cholesterol	B-Chemical
,	,	O
triglycerides	triglycerides	O
,	,	O
free	free	O
serum	serum	O
fatty	fatty	O
acid	acid	O
,	,	O
cardiac	cardiac	O
tissue	tissue	O
malondialdehyde	malondialdehyde	B-Chemical
(	(	O
MDA	mda	O
)	)	O
,	,	O
and	and	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
levels	levels	O
and	and	O
a	a	O
significant	significant	O
decrease	decrease	O
in	in	O
levels	levels	O
of	of	O
glutathione	glutathione	B-Chemical
and	and	O
superoxide	superoxide	B-Chemical
dismutase	dismutase	I-Chemical
in	in	O
cardiac	cardiac	O
tissue	tissue	O
as	as	O
compared	compared	O
to	to	O
the	the	O
normal	normal	O
control	control	O
group	group	O
(	(	O
P	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

Pretreatment	pretreatment	O
with	with	O
S.	s.	O
virgaurea	virgaurea	O
extract	extract	O
for	for	O
5	5	O
weeks	weeks	O
at	at	O
a	a	O
dose	dose	O
of	of	O
250	250	O
mg/kg	mg/kg	O
followed	followed	O
by	by	O
isoproterenol	isoproterenol	B-Chemical
injection	injection	O
significantly	significantly	O
prevented	prevented	O
the	the	O
observed	observed	O
alterations	alterations	O
.	.	O

Captopril	captopril	B-Chemical
(	(	O
50	50	O
mg/kg/day	mg/kg/day	O
,	,	O
given	given	O
orally	orally	O
)	)	O
,	,	O
an	an	O
inhibitor	inhibitor	O
of	of	O
angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	O
used	used	O
as	as	O
a	a	O
standard	standard	O
cardioprotective	cardioprotective	O
drug	drug	O
,	,	O
was	was	O
used	used	O
as	as	O
a	a	O
positive	positive	O
control	control	O
in	in	O
this	this	O
study	study	O
.	.	O

The	the	O
data	data	O
of	of	O
the	the	O
present	present	O
study	study	O
suggest	suggest	O
that	that	O
S.	s.	O
virgaurea	virgaurea	O
extract	extract	O
exerts	exerts	O
its	its	O
protective	protective	O
effect	effect	O
by	by	O
decreasing	decreasing	O
MDA	mda	O
level	level	O
and	and	O
increasing	increasing	O
the	the	O
antioxidant	antioxidant	O
status	status	O
in	in	O
isoproterenol-treated	isoproterenol-treated	O
rats	rats	O
.	.	O

The	the	O
study	study	O
emphasizes	emphasizes	O
the	the	O
beneficial	beneficial	O
action	action	O
of	of	O
S.	s.	O
virgaurea	virgaurea	O
extract	extract	O
as	as	O
a	a	O
cardioprotective	cardioprotective	O
agent	agent	O
.	.	O

"	"	O
Real-world	real-world	O
"	"	O
data	data	O
on	on	O
the	the	O
efficacy	efficacy	O
and	and	O
safety	safety	O
of	of	O
lenalidomide	lenalidomide	O
and	and	O
dexamethasone	dexamethasone	B-Chemical
in	in	O
patients	patients	O
with	with	O
relapsed/refractory	relapsed/refractory	O
multiple	multiple	B-Disease
myeloma	myeloma	I-Disease
who	who	O
were	were	O
treated	treated	O
according	according	O
to	to	O
the	the	O
standard	standard	O
clinical	clinical	O
practice	practice	O
:	:	O
a	a	O
study	study	O
of	of	O
the	the	O
Greek	greek	O
Myeloma	myeloma	O
Study	study	O
Group	group	O
.	.	O

Lenalidomide	lenalidomide	O
and	and	O
dexamethasone	dexamethasone	B-Chemical
(	(	O
RD	rd	O
)	)	O
is	is	O
a	a	O
standard	standard	O
of	of	O
care	care	O
for	for	O
relapsed/refractory	relapsed/refractory	O
multiple	multiple	B-Disease
myeloma	myeloma	I-Disease
(	(	O
RRMM	rrmm	O
)	)	O
,	,	O
but	but	O
there	there	O
is	is	O
limited	limited	O
published	published	O
data	data	O
on	on	O
its	its	O
efficacy	efficacy	O
and	and	O
safety	safety	O
in	in	O
the	the	O
"	"	O
real	real	O
world	world	O
"	"	O
(	(	O
RW	rw	O
)	)	O
,	,	O
according	according	O
to	to	O
the	the	O
International	international	O
Society	society	O
of	of	O
Pharmacoeconomics	pharmacoeconomics	O
and	and	O
Outcomes	outcomes	O
Research	research	O
definition	definition	O
.	.	O

We	we	O
studied	studied	O
212	212	O
RRMM	rrmm	O
patients	patients	O
who	who	O
received	received	O
RD	rd	O
in	in	O
RW	rw	O
.	.	O

Objective	objective	O
response	response	O
(	(	O
>	>	O
PR	pr	O
(	(	O
partial	partial	O
response	response	O
)	)	O
)	)	O
rate	rate	O
was	was	O
77.4	77.4	O
%	%	O
(	(	O
complete	complete	O
response	response	O
(	(	O
CR	cr	B-Chemical
)	)	O
,	,	O
20.2	20.2	O
%	%	O
)	)	O
.	.	O

Median	median	O
time	time	O
to	to	O
first	first	O
and	and	O
best	best	O
response	response	O
was	was	O
2	2	O
and	and	O
5	5	O
months	months	O
,	,	O
respectively	respectively	O
.	.	O

Median	median	O
time	time	O
to	to	O
CR	cr	B-Chemical
when	when	O
RD	rd	O
was	was	O
given	given	O
as	as	O
2nd	2nd	O
or	or	O
>	>	O
2(nd)-line	2(nd)-line	O
treatment	treatment	O
at	at	O
4	4	O
and	and	O
11	11	O
months	months	O
,	,	O
respectively	respectively	O
.	.	O

Quality	quality	O
of	of	O
response	response	O
was	was	O
independent	independent	O
of	of	O
previous	previous	O
lines	lines	O
of	of	O
therapies	therapies	O
or	or	O
previous	previous	O
exposure	exposure	O
to	to	O
thalidomide	thalidomide	B-Chemical
or	or	O
bortezomib	bortezomib	O
.	.	O

Median	median	O
duration	duration	O
of	of	O
response	response	O
was	was	O
34.4	34.4	O
months	months	O
,	,	O
and	and	O
it	it	O
was	was	O
higher	higher	O
in	in	O
patients	patients	O
who	who	O
received	received	O
RD	rd	O
until	until	O
progression	progression	O
(	(	O
not	not	O
reached	reached	O
versus	versus	O
19	19	O
months	months	O
,	,	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

Improvement	improvement	O
of	of	O
humoral	humoral	O
immunity	immunity	O
occurred	occurred	O
in	in	O
60	60	O
%	%	O
of	of	O
responders	responders	O
(	(	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
and	and	O
in	in	O
the	the	O
majority	majority	O
of	of	O
patients	patients	O
who	who	O
achieved	achieved	O
stable	stable	O
disease	disease	O
.	.	O

Adverse	adverse	O
events	events	O
were	were	O
reported	reported	O
in	in	O
68.9	68.9	O
%	%	O
of	of	O
patients	patients	O
(	(	O
myelosuppression	myelosuppression	B-Disease
in	in	O
49.4	49.4	O
%	%	O
)	)	O
and	and	O
12.7	12.7	O
%	%	O
of	of	O
patients	patients	O
needed	needed	O
hospitalization	hospitalization	O
.	.	O

Peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
was	was	O
observed	observed	O
only	only	O
in	in	O
2.5	2.5	O
%	%	O
of	of	O
patients	patients	O
and	and	O
deep	deep	B-Disease
vein	vein	I-Disease
thrombosis	thrombosis	B-Disease
in	in	O
5.7	5.7	O
%	%	O
.	.	O

Dose	dose	O
reductions	reductions	O
were	were	O
needed	needed	O
in	in	O
31	31	O
%	%	O
of	of	O
patients	patients	O
and	and	O
permanent	permanent	O
discontinuation	discontinuation	O
in	in	O
38.9	38.9	O
%	%	O
.	.	O

Median	median	O
time	time	O
to	to	O
treatment	treatment	O
discontinuation	discontinuation	O
was	was	O
16.8	16.8	O
months	months	O
.	.	O

Performance	performance	O
status	status	O
(	(	O
PS	ps	O
)	)	O
and	and	O
initial	initial	O
lenalidomide	lenalidomide	O
dose	dose	O
predicted	predicted	O
for	for	O
treatment	treatment	O
discontinuation	discontinuation	O
.	.	O

Extra-medullary	extra-medullary	O
relapses	relapses	O
occurred	occurred	O
in	in	O
3.8	3.8	O
%	%	O
of	of	O
patients	patients	O
.	.	O

Our	our	O
study	study	O
confirms	confirms	O
that	that	O
RD	rd	O
is	is	O
effective	effective	O
and	and	O
safe	safe	O
in	in	O
RRMM	rrmm	O
in	in	O
the	the	O
RW	rw	O
;	;	O
it	it	O
produces	produces	O
durable	durable	O
responses	responses	O
especially	especially	O
in	in	O
patients	patients	O
who	who	O
continue	continue	O
on	on	O
treatment	treatment	O
till	till	O
progression	progression	O
and	and	O
improves	improves	O
humoral	humoral	O
immunity	immunity	O
even	even	O
in	in	O
patients	patients	O
with	with	O
stable	stable	O
disease	disease	O
.	.	O

The	the	O
cytogenetic	cytogenetic	O
action	action	O
of	of	O
ifosfamide	ifosfamide	B-Chemical
,	,	O
mesna	mesna	B-Chemical
,	,	O
and	and	O
their	their	O
combination	combination	O
on	on	O
peripheral	peripheral	O
rabbit	rabbit	O
lymphocytes	lymphocytes	O
:	:	O
an	an	O
in	in	O
vivo/in	vivo/in	O
vitro	vitro	O
cytogenetic	cytogenetic	O
study	study	O
.	.	O

Ifosfamide	ifosfamide	B-Chemical
(	(	O
IFO	ifo	O
)	)	O
is	is	O
an	an	O
alkylating	alkylating	O
nitrogen	nitrogen	O
mustard	mustard	O
,	,	O
administrated	administrated	O
as	as	O
an	an	O
antineoplasmic	antineoplasmic	O
agent	agent	O
.	.	O

It	it	O
is	is	O
characterized	characterized	O
by	by	O
its	its	O
intense	intense	O
urotoxic	urotoxic	O
action	action	O
,	,	O
leading	leading	O
to	to	O
hemorrhagic	hemorrhagic	B-Disease
cystitis	cystitis	B-Disease
.	.	O

This	this	O
side	side	O
effect	effect	O
of	of	O
IFO	ifo	O
raises	raises	O
the	the	O
requirement	requirement	O
for	for	O
the	the	O
co-administration	co-administration	O
with	with	O
sodium	sodium	B-Chemical
2-sulfanylethanesulfonate	2-sulfanylethanesulfonate	O
(	(	O
Mesna	mesna	B-Chemical
)	)	O
aiming	aiming	O
to	to	O
avoid	avoid	O
or	or	O
minimize	minimize	O
this	this	O
effect	effect	O
.	.	O

IFO	ifo	O
and	and	O
Mesna	mesna	B-Chemical
were	were	O
administrated	administrated	O
separately	separately	O
on	on	O
rabbit	rabbit	O
's	's	O
lymphocytes	lymphocytes	O
in	in	O
vivo	vivo	O
,	,	O
which	which	O
were	were	O
later	later	O
developed	developed	O
in	in	O
vitro	vitro	O
.	.	O

Cytogenetic	cytogenetic	O
markers	markers	O
for	for	O
sister	sister	O
chromatid	chromatid	O
exchanges	exchanges	O
(	(	O
SCEs	sces	O
)	)	O
,	,	O
proliferation	proliferation	O
rate	rate	O
index	index	O
(	(	O
PRI	pri	O
)	)	O
and	and	O
Mitotic	mitotic	O
Index	index	O
were	were	O
recorded	recorded	O
.	.	O

Mesna	mesna	B-Chemical
's	's	O
action	action	O
,	,	O
in	in	O
conjunction	conjunction	O
with	with	O
IFO	ifo	O
reduces	reduces	O
the	the	O
frequency	frequency	O
of	of	O
SCEs	sces	O
,	,	O
in	in	O
comparison	comparison	O
with	with	O
the	the	O
SCEs	sces	O
recordings	recordings	O
obtained	obtained	O
when	when	O
IFO	ifo	O
is	is	O
administered	administered	O
alone	alone	O
.	.	O

In	in	O
addition	addition	O
to	to	O
this	this	O
,	,	O
when	when	O
high	high	O
concentrations	concentrations	O
of	of	O
Mesna	mesna	B-Chemical
were	were	O
administered	administered	O
alone	alone	O
significant	significant	O
reductions	reductions	O
of	of	O
the	the	O
PRI	pri	O
were	were	O
noted	noted	O
,	,	O
than	than	O
with	with	O
IFO	ifo	O
acting	acting	O
at	at	O
the	the	O
same	same	O
concentration	concentration	O
on	on	O
the	the	O
lymphocytes	lymphocytes	O
.	.	O

Mesna	mesna	B-Chemical
significantly	significantly	O
reduces	reduces	O
IFO	ifo	O
's	's	O
genotoxicity	genotoxicity	O
,	,	O
while	while	O
when	when	O
administered	administered	O
in	in	O
high	high	O
concentrations	concentrations	O
it	it	O
acts	acts	O
in	in	O
an	an	O
inhibitory	inhibitory	O
fashion	fashion	O
on	on	O
the	the	O
cytostatic	cytostatic	O
action	action	O
of	of	O
the	the	O
drug	drug	O
.	.	O

Risk	risk	O
factors	factors	O
and	and	O
predictors	predictors	O
of	of	O
levodopa-induced	levodopa-induced	O
dyskinesia	dyskinesia	B-Disease
among	among	O
multiethnic	multiethnic	O
Malaysians	malaysians	O
with	with	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

Chronic	chronic	O
pulsatile	pulsatile	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
for	for	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
(	(	O
PD	pd	B-Disease
)	)	O
leads	leads	O
to	to	O
the	the	O
development	development	O
of	of	O
motor	motor	O
fluctuations	fluctuations	O
and	and	O
dyskinesia	dyskinesia	B-Disease
.	.	O

We	we	O
studied	studied	O
the	the	O
prevalence	prevalence	O
and	and	O
predictors	predictors	O
of	of	O
levodopa-induced	levodopa-induced	O
dyskinesia	dyskinesia	B-Disease
among	among	O
multiethnic	multiethnic	O
Malaysian	malaysian	O
patients	patients	O
with	with	O
PD	pd	B-Disease
.	.	O

METHODS	methods	O
:	:	O
This	this	O
is	is	O
a	a	O
cross-sectional	cross-sectional	O
study	study	O
involving	involving	O
95	95	O
patients	patients	O
with	with	O
PD	pd	B-Disease
on	on	O
uninterrupted	uninterrupted	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
for	for	O
at	at	O
least	least	O
6	6	O
months	months	O
.	.	O

The	the	O
instrument	instrument	O
used	used	O
was	was	O
the	the	O
UPDRS	updrs	O
questionnaires	questionnaires	O
.	.	O

The	the	O
predictors	predictors	O
of	of	O
dyskinesia	dyskinesia	B-Disease
were	were	O
determined	determined	O
using	using	O
multivariate	multivariate	O
logistic	logistic	O
regression	regression	O
analysis	analysis	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
mean	mean	O
age	age	O
was	was	O
65.6	65.6	O
+	+	O
8.5	8.5	O
years	years	O
.	.	O

The	the	O
mean	mean	O
onset	onset	O
age	age	O
was	was	O
58.5	58.5	O
+	+	O
9.8	9.8	O
years	years	O
.	.	O

The	the	O
median	median	O
disease	disease	O
duration	duration	O
was	was	O
6	6	O
(	(	O
7	7	O
)	)	O
years	years	O
.	.	O

Dyskinesia	dyskinesia	B-Disease
was	was	O
present	present	O
in	in	O
44	44	O
%	%	O
(	(	O
n	n	O
=	=	O
42	42	O
)	)	O
with	with	O
median	median	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
of	of	O
3	3	O
years	years	O
.	.	O

There	there	O
were	were	O
64.3	64.3	O
%	%	O
Chinese	chinese	O
,	,	O
31	31	O
%	%	O
Malays	malays	O
,	,	O
and	and	O
3.7	3.7	O
%	%	O
Indians	indians	O
and	and	O
other	other	O
ethnic	ethnic	O
groups	groups	O
.	.	O

Eighty-one	eighty-one	O
percent	percent	O
of	of	O
patients	patients	O
with	with	O
dyskinesia	dyskinesia	B-Disease
had	had	O
clinical	clinical	O
fluctuations	fluctuations	O
.	.	O

Patients	patients	O
with	with	O
dyskinesia	dyskinesia	B-Disease
had	had	O
lower	lower	O
onset	onset	O
age	age	O
(	(	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
,	,	O
longer	longer	O
duration	duration	O
of	of	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
(	(	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
,	,	O
longer	longer	O
disease	disease	O
duration	duration	O
(	(	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
,	,	O
higher	higher	O
total	total	O
daily	daily	O
levodopa	levodopa	B-Chemical
dose	dose	O
(	(	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
,	,	O
and	and	O
higher	higher	O
total	total	O
UPDRS	updrs	O
scores	scores	O
(	(	O
p	p	O
=	=	O
0.005	0.005	O
)	)	O
than	than	O
patients	patients	O
without	without	O
dyskinesia	dyskinesia	B-Disease
.	.	O

The	the	O
three	three	O
significant	significant	O
predictors	predictors	O
of	of	O
dyskinesia	dyskinesia	B-Disease
were	were	O
duration	duration	O
of	of	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
,	,	O
onset	onset	O
age	age	O
,	,	O
and	and	O
total	total	O
daily	daily	O
levodopa	levodopa	B-Chemical
dose	dose	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
prevalence	prevalence	O
of	of	O
levodopa-induced	levodopa-induced	O
dyskinesia	dyskinesia	B-Disease
in	in	O
our	our	O
patients	patients	O
was	was	O
44	44	O
%	%	O
.	.	O

The	the	O
most	most	O
significant	significant	O
predictors	predictors	O
were	were	O
duration	duration	O
of	of	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
,	,	O
total	total	O
daily	daily	O
levodopa	levodopa	B-Chemical
dose	dose	O
,	,	O
and	and	O
onset	onset	O
age	age	O
.	.	O

Dose-dependent	dose-dependent	O
neurotoxicity	neurotoxicity	B-Disease
of	of	O
high-dose	high-dose	O
busulfan	busulfan	B-Chemical
in	in	O
children	children	O
:	:	O
a	a	O
clinical	clinical	O
and	and	O
pharmacological	pharmacological	O
study	study	O
.	.	O

Busulfan	busulfan	B-Chemical
is	is	O
known	known	O
to	to	O
be	be	O
neurotoxic	neurotoxic	B-Disease
in	in	O
animals	animals	O
and	and	O
humans	humans	O
,	,	O
but	but	O
its	its	O
acute	acute	O
neurotoxicity	neurotoxicity	B-Disease
remains	remains	O
poorly	poorly	O
characterized	characterized	O
in	in	O
children	children	O
.	.	O

We	we	O
report	report	O
here	here	O
a	a	O
retrospective	retrospective	O
study	study	O
of	of	O
123	123	O
children	children	O
(	(	O
median	median	O
age	age	O
,	,	O
6.5	6.5	O
years	years	O
)	)	O
receiving	receiving	O
high-dose	high-dose	O
busulfan	busulfan	B-Chemical
in	in	O
combined	combined	O
chemotherapy	chemotherapy	O
before	before	O
bone	bone	O
marrow	marrow	O
transplantation	transplantation	O
for	for	O
malignant	malignant	O
solid	solid	O
tumors	tumors	B-Disease
,	,	O
brain	brain	O
tumors	tumors	B-Disease
excluded	excluded	O
.	.	O

Busulfan	busulfan	B-Chemical
was	was	O
given	given	O
p.o	p.o	O
.	.	O
,	,	O
every	every	O
6	6	O
hours	hours	O
for	for	O
16	16	O
doses	doses	O
over	over	O
4	4	O
days	days	O
.	.	O

Two	two	O
total	total	O
doses	doses	O
were	were	O
consecutively	consecutively	O
used	used	O
:	:	O
16	16	O
mg/kg	mg/kg	O
,	,	O
then	then	O
600	600	O
mg/m2	mg/m2	O
.	.	O

The	the	O
dose	dose	O
calculation	calculation	O
on	on	O
the	the	O
basis	basis	O
of	of	O
body	body	O
surface	surface	O
area	area	O
results	results	O
in	in	O
higher	higher	O
doses	doses	O
in	in	O
young	young	O
children	children	O
than	than	O
in	in	O
older	older	O
patients	patients	O
(	(	O
16	16	O
to	to	O
28	28	O
mg/kg	mg/kg	O
)	)	O
.	.	O

Ninety-six	ninety-six	O
patients	patients	O
were	were	O
not	not	O
given	given	O
anticonvulsive	anticonvulsive	O
prophylaxis	prophylaxis	O
;	;	O
7	7	O
(	(	O
7.5	7.5	O
%	%	O
)	)	O
developed	developed	O
seizures	seizures	B-Disease
during	during	O
the	the	O
4	4	O
days	days	O
of	of	O
the	the	O
busulfan	busulfan	B-Chemical
course	course	O
or	or	O
within	within	O
24	24	O
h	h	B-Chemical
after	after	O
the	the	O
last	last	O
dosing	dosing	O
.	.	O

When	when	O
the	the	O
total	total	O
busulfan	busulfan	B-Chemical
dose	dose	O
was	was	O
taken	taken	O
into	into	O
account	account	O
,	,	O
there	there	O
was	was	O
a	a	O
significant	significant	O
difference	difference	O
in	in	O
terms	terms	O
of	of	O
neurotoxicity	neurotoxicity	B-Disease
incidence	incidence	O
among	among	O
patients	patients	O
under	under	O
16	16	O
mg/kg	mg/kg	O
(	(	O
1	1	O
of	of	O
57	57	O
,	,	O
1.7	1.7	O
%	%	O
)	)	O
and	and	O
patients	patients	O
under	under	O
600	600	O
mg/m2	mg/m2	O
(	(	O
6	6	O
of	of	O
39	39	O
,	,	O
15.4	15.4	O
%	%	O
)	)	O
(	(	O
P	p	O
less	less	O
than	than	O
0.02	0.02	O
)	)	O
.	.	O

Twenty-seven	twenty-seven	O
patients	patients	O
were	were	O
given	given	O
a	a	O
600-mg/m2	600-mg/m2	O
busulfan	busulfan	B-Chemical
total	total	O
dose	dose	O
with	with	O
continuous	continuous	O
i.v	i.v	O
.	.	O

infusion	infusion	O
of	of	O
clonazepam	clonazepam	O
;	;	O
none	none	O
had	had	O
any	any	O
neurological	neurological	O
symptoms	symptoms	O
.	.	O

Busulfan	busulfan	B-Chemical
levels	levels	O
were	were	O
measured	measured	O
by	by	O
a	a	O
gas	gas	O
chromatographic-mass	chromatographic-mass	O
spectrometry	spectrometry	O
assay	assay	O
in	in	O
the	the	O
plasma	plasma	O
and	and	O
cerebrospinal	cerebrospinal	O
fluid	fluid	O
of	of	O
9	9	O
children	children	O
without	without	O
central	central	O
nervous	nervous	O
system	system	O
disease	disease	O
under	under	O
600	600	O
mg/m2	mg/m2	O
busulfan	busulfan	B-Chemical
with	with	O
clonazepam	clonazepam	O
:	:	O
busulfan	busulfan	B-Chemical
cerebrospinal	cerebrospinal	O
fluid	fluid	O
:	:	O
plasma	plasma	O
ratio	ratio	O
was	was	O
1.39	1.39	O
.	.	O

This	this	O
was	was	O
significantly	significantly	O
different	different	O
(	(	O
P	p	O
less	less	O
than	than	O
0.02	0.02	O
)	)	O
from	from	O
the	the	O
cerebrospinal	cerebrospinal	O
fluid	fluid	O
:	:	O
plasma	plasma	O
ratio	ratio	O
previously	previously	O
defined	defined	O
in	in	O
children	children	O
receiving	receiving	O
a	a	O
16-mg/kg	16-mg/kg	O
total	total	O
dose	dose	O
of	of	O
busulfan	busulfan	B-Chemical
.	.	O

This	this	O
study	study	O
shows	shows	O
that	that	O
busulfan	busulfan	B-Chemical
neurotoxicity	neurotoxicity	B-Disease
is	is	O
dose-dependent	dose-dependent	O
in	in	O
children	children	O
and	and	O
efficiently	efficiently	O
prevented	prevented	O
by	by	O
clonazepam	clonazepam	O
.	.	O

A	a	O
busulfan	busulfan	B-Chemical
dose	dose	O
calculated	calculated	O
on	on	O
the	the	O
basis	basis	O
of	of	O
body	body	O
surface	surface	O
area	area	O
,	,	O
resulting	resulting	O
in	in	O
higher	higher	O
doses	doses	O
in	in	O
young	young	O
children	children	O
,	,	O
was	was	O
followed	followed	O
by	by	O
increased	increased	O
neurotoxicity	neurotoxicity	B-Disease
,	,	O
close	close	O
to	to	O
neurotoxicity	neurotoxicity	B-Disease
incidence	incidence	O
observed	observed	O
in	in	O
adults	adults	O
.	.	O

Since	since	O
plasma	plasma	O
pharmacokinetic	pharmacokinetic	O
studies	studies	O
showed	showed	O
a	a	O
faster	faster	O
busulfan	busulfan	B-Chemical
clearance	clearance	O
in	in	O
children	children	O
than	than	O
in	in	O
adults	adults	O
,	,	O
this	this	O
new	new	O
dose	dose	O
may	may	O
approximate	approximate	O
more	more	O
closely	closely	O
the	the	O
adult	adult	O
systemic	systemic	O
exposure	exposure	O
obtained	obtained	O
after	after	O
the	the	O
usual	usual	O
16-mg/kg	16-mg/kg	O
total	total	O
dose	dose	O
,	,	O
with	with	O
potential	potential	O
inferences	inferences	O
in	in	O
terms	terms	O
of	of	O
anticancer	anticancer	O
or	or	O
myeloablative	myeloablative	O
effects	effects	O
.	.	O

The	the	O
busulfan	busulfan	B-Chemical
dose	dose	O
in	in	O
children	children	O
and	and	O
infants	infants	O
undergoing	undergoing	O
bone	bone	O
marrow	marrow	O
transplantation	transplantation	O
should	should	O
be	be	O
reconsidered	reconsidered	O
on	on	O
the	the	O
basis	basis	O
of	of	O
pharmacokinetic	pharmacokinetic	O
studies	studies	O
.	.	O

An	an	O
unexpected	unexpected	O
diagnosis	diagnosis	O
in	in	O
a	a	O
renal-transplant	renal-transplant	O
patient	patient	O
with	with	O
proteinuria	proteinuria	B-Disease
treated	treated	O
with	with	O
everolimus	everolimus	B-Chemical
:	:	O
AL	al	O
amyloidosis	amyloidosis	O
.	.	O

Proteinuria	proteinuria	B-Disease
is	is	O
an	an	O
expected	expected	O
complication	complication	O
in	in	O
transplant	transplant	O
patients	patients	O
treated	treated	O
with	with	O
mammalian	mammalian	O
target	target	O
of	of	O
rapamycin	rapamycin	B-Chemical
inhibitors	inhibitors	O
(	(	O
mTOR-i	mtor-i	O
)	)	O
.	.	O

However	however	O
,	,	O
clinical	clinical	O
suspicion	suspicion	O
should	should	O
always	always	O
be	be	O
supported	supported	O
by	by	O
histological	histological	O
evidence	evidence	O
in	in	O
order	order	O
to	to	O
investigate	investigate	O
potential	potential	O
alternate	alternate	O
diagnoses	diagnoses	O
such	such	O
as	as	O
acute	acute	O
or	or	O
chronic	chronic	O
rejection	rejection	O
,	,	O
interstitial	interstitial	O
fibrosis	fibrosis	B-Disease
and	and	O
tubular	tubular	O
atrophy	atrophy	B-Disease
,	,	O
or	or	O
recurrent	recurrent	O
or	or	O
de	de	O
novo	novo	O
glomerulopathy	glomerulopathy	O
.	.	O

In	in	O
this	this	O
case	case	O
we	we	O
report	report	O
the	the	O
unexpected	unexpected	O
diagnosis	diagnosis	O
of	of	O
amyloidosis	amyloidosis	O
in	in	O
a	a	O
renal-transplant	renal-transplant	O
patient	patient	O
with	with	O
pre-transplant	pre-transplant	O
monoclonal	monoclonal	O
gammapathy	gammapathy	O
of	of	O
undetermined	undetermined	O
significance	significance	O
who	who	O
developed	developed	O
proteinuria	proteinuria	B-Disease
after	after	O
conversion	conversion	O
from	from	O
tacrolimus	tacrolimus	B-Chemical
to	to	O
everolimus	everolimus	B-Chemical
.	.	O

Long-term	long-term	O
oral	oral	O
galactose	galactose	O
treatment	treatment	O
prevents	prevents	O
cognitive	cognitive	B-Disease
deficits	deficits	I-Disease
in	in	O
male	male	O
Wistar	wistar	O
rats	rats	O
treated	treated	O
intracerebroventricularly	intracerebroventricularly	O
with	with	O
streptozotocin	streptozotocin	B-Chemical
.	.	O

Basic	basic	O
and	and	O
clinical	clinical	O
research	research	O
has	has	O
demonstrated	demonstrated	O
that	that	O
dementia	dementia	B-Disease
of	of	O
sporadic	sporadic	O
Alzheimer	alzheimer	B-Disease
's	's	I-Disease
disease	disease	I-Disease
(	(	O
sAD	sad	O
)	)	O
type	type	O
is	is	O
associated	associated	O
with	with	O
dysfunction	dysfunction	O
of	of	O
the	the	O
insulin-receptor	insulin-receptor	O
(	(	O
IR	ir	O
)	)	O
system	system	O
followed	followed	O
by	by	O
decreased	decreased	O
glucose	glucose	B-Chemical
transport	transport	O
via	via	O
glucose	glucose	B-Chemical
transporter	transporter	O
GLUT4	glut4	O
and	and	O
decreased	decreased	O
glucose	glucose	B-Chemical
metabolism	metabolism	O
in	in	O
brain	brain	O
cells	cells	O
.	.	O

An	an	O
alternative	alternative	O
source	source	O
of	of	O
energy	energy	O
is	is	O
d-galactose	d-galactose	O
(	(	O
the	the	O
C-4-epimer	c-4-epimer	O
of	of	O
d-glucose	d-glucose	O
)	)	O
which	which	O
is	is	O
transported	transported	O
into	into	O
the	the	O
brain	brain	O
by	by	O
insulin-independent	insulin-independent	O
GLUT3	glut3	O
transporter	transporter	O
where	where	O
it	it	O
might	might	O
be	be	O
metabolized	metabolized	O
to	to	O
glucose	glucose	B-Chemical
via	via	O
the	the	O
Leloir	leloir	O
pathway	pathway	O
.	.	O

Exclusively	exclusively	O
parenteral	parenteral	O
daily	daily	O
injections	injections	O
of	of	O
galactose	galactose	O
induce	induce	O
memory	memory	O
deterioration	deterioration	O
in	in	O
rodents	rodents	O
and	and	O
are	are	O
used	used	O
to	to	O
generate	generate	O
animal	animal	O
aging	aging	O
model	model	O
,	,	O
but	but	O
the	the	O
effects	effects	O
of	of	O
oral	oral	O
galactose	galactose	O
treatment	treatment	O
on	on	O
cognitive	cognitive	O
functions	functions	O
have	have	O
never	never	O
been	been	O
tested	tested	O
.	.	O

We	we	O
have	have	O
investigated	investigated	O
the	the	O
effects	effects	O
of	of	O
continuous	continuous	O
daily	daily	O
oral	oral	O
galactose	galactose	O
(	(	O
200	200	O
mg/kg/day	mg/kg/day	O
)	)	O
treatment	treatment	O
on	on	O
cognitive	cognitive	B-Disease
deficits	deficits	I-Disease
in	in	O
streptozotocin-induced	streptozotocin-induced	O
(	(	O
STZ-icv	stz-icv	O
)	)	O
rat	rat	O
model	model	O
of	of	O
sAD	sad	O
,	,	O
tested	tested	O
by	by	O
Morris	morris	O
Water	water	O
Maze	maze	O
and	and	O
Passive	passive	O
Avoidance	avoidance	O
test	test	O
,	,	O
respectively	respectively	O
.	.	O

One	one	O
month	month	O
of	of	O
oral	oral	O
galactose	galactose	O
treatment	treatment	O
initiated	initiated	O
immediately	immediately	O
after	after	O
the	the	O
STZ-icv	stz-icv	O
administration	administration	O
,	,	O
successfully	successfully	O
prevented	prevented	O
development	development	O
of	of	O
the	the	O
STZ-icv-induced	stz-icv-induced	O
cognitive	cognitive	B-Disease
deficits	deficits	I-Disease
.	.	O

Beneficial	beneficial	O
effect	effect	O
of	of	O
oral	oral	O
galactose	galactose	O
was	was	O
independent	independent	O
of	of	O
the	the	O
rat	rat	O
age	age	O
and	and	O
of	of	O
the	the	O
galactose	galactose	O
dose	dose	O
ranging	ranging	O
from	from	O
100	100	O
to	to	O
300	300	O
mg/kg/day	mg/kg/day	O
.	.	O

Additionally	additionally	O
,	,	O
oral	oral	O
galactose	galactose	O
administration	administration	O
led	led	O
to	to	O
the	the	O
appearance	appearance	O
of	of	O
galactose	galactose	O
in	in	O
the	the	O
blood	blood	O
.	.	O

The	the	O
increase	increase	O
of	of	O
galactose	galactose	O
concentration	concentration	O
in	in	O
the	the	O
cerebrospinal	cerebrospinal	O
fluid	fluid	O
was	was	O
several	several	O
times	times	O
lower	lower	O
after	after	O
oral	oral	O
than	than	O
after	after	O
parenteral	parenteral	O
administration	administration	O
of	of	O
the	the	O
same	same	O
galactose	galactose	O
dose	dose	O
.	.	O

Oral	oral	O
galactose	galactose	O
exposure	exposure	O
might	might	O
have	have	O
beneficial	beneficial	O
effects	effects	O
on	on	O
learning	learning	O
and	and	O
memory	memory	O
ability	ability	O
and	and	O
could	could	O
be	be	O
worth	worth	O
investigating	investigating	O
for	for	O
improvement	improvement	O
of	of	O
cognitive	cognitive	B-Disease
deficits	deficits	I-Disease
associated	associated	O
with	with	O
glucose	glucose	B-Chemical
hypometabolism	hypometabolism	O
in	in	O
AD	ad	O
.	.	O

An	an	O
investigation	investigation	O
of	of	O
the	the	O
pattern	pattern	O
of	of	O
kidney	kidney	O
injury	injury	O
in	in	O
HIV-positive	hiv-positive	O
persons	persons	O
exposed	exposed	O
to	to	O
tenofovir	tenofovir	O
disoproxil	disoproxil	O
fumarate	fumarate	O
:	:	O
an	an	O
examination	examination	O
of	of	O
a	a	O
large	large	O
population	population	O
database	database	O
(	(	O
MHRA	mhra	O
database).The	database).the	O
potential	potential	O
for	for	O
tenofovir	tenofovir	O
to	to	O
cause	cause	O
a	a	O
range	range	O
of	of	O
kidney	kidney	O
syndromes	syndromes	O
has	has	O
been	been	O
established	established	O
from	from	O
mechanistic	mechanistic	O
and	and	O
randomised	randomised	O
clinical	clinical	O
trials	trials	O
.	.	O

However	however	O
,	,	O
the	the	O
exact	exact	O
pattern	pattern	O
of	of	O
kidney	kidney	O
involvement	involvement	O
is	is	O
still	still	O
uncertain	uncertain	O
.	.	O

We	we	O
undertook	undertook	O
a	a	O
descriptive	descriptive	O
analysis	analysis	O
of	of	O
Yellow	yellow	O
Card	card	O
records	records	O
of	of	O
407	407	O
HIV-positive	hiv-positive	O
persons	persons	O
taking	taking	O
tenofovir	tenofovir	O
disoproxil	disoproxil	O
fumarate	fumarate	O
(	(	O
TDF	tdf	O
)	)	O
as	as	O
part	part	O
of	of	O
their	their	O
antiretroviral	antiretroviral	O
therapy	therapy	O
regimen	regimen	O
and	and	O
submitted	submitted	O
to	to	O
the	the	O
Medicines	medicines	O
and	and	O
Healthcare	healthcare	O
Products	products	O
Regulatory	regulatory	O
Agency	agency	O
(	(	O
MHRA	mhra	O
)	)	O
with	with	O
suspected	suspected	O
kidney	kidney	O
adverse	adverse	O
effects	effects	O
.	.	O

Reports	reports	O
that	that	O
satisfy	satisfy	O
defined	defined	O
criteria	criteria	O
were	were	O
classified	classified	O
as	as	O
acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
,	,	O
kidney	kidney	O
tubular	tubular	O
dysfunction	dysfunction	O
and	and	O
Fanconi	fanconi	B-Disease
syndrome	syndrome	I-Disease
.	.	O

Of	of	O
the	the	O
407	407	O
Yellow	yellow	O
Card	card	O
records	records	O
analysed	analysed	O
,	,	O
106	106	O
satisfied	satisfied	O
criteria	criteria	O
for	for	O
TDF-related	tdf-related	O
kidney	kidney	B-Disease
disease	disease	I-Disease
,	,	O
of	of	O
which	which	O
53	53	O
(	(	O
50	50	O
%	%	O
)	)	O
had	had	O
features	features	O
of	of	O
kidney	kidney	O
tubular	tubular	O
dysfunction	dysfunction	O
,	,	O
35	35	O
(	(	O
33	33	O
%	%	O
)	)	O
were	were	O
found	found	O
to	to	O
have	have	O
features	features	O
of	of	O
glomerular	glomerular	O
dysfunction	dysfunction	O
and	and	O
18	18	O
(	(	O
17	17	O
%	%	O
)	)	O
had	had	O
Fanconi	fanconi	B-Disease
syndrome	syndrome	I-Disease
.	.	O

The	the	O
median	median	O
TDF	tdf	O
exposure	exposure	O
was	was	O
316	316	O
days	days	O
(	(	O
interquartile	interquartile	O
range	range	O
120	120	O
-	-	O
740	740	O
)	)	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
hospitalisation	hospitalisation	O
for	for	O
TDF	tdf	O
kidney	kidney	O
adverse	adverse	O
effects	effects	O
was	was	O
high	high	O
,	,	O
particularly	particularly	O
amongst	amongst	O
patients	patients	O
with	with	O
features	features	O
of	of	O
Fanconi	fanconi	B-Disease
syndrome	syndrome	I-Disease
.	.	O

The	the	O
pattern	pattern	O
of	of	O
kidney	kidney	O
syndromes	syndromes	O
in	in	O
this	this	O
population	population	O
series	series	O
mirrors	mirrors	O
that	that	O
reported	reported	O
in	in	O
randomised	randomised	O
clinical	clinical	O
trials	trials	O
.	.	O

Cessation	cessation	O
of	of	O
TDF	tdf	O
was	was	O
associated	associated	O
with	with	O
complete	complete	O
restoration	restoration	O
of	of	O
kidney	kidney	O
function	function	O
in	in	O
up	up	O
half	half	O
of	of	O
the	the	O
patients	patients	O
in	in	O
this	this	O
report	report	O
.	.	O

Incidence	incidence	O
of	of	O
postoperative	postoperative	O
delirium	delirium	B-Disease
is	is	O
high	high	O
even	even	O
in	in	O
a	a	O
population	population	O
without	without	O
known	known	O
risk	risk	O
factors	factors	O
.	.	O

PURPOSE	purpose	O
:	:	O
Postoperative	postoperative	O
delirium	delirium	B-Disease
is	is	O
a	a	O
recognized	recognized	O
complication	complication	O
in	in	O
populations	populations	O
at	at	O
risk	risk	O
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
is	is	O
to	to	O
assess	assess	O
the	the	O
prevalence	prevalence	O
of	of	O
early	early	O
postoperative	postoperative	O
delirium	delirium	B-Disease
in	in	O
a	a	O
population	population	O
without	without	O
known	known	O
risk	risk	O
factors	factors	O
admitted	admitted	O
to	to	O
the	the	O
ICU	icu	O
for	for	O
postoperative	postoperative	O
monitoring	monitoring	O
after	after	O
elective	elective	O
major	major	O
surgery	surgery	O
.	.	O

The	the	O
secondary	secondary	O
outcome	outcome	O
investigated	investigated	O
is	is	O
to	to	O
identify	identify	O
eventual	eventual	O
independent	independent	O
risk	risk	O
factors	factors	O
among	among	O
demographic	demographic	O
data	data	O
and	and	O
anesthetic	anesthetic	O
drugs	drugs	O
used	used	O
.	.	O

METHODS	methods	O
:	:	O
An	an	O
observational	observational	O
,	,	O
prospective	prospective	O
study	study	O
was	was	O
conducted	conducted	O
on	on	O
a	a	O
consecutive	consecutive	O
cohort	cohort	O
of	of	O
patients	patients	O
admitted	admitted	O
to	to	O
our	our	O
ICU	icu	O
within	within	O
and	and	O
for	for	O
at	at	O
least	least	O
24	24	O
h	h	B-Chemical
after	after	O
major	major	O
surgical	surgical	O
procedures	procedures	O
.	.	O

Exclusion	exclusion	O
criteria	criteria	O
were	were	O
any	any	O
preexisting	preexisting	O
predisposing	predisposing	O
factor	factor	O
for	for	O
delirium	delirium	B-Disease
or	or	O
other	other	O
potentially	potentially	O
confounding	confounding	O
neurological	neurological	O
dysfunctions	dysfunctions	O
.	.	O

Patients	patients	O
were	were	O
assessed	assessed	O
daily	daily	O
using	using	O
the	the	O
confusion	confusion	B-Disease
assessment	assessment	O
method	method	O
for	for	O
the	the	O
ICU	icu	O
scale	scale	O
for	for	O
3	3	O
days	days	O
after	after	O
the	the	O
surgical	surgical	O
procedure	procedure	O
.	.	O

Early	early	O
postoperative	postoperative	O
delirium	delirium	B-Disease
incidence	incidence	O
risk	risk	O
factors	factors	O
were	were	O
then	then	O
assessed	assessed	O
through	through	O
three	three	O
different	different	O
multiple	multiple	O
regression	regression	O
models	models	O
.	.	O

RESULTS	results	O
:	:	O
According	according	O
to	to	O
the	the	O
confusion	confusion	B-Disease
assessment	assessment	O
method	method	O
for	for	O
the	the	O
ICU	icu	O
scale	scale	O
,	,	O
28	28	O
%	%	O
of	of	O
patients	patients	O
were	were	O
diagnosed	diagnosed	O
with	with	O
early	early	O
postoperative	postoperative	O
delirium	delirium	B-Disease
.	.	O

The	the	O
use	use	O
of	of	O
thiopentone	thiopentone	B-Chemical
was	was	O
significantly	significantly	O
associated	associated	O
with	with	O
an	an	O
eight-fold-higher	eight-fold-higher	O
risk	risk	O
for	for	O
delirium	delirium	B-Disease
compared	compared	O
to	to	O
propofol	propofol	B-Chemical
(	(	O
57.1	57.1	O
%	%	O
vs.	vs.	O
7.1	7.1	O
%	%	O
,	,	O
RR	rr	O
=	=	O
8.0	8.0	O
,	,	O
X2	x2	O
=	=	O
4.256	4.256	O
;	;	O
df	df	O
=	=	O
1	1	O
;	;	O
0.05	0.05	O
<	<	O
p	p	O
<	<	O
0.02	0.02	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
In	in	O
this	this	O
study	study	O
early	early	O
postoperative	postoperative	O
delirium	delirium	B-Disease
was	was	O
found	found	O
to	to	O
be	be	O
a	a	O
very	very	O
common	common	O
complication	complication	O
after	after	O
major	major	O
surgery	surgery	O
,	,	O
even	even	O
in	in	O
a	a	O
population	population	O
without	without	O
known	known	O
risk	risk	O
factors	factors	O
.	.	O

Thiopentone	thiopentone	B-Chemical
was	was	O
independently	independently	O
associated	associated	O
with	with	O
an	an	O
increase	increase	O
in	in	O
its	its	O
relative	relative	O
risk	risk	O
.	.	O

A	a	O
single	single	O
neurotoxic	neurotoxic	B-Disease
dose	dose	O
of	of	O
methamphetamine	methamphetamine	B-Chemical
induces	induces	O
a	a	O
long-lasting	long-lasting	O
depressive-like	depressive-like	O
behaviour	behaviour	O
in	in	O
mice	mice	O
.	.	O

Methamphetamine	methamphetamine	B-Chemical
(	(	O
METH	meth	B-Chemical
)	)	O
triggers	triggers	O
a	a	O
disruption	disruption	O
of	of	O
the	the	O
monoaminergic	monoaminergic	O
system	system	O
and	and	O
METH	meth	B-Chemical
abuse	abuse	O
leads	leads	O
to	to	O
negative	negative	O
emotional	emotional	O
states	states	O
including	including	O
depressive	depressive	B-Disease
symptoms	symptoms	O
during	during	O
drug	drug	O
withdrawal	withdrawal	O
.	.	O

However	however	O
,	,	O
it	it	O
is	is	O
currently	currently	O
unknown	unknown	O
if	if	O
the	the	O
acute	acute	O
toxic	toxic	O
dosage	dosage	O
of	of	O
METH	meth	B-Chemical
also	also	O
causes	causes	O
a	a	O
long-lasting	long-lasting	O
depressive	depressive	B-Disease
phenotype	phenotype	O
and	and	O
persistent	persistent	O
monoaminergic	monoaminergic	O
deficits	deficits	O
.	.	O

Thus	thus	O
,	,	O
we	we	O
now	now	O
assessed	assessed	O
the	the	O
depressive-like	depressive-like	O
behaviour	behaviour	O
in	in	O
mice	mice	O
at	at	O
early	early	O
and	and	O
long-term	long-term	O
periods	periods	O
following	following	O
a	a	O
single	single	O
high	high	O
METH	meth	B-Chemical
dose	dose	O
(	(	O
30	30	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
.	.	O

METH	meth	B-Chemical
did	did	O
not	not	O
alter	alter	O
the	the	O
motor	motor	O
function	function	O
and	and	O
procedural	procedural	O
memory	memory	O
of	of	O
mice	mice	O
as	as	O
assessed	assessed	O
by	by	O
swimming	swimming	O
speed	speed	O
and	and	O
escape	escape	O
latency	latency	O
to	to	O
find	find	O
the	the	O
platform	platform	O
in	in	O
a	a	O
cued	cued	O
version	version	O
of	of	O
the	the	O
water	water	O
maze	maze	O
task	task	O
.	.	O

However	however	O
,	,	O
METH	meth	B-Chemical
significantly	significantly	O
increased	increased	O
the	the	O
immobility	immobility	O
time	time	O
in	in	O
the	the	O
tail	tail	O
suspension	suspension	O
test	test	O
at	at	O
3	3	O
and	and	O
49	49	O
days	days	O
post-administration	post-administration	O
.	.	O

This	this	O
depressive-like	depressive-like	O
profile	profile	O
induced	induced	O
by	by	O
METH	meth	B-Chemical
was	was	O
accompanied	accompanied	O
by	by	O
a	a	O
marked	marked	O
depletion	depletion	O
of	of	O
frontostriatal	frontostriatal	O
dopaminergic	dopaminergic	O
and	and	O
serotonergic	serotonergic	O
neurotransmission	neurotransmission	O
,	,	O
indicated	indicated	O
by	by	O
a	a	O
reduction	reduction	O
in	in	O
the	the	O
levels	levels	O
of	of	O
dopamine	dopamine	B-Chemical
,	,	O
DOPAC	dopac	B-Chemical
and	and	O
HVA	hva	O
,	,	O
tyrosine	tyrosine	B-Chemical
hydroxylase	hydroxylase	O
and	and	O
serotonin	serotonin	B-Chemical
,	,	O
observed	observed	O
at	at	O
both	both	O
3	3	O
and	and	O
49	49	O
days	days	O
post-administration	post-administration	O
.	.	O

In	in	O
parallel	parallel	O
,	,	O
another	another	O
neurochemical	neurochemical	O
feature	feature	O
of	of	O
depression	depression	B-Disease
--	--	O
astroglial	astroglial	O
dysfunction	dysfunction	O
--	--	O
was	was	O
unaffected	unaffected	O
in	in	O
the	the	O
cortex	cortex	O
and	and	O
the	the	O
striatal	striatal	O
levels	levels	O
of	of	O
the	the	O
astrocytic	astrocytic	O
protein	protein	O
marker	marker	O
,	,	O
glial	glial	B-Chemical
fibrillary	fibrillary	I-Chemical
acidic	acidic	I-Chemical
protein	protein	I-Chemical
,	,	O
were	were	O
only	only	O
transiently	transiently	O
increased	increased	O
at	at	O
3	3	O
days	days	O
.	.	O

These	these	O
findings	findings	O
demonstrate	demonstrate	O
for	for	O
the	the	O
first	first	O
time	time	O
that	that	O
a	a	O
single	single	O
high	high	O
dose	dose	O
of	of	O
METH	meth	B-Chemical
induces	induces	O
long-lasting	long-lasting	O
depressive-like	depressive-like	O
behaviour	behaviour	O
in	in	O
mice	mice	O
associated	associated	O
with	with	O
a	a	O
persistent	persistent	O
disruption	disruption	O
of	of	O
frontostriatal	frontostriatal	O
dopaminergic	dopaminergic	O
and	and	O
serotonergic	serotonergic	O
homoeostasis	homoeostasis	O
.	.	O

Linezolid-induced	linezolid-induced	O
optic	optic	O
neuropathy	neuropathy	B-Disease
.	.	O

Many	many	O
systemic	systemic	O
antimicrobials	antimicrobials	O
have	have	O
been	been	O
implicated	implicated	O
to	to	O
cause	cause	O
ocular	ocular	O
adverse	adverse	O
effects	effects	O
.	.	O

This	this	O
is	is	O
especially	especially	O
relevant	relevant	O
in	in	O
multidrug	multidrug	O
therapy	therapy	O
where	where	O
more	more	O
than	than	O
one	one	O
drug	drug	O
can	can	O
cause	cause	O
a	a	O
similar	similar	O
ocular	ocular	O
adverse	adverse	O
effect	effect	O
.	.	O

We	we	O
describe	describe	O
a	a	O
case	case	O
of	of	O
progressive	progressive	O
loss	loss	O
of	of	O
vision	vision	O
associated	associated	O
with	with	O
linezolid	linezolid	O
therapy	therapy	O
.	.	O

A	a	O
45-year-old	45-year-old	O
male	male	O
patient	patient	O
who	who	O
was	was	O
on	on	O
treatment	treatment	O
with	with	O
multiple	multiple	O
second-line	second-line	O
anti-tuberculous	anti-tuberculous	O
drugs	drugs	O
including	including	O
linezolid	linezolid	O
and	and	O
ethambutol	ethambutol	O
for	for	O
extensively	extensively	O
drug-resistant	drug-resistant	O
tuberculosis	tuberculosis	B-Disease
(	(	O
XDR-TB	xdr-tb	O
)	)	O
presented	presented	O
to	to	O
us	us	O
with	with	O
painless	painless	O
progressive	progressive	O
loss	loss	O
of	of	O
vision	vision	O
in	in	O
both	both	O
eyes	eyes	O
.	.	O

Color	color	O
vision	vision	O
was	was	O
defective	defective	O
and	and	O
fundus	fundus	O
examination	examination	O
revealed	revealed	O
optic	optic	O
disc	disc	O
edema	edema	B-Disease
in	in	O
both	both	O
eyes	eyes	O
.	.	O

Ethambutol-induced	ethambutol-induced	O
toxic	toxic	O
optic	optic	O
neuropathy	neuropathy	B-Disease
was	was	O
suspected	suspected	O
and	and	O
tablet	tablet	O
ethambutol	ethambutol	O
was	was	O
withdrawn	withdrawn	O
.	.	O

Deterioration	deterioration	O
of	of	O
vision	vision	O
occurred	occurred	O
despite	despite	O
withdrawal	withdrawal	O
of	of	O
ethambutol	ethambutol	O
.	.	O

Discontinuation	discontinuation	O
of	of	O
linezolid	linezolid	O
resulted	resulted	O
in	in	O
marked	marked	O
improvement	improvement	O
of	of	O
vision	vision	O
.	.	O

Our	our	O
report	report	O
emphasizes	emphasizes	O
the	the	O
need	need	O
for	for	O
monitoring	monitoring	O
of	of	O
visual	visual	O
function	function	O
in	in	O
patients	patients	O
on	on	O
long-term	long-term	O
linezolid	linezolid	O
treatment	treatment	O
.	.	O

Resuscitation	resuscitation	O
with	with	O
lipid	lipid	O
,	,	O
epinephrine	epinephrine	B-Chemical
,	,	O
or	or	O
both	both	O
in	in	O
levobupivacaine-induced	levobupivacaine-induced	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
in	in	O
newborn	newborn	O
piglets	piglets	O
.	.	O

BACKGROUND	background	O
:	:	O
The	the	O
optimal	optimal	O
dosing	dosing	O
regimens	regimens	O
of	of	O
lipid	lipid	O
emulsion	emulsion	O
,	,	O
epinephrine	epinephrine	B-Chemical
,	,	O
or	or	O
both	both	O
are	are	O
not	not	O
yet	yet	O
determined	determined	O
in	in	O
neonates	neonates	O
in	in	O
cases	cases	O
of	of	O
local	local	O
anaesthetic	anaesthetic	O
systemic	systemic	O
toxicity	toxicity	B-Disease
(	(	O
LAST	last	O
)	)	O
.	.	O

METHODS	methods	O
:	:	O
Newborn	newborn	O
piglets	piglets	O
received	received	O
levobupivacaine	levobupivacaine	O
until	until	O
cardiovascular	cardiovascular	O
collapse	collapse	O
occurred	occurred	O
.	.	O

Standard	standard	O
cardiopulmonary	cardiopulmonary	O
resuscitation	resuscitation	O
was	was	O
started	started	O
and	and	O
electrocardiogram	electrocardiogram	O
(	(	O
ECG	ecg	O
)	)	O
was	was	O
monitored	monitored	O
for	for	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
,	,	O
fibrillation	fibrillation	O
,	,	O
or	or	O
QRS	qrs	O
prolongation	prolongation	O
.	.	O

Piglets	piglets	O
were	were	O
then	then	O
randomly	randomly	O
allocated	allocated	O
to	to	O
four	four	O
groups	groups	O
:	:	O
control	control	O
(	(	O
saline	saline	O
)	)	O
,	,	O
Intralipid	intralipid	O
(	(	O
)	)	O
alone	alone	O
,	,	O
epinephrine	epinephrine	B-Chemical
alone	alone	O
,	,	O
or	or	O
a	a	O
combination	combination	O
of	of	O
Intralipd	intralipd	O
plus	plus	O
epinephrine	epinephrine	B-Chemical
.	.	O

Resuscitation	resuscitation	O
continued	continued	O
for	for	O
30	30	O
min	min	O
or	or	O
until	until	O
there	there	O
was	was	O
a	a	O
return	return	O
of	of	O
spontaneous	spontaneous	O
circulation	circulation	O
(	(	O
ROSC	rosc	O
)	)	O
accompanied	accompanied	O
by	by	O
a	a	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
at	at	O
or	or	O
superior	superior	O
to	to	O
the	the	O
baseline	baseline	O
pressure	pressure	O
and	and	O
normal	normal	O
sinus	sinus	O
rhythm	rhythm	O
for	for	O
a	a	O
period	period	O
of	of	O
30	30	O
min	min	O
.	.	O

RESULTS	results	O
:	:	O
ROSC	rosc	O
was	was	O
achieved	achieved	O
in	in	O
only	only	O
one	one	O
of	of	O
the	the	O
control	control	O
piglets	piglets	O
compared	compared	O
with	with	O
most	most	O
of	of	O
the	the	O
treated	treated	O
piglets	piglets	O
.	.	O

Mortality	mortality	O
was	was	O
not	not	O
significantly	significantly	O
different	different	O
between	between	O
the	the	O
three	three	O
treatment	treatment	O
groups	groups	O
,	,	O
but	but	O
was	was	O
significantly	significantly	O
lower	lower	O
in	in	O
all	all	O
the	the	O
treatment	treatment	O
groups	groups	O
compared	compared	O
with	with	O
control	control	O
.	.	O

The	the	O
number	number	O
of	of	O
ECG	ecg	O
abnormalities	abnormalities	O
was	was	O
zero	zero	O
in	in	O
the	the	O
Intralipid	intralipid	O
only	only	O
group	group	O
,	,	O
but	but	O
14	14	O
and	and	O
17	17	O
,	,	O
respectively	respectively	O
,	,	O
in	in	O
the	the	O
epinephrine	epinephrine	B-Chemical
and	and	O
epinephrine	epinephrine	B-Chemical
plus	plus	O
lipid	lipid	O
groups	groups	O
(	(	O
P<0.05	p<0.05	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Lipid	lipid	O
emulsion	emulsion	O
with	with	O
or	or	O
without	without	O
epinephrine	epinephrine	B-Chemical
,	,	O
or	or	O
epinephrine	epinephrine	B-Chemical
alone	alone	O
were	were	O
equally	equally	O
effective	effective	O
in	in	O
achieving	achieving	O
a	a	O
return	return	O
to	to	O
spontaneous	spontaneous	O
circulation	circulation	O
in	in	O
this	this	O
model	model	O
of	of	O
LAST	last	O
.	.	O

Epinephrine	epinephrine	B-Chemical
alone	alone	O
or	or	O
in	in	O
combination	combination	O
with	with	O
lipid	lipid	O
was	was	O
associated	associated	O
with	with	O
an	an	O
increased	increased	O
number	number	O
of	of	O
ECG	ecg	O
abnormalities	abnormalities	O
compared	compared	O
with	with	O
lipid	lipid	O
emulsion	emulsion	O
alone	alone	O
.	.	O

Incidence	incidence	O
of	of	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
type	type	O
II	ii	O
and	and	O
postoperative	postoperative	O
recovery	recovery	O
of	of	O
platelet	platelet	O
count	count	O
in	in	O
liver	liver	O
graft	graft	O
recipients	recipients	O
:	:	O
a	a	O
retrospective	retrospective	O
cohort	cohort	O
analysis	analysis	O
.	.	O

BACKGROUND	background	O
:	:	O
Thrombocytopenia	thrombocytopenia	B-Disease
in	in	O
patients	patients	O
with	with	O
end-stage	end-stage	O
liver	liver	B-Disease
disease	disease	I-Disease
is	is	O
a	a	O
common	common	O
disorder	disorder	O
caused	caused	O
mainly	mainly	O
by	by	O
portal	portal	O
hypertension	hypertension	B-Disease
,	,	O
low	low	O
levels	levels	O
of	of	O
thrombopoetin	thrombopoetin	O
,	,	O
and	and	O
endotoxemia	endotoxemia	O
.	.	O

The	the	O
impact	impact	O
of	of	O
immune-mediated	immune-mediated	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
type	type	O
II	ii	O
(	(	O
HIT	hit	B-Disease
type	type	O
II	ii	O
)	)	O
as	as	O
a	a	O
cause	cause	O
of	of	O
thrombocytopenia	thrombocytopenia	B-Disease
after	after	O
liver	liver	O
transplantation	transplantation	O
is	is	O
not	not	O
yet	yet	O
understood	understood	O
,	,	O
with	with	O
few	few	O
literature	literature	O
citations	citations	O
reporting	reporting	O
contradictory	contradictory	O
results	results	O
.	.	O

The	the	O
aim	aim	O
of	of	O
our	our	O
study	study	O
was	was	O
to	to	O
demonstrate	demonstrate	O
the	the	O
perioperative	perioperative	O
course	course	O
of	of	O
thrombocytopenia	thrombocytopenia	B-Disease
after	after	O
liver	liver	O
transplantation	transplantation	O
and	and	O
determine	determine	O
the	the	O
occurrence	occurrence	O
of	of	O
clinical	clinical	O
HIT	hit	B-Disease
type	type	O
II	ii	O
.	.	O

METHOD	method	O
:	:	O
We	we	O
retrospectively	retrospectively	O
evaluated	evaluated	O
the	the	O
medical	medical	O
records	records	O
of	of	O
205	205	O
consecutive	consecutive	O
adult	adult	O
patients	patients	O
who	who	O
underwent	underwent	O
full-size	full-size	O
liver	liver	O
transplantation	transplantation	O
between	between	O
January	january	O
2006	2006	O
and	and	O
December	december	O
2010	2010	O
due	due	O
to	to	O
end-stage	end-stage	O
or	or	O
malignant	malignant	O
liver	liver	B-Disease
disease	disease	I-Disease
.	.	O

Preoperative	preoperative	O
platelet	platelet	O
count	count	O
,	,	O
postoperative	postoperative	O
course	course	O
of	of	O
platelets	platelets	O
,	,	O
and	and	O
clinical	clinical	O
signs	signs	O
of	of	O
HIT	hit	B-Disease
type	type	O
II	ii	O
were	were	O
analyzed	analyzed	O
.	.	O

RESULTS	results	O
:	:	O
A	a	O
total	total	O
of	of	O
155	155	O
(	(	O
75.6	75.6	O
%	%	O
)	)	O
of	of	O
205	205	O
patients	patients	O
had	had	O
thrombocytopenia	thrombocytopenia	B-Disease
before	before	O
transplantation	transplantation	O
,	,	O
significantly	significantly	O
influenced	influenced	O
by	by	O
Model	model	O
of	of	O
End-Stage	end-stage	O
Liver	liver	B-Disease
Disease	disease	I-Disease
score	score	O
and	and	O
liver	liver	B-Disease
cirrhosis	cirrhosis	B-Disease
.	.	O

The	the	O
platelet	platelet	O
count	count	O
exceeded	exceeded	O
100,000/uL	100,000/ul	O
in	in	O
most	most	O
of	of	O
the	the	O
patients	patients	O
(	(	O
n	n	O
=	=	O
193	193	O
)	)	O
at	at	O
a	a	O
medium	medium	O
of	of	O
7	7	O
d.	d.	O
Regarding	regarding	O
HIT	hit	B-Disease
II	ii	O
,	,	O
there	there	O
were	were	O
four	four	O
(	(	O
1.95	1.95	O
%	%	O
)	)	O
patients	patients	O
with	with	O
a	a	O
background	background	O
of	of	O
HIT	hit	B-Disease
type	type	O
II	ii	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
incidence	incidence	O
of	of	O
HIT	hit	B-Disease
in	in	O
patients	patients	O
with	with	O
end-stage	end-stage	O
hepatic	hepatic	B-Disease
failure	failure	I-Disease
is	is	O
,	,	O
with	with	O
about	about	O
1.95	1.95	O
%	%	O
,	,	O
rare	rare	O
.	.	O

For	for	O
further	further	O
reduction	reduction	O
of	of	O
HIT	hit	B-Disease
type	type	O
II	ii	O
,	,	O
the	the	O
use	use	O
of	of	O
intravenous	intravenous	O
heparin	heparin	B-Chemical
should	should	O
be	be	O
avoided	avoided	O
and	and	O
the	the	O
prophylactic	prophylactic	O
anticoagulation	anticoagulation	O
should	should	O
be	be	O
performed	performed	O
with	with	O
low-molecular-weight	low-molecular-weight	O
heparin	heparin	B-Chemical
after	after	O
normalization	normalization	O
of	of	O
platelet	platelet	O
count	count	O
.	.	O

Takotsubo	takotsubo	B-Disease
syndrome	syndrome	I-Disease
(	(	O
or	or	O
apical	apical	B-Disease
ballooning	ballooning	I-Disease
syndrome	syndrome	I-Disease
)	)	O
secondary	secondary	O
to	to	O
Zolmitriptan	zolmitriptan	O
.	.	O

Takotsubo	takotsubo	B-Disease
syndrome	syndrome	I-Disease
(	(	O
TS	ts	O
)	)	O
,	,	O
also	also	O
known	known	O
as	as	O
broken	broken	B-Disease
heart	heart	I-Disease
syndrome	syndrome	I-Disease
,	,	O
is	is	O
characterized	characterized	O
by	by	O
left	left	O
ventricle	ventricle	O
apical	apical	O
ballooning	ballooning	O
with	with	O
elevated	elevated	O
cardiac	cardiac	O
biomarkers	biomarkers	O
and	and	O
electrocardiographic	electrocardiographic	O
changes	changes	O
suggestive	suggestive	O
of	of	O
an	an	O
acute	acute	B-Disease
coronary	coronary	I-Disease
syndrome	syndrome	I-Disease
(	(	O
ie	ie	O
,	,	O
ST-segment	st-segment	O
elevation	elevation	O
,	,	O
T	t	O
wave	wave	O
inversions	inversions	O
,	,	O
and	and	O
pathologic	pathologic	O
Q	q	O
waves	waves	O
)	)	O
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
54-year-old	54-year-old	O
woman	woman	O
with	with	O
medical	medical	O
history	history	O
of	of	O
mitral	mitral	B-Disease
valve	valve	I-Disease
prolapse	prolapse	I-Disease
and	and	O
migraines	migraines	O
,	,	O
who	who	O
was	was	O
admitted	admitted	O
to	to	O
the	the	O
hospital	hospital	O
for	for	O
substernal	substernal	O
chest	chest	B-Disease
pain	pain	B-Disease
and	and	O
electrocardiogram	electrocardiogram	O
demonstrated	demonstrated	O
1/2	1/2	O
mm	mm	O
ST-segment	st-segment	O
elevation	elevation	O
in	in	O
leads	leads	O
II	ii	O
,	,	O
III	iii	O
,	,	O
aVF	avf	O
,	,	O
V5	v5	O
,	,	O
and	and	O
V6	v6	O
and	and	O
positive	positive	O
troponin	troponin	O
I.	i.	O
Emergent	emergent	O
coronary	coronary	O
angiogram	angiogram	O
revealed	revealed	O
normal	normal	O
coronary	coronary	O
arteries	arteries	O
with	with	O
moderately	moderately	O
reduced	reduced	O
left	left	O
ventricular	ventricular	O
ejection	ejection	O
fraction	fraction	O
with	with	O
wall	wall	O
motion	motion	O
abnormalities	abnormalities	O
consistent	consistent	O
with	with	O
TS	ts	O
.	.	O

Detailed	detailed	O
history	history	O
obtained	obtained	O
retrospectively	retrospectively	O
revealed	revealed	O
that	that	O
the	the	O
patient	patient	O
took	took	O
zolmitriptan	zolmitriptan	O
sparingly	sparingly	O
only	only	O
when	when	O
she	she	O
had	had	O
migraines	migraines	O
.	.	O

But	but	O
before	before	O
this	this	O
event	event	O
,	,	O
she	she	O
was	was	O
taking	taking	O
zolmitriptan	zolmitriptan	O
2	2	O
-	-	O
3	3	O
times	times	O
daily	daily	O
for	for	O
several	several	O
days	days	O
because	because	O
of	of	O
a	a	O
persistent	persistent	O
migraine	migraine	B-Disease
headache	headache	B-Disease
.	.	O

She	she	O
otherwise	otherwise	O
reported	reported	O
that	that	O
she	she	O
is	is	O
quite	quite	O
active	active	O
,	,	O
rides	rides	O
horses	horses	O
,	,	O
and	and	O
does	does	O
show	show	O
jumping	jumping	O
without	without	O
any	any	O
limitations	limitations	O
in	in	O
her	her	O
physical	physical	O
activity	activity	O
.	.	O

There	there	O
was	was	O
no	no	O
evidence	evidence	O
of	of	O
any	any	O
recent	recent	O
stress	stress	O
or	or	O
status	status	O
migrainosus	migrainosus	O
.	.	O

Extensive	extensive	O
literature	literature	O
search	search	O
revealed	revealed	O
multiple	multiple	O
cases	cases	O
of	of	O
coronary	coronary	B-Disease
artery	artery	I-Disease
vasospasm	vasospasm	B-Disease
secondary	secondary	O
to	to	O
zolmitriptan	zolmitriptan	O
,	,	O
but	but	O
none	none	O
of	of	O
the	the	O
cases	cases	O
were	were	O
associated	associated	O
with	with	O
TS	ts	O
.	.	O

Depression	depression	B-Disease
,	,	O
impulsiveness	impulsiveness	O
,	,	O
sleep	sleep	O
,	,	O
and	and	O
memory	memory	O
in	in	O
past	past	O
and	and	O
present	present	O
polydrug	polydrug	O
users	users	O
of	of	O
3,4-methylenedioxymethamphetamine	3,4-methylenedioxymethamphetamine	B-Chemical
(	(	O
MDMA	mdma	B-Chemical
,	,	O
ecstasy).RATIONALE	ecstasy).rationale	O
:	:	O
Ecstasy	ecstasy	B-Chemical
(	(	O
3,4-methylenedioxymethamphetamine	3,4-methylenedioxymethamphetamine	B-Chemical
,	,	O
MDMA	mdma	B-Chemical
)	)	O
is	is	O
a	a	O
worldwide	worldwide	O
recreational	recreational	O
drug	drug	O
of	of	O
abuse	abuse	O
.	.	O

Unfortunately	unfortunately	O
,	,	O
the	the	O
results	results	O
from	from	O
human	human	O
research	research	O
investigating	investigating	O
its	its	O
psychological	psychological	O
effects	effects	O
have	have	O
been	been	O
inconsistent	inconsistent	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
The	the	O
present	present	O
study	study	O
aimed	aimed	O
to	to	O
be	be	O
the	the	O
largest	largest	O
to	to	O
date	date	O
in	in	O
sample	sample	O
size	size	O
and	and	O
5HT-related	5ht-related	O
behaviors	behaviors	O
;	;	O
the	the	O
first	first	O
to	to	O
compare	compare	O
present	present	O
ecstasy	ecstasy	B-Chemical
users	users	O
with	with	O
past	past	O
users	users	O
after	after	O
an	an	O
abstinence	abstinence	O
of	of	O
4	4	O
or	or	O
more	more	O
years	years	O
,	,	O
and	and	O
the	the	O
first	first	O
to	to	O
include	include	O
robust	robust	O
controls	controls	O
for	for	O
other	other	O
recreational	recreational	O
substances	substances	O
.	.	O

METHODS	methods	O
:	:	O
A	a	O
sample	sample	O
of	of	O
997	997	O
participants	participants	O
(	(	O
52	52	O
%	%	O
male	male	O
)	)	O
was	was	O
recruited	recruited	O
to	to	O
four	four	O
control	control	O
groups	groups	O
(	(	O
non-drug	non-drug	O
(	(	O
ND	nd	O
)	)	O
,	,	O
alcohol/nicotine	alcohol/nicotine	O
(	(	O
AN	an	O
)	)	O
,	,	O
cannabis/alcohol/nicotine	cannabis/alcohol/nicotine	O
(	(	O
CAN	can	O
)	)	O
,	,	O
non-ecstasy	non-ecstasy	O
polydrug	polydrug	O
(	(	O
PD	pd	B-Disease
)	)	O
)	)	O
,	,	O
and	and	O
two	two	O
ecstasy	ecstasy	B-Chemical
polydrug	polydrug	O
groups	groups	O
(	(	O
present	present	O
(	(	O
MDMA	mdma	B-Chemical
)	)	O
and	and	O
past	past	O
users	users	O
(	(	O
EX-MDMA	ex-mdma	O
)	)	O
.	.	O

Participants	participants	O
completed	completed	O
a	a	O
drug	drug	O
history	history	O
questionnaire	questionnaire	O
,	,	O
Beck	beck	O
Depression	depression	B-Disease
Inventory	inventory	O
,	,	O
Barratt	barratt	O
Impulsiveness	impulsiveness	O
Scale	scale	O
,	,	O
Pittsburgh	pittsburgh	O
Sleep	sleep	O
Quality	quality	O
Index	index	O
,	,	O
and	and	O
Wechsler	wechsler	O
Memory	memory	O
Scale-Revised	scale-revised	O
which	which	O
,	,	O
in	in	O
total	total	O
,	,	O
provided	provided	O
13	13	O
psychometric	psychometric	O
measures	measures	O
.	.	O

RESULTS	results	O
:	:	O
While	while	O
the	the	O
CAN	can	O
and	and	O
PD	pd	B-Disease
groups	groups	O
tended	tended	O
to	to	O
record	record	O
greater	greater	O
deficits	deficits	O
than	than	O
the	the	O
non-drug	non-drug	O
controls	controls	O
,	,	O
the	the	O
MDMA	mdma	B-Chemical
and	and	O
EX-MDMA	ex-mdma	O
groups	groups	O
recorded	recorded	O
greater	greater	O
deficits	deficits	O
than	than	O
all	all	O
the	the	O
control	control	O
groups	groups	O
on	on	O
ten	ten	O
of	of	O
the	the	O
13	13	O
psychometric	psychometric	O
measures	measures	O
.	.	O

Strikingly	strikingly	O
,	,	O
despite	despite	O
prolonged	prolonged	O
abstinence	abstinence	O
(	(	O
mean	mean	O
,	,	O
4.98	4.98	O
;	;	O
range	range	O
,	,	O
4	4	O
-	-	O
9	9	O
years	years	O
)	)	O
,	,	O
past	past	O
ecstasy	ecstasy	B-Chemical
users	users	O
showed	showed	O
few	few	O
signs	signs	O
of	of	O
recovery	recovery	O
.	.	O

Compared	compared	O
with	with	O
present	present	O
ecstasy	ecstasy	B-Chemical
users	users	O
,	,	O
the	the	O
past	past	O
users	users	O
showed	showed	O
no	no	O
change	change	O
for	for	O
ten	ten	O
measures	measures	O
,	,	O
increased	increased	O
impairment	impairment	O
for	for	O
two	two	O
measures	measures	O
,	,	O
and	and	O
improvement	improvement	O
on	on	O
just	just	O
one	one	O
measure	measure	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Given	given	O
this	this	O
record	record	O
of	of	O
impaired	impaired	O
memory	memory	O
and	and	O
clinically	clinically	O
significant	significant	O
levels	levels	O
of	of	O
depression	depression	B-Disease
,	,	O
impulsiveness	impulsiveness	O
,	,	O
and	and	O
sleep	sleep	O
disturbance	disturbance	O
,	,	O
the	the	O
prognosis	prognosis	O
for	for	O
the	the	O
current	current	O
generation	generation	O
of	of	O
ecstasy	ecstasy	B-Chemical
users	users	O
is	is	O
a	a	O
major	major	O
cause	cause	O
for	for	O
concern	concern	O
.	.	O

Association	association	O
of	of	O
common	common	O
genetic	genetic	O
variants	variants	O
of	of	O
HOMER1	homer1	O
gene	gene	O
with	with	O
levodopa	levodopa	B-Chemical
adverse	adverse	O
effects	effects	O
in	in	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
patients	patients	O
.	.	O

Levodopa	levodopa	B-Chemical
is	is	O
the	the	O
most	most	O
effective	effective	O
symptomatic	symptomatic	O
therapy	therapy	O
for	for	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
,	,	O
but	but	O
its	its	O
chronic	chronic	O
use	use	O
could	could	O
lead	lead	O
to	to	O
chronic	chronic	O
adverse	adverse	O
outcomes	outcomes	O
,	,	O
such	such	O
as	as	O
motor	motor	O
fluctuations	fluctuations	O
,	,	O
dyskinesia	dyskinesia	B-Disease
and	and	O
visual	visual	B-Disease
hallucinations	hallucinations	B-Disease
.	.	O

HOMER1	homer1	O
is	is	O
a	a	O
protein	protein	O
with	with	O
pivotal	pivotal	O
function	function	O
in	in	O
glutamate	glutamate	B-Chemical
transmission	transmission	O
,	,	O
which	which	O
has	has	O
been	been	O
related	related	O
to	to	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
these	these	O
complications	complications	O
.	.	O

This	this	O
study	study	O
investigates	investigates	O
whether	whether	O
polymorphisms	polymorphisms	O
in	in	O
the	the	O
HOMER1	homer1	O
gene	gene	O
promoter	promoter	O
region	region	O
are	are	O
associated	associated	O
with	with	O
the	the	O
occurrence	occurrence	O
of	of	O
the	the	O
chronic	chronic	O
complications	complications	O
of	of	O
levodopa	levodopa	B-Chemical
therapy	therapy	O
.	.	O

A	a	O
total	total	O
of	of	O
205	205	O
patients	patients	O
with	with	O
idiopathic	idiopathic	B-Disease
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
were	were	O
investigated	investigated	O
.	.	O

Patients	patients	O
were	were	O
genotyped	genotyped	O
for	for	O
rs4704559	rs4704559	O
,	,	O
rs10942891	rs10942891	O
and	and	O
rs4704560	rs4704560	O
by	by	O
allelic	allelic	O
discrimination	discrimination	O
with	with	O
Taqman	taqman	O
assays	assays	O
.	.	O

The	the	O
rs4704559	rs4704559	O
G	g	O
allele	allele	O
was	was	O
associated	associated	O
with	with	O
a	a	O
lower	lower	O
prevalence	prevalence	O
of	of	O
dyskinesia	dyskinesia	B-Disease
(	(	O
prevalence	prevalence	O
ratio	ratio	O
(PR)=0.615	(pr)=0.615	O
,	,	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
(	(	O
CI	ci	O
)	)	O
0.426	0.426	O
-	-	O
0.887	0.887	O
,	,	O
P=0.009	p=0.009	O
)	)	O
and	and	O
visual	visual	B-Disease
hallucinations	hallucinations	B-Disease
(	(	O
PR=0.515	pr=0.515	O
,	,	O
95	95	O
%	%	O
CI	ci	O
0.295	0.295	O
-	-	O
0.899	0.899	O
,	,	O
P=0.020	p=0.020	O
)	)	O
.	.	O

Our	our	O
data	data	O
suggest	suggest	O
that	that	O
HOMER1	homer1	O
rs4704559	rs4704559	O
G	g	O
allele	allele	O
has	has	O
a	a	O
protective	protective	O
role	role	O
for	for	O
the	the	O
development	development	O
of	of	O
levodopa	levodopa	B-Chemical
adverse	adverse	O
effects	effects	O
.	.	O

Crocin	crocin	O
improves	improves	O
lipid	lipid	O
dysregulation	dysregulation	O
in	in	O
subacute	subacute	O
diazinon	diazinon	O
exposure	exposure	O
through	through	O
ERK1/2	erk1/2	O
pathway	pathway	O
in	in	O
rat	rat	O
liver	liver	O
.	.	O

INTRODUCTION	introduction	O
:	:	O
Diazinon	diazinon	O
Yis	yis	O
one	one	O
of	of	O
the	the	O
most	most	O
broadly	broadly	O
used	used	O
organophosphorus	organophosphorus	O
insecticides	insecticides	O
in	in	O
agriculture	agriculture	O
.	.	O

It	it	O
has	has	O
been	been	O
shown	shown	O
that	that	O
exposure	exposure	O
to	to	O
diazinon	diazinon	O
may	may	O
interfere	interfere	O
with	with	O
lipid	lipid	O
metabolism	metabolism	O
.	.	O

Moreover	moreover	O
,	,	O
the	the	O
hypolipidemic	hypolipidemic	O
effect	effect	O
of	of	O
crocin	crocin	O
has	has	O
been	been	O
established	established	O
.	.	O

Earlier	earlier	O
studies	studies	O
revealed	revealed	O
the	the	O
major	major	O
role	role	O
of	of	O
Extracellular	extracellular	O
signal-regulated	signal-regulated	O
kinase	kinase	O
(	(	O
ERK	erk	O
)	)	O
pathways	pathways	O
in	in	O
low-density	low-density	O
lipoprotein	lipoprotein	O
receptor	receptor	O
(	(	O
LDLr	ldlr	O
)	)	O
expression	expression	O
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
evaluate	evaluate	O
changes	changes	O
in	in	O
the	the	O
regulation	regulation	O
of	of	O
lipid	lipid	O
metabolism	metabolism	O
,	,	O
ERK	erk	O
and	and	O
LDLr	ldlr	O
expression	expression	O
in	in	O
the	the	O
liver	liver	O
of	of	O
rats	rats	O
exposed	exposed	O
to	to	O
subacute	subacute	O
diazinon	diazinon	O
.	.	O

Furthermore	furthermore	O
ameliorating	ameliorating	O
effect	effect	O
of	of	O
crocin	crocin	O
on	on	O
diazinon	diazinon	O
induced	induced	O
disturbed	disturbed	O
cholesterol	cholesterol	B-Chemical
homeostasis	homeostasis	O
was	was	O
studied	studied	O
.	.	O

METHODS	methods	O
:	:	O
24	24	O
Rats	rats	O
were	were	O
divided	divided	O
into	into	O
4	4	O
groups	groups	O
and	and	O
received	received	O
following	following	O
treatments	treatments	O
for	for	O
4	4	O
weeks	weeks	O
;	;	O
Corn	corn	B-Chemical
oil	oil	I-Chemical
(	(	O
control	control	O
)	)	O
,	,	O
diazinon	diazinon	O
(	(	O
15mg/kg	15mg/kg	O
per	per	O
day	day	O
,	,	O
orally	orally	O
)	)	O
and	and	O
crocin	crocin	O
(	(	O
12.5	12.5	O
and	and	O
25mg/kg	25mg/kg	O
per	per	O
day	day	O
,	,	O
intraperitoneally	intraperitoneally	O
)	)	O
in	in	O
combination	combination	O
with	with	O
diazinon	diazinon	O
(	(	O
15	15	O
mg/kg	mg/kg	O
)	)	O
.	.	O

The	the	O
levels	levels	O
of	of	O
cholesterol	cholesterol	B-Chemical
,	,	O
triglyceride	triglyceride	O
and	and	O
LDL	ldl	O
in	in	O
blood	blood	O
of	of	O
rats	rats	O
were	were	O
analyzed	analyzed	O
.	.	O

Moreover	moreover	O
mRNA	mrna	O
levels	levels	O
of	of	O
LDLr	ldlr	O
and	and	O
ERK1/2	erk1/2	O
as	as	O
well	well	O
as	as	O
protein	protein	O
levels	levels	O
of	of	O
total	total	O
and	and	O
activated	activated	O
forms	forms	O
of	of	O
ERK1/2	erk1/2	O
in	in	O
rat	rat	O
liver	liver	O
were	were	O
evaluated	evaluated	O
by	by	O
Western	western	O
blotting	blotting	O
and	and	O
quantitative	quantitative	O
real	real	O
time	time	O
polymerase	polymerase	O
chain	chain	O
reaction	reaction	O
analysis	analysis	O
.	.	O

RESULTS	results	O
:	:	O
Our	our	O
data	data	O
showed	showed	O
that	that	O
subacute	subacute	O
exposure	exposure	O
to	to	O
diazinon	diazinon	O
significantly	significantly	O
increased	increased	O
concentrations	concentrations	O
of	of	O
cholesterol	cholesterol	B-Chemical
,	,	O
triglyceride	triglyceride	O
and	and	O
LDL	ldl	O
.	.	O

Moreover	moreover	O
diazinon	diazinon	O
decreased	decreased	O
ERK1/2	erk1/2	O
protein	protein	O
phosphorylation	phosphorylation	O
and	and	O
LDLr	ldlr	O
transcript	transcript	O
.	.	O

Crocin	crocin	O
reduced	reduced	O
inhibition	inhibition	O
of	of	O
ERK	erk	O
activation	activation	O
and	and	O
diazinon-induced	diazinon-induced	O
hyperlipemia	hyperlipemia	O
and	and	O
increased	increased	O
levels	levels	O
of	of	O
LDLr	ldlr	O
transcript	transcript	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Crocin	crocin	O
may	may	O
be	be	O
considered	considered	O
as	as	O
a	a	O
novel	novel	O
protective	protective	O
agent	agent	O
in	in	O
diazinon-induced	diazinon-induced	O
hyperlipemia	hyperlipemia	O
through	through	O
modulating	modulating	O
of	of	O
ERK	erk	O
pathway	pathway	O
and	and	O
increase	increase	O
of	of	O
LDLr	ldlr	O
expression	expression	O
.	.	O

GEM-P	gem-p	O
chemotherapy	chemotherapy	O
is	is	O
active	active	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
relapsed	relapsed	O
Hodgkin	hodgkin	B-Disease
lymphoma	lymphoma	I-Disease
.	.	O

Hodgkin	hodgkin	B-Disease
lymphoma	lymphoma	I-Disease
(	(	O
HL	hl	O
)	)	O
is	is	O
a	a	O
relatively	relatively	O
chemosensitive	chemosensitive	O
malignancy	malignancy	B-Disease
.	.	O

However	however	O
,	,	O
for	for	O
those	those	O
who	who	O
relapse	relapse	O
,	,	O
high-dose	high-dose	O
chemotherapy	chemotherapy	O
with	with	O
autologous	autologous	O
stem	stem	O
cell	cell	O
transplant	transplant	O
is	is	O
the	the	O
treatment	treatment	O
of	of	O
choice	choice	O
which	which	O
relies	relies	O
on	on	O
adequate	adequate	O
disease	disease	O
control	control	O
with	with	O
salvage	salvage	O
chemotherapy	chemotherapy	O
.	.	O

Regimens	regimens	O
commonly	commonly	O
used	used	O
often	often	O
require	require	O
inpatient	inpatient	O
administration	administration	O
and	and	O
can	can	O
be	be	O
difficult	difficult	O
to	to	O
deliver	deliver	O
due	due	O
to	to	O
toxicity	toxicity	B-Disease
.	.	O

Gemcitabine	gemcitabine	B-Chemical
and	and	O
cisplatin	cisplatin	B-Chemical
have	have	O
activity	activity	O
in	in	O
HL	hl	O
,	,	O
non-overlapping	non-overlapping	O
toxicity	toxicity	B-Disease
with	with	O
first-line	first-line	O
chemotherapeutics	chemotherapeutics	O
,	,	O
and	and	O
may	may	O
be	be	O
delivered	delivered	O
in	in	O
an	an	O
outpatient	outpatient	O
setting	setting	O
.	.	O

In	in	O
this	this	O
retrospective	retrospective	O
single-centre	single-centre	O
analysis	analysis	O
,	,	O
patients	patients	O
with	with	O
relapsed	relapsed	O
or	or	O
refractory	refractory	O
HL	hl	O
treated	treated	O
with	with	O
gemcitabine	gemcitabine	B-Chemical
1,000	1,000	O
mg/m(2	mg/m(2	O
)	)	O
day	day	O
(D)1	(d)1	O
,	,	O
D8	d8	O
and	and	O
D15	d15	O
;	;	O
methylprednisolone	methylprednisolone	B-Chemical
1,000	1,000	O
mg	mg	O
D1	d1	O
-	-	O
5	5	O
;	;	O
and	and	O
cisplatin	cisplatin	B-Chemical
100	100	O
mg/m(2	mg/m(2	O
)	)	O
D15	d15	O
,	,	O
every	every	O
28	28	O
days	days	O
(	(	O
GEM-P	gem-p	O
)	)	O
were	were	O
included	included	O
.	.	O

Demographic	demographic	O
,	,	O
survival	survival	O
,	,	O
response	response	O
and	and	O
toxicity	toxicity	B-Disease
data	data	O
were	were	O
recorded	recorded	O
.	.	O

Forty-one	forty-one	O
eligible	eligible	O
patients	patients	O
were	were	O
identified	identified	O
:	:	O
median	median	O
age	age	O
27	27	O
.	.	O

One	one	O
hundred	hundred	O
and	and	O
twenty-two	twenty-two	O
cycles	cycles	O
of	of	O
GEM-P	gem-p	O
were	were	O
administered	administered	O
in	in	O
total	total	O
(	(	O
median	median	O
3	3	O
cycles	cycles	O
;	;	O
range	range	O
1	1	O
-	-	O
6	6	O
)	)	O
.	.	O

Twenty	twenty	O
of	of	O
41	41	O
(	(	O
48	48	O
%	%	O
)	)	O
patients	patients	O
received	received	O
GEM-P	gem-p	O
as	as	O
second-line	second-line	O
treatment	treatment	O
and	and	O
11/41	11/41	O
(	(	O
27	27	O
%	%	O
)	)	O
as	as	O
third-line	third-line	O
therapy	therapy	O
.	.	O

Overall	overall	O
response	response	O
rate	rate	O
(	(	O
ORR	orr	O
)	)	O
to	to	O
GEM-P	gem-p	O
in	in	O
the	the	O
entire	entire	O
cohort	cohort	O
was	was	O
80	80	O
%	%	O
(	(	O
complete	complete	O
response	response	O
(	(	O
CR	cr	B-Chemical
)	)	O
37	37	O
%	%	O
,	,	O
partial	partial	O
response	response	O
44	44	O
%	%	O
)	)	O
with	with	O
14/15	14/15	O
CR	cr	B-Chemical
confirmed	confirmed	O
as	as	O
a	a	O
metabolic	metabolic	O
CR	cr	B-Chemical
on	on	O
PET	pet	O
and	and	O
ORR	orr	O
of	of	O
85	85	O
%	%	O
in	in	O
the	the	O
20	20	O
second-line	second-line	O
patients	patients	O
.	.	O

The	the	O
most	most	O
common	common	O
grade	grade	O
3/4	3/4	O
toxicities	toxicities	B-Disease
were	were	O
haematological	haematological	O
:	:	O
neutropenia	neutropenia	B-Disease
54	54	O
%	%	O
and	and	O
thrombocytopenia	thrombocytopenia	B-Disease
51	51	O
%	%	O
.	.	O

Median	median	O
follow-up	follow-up	O
from	from	O
the	the	O
start	start	O
of	of	O
GEM-P	gem-p	O
was	was	O
4.5	4.5	O
years	years	O
.	.	O

Following	following	O
GEM-P	gem-p	O
,	,	O
5-year	5-year	O
progression-free	progression-free	O
survival	survival	O
was	was	O
46	46	O
%	%	O
(	(	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
(	(	O
CI	ci	O
)	)	O
,	,	O
30	30	O
-	-	O
62	62	O
%	%	O
)	)	O
and	and	O
5-year	5-year	O
overall	overall	O
survival	survival	O
was	was	O
59	59	O
%	%	O
(	(	O
95	95	O
%	%	O
CI	ci	O
,	,	O
43	43	O
-	-	O
74	74	O
%	%	O
)	)	O
.	.	O

Fourteen	fourteen	O
of	of	O
41	41	O
patients	patients	O
proceeded	proceeded	O
directly	directly	O
to	to	O
autologous	autologous	O
transplant	transplant	O
.	.	O

GEM-P	gem-p	O
is	is	O
a	a	O
salvage	salvage	O
chemotherapy	chemotherapy	O
with	with	O
relatively	relatively	O
high	high	O
response	response	O
rates	rates	O
,	,	O
leading	leading	O
to	to	O
successful	successful	O
transplantation	transplantation	O
in	in	O
appropriate	appropriate	O
patients	patients	O
,	,	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
relapsed	relapsed	O
or	or	O
refractory	refractory	O
HL	hl	O
.	.	O

Basal	basal	O
functioning	functioning	O
of	of	O
the	the	O
hypothalamic-pituitary-adrenal	hypothalamic-pituitary-adrenal	O
(	(	O
HPA	hpa	O
)	)	O
axis	axis	O
and	and	O
psychological	psychological	O
distress	distress	O
in	in	O
recreational	recreational	O
ecstasy	ecstasy	B-Chemical
polydrug	polydrug	O
users	users	O
.	.	O

RATIONALE	rationale	O
:	:	O
Ecstasy	ecstasy	B-Chemical
(	(	O
MDMA	mdma	B-Chemical
)	)	O
is	is	O
a	a	O
psychostimulant	psychostimulant	O
drug	drug	O
which	which	O
is	is	O
increasingly	increasingly	O
associated	associated	O
with	with	O
psychobiological	psychobiological	O
dysfunction	dysfunction	O
.	.	O

While	while	O
some	some	O
recent	recent	O
studies	studies	O
suggest	suggest	O
acute	acute	O
changes	changes	O
in	in	O
neuroendocrine	neuroendocrine	O
function	function	O
,	,	O
less	less	O
is	is	O
known	known	O
about	about	O
long-term	long-term	O
changes	changes	O
in	in	O
HPA	hpa	O
functionality	functionality	O
in	in	O
recreational	recreational	O
users	users	O
.	.	O

OBJECTIVES	objectives	O
:	:	O
The	the	O
current	current	O
study	study	O
is	is	O
the	the	O
first	first	O
to	to	O
explore	explore	O
the	the	O
effects	effects	O
of	of	O
ecstasy-polydrug	ecstasy-polydrug	O
use	use	O
on	on	O
psychological	psychological	O
distress	distress	O
and	and	O
basal	basal	O
functioning	functioning	O
of	of	O
the	the	O
HPA	hpa	O
axis	axis	O
through	through	O
assessing	assessing	O
the	the	O
secretion	secretion	O
of	of	O
cortisol	cortisol	B-Chemical
across	across	O
the	the	O
diurnal	diurnal	O
period	period	O
.	.	O

METHOD	method	O
:	:	O
Seventy-six	seventy-six	O
participants	participants	O
(	(	O
21	21	O
nonusers	nonusers	O
,	,	O
29	29	O
light	light	O
ecstasy-polydrug	ecstasy-polydrug	O
users	users	O
,	,	O
26	26	O
heavy	heavy	O
ecstasy-polydrug	ecstasy-polydrug	O
users	users	O
)	)	O
completed	completed	O
a	a	O
substance	substance	O
use	use	O
inventory	inventory	O
and	and	O
measures	measures	O
of	of	O
psychological	psychological	O
distress	distress	O
at	at	O
baseline	baseline	O
,	,	O
then	then	O
two	two	O
consecutive	consecutive	O
days	days	O
of	of	O
cortisol	cortisol	B-Chemical
sampling	sampling	O
(	(	O
on	on	O
awakening	awakening	O
,	,	O
30	30	O
min	min	O
post	post	O
awakening	awakening	O
,	,	O
between	between	O
1400	1400	O
and	and	O
1600	1600	O
hours	hours	O
and	and	O
pre	pre	O
bedtime	bedtime	O
)	)	O
.	.	O

On	on	O
day	day	O
2	2	O
,	,	O
participants	participants	O
also	also	O
attended	attended	O
the	the	O
laboratory	laboratory	O
to	to	O
complete	complete	O
a	a	O
20-min	20-min	O
multitasking	multitasking	O
stressor	stressor	O
.	.	O

RESULTS	results	O
:	:	O
Both	both	O
user	user	O
groups	groups	O
exhibited	exhibited	O
significantly	significantly	O
greater	greater	O
levels	levels	O
of	of	O
anxiety	anxiety	B-Disease
and	and	O
depression	depression	B-Disease
than	than	O
nonusers	nonusers	O
.	.	O

On	on	O
day	day	O
1	1	O
,	,	O
all	all	O
participants	participants	O
exhibited	exhibited	O
a	a	O
typical	typical	O
cortisol	cortisol	B-Chemical
profile	profile	O
,	,	O
though	though	O
light	light	O
users	users	O
had	had	O
significantly	significantly	O
elevated	elevated	O
levels	levels	O
pre-bed	pre-bed	O
.	.	O

On	on	O
day	day	O
2	2	O
,	,	O
heavy	heavy	O
users	users	O
demonstrated	demonstrated	O
elevated	elevated	O
levels	levels	O
upon	upon	O
awakening	awakening	O
and	and	O
all	all	O
ecstasy-polydrug	ecstasy-polydrug	O
users	users	O
demonstrated	demonstrated	O
elevated	elevated	O
pre-bed	pre-bed	O
levels	levels	O
compared	compared	O
to	to	O
non-users	non-users	O
.	.	O

Significant	significant	O
between	between	O
group	group	O
differences	differences	O
were	were	O
also	also	O
observed	observed	O
in	in	O
afternoon	afternoon	O
cortisol	cortisol	B-Chemical
levels	levels	O
and	and	O
in	in	O
overall	overall	O
cortisol	cortisol	B-Chemical
secretion	secretion	O
across	across	O
the	the	O
day	day	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
increases	increases	O
in	in	O
anxiety	anxiety	B-Disease
and	and	O
depression	depression	B-Disease
are	are	O
in	in	O
line	line	O
with	with	O
previous	previous	O
observations	observations	O
in	in	O
recreational	recreational	O
ecstasy-polydrug	ecstasy-polydrug	O
users	users	O
.	.	O

Dysregulated	dysregulated	O
diurnal	diurnal	O
cortisol	cortisol	B-Chemical
may	may	O
be	be	O
indicative	indicative	O
of	of	O
inappropriate	inappropriate	O
anticipation	anticipation	O
of	of	O
forthcoming	forthcoming	O
demands	demands	O
and	and	O
hypersecretion	hypersecretion	O
may	may	O
lead	lead	O
to	to	O
the	the	O
increased	increased	O
psychological	psychological	O
and	and	O
physical	physical	O
morbidity	morbidity	O
associated	associated	O
with	with	O
heavy	heavy	O
recreational	recreational	O
use	use	O
of	of	O
ecstasy	ecstasy	B-Chemical
.	.	O

Ifosfamide	ifosfamide	B-Chemical
related	related	O
encephalopathy	encephalopathy	B-Disease
:	:	O
the	the	O
need	need	O
for	for	O
a	a	O
timely	timely	O
EEG	eeg	O
evaluation	evaluation	O
.	.	O

BACKGROUND	background	O
:	:	O
Ifosfamide	ifosfamide	B-Chemical
is	is	O
an	an	O
alkylating	alkylating	O
agent	agent	O
useful	useful	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
a	a	O
wide	wide	O
range	range	O
of	of	O
cancers	cancers	B-Disease
including	including	O
sarcomas	sarcomas	O
,	,	O
lymphoma	lymphoma	O
,	,	O
gynecologic	gynecologic	O
and	and	O
testicular	testicular	O
cancers	cancers	B-Disease
.	.	O

Encephalopathy	encephalopathy	B-Disease
has	has	O
been	been	O
reported	reported	O
in	in	O
10	10	O
-	-	O
40	40	O
%	%	O
of	of	O
patients	patients	O
receiving	receiving	O
high-dose	high-dose	O
IV	iv	O
ifosfamide	ifosfamide	B-Chemical
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
highlight	highlight	O
the	the	O
role	role	O
of	of	O
electroencephalogram	electroencephalogram	O
(	(	O
EEG	eeg	O
)	)	O
in	in	O
the	the	O
early	early	O
detection	detection	O
and	and	O
management	management	O
of	of	O
ifosfamide	ifosfamide	B-Chemical
related	related	O
encephalopathy	encephalopathy	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Retrospective	retrospective	O
chart	chart	O
review	review	O
including	including	O
clinical	clinical	O
data	data	O
and	and	O
EEG	eeg	O
recordings	recordings	O
was	was	O
done	done	O
on	on	O
five	five	O
patients	patients	O
,	,	O
admitted	admitted	O
to	to	O
MD	md	O
Anderson	anderson	O
Cancer	cancer	B-Disease
Center	center	O
between	between	O
years	years	O
2009	2009	O
and	and	O
2012	2012	O
,	,	O
who	who	O
developed	developed	O
ifosfamide	ifosfamide	B-Chemical
related	related	O
acute	acute	O
encephalopathy	encephalopathy	B-Disease
.	.	O

RESULTS	results	O
:	:	O
All	all	O
five	five	O
patients	patients	O
experienced	experienced	O
symptoms	symptoms	O
of	of	O
encephalopathy	encephalopathy	B-Disease
soon	soon	O
after	after	O
(	(	O
within	within	O
12	12	O
h-2	h-2	O
days	days	O
)	)	O
receiving	receiving	O
ifosfamide	ifosfamide	B-Chemical
.	.	O

Two	two	O
patients	patients	O
developed	developed	O
generalized	generalized	O
convulsions	convulsions	B-Disease
while	while	O
one	one	O
patient	patient	O
developed	developed	O
continuous	continuous	O
non-convulsive	non-convulsive	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
(	(	O
NCSE	ncse	O
)	)	O
that	that	O
required	required	O
ICU	icu	O
admission	admission	O
and	and	O
intubation	intubation	O
.	.	O

Initial	initial	O
EEG	eeg	O
showed	showed	O
epileptiform	epileptiform	O
discharges	discharges	O
in	in	O
three	three	O
patients	patients	O
;	;	O
run	run	O
of	of	O
triphasic	triphasic	O
waves	waves	O
in	in	O
one	one	O
patient	patient	O
and	and	O
moderate	moderate	O
degree	degree	O
diffuse	diffuse	O
generalized	generalized	O
slowing	slowing	O
.	.	O

Mixed	mixed	O
pattern	pattern	O
with	with	O
the	the	O
presence	presence	O
of	of	O
both	both	O
sharps	sharps	O
and	and	O
triphasic	triphasic	O
waves	waves	O
were	were	O
also	also	O
noted	noted	O
.	.	O

Repeat	repeat	O
EEGs	eegs	O
within	within	O
24_h	24_h	O
of	of	O
symptom	symptom	O
onset	onset	O
showed	showed	O
marked	marked	O
improvement	improvement	O
that	that	O
was	was	O
correlated	correlated	O
with	with	O
clinical	clinical	O
improvement	improvement	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Severity	severity	O
of	of	O
ifosfamide	ifosfamide	B-Chemical
related	related	O
encephalopathy	encephalopathy	B-Disease
correlates	correlates	O
with	with	O
EEG	eeg	O
changes	changes	O
.	.	O

We	we	O
suggest	suggest	O
a	a	O
timely	timely	O
EEG	eeg	O
evaluation	evaluation	O
for	for	O
patients	patients	O
receiving	receiving	O
ifosfamide	ifosfamide	B-Chemical
who	who	O
develop	develop	O
features	features	O
of	of	O
encephalopathy	encephalopathy	B-Disease
.	.	O

Incidence	incidence	O
of	of	O
contrast-induced	contrast-induced	O
nephropathy	nephropathy	B-Disease
in	in	O
hospitalised	hospitalised	O
patients	patients	O
with	with	O
cancer	cancer	B-Disease
.	.	O

OBJECTIVES	objectives	O
:	:	O
To	to	O
determine	determine	O
the	the	O
frequency	frequency	O
of	of	O
and	and	O
possible	possible	O
factors	factors	O
related	related	O
to	to	O
contrast-induced	contrast-induced	O
nephropathy	nephropathy	B-Disease
(	(	O
CIN	cin	O
)	)	O
in	in	O
hospitalised	hospitalised	O
patients	patients	O
with	with	O
cancer	cancer	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Ninety	ninety	O
adult	adult	O
patients	patients	O
were	were	O
enrolled	enrolled	O
.	.	O

Patients	patients	O
with	with	O
risk	risk	O
factors	factors	O
for	for	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
were	were	O
excluded	excluded	O
.	.	O

Blood	blood	O
samples	samples	O
were	were	O
examined	examined	O
the	the	O
day	day	O
before	before	O
contrast-enhanced	contrast-enhanced	O
computed	computed	O
tomography	tomography	O
(	(	O
CT	ct	O
)	)	O
and	and	O
serially	serially	O
for	for	O
3	3	O
days	days	O
thereafter	thereafter	O
.	.	O

CIN	cin	O
was	was	O
defined	defined	O
as	as	O
an	an	O
increase	increase	O
in	in	O
serum	serum	O
creatinine	creatinine	B-Chemical
(	(	O
Cr	cr	B-Chemical
)	)	O
of	of	O
0.5	0.5	O
mg/dl	mg/dl	O
or	or	O
more	more	O
,	,	O
or	or	O
elevation	elevation	O
of	of	O
Cr	cr	B-Chemical
to	to	O
25	25	O
%	%	O
over	over	O
baseline	baseline	O
.	.	O

Relationships	relationships	O
between	between	O
CIN	cin	O
and	and	O
possible	possible	O
risk	risk	O
factors	factors	O
were	were	O
investigated	investigated	O
.	.	O

RESULTS	results	O
:	:	O
CIN	cin	O
was	was	O
detected	detected	O
in	in	O
18/90	18/90	O
(	(	O
20	20	O
%	%	O
)	)	O
patients	patients	O
.	.	O

CIN	cin	O
developed	developed	O
in	in	O
25.5	25.5	O
%	%	O
patients	patients	O
who	who	O
underwent	underwent	O
chemotherapy	chemotherapy	O
and	and	O
in	in	O
11	11	O
%	%	O
patients	patients	O
who	who	O
did	did	O
not	not	O
(	(	O
P	p	O
=	=	O
0.1	0.1	O
)	)	O
.	.	O

CIN	cin	O
more	more	O
frequently	frequently	O
developed	developed	O
in	in	O
patients	patients	O
who	who	O
had	had	O
undergone	undergone	O
CT	ct	O
within	within	O
45	45	O
days	days	O
after	after	O
the	the	O
last	last	O
chemotherapy	chemotherapy	O
(	(	O
P	p	O
=	=	O
0.005	0.005	O
)	)	O
;	;	O
it	it	O
was	was	O
also	also	O
an	an	O
independent	independent	O
risk	risk	O
factor	factor	O
(	(	O
P	p	O
=	=	O
0.017	0.017	O
)	)	O
.	.	O

CIN	cin	O
was	was	O
significantly	significantly	O
more	more	O
after	after	O
treatment	treatment	O
with	with	O
bevacizumab/irinotecan	bevacizumab/irinotecan	O
(	(	O
P	p	O
=	=	O
0.021	0.021	O
)	)	O
and	and	O
in	in	O
patients	patients	O
with	with	O
hypertension	hypertension	B-Disease
(	(	O
P	p	O
=	=	O
0.044	0.044	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
incidence	incidence	O
of	of	O
CIN	cin	O
after	after	O
CT	ct	O
in	in	O
hospitalised	hospitalised	O
oncological	oncological	O
patients	patients	O
was	was	O
20	20	O
%	%	O
.	.	O

CIN	cin	O
developed	developed	O
4.5-times	4.5-times	O
more	more	O
frequently	frequently	O
in	in	O
patients	patients	O
with	with	O
cancer	cancer	B-Disease
who	who	O
had	had	O
undergone	undergone	O
recent	recent	O
chemotherapy	chemotherapy	O
.	.	O

Hypertension	hypertension	B-Disease
and	and	O
the	the	O
combination	combination	O
of	of	O
bevacizumab/irinotecan	bevacizumab/irinotecan	O
may	may	O
be	be	O
additional	additional	O
risk	risk	O
factors	factors	O
for	for	O
CIN	cin	O
development	development	O
.	.	O

KEY	key	O
POINTS	points	O
:	:	O
.	.	O

Contrast-induced	contrast-induced	O
nephropathy	nephropathy	B-Disease
(	(	O
CIN	cin	O
)	)	O
is	is	O
a	a	O
concern	concern	O
for	for	O
oncological	oncological	O
patients	patients	O
undergoing	undergoing	O
CT	ct	O
.	.	O
.	.	O

CIN	cin	O
occurs	occurs	O
more	more	O
often	often	O
when	when	O
CT	ct	O
is	is	O
performed	performed	O
<	<	O
45	45	O
days	days	O
after	after	O
chemotherapy	chemotherapy	O
.	.	O
.	.	O

Hypertension	hypertension	B-Disease
and	and	O
treatment	treatment	O
with	with	O
bevacizumab	bevacizumab	O
appear	appear	O
to	to	O
be	be	O
additional	additional	O
risk	risk	O
factors	factors	O
.	.	O

Syndrome	syndrome	O
of	of	O
inappropriate	inappropriate	O
antidiuretic	antidiuretic	O
hormone	hormone	O
secretion	secretion	O
associated	associated	O
with	with	O
desvenlafaxine	desvenlafaxine	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
report	report	O
a	a	O
case	case	O
of	of	O
syndrome	syndrome	O
of	of	O
inappropriate	inappropriate	O
anti-diuretic	anti-diuretic	O
hormone	hormone	O
(	(	O
SIADH	siadh	O
)	)	O
secretion	secretion	O
associated	associated	O
with	with	O
desvenlafaxine	desvenlafaxine	O
.	.	O

CASE	case	O
SUMMARY	summary	O
:	:	O
A	a	O
57-year	57-year	O
old	old	O
female	female	O
with	with	O
hyponatraemia	hyponatraemia	O
.	.	O

Her	her	O
medications	medications	O
included	included	O
desvenlafaxine	desvenlafaxine	O
,	,	O
and	and	O
symptoms	symptoms	O
included	included	O
nausea	nausea	B-Disease
,	,	O
anxiety	anxiety	B-Disease
and	and	O
confusion	confusion	B-Disease
.	.	O

The	the	O
serum	serum	O
sodium	sodium	B-Chemical
at	at	O
this	this	O
time	time	O
was	was	O
120	120	O
mmol/L	mmol/l	O
,	,	O
serum	serum	O
osmolality	osmolality	O
was	was	O
263	263	O
mosmol/kg	mosmol/kg	O
,	,	O
urine	urine	O
osmolality	osmolality	O
410	410	O
mosmol/kg	mosmol/kg	O
and	and	O
urine	urine	O
sodium	sodium	B-Chemical
63	63	O
mmol/L	mmol/l	O
,	,	O
consistent	consistent	O
with	with	O
a	a	O
diagnosis	diagnosis	O
of	of	O
SIADH	siadh	O
.	.	O

Desvenlafaxine	desvenlafaxine	O
was	was	O
ceased	ceased	O
and	and	O
fluid	fluid	O
restriction	restriction	O
implemented	implemented	O
.	.	O

After	after	O
4	4	O
days	days	O
the	the	O
sodium	sodium	B-Chemical
increased	increased	O
to	to	O
128	128	O
mmol/L	mmol/l	O
and	and	O
fluid	fluid	O
restriction	restriction	O
was	was	O
relaxed	relaxed	O
.	.	O

During	during	O
her	her	O
further	further	O
3	3	O
weeks	weeks	O
inpatient	inpatient	O
admission	admission	O
the	the	O
serum	serum	O
sodium	sodium	B-Chemical
ranged	ranged	O
from	from	O
134	134	O
to	to	O
137	137	O
mmol/L	mmol/l	O
during	during	O
treatment	treatment	O
with	with	O
mirtazapine	mirtazapine	O
.	.	O

DISCUSSION	discussion	O
:	:	O
SIADH	siadh	O
has	has	O
been	been	O
widely	widely	O
reported	reported	O
with	with	O
a	a	O
range	range	O
of	of	O
antidepressants	antidepressants	B-Chemical
.	.	O

This	this	O
case	case	O
report	report	O
suggests	suggests	O
that	that	O
desvenlafaxine	desvenlafaxine	O
might	might	O
cause	cause	O
clinically	clinically	O
significant	significant	O
hyponatremia	hyponatremia	B-Disease
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Clinicians	clinicians	O
should	should	O
be	be	O
aware	aware	O
of	of	O
the	the	O
potential	potential	O
for	for	O
antidepressants	antidepressants	B-Chemical
to	to	O
cause	cause	O
hyponatremia	hyponatremia	B-Disease
,	,	O
and	and	O
take	take	O
appropriate	appropriate	O
corrective	corrective	O
action	action	O
where	where	O
necessary	necessary	O
.	.	O

Oxidative	oxidative	O
stress	stress	O
on	on	O
cardiotoxicity	cardiotoxicity	B-Disease
after	after	O
treatment	treatment	O
with	with	O
single	single	O
and	and	O
multiple	multiple	O
doses	doses	O
of	of	O
doxorubicin	doxorubicin	B-Chemical
.	.	O

The	the	O
mechanism	mechanism	O
of	of	O
doxorubicin	doxorubicin	B-Chemical
(DOX)-induced	(dox)-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
remains	remains	O
controversial	controversial	O
.	.	O

Wistar	wistar	O
rats	rats	O
(	(	O
n	n	O
=	=	O
66	66	O
)	)	O
received	received	O
DOX	dox	B-Chemical
injections	injections	O
intraperitoneally	intraperitoneally	O
and	and	O
were	were	O
randomly	randomly	O
assigned	assigned	O
to	to	O
2	2	O
experimental	experimental	O
protocols	protocols	O
:	:	O
(	(	O
1	1	O
)	)	O
rats	rats	O
were	were	O
killed	killed	O
before	before	O
(	(	O
-24	-24	O
h	h	B-Chemical
,	,	O
n	n	O
=	=	O
8)	8)	O
and	and	O
24	24	O
h	h	B-Chemical
after	after	O
(	(	O
+	+	O
24	24	O
h	h	B-Chemical
,	,	O
n	n	O
=	=	O
8)	8)	O
a	a	O
single	single	O
dose	dose	O
of	of	O
DOX	dox	B-Chemical
(	(	O
4	4	O
mg/kg	mg/kg	O
body	body	B-Disease
weight	weight	I-Disease
)	)	O
to	to	O
determine	determine	O
the	the	O
DOX	dox	B-Chemical
acute	acute	O
effect	effect	O
and	and	O
(	(	O
2	2	O
)	)	O
rats	rats	O
(	(	O
n	n	O
=	=	O
58	58	O
)	)	O
received	received	O
4	4	O
injections	injections	O
of	of	O
DOX	dox	B-Chemical
(	(	O
4	4	O
mg/kg	mg/kg	O
body	body	O
weight/week	weight/week	O
)	)	O
and	and	O
were	were	O
killed	killed	O
before	before	O
the	the	O
first	first	O
injection	injection	O
(	(	O
M0	m0	O
)	)	O
and	and	O
1	1	O
week	week	O
after	after	O
each	each	O
injection	injection	O
(	(	O
M1	m1	O
,	,	O
M2	m2	O
,	,	O
M3	m3	O
,	,	O
and	and	O
M4	m4	O
)	)	O
to	to	O
determine	determine	O
the	the	O
chronological	chronological	O
effects	effects	O
.	.	O

Animals	animals	O
used	used	O
at	at	O
M0	m0	O
(	(	O
n	n	O
=	=	O
8)	8)	O
were	were	O
also	also	O
used	used	O
at	at	O
moment	moment	O
-24	-24	O
h	h	B-Chemical
of	of	O
acute	acute	O
study	study	O
.	.	O

Cardiac	cardiac	O
total	total	O
antioxidant	antioxidant	O
performance	performance	O
(	(	O
TAP	tap	O
)	)	O
,	,	O
DNA	dna	O
damage	damage	O
,	,	O
and	and	O
morphology	morphology	O
analyses	analyses	O
were	were	O
carried	carried	O
out	out	O
at	at	O
each	each	O
time	time	O
point	point	O
.	.	O

Single	single	O
dose	dose	O
of	of	O
DOX	dox	B-Chemical
was	was	O
associated	associated	O
with	with	O
increased	increased	O
cardiac	cardiac	O
disarrangement	disarrangement	O
,	,	O
necrosis	necrosis	B-Disease
,	,	O
and	and	O
DNA	dna	O
damage	damage	O
(	(	O
strand	strand	O
breaks	breaks	O
(	(	O
SBs	sbs	O
)	)	O
and	and	O
oxidized	oxidized	O
pyrimidines	pyrimidines	O
)	)	O
and	and	O
decreased	decreased	O
TAP	tap	O
.	.	O

The	the	O
chronological	chronological	O
study	study	O
showed	showed	O
an	an	O
effect	effect	O
of	of	O
a	a	O
cumulative	cumulative	O
dose	dose	O
on	on	O
body	body	B-Disease
weight	weight	I-Disease
(	(	O
R	r	O
=	=	O
-0.99	-0.99	O
,	,	O
p	p	O
=	=	O
0.011	0.011	O
)	)	O
,	,	O
necrosis	necrosis	B-Disease
(	(	O
R	r	O
=	=	O
1.00	1.00	O
,	,	O
p	p	O
=	=	O
0.004	0.004	O
)	)	O
,	,	O
TAP	tap	O
(	(	O
R	r	O
=	=	O
0.95	0.95	O
,	,	O
p	p	O
=	=	O
0.049	0.049	O
)	)	O
,	,	O
and	and	O
DNA	dna	O
SBs	sbs	O
(	(	O
R	r	O
=	=	O
-0.95	-0.95	O
,	,	O
p	p	O
=	=	O
0.049	0.049	O
)	)	O
.	.	O

DNA	dna	O
SBs	sbs	O
damage	damage	O
was	was	O
negatively	negatively	O
associated	associated	O
with	with	O
TAP	tap	O
(	(	O
R	r	O
=	=	O
-0.98	-0.98	O
,	,	O
p	p	O
=	=	O
0.018	0.018	O
)	)	O
,	,	O
and	and	O
necrosis	necrosis	B-Disease
(	(	O
R	r	O
=	=	O
-0.97	-0.97	O
,	,	O
p	p	O
=	=	O
0.027	0.027	O
)	)	O
.	.	O

Our	our	O
results	results	O
suggest	suggest	O
that	that	O
oxidative	oxidative	O
damage	damage	O
is	is	O
associated	associated	O
with	with	O
acute	acute	O
cardiotoxicity	cardiotoxicity	B-Disease
induced	induced	O
by	by	O
a	a	O
single	single	O
dose	dose	O
of	of	O
DOX	dox	B-Chemical
only	only	O
.	.	O

Increased	increased	O
resistance	resistance	O
to	to	O
the	the	O
oxidative	oxidative	O
stress	stress	O
is	is	O
plausible	plausible	O
for	for	O
the	the	O
multiple	multiple	O
dose	dose	O
of	of	O
DOX	dox	B-Chemical
.	.	O

Thus	thus	O
,	,	O
different	different	O
mechanisms	mechanisms	O
may	may	O
be	be	O
involved	involved	O
in	in	O
acute	acute	O
toxicity	toxicity	B-Disease
versus	versus	O
chronic	chronic	O
toxicity	toxicity	B-Disease
.	.	O

Tacrolimus-related	tacrolimus-related	O
seizure	seizure	B-Disease
after	after	O
pediatric	pediatric	O
liver	liver	O
transplantation	transplantation	O
--	--	O
a	a	O
single-center	single-center	O
experience	experience	O
.	.	O

To	to	O
identify	identify	O
the	the	O
risk	risk	O
factors	factors	O
for	for	O
new-onset	new-onset	O
seizures	seizures	B-Disease
after	after	O
pediatric	pediatric	O
LT	lt	O
and	and	O
to	to	O
assess	assess	O
their	their	O
clinical	clinical	O
implications	implications	O
and	and	O
long-term	long-term	O
prognosis	prognosis	O
.	.	O

The	the	O
clinical	clinical	O
and	and	O
laboratory	laboratory	O
data	data	O
of	of	O
27	27	O
consecutive	consecutive	O
children	children	O
who	who	O
underwent	underwent	O
LT	lt	O
from	from	O
January	january	O
2007	2007	O
to	to	O
December	december	O
2010	2010	O
in	in	O
our	our	O
center	center	O
were	were	O
analyzed	analyzed	O
retrospectively	retrospectively	O
.	.	O

Patients	patients	O
were	were	O
divided	divided	O
into	into	O
seizures	seizures	B-Disease
group	group	O
and	and	O
a	a	O
non-seizures	non-seizures	O
group	group	O
.	.	O

Pre-operative	pre-operative	O
,	,	O
intra-operative	intra-operative	O
,	,	O
and	and	O
post-operative	post-operative	O
data	data	O
were	were	O
collected	collected	O
.	.	O

Seizures	seizures	B-Disease
occurred	occurred	O
in	in	O
four	four	O
children	children	O
,	,	O
an	an	O
incidence	incidence	O
of	of	O
14.8	14.8	O
%	%	O
.	.	O

All	all	O
exhibited	exhibited	O
generalized	generalized	O
tonic-clonic	tonic-clonic	O
seizures	seizures	B-Disease
within	within	O
the	the	O
first	first	O
two	two	O
wk	wk	O
after	after	O
LT	lt	O
.	.	O

Univariate	univariate	O
analysis	analysis	O
showed	showed	O
that	that	O
the	the	O
risk	risk	O
factors	factors	O
associated	associated	O
with	with	O
seizures	seizures	B-Disease
after	after	O
pediatric	pediatric	O
LT	lt	O
included	included	O
gender	gender	O
,	,	O
pediatric	pediatric	O
end-stage	end-stage	O
liver	liver	B-Disease
disease	disease	I-Disease
score	score	O
before	before	O
surgery	surgery	O
,	,	O
Child-Pugh	child-pugh	O
score	score	O
before	before	O
surgery	surgery	O
,	,	O
serum	serum	O
total	total	O
bilirubin	bilirubin	B-Chemical
after	after	O
surgery	surgery	O
,	,	O
and	and	O
trough	trough	O
TAC	tac	B-Chemical
level	level	O
.	.	O

Multivariate	multivariate	O
analysis	analysis	O
showed	showed	O
that	that	O
trough	trough	O
TAC	tac	B-Chemical
level	level	O
was	was	O
the	the	O
only	only	O
independent	independent	O
risk	risk	O
factor	factor	O
associated	associated	O
with	with	O
the	the	O
seizures	seizures	B-Disease
.	.	O

All	all	O
children	children	O
who	who	O
experienced	experienced	O
seizures	seizures	B-Disease
survived	survived	O
with	with	O
good	good	O
graft	graft	O
function	function	O
and	and	O
remained	remained	O
seizure-free	seizure-free	O
without	without	O
anti-epileptic	anti-epileptic	O
drugs	drugs	O
over	over	O
a	a	O
mean	mean	O
follow-up	follow-up	O
period	period	O
of	of	O
33.7	33.7	O
+	+	O
14.6	14.6	O
months	months	O
.	.	O

High	high	O
trough	trough	O
TAC	tac	B-Chemical
level	level	O
was	was	O
the	the	O
predominant	predominant	O
factor	factor	O
that	that	O
contributed	contributed	O
to	to	O
seizures	seizures	B-Disease
in	in	O
the	the	O
early	early	O
post-operative	post-operative	O
period	period	O
after	after	O
pediatric	pediatric	O
LT	lt	O
.	.	O

High	high	O
PELD	peld	O
and	and	O
Child-Pugh	child-pugh	O
scores	scores	O
before	before	O
LT	lt	O
and	and	O
high	high	O
post-operative	post-operative	O
serum	serum	O
Tbil	tbil	O
may	may	O
be	be	O
contributory	contributory	O
risk	risk	O
factors	factors	O
for	for	O
TAC-related	tac-related	O
seizures	seizures	B-Disease
.	.	O

The	the	O
flavonoid	flavonoid	O
apigenin	apigenin	O
delays	delays	O
forgetting	forgetting	O
of	of	O
passive	passive	O
avoidance	avoidance	O
conditioning	conditioning	O
in	in	O
rats	rats	O
.	.	O

The	the	O
present	present	O
experiments	experiments	O
were	were	O
performed	performed	O
to	to	O
study	study	O
the	the	O
effect	effect	O
of	of	O
the	the	O
flavonoid	flavonoid	O
apigenin	apigenin	O
(	(	O
20	20	O
mg/kg	mg/kg	O
intraperitoneally	intraperitoneally	O
(	(	O
i.p	i.p	O
.	.	O
)	)	O
,	,	O
1	1	O
h	h	B-Chemical
before	before	O
acquisition	acquisition	O
)	)	O
,	,	O
on	on	O
24	24	O
h	h	B-Chemical
retention	retention	O
performance	performance	O
and	and	O
forgetting	forgetting	O
of	of	O
a	a	O
step-through	step-through	O
passive	passive	O
avoidance	avoidance	O
task	task	O
,	,	O
in	in	O
young	young	O
male	male	O
Wistar	wistar	O
rats	rats	O
.	.	O

There	there	O
were	were	O
no	no	O
differences	differences	O
between	between	O
saline-	saline-	O
and	and	O
apigenin-treated	apigenin-treated	O
groups	groups	O
in	in	O
the	the	O
24	24	O
h	h	B-Chemical
retention	retention	O
trial	trial	O
.	.	O

Furthermore	furthermore	O
,	,	O
apigenin	apigenin	O
did	did	O
not	not	O
prevent	prevent	O
the	the	O
amnesia	amnesia	B-Disease
induced	induced	O
by	by	O
scopolamine	scopolamine	B-Chemical
(	(	O
1mg/kg	1mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
,	,	O
30	30	O
min	min	O
before	before	O
the	the	O
acquisition	acquisition	O
)	)	O
.	.	O

The	the	O
saline-	saline-	O
and	and	O
apigenin-treated	apigenin-treated	O
rats	rats	O
that	that	O
did	did	O
not	not	O
step	step	O
through	through	O
into	into	O
the	the	O
dark	dark	O
compartment	compartment	O
during	during	O
the	the	O
cut-off	cut-off	O
time	time	O
(	(	O
540	540	O
s	s	O
)	)	O
were	were	O
retested	retested	O
weekly	weekly	O
for	for	O
up	up	O
to	to	O
eight	eight	O
weeks	weeks	O
.	.	O

In	in	O
the	the	O
saline	saline	O
treated	treated	O
group	group	O
,	,	O
the	the	O
first	first	O
significant	significant	O
decline	decline	O
in	in	O
passive	passive	O
avoidance	avoidance	O
response	response	O
was	was	O
observed	observed	O
at	at	O
four	four	O
weeks	weeks	O
,	,	O
and	and	O
complete	complete	O
memory	memory	O
loss	loss	O
was	was	O
found	found	O
five	five	O
weeks	weeks	O
after	after	O
the	the	O
acquisition	acquisition	O
of	of	O
the	the	O
passive	passive	O
avoidance	avoidance	O
task	task	O
.	.	O

At	at	O
the	the	O
end	end	O
of	of	O
the	the	O
experimental	experimental	O
period	period	O
,	,	O
60	60	O
%	%	O
of	of	O
the	the	O
animals	animals	O
treated	treated	O
with	with	O
apigenin	apigenin	O
still	still	O
did	did	O
not	not	O
step	step	O
through	through	O
.	.	O

These	these	O
data	data	O
suggest	suggest	O
that	that	O
1	1	O
)	)	O
apigenin	apigenin	O
delays	delays	O
the	the	O
long-term	long-term	O
forgetting	forgetting	O
but	but	O
did	did	O
not	not	O
modulate	modulate	O
the	the	O
24	24	O
h	h	B-Chemical
retention	retention	O
of	of	O
fear	fear	O
memory	memory	O
and	and	O
2	2	O
)	)	O
the	the	O
obtained	obtained	O
beneficial	beneficial	O
effect	effect	O
of	of	O
apigenin	apigenin	O
on	on	O
the	the	O
passive	passive	O
avoidance	avoidance	O
conditioning	conditioning	O
is	is	O
mediated	mediated	O
by	by	O
mechanisms	mechanisms	O
that	that	O
do	do	O
not	not	O
implicate	implicate	O
its	its	O
action	action	O
on	on	O
the	the	O
muscarinic	muscarinic	O
cholinergic	cholinergic	O
system	system	O
.	.	O

Histamine	histamine	B-Chemical
antagonists	antagonists	I-Chemical
and	and	O
d-tubocurarine-induced	d-tubocurarine-induced	O
hypotension	hypotension	B-Disease
in	in	O
cardiac	cardiac	O
surgical	surgical	O
patients	patients	O
.	.	O

Hemodynamic	hemodynamic	O
effects	effects	O
and	and	O
histamine	histamine	B-Chemical
release	release	O
by	by	O
bolus	bolus	O
injection	injection	O
of	of	O
0.35	0.35	O
mg/kg	mg/kg	O
of	of	O
d-tubocurarine	d-tubocurarine	O
were	were	O
studied	studied	O
in	in	O
24	24	O
patients	patients	O
.	.	O

H1-	h1-	O
and	and	O
H2-histamine	h2-histamine	O
antagonists	antagonists	O
or	or	O
placebo	placebo	O
were	were	O
given	given	O
before	before	O
dosing	dosing	O
with	with	O
d-tubocurarine	d-tubocurarine	O
in	in	O
a	a	O
randomized	randomized	O
double-blind	double-blind	O
fashion	fashion	O
to	to	O
four	four	O
groups	groups	O
:	:	O
group	group	O
1	1	O
-	-	O
-placebo	-placebo	O
;	;	O
group	group	O
2	2	O
-	-	O
-cimetidine	-cimetidine	O
,	,	O
4	4	O
mg/kg	mg/kg	O
,	,	O
plus	plus	O
placebo	placebo	O
;	;	O
group	group	O
3	3	O
-	-	O
-chlorpheniramine	-chlorpheniramine	O
,	,	O
0.1	0.1	O
mg/kg	mg/kg	O
,	,	O
plus	plus	O
placebo	placebo	O
;	;	O
and	and	O
group	group	O
4	4	O
-	-	O
-cimetidine	-cimetidine	O
plus	plus	O
chlorpheniramine	chlorpheniramine	O
.	.	O

Histamine	histamine	B-Chemical
release	release	O
occurred	occurred	O
in	in	O
most	most	O
patients	patients	O
,	,	O
the	the	O
highest	highest	O
level	level	O
2	2	O
minutes	minutes	O
after	after	O
d-tubocurarine	d-tubocurarine	O
dosing	dosing	O
.	.	O

Group	group	O
1	1	O
had	had	O
a	a	O
moderate	moderate	O
negative	negative	O
correlation	correlation	O
between	between	O
plasma	plasma	O
histamine	histamine	B-Chemical
change	change	O
and	and	O
systemic	systemic	O
vascular	vascular	O
resistance	resistance	O
(	(	O
r	r	O
=	=	O
0.58	0.58	O
;	;	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
not	not	O
present	present	O
in	in	O
group	group	O
4	4	O
.	.	O

Prior	prior	O
dosing	dosing	O
with	with	O
antagonists	antagonists	O
partially	partially	O
prevented	prevented	O
the	the	O
fall	fall	O
in	in	O
systemic	systemic	O
vascular	vascular	O
resistance	resistance	O
.	.	O

These	these	O
data	data	O
demonstrate	demonstrate	O
that	that	O
the	the	O
hemodynamic	hemodynamic	O
changes	changes	O
associated	associated	O
with	with	O
d-tubocurarine	d-tubocurarine	O
dosing	dosing	O
are	are	O
only	only	O
partially	partially	O
explained	explained	O
by	by	O
histamine	histamine	B-Chemical
release	release	O
.	.	O

Thus	thus	O
prior	prior	O
dosing	dosing	O
with	with	O
H1-	h1-	O
and	and	O
H2-antagonists	h2-antagonists	O
provides	provides	O
only	only	O
partial	partial	O
protection	protection	O
.	.	O

Cholecystokinin-octapeptide	cholecystokinin-octapeptide	O
restored	restored	O
morphine-induced	morphine-induced	O
hippocampal	hippocampal	O
long-term	long-term	O
potentiation	potentiation	O
impairment	impairment	O
in	in	O
rats	rats	O
.	.	O

Cholecystokinin-octapeptide	cholecystokinin-octapeptide	O
(	(	O
CCK-8	cck-8	O
)	)	O
,	,	O
which	which	O
is	is	O
a	a	O
typical	typical	O
brain-gut	brain-gut	O
peptide	peptide	O
,	,	O
exerts	exerts	O
a	a	O
wide	wide	O
range	range	O
of	of	O
biological	biological	O
activities	activities	O
on	on	O
the	the	O
central	central	O
nervous	nervous	O
system	system	O
.	.	O

We	we	O
have	have	O
previously	previously	O
reported	reported	O
that	that	O
CCK-8	cck-8	O
significantly	significantly	O
alleviated	alleviated	O
morphine-induced	morphine-induced	O
amnesia	amnesia	B-Disease
and	and	O
reversed	reversed	O
spine	spine	O
density	density	O
decreases	decreases	O
in	in	O
the	the	O
CA1	ca1	O
region	region	O
of	of	O
the	the	O
hippocampus	hippocampus	O
in	in	O
morphine-treated	morphine-treated	O
animals	animals	O
.	.	O

Here	here	O
,	,	O
we	we	O
investigated	investigated	O
the	the	O
effects	effects	O
of	of	O
CCK-8	cck-8	O
on	on	O
long-term	long-term	O
potentiation	potentiation	O
(	(	O
LTP	ltp	O
)	)	O
in	in	O
the	the	O
lateral	lateral	O
perforant	perforant	O
path	path	O
(LPP)-granule	(lpp)-granule	O
cell	cell	O
synapse	synapse	O
of	of	O
rat	rat	O
dentate	dentate	O
gyrus	gyrus	O
(	(	O
DG	dg	O
)	)	O
in	in	O
acute	acute	O
saline	saline	O
or	or	O
morphine-treated	morphine-treated	O
rats	rats	O
.	.	O

Population	population	O
spikes	spikes	O
(	(	O
PS	ps	O
)	)	O
,	,	O
which	which	O
were	were	O
evoked	evoked	O
by	by	O
stimulation	stimulation	O
of	of	O
the	the	O
LPP	lpp	O
,	,	O
were	were	O
recorded	recorded	O
in	in	O
the	the	O
DG	dg	O
region	region	O
.	.	O

Acute	acute	O
morphine	morphine	B-Chemical
(	(	O
30mg/kg	30mg/kg	O
,	,	O
s.c	s.c	O
.	.	O
)	)	O
treatment	treatment	O
significantly	significantly	O
attenuated	attenuated	O
hippocampal	hippocampal	O
LTP	ltp	O
and	and	O
CCK-8	cck-8	O
(	(	O
1ug	1ug	O
,	,	O
i.c.v	i.c.v	O
.	.	O
)	)	O
restored	restored	O
the	the	O
amplitude	amplitude	O
of	of	O
PS	ps	O
that	that	O
was	was	O
attenuated	attenuated	O
by	by	O
morphine	morphine	B-Chemical
injection	injection	O
.	.	O

Furthermore	furthermore	O
,	,	O
microinjection	microinjection	O
of	of	O
CCK-8	cck-8	O
(	(	O
0.1	0.1	O
and	and	O
1ug	1ug	O
,	,	O
i.c.v	i.c.v	O
.	.	O
)	)	O
also	also	O
significantly	significantly	O
augmented	augmented	O
hippocampal	hippocampal	O
LTP	ltp	O
in	in	O
saline-treated	saline-treated	O
(	(	O
1ml/kg	1ml/kg	O
,	,	O
s.c	s.c	O
.	.	O
)	)	O
rats	rats	O
.	.	O

Pre-treatment	pre-treatment	O
of	of	O
the	the	O
CCK2	cck2	O
receptor	receptor	O
antagonist	antagonist	O
L-365,260	l-365,260	O
(	(	O
10ug	10ug	O
,	,	O
i.c.v	i.c.v	O
)	)	O
reversed	reversed	O
the	the	O
effects	effects	O
of	of	O
CCK-8	cck-8	O
,	,	O
but	but	O
the	the	O
CCK1	cck1	O
receptor	receptor	O
antagonist	antagonist	O
L-364,718	l-364,718	O
(	(	O
10ug	10ug	O
,	,	O
i.c.v	i.c.v	O
)	)	O
did	did	O
not	not	O
.	.	O

The	the	O
present	present	O
results	results	O
demonstrate	demonstrate	O
that	that	O
CCK-8	cck-8	O
attenuates	attenuates	O
the	the	O
effect	effect	O
of	of	O
morphine	morphine	B-Chemical
on	on	O
hippocampal	hippocampal	O
LTP	ltp	O
through	through	O
CCK2	cck2	O
receptors	receptors	O
and	and	O
suggest	suggest	O
an	an	O
ameliorative	ameliorative	O
function	function	O
of	of	O
CCK-8	cck-8	O
on	on	O
morphine-induced	morphine-induced	O
memory	memory	B-Disease
impairment	impairment	I-Disease
.	.	O

Glial	glial	O
activation	activation	O
and	and	O
post-synaptic	post-synaptic	O
neurotoxicity	neurotoxicity	B-Disease
:	:	O
the	the	O
key	key	O
events	events	O
in	in	O
Streptozotocin	streptozotocin	B-Chemical
(	(	O
ICV	icv	O
)	)	O
induced	induced	O
memory	memory	B-Disease
impairment	impairment	I-Disease
in	in	O
rats	rats	O
.	.	O

In	in	O
the	the	O
present	present	O
study	study	O
the	the	O
role	role	O
of	of	O
glial	glial	O
activation	activation	O
and	and	O
post	post	O
synaptic	synaptic	O
toxicity	toxicity	B-Disease
in	in	O
ICV	icv	O
Streptozotocin	streptozotocin	B-Chemical
(	(	O
STZ	stz	O
)	)	O
induced	induced	O
memory	memory	O
impaired	impaired	O
rats	rats	O
was	was	O
explored	explored	O
.	.	O

In	in	O
experiment	experiment	O
set	set	O
up	up	O
1	1	O
:	:	O
Memory	memory	O
deficit	deficit	O
was	was	O
found	found	O
in	in	O
Morris	morris	O
water	water	O
maze	maze	O
test	test	O
on	on	O
14	14	O
-	-	O
16	16	O
days	days	O
after	after	O
STZ	stz	O
(	(	O
ICV	icv	O
;	;	O
3mg/Kg	3mg/kg	O
)	)	O
administration	administration	O
.	.	O

STZ	stz	O
causes	causes	O
increased	increased	O
expression	expression	O
of	of	O
GFAP	gfap	O
,	,	O
CD11b	cd11b	O
and	and	O
TNF-a	tnf-a	O
indicating	indicating	O
glial	glial	O
activation	activation	O
and	and	O
neuroinflammation	neuroinflammation	O
.	.	O

STZ	stz	O
also	also	O
significantly	significantly	O
increased	increased	O
the	the	O
level	level	O
of	of	O
ROS	ros	O
,	,	O
nitrite	nitrite	O
,	,	O
Ca(2	ca(2	O
+	+	O
)	)	O
and	and	O
reduced	reduced	O
the	the	O
mitochondrial	mitochondrial	O
activity	activity	O
in	in	O
synaptosomal	synaptosomal	O
preparation	preparation	O
illustrating	illustrating	O
free	free	O
radical	radical	O
generation	generation	O
and	and	O
excitotoxicity	excitotoxicity	O
.	.	O

Increased	increased	O
expression	expression	O
and	and	O
activity	activity	O
of	of	O
Caspase-3	caspase-3	O
was	was	O
also	also	O
observed	observed	O
in	in	O
STZ	stz	O
treated	treated	O
rat	rat	O
which	which	O
specify	specify	O
apoptotic	apoptotic	O
cell	cell	O
death	death	B-Disease
in	in	O
hippocampus	hippocampus	O
and	and	O
cortex	cortex	O
.	.	O

STZ	stz	O
treatment	treatment	O
showed	showed	O
decrease	decrease	O
expression	expression	O
of	of	O
post	post	O
synaptic	synaptic	O
markers	markers	O
CaMKIIa	camkiia	O
and	and	O
PSD-95	psd-95	O
,	,	O
while	while	O
,	,	O
expression	expression	O
of	of	O
pre	pre	O
synaptic	synaptic	O
markers	markers	O
(	(	O
synaptophysin	synaptophysin	O
and	and	O
SNAP-25	snap-25	O
)	)	O
remains	remains	O
unaltered	unaltered	O
indicating	indicating	O
selective	selective	O
post	post	O
synaptic	synaptic	O
neurotoxicity	neurotoxicity	B-Disease
.	.	O

Oral	oral	O
treatment	treatment	O
with	with	O
Memantine	memantine	O
(	(	O
10mg/kg	10mg/kg	O
)	)	O
and	and	O
Ibuprofen	ibuprofen	B-Chemical
(	(	O
50	50	O
mg/kg	mg/kg	O
)	)	O
daily	daily	O
for	for	O
13	13	O
days	days	O
attenuated	attenuated	O
STZ	stz	O
induced	induced	O
glial	glial	O
activation	activation	O
,	,	O
apoptotic	apoptotic	O
cell	cell	O
death	death	B-Disease
and	and	O
post	post	O
synaptic	synaptic	O
neurotoxicity	neurotoxicity	B-Disease
in	in	O
rat	rat	O
brain	brain	O
.	.	O

Further	further	O
,	,	O
in	in	O
experiment	experiment	O
set	set	O
up	up	O
2	2	O
:	:	O
where	where	O
memory	memory	O
function	function	O
was	was	O
not	not	O
affected	affected	O
i.e.	i.e.	O
7	7	O
-	-	O
9	9	O
days	days	O
after	after	O
STZ	stz	O
treatment	treatment	O
.	.	O

The	the	O
level	level	O
of	of	O
GFAP	gfap	O
,	,	O
CD11b	cd11b	O
,	,	O
TNF-a	tnf-a	O
,	,	O
ROS	ros	O
and	and	O
nitrite	nitrite	O
levels	levels	O
were	were	O
increased	increased	O
.	.	O

On	on	O
the	the	O
other	other	O
hand	hand	O
,	,	O
apoptotic	apoptotic	O
marker	marker	O
,	,	O
synaptic	synaptic	O
markers	markers	O
,	,	O
mitochondrial	mitochondrial	O
activity	activity	O
and	and	O
Ca(2	ca(2	O
+	+	O
)	)	O
levels	levels	O
remained	remained	O
unaffected	unaffected	O
.	.	O

Collective	collective	O
data	data	O
indicates	indicates	O
that	that	O
neuroinflammatory	neuroinflammatory	O
process	process	O
and	and	O
oxidative	oxidative	O
stress	stress	O
occurs	occurs	O
earlier	earlier	O
to	to	O
apoptosis	apoptosis	O
and	and	O
does	does	O
not	not	O
affect	affect	O
memory	memory	O
function	function	O
.	.	O

Present	present	O
study	study	O
clearly	clearly	O
suggests	suggests	O
that	that	O
glial	glial	O
activation	activation	O
and	and	O
post	post	O
synaptic	synaptic	O
neurotoxicity	neurotoxicity	B-Disease
are	are	O
the	the	O
key	key	O
factors	factors	O
in	in	O
STZ	stz	O
induced	induced	O
memory	memory	B-Disease
impairment	impairment	I-Disease
and	and	O
neuronal	neuronal	O
cell	cell	O
death	death	B-Disease
.	.	O

Comparison	comparison	O
of	of	O
effects	effects	O
of	of	O
isotonic	isotonic	O
sodium	sodium	B-Chemical
chloride	chloride	I-Chemical
with	with	O
diltiazem	diltiazem	B-Chemical
in	in	O
prevention	prevention	O
of	of	O
contrast-induced	contrast-induced	O
nephropathy	nephropathy	B-Disease
.	.	O

INTRODUCTION	introduction	O
AND	and	O
OBJECTIVE	objective	O
:	:	O
Contrast-induced	contrast-induced	O
nephropathy	nephropathy	B-Disease
(	(	O
CIN	cin	O
)	)	O
significantly	significantly	O
increases	increases	O
the	the	O
morbidity	morbidity	O
and	and	O
mortality	mortality	O
of	of	O
patients	patients	O
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
is	is	O
to	to	O
investigate	investigate	O
and	and	O
compare	compare	O
the	the	O
protective	protective	O
effects	effects	O
of	of	O
isotonic	isotonic	O
sodium	sodium	B-Chemical
chloride	chloride	I-Chemical
with	with	O
sodium	sodium	B-Chemical
bicarbonate	bicarbonate	I-Chemical
infusion	infusion	O
and	and	O
isotonic	isotonic	O
sodium	sodium	B-Chemical
chloride	chloride	I-Chemical
infusion	infusion	O
with	with	O
diltiazem	diltiazem	B-Chemical
,	,	O
a	a	O
calcium	calcium	B-Chemical
channel	channel	O
blocker	blocker	O
,	,	O
in	in	O
preventing	preventing	O
CIN	cin	O
.	.	O

MATERIALS	materials	O
AND	and	O
METHODS	methods	O
:	:	O
Our	our	O
study	study	O
included	included	O
patients	patients	O
who	who	O
were	were	O
administered	administered	O
30	30	O
-	-	O
60	60	O
mL	ml	O
of	of	O
iodinated	iodinated	O
contrast	contrast	B-Chemical
agent	agent	I-Chemical
for	for	O
percutaneous	percutaneous	O
coronary	coronary	O
angiography	angiography	O
(	(	O
PCAG	pcag	O
)	)	O
,	,	O
all	all	O
with	with	O
creatinine	creatinine	B-Chemical
values	values	O
between	between	O
1.1	1.1	O
and	and	O
3.1	3.1	O
mg/dL.	mg/dl.	O
Patients	patients	O
were	were	O
divided	divided	O
into	into	O
three	three	O
groups	groups	O
and	and	O
each	each	O
group	group	O
had	had	O
20	20	O
patients	patients	O
.	.	O

The	the	O
first	first	O
group	group	O
of	of	O
patients	patients	O
was	was	O
administered	administered	O
isotonic	isotonic	O
sodium	sodium	B-Chemical
chloride	chloride	I-Chemical
;	;	O
the	the	O
second	second	O
group	group	O
was	was	O
administered	administered	O
a	a	O
solution	solution	O
that	that	O
of	of	O
5	5	O
%	%	O
dextrose	dextrose	O
and	and	O
sodium	sodium	B-Chemical
bicarbonate	bicarbonate	I-Chemical
,	,	O
while	while	O
the	the	O
third	third	O
group	group	O
was	was	O
administered	administered	O
isotonic	isotonic	O
sodium	sodium	B-Chemical
chloride	chloride	I-Chemical
before	before	O
and	and	O
after	after	O
the	the	O
contrast	contrast	O
injection	injection	O
.	.	O

The	the	O
third	third	O
group	group	O
received	received	O
an	an	O
additional	additional	O
injection	injection	O
of	of	O
diltiazem	diltiazem	B-Chemical
the	the	O
day	day	O
before	before	O
and	and	O
first	first	O
2	2	O
days	days	O
after	after	O
the	the	O
contrast	contrast	O
injection	injection	O
.	.	O

All	all	O
of	of	O
the	the	O
patients	patients	O
'	'	O
plasma	plasma	O
blood	blood	B-Chemical
urea	urea	B-Chemical
nitrogen	nitrogen	I-Chemical
(	(	O
BUN	bun	O
)	)	O
and	and	O
creatinine	creatinine	B-Chemical
levels	levels	O
were	were	O
measured	measured	O
on	on	O
the	the	O
second	second	O
and	and	O
seventh	seventh	O
day	day	O
after	after	O
the	the	O
administration	administration	O
of	of	O
intravenous	intravenous	O
contrast	contrast	B-Chemical
material	material	I-Chemical
.	.	O

RESULTS	results	O
:	:	O
The	the	O
basal	basal	O
creatinine	creatinine	B-Chemical
levels	levels	O
were	were	O
similar	similar	O
for	for	O
all	all	O
three	three	O
groups	groups	O
(	(	O
p	p	O
>	>	O
0.05	0.05	O
)	)	O
.	.	O

Among	among	O
a	a	O
total	total	O
of	of	O
60	60	O
patients	patients	O
included	included	O
in	in	O
the	the	O
study	study	O
,	,	O
16	16	O
patients	patients	O
developed	developed	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
(	(	O
ARF	arf	O
)	)	O
on	on	O
the	the	O
second	second	O
day	day	O
after	after	O
contrast	contrast	B-Chemical
material	material	I-Chemical
was	was	O
injected	injected	O
(	(	O
26.6	26.6	O
%	%	O
)	)	O
.	.	O

The	the	O
number	number	O
of	of	O
patients	patients	O
who	who	O
developed	developed	O
ARF	arf	O
on	on	O
the	the	O
second	second	O
day	day	O
after	after	O
the	the	O
injection	injection	O
in	in	O
the	the	O
first	first	O
group	group	O
was	was	O
five	five	O
(	(	O
25	25	O
%	%	O
)	)	O
,	,	O
in	in	O
the	the	O
second	second	O
group	group	O
was	was	O
six	six	O
(	(	O
30	30	O
%	%	O
)	)	O
and	and	O
the	the	O
third	third	O
group	group	O
was	was	O
five	five	O
(	(	O
25	25	O
%	%	O
)	)	O
(	(	O
p	p	O
>	>	O
0.05	0.05	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
There	there	O
was	was	O
no	no	O
significant	significant	O
difference	difference	O
between	between	O
isotonic	isotonic	O
sodium	sodium	B-Chemical
chloride	chloride	I-Chemical
,	,	O
sodium	sodium	B-Chemical
bicarbonate	bicarbonate	I-Chemical
and	and	O
isotonic	isotonic	O
sodium	sodium	B-Chemical
chloride	chloride	I-Chemical
with	with	O
diltiazem	diltiazem	B-Chemical
application	application	O
in	in	O
prevention	prevention	O
of	of	O
CIN	cin	O
.	.	O

Neurocognitive	neurocognitive	O
and	and	O
neuroradiologic	neuroradiologic	O
central	central	O
nervous	nervous	O
system	system	O
late	late	O
effects	effects	O
in	in	O
children	children	O
treated	treated	O
on	on	O
Pediatric	pediatric	O
Oncology	oncology	O
Group	group	O
(	(	O
POG	pog	O
)	)	O
P9605	p9605	B-Chemical
(	(	O
standard	standard	O
risk	risk	O
)	)	O
and	and	O
P9201	p9201	O
(	(	O
lesser	lesser	O
risk	risk	O
)	)	O
acute	acute	B-Disease
lymphoblastic	lymphoblastic	I-Disease
leukemia	leukemia	I-Disease
protocols	protocols	O
(	(	O
ACCL0131	accl0131	O
):	):	O
a	a	O
methotrexate	methotrexate	B-Chemical
consequence	consequence	O
?	?	O

A	a	O
report	report	O
from	from	O
the	the	O
Children	children	O
's	's	O
Oncology	oncology	O
Group	group	O
.	.	O

Concerns	concerns	O
about	about	O
long-term	long-term	O
methotrexate	methotrexate	B-Chemical
(	(	O
MTX	mtx	B-Chemical
)	)	O
neurotoxicity	neurotoxicity	B-Disease
in	in	O
the	the	O
1990s	1990s	O
led	led	O
to	to	O
modifications	modifications	O
in	in	O
intrathecal	intrathecal	O
(	(	O
IT	it	O
)	)	O
therapy	therapy	O
,	,	O
leucovorin	leucovorin	O
rescue	rescue	O
,	,	O
and	and	O
frequency	frequency	O
of	of	O
systemic	systemic	O
MTX	mtx	B-Chemical
administration	administration	O
in	in	O
children	children	O
with	with	O
acute	acute	B-Disease
lymphoblastic	lymphoblastic	I-Disease
leukemia	leukemia	I-Disease
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
neurocognitive	neurocognitive	O
outcomes	outcomes	O
and	and	O
neuroradiologic	neuroradiologic	O
evidence	evidence	O
of	of	O
leukoencephalopathy	leukoencephalopathy	B-Disease
were	were	O
compared	compared	O
in	in	O
children	children	O
treated	treated	O
with	with	O
intense	intense	O
central	central	O
nervous	nervous	O
system	system	O
(CNS)-directed	(cns)-directed	O
therapy	therapy	O
(	(	O
P9605	p9605	B-Chemical
)	)	O
versus	versus	O
those	those	O
receiving	receiving	O
fewer	fewer	O
CNS-directed	cns-directed	O
treatment	treatment	O
days	days	O
during	during	O
intensive	intensive	O
consolidation	consolidation	O
(	(	O
P9201	p9201	O
)	)	O
.	.	O

A	a	O
total	total	O
of	of	O
66	66	O
children	children	O
from	from	O
16	16	O
Pediatric	pediatric	O
Oncology	oncology	O
Group	group	O
institutions	institutions	O
with	with	O
"	"	O
standard-risk	standard-risk	O
"	"	O
acute	acute	B-Disease
lymphoblastic	lymphoblastic	I-Disease
leukemia	leukemia	I-Disease
,	,	O
1.00	1.00	O
to	to	O
9.99	9.99	O
years	years	O
at	at	O
diagnosis	diagnosis	O
,	,	O
without	without	O
evidence	evidence	O
of	of	O
CNS	cns	O
leukemia	leukemia	O
at	at	O
diagnosis	diagnosis	O
were	were	O
enrolled	enrolled	O
on	on	O
ACCL0131	accl0131	O
:	:	O
28	28	O
from	from	O
P9201	p9201	O
and	and	O
38	38	O
from	from	O
P9605	p9605	B-Chemical
.	.	O

Magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
scans	scans	O
and	and	O
standard	standard	O
neuropsychological	neuropsychological	O
tests	tests	O
were	were	O
performed	performed	O
>	>	O
2.6	2.6	O
years	years	O
after	after	O
the	the	O
end	end	O
of	of	O
treatment	treatment	O
.	.	O

Significantly	significantly	O
more	more	O
P9605	p9605	B-Chemical
patients	patients	O
developed	developed	O
leukoencephalopathy	leukoencephalopathy	B-Disease
compared	compared	O
with	with	O
P9201	p9201	O
patients	patients	O
(	(	O
68	68	O
%	%	O
,	,	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
49%-83	49%-83	O
%	%	O
vs.	vs.	O
22	22	O
%	%	O
,	,	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
5%-44	5%-44	O
%	%	O
;	;	O
P=0.001	p=0.001	O
)	)	O
identified	identified	O
as	as	O
late	late	O
as	as	O
7.7	7.7	O
years	years	O
after	after	O
the	the	O
end	end	O
of	of	O
treatment	treatment	O
.	.	O

Overall	overall	O
,	,	O
40	40	O
%	%	O
of	of	O
patients	patients	O
scored	scored	O
<	<	O
85	85	O
on	on	O
either	either	O
Verbal	verbal	O
or	or	O
Performance	performance	O
IQ	iq	O
.	.	O

Children	children	O
on	on	O
both	both	O
studies	studies	O
had	had	O
significant	significant	O
attention	attention	O
problems	problems	O
,	,	O
but	but	O
P9605	p9605	B-Chemical
children	children	O
scored	scored	O
below	below	O
average	average	O
on	on	O
more	more	O
neurocognitive	neurocognitive	O
measures	measures	O
than	than	O
those	those	O
treated	treated	O
on	on	O
P9201	p9201	O
(	(	O
82	82	O
%	%	O
,	,	O
14/17	14/17	O
measures	measures	O
vs.	vs.	O
24	24	O
%	%	O
,	,	O
4/17	4/17	O
measures	measures	O
)	)	O
.	.	O

This	this	O
supports	supports	O
ongoing	ongoing	O
concerns	concerns	O
about	about	O
intensive	intensive	O
MTX	mtx	B-Chemical
exposure	exposure	O
as	as	O
a	a	O
major	major	O
contributor	contributor	O
to	to	O
CNS	cns	O
late	late	O
effects	effects	O
.	.	O

Tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
overdosage-induced	overdosage-induced	O
generalized	generalized	O
seizure	seizure	B-Disease
in	in	O
renal	renal	B-Disease
failure	failure	I-Disease
.	.	O

We	we	O
report	report	O
a	a	O
45-year-old	45-year-old	O
lady	lady	O
with	with	O
chronic	chronic	O
kidney	kidney	B-Disease
disease	disease	I-Disease
stage	stage	O
4	4	O
due	due	O
to	to	O
chronic	chronic	O
tubulointerstial	tubulointerstial	O
disease	disease	O
.	.	O

She	she	O
was	was	O
admitted	admitted	O
to	to	O
our	our	O
center	center	O
for	for	O
severe	severe	O
anemia	anemia	B-Disease
due	due	O
to	to	O
menorrhagia	menorrhagia	O
and	and	O
deterioration	deterioration	O
of	of	O
renal	renal	O
function	function	O
.	.	O

She	she	O
was	was	O
infused	infused	O
three	three	O
units	units	O
of	of	O
packed	packed	O
cells	cells	O
during	during	O
a	a	O
session	session	O
of	of	O
hemodialysis	hemodialysis	O
.	.	O

Tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
(	(	O
TNA	tna	O
)	)	O
1	1	O
g	g	O
8-hourly	8-hourly	O
was	was	O
administered	administered	O
to	to	O
her	her	O
to	to	O
control	control	O
bleeding	bleeding	B-Disease
per	per	O
vaginum	vaginum	O
.	.	O

Two	two	O
hours	hours	O
after	after	O
the	the	O
sixth	sixth	O
dose	dose	O
of	of	O
TNA	tna	O
,	,	O
she	she	O
had	had	O
an	an	O
episode	episode	O
of	of	O
generalized	generalized	O
tonic	tonic	O
clonic	clonic	O
convulsions	convulsions	B-Disease
.	.	O

TNA	tna	O
was	was	O
discontinued	discontinued	O
.	.	O

Investigations	investigations	O
of	of	O
the	the	O
patient	patient	O
revealed	revealed	O
no	no	O
biochemical	biochemical	O
or	or	O
structural	structural	O
central	central	O
nervous	nervous	O
system	system	O
abnormalities	abnormalities	O
that	that	O
could	could	O
have	have	O
provoked	provoked	O
the	the	O
convulsions	convulsions	B-Disease
.	.	O

She	she	O
did	did	O
not	not	O
require	require	O
any	any	O
further	further	O
dialytic	dialytic	O
support	support	O
.	.	O

She	she	O
had	had	O
no	no	O
further	further	O
episodes	episodes	O
of	of	O
convulsion	convulsion	B-Disease
till	till	O
dis-charge	dis-charge	O
and	and	O
during	during	O
the	the	O
two	two	O
months	months	O
of	of	O
follow-up	follow-up	O
.	.	O

Thus	thus	O
,	,	O
the	the	O
precipitating	precipitating	O
cause	cause	O
of	of	O
convulsions	convulsions	B-Disease
was	was	O
believed	believed	O
to	to	O
be	be	O
an	an	O
overdose	overdose	B-Disease
of	of	O
TNA	tna	O
.	.	O

Pre-treatment	pre-treatment	O
of	of	O
bupivacaine-induced	bupivacaine-induced	O
cardiovascular	cardiovascular	O
depression	depression	B-Disease
using	using	O
different	different	O
lipid	lipid	O
formulations	formulations	O
of	of	O
propofol	propofol	B-Chemical
.	.	O

BACKGROUND	background	O
:	:	O
Pre-treatment	pre-treatment	O
with	with	O
lipid	lipid	O
emulsions	emulsions	O
has	has	O
been	been	O
shown	shown	O
to	to	O
increase	increase	O
lethal	lethal	O
doses	doses	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
,	,	O
and	and	O
the	the	O
lipid	lipid	O
content	content	O
of	of	O
propofol	propofol	B-Chemical
may	may	O
alleviate	alleviate	O
bupivacaine-induced	bupivacaine-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
is	is	O
to	to	O
investigate	investigate	O
the	the	O
effects	effects	O
of	of	O
propofol	propofol	B-Chemical
in	in	O
intralipid	intralipid	O
or	or	O
medialipid	medialipid	O
emulsions	emulsions	O
on	on	O
bupivacaine-induced	bupivacaine-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Rats	rats	O
were	were	O
anaesthetised	anaesthetised	O
with	with	O
ketamine	ketamine	B-Chemical
and	and	O
were	were	O
given	given	O
0.5	0.5	O
mg/kg/min	mg/kg/min	O
propofol	propofol	B-Chemical
in	in	O
intralipid	intralipid	O
(	(	O
Group	group	O
P	p	O
)	)	O
,	,	O
propofol	propofol	B-Chemical
in	in	O
medialipid	medialipid	O
(	(	O
Group	group	O
L	l	O
)	)	O
,	,	O
or	or	O
saline	saline	O
(	(	O
Group	group	O
C	c	O
)	)	O
over	over	O
20	20	O
min	min	O
.	.	O

Thereafter	thereafter	O
,	,	O
2	2	O
mg/kg/min	mg/kg/min	O
bupivacaine	bupivacaine	B-Chemical
0.5	0.5	O
%	%	O
was	was	O
infused	infused	O
.	.	O

We	we	O
recorded	recorded	O
time	time	O
to	to	O
first	first	O
dysrhythmia	dysrhythmia	O
occurrence	occurrence	O
,	,	O
respective	respective	O
times	times	O
to	to	O
25	25	O
%	%	O
and	and	O
50	50	O
%	%	O
reduction	reduction	O
of	of	O
the	the	O
heart	heart	O
rate	rate	O
(	(	O
HR	hr	O
)	)	O
and	and	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
,	,	O
and	and	O
time	time	O
to	to	O
asystole	asystole	B-Disease
and	and	O
total	total	O
amount	amount	O
of	of	O
bupivacaine	bupivacaine	B-Chemical
consumption	consumption	O
.	.	O

Blood	blood	O
and	and	O
tissue	tissue	O
samples	samples	O
were	were	O
collected	collected	O
following	following	O
asystole	asystole	B-Disease
.	.	O

RESULTS	results	O
:	:	O
The	the	O
time	time	O
to	to	O
first	first	O
dysrhythmia	dysrhythmia	O
occurrence	occurrence	O
,	,	O
time	time	O
to	to	O
25	25	O
%	%	O
and	and	O
50	50	O
%	%	O
reductions	reductions	O
in	in	O
HR	hr	O
,	,	O
and	and	O
time	time	O
to	to	O
asystole	asystole	B-Disease
were	were	O
longer	longer	O
in	in	O
Group	group	O
P	p	O
than	than	O
the	the	O
other	other	O
groups	groups	O
.	.	O

The	the	O
cumulative	cumulative	O
bupivacaine	bupivacaine	B-Chemical
dose	dose	O
given	given	O
at	at	O
those	those	O
time	time	O
points	points	O
was	was	O
higher	higher	O
in	in	O
Group	group	O
P.	p.	O
Plasma	plasma	O
bupivacaine	bupivacaine	B-Chemical
levels	levels	O
were	were	O
significantly	significantly	O
lower	lower	O
in	in	O
Group	group	O
P	p	O
than	than	O
in	in	O
Group	group	O
C.	c.	O
Bupivacaine	bupivacaine	B-Chemical
levels	levels	O
in	in	O
the	the	O
brain	brain	O
and	and	O
heart	heart	O
were	were	O
significantly	significantly	O
lower	lower	O
in	in	O
Group	group	O
P	p	O
and	and	O
Group	group	O
L	l	O
than	than	O
in	in	O
Group	group	O
C.	c.	O
CONCLUSION	conclusion	O
:	:	O
We	we	O
conclude	conclude	O
that	that	O
pre-treatment	pre-treatment	O
with	with	O
propofol	propofol	B-Chemical
in	in	O
intralipid	intralipid	O
,	,	O
compared	compared	O
with	with	O
propofol	propofol	B-Chemical
in	in	O
medialipid	medialipid	O
or	or	O
saline	saline	O
,	,	O
delayed	delayed	O
the	the	O
onset	onset	O
of	of	O
bupivacaine-induced	bupivacaine-induced	O
cardiotoxic	cardiotoxic	B-Disease
effects	effects	O
as	as	O
well	well	O
as	as	O
reduced	reduced	O
plasma	plasma	O
bupivacaine	bupivacaine	B-Chemical
levels	levels	O
.	.	O

Further	further	O
studies	studies	O
are	are	O
needed	needed	O
to	to	O
explore	explore	O
tissue	tissue	O
bupivacaine	bupivacaine	B-Chemical
levels	levels	O
of	of	O
propofol	propofol	B-Chemical
in	in	O
medialipid	medialipid	O
and	and	O
adapt	adapt	O
these	these	O
results	results	O
to	to	O
clinical	clinical	O
practice	practice	O
.	.	O

Drug-Induced	drug-induced	O
Acute	acute	O
Liver	liver	B-Disease
Injury	injury	I-Disease
Within	within	O
12	12	O
Hours	hours	O
After	after	O
Fluvastatin	fluvastatin	O
Therapy	therapy	O
.	.	O

Although	although	O
statins	statins	B-Chemical
are	are	O
generally	generally	O
well-tolerated	well-tolerated	O
drugs	drugs	O
,	,	O
recent	recent	O
cases	cases	O
of	of	O
drug-induced	drug-induced	O
liver	liver	B-Disease
injury	injury	I-Disease
associated	associated	O
with	with	O
their	their	O
use	use	O
have	have	O
been	been	O
reported	reported	O
.	.	O

A	a	O
52-year-old	52-year-old	O
Chinese	chinese	O
man	man	O
reported	reported	O
with	with	O
liver	liver	B-Disease
damage	damage	I-Disease
,	,	O
which	which	O
appeared	appeared	O
12	12	O
hours	hours	O
after	after	O
beginning	beginning	O
treatment	treatment	O
with	with	O
fluvastatin	fluvastatin	O
.	.	O

Patient	patient	O
presented	presented	O
with	with	O
complaints	complaints	O
of	of	O
increasing	increasing	O
nausea	nausea	B-Disease
,	,	O
anorexia	anorexia	O
,	,	O
and	and	O
upper	upper	O
abdominal	abdominal	B-Disease
pain	pain	B-Disease
.	.	O

His	his	O
laboratory	laboratory	O
values	values	O
showed	showed	O
elevated	elevated	O
creatine	creatine	B-Chemical
kinase	kinase	I-Chemical
and	and	O
transaminases	transaminases	O
.	.	O

Testing	testing	O
for	for	O
autoantibodies	autoantibodies	O
was	was	O
also	also	O
negative	negative	O
.	.	O

The	the	O
liver	liver	O
biochemistries	biochemistries	O
eventually	eventually	O
normalized	normalized	O
within	within	O
3	3	O
weeks	weeks	O
of	of	O
stopping	stopping	O
the	the	O
fluvastatin	fluvastatin	O
.	.	O

Therefore	therefore	O
,	,	O
when	when	O
prescribing	prescribing	O
statins	statins	B-Chemical
,	,	O
the	the	O
possibility	possibility	O
of	of	O
hepatic	hepatic	B-Disease
damage	damage	I-Disease
should	should	O
be	be	O
taken	taken	O
into	into	O
account	account	O
.	.	O

Fluconazole	fluconazole	O
associated	associated	O
agranulocytosis	agranulocytosis	O
and	and	O
thrombocytopenia	thrombocytopenia	B-Disease
.	.	O

CASE	case	O
:	:	O
We	we	O
describe	describe	O
a	a	O
second	second	O
case	case	O
of	of	O
fluconazole	fluconazole	O
associated	associated	O
agranulocytosis	agranulocytosis	O
with	with	O
thrombocytopenia	thrombocytopenia	B-Disease
and	and	O
recovery	recovery	O
upon	upon	O
discontinuation	discontinuation	O
of	of	O
therapy	therapy	O
.	.	O

The	the	O
patient	patient	O
began	began	O
to	to	O
have	have	O
changes	changes	O
in	in	O
white	white	O
blood	blood	O
cells	cells	O
and	and	O
platelets	platelets	O
within	within	O
48	48	O
h	h	B-Chemical
of	of	O
administration	administration	O
of	of	O
fluconazole	fluconazole	O
and	and	O
began	began	O
to	to	O
recover	recover	O
with	with	O
48	48	O
h	h	B-Chemical
of	of	O
discontinuation	discontinuation	O
.	.	O

This	this	O
case	case	O
highlights	highlights	O
that	that	O
drug-induced	drug-induced	O
blood	blood	O
dyscrasias	dyscrasias	O
can	can	O
occur	occur	O
unexpectedly	unexpectedly	O
as	as	O
a	a	O
result	result	O
of	of	O
treatment	treatment	O
with	with	O
a	a	O
commonly	commonly	O
used	used	O
drug	drug	O
thought	thought	O
to	to	O
be	be	O
"	"	O
safe	safe	O
"	"	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
According	according	O
to	to	O
Naranjo	naranjo	O
's	's	O
algorithm	algorithm	O
the	the	O
likelihood	likelihood	O
that	that	O
our	our	O
patient	patient	O
's	's	O
agranulocytosis	agranulocytosis	O
and	and	O
thrombocytopenia	thrombocytopenia	B-Disease
occurred	occurred	O
as	as	O
a	a	O
result	result	O
of	of	O
therapy	therapy	O
with	with	O
fluconazole	fluconazole	O
is	is	O
probable	probable	O
,	,	O
with	with	O
a	a	O
total	total	O
of	of	O
six	six	O
points	points	O
.	.	O

We	we	O
feel	feel	O
that	that	O
the	the	O
weight	weight	O
of	of	O
the	the	O
overall	overall	O
evidence	evidence	O
of	of	O
this	this	O
evidence	evidence	O
is	is	O
strong	strong	O
.	.	O

In	in	O
particular	particular	O
the	the	O
temporal	temporal	O
relationship	relationship	O
of	of	O
bone	bone	B-Disease
marrow	marrow	I-Disease
suppression	suppression	I-Disease
to	to	O
the	the	O
initiation	initiation	O
of	of	O
fluconazole	fluconazole	O
and	and	O
the	the	O
abatement	abatement	O
of	of	O
symptoms	symptoms	O
that	that	O
rapidly	rapidly	O
reversed	reversed	O
immediately	immediately	O
following	following	O
discontinuation	discontinuation	O
.	.	O

Two-dimensional	two-dimensional	O
speckle	speckle	O
tracking	tracking	O
echocardiography	echocardiography	O
combined	combined	O
with	with	O
high-sensitive	high-sensitive	O
cardiac	cardiac	O
troponin	troponin	B-Chemical
T	t	I-Chemical
in	in	O
early	early	O
detection	detection	O
and	and	O
prediction	prediction	O
of	of	O
cardiotoxicity	cardiotoxicity	B-Disease
during	during	O
epirubicine-based	epirubicine-based	O
chemotherapy	chemotherapy	O
.	.	O

AIMS	aims	O
:	:	O
To	to	O
investigate	investigate	O
whether	whether	O
alterations	alterations	O
of	of	O
myocardial	myocardial	O
strain	strain	O
and	and	O
high-sensitive	high-sensitive	O
cardiac	cardiac	O
troponin	troponin	B-Chemical
T	t	I-Chemical
(	(	O
cTnT	ctnt	O
)	)	O
could	could	O
predict	predict	O
future	future	O
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
patients	patients	O
after	after	O
epirubicin	epirubicin	O
exposure	exposure	O
.	.	O

METHODS	methods	O
:	:	O
Seventy-five	seventy-five	O
patients	patients	O
with	with	O
non-Hodgkin	non-hodgkin	O
lymphoma	lymphoma	O
treated	treated	O
with	with	O
epirubicin	epirubicin	O
were	were	O
studied	studied	O
.	.	O

Blood	blood	O
collection	collection	O
and	and	O
echocardiography	echocardiography	O
were	were	O
performed	performed	O
at	at	O
baseline	baseline	O
,	,	O
1	1	O
day	day	O
after	after	O
the	the	O
third	third	O
cycle	cycle	O
,	,	O
and	and	O
1	1	O
day	day	O
after	after	O
completion	completion	O
of	of	O
chemotherapy	chemotherapy	O
.	.	O

Patients	patients	O
were	were	O
studied	studied	O
using	using	O
echocardiography	echocardiography	O
during	during	O
follow-up	follow-up	O
.	.	O

Global	global	O
longitudinal	longitudinal	O
(	(	O
GLS	gls	O
)	)	O
,	,	O
circumferential	circumferential	O
(	(	O
GCS	gcs	O
)	)	O
,	,	O
and	and	O
radial	radial	O
strain	strain	O
(	(	O
GRS	grs	O
)	)	O
were	were	O
calculated	calculated	O
using	using	O
speckle	speckle	O
tracking	tracking	O
echocardiography	echocardiography	O
.	.	O

Left	left	O
ventricular	ventricular	O
ejection	ejection	O
fraction	fraction	O
was	was	O
analysed	analysed	O
by	by	O
real-time	real-time	O
3D	3d	O
echocardiography	echocardiography	O
.	.	O

Cardiotoxicity	cardiotoxicity	B-Disease
was	was	O
defined	defined	O
as	as	O
a	a	O
reduction	reduction	O
of	of	O
the	the	O
LVEF	lvef	O
of	of	O
>	>	O
5	5	O
%	%	O
to	to	O
<	<	O
55	55	O
%	%	O
with	with	O
symptoms	symptoms	O
of	of	O
heart	heart	B-Disease
failure	failure	I-Disease
or	or	O
an	an	O
asymptomatic	asymptomatic	O
reduction	reduction	O
of	of	O
the	the	O
LVEF	lvef	O
of	of	O
>	>	O
10	10	O
%	%	O
to	to	O
<	<	O
55	55	O
%	%	O
.	.	O

RESULTS	results	O
:	:	O
Fourteen	fourteen	O
patients	patients	O
(	(	O
18.67	18.67	O
%	%	O
)	)	O
developed	developed	O
cardiotoxicity	cardiotoxicity	B-Disease
after	after	O
treatment	treatment	O
.	.	O

GLS	gls	O
(	(	O
-18.48	-18.48	O
+	+	O
1.72	1.72	O
%	%	O
vs.	vs.	O
-15.96	-15.96	O
+	+	O
1.6	1.6	O
%	%	O
)	)	O
,	,	O
GCS	gcs	O
(	(	O
-20.93	-20.93	O
+	+	O
2.86	2.86	O
%	%	O
vs.	vs.	O
-19.20	-19.20	O
+	+	O
3.21	3.21	O
%	%	O
)	)	O
,	,	O
and	and	O
GRS	grs	O
(	(	O
39.23	39.23	O
+	+	O
6.44	6.44	O
%	%	O
vs.	vs.	O
34.98	34.98	O
+	+	O
6.2	6.2	O
%	%	O
)	)	O
were	were	O
markedly	markedly	O
reduced	reduced	O
and	and	O
cTnT	ctnt	O
was	was	O
elevated	elevated	O
from	from	O
0.0010	0.0010	O
+	+	O
0.0020	0.0020	O
to	to	O
0.0073	0.0073	O
+	+	O
0.0038	0.0038	O
ng/mL	ng/ml	O
(	(	O
P	p	O
all	all	O
<	<	O
0.01	0.01	O
)	)	O
at	at	O
the	the	O
completion	completion	O
of	of	O
chemotherapy	chemotherapy	O
compared	compared	O
with	with	O
baseline	baseline	O
values	values	O
.	.	O

A	a	O
>	>	O
15.9	15.9	O
%	%	O
decrease	decrease	O
in	in	O
GLS	gls	O
[	[	O
sensitivity	sensitivity	O
,	,	O
86	86	O
%	%	O
;	;	O
specificity	specificity	O
,	,	O
75	75	O
%	%	O
;	;	O
area	area	O
under	under	O
the	the	O
curve	curve	O
(	(	O
AUC	auc	O
)	)	O
=	=	O
0.815	0.815	O
;	;	O
P	p	O
=	=	O
0.001	0.001	O
]	]	O
and	and	O
a	a	O
>	>	O
0.004	0.004	O
ng/mL	ng/ml	O
elevation	elevation	O
in	in	O
cTnT	ctnt	O
(	(	O
sensitivity	sensitivity	O
,	,	O
79	79	O
%	%	O
;	;	O
specificity	specificity	O
,	,	O
64	64	O
%	%	O
;	;	O
AUC	auc	O
=	=	O
0.757	0.757	O
;	;	O
P	p	O
=	=	O
0.005	0.005	O
)	)	O
from	from	O
baseline	baseline	O
to	to	O
the	the	O
third	third	O
cycle	cycle	O
of	of	O
chemotherapy	chemotherapy	O
predicted	predicted	O
later	later	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

The	the	O
decrease	decrease	O
in	in	O
GLS	gls	O
remained	remained	O
the	the	O
only	only	O
independent	independent	O
predictor	predictor	O
of	of	O
cardiotoxicity	cardiotoxicity	B-Disease
(	(	O
P	p	O
=	=	O
0.000	0.000	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
GLS	gls	O
combined	combined	O
with	with	O
cTnT	ctnt	O
may	may	O
provide	provide	O
a	a	O
reliable	reliable	O
and	and	O
non-invasive	non-invasive	O
method	method	O
to	to	O
predict	predict	O
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
patients	patients	O
receiving	receiving	O
anthracycline-based	anthracycline-based	O
chemotherapy	chemotherapy	O
.	.	O

Prevention	prevention	O
of	of	O
etomidate-induced	etomidate-induced	O
myoclonus	myoclonus	B-Disease
:	:	O
which	which	O
is	is	O
superior	superior	O
:	:	O
Fentanyl	fentanyl	B-Chemical
,	,	O
midazolam	midazolam	B-Chemical
,	,	O
or	or	O
a	a	O
combination	combination	O
?	?	O
A	a	O
Retrospective	retrospective	O
comparative	comparative	O
study	study	O
.	.	O

BACKGROUND	background	O
:	:	O
In	in	O
this	this	O
retrospective	retrospective	O
comparative	comparative	O
study	study	O
,	,	O
we	we	O
aimed	aimed	O
to	to	O
compare	compare	O
the	the	O
effectiveness	effectiveness	O
of	of	O
fentanyl	fentanyl	B-Chemical
,	,	O
midazolam	midazolam	B-Chemical
,	,	O
and	and	O
a	a	O
combination	combination	O
of	of	O
fentanyl	fentanyl	B-Chemical
and	and	O
midazolam	midazolam	B-Chemical
to	to	O
prevent	prevent	O
etomidate-induced	etomidate-induced	O
myoclonus	myoclonus	B-Disease
.	.	O

MATERIAL	material	O
AND	and	O
METHODS	methods	O
:	:	O
This	this	O
study	study	O
was	was	O
performed	performed	O
based	based	O
on	on	O
anesthesia	anesthesia	O
records	records	O
.	.	O

Depending	depending	O
on	on	O
the	the	O
drugs	drugs	O
that	that	O
would	would	O
be	be	O
given	given	O
before	before	O
the	the	O
induction	induction	O
of	of	O
anesthesia	anesthesia	O
with	with	O
etomidate	etomidate	O
,	,	O
the	the	O
patients	patients	O
were	were	O
separated	separated	O
into	into	O
4	4	O
groups	groups	O
:	:	O
no	no	O
pretreatment	pretreatment	O
(	(	O
Group	group	O
NP	np	O
)	)	O
,	,	O
fentanyl	fentanyl	B-Chemical
1	1	O
ug.kg-1	ug.kg-1	O
(	(	O
Group	group	O
F	f	O
)	)	O
,	,	O
midazolam	midazolam	B-Chemical
0.03	0.03	O
mg.kg-1	mg.kg-1	O
(	(	O
Group	group	O
M	m	O
)	)	O
,	,	O
and	and	O
midazolam	midazolam	B-Chemical
0.015	0.015	O
mg.kg-1	mg.kg-1	O
+	+	O
fentanyl	fentanyl	B-Chemical
0.5	0.5	O
ug.kg-1	ug.kg-1	O
(	(	O
Group	group	O
FM	fm	O
)	)	O
.	.	O

Patients	patients	O
who	who	O
received	received	O
the	the	O
same	same	O
anesthetic	anesthetic	O
procedure	procedure	O
were	were	O
selected	selected	O
:	:	O
2	2	O
minutes	minutes	O
after	after	O
intravenous	intravenous	O
injections	injections	O
of	of	O
the	the	O
pretreatment	pretreatment	O
drugs	drugs	O
,	,	O
anesthesia	anesthesia	O
is	is	O
induced	induced	O
with	with	O
0.3	0.3	O
mg.kg-1	mg.kg-1	O
etomidate	etomidate	O
injected	injected	O
intravenously	intravenously	O
over	over	O
a	a	O
period	period	O
of	of	O
20	20	O
-	-	O
30	30	O
seconds	seconds	O
.	.	O

Myoclonic	myoclonic	O
movements	movements	O
are	are	O
evaluated	evaluated	O
,	,	O
which	which	O
were	were	O
observed	observed	O
and	and	O
graded	graded	O
according	according	O
to	to	O
clinical	clinical	O
severity	severity	O
during	during	O
the	the	O
2	2	O
minutes	minutes	O
after	after	O
etomidate	etomidate	O
injection	injection	O
.	.	O

The	the	O
severity	severity	O
of	of	O
pain	pain	B-Disease
due	due	O
to	to	O
etomidate	etomidate	O
injection	injection	O
,	,	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
,	,	O
heart	heart	O
rate	rate	O
,	,	O
and	and	O
adverse	adverse	O
effects	effects	O
were	were	O
also	also	O
evaluated	evaluated	O
.	.	O

RESULTS	results	O
:	:	O
Study	study	O
results	results	O
showed	showed	O
that	that	O
myoclonus	myoclonus	B-Disease
incidence	incidence	O
was	was	O
85	85	O
%	%	O
,	,	O
40	40	O
%	%	O
,	,	O
70	70	O
%	%	O
,	,	O
and	and	O
25	25	O
%	%	O
in	in	O
Group	group	O
NP	np	O
,	,	O
Group	group	O
F	f	O
,	,	O
Group	group	O
M	m	O
,	,	O
and	and	O
Group	group	O
FM	fm	O
,	,	O
respectively	respectively	O
,	,	O
and	and	O
were	were	O
significantly	significantly	O
lower	lower	O
in	in	O
Group	group	O
F	f	O
and	and	O
Group	group	O
FM	fm	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
We	we	O
conclude	conclude	O
that	that	O
pretreatment	pretreatment	O
with	with	O
fentanyl	fentanyl	B-Chemical
or	or	O
combination	combination	O
of	of	O
fentanyl	fentanyl	B-Chemical
and	and	O
midazolam	midazolam	B-Chemical
was	was	O
effective	effective	O
in	in	O
preventing	preventing	O
etomidate-induced	etomidate-induced	O
myoclonus	myoclonus	B-Disease
.	.	O

Convulsant	convulsant	O
effect	effect	O
of	of	O
lindane	lindane	B-Chemical
and	and	O
regional	regional	O
brain	brain	O
concentration	concentration	O
of	of	O
GABA	gaba	B-Chemical
and	and	O
dopamine	dopamine	B-Chemical
.	.	O

Lindane	lindane	B-Chemical
(	(	O
gamma-hexachlorocyclohexane	gamma-hexachlorocyclohexane	O
)	)	O
is	is	O
an	an	O
organochlorine	organochlorine	O
insecticide	insecticide	O
with	with	O
known	known	O
neurotoxic	neurotoxic	B-Disease
effects	effects	O
.	.	O

Its	its	O
mechanism	mechanism	O
of	of	O
action	action	O
is	is	O
not	not	O
well	well	O
understood	understood	O
although	although	O
it	it	O
has	has	O
been	been	O
proposed	proposed	O
that	that	O
lindane	lindane	B-Chemical
acts	acts	O
as	as	O
a	a	O
non-competitive	non-competitive	O
antagonist	antagonist	O
at	at	O
the	the	O
gamma-aminobutyric	gamma-aminobutyric	O
acid	acid	O
(GABA)-A	(gaba)-a	O
receptor	receptor	O
.	.	O

We	we	O
studied	studied	O
the	the	O
effect	effect	O
of	of	O
lindane	lindane	B-Chemical
(	(	O
150	150	O
mg/kg	mg/kg	O
)	)	O
on	on	O
the	the	O
GABAergic	gabaergic	O
and	and	O
dopaminergic	dopaminergic	O
systems	systems	O
by	by	O
measuring	measuring	O
the	the	O
concentration	concentration	O
of	of	O
GABA	gaba	B-Chemical
,	,	O
dopamine	dopamine	B-Chemical
and	and	O
its	its	O
metabolites	metabolites	O
in	in	O
7	7	O
brain	brain	O
areas	areas	O
at	at	O
the	the	O
onset	onset	O
of	of	O
seizures	seizures	B-Disease
.	.	O

All	all	O
animals	animals	O
suffered	suffered	O
tonic	tonic	O
convulsions	convulsions	B-Disease
at	at	O
18.3	18.3	O
+	+	O
/-	/-	O
1.4	1.4	O
min	min	O
after	after	O
lindane	lindane	B-Chemical
administration	administration	O
.	.	O

The	the	O
concentration	concentration	O
of	of	O
GABA	gaba	B-Chemical
was	was	O
only	only	O
slightly	slightly	O
but	but	O
significantly	significantly	O
decreased	decreased	O
in	in	O
the	the	O
colliculi	colliculi	O
without	without	O
modifications	modifications	O
in	in	O
the	the	O
other	other	O
areas	areas	O
.	.	O

The	the	O
concentration	concentration	O
of	of	O
dopamine	dopamine	B-Chemical
was	was	O
increased	increased	O
in	in	O
the	the	O
mesencephalon	mesencephalon	O
and	and	O
that	that	O
of	of	O
its	its	O
metabolite	metabolite	O
DOPAC	dopac	B-Chemical
was	was	O
also	also	O
increased	increased	O
in	in	O
the	the	O
mesencephalon	mesencephalon	O
and	and	O
the	the	O
striatum	striatum	O
.	.	O

Cholestatic	cholestatic	O
presentation	presentation	O
of	of	O
yellow	yellow	O
phosphorus	phosphorus	O
poisoning	poisoning	B-Disease
.	.	O

Yellow	yellow	O
phosphorus	phosphorus	O
,	,	O
a	a	O
component	component	O
of	of	O
certain	certain	O
pesticide	pesticide	O
pastes	pastes	O
and	and	O
fireworks	fireworks	O
,	,	O
is	is	O
well	well	O
known	known	O
to	to	O
cause	cause	O
hepatotoxicity	hepatotoxicity	B-Disease
.	.	O

Poisoning	poisoning	B-Disease
with	with	O
yellow	yellow	O
phosphorus	phosphorus	O
classically	classically	O
manifests	manifests	O
with	with	O
acute	acute	O
hepatitis	hepatitis	B-Disease
leading	leading	O
to	to	O
acute	acute	B-Disease
liver	liver	B-Disease
failure	failure	I-Disease
which	which	O
may	may	O
need	need	O
liver	liver	O
transplantation	transplantation	O
.	.	O

We	we	O
present	present	O
a	a	O
case	case	O
of	of	O
yellow	yellow	O
phosphorus	phosphorus	O
poisoning	poisoning	B-Disease
in	in	O
which	which	O
a	a	O
patient	patient	O
presented	presented	O
with	with	O
florid	florid	O
clinical	clinical	O
features	features	O
of	of	O
cholestasis	cholestasis	B-Disease
highlighting	highlighting	O
the	the	O
fact	fact	O
that	that	O
cholestasis	cholestasis	B-Disease
can	can	O
rarely	rarely	O
be	be	O
a	a	O
presenting	presenting	O
feature	feature	O
of	of	O
yellow	yellow	O
phosphorus	phosphorus	O
hepatotoxicity	hepatotoxicity	B-Disease
.	.	O

Vasovagal	vasovagal	O
syncope	syncope	B-Disease
and	and	O
severe	severe	O
bradycardia	bradycardia	B-Disease
following	following	O
intranasal	intranasal	O
dexmedetomidine	dexmedetomidine	O
for	for	O
pediatric	pediatric	O
procedural	procedural	O
sedation	sedation	O
.	.	O

We	we	O
report	report	O
syncope	syncope	B-Disease
and	and	O
bradycardia	bradycardia	B-Disease
in	in	O
an	an	O
11-year-old	11-year-old	O
girl	girl	O
following	following	O
administration	administration	O
of	of	O
intranasal	intranasal	O
dexmedetomidine	dexmedetomidine	O
for	for	O
sedation	sedation	O
for	for	O
a	a	O
voiding	voiding	O
cystourethrogram	cystourethrogram	O
.	.	O

Following	following	O
successful	successful	O
completion	completion	O
of	of	O
VCUG	vcug	O
and	and	O
a	a	O
60-min	60-min	O
recovery	recovery	O
period	period	O
,	,	O
the	the	O
patient	patient	O
's	's	O
level	level	O
of	of	O
consciousness	consciousness	O
and	and	O
vital	vital	O
signs	signs	O
returned	returned	O
to	to	O
presedation	presedation	O
levels	levels	O
.	.	O

Upon	upon	O
leaving	leaving	O
the	the	O
sedation	sedation	O
area	area	O
,	,	O
the	the	O
patient	patient	O
collapsed	collapsed	O
,	,	O
with	with	O
no	no	O
apparent	apparent	O
inciting	inciting	O
event	event	O
.	.	O

The	the	O
patient	patient	O
quickly	quickly	O
regained	regained	O
consciousness	consciousness	O
and	and	O
no	no	O
injury	injury	O
occurred	occurred	O
.	.	O

The	the	O
primary	primary	O
abnormality	abnormality	O
found	found	O
was	was	O
persistent	persistent	O
bradycardia	bradycardia	B-Disease
,	,	O
and	and	O
she	she	O
was	was	O
admitted	admitted	O
to	to	O
the	the	O
hospital	hospital	O
for	for	O
telemetric	telemetric	O
observation	observation	O
.	.	O

The	the	O
bradycardia	bradycardia	B-Disease
lasted	lasted	O
~2	~2	O
h	h	B-Chemical
,	,	O
and	and	O
further	further	O
cardiac	cardiac	O
workup	workup	O
revealed	revealed	O
no	no	O
underlying	underlying	O
abnormality	abnormality	O
.	.	O

Unanticipated	unanticipated	O
and	and	O
previously	previously	O
unreported	unreported	O
outcomes	outcomes	O
may	may	O
be	be	O
witnessed	witnessed	O
as	as	O
we	we	O
expand	expand	O
the	the	O
use	use	O
of	of	O
certain	certain	O
sedatives	sedatives	O
to	to	O
alternative	alternative	O
routes	routes	O
of	of	O
administration	administration	O
.	.	O

Paradoxical	paradoxical	O
severe	severe	O
agitation	agitation	B-Disease
induced	induced	O
by	by	O
add-on	add-on	O
high-doses	high-doses	O
quetiapine	quetiapine	O
in	in	O
schizo-affective	schizo-affective	O
disorder	disorder	O
.	.	O

We	we	O
report	report	O
the	the	O
case	case	O
of	of	O
a	a	O
35-year-old	35-year-old	O
patient	patient	O
suffering	suffering	O
from	from	O
schizo-affective	schizo-affective	O
disorder	disorder	O
since	since	O
the	the	O
age	age	O
of	of	O
19	19	O
years	years	O
,	,	O
treated	treated	O
by	by	O
a	a	O
combination	combination	O
of	of	O
first-generation	first-generation	O
antipsychotics	antipsychotics	B-Chemical
,	,	O
zuclopenthixol	zuclopenthixol	O
(	(	O
100	100	O
mg/day	mg/day	O
)	)	O
and	and	O
lithium	lithium	B-Chemical
(	(	O
1200	1200	O
mg/day	mg/day	O
)	)	O
(	(	O
serum	serum	O
lithium=0.85	lithium=0.85	O
mEq/l	meq/l	O
)	)	O
.	.	O

This	this	O
patient	patient	O
had	had	O
no	no	O
associated	associated	O
personality	personality	O
disorder	disorder	O
(	(	O
particularly	particularly	O
no	no	O
antisocial	antisocial	O
disorder	disorder	O
)	)	O
and	and	O
no	no	O
substance	substance	O
abuse	abuse	O
disorder	disorder	O
.	.	O

Within	within	O
the	the	O
48	48	O
h	h	B-Chemical
following	following	O
the	the	O
gradual	gradual	O
introduction	introduction	O
of	of	O
quetiapine	quetiapine	O
(	(	O
up	up	O
to	to	O
600	600	O
mg/day	mg/day	O
)	)	O
,	,	O
the	the	O
patient	patient	O
presented	presented	O
severe	severe	O
agitation	agitation	B-Disease
without	without	O
an	an	O
environmental	environmental	O
explanation	explanation	O
,	,	O
contrasting	contrasting	O
with	with	O
the	the	O
absence	absence	O
of	of	O
a	a	O
history	history	O
of	of	O
aggressiveness	aggressiveness	B-Disease
or	or	O
personality	personality	O
disorder	disorder	O
.	.	O

The	the	O
diagnoses	diagnoses	O
of	of	O
manic	manic	B-Disease
shift	shift	O
and	and	O
akathisia	akathisia	B-Disease
were	were	O
dismissed	dismissed	O
.	.	O

The	the	O
withdrawal	withdrawal	O
and	and	O
the	the	O
gradual	gradual	O
reintroduction	reintroduction	O
of	of	O
quetiapine	quetiapine	O
2	2	O
weeks	weeks	O
later	later	O
,	,	O
which	which	O
led	led	O
to	to	O
another	another	O
severe	severe	O
agitation	agitation	B-Disease
,	,	O
enabled	enabled	O
us	us	O
to	to	O
attribute	attribute	O
the	the	O
agitation	agitation	B-Disease
specifically	specifically	O
to	to	O
quetiapine	quetiapine	O
.	.	O

Antioxidant	antioxidant	O
effects	effects	O
of	of	O
bovine	bovine	O
lactoferrin	lactoferrin	O
on	on	O
dexamethasone-induced	dexamethasone-induced	O
hypertension	hypertension	B-Disease
in	in	O
rat	rat	O
.	.	O

Dexamethasone-	dexamethasone-	O
(	(	O
Dex-	dex-	O
)	)	O
induced	induced	O
hypertension	hypertension	B-Disease
is	is	O
associated	associated	O
with	with	O
enhanced	enhanced	O
oxidative	oxidative	O
stress	stress	O
.	.	O

Lactoferrin	lactoferrin	O
(	(	O
LF	lf	O
)	)	O
is	is	O
an	an	O
iron-binding	iron-binding	O
glycoprotein	glycoprotein	O
with	with	O
antihypertensive	antihypertensive	O
properties	properties	O
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
we	we	O
investigated	investigated	O
the	the	O
effect	effect	O
of	of	O
chronic	chronic	O
administration	administration	O
of	of	O
LF	lf	O
on	on	O
oxidative	oxidative	O
stress	stress	O
and	and	O
hypertension	hypertension	B-Disease
upon	upon	O
Dex	dex	B-Chemical
administration	administration	O
.	.	O

Male	male	O
Wistar	wistar	O
rats	rats	O
were	were	O
treated	treated	O
by	by	O
Dex	dex	B-Chemical
(	(	O
30	30	O
_	 	O
u	u	O
g/kg/day	g/kg/day	O
subcutaneously	subcutaneously	O
)	)	O
or	or	O
saline	saline	O
for	for	O
14	14	O
days	days	O
.	.	O

Oral	oral	O
bovine	bovine	O
LF	lf	O
(	(	O
30	30	O
,	,	O
100	100	O
,	,	O
300	300	O
mg/kg	mg/kg	O
)	)	O
was	was	O
given	given	O
from	from	O
day	day	O
8	8	O
to	to	O
14	14	O
in	in	O
a	a	O
reversal	reversal	O
study	study	O
.	.	O

In	in	O
a	a	O
prevention	prevention	O
study	study	O
,	,	O
rats	rats	O
received	received	O
4	4	O
days	days	O
of	of	O
LF	lf	O
treatment	treatment	O
followed	followed	O
by	by	O
Dex	dex	B-Chemical
and	and	O
continued	continued	O
during	during	O
the	the	O
test	test	O
period	period	O
.	.	O

Systolic	systolic	O
blood	blood	O
pressure	pressure	O
(	(	O
SBP	sbp	O
)	)	O
was	was	O
measured	measured	O
using	using	O
tail-cuff	tail-cuff	O
method	method	O
.	.	O

Thymus	thymus	O
weight	weight	O
was	was	O
used	used	O
as	as	O
a	a	O
marker	marker	O
of	of	O
glucocorticoid	glucocorticoid	O
activity	activity	O
.	.	O

Plasma	plasma	O
hydrogen	hydrogen	B-Chemical
peroxide	peroxide	I-Chemical
(	(	O
H2O2	h2o2	O
)	)	O
concentration	concentration	O
and	and	O
ferric	ferric	O
reducing	reducing	O
antioxidant	antioxidant	O
power	power	O
(	(	O
FRAP	frap	O
)	)	O
value	value	O
were	were	O
determined	determined	O
.	.	O

Dexamethasone	dexamethasone	B-Chemical
significantly	significantly	O
increased	increased	O
SBP	sbp	O
and	and	O
plasma	plasma	O
H2O2	h2o2	O
level	level	O
and	and	O
decreased	decreased	O
thymus	thymus	O
and	and	O
body	body	B-Disease
weights	weights	I-Disease
.	.	O

LF	lf	O
lowered	lowered	O
(	(	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
and	and	O
dose	dose	O
dependently	dependently	O
prevented	prevented	O
(	(	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
Dex-induced	dex-induced	O
hypertension	hypertension	B-Disease
.	.	O

LF	lf	O
prevented	prevented	O
body	body	B-Disease
weight	weight	B-Disease
loss	loss	I-Disease
and	and	O
significantly	significantly	O
reduced	reduced	O
the	the	O
elevated	elevated	O
plasma	plasma	O
H2O2	h2o2	O
and	and	O
increased	increased	O
FRAP	frap	O
values	values	O
.	.	O

Chronic	chronic	O
administration	administration	O
of	of	O
LF	lf	O
strongly	strongly	O
reduced	reduced	O
the	the	O
blood	blood	O
pressure	pressure	O
and	and	O
production	production	O
of	of	O
ROS	ros	O
and	and	O
improved	improved	O
antioxidant	antioxidant	O
capacity	capacity	O
in	in	O
Dex-induced	dex-induced	O
hypertension	hypertension	B-Disease
,	,	O
suggesting	suggesting	O
the	the	O
role	role	O
of	of	O
inhibition	inhibition	O
of	of	O
oxidative	oxidative	O
stress	stress	O
as	as	O
another	another	O
mechanism	mechanism	O
of	of	O
antihypertensive	antihypertensive	O
action	action	O
of	of	O
LF	lf	O
.	.	O

The	the	O
association	association	O
between	between	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
and	and	O
convulsive	convulsive	B-Disease
seizures	seizures	B-Disease
after	after	O
cardiac	cardiac	O
surgery	surgery	O
:	:	O
a	a	O
multivariate	multivariate	O
analysis	analysis	O
in	in	O
11	11	O
529	529	O
patients	patients	O
.	.	O

Because	because	O
of	of	O
a	a	O
lack	lack	O
of	of	O
contemporary	contemporary	O
data	data	O
regarding	regarding	O
seizures	seizures	B-Disease
after	after	O
cardiac	cardiac	O
surgery	surgery	O
,	,	O
we	we	O
undertook	undertook	O
a	a	O
retrospective	retrospective	O
analysis	analysis	O
of	of	O
prospectively	prospectively	O
collected	collected	O
data	data	O
from	from	O
11	11	O
529	529	O
patients	patients	O
in	in	O
whom	whom	O
cardiopulmonary	cardiopulmonary	O
bypass	bypass	O
was	was	O
used	used	O
from	from	O
January	january	O
2004	2004	O
to	to	O
December	december	O
2010	2010	O
.	.	O

A	a	O
convulsive	convulsive	B-Disease
seizure	seizure	B-Disease
was	was	O
defined	defined	O
as	as	O
a	a	O
transient	transient	O
episode	episode	O
of	of	O
disturbed	disturbed	O
brain	brain	O
function	function	O
characterised	characterised	O
by	by	O
abnormal	abnormal	O
involuntary	involuntary	O
motor	motor	O
movements	movements	O
.	.	O

Multivariate	multivariate	O
regression	regression	O
analysis	analysis	O
was	was	O
performed	performed	O
to	to	O
identify	identify	O
independent	independent	O
predictors	predictors	O
of	of	O
postoperative	postoperative	O
seizures	seizures	B-Disease
.	.	O

A	a	O
total	total	O
of	of	O
100	100	O
(	(	O
0.9	0.9	O
%	%	O
)	)	O
patients	patients	O
developed	developed	O
postoperative	postoperative	O
convulsive	convulsive	B-Disease
seizures	seizures	B-Disease
.	.	O

Generalised	generalised	O
and	and	O
focal	focal	O
seizures	seizures	B-Disease
were	were	O
identified	identified	O
in	in	O
68	68	O
and	and	O
32	32	O
patients	patients	O
,	,	O
respectively	respectively	O
.	.	O

The	the	O
median	median	O
(	(	O
IQR	iqr	O
[	[	O
range	range	O
]	]	O
)	)	O
time	time	O
after	after	O
surgery	surgery	O
when	when	O
the	the	O
seizure	seizure	B-Disease
occurred	occurred	O
was	was	O
7	7	O
(	(	O
6	6	O
-	-	O
12	12	O
[	[	O
1	1	O
-	-	O
216	216	O
]	]	O
)	)	O
h	h	B-Chemical
and	and	O
8	8	O
(	(	O
6	6	O
-	-	O
11	11	O
[	[	O
4	4	O
-	-	O
18	18	O
]	]	O
)	)	O
h	h	B-Chemical
,	,	O
respectively	respectively	O
.	.	O

Epileptiform	epileptiform	O
findings	findings	O
on	on	O
electroencephalography	electroencephalography	O
were	were	O
seen	seen	O
in	in	O
19	19	O
patients	patients	O
.	.	O

Independent	independent	O
predictors	predictors	O
of	of	O
postoperative	postoperative	O
seizures	seizures	B-Disease
included	included	O
age	age	O
,	,	O
female	female	O
sex	sex	O
,	,	O
redo	redo	O
cardiac	cardiac	O
surgery	surgery	O
,	,	O
calcification	calcification	B-Disease
of	of	O
ascending	ascending	O
aorta	aorta	O
,	,	O
congestive	congestive	B-Disease
heart	heart	B-Disease
failure	failure	I-Disease
,	,	O
deep	deep	O
hypothermic	hypothermic	O
circulatory	circulatory	O
arrest	arrest	O
,	,	O
duration	duration	O
of	of	O
aortic	aortic	O
cross-clamp	cross-clamp	O
and	and	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
.	.	O

When	when	O
tested	tested	O
in	in	O
a	a	O
multivariate	multivariate	O
regression	regression	O
analysis	analysis	O
,	,	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
was	was	O
a	a	O
strong	strong	O
independent	independent	O
predictor	predictor	O
of	of	O
seizures	seizures	B-Disease
(	(	O
OR	or	O
14.3	14.3	O
,	,	O
95	95	O
%	%	O
CI	ci	O
5.5	5.5	O
-	-	O
36.7	36.7	O
;	;	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

Patients	patients	O
with	with	O
convulsive	convulsive	B-Disease
seizures	seizures	B-Disease
had	had	O
2.5	2.5	O
times	times	O
higher	higher	O
in-hospital	in-hospital	O
mortality	mortality	O
rates	rates	O
and	and	O
twice	twice	O
the	the	O
length	length	O
of	of	O
hospital	hospital	O
stay	stay	O
compared	compared	O
with	with	O
patients	patients	O
without	without	O
convulsive	convulsive	B-Disease
seizures	seizures	B-Disease
.	.	O

Mean	mean	O
(	(	O
IQR	iqr	O
[	[	O
range	range	O
]	]	O
)	)	O
length	length	O
of	of	O
stay	stay	O
in	in	O
the	the	O
intensive	intensive	O
care	care	O
unit	unit	O
was	was	O
115	115	O
(	(	O
49	49	O
-	-	O
228	228	O
[	[	O
32	32	O
-	-	O
481	481	O
]	]	O
)	)	O
h	h	B-Chemical
in	in	O
patients	patients	O
with	with	O
convulsive	convulsive	B-Disease
seizures	seizures	B-Disease
compared	compared	O
with	with	O
26	26	O
(	(	O
22	22	O
-	-	O
69	69	O
[	[	O
14	14	O
-	-	O
1080	1080	O
]	]	O
)	)	O
h	h	B-Chemical
in	in	O
patients	patients	O
without	without	O
seizures	seizures	B-Disease
(	(	O
p	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

Convulsive	convulsive	B-Disease
seizures	seizures	B-Disease
are	are	O
a	a	O
serious	serious	O
postoperative	postoperative	B-Disease
complication	complication	I-Disease
after	after	O
cardiac	cardiac	O
surgery	surgery	O
.	.	O

As	as	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
is	is	O
the	the	O
only	only	O
modifiable	modifiable	O
factor	factor	O
,	,	O
its	its	O
administration	administration	O
,	,	O
particularly	particularly	O
in	in	O
doses	doses	O
exceeding	exceeding	O
80	80	O
mg.kg(-1	mg.kg(-1	O
)	)	O
,	,	O
should	should	O
be	be	O
weighed	weighed	O
against	against	O
the	the	O
risk	risk	O
of	of	O
postoperative	postoperative	O
seizures	seizures	B-Disease
.	.	O

Dysfunctional	dysfunctional	O
overnight	overnight	O
memory	memory	O
consolidation	consolidation	O
in	in	O
ecstasy	ecstasy	B-Chemical
users	users	O
.	.	O

Sleep	sleep	O
plays	plays	O
an	an	O
important	important	O
role	role	O
in	in	O
the	the	O
consolidation	consolidation	O
and	and	O
integration	integration	O
of	of	O
memory	memory	O
in	in	O
a	a	O
process	process	O
called	called	O
overnight	overnight	O
memory	memory	O
consolidation	consolidation	O
.	.	O

Previous	previous	O
studies	studies	O
indicate	indicate	O
that	that	O
ecstasy	ecstasy	B-Chemical
users	users	O
have	have	O
marked	marked	O
and	and	O
persistent	persistent	O
neurocognitive	neurocognitive	O
and	and	O
sleep-related	sleep-related	O
impairments	impairments	O
.	.	O

We	we	O
extend	extend	O
past	past	O
research	research	O
by	by	O
examining	examining	O
overnight	overnight	O
memory	memory	O
consolidation	consolidation	O
among	among	O
regular	regular	O
ecstasy	ecstasy	B-Chemical
users	users	O
(	(	O
n=12	n=12	O
)	)	O
and	and	O
drug	drug	O
naive	naive	O
healthy	healthy	O
controls	controls	O
(	(	O
n=26	n=26	O
)	)	O
.	.	O

Memory	memory	O
recall	recall	O
of	of	O
word	word	O
pairs	pairs	O
was	was	O
evaluated	evaluated	O
before	before	O
and	and	O
after	after	O
a	a	O
period	period	O
of	of	O
sleep	sleep	O
,	,	O
with	with	O
and	and	O
without	without	O
interference	interference	O
prior	prior	O
to	to	O
testing	testing	O
.	.	O

In	in	O
addition	addition	O
,	,	O
we	we	O
assessed	assessed	O
neurocognitive	neurocognitive	O
performances	performances	O
across	across	O
tasks	tasks	O
of	of	O
learning	learning	O
,	,	O
memory	memory	O
and	and	O
executive	executive	O
functioning	functioning	O
.	.	O

Ecstasy	ecstasy	B-Chemical
users	users	O
demonstrated	demonstrated	O
impaired	impaired	O
overnight	overnight	O
memory	memory	O
consolidation	consolidation	O
,	,	O
a	a	O
finding	finding	O
that	that	O
was	was	O
more	more	O
pronounced	pronounced	O
following	following	O
associative	associative	O
interference	interference	O
.	.	O

Additionally	additionally	O
,	,	O
ecstasy	ecstasy	B-Chemical
users	users	O
demonstrated	demonstrated	O
impairments	impairments	O
on	on	O
tasks	tasks	O
recruiting	recruiting	O
frontostriatal	frontostriatal	O
and	and	O
hippocampal	hippocampal	O
neural	neural	O
circuitry	circuitry	O
,	,	O
in	in	O
the	the	O
domains	domains	O
of	of	O
proactive	proactive	O
interference	interference	O
memory	memory	O
,	,	O
long-term	long-term	O
memory	memory	O
,	,	O
encoding	encoding	O
,	,	O
working	working	O
memory	memory	O
and	and	O
complex	complex	O
planning	planning	O
.	.	O

We	we	O
suggest	suggest	O
that	that	O
ecstasy-associated	ecstasy-associated	O
dysfunction	dysfunction	O
in	in	O
fronto-temporal	fronto-temporal	O
circuitry	circuitry	O
may	may	O
underlie	underlie	O
overnight	overnight	O
consolidation	consolidation	O
memory	memory	O
impairments	impairments	O
in	in	O
regular	regular	O
ecstasy	ecstasy	B-Chemical
users	users	O
.	.	O

Normoammonemic	normoammonemic	O
encephalopathy	encephalopathy	B-Disease
:	:	O
solely	solely	O
valproate	valproate	B-Chemical
induced	induced	O
or	or	O
multiple	multiple	O
mechanisms?A	mechanisms?a	O
77-year-old	77-year-old	O
woman	woman	O
presented	presented	O
with	with	O
subacute	subacute	O
onset	onset	O
progressive	progressive	O
confusion	confusion	B-Disease
,	,	O
aggression	aggression	B-Disease
,	,	O
auditory	auditory	O
hallucinations	hallucinations	B-Disease
and	and	O
delusions	delusions	O
.	.	O

In	in	O
the	the	O
preceding	preceding	O
months	months	O
,	,	O
the	the	O
patient	patient	O
had	had	O
a	a	O
number	number	O
of	of	O
admissions	admissions	O
with	with	O
transient	transient	O
unilateral	unilateral	O
hemiparesis	hemiparesis	O
with	with	O
facial	facial	O
droop	droop	O
,	,	O
and	and	O
had	had	O
been	been	O
started	started	O
on	on	O
valproate	valproate	B-Chemical
for	for	O
presumed	presumed	O
hemiplegic	hemiplegic	O
migraine	migraine	B-Disease
.	.	O

Valproate	valproate	B-Chemical
was	was	O
withdrawn	withdrawn	O
soon	soon	O
after	after	O
admission	admission	O
and	and	O
her	her	O
cognitive	cognitive	O
abilities	abilities	O
have	have	O
gradually	gradually	O
improved	improved	O
over	over	O
3	3	O
months	months	O
of	of	O
follow-up	follow-up	O
.	.	O

Valproate	valproate	B-Chemical
levels	levels	O
taken	taken	O
prior	prior	O
to	to	O
withdrawal	withdrawal	O
were	were	O
subtherapeutic	subtherapeutic	O
and	and	O
the	the	O
patient	patient	O
was	was	O
normoammonaemic	normoammonaemic	O
.	.	O

EEG	eeg	O
undertaken	undertaken	O
during	during	O
inpatient	inpatient	O
stay	stay	O
showed	showed	O
changes	changes	O
consistent	consistent	O
with	with	O
encephalopathy	encephalopathy	B-Disease
,	,	O
and	and	O
low	low	O
titre	titre	O
N-methyl-D-aspartate	n-methyl-d-aspartate	O
(	(	O
NMDA	nmda	B-Chemical
)	)	O
receptor	receptor	O
antibodies	antibodies	O
were	were	O
present	present	O
in	in	O
this	this	O
patient	patient	O
.	.	O

The	the	O
possible	possible	O
aetiologies	aetiologies	O
of	of	O
valproate-induced	valproate-induced	O
encephalopathy	encephalopathy	B-Disease
and	and	O
NMDA	nmda	B-Chemical
receptor-associated	receptor-associated	O
encephalitis	encephalitis	O
present	present	O
a	a	O
diagnostic	diagnostic	O
dilemma	dilemma	O
.	.	O

We	we	O
present	present	O
a	a	O
putative	putative	O
combinatorial	combinatorial	O
hypothesis	hypothesis	O
to	to	O
explain	explain	O
this	this	O
patient	patient	O
's	's	O
symptoms	symptoms	O
.	.	O

Cerebellar	cerebellar	O
and	and	O
oculomotor	oculomotor	O
dysfunction	dysfunction	O
induced	induced	O
by	by	O
rapid	rapid	O
infusion	infusion	O
of	of	O
pethidine	pethidine	B-Chemical
.	.	O

Pethidine	pethidine	B-Chemical
is	is	O
an	an	O
opioid	opioid	O
that	that	O
gains	gains	O
its	its	O
popularity	popularity	O
for	for	O
the	the	O
effective	effective	O
pain	pain	B-Disease
control	control	O
through	through	O
acting	acting	O
on	on	O
the	the	O
opioid-receptors	opioid-receptors	O
.	.	O

However	however	O
,	,	O
rapid	rapid	O
pain	pain	B-Disease
relief	relief	O
sometimes	sometimes	O
brings	brings	O
about	about	O
unfavourable	unfavourable	O
side	side	O
effects	effects	O
that	that	O
largely	largely	O
limit	limit	O
its	its	O
clinical	clinical	O
utility	utility	O
.	.	O

Common	common	O
side	side	O
effects	effects	O
include	include	O
nausea	nausea	B-Disease
,	,	O
vomiting	vomiting	B-Disease
and	and	O
hypotension	hypotension	B-Disease
.	.	O

In	in	O
patients	patients	O
with	with	O
impaired	impaired	O
renal	renal	O
and	and	O
liver	liver	O
function	function	O
,	,	O
and	and	O
those	those	O
who	who	O
need	need	O
long-term	long-term	O
pain	pain	B-Disease
control	control	O
,	,	O
pethidine	pethidine	B-Chemical
may	may	O
cause	cause	O
excitatory	excitatory	O
central	central	O
nervous	nervous	O
system	system	O
(	(	O
CNS	cns	O
)	)	O
effects	effects	O
through	through	O
its	its	O
neurotoxic	neurotoxic	B-Disease
metabolite	metabolite	O
,	,	O
norpethidine	norpethidine	O
,	,	O
resulting	resulting	O
in	in	O
irritability	irritability	B-Disease
and	and	O
seizure	seizure	B-Disease
attack	attack	O
.	.	O

On	on	O
the	the	O
contrary	contrary	O
,	,	O
though	though	O
not	not	O
clinically	clinically	O
apparent	apparent	O
,	,	O
pethidine	pethidine	B-Chemical
potentially	potentially	O
causes	causes	O
inhibitory	inhibitory	O
impacts	impacts	O
on	on	O
the	the	O
CNS	cns	O
and	and	O
impairs	impairs	O
normal	normal	O
cerebellar	cerebellar	O
and	and	O
oculomotor	oculomotor	O
function	function	O
in	in	O
the	the	O
short	short	O
term	term	O
.	.	O

In	in	O
this	this	O
case	case	O
report	report	O
,	,	O
we	we	O
highlight	highlight	O
opioid	opioid	O
's	's	O
inhibitory	inhibitory	O
side	side	O
effects	effects	O
on	on	O
the	the	O
cerebellar	cerebellar	O
structure	structure	O
that	that	O
causes	causes	O
dysmetria	dysmetria	O
,	,	O
dysarthria	dysarthria	O
,	,	O
reduced	reduced	O
smooth	smooth	O
pursuit	pursuit	O
gain	gain	O
and	and	O
decreased	decreased	O
saccadic	saccadic	O
velocity	velocity	O
.	.	O

Baboon	baboon	O
syndrome	syndrome	O
induced	induced	O
by	by	O
ketoconazole	ketoconazole	B-Chemical
.	.	O

A	a	O
27-year-old	27-year-old	O
male	male	O
patient	patient	O
presented	presented	O
with	with	O
a	a	O
maculopapular	maculopapular	O
eruption	eruption	O
on	on	O
the	the	O
flexural	flexural	O
areas	areas	O
and	and	O
buttocks	buttocks	O
after	after	O
using	using	O
oral	oral	O
ketoconazole	ketoconazole	B-Chemical
.	.	O

The	the	O
patient	patient	O
was	was	O
diagnosed	diagnosed	O
with	with	O
drug-induced	drug-induced	O
baboon	baboon	O
syndrome	syndrome	O
based	based	O
on	on	O
his	his	O
history	history	O
,	,	O
which	which	O
included	included	O
prior	prior	O
sensitivity	sensitivity	O
to	to	O
topical	topical	O
ketoconazole	ketoconazole	B-Chemical
,	,	O
a	a	O
physical	physical	O
examination	examination	O
,	,	O
and	and	O
histopathological	histopathological	O
findings	findings	O
.	.	O

Baboon	baboon	O
syndrome	syndrome	O
is	is	O
a	a	O
drug-	drug-	O
or	or	O
contact	contact	O
allergen-related	allergen-related	O
maculopapular	maculopapular	O
eruption	eruption	O
that	that	O
typically	typically	O
involves	involves	O
the	the	O
flexural	flexural	O
and	and	O
gluteal	gluteal	O
areas	areas	O
.	.	O

To	to	O
the	the	O
best	best	O
of	of	O
our	our	O
knowledge	knowledge	O
,	,	O
this	this	O
is	is	O
the	the	O
first	first	O
reported	reported	O
case	case	O
of	of	O
ketoconazole-induced	ketoconazole-induced	O
baboon	baboon	O
syndrome	syndrome	O
in	in	O
the	the	O
English	english	O
literature	literature	O
.	.	O

A	a	O
Case	case	O
of	of	O
Sudden	sudden	O
Cardiac	cardiac	O
Death	death	B-Disease
due	due	O
to	to	O
Pilsicainide-Induced	pilsicainide-induced	O
Torsades	torsades	B-Disease
de	de	I-Disease
Pointes	pointes	I-Disease
.	.	O

An	an	O
84-year-old	84-year-old	O
male	male	O
received	received	O
oral	oral	O
pilsicainide	pilsicainide	O
,	,	O
a	a	O
pure	pure	O
sodium	sodium	B-Chemical
channel	channel	O
blocker	blocker	O
with	with	O
slow	slow	O
recovery	recovery	O
kinetics	kinetics	O
,	,	O
to	to	O
convert	convert	O
his	his	O
paroxysmal	paroxysmal	B-Disease
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
to	to	O
a	a	O
sinus	sinus	O
rhythm	rhythm	O
;	;	O
the	the	O
patient	patient	O
developed	developed	O
sudden	sudden	O
cardiac	cardiac	O
death	death	B-Disease
two	two	O
days	days	O
later	later	O
.	.	O

The	the	O
Holter	holter	O
electrocardiogram	electrocardiogram	O
,	,	O
which	which	O
was	was	O
worn	worn	O
by	by	O
chance	chance	O
,	,	O
revealed	revealed	O
torsade	torsade	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
with	with	O
gradually	gradually	O
prolonged	prolonged	O
QT	qt	O
intervals	intervals	O
.	.	O

This	this	O
drug	drug	O
is	is	O
rapidly	rapidly	O
absorbed	absorbed	O
from	from	O
the	the	O
gastrointestinal	gastrointestinal	O
tract	tract	O
,	,	O
and	and	O
most	most	O
of	of	O
it	it	O
is	is	O
excreted	excreted	O
from	from	O
the	the	O
kidney	kidney	O
.	.	O

Although	although	O
the	the	O
patient	patient	O
's	's	O
renal	renal	O
function	function	O
was	was	O
not	not	O
highly	highly	O
impaired	impaired	O
and	and	O
the	the	O
dose	dose	O
of	of	O
pilsicainide	pilsicainide	O
was	was	O
low	low	O
,	,	O
the	the	O
plasma	plasma	O
concentration	concentration	O
of	of	O
pilsicainide	pilsicainide	O
may	may	O
have	have	O
been	been	O
high	high	O
,	,	O
which	which	O
can	can	O
produce	produce	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
in	in	O
the	the	O
octogenarian	octogenarian	O
.	.	O

Although	although	O
the	the	O
oral	oral	O
administration	administration	O
of	of	O
class	class	O
IC	ic	O
drugs	drugs	O
,	,	O
including	including	O
pilsicainide	pilsicainide	O
,	,	O
is	is	O
effective	effective	O
to	to	O
terminate	terminate	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
,	,	O
careful	careful	O
consideration	consideration	O
must	must	O
be	be	O
taken	taken	O
before	before	O
giving	giving	O
these	these	O
drugs	drugs	O
to	to	O
octogenarians	octogenarians	O
.	.	O

All-trans	all-trans	O
retinoic	retinoic	O
acid-induced	acid-induced	O
inflammatory	inflammatory	O
myositis	myositis	O
in	in	O
a	a	O
patient	patient	O
with	with	O
acute	acute	O
promyelocytic	promyelocytic	O
leukemia	leukemia	O
.	.	O

All-trans	all-trans	O
retinoic	retinoic	O
acid	acid	O
(	(	O
ATRA	atra	O
)	)	O
,	,	O
a	a	O
component	component	O
of	of	O
standard	standard	O
therapy	therapy	O
for	for	O
acute	acute	O
promyelocytic	promyelocytic	O
leukemia	leukemia	O
(	(	O
APL	apl	O
)	)	O
,	,	O
is	is	O
associated	associated	O
with	with	O
potentially	potentially	O
serious	serious	O
but	but	O
treatable	treatable	O
adverse	adverse	O
effects	effects	O
involving	involving	O
numerous	numerous	O
organ	organ	O
systems	systems	O
,	,	O
including	including	O
rare	rare	O
skeletal	skeletal	O
muscle	muscle	O
involvement	involvement	O
.	.	O

Only	only	O
a	a	O
handful	handful	O
of	of	O
cases	cases	O
of	of	O
ATRA-induced	atra-induced	O
myositis	myositis	O
in	in	O
children	children	O
have	have	O
been	been	O
reported	reported	O
,	,	O
and	and	O
none	none	O
in	in	O
the	the	O
radiology	radiology	O
literature	literature	O
.	.	O

We	we	O
present	present	O
such	such	O
a	a	O
case	case	O
in	in	O
a	a	O
15-year-old	15-year-old	O
boy	boy	O
with	with	O
APL	apl	O
,	,	O
where	where	O
recognition	recognition	O
of	of	O
imaging	imaging	O
findings	findings	O
played	played	O
a	a	O
crucial	crucial	O
role	role	O
in	in	O
making	making	O
the	the	O
diagnosis	diagnosis	O
and	and	O
facilitated	facilitated	O
prompt	prompt	O
,	,	O
effective	effective	O
treatment	treatment	O
.	.	O

Tolerability	tolerability	O
of	of	O
lomustine	lomustine	O
in	in	O
combination	combination	O
with	with	O
cyclophosphamide	cyclophosphamide	B-Chemical
in	in	O
dogs	dogs	O
with	with	O
lymphoma	lymphoma	O
.	.	O

This	this	O
retrospective	retrospective	O
study	study	O
describes	describes	O
toxicity	toxicity	B-Disease
associated	associated	O
with	with	O
a	a	O
protocol	protocol	O
of	of	O
lomustine	lomustine	O
(	(	O
CCNU	ccnu	O
)	)	O
and	and	O
cyclophosphamide	cyclophosphamide	B-Chemical
(	(	O
CTX	ctx	O
)	)	O
in	in	O
dogs	dogs	O
with	with	O
lymphoma	lymphoma	O
.	.	O

CCNU	ccnu	O
was	was	O
administered	administered	O
per	per	O
os	os	O
(	(	O
PO	po	O
)	)	O
at	at	O
a	a	O
targeted	targeted	O
dosage	dosage	O
of	of	O
60	60	O
mg/m(2	mg/m(2	O
)	)	O
body	body	O
surface	surface	O
area	area	O
on	on	O
day	day	O
0	0	O
,	,	O
CTX	ctx	O
was	was	O
administered	administered	O
PO	po	O
at	at	O
a	a	O
targeted	targeted	O
dosage	dosage	O
of	of	O
250	250	O
mg/m(2	mg/m(2	O
)	)	O
divided	divided	O
over	over	O
days	days	O
0	0	O
through	through	O
4	4	O
,	,	O
and	and	O
all	all	O
dogs	dogs	O
received	received	O
prophylactic	prophylactic	O
antibiotics	antibiotics	O
.	.	O

Ninety	ninety	O
treatments	treatments	O
were	were	O
given	given	O
to	to	O
the	the	O
57	57	O
dogs	dogs	O
included	included	O
in	in	O
the	the	O
study	study	O
.	.	O

Neutropenia	neutropenia	B-Disease
was	was	O
the	the	O
principal	principal	O
toxic	toxic	O
effect	effect	O
,	,	O
and	and	O
the	the	O
overall	overall	O
frequency	frequency	O
of	of	O
grade	grade	O
4	4	O
neutropenia	neutropenia	B-Disease
after	after	O
the	the	O
first	first	O
treatment	treatment	O
of	of	O
CCNU/CTX	ccnu/ctx	O
was	was	O
30	30	O
%	%	O
(	(	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
,	,	O
19	19	O
-	-	O
43	43	O
%	%	O
)	)	O
.	.	O

The	the	O
mean	mean	O
body	body	B-Disease
weight	weight	I-Disease
of	of	O
dogs	dogs	O
with	with	O
grade	grade	O
4	4	O
neutropenia	neutropenia	B-Disease
(	(	O
19.7	19.7	O
kg	kg	O
+	+	O
13.4	13.4	O
kg	kg	O
)	)	O
was	was	O
significantly	significantly	O
less	less	O
than	than	O
the	the	O
mean	mean	O
body	body	B-Disease
weight	weight	I-Disease
of	of	O
dogs	dogs	O
that	that	O
did	did	O
not	not	O
develop	develop	O
grade	grade	O
4	4	O
neutropenia	neutropenia	B-Disease
(	(	O
31.7	31.7	O
kg	kg	O
+	+	O
12.4	12.4	O
kg	kg	O
;	;	O
P	p	O
=	=	O
.005	.005	O
)	)	O
.	.	O

One	one	O
dog	dog	O
(	(	O
3	3	O
%	%	O
)	)	O
developed	developed	O
hematologic	hematologic	O
changes	changes	O
suggestive	suggestive	O
of	of	O
hepatotoxicity	hepatotoxicity	B-Disease
.	.	O

No	no	O
dogs	dogs	O
had	had	O
evidence	evidence	O
of	of	O
either	either	O
renal	renal	B-Disease
toxicity	toxicity	B-Disease
or	or	O
hemorrhagic	hemorrhagic	B-Disease
cystitis	cystitis	B-Disease
.	.	O

Adverse	adverse	O
gastrointestinal	gastrointestinal	O
effects	effects	O
were	were	O
uncommon	uncommon	O
.	.	O

On	on	O
the	the	O
basis	basis	O
of	of	O
the	the	O
findings	findings	O
reported	reported	O
herein	herein	O
,	,	O
a	a	O
dose	dose	O
of	of	O
60	60	O
mg/m(2	mg/m(2	O
)	)	O
of	of	O
CCNU	ccnu	O
combined	combined	O
with	with	O
250	250	O
mg/m(2	mg/m(2	O
)	)	O
of	of	O
CTX	ctx	O
(	(	O
divided	divided	O
over	over	O
5	5	O
days	days	O
)	)	O
q	q	O
4	4	O
wk	wk	O
is	is	O
tolerable	tolerable	O
in	in	O
tumor-bearing	tumor-bearing	O
dogs	dogs	O
.	.	O

Nelarabine	nelarabine	B-Chemical
neurotoxicity	neurotoxicity	B-Disease
with	with	O
concurrent	concurrent	O
intrathecal	intrathecal	O
chemotherapy	chemotherapy	O
:	:	O
Case	case	O
report	report	O
and	and	O
review	review	O
of	of	O
literature	literature	O
.	.	O

Severe	severe	O
nelarabine	nelarabine	B-Chemical
neurotoxicity	neurotoxicity	B-Disease
in	in	O
a	a	O
patient	patient	O
who	who	O
received	received	O
concurrent	concurrent	O
intrathecal	intrathecal	O
(	(	O
IT	it	O
)	)	O
chemotherapy	chemotherapy	O
is	is	O
reported	reported	O
.	.	O

A	a	O
37-year-old	37-year-old	O
Caucasian	caucasian	O
woman	woman	O
with	with	O
a	a	O
history	history	O
of	of	O
T-cell	t-cell	O
lymphoblastic	lymphoblastic	O
lymphoma	lymphoma	O
was	was	O
admitted	admitted	O
for	for	O
relapsed	relapsed	O
disease	disease	O
.	.	O

She	she	O
was	was	O
originally	originally	O
treated	treated	O
with	with	O
induction	induction	O
chemotherapy	chemotherapy	O
followed	followed	O
by	by	O
an	an	O
autologous	autologous	O
transplant	transplant	O
.	.	O

She	she	O
developed	developed	O
relapsed	relapsed	O
disease	disease	O
10	10	O
months	months	O
later	later	O
with	with	O
leukemic	leukemic	O
involvement	involvement	O
.	.	O

She	she	O
was	was	O
re-induced	re-induced	O
with	with	O
nelarabine	nelarabine	B-Chemical
1500	1500	O
mg/m(2	mg/m(2	O
)	)	O
on	on	O
days	days	O
1	1	O
,	,	O
3	3	O
,	,	O
and	and	O
5	5	O
with	with	O
1	1	O
dose	dose	O
of	of	O
IT	it	O
cytarabine	cytarabine	O
100	100	O
mg	mg	O
on	on	O
day	day	O
2	2	O
as	as	O
central	central	O
nervous	nervous	O
system	system	O
(	(	O
CNS	cns	O
)	)	O
prophylaxis	prophylaxis	O
.	.	O

At	at	O
the	the	O
time	time	O
of	of	O
treatment	treatment	O
,	,	O
she	she	O
was	was	O
on	on	O
continuous	continuous	O
renal	renal	O
replacement	replacement	O
therapy	therapy	O
due	due	O
to	to	O
sequelae	sequelae	O
of	of	O
tumor	tumor	B-Disease
lysis	lysis	I-Disease
syndrome	syndrome	I-Disease
(	(	O
TLS	tls	O
)	)	O
.	.	O

She	she	O
tolerated	tolerated	O
therapy	therapy	O
well	well	O
,	,	O
entered	entered	O
a	a	O
complete	complete	O
remission	remission	O
,	,	O
and	and	O
recovered	recovered	O
her	her	O
renal	renal	O
function	function	O
.	.	O

She	she	O
received	received	O
a	a	O
second	second	O
cycle	cycle	O
of	of	O
nelarabine	nelarabine	B-Chemical
without	without	O
additional	additional	O
IT	it	O
prophylaxis	prophylaxis	O
one	one	O
month	month	O
later	later	O
.	.	O

A	a	O
week	week	O
after	after	O
this	this	O
second	second	O
cycle	cycle	O
,	,	O
she	she	O
noted	noted	O
numbness	numbness	O
in	in	O
her	her	O
lower	lower	O
extremities	extremities	O
.	.	O

Predominantly	predominantly	O
sensory	sensory	O
,	,	O
though	though	O
also	also	O
motor	motor	O
and	and	O
autonomic	autonomic	O
,	,	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
started	started	O
in	in	O
her	her	O
feet	feet	O
,	,	O
ascended	ascended	O
proximally	proximally	O
to	to	O
the	the	O
mid-thoracic	mid-thoracic	O
region	region	O
,	,	O
and	and	O
eventually	eventually	O
included	included	O
her	her	O
distal	distal	O
upper	upper	O
extremities	extremities	O
.	.	O

A	a	O
magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
(	(	O
MRI	mri	O
)	)	O
of	of	O
her	her	O
spine	spine	O
demonstrated	demonstrated	O
changes	changes	O
from	from	O
C2	c2	O
to	to	O
C6	c6	O
consistent	consistent	O
with	with	O
subacute	subacute	B-Disease
combined	combined	I-Disease
degeneration	degeneration	I-Disease
.	.	O

Nelarabine	nelarabine	B-Chemical
was	was	O
felt	felt	O
to	to	O
be	be	O
the	the	O
cause	cause	O
of	of	O
her	her	O
symptoms	symptoms	O
.	.	O

Her	her	O
neuropathy	neuropathy	B-Disease
stabilized	stabilized	O
and	and	O
showed	showed	O
slight	slight	O
improvement	improvement	O
and	and	O
ultimately	ultimately	O
received	received	O
an	an	O
unrelated	unrelated	O
,	,	O
reduced-intensity	reduced-intensity	O
allogeneic	allogeneic	O
transplant	transplant	O
while	while	O
in	in	O
complete	complete	O
remission	remission	O
,	,	O
but	but	O
relapsed	relapsed	O
disease	disease	O
10	10	O
weeks	weeks	O
later	later	O
.	.	O

She	she	O
is	is	O
currently	currently	O
being	being	O
treated	treated	O
with	with	O
best	best	O
supportive	supportive	O
care	care	O
.	.	O

To	to	O
our	our	O
knowledge	knowledge	O
,	,	O
this	this	O
is	is	O
the	the	O
first	first	O
published	published	O
case	case	O
report	report	O
of	of	O
severe	severe	O
neurotoxicity	neurotoxicity	B-Disease
caused	caused	O
by	by	O
nelarabine	nelarabine	B-Chemical
in	in	O
a	a	O
patient	patient	O
who	who	O
received	received	O
concurrent	concurrent	O
IT	it	O
chemotherapy	chemotherapy	O
.	.	O

Valproate-induced	valproate-induced	O
hyperammonemic	hyperammonemic	O
encephalopathy	encephalopathy	B-Disease
in	in	O
a	a	O
renal	renal	O
transplanted	transplanted	O
patient	patient	O
.	.	O

Neurological	neurological	O
complications	complications	O
after	after	O
renal	renal	O
transplantation	transplantation	O
constitute	constitute	O
an	an	O
important	important	O
cause	cause	O
of	of	O
morbidity	morbidity	O
and	and	O
mortality	mortality	O
.	.	O

Their	their	O
differential	differential	O
diagnosis	diagnosis	O
is	is	O
difficult	difficult	O
and	and	O
essential	essential	O
for	for	O
subsequent	subsequent	O
patient	patient	O
's	's	O
management	management	O
.	.	O

Valproate-induced	valproate-induced	O
hyperammonemic	hyperammonemic	O
encephalopathy	encephalopathy	B-Disease
is	is	O
an	an	O
uncommon	uncommon	O
but	but	O
serious	serious	O
effect	effect	O
of	of	O
valproate	valproate	B-Chemical
treatment	treatment	O
.	.	O

Here	here	O
,	,	O
we	we	O
describe	describe	O
the	the	O
case	case	O
of	of	O
a	a	O
15-year-old	15-year-old	O
girl	girl	O
who	who	O
was	was	O
on	on	O
a	a	O
long-term	long-term	O
therapy	therapy	O
with	with	O
valproate	valproate	B-Chemical
due	due	O
to	to	O
epilepsy	epilepsy	B-Disease
and	and	O
revealed	revealed	O
impaired	impaired	O
consciousness	consciousness	O
with	with	O
hyperammonemia	hyperammonemia	B-Disease
12	12	O
days	days	O
after	after	O
renal	renal	O
transplantation	transplantation	O
.	.	O

After	after	O
withdraw	withdraw	O
of	of	O
valproate	valproate	B-Chemical
,	,	O
patients	patients	O
'	'	O
symptoms	symptoms	O
resolved	resolved	O
within	within	O
24	24	O
h.	h.	O
Clinicians	clinicians	O
should	should	O
increase	increase	O
their	their	O
awareness	awareness	O
for	for	O
potential	potential	O
complication	complication	O
of	of	O
valproate	valproate	B-Chemical
,	,	O
especially	especially	O
in	in	O
transplanted	transplanted	O
patients	patients	O
.	.	O

Necrotising	necrotising	O
fasciitis	fasciitis	O
after	after	O
bortezomib	bortezomib	O
and	and	O
dexamethasone-containing	dexamethasone-containing	O
regimen	regimen	O
in	in	O
an	an	O
elderly	elderly	O
patient	patient	O
of	of	O
Waldenstrom	waldenstrom	O
macroglobulinaemia	macroglobulinaemia	O
.	.	O

Bortezomib	bortezomib	O
and	and	O
high-dose	high-dose	O
dexamethasone-containing	dexamethasone-containing	O
regimens	regimens	O
are	are	O
considered	considered	O
to	to	O
be	be	O
generally	generally	O
tolerable	tolerable	O
with	with	O
few	few	O
severe	severe	O
bacterial	bacterial	B-Disease
infections	infections	B-Disease
in	in	O
patients	patients	O
with	with	O
B-cell	b-cell	O
malignancies	malignancies	B-Disease
.	.	O

However	however	O
,	,	O
information	information	O
is	is	O
limited	limited	O
concerning	concerning	O
the	the	O
safety	safety	O
of	of	O
the	the	O
regimen	regimen	O
in	in	O
elderly	elderly	O
patients	patients	O
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
a	a	O
76-year-old	76-year-old	O
man	man	O
with	with	O
Waldenstrom	waldenstrom	O
macroglobulinaemia	macroglobulinaemia	O
who	who	O
suffered	suffered	O
necrotising	necrotising	O
fasciitis	fasciitis	O
without	without	O
neutropenia	neutropenia	B-Disease
after	after	O
the	the	O
combination	combination	O
treatment	treatment	O
with	with	O
bortezomib	bortezomib	O
,	,	O
high-dose	high-dose	O
dexamethasone	dexamethasone	B-Chemical
and	and	O
rituximab	rituximab	O
.	.	O

Despite	despite	O
immediate	immediate	O
intravenous	intravenous	O
antimicrobial	antimicrobial	O
therapy	therapy	O
,	,	O
he	he	O
succumbed	succumbed	O
23	23	O
h	h	B-Chemical
after	after	O
the	the	O
onset	onset	O
.	.	O

Physicians	physicians	O
should	should	O
recognise	recognise	O
the	the	O
possibility	possibility	O
of	of	O
fatal	fatal	O
bacterial	bacterial	B-Disease
infections	infections	B-Disease
related	related	O
to	to	O
bortezomib	bortezomib	O
plus	plus	O
high-dose	high-dose	O
dexamethasone	dexamethasone	B-Chemical
in	in	O
elderly	elderly	O
patients	patients	O
,	,	O
and	and	O
we	we	O
believe	believe	O
this	this	O
case	case	O
warrants	warrants	O
further	further	O
investigation	investigation	O
.	.	O

An	an	O
integrated	integrated	O
characterization	characterization	O
of	of	O
serological	serological	O
,	,	O
pathological	pathological	O
,	,	O
and	and	O
functional	functional	O
events	events	O
in	in	O
doxorubicin-induced	doxorubicin-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

Many	many	O
efficacious	efficacious	O
cancer	cancer	B-Disease
treatments	treatments	O
cause	cause	O
significant	significant	O
cardiac	cardiac	O
morbidity	morbidity	O
,	,	O
yet	yet	O
biomarkers	biomarkers	O
or	or	O
functional	functional	O
indices	indices	O
of	of	O
early	early	O
damage	damage	O
,	,	O
which	which	O
would	would	O
allow	allow	O
monitoring	monitoring	O
and	and	O
intervention	intervention	O
,	,	O
are	are	O
lacking	lacking	O
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
we	we	O
have	have	O
utilized	utilized	O
a	a	O
rat	rat	O
model	model	O
of	of	O
progressive	progressive	O
doxorubicin	doxorubicin	B-Chemical
(DOX)-induced	(dox)-induced	O
cardiomyopathy	cardiomyopathy	B-Disease
,	,	O
applying	applying	O
multiple	multiple	O
approaches	approaches	O
,	,	O
including	including	O
cardiac	cardiac	O
magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
(	(	O
MRI	mri	O
)	)	O
,	,	O
to	to	O
provide	provide	O
the	the	O
most	most	O
comprehensive	comprehensive	O
characterization	characterization	O
to	to	O
date	date	O
of	of	O
the	the	O
timecourse	timecourse	O
of	of	O
serological	serological	O
,	,	O
pathological	pathological	O
,	,	O
and	and	O
functional	functional	O
events	events	O
underlying	underlying	O
this	this	O
toxicity	toxicity	B-Disease
.	.	O

Hannover	hannover	O
Wistar	wistar	O
rats	rats	O
were	were	O
dosed	dosed	O
with	with	O
1.25	1.25	O
mg/kg	mg/kg	O
DOX	dox	B-Chemical
weekly	weekly	O
for	for	O
8	8	O
weeks	weeks	O
followed	followed	O
by	by	O
a	a	O
4	4	O
week	week	O
off-dosing	off-dosing	O
"	"	O
recovery	recovery	O
"	"	O
period	period	O
.	.	O

Electron	electron	O
microscopy	microscopy	O
of	of	O
the	the	O
myocardium	myocardium	O
revealed	revealed	O
subcellular	subcellular	O
degeneration	degeneration	O
and	and	O
marked	marked	O
mitochondrial	mitochondrial	O
changes	changes	O
after	after	O
a	a	O
single	single	O
dose	dose	O
.	.	O

Histopathological	histopathological	O
analysis	analysis	O
revealed	revealed	O
progressive	progressive	O
cardiomyocyte	cardiomyocyte	O
degeneration	degeneration	O
,	,	O
hypertrophy/cytomegaly	hypertrophy/cytomegaly	O
,	,	O
and	and	O
extensive	extensive	O
vacuolation	vacuolation	O
after	after	O
two	two	O
doses	doses	O
.	.	O

Extensive	extensive	O
replacement	replacement	O
fibrosis	fibrosis	B-Disease
(	(	O
quantified	quantified	O
by	by	O
Sirius	sirius	O
red	red	O
staining	staining	O
)	)	O
developed	developed	O
during	during	O
the	the	O
off-dosing	off-dosing	O
period	period	O
.	.	O

Functional	functional	O
indices	indices	O
assessed	assessed	O
by	by	O
cardiac	cardiac	O
MRI	mri	O
(	(	O
including	including	O
left	left	O
ventricular	ventricular	O
ejection	ejection	O
fraction	fraction	O
(	(	O
LVEF	lvef	O
)	)	O
,	,	O
cardiac	cardiac	O
output	output	O
,	,	O
and	and	O
E/A	e/a	O
ratio	ratio	O
)	)	O
declined	declined	O
progressively	progressively	O
,	,	O
reaching	reaching	O
statistical	statistical	O
significance	significance	O
after	after	O
two	two	O
doses	doses	O
and	and	O
culminating	culminating	O
in	in	O
"	"	O
clinical	clinical	O
"	"	O
LV	lv	O
dysfunction	dysfunction	O
by	by	O
12	12	O
weeks	weeks	O
.	.	O

Significant	significant	O
increases	increases	O
in	in	O
peak	peak	O
myocardial	myocardial	O
contrast	contrast	O
enhancement	enhancement	O
and	and	O
serological	serological	O
cardiac	cardiac	O
troponin	troponin	B-Chemical
I	i	I-Chemical
(	(	O
cTnI	ctni	O
)	)	O
emerged	emerged	O
after	after	O
eight	eight	O
doses	doses	O
,	,	O
importantly	importantly	O
preceding	preceding	O
the	the	O
LVEF	lvef	O
decline	decline	O
to	to	O
<	<	O
50	50	O
%	%	O
.	.	O

Troponin	troponin	B-Chemical
I	i	I-Chemical
levels	levels	O
positively	positively	O
correlated	correlated	O
with	with	O
delayed	delayed	O
and	and	O
peak	peak	O
gadolinium	gadolinium	O
contrast	contrast	O
enhancement	enhancement	O
,	,	O
histopathological	histopathological	O
grading	grading	O
,	,	O
and	and	O
diastolic	diastolic	O
dysfunction	dysfunction	O
.	.	O

In	in	O
summary	summary	O
,	,	O
subcellular	subcellular	O
cardiomyocyte	cardiomyocyte	O
degeneration	degeneration	O
was	was	O
the	the	O
earliest	earliest	O
marker	marker	O
,	,	O
followed	followed	O
by	by	O
progressive	progressive	O
functional	functional	O
decline	decline	O
and	and	O
histopathological	histopathological	O
manifestations	manifestations	O
.	.	O

Myocardial	myocardial	O
contrast	contrast	O
enhancement	enhancement	O
and	and	O
elevations	elevations	O
in	in	O
cTnI	ctni	O
occurred	occurred	O
later	later	O
.	.	O

However	however	O
,	,	O
all	all	O
indices	indices	O
predated	predated	O
"	"	O
clinical	clinical	O
"	"	O
LV	lv	O
dysfunction	dysfunction	O
and	and	O
thus	thus	O
warrant	warrant	O
further	further	O
evaluation	evaluation	O
as	as	O
predictive	predictive	O
biomarkers	biomarkers	O
.	.	O

Intradermal	intradermal	O
glutamate	glutamate	B-Chemical
and	and	O
capsaicin	capsaicin	B-Chemical
injections	injections	O
:	:	O
intra-	intra-	O
and	and	O
interindividual	interindividual	O
variability	variability	O
of	of	O
provoked	provoked	O
hyperalgesia	hyperalgesia	B-Disease
and	and	O
allodynia	allodynia	O
.	.	O

Intradermal	intradermal	O
injections	injections	O
of	of	O
glutamate	glutamate	B-Chemical
and	and	O
capsaicin	capsaicin	B-Chemical
are	are	O
attractive	attractive	O
to	to	O
use	use	O
in	in	O
human	human	O
experimental	experimental	O
pain	pain	B-Disease
models	models	O
because	because	O
hyperalgesia	hyperalgesia	B-Disease
and	and	O
allodynia	allodynia	O
mimic	mimic	O
isolated	isolated	O
aspects	aspects	O
of	of	O
clinical	clinical	O
pain	pain	B-Disease
disorders	disorders	O
.	.	O

The	the	O
aim	aim	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
the	the	O
reproducibility	reproducibility	O
of	of	O
these	these	O
models	models	O
.	.	O

Twenty	twenty	O
healthy	healthy	O
male	male	O
volunteers	volunteers	O
(	(	O
mean	mean	O
age	age	O
24	24	O
years	years	O
;	;	O
range	range	O
18	18	O
-	-	O
38	38	O
years	years	O
)	)	O
received	received	O
intradermal	intradermal	O
injections	injections	O
of	of	O
glutamate	glutamate	B-Chemical
and	and	O
capsaicin	capsaicin	B-Chemical
in	in	O
the	the	O
volar	volar	O
forearm	forearm	O
.	.	O

Magnitudes	magnitudes	O
of	of	O
secondary	secondary	O
pinprick	pinprick	O
hyperalgesia	hyperalgesia	B-Disease
and	and	O
brush-evoked	brush-evoked	O
allodynia	allodynia	O
were	were	O
investigated	investigated	O
using	using	O
von	von	O
Frey	frey	O
filaments	filaments	O
(	(	O
gauges	gauges	O
10	10	O
,	,	O
15	15	O
,	,	O
60	60	O
and	and	O
100	100	O
g	g	O
)	)	O
and	and	O
brush	brush	O
strokes	strokes	B-Disease
.	.	O

Areas	areas	O
of	of	O
secondary	secondary	B-Disease
hyperalgesia	hyperalgesia	B-Disease
and	and	O
allodynia	allodynia	O
were	were	O
quantified	quantified	O
immediately	immediately	O
after	after	O
injection	injection	O
and	and	O
after	after	O
15	15	O
,	,	O
30	30	O
and	and	O
60	60	O
min	min	O
.	.	O

Two	two	O
identical	identical	O
experiments	experiments	O
separated	separated	O
by	by	O
at	at	O
least	least	O
7	7	O
days	days	O
were	were	O
performed	performed	O
.	.	O

Reproducibility	reproducibility	O
across	across	O
and	and	O
within	within	O
volunteers	volunteers	O
(	(	O
inter-	inter-	O
and	and	O
intra-individual	intra-individual	O
variation	variation	O
,	,	O
respectively	respectively	O
)	)	O
was	was	O
assessed	assessed	O
using	using	O
intraclass	intraclass	O
correlation	correlation	O
coefficient	coefficient	O
(	(	O
ICC	icc	O
)	)	O
and	and	O
coefficient	coefficient	O
of	of	O
variation	variation	O
(	(	O
CV	cv	O
)	)	O
.	.	O

Secondary	secondary	O
pinprick	pinprick	O
hyperalgesia	hyperalgesia	B-Disease
was	was	O
observed	observed	O
as	as	O
a	a	O
marked	marked	O
increase	increase	O
in	in	O
the	the	O
visual	visual	O
analogue	analogue	O
scale	scale	O
(	(	O
VAS	vas	O
)	)	O
response	response	O
to	to	O
von	von	O
Frey	frey	O
gauges	gauges	O
60	60	O
and	and	O
100	100	O
g	g	O
(	(	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
after	after	O
glutamate	glutamate	B-Chemical
injection	injection	O
.	.	O

For	for	O
capsaicin	capsaicin	B-Chemical
,	,	O
secondary	secondary	O
pinprick	pinprick	O
hyperalgesia	hyperalgesia	B-Disease
was	was	O
detected	detected	O
with	with	O
all	all	O
von	von	O
Frey	frey	O
gauges	gauges	O
(	(	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

Glutamate	glutamate	B-Chemical
evoked	evoked	O
reproducible	reproducible	O
VAS	vas	O
response	response	O
to	to	O
all	all	O
von	von	O
Frey	frey	O
gauges	gauges	O
(	(	O
ICC	icc	O
>	>	O
0.60	0.60	O
)	)	O
and	and	O
brush	brush	O
strokes	strokes	B-Disease
(	(	O
ICC	icc	O
>	>	O
0.83	0.83	O
)	)	O
.	.	O

Capsaicin	capsaicin	B-Chemical
injection	injection	O
was	was	O
reproducible	reproducible	O
for	for	O
secondary	secondary	B-Disease
hyperalgesia	hyperalgesia	B-Disease
(	(	O
ICC	icc	O
>	>	O
0.70	0.70	O
)	)	O
and	and	O
allodynia	allodynia	O
(	(	O
ICC	icc	O
>	>	O
0.71	0.71	O
)	)	O
.	.	O

Intra-individual	intra-individual	O
variability	variability	O
was	was	O
generally	generally	O
lower	lower	O
for	for	O
the	the	O
VAS	vas	O
response	response	O
to	to	O
von	von	O
Frey	frey	O
and	and	O
brush	brush	O
compared	compared	O
with	with	O
areas	areas	O
of	of	O
secondary	secondary	B-Disease
hyperalgesia	hyperalgesia	B-Disease
and	and	O
allodynia	allodynia	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
glutamate	glutamate	B-Chemical
and	and	O
capsaicin	capsaicin	B-Chemical
yield	yield	O
reproducible	reproducible	O
hyperalgesic	hyperalgesic	O
and	and	O
allodynic	allodynic	O
responses	responses	O
,	,	O
and	and	O
the	the	O
present	present	O
model	model	O
is	is	O
well	well	O
suited	suited	O
for	for	O
basic	basic	O
research	research	O
,	,	O
as	as	O
well	well	O
as	as	O
for	for	O
assessing	assessing	O
the	the	O
modulation	modulation	O
of	of	O
central	central	O
phenomena	phenomena	O
.	.	O

Ocular-specific	ocular-specific	O
ER	er	O
stress	stress	O
reduction	reduction	O
rescues	rescues	O
glaucoma	glaucoma	B-Disease
in	in	O
murine	murine	O
glucocorticoid-induced	glucocorticoid-induced	O
glaucoma	glaucoma	B-Disease
.	.	O

Administration	administration	O
of	of	O
glucocorticoids	glucocorticoids	O
induces	induces	O
ocular	ocular	B-Disease
hypertension	hypertension	B-Disease
in	in	O
some	some	O
patients	patients	O
.	.	O

If	if	O
untreated	untreated	O
,	,	O
these	these	O
patients	patients	O
can	can	O
develop	develop	O
a	a	O
secondary	secondary	O
glaucoma	glaucoma	B-Disease
that	that	O
resembles	resembles	O
primary	primary	O
open-angle	open-angle	O
glaucoma	glaucoma	B-Disease
(	(	O
POAG	poag	O
)	)	O
.	.	O

The	the	O
underlying	underlying	O
pathology	pathology	O
of	of	O
glucocorticoid-induced	glucocorticoid-induced	O
glaucoma	glaucoma	B-Disease
is	is	O
not	not	O
fully	fully	O
understood	understood	O
,	,	O
due	due	O
in	in	O
part	part	O
to	to	O
lack	lack	O
of	of	O
an	an	O
appropriate	appropriate	O
animal	animal	O
model	model	O
.	.	O

Here	here	O
,	,	O
we	we	O
developed	developed	O
a	a	O
murine	murine	O
model	model	O
of	of	O
glucocorticoid-induced	glucocorticoid-induced	O
glaucoma	glaucoma	B-Disease
that	that	O
exhibits	exhibits	O
glaucoma	glaucoma	B-Disease
features	features	O
that	that	O
are	are	O
observed	observed	O
in	in	O
patients	patients	O
.	.	O

Treatment	treatment	O
of	of	O
WT	wt	O
mice	mice	O
with	with	O
topical	topical	O
ocular	ocular	O
0.1	0.1	O
%	%	O
dexamethasone	dexamethasone	B-Chemical
led	led	O
to	to	O
elevation	elevation	O
of	of	O
intraocular	intraocular	O
pressure	pressure	O
(	(	O
IOP	iop	O
)	)	O
,	,	O
functional	functional	O
and	and	O
structural	structural	O
loss	loss	O
of	of	O
retinal	retinal	O
ganglion	ganglion	O
cells	cells	O
,	,	O
and	and	O
axonal	axonal	O
degeneration	degeneration	O
,	,	O
resembling	resembling	O
glucocorticoid-induced	glucocorticoid-induced	O
glaucoma	glaucoma	B-Disease
in	in	O
human	human	O
patients	patients	O
.	.	O

Furthermore	furthermore	O
,	,	O
dexamethasone-induced	dexamethasone-induced	O
ocular	ocular	B-Disease
hypertension	hypertension	B-Disease
was	was	O
associated	associated	O
with	with	O
chronic	chronic	O
ER	er	O
stress	stress	O
of	of	O
the	the	O
trabecular	trabecular	O
meshwork	meshwork	O
(	(	O
TM	tm	O
)	)	O
.	.	O

Similar	similar	O
to	to	O
patients	patients	O
,	,	O
withdrawal	withdrawal	O
of	of	O
dexamethasone	dexamethasone	B-Chemical
treatment	treatment	O
reduced	reduced	O
elevated	elevated	O
IOP	iop	O
and	and	O
ER	er	O
stress	stress	O
in	in	O
this	this	O
animal	animal	O
model	model	O
.	.	O

Dexamethasone	dexamethasone	B-Chemical
induced	induced	O
the	the	O
transcriptional	transcriptional	O
factor	factor	O
CHOP	chop	O
,	,	O
a	a	O
marker	marker	O
for	for	O
chronic	chronic	O
ER	er	O
stress	stress	O
,	,	O
in	in	O
the	the	O
anterior	anterior	O
segment	segment	O
tissues	tissues	O
,	,	O
and	and	O
Chop	chop	O
deletion	deletion	O
reduced	reduced	O
ER	er	O
stress	stress	O
in	in	O
these	these	O
tissues	tissues	O
and	and	O
prevented	prevented	O
dexamethasone-induced	dexamethasone-induced	O
ocular	ocular	B-Disease
hypertension	hypertension	B-Disease
.	.	O

Furthermore	furthermore	O
,	,	O
reduction	reduction	O
of	of	O
ER	er	O
stress	stress	O
in	in	O
the	the	O
TM	tm	O
with	with	O
sodium	sodium	B-Chemical
4-phenylbutyrate	4-phenylbutyrate	O
prevented	prevented	O
dexamethasone-induced	dexamethasone-induced	O
ocular	ocular	B-Disease
hypertension	hypertension	B-Disease
in	in	O
WT	wt	O
mice	mice	O
.	.	O

Our	our	O
data	data	O
indicate	indicate	O
that	that	O
ER	er	O
stress	stress	O
contributes	contributes	O
to	to	O
glucocorticoid-induced	glucocorticoid-induced	O
ocular	ocular	B-Disease
hypertension	hypertension	B-Disease
and	and	O
suggest	suggest	O
that	that	O
reducing	reducing	O
ER	er	O
stress	stress	O
has	has	O
potential	potential	O
as	as	O
a	a	O
therapeutic	therapeutic	O
strategy	strategy	O
for	for	O
treating	treating	O
glucocorticoid-induced	glucocorticoid-induced	O
glaucoma	glaucoma	B-Disease
.	.	O

Effects	effects	O
of	of	O
ginsenosides	ginsenosides	O
on	on	O
opioid-induced	opioid-induced	O
hyperalgesia	hyperalgesia	B-Disease
in	in	O
mice	mice	O
.	.	O

Opioid-induced	opioid-induced	O
hyperalgesia	hyperalgesia	B-Disease
(	(	O
OIH	oih	O
)	)	O
is	is	O
characterized	characterized	O
by	by	O
nociceptive	nociceptive	O
sensitization	sensitization	O
caused	caused	O
by	by	O
the	the	O
cessation	cessation	O
of	of	O
chronic	chronic	O
opioid	opioid	O
use	use	O
.	.	O

OIH	oih	O
can	can	O
limit	limit	O
the	the	O
clinical	clinical	O
use	use	O
of	of	O
opioid	opioid	O
analgesics	analgesics	O
and	and	O
complicate	complicate	O
withdrawal	withdrawal	O
from	from	O
opioid	opioid	O
addiction	addiction	O
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
we	we	O
investigated	investigated	O
the	the	O
effects	effects	O
of	of	O
Re	re	O
,	,	O
Rg1	rg1	B-Chemical
,	,	O
and	and	O
Rb1	rb1	O
ginsenosides	ginsenosides	O
,	,	O
the	the	O
bioactive	bioactive	O
components	components	O
of	of	O
ginseng	ginseng	O
,	,	O
on	on	O
OIH	oih	O
.	.	O

OIH	oih	O
was	was	O
achieved	achieved	O
in	in	O
mice	mice	O
after	after	O
subcutaneous	subcutaneous	O
administration	administration	O
of	of	O
morphine	morphine	B-Chemical
for	for	O
7	7	O
consecutive	consecutive	O
days	days	O
three	three	O
times	times	O
per	per	O
day	day	O
.	.	O

During	during	O
withdrawal	withdrawal	O
(	(	O
days	days	O
8	8	O
and	and	O
9	9	O
)	)	O
,	,	O
these	these	O
mice	mice	O
were	were	O
administered	administered	O
Re	re	O
,	,	O
Rg1	rg1	B-Chemical
,	,	O
or	or	O
Rb1	rb1	O
intragastrically	intragastrically	O
two	two	O
times	times	O
per	per	O
day	day	O
.	.	O

On	on	O
the	the	O
test	test	O
day	day	O
(	(	O
day	day	O
10	10	O
)	)	O
,	,	O
mice	mice	O
were	were	O
subjected	subjected	O
to	to	O
the	the	O
thermal	thermal	O
sensitivity	sensitivity	O
test	test	O
and	and	O
the	the	O
acetic	acetic	O
acid-induced	acid-induced	O
writhing	writhing	O
test	test	O
.	.	O

Re	re	O
(	(	O
300	300	O
mg/kg	mg/kg	O
)	)	O
inhibited	inhibited	O
OIH	oih	O
in	in	O
both	both	O
the	the	O
thermal	thermal	O
sensitivity	sensitivity	O
test	test	O
and	and	O
the	the	O
acetic	acetic	O
acid-induced	acid-induced	O
writhing	writhing	O
test	test	O
.	.	O

However	however	O
,	,	O
the	the	O
Rg1	rg1	B-Chemical
and	and	O
Rb1	rb1	O
ginsenosides	ginsenosides	O
failed	failed	O
to	to	O
prevent	prevent	O
OIH	oih	O
in	in	O
either	either	O
test	test	O
.	.	O

Furthermore	furthermore	O
,	,	O
Rg1	rg1	B-Chemical
showed	showed	O
a	a	O
tendency	tendency	O
to	to	O
aggravate	aggravate	O
OIH	oih	O
in	in	O
the	the	O
acetic	acetic	O
acid-induced	acid-induced	O
writhing	writhing	O
test	test	O
.	.	O

Our	our	O
data	data	O
suggested	suggested	O
that	that	O
the	the	O
ginsenoside	ginsenoside	B-Chemical
Re	re	I-Chemical
,	,	O
but	but	O
not	not	O
Rg1	rg1	B-Chemical
or	or	O
Rb1	rb1	O
,	,	O
may	may	O
contribute	contribute	O
toward	toward	O
reversal	reversal	O
of	of	O
OIH	oih	O
.	.	O

A	a	O
comparison	comparison	O
of	of	O
severe	severe	O
hemodynamic	hemodynamic	O
disturbances	disturbances	O
between	between	O
dexmedetomidine	dexmedetomidine	O
and	and	O
propofol	propofol	B-Chemical
for	for	O
sedation	sedation	O
in	in	O
neurocritical	neurocritical	O
care	care	O
patients	patients	O
.	.	O

OBJECTIVE	objective	O
:	:	O
Dexmedetomidine	dexmedetomidine	O
and	and	O
propofol	propofol	B-Chemical
are	are	O
commonly	commonly	O
used	used	O
sedatives	sedatives	O
in	in	O
neurocritical	neurocritical	O
care	care	O
as	as	O
they	they	O
allow	allow	O
for	for	O
frequent	frequent	O
neurologic	neurologic	O
examinations	examinations	O
.	.	O

However	however	O
,	,	O
both	both	O
agents	agents	O
are	are	O
associated	associated	O
with	with	O
significant	significant	O
hemodynamic	hemodynamic	O
side	side	O
effects	effects	O
.	.	O

The	the	O
primary	primary	O
objective	objective	O
of	of	O
this	this	O
study	study	O
is	is	O
to	to	O
compare	compare	O
the	the	O
prevalence	prevalence	O
of	of	O
severe	severe	O
hemodynamic	hemodynamic	O
effects	effects	O
in	in	O
neurocritical	neurocritical	O
care	care	O
patients	patients	O
receiving	receiving	O
dexmedetomidine	dexmedetomidine	O
and	and	O
propofol	propofol	B-Chemical
.	.	O

DESIGN	design	O
:	:	O
Multicenter	multicenter	O
,	,	O
retrospective	retrospective	O
,	,	O
propensity-matched	propensity-matched	O
cohort	cohort	O
study	study	O
.	.	O

SETTING	setting	O
:	:	O
Neurocritical	neurocritical	O
care	care	O
units	units	O
at	at	O
two	two	O
academic	academic	O
medical	medical	O
centers	centers	O
with	with	O
dedicated	dedicated	O
neurocritical	neurocritical	O
care	care	O
teams	teams	O
and	and	O
board-certified	board-certified	O
neurointensivists	neurointensivists	O
.	.	O

PATIENTS	patients	O
:	:	O
Neurocritical	neurocritical	O
care	care	O
patients	patients	O
admitted	admitted	O
between	between	O
July	july	O
2009	2009	O
and	and	O
September	september	O
2012	2012	O
were	were	O
evaluated	evaluated	O
and	and	O
then	then	O
matched	matched	O
1:1	1:1	O
based	based	O
on	on	O
propensity	propensity	O
scoring	scoring	O
of	of	O
baseline	baseline	O
characteristics	characteristics	O
.	.	O

INTERVENTIONS	interventions	O
:	:	O
Continuous	continuous	O
sedation	sedation	O
with	with	O
dexmedetomidine	dexmedetomidine	O
or	or	O
propofol	propofol	B-Chemical
.	.	O

MEASUREMENTS	measurements	O
AND	and	O
MAIN	main	O
RESULTS	results	O
:	:	O
A	a	O
total	total	O
of	of	O
342	342	O
patients	patients	O
(	(	O
105	105	O
dexmedetomidine	dexmedetomidine	O
and	and	O
237	237	O
propofol	propofol	B-Chemical
)	)	O
were	were	O
included	included	O
in	in	O
the	the	O
analysis	analysis	O
,	,	O
with	with	O
190	190	O
matched	matched	O
(	(	O
95	95	O
in	in	O
each	each	O
group	group	O
)	)	O
by	by	O
propensity	propensity	O
score	score	O
.	.	O

The	the	O
primary	primary	O
outcome	outcome	O
of	of	O
this	this	O
study	study	O
was	was	O
a	a	O
composite	composite	O
of	of	O
severe	severe	O
hypotension	hypotension	B-Disease
(	(	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
<	<	O
60	60	O
mm	mm	O
Hg	hg	O
)	)	O
and	and	O
bradycardia	bradycardia	B-Disease
(	(	O
heart	heart	O
rate	rate	O
<	<	O
50	50	O
beats/min	beats/min	O
)	)	O
during	during	O
sedative	sedative	O
infusion	infusion	O
.	.	O

No	no	O
difference	difference	O
in	in	O
the	the	O
primary	primary	O
composite	composite	O
outcome	outcome	O
in	in	O
both	both	O
the	the	O
unmatched	unmatched	O
(	(	O
30	30	O
%	%	O
vs	vs	O
30	30	O
%	%	O
,	,	O
p	p	O
=	=	O
0.94	0.94	O
)	)	O
or	or	O
matched	matched	O
cohorts	cohorts	O
(	(	O
28	28	O
%	%	O
vs	vs	O
34	34	O
%	%	O
,	,	O
p	p	O
=	=	O
0.35	0.35	O
)	)	O
could	could	O
be	be	O
found	found	O
.	.	O

When	when	O
analyzed	analyzed	O
separately	separately	O
,	,	O
no	no	O
differences	differences	O
could	could	O
be	be	O
found	found	O
in	in	O
the	the	O
prevalence	prevalence	O
of	of	O
severe	severe	O
hypotension	hypotension	B-Disease
or	or	O
bradycardia	bradycardia	B-Disease
in	in	O
either	either	O
the	the	O
unmatched	unmatched	O
or	or	O
matched	matched	O
cohorts	cohorts	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Severe	severe	O
hypotension	hypotension	B-Disease
and	and	O
bradycardia	bradycardia	B-Disease
occur	occur	O
at	at	O
similar	similar	O
prevalence	prevalence	O
in	in	O
neurocritical	neurocritical	O
care	care	O
patients	patients	O
who	who	O
receive	receive	O
dexmedetomidine	dexmedetomidine	O
or	or	O
propofol	propofol	B-Chemical
.	.	O

Providers	providers	O
should	should	O
similarly	similarly	O
consider	consider	O
the	the	O
likelihood	likelihood	O
of	of	O
hypotension	hypotension	B-Disease
or	or	O
bradycardia	bradycardia	B-Disease
before	before	O
starting	starting	O
either	either	O
sedative	sedative	O
.	.	O

Hydroxytyrosol	hydroxytyrosol	O
ameliorates	ameliorates	O
oxidative	oxidative	O
stress	stress	O
and	and	O
mitochondrial	mitochondrial	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
doxorubicin-induced	doxorubicin-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
in	in	O
rats	rats	O
with	with	O
breast	breast	B-Disease
cancer	cancer	B-Disease
.	.	O

Oxidative	oxidative	O
stress	stress	O
is	is	O
involved	involved	O
in	in	O
several	several	O
processes	processes	O
including	including	O
cancer	cancer	B-Disease
,	,	O
aging	aging	O
and	and	O
cardiovascular	cardiovascular	B-Disease
disease	disease	I-Disease
,	,	O
and	and	O
has	has	O
been	been	O
shown	shown	O
to	to	O
potentiate	potentiate	O
the	the	O
therapeutic	therapeutic	O
effect	effect	O
of	of	O
drugs	drugs	O
such	such	O
as	as	O
doxorubicin	doxorubicin	B-Chemical
.	.	O

Doxorubicin	doxorubicin	B-Chemical
causes	causes	O
significant	significant	O
cardiotoxicity	cardiotoxicity	B-Disease
characterized	characterized	O
by	by	O
marked	marked	O
increases	increases	O
in	in	O
oxidative	oxidative	O
stress	stress	O
and	and	O
mitochondrial	mitochondrial	B-Disease
dysfunction	dysfunction	I-Disease
.	.	O

Herein	herein	O
,	,	O
we	we	O
investigate	investigate	O
whether	whether	O
doxorubicin-associated	doxorubicin-associated	O
chronic	chronic	O
cardiac	cardiac	B-Disease
toxicity	toxicity	B-Disease
can	can	O
be	be	O
ameliorated	ameliorated	O
with	with	O
the	the	O
antioxidant	antioxidant	O
hydroxytyrosol	hydroxytyrosol	O
in	in	O
rats	rats	O
with	with	O
breast	breast	B-Disease
cancer	cancer	B-Disease
.	.	O

Thirty-six	thirty-six	O
rats	rats	O
bearing	bearing	O
breast	breast	O
tumors	tumors	B-Disease
induced	induced	O
chemically	chemically	O
were	were	O
divided	divided	O
into	into	O
4	4	O
groups	groups	O
:	:	O
control	control	O
,	,	O
hydroxytyrosol	hydroxytyrosol	O
(	(	O
0.5mg/kg	0.5mg/kg	O
,	,	O
5days/week	5days/week	O
)	)	O
,	,	O
doxorubicin	doxorubicin	B-Chemical
(	(	O
1mg/kg/week	1mg/kg/week	O
)	)	O
,	,	O
and	and	O
doxorubicin	doxorubicin	B-Chemical
plus	plus	O
hydroxytyrosol	hydroxytyrosol	O
.	.	O

Cardiac	cardiac	O
disturbances	disturbances	O
at	at	O
the	the	O
cellular	cellular	O
and	and	O
mitochondrial	mitochondrial	O
level	level	O
,	,	O
mitochondrial	mitochondrial	O
electron	electron	O
transport	transport	O
chain	chain	O
complexes	complexes	O
I-IV	i-iv	O
and	and	O
apoptosis-inducing	apoptosis-inducing	O
factor	factor	O
,	,	O
and	and	O
oxidative	oxidative	O
stress	stress	O
markers	markers	O
have	have	O
been	been	O
analyzed	analyzed	O
.	.	O

Hydroxytyrosol	hydroxytyrosol	O
improved	improved	O
the	the	O
cardiac	cardiac	O
disturbances	disturbances	O
enhanced	enhanced	O
by	by	O
doxorubicin	doxorubicin	B-Chemical
by	by	O
significantly	significantly	O
reducing	reducing	O
the	the	O
percentage	percentage	O
of	of	O
altered	altered	O
mitochondria	mitochondria	O
and	and	O
oxidative	oxidative	O
damage	damage	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
hydroxytyrosol	hydroxytyrosol	O
improve	improve	O
the	the	O
mitochondrial	mitochondrial	O
electron	electron	O
transport	transport	O
chain	chain	O
.	.	O

This	this	O
study	study	O
demonstrates	demonstrates	O
that	that	O
hydroxytyrosol	hydroxytyrosol	O
protect	protect	O
rat	rat	O
heart	heart	O
damage	damage	O
provoked	provoked	O
by	by	O
doxorubicin	doxorubicin	B-Chemical
decreasing	decreasing	O
oxidative	oxidative	O
damage	damage	O
and	and	O
mitochondrial	mitochondrial	O
alterations	alterations	O
.	.	O

Amiodarone-induced	amiodarone-induced	O
myxoedema	myxoedema	O
coma	coma	B-Disease
.	.	O

A	a	O
62-year-old	62-year-old	O
man	man	O
was	was	O
found	found	O
to	to	O
have	have	O
bradycardia	bradycardia	B-Disease
,	,	O
hypothermia	hypothermia	B-Disease
and	and	O
respiratory	respiratory	B-Disease
failure	failure	I-Disease
3	3	O
weeks	weeks	O
after	after	O
initiation	initiation	O
of	of	O
amiodarone	amiodarone	B-Chemical
therapy	therapy	O
for	for	O
atrial	atrial	B-Disease
fibrillation	fibrillation	I-Disease
.	.	O

Thyroid-stimulating	thyroid-stimulating	O
hormone	hormone	O
was	was	O
found	found	O
to	to	O
be	be	O
168	168	O
uIU/mL	uiu/ml	O
(	(	O
nl	nl	O
.	.	O
0.3	0.3	O
-	-	O
5	5	O
uIU/mL	uiu/ml	O
)	)	O
and	and	O
free	free	O
thyroxine	thyroxine	B-Chemical
(	(	O
FT4	ft4	O
)	)	O
was	was	O
<	<	O
0.2	0.2	O
ng/dL	ng/dl	O
(	(	O
nl	nl	O
.	.	O
0.8	0.8	O
-	-	O
1.8	1.8	O
ng/dL	ng/dl	O
)	)	O
.	.	O

He	he	O
received	received	O
intravenous	intravenous	O
fluids	fluids	O
,	,	O
vasopressor	vasopressor	O
therapy	therapy	O
and	and	O
stress	stress	O
dose	dose	O
steroids	steroids	B-Chemical
;	;	O
he	he	O
was	was	O
intubated	intubated	O
and	and	O
admitted	admitted	O
to	to	O
the	the	O
intensive	intensive	O
care	care	O
unit	unit	O
.	.	O

He	he	O
received	received	O
500	500	O
ug	ug	O
of	of	O
intravenous	intravenous	O
levothyroxine	levothyroxine	O
in	in	O
the	the	O
first	first	O
18	18	O
h	h	B-Chemical
of	of	O
therapy	therapy	O
,	,	O
and	and	O
150	150	O
ug	ug	O
intravenous	intravenous	O
daily	daily	O
thereafter	thereafter	O
.	.	O

Haemodynamic	haemodynamic	O
improvement	improvement	O
,	,	O
along	along	O
with	with	O
complete	complete	O
recovery	recovery	O
of	of	O
mental	mental	O
status	status	O
,	,	O
occurred	occurred	O
after	after	O
48	48	O
h.	h.	O
Twelve	twelve	O
hours	hours	O
after	after	O
the	the	O
initiation	initiation	O
of	of	O
therapy	therapy	O
,	,	O
FT4	ft4	O
was	was	O
0.96	0.96	O
ng/dL.	ng/dl.	O
The	the	O
patient	patient	O
was	was	O
maintained	maintained	O
on	on	O
levothyroxine	levothyroxine	O
175	175	O
(	(	O
g	g	O
POorally	poorally	O
daily	daily	O
.	.	O

A	a	O
thyroid	thyroid	O
ultrasound	ultrasound	O
showed	showed	O
diffuse	diffuse	O
heterogeneity	heterogeneity	O
.	.	O

The	the	O
24	24	O
hour	hour	O
excretion	excretion	O
of	of	O
iodine	iodine	O
was	was	O
3657	3657	O
(	(	O
mcg	mcg	O
(	(	O
25	25	O
-	-	O
756	756	O
(	(	O
mcg	mcg	O
)	)	O
.	.	O

The	the	O
only	only	O
two	two	O
cases	cases	O
of	of	O
amiodarone-induced	amiodarone-induced	O
myxoedema	myxoedema	O
coma	coma	B-Disease
in	in	O
the	the	O
literature	literature	O
report	report	O
patient	patient	O
death	death	B-Disease
despite	despite	O
supportive	supportive	O
therapy	therapy	O
and	and	O
thyroid	thyroid	O
hormone	hormone	O
replacement	replacement	O
.	.	O

This	this	O
case	case	O
represents	represents	O
the	the	O
most	most	O
thoroughly	thoroughly	O
investigated	investigated	O
case	case	O
of	of	O
amiodarone-induced	amiodarone-induced	O
myxoedema	myxoedema	O
coma	coma	B-Disease
with	with	O
a	a	O
history	history	O
significant	significant	O
for	for	O
subclinical	subclinical	O
thyroid	thyroid	O
disease	disease	O
.	.	O

Use	use	O
of	of	O
argatroban	argatroban	B-Chemical
and	and	O
catheter-directed	catheter-directed	O
thrombolysis	thrombolysis	O
with	with	O
alteplase	alteplase	O
in	in	O
an	an	O
oncology	oncology	O
patient	patient	O
with	with	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
with	with	O
thrombosis	thrombosis	B-Disease
.	.	O

PURPOSE	purpose	O
:	:	O
The	the	O
case	case	O
of	of	O
an	an	O
oncology	oncology	O
patient	patient	O
who	who	O
developed	developed	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
with	with	O
thrombosis	thrombosis	B-Disease
(	(	O
HITT	hitt	B-Disease
)	)	O
and	and	O
was	was	O
treated	treated	O
with	with	O
argatroban	argatroban	B-Chemical
plus	plus	O
catheter-directed	catheter-directed	O
thrombolysis	thrombolysis	O
(	(	O
CDT	cdt	O
)	)	O
with	with	O
alteplase	alteplase	O
is	is	O
presented	presented	O
.	.	O

SUMMARY	summary	O
:	:	O
A	a	O
63-year-old	63-year-old	O
Caucasian	caucasian	O
man	man	O
with	with	O
renal	renal	O
amyloidosis	amyloidosis	O
undergoing	undergoing	O
peripheral	peripheral	O
blood	blood	O
stem	stem	O
cell	cell	O
collection	collection	O
for	for	O
an	an	O
autologous	autologous	O
stem	stem	O
cell	cell	O
transplant	transplant	O
developed	developed	O
extensive	extensive	O
bilateral	bilateral	O
upper-extremity	upper-extremity	O
deep	deep	B-Disease
venous	venous	B-Disease
thrombosis	thrombosis	B-Disease
(	(	O
DVT	dvt	O
)	)	O
and	and	O
pulmonary	pulmonary	B-Disease
embolism	embolism	I-Disease
secondary	secondary	O
to	to	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
.	.	O

A	a	O
continuous	continuous	O
i.v	i.v	O
.	.	O

infusion	infusion	O
of	of	O
argatroban	argatroban	B-Chemical
was	was	O
initiated	initiated	O
,	,	O
and	and	O
the	the	O
patient	patient	O
was	was	O
managed	managed	O
on	on	O
the	the	O
general	general	O
medical	medical	O
floor	floor	O
.	.	O

After	after	O
one	one	O
week	week	O
of	of	O
therapy	therapy	O
,	,	O
he	he	O
was	was	O
transferred	transferred	O
to	to	O
the	the	O
intensive	intensive	O
care	care	O
unit	unit	O
with	with	O
cardiopulmonary	cardiopulmonary	O
compromise	compromise	O
related	related	O
to	to	O
superior	superior	O
vena	vena	O
cava	cava	O
(	(	O
SVC	svc	O
)	)	O
syndrome	syndrome	O
.	.	O

A	a	O
percutaneous	percutaneous	O
mechanical	mechanical	O
thrombectomy	thrombectomy	O
and	and	O
CDT	cdt	O
with	with	O
alteplase	alteplase	O
were	were	O
attempted	attempted	O
,	,	O
but	but	O
the	the	O
procedure	procedure	O
was	was	O
aborted	aborted	O
due	due	O
to	to	O
epistaxis	epistaxis	O
.	.	O

The	the	O
epistaxis	epistaxis	O
resolved	resolved	O
the	the	O
next	next	O
day	day	O
,	,	O
and	and	O
the	the	O
patient	patient	O
was	was	O
restarted	restarted	O
on	on	O
argatroban	argatroban	B-Chemical
.	.	O

A	a	O
second	second	O
percutaneous	percutaneous	O
mechanical	mechanical	O
thrombectomy	thrombectomy	O
was	was	O
performed	performed	O
six	six	O
days	days	O
later	later	O
and	and	O
resulted	resulted	O
in	in	O
partial	partial	O
revascularization	revascularization	O
of	of	O
the	the	O
SVC	svc	O
and	and	O
central	central	O
veins	veins	O
.	.	O

Postthrombectomy	postthrombectomy	O
continuous	continuous	O
CDT	cdt	O
with	with	O
alteplase	alteplase	O
was	was	O
commenced	commenced	O
while	while	O
argatroban	argatroban	B-Chemical
was	was	O
withheld	withheld	O
,	,	O
and	and	O
complete	complete	O
patency	patency	O
of	of	O
the	the	O
SVC	svc	O
and	and	O
central	central	O
veins	veins	O
was	was	O
achieved	achieved	O
after	after	O
three	three	O
days	days	O
of	of	O
therapy	therapy	O
.	.	O

Alteplase	alteplase	O
was	was	O
discontinued	discontinued	O
,	,	O
and	and	O
the	the	O
patient	patient	O
was	was	O
reinitiated	reinitiated	O
on	on	O
argatroban	argatroban	B-Chemical
;	;	O
ultimately	ultimately	O
,	,	O
he	he	O
was	was	O
transitioned	transitioned	O
to	to	O
warfarin	warfarin	B-Chemical
for	for	O
long-term	long-term	O
anticoagulation	anticoagulation	O
.	.	O

Although	although	O
the	the	O
patient	patient	O
recovered	recovered	O
,	,	O
he	he	O
experienced	experienced	O
permanent	permanent	O
vision	vision	O
and	and	O
hearing	hearing	B-Disease
loss	loss	I-Disease
,	,	O
as	as	O
well	well	O
as	as	O
end-stage	end-stage	O
renal	renal	O
disease	disease	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
A	a	O
63-year-old	63-year-old	O
man	man	O
with	with	O
renal	renal	O
amyloidosis	amyloidosis	O
and	and	O
SVC	svc	O
syndrome	syndrome	O
secondary	secondary	O
to	to	O
HITT	hitt	B-Disease
was	was	O
successfully	successfully	O
treated	treated	O
with	with	O
argatroban	argatroban	B-Chemical
and	and	O
CDT	cdt	O
with	with	O
alteplase	alteplase	O
.	.	O

Effects	effects	O
of	of	O
dehydroepiandrosterone	dehydroepiandrosterone	O
in	in	O
amphetamine-induced	amphetamine-induced	O
schizophrenia	schizophrenia	B-Disease
models	models	O
in	in	O
mice	mice	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
examine	examine	O
the	the	O
effects	effects	O
of	of	O
dehydroepiandrosterone	dehydroepiandrosterone	O
(	(	O
DHEA	dhea	O
)	)	O
on	on	O
animal	animal	O
models	models	O
of	of	O
schizophrenia	schizophrenia	B-Disease
.	.	O

METHODS	methods	O
:	:	O
Seventy	seventy	O
Swiss	swiss	O
albino	albino	O
female	female	O
mice	mice	O
(	(	O
25	25	O
-	-	O
35	35	O
g	g	O
)	)	O
were	were	O
divided	divided	O
into	into	O
4	4	O
groups	groups	O
:	:	O
amphetamine-free	amphetamine-free	O
(	(	O
control	control	O
)	)	O
,	,	O
amphetamine	amphetamine	B-Chemical
,	,	O
50	50	O
,	,	O
and	and	O
100	100	O
mg/kg	mg/kg	O
DHEA	dhea	O
.	.	O

The	the	O
DHEA	dhea	O
was	was	O
administered	administered	O
intraperitoneally	intraperitoneally	O
(	(	O
ip	ip	O
)	)	O
for	for	O
5	5	O
days	days	O
.	.	O

Amphetamine	amphetamine	B-Chemical
(	(	O
3	3	O
mg/kg	mg/kg	O
ip	ip	O
)	)	O
induced	induced	O
hyper	hyper	O
locomotion	locomotion	O
,	,	O
apomorphine	apomorphine	B-Chemical
(	(	O
1.5	1.5	O
mg/kg	mg/kg	O
subcutaneously	subcutaneously	O
[	[	O
sc	sc	O
]	]	O
)	)	O
induced	induced	O
climbing	climbing	O
,	,	O
and	and	O
haloperidol	haloperidol	B-Chemical
(	(	O
1.5	1.5	O
mg/kg	mg/kg	O
sc	sc	O
)	)	O
induced	induced	O
catalepsy	catalepsy	B-Disease
tests	tests	O
were	were	O
used	used	O
as	as	O
animal	animal	O
models	models	O
of	of	O
schizophrenia	schizophrenia	B-Disease
.	.	O

The	the	O
study	study	O
was	was	O
conducted	conducted	O
at	at	O
the	the	O
Animal	animal	O
Experiment	experiment	O
Laboratories	laboratories	O
,	,	O
Department	department	O
of	of	O
Pharmacology	pharmacology	O
,	,	O
Medical	medical	O
School	school	O
,	,	O
Eskisehir	eskisehir	O
Osmangazi	osmangazi	O
University	university	O
,	,	O
Eskisehir	eskisehir	O
,	,	O
Turkey	turkey	O
between	between	O
March	march	O
and	and	O
May	may	O
2012	2012	O
.	.	O

Statistical	statistical	O
analysis	analysis	O
was	was	O
carried	carried	O
out	out	O
using	using	O
Kruskal-Wallis	kruskal-wallis	O
test	test	O
for	for	O
hyper	hyper	O
locomotion	locomotion	O
,	,	O
and	and	O
one-way	one-way	O
ANOVA	anova	O
for	for	O
climbing	climbing	O
and	and	O
catalepsy	catalepsy	B-Disease
tests	tests	O
.	.	O

RESULTS	results	O
:	:	O
In	in	O
the	the	O
amphetamine-induced	amphetamine-induced	O
locomotion	locomotion	O
test	test	O
,	,	O
there	there	O
were	were	O
significant	significant	O
increases	increases	O
in	in	O
all	all	O
movements	movements	O
compared	compared	O
with	with	O
the	the	O
amphetamine-free	amphetamine-free	O
group	group	O
.	.	O

Both	both	O
DHEA	dhea	O
50	50	O
mg/kg	mg/kg	O
(	(	O
p<0.05	p<0.05	O
)	)	O
,	,	O
and	and	O
100	100	O
mg/kg	mg/kg	O
(	(	O
p<0.01	p<0.01	O
)	)	O
significantly	significantly	O
decreased	decreased	O
all	all	O
movements	movements	O
compared	compared	O
with	with	O
the	the	O
amphetamine-induced	amphetamine-induced	O
locomotion	locomotion	O
group	group	O
.	.	O

There	there	O
was	was	O
a	a	O
significant	significant	O
difference	difference	O
between	between	O
groups	groups	O
in	in	O
the	the	O
haloperidol-induced	haloperidol-induced	O
catalepsy	catalepsy	B-Disease
test	test	O
(	(	O
p<0.05	p<0.05	O
)	)	O
.	.	O

There	there	O
was	was	O
no	no	O
significant	significant	O
difference	difference	O
between	between	O
groups	groups	O
in	in	O
terms	terms	O
of	of	O
total	total	O
climbing	climbing	O
time	time	O
in	in	O
the	the	O
apomorphine-induced	apomorphine-induced	O
climbing	climbing	O
test	test	O
(	(	O
p>0.05	p>0.05	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
We	we	O
observed	observed	O
that	that	O
DHEA	dhea	O
reduced	reduced	O
locomotor	locomotor	O
activity	activity	O
and	and	O
increased	increased	O
catalepsy	catalepsy	B-Disease
at	at	O
both	both	O
doses	doses	O
,	,	O
while	while	O
it	it	O
had	had	O
no	no	O
effect	effect	O
on	on	O
climbing	climbing	O
behavior	behavior	O
.	.	O

We	we	O
suggest	suggest	O
that	that	O
DHEA	dhea	O
displays	displays	O
typical	typical	O
neuroleptic-like	neuroleptic-like	O
effects	effects	O
,	,	O
and	and	O
may	may	O
be	be	O
used	used	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
schizophrenia	schizophrenia	B-Disease
.	.	O

Availability	availability	O
of	of	O
human	human	O
induced	induced	O
pluripotent	pluripotent	O
stem	stem	O
cell-derived	cell-derived	O
cardiomyocytes	cardiomyocytes	O
in	in	O
assessment	assessment	O
of	of	O
drug	drug	O
potential	potential	O
for	for	O
QT	qt	O
prolongation	prolongation	O
.	.	O

Field	field	O
potential	potential	O
duration	duration	O
(	(	O
FPD	fpd	O
)	)	O
in	in	O
human-induced	human-induced	O
pluripotent	pluripotent	O
stem	stem	O
cell-derived	cell-derived	O
cardiomyocytes	cardiomyocytes	O
(	(	O
hiPS-CMs	hips-cms	O
)	)	O
,	,	O
which	which	O
can	can	O
express	express	O
QT	qt	O
interval	interval	O
in	in	O
an	an	O
electrocardiogram	electrocardiogram	O
,	,	O
is	is	O
reported	reported	O
to	to	O
be	be	O
a	a	O
useful	useful	O
tool	tool	O
to	to	O
predict	predict	O
K(+	k(+	O
)	)	O
channel	channel	O
and	and	O
Ca(2	ca(2	O
+	+	O
)	)	O
channel	channel	O
blocker	blocker	O
effects	effects	O
on	on	O
QT	qt	O
interval	interval	O
.	.	O

However	however	O
,	,	O
there	there	O
is	is	O
no	no	O
report	report	O
showing	showing	O
that	that	O
this	this	O
technique	technique	O
can	can	O
be	be	O
used	used	O
to	to	O
predict	predict	O
multichannel	multichannel	O
blocker	blocker	O
potential	potential	O
for	for	O
QT	qt	O
prolongation	prolongation	O
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
is	is	O
to	to	O
show	show	O
that	that	O
FPD	fpd	O
from	from	O
MEA	mea	O
(	(	O
Multielectrode	multielectrode	O
array	array	O
)	)	O
of	of	O
hiPS-CMs	hips-cms	O
can	can	O
detect	detect	O
QT	qt	O
prolongation	prolongation	O
induced	induced	O
by	by	O
multichannel	multichannel	O
blockers	blockers	O
.	.	O

hiPS-CMs	hips-cms	O
were	were	O
seeded	seeded	O
onto	onto	O
MEA	mea	O
and	and	O
FPD	fpd	O
was	was	O
measured	measured	O
for	for	O
2min	2min	O
every	every	O
10min	10min	O
for	for	O
30min	30min	O
after	after	O
drug	drug	O
exposure	exposure	O
for	for	O
the	the	O
vehicle	vehicle	O
and	and	O
each	each	O
drug	drug	O
concentration	concentration	O
.	.	O

IKr	ikr	O
and	and	O
IKs	iks	O
blockers	blockers	O
concentration-dependently	concentration-dependently	O
prolonged	prolonged	O
corrected	corrected	O
FPD	fpd	O
(	(	O
FPDc	fpdc	O
)	)	O
,	,	O
whereas	whereas	O
Ca(2	ca(2	O
+	+	O
)	)	O
channel	channel	O
blockers	blockers	O
concentration-dependently	concentration-dependently	O
shortened	shortened	O
FPDc	fpdc	O
.	.	O

Also	also	O
,	,	O
the	the	O
multichannel	multichannel	O
blockers	blockers	O
Amiodarone	amiodarone	B-Chemical
,	,	O
Paroxetine	paroxetine	B-Chemical
,	,	O
Terfenadine	terfenadine	B-Chemical
and	and	O
Citalopram	citalopram	B-Chemical
prolonged	prolonged	O
FPDc	fpdc	O
in	in	O
a	a	O
concentration	concentration	O
dependent	dependent	O
manner	manner	O
.	.	O

Finally	finally	O
,	,	O
the	the	O
IKr	ikr	O
blockers	blockers	O
,	,	O
Terfenadine	terfenadine	B-Chemical
and	and	O
Citalopram	citalopram	B-Chemical
,	,	O
which	which	O
are	are	O
reported	reported	O
to	to	O
cause	cause	O
Torsade	torsade	B-Disease
de	de	I-Disease
Pointes	pointes	I-Disease
(	(	O
TdP	tdp	B-Disease
)	)	O
in	in	O
clinical	clinical	O
practice	practice	O
,	,	O
produced	produced	O
early	early	O
afterdepolarization	afterdepolarization	O
(	(	O
EAD	ead	O
)	)	O
.	.	O

hiPS-CMs	hips-cms	O
using	using	O
MEA	mea	O
system	system	O
and	and	O
FPDc	fpdc	O
can	can	O
predict	predict	O
the	the	O
effects	effects	O
of	of	O
drug	drug	O
candidates	candidates	O
on	on	O
QT	qt	O
interval	interval	O
.	.	O

This	this	O
study	study	O
also	also	O
shows	shows	O
that	that	O
this	this	O
assay	assay	O
can	can	O
help	help	O
detect	detect	O
EAD	ead	O
for	for	O
drugs	drugs	O
with	with	O
TdP	tdp	B-Disease
potential	potential	O
.	.	O

Dermal	dermal	O
developmental	developmental	O
toxicity	toxicity	B-Disease
of	of	O
N-phenylimide	n-phenylimide	O
herbicides	herbicides	O
in	in	O
rats	rats	O
.	.	O

BACKGROUND	background	O
:	:	O
S-53482	s-53482	O
and	and	O
S-23121	s-23121	O
are	are	O
N-phenylimide	n-phenylimide	O
herbicides	herbicides	O
and	and	O
produced	produced	O
embryolethality	embryolethality	O
,	,	O
teratogenicity	teratogenicity	O
(	(	O
mainly	mainly	O
ventricular	ventricular	O
septal	septal	O
defects	defects	O
and	and	O
wavy	wavy	O
ribs	ribs	O
)	)	O
,	,	O
and	and	O
growth	growth	O
retardation	retardation	O
in	in	O
rats	rats	O
in	in	O
conventional	conventional	O
oral	oral	O
developmental	developmental	O
toxicity	toxicity	B-Disease
studies	studies	O
.	.	O

Our	our	O
objective	objective	O
in	in	O
this	this	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
whether	whether	O
the	the	O
compounds	compounds	O
induce	induce	O
developmental	developmental	O
toxicity	toxicity	B-Disease
via	via	O
the	the	O
dermal	dermal	O
route	route	O
,	,	O
which	which	O
is	is	O
more	more	O
relevant	relevant	O
to	to	O
occupational	occupational	O
exposure	exposure	O
,	,	O
hence	hence	O
better	better	O
addressing	addressing	O
human	human	O
health	health	O
risks	risks	O
.	.	O

METHODS	methods	O
:	:	O
S-53482	s-53482	O
was	was	O
administered	administered	O
dermally	dermally	O
to	to	O
rats	rats	O
at	at	O
30	30	O
,	,	O
100	100	O
,	,	O
and	and	O
300	300	O
mg/kg	mg/kg	O
during	during	O
organogenesis	organogenesis	O
,	,	O
and	and	O
S-23121	s-23121	O
was	was	O
administered	administered	O
at	at	O
200	200	O
,	,	O
400	400	O
,	,	O
and	and	O
800	800	O
mg/kg	mg/kg	O
(	(	O
the	the	O
maximum	maximum	O
applicable	applicable	O
dose	dose	O
level	level	O
)	)	O
.	.	O

Fetuses	fetuses	O
were	were	O
obtained	obtained	O
by	by	O
a	a	O
Cesarean	cesarean	O
section	section	O
and	and	O
examined	examined	O
for	for	O
external	external	O
,	,	O
visceral	visceral	O
,	,	O
and	and	O
skeletal	skeletal	O
alterations	alterations	O
.	.	O

RESULTS	results	O
:	:	O
Dermal	dermal	O
exposure	exposure	O
of	of	O
rats	rats	O
to	to	O
S-53482	s-53482	O
at	at	O
300	300	O
mg/kg	mg/kg	O
produced	produced	O
patterns	patterns	O
of	of	O
developmental	developmental	O
toxicity	toxicity	B-Disease
similar	similar	O
to	to	O
those	those	O
resulting	resulting	O
from	from	O
oral	oral	O
exposure	exposure	O
.	.	O

Toxicity	toxicity	B-Disease
included	included	O
embryolethality	embryolethality	O
,	,	O
teratogenicity	teratogenicity	O
,	,	O
and	and	O
growth	growth	O
retardation	retardation	O
.	.	O

Dermal	dermal	O
administration	administration	O
of	of	O
S-23121	s-23121	O
at	at	O
800	800	O
mg/kg	mg/kg	O
resulted	resulted	O
in	in	O
an	an	O
increased	increased	O
incidence	incidence	O
of	of	O
embryonic	embryonic	O
death	death	B-Disease
and	and	O
ventricular	ventricular	O
septal	septal	O
defect	defect	O
,	,	O
but	but	O
retarded	retarded	O
fetal	fetal	O
growth	growth	O
was	was	O
not	not	O
observed	observed	O
as	as	O
it	it	O
was	was	O
following	following	O
oral	oral	O
exposure	exposure	O
to	to	O
S-23121	s-23121	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Based	based	O
on	on	O
the	the	O
results	results	O
,	,	O
S-53482	s-53482	O
and	and	O
S-23121	s-23121	O
were	were	O
teratogenic	teratogenic	O
when	when	O
administered	administered	O
dermally	dermally	O
to	to	O
pregnant	pregnant	O
rats	rats	O
as	as	O
were	were	O
the	the	O
compounds	compounds	O
administered	administered	O
orally	orally	O
.	.	O

Thus	thus	O
,	,	O
investigation	investigation	O
of	of	O
the	the	O
mechanism	mechanism	O
and	and	O
its	its	O
human	human	O
relevancy	relevancy	O
become	become	O
more	more	O
important	important	O
.	.	O

Rates	rates	O
of	of	O
Renal	renal	B-Disease
Toxicity	toxicity	B-Disease
in	in	O
Cancer	cancer	B-Disease
Patients	patients	O
Receiving	receiving	O
Cisplatin	cisplatin	B-Chemical
With	with	O
and	and	O
Without	without	O
Mannitol	mannitol	B-Chemical
.	.	O

BACKGROUND	background	O
:	:	O
Cisplatin	cisplatin	B-Chemical
is	is	O
a	a	O
widely	widely	O
used	used	O
antineoplastic	antineoplastic	O
.	.	O

One	one	O
of	of	O
the	the	O
major	major	O
complications	complications	O
of	of	O
cisplatin	cisplatin	B-Chemical
use	use	O
is	is	O
dose-limiting	dose-limiting	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

There	there	O
are	are	O
many	many	O
strategies	strategies	O
to	to	O
prevent	prevent	O
this	this	O
toxicity	toxicity	B-Disease
,	,	O
including	including	O
the	the	O
use	use	O
of	of	O
mannitol	mannitol	B-Chemical
as	as	O
a	a	O
nephroprotectant	nephroprotectant	O
in	in	O
combination	combination	O
with	with	O
hydration	hydration	O
.	.	O

OBJECTIVE	objective	O
:	:	O
We	we	O
aimed	aimed	O
to	to	O
evaluate	evaluate	O
the	the	O
rates	rates	O
of	of	O
cisplatin-induced	cisplatin-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
in	in	O
cancer	cancer	B-Disease
patients	patients	O
receiving	receiving	O
single-agent	single-agent	O
cisplatin	cisplatin	B-Chemical
with	with	O
and	and	O
without	without	O
mannitol	mannitol	B-Chemical
.	.	O

METHODS	methods	O
:	:	O
This	this	O
single-center	single-center	O
retrospective	retrospective	O
analysis	analysis	O
was	was	O
a	a	O
quasi	quasi	O
experiment	experiment	O
created	created	O
by	by	O
the	the	O
national	national	O
mannitol	mannitol	B-Chemical
shortage	shortage	O
.	.	O

Data	data	O
were	were	O
collected	collected	O
on	on	O
adult	adult	O
cancer	cancer	B-Disease
patients	patients	O
receiving	receiving	O
single-agent	single-agent	O
cisplatin	cisplatin	B-Chemical
as	as	O
an	an	O
outpatient	outpatient	O
from	from	O
January	january	O
2011	2011	O
to	to	O
September	september	O
2012	2012	O
.	.	O

The	the	O
primary	primary	O
outcome	outcome	O
was	was	O
acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
(	(	O
AKI	aki	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
We	we	O
evaluated	evaluated	O
143	143	O
patients	patients	O
who	who	O
received	received	O
single-agent	single-agent	O
cisplatin	cisplatin	B-Chemical
;	;	O
97.2	97.2	O
%	%	O
of	of	O
patients	patients	O
had	had	O
head	head	O
and	and	O
neck	neck	O
cancer	cancer	B-Disease
as	as	O
their	their	O
primary	primary	O
malignancy	malignancy	B-Disease
.	.	O

Patients	patients	O
who	who	O
did	did	O
not	not	O
receive	receive	O
mannitol	mannitol	B-Chemical
were	were	O
more	more	O
likely	likely	O
to	to	O
develop	develop	O
nephrotoxicity	nephrotoxicity	B-Disease
:	:	O
odds	odds	O
ratio	ratio	O
[	[	O
OR	or	O
]	]	O
=	=	O
2.646	2.646	O
(	(	O
95	95	O
%	%	O
CI	ci	O
=	=	O
1.008	1.008	O
,	,	O
6.944	6.944	O
;	;	O
P	p	O
=	=	O
0.048	0.048	O
)	)	O
.	.	O

Patients	patients	O
who	who	O
received	received	O
the	the	O
100	100	O
mg/m(2	mg/m(2	O
)	)	O
dosing	dosing	O
and	and	O
patients	patients	O
who	who	O
had	had	O
a	a	O
history	history	O
of	of	O
hypertension	hypertension	B-Disease
also	also	O
had	had	O
a	a	O
higher	higher	O
likelihood	likelihood	O
of	of	O
developing	developing	O
nephrotoxicity	nephrotoxicity	B-Disease
:	:	O
OR	or	O
=	=	O
11.494	11.494	O
(	(	O
95	95	O
%	%	O
CI	ci	O
=	=	O
4.149	4.149	O
,	,	O
32.258	32.258	O
;	;	O
P	p	O
<	<	O
0.0001	0.0001	O
)	)	O
and	and	O
OR	or	O
=	=	O
3.219	3.219	O
(	(	O
95	95	O
%	%	O
CI	ci	O
=	=	O
1.228	1.228	O
,	,	O
8.439	8.439	O
;	;	O
P	p	O
=	=	O
0.017	0.017	O
)	)	O
,	,	O
respectively	respectively	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
When	when	O
limited	limited	O
quantities	quantities	O
of	of	O
mannitol	mannitol	B-Chemical
are	are	O
available	available	O
,	,	O
it	it	O
should	should	O
preferentially	preferentially	O
be	be	O
given	given	O
to	to	O
patients	patients	O
at	at	O
particularly	particularly	O
high	high	O
risk	risk	O
of	of	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

Our	our	O
analysis	analysis	O
suggests	suggests	O
that	that	O
those	those	O
patients	patients	O
receiving	receiving	O
the	the	O
dosing	dosing	O
schedule	schedule	O
of	of	O
100	100	O
mg/m(2	mg/m(2	O
)	)	O
cisplatin	cisplatin	B-Chemical
every	every	O
3	3	O
weeks	weeks	O
and	and	O
those	those	O
with	with	O
hypertension	hypertension	B-Disease
are	are	O
at	at	O
the	the	O
greatest	greatest	O
risk	risk	O
of	of	O
nephrotoxicity	nephrotoxicity	B-Disease
and	and	O
would	would	O
benefit	benefit	O
from	from	O
the	the	O
addition	addition	O
of	of	O
mannitol	mannitol	B-Chemical
.	.	O

Metformin	metformin	O
protects	protects	O
against	against	O
seizures	seizures	B-Disease
,	,	O
learning	learning	O
and	and	O
memory	memory	O
impairments	impairments	O
and	and	O
oxidative	oxidative	O
damage	damage	O
induced	induced	O
by	by	O
pentylenetetrazole-induced	pentylenetetrazole-induced	O
kindling	kindling	O
in	in	O
mice	mice	O
.	.	O

Cognitive	cognitive	B-Disease
impairment	impairment	I-Disease
,	,	O
the	the	O
most	most	O
common	common	O
and	and	O
severe	severe	O
comorbidity	comorbidity	O
of	of	O
epilepsy	epilepsy	B-Disease
,	,	O
greatly	greatly	O
diminishes	diminishes	O
the	the	O
quality	quality	O
of	of	O
life	life	O
.	.	O

However	however	O
,	,	O
current	current	O
therapeutic	therapeutic	O
interventions	interventions	O
for	for	O
epilepsy	epilepsy	B-Disease
can	can	O
also	also	O
cause	cause	O
untoward	untoward	O
cognitive	cognitive	O
effects	effects	O
.	.	O

Thus	thus	O
,	,	O
there	there	O
is	is	O
an	an	O
urgent	urgent	O
need	need	O
for	for	O
new	new	O
kinds	kinds	O
of	of	O
agents	agents	O
targeting	targeting	O
both	both	O
seizures	seizures	B-Disease
and	and	O
cognition	cognition	O
deficits	deficits	O
.	.	O

Oxidative	oxidative	O
stress	stress	O
is	is	O
considered	considered	O
to	to	O
play	play	O
an	an	O
important	important	O
role	role	O
in	in	O
epileptogenesis	epileptogenesis	O
and	and	O
cognitive	cognitive	B-Disease
deficits	deficits	I-Disease
,	,	O
and	and	O
antioxidants	antioxidants	O
have	have	O
a	a	O
putative	putative	O
antiepileptic	antiepileptic	O
potential	potential	O
.	.	O

Metformin	metformin	O
,	,	O
the	the	O
most	most	O
commonly	commonly	O
prescribed	prescribed	O
antidiabetic	antidiabetic	O
oral	oral	O
drug	drug	O
,	,	O
has	has	O
antioxidant	antioxidant	O
properties	properties	O
.	.	O

This	this	O
study	study	O
was	was	O
designed	designed	O
to	to	O
evaluate	evaluate	O
the	the	O
ameliorative	ameliorative	O
effects	effects	O
of	of	O
metformin	metformin	O
on	on	O
seizures	seizures	B-Disease
,	,	O
cognitive	cognitive	B-Disease
impairment	impairment	I-Disease
and	and	O
brain	brain	O
oxidative	oxidative	O
stress	stress	O
markers	markers	O
observed	observed	O
in	in	O
pentylenetetrazole-induced	pentylenetetrazole-induced	O
kindling	kindling	O
animals	animals	O
.	.	O

Male	male	O
C57BL/6	c57bl/6	O
mice	mice	O
were	were	O
administered	administered	O
with	with	O
subconvulsive	subconvulsive	O
dose	dose	O
of	of	O
pentylenetetrazole	pentylenetetrazole	O
(	(	O
37	37	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
every	every	O
other	other	O
day	day	O
for	for	O
14	14	O
injections	injections	O
.	.	O

Metformin	metformin	O
was	was	O
injected	injected	O
intraperitoneally	intraperitoneally	O
in	in	O
dose	dose	O
of	of	O
200mg/kg	200mg/kg	O
along	along	O
with	with	O
alternate-day	alternate-day	O
PTZ	ptz	B-Chemical
.	.	O

We	we	O
found	found	O
that	that	O
metformin	metformin	O
suppressed	suppressed	O
the	the	O
progression	progression	O
of	of	O
kindling	kindling	O
,	,	O
ameliorated	ameliorated	O
the	the	O
cognitive	cognitive	B-Disease
impairment	impairment	I-Disease
and	and	O
decreased	decreased	O
brain	brain	O
oxidative	oxidative	O
stress	stress	O
.	.	O

Thus	thus	O
the	the	O
present	present	O
study	study	O
concluded	concluded	O
that	that	O
metformin	metformin	O
may	may	O
be	be	O
a	a	O
potential	potential	O
agent	agent	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
epilepsy	epilepsy	B-Disease
as	as	O
well	well	O
as	as	O
a	a	O
protective	protective	O
medicine	medicine	O
against	against	O
cognitive	cognitive	B-Disease
impairment	impairment	I-Disease
induced	induced	O
by	by	O
seizures	seizures	B-Disease
.	.	O

P53	p53	O
inhibition	inhibition	O
exacerbates	exacerbates	O
late-stage	late-stage	O
anthracycline	anthracycline	B-Chemical
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

AIMS	aims	O
:	:	O
Doxorubicin	doxorubicin	B-Chemical
(	(	O
DOX	dox	B-Chemical
)	)	O
is	is	O
an	an	O
effective	effective	O
anti-cancer	anti-cancer	O
therapeutic	therapeutic	O
,	,	O
but	but	O
is	is	O
associated	associated	O
with	with	O
both	both	O
acute	acute	O
and	and	O
late-stage	late-stage	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

Children	children	O
are	are	O
particularly	particularly	O
sensitive	sensitive	O
to	to	O
DOX-induced	dox-induced	O
heart	heart	B-Disease
failure	failure	I-Disease
.	.	O

Here	here	O
,	,	O
the	the	O
impact	impact	O
of	of	O
p53	p53	O
inhibition	inhibition	O
on	on	O
acute	acute	O
vs.	vs.	O
late-stage	late-stage	O
DOX	dox	B-Chemical
cardiotoxicity	cardiotoxicity	B-Disease
was	was	O
examined	examined	O
in	in	O
a	a	O
juvenile	juvenile	O
model	model	O
.	.	O

METHODS	methods	O
AND	and	O
RESULTS	results	O
:	:	O
Two-week-old	two-week-old	O
MHC-CB7	mhc-cb7	O
mice	mice	O
(	(	O
which	which	O
express	express	O
dominant-interfering	dominant-interfering	O
p53	p53	O
in	in	O
cardiomyocytes	cardiomyocytes	O
)	)	O
and	and	O
their	their	O
non-transgenic	non-transgenic	O
(	(	O
NON-TXG	non-txg	O
)	)	O
littermates	littermates	O
received	received	O
weekly	weekly	O
DOX	dox	B-Chemical
injections	injections	O
for	for	O
5	5	O
weeks	weeks	O
(	(	O
25	25	O
mg/kg	mg/kg	O
cumulative	cumulative	O
dose	dose	O
)	)	O
.	.	O

One	one	O
week	week	O
after	after	O
the	the	O
last	last	O
DOX	dox	B-Chemical
treatment	treatment	O
(	(	O
acute	acute	O
stage	stage	O
)	)	O
,	,	O
MHC-CB7	mhc-cb7	O
mice	mice	O
exhibited	exhibited	O
improved	improved	O
cardiac	cardiac	O
function	function	O
and	and	O
lower	lower	O
levels	levels	O
of	of	O
cardiomyocyte	cardiomyocyte	O
apoptosis	apoptosis	O
when	when	O
compared	compared	O
with	with	O
the	the	O
NON-TXG	non-txg	O
mice	mice	O
.	.	O

Surprisingly	surprisingly	O
,	,	O
by	by	O
13	13	O
weeks	weeks	O
following	following	O
the	the	O
last	last	O
DOX	dox	B-Chemical
treatment	treatment	O
(	(	O
late	late	O
stage	stage	O
)	)	O
,	,	O
MHC-CB7	mhc-cb7	O
exhibited	exhibited	O
a	a	O
progressive	progressive	O
decrease	decrease	O
in	in	O
cardiac	cardiac	O
function	function	O
and	and	O
higher	higher	O
rates	rates	O
of	of	O
cardiomyocyte	cardiomyocyte	O
apoptosis	apoptosis	O
when	when	O
compared	compared	O
with	with	O
NON-TXG	non-txg	O
mice	mice	O
.	.	O

p53	p53	O
inhibition	inhibition	O
blocked	blocked	O
transient	transient	O
DOX-induced	dox-induced	O
STAT3	stat3	O
activation	activation	O
in	in	O
MHC-CB7	mhc-cb7	O
mice	mice	O
,	,	O
which	which	O
was	was	O
associated	associated	O
with	with	O
enhanced	enhanced	O
induction	induction	O
of	of	O
the	the	O
DNA	dna	O
repair	repair	O
proteins	proteins	O
Ku70	ku70	O
and	and	O
Ku80	ku80	O
.	.	O

Mice	mice	O
with	with	O
cardiomyocyte-restricted	cardiomyocyte-restricted	O
deletion	deletion	O
of	of	O
STAT3	stat3	O
exhibited	exhibited	O
worse	worse	O
cardiac	cardiac	O
function	function	O
,	,	O
higher	higher	O
levels	levels	O
of	of	O
cardiomyocyte	cardiomyocyte	O
apoptosis	apoptosis	O
,	,	O
and	and	O
a	a	O
greater	greater	O
induction	induction	O
of	of	O
Ku70	ku70	O
and	and	O
Ku80	ku80	O
in	in	O
response	response	O
to	to	O
DOX	dox	B-Chemical
treatment	treatment	O
during	during	O
the	the	O
acute	acute	O
stage	stage	O
when	when	O
compared	compared	O
with	with	O
control	control	O
animals	animals	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
These	these	O
data	data	O
support	support	O
a	a	O
model	model	O
wherein	wherein	O
a	a	O
p53-dependent	p53-dependent	O
cardioprotective	cardioprotective	O
pathway	pathway	O
,	,	O
mediated	mediated	O
via	via	O
STAT3	stat3	O
activation	activation	O
,	,	O
mitigates	mitigates	O
DOX-induced	dox-induced	O
myocardial	myocardial	O
stress	stress	O
during	during	O
drug	drug	O
delivery	delivery	O
.	.	O

Furthermore	furthermore	O
,	,	O
these	these	O
data	data	O
suggest	suggest	O
an	an	O
explanation	explanation	O
as	as	O
to	to	O
how	how	O
p53	p53	O
inhibition	inhibition	O
can	can	O
result	result	O
in	in	O
cardioprotection	cardioprotection	O
during	during	O
drug	drug	O
treatment	treatment	O
and	and	O
,	,	O
paradoxically	paradoxically	O
,	,	O
enhanced	enhanced	O
cardiotoxicity	cardiotoxicity	B-Disease
long	long	O
after	after	O
the	the	O
cessation	cessation	O
of	of	O
drug	drug	O
treatment	treatment	O
.	.	O

Metronidazole-induced	metronidazole-induced	O
encephalopathy	encephalopathy	B-Disease
:	:	O
an	an	O
uncommon	uncommon	O
scenario	scenario	O
.	.	O

Metronidazole	metronidazole	B-Chemical
can	can	O
produce	produce	O
neurological	neurological	O
complications	complications	O
although	although	O
it	it	O
is	is	O
not	not	O
a	a	O
common	common	O
scenario	scenario	O
.	.	O

We	we	O
present	present	O
a	a	O
case	case	O
where	where	O
a	a	O
patient	patient	O
developed	developed	O
features	features	O
of	of	O
encephalopathy	encephalopathy	B-Disease
following	following	O
prolonged	prolonged	O
metronidazole	metronidazole	B-Chemical
intake	intake	O
.	.	O

Magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
(	(	O
MRI	mri	O
)	)	O
brain	brain	O
showed	showed	O
abnormal	abnormal	O
signal	signal	O
intensity	intensity	O
involving	involving	O
both	both	O
dentate	dentate	O
nuclei	nuclei	O
of	of	O
cerebellum	cerebellum	O
and	and	O
splenium	splenium	O
of	of	O
corpus	corpus	O
callosum	callosum	O
.	.	O

The	the	O
diagnosis	diagnosis	O
of	of	O
metronidazole	metronidazole	B-Chemical
toxicity	toxicity	B-Disease
was	was	O
made	made	O
by	by	O
the	the	O
MRI	mri	O
findings	findings	O
and	and	O
supported	supported	O
clinically	clinically	O
.	.	O

Aconitine-induced	aconitine-induced	O
Ca2	ca2	O
+	+	O
overload	overload	O
causes	causes	O
arrhythmia	arrhythmia	B-Disease
and	and	O
triggers	triggers	O
apoptosis	apoptosis	O
through	through	O
p38	p38	O
MAPK	mapk	O
signaling	signaling	O
pathway	pathway	O
in	in	O
rats	rats	O
.	.	O

Aconitine	aconitine	O
is	is	O
a	a	O
major	major	O
bioactive	bioactive	O
diterpenoid	diterpenoid	O
alkaloid	alkaloid	O
with	with	O
high	high	O
content	content	O
derived	derived	O
from	from	O
herbal	herbal	O
aconitum	aconitum	O
plants	plants	O
.	.	O

Emerging	emerging	O
evidence	evidence	O
indicates	indicates	O
that	that	O
voltage-dependent	voltage-dependent	O
Na(+	na(+	O
)	)	O
channels	channels	O
have	have	O
pivotal	pivotal	O
roles	roles	O
in	in	O
the	the	O
cardiotoxicity	cardiotoxicity	B-Disease
of	of	O
aconitine	aconitine	O
.	.	O

However	however	O
,	,	O
no	no	O
reports	reports	O
are	are	O
available	available	O
on	on	O
the	the	O
role	role	O
of	of	O
Ca(2	ca(2	O
+	+	O
)	)	O
in	in	O
aconitine	aconitine	O
poisoning	poisoning	B-Disease
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
we	we	O
explored	explored	O
the	the	O
importance	importance	O
of	of	O
pathological	pathological	O
Ca(2	ca(2	O
+	+	O
)	)	O
signaling	signaling	O
in	in	O
aconitine	aconitine	O
poisoning	poisoning	B-Disease
in	in	O
vitro	vitro	O
and	and	O
in	in	O
vivo	vivo	O
.	.	O

We	we	O
found	found	O
that	that	O
Ca(2	ca(2	O
+	+	O
)	)	O
overload	overload	O
lead	lead	O
to	to	O
accelerated	accelerated	O
beating	beating	O
rhythm	rhythm	O
in	in	O
adult	adult	O
rat	rat	O
ventricular	ventricular	O
myocytes	myocytes	O
and	and	O
caused	caused	O
arrhythmia	arrhythmia	B-Disease
in	in	O
conscious	conscious	O
freely	freely	O
moving	moving	O
rats	rats	O
.	.	O

To	to	O
investigate	investigate	O
effects	effects	O
of	of	O
aconitine	aconitine	O
on	on	O
myocardial	myocardial	B-Disease
injury	injury	I-Disease
,	,	O
we	we	O
performed	performed	O
cytotoxicity	cytotoxicity	O
assay	assay	O
in	in	O
neonatal	neonatal	O
rat	rat	O
ventricular	ventricular	O
myocytes	myocytes	O
(	(	O
NRVMs	nrvms	O
)	)	O
,	,	O
as	as	O
well	well	O
as	as	O
measured	measured	O
lactate	lactate	B-Chemical
dehydrogenase	dehydrogenase	O
level	level	O
in	in	O
the	the	O
culture	culture	O
medium	medium	O
of	of	O
NRVMs	nrvms	O
and	and	O
activities	activities	O
of	of	O
serum	serum	O
cardiac	cardiac	O
enzymes	enzymes	O
in	in	O
rats	rats	O
.	.	O

The	the	O
results	results	O
showed	showed	O
that	that	O
aconitine	aconitine	O
resulted	resulted	O
in	in	O
myocardial	myocardial	B-Disease
injury	injury	I-Disease
and	and	O
reduced	reduced	O
NRVMs	nrvms	O
viability	viability	O
dose-dependently	dose-dependently	O
.	.	O

To	to	O
confirm	confirm	O
the	the	O
pro-apoptotic	pro-apoptotic	O
effects	effects	O
,	,	O
we	we	O
performed	performed	O
flow	flow	O
cytometric	cytometric	O
detection	detection	O
,	,	O
cardiac	cardiac	O
histology	histology	O
,	,	O
transmission	transmission	O
electron	electron	O
microscopy	microscopy	O
and	and	O
terminal	terminal	O
deoxynucleotidyl	deoxynucleotidyl	O
transferase-mediated	transferase-mediated	O
dUTP-biotin	dutp-biotin	O
nick	nick	O
end	end	O
labeling	labeling	O
assay	assay	O
.	.	O

The	the	O
results	results	O
showed	showed	O
that	that	O
aconitine	aconitine	O
stimulated	stimulated	O
apoptosis	apoptosis	O
time-dependently	time-dependently	O
.	.	O

The	the	O
expression	expression	O
analysis	analysis	O
of	of	O
Ca(2	ca(2	O
+	+	O
)	)	O
handling	handling	O
proteins	proteins	O
demonstrated	demonstrated	O
that	that	O
aconitine	aconitine	O
promoted	promoted	O
Ca(2	ca(2	O
+	+	O
)	)	O
overload	overload	O
through	through	O
the	the	O
expression	expression	O
regulation	regulation	O
of	of	O
Ca(2	ca(2	O
+	+	O
)	)	O
handling	handling	O
proteins	proteins	O
.	.	O

The	the	O
expression	expression	O
analysis	analysis	O
of	of	O
apoptosis-related	apoptosis-related	O
proteins	proteins	O
revealed	revealed	O
that	that	O
pro-apoptotic	pro-apoptotic	O
protein	protein	O
expression	expression	O
was	was	O
upregulated	upregulated	O
,	,	O
and	and	O
anti-apoptotic	anti-apoptotic	O
protein	protein	O
BCL-2	bcl-2	O
expression	expression	O
was	was	O
downregulated	downregulated	O
.	.	O

Furthermore	furthermore	O
,	,	O
increased	increased	O
phosphorylation	phosphorylation	O
of	of	O
MAPK	mapk	O
family	family	O
members	members	O
,	,	O
especially	especially	O
the	the	O
P-P38/P38	p-p38/p38	O
ratio	ratio	O
was	was	O
found	found	O
in	in	O
cardiac	cardiac	O
tissues	tissues	O
.	.	O

Hence	hence	O
,	,	O
our	our	O
results	results	O
suggest	suggest	O
that	that	O
aconitine	aconitine	O
significantly	significantly	O
aggravates	aggravates	O
Ca(2	ca(2	O
+	+	O
)	)	O
overload	overload	O
and	and	O
causes	causes	O
arrhythmia	arrhythmia	B-Disease
and	and	O
finally	finally	O
promotes	promotes	O
apoptotic	apoptotic	O
development	development	O
via	via	O
phosphorylation	phosphorylation	O
of	of	O
P38	p38	O
mitogen-activated	mitogen-activated	O
protein	protein	O
kinase	kinase	O
.	.	O

Chronic	chronic	O
treatment	treatment	O
with	with	O
metformin	metformin	O
suppresses	suppresses	O
toll-like	toll-like	O
receptor	receptor	O
4	4	O
signaling	signaling	O
and	and	O
attenuates	attenuates	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
following	following	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

Acute	acute	O
treatment	treatment	O
with	with	O
metformin	metformin	O
has	has	O
a	a	O
protective	protective	O
effect	effect	O
in	in	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
by	by	O
suppression	suppression	O
of	of	O
inflammatory	inflammatory	O
responses	responses	O
due	due	O
to	to	O
activation	activation	O
of	of	O
AMP-activated	amp-activated	O
protein	protein	O
kinase	kinase	O
(	(	O
AMPK	ampk	O
)	)	O
.	.	O

In	in	O
the	the	O
present	present	O
study	study	O
,	,	O
the	the	O
effect	effect	O
of	of	O
chronic	chronic	O
pre-treatment	pre-treatment	O
with	with	O
metformin	metformin	O
on	on	O
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
and	and	O
toll-like	toll-like	O
receptor	receptor	O
4	4	O
(	(	O
TLR4	tlr4	O
)	)	O
activities	activities	O
following	following	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
and	and	O
their	their	O
relation	relation	O
with	with	O
AMPK	ampk	O
were	were	O
assessed	assessed	O
.	.	O

Male	male	O
Wistar	wistar	O
rats	rats	O
were	were	O
randomly	randomly	O
assigned	assigned	O
to	to	O
one	one	O
of	of	O
5	5	O
groups	groups	O
(	(	O
n=6	n=6	O
):	):	O
normal	normal	O
control	control	O
and	and	O
groups	groups	O
were	were	O
injected	injected	O
isoproterenol	isoproterenol	B-Chemical
after	after	O
chronic	chronic	O
pre-treatment	pre-treatment	O
with	with	O
0	0	O
,	,	O
25	25	O
,	,	O
50	50	O
,	,	O
or	or	O
100mg/kg	100mg/kg	O
of	of	O
metformin	metformin	O
twice	twice	O
daily	daily	O
for	for	O
14	14	O
days	days	O
.	.	O

Isoproterenol	isoproterenol	B-Chemical
(	(	O
100mg/kg	100mg/kg	O
)	)	O
was	was	O
injected	injected	O
subcutaneously	subcutaneously	O
on	on	O
the	the	O
13th	13th	O
and	and	O
14th	14th	O
days	days	O
to	to	O
induce	induce	O
acute	acute	B-Disease
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

Isoproterenol	isoproterenol	B-Chemical
alone	alone	O
decreased	decreased	O
left	left	O
ventricular	ventricular	O
systolic	systolic	O
pressure	pressure	O
and	and	O
myocardial	myocardial	O
contractility	contractility	O
indexed	indexed	O
as	as	O
LVdp/dtmax	lvdp/dtmax	O
and	and	O
LVdp/dtmin	lvdp/dtmin	O
.	.	O

The	the	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
was	was	O
significantly	significantly	O
lower	lower	O
in	in	O
the	the	O
groups	groups	O
treated	treated	O
with	with	O
25	25	O
and	and	O
50mg/kg	50mg/kg	O
of	of	O
metformin	metformin	O
.	.	O

Metfromin	metfromin	O
markedly	markedly	O
lowered	lowered	O
isoproterenol-induced	isoproterenol-induced	O
elevation	elevation	O
in	in	O
the	the	O
levels	levels	O
of	of	O
TLR4	tlr4	O
mRNA	mrna	O
,	,	O
myeloid	myeloid	O
differentiation	differentiation	O
protein	protein	O
88	88	O
(	(	O
MyD88	myd88	O
)	)	O
,	,	O
tumor	tumor	B-Disease
necrosis	necrosis	B-Disease
factor-alpha	factor-alpha	O
(	(	O
TNF-a	tnf-a	O
)	)	O
,	,	O
and	and	O
interleukin	interleukin	O
6	6	O
(	(	O
IL-6	il-6	O
)	)	O
in	in	O
the	the	O
heart	heart	O
tissues	tissues	O
.	.	O

Similar	similar	O
changes	changes	O
were	were	O
also	also	O
seen	seen	O
in	in	O
the	the	O
serum	serum	O
levels	levels	O
of	of	O
TNF-a	tnf-a	O
and	and	O
IL-6	il-6	O
.	.	O

However	however	O
,	,	O
the	the	O
lower	lower	O
doses	doses	O
of	of	O
25	25	O
and	and	O
50mg/kg	50mg/kg	O
were	were	O
more	more	O
effective	effective	O
than	than	O
100mg/kg	100mg/kg	O
.	.	O

Phosphorylated	phosphorylated	O
AMPKa	ampka	O
(	(	O
p-AMPK	p-ampk	O
)	)	O
in	in	O
the	the	O
myocardium	myocardium	O
was	was	O
significantly	significantly	O
elevated	elevated	O
by	by	O
25mg/kg	25mg/kg	O
of	of	O
metformin	metformin	O
,	,	O
slightly	slightly	O
by	by	O
50mg/kg	50mg/kg	O
,	,	O
but	but	O
not	not	O
by	by	O
100mg/kg	100mg/kg	O
.	.	O

Chronic	chronic	O
pre-treatment	pre-treatment	O
with	with	O
metformin	metformin	O
reduces	reduces	O
post-myocardial	post-myocardial	O
infarction	infarction	B-Disease
cardiac	cardiac	B-Disease
dysfunction	dysfunction	I-Disease
and	and	O
suppresses	suppresses	O
inflammatory	inflammatory	O
responses	responses	O
,	,	O
possibly	possibly	O
through	through	O
inhibition	inhibition	O
of	of	O
TLR4	tlr4	O
activities	activities	O
.	.	O

This	this	O
mechanism	mechanism	O
can	can	O
be	be	O
considered	considered	O
as	as	O
a	a	O
target	target	O
to	to	O
protect	protect	O
infarcted	infarcted	O
myocardium	myocardium	O
.	.	O

Unusual	unusual	O
complications	complications	O
of	of	O
antithyroid	antithyroid	O
drug	drug	O
therapy	therapy	O
:	:	O
four	four	O
case	case	O
reports	reports	O
and	and	O
review	review	O
of	of	O
literature	literature	O
.	.	O

Two	two	O
cases	cases	O
of	of	O
propylthiouracil-associated	propylthiouracil-associated	O
acute	acute	O
hepatitis	hepatitis	B-Disease
,	,	O
one	one	O
case	case	O
of	of	O
fatal	fatal	O
methimazole-associated	methimazole-associated	O
hepatocellular	hepatocellular	O
necrosis	necrosis	B-Disease
and	and	O
one	one	O
case	case	O
of	of	O
propylthiouracil-associated	propylthiouracil-associated	O
lupus-like	lupus-like	O
syndrome	syndrome	O
are	are	O
described	described	O
.	.	O

The	the	O
literature	literature	O
related	related	O
to	to	O
antithyroid	antithyroid	O
drug	drug	O
side	side	O
effects	effects	O
and	and	O
the	the	O
mechanisms	mechanisms	O
for	for	O
their	their	O
occurrence	occurrence	O
are	are	O
reviewed	reviewed	O
and	and	O
the	the	O
efficacy	efficacy	O
and	and	O
complications	complications	O
of	of	O
thyroidectomy	thyroidectomy	O
and	and	O
radioiodine	radioiodine	O
compared	compared	O
to	to	O
those	those	O
of	of	O
antithyroid	antithyroid	B-Chemical
drugs	drugs	I-Chemical
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
in	in	O
most	most	O
circumstances	circumstances	O
131I	131i	O
is	is	O
the	the	O
therapy	therapy	O
of	of	O
choice	choice	O
for	for	O
hyperthyroidism	hyperthyroidism	B-Disease
.	.	O

Neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
induced	induced	O
by	by	O
combination	combination	O
therapy	therapy	O
with	with	O
tetrabenazine	tetrabenazine	O
and	and	O
tiapride	tiapride	O
in	in	O
a	a	O
Japanese	japanese	O
patient	patient	O
with	with	O
Huntington	huntington	O
's	's	O
disease	disease	O
at	at	O
the	the	O
terminal	terminal	O
stage	stage	O
of	of	O
recurrent	recurrent	O
breast	breast	B-Disease
cancer	cancer	B-Disease
.	.	O

We	we	O
herein	herein	O
describe	describe	O
the	the	O
case	case	O
of	of	O
an	an	O
81-year-old	81-year-old	O
Japanese	japanese	O
woman	woman	O
with	with	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
that	that	O
occurred	occurred	O
36	36	O
days	days	O
after	after	O
the	the	O
initiation	initiation	O
of	of	O
combination	combination	O
therapy	therapy	O
with	with	O
tiapride	tiapride	O
(	(	O
75	75	O
mg/day	mg/day	O
)	)	O
and	and	O
tetrabenazine	tetrabenazine	O
(	(	O
12.5	12.5	O
mg/day	mg/day	O
)	)	O
for	for	O
Huntington	huntington	O
's	's	O
disease	disease	O
.	.	O

The	the	O
patient	patient	O
had	had	O
been	been	O
treated	treated	O
with	with	O
tiapride	tiapride	O
or	or	O
tetrabenazine	tetrabenazine	O
alone	alone	O
without	without	O
any	any	O
adverse	adverse	O
effects	effects	O
before	before	O
the	the	O
administration	administration	O
of	of	O
the	the	O
combination	combination	O
therapy	therapy	O
.	.	O

She	she	O
also	also	O
had	had	O
advanced	advanced	O
breast	breast	B-Disease
cancer	cancer	B-Disease
when	when	O
the	the	O
combination	combination	O
therapy	therapy	O
was	was	O
initiated	initiated	O
.	.	O

To	to	O
the	the	O
best	best	O
of	of	O
our	our	O
knowledge	knowledge	O
,	,	O
the	the	O
occurrence	occurrence	O
of	of	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
due	due	O
to	to	O
combination	combination	O
therapy	therapy	O
with	with	O
tetrabenazine	tetrabenazine	O
and	and	O
tiapride	tiapride	O
has	has	O
not	not	O
been	been	O
previously	previously	O
reported	reported	O
.	.	O

Tetrabenazine	tetrabenazine	O
should	should	O
be	be	O
administered	administered	O
very	very	O
carefully	carefully	O
in	in	O
combination	combination	O
with	with	O
other	other	O
neuroleptic	neuroleptic	B-Chemical
drugs	drugs	I-Chemical
,	,	O
particularly	particularly	O
in	in	O
patients	patients	O
with	with	O
a	a	O
worsening	worsening	O
general	general	O
condition	condition	O
.	.	O

A	a	O
metoprolol-terbinafine	metoprolol-terbinafine	O
combination	combination	O
induced	induced	O
bradycardia	bradycardia	B-Disease
.	.	O

To	to	O
report	report	O
a	a	O
sinus	sinus	B-Disease
bradycardia	bradycardia	B-Disease
induced	induced	O
by	by	O
metoprolol	metoprolol	B-Chemical
and	and	O
terbinafine	terbinafine	O
drug-drug	drug-drug	O
interaction	interaction	O
and	and	O
its	its	O
management	management	O
.	.	O

A	a	O
63	63	O
year-old	year-old	O
Caucasian	caucasian	O
man	man	O
on	on	O
metoprolol	metoprolol	B-Chemical
200	200	O
mg/day	mg/day	O
for	for	O
stable	stable	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
was	was	O
prescribed	prescribed	O
a	a	O
90-day	90-day	O
course	course	O
of	of	O
oral	oral	O
terbinafine	terbinafine	O
250	250	O
mg/day	mg/day	O
for	for	O
onychomycosis	onychomycosis	O
.	.	O

On	on	O
the	the	O
49th	49th	O
day	day	O
of	of	O
terbinafine	terbinafine	O
therapy	therapy	O
,	,	O
he	he	O
was	was	O
brought	brought	O
to	to	O
the	the	O
emergency	emergency	O
room	room	O
for	for	O
a	a	O
decrease	decrease	O
of	of	O
his	his	O
global	global	O
health	health	O
status	status	O
,	,	O
confusion	confusion	B-Disease
and	and	O
falls	falls	O
.	.	O

The	the	O
electrocardiogram	electrocardiogram	O
revealed	revealed	O
a	a	O
37	37	O
beats/min	beats/min	O
sinus	sinus	B-Disease
bradycardia	bradycardia	B-Disease
.	.	O

A	a	O
score	score	O
of	of	O
7	7	O
on	on	O
the	the	O
Naranjo	naranjo	O
adverse	adverse	O
drug	drug	O
reaction	reaction	O
probability	probability	O
scale	scale	O
indicates	indicates	O
a	a	O
probable	probable	O
relationship	relationship	O
between	between	O
the	the	O
patient	patient	O
's	's	O
sinus	sinus	B-Disease
bradycardia	bradycardia	B-Disease
and	and	O
the	the	O
drug	drug	O
interaction	interaction	O
between	between	O
metoprolol	metoprolol	B-Chemical
and	and	O
terbinafine	terbinafine	O
.	.	O

The	the	O
heart	heart	O
rate	rate	O
ameliorated	ameliorated	O
first	first	O
with	with	O
a	a	O
decrease	decrease	O
in	in	O
the	the	O
dose	dose	O
of	of	O
metoprolol	metoprolol	B-Chemical
.	.	O

It	it	O
was	was	O
subsequently	subsequently	O
changed	changed	O
to	to	O
bisoprolol	bisoprolol	O
and	and	O
the	the	O
heart	heart	O
rate	rate	O
remained	remained	O
normal	normal	O
.	.	O

By	by	O
inhibiting	inhibiting	O
the	the	O
cytochrome	cytochrome	O
P450	p450	O
2D6	2d6	O
,	,	O
terbinafine	terbinafine	O
had	had	O
decreased	decreased	O
metoprolol	metoprolol	B-Chemical
's	's	O
clearance	clearance	O
,	,	O
leading	leading	O
in	in	O
metoprolol	metoprolol	B-Chemical
accumulation	accumulation	O
which	which	O
has	has	O
resulted	resulted	O
in	in	O
clinically	clinically	O
significant	significant	O
sinus	sinus	B-Disease
bradycardia	bradycardia	B-Disease
.	.	O

Optochiasmatic	optochiasmatic	O
and	and	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
due	due	O
to	to	O
ethambutol	ethambutol	O
overtreatment	overtreatment	O
.	.	O

Ethambutol	ethambutol	O
is	is	O
known	known	O
to	to	O
cause	cause	O
optic	optic	O
neuropathy	neuropathy	B-Disease
and	and	O
,	,	O
more	more	O
rarely	rarely	O
,	,	O
axonal	axonal	O
polyneuropathy	polyneuropathy	B-Disease
.	.	O

We	we	O
characterize	characterize	O
the	the	O
clinical	clinical	O
,	,	O
neurophysiological	neurophysiological	O
,	,	O
and	and	O
neuroimaging	neuroimaging	O
findings	findings	O
in	in	O
a	a	O
72-year-old	72-year-old	O
man	man	O
who	who	O
developed	developed	O
visual	visual	B-Disease
loss	loss	I-Disease
and	and	O
paresthesias	paresthesias	O
after	after	O
11	11	O
weeks	weeks	O
of	of	O
exposure	exposure	O
to	to	O
a	a	O
supratherapeutic	supratherapeutic	O
dose	dose	O
of	of	O
ethambutol	ethambutol	O
.	.	O

This	this	O
case	case	O
demonstrates	demonstrates	O
the	the	O
selective	selective	O
vulnerability	vulnerability	O
of	of	O
the	the	O
anterior	anterior	O
visual	visual	O
pathways	pathways	O
and	and	O
peripheral	peripheral	O
nerves	nerves	O
to	to	O
ethambutol	ethambutol	O
toxicity	toxicity	B-Disease
.	.	O

Testosterone	testosterone	B-Chemical
ameliorates	ameliorates	O
streptozotocin-induced	streptozotocin-induced	O
memory	memory	B-Disease
impairment	impairment	I-Disease
in	in	O
male	male	O
rats	rats	O
.	.	O

AIM	aim	O
:	:	O
To	to	O
study	study	O
the	the	O
effects	effects	O
of	of	O
testosterone	testosterone	B-Chemical
on	on	O
streptozotocin	streptozotocin	B-Chemical
(STZ)-induced	(stz)-induced	O
memory	memory	B-Disease
impairment	impairment	I-Disease
in	in	O
male	male	O
rats	rats	O
.	.	O

METHODS	methods	O
:	:	O
Adult	adult	O
male	male	O
Wistar	wistar	O
rats	rats	O
were	were	O
intracerebroventricularly	intracerebroventricularly	O
(	(	O
icv	icv	O
)	)	O
infused	infused	O
with	with	O
STZ	stz	O
(	(	O
750	750	O
ug	ug	O
)	)	O
on	on	O
d	d	O
1	1	O
and	and	O
d	d	O
3	3	O
,	,	O
and	and	O
a	a	O
passive	passive	O
avoidance	avoidance	O
task	task	O
was	was	O
assessed	assessed	O
2	2	O
weeks	weeks	O
after	after	O
the	the	O
first	first	O
injection	injection	O
of	of	O
STZ	stz	O
.	.	O

Castration	castration	O
surgery	surgery	O
was	was	O
performed	performed	O
in	in	O
another	another	O
group	group	O
of	of	O
rats	rats	O
,	,	O
and	and	O
the	the	O
passive	passive	O
avoidance	avoidance	O
task	task	O
was	was	O
assessed	assessed	O
4	4	O
weeks	weeks	O
after	after	O
the	the	O
operation	operation	O
.	.	O

Testosterone	testosterone	B-Chemical
(	(	O
1	1	O
mg.kg(-1).d(-1	mg.kg(-1).d(-1	O
)	)	O
,	,	O
sc	sc	O
)	)	O
,	,	O
the	the	O
androgen	androgen	O
receptor	receptor	O
antagonist	antagonist	O
flutamide	flutamide	O
(	(	O
10	10	O
mg.kg(-1).d(-1	mg.kg(-1).d(-1	O
)	)	O
,	,	O
ip	ip	O
)	)	O
,	,	O
the	the	O
estrogen	estrogen	B-Chemical
receptor	receptor	O
antagonist	antagonist	O
tamoxifen	tamoxifen	B-Chemical
(	(	O
1	1	O
mg.kg(-1).d(-1	mg.kg(-1).d(-1	O
)	)	O
,	,	O
ip	ip	O
)	)	O
or	or	O
the	the	O
aromatase	aromatase	O
inhibitor	inhibitor	O
letrozole	letrozole	O
(	(	O
4	4	O
mg.kg(-1).d(-1	mg.kg(-1).d(-1	O
)	)	O
,	,	O
ip	ip	O
)	)	O
were	were	O
administered	administered	O
for	for	O
6	6	O
d	d	O
after	after	O
the	the	O
first	first	O
injection	injection	O
of	of	O
STZ	stz	O
.	.	O

RESULTS	results	O
:	:	O
STZ	stz	O
administration	administration	O
and	and	O
castration	castration	O
markedly	markedly	O
decreased	decreased	O
both	both	O
STL1	stl1	O
(	(	O
the	the	O
short	short	O
memory	memory	O
)	)	O
and	and	O
STL2	stl2	O
(	(	O
the	the	O
long	long	O
memory	memory	O
)	)	O
in	in	O
passive	passive	O
avoidance	avoidance	O
tests	tests	O
.	.	O

Testosterone	testosterone	B-Chemical
replacement	replacement	O
almost	almost	O
restored	restored	O
the	the	O
STL1	stl1	O
and	and	O
STL2	stl2	O
in	in	O
castrated	castrated	O
rats	rats	O
,	,	O
and	and	O
significantly	significantly	O
prolonged	prolonged	O
the	the	O
STL1	stl1	O
and	and	O
STL2	stl2	O
in	in	O
STZ-treated	stz-treated	O
rats	rats	O
.	.	O

Administration	administration	O
of	of	O
flutamide	flutamide	O
,	,	O
letrozole	letrozole	O
or	or	O
tamoxifen	tamoxifen	B-Chemical
significantly	significantly	O
impaired	impaired	O
the	the	O
memory	memory	O
in	in	O
intact	intact	O
rats	rats	O
,	,	O
and	and	O
significantly	significantly	O
attenuated	attenuated	O
the	the	O
testosterone	testosterone	B-Chemical
replacement	replacement	O
in	in	O
improving	improving	O
STZ-	stz-	O
and	and	O
castration-induced	castration-induced	O
memory	memory	B-Disease
impairment	impairment	I-Disease
.	.	O

CONCLUSION	conclusion	O
:	:	O
Testosterone	testosterone	B-Chemical
administration	administration	O
ameliorates	ameliorates	O
STZ-	stz-	O
and	and	O
castration-induced	castration-induced	O
memory	memory	B-Disease
impairment	impairment	I-Disease
in	in	O
male	male	O
Wistar	wistar	O
rats	rats	O
.	.	O

Behavioral	behavioral	O
and	and	O
neurochemical	neurochemical	O
studies	studies	O
in	in	O
mice	mice	O
pretreated	pretreated	O
with	with	O
garcinielliptone	garcinielliptone	B-Chemical
FC	fc	I-Chemical
in	in	O
pilocarpine-induced	pilocarpine-induced	O
seizures	seizures	B-Disease
.	.	O

Garcinielliptone	garcinielliptone	B-Chemical
FC	fc	I-Chemical
(	(	O
GFC	gfc	O
)	)	O
isolated	isolated	O
from	from	O
hexanic	hexanic	O
fraction	fraction	O
seed	seed	O
extract	extract	O
of	of	O
species	species	O
Platonia	platonia	O
insignis	insignis	O
Mart	mart	O
.	.	O
It	it	O
is	is	O
widely	widely	O
used	used	O
in	in	O
folk	folk	O
medicine	medicine	O
to	to	O
treat	treat	O
skin	skin	B-Disease
diseases	diseases	I-Disease
in	in	O
both	both	O
humans	humans	O
and	and	O
animals	animals	O
as	as	O
well	well	O
as	as	O
the	the	O
seed	seed	O
decoction	decoction	O
has	has	O
been	been	O
used	used	O
to	to	O
treat	treat	O
diarrheas	diarrheas	O
and	and	O
inflammatory	inflammatory	O
diseases	diseases	O
.	.	O

However	however	O
,	,	O
there	there	O
is	is	O
no	no	O
research	research	O
on	on	O
GFC	gfc	O
effects	effects	O
in	in	O
the	the	O
central	central	O
nervous	nervous	O
system	system	O
of	of	O
rodents	rodents	O
.	.	O

The	the	O
present	present	O
study	study	O
aimed	aimed	O
to	to	O
evaluate	evaluate	O
the	the	O
GFC	gfc	O
effects	effects	O
at	at	O
doses	doses	O
of	of	O
25	25	O
,	,	O
50	50	O
or	or	O
75	75	O
mg/kg	mg/kg	O
on	on	O
seizure	seizure	B-Disease
parameters	parameters	O
to	to	O
determine	determine	O
their	their	O
anticonvulsant	anticonvulsant	O
activity	activity	O
and	and	O
its	its	O
effects	effects	O
on	on	O
amino	amino	B-Chemical
acid	acid	I-Chemical
(	(	O
r-aminobutyric	r-aminobutyric	O
acid	acid	O
(	(	O
GABA	gaba	B-Chemical
)	)	O
,	,	O
glutamine	glutamine	O
,	,	O
aspartate	aspartate	B-Chemical
and	and	O
glutathione	glutathione	B-Chemical
)	)	O
levels	levels	O
as	as	O
well	well	O
as	as	O
on	on	O
acetylcholinesterase	acetylcholinesterase	O
(	(	O
AChE	ache	O
)	)	O
activity	activity	O
in	in	O
mice	mice	O
hippocampus	hippocampus	O
after	after	O
seizures	seizures	B-Disease
.	.	O

GFC	gfc	O
produced	produced	O
an	an	O
increased	increased	O
latency	latency	O
to	to	O
first	first	O
seizure	seizure	B-Disease
,	,	O
at	at	O
doses	doses	O
25mg/kg	25mg/kg	O
(	(	O
20.12	20.12	O
+	+	O
2.20	2.20	O
min	min	O
)	)	O
,	,	O
50mg/kg	50mg/kg	O
(	(	O
20.95	20.95	O
+	+	O
2.21	2.21	O
min	min	O
)	)	O
or	or	O
75	75	O
mg/kg	mg/kg	O
(	(	O
23.43	23.43	O
+	+	O
1.99	1.99	O
min	min	O
)	)	O
when	when	O
compared	compared	O
with	with	O
seized	seized	O
mice	mice	O
.	.	O

In	in	O
addition	addition	O
,	,	O
GABA	gaba	B-Chemical
content	content	O
of	of	O
mice	mice	O
hippocampus	hippocampus	O
treated	treated	O
with	with	O
GFC75	gfc75	O
plus	plus	O
P400	p400	O
showed	showed	O
an	an	O
increase	increase	O
of	of	O
46.90	46.90	O
%	%	O
when	when	O
compared	compared	O
with	with	O
seized	seized	O
mice	mice	O
.	.	O

In	in	O
aspartate	aspartate	B-Chemical
,	,	O
glutamine	glutamine	O
and	and	O
glutamate	glutamate	B-Chemical
levels	levels	O
detected	detected	O
a	a	O
decrease	decrease	O
of	of	O
5.21	5.21	O
%	%	O
,	,	O
13.55	13.55	O
%	%	O
and	and	O
21.80	21.80	O
%	%	O
,	,	O
respectively	respectively	O
in	in	O
mice	mice	O
hippocampus	hippocampus	O
treated	treated	O
with	with	O
GFC75	gfc75	O
plus	plus	O
P400	p400	O
when	when	O
compared	compared	O
with	with	O
seized	seized	O
mice	mice	O
.	.	O

Hippocampus	hippocampus	O
mice	mice	O
treated	treated	O
with	with	O
GFC75	gfc75	O
plus	plus	O
P400	p400	O
showed	showed	O
an	an	O
increase	increase	O
in	in	O
AChE	ache	O
activity	activity	O
(	(	O
63.30	63.30	O
%	%	O
)	)	O
when	when	O
compared	compared	O
with	with	O
seized	seized	O
mice	mice	O
.	.	O

The	the	O
results	results	O
indicate	indicate	O
that	that	O
GFC	gfc	O
can	can	O
exert	exert	O
anticonvulsant	anticonvulsant	O
activity	activity	O
and	and	O
reduce	reduce	O
the	the	O
frequency	frequency	O
of	of	O
installation	installation	O
of	of	O
pilocarpine-induced	pilocarpine-induced	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
,	,	O
as	as	O
demonstrated	demonstrated	O
by	by	O
increase	increase	O
in	in	O
latency	latency	O
to	to	O
first	first	O
seizure	seizure	B-Disease
and	and	O
decrease	decrease	O
in	in	O
mortality	mortality	O
rate	rate	O
of	of	O
animals	animals	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
our	our	O
data	data	O
suggest	suggest	O
that	that	O
GFC	gfc	O
may	may	O
influence	influence	O
in	in	O
epileptogenesis	epileptogenesis	O
and	and	O
promote	promote	O
anticonvulsant	anticonvulsant	O
actions	actions	O
in	in	O
pilocarpine	pilocarpine	B-Chemical
model	model	O
by	by	O
modulating	modulating	O
the	the	O
GABA	gaba	B-Chemical
and	and	O
glutamate	glutamate	B-Chemical
contents	contents	O
and	and	O
of	of	O
AChE	ache	O
activity	activity	O
in	in	O
seized	seized	O
mice	mice	O
hippocampus	hippocampus	O
.	.	O

This	this	O
compound	compound	O
may	may	O
be	be	O
useful	useful	O
to	to	O
produce	produce	O
neuronal	neuronal	O
protection	protection	O
and	and	O
it	it	O
can	can	O
be	be	O
considered	considered	O
as	as	O
an	an	O
anticonvulsant	anticonvulsant	O
agent	agent	O
.	.	O

Standard	standard	O
operating	operating	O
procedures	procedures	O
for	for	O
antibiotic	antibiotic	O
therapy	therapy	O
and	and	O
the	the	O
occurrence	occurrence	O
of	of	O
acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
:	:	O
a	a	O
prospective	prospective	O
,	,	O
clinical	clinical	O
,	,	O
non-interventional	non-interventional	O
,	,	O
observational	observational	O
study	study	O
.	.	O

INTRODUCTION	introduction	O
:	:	O
Acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
(	(	O
AKI	aki	O
)	)	O
occurs	occurs	O
in	in	O
7	7	O
%	%	O
of	of	O
hospitalized	hospitalized	O
and	and	O
66	66	O
%	%	O
of	of	O
Intensive	intensive	O
Care	care	O
Unit	unit	O
(	(	O
ICU	icu	O
)	)	O
patients	patients	O
.	.	O

It	it	O
increases	increases	O
mortality	mortality	O
,	,	O
hospital	hospital	O
length	length	O
of	of	O
stay	stay	O
,	,	O
and	and	O
costs	costs	O
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
,	,	O
whether	whether	O
there	there	O
is	is	O
an	an	O
association	association	O
between	between	O
adherence	adherence	O
to	to	O
guidelines	guidelines	O
(	(	O
standard	standard	O
operating	operating	O
procedures	procedures	O
(	(	O
SOP	sop	O
)	)	O
)	)	O
for	for	O
potentially	potentially	O
nephrotoxic	nephrotoxic	B-Disease
antibiotics	antibiotics	O
and	and	O
the	the	O
occurrence	occurrence	O
of	of	O
AKI	aki	O
.	.	O

METHODS	methods	O
:	:	O
This	this	O
study	study	O
was	was	O
carried	carried	O
out	out	O
as	as	O
a	a	O
prospective	prospective	O
,	,	O
clinical	clinical	O
,	,	O
non-interventional	non-interventional	O
,	,	O
observational	observational	O
study	study	O
.	.	O

Data	data	O
collection	collection	O
was	was	O
performed	performed	O
over	over	O
a	a	O
total	total	O
of	of	O
170	170	O
days	days	O
in	in	O
three	three	O
ICUs	icus	O
at	at	O
Charite	charite	O
-	-	O
Universitaetsmedizin	universitaetsmedizin	O
Berlin	berlin	O
.	.	O

A	a	O
total	total	O
of	of	O
675	675	O
patients	patients	O
were	were	O
included	included	O
;	;	O
163	163	O
of	of	O
these	these	O
had	had	O
therapy	therapy	O
with	with	O
vancomycin	vancomycin	B-Chemical
,	,	O
gentamicin	gentamicin	B-Chemical
,	,	O
or	or	O
tobramycin	tobramycin	B-Chemical
;	;	O
were	were	O
>	>	O
18	18	O
years	years	O
;	;	O
and	and	O
treated	treated	O
in	in	O
the	the	O
ICU	icu	O
for	for	O
>	>	O
24	24	O
hours	hours	O
.	.	O

Patients	patients	O
with	with	O
an	an	O
adherence	adherence	O
to	to	O
SOP	sop	O
>	>	O
70	70	O
%	%	O
were	were	O
classified	classified	O
into	into	O
the	the	O
high	high	O
adherence	adherence	O
group	group	O
(	(	O
HAG	hag	O
)	)	O
and	and	O
patients	patients	O
with	with	O
an	an	O
adherence	adherence	O
of	of	O
<	<	O
70	70	O
%	%	O
into	into	O
the	the	O
low	low	O
adherence	adherence	O
group	group	O
(	(	O
LAG	lag	O
)	)	O
.	.	O

AKI	aki	O
was	was	O
defined	defined	O
according	according	O
to	to	O
RIFLE	rifle	O
criteria	criteria	O
.	.	O

Adherence	adherence	O
to	to	O
SOPs	sops	O
was	was	O
evaluated	evaluated	O
by	by	O
retrospective	retrospective	O
expert	expert	O
audit	audit	O
.	.	O

Development	development	O
of	of	O
AKI	aki	O
was	was	O
compared	compared	O
between	between	O
groups	groups	O
with	with	O
exact	exact	O
Chi2-test	chi2-test	O
and	and	O
multivariate	multivariate	O
logistic	logistic	O
regression	regression	O
analysis	analysis	O
(	(	O
two-sided	two-sided	O
P	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
LAG	lag	O
consisted	consisted	O
of	of	O
75	75	O
patients	patients	O
(	(	O
46	46	O
%	%	O
)	)	O
versus	versus	O
88	88	O
HAG	hag	O
patients	patients	O
(	(	O
54	54	O
%	%	O
)	)	O
.	.	O

AKI	aki	O
occurred	occurred	O
significantly	significantly	O
more	more	O
often	often	O
in	in	O
LAG	lag	O
with	with	O
36	36	O
%	%	O
versus	versus	O
21	21	O
%	%	O
in	in	O
HAG	hag	O
(	(	O
P	p	O
=	=	O
0.035	0.035	O
)	)	O
.	.	O

Basic	basic	O
characteristics	characteristics	O
were	were	O
comparable	comparable	O
,	,	O
except	except	O
an	an	O
increased	increased	O
rate	rate	O
of	of	O
soft	soft	B-Disease
tissue	tissue	I-Disease
infections	infections	B-Disease
in	in	O
LAG	lag	O
.	.	O

Multivariate	multivariate	O
analysis	analysis	O
revealed	revealed	O
an	an	O
odds	odds	O
ratio	ratio	O
of	of	O
2.5-fold	2.5-fold	O
for	for	O
LAG	lag	O
to	to	O
develop	develop	O
AKI	aki	O
compared	compared	O
with	with	O
HAG	hag	O
(	(	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
1.195	1.195	O
to	to	O
5.124	5.124	O
,	,	O
P	p	O
=	=	O
0.039	0.039	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Low	low	O
adherence	adherence	O
to	to	O
SOPs	sops	O
for	for	O
potentially	potentially	O
nephrotoxic	nephrotoxic	B-Disease
antibiotics	antibiotics	O
was	was	O
associated	associated	O
with	with	O
a	a	O
higher	higher	O
occurrence	occurrence	O
of	of	O
AKI	aki	O
.	.	O

TRIAL	trial	O
REGISTRATION	registration	O
:	:	O
Current	current	O
Controlled	controlled	O
Trials	trials	O
ISRCTN54598675	isrctn54598675	O
.	.	O

Registered	registered	O
17	17	O
August	august	O
2007	2007	O
.	.	O

Rhabdomyolysis	rhabdomyolysis	B-Disease
in	in	O
a	a	O
hepatitis	hepatitis	B-Disease
C	c	I-Disease
virus	virus	O
infected	infected	O
patient	patient	O
treated	treated	O
with	with	O
telaprevir	telaprevir	O
and	and	O
simvastatin	simvastatin	B-Chemical
.	.	O

A	a	O
46-year	46-year	O
old	old	O
man	man	O
with	with	O
a	a	O
chronic	chronic	B-Disease
hepatitis	hepatitis	B-Disease
C	c	I-Disease
virus	virus	O
infection	infection	B-Disease
received	received	O
triple	triple	O
therapy	therapy	O
with	with	O
ribavirin	ribavirin	B-Chemical
,	,	O
pegylated	pegylated	O
interferon	interferon	O
and	and	O
telaprevir	telaprevir	O
.	.	O

The	the	O
patient	patient	O
also	also	O
received	received	O
simvastatin	simvastatin	B-Chemical
.	.	O

One	one	O
month	month	O
after	after	O
starting	starting	O
the	the	O
antiviral	antiviral	O
therapy	therapy	O
,	,	O
the	the	O
patient	patient	O
was	was	O
admitted	admitted	O
to	to	O
the	the	O
hospital	hospital	O
because	because	O
he	he	O
developed	developed	O
rhabdomyolysis	rhabdomyolysis	B-Disease
.	.	O

At	at	O
admission	admission	O
simvastatin	simvastatin	B-Chemical
and	and	O
all	all	O
antiviral	antiviral	B-Chemical
drugs	drugs	I-Chemical
were	were	O
discontinued	discontinued	O
because	because	O
toxicity	toxicity	B-Disease
due	due	O
to	to	O
a	a	O
drug-drug	drug-drug	O
interaction	interaction	O
was	was	O
suspected	suspected	O
.	.	O

The	the	O
creatine	creatine	B-Chemical
kinase	kinase	I-Chemical
peaked	peaked	O
at	at	O
62,246	62,246	O
IU/L	iu/l	O
and	and	O
the	the	O
patient	patient	O
was	was	O
treated	treated	O
with	with	O
intravenous	intravenous	O
normal	normal	O
saline	saline	O
.	.	O

The	the	O
patient	patient	O
's	's	O
renal	renal	O
function	function	O
remained	remained	O
unaffected	unaffected	O
.	.	O

Fourteen	fourteen	O
days	days	O
after	after	O
hospitalization	hospitalization	O
,	,	O
creatine	creatine	B-Chemical
kinase	kinase	I-Chemical
level	level	O
had	had	O
returned	returned	O
to	to	O
230	230	O
IU/L	iu/l	O
and	and	O
the	the	O
patient	patient	O
was	was	O
discharged	discharged	O
.	.	O

Telaprevir	telaprevir	O
was	was	O
considered	considered	O
the	the	O
probable	probable	O
causative	causative	O
agent	agent	O
of	of	O
an	an	O
interaction	interaction	O
with	with	O
simvastatin	simvastatin	B-Chemical
according	according	O
to	to	O
the	the	O
Drug	drug	O
Interaction	interaction	O
Probability	probability	O
Scale	scale	O
.	.	O

The	the	O
interaction	interaction	O
is	is	O
due	due	O
to	to	O
inhibition	inhibition	O
of	of	O
CYP3A4-mediated	cyp3a4-mediated	O
simvastatin	simvastatin	B-Chemical
clearance	clearance	O
.	.	O

Simvastatin	simvastatin	B-Chemical
plasma	plasma	O
concentration	concentration	O
increased	increased	O
30	30	O
times	times	O
in	in	O
this	this	O
patient	patient	O
and	and	O
statin	statin	B-Chemical
induced	induced	O
muscle	muscle	O
toxicity	toxicity	B-Disease
is	is	O
related	related	O
to	to	O
the	the	O
concentration	concentration	O
of	of	O
the	the	O
statin	statin	B-Chemical
in	in	O
blood	blood	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
with	with	O
this	this	O
case	case	O
we	we	O
illustrate	illustrate	O
that	that	O
telaprevir	telaprevir	O
as	as	O
well	well	O
as	as	O
statins	statins	B-Chemical
are	are	O
susceptible	susceptible	O
to	to	O
clinical	clinical	O
relevant	relevant	O
drug-drug	drug-drug	O
interactions	interactions	O
.	.	O

Combination	combination	O
of	of	O
bortezomib	bortezomib	O
,	,	O
thalidomide	thalidomide	B-Chemical
,	,	O
and	and	O
dexamethasone	dexamethasone	B-Chemical
(	(	O
VTD	vtd	O
)	)	O
as	as	O
a	a	O
consolidation	consolidation	O
therapy	therapy	O
after	after	O
autologous	autologous	O
stem	stem	O
cell	cell	O
transplantation	transplantation	O
for	for	O
symptomatic	symptomatic	O
multiple	multiple	B-Disease
myeloma	myeloma	I-Disease
in	in	O
Japanese	japanese	O
patients	patients	O
.	.	O

Consolidation	consolidation	O
therapy	therapy	O
for	for	O
patients	patients	O
with	with	O
multiple	multiple	B-Disease
myeloma	myeloma	I-Disease
(	(	O
MM	mm	O
)	)	O
has	has	O
been	been	O
widely	widely	O
adopted	adopted	O
to	to	O
improve	improve	O
treatment	treatment	O
response	response	O
following	following	O
autologous	autologous	O
stem	stem	O
cell	cell	O
transplantation	transplantation	O
.	.	O

In	in	O
this	this	O
study	study	O
,	,	O
we	we	O
retrospectively	retrospectively	O
analyzed	analyzed	O
the	the	O
safety	safety	O
and	and	O
efficacy	efficacy	O
of	of	O
combination	combination	O
regimen	regimen	O
of	of	O
bortezomib	bortezomib	O
,	,	O
thalidomide	thalidomide	B-Chemical
,	,	O
and	and	O
dexamethasone	dexamethasone	B-Chemical
(	(	O
VTD	vtd	O
)	)	O
as	as	O
consolidation	consolidation	O
therapy	therapy	O
in	in	O
24	24	O
Japanese	japanese	O
patients	patients	O
with	with	O
newly	newly	O
diagnosed	diagnosed	O
MM	mm	O
.	.	O

VTD	vtd	O
consisted	consisted	O
of	of	O
bortezomib	bortezomib	O
at	at	O
a	a	O
dose	dose	O
of	of	O
1.3	1.3	O
mg/m(2	mg/m(2	O
)	)	O
and	and	O
dexamethasone	dexamethasone	B-Chemical
at	at	O
a	a	O
dose	dose	O
of	of	O
40	40	O
mg/day	mg/day	O
on	on	O
days	days	O
1	1	O
,	,	O
8	8	O
,	,	O
15	15	O
,	,	O
and	and	O
22	22	O
of	of	O
a	a	O
35-day	35-day	O
cycle	cycle	O
,	,	O
with	with	O
daily	daily	O
oral	oral	O
thalidomide	thalidomide	B-Chemical
at	at	O
a	a	O
dose	dose	O
of	of	O
100	100	O
mg/day	mg/day	O
.	.	O

Grade	grade	O
3	3	O
-	-	O
4	4	O
neutropenia	neutropenia	B-Disease
and	and	O
thrombocytopenia	thrombocytopenia	B-Disease
were	were	O
documented	documented	O
in	in	O
four	four	O
and	and	O
three	three	O
patients	patients	O
(	(	O
17	17	O
and	and	O
13	13	O
%	%	O
)	)	O
,	,	O
respectively	respectively	O
,	,	O
but	but	O
drug	drug	O
dose	dose	O
reduction	reduction	O
due	due	O
to	to	O
cytopenia	cytopenia	O
was	was	O
not	not	O
required	required	O
in	in	O
any	any	O
case	case	O
.	.	O

Peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
was	was	O
common	common	O
(	(	O
63	63	O
%	%	O
)	)	O
,	,	O
but	but	O
severe	severe	O
grade	grade	O
3	3	O
-	-	O
4	4	O
peripheral	peripheral	B-Disease
neuropathy	neuropathy	B-Disease
was	was	O
not	not	O
observed	observed	O
.	.	O

Very	very	O
good	good	O
partial	partial	O
response	response	O
or	or	O
better	better	O
response	response	O
(	(	O
>	>	O
VGPR	vgpr	O
)	)	O
rates	rates	O
before	before	O
and	and	O
after	after	O
consolidation	consolidation	O
therapy	therapy	O
were	were	O
54	54	O
and	and	O
79	79	O
%	%	O
,	,	O
respectively	respectively	O
.	.	O

Patients	patients	O
had	had	O
a	a	O
significant	significant	O
probability	probability	O
of	of	O
improving	improving	O
from	from	O
<	<	O
VGPR	vgpr	O
before	before	O
consolidation	consolidation	O
therapy	therapy	O
to	to	O
>	>	O
VGPR	vgpr	O
after	after	O
consolidation	consolidation	O
therapy	therapy	O
(	(	O
p	p	O
=	=	O
0.041	0.041	O
)	)	O
.	.	O

The	the	O
VTD	vtd	O
regimen	regimen	O
may	may	O
be	be	O
safe	safe	O
and	and	O
effective	effective	O
as	as	O
a	a	O
consolidation	consolidation	O
therapy	therapy	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
MM	mm	O
in	in	O
Japanese	japanese	O
population	population	O
.	.	O

Conversion	conversion	O
to	to	O
sirolimus	sirolimus	B-Chemical
ameliorates	ameliorates	O
cyclosporine-induced	cyclosporine-induced	O
nephropathy	nephropathy	B-Disease
in	in	O
the	the	O
rat	rat	O
:	:	O
focus	focus	O
on	on	O
serum	serum	O
,	,	O
urine	urine	O
,	,	O
gene	gene	O
,	,	O
and	and	O
protein	protein	O
renal	renal	O
expression	expression	O
biomarkers	biomarkers	O
.	.	O

Protocols	protocols	O
of	of	O
conversion	conversion	O
from	from	O
cyclosporin	cyclosporin	B-Chemical
A	a	I-Chemical
(	(	O
CsA	csa	B-Chemical
)	)	O
to	to	O
sirolimus	sirolimus	B-Chemical
(	(	O
SRL	srl	B-Chemical
)	)	O
have	have	O
been	been	O
widely	widely	O
used	used	O
in	in	O
immunotherapy	immunotherapy	O
after	after	O
transplantation	transplantation	O
to	to	O
prevent	prevent	O
CsA-induced	csa-induced	O
nephropathy	nephropathy	B-Disease
,	,	O
but	but	O
the	the	O
molecular	molecular	O
mechanisms	mechanisms	O
underlying	underlying	O
these	these	O
protocols	protocols	O
remain	remain	O
nuclear	nuclear	O
.	.	O

This	this	O
study	study	O
aimed	aimed	O
to	to	O
identify	identify	O
the	the	O
molecular	molecular	O
pathways	pathways	O
and	and	O
putative	putative	O
biomarkers	biomarkers	O
of	of	O
CsA-to-SRL	csa-to-srl	O
conversion	conversion	O
in	in	O
a	a	O
rat	rat	O
model	model	O
.	.	O

Four	four	O
animal	animal	O
groups	groups	O
(	(	O
n	n	O
=	=	O
6	6	O
)	)	O
were	were	O
tested	tested	O
during	during	O
9	9	O
weeks	weeks	O
:	:	O
control	control	O
,	,	O
CsA	csa	B-Chemical
,	,	O
SRL	srl	B-Chemical
,	,	O
and	and	O
conversion	conversion	O
(	(	O
CsA	csa	B-Chemical
for	for	O
3	3	O
weeks	weeks	O
followed	followed	O
by	by	O
SRL	srl	B-Chemical
for	for	O
6	6	O
weeks	weeks	O
)	)	O
.	.	O

Classical	classical	O
and	and	O
emergent	emergent	O
serum	serum	O
,	,	O
urinary	urinary	O
,	,	O
and	and	O
kidney	kidney	O
tissue	tissue	O
(	(	O
gene	gene	O
and	and	O
protein	protein	O
expression	expression	O
)	)	O
markers	markers	O
were	were	O
assessed	assessed	O
.	.	O

Renal	renal	O
lesions	lesions	O
were	were	O
analyzed	analyzed	O
in	in	O
hematoxylin	hematoxylin	O
and	and	O
eosin	eosin	O
,	,	O
periodic	periodic	O
acid-Schiff	acid-schiff	O
,	,	O
and	and	O
Masson	masson	O
's	's	O
trichrome	trichrome	O
stains	stains	O
.	.	O

SRL-treated	srl-treated	O
rats	rats	O
presented	presented	O
proteinuria	proteinuria	B-Disease
and	and	O
NGAL	ngal	O
(	(	O
serum	serum	O
and	and	O
urinary	urinary	O
)	)	O
as	as	O
the	the	O
best	best	O
markers	markers	O
of	of	O
renal	renal	O
impairment	impairment	O
.	.	O

Short	short	O
CsA	csa	B-Chemical
treatment	treatment	O
presented	presented	O
slight	slight	O
or	or	O
even	even	O
absent	absent	O
kidney	kidney	O
lesions	lesions	O
and	and	O
TGF-b	tgf-b	O
,	,	O
NF-	nf-	O
kb	kb	O
,	,	O
mTOR	mtor	O
,	,	O
PCNA	pcna	B-Chemical
,	,	O
TP53	tp53	O
,	,	O
KIM-1	kim-1	O
,	,	O
and	and	O
CTGF	ctgf	O
as	as	O
relevant	relevant	O
gene	gene	O
and	and	O
protein	protein	O
changes	changes	O
.	.	O

Prolonged	prolonged	O
CsA	csa	B-Chemical
exposure	exposure	O
aggravated	aggravated	O
renal	renal	B-Disease
damage	damage	I-Disease
,	,	O
without	without	O
clear	clear	O
changes	changes	O
on	on	O
the	the	O
traditional	traditional	O
markers	markers	O
,	,	O
but	but	O
with	with	O
changes	changes	O
in	in	O
serums	serums	O
TGF-	tgf-	O
b	b	O
and	and	O
IL-7	il-7	O
,	,	O
TBARs	tbars	B-Chemical
clearance	clearance	O
,	,	O
and	and	O
kidney	kidney	O
TGF-b	tgf-b	O
and	and	O
mTOR	mtor	O
.	.	O

Conversion	conversion	O
to	to	O
SRL	srl	B-Chemical
prevented	prevented	O
CsA-induced	csa-induced	O
renal	renal	B-Disease
damage	damage	I-Disease
evolution	evolution	O
(	(	O
absent/mild	absent/mild	O
grade	grade	O
lesions	lesions	O
)	)	O
,	,	O
while	while	O
NGAL	ngal	O
(	(	O
serum	serum	O
versus	versus	O
urine	urine	O
)	)	O
seems	seems	O
to	to	O
be	be	O
a	a	O
feasible	feasible	O
biomarker	biomarker	O
of	of	O
CsA	csa	B-Chemical
replacement	replacement	O
to	to	O
SRL	srl	B-Chemical
.	.	O

Kinin	kinin	O
B2	b2	O
receptor	receptor	O
deletion	deletion	O
and	and	O
blockage	blockage	O
ameliorates	ameliorates	O
cisplatin-induced	cisplatin-induced	O
acute	acute	B-Disease
renal	renal	B-Disease
injury	injury	I-Disease
.	.	O

Cisplatin	cisplatin	B-Chemical
treatment	treatment	O
has	has	O
been	been	O
adopted	adopted	O
in	in	O
some	some	O
chemotherapies	chemotherapies	O
;	;	O
however	however	O
,	,	O
this	this	O
drug	drug	O
can	can	O
induce	induce	O
acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
due	due	O
its	its	O
ability	ability	O
to	to	O
negatively	negatively	O
affect	affect	O
renal	renal	O
function	function	O
,	,	O
augment	augment	O
serum	serum	O
levels	levels	O
of	of	O
creatinine	creatinine	B-Chemical
and	and	O
urea	urea	B-Chemical
,	,	O
increase	increase	O
the	the	O
acute	acute	B-Disease
tubular	tubular	B-Disease
necrosis	necrosis	B-Disease
score	score	O
and	and	O
up-regulate	up-regulate	O
cytokines	cytokines	O
(	(	O
e.g.	e.g.	O
,	,	O
IL-1b	il-1b	O
and	and	O
TNF-a	tnf-a	O
)	)	O
.	.	O

The	the	O
kinin	kinin	O
B2	b2	O
receptor	receptor	O
has	has	O
been	been	O
associated	associated	O
with	with	O
the	the	O
inflammation	inflammation	B-Disease
process	process	O
,	,	O
as	as	O
well	well	O
as	as	O
the	the	O
regulation	regulation	O
of	of	O
cytokine	cytokine	O
expression	expression	O
,	,	O
and	and	O
its	its	O
deletion	deletion	O
resulted	resulted	O
in	in	O
an	an	O
improvement	improvement	O
in	in	O
the	the	O
diabetic	diabetic	B-Disease
nephropathy	nephropathy	B-Disease
status	status	O
.	.	O

To	to	O
examine	examine	O
the	the	O
role	role	O
of	of	O
the	the	O
kinin	kinin	O
B2	b2	O
receptor	receptor	O
in	in	O
cisplatin-induced	cisplatin-induced	O
acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
,	,	O
kinin	kinin	O
B2	b2	O
receptor	receptor	O
knockout	knockout	O
mice	mice	O
were	were	O
challenged	challenged	O
with	with	O
cisplatin	cisplatin	B-Chemical
.	.	O

Additionally	additionally	O
,	,	O
WT	wt	O
mice	mice	O
were	were	O
treated	treated	O
with	with	O
a	a	O
B2	b2	O
receptor	receptor	O
antagonist	antagonist	O
after	after	O
cisplatin	cisplatin	B-Chemical
administration	administration	O
.	.	O

B2	b2	O
receptor-deficient	receptor-deficient	O
mice	mice	O
were	were	O
less	less	O
sensitive	sensitive	O
to	to	O
this	this	O
drug	drug	O
than	than	O
the	the	O
WT	wt	O
mice	mice	O
,	,	O
as	as	O
shown	shown	O
by	by	O
reduced	reduced	O
weight	weight	B-Disease
loss	loss	I-Disease
,	,	O
better	better	O
preservation	preservation	O
of	of	O
kidney	kidney	O
function	function	O
,	,	O
down	down	O
regulation	regulation	O
of	of	O
inflammatory	inflammatory	O
cytokines	cytokines	O
and	and	O
less	less	O
acute	acute	B-Disease
tubular	tubular	B-Disease
necrosis	necrosis	B-Disease
.	.	O

Moreover	moreover	O
,	,	O
treatment	treatment	O
with	with	O
the	the	O
kinin	kinin	O
B2	b2	O
receptor	receptor	O
antagonist	antagonist	O
effectively	effectively	O
reduced	reduced	O
the	the	O
levels	levels	O
of	of	O
serum	serum	O
creatinine	creatinine	B-Chemical
and	and	O
blood	blood	O
urea	urea	B-Chemical
after	after	O
cisplatin	cisplatin	B-Chemical
administration	administration	O
.	.	O

Thus	thus	O
,	,	O
our	our	O
data	data	O
suggest	suggest	O
that	that	O
the	the	O
kinin	kinin	O
B2	b2	O
receptor	receptor	O
is	is	O
involved	involved	O
in	in	O
cisplatin-induced	cisplatin-induced	O
acute	acute	B-Disease
kidney	kidney	I-Disease
injury	injury	I-Disease
by	by	O
mediating	mediating	O
the	the	O
necrotic	necrotic	B-Disease
process	process	O
and	and	O
the	the	O
expression	expression	O
of	of	O
inflammatory	inflammatory	O
cytokines	cytokines	O
,	,	O
thus	thus	O
resulting	resulting	O
in	in	O
declined	declined	O
renal	renal	O
function	function	O
.	.	O

These	these	O
results	results	O
highlight	highlight	O
the	the	O
kinin	kinin	O
B2	b2	O
receptor	receptor	O
antagonist	antagonist	O
treatment	treatment	O
in	in	O
amelioration	amelioration	O
of	of	O
nephrotoxicity	nephrotoxicity	B-Disease
induced	induced	O
by	by	O
cisplatin	cisplatin	B-Chemical
therapy	therapy	O
.	.	O

Safety	safety	O
and	and	O
efficacy	efficacy	O
of	of	O
fluocinolone	fluocinolone	B-Chemical
acetonide	acetonide	I-Chemical
intravitreal	intravitreal	O
implant	implant	O
(	(	O
0.59	0.59	O
mg	mg	O
)	)	O
in	in	O
birdshot	birdshot	O
retinochoroidopathy	retinochoroidopathy	O
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
report	report	O
the	the	O
treatment	treatment	O
outcomes	outcomes	O
of	of	O
the	the	O
fluocinolone	fluocinolone	B-Chemical
acetonide	acetonide	I-Chemical
intravitreal	intravitreal	O
implant	implant	O
(	(	O
0.59	0.59	O
mg	mg	O
)	)	O
in	in	O
patients	patients	O
with	with	O
birdshot	birdshot	O
retinochoroidopathy	retinochoroidopathy	O
whose	whose	O
disease	disease	O
is	is	O
refractory	refractory	O
or	or	O
intolerant	intolerant	O
to	to	O
conventional	conventional	O
immunomodulatory	immunomodulatory	O
therapy	therapy	O
.	.	O

METHODS	methods	O
:	:	O
A	a	O
retrospective	retrospective	O
case	case	O
series	series	O
involving	involving	O
11	11	O
birdshot	birdshot	O
retinochoroidopathy	retinochoroidopathy	O
patients	patients	O
(	(	O
11	11	O
eyes	eyes	O
)	)	O
.	.	O

Eleven	eleven	O
patients	patients	O
(	(	O
11	11	O
eyes	eyes	O
)	)	O
underwent	underwent	O
surgery	surgery	O
for	for	O
fluocinolone	fluocinolone	B-Chemical
acetonide	acetonide	I-Chemical
implant	implant	O
(	(	O
0.59	0.59	O
mg	mg	O
)	)	O
.	.	O

Treatment	treatment	O
outcomes	outcomes	O
of	of	O
interest	interest	O
were	were	O
noted	noted	O
at	at	O
baseline	baseline	O
,	,	O
before	before	O
fluocinolone	fluocinolone	B-Chemical
acetonide	acetonide	I-Chemical
implant	implant	O
,	,	O
and	and	O
then	then	O
at	at	O
6	6	O
months	months	O
,	,	O
1	1	O
year	year	O
,	,	O
2	2	O
years	years	O
,	,	O
3	3	O
years	years	O
,	,	O
and	and	O
beyond	beyond	O
3	3	O
years	years	O
.	.	O

Disease	disease	O
activity	activity	O
markers	markers	O
,	,	O
including	including	O
signs	signs	O
of	of	O
ocular	ocular	O
inflammation	inflammation	B-Disease
,	,	O
evidence	evidence	O
of	of	O
retinal	retinal	B-Disease
vasculitis	vasculitis	B-Disease
,	,	O
Swedish	swedish	O
interactive	interactive	O
threshold	threshold	O
algorithm-short	algorithm-short	O
wavelength	wavelength	O
automated	automated	O
perimetry	perimetry	O
Humphrey	humphrey	O
visual	visual	O
field	field	O
analysis	analysis	O
,	,	O
electroretinographic	electroretinographic	O
parameters	parameters	O
,	,	O
and	and	O
optical	optical	O
coherence	coherence	O
tomography	tomography	O
were	were	O
recorded	recorded	O
.	.	O

Data	data	O
on	on	O
occurrence	occurrence	O
of	of	O
cataract	cataract	B-Disease
and	and	O
raised	raised	O
intraocular	intraocular	O
pressure	pressure	O
were	were	O
collected	collected	O
in	in	O
all	all	O
eyes	eyes	O
.	.	O

RESULTS	results	O
:	:	O
Intraocular	intraocular	O
inflammation	inflammation	B-Disease
was	was	O
present	present	O
in	in	O
54.5	54.5	O
,	,	O
9.9	9.9	O
,	,	O
11.1	11.1	O
,	,	O
and	and	O
0	0	O
%	%	O
of	of	O
patients	patients	O
at	at	O
baseline	baseline	O
,	,	O
6	6	O
months	months	O
,	,	O
1	1	O
year	year	O
,	,	O
2	2	O
years	years	O
,	,	O
3	3	O
years	years	O
,	,	O
and	and	O
beyond	beyond	O
3	3	O
years	years	O
after	after	O
receiving	receiving	O
the	the	O
implant	implant	O
,	,	O
respectively	respectively	O
.	.	O

Active	active	O
vasculitis	vasculitis	B-Disease
was	was	O
noted	noted	O
in	in	O
36.3	36.3	O
%	%	O
patients	patients	O
at	at	O
baseline	baseline	O
and	and	O
0	0	O
%	%	O
at	at	O
3	3	O
years	years	O
of	of	O
follow-up	follow-up	O
.	.	O

More	more	O
than	than	O
20	20	O
%	%	O
(	(	O
47.61	47.61	O
-	-	O
67.2	67.2	O
%	%	O
)	)	O
reduction	reduction	O
in	in	O
central	central	O
retinal	retinal	O
thickness	thickness	O
was	was	O
noted	noted	O
in	in	O
all	all	O
patients	patients	O
with	with	O
cystoid	cystoid	B-Disease
macular	macular	B-Disease
edema	edema	B-Disease
at	at	O
6	6	O
months	months	O
,	,	O
1	1	O
year	year	O
,	,	O
2	2	O
years	years	O
,	,	O
and	and	O
3	3	O
years	years	O
postimplant	postimplant	O
.	.	O

At	at	O
baseline	baseline	O
,	,	O
54.5	54.5	O
%	%	O
patients	patients	O
were	were	O
on	on	O
immunomodulatory	immunomodulatory	O
agents	agents	O
.	.	O

This	this	O
percentage	percentage	O
decreased	decreased	O
to	to	O
45.45	45.45	O
,	,	O
44.4	44.4	O
,	,	O
and	and	O
14.28	14.28	O
%	%	O
at	at	O
1	1	O
year	year	O
,	,	O
2	2	O
years	years	O
,	,	O
and	and	O
3	3	O
years	years	O
postimplant	postimplant	O
,	,	O
respectively	respectively	O
.	.	O

Adverse	adverse	O
events	events	O
included	included	O
increased	increased	O
intraocular	intraocular	O
pressure	pressure	O
(	(	O
54.5	54.5	O
%	%	O
)	)	O
and	and	O
cataract	cataract	B-Disease
formation	formation	O
(	(	O
100	100	O
%	%	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
data	data	O
suggest	suggest	O
that	that	O
fluocinolone	fluocinolone	B-Chemical
acetonide	acetonide	I-Chemical
implant	implant	O
(	(	O
0.59	0.59	O
mg	mg	O
)	)	O
helps	helps	O
to	to	O
control	control	O
inflammation	inflammation	B-Disease
in	in	O
otherwise	otherwise	O
treatment-refractory	treatment-refractory	O
cases	cases	O
of	of	O
birdshot	birdshot	O
retinochoroidopathy	retinochoroidopathy	O
.	.	O

It	it	O
is	is	O
associated	associated	O
with	with	O
significant	significant	O
side	side	O
effects	effects	O
of	of	O
cataract	cataract	B-Disease
and	and	O
ocular	ocular	B-Disease
hypertension	hypertension	B-Disease
requiring	requiring	O
treatment	treatment	O
.	.	O

Optimal	optimal	O
precurarizing	precurarizing	O
dose	dose	O
of	of	O
rocuronium	rocuronium	O
to	to	O
decrease	decrease	O
fasciculation	fasciculation	B-Disease
and	and	O
myalgia	myalgia	B-Disease
following	following	O
succinylcholine	succinylcholine	B-Chemical
administration	administration	O
.	.	O

BACKGROUND	background	O
:	:	O
Succinylcholine	succinylcholine	B-Chemical
commonly	commonly	O
produces	produces	O
frequent	frequent	O
adverse	adverse	O
effects	effects	O
,	,	O
including	including	O
muscle	muscle	O
fasciculation	fasciculation	B-Disease
and	and	O
myalgia	myalgia	B-Disease
.	.	O

The	the	O
current	current	O
study	study	O
identified	identified	O
the	the	O
optimal	optimal	O
dose	dose	O
of	of	O
rocuronium	rocuronium	O
to	to	O
prevent	prevent	O
succinylcholine-induced	succinylcholine-induced	O
fasciculation	fasciculation	B-Disease
and	and	O
myalgia	myalgia	B-Disease
and	and	O
evaluated	evaluated	O
the	the	O
influence	influence	O
of	of	O
rocuronium	rocuronium	O
on	on	O
the	the	O
speed	speed	O
of	of	O
onset	onset	O
produced	produced	O
by	by	O
succinylcholine	succinylcholine	B-Chemical
.	.	O

METHODS	methods	O
:	:	O
This	this	O
randomized	randomized	O
,	,	O
double-blinded	double-blinded	O
study	study	O
was	was	O
conducted	conducted	O
in	in	O
100	100	O
patients	patients	O
randomly	randomly	O
allocated	allocated	O
into	into	O
five	five	O
groups	groups	O
of	of	O
20	20	O
patients	patients	O
each	each	O
.	.	O

Patients	patients	O
were	were	O
randomized	randomized	O
to	to	O
receive	receive	O
0.02	0.02	O
,	,	O
0.03	0.03	O
,	,	O
0.04	0.04	O
,	,	O
0.05	0.05	O
and	and	O
0.06	0.06	O
mg/kg	mg/kg	O
rocuronium	rocuronium	O
as	as	O
a	a	O
precurarizing	precurarizing	O
dose	dose	O
.	.	O

Neuromuscular	neuromuscular	O
monitoring	monitoring	O
after	after	O
each	each	O
precurarizing	precurarizing	O
dose	dose	O
was	was	O
recorded	recorded	O
from	from	O
the	the	O
adductor	adductor	O
pollicis	pollicis	O
muscle	muscle	O
using	using	O
acceleromyography	acceleromyography	O
with	with	O
train-of-four	train-of-four	O
stimulation	stimulation	O
of	of	O
the	the	O
ulnar	ulnar	O
nerve	nerve	O
.	.	O

All	all	O
patients	patients	O
received	received	O
succinylcholine	succinylcholine	B-Chemical
1.5	1.5	O
mg/kg	mg/kg	O
at	at	O
2	2	O
minutes	minutes	O
after	after	O
the	the	O
precurarization	precurarization	O
,	,	O
and	and	O
were	were	O
assessed	assessed	O
the	the	O
incidence	incidence	O
and	and	O
severity	severity	O
of	of	O
fasciculations	fasciculations	O
,	,	O
while	while	O
myalgia	myalgia	B-Disease
was	was	O
assessed	assessed	O
at	at	O
24	24	O
hours	hours	O
after	after	O
surgery	surgery	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
incidence	incidence	O
and	and	O
severity	severity	O
of	of	O
visible	visible	O
muscle	muscle	O
fasciculation	fasciculation	B-Disease
was	was	O
significantly	significantly	O
less	less	O
with	with	O
increasing	increasing	O
the	the	O
amount	amount	O
of	of	O
precurarizing	precurarizing	O
dose	dose	O
of	of	O
rocuronium	rocuronium	O
(	(	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

Those	those	O
of	of	O
myalgia	myalgia	B-Disease
tend	tend	O
to	to	O
decrease	decrease	O
according	according	O
to	to	O
increasing	increasing	O
the	the	O
amount	amount	O
of	of	O
precurarizing	precurarizing	O
dose	dose	O
of	of	O
rocuronium	rocuronium	O
,	,	O
but	but	O
there	there	O
was	was	O
no	no	O
significance	significance	O
(	(	O
P	p	O
=	=	O
0.072	0.072	O
)	)	O
.	.	O

The	the	O
onset	onset	O
time	time	O
of	of	O
succinylcholine	succinylcholine	B-Chemical
was	was	O
significantly	significantly	O
longer	longer	O
with	with	O
increasing	increasing	O
the	the	O
amount	amount	O
of	of	O
precurarizing	precurarizing	O
dose	dose	O
of	of	O
rocuronium	rocuronium	O
(	(	O
P	p	O
<	<	O
0.001	0.001	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Precurarization	precurarization	O
with	with	O
0.04	0.04	O
mg/kg	mg/kg	O
rocuronium	rocuronium	O
was	was	O
the	the	O
optimal	optimal	O
dose	dose	O
considering	considering	O
the	the	O
reduction	reduction	O
in	in	O
the	the	O
incidence	incidence	O
and	and	O
severity	severity	O
of	of	O
fasciculation	fasciculation	B-Disease
and	and	O
myalgia	myalgia	B-Disease
with	with	O
acceptable	acceptable	O
onset	onset	O
time	time	O
,	,	O
and	and	O
the	the	O
safe	safe	O
and	and	O
effective	effective	O
precurarization	precurarization	O
.	.	O

Absence	absence	O
of	of	O
PKC-alpha	pkc-alpha	O
attenuates	attenuates	O
lithium-induced	lithium-induced	O
nephrogenic	nephrogenic	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
.	.	O

Lithium	lithium	B-Chemical
,	,	O
an	an	O
effective	effective	O
antipsychotic	antipsychotic	O
,	,	O
induces	induces	O
nephrogenic	nephrogenic	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
(	(	O
NDI	ndi	O
)	)	O
in	in	O
_	 	O
40	40	O
%	%	O
of	of	O
patients	patients	O
.	.	O

The	the	O
decreased	decreased	O
capacity	capacity	O
to	to	O
concentrate	concentrate	O
urine	urine	O
is	is	O
likely	likely	O
due	due	O
to	to	O
lithium	lithium	B-Chemical
acutely	acutely	O
disrupting	disrupting	O
the	the	O
cAMP	camp	O
pathway	pathway	O
and	and	O
chronically	chronically	O
reducing	reducing	O
urea	urea	B-Chemical
transporter	transporter	O
(	(	O
UT-A1	ut-a1	O
)	)	O
and	and	O
water	water	O
channel	channel	O
(	(	O
AQP2	aqp2	O
)	)	O
expression	expression	O
in	in	O
the	the	O
inner	inner	O
medulla	medulla	O
.	.	O

Targeting	targeting	O
an	an	O
alternative	alternative	O
signaling	signaling	O
pathway	pathway	O
,	,	O
such	such	O
as	as	O
PKC-mediated	pkc-mediated	O
signaling	signaling	O
,	,	O
may	may	O
be	be	O
an	an	O
effective	effective	O
method	method	O
of	of	O
treating	treating	O
lithium-induced	lithium-induced	O
polyuria	polyuria	B-Disease
.	.	O

PKC-alpha	pkc-alpha	O
null	null	O
mice	mice	O
(	(	O
PKCa	pkca	O
KO	ko	O
)	)	O
and	and	O
strain-matched	strain-matched	O
wild	wild	O
type	type	O
(	(	O
WT	wt	O
)	)	O
controls	controls	O
were	were	O
treated	treated	O
with	with	O
lithium	lithium	B-Chemical
for	for	O
0	0	O
,	,	O
3	3	O
or	or	O
5	5	O
days	days	O
.	.	O

WT	wt	O
mice	mice	O
had	had	O
increased	increased	O
urine	urine	O
output	output	O
and	and	O
lowered	lowered	O
urine	urine	O
osmolality	osmolality	O
after	after	O
3	3	O
and	and	O
5	5	O
days	days	O
of	of	O
treatment	treatment	O
whereas	whereas	O
PKCa	pkca	O
KO	ko	O
mice	mice	O
had	had	O
no	no	O
change	change	O
in	in	O
urine	urine	O
output	output	O
or	or	O
concentration	concentration	O
.	.	O

Western	western	O
blot	blot	O
analysis	analysis	O
revealed	revealed	O
that	that	O
AQP2	aqp2	O
expression	expression	O
in	in	O
medullary	medullary	O
tissues	tissues	O
was	was	O
lowered	lowered	O
after	after	O
3	3	O
and	and	O
5	5	O
days	days	O
in	in	O
WT	wt	O
mice	mice	O
;	;	O
however	however	O
,	,	O
AQP2	aqp2	O
was	was	O
unchanged	unchanged	O
in	in	O
PKCa	pkca	O
KO	ko	O
.	.	O

Similar	similar	O
results	results	O
were	were	O
observed	observed	O
with	with	O
UT-A1	ut-a1	O
expression	expression	O
.	.	O

Animals	animals	O
were	were	O
also	also	O
treated	treated	O
with	with	O
lithium	lithium	B-Chemical
for	for	O
6	6	O
weeks	weeks	O
.	.	O

Lithium-treated	lithium-treated	O
WT	wt	O
mice	mice	O
had	had	O
19-fold	19-fold	O
increased	increased	O
urine	urine	O
output	output	O
whereas	whereas	O
treated	treated	O
PKCa	pkca	O
KO	ko	O
animals	animals	O
had	had	O
a	a	O
4-fold	4-fold	O
increase	increase	O
in	in	O
output	output	O
.	.	O

AQP2	aqp2	O
and	and	O
UT-A1	ut-a1	O
expression	expression	O
was	was	O
lowered	lowered	O
in	in	O
6	6	O
week	week	O
lithium-treated	lithium-treated	O
WT	wt	O
animals	animals	O
whereas	whereas	O
in	in	O
treated	treated	O
PKCa	pkca	O
KO	ko	O
mice	mice	O
,	,	O
AQP2	aqp2	O
was	was	O
only	only	O
reduced	reduced	O
by	by	O
2-fold	2-fold	O
and	and	O
UT-A1	ut-a1	O
expression	expression	O
was	was	O
unaffected	unaffected	O
.	.	O

Urinary	urinary	O
sodium	sodium	B-Chemical
,	,	O
potassium	potassium	B-Chemical
and	and	O
calcium	calcium	B-Chemical
were	were	O
elevated	elevated	O
in	in	O
lithium-fed	lithium-fed	O
WT	wt	O
but	but	O
not	not	O
in	in	O
lithium-fed	lithium-fed	O
PKCa	pkca	O
KO	ko	O
mice	mice	O
.	.	O

Our	our	O
data	data	O
show	show	O
that	that	O
ablation	ablation	O
of	of	O
PKCa	pkca	O
preserves	preserves	O
AQP2	aqp2	O
and	and	O
UT-A1	ut-a1	O
protein	protein	O
expression	expression	O
and	and	O
localization	localization	O
in	in	O
lithium-induced	lithium-induced	O
NDI	ndi	O
,	,	O
and	and	O
prevents	prevents	O
the	the	O
development	development	O
of	of	O
the	the	O
severe	severe	O
polyuria	polyuria	B-Disease
associated	associated	O
with	with	O
lithium	lithium	B-Chemical
therapy	therapy	O
.	.	O

Is	is	O
Dysguesia	dysguesia	O
Going	going	O
to	to	O
be	be	O
a	a	O
Rare	rare	O
or	or	O
a	a	O
Common	common	O
Side-effect	side-effect	O
of	of	O
Amlodipine?A	amlodipine?a	O
very	very	O
rare	rare	O
side-effect	side-effect	O
of	of	O
amlodipine	amlodipine	O
is	is	O
dysguesia	dysguesia	O
.	.	O

A	a	O
review	review	O
of	of	O
the	the	O
literature	literature	O
produced	produced	O
only	only	O
one	one	O
case	case	O
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
about	about	O
a	a	O
female	female	O
with	with	O
essential	essential	B-Disease
hypertension	hypertension	B-Disease
on	on	O
drug	drug	O
treatment	treatment	O
with	with	O
amlodipine	amlodipine	O
developed	developed	O
loss	loss	O
of	of	O
taste	taste	O
sensation	sensation	O
.	.	O

Condition	condition	O
moderately	moderately	O
improved	improved	O
on	on	O
stoppage	stoppage	O
of	of	O
the	the	O
drug	drug	O
for	for	O
25	25	O
days	days	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
amlodipine	amlodipine	O
can	can	O
cause	cause	O
dysguesia	dysguesia	O
.	.	O

Here	here	O
,	,	O
we	we	O
describe	describe	O
the	the	O
clinical	clinical	O
presentation	presentation	O
and	and	O
review	review	O
the	the	O
relevant	relevant	O
literature	literature	O
on	on	O
amlodipine	amlodipine	O
and	and	O
dysguesia	dysguesia	O
.	.	O

Rhabdomyolysis	rhabdomyolysis	B-Disease
in	in	O
association	association	O
with	with	O
simvastatin	simvastatin	B-Chemical
and	and	O
dosage	dosage	O
increment	increment	O
in	in	O
clarithromycin	clarithromycin	O
.	.	O

Clarithromycin	clarithromycin	O
is	is	O
the	the	O
most	most	O
documented	documented	O
cytochrome	cytochrome	O
P450	p450	O
3A4	3a4	O
(	(	O
CYP3A4	cyp3a4	O
)	)	O
inhibitor	inhibitor	O
to	to	O
cause	cause	O
an	an	O
adverse	adverse	O
interaction	interaction	O
with	with	O
simvastatin	simvastatin	B-Chemical
.	.	O

This	this	O
particular	particular	O
case	case	O
is	is	O
of	of	O
interest	interest	O
as	as	O
rhabdomyolysis	rhabdomyolysis	B-Disease
only	only	O
occurred	occurred	O
after	after	O
an	an	O
increase	increase	O
in	in	O
the	the	O
dose	dose	O
of	of	O
clarithromycin	clarithromycin	O
.	.	O

The	the	O
patient	patient	O
developed	developed	O
raised	raised	O
cardiac	cardiac	O
biomarkers	biomarkers	O
without	without	O
any	any	O
obvious	obvious	O
cardiac	cardiac	O
issues	issues	O
,	,	O
a	a	O
phenomenon	phenomenon	O
that	that	O
has	has	O
been	been	O
linked	linked	O
to	to	O
rhabdomyolysis	rhabdomyolysis	B-Disease
previously	previously	O
.	.	O

To	to	O
date	date	O
,	,	O
there	there	O
has	has	O
been	been	O
no	no	O
reported	reported	O
effect	effect	O
of	of	O
rhabdomyolysis	rhabdomyolysis	B-Disease
on	on	O
the	the	O
structure	structure	O
and	and	O
function	function	O
of	of	O
cardiac	cardiac	O
muscle	muscle	O
.	.	O

Clinicians	clinicians	O
need	need	O
to	to	O
be	be	O
aware	aware	O
of	of	O
prescribing	prescribing	O
concomitant	concomitant	O
medications	medications	O
that	that	O
increase	increase	O
the	the	O
risk	risk	O
of	of	O
myopathy	myopathy	B-Disease
or	or	O
inhibit	inhibit	O
the	the	O
CYP3A4	cyp3a4	O
enzyme	enzyme	O
.	.	O

Our	our	O
case	case	O
suggests	suggests	O
that	that	O
troponin	troponin	O
elevation	elevation	O
could	could	O
be	be	O
associated	associated	O
with	with	O
statin	statin	B-Chemical
induced	induced	O
rhabdomyolysis	rhabdomyolysis	B-Disease
,	,	O
which	which	O
may	may	O
warrant	warrant	O
further	further	O
studies	studies	O
.	.	O

Characterization	characterization	O
of	of	O
a	a	O
novel	novel	O
BCHE	bche	O
"	"	O
silent	silent	O
"	"	O
allele	allele	O
:	:	O
point	point	O
mutation	mutation	O
(	(	O
p.	p.	O
Val204Asp	val204asp	O
)	)	O
causes	causes	O
loss	loss	O
of	of	O
activity	activity	O
and	and	O
prolonged	prolonged	O
apnea	apnea	B-Disease
with	with	O
suxamethonium	suxamethonium	B-Chemical
.	.	O

Butyrylcholinesterase	butyrylcholinesterase	B-Disease
deficiency	deficiency	I-Disease
is	is	O
characterized	characterized	O
by	by	O
prolonged	prolonged	O
apnea	apnea	B-Disease
after	after	O
the	the	O
use	use	O
of	of	O
muscle	muscle	O
relaxants	relaxants	O
(	(	O
suxamethonium	suxamethonium	B-Chemical
or	or	O
mivacurium	mivacurium	O
)	)	O
in	in	O
patients	patients	O
who	who	O
have	have	O
mutations	mutations	O
in	in	O
the	the	O
BCHE	bche	O
gene	gene	O
.	.	O

Here	here	O
,	,	O
we	we	O
report	report	O
a	a	O
case	case	O
of	of	O
prolonged	prolonged	O
neuromuscular	neuromuscular	O
block	block	O
after	after	O
administration	administration	O
of	of	O
suxamethonium	suxamethonium	B-Chemical
leading	leading	O
to	to	O
the	the	O
discovery	discovery	O
of	of	O
a	a	O
novel	novel	O
BCHE	bche	O
variant	variant	O
(	(	O
c.695T	c.695t	O
>	>	O
A	a	O
,	,	O
p.	p.	O
Val204Asp	val204asp	O
)	)	O
.	.	O

Inhibition	inhibition	O
studies	studies	O
,	,	O
kinetic	kinetic	O
analysis	analysis	O
and	and	O
molecular	molecular	O
dynamics	dynamics	O
were	were	O
undertaken	undertaken	O
to	to	O
understand	understand	O
how	how	O
this	this	O
mutation	mutation	O
disrupts	disrupts	O
the	the	O
catalytic	catalytic	O
triad	triad	O
and	and	O
determines	determines	O
a	a	O
"	"	O
silent	silent	O
"	"	O
phenotype	phenotype	O
.	.	O

Low	low	O
activity	activity	O
of	of	O
patient	patient	O
plasma	plasma	O
butyrylcholinesterase	butyrylcholinesterase	O
with	with	O
butyrylthiocholine	butyrylthiocholine	O
(	(	O
BTC	btc	O
)	)	O
and	and	O
benzoylcholine	benzoylcholine	O
,	,	O
and	and	O
values	values	O
of	of	O
dibucaine	dibucaine	O
and	and	O
fluoride	fluoride	O
numbers	numbers	O
fit	fit	O
with	with	O
heterozygous	heterozygous	O
atypical	atypical	O
silent	silent	O
genotype	genotype	O
.	.	O

Electrophoretic	electrophoretic	O
analysis	analysis	O
of	of	O
plasma	plasma	O
BChE	bche	O
of	of	O
the	the	O
proband	proband	O
and	and	O
his	his	O
mother	mother	O
showed	showed	O
that	that	O
patient	patient	O
has	has	O
a	a	O
reduced	reduced	O
amount	amount	O
of	of	O
tetrameric	tetrameric	O
enzyme	enzyme	O
in	in	O
plasma	plasma	O
and	and	O
that	that	O
minor	minor	O
fast-moving	fast-moving	O
BChE	bche	O
components	components	O
:	:	O
monomer	monomer	O
,	,	O
dimer	dimer	O
,	,	O
and	and	O
monomer-albumin	monomer-albumin	O
conjugate	conjugate	O
are	are	O
missing	missing	O
.	.	O

Kinetic	kinetic	O
analysis	analysis	O
showed	showed	O
that	that	O
the	the	O
p.	p.	O
Val204Asp/p	val204asp/p	O
.	.	O

Asp70Gly-p	asp70gly-p	O
.	.	O

Ala539Thr	ala539thr	O
BChE	bche	O
displays	displays	O
a	a	O
pure	pure	O
Michaelian	michaelian	O
behavior	behavior	O
with	with	O
BTC	btc	O
as	as	O
the	the	O
substrate	substrate	O
.	.	O

Both	both	O
catalytic	catalytic	O
parameters	parameters	O
Km	km	O
=	=	O
265	265	O
uM	um	O
for	for	O
BTC	btc	O
,	,	O
two	two	O
times	times	O
higher	higher	O
than	than	O
that	that	O
of	of	O
the	the	O
atypical	atypical	O
enzyme	enzyme	O
,	,	O
and	and	O
a	a	O
low	low	O
Vmax	vmax	O
are	are	O
consistent	consistent	O
with	with	O
the	the	O
absence	absence	O
of	of	O
activity	activity	O
against	against	O
suxamethonium	suxamethonium	B-Chemical
.	.	O

Molecular	molecular	O
dynamic	dynamic	O
(	(	O
MD	md	O
)	)	O
simulations	simulations	O
showed	showed	O
that	that	O
the	the	O
overall	overall	O
effect	effect	O
of	of	O
the	the	O
mutation	mutation	O
p.	p.	O
Val204Asp	val204asp	O
is	is	O
disruption	disruption	O
of	of	O
hydrogen	hydrogen	O
bonding	bonding	O
between	between	O
Gln223	gln223	O
and	and	O
Glu441	glu441	O
,	,	O
leading	leading	O
Ser198	ser198	O
and	and	O
His438	his438	O
to	to	O
move	move	O
away	away	O
from	from	O
each	each	O
other	other	O
with	with	O
subsequent	subsequent	O
disruption	disruption	O
of	of	O
the	the	O
catalytic	catalytic	O
triad	triad	O
functionality	functionality	O
regardless	regardless	O
of	of	O
the	the	O
type	type	O
of	of	O
substrate	substrate	O
.	.	O

MD	md	O
also	also	O
showed	showed	O
that	that	O
the	the	O
enzyme	enzyme	O
volume	volume	O
is	is	O
increased	increased	O
,	,	O
suggesting	suggesting	O
a	a	O
pre-denaturation	pre-denaturation	O
state	state	O
.	.	O

This	this	O
fits	fits	O
with	with	O
the	the	O
reduced	reduced	O
concentration	concentration	O
of	of	O
p.	p.	O
Ala204Asp/p	ala204asp/p	O
.	.	O

Asp70Gly-p	asp70gly-p	O
.	.	O

Ala539Thr	ala539thr	O
tetrameric	tetrameric	O
enzyme	enzyme	O
in	in	O
the	the	O
plasma	plasma	O
and	and	O
non-detectable	non-detectable	O
fast	fast	O
moving-bands	moving-bands	O
on	on	O
electrophoresis	electrophoresis	O
gels	gels	O
.	.	O

Delayed	delayed	O
anemia	anemia	B-Disease
after	after	O
treatment	treatment	O
with	with	O
injectable	injectable	O
artesunate	artesunate	O
in	in	O
the	the	O
Democratic	democratic	O
Republic	republic	O
of	of	O
the	the	O
Congo	congo	O
:	:	O
a	a	O
manageable	manageable	O
issue	issue	O
.	.	O

Cases	cases	O
of	of	O
delayed	delayed	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
have	have	O
been	been	O
described	described	O
after	after	O
treatment	treatment	O
with	with	O
injectable	injectable	O
artesunate	artesunate	O
,	,	O
the	the	O
current	current	O
World	world	O
Health	health	O
Organization	organization	O
(WHO)-recommended	(who)-recommended	O
first-line	first-line	O
drug	drug	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
severe	severe	O
malaria	malaria	O
.	.	O

A	a	O
total	total	O
of	of	O
350	350	O
patients	patients	O
(	(	O
215	215	O
[	[	O
61.4	61.4	O
%	%	O
]	]	O
<	<	O
5	5	O
years	years	O
of	of	O
age	age	O
and	and	O
135	135	O
[	[	O
38.6	38.6	O
%	%	O
]	]	O
>	>	O
5	5	O
years	years	O
of	of	O
age	age	O
)	)	O
were	were	O
followed-up	followed-up	O
after	after	O
treatment	treatment	O
with	with	O
injectable	injectable	O
artesunate	artesunate	O
for	for	O
severe	severe	O
malaria	malaria	O
in	in	O
hospitals	hospitals	O
and	and	O
health	health	O
centers	centers	O
of	of	O
the	the	O
Democratic	democratic	O
Republic	republic	O
of	of	O
the	the	O
Congo	congo	O
.	.	O

Complete	complete	O
series	series	O
of	of	O
hemoglobin	hemoglobin	O
(	(	O
Hb	hb	O
)	)	O
measurements	measurements	O
were	were	O
available	available	O
for	for	O
201	201	O
patients	patients	O
.	.	O

A	a	O
decrease	decrease	O
in	in	O
Hb	hb	O
levels	levels	O
between	between	O
2	2	O
and	and	O
5	5	O
g/dL	g/dl	O
was	was	O
detected	detected	O
in	in	O
23	23	O
(	(	O
11.4	11.4	O
%	%	O
)	)	O
patients	patients	O
during	during	O
the	the	O
follow-up	follow-up	O
period	period	O
.	.	O

For	for	O
five	five	O
patients	patients	O
,	,	O
Hb	hb	O
levels	levels	O
decreased	decreased	O
below	below	O
5	5	O
g/dL	g/dl	O
during	during	O
at	at	O
least	least	O
one	one	O
follow-up	follow-up	O
visit	visit	O
.	.	O

All	all	O
cases	cases	O
of	of	O
delayed	delayed	O
anemia	anemia	B-Disease
were	were	O
clinically	clinically	O
manageable	manageable	O
and	and	O
resolved	resolved	O
within	within	O
one	one	O
month	month	O
.	.	O

Regulation	regulation	O
of	of	O
signal	signal	O
transducer	transducer	O
and	and	O
activator	activator	O
of	of	O
transcription	transcription	O
3	3	O
and	and	O
apoptotic	apoptotic	O
pathways	pathways	O
by	by	O
betaine	betaine	O
attenuates	attenuates	O
isoproterenol-induced	isoproterenol-induced	O
acute	acute	O
myocardial	myocardial	B-Disease
injury	injury	I-Disease
in	in	O
rats	rats	O
.	.	O

The	the	O
present	present	O
study	study	O
was	was	O
designed	designed	O
to	to	O
investigate	investigate	O
the	the	O
cardioprotective	cardioprotective	O
effects	effects	O
of	of	O
betaine	betaine	O
on	on	O
acute	acute	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
induced	induced	O
experimentally	experimentally	O
in	in	O
rats	rats	O
focusing	focusing	O
on	on	O
regulation	regulation	O
of	of	O
signal	signal	O
transducer	transducer	O
and	and	O
activator	activator	O
of	of	O
transcription	transcription	O
3	3	O
(	(	O
STAT3	stat3	O
)	)	O
and	and	O
apoptotic	apoptotic	O
pathways	pathways	O
as	as	O
the	the	O
potential	potential	O
mechanism	mechanism	O
underlying	underlying	O
the	the	O
drug	drug	O
effect	effect	O
.	.	O

Male	male	O
Sprague	sprague	O
Dawley	dawley	O
rats	rats	O
were	were	O
treated	treated	O
with	with	O
betaine	betaine	O
(	(	O
100	100	O
,	,	O
200	200	O
,	,	O
and	and	O
400	400	O
mg/kg	mg/kg	O
)	)	O
orally	orally	O
for	for	O
40	40	O
days	days	O
.	.	O

Acute	acute	O
myocardial	myocardial	O
ischemic	ischemic	O
injury	injury	O
was	was	O
induced	induced	O
in	in	O
rats	rats	O
by	by	O
subcutaneous	subcutaneous	O
injection	injection	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
(	(	O
85	85	O
mg/kg	mg/kg	O
)	)	O
,	,	O
for	for	O
two	two	O
consecutive	consecutive	O
days	days	O
.	.	O

Serum	serum	O
cardiac	cardiac	O
marker	marker	O
enzyme	enzyme	O
,	,	O
histopathological	histopathological	O
variables	variables	O
and	and	O
expression	expression	O
of	of	O
protein	protein	O
levels	levels	O
were	were	O
analyzed	analyzed	O
.	.	O

Oral	oral	O
administration	administration	O
of	of	O
betaine	betaine	O
(	(	O
200	200	O
and	and	O
400	400	O
mg/kg	mg/kg	O
)	)	O
significantly	significantly	O
reduced	reduced	O
the	the	O
level	level	O
of	of	O
cardiac	cardiac	O
marker	marker	O
enzyme	enzyme	O
in	in	O
the	the	O
serum	serum	O
and	and	O
prevented	prevented	O
left	left	B-Disease
ventricular	ventricular	B-Disease
remodeling	remodeling	I-Disease
.	.	O

Western	western	O
blot	blot	O
analysis	analysis	O
showed	showed	O
that	that	O
isoproterenol-induced	isoproterenol-induced	O
phosphorylation	phosphorylation	O
of	of	O
STAT3	stat3	O
was	was	O
maintained	maintained	O
or	or	O
further	further	O
enhanced	enhanced	O
by	by	O
betaine	betaine	O
treatment	treatment	O
in	in	O
myocardium	myocardium	O
.	.	O

Furthermore	furthermore	O
,	,	O
betaine	betaine	O
(	(	O
200	200	O
and	and	O
400	400	O
mg/kg	mg/kg	O
)	)	O
treatment	treatment	O
increased	increased	O
the	the	O
ventricular	ventricular	O
expression	expression	O
of	of	O
Bcl-2	bcl-2	O
and	and	O
reduced	reduced	O
the	the	O
level	level	O
of	of	O
Bax	bax	O
,	,	O
therefore	therefore	O
causing	causing	O
a	a	O
significant	significant	O
increase	increase	O
in	in	O
the	the	O
ratio	ratio	O
of	of	O
Bcl-2/Bax	bcl-2/bax	O
.	.	O

The	the	O
protective	protective	O
role	role	O
of	of	O
betaine	betaine	O
on	on	O
myocardial	myocardial	B-Disease
damage	damage	I-Disease
was	was	O
further	further	O
confirmed	confirmed	O
by	by	O
histopathological	histopathological	O
examination	examination	O
.	.	O

In	in	O
summary	summary	O
,	,	O
our	our	O
results	results	O
showed	showed	O
that	that	O
betaine	betaine	O
pretreatment	pretreatment	O
attenuated	attenuated	O
isoproterenol-induced	isoproterenol-induced	O
acute	acute	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
via	via	O
the	the	O
regulation	regulation	O
of	of	O
STAT3	stat3	O
and	and	O
apoptotic	apoptotic	O
pathways	pathways	O
.	.	O

Quetiapine-induced	quetiapine-induced	O
neutropenia	neutropenia	B-Disease
in	in	O
a	a	O
bipolar	bipolar	B-Disease
patient	patient	O
with	with	O
hepatocellular	hepatocellular	B-Disease
carcinoma	carcinoma	B-Disease
.	.	O

OBJECTIVE	objective	O
:	:	O
Quetiapine	quetiapine	O
is	is	O
a	a	O
dibenzothiazepine	dibenzothiazepine	O
derivative	derivative	O
,	,	O
similar	similar	O
to	to	O
clozapine	clozapine	B-Chemical
,	,	O
which	which	O
has	has	O
the	the	O
highest	highest	O
risk	risk	O
of	of	O
causing	causing	O
blood	blood	O
dyscrasias	dyscrasias	O
,	,	O
especially	especially	O
neutropenia	neutropenia	B-Disease
.	.	O

There	there	O
are	are	O
some	some	O
case	case	O
reports	reports	O
about	about	O
this	this	O
side	side	O
effect	effect	O
of	of	O
quetiapine	quetiapine	O
,	,	O
but	but	O
possible	possible	O
risk	risk	O
factors	factors	O
are	are	O
seldom	seldom	O
discussed	discussed	O
and	and	O
identified	identified	O
.	.	O

A	a	O
case	case	O
of	of	O
a	a	O
patient	patient	O
with	with	O
hepatocellular	hepatocellular	B-Disease
carcinoma	carcinoma	B-Disease
that	that	O
developed	developed	O
neutropenia	neutropenia	B-Disease
after	after	O
treatment	treatment	O
with	with	O
quetiapine	quetiapine	O
is	is	O
described	described	O
here	here	O
.	.	O

CASE	case	O
REPORT	report	O
:	:	O
A	a	O
62-year-old	62-year-old	O
Taiwanese	taiwanese	O
widow	widow	O
with	with	O
bipolar	bipolar	B-Disease
disorder	disorder	I-Disease
was	was	O
diagnosed	diagnosed	O
with	with	O
hepatocellular	hepatocellular	B-Disease
carcinoma	carcinoma	B-Disease
at	at	O
age	age	O
60	60	O
.	.	O

She	she	O
developed	developed	O
leucopenia	leucopenia	O
after	after	O
being	being	O
treated	treated	O
with	with	O
quetiapine	quetiapine	O
.	.	O
After	after	O
quetiapine	quetiapine	O
was	was	O
discontinued	discontinued	O
,	,	O
her	her	O
white	white	O
blood	blood	O
cell	cell	O
count	count	O
returned	returned	O
to	to	O
normal	normal	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Although	although	O
neutropenia	neutropenia	B-Disease
is	is	O
not	not	O
a	a	O
common	common	O
side	side	O
effect	effect	O
of	of	O
quetiapine	quetiapine	O
,	,	O
physicians	physicians	O
should	should	O
be	be	O
cautious	cautious	O
about	about	O
its	its	O
presentation	presentation	O
and	and	O
associated	associated	O
risk	risk	O
factors	factors	O
.	.	O

Hepatic	hepatic	O
dysfunction	dysfunction	O
may	may	O
be	be	O
one	one	O
of	of	O
the	the	O
possible	possible	O
risk	risk	O
factors	factors	O
,	,	O
and	and	O
concomitant	concomitant	O
fever	fever	B-Disease
may	may	O
be	be	O
a	a	O
diagnostic	diagnostic	O
marker	marker	O
for	for	O
adverse	adverse	O
reaction	reaction	O
to	to	O
quetiapine	quetiapine	O
.	.	O

Lateral	lateral	O
antebrachial	antebrachial	O
cutaneous	cutaneous	O
neuropathy	neuropathy	B-Disease
after	after	O
steroid	steroid	B-Chemical
injection	injection	O
at	at	O
lateral	lateral	O
epicondyle	epicondyle	O
.	.	O

BACKGROUND	background	O
AND	and	O
OBJECTIVES	objectives	O
:	:	O
This	this	O
report	report	O
aimed	aimed	O
to	to	O
present	present	O
a	a	O
case	case	O
of	of	O
lateral	lateral	O
antebrachial	antebrachial	O
cutaneous	cutaneous	O
neuropathy	neuropathy	B-Disease
(	(	O
LACNP	lacnp	O
)	)	O
that	that	O
occurred	occurred	O
after	after	O
a	a	O
steroid	steroid	B-Chemical
injection	injection	O
in	in	O
the	the	O
lateral	lateral	O
epicondyle	epicondyle	O
to	to	O
treat	treat	O
lateral	lateral	O
epicondylitis	epicondylitis	O
in	in	O
a	a	O
40-year-old	40-year-old	O
woman	woman	O
.	.	O

MATERIAL	material	O
AND	and	O
METHOD	method	O
:	:	O
A	a	O
40-year-old	40-year-old	O
woman	woman	O
presented	presented	O
with	with	O
decreased	decreased	O
sensation	sensation	O
and	and	O
paresthesia	paresthesia	O
over	over	O
her	her	O
right	right	O
lateral	lateral	O
forearm	forearm	O
;	;	O
the	the	O
paresthesia	paresthesia	O
had	had	O
occurred	occurred	O
after	after	O
a	a	O
steroid	steroid	B-Chemical
injection	injection	O
in	in	O
the	the	O
right	right	O
lateral	lateral	O
epicondyle	epicondyle	O
3	3	O
months	months	O
before	before	O
.	.	O

Her	her	O
sensation	sensation	O
of	of	O
light	light	O
touch	touch	O
and	and	O
pain	pain	B-Disease
was	was	O
diminished	diminished	O
over	over	O
the	the	O
lateral	lateral	O
side	side	O
of	of	O
the	the	O
right	right	O
forearm	forearm	O
and	and	O
wrist	wrist	O
area	area	O
.	.	O

RESULTS	results	O
:	:	O
The	the	O
sensory	sensory	O
action	action	O
potential	potential	O
amplitude	amplitude	O
of	of	O
the	the	O
right	right	O
lateral	lateral	O
antebrachial	antebrachial	O
cutaneous	cutaneous	O
nerve	nerve	O
(	(	O
LACN	lacn	O
)	)	O
(	(	O
6.2	6.2	O
uV	uv	O
)	)	O
was	was	O
lower	lower	O
than	than	O
that	that	O
of	of	O
the	the	O
left	left	O
(	(	O
13.1	13.1	O
uV	uv	O
)	)	O
.	.	O

The	the	O
difference	difference	O
of	of	O
amplitude	amplitude	O
between	between	O
both	both	O
sides	sides	O
was	was	O
significant	significant	O
because	because	O
there	there	O
was	was	O
more	more	O
than	than	O
a	a	O
50	50	O
%	%	O
reduction	reduction	O
.	.	O

She	she	O
was	was	O
diagnosed	diagnosed	O
with	with	O
right	right	O
LACNP	lacnp	O
(	(	O
mainly	mainly	O
axonal	axonal	O
involvement	involvement	O
)	)	O
on	on	O
the	the	O
basis	basis	O
of	of	O
the	the	O
clinical	clinical	O
manifestation	manifestation	O
and	and	O
the	the	O
electrodiagnostic	electrodiagnostic	O
findings	findings	O
.	.	O

Her	her	O
symptoms	symptoms	O
improved	improved	O
through	through	O
physical	physical	O
therapy	therapy	O
but	but	O
persisted	persisted	O
to	to	O
some	some	O
degree	degree	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
This	this	O
report	report	O
describes	describes	O
the	the	O
case	case	O
of	of	O
a	a	O
woman	woman	O
with	with	O
LACNP	lacnp	O
that	that	O
developed	developed	O
after	after	O
a	a	O
steroid	steroid	B-Chemical
injection	injection	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
lateral	lateral	O
epicondylitis	epicondylitis	O
.	.	O

An	an	O
electrodiagnostic	electrodiagnostic	O
study	study	O
,	,	O
including	including	O
a	a	O
nerve	nerve	O
conduction	conduction	O
study	study	O
of	of	O
the	the	O
LACN	lacn	O
,	,	O
was	was	O
helpful	helpful	O
to	to	O
diagnose	diagnose	O
right	right	O
LACNP	lacnp	O
and	and	O
to	to	O
find	find	O
the	the	O
passage	passage	O
of	of	O
the	the	O
LACN	lacn	O
on	on	O
the	the	O
lateral	lateral	O
epicondyle	epicondyle	O
.	.	O

Curcumin	curcumin	B-Chemical
prevents	prevents	O
maleate-induced	maleate-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
:	:	O
relation	relation	O
to	to	O
hemodynamic	hemodynamic	O
alterations	alterations	O
,	,	O
oxidative	oxidative	O
stress	stress	O
,	,	O
mitochondrial	mitochondrial	O
oxygen	oxygen	B-Chemical
consumption	consumption	O
and	and	O
activity	activity	O
of	of	O
respiratory	respiratory	O
complex	complex	O
I.The	i.the	O
potential	potential	O
protective	protective	O
effect	effect	O
of	of	O
the	the	O
dietary	dietary	O
antioxidant	antioxidant	O
curcumin	curcumin	B-Chemical
(	(	O
120	120	O
mg/Kg/day	mg/kg/day	O
for	for	O
6	6	O
days	days	O
)	)	O
against	against	O
the	the	O
renal	renal	B-Disease
injury	injury	I-Disease
induced	induced	O
by	by	O
maleate	maleate	O
was	was	O
evaluated	evaluated	O
.	.	O

Tubular	tubular	O
proteinuria	proteinuria	B-Disease
and	and	O
oxidative	oxidative	O
stress	stress	O
were	were	O
induced	induced	O
by	by	O
a	a	O
single	single	O
injection	injection	O
of	of	O
maleate	maleate	O
(	(	O
400	400	O
mg/kg	mg/kg	O
)	)	O
in	in	O
rats	rats	O
.	.	O

Maleate-induced	maleate-induced	O
renal	renal	B-Disease
injury	injury	I-Disease
included	included	O
increase	increase	O
in	in	O
renal	renal	O
vascular	vascular	O
resistance	resistance	O
and	and	O
in	in	O
the	the	O
urinary	urinary	O
excretion	excretion	O
of	of	O
total	total	O
protein	protein	O
,	,	O
glucose	glucose	B-Chemical
,	,	O
sodium	sodium	B-Chemical
,	,	O
neutrophil	neutrophil	O
gelatinase-associated	gelatinase-associated	O
lipocalin	lipocalin	O
(	(	O
NGAL	ngal	O
)	)	O
and	and	O
N-acetyl	n-acetyl	O
b-D-glucosaminidase	b-d-glucosaminidase	O
(	(	O
NAG	nag	O
)	)	O
,	,	O
upregulation	upregulation	O
of	of	O
kidney	kidney	O
injury	injury	O
molecule	molecule	O
(KIM)-1	(kim)-1	O
,	,	O
decrease	decrease	O
in	in	O
renal	renal	O
blood	blood	O
flow	flow	O
and	and	O
claudin-2	claudin-2	O
expression	expression	O
besides	besides	O
of	of	O
necrosis	necrosis	B-Disease
and	and	O
apoptosis	apoptosis	O
of	of	O
tubular	tubular	O
cells	cells	O
on	on	O
24	24	O
h.	h.	O
Oxidative	oxidative	O
stress	stress	O
was	was	O
determined	determined	O
by	by	O
measuring	measuring	O
the	the	O
oxidation	oxidation	O
of	of	O
lipids	lipids	O
and	and	O
proteins	proteins	O
and	and	O
diminution	diminution	O
in	in	O
renal	renal	O
Nrf2	nrf2	O
levels	levels	O
.	.	O

Studies	studies	O
were	were	O
also	also	O
conducted	conducted	O
in	in	O
renal	renal	O
epithelial	epithelial	O
LLC-PK1	llc-pk1	O
cells	cells	O
and	and	O
in	in	O
mitochondria	mitochondria	O
isolated	isolated	O
from	from	O
kidneys	kidneys	O
of	of	O
all	all	O
the	the	O
experimental	experimental	O
groups	groups	O
.	.	O

Maleate	maleate	O
induced	induced	O
cell	cell	O
damage	damage	O
and	and	O
reactive	reactive	B-Chemical
oxygen	oxygen	B-Chemical
species	species	I-Chemical
(	(	O
ROS	ros	O
)	)	O
production	production	O
in	in	O
LLC-PK1	llc-pk1	O
cells	cells	O
in	in	O
culture	culture	O
.	.	O

In	in	O
addition	addition	O
,	,	O
maleate	maleate	O
treatment	treatment	O
reduced	reduced	O
oxygen	oxygen	B-Chemical
consumption	consumption	O
in	in	O
ADP-stimulated	adp-stimulated	O
mitochondria	mitochondria	O
and	and	O
diminished	diminished	O
respiratory	respiratory	O
control	control	O
index	index	O
when	when	O
using	using	O
malate/glutamate	malate/glutamate	O
as	as	O
substrate	substrate	O
.	.	O

The	the	O
activities	activities	O
of	of	O
both	both	O
complex	complex	O
I	i	O
and	and	O
aconitase	aconitase	O
were	were	O
also	also	O
diminished	diminished	O
.	.	O

All	all	O
the	the	O
above-described	above-described	O
alterations	alterations	O
were	were	O
prevented	prevented	O
by	by	O
curcumin	curcumin	B-Chemical
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
curcumin	curcumin	B-Chemical
is	is	O
able	able	O
to	to	O
attenuate	attenuate	O
in	in	O
vivo	vivo	O
maleate-induced	maleate-induced	O
nephropathy	nephropathy	B-Disease
and	and	O
in	in	O
vitro	vitro	O
cell	cell	O
damage	damage	O
.	.	O

The	the	O
in	in	O
vivo	vivo	O
protection	protection	O
was	was	O
associated	associated	O
to	to	O
the	the	O
prevention	prevention	O
of	of	O
oxidative	oxidative	O
stress	stress	O
and	and	O
preservation	preservation	O
of	of	O
mitochondrial	mitochondrial	O
oxygen	oxygen	B-Chemical
consumption	consumption	O
and	and	O
activity	activity	O
of	of	O
respiratory	respiratory	O
complex	complex	O
I	i	O
,	,	O
and	and	O
the	the	O
in	in	O
vitro	vitro	O
protection	protection	O
was	was	O
associated	associated	O
to	to	O
the	the	O
prevention	prevention	O
of	of	O
ROS	ros	O
production	production	O
.	.	O

Anticonvulsant	anticonvulsant	O
actions	actions	O
of	of	O
MK-801	mk-801	B-Chemical
on	on	O
the	the	O
lithium-pilocarpine	lithium-pilocarpine	O
model	model	O
of	of	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
in	in	O
rats	rats	O
.	.	O

MK-801	mk-801	B-Chemical
,	,	O
a	a	O
noncompetitive	noncompetitive	O
N-methyl-D-aspartate	n-methyl-d-aspartate	O
(	(	O
NMDA	nmda	B-Chemical
)	)	O
receptor	receptor	O
antagonist	antagonist	O
,	,	O
was	was	O
tested	tested	O
for	for	O
anticonvulsant	anticonvulsant	O
effects	effects	O
in	in	O
rats	rats	O
using	using	O
two	two	O
seizure	seizure	B-Disease
models	models	O
,	,	O
coadministration	coadministration	O
of	of	O
lithium	lithium	B-Chemical
and	and	O
pilocarpine	pilocarpine	B-Chemical
and	and	O
administration	administration	O
of	of	O
a	a	O
high	high	O
dose	dose	O
of	of	O
pilocarpine	pilocarpine	B-Chemical
alone	alone	O
.	.	O

Three	three	O
major	major	O
results	results	O
are	are	O
reported	reported	O
.	.	O

First	first	O
,	,	O
pretreatment	pretreatment	O
with	with	O
MK-801	mk-801	B-Chemical
produced	produced	O
an	an	O
effective	effective	O
and	and	O
dose-dependent	dose-dependent	O
anticonvulsant	anticonvulsant	O
action	action	O
with	with	O
the	the	O
lithium-pilocarpine	lithium-pilocarpine	O
model	model	O
but	but	O
not	not	O
with	with	O
rats	rats	O
treated	treated	O
with	with	O
pilocarpine	pilocarpine	B-Chemical
alone	alone	O
,	,	O
suggesting	suggesting	O
that	that	O
different	different	O
biochemical	biochemical	O
mechanisms	mechanisms	O
control	control	O
seizures	seizures	B-Disease
in	in	O
these	these	O
two	two	O
models	models	O
.	.	O

Second	second	O
,	,	O
the	the	O
anticonvulsant	anticonvulsant	O
effect	effect	O
of	of	O
MK-801	mk-801	B-Chemical
in	in	O
the	the	O
lithium-pilocarpine	lithium-pilocarpine	O
model	model	O
only	only	O
occurred	occurred	O
after	after	O
initial	initial	O
periods	periods	O
of	of	O
seizure	seizure	B-Disease
activity	activity	O
.	.	O

This	this	O
observation	observation	O
is	is	O
suggested	suggested	O
to	to	O
be	be	O
an	an	O
in	in	O
vivo	vivo	O
demonstration	demonstration	O
of	of	O
the	the	O
conclusion	conclusion	O
derived	derived	O
from	from	O
in	in	O
vitro	vitro	O
experiments	experiments	O
that	that	O
MK-801	mk-801	B-Chemical
binding	binding	O
requires	requires	O
agonist-induced	agonist-induced	O
opening	opening	O
of	of	O
the	the	O
channel	channel	O
sites	sites	O
of	of	O
the	the	O
NMDA	nmda	B-Chemical
receptor	receptor	O
.	.	O

Third	third	O
,	,	O
although	although	O
it	it	O
is	is	O
relatively	relatively	O
easy	easy	O
to	to	O
block	block	O
seizures	seizures	B-Disease
induced	induced	O
by	by	O
lithium	lithium	B-Chemical
and	and	O
pilocarpine	pilocarpine	B-Chemical
by	by	O
administration	administration	O
of	of	O
anticonvulsants	anticonvulsants	O
prior	prior	O
to	to	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
it	it	O
is	is	O
more	more	O
difficult	difficult	O
to	to	O
terminate	terminate	O
ongoing	ongoing	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
and	and	O
block	block	O
the	the	O
lethality	lethality	O
of	of	O
the	the	O
seizures	seizures	B-Disease
.	.	O

Administration	administration	O
of	of	O
MK-801	mk-801	B-Chemical
30	30	O
or	or	O
60	60	O
min	min	O
after	after	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
i.e.	i.e.	O
,	,	O
during	during	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
,	,	O
gradually	gradually	O
reduced	reduced	O
electrical	electrical	O
and	and	O
behavioral	behavioral	O
seizure	seizure	B-Disease
activity	activity	O
and	and	O
greatly	greatly	O
enhanced	enhanced	O
the	the	O
survival	survival	O
rate	rate	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
activation	activation	O
of	of	O
NMDA	nmda	B-Chemical
receptors	receptors	O
plays	plays	O
an	an	O
important	important	O
role	role	O
in	in	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
and	and	O
brain	brain	B-Disease
damage	damage	I-Disease
in	in	O
the	the	O
lithium-pilocarpine	lithium-pilocarpine	O
model	model	O
.	.	O

This	this	O
was	was	O
further	further	O
supported	supported	O
by	by	O
results	results	O
showing	showing	O
that	that	O
nonconvulsive	nonconvulsive	O
doses	doses	O
of	of	O
NMDA	nmda	B-Chemical
and	and	O
pilocarpine	pilocarpine	B-Chemical
were	were	O
synergistic	synergistic	O
,	,	O
resulting	resulting	O
in	in	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
and	and	O
subsequent	subsequent	O
mortality	mortality	O
.	.	O

Continuous	continuous	O
infusion	infusion	O
tobramycin	tobramycin	B-Chemical
combined	combined	O
with	with	O
carbenicillin	carbenicillin	O
for	for	O
infections	infections	B-Disease
in	in	O
cancer	cancer	B-Disease
patients	patients	O
.	.	O

The	the	O
cure	cure	O
rate	rate	O
of	of	O
infections	infections	B-Disease
in	in	O
cancer	cancer	B-Disease
patients	patients	O
is	is	O
adversely	adversely	O
affected	affected	O
by	by	O
neutropenia	neutropenia	B-Disease
(	(	O
less	less	O
than	than	O
1,000/mm3	1,000/mm3	O
)	)	O
.	.	O

In	in	O
particular	particular	O
,	,	O
patients	patients	O
with	with	O
severe	severe	O
neutropenia	neutropenia	B-Disease
(	(	O
less	less	O
than	than	O
100/mm3	100/mm3	O
)	)	O
have	have	O
shown	shown	O
a	a	O
poor	poor	O
response	response	O
to	to	O
antibiotics	antibiotics	O
.	.	O

To	to	O
overcome	overcome	O
the	the	O
adverse	adverse	O
effects	effects	O
of	of	O
neutropenia	neutropenia	B-Disease
,	,	O
tobramycin	tobramycin	B-Chemical
was	was	O
given	given	O
by	by	O
continuous	continuous	O
infusion	infusion	O
and	and	O
combined	combined	O
with	with	O
intermittent	intermittent	O
carbenicillin	carbenicillin	O
.	.	O

Tobramycin	tobramycin	B-Chemical
was	was	O
given	given	O
to	to	O
a	a	O
total	total	O
daily	daily	O
dose	dose	O
of	of	O
300	300	O
mg/m2	mg/m2	O
and	and	O
carbenicillin	carbenicillin	O
was	was	O
given	given	O
at	at	O
a	a	O
dose	dose	O
of	of	O
5	5	O
gm	gm	B-Chemical
every	every	O
four	four	O
hours	hours	O
.	.	O

There	there	O
were	were	O
125	125	O
infectious	infectious	O
episodes	episodes	O
in	in	O
116	116	O
cancer	cancer	B-Disease
patients	patients	O
receiving	receiving	O
myelosuppressive	myelosuppressive	O
chemotherapy	chemotherapy	O
.	.	O

The	the	O
overall	overall	O
cure	cure	O
rate	rate	O
was	was	O
70	70	O
%	%	O
.	.	O

Pneumonia	pneumonia	O
was	was	O
the	the	O
most	most	O
common	common	O
infection	infection	B-Disease
and	and	O
61	61	O
%	%	O
of	of	O
59	59	O
episodes	episodes	O
were	were	O
cured	cured	O
.	.	O

Gram-negative	gram-negative	O
bacilli	bacilli	O
were	were	O
the	the	O
most	most	O
common	common	O
causative	causative	O
organisms	organisms	O
and	and	O
69	69	O
%	%	O
of	of	O
these	these	O
infections	infections	B-Disease
were	were	O
cured	cured	O
.	.	O

The	the	O
most	most	O
common	common	O
pathogen	pathogen	O
was	was	O
Klebsiella	klebsiella	O
pneumoniae	pneumoniae	O
and	and	O
this	this	O
,	,	O
together	together	O
with	with	O
Escherichia	escherichia	O
coli	coli	O
and	and	O
Pseudomonas	pseudomonas	O
aeruginosa	aeruginosa	O
,	,	O
accounted	accounted	O
for	for	O
74	74	O
%	%	O
of	of	O
all	all	O
gram-negative	gram-negative	O
bacillary	bacillary	O
infections	infections	B-Disease
.	.	O

Response	response	O
was	was	O
not	not	O
influenced	influenced	O
by	by	O
the	the	O
initial	initial	O
neutrophil	neutrophil	O
count	count	O
,	,	O
with	with	O
a	a	O
62	62	O
%	%	O
cure	cure	O
rate	rate	O
for	for	O
39	39	O
episodes	episodes	O
associated	associated	O
with	with	O
severe	severe	O
neutropenia	neutropenia	B-Disease
.	.	O

However	however	O
,	,	O
failure	failure	O
of	of	O
the	the	O
neutrophil	neutrophil	O
count	count	O
to	to	O
increase	increase	O
during	during	O
therapy	therapy	O
adversely	adversely	O
affected	affected	O
response	response	O
.	.	O

Azotemia	azotemia	O
was	was	O
the	the	O
major	major	O
side	side	O
effect	effect	O
recognized	recognized	O
,	,	O
and	and	O
it	it	O
occurred	occurred	O
in	in	O
11	11	O
%	%	O
of	of	O
episodes	episodes	O
.	.	O

Major	major	O
azotemia	azotemia	O
(	(	O
serum	serum	O
creatinine	creatinine	B-Chemical
greater	greater	O
than	than	O
2.5	2.5	O
mg/dl	mg/dl	O
or	or	O
BUN	bun	O
greater	greater	O
than	than	O
50	50	O
mg/dl	mg/dl	O
)	)	O
occurred	occurred	O
in	in	O
only	only	O
2	2	O
%	%	O
.	.	O

Azotemia	azotemia	O
was	was	O
not	not	O
related	related	O
to	to	O
duration	duration	O
of	of	O
therapy	therapy	O
or	or	O
serum	serum	O
tobramycin	tobramycin	B-Chemical
concentration	concentration	O
.	.	O

This	this	O
antibiotic	antibiotic	O
regimen	regimen	O
showed	showed	O
both	both	O
therapeutic	therapeutic	O
efficacy	efficacy	O
and	and	O
acceptable	acceptable	O
renal	renal	B-Disease
toxicity	toxicity	B-Disease
for	for	O
these	these	O
patients	patients	O
.	.	O

Incidence	incidence	O
of	of	O
solid	solid	O
tumours	tumours	O
among	among	O
pesticide	pesticide	O
applicators	applicators	O
exposed	exposed	O
to	to	O
the	the	O
organophosphate	organophosphate	O
insecticide	insecticide	O
diazinon	diazinon	O
in	in	O
the	the	O
Agricultural	agricultural	O
Health	health	O
Study	study	O
:	:	O
an	an	O
updated	updated	O
analysis	analysis	O
.	.	O

OBJECTIVE	objective	O
:	:	O
Diazinon	diazinon	O
,	,	O
a	a	O
common	common	O
organophosphate	organophosphate	O
insecticide	insecticide	O
with	with	O
genotoxic	genotoxic	O
properties	properties	O
,	,	O
was	was	O
previously	previously	O
associated	associated	O
with	with	O
lung	lung	O
cancer	cancer	B-Disease
in	in	O
the	the	O
Agricultural	agricultural	O
Health	health	O
Study	study	O
(	(	O
AHS	ahs	O
)	)	O
cohort	cohort	O
,	,	O
but	but	O
few	few	O
other	other	O
epidemiological	epidemiological	O
studies	studies	O
have	have	O
examined	examined	O
diazinon-associated	diazinon-associated	O
cancer	cancer	B-Disease
risk	risk	O
.	.	O

We	we	O
used	used	O
updated	updated	O
diazinon	diazinon	O
exposure	exposure	O
and	and	O
cancer	cancer	B-Disease
incidence	incidence	O
information	information	O
to	to	O
evaluate	evaluate	O
solid	solid	O
tumour	tumour	O
risk	risk	O
in	in	O
the	the	O
AHS	ahs	O
.	.	O

METHODS	methods	O
:	:	O
Male	male	O
pesticide	pesticide	O
applicators	applicators	O
in	in	O
Iowa	iowa	O
and	and	O
North	north	O
Carolina	carolina	O
reported	reported	O
lifetime	lifetime	O
diazinon	diazinon	O
use	use	O
at	at	O
enrolment	enrolment	O
(	(	O
1993	1993	O
-	-	O
1997	1997	O
)	)	O
and	and	O
follow-up	follow-up	O
(	(	O
1998	1998	O
-	-	O
2005	2005	O
)	)	O
;	;	O
cancer	cancer	B-Disease
incidence	incidence	O
was	was	O
assessed	assessed	O
through	through	O
2010(North	2010(north	O
Carolina)/2011(Iowa	carolina)/2011(iowa	O
)	)	O
.	.	O

Among	among	O
applicators	applicators	O
with	with	O
usage	usage	O
information	information	O
sufficient	sufficient	O
to	to	O
evaluate	evaluate	O
exposure-response	exposure-response	O
patterns	patterns	O
,	,	O
we	we	O
used	used	O
Poisson	poisson	O
regression	regression	O
to	to	O
estimate	estimate	O
adjusted	adjusted	O
rate	rate	O
ratios	ratios	O
(	(	O
RRs	rrs	O
)	)	O
and	and	O
95	95	O
%	%	O
CI	ci	O
for	for	O
cancer	cancer	B-Disease
sites	sites	O
with	with	O
>	>	O
10	10	O
exposed	exposed	O
cases	cases	O
for	for	O
both	both	O
lifetime	lifetime	O
(	(	O
LT	lt	O
)	)	O
exposure	exposure	O
days	days	O
and	and	O
intensity-weighted	intensity-weighted	O
(	(	O
IW	iw	O
)	)	O
lifetime	lifetime	O
exposure	exposure	O
days	days	O
(	(	O
accounting	accounting	O
for	for	O
factors	factors	O
impacting	impacting	O
exposure	exposure	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
We	we	O
observed	observed	O
elevated	elevated	O
lung	lung	O
cancer	cancer	B-Disease
risks	risks	O
(	(	O
N=283	n=283	O
)	)	O
among	among	O
applicators	applicators	O
with	with	O
the	the	O
greatest	greatest	O
number	number	O
of	of	O
LT	lt	O
(	(	O
RR=1.60	rr=1.60	O
;	;	O
95	95	O
%	%	O
CI	ci	O
1.11	1.11	O
to	to	O
2.31	2.31	O
;	;	O
Ptrend=0.02	ptrend=0.02	O
)	)	O
and	and	O
IW	iw	O
days	days	O
of	of	O
diazinon	diazinon	O
use	use	O
(	(	O
RR=1.41	rr=1.41	O
;	;	O
95	95	O
%	%	O
CI	ci	O
0.98	0.98	O
to	to	O
2.04	2.04	O
;	;	O
Ptrend=0.08	ptrend=0.08	O
)	)	O
.	.	O

Kidney	kidney	O
cancer	cancer	B-Disease
(	(	O
N=94	n=94	O
)	)	O
risks	risks	O
were	were	O
non-significantly	non-significantly	O
elevated	elevated	O
(	(	O
RRLT	rrlt	O
days=1.77	days=1.77	O
;	;	O
95	95	O
%	%	O
CI	ci	O
0.90	0.90	O
to	to	O
3.51	3.51	O
;	;	O
Ptrend=0.09	ptrend=0.09	O
;	;	O
RRIW	rriw	O
days	days	O
1.37	1.37	O
;	;	O
95	95	O
%	%	O
CI	ci	O
0.64	0.64	O
to	to	O
2.92	2.92	O
;	;	O
Ptrend=0.50	ptrend=0.50	O
)	)	O
,	,	O
as	as	O
were	were	O
risks	risks	O
for	for	O
aggressive	aggressive	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
(	(	O
N=656	n=656	O
)	)	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Our	our	O
updated	updated	O
evaluation	evaluation	O
of	of	O
diazinon	diazinon	O
provides	provides	O
additional	additional	O
evidence	evidence	O
of	of	O
an	an	O
association	association	O
with	with	O
lung	lung	O
cancer	cancer	B-Disease
risk	risk	O
.	.	O

Newly	newly	O
identified	identified	O
links	links	O
to	to	O
kidney	kidney	O
cancer	cancer	B-Disease
and	and	O
associations	associations	O
with	with	O
aggressive	aggressive	O
prostate	prostate	B-Disease
cancer	cancer	B-Disease
require	require	O
further	further	O
evaluation	evaluation	O
.	.	O

Associations	associations	O
of	of	O
Ozone	ozone	O
and	and	O
PM2.5	pm2.5	O
Concentrations	concentrations	O
With	with	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
Disease	disease	I-Disease
Among	among	O
Participants	participants	O
in	in	O
the	the	O
Agricultural	agricultural	O
Health	health	O
Study	study	O
.	.	O

OBJECTIVE	objective	O
:	:	O
This	this	O
study	study	O
describes	describes	O
associations	associations	O
of	of	O
ozone	ozone	O
and	and	O
fine	fine	O
particulate	particulate	B-Chemical
matter	matter	I-Chemical
with	with	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
observed	observed	O
among	among	O
farmers	farmers	O
in	in	O
North	north	O
Carolina	carolina	O
and	and	O
Iowa	iowa	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
used	used	O
logistic	logistic	O
regression	regression	O
to	to	O
determine	determine	O
the	the	O
associations	associations	O
of	of	O
these	these	O
pollutants	pollutants	O
with	with	O
self-reported	self-reported	O
,	,	O
doctor-diagnosed	doctor-diagnosed	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

Daily	daily	O
predicted	predicted	O
pollutant	pollutant	O
concentrations	concentrations	O
were	were	O
used	used	O
to	to	O
derive	derive	O
surrogates	surrogates	O
of	of	O
long-term	long-term	O
exposure	exposure	O
and	and	O
link	link	O
them	them	O
to	to	O
study	study	O
participants	participants	O
'	'	O
geocoded	geocoded	O
addresses	addresses	O
.	.	O

RESULTS	results	O
:	:	O
We	we	O
observed	observed	O
positive	positive	O
associations	associations	O
of	of	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
with	with	O
ozone	ozone	O
(	(	O
odds	odds	O
ratio	ratio	O
=	=	O
1.39	1.39	O
;	;	O
95	95	O
%	%	O
CI	ci	O
:	:	O
0.98	0.98	O
to	to	O
1.98	1.98	O
)	)	O
and	and	O
fine	fine	O
particulate	particulate	B-Chemical
matter	matter	I-Chemical
(	(	O
odds	odds	O
ratio	ratio	O
=	=	O
1.34	1.34	O
;	;	O
95	95	O
%	%	O
CI	ci	O
:	:	O
0.93	0.93	O
to	to	O
1.93	1.93	O
)	)	O
in	in	O
North	north	O
Carolina	carolina	O
but	but	O
not	not	O
in	in	O
Iowa	iowa	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
The	the	O
plausibility	plausibility	O
of	of	O
an	an	O
effect	effect	O
of	of	O
ambient	ambient	O
concentrations	concentrations	O
of	of	O
these	these	O
pollutants	pollutants	O
on	on	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
risk	risk	O
is	is	O
supported	supported	O
by	by	O
experimental	experimental	O
data	data	O
demonstrating	demonstrating	O
damage	damage	O
to	to	O
dopaminergic	dopaminergic	O
neurons	neurons	O
at	at	O
relevant	relevant	O
concentrations	concentrations	O
.	.	O

Additional	additional	O
studies	studies	O
are	are	O
needed	needed	O
to	to	O
address	address	O
uncertainties	uncertainties	O
related	related	O
to	to	O
confounding	confounding	O
and	and	O
to	to	O
examine	examine	O
temporal	temporal	O
aspects	aspects	O
of	of	O
the	the	O
associations	associations	O
we	we	O
observed	observed	O
.	.	O

Low	low	O
functional	functional	O
programming	programming	O
of	of	O
renal	renal	O
AT2R	at2r	O
mediates	mediates	O
the	the	O
developmental	developmental	O
origin	origin	O
of	of	O
glomerulosclerosis	glomerulosclerosis	B-Disease
in	in	O
adult	adult	O
offspring	offspring	O
induced	induced	O
by	by	O
prenatal	prenatal	O
caffeine	caffeine	B-Chemical
exposure	exposure	O
.	.	O

UNASSIGNED	unassigned	O
:	:	O
Our	our	O
previous	previous	O
study	study	O
has	has	O
indicated	indicated	O
that	that	O
prenatal	prenatal	O
caffeine	caffeine	B-Chemical
exposure	exposure	O
(	(	O
PCE	pce	O
)	)	O
could	could	O
induce	induce	O
intrauterine	intrauterine	O
growth	growth	O
retardation	retardation	O
(	(	O
IUGR	iugr	O
)	)	O
of	of	O
offspring	offspring	O
.	.	O

Recent	recent	O
research	research	O
suggested	suggested	O
that	that	O
IUGR	iugr	O
is	is	O
a	a	O
risk	risk	O
factor	factor	O
for	for	O
glomerulosclerosis	glomerulosclerosis	B-Disease
.	.	O

However	however	O
,	,	O
whether	whether	O
PCE	pce	O
could	could	O
induce	induce	O
glomerulosclerosis	glomerulosclerosis	B-Disease
and	and	O
its	its	O
underlying	underlying	O
mechanisms	mechanisms	O
remain	remain	O
unknown	unknown	O
.	.	O

This	this	O
study	study	O
aimed	aimed	O
to	to	O
demonstrate	demonstrate	O
the	the	O
induction	induction	O
to	to	O
glomerulosclerosis	glomerulosclerosis	B-Disease
in	in	O
adult	adult	O
offspring	offspring	O
by	by	O
PCE	pce	O
and	and	O
its	its	O
intrauterine	intrauterine	O
programming	programming	O
mechanisms	mechanisms	O
.	.	O

A	a	O
rat	rat	O
model	model	O
of	of	O
IUGR	iugr	O
was	was	O
established	established	O
by	by	O
PCE	pce	O
,	,	O
male	male	O
fetuses	fetuses	O
and	and	O
adult	adult	O
offspring	offspring	O
at	at	O
the	the	O
age	age	O
of	of	O
postnatal	postnatal	O
week	week	O
24	24	O
were	were	O
euthanized	euthanized	O
.	.	O

The	the	O
results	results	O
revealed	revealed	O
that	that	O
the	the	O
adult	adult	O
offspring	offspring	O
kidneys	kidneys	O
in	in	O
the	the	O
PCE	pce	O
group	group	O
exhibited	exhibited	O
glomerulosclerosis	glomerulosclerosis	B-Disease
as	as	O
well	well	O
as	as	O
interstitial	interstitial	O
fibrosis	fibrosis	B-Disease
,	,	O
accompanied	accompanied	O
by	by	O
elevated	elevated	O
levels	levels	O
of	of	O
serum	serum	O
creatinine	creatinine	B-Chemical
and	and	O
urine	urine	O
protein	protein	O
.	.	O

Renal	renal	O
angiotensin	angiotensin	B-Chemical
II	ii	I-Chemical
receptor	receptor	O
type	type	O
2	2	O
(	(	O
AT2R	at2r	O
)	)	O
gene	gene	O
expression	expression	O
in	in	O
adult	adult	O
offspring	offspring	O
was	was	O
reduced	reduced	O
by	by	O
PCE	pce	O
,	,	O
whereas	whereas	O
the	the	O
renal	renal	O
angiotensin	angiotensin	B-Chemical
II	ii	I-Chemical
receptor	receptor	O
type	type	O
1a	1a	O
(AT1aR)/AT2R	(at1ar)/at2r	O
expression	expression	O
ratio	ratio	O
was	was	O
increased	increased	O
.	.	O

The	the	O
fetal	fetal	O
kidneys	kidneys	O
in	in	O
the	the	O
PCE	pce	O
group	group	O
displayed	displayed	O
an	an	O
enlarged	enlarged	O
Bowman	bowman	O
's	's	O
space	space	O
and	and	O
a	a	O
shrunken	shrunken	O
glomerular	glomerular	O
tuft	tuft	O
,	,	O
accompanied	accompanied	O
by	by	O
a	a	O
reduced	reduced	O
cortex	cortex	O
width	width	O
and	and	O
an	an	O
increase	increase	O
in	in	O
the	the	O
nephrogenic	nephrogenic	O
zone/cortical	zone/cortical	O
zone	zone	O
ratio	ratio	O
.	.	O

Observation	observation	O
by	by	O
electronic	electronic	O
microscope	microscope	O
revealed	revealed	O
structural	structural	O
damage	damage	O
of	of	O
podocytes	podocytes	O
;	;	O
the	the	O
reduced	reduced	O
expression	expression	O
level	level	O
of	of	O
podocyte	podocyte	O
marker	marker	O
genes	genes	O
,	,	O
nephrin	nephrin	O
and	and	O
podocin	podocin	O
,	,	O
was	was	O
also	also	O
detected	detected	O
by	by	O
q-PCR	q-pcr	O
.	.	O

Moreover	moreover	O
,	,	O
AT2R	at2r	O
gene	gene	O
and	and	O
protein	protein	O
expressions	expressions	O
in	in	O
fetal	fetal	O
kidneys	kidneys	O
were	were	O
inhibited	inhibited	O
by	by	O
PCE	pce	O
,	,	O
associated	associated	O
with	with	O
the	the	O
repression	repression	O
of	of	O
the	the	O
gene	gene	O
expression	expression	O
of	of	O
glial-cell-line-derived	glial-cell-line-derived	O
neurotrophic	neurotrophic	O
factor	factor	O
(GDNF)/tyrosine	(gdnf)/tyrosine	O
kinase	kinase	O
receptor	receptor	O
(	(	O
c-Ret	c-ret	O
)	)	O
signaling	signaling	O
pathway	pathway	O
.	.	O

These	these	O
results	results	O
demonstrated	demonstrated	O
that	that	O
PCE	pce	O
could	could	O
induce	induce	O
dysplasia	dysplasia	O
of	of	O
fetal	fetal	O
kidneys	kidneys	O
as	as	O
well	well	O
as	as	O
glomerulosclerosis	glomerulosclerosis	B-Disease
of	of	O
adult	adult	O
offspring	offspring	O
,	,	O
and	and	O
the	the	O
low	low	O
functional	functional	O
programming	programming	O
of	of	O
renal	renal	O
AT2R	at2r	O
might	might	O
mediate	mediate	O
the	the	O
developmental	developmental	O
origin	origin	O
of	of	O
adult	adult	O
glomerulosclerosis	glomerulosclerosis	B-Disease
.	.	O

1,3-Butadiene	1,3-butadiene	O
,	,	O
CML	cml	O
and	and	O
the	the	O
t(9:22	t(9:22	O
)	)	O
translocation	translocation	O
:	:	O
A	a	O
reality	reality	O
check	check	O
.	.	O

UNASSIGNED	unassigned	O
:	:	O
Epidemiological	epidemiological	O
studies	studies	O
of	of	O
1,3-butadiene	1,3-butadiene	O
have	have	O
suggest	suggest	O
that	that	O
exposures	exposures	O
to	to	O
humans	humans	O
are	are	O
associated	associated	O
with	with	O
chronic	chronic	O
myeloid	myeloid	O
leukemia	leukemia	O
(	(	O
CML	cml	O
)	)	O
.	.	O

CML	cml	O
has	has	O
a	a	O
well-documented	well-documented	O
association	association	O
with	with	O
ionizing	ionizing	O
radiation	radiation	O
,	,	O
but	but	O
reports	reports	O
of	of	O
associations	associations	O
with	with	O
chemical	chemical	O
exposures	exposures	O
have	have	O
been	been	O
questioned	questioned	O
.	.	O

Ionizing	ionizing	O
radiation	radiation	O
is	is	O
capable	capable	O
of	of	O
inducing	inducing	O
the	the	O
requisite	requisite	O
CML-associated	cml-associated	O
t(9:22	t(9:22	O
)	)	O
translocation	translocation	O
(	(	O
Philadelphia	philadelphia	B-Disease
chromosome	chromosome	I-Disease
)	)	O
in	in	O
appropriate	appropriate	O
cells	cells	O
in	in	O
vitro	vitro	O
but	but	O
,	,	O
thus	thus	O
far	far	O
,	,	O
chemicals	chemicals	O
have	have	O
not	not	O
shown	shown	O
this	this	O
capacity	capacity	O
.	.	O

We	we	O
have	have	O
proposed	proposed	O
that	that	O
1,3-butadiene	1,3-butadiene	O
metabolites	metabolites	O
be	be	O
so	so	O
tested	tested	O
as	as	O
a	a	O
reality	reality	O
check	check	O
on	on	O
the	the	O
epidemiological	epidemiological	O
reports	reports	O
.	.	O

In	in	O
order	order	O
to	to	O
conduct	conduct	O
reliable	reliable	O
testing	testing	O
in	in	O
this	this	O
regard	regard	O
,	,	O
it	it	O
is	is	O
essential	essential	O
that	that	O
a	a	O
positive	positive	O
control	control	O
for	for	O
induction	induction	O
be	be	O
available	available	O
.	.	O

We	we	O
have	have	O
used	used	O
ionizing	ionizing	O
radiation	radiation	O
to	to	O
develop	develop	O
such	such	O
a	a	O
control	control	O
.	.	O

Results	results	O
described	described	O
here	here	O
demonstrate	demonstrate	O
that	that	O
this	this	O
agent	agent	O
does	does	O
in	in	O
fact	fact	O
induce	induce	O
pathogenic	pathogenic	O
t(9:22	t(9:22	O
)	)	O
translocations	translocations	O
in	in	O
a	a	O
human	human	O
myeloid	myeloid	O
cell	cell	O
line	line	O
in	in	O
vitro	vitro	O
,	,	O
but	but	O
does	does	O
so	so	O
at	at	O
low	low	O
frequencies	frequencies	O
.	.	O

Conditions	conditions	O
that	that	O
will	will	O
be	be	O
required	required	O
for	for	O
studies	studies	O
of	of	O
1,3-butadiene	1,3-butadiene	O
are	are	O
discussed	discussed	O
.	.	O

Cancer	cancer	B-Disease
incidence	incidence	O
and	and	O
metolachlor	metolachlor	O
use	use	O
in	in	O
the	the	O
Agricultural	agricultural	O
Health	health	O
Study	study	O
:	:	O
An	an	O
update	update	O
.	.	O

UNASSIGNED	unassigned	O
:	:	O
Metolachlor	metolachlor	O
,	,	O
a	a	O
widely	widely	O
used	used	O
herbicide	herbicide	O
,	,	O
is	is	O
classified	classified	O
as	as	O
a	a	O
Group	group	O
C	c	O
carcinogen	carcinogen	O
by	by	O
the	the	O
U.S.	u.s.	O
Environmental	environmental	O
Protection	protection	O
Agency	agency	O
based	based	O
on	on	O
increased	increased	O
liver	liver	B-Disease
neoplasms	neoplasms	I-Disease
in	in	O
female	female	O
rats	rats	O
.	.	O

Epidemiologic	epidemiologic	O
studies	studies	O
of	of	O
the	the	O
health	health	O
effects	effects	O
of	of	O
metolachlor	metolachlor	O
have	have	O
been	been	O
limited	limited	O
.	.	O

The	the	O
Agricultural	agricultural	O
Health	health	O
Study	study	O
(	(	O
AHS	ahs	O
)	)	O
is	is	O
a	a	O
prospective	prospective	O
cohort	cohort	O
study	study	O
including	including	O
licensed	licensed	O
private	private	O
and	and	O
commercial	commercial	O
pesticide	pesticide	O
applicators	applicators	O
in	in	O
Iowa	iowa	O
and	and	O
North	north	O
Carolina	carolina	O
enrolled	enrolled	O
1993	1993	O
-	-	O
1997	1997	O
.	.	O

We	we	O
evaluated	evaluated	O
cancer	cancer	B-Disease
incidence	incidence	O
through	through	O
2010/2011	2010/2011	O
(	(	O
NC/IA	nc/ia	O
)	)	O
for	for	O
49,616	49,616	O
applicators	applicators	O
,	,	O
53	53	O
%	%	O
of	of	O
whom	whom	O
reported	reported	O
ever	ever	O
using	using	O
metolachlor	metolachlor	O
.	.	O

We	we	O
used	used	O
Poisson	poisson	O
regression	regression	O
to	to	O
evaluate	evaluate	O
relations	relations	O
between	between	O
two	two	O
metrics	metrics	O
of	of	O
metolachlor	metolachlor	O
use	use	O
(	(	O
lifetime	lifetime	O
days	days	O
,	,	O
intensity-weighted	intensity-weighted	O
lifetime	lifetime	O
days	days	O
)	)	O
and	and	O
cancer	cancer	B-Disease
incidence	incidence	O
.	.	O

We	we	O
saw	saw	O
no	no	O
association	association	O
between	between	O
metolachlor	metolachlor	O
use	use	O
and	and	O
incidence	incidence	O
of	of	O
all	all	O
cancers	cancers	B-Disease
combined	combined	O
(	(	O
n	n	O
=	=	O
5,701	5,701	O
with	with	O
a	a	O
5-year	5-year	O
lag	lag	O
)	)	O
or	or	O
most	most	O
site-specific	site-specific	O
cancers	cancers	B-Disease
.	.	O

For	for	O
liver	liver	B-Disease
cancer	cancer	B-Disease
,	,	O
in	in	O
analyses	analyses	O
restricted	restricted	O
to	to	O
exposed	exposed	O
workers	workers	O
,	,	O
elevations	elevations	O
observed	observed	O
at	at	O
higher	higher	O
categories	categories	O
of	of	O
use	use	O
were	were	O
not	not	O
statistically	statistically	O
significant	significant	O
.	.	O

However	however	O
,	,	O
trends	trends	O
for	for	O
both	both	O
lifetime	lifetime	O
and	and	O
intensity-weighted	intensity-weighted	O
lifetime	lifetime	O
days	days	O
of	of	O
metolachor	metolachor	O
use	use	O
were	were	O
positive	positive	O
and	and	O
statistically	statistically	O
significant	significant	O
with	with	O
an	an	O
unexposed	unexposed	O
reference	reference	O
group	group	O
.	.	O

A	a	O
similar	similar	O
pattern	pattern	O
was	was	O
observed	observed	O
for	for	O
follicular	follicular	O
cell	cell	O
lymphoma	lymphoma	O
,	,	O
but	but	O
no	no	O
other	other	O
lymphoma	lymphoma	O
subtypes	subtypes	O
.	.	O

An	an	O
earlier	earlier	O
suggestion	suggestion	O
of	of	O
increased	increased	O
lung	lung	O
cancer	cancer	B-Disease
risk	risk	O
at	at	O
high	high	O
levels	levels	O
of	of	O
metolachlor	metolachlor	O
use	use	O
in	in	O
this	this	O
cohort	cohort	O
was	was	O
not	not	O
confirmed	confirmed	O
in	in	O
this	this	O
update	update	O
.	.	O

This	this	O
suggestion	suggestion	O
of	of	O
an	an	O
association	association	O
between	between	O
metolachlor	metolachlor	O
and	and	O
liver	liver	B-Disease
cancer	cancer	B-Disease
among	among	O
pesticide	pesticide	O
applicators	applicators	O
is	is	O
a	a	O
novel	novel	O
finding	finding	O
and	and	O
echoes	echoes	O
observation	observation	O
of	of	O
increased	increased	O
liver	liver	B-Disease
neoplasms	neoplasms	I-Disease
in	in	O
some	some	O
animal	animal	O
studies	studies	O
.	.	O

However	however	O
,	,	O
our	our	O
findings	findings	O
for	for	O
both	both	O
liver	liver	B-Disease
cancer	cancer	B-Disease
and	and	O
follicular	follicular	O
cell	cell	O
lymphoma	lymphoma	O
warrant	warrant	O
follow-up	follow-up	O
to	to	O
better	better	O
differentiate	differentiate	O
effects	effects	O
of	of	O
metolachlor	metolachlor	O
use	use	O
from	from	O
other	other	O
factors	factors	O
.	.	O

Mechanisms	mechanisms	O
Underlying	underlying	O
Latent	latent	O
Disease	disease	O
Risk	risk	O
Associated	associated	O
with	with	O
Early-Life	early-life	O
Arsenic	arsenic	O
Exposure	exposure	O
:	:	O
Current	current	O
Research	research	O
Trends	trends	O
and	and	O
Scientific	scientific	O
Gaps	gaps	O
.	.	O

BACKGROUND	background	O
:	:	O
Millions	millions	O
of	of	O
individuals	individuals	O
worldwide	worldwide	O
,	,	O
particularly	particularly	O
those	those	O
living	living	O
in	in	O
rural	rural	O
and	and	O
developing	developing	O
areas	areas	O
,	,	O
are	are	O
exposed	exposed	O
to	to	O
harmful	harmful	O
levels	levels	O
of	of	O
inorganic	inorganic	O
arsenic	arsenic	O
(	(	O
iAs	ias	O
)	)	O
in	in	O
their	their	O
drinking	drinking	B-Chemical
water	water	I-Chemical
.	.	O

Inorganic	inorganic	O
As	as	O
exposure	exposure	O
during	during	O
key	key	O
developmental	developmental	O
periods	periods	O
is	is	O
associated	associated	O
with	with	O
a	a	O
variety	variety	O
of	of	O
adverse	adverse	O
health	health	O
effects	effects	O
including	including	O
those	those	O
that	that	O
are	are	O
evident	evident	O
in	in	O
adulthood	adulthood	O
.	.	O

There	there	O
is	is	O
considerable	considerable	O
interest	interest	O
in	in	O
identifying	identifying	O
the	the	O
molecular	molecular	O
mechanisms	mechanisms	O
that	that	O
relate	relate	O
early-life	early-life	O
iAs	ias	O
exposure	exposure	O
to	to	O
the	the	O
development	development	O
of	of	O
these	these	O
latent	latent	O
diseases	diseases	O
,	,	O
particularly	particularly	O
in	in	O
relationship	relationship	O
to	to	O
cancer	cancer	B-Disease
.	.	O

OBJECTIVES	objectives	O
:	:	O
This	this	O
work	work	O
summarizes	summarizes	O
research	research	O
on	on	O
the	the	O
molecular	molecular	O
mechanisms	mechanisms	O
that	that	O
underlie	underlie	O
the	the	O
increased	increased	O
risk	risk	O
of	of	O
cancer	cancer	B-Disease
development	development	O
in	in	O
adulthood	adulthood	O
that	that	O
is	is	O
associated	associated	O
with	with	O
early-life	early-life	O
iAs	ias	O
exposure	exposure	O
.	.	O

DISCUSSION	discussion	O
:	:	O
Epigenetic	epigenetic	O
reprogramming	reprogramming	O
that	that	O
imparts	imparts	O
functional	functional	O
changes	changes	O
in	in	O
gene	gene	O
expression	expression	O
,	,	O
the	the	O
development	development	O
of	of	O
cancer	cancer	B-Disease
stem	stem	O
cells	cells	O
,	,	O
and	and	O
immunomodulation	immunomodulation	O
are	are	O
plausible	plausible	O
underlying	underlying	O
mechanisms	mechanisms	O
by	by	O
which	which	O
early-life	early-life	O
iAs	ias	O
exposure	exposure	O
elicits	elicits	O
latent	latent	O
carcinogenic	carcinogenic	O
effects	effects	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Evidence	evidence	O
is	is	O
mounting	mounting	O
that	that	O
relates	relates	O
early-life	early-life	O
iAs	ias	O
exposure	exposure	O
and	and	O
cancer	cancer	B-Disease
development	development	O
later	later	O
in	in	O
life	life	O
.	.	O

Future	future	O
research	research	O
should	should	O
include	include	O
animal	animal	O
studies	studies	O
that	that	O
address	address	O
mechanistic	mechanistic	O
hypotheses	hypotheses	O
and	and	O
studies	studies	O
of	of	O
human	human	O
populations	populations	O
that	that	O
integrate	integrate	O
early-life	early-life	O
exposure	exposure	O
,	,	O
molecular	molecular	O
alterations	alterations	O
,	,	O
and	and	O
latent	latent	O
disease	disease	O
outcomes	outcomes	O
.	.	O

Nifedipine	nifedipine	B-Chemical
induced	induced	O
bradycardia	bradycardia	B-Disease
in	in	O
a	a	O
patient	patient	O
with	with	O
autonomic	autonomic	B-Disease
neuropathy	neuropathy	B-Disease
.	.	O

An	an	O
80	80	O
year	year	O
old	old	O
diabetic	diabetic	B-Disease
male	male	O
with	with	O
evidence	evidence	O
of	of	O
peripheral	peripheral	O
and	and	O
autonomic	autonomic	B-Disease
neuropathy	neuropathy	B-Disease
was	was	O
admitted	admitted	O
with	with	O
chest	chest	B-Disease
pain	pain	B-Disease
.	.	O

He	he	O
was	was	O
found	found	O
to	to	O
have	have	O
atrial	atrial	B-Disease
flutter	flutter	I-Disease
at	at	O
a	a	O
ventricular	ventricular	O
rate	rate	O
of	of	O
70/min	70/min	O
which	which	O
slowed	slowed	O
down	down	O
to	to	O
30	30	O
-	-	O
40/min	40/min	O
when	when	O
nifedipine	nifedipine	B-Chemical
(	(	O
60	60	O
mg	mg	O
)	)	O
in	in	O
3	3	O
divided	divided	O
doses	doses	O
,	,	O
during	during	O
which	which	O
he	he	O
was	was	O
paced	paced	O
at	at	O
a	a	O
rate	rate	O
of	of	O
70/min	70/min	O
.	.	O

This	this	O
is	is	O
inconsistent	inconsistent	O
with	with	O
the	the	O
well-established	well-established	O
finding	finding	O
that	that	O
nifedipine	nifedipine	B-Chemical
induces	induces	O
tachycardia	tachycardia	B-Disease
in	in	O
normally	normally	O
innervated	innervated	O
hearts	hearts	O
.	.	O

However	however	O
,	,	O
in	in	O
hearts	hearts	O
deprived	deprived	O
of	of	O
compensatory	compensatory	O
sympathetic	sympathetic	O
drive	drive	O
,	,	O
it	it	O
may	may	O
lead	lead	O
to	to	O
bradycardia	bradycardia	B-Disease
.	.	O

The	the	O
effect	effect	O
of	of	O
haloperidol	haloperidol	B-Chemical
in	in	O
cocaine	cocaine	B-Chemical
and	and	O
amphetamine	amphetamine	B-Chemical
intoxication	intoxication	O
.	.	O

The	the	O
effectiveness	effectiveness	O
of	of	O
haloperidol	haloperidol	B-Chemical
pretreatment	pretreatment	O
in	in	O
preventing	preventing	O
the	the	O
toxic	toxic	O
effects	effects	O
of	of	O
high	high	O
doses	doses	O
of	of	O
amphetamine	amphetamine	B-Chemical
and	and	O
cocaine	cocaine	B-Chemical
was	was	O
studied	studied	O
in	in	O
rats	rats	O
.	.	O

In	in	O
this	this	O
model	model	O
,	,	O
toxic	toxic	O
effects	effects	O
were	were	O
induced	induced	O
by	by	O
intraperitoneal	intraperitoneal	O
(	(	O
i.p	i.p	O
.	.	O
)	)	O
injection	injection	O
of	of	O
amphetamine	amphetamine	B-Chemical
75	75	O
mg/kg	mg/kg	O
(	(	O
100	100	O
%	%	O
death	death	B-Disease
rate	rate	O
)	)	O
or	or	O
cocaine	cocaine	B-Chemical
70	70	O
mg/kg	mg/kg	O
(	(	O
82	82	O
%	%	O
death	death	B-Disease
rate	rate	O
)	)	O
.	.	O

Haloperidol	haloperidol	B-Chemical
failed	failed	O
to	to	O
prevent	prevent	O
amphetamine-induced	amphetamine-induced	O
seizures	seizures	B-Disease
,	,	O
but	but	O
did	did	O
lower	lower	O
the	the	O
mortality	mortality	O
rate	rate	O
at	at	O
most	most	O
doses	doses	O
tested	tested	O
.	.	O

Haloperidol	haloperidol	B-Chemical
decreased	decreased	O
the	the	O
incidence	incidence	O
of	of	O
cocaine-induced	cocaine-induced	O
seizures	seizures	B-Disease
at	at	O
the	the	O
two	two	O
highest	highest	O
doses	doses	O
,	,	O
but	but	O
the	the	O
lowering	lowering	O
of	of	O
the	the	O
mortality	mortality	O
rate	rate	O
did	did	O
not	not	O
reach	reach	O
statistical	statistical	O
significance	significance	O
at	at	O
any	any	O
dose	dose	O
.	.	O

These	these	O
data	data	O
suggest	suggest	O
a	a	O
protective	protective	O
role	role	O
for	for	O
the	the	O
central	central	O
dopamine	dopamine	B-Chemical
blocker	blocker	O
haloperidol	haloperidol	B-Chemical
against	against	O
death	death	B-Disease
from	from	O
high-dose	high-dose	O
amphetamine	amphetamine	B-Chemical
exposure	exposure	O
without	without	O
reducing	reducing	O
the	the	O
incidence	incidence	O
of	of	O
seizures	seizures	B-Disease
.	.	O

In	in	O
contrast	contrast	O
,	,	O
haloperidol	haloperidol	B-Chemical
demonstrated	demonstrated	O
an	an	O
ability	ability	O
to	to	O
reduce	reduce	O
cocaine-induced	cocaine-induced	O
seizures	seizures	B-Disease
without	without	O
significantly	significantly	O
reducing	reducing	O
mortality	mortality	O
.	.	O

Autoradiographic	autoradiographic	O
evidence	evidence	O
of	of	O
estrogen	estrogen	B-Chemical
binding	binding	O
sites	sites	O
in	in	O
nuclei	nuclei	O
of	of	O
diethylstilbesterol	diethylstilbesterol	O
induced	induced	O
hamster	hamster	O
renal	renal	O
carcinomas	carcinomas	O
.	.	O

Estrogen	estrogen	B-Chemical
binding	binding	O
sites	sites	O
were	were	O
demonstrated	demonstrated	O
by	by	O
autoradiography	autoradiography	O
in	in	O
one	one	O
transplantable	transplantable	O
and	and	O
five	five	O
primary	primary	O
diethylstilbesterol	diethylstilbesterol	O
induced	induced	O
renal	renal	O
carcinomas	carcinomas	O
in	in	O
three	three	O
hamsters	hamsters	O
.	.	O

Radiolabelling	radiolabelling	O
,	,	O
following	following	O
the	the	O
in	in	O
vivo	vivo	O
injection	injection	O
of	of	O
3H-17	3h-17	O
beta	beta	O
estradiol	estradiol	B-Chemical
,	,	O
was	was	O
increased	increased	O
only	only	O
over	over	O
the	the	O
nuclei	nuclei	O
of	of	O
tumor	tumor	B-Disease
cells	cells	O
;	;	O
stereologic	stereologic	O
analysis	analysis	O
revealed	revealed	O
a	a	O
4.5-	4.5-	O
to	to	O
6.7-times	6.7-times	O
higher	higher	O
concentration	concentration	O
of	of	O
reduced	reduced	O
silver	silver	O
grains	grains	O
over	over	O
nuclei	nuclei	O
than	than	O
cytoplasm	cytoplasm	O
of	of	O
these	these	O
cells	cells	O
.	.	O

Despite	despite	O
rapid	rapid	O
tubular	tubular	O
excretion	excretion	O
of	of	O
estradiol	estradiol	B-Chemical
which	which	O
peaked	peaked	O
in	in	O
less	less	O
than	than	O
1	1	O
h	h	B-Chemical
,	,	O
the	the	O
normal	normal	O
cells	cells	O
did	did	O
not	not	O
appear	appear	O
to	to	O
bind	bind	O
the	the	O
ligand	ligand	O
.	.	O

This	this	O
is	is	O
the	the	O
first	first	O
published	published	O
report	report	O
documenting	documenting	O
the	the	O
preferential	preferential	O
in	in	O
vivo	vivo	O
binding	binding	O
of	of	O
estrogen	estrogen	B-Chemical
to	to	O
nuclei	nuclei	O
of	of	O
cells	cells	O
in	in	O
estrogen	estrogen	B-Chemical
induced	induced	O
hamster	hamster	O
renal	renal	O
carcinomas	carcinomas	O
.	.	O

Bradycardia	bradycardia	B-Disease
due	due	O
to	to	O
biperiden	biperiden	O
.	.	O

In	in	O
a	a	O
38-year-old	38-year-old	O
male	male	O
patient	patient	O
suffering	suffering	O
from	from	O
a	a	O
severe	severe	O
postzosteric	postzosteric	O
trigeminal	trigeminal	B-Disease
neuralgia	neuralgia	I-Disease
,	,	O
intravenous	intravenous	O
application	application	O
of	of	O
10	10	O
mg	mg	O
biperiden	biperiden	B-Chemical
lactate	lactate	B-Chemical
led	led	O
to	to	O
a	a	O
long-lasting	long-lasting	O
paradoxical	paradoxical	O
reaction	reaction	O
characterized	characterized	O
by	by	O
considerable	considerable	O
bradycardia	bradycardia	B-Disease
,	,	O
dysarthria	dysarthria	O
,	,	O
and	and	O
dysphagia	dysphagia	O
.	.	O

The	the	O
heart	heart	O
rate	rate	O
was	was	O
back	back	O
to	to	O
normal	normal	O
within	within	O
12	12	O
hours	hours	O
upon	upon	O
administration	administration	O
of	of	O
orciprenaline	orciprenaline	O
under	under	O
cardiac	cardiac	O
monitoring	monitoring	O
in	in	O
an	an	O
intensive	intensive	O
care	care	O
unit	unit	O
.	.	O

Bradycardia	bradycardia	B-Disease
induced	induced	O
by	by	O
biperiden	biperiden	O
is	is	O
attributed	attributed	O
to	to	O
the	the	O
speed	speed	O
of	of	O
injection	injection	O
and	and	O
to	to	O
a	a	O
dose-related	dose-related	O
dual	dual	O
effect	effect	O
of	of	O
atropine-like	atropine-like	O
drugs	drugs	O
on	on	O
muscarine	muscarine	O
receptors	receptors	O
.	.	O

Deliberate	deliberate	O
hypotension	hypotension	B-Disease
induced	induced	O
by	by	O
labetalol	labetalol	B-Chemical
with	with	O
halothane	halothane	B-Chemical
,	,	O
enflurane	enflurane	B-Chemical
or	or	O
isoflurane	isoflurane	B-Chemical
for	for	O
middle-ear	middle-ear	O
surgery	surgery	O
.	.	O

The	the	O
feasibility	feasibility	O
of	of	O
using	using	O
labetalol	labetalol	B-Chemical
,	,	O
an	an	O
alpha-	alpha-	O
and	and	O
beta-adrenergic	beta-adrenergic	O
blocking	blocking	O
agent	agent	O
,	,	O
as	as	O
a	a	O
hypotensive	hypotensive	B-Disease
agent	agent	O
in	in	O
combination	combination	O
with	with	O
inhalation	inhalation	O
anaesthetics	anaesthetics	O
(	(	O
halothane	halothane	B-Chemical
,	,	O
enflurane	enflurane	B-Chemical
or	or	O
isoflurane	isoflurane	B-Chemical
)	)	O
was	was	O
studied	studied	O
in	in	O
23	23	O
adult	adult	O
patients	patients	O
undergoing	undergoing	O
middle-ear	middle-ear	O
surgery	surgery	O
.	.	O

The	the	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
was	was	O
decreased	decreased	O
from	from	O
86	86	O
+	+	O
/-	/-	O
5	5	O
(	(	O
s.e	s.e	O
.	.	O
mean	mean	O
)	)	O
mmHg	mmhg	O
to	to	O
52	52	O
+	+	O
/-	/-	O
1	1	O
mmHg	mmhg	O
(	(	O
11.5	11.5	O
+	+	O
/-	/-	O
0.7	0.7	O
to	to	O
6.9	6.9	O
+	+	O
/-	/-	O
0.1	0.1	O
kPa	kpa	O
)	)	O
for	for	O
98	98	O
+	+	O
/-	/-	O
10	10	O
min	min	O
in	in	O
the	the	O
halothane	halothane	B-Chemical
(	(	O
H	h	B-Chemical
)	)	O
group	group	O
,	,	O
from	from	O
79	79	O
+	+	O
/-	/-	O
5	5	O
to	to	O
53	53	O
+	+	O
/-	/-	O
1	1	O
mmHg	mmhg	O
(	(	O
10.5	10.5	O
+	+	O
/-	/-	O
0.7	0.7	O
to	to	O
7.1	7.1	O
+	+	O
/-	/-	O
0.1	0.1	O
kPa	kpa	O
)	)	O
for	for	O
129	129	O
+	+	O
/-	/-	O
11	11	O
min	min	O
in	in	O
the	the	O
enflurane	enflurane	B-Chemical
(	(	O
E	e	O
)	)	O
group	group	O
,	,	O
and	and	O
from	from	O
80	80	O
+	+	O
/-	/-	O
4	4	O
to	to	O
49	49	O
+	+	O
/-	/-	O
1	1	O
mmHg	mmhg	O
(	(	O
10.7	10.7	O
+	+	O
/-	/-	O
0.5	0.5	O
to	to	O
6.5	6.5	O
+	+	O
/-	/-	O
0.1	0.1	O
kPa	kpa	O
)	)	O
for	for	O
135	135	O
+	+	O
/-	/-	O
15	15	O
min	min	O
in	in	O
the	the	O
isoflurane	isoflurane	B-Chemical
(	(	O
I	i	O
)	)	O
group	group	O
.	.	O

The	the	O
mean	mean	O
H	h	B-Chemical
concentration	concentration	O
during	during	O
hypotension	hypotension	B-Disease
in	in	O
the	the	O
inspiratory	inspiratory	O
gas	gas	O
was	was	O
0.7	0.7	O
+	+	O
/-	/-	O
0.1	0.1	O
vol%	vol%	O
,	,	O
the	the	O
mean	mean	O
E	e	O
concentration	concentration	O
1.6	1.6	O
+	+	O
/-	/-	O
0.2	0.2	O
vol%	vol%	O
,	,	O
and	and	O
the	the	O
mean	mean	O
I	i	O
concentration	concentration	O
1.0	1.0	O
+	+	O
/-	/-	O
0.1	0.1	O
vol%	vol%	O
.	.	O

In	in	O
addition	addition	O
,	,	O
the	the	O
patients	patients	O
received	received	O
fentanyl	fentanyl	B-Chemical
and	and	O
d-tubocurarine	d-tubocurarine	O
.	.	O

The	the	O
initial	initial	O
dose	dose	O
of	of	O
labetalol	labetalol	B-Chemical
for	for	O
lowering	lowering	O
blood	blood	O
pressure	pressure	O
was	was	O
similar	similar	O
,	,	O
0.52	0.52	O
-	-	O
0.59	0.59	O
mg/kg	mg/kg	O
,	,	O
in	in	O
all	all	O
the	the	O
groups	groups	O
.	.	O

During	during	O
hypotension	hypotension	B-Disease
,	,	O
the	the	O
heart	heart	O
rate	rate	O
was	was	O
stable	stable	O
without	without	O
tachy-	tachy-	O
or	or	O
bradycardia	bradycardia	B-Disease
.	.	O

The	the	O
operating	operating	O
conditions	conditions	O
regarding	regarding	O
bleeding	bleeding	B-Disease
were	were	O
estimated	estimated	O
in	in	O
a	a	O
double-blind	double-blind	O
manner	manner	O
,	,	O
and	and	O
did	did	O
not	not	O
differ	differ	O
significantly	significantly	O
between	between	O
the	the	O
groups	groups	O
.	.	O

During	during	O
hypotension	hypotension	B-Disease
,	,	O
the	the	O
serum	serum	O
creatinine	creatinine	B-Chemical
concentration	concentration	O
rose	rose	O
significantly	significantly	O
in	in	O
all	all	O
groups	groups	O
from	from	O
the	the	O
values	values	O
before	before	O
hypotension	hypotension	B-Disease
and	and	O
returned	returned	O
postoperatively	postoperatively	O
to	to	O
the	the	O
initial	initial	O
level	level	O
in	in	O
the	the	O
other	other	O
groups	groups	O
,	,	O
except	except	O
the	the	O
isoflurane	isoflurane	B-Chemical
group	group	O
.	.	O

After	after	O
hypotension	hypotension	B-Disease
there	there	O
was	was	O
no	no	O
rebound	rebound	O
phenomenon	phenomenon	O
in	in	O
either	either	O
blood	blood	O
pressure	pressure	O
or	or	O
heart	heart	O
rate	rate	O
.	.	O

These	these	O
results	results	O
indicate	indicate	O
that	that	O
labetalol	labetalol	B-Chemical
induces	induces	O
easily	easily	O
adjustable	adjustable	O
hypotension	hypotension	B-Disease
without	without	O
compensatory	compensatory	O
tachycardia	tachycardia	B-Disease
and	and	O
rebound	rebound	O
hypertension	hypertension	B-Disease
.	.	O

Convulsion	convulsion	B-Disease
following	following	O
intravenous	intravenous	O
fluorescein	fluorescein	B-Chemical
angiography	angiography	O
.	.	O

Tonic-clonic	tonic-clonic	O
seizures	seizures	B-Disease
followed	followed	O
intravenous	intravenous	O
fluorescein	fluorescein	B-Chemical
injection	injection	O
for	for	O
fundus	fundus	O
angiography	angiography	O
in	in	O
a	a	O
47-year-old	47-year-old	O
male	male	O
.	.	O

Despite	despite	O
precautions	precautions	O
this	this	O
adverse	adverse	O
reaction	reaction	O
recurred	recurred	O
on	on	O
re-exposure	re-exposure	O
to	to	O
intravenous	intravenous	O
fluorescein	fluorescein	B-Chemical
.	.	O

Pharmacology	pharmacology	O
of	of	O
ACC-9653	acc-9653	O
(	(	O
phenytoin	phenytoin	B-Chemical
prodrug).ACC-9653	prodrug).acc-9653	O
,	,	O
the	the	O
disodium	disodium	O
phosphate	phosphate	B-Chemical
ester	ester	O
of	of	O
3-hydroxymethyl-5,5-diphenylhydantoin	3-hydroxymethyl-5,5-diphenylhydantoin	O
,	,	O
is	is	O
a	a	O
prodrug	prodrug	O
of	of	O
phenytoin	phenytoin	B-Chemical
with	with	O
advantageous	advantageous	O
physicochemical	physicochemical	O
properties	properties	O
.	.	O

ACC-9653	acc-9653	O
is	is	O
rapidly	rapidly	O
converted	converted	O
enzymatically	enzymatically	O
to	to	O
phenytoin	phenytoin	B-Chemical
in	in	O
vivo	vivo	O
.	.	O

ACC-9653	acc-9653	O
and	and	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
have	have	O
equivalent	equivalent	O
anticonvulsant	anticonvulsant	O
activity	activity	O
against	against	O
seizures	seizures	B-Disease
induced	induced	O
by	by	O
maximal	maximal	O
electroshock	electroshock	O
(	(	O
MES	mes	O
)	)	O
in	in	O
mice	mice	O
following	following	O
i.p	i.p	O
.	.	O
,	,	O
oral	oral	O
,	,	O
or	or	O
i.v	i.v	O
.	.	O
administration	administration	O
.	.	O

The	the	O
ED50	ed50	O
doses	doses	O
were	were	O
16	16	O
mg/kg	mg/kg	O
for	for	O
i.v	i.v	O
.	.	O

ACC-9653	acc-9653	O
and	and	O
8	8	O
mg/kg	mg/kg	O
for	for	O
i.v	i.v	O
.	.	O

phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
.	.	O

ACC-9653	acc-9653	O
and	and	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
have	have	O
similar	similar	O
antiarrhythmic	antiarrhythmic	O
activity	activity	O
against	against	O
ouabain-induced	ouabain-induced	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
in	in	O
anesthetized	anesthetized	O
dogs	dogs	O
.	.	O

The	the	O
total	total	O
doses	doses	O
of	of	O
ACC-9653	acc-9653	O
or	or	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
necessary	necessary	O
to	to	O
convert	convert	O
the	the	O
arrhythmia	arrhythmia	B-Disease
to	to	O
a	a	O
normal	normal	O
sinus	sinus	O
rhythm	rhythm	O
were	were	O
24	24	O
+	+	O
/-	/-	O
6	6	O
and	and	O
14	14	O
+	+	O
/-	/-	O
3	3	O
mg/kg	mg/kg	O
,	,	O
respectively	respectively	O
.	.	O

Only	only	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
displayed	displayed	O
in	in	O
vitro	vitro	O
antiarrhythmic	antiarrhythmic	O
activity	activity	O
against	against	O
strophanthidin-induced	strophanthidin-induced	O
arrhythmias	arrhythmias	B-Disease
in	in	O
guinea	guinea	O
pig	pig	O
right	right	O
atria	atria	O
.	.	O

In	in	O
anesthetized	anesthetized	O
dogs	dogs	O
,	,	O
a	a	O
high	high	O
dose	dose	O
of	of	O
ACC-9653	acc-9653	O
(	(	O
31	31	O
mg/kg	mg/kg	O
)	)	O
was	was	O
infused	infused	O
over	over	O
15	15	O
,	,	O
20	20	O
,	,	O
and	and	O
30	30	O
min	min	O
and	and	O
the	the	O
responses	responses	O
were	were	O
compared	compared	O
to	to	O
an	an	O
equimolar	equimolar	O
dose	dose	O
of	of	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
(	(	O
21	21	O
mg/kg	mg/kg	O
)	)	O
.	.	O

The	the	O
ACC-9653	acc-9653	O
and	and	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
treatments	treatments	O
produced	produced	O
similar	similar	O
marked	marked	O
reductions	reductions	O
in	in	O
diastolic	diastolic	O
blood	blood	O
pressure	pressure	O
and	and	O
contractile	contractile	O
force	force	O
(	(	O
LVdP/dt	lvdp/dt	O
)	)	O
.	.	O

The	the	O
maximum	maximum	O
effects	effects	O
of	of	O
each	each	O
treatment	treatment	O
occurred	occurred	O
at	at	O
the	the	O
time	time	O
of	of	O
maximum	maximum	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
levels	levels	O
.	.	O

Acute	acute	O
toxicity	toxicity	B-Disease
studies	studies	O
of	of	O
ACC-9653	acc-9653	O
and	and	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
were	were	O
carried	carried	O
out	out	O
in	in	O
mice	mice	O
,	,	O
rats	rats	O
,	,	O
rabbits	rabbits	O
,	,	O
and	and	O
dogs	dogs	O
by	by	O
i.v	i.v	O
.	.	O
,	,	O
i.m	i.m	O
.	.	O
,	,	O
and	and	O
i.p	i.p	O
.	.	O

routes	routes	O
of	of	O
administration	administration	O
.	.	O

The	the	O
systemic	systemic	O
toxic	toxic	O
signs	signs	O
of	of	O
both	both	O
agents	agents	O
were	were	O
similar	similar	O
and	and	O
occurred	occurred	O
at	at	O
approximately	approximately	O
equivalent	equivalent	O
doses	doses	O
.	.	O

Importantly	importantly	O
,	,	O
the	the	O
local	local	O
irritation	irritation	O
of	of	O
ACC-9653	acc-9653	O
was	was	O
markedly	markedly	O
less	less	O
than	than	O
phenytoin	phenytoin	B-Chemical
sodium	sodium	B-Chemical
following	following	O
i.m	i.m	O
.	.	O

administration.(ABSTRACT	administration.(abstract	O
TRUNCATED	truncated	O
AT	at	O
250	250	O
WORDS	words	O
)	)	O

Tachyphylaxis	tachyphylaxis	O
to	to	O
systemic	systemic	O
but	but	O
not	not	O
to	to	O
airway	airway	O
responses	responses	O
during	during	O
prolonged	prolonged	O
therapy	therapy	O
with	with	O
high	high	O
dose	dose	O
inhaled	inhaled	O
salbutamol	salbutamol	B-Chemical
in	in	O
asthmatics	asthmatics	O
.	.	O

High	high	O
doses	doses	O
of	of	O
inhaled	inhaled	O
salbutamol	salbutamol	B-Chemical
produce	produce	O
substantial	substantial	O
improvements	improvements	O
in	in	O
airway	airway	O
response	response	O
in	in	O
patients	patients	O
with	with	O
asthma	asthma	O
,	,	O
and	and	O
are	are	O
associated	associated	O
with	with	O
dose-dependent	dose-dependent	O
systemic	systemic	O
beta-adrenoceptor	beta-adrenoceptor	O
responses	responses	O
.	.	O

The	the	O
purpose	purpose	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
investigate	investigate	O
whether	whether	O
tachyphylaxis	tachyphylaxis	O
occurs	occurs	O
during	during	O
prolonged	prolonged	O
treatment	treatment	O
with	with	O
high	high	O
dose	dose	O
inhaled	inhaled	O
salbutamol	salbutamol	B-Chemical
.	.	O

Twelve	twelve	O
asthmatic	asthmatic	O
patients	patients	O
(	(	O
FEV1	fev1	O
,	,	O
81	81	O
+	+	O
/-	/-	O
4	4	O
%	%	O
predicted	predicted	O
)	)	O
,	,	O
requiring	requiring	O
only	only	O
occasional	occasional	O
inhaled	inhaled	O
beta-agonists	beta-agonists	O
as	as	O
their	their	O
sole	sole	O
therapy	therapy	O
,	,	O
were	were	O
given	given	O
a	a	O
14-day	14-day	O
treatment	treatment	O
with	with	O
high	high	O
dose	dose	O
inhaled	inhaled	O
salbutamol	salbutamol	B-Chemical
(	(	O
HDS	hds	O
)	)	O
,	,	O
4,000	4,000	O
micrograms	micrograms	O
daily	daily	O
,	,	O
low	low	O
dose	dose	O
inhaled	inhaled	O
salbutamol	salbutamol	B-Chemical
(	(	O
LDS	lds	O
)	)	O
,	,	O
800	800	O
micrograms	micrograms	O
daily	daily	O
,	,	O
or	or	O
placebo	placebo	O
(	(	O
PI	pi	O
)	)	O
by	by	O
metered-dose	metered-dose	O
inhaler	inhaler	O
in	in	O
a	a	O
double-blind	double-blind	O
,	,	O
randomized	randomized	O
crossover	crossover	O
design	design	O
.	.	O

During	during	O
the	the	O
14-day	14-day	O
run-in	run-in	O
and	and	O
during	during	O
washout	washout	O
periods	periods	O
,	,	O
inhaled	inhaled	O
beta-agonists	beta-agonists	O
were	were	O
withheld	withheld	O
and	and	O
ipratropium	ipratropium	O
bromide	bromide	O
was	was	O
substituted	substituted	O
for	for	O
rescue	rescue	O
purposes	purposes	O
.	.	O

At	at	O
the	the	O
end	end	O
of	of	O
each	each	O
14-day	14-day	O
treatment	treatment	O
,	,	O
a	a	O
dose-response	dose-response	O
curve	curve	O
(	(	O
DRC	drc	O
)	)	O
was	was	O
performed	performed	O
,	,	O
and	and	O
airway	airway	O
(	(	O
FEV1	fev1	O
,	,	O
FEF25	fef25	O
-	-	O
75	75	O
)	)	O
chronotropic	chronotropic	O
(	(	O
HR	hr	O
)	)	O
,	,	O
tremor	tremor	B-Disease
,	,	O
and	and	O
metabolic	metabolic	O
(	(	O
K	k	B-Chemical
,	,	O
Glu	glu	O
)	)	O
responses	responses	O
were	were	O
measured	measured	O
at	at	O
each	each	O
step	step	O
(	(	O
from	from	O
100	100	O
to	to	O
4,000	4,000	O
micrograms	micrograms	O
)	)	O
.	.	O

Treatment	treatment	O
had	had	O
no	no	O
significant	significant	O
effect	effect	O
on	on	O
baseline	baseline	O
values	values	O
.	.	O

There	there	O
were	were	O
dose-dependent	dose-dependent	O
increases	increases	O
in	in	O
FEV1	fev1	O
and	and	O
FEF25	fef25	O
-	-	O
75	75	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
and	and	O
pretreatment	pretreatment	O
with	with	O
HDS	hds	O
did	did	O
not	not	O
displace	displace	O
the	the	O
DRC	drc	O
to	to	O
the	the	O
right	right	O
.	.	O

DRC	drc	O
for	for	O
HR	hr	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
K	k	B-Chemical
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
and	and	O
Glu	glu	O
(	(	O
p	p	O
less	less	O
than	than	O
0.005	0.005	O
)	)	O
were	were	O
attenuated	attenuated	O
after	after	O
treatment	treatment	O
with	with	O
HDS	hds	O
compared	compared	O
with	with	O
PI	pi	O
.	.	O

There	there	O
were	were	O
also	also	O
differences	differences	O
between	between	O
HDS	hds	O
and	and	O
LDS	lds	O
for	for	O
HR	hr	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
and	and	O
Glu	glu	O
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
responses	responses	O
.	.	O

Frequency	frequency	O
and	and	O
severity	severity	O
of	of	O
subjective	subjective	O
adverse	adverse	O
effects	effects	O
were	were	O
also	also	O
reduced	reduced	O
after	after	O
HDS	hds	O
:	:	O
tremor	tremor	B-Disease
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
palpitations	palpitations	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001).(ABSTRACT	0.001).(abstract	O
TRUNCATED	truncated	O
AT	at	O
250	250	O
WORDS	words	O
)	)	O

Phenytoin	phenytoin	B-Chemical
induced	induced	O
fatal	fatal	O
hepatic	hepatic	B-Disease
injury	injury	I-Disease
.	.	O

A	a	O
61	61	O
year	year	O
old	old	O
female	female	O
developed	developed	O
fatal	fatal	O
hepatic	hepatic	B-Disease
failure	failure	I-Disease
after	after	O
phenytoin	phenytoin	B-Chemical
administration	administration	O
.	.	O

A	a	O
typical	typical	O
multisystem	multisystem	O
clinical	clinical	O
pattern	pattern	O
precedes	precedes	O
the	the	O
manifestations	manifestations	O
of	of	O
hepatic	hepatic	B-Disease
injury	injury	I-Disease
.	.	O

The	the	O
hematologic	hematologic	O
,	,	O
biochemical	biochemical	O
and	and	O
pathologic	pathologic	O
features	features	O
indicate	indicate	O
a	a	O
mixed	mixed	O
hepatocellular	hepatocellular	O
damage	damage	O
due	due	O
to	to	O
drug	drug	B-Disease
hypersensitivity	hypersensitivity	B-Disease
.	.	O

In	in	O
a	a	O
patient	patient	O
receiving	receiving	O
phenytoin	phenytoin	B-Chemical
who	who	O
presents	presents	O
a	a	O
viral-like	viral-like	O
illness	illness	O
,	,	O
early	early	O
recognition	recognition	O
and	and	O
discontinuation	discontinuation	O
of	of	O
the	the	O
drug	drug	O
are	are	O
mandatory	mandatory	O
.	.	O

Treatment	treatment	O
of	of	O
lethal	lethal	O
pertussis	pertussis	B-Chemical
vaccine	vaccine	I-Chemical
reaction	reaction	O
with	with	O
histamine	histamine	B-Chemical
H1	h1	I-Chemical
antagonists	antagonists	I-Chemical
.	.	O

We	we	O
studied	studied	O
mortality	mortality	O
after	after	O
pertussis	pertussis	O
immunization	immunization	O
in	in	O
the	the	O
mouse	mouse	O
.	.	O

Without	without	O
treatment	treatment	O
,	,	O
73	73	O
of	of	O
92	92	O
animals	animals	O
(	(	O
80	80	O
%	%	O
)	)	O
died	died	O
after	after	O
injection	injection	O
of	of	O
bovine	bovine	O
serum	serum	B-Chemical
albumin	albumin	I-Chemical
(	(	O
BSA	bsa	O
)	)	O
on	on	O
day	day	O
+	+	O
7	7	O
of	of	O
pertussis	pertussis	O
immunization	immunization	O
.	.	O

After	after	O
pretreatment	pretreatment	O
with	with	O
3	3	O
mg	mg	O
of	of	O
cyproheptadine	cyproheptadine	O
,	,	O
2	2	O
mg	mg	O
mianserin	mianserin	O
,	,	O
or	or	O
2	2	O
mg	mg	O
chlorpheniramine	chlorpheniramine	O
,	,	O
only	only	O
5	5	O
of	of	O
105	105	O
animals	animals	O
(	(	O
5	5	O
%	%	O
)	)	O
died	died	O
after	after	O
receiving	receiving	O
BSA	bsa	O
on	on	O
day	day	O
+	+	O
7	7	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
.	.	O

Blockade	blockade	O
of	of	O
histamine	histamine	B-Chemical
H1	h1	O
receptors	receptors	O
may	may	O
reduce	reduce	O
mortality	mortality	O
in	in	O
pertussis	pertussis	O
immunization-induced	immunization-induced	O
encephalopathy	encephalopathy	B-Disease
in	in	O
mice	mice	O
.	.	O

Support	support	O
for	for	O
adrenaline-hypertension	adrenaline-hypertension	O
hypothesis	hypothesis	O
:	:	O
18	18	O
hour	hour	O
pressor	pressor	O
effect	effect	O
after	after	O
6	6	O
hours	hours	O
adrenaline	adrenaline	B-Chemical
infusion	infusion	O
.	.	O

In	in	O
a	a	O
double	double	O
blind	blind	O
,	,	O
crossover	crossover	O
study	study	O
6	6	O
h	h	B-Chemical
infusions	infusions	O
of	of	O
adrenaline	adrenaline	B-Chemical
(	(	O
15	15	O
ng/kg/min	ng/kg/min	O
;	;	O
1	1	O
ng	ng	O
=	=	O
5.458	5.458	O
pmol	pmol	O
)	)	O
,	,	O
noradrenaline	noradrenaline	B-Chemical
(	(	O
30	30	O
ng/kg/min	ng/kg/min	O
;	;	O
1	1	O
ng	ng	O
=	=	O
5.911	5.911	O
pmol	pmol	O
)	)	O
,	,	O
and	and	O
a	a	O
5	5	O
%	%	O
dextrose	dextrose	O
solution	solution	O
(	(	O
5.4	5.4	O
ml/h	ml/h	O
)	)	O
,	,	O
were	were	O
given	given	O
to	to	O
ten	ten	O
healthy	healthy	O
volunteers	volunteers	O
in	in	O
random	random	O
order	order	O
2	2	O
weeks	weeks	O
apart	apart	O
.	.	O

By	by	O
means	means	O
of	of	O
intra-arterial	intra-arterial	O
ambulatory	ambulatory	O
monitoring	monitoring	O
the	the	O
haemodynamic	haemodynamic	O
effects	effects	O
were	were	O
followed	followed	O
for	for	O
18	18	O
h	h	B-Chemical
after	after	O
the	the	O
infusions	infusions	O
were	were	O
stopped	stopped	O
.	.	O

Adrenaline	adrenaline	B-Chemical
,	,	O
but	but	O
not	not	O
noradrenaline	noradrenaline	B-Chemical
,	,	O
caused	caused	O
a	a	O
delayed	delayed	O
and	and	O
protracted	protracted	O
pressor	pressor	O
effect	effect	O
.	.	O

Over	over	O
the	the	O
total	total	O
postinfusion	postinfusion	O
period	period	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
arterial	arterial	O
pressure	pressure	O
were	were	O
6	6	O
(	(	O
SEM	sem	O
2)%	2)%	O
and	and	O
7	7	O
(2)%	(2)%	O
,	,	O
respectively	respectively	O
,	,	O
higher	higher	O
than	than	O
after	after	O
dextrose	dextrose	O
infusion	infusion	O
(	(	O
ANOVA	anova	O
,	,	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
.	.	O

Thus	thus	O
,	,	O
"	"	O
stress	stress	O
"	"	O
levels	levels	O
of	of	O
adrenaline	adrenaline	B-Chemical
(	(	O
230	230	O
pg/ml	pg/ml	O
)	)	O
for	for	O
6	6	O
h	h	B-Chemical
cause	cause	O
a	a	O
delayed	delayed	O
and	and	O
protracted	protracted	O
pressor	pressor	O
effect	effect	O
.	.	O

These	these	O
findings	findings	O
are	are	O
strong	strong	O
support	support	O
for	for	O
the	the	O
adrenaline-hypertension	adrenaline-hypertension	O
hypothesis	hypothesis	O
in	in	O
man	man	O
.	.	O

Effect	effect	O
of	of	O
alkylxanthines	alkylxanthines	O
on	on	O
gentamicin-induced	gentamicin-induced	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
in	in	O
the	the	O
rat	rat	O
.	.	O

Adenosine	adenosine	B-Chemical
antagonists	antagonists	O
have	have	O
been	been	O
previously	previously	O
shown	shown	O
to	to	O
be	be	O
of	of	O
benefit	benefit	O
in	in	O
some	some	O
ischaemic	ischaemic	O
and	and	O
nephrotoxic	nephrotoxic	B-Disease
models	models	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
(	(	O
ARF	arf	O
)	)	O
.	.	O

In	in	O
the	the	O
present	present	O
study	study	O
,	,	O
the	the	O
effects	effects	O
of	of	O
three	three	O
alkylxanthines	alkylxanthines	O
with	with	O
different	different	O
potencies	potencies	O
as	as	O
adenosine	adenosine	B-Chemical
antagonists	antagonists	O
8-phenyltheophylline	8-phenyltheophylline	O
,	,	O
theophylline	theophylline	B-Chemical
and	and	O
enprofylline	enprofylline	O
,	,	O
were	were	O
examined	examined	O
in	in	O
rats	rats	O
developing	developing	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
after	after	O
4	4	O
daily	daily	O
injections	injections	O
of	of	O
gentamicin	gentamicin	B-Chemical
(	(	O
200	200	O
mg	mg	O
kg-1	kg-1	O
)	)	O
.	.	O

Renal	renal	O
function	function	O
was	was	O
assessed	assessed	O
by	by	O
biochemical	biochemical	O
(	(	O
plasma	plasma	O
urea	urea	B-Chemical
and	and	O
creatinine	creatinine	B-Chemical
)	)	O
,	,	O
functional	functional	O
(	(	O
urine	urine	O
analysis	analysis	O
and	and	O
[3H]inulin	[3h]inulin	O
and	and	O
[14C]p-aminohippuric	[14c]p-aminohippuric	O
acid	acid	O
clearances	clearances	O
)	)	O
and	and	O
morphological	morphological	O
(	(	O
degree	degree	O
of	of	O
necrosis	necrosis	B-Disease
)	)	O
indices	indices	O
.	.	O

The	the	O
various	various	O
drug	drug	O
treatments	treatments	O
produced	produced	O
improvements	improvements	O
in	in	O
some	some	O
,	,	O
but	but	O
not	not	O
all	all	O
,	,	O
measurements	measurements	O
of	of	O
renal	renal	O
function	function	O
.	.	O

However	however	O
,	,	O
any	any	O
improvement	improvement	O
produced	produced	O
by	by	O
drug	drug	O
treatment	treatment	O
was	was	O
largely	largely	O
a	a	O
result	result	O
of	of	O
a	a	O
beneficial	beneficial	O
effect	effect	O
exerted	exerted	O
by	by	O
its	its	O
vehicle	vehicle	O
(	(	O
polyethylene	polyethylene	O
glycol	glycol	O
and	and	O
NaOH	naoh	O
)	)	O
.	.	O

The	the	O
lack	lack	O
of	of	O
any	any	O
consistent	consistent	O
protective	protective	O
effect	effect	O
noted	noted	O
with	with	O
the	the	O
alkylxanthines	alkylxanthines	O
tested	tested	O
in	in	O
the	the	O
present	present	O
study	study	O
indicates	indicates	O
that	that	O
adenosine	adenosine	B-Chemical
plays	plays	O
little	little	O
,	,	O
if	if	O
any	any	O
,	,	O
pathophysiological	pathophysiological	O
role	role	O
in	in	O
gentamicin-induced	gentamicin-induced	O
ARF	arf	O
.	.	O

Adverse	adverse	O
ocular	ocular	O
reactions	reactions	O
possibly	possibly	O
associated	associated	O
with	with	O
isotretinoin	isotretinoin	O
.	.	O

A	a	O
total	total	O
of	of	O
261	261	O
adverse	adverse	O
ocular	ocular	O
reactions	reactions	O
occurred	occurred	O
in	in	O
237	237	O
patients	patients	O
who	who	O
received	received	O
isotretinoin	isotretinoin	O
,	,	O
a	a	O
commonly	commonly	O
used	used	O
drug	drug	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
severe	severe	O
cystic	cystic	O
acne	acne	B-Disease
.	.	O

Blepharoconjunctivitis	blepharoconjunctivitis	O
,	,	O
subjective	subjective	O
complaints	complaints	O
of	of	O
dry	dry	O
eyes	eyes	O
,	,	O
blurred	blurred	O
vision	vision	O
,	,	O
contact	contact	O
lens	lens	O
intolerance	intolerance	O
,	,	O
and	and	O
photodermatitis	photodermatitis	O
are	are	O
reversible	reversible	O
side	side	O
effects	effects	O
.	.	O

More	more	O
serious	serious	O
ocular	ocular	O
adverse	adverse	O
reactions	reactions	O
include	include	O
papilledema	papilledema	O
,	,	O
pseudotumor	pseudotumor	B-Disease
cerebri	cerebri	I-Disease
,	,	O
and	and	O
white	white	O
or	or	O
gray	gray	O
subepithelial	subepithelial	O
corneal	corneal	O
opacities	opacities	O
;	;	O
all	all	O
of	of	O
these	these	O
are	are	O
reversible	reversible	O
if	if	O
the	the	O
drug	drug	O
is	is	O
discontinued	discontinued	O
.	.	O

Reported	reported	O
cases	cases	O
of	of	O
decreased	decreased	O
dark	dark	O
adaptation	adaptation	O
are	are	O
under	under	O
investigation	investigation	O
.	.	O

Isotretinoin	isotretinoin	O
is	is	O
contraindicated	contraindicated	O
in	in	O
pregnancy	pregnancy	O
because	because	O
of	of	O
the	the	O
many	many	O
reported	reported	O
congenital	congenital	B-Disease
abnormalities	abnormalities	I-Disease
after	after	O
maternal	maternal	O
use	use	O
(	(	O
including	including	O
microphthalmos	microphthalmos	O
,	,	O
orbital	orbital	O
hypertelorism	hypertelorism	O
,	,	O
and	and	O
optic	optic	O
nerve	nerve	O
hypoplasia	hypoplasia	O
)	)	O
.	.	O

Procaterol	procaterol	O
and	and	O
terbutaline	terbutaline	B-Chemical
in	in	O
bronchial	bronchial	O
asthma	asthma	O
.	.	O

A	a	O
double-blind	double-blind	O
,	,	O
placebo-controlled	placebo-controlled	O
,	,	O
cross-over	cross-over	O
study	study	O
.	.	O

Procaterol	procaterol	O
,	,	O
a	a	O
new	new	O
beta-2	beta-2	O
adrenoceptor	adrenoceptor	O
stimulant	stimulant	O
,	,	O
was	was	O
studied	studied	O
in	in	O
a	a	O
double-blind	double-blind	O
,	,	O
placebo-controlled	placebo-controlled	O
,	,	O
cross-over	cross-over	O
trial	trial	O
in	in	O
patients	patients	O
with	with	O
bronchial	bronchial	O
asthma	asthma	O
.	.	O

Oral	oral	O
procaterol	procaterol	O
50	50	O
micrograms	micrograms	O
b.d	b.d	O
.	.	O
,	,	O
procaterol	procaterol	O
100	100	O
micrograms	micrograms	O
b.d	b.d	O
.	.	O
,	,	O
and	and	O
terbutaline	terbutaline	B-Chemical
5	5	O
mg	mg	O
t.i.d	t.i.d	O
.	.	O
,	,	O
were	were	O
compared	compared	O
when	when	O
given	given	O
randomly	randomly	O
in	in	O
1-week	1-week	O
treatment	treatment	O
periods	periods	O
.	.	O

The	the	O
best	best	O
clinical	clinical	O
effect	effect	O
was	was	O
found	found	O
with	with	O
terbutaline	terbutaline	B-Chemical
.	.	O

Both	both	O
anti-asthmatic	anti-asthmatic	O
and	and	O
tremorgenic	tremorgenic	O
effects	effects	O
of	of	O
procaterol	procaterol	O
were	were	O
dose-related	dose-related	O
.	.	O

Procaterol	procaterol	O
appeared	appeared	O
effective	effective	O
in	in	O
the	the	O
doses	doses	O
tested	tested	O
,	,	O
and	and	O
a	a	O
twice	twice	O
daily	daily	O
regimen	regimen	O
would	would	O
appear	appear	O
to	to	O
be	be	O
suitable	suitable	O
with	with	O
this	this	O
drug	drug	O
.	.	O

Subacute	subacute	O
effects	effects	O
of	of	O
propranolol	propranolol	B-Chemical
and	and	O
B	b	O
24/76	24/76	O
on	on	O
isoproterenol-induced	isoproterenol-induced	O
rat	rat	O
heart	heart	O
hypertrophy	hypertrophy	B-Disease
in	in	O
correlation	correlation	O
with	with	O
blood	blood	O
pressure	pressure	O
.	.	O

We	we	O
compared	compared	O
the	the	O
potential	potential	O
beta-receptor	beta-receptor	O
blocker	blocker	O
,	,	O
B	b	O
24/76	24/76	O
i.e.	i.e.	O
1-(2,4-dichlorophenoxy)-3[2	1-(2,4-dichlorophenoxy)-3[2	O
-	-	O
3,4-dimethoxyphenyl)ethanolamino]-prop	3,4-dimethoxyphenyl)ethanolamino]-prop	O
an-2-ol	an-2-ol	O
,	,	O
which	which	O
is	is	O
characterized	characterized	O
by	by	O
beta	beta	O
1-adrenoceptor	1-adrenoceptor	O
blocking	blocking	O
and	and	O
beta	beta	O
2-adrenoceptor	2-adrenoceptor	O
stimulating	stimulating	O
properties	properties	O
with	with	O
propranolol	propranolol	B-Chemical
.	.	O

The	the	O
studies	studies	O
were	were	O
performed	performed	O
using	using	O
an	an	O
experimental	experimental	O
model	model	O
of	of	O
isoproterenol-induced	isoproterenol-induced	O
heart	heart	O
hypertrophy	hypertrophy	B-Disease
in	in	O
rats	rats	O
.	.	O

A	a	O
correlation	correlation	O
of	of	O
the	the	O
blood	blood	O
pressure	pressure	O
was	was	O
neither	neither	O
found	found	O
in	in	O
the	the	O
development	development	O
nor	nor	O
in	in	O
the	the	O
attempt	attempt	O
to	to	O
suppress	suppress	O
the	the	O
development	development	O
of	of	O
heart	heart	O
hypertrophy	hypertrophy	B-Disease
with	with	O
the	the	O
two	two	O
beta-receptor	beta-receptor	O
blockers	blockers	O
.	.	O

Both	both	O
beta-blockers	beta-blockers	O
influenced	influenced	O
the	the	O
development	development	O
of	of	O
hypertrophy	hypertrophy	B-Disease
to	to	O
a	a	O
different	different	O
,	,	O
but	but	O
not	not	O
reproducible	reproducible	O
extent	extent	O
.	.	O

It	it	O
was	was	O
possible	possible	O
to	to	O
suppress	suppress	O
the	the	O
increased	increased	O
ornithine	ornithine	O
decarboxylase	decarboxylase	O
activity	activity	O
with	with	O
both	both	O
beta-blockers	beta-blockers	O
in	in	O
hypertrophied	hypertrophied	O
hearts	hearts	O
,	,	O
but	but	O
there	there	O
was	was	O
no	no	O
effect	effect	O
on	on	O
the	the	O
heart	heart	O
mass	mass	O
.	.	O

Neither	neither	O
propranolol	propranolol	B-Chemical
nor	nor	O
B	b	O
24/76	24/76	O
could	could	O
stop	stop	O
the	the	O
changes	changes	O
in	in	O
the	the	O
characteristic	characteristic	O
myosin	myosin	O
isoenzyme	isoenzyme	O
pattern	pattern	O
of	of	O
the	the	O
hypertrophied	hypertrophied	O
rat	rat	O
heart	heart	O
.	.	O

Thus	thus	O
,	,	O
the	the	O
investigations	investigations	O
did	did	O
not	not	O
provide	provide	O
any	any	O
evidence	evidence	O
that	that	O
the	the	O
beta-receptor	beta-receptor	O
blockers	blockers	O
propranolol	propranolol	B-Chemical
and	and	O
B	b	O
24/76	24/76	O
have	have	O
the	the	O
potency	potency	O
to	to	O
prevent	prevent	O
isoproterenol	isoproterenol	B-Chemical
from	from	O
producing	producing	O
heart	heart	O
hypertrophy	hypertrophy	B-Disease
.	.	O

Increased	increased	O
anxiogenic	anxiogenic	O
effects	effects	O
of	of	O
caffeine	caffeine	B-Chemical
in	in	O
panic	panic	B-Disease
disorders	disorders	I-Disease
.	.	O

The	the	O
effects	effects	O
of	of	O
oral	oral	O
administration	administration	O
of	of	O
caffeine	caffeine	B-Chemical
(	(	O
10	10	O
mg/kg	mg/kg	O
)	)	O
on	on	O
behavioral	behavioral	O
ratings	ratings	O
,	,	O
somatic	somatic	O
symptoms	symptoms	O
,	,	O
blood	blood	O
pressure	pressure	O
and	and	O
plasma	plasma	O
levels	levels	O
of	of	O
3-methoxy-4-hydroxyphenethyleneglycol	3-methoxy-4-hydroxyphenethyleneglycol	O
(	(	O
MHPG	mhpg	O
)	)	O
and	and	O
cortisol	cortisol	B-Chemical
were	were	O
determined	determined	O
in	in	O
17	17	O
healthy	healthy	O
subjects	subjects	O
and	and	O
21	21	O
patients	patients	O
meeting	meeting	O
DSM-III	dsm-iii	O
criteria	criteria	O
for	for	O
agoraphobia	agoraphobia	B-Disease
with	with	O
panic	panic	B-Disease
attacks	attacks	I-Disease
or	or	O
panic	panic	B-Disease
disorder	disorder	I-Disease
.	.	O

Caffeine	caffeine	B-Chemical
produced	produced	O
significantly	significantly	O
greater	greater	O
increases	increases	O
in	in	O
subject-rated	subject-rated	O
anxiety	anxiety	B-Disease
,	,	O
nervousness	nervousness	O
,	,	O
fear	fear	O
,	,	O
nausea	nausea	B-Disease
,	,	O
palpitations	palpitations	O
,	,	O
restlessness	restlessness	B-Disease
,	,	O
and	and	O
tremors	tremors	B-Disease
in	in	O
the	the	O
patients	patients	O
compared	compared	O
with	with	O
healthy	healthy	O
subjects	subjects	O
.	.	O

In	in	O
the	the	O
patients	patients	O
,	,	O
but	but	O
not	not	O
the	the	O
healthy	healthy	O
subjects	subjects	O
,	,	O
these	these	O
symptoms	symptoms	O
were	were	O
significantly	significantly	O
correlated	correlated	O
with	with	O
plasma	plasma	O
caffeine	caffeine	B-Chemical
levels	levels	O
.	.	O

Seventy-one	seventy-one	O
percent	percent	O
of	of	O
the	the	O
patients	patients	O
reported	reported	O
that	that	O
the	the	O
behavioral	behavioral	O
effects	effects	O
of	of	O
caffeine	caffeine	B-Chemical
were	were	O
similar	similar	O
to	to	O
those	those	O
experienced	experienced	O
during	during	O
panic	panic	B-Disease
attacks	attacks	I-Disease
.	.	O

Caffeine	caffeine	B-Chemical
did	did	O
not	not	O
alter	alter	O
plasma	plasma	O
MHPG	mhpg	O
levels	levels	O
in	in	O
either	either	O
the	the	O
healthy	healthy	O
subjects	subjects	O
or	or	O
patients	patients	O
.	.	O

Caffeine	caffeine	B-Chemical
increased	increased	O
plasma	plasma	O
cortisol	cortisol	B-Chemical
levels	levels	O
equally	equally	O
in	in	O
the	the	O
patient	patient	O
and	and	O
healthy	healthy	O
groups	groups	O
.	.	O

Because	because	O
caffeine	caffeine	B-Chemical
is	is	O
an	an	O
adenosine	adenosine	B-Chemical
receptor	receptor	O
antagonist	antagonist	O
,	,	O
these	these	O
results	results	O
suggest	suggest	O
that	that	O
some	some	O
panic	panic	B-Disease
disorder	disorder	I-Disease
patients	patients	O
may	may	O
have	have	O
abnormalities	abnormalities	O
in	in	O
neuronal	neuronal	O
systems	systems	O
involving	involving	O
adenosine	adenosine	B-Chemical
.	.	O

Patients	patients	O
with	with	O
anxiety	anxiety	B-Disease
disorders	disorders	I-Disease
may	may	O
benefit	benefit	O
by	by	O
avoiding	avoiding	O
caffeine-containing	caffeine-containing	O
foods	foods	O
and	and	O
beverages	beverages	O
.	.	O

Comparison	comparison	O
of	of	O
the	the	O
effect	effect	O
of	of	O
oxitropium	oxitropium	O
bromide	bromide	O
and	and	O
of	of	O
slow-release	slow-release	O
theophylline	theophylline	B-Chemical
on	on	O
nocturnal	nocturnal	O
asthma	asthma	O
.	.	O

The	the	O
effects	effects	O
of	of	O
a	a	O
new	new	O
inhaled	inhaled	O
antimuscarinic	antimuscarinic	O
drug	drug	O
,	,	O
oxitropium	oxitropium	O
bromide	bromide	O
,	,	O
and	and	O
of	of	O
a	a	O
slow-release	slow-release	O
theophylline	theophylline	B-Chemical
preparation	preparation	O
upon	upon	O
nocturnal	nocturnal	O
asthma	asthma	O
were	were	O
compared	compared	O
in	in	O
a	a	O
placebo-controlled	placebo-controlled	O
double-blind	double-blind	O
study	study	O
.	.	O

Two	two	O
samples	samples	O
were	were	O
studied	studied	O
:	:	O
12	12	O
patients	patients	O
received	received	O
oxitropium	oxitropium	O
at	at	O
600	600	O
micrograms	micrograms	O
(	(	O
6	6	O
subjects	subjects	O
)	)	O
or	or	O
at	at	O
400	400	O
micrograms	micrograms	O
t.i.d	t.i.d	O
.	.	O
(	(	O
6	6	O
subjects	subjects	O
)	)	O
whereas	whereas	O
11	11	O
received	received	O
theophylline	theophylline	B-Chemical
at	at	O
300	300	O
mg	mg	O
b.i.d	b.i.d	O
.	.	O

Morning	morning	O
dipping	dipping	O
,	,	O
assessed	assessed	O
by	by	O
the	the	O
fall	fall	O
in	in	O
peak	peak	O
flow	flow	O
overnight	overnight	O
,	,	O
was	was	O
significantly	significantly	O
reduced	reduced	O
in	in	O
the	the	O
periods	periods	O
when	when	O
either	either	O
active	active	O
drug	drug	O
was	was	O
taken	taken	O
,	,	O
whereas	whereas	O
no	no	O
difference	difference	O
was	was	O
noticed	noticed	O
during	during	O
the	the	O
placebo	placebo	O
administration	administration	O
.	.	O

No	no	O
significant	significant	O
difference	difference	O
was	was	O
noticed	noticed	O
between	between	O
results	results	O
obtained	obtained	O
with	with	O
either	either	O
active	active	O
drug	drug	O
,	,	O
as	as	O
well	well	O
as	as	O
with	with	O
either	either	O
dosage	dosage	O
of	of	O
oxitropium	oxitropium	O
.	.	O

No	no	O
subject	subject	O
reported	reported	O
side	side	O
effects	effects	O
of	of	O
oxitropium	oxitropium	O
,	,	O
as	as	O
compared	compared	O
to	to	O
three	three	O
subjects	subjects	O
reporting	reporting	O
nausea	nausea	B-Disease
,	,	O
vomiting	vomiting	B-Disease
and	and	O
tremors	tremors	B-Disease
after	after	O
theophylline	theophylline	B-Chemical
.	.	O

Oxitropium	oxitropium	O
proves	proves	O
to	to	O
be	be	O
a	a	O
valuable	valuable	O
alternative	alternative	O
to	to	O
theophylline	theophylline	B-Chemical
in	in	O
nocturnal	nocturnal	O
asthma	asthma	O
,	,	O
since	since	O
it	it	O
is	is	O
equally	equally	O
potent	potent	O
,	,	O
safer	safer	O
and	and	O
does	does	O
not	not	O
require	require	O
the	the	O
titration	titration	O
of	of	O
dosage	dosage	O
.	.	O

Penicillin	penicillin	B-Chemical
anaphylaxis	anaphylaxis	B-Disease
.	.	O

A	a	O
case	case	O
of	of	O
oral	oral	O
penicillin	penicillin	B-Chemical
anaphylaxis	anaphylaxis	B-Disease
is	is	O
described	described	O
,	,	O
and	and	O
the	the	O
terminology	terminology	O
,	,	O
occurrence	occurrence	O
,	,	O
clinical	clinical	O
manifestations	manifestations	O
,	,	O
pathogenesis	pathogenesis	O
,	,	O
prevention	prevention	O
,	,	O
and	and	O
treatment	treatment	O
of	of	O
anaphylaxis	anaphylaxis	B-Disease
are	are	O
reviewed	reviewed	O
.	.	O

Emergency	emergency	O
physicians	physicians	O
should	should	O
be	be	O
aware	aware	O
of	of	O
oral	oral	O
penicillin	penicillin	B-Chemical
anaphylaxis	anaphylaxis	B-Disease
in	in	O
order	order	O
to	to	O
prevent	prevent	O
its	its	O
occurrence	occurrence	O
by	by	O
prescribing	prescribing	O
the	the	O
antibiotic	antibiotic	O
judiciously	judiciously	O
and	and	O
knowledgeably	knowledgeably	O
and	and	O
to	to	O
offer	offer	O
optimal	optimal	O
medical	medical	O
therapy	therapy	O
once	once	O
this	this	O
life-threatening	life-threatening	O
reaction	reaction	O
has	has	O
begun	begun	O
.	.	O

Reversible	reversible	O
valproic	valproic	O
acid-induced	acid-induced	O
dementia	dementia	B-Disease
:	:	O
a	a	O
case	case	O
report	report	O
.	.	O

Reversible	reversible	O
valproic	valproic	O
acid-induced	acid-induced	O
dementia	dementia	B-Disease
was	was	O
documented	documented	O
in	in	O
a	a	O
21-year-old	21-year-old	O
man	man	O
with	with	O
epilepsy	epilepsy	B-Disease
who	who	O
had	had	O
a	a	O
3-year	3-year	O
history	history	O
of	of	O
insidious	insidious	O
progressive	progressive	O
decline	decline	O
in	in	O
global	global	O
cognitive	cognitive	O
abilities	abilities	O
documented	documented	O
by	by	O
serial	serial	O
neuropsychological	neuropsychological	O
studies	studies	O
.	.	O

Repeat	repeat	O
neuropsychological	neuropsychological	O
testing	testing	O
7	7	O
weeks	weeks	O
after	after	O
discontinuation	discontinuation	O
of	of	O
the	the	O
drug	drug	O
revealed	revealed	O
dramatic	dramatic	O
improvement	improvement	O
in	in	O
IQ	iq	O
,	,	O
memory	memory	O
,	,	O
naming	naming	O
,	,	O
and	and	O
other	other	O
tasks	tasks	O
commensurate	commensurate	O
with	with	O
clinical	clinical	O
recovery	recovery	O
in	in	O
his	his	O
intellectual	intellectual	O
capacity	capacity	O
.	.	O

Possible	possible	O
pathophysiological	pathophysiological	O
mechanisms	mechanisms	O
which	which	O
may	may	O
have	have	O
been	been	O
operative	operative	O
in	in	O
this	this	O
case	case	O
include	include	O
:	:	O
a	a	O
direct	direct	O
central	central	O
nervous	nervous	O
system	system	O
(	(	O
CNS	cns	O
)	)	O
toxic	toxic	O
effect	effect	O
of	of	O
valproic	valproic	B-Chemical
acid	acid	I-Chemical
;	;	O
a	a	O
paradoxical	paradoxical	O
epileptogenic	epileptogenic	O
effect	effect	O
secondary	secondary	O
to	to	O
the	the	O
drug	drug	O
;	;	O
and	and	O
an	an	O
indirect	indirect	O
CNS	cns	O
toxic	toxic	O
effect	effect	O
mediated	mediated	O
through	through	O
valproic	valproic	O
acid-induced	acid-induced	O
hyperammonemia	hyperammonemia	B-Disease
.	.	O

Reversal	reversal	O
of	of	O
scopolamine-induced	scopolamine-induced	O
amnesia	amnesia	B-Disease
of	of	O
passive	passive	O
avoidance	avoidance	O
by	by	O
pre-	pre-	O
and	and	O
post-training	post-training	O
naloxone	naloxone	B-Chemical
.	.	O

In	in	O
a	a	O
series	series	O
of	of	O
five	five	O
experiments	experiments	O
,	,	O
the	the	O
modulating	modulating	O
role	role	O
of	of	O
naloxone	naloxone	B-Chemical
on	on	O
a	a	O
scopolamine-induced	scopolamine-induced	O
retention	retention	O
deficit	deficit	O
in	in	O
a	a	O
passive	passive	O
avoidance	avoidance	O
paradigm	paradigm	O
was	was	O
investigated	investigated	O
in	in	O
mice	mice	O
.	.	O

Scopolamine	scopolamine	B-Chemical
,	,	O
but	but	O
not	not	O
methyl	methyl	O
scopolamine	scopolamine	B-Chemical
(	(	O
1	1	O
and	and	O
3	3	O
mg/kg	mg/kg	O
)	)	O
,	,	O
induced	induced	O
an	an	O
amnesia	amnesia	B-Disease
as	as	O
measured	measured	O
by	by	O
latency	latency	O
and	and	O
duration	duration	O
parameters	parameters	O
.	.	O

Naloxone	naloxone	B-Chemical
(	(	O
0.3	0.3	O
,	,	O
1	1	O
,	,	O
3	3	O
,	,	O
and	and	O
10	10	O
mg/kg	mg/kg	O
)	)	O
injected	injected	O
prior	prior	O
to	to	O
training	training	O
attenuated	attenuated	O
the	the	O
retention	retention	O
deficit	deficit	O
with	with	O
a	a	O
peak	peak	O
of	of	O
activity	activity	O
at	at	O
3	3	O
mg/kg	mg/kg	O
.	.	O

The	the	O
effect	effect	O
of	of	O
naloxone	naloxone	B-Chemical
could	could	O
be	be	O
antagonized	antagonized	O
with	with	O
morphine	morphine	B-Chemical
(	(	O
1	1	O
,	,	O
3	3	O
,	,	O
and	and	O
10	10	O
mg/kg	mg/kg	O
)	)	O
,	,	O
demonstrating	demonstrating	O
the	the	O
opioid	opioid	O
specificity	specificity	O
of	of	O
the	the	O
naloxone	naloxone	B-Chemical
effect	effect	O
.	.	O

Post-training	post-training	O
administration	administration	O
of	of	O
naloxone	naloxone	B-Chemical
(	(	O
3	3	O
mg/kg	mg/kg	O
)	)	O
as	as	O
a	a	O
single	single	O
or	or	O
as	as	O
a	a	O
split	split	O
dose	dose	O
also	also	O
attenuated	attenuated	O
the	the	O
scopolamine-induced	scopolamine-induced	O
amnesia	amnesia	B-Disease
.	.	O

Control	control	O
experiments	experiments	O
indicated	indicated	O
that	that	O
neither	neither	O
an	an	O
increase	increase	O
in	in	O
pain	pain	B-Disease
sensitivity	sensitivity	O
(	(	O
pre-training	pre-training	O
naloxone	naloxone	B-Chemical
)	)	O
nor	nor	O
an	an	O
induced	induced	O
aversive	aversive	O
state	state	O
(	(	O
post-training	post-training	O
naloxone	naloxone	B-Chemical
)	)	O
appear	appear	O
to	to	O
be	be	O
responsible	responsible	O
for	for	O
the	the	O
influence	influence	O
of	of	O
naloxone	naloxone	B-Chemical
on	on	O
the	the	O
scopolamine-induced	scopolamine-induced	O
retention	retention	O
deficit	deficit	O
.	.	O

These	these	O
results	results	O
extend	extend	O
previous	previous	O
findings	findings	O
implicating	implicating	O
a	a	O
cholinergic-opioid	cholinergic-opioid	O
interaction	interaction	O
in	in	O
memory	memory	O
processes	processes	O
.	.	O

A	a	O
possible	possible	O
mechanism	mechanism	O
for	for	O
this	this	O
interaction	interaction	O
involving	involving	O
the	the	O
septo-hippocampal	septo-hippocampal	O
cholinergic	cholinergic	O
pathway	pathway	O
is	is	O
discussed	discussed	O
.	.	O

Electron	electron	O
microscopic	microscopic	O
investigations	investigations	O
of	of	O
the	the	O
cyclophosphamide-induced	cyclophosphamide-induced	O
lesions	lesions	O
of	of	O
the	the	O
urinary	urinary	O
bladder	bladder	O
of	of	O
the	the	O
rat	rat	O
and	and	O
their	their	O
prevention	prevention	O
by	by	O
mesna	mesna	B-Chemical
.	.	O

Fully	fully	O
developed	developed	O
cyclophosphamide-induced	cyclophosphamide-induced	O
cystitis	cystitis	B-Disease
is	is	O
characterized	characterized	O
by	by	O
nearly	nearly	O
complete	complete	O
detachment	detachment	O
of	of	O
the	the	O
urothelium	urothelium	O
,	,	O
severe	severe	O
submucosal	submucosal	O
edema	edema	B-Disease
owing	owing	O
to	to	O
damage	damage	O
to	to	O
the	the	O
microvascular	microvascular	O
bed	bed	O
and	and	O
focal	focal	O
muscle	muscle	O
necroses	necroses	O
.	.	O

The	the	O
initial	initial	O
response	response	O
to	to	O
the	the	O
primary	primary	O
attack	attack	O
by	by	O
the	the	O
cyclophosphamide	cyclophosphamide	B-Chemical
metabolites	metabolites	O
seems	seems	O
to	to	O
be	be	O
fragmentation	fragmentation	O
of	of	O
the	the	O
luminal	luminal	B-Chemical
membrane	membrane	O
.	.	O

This	this	O
damages	damages	O
the	the	O
cellular	cellular	O
barrier	barrier	O
against	against	O
the	the	O
hypertonic	hypertonic	O
urine	urine	O
.	.	O

Subsequent	subsequent	O
breaks	breaks	O
in	in	O
the	the	O
lateral	lateral	O
cell	cell	O
membranes	membranes	O
of	of	O
the	the	O
superficial	superficial	O
cells	cells	O
and	and	O
in	in	O
all	all	O
the	the	O
plasma	plasma	O
membranes	membranes	O
of	of	O
the	the	O
intermediate	intermediate	O
and	and	O
basal	basal	O
cells	cells	O
,	,	O
intercellular	intercellular	O
and	and	O
intracellular	intracellular	O
edema	edema	B-Disease
and	and	O
disintegration	disintegration	O
of	of	O
the	the	O
desmosomes	desmosomes	O
and	and	O
hemidesmosomes	hemidesmosomes	O
lead	lead	O
to	to	O
progressive	progressive	O
degeneration	degeneration	O
and	and	O
detachment	detachment	O
of	of	O
the	the	O
epithelial	epithelial	O
cells	cells	O
with	with	O
exposure	exposure	O
and	and	O
splitting	splitting	O
of	of	O
the	the	O
basal	basal	O
membrane	membrane	O
.	.	O

The	the	O
morphological	morphological	O
changes	changes	O
of	of	O
the	the	O
endothelial	endothelial	O
cells	cells	O
,	,	O
which	which	O
become	become	O
more	more	O
pronounced	pronounced	O
in	in	O
the	the	O
later	later	O
stages	stages	O
of	of	O
the	the	O
experiment	experiment	O
,	,	O
the	the	O
involvement	involvement	O
of	of	O
blood	blood	O
vessels	vessels	O
regardless	regardless	O
of	of	O
their	their	O
diameter	diameter	O
and	and	O
the	the	O
location-dependent	location-dependent	O
extent	extent	O
of	of	O
the	the	O
damage	damage	O
indicate	indicate	O
a	a	O
direct	direct	O
type	type	O
of	of	O
damage	damage	O
which	which	O
is	is	O
preceded	preceded	O
by	by	O
a	a	O
mediator-induced	mediator-induced	O
increase	increase	O
in	in	O
permeability	permeability	O
,	,	O
the	the	O
morphological	morphological	O
correlate	correlate	O
of	of	O
which	which	O
is	is	O
the	the	O
formation	formation	O
of	of	O
gaps	gaps	O
in	in	O
the	the	O
interendothelial	interendothelial	O
cell	cell	O
connections	connections	O
on	on	O
the	the	O
venules	venules	O
.	.	O

These	these	O
changes	changes	O
can	can	O
be	be	O
effectively	effectively	O
prevented	prevented	O
by	by	O
mesna	mesna	B-Chemical
.	.	O

The	the	O
only	only	O
sign	sign	O
of	of	O
a	a	O
possible	possible	O
involvement	involvement	O
is	is	O
the	the	O
increase	increase	O
in	in	O
the	the	O
number	number	O
of	of	O
specific	specific	O
granules	granules	O
with	with	O
a	a	O
presumed	presumed	O
lysosomal	lysosomal	O
function	function	O
in	in	O
the	the	O
superficial	superficial	O
cells	cells	O
.	.	O

Increase	increase	O
in	in	O
intragastric	intragastric	O
pressure	pressure	O
during	during	O
suxamethonium-induced	suxamethonium-induced	O
muscle	muscle	O
fasciculations	fasciculations	O
in	in	O
children	children	O
:	:	O
inhibition	inhibition	O
by	by	O
alfentanil	alfentanil	B-Chemical
.	.	O

Changes	changes	O
in	in	O
intragastric	intragastric	O
pressure	pressure	O
after	after	O
the	the	O
administration	administration	O
of	of	O
suxamethonium	suxamethonium	B-Chemical
1.5	1.5	O
mg	mg	O
kg-1	kg-1	O
i.v	i.v	O
.	.	O
were	were	O
studied	studied	O
in	in	O
32	32	O
children	children	O
(	(	O
mean	mean	O
age	age	O
6.9	6.9	O
yr	yr	O
)	)	O
pretreated	pretreated	O
with	with	O
either	either	O
physiological	physiological	O
saline	saline	O
or	or	O
alfentanil	alfentanil	B-Chemical
50	50	O
micrograms	micrograms	O
kg-1	kg-1	O
.	.	O

Anaesthesia	anaesthesia	O
was	was	O
induced	induced	O
with	with	O
thiopentone	thiopentone	B-Chemical
5	5	O
mg	mg	O
kg-1	kg-1	O
.	.	O

The	the	O
incidence	incidence	O
and	and	O
intensity	intensity	O
of	of	O
muscle	muscle	O
fasciculations	fasciculations	O
caused	caused	O
by	by	O
suxamethonium	suxamethonium	B-Chemical
were	were	O
significantly	significantly	O
greater	greater	O
in	in	O
the	the	O
control	control	O
than	than	O
in	in	O
the	the	O
alfentanil	alfentanil	B-Chemical
group	group	O
.	.	O

The	the	O
intragastric	intragastric	O
pressure	pressure	O
during	during	O
muscle	muscle	O
fasciculations	fasciculations	O
was	was	O
significantly	significantly	O
higher	higher	O
in	in	O
the	the	O
control	control	O
group	group	O
(	(	O
16	16	O
+	+	O
/-	/-	O
0.7	0.7	O
(	(	O
SEM	sem	O
)	)	O
cm	cm	B-Disease
H2O	h2o	B-Chemical
)	)	O
than	than	O
in	in	O
the	the	O
alfentanil	alfentanil	B-Chemical
group	group	O
(	(	O
7.7	7.7	O
+	+	O
/-	/-	O
1.5	1.5	O
(	(	O
SEM	sem	O
)	)	O
cm	cm	B-Disease
H2O	h2o	B-Chemical
)	)	O
.	.	O

The	the	O
increase	increase	O
in	in	O
intragastric	intragastric	O
pressure	pressure	O
was	was	O
directly	directly	O
related	related	O
to	to	O
the	the	O
intensity	intensity	O
of	of	O
muscle	muscle	O
fasciculations	fasciculations	O
(	(	O
regression	regression	O
line	line	O
:	:	O
y	y	O
=	=	O
0.5	0.5	O
+	+	O
4.78x	4.78x	O
with	with	O
r	r	O
of	of	O
0.78	0.78	O
)	)	O
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
intragastric	intragastric	O
pressure	pressure	O
increases	increases	O
significantly	significantly	O
during	during	O
muscle	muscle	O
fasciculations	fasciculations	O
caused	caused	O
by	by	O
suxamethonium	suxamethonium	B-Chemical
in	in	O
healthy	healthy	O
children	children	O
.	.	O

Alfentanil	alfentanil	B-Chemical
50	50	O
micrograms	micrograms	O
kg-1	kg-1	O
effectively	effectively	O
inhibits	inhibits	O
the	the	O
incidence	incidence	O
and	and	O
intensity	intensity	O
of	of	O
suxamethonium-induced	suxamethonium-induced	O
muscle	muscle	O
fasciculations	fasciculations	O
;	;	O
moreover	moreover	O
,	,	O
intragastric	intragastric	O
pressure	pressure	O
remains	remains	O
at	at	O
its	its	O
control	control	O
value	value	O
.	.	O

Acute	acute	O
insulin	insulin	O
treatment	treatment	O
normalizes	normalizes	O
the	the	O
resistance	resistance	O
to	to	O
the	the	O
cardiotoxic	cardiotoxic	B-Disease
effect	effect	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
in	in	O
streptozotocin	streptozotocin	B-Chemical
diabetic	diabetic	B-Disease
rats	rats	O
.	.	O

A	a	O
morphometric	morphometric	O
study	study	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
induced	induced	O
myocardial	myocardial	O
fibrosis	fibrosis	B-Disease
.	.	O

The	the	O
acute	acute	O
effect	effect	O
of	of	O
insulin	insulin	O
treatment	treatment	O
on	on	O
the	the	O
earlier	earlier	O
reported	reported	O
protective	protective	O
effect	effect	O
of	of	O
streptozotocin	streptozotocin	B-Chemical
diabetes	diabetes	B-Disease
against	against	O
the	the	O
cardiotoxic	cardiotoxic	B-Disease
effect	effect	O
of	of	O
high	high	O
doses	doses	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
(	(	O
ISO	iso	B-Chemical
)	)	O
was	was	O
investigated	investigated	O
in	in	O
rats	rats	O
.	.	O

Thirty	thirty	O
to	to	O
135	135	O
min	min	O
after	after	O
the	the	O
injection	injection	O
of	of	O
crystalline	crystalline	O
insulin	insulin	O
,	,	O
ISO	iso	B-Chemical
was	was	O
given	given	O
subcutaneously	subcutaneously	O
and	and	O
when	when	O
ISO	iso	B-Chemical
induced	induced	O
fibrosis	fibrosis	B-Disease
in	in	O
the	the	O
myocardium	myocardium	O
was	was	O
morphometrically	morphometrically	O
analyzed	analyzed	O
7	7	O
days	days	O
later	later	O
,	,	O
a	a	O
highly	highly	O
significant	significant	O
correlation	correlation	O
(	(	O
r	r	O
=	=	O
0.83	0.83	O
,	,	O
2	2	O
p	p	O
=	=	O
0.006	0.006	O
)	)	O
to	to	O
the	the	O
slope	slope	O
of	of	O
the	the	O
fall	fall	O
in	in	O
blood	blood	B-Chemical
glucose	glucose	B-Chemical
after	after	O
insulin	insulin	O
treatment	treatment	O
appeared	appeared	O
.	.	O

The	the	O
myocardial	myocardial	O
content	content	O
of	of	O
catecholamines	catecholamines	B-Chemical
was	was	O
estimated	estimated	O
in	in	O
these	these	O
8	8	O
day	day	O
diabetic	diabetic	B-Disease
rats	rats	O
.	.	O

The	the	O
norepinephrine	norepinephrine	B-Chemical
content	content	O
was	was	O
significantly	significantly	O
increased	increased	O
while	while	O
epinephrine	epinephrine	B-Chemical
remained	remained	O
unchanged	unchanged	O
.	.	O

An	an	O
enhanced	enhanced	O
sympathetic	sympathetic	O
nervous	nervous	O
system	system	O
activity	activity	O
with	with	O
a	a	O
consequent	consequent	O
down	down	O
regulation	regulation	O
of	of	O
the	the	O
myocardial	myocardial	O
beta-adrenergic	beta-adrenergic	O
receptors	receptors	O
could	could	O
,	,	O
therefore	therefore	O
,	,	O
explain	explain	O
this	this	O
catecholamine	catecholamine	B-Chemical
resistance	resistance	O
.	.	O

The	the	O
rapid	rapid	O
reversion	reversion	O
after	after	O
insulin	insulin	O
treatment	treatment	O
excludes	excludes	O
the	the	O
possibility	possibility	O
that	that	O
streptozotocin	streptozotocin	B-Chemical
in	in	O
itself	itself	O
causes	causes	O
the	the	O
ISO	iso	B-Chemical
resistance	resistance	O
and	and	O
points	points	O
towards	towards	O
a	a	O
direct	direct	O
insulin	insulin	O
effect	effect	O
on	on	O
myocardial	myocardial	O
catecholamine	catecholamine	B-Chemical
sensitivity	sensitivity	O
in	in	O
diabetic	diabetic	B-Disease
rats	rats	O
.	.	O

The	the	O
phenomenon	phenomenon	O
described	described	O
might	might	O
elucidate	elucidate	O
pathogenetic	pathogenetic	O
mechanisms	mechanisms	O
behind	behind	O
toxic	toxic	O
myocardial	myocardial	O
cell	cell	O
degeneration	degeneration	O
and	and	O
may	may	O
possibly	possibly	O
have	have	O
relevance	relevance	O
for	for	O
acute	acute	O
cardiovascular	cardiovascular	O
complications	complications	O
in	in	O
diabetic	diabetic	B-Disease
patients	patients	O
.	.	O

Differential	differential	O
effects	effects	O
of	of	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
on	on	O
seizures	seizures	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
in	in	O
rats	rats	O
.	.	O

The	the	O
muscarinic	muscarinic	O
cholinergic	cholinergic	O
agonist	agonist	O
pilocarpine	pilocarpine	B-Chemical
induces	induces	O
in	in	O
rats	rats	O
seizures	seizures	B-Disease
and	and	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
followed	followed	O
by	by	O
widespread	widespread	O
damage	damage	O
to	to	O
the	the	O
forebrain	forebrain	O
.	.	O

The	the	O
present	present	O
study	study	O
was	was	O
designed	designed	O
to	to	O
investigate	investigate	O
the	the	O
effect	effect	O
of	of	O
5	5	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
,	,	O
sodium	sodium	B-Chemical
salicylate	salicylate	I-Chemical
,	,	O
phenylbutazone	phenylbutazone	O
,	,	O
indomethacin	indomethacin	B-Chemical
,	,	O
ibuprofen	ibuprofen	B-Chemical
and	and	O
mefenamic	mefenamic	B-Chemical
acid	acid	I-Chemical
,	,	O
on	on	O
seizures	seizures	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
.	.	O

Pretreatment	pretreatment	O
of	of	O
rats	rats	O
with	with	O
sodium	sodium	B-Chemical
salicylate	salicylate	I-Chemical
,	,	O
ED50	ed50	O
103	103	O
mg/kg	mg/kg	O
(	(	O
60	60	O
-	-	O
174	174	O
)	)	O
,	,	O
and	and	O
phenylbutazone	phenylbutazone	O
,	,	O
59	59	O
mg/kg	mg/kg	O
(	(	O
50	50	O
-	-	O
70	70	O
)	)	O
converted	converted	O
the	the	O
non-convulsant	non-convulsant	O
dose	dose	O
of	of	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
200	200	O
mg/kg	mg/kg	O
,	,	O
to	to	O
a	a	O
convulsant	convulsant	O
one	one	O
.	.	O

Indomethacin	indomethacin	B-Chemical
,	,	O
1	1	O
-	-	O
10	10	O
mg/kg	mg/kg	O
,	,	O
and	and	O
ibuprofen	ibuprofen	B-Chemical
,	,	O
10	10	O
-	-	O
100	100	O
mg/kg	mg/kg	O
,	,	O
failed	failed	O
to	to	O
modulate	modulate	O
seizures	seizures	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
.	.	O

Mefenamic	mefenamic	B-Chemical
acid	acid	I-Chemical
,	,	O
26	26	O
(	(	O
22	22	O
-	-	O
30	30	O
)	)	O
mg/kg	mg/kg	O
,	,	O
prevented	prevented	O
seizures	seizures	B-Disease
and	and	O
protected	protected	O
rats	rats	O
from	from	O
seizure-related	seizure-related	O
brain	brain	B-Disease
damage	damage	I-Disease
induced	induced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
380	380	O
mg/kg	mg/kg	O
.	.	O

These	these	O
results	results	O
indicate	indicate	O
that	that	O
non-steroidal	non-steroidal	O
anti-inflammatory	anti-inflammatory	O
drugs	drugs	O
differentially	differentially	O
modulate	modulate	O
the	the	O
threshold	threshold	O
for	for	O
pilocarpine-induced	pilocarpine-induced	O
seizures	seizures	B-Disease
.	.	O

Acute	acute	O
neurologic	neurologic	O
dysfunction	dysfunction	O
after	after	O
high-dose	high-dose	O
etoposide	etoposide	B-Chemical
therapy	therapy	O
for	for	O
malignant	malignant	O
glioma	glioma	O
.	.	O

Etoposide	etoposide	B-Chemical
(	(	O
VP-16	vp-16	O
-	-	O
213	213	O
)	)	O
has	has	O
been	been	O
used	used	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
many	many	O
solid	solid	O
tumors	tumors	B-Disease
and	and	O
hematologic	hematologic	O
malignancies	malignancies	B-Disease
.	.	O

When	when	O
used	used	O
in	in	O
high	high	O
doses	doses	O
and	and	O
in	in	O
conjunction	conjunction	O
with	with	O
autologous	autologous	O
bone	bone	O
marrow	marrow	O
transplantation	transplantation	O
,	,	O
this	this	O
agent	agent	O
has	has	O
activity	activity	O
against	against	O
several	several	O
treatment-resistant	treatment-resistant	O
cancers	cancers	B-Disease
including	including	O
malignant	malignant	O
glioma	glioma	O
.	.	O

In	in	O
six	six	O
of	of	O
eight	eight	O
patients	patients	O
(	(	O
75	75	O
%	%	O
)	)	O
who	who	O
we	we	O
treated	treated	O
for	for	O
recurrent	recurrent	O
or	or	O
resistant	resistant	O
glioma	glioma	O
,	,	O
sudden	sudden	O
severe	severe	O
neurologic	neurologic	O
deterioration	deterioration	O
occurred	occurred	O
.	.	O

This	this	O
developed	developed	O
a	a	O
median	median	O
of	of	O
9	9	O
days	days	O
after	after	O
initiation	initiation	O
of	of	O
high-dose	high-dose	O
etoposide	etoposide	B-Chemical
therapy	therapy	O
.	.	O

Significant	significant	O
clinical	clinical	O
manifestations	manifestations	O
have	have	O
included	included	O
confusion	confusion	B-Disease
,	,	O
papilledema	papilledema	O
,	,	O
somnolence	somnolence	B-Disease
,	,	O
exacerbation	exacerbation	O
of	of	O
motor	motor	O
deficits	deficits	O
,	,	O
and	and	O
sharp	sharp	O
increase	increase	O
in	in	O
seizure	seizure	B-Disease
activity	activity	O
.	.	O

These	these	O
abnormalities	abnormalities	O
resolved	resolved	O
rapidly	rapidly	O
after	after	O
initiation	initiation	O
of	of	O
high-dose	high-dose	O
intravenous	intravenous	O
dexamethasone	dexamethasone	B-Chemical
therapy	therapy	O
.	.	O

In	in	O
all	all	O
patients	patients	O
,	,	O
computerized	computerized	O
tomographic	tomographic	O
(	(	O
CT	ct	O
)	)	O
brain	brain	O
scans	scans	O
demonstrated	demonstrated	O
stability	stability	O
in	in	O
tumor	tumor	B-Disease
size	size	O
and	and	O
peritumor	peritumor	O
edema	edema	B-Disease
when	when	O
compared	compared	O
with	with	O
pretransplant	pretransplant	O
scans	scans	O
.	.	O

This	this	O
complication	complication	O
appears	appears	O
to	to	O
represent	represent	O
a	a	O
significant	significant	O
new	new	O
toxicity	toxicity	B-Disease
of	of	O
high-dose	high-dose	O
etoposide	etoposide	B-Chemical
therapy	therapy	O
for	for	O
malignant	malignant	O
glioma	glioma	O
.	.	O

Progressive	progressive	O
bile	bile	O
duct	duct	O
injury	injury	O
after	after	O
thiabendazole	thiabendazole	O
administration	administration	O
.	.	O

A	a	O
27-yr-old	27-yr-old	O
man	man	O
developed	developed	O
jaundice	jaundice	B-Disease
2	2	O
wk	wk	O
after	after	O
exposure	exposure	O
to	to	O
thiabendazole	thiabendazole	O
.	.	O

Cholestasis	cholestasis	B-Disease
persisted	persisted	O
for	for	O
3	3	O
yr	yr	O
,	,	O
at	at	O
which	which	O
time	time	O
a	a	O
liver	liver	O
transplant	transplant	O
was	was	O
performed	performed	O
.	.	O

Two	two	O
liver	liver	O
biopsy	biopsy	O
specimens	specimens	O
and	and	O
the	the	O
hepatectomy	hepatectomy	O
specimen	specimen	O
were	were	O
remarkable	remarkable	O
for	for	O
almost	almost	O
complete	complete	O
disappearance	disappearance	O
of	of	O
interlobular	interlobular	O
bile	bile	O
ducts	ducts	O
.	.	O

Prominent	prominent	O
fibrosis	fibrosis	B-Disease
and	and	O
hepatocellular	hepatocellular	O
regeneration	regeneration	O
were	were	O
also	also	O
present	present	O
;	;	O
however	however	O
,	,	O
the	the	O
lobular	lobular	O
architecture	architecture	O
was	was	O
preserved	preserved	O
.	.	O

This	this	O
case	case	O
represents	represents	O
an	an	O
example	example	O
of	of	O
"	"	O
idiosyncratic	idiosyncratic	O
"	"	O
drug-induced	drug-induced	O
liver	liver	B-Disease
damage	damage	I-Disease
in	in	O
which	which	O
the	the	O
primary	primary	O
target	target	O
of	of	O
injury	injury	O
is	is	O
the	the	O
bile	bile	O
duct	duct	O
.	.	O

An	an	O
autoimmune	autoimmune	O
pathogenesis	pathogenesis	O
of	of	O
the	the	O
bile	bile	O
duct	duct	O
destruction	destruction	O
is	is	O
suggested	suggested	O
.	.	O

Differential	differential	O
effects	effects	O
of	of	O
1,4-dihydropyridine	1,4-dihydropyridine	O
calcium	calcium	B-Chemical
channel	channel	I-Chemical
blockers	blockers	I-Chemical
:	:	O
therapeutic	therapeutic	O
implications	implications	O
.	.	O

Increasing	increasing	O
recognition	recognition	O
of	of	O
the	the	O
importance	importance	O
of	of	O
calcium	calcium	B-Chemical
in	in	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
cardiovascular	cardiovascular	B-Disease
disease	disease	I-Disease
has	has	O
stimulated	stimulated	O
research	research	O
into	into	O
the	the	O
use	use	O
of	of	O
calcium	calcium	B-Chemical
channel	channel	O
blocking	blocking	O
agents	agents	O
for	for	O
treatment	treatment	O
of	of	O
a	a	O
variety	variety	O
of	of	O
cardiovascular	cardiovascular	B-Disease
diseases	diseases	I-Disease
.	.	O

The	the	O
favorable	favorable	O
efficacy	efficacy	O
and	and	O
tolerability	tolerability	O
profiles	profiles	O
of	of	O
these	these	O
agents	agents	O
make	make	O
them	them	O
attractive	attractive	O
therapeutic	therapeutic	O
modalities	modalities	O
.	.	O

Clinical	clinical	O
applications	applications	O
of	of	O
calcium	calcium	B-Chemical
channel	channel	I-Chemical
blockers	blockers	I-Chemical
parallel	parallel	O
their	their	O
tissue	tissue	O
selectivity	selectivity	O
.	.	O

In	in	O
contrast	contrast	O
to	to	O
verapamil	verapamil	B-Chemical
and	and	O
diltiazem	diltiazem	B-Chemical
,	,	O
which	which	O
are	are	O
roughly	roughly	O
equipotent	equipotent	O
in	in	O
their	their	O
actions	actions	O
on	on	O
the	the	O
heart	heart	O
and	and	O
vascular	vascular	O
smooth	smooth	O
muscle	muscle	O
,	,	O
the	the	O
dihydropyridine	dihydropyridine	O
calcium	calcium	B-Chemical
channel	channel	I-Chemical
blockers	blockers	I-Chemical
are	are	O
a	a	O
group	group	O
of	of	O
potent	potent	O
peripheral	peripheral	O
vasodilator	vasodilator	B-Chemical
agents	agents	I-Chemical
that	that	O
exert	exert	O
minimal	minimal	O
electrophysiologic	electrophysiologic	O
effects	effects	O
on	on	O
cardiac	cardiac	O
nodal	nodal	O
or	or	O
conduction	conduction	O
tissue	tissue	O
.	.	O

As	as	O
the	the	O
first	first	O
dihydropyridine	dihydropyridine	O
available	available	O
for	for	O
use	use	O
in	in	O
the	the	O
United	united	O
States	states	O
,	,	O
nifedipine	nifedipine	B-Chemical
controls	controls	O
angina	angina	O
and	and	O
hypertension	hypertension	B-Disease
with	with	O
minimal	minimal	O
depression	depression	B-Disease
of	of	O
cardiac	cardiac	O
function	function	O
.	.	O

Additional	additional	O
members	members	O
of	of	O
this	this	O
group	group	O
of	of	O
calcium	calcium	B-Chemical
channel	channel	I-Chemical
blockers	blockers	I-Chemical
have	have	O
been	been	O
studied	studied	O
for	for	O
a	a	O
variety	variety	O
of	of	O
indications	indications	O
for	for	O
which	which	O
they	they	O
may	may	O
offer	offer	O
advantages	advantages	O
over	over	O
current	current	O
therapy	therapy	O
.	.	O

Once	once	O
or	or	O
twice	twice	O
daily	daily	O
dosage	dosage	O
possible	possible	O
with	with	O
nitrendipine	nitrendipine	B-Chemical
and	and	O
nisoldipine	nisoldipine	O
offers	offers	O
a	a	O
convenient	convenient	O
administration	administration	O
schedule	schedule	O
,	,	O
which	which	O
encourages	encourages	O
patient	patient	O
compliance	compliance	O
in	in	O
long-term	long-term	O
therapy	therapy	O
of	of	O
hypertension	hypertension	B-Disease
.	.	O

The	the	O
coronary	coronary	O
vasodilating	vasodilating	O
properties	properties	O
of	of	O
nisoldipine	nisoldipine	O
have	have	O
led	led	O
to	to	O
the	the	O
investigation	investigation	O
of	of	O
this	this	O
agent	agent	O
for	for	O
use	use	O
in	in	O
angina	angina	O
.	.	O

Selectivity	selectivity	O
for	for	O
the	the	O
cerebrovascular	cerebrovascular	O
bed	bed	O
makes	makes	O
nimodipine	nimodipine	B-Chemical
potentially	potentially	O
useful	useful	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
subarachnoid	subarachnoid	B-Disease
hemorrhage	hemorrhage	B-Disease
,	,	O
migraine	migraine	B-Disease
headache	headache	B-Disease
,	,	O
dementia	dementia	B-Disease
,	,	O
and	and	O
stroke	stroke	B-Disease
.	.	O

In	in	O
general	general	O
,	,	O
the	the	O
dihydropyridine	dihydropyridine	O
calcium	calcium	B-Chemical
channel	channel	I-Chemical
blockers	blockers	I-Chemical
are	are	O
usually	usually	O
well	well	O
tolerated	tolerated	O
,	,	O
with	with	O
headache	headache	B-Disease
,	,	O
facial	facial	O
flushing	flushing	O
,	,	O
palpitations	palpitations	O
,	,	O
edema	edema	B-Disease
,	,	O
nausea	nausea	B-Disease
,	,	O
anorexia	anorexia	O
,	,	O
and	and	O
dizziness	dizziness	B-Disease
being	being	O
the	the	O
more	more	O
common	common	O
adverse	adverse	O
effects	effects	O
.	.	O

The	the	O
enhancement	enhancement	O
of	of	O
aminonucleoside	aminonucleoside	B-Chemical
nephrosis	nephrosis	B-Disease
by	by	O
the	the	O
co-administration	co-administration	O
of	of	O
protamine	protamine	O
.	.	O

An	an	O
experimental	experimental	O
model	model	O
of	of	O
focal	focal	O
segmental	segmental	O
glomerular	glomerular	B-Disease
sclerosis	sclerosis	I-Disease
(	(	O
FSGS	fsgs	O
)	)	O
was	was	O
developed	developed	O
in	in	O
rats	rats	O
by	by	O
the	the	O
combined	combined	O
administration	administration	O
of	of	O
puromycin-aminonucleoside	puromycin-aminonucleoside	O
(	(	O
AMNS	amns	O
)	)	O
and	and	O
protamine	protamine	O
sulfate	sulfate	O
(	(	O
PS	ps	O
)	)	O
.	.	O

Male	male	O
Sprague-Dawley	sprague-dawley	O
rats	rats	O
,	,	O
uninephrectomized	uninephrectomized	O
three	three	O
weeks	weeks	O
before	before	O
,	,	O
received	received	O
daily	daily	O
injections	injections	O
of	of	O
subcutaneous	subcutaneous	O
AMNS	amns	O
(	(	O
1	1	O
mg/100	mg/100	O
g	g	O
body	body	O
wt	wt	O
)	)	O
and	and	O
intravenous	intravenous	O
PS	ps	O
(	(	O
2	2	O
separated	separated	O
doses	doses	O
of	of	O
2.5	2.5	O
mg/100	mg/100	O
g	g	O
body	body	O
wt	wt	O
)	)	O
for	for	O
four	four	O
days	days	O
.	.	O

The	the	O
series	series	O
of	of	O
injections	injections	O
were	were	O
repeated	repeated	O
another	another	O
three	three	O
times	times	O
at	at	O
10	10	O
day	day	O
intervals	intervals	O
.	.	O

The	the	O
animals	animals	O
were	were	O
sacrificed	sacrificed	O
on	on	O
days	days	O
24	24	O
,	,	O
52	52	O
,	,	O
and	and	O
80	80	O
.	.	O

They	they	O
developed	developed	O
nephrotic	nephrotic	B-Disease
syndrome	syndrome	I-Disease
and	and	O
finally	finally	O
renal	renal	B-Disease
failure	failure	I-Disease
.	.	O

The	the	O
time-course	time-course	O
curve	curve	O
of	of	O
creatinine	creatinine	B-Chemical
clearance	clearance	O
dropped	dropped	O
and	and	O
showed	showed	O
significant	significant	O
difference	difference	O
(	(	O
P	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
from	from	O
that	that	O
of	of	O
each	each	O
control	control	O
group	group	O
,	,	O
such	such	O
as	as	O
,	,	O
AMNS	amns	O
alone	alone	O
,	,	O
PS	ps	O
alone	alone	O
or	or	O
saline	saline	O
injected	injected	O
.	.	O

Their	their	O
glomeruli	glomeruli	O
showed	showed	O
changes	changes	O
of	of	O
progressive	progressive	O
FSGS	fsgs	O
.	.	O

The	the	O
ultrastructural	ultrastructural	O
studies	studies	O
in	in	O
the	the	O
initial	initial	O
stage	stage	O
revealed	revealed	O
significant	significant	O
lack	lack	O
of	of	O
particles	particles	O
of	of	O
perfused	perfused	O
ruthenium	ruthenium	B-Chemical
red	red	I-Chemical
on	on	O
the	the	O
lamina	lamina	O
rara	rara	O
externa	externa	O
and	and	O
marked	marked	O
changes	changes	O
in	in	O
epithelial	epithelial	O
cell	cell	O
cytoplasm	cytoplasm	O
.	.	O

Therefore	therefore	O
,	,	O
it	it	O
is	is	O
suggested	suggested	O
that	that	O
the	the	O
administration	administration	O
of	of	O
PS	ps	O
enhances	enhances	O
the	the	O
toxicity	toxicity	B-Disease
of	of	O
AMNS	amns	O
on	on	O
the	the	O
glomerulus	glomerulus	O
and	and	O
readily	readily	O
produces	produces	O
progressive	progressive	O
FSGS	fsgs	O
in	in	O
rats	rats	O
resulting	resulting	O
in	in	O
the	the	O
end-stage	end-stage	O
renal	renal	O
disease	disease	O
.	.	O

Theophylline	theophylline	B-Chemical
neurotoxicity	neurotoxicity	B-Disease
in	in	O
pregnant	pregnant	O
rats	rats	O
.	.	O

The	the	O
purpose	purpose	O
of	of	O
this	this	O
investigation	investigation	O
was	was	O
to	to	O
determine	determine	O
whether	whether	O
the	the	O
neurotoxicity	neurotoxicity	B-Disease
of	of	O
theophylline	theophylline	B-Chemical
is	is	O
altered	altered	O
in	in	O
advanced	advanced	O
pregnancy	pregnancy	O
.	.	O

Sprague-Dawley	sprague-dawley	O
rats	rats	O
that	that	O
were	were	O
20	20	O
days	days	O
pregnant	pregnant	O
and	and	O
nonpregnant	nonpregnant	O
rats	rats	O
of	of	O
the	the	O
same	same	O
age	age	O
and	and	O
strain	strain	O
received	received	O
infusions	infusions	O
of	of	O
aminophylline	aminophylline	B-Chemical
until	until	O
onset	onset	O
of	of	O
maximal	maximal	O
seizures	seizures	B-Disease
which	which	O
occurred	occurred	O
after	after	O
28	28	O
and	and	O
30	30	O
minutes	minutes	O
respectively	respectively	O
.	.	O

Theophylline	theophylline	B-Chemical
concentrations	concentrations	O
at	at	O
this	this	O
endpoint	endpoint	O
in	in	O
serum	serum	O
(	(	O
total	total	O
)	)	O
and	and	O
CSF	csf	O
were	were	O
similar	similar	O
but	but	O
serum	serum	O
(	(	O
free	free	O
)	)	O
and	and	O
brain	brain	O
concentrations	concentrations	O
were	were	O
slightly	slightly	O
different	different	O
in	in	O
pregnant	pregnant	O
rats	rats	O
.	.	O

Theophylline	theophylline	B-Chemical
serum	serum	O
protein	protein	O
binding	binding	O
determined	determined	O
by	by	O
equilibrium	equilibrium	O
dialysis	dialysis	O
was	was	O
lower	lower	O
in	in	O
pregnant	pregnant	O
rats	rats	O
.	.	O

Fetal	fetal	O
serum	serum	O
concentrations	concentrations	O
at	at	O
onset	onset	O
of	of	O
seizures	seizures	B-Disease
in	in	O
the	the	O
mother	mother	O
were	were	O
similar	similar	O
to	to	O
maternal	maternal	O
brain	brain	O
and	and	O
CSF	csf	O
concentrations	concentrations	O
and	and	O
correlated	correlated	O
significantly	significantly	O
with	with	O
the	the	O
former	former	O
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
advanced	advanced	O
pregnancy	pregnancy	O
has	has	O
a	a	O
negligible	negligible	O
effect	effect	O
on	on	O
the	the	O
neurotoxic	neurotoxic	B-Disease
response	response	O
to	to	O
theophylline	theophylline	B-Chemical
in	in	O
rats	rats	O
.	.	O

Hyperkalemia	hyperkalemia	B-Disease
induced	induced	O
by	by	O
indomethacin	indomethacin	B-Chemical
and	and	O
naproxen	naproxen	O
and	and	O
reversed	reversed	O
by	by	O
fludrocortisone	fludrocortisone	O
.	.	O

We	we	O
have	have	O
described	described	O
a	a	O
patient	patient	O
with	with	O
severe	severe	O
rheumatoid	rheumatoid	B-Disease
arthritis	arthritis	B-Disease
and	and	O
a	a	O
history	history	O
of	of	O
mefenamic	mefenamic	B-Chemical
acid	acid	I-Chemical
nephropathy	nephropathy	B-Disease
in	in	O
whom	whom	O
hyperkalemia	hyperkalemia	B-Disease
and	and	O
inappropriate	inappropriate	O
hypoaldosteronism	hypoaldosteronism	O
were	were	O
caused	caused	O
by	by	O
both	both	O
indomethacin	indomethacin	B-Chemical
and	and	O
naproxen	naproxen	O
,	,	O
without	without	O
major	major	O
decline	decline	O
in	in	O
renal	renal	O
function	function	O
.	.	O

It	it	O
is	is	O
likely	likely	O
that	that	O
preexisting	preexisting	O
renal	renal	O
disease	disease	O
predisposed	predisposed	O
this	this	O
patient	patient	O
to	to	O
type	type	O
IV	iv	O
renal	renal	O
tubular	tubular	O
acidosis	acidosis	B-Disease
with	with	O
prostaglandin	prostaglandin	O
synthetase	synthetase	O
inhibitors	inhibitors	O
.	.	O

Because	because	O
he	he	O
was	was	O
unable	unable	O
to	to	O
discontinue	discontinue	O
nonsteroidal	nonsteroidal	O
anti-inflammatory	anti-inflammatory	O
drug	drug	O
therapy	therapy	O
,	,	O
fludrocortisone	fludrocortisone	O
was	was	O
added	added	O
,	,	O
correcting	correcting	O
the	the	O
hyperkalemia	hyperkalemia	B-Disease
and	and	O
allowing	allowing	O
indomethacin	indomethacin	B-Chemical
therapy	therapy	O
to	to	O
be	be	O
continued	continued	O
safely	safely	O
.	.	O

Hypotension	hypotension	B-Disease
as	as	O
a	a	O
manifestation	manifestation	O
of	of	O
cardiotoxicity	cardiotoxicity	B-Disease
in	in	O
three	three	O
patients	patients	O
receiving	receiving	O
cisplatin	cisplatin	B-Chemical
and	and	O
5-fluorouracil	5-fluorouracil	B-Chemical
.	.	O

Cardiac	cardiac	O
symptoms	symptoms	O
,	,	O
including	including	O
hypotension	hypotension	B-Disease
,	,	O
developed	developed	O
in	in	O
three	three	O
patients	patients	O
with	with	O
advanced	advanced	O
colorectal	colorectal	O
carcinoma	carcinoma	B-Disease
while	while	O
being	being	O
treated	treated	O
with	with	O
cisplatin	cisplatin	B-Chemical
(	(	O
CDDP	cddp	O
)	)	O
and	and	O
5-fluorouracil	5-fluorouracil	B-Chemical
(	(	O
5-FU	5-fu	B-Chemical
)	)	O
.	.	O

In	in	O
two	two	O
patients	patients	O
,	,	O
hypotension	hypotension	B-Disease
was	was	O
associated	associated	O
with	with	O
severe	severe	O
left	left	O
ventricular	ventricular	B-Disease
dysfunction	dysfunction	I-Disease
.	.	O

All	all	O
three	three	O
patients	patients	O
required	required	O
therapy	therapy	O
discontinuation	discontinuation	O
.	.	O

Cardiac	cardiac	O
enzymes	enzymes	O
remained	remained	O
normal	normal	O
despite	despite	O
transient	transient	O
electrocardiographic	electrocardiographic	O
(	(	O
EKG	ekg	O
)	)	O
changes	changes	O
.	.	O

The	the	O
presentation	presentation	O
and	and	O
cardiac	cardiac	O
evaluation	evaluation	O
(	(	O
hemodynamic	hemodynamic	O
,	,	O
echocardiographic	echocardiographic	O
,	,	O
and	and	O
scintigraphic	scintigraphic	O
)	)	O
of	of	O
these	these	O
patients	patients	O
suggest	suggest	O
new	new	O
manifestations	manifestations	O
of	of	O
5-FU	5-fu	B-Chemical
cardiotoxicity	cardiotoxicity	B-Disease
that	that	O
may	may	O
be	be	O
influenced	influenced	O
by	by	O
CDDP	cddp	O
.	.	O

The	the	O
possible	possible	O
pathophysiologic	pathophysiologic	O
mechanisms	mechanisms	O
are	are	O
discussed	discussed	O
.	.	O

Fatal	fatal	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
in	in	O
a	a	O
patient	patient	O
treated	treated	O
with	with	O
carbamazepine	carbamazepine	B-Chemical
.	.	O

A	a	O
case	case	O
of	of	O
fatal	fatal	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
due	due	O
to	to	O
carbamazepine	carbamazepine	B-Chemical
treatment	treatment	O
in	in	O
an	an	O
epileptic	epileptic	B-Disease
woman	woman	O
is	is	O
reported	reported	O
.	.	O

Despite	despite	O
concerns	concerns	O
of	of	O
fatal	fatal	O
bone	bone	O
marrow	marrow	O
toxicity	toxicity	B-Disease
due	due	O
to	to	O
carbamazepine	carbamazepine	B-Chemical
,	,	O
this	this	O
is	is	O
only	only	O
the	the	O
fourth	fourth	O
documented	documented	O
and	and	O
published	published	O
report	report	O
.	.	O

Carbamazepine	carbamazepine	B-Chemical
is	is	O
a	a	O
safe	safe	O
drug	drug	O
,	,	O
but	but	O
physicians	physicians	O
and	and	O
patients	patients	O
should	should	O
be	be	O
aware	aware	O
of	of	O
the	the	O
exceedingly	exceedingly	O
rare	rare	O
but	but	O
potentially	potentially	O
fatal	fatal	O
side	side	O
effects	effects	O
,	,	O
better	better	O
prevented	prevented	O
by	by	O
clinical	clinical	O
than	than	O
by	by	O
laboratory	laboratory	O
monitoring	monitoring	O
.	.	O

Participation	participation	O
of	of	O
a	a	O
bulbospinal	bulbospinal	O
serotonergic	serotonergic	O
pathway	pathway	O
in	in	O
the	the	O
rat	rat	O
brain	brain	O
in	in	O
clonidine-induced	clonidine-induced	O
hypotension	hypotension	B-Disease
and	and	O
bradycardia	bradycardia	B-Disease
.	.	O

The	the	O
effects	effects	O
of	of	O
microinjection	microinjection	O
of	of	O
clonidine	clonidine	B-Chemical
(	(	O
1	1	O
-	-	O
10	10	O
micrograms	micrograms	O
in	in	O
1	1	O
microliter	microliter	O
)	)	O
into	into	O
a	a	O
region	region	O
adjacent	adjacent	O
to	to	O
the	the	O
ventrolateral	ventrolateral	O
surface	surface	O
of	of	O
the	the	O
medulla	medulla	O
oblongata	oblongata	O
on	on	O
cardiovascular	cardiovascular	O
function	function	O
were	were	O
assessed	assessed	O
in	in	O
urethane-anesthetized	urethane-anesthetized	O
rats	rats	O
.	.	O

Intramedullary	intramedullary	O
administration	administration	O
of	of	O
clonidine	clonidine	B-Chemical
,	,	O
but	but	O
not	not	O
saline	saline	O
vehicle	vehicle	O
,	,	O
caused	caused	O
a	a	O
dose-dependent	dose-dependent	O
decrease	decrease	O
in	in	O
both	both	O
the	the	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
and	and	O
the	the	O
heart	heart	O
rate	rate	O
.	.	O

The	the	O
clonidine-induced	clonidine-induced	O
hypotension	hypotension	B-Disease
was	was	O
antagonized	antagonized	O
by	by	O
prior	prior	O
spinal	spinal	O
transection	transection	O
,	,	O
but	but	O
not	not	O
bilateral	bilateral	O
vagotomy	vagotomy	O
.	.	O

On	on	O
the	the	O
other	other	O
hand	hand	O
,	,	O
the	the	O
clonidine-induced	clonidine-induced	O
bradycardia	bradycardia	B-Disease
was	was	O
antagonized	antagonized	O
by	by	O
prior	prior	O
bilateral	bilateral	O
vagotomy	vagotomy	O
,	,	O
but	but	O
not	not	O
spinal	spinal	O
transection	transection	O
.	.	O

Furthermore	furthermore	O
,	,	O
selective	selective	O
destruction	destruction	O
of	of	O
the	the	O
spinal	spinal	O
5-HT	5-ht	B-Chemical
nerves	nerves	O
,	,	O
produced	produced	O
by	by	O
bilateral	bilateral	O
spinal	spinal	O
injection	injection	O
of	of	O
5,7-dihydroxytryptamine	5,7-dihydroxytryptamine	O
,	,	O
reduced	reduced	O
the	the	O
magnitude	magnitude	O
of	of	O
the	the	O
vasodepressor	vasodepressor	O
or	or	O
the	the	O
bradycardiac	bradycardiac	O
responses	responses	O
to	to	O
clonidine	clonidine	B-Chemical
microinjected	microinjected	O
into	into	O
the	the	O
area	area	O
near	near	O
the	the	O
ventrolateral	ventrolateral	O
surface	surface	O
of	of	O
the	the	O
medulla	medulla	O
oblongata	oblongata	O
in	in	O
rats	rats	O
.	.	O

The	the	O
data	data	O
indicate	indicate	O
that	that	O
a	a	O
bulbospinal	bulbospinal	O
serotonergic	serotonergic	O
pathway	pathway	O
is	is	O
involved	involved	O
in	in	O
development	development	O
of	of	O
clonidine-induced	clonidine-induced	O
hypotension	hypotension	B-Disease
and	and	O
bradycardia	bradycardia	B-Disease
.	.	O

The	the	O
induced	induced	O
hypotension	hypotension	B-Disease
is	is	O
brought	brought	O
about	about	O
by	by	O
a	a	O
decrease	decrease	O
in	in	O
sympathetic	sympathetic	O
efferent	efferent	O
activity	activity	O
,	,	O
whereas	whereas	O
the	the	O
induced	induced	O
bradycardia	bradycardia	B-Disease
was	was	O
due	due	O
to	to	O
an	an	O
increase	increase	O
in	in	O
vagal	vagal	O
efferent	efferent	O
activity	activity	O
.	.	O

Hypertension	hypertension	B-Disease
in	in	O
neuroblastoma	neuroblastoma	O
induced	induced	O
by	by	O
imipramine	imipramine	O
.	.	O

Hypertension	hypertension	B-Disease
is	is	O
a	a	O
well-known	well-known	O
finding	finding	O
in	in	O
some	some	O
patients	patients	O
with	with	O
neuroblastoma	neuroblastoma	O
.	.	O

However	however	O
,	,	O
it	it	O
has	has	O
not	not	O
previously	previously	O
been	been	O
described	described	O
in	in	O
association	association	O
with	with	O
the	the	O
use	use	O
of	of	O
Imipramine	imipramine	O
.	.	O

We	we	O
report	report	O
the	the	O
occurrence	occurrence	O
of	of	O
severe	severe	O
hypertension	hypertension	B-Disease
(	(	O
blood	blood	O
pressure	pressure	O
190/160	190/160	O
)	)	O
in	in	O
a	a	O
4-year-old	4-year-old	O
girl	girl	O
with	with	O
neuroblastoma	neuroblastoma	O
who	who	O
was	was	O
given	given	O
Imipramine	imipramine	O
to	to	O
control	control	O
a	a	O
behavior	behavior	O
disorder	disorder	O
.	.	O

It	it	O
was	was	O
determined	determined	O
later	later	O
that	that	O
this	this	O
patient	patient	O
's	's	O
tumor	tumor	B-Disease
was	was	O
recurring	recurring	O
at	at	O
the	the	O
time	time	O
of	of	O
her	her	O
hypertensive	hypertensive	B-Disease
episode	episode	O
.	.	O

Since	since	O
she	she	O
had	had	O
no	no	O
blood	blood	O
pressure	pressure	O
elevation	elevation	O
at	at	O
initial	initial	O
diagnosis	diagnosis	O
and	and	O
none	none	O
following	following	O
discontinuation	discontinuation	O
of	of	O
the	the	O
Imipramine	imipramine	O
(	(	O
when	when	O
she	she	O
was	was	O
in	in	O
florid	florid	O
relapse	relapse	O
)	)	O
,	,	O
we	we	O
believe	believe	O
that	that	O
this	this	O
drug	drug	O
rather	rather	O
than	than	O
her	her	O
underlying	underlying	O
disease	disease	O
alone	alone	O
caused	caused	O
her	her	O
hypertension	hypertension	B-Disease
.	.	O

The	the	O
mechanism	mechanism	O
for	for	O
this	this	O
reaction	reaction	O
is	is	O
believed	believed	O
to	to	O
be	be	O
increased	increased	O
levels	levels	O
of	of	O
vasoactive	vasoactive	O
catecholamines	catecholamines	B-Chemical
due	due	O
to	to	O
interference	interference	O
of	of	O
their	their	O
physiologic	physiologic	O
inactivation	inactivation	O
by	by	O
Imipramine	imipramine	O
.	.	O

From	from	O
this	this	O
experience	experience	O
,	,	O
we	we	O
urge	urge	O
extreme	extreme	O
caution	caution	O
in	in	O
the	the	O
use	use	O
of	of	O
tricyclic	tricyclic	O
antidepressants	antidepressants	B-Chemical
in	in	O
children	children	O
with	with	O
active	active	O
neuroblastoma	neuroblastoma	O
.	.	O

Rechallenge	rechallenge	O
of	of	O
patients	patients	O
who	who	O
developed	developed	O
oral	oral	O
candidiasis	candidiasis	O
or	or	O
hoarseness	hoarseness	B-Disease
with	with	O
beclomethasone	beclomethasone	O
dipropionate	dipropionate	O
.	.	O

Of	of	O
158	158	O
asthmatic	asthmatic	O
patients	patients	O
who	who	O
were	were	O
placed	placed	O
on	on	O
inhaled	inhaled	O
beclomethasone	beclomethasone	O
,	,	O
15	15	O
(	(	O
9.5	9.5	O
%	%	O
)	)	O
developed	developed	O
either	either	O
hoarseness	hoarseness	B-Disease
(	(	O
8)	8)	O
,	,	O
oral	oral	O
thrush	thrush	O
(	(	O
6	6	O
)	)	O
,	,	O
or	or	O
both	both	O
(	(	O
1	1	O
)	)	O
.	.	O

When	when	O
their	their	O
adverse	adverse	O
reactions	reactions	O
subsided	subsided	O
,	,	O
seven	seven	O
of	of	O
these	these	O
15	15	O
patients	patients	O
were	were	O
rechallenged	rechallenged	O
with	with	O
inhaled	inhaled	O
beclomethasone	beclomethasone	O
.	.	O

These	these	O
included	included	O
five	five	O
cases	cases	O
who	who	O
developed	developed	O
hoarseness	hoarseness	B-Disease
and	and	O
three	three	O
who	who	O
developed	developed	O
Candidiasis	candidiasis	O
.	.	O

One	one	O
patient	patient	O
had	had	O
both	both	O
.	.	O

Oral	oral	O
thrush	thrush	O
did	did	O
not	not	O
recur	recur	O
,	,	O
but	but	O
60	60	O
%	%	O
(	(	O
3/5	3/5	O
)	)	O
of	of	O
patients	patients	O
with	with	O
hoarseness	hoarseness	B-Disease
had	had	O
recurrence	recurrence	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
patients	patients	O
may	may	O
be	be	O
restarted	restarted	O
on	on	O
inhaled	inhaled	O
beclomethasone	beclomethasone	O
when	when	O
clinically	clinically	O
indicated	indicated	O
;	;	O
however	however	O
,	,	O
because	because	O
of	of	O
the	the	O
high	high	O
recurrence	recurrence	O
rate	rate	O
,	,	O
patients	patients	O
who	who	O
develop	develop	O
hoarseness	hoarseness	B-Disease
should	should	O
not	not	O
be	be	O
re-challenged	re-challenged	O
.	.	O

Concomitant	concomitant	O
use	use	O
of	of	O
oral	oral	O
prednisone	prednisone	B-Chemical
and	and	O
topical	topical	O
beclomethasone	beclomethasone	O
may	may	O
increase	increase	O
the	the	O
risk	risk	O
of	of	O
developing	developing	O
hoarseness	hoarseness	B-Disease
or	or	O
candidiasis	candidiasis	O
.	.	O

Cyclophosphamide	cyclophosphamide	B-Chemical
cardiotoxicity	cardiotoxicity	B-Disease
:	:	O
an	an	O
analysis	analysis	O
of	of	O
dosing	dosing	O
as	as	O
a	a	O
risk	risk	O
factor	factor	O
.	.	O

Patients	patients	O
who	who	O
undergo	undergo	O
bone	bone	O
marrow	marrow	O
transplantation	transplantation	O
are	are	O
generally	generally	O
immunosuppressed	immunosuppressed	O
with	with	O
a	a	O
dose	dose	O
of	of	O
cyclophosphamide	cyclophosphamide	B-Chemical
(	(	O
CYA	cya	O
)	)	O
which	which	O
is	is	O
usually	usually	O
calculated	calculated	O
based	based	O
on	on	O
the	the	O
patient	patient	O
's	's	O
weight	weight	O
.	.	O

At	at	O
these	these	O
high	high	O
doses	doses	O
of	of	O
CYA	cya	O
,	,	O
serious	serious	O
cardiotoxicity	cardiotoxicity	B-Disease
may	may	O
occur	occur	O
,	,	O
but	but	O
definitive	definitive	O
risk	risk	O
factors	factors	O
for	for	O
the	the	O
development	development	O
of	of	O
such	such	O
cardiotoxicity	cardiotoxicity	B-Disease
have	have	O
not	not	O
been	been	O
described	described	O
.	.	O

Since	since	O
chemotherapeutic	chemotherapeutic	O
agent	agent	O
toxicity	toxicity	B-Disease
generally	generally	O
correlates	correlates	O
with	with	O
dose	dose	O
per	per	O
body	body	O
surface	surface	O
area	area	O
,	,	O
we	we	O
retrospectively	retrospectively	O
calculated	calculated	O
the	the	O
dose	dose	O
of	of	O
CYA	cya	O
in	in	O
patients	patients	O
transplanted	transplanted	O
at	at	O
our	our	O
institution	institution	O
to	to	O
determine	determine	O
whether	whether	O
the	the	O
incidence	incidence	O
of	of	O
CYA	cya	O
cardiotoxicity	cardiotoxicity	B-Disease
correlated	correlated	O
with	with	O
the	the	O
dose	dose	O
per	per	O
body	body	O
surface	surface	O
area	area	O
.	.	O

Eighty	eighty	O
patients	patients	O
who	who	O
were	were	O
to	to	O
receive	receive	O
CYA	cya	O
50	50	O
mg/kg/d	mg/kg/d	O
for	for	O
four	four	O
days	days	O
as	as	O
preparation	preparation	O
for	for	O
marrow	marrow	O
grafting	grafting	O
underwent	underwent	O
a	a	O
total	total	O
of	of	O
84	84	O
transplants	transplants	O
for	for	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
,	,	O
Wiskott-Aldrich	wiskott-aldrich	O
syndrome	syndrome	O
,	,	O
or	or	O
severe	severe	B-Disease
combined	combined	I-Disease
immunodeficiency	immunodeficiency	I-Disease
syndrome	syndrome	I-Disease
.	.	O

Fourteen	fourteen	O
of	of	O
84	84	O
(	(	O
17	17	O
%	%	O
)	)	O
patients	patients	O
had	had	O
symptoms	symptoms	B-Disease
and	and	I-Disease
signs	signs	I-Disease
consistent	consistent	O
with	with	O
CYA	cya	O
cardiotoxicity	cardiotoxicity	B-Disease
within	within	O
ten	ten	O
days	days	O
of	of	O
receiving	receiving	O
1	1	O
to	to	O
4	4	O
doses	doses	O
of	of	O
CYA	cya	O
.	.	O

Six	six	O
of	of	O
the	the	O
14	14	O
patients	patients	O
died	died	O
with	with	O
congestive	congestive	B-Disease
heart	heart	B-Disease
failure	failure	I-Disease
.	.	O

The	the	O
dose	dose	O
of	of	O
CYA	cya	O
per	per	O
body	body	O
surface	surface	O
area	area	O
was	was	O
calculated	calculated	O
for	for	O
all	all	O
patients	patients	O
and	and	O
the	the	O
patients	patients	O
were	were	O
divided	divided	O
into	into	O
two	two	O
groups	groups	O
based	based	O
on	on	O
daily	daily	O
CYA	cya	O
dose	dose	O
:	:	O
Group	group	O
1	1	O
,	,	O
CYA	cya	O
less	less	O
than	than	O
or	or	O
equal	equal	O
to	to	O
1.55	1.55	O
g/m2/d	g/m2/d	O
;	;	O
Group	group	O
2	2	O
,	,	O
CYA	cya	O
greater	greater	O
than	than	O
1.55	1.55	O
g/m2/d	g/m2/d	O
.	.	O

Cardiotoxicity	cardiotoxicity	B-Disease
that	that	O
was	was	O
thought	thought	O
to	to	O
be	be	O
related	related	O
to	to	O
CYA	cya	O
occurred	occurred	O
in	in	O
1/32	1/32	O
(	(	O
3	3	O
%	%	O
)	)	O
of	of	O
patients	patients	O
in	in	O
Group	group	O
1	1	O
and	and	O
in	in	O
13/52	13/52	O
(	(	O
25	25	O
%	%	O
)	)	O
patients	patients	O
in	in	O
Group	group	O
2	2	O
(	(	O
P	p	O
less	less	O
than	than	O
0.025	0.025	O
)	)	O
.	.	O

Congestive	congestive	B-Disease
heart	heart	B-Disease
failure	failure	I-Disease
caused	caused	O
or	or	O
contributed	contributed	O
to	to	O
death	death	B-Disease
in	in	O
0/32	0/32	O
patients	patients	O
in	in	O
Group	group	O
1	1	O
v	v	O
6/52	6/52	O
(	(	O
12	12	O
%	%	O
)	)	O
of	of	O
patients	patients	O
in	in	O
Group	group	O
2	2	O
(	(	O
P	p	O
less	less	O
than	than	O
0.25	0.25	O
)	)	O
.	.	O

There	there	O
was	was	O
no	no	O
difference	difference	O
in	in	O
the	the	O
rate	rate	O
of	of	O
engraftment	engraftment	O
of	of	O
evaluable	evaluable	O
patients	patients	O
in	in	O
the	the	O
two	two	O
groups	groups	O
(	(	O
P	p	O
greater	greater	O
than	than	O
0.5	0.5	O
)	)	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
the	the	O
CYA	cya	O
cardiotoxicity	cardiotoxicity	B-Disease
correlates	correlates	O
with	with	O
CYA	cya	O
dosage	dosage	O
as	as	O
calculated	calculated	O
by	by	O
body	body	O
surface	surface	O
area	area	O
,	,	O
and	and	O
that	that	O
patients	patients	O
with	with	O
aplastic	aplastic	B-Disease
anemia	anemia	B-Disease
and	and	O
immunodeficiencies	immunodeficiencies	O
can	can	O
be	be	O
effectively	effectively	O
prepared	prepared	O
for	for	O
bone	bone	O
marrow	marrow	O
grafting	grafting	O
at	at	O
a	a	O
CYA	cya	O
dose	dose	O
of	of	O
1.55	1.55	O
g/m2/d	g/m2/d	O
for	for	O
four	four	O
days	days	O
with	with	O
a	a	O
lower	lower	O
incidence	incidence	O
of	of	O
cardiotoxicity	cardiotoxicity	B-Disease
than	than	O
patients	patients	O
whose	whose	O
CYA	cya	O
dosage	dosage	O
is	is	O
calculated	calculated	O
based	based	O
on	on	O
weight	weight	O
.	.	O

This	this	O
study	study	O
reaffirms	reaffirms	O
the	the	O
principle	principle	O
that	that	O
drug	drug	O
toxicity	toxicity	B-Disease
correlates	correlates	O
with	with	O
dose	dose	O
per	per	O
body	body	O
surface	surface	O
area	area	O
.	.	O

Studies	studies	O
of	of	O
risk	risk	O
factors	factors	O
for	for	O
aminoglycoside	aminoglycoside	B-Chemical
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

The	the	O
epidemiology	epidemiology	O
of	of	O
aminoglycoside-induced	aminoglycoside-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
is	is	O
not	not	O
fully	fully	O
understood	understood	O
.	.	O

Experimental	experimental	O
studies	studies	O
in	in	O
healthy	healthy	O
human	human	O
volunteers	volunteers	O
indicate	indicate	O
aminoglycosides	aminoglycosides	B-Chemical
cause	cause	O
proximal	proximal	O
tubular	tubular	O
damage	damage	O
in	in	O
most	most	O
patients	patients	O
,	,	O
but	but	O
rarely	rarely	O
,	,	O
if	if	O
ever	ever	O
,	,	O
cause	cause	O
glomerular	glomerular	O
or	or	O
tubular	tubular	O
dysfunction	dysfunction	O
.	.	O

Clinical	clinical	O
trials	trials	O
of	of	O
aminoglycosides	aminoglycosides	B-Chemical
in	in	O
seriously	seriously	O
ill	ill	O
patients	patients	O
indicate	indicate	O
that	that	O
the	the	O
relative	relative	O
risk	risk	O
for	for	O
developing	developing	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
during	during	O
therapy	therapy	O
ranges	ranges	O
from	from	O
8	8	O
to	to	O
10	10	O
and	and	O
that	that	O
the	the	O
attributable	attributable	O
risk	risk	O
is	is	O
70	70	O
%	%	O
to	to	O
80	80	O
%	%	O
.	.	O

Further	further	O
analysis	analysis	O
of	of	O
these	these	O
data	data	O
suggests	suggests	O
that	that	O
the	the	O
duration	duration	O
of	of	O
therapy	therapy	O
,	,	O
plasma	plasma	O
aminoglycoside	aminoglycoside	B-Chemical
levels	levels	O
,	,	O
liver	liver	B-Disease
disease	disease	I-Disease
,	,	O
advanced	advanced	O
age	age	O
,	,	O
high	high	O
initial	initial	O
estimated	estimated	O
creatinine	creatinine	B-Chemical
clearance	clearance	O
and	and	O
,	,	O
possibly	possibly	O
,	,	O
female	female	O
gender	gender	O
all	all	O
increase	increase	O
the	the	O
risk	risk	O
for	for	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

Other	other	O
causes	causes	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
,	,	O
such	such	O
as	as	O
shock	shock	B-Disease
,	,	O
appear	appear	O
to	to	O
have	have	O
an	an	O
additive	additive	O
effect	effect	O
.	.	O

Predictive	predictive	O
models	models	O
have	have	O
been	been	O
developed	developed	O
from	from	O
these	these	O
analyses	analyses	O
that	that	O
should	should	O
be	be	O
useful	useful	O
for	for	O
identifying	identifying	O
patients	patients	O
at	at	O
high	high	O
risk	risk	O
.	.	O

These	these	O
models	models	O
may	may	O
also	also	O
be	be	O
useful	useful	O
in	in	O
developing	developing	O
insights	insights	O
into	into	O
the	the	O
pathophysiology	pathophysiology	O
of	of	O
aminoglycoside-induced	aminoglycoside-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

Central	central	O
action	action	O
of	of	O
narcotic	narcotic	O
analgesics	analgesics	O
.	.	O

Part	part	O
IV	iv	O
.	.	O

Noradrenergic	noradrenergic	O
influences	influences	O
on	on	O
the	the	O
activity	activity	O
of	of	O
analgesics	analgesics	O
in	in	O
rats	rats	O
.	.	O

The	the	O
effect	effect	O
of	of	O
clonidine	clonidine	B-Chemical
,	,	O
naphazoline	naphazoline	O
and	and	O
xylometazoline	xylometazoline	O
on	on	O
analgesia	analgesia	O
induced	induced	O
by	by	O
morphine	morphine	B-Chemical
,	,	O
codeine	codeine	O
,	,	O
fentanyl	fentanyl	B-Chemical
and	and	O
pentazocine	pentazocine	B-Chemical
,	,	O
and	and	O
on	on	O
cataleptic	cataleptic	O
effect	effect	O
of	of	O
morphine	morphine	B-Chemical
,	,	O
codine	codine	O
and	and	O
fentanyl	fentanyl	B-Chemical
was	was	O
studied	studied	O
in	in	O
rats	rats	O
.	.	O

The	the	O
biochemical	biochemical	O
assays	assays	O
on	on	O
the	the	O
influence	influence	O
of	of	O
four	four	O
analgesics	analgesics	O
on	on	O
the	the	O
brain	brain	O
concentration	concentration	O
and	and	O
turnover	turnover	O
of	of	O
noradrenaline	noradrenaline	B-Chemical
(	(	O
NA	na	B-Chemical
)	)	O
were	were	O
also	also	O
performed	performed	O
.	.	O

It	it	O
was	was	O
found	found	O
that	that	O
three	three	O
drugs	drugs	O
stimulating	stimulating	O
central	central	O
NA	na	B-Chemical
receptors	receptors	O
failed	failed	O
to	to	O
affect	affect	O
the	the	O
analgesic	analgesic	O
ED50	ed50	O
of	of	O
all	all	O
antinociceptive	antinociceptive	O
agents	agents	O
and	and	O
they	they	O
enhanced	enhanced	O
catalepsy	catalepsy	B-Disease
induced	induced	O
by	by	O
morphine	morphine	B-Chemical
and	and	O
fentanyl	fentanyl	B-Chemical
.	.	O

Codeine	codeine	O
catalepsy	catalepsy	B-Disease
was	was	O
increased	increased	O
by	by	O
clonidine	clonidine	B-Chemical
and	and	O
decreased	decreased	O
by	by	O
naphazoline	naphazoline	O
and	and	O
xylometazoline	xylometazoline	O
.	.	O

The	the	O
brain	brain	O
concentration	concentration	O
of	of	O
NA	na	B-Chemical
was	was	O
not	not	O
changed	changed	O
by	by	O
morphine	morphine	B-Chemical
and	and	O
fentanyl	fentanyl	B-Chemical
,	,	O
but	but	O
one	one	O
of	of	O
the	the	O
doses	doses	O
of	of	O
codeine	codeine	O
(	(	O
45	45	O
mg/kg	mg/kg	O
)	)	O
slightly	slightly	O
enhanced	enhanced	O
it	it	O
.	.	O

Pentazocine	pentazocine	B-Chemical
dose-dependently	dose-dependently	O
decreased	decreased	O
the	the	O
brain	brain	O
level	level	O
of	of	O
NA	na	B-Chemical
.	.	O

The	the	O
rate	rate	O
of	of	O
NA	na	B-Chemical
turnover	turnover	O
was	was	O
not	not	O
altered	altered	O
by	by	O
analgesics	analgesics	O
except	except	O
for	for	O
the	the	O
higher	higher	O
dose	dose	O
of	of	O
fentanyl	fentanyl	B-Chemical
(	(	O
0.2	0.2	O
mg/kg	mg/kg	O
)	)	O
following	following	O
which	which	O
the	the	O
disappearance	disappearance	O
of	of	O
NA	na	B-Chemical
from	from	O
the	the	O
brain	brain	O
was	was	O
diminished	diminished	O
.	.	O

The	the	O
results	results	O
are	are	O
discussed	discussed	O
in	in	O
the	the	O
light	light	O
of	of	O
various	various	O
and	and	O
non-uniform	non-uniform	O
data	data	O
from	from	O
the	the	O
literature	literature	O
.	.	O

It	it	O
is	is	O
suggested	suggested	O
that	that	O
in	in	O
rats	rats	O
the	the	O
brain	brain	O
NA	na	B-Chemical
plays	plays	O
a	a	O
less	less	O
important	important	O
function	function	O
than	than	O
the	the	O
other	other	O
monoamines	monoamines	O
in	in	O
the	the	O
behavioural	behavioural	O
activity	activity	O
of	of	O
potent	potent	O
analgesics	analgesics	O
.	.	O

Flurothyl	flurothyl	O
seizure	seizure	B-Disease
thresholds	thresholds	O
in	in	O
mice	mice	O
treated	treated	O
neonatally	neonatally	O
with	with	O
a	a	O
single	single	O
injection	injection	O
of	of	O
monosodium	monosodium	O
glutamate	glutamate	B-Chemical
(	(	O
MSG	msg	O
):	):	O
evaluation	evaluation	O
of	of	O
experimental	experimental	O
parameters	parameters	O
in	in	O
flurothyl	flurothyl	O
seizure	seizure	B-Disease
testing	testing	O
.	.	O

Monosodium	monosodium	O
glutamate	glutamate	B-Chemical
(	(	O
MSG	msg	O
)	)	O
administration	administration	O
to	to	O
neonatal	neonatal	O
rodents	rodents	O
produces	produces	O
convulsions	convulsions	B-Disease
and	and	O
results	results	O
in	in	O
numerous	numerous	O
biochemical	biochemical	O
and	and	O
behavioral	behavioral	O
deficits	deficits	O
.	.	O

These	these	O
studies	studies	O
were	were	O
undertaken	undertaken	O
to	to	O
determine	determine	O
if	if	O
neonatal	neonatal	O
administration	administration	O
of	of	O
MSG	msg	O
produced	produced	O
permanent	permanent	O
alterations	alterations	O
in	in	O
seizure	seizure	B-Disease
susceptibility	susceptibility	O
,	,	O
since	since	O
previous	previous	O
investigations	investigations	O
were	were	O
inconclusive	inconclusive	O
.	.	O

A	a	O
flurothyl	flurothyl	O
ether	ether	O
seizure	seizure	B-Disease
screening	screening	O
technique	technique	O
was	was	O
used	used	O
to	to	O
evaluate	evaluate	O
seizure	seizure	B-Disease
susceptibility	susceptibility	O
in	in	O
adult	adult	O
mice	mice	O
that	that	O
received	received	O
neonatal	neonatal	O
injections	injections	O
of	of	O
MSG	msg	O
(	(	O
4	4	O
mg/g	mg/g	O
and	and	O
1	1	O
mg/g	mg/g	O
)	)	O
.	.	O

MSG	msg	O
treatment	treatment	O
resulted	resulted	O
in	in	O
significant	significant	O
reductions	reductions	O
in	in	O
whole	whole	O
brain	brain	O
weight	weight	O
but	but	O
did	did	O
not	not	O
alter	alter	O
seizure	seizure	B-Disease
threshold	threshold	O
.	.	O

A	a	O
naloxone	naloxone	B-Chemical
(	(	O
5	5	O
mg/kg	mg/kg	O
)	)	O
challenge	challenge	O
was	was	O
also	also	O
ineffective	ineffective	O
in	in	O
altering	altering	O
the	the	O
seizure	seizure	B-Disease
thresholds	thresholds	O
of	of	O
either	either	O
control	control	O
of	of	O
MSG-treated	msg-treated	O
mice	mice	O
.	.	O

Flurothyl	flurothyl	O
ether	ether	O
produced	produced	O
hypothermia	hypothermia	B-Disease
which	which	O
was	was	O
correlated	correlated	O
with	with	O
the	the	O
duration	duration	O
of	of	O
flurothyl	flurothyl	O
exposure	exposure	O
;	;	O
however	however	O
,	,	O
the	the	O
relationship	relationship	O
of	of	O
hypothermia	hypothermia	B-Disease
to	to	O
seizure	seizure	B-Disease
induction	induction	O
was	was	O
unclear	unclear	O
.	.	O

Flurothyl	flurothyl	O
seizure	seizure	B-Disease
testing	testing	O
proved	proved	O
to	to	O
be	be	O
a	a	O
rapid	rapid	O
and	and	O
reliable	reliable	O
technique	technique	O
with	with	O
which	which	O
to	to	O
evaluate	evaluate	O
seizure	seizure	B-Disease
susceptibility	susceptibility	O
.	.	O

Susceptibility	susceptibility	O
to	to	O
seizures	seizures	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
in	in	O
rats	rats	O
after	after	O
microinjection	microinjection	O
of	of	O
isoniazid	isoniazid	B-Chemical
or	or	O
gamma-vinyl-GABA	gamma-vinyl-gaba	O
into	into	O
the	the	O
substantia	substantia	O
nigra	nigra	O
.	.	O

Pilocarpine	pilocarpine	B-Chemical
,	,	O
given	given	O
intraperitoneally	intraperitoneally	O
to	to	O
rats	rats	O
,	,	O
reproduces	reproduces	O
the	the	O
neuropathological	neuropathological	O
sequelae	sequelae	O
of	of	O
temporal	temporal	B-Disease
lobe	lobe	I-Disease
epilepsy	epilepsy	B-Disease
and	and	O
provides	provides	O
a	a	O
relevant	relevant	O
animal	animal	O
model	model	O
for	for	O
studying	studying	O
mechanisms	mechanisms	O
of	of	O
buildup	buildup	O
of	of	O
convulsive	convulsive	B-Disease
activity	activity	O
and	and	O
pathways	pathways	O
operative	operative	O
in	in	O
the	the	O
generalization	generalization	O
and	and	O
propagation	propagation	O
of	of	O
seizures	seizures	B-Disease
within	within	O
the	the	O
forebrain	forebrain	O
.	.	O

In	in	O
the	the	O
present	present	O
study	study	O
,	,	O
the	the	O
effects	effects	O
of	of	O
manipulating	manipulating	O
the	the	O
activity	activity	O
of	of	O
the	the	O
gamma-aminobutyric	gamma-aminobutyric	O
acid	acid	O
(GABA)-mediated	(gaba)-mediated	O
synaptic	synaptic	O
inhibition	inhibition	O
within	within	O
the	the	O
substantia	substantia	O
nigra	nigra	O
on	on	O
seizures	seizures	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
in	in	O
rats	rats	O
,	,	O
were	were	O
investigated	investigated	O
.	.	O

In	in	O
animals	animals	O
pretreated	pretreated	O
with	with	O
microinjections	microinjections	O
of	of	O
isoniazid	isoniazid	B-Chemical
,	,	O
150	150	O
micrograms	micrograms	O
,	,	O
an	an	O
inhibitor	inhibitor	O
of	of	O
activity	activity	O
of	of	O
the	the	O
GABA-synthesizing	gaba-synthesizing	O
enzyme	enzyme	O
,	,	O
L-glutamic	l-glutamic	O
acid	acid	O
decarboxylase	decarboxylase	O
,	,	O
into	into	O
the	the	O
substantia	substantia	O
nigra	nigra	O
pars	pars	O
reticulata	reticulata	O
(	(	O
SNR	snr	O
)	)	O
,	,	O
bilaterally	bilaterally	O
,	,	O
non-convulsant	non-convulsant	O
doses	doses	O
of	of	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
100	100	O
and	and	O
200	200	O
mg/kg	mg/kg	O
,	,	O
resulted	resulted	O
in	in	O
severe	severe	O
motor	motor	O
limbic	limbic	O
seizures	seizures	B-Disease
and	and	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
.	.	O

Electroencephalographic	electroencephalographic	O
and	and	O
behavioral	behavioral	O
monitoring	monitoring	O
revealed	revealed	O
a	a	O
profound	profound	O
reduction	reduction	O
of	of	O
the	the	O
threshold	threshold	O
for	for	O
pilocarpine-induced	pilocarpine-induced	O
convulsions	convulsions	B-Disease
.	.	O

Morphological	morphological	O
analysis	analysis	O
of	of	O
frontal	frontal	O
forebrain	forebrain	O
sections	sections	O
with	with	O
light	light	O
microscopy	microscopy	O
revealed	revealed	O
seizure-related	seizure-related	O
damage	damage	O
to	to	O
the	the	O
hippocampal	hippocampal	O
formation	formation	O
,	,	O
thalamus	thalamus	O
,	,	O
amygdala	amygdala	O
,	,	O
olfactory	olfactory	O
cortex	cortex	O
,	,	O
substantia	substantia	O
nigra	nigra	O
and	and	O
neocortex	neocortex	O
,	,	O
which	which	O
is	is	O
typically	typically	O
observed	observed	O
with	with	O
pilocarpine	pilocarpine	B-Chemical
in	in	O
doses	doses	O
exceeding	exceeding	O
350	350	O
mg/kg	mg/kg	O
.	.	O

Bilateral	bilateral	O
intrastriatal	intrastriatal	O
injections	injections	O
of	of	O
isoniazid	isoniazid	B-Chemical
did	did	O
not	not	O
augment	augment	O
seizures	seizures	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
200	200	O
mg/kg	mg/kg	O
.	.	O

Application	application	O
of	of	O
an	an	O
irreversible	irreversible	O
inhibitor	inhibitor	O
of	of	O
GABA	gaba	B-Chemical
transaminase	transaminase	O
,	,	O
gamma-vinyl-GABA	gamma-vinyl-gaba	O
(	(	O
D	d	O
,	,	O
L-4-amino-hex-5-enoic	l-4-amino-hex-5-enoic	O
acid	acid	O
)	)	O
,	,	O
5	5	O
micrograms	micrograms	O
,	,	O
into	into	O
the	the	O
SNR	snr	O
,	,	O
bilaterally	bilaterally	O
,	,	O
suppressed	suppressed	O
the	the	O
appearance	appearance	O
of	of	O
electrographic	electrographic	O
and	and	O
behavioral	behavioral	O
seizures	seizures	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
380	380	O
mg/kg	mg/kg	O
.	.	O

This	this	O
treatment	treatment	O
was	was	O
also	also	O
sufficient	sufficient	O
to	to	O
protect	protect	O
animals	animals	O
from	from	O
the	the	O
occurrence	occurrence	O
of	of	O
brain	brain	B-Disease
damage	damage	I-Disease
.	.	O

Microinjections	microinjections	O
of	of	O
gamma-vinyl-GABA	gamma-vinyl-gaba	O
,	,	O
5	5	O
micrograms	micrograms	O
,	,	O
into	into	O
the	the	O
dorsal	dorsal	O
striatum	striatum	O
,	,	O
bilaterally	bilaterally	O
,	,	O
failed	failed	O
to	to	O
prevent	prevent	O
the	the	O
development	development	O
of	of	O
convulsions	convulsions	B-Disease
produced	produced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
380	380	O
mg/kg	mg/kg	O
.	.	O

The	the	O
results	results	O
demonstrate	demonstrate	O
that	that	O
the	the	O
threshold	threshold	O
for	for	O
pilocarpine-induced	pilocarpine-induced	O
seizures	seizures	B-Disease
in	in	O
rats	rats	O
is	is	O
subjected	subjected	O
to	to	O
the	the	O
regulation	regulation	O
of	of	O
the	the	O
GABA-mediated	gaba-mediated	O
synaptic	synaptic	O
inhibition	inhibition	O
within	within	O
the	the	O
substantia	substantia	O
nigra	nigra	O
.	.	O

Human	human	O
and	and	O
canine	canine	O
ventricular	ventricular	O
vasoactive	vasoactive	O
intestinal	intestinal	O
polypeptide	polypeptide	O
:	:	O
decrease	decrease	O
with	with	O
heart	heart	B-Disease
failure	failure	I-Disease
.	.	O

Vasoactive	vasoactive	O
intestinal	intestinal	O
polypeptide	polypeptide	O
(	(	O
VIP	vip	O
)	)	O
is	is	O
a	a	O
systemic	systemic	O
and	and	O
coronary	coronary	O
vasodilator	vasodilator	O
that	that	O
may	may	O
have	have	O
positive	positive	O
inotropic	inotropic	O
properties	properties	O
.	.	O

Myocardial	myocardial	O
levels	levels	O
of	of	O
VIP	vip	O
were	were	O
assayed	assayed	O
before	before	O
and	and	O
after	after	O
the	the	O
development	development	O
of	of	O
heart	heart	B-Disease
failure	failure	I-Disease
in	in	O
two	two	O
canine	canine	O
models	models	O
.	.	O

In	in	O
the	the	O
first	first	O
,	,	O
cobalt	cobalt	O
cardiomyopathy	cardiomyopathy	B-Disease
was	was	O
induced	induced	O
in	in	O
eight	eight	O
dogs	dogs	O
;	;	O
VIP	vip	O
(	(	O
by	by	O
radioimmunoassay	radioimmunoassay	O
)	)	O
decreased	decreased	O
from	from	O
35	35	O
+	+	O
/-	/-	O
11	11	O
pg/mg	pg/mg	O
protein	protein	O
(	(	O
mean	mean	O
+	+	O
/-	/-	O
SD	sd	O
)	)	O
to	to	O
5	5	O
+	+	O
/-	/-	O
4	4	O
pg/mg	pg/mg	O
protein	protein	O
(	(	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

In	in	O
six	six	O
dogs	dogs	O
with	with	O
doxorubicin-induced	doxorubicin-induced	O
heart	heart	B-Disease
failure	failure	I-Disease
,	,	O
VIP	vip	O
decreased	decreased	O
from	from	O
31	31	O
+	+	O
/-	/-	O
7	7	O
to	to	O
11	11	O
+	+	O
/-	/-	O
4	4	O
pg/mg	pg/mg	O
protein	protein	O
(	(	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

In	in	O
addition	addition	O
,	,	O
VIP	vip	O
content	content	O
of	of	O
left	left	O
ventricular	ventricular	O
muscle	muscle	O
of	of	O
resected	resected	O
failing	failing	O
hearts	hearts	O
in	in	O
10	10	O
patients	patients	O
receiving	receiving	O
a	a	O
heart	heart	O
transplant	transplant	O
was	was	O
compared	compared	O
with	with	O
the	the	O
papillary	papillary	O
muscles	muscles	O
in	in	O
14	14	O
patients	patients	O
(	(	O
five	five	O
with	with	O
rheumatic	rheumatic	O
disease	disease	O
,	,	O
nine	nine	O
with	with	O
myxomatous	myxomatous	O
degeneration	degeneration	O
)	)	O
receiving	receiving	O
mitral	mitral	O
valve	valve	O
prostheses	prostheses	O
.	.	O

The	the	O
lowest	lowest	O
myocardial	myocardial	O
VIP	vip	O
concentration	concentration	O
was	was	O
found	found	O
in	in	O
the	the	O
hearts	hearts	O
of	of	O
patients	patients	O
with	with	O
coronary	coronary	B-Disease
disease	disease	I-Disease
(	(	O
one	one	O
patient	patient	O
receiving	receiving	O
a	a	O
transplant	transplant	O
and	and	O
three	three	O
receiving	receiving	O
mitral	mitral	O
prostheses	prostheses	O
)	)	O
(	(	O
6.3	6.3	O
+	+	O
/-	/-	O
1.9	1.9	O
pg/mg	pg/mg	O
protein	protein	O
)	)	O
.	.	O

The	the	O
other	other	O
patients	patients	O
undergoing	undergoing	O
transplantation	transplantation	O
had	had	O
an	an	O
average	average	O
ejection	ejection	O
fraction	fraction	O
of	of	O
17	17	O
%	%	O
+	+	O
/-	/-	O
6	6	O
%	%	O
and	and	O
a	a	O
VIP	vip	O
level	level	O
of	of	O
8.8	8.8	O
+	+	O
/-	/-	O
3.9	3.9	O
pg/mg	pg/mg	O
protein	protein	O
.	.	O

The	the	O
hearts	hearts	O
without	without	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
(	(	O
average	average	O
ejection	ejection	O
fraction	fraction	O
of	of	O
this	this	O
group	group	O
62	62	O
%	%	O
+	+	O
/-	/-	O
10	10	O
%	%	O
)	)	O
had	had	O
a	a	O
VIP	vip	O
concentration	concentration	O
of	of	O
14.1	14.1	O
+	+	O
/-	/-	O
7.9	7.9	O
pg/mg	pg/mg	O
protein	protein	O
,	,	O
and	and	O
this	this	O
was	was	O
greater	greater	O
than	than	O
in	in	O
hearts	hearts	O
of	of	O
the	the	O
patients	patients	O
with	with	O
coronary	coronary	B-Disease
disease	disease	I-Disease
and	and	O
the	the	O
hearts	hearts	O
of	of	O
patients	patients	O
receiving	receiving	O
a	a	O
transplant	transplant	O
(	(	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

Myocardial	myocardial	O
catecholamines	catecholamines	B-Chemical
were	were	O
also	also	O
determined	determined	O
in	in	O
14	14	O
subjects	subjects	O
;	;	O
a	a	O
weak	weak	O
correlation	correlation	O
(	(	O
r	r	O
=	=	O
0.57	0.57	O
,	,	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
between	between	O
the	the	O
tissue	tissue	O
concentrations	concentrations	O
of	of	O
VIP	vip	O
and	and	O
norepinephrine	norepinephrine	B-Chemical
was	was	O
noted.(ABSTRACT	noted.(abstract	O
TRUNCATED	truncated	O
AT	at	O
250	250	O
WORDS	words	O
)	)	O

Non-invasive	non-invasive	O
detection	detection	O
of	of	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
by	by	O
body	body	O
surface	surface	O
electrocardiographic	electrocardiographic	O
mapping	mapping	O
after	after	O
dipyridamole	dipyridamole	B-Chemical
infusion	infusion	O
.	.	O

Electrocardiographic	electrocardiographic	O
changes	changes	O
after	after	O
dipyridamole	dipyridamole	B-Chemical
infusion	infusion	O
(	(	O
0.568	0.568	O
mg/kg/4	mg/kg/4	O
min	min	O
)	)	O
were	were	O
studied	studied	O
in	in	O
41	41	O
patients	patients	O
with	with	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
and	and	O
compared	compared	O
with	with	O
those	those	O
after	after	O
submaximal	submaximal	O
treadmill	treadmill	O
exercise	exercise	O
by	by	O
use	use	O
of	of	O
the	the	O
body	body	O
surface	surface	O
mapping	mapping	O
technique	technique	O
.	.	O

Patients	patients	O
were	were	O
divided	divided	O
into	into	O
three	three	O
groups	groups	O
;	;	O
19	19	O
patients	patients	O
without	without	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
(	(	O
non-MI	non-mi	O
group	group	O
)	)	O
,	,	O
14	14	O
with	with	O
anterior	anterior	O
infarction	infarction	B-Disease
(	(	O
ANT-MI	ant-mi	O
)	)	O
and	and	O
eight	eight	O
with	with	O
inferior	inferior	O
infarction	infarction	B-Disease
(	(	O
INF-MI	inf-mi	O
)	)	O
.	.	O

Eighty-seven	eighty-seven	O
unipolar	unipolar	O
electrocardiograms	electrocardiograms	O
(	(	O
ECGs	ecgs	O
)	)	O
distributed	distributed	O
over	over	O
the	the	O
entire	entire	O
thoracic	thoracic	O
surface	surface	O
were	were	O
simultaneously	simultaneously	O
recorded	recorded	O
.	.	O

After	after	O
dipyridamole	dipyridamole	B-Chemical
,	,	O
ischemic	ischemic	O
ST-segment	st-segment	O
depression	depression	B-Disease
(	(	O
0.05	0.05	O
mV	mv	O
or	or	O
more	more	O
)	)	O
was	was	O
observed	observed	O
in	in	O
84	84	O
%	%	O
of	of	O
the	the	O
non-MI	non-mi	O
group	group	O
,	,	O
29	29	O
%	%	O
of	of	O
the	the	O
ANT-MI	ant-mi	O
group	group	O
,	,	O
63	63	O
%	%	O
of	of	O
the	the	O
INF-MI	inf-mi	O
group	group	O
and	and	O
61	61	O
%	%	O
of	of	O
the	the	O
total	total	O
population	population	O
.	.	O

Exercise-induced	exercise-induced	O
ST	st	O
depression	depression	B-Disease
was	was	O
observed	observed	O
in	in	O
84	84	O
%	%	O
of	of	O
the	the	O
non-MI	non-mi	O
group	group	O
,	,	O
43	43	O
%	%	O
of	of	O
the	the	O
ANT-MI	ant-mi	O
group	group	O
,	,	O
38	38	O
%	%	O
of	of	O
the	the	O
INF-MI	inf-mi	O
group	group	O
and	and	O
61	61	O
%	%	O
of	of	O
the	the	O
total	total	O
.	.	O

For	for	O
individual	individual	O
patients	patients	O
,	,	O
there	there	O
were	were	O
no	no	O
obvious	obvious	O
differences	differences	O
between	between	O
the	the	O
body	body	O
surface	surface	O
distribution	distribution	O
of	of	O
ST	st	O
depression	depression	B-Disease
in	in	O
both	both	O
tests	tests	O
.	.	O

The	the	O
increase	increase	O
in	in	O
pressure	pressure	O
rate	rate	O
product	product	O
after	after	O
dipyridamole	dipyridamole	B-Chemical
was	was	O
significantly	significantly	O
less	less	O
than	than	O
that	that	O
during	during	O
the	the	O
treadmill	treadmill	O
exercise	exercise	O
.	.	O

The	the	O
data	data	O
suggest	suggest	O
that	that	O
the	the	O
dipyridamole-induced	dipyridamole-induced	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
is	is	O
caused	caused	O
by	by	O
the	the	O
inhomogenous	inhomogenous	O
distribution	distribution	O
of	of	O
myocardial	myocardial	O
blood	blood	O
flow	flow	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
the	the	O
dipyridamole	dipyridamole	B-Chemical
ECG	ecg	O
test	test	O
is	is	O
as	as	O
useful	useful	O
as	as	O
the	the	O
exercise	exercise	O
ECG	ecg	O
test	test	O
for	for	O
the	the	O
assessment	assessment	O
of	of	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
.	.	O

Bradycardia	bradycardia	B-Disease
after	after	O
high-dose	high-dose	O
intravenous	intravenous	O
methylprednisolone	methylprednisolone	B-Chemical
therapy	therapy	O
.	.	O

In	in	O
5	5	O
consecutive	consecutive	O
patients	patients	O
with	with	O
rheumatoid	rheumatoid	B-Disease
arthritis	arthritis	B-Disease
who	who	O
received	received	O
intravenous	intravenous	O
high-dose	high-dose	O
methylprednisolone	methylprednisolone	B-Chemical
(	(	O
MP	mp	O
)	)	O
therapy	therapy	O
(	(	O
1	1	O
g	g	O
daily	daily	O
for	for	O
2	2	O
or	or	O
3	3	O
consecutive	consecutive	O
days	days	O
)	)	O
,	,	O
a	a	O
decline	decline	O
in	in	O
pulse	pulse	O
rate	rate	O
was	was	O
observed	observed	O
,	,	O
most	most	O
pronounced	pronounced	O
on	on	O
day	day	O
4	4	O
.	.	O

In	in	O
one	one	O
of	of	O
the	the	O
5	5	O
patients	patients	O
the	the	O
bradycardia	bradycardia	B-Disease
was	was	O
associated	associated	O
with	with	O
complaints	complaints	O
of	of	O
substernal	substernal	O
pressure	pressure	O
.	.	O

Reversal	reversal	O
to	to	O
normal	normal	O
heart	heart	O
rate	rate	O
was	was	O
found	found	O
on	on	O
day	day	O
7	7	O
.	.	O

Electrocardiographic	electrocardiographic	O
registrations	registrations	O
showed	showed	O
sinus	sinus	B-Disease
bradycardia	bradycardia	B-Disease
in	in	O
all	all	O
cases	cases	O
.	.	O

No	no	O
significant	significant	O
changes	changes	O
in	in	O
plasma	plasma	O
concentrations	concentrations	O
of	of	O
electrolytes	electrolytes	O
were	were	O
found	found	O
.	.	O

Careful	careful	O
observation	observation	O
of	of	O
patients	patients	O
receiving	receiving	O
high-dose	high-dose	O
MP	mp	O
is	is	O
recommended	recommended	O
.	.	O

High-dose	high-dose	O
MP	mp	O
may	may	O
be	be	O
contraindicated	contraindicated	O
in	in	O
patients	patients	O
with	with	O
known	known	O
heart	heart	B-Disease
disease	disease	I-Disease
.	.	O

Two	two	O
cases	cases	O
of	of	O
downbeat	downbeat	O
nystagmus	nystagmus	O
and	and	O
oscillopsia	oscillopsia	O
associated	associated	O
with	with	O
carbamazepine	carbamazepine	B-Chemical
.	.	O

Downbeat	downbeat	O
nystagmus	nystagmus	O
is	is	O
often	often	O
associated	associated	O
with	with	O
structural	structural	O
lesions	lesions	O
at	at	O
the	the	O
craniocervical	craniocervical	O
junction	junction	O
,	,	O
but	but	O
has	has	O
occasionally	occasionally	O
been	been	O
reported	reported	O
as	as	O
a	a	O
manifestation	manifestation	O
of	of	O
metabolic	metabolic	O
imbalance	imbalance	O
or	or	O
drug	drug	O
intoxication	intoxication	O
.	.	O

We	we	O
recorded	recorded	O
the	the	O
eye	eye	O
movements	movements	O
of	of	O
two	two	O
patients	patients	O
with	with	O
reversible	reversible	O
downbeat	downbeat	O
nystagmus	nystagmus	O
related	related	O
to	to	O
carbamazepine	carbamazepine	B-Chemical
therapy	therapy	O
.	.	O

The	the	O
nystagmus	nystagmus	O
of	of	O
both	both	O
patients	patients	O
resolved	resolved	O
after	after	O
reduction	reduction	O
of	of	O
the	the	O
serum	serum	O
carbamazepine	carbamazepine	B-Chemical
levels	levels	O
.	.	O

Neuroradiologic	neuroradiologic	O
investigations	investigations	O
including	including	O
magnetic	magnetic	O
resonance	resonance	O
imaging	imaging	O
scans	scans	O
in	in	O
both	both	O
patients	patients	O
showed	showed	O
no	no	O
evidence	evidence	O
of	of	O
intracranial	intracranial	O
abnormality	abnormality	O
.	.	O

In	in	O
patients	patients	O
with	with	O
downbeat	downbeat	O
nystagmus	nystagmus	O
who	who	O
are	are	O
taking	taking	O
anticonvulsant	anticonvulsant	O
medications	medications	O
,	,	O
consideration	consideration	O
should	should	O
be	be	O
given	given	O
to	to	O
reduction	reduction	O
in	in	O
dose	dose	O
before	before	O
further	further	O
investigation	investigation	O
is	is	O
undertaken	undertaken	O
.	.	O

Improvement	improvement	O
by	by	O
denopamine	denopamine	O
(	(	O
TA-064	ta-064	O
)	)	O
of	of	O
pentobarbital-induced	pentobarbital-induced	O
cardiac	cardiac	B-Disease
failure	failure	I-Disease
in	in	O
the	the	O
dog	dog	O
heart-lung	heart-lung	O
preparation	preparation	O
.	.	O

The	the	O
efficacy	efficacy	O
of	of	O
denopamine	denopamine	O
,	,	O
an	an	O
orally	orally	O
active	active	O
beta	beta	O
1-adrenoceptor	1-adrenoceptor	O
agonist	agonist	O
,	,	O
in	in	O
improving	improving	O
cardiac	cardiac	B-Disease
failure	failure	I-Disease
was	was	O
assessed	assessed	O
in	in	O
dog	dog	O
heart-lung	heart-lung	O
preparations	preparations	O
.	.	O

Cardiac	cardiac	O
functions	functions	O
depressed	depressed	B-Disease
by	by	O
pentobarbital	pentobarbital	B-Chemical
(	(	O
118	118	O
+	+	O
/-	/-	O
28	28	O
mg	mg	O
;	;	O
mean	mean	O
value	value	O
+	+	O
/-	/-	O
SD	sd	O
)	)	O
such	such	O
that	that	O
cardiac	cardiac	O
output	output	O
and	and	O
maximum	maximum	O
rate	rate	O
of	of	O
rise	rise	O
of	of	O
left	left	O
ventricular	ventricular	O
pressure	pressure	O
(	(	O
LV	lv	O
dP/dt	dp/dt	O
max	max	O
)	)	O
had	had	O
been	been	O
reduced	reduced	O
by	by	O
about	about	O
35	35	O
%	%	O
and	and	O
26	26	O
%	%	O
of	of	O
the	the	O
respective	respective	O
controls	controls	O
were	were	O
improved	improved	O
by	by	O
denopamine	denopamine	O
(	(	O
10	10	O
-	-	O
300	300	O
micrograms	micrograms	O
)	)	O
in	in	O
a	a	O
dose-dependent	dose-dependent	O
manner	manner	O
.	.	O

With	with	O
100	100	O
micrograms	micrograms	O
denopamine	denopamine	O
,	,	O
almost	almost	O
complete	complete	O
restoration	restoration	O
of	of	O
cardiac	cardiac	O
performance	performance	O
was	was	O
attained	attained	O
,	,	O
associated	associated	O
with	with	O
a	a	O
slight	slight	O
increase	increase	O
in	in	O
heart	heart	O
rate	rate	O
.	.	O

No	no	O
arrhythmias	arrhythmias	B-Disease
were	were	O
induced	induced	O
by	by	O
these	these	O
doses	doses	O
of	of	O
denopamine	denopamine	O
.	.	O

The	the	O
results	results	O
warrant	warrant	O
clinical	clinical	O
trials	trials	O
of	of	O
denopamine	denopamine	O
in	in	O
the	the	O
treatment	treatment	O
of	of	O
cardiac	cardiac	B-Disease
failure	failure	I-Disease
.	.	O

Clonazepam	clonazepam	O
monotherapy	monotherapy	O
for	for	O
epilepsy	epilepsy	B-Disease
in	in	O
childhood	childhood	O
.	.	O

Sixty	sixty	O
patients	patients	O
(	(	O
age-range	age-range	O
one	one	O
month	month	O
to	to	O
14	14	O
years	years	O
)	)	O
with	with	O
other	other	O
types	types	O
of	of	O
epilepsy	epilepsy	B-Disease
than	than	O
infantile	infantile	O
spasms	spasms	O
were	were	O
treated	treated	O
with	with	O
clonazepam	clonazepam	O
.	.	O

Disappearance	disappearance	O
of	of	O
seizures	seizures	B-Disease
and	and	O
normalization	normalization	O
of	of	O
abnormal	abnormal	O
EEG	eeg	O
with	with	O
disappearance	disappearance	O
of	of	O
seizures	seizures	B-Disease
were	were	O
recognized	recognized	O
in	in	O
77	77	O
%	%	O
and	and	O
50	50	O
%	%	O
,	,	O
respectively	respectively	O
.	.	O

Seizures	seizures	B-Disease
disappeared	disappeared	O
in	in	O
71	71	O
%	%	O
of	of	O
the	the	O
patients	patients	O
with	with	O
generalized	generalized	O
seizures	seizures	B-Disease
and	and	O
89	89	O
%	%	O
of	of	O
partial	partial	O
seizures	seizures	B-Disease
.	.	O

Improvement	improvement	O
of	of	O
abnormal	abnormal	O
EEG	eeg	O
was	was	O
noticed	noticed	O
in	in	O
76	76	O
%	%	O
of	of	O
diffuse	diffuse	O
paroxysms	paroxysms	O
and	and	O
in	in	O
67	67	O
%	%	O
of	of	O
focal	focal	O
paroxysms	paroxysms	O
.	.	O

In	in	O
excellent	excellent	O
cases	cases	O
,	,	O
mean	mean	O
effective	effective	O
dosages	dosages	O
were	were	O
0.086	0.086	O
+	+	O
/-	/-	O
0.021	0.021	O
mg/kg/day	mg/kg/day	O
in	in	O
infants	infants	O
and	and	O
0.057	0.057	O
+	+	O
/-	/-	O
0.022	0.022	O
mg/kg/day	mg/kg/day	O
in	in	O
schoolchildren	schoolchildren	O
,	,	O
this	this	O
difference	difference	O
was	was	O
statistically	statistically	O
significant	significant	O
(	(	O
p	p	O
less	less	O
than	than	O
0.005	0.005	O
)	)	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
side	side	O
effects	effects	O
such	such	O
as	as	O
drowsiness	drowsiness	O
and	and	O
ataxia	ataxia	B-Disease
was	was	O
only	only	O
5	5	O
%	%	O
.	.	O

Postmarketing	postmarketing	O
study	study	O
of	of	O
timolol-hydrochlorothiazide	timolol-hydrochlorothiazide	O
antihypertensive	antihypertensive	O
therapy	therapy	O
.	.	O

A	a	O
postmarketing	postmarketing	O
surveillance	surveillance	O
study	study	O
was	was	O
conducted	conducted	O
to	to	O
determine	determine	O
the	the	O
safety	safety	O
and	and	O
efficacy	efficacy	O
of	of	O
a	a	O
fixed-ratio	fixed-ratio	O
combination	combination	O
containing	containing	O
10	10	O
mg	mg	O
of	of	O
timolol	timolol	B-Chemical
maleate	maleate	O
and	and	O
25	25	O
mg	mg	O
of	of	O
hydrochlorothiazide	hydrochlorothiazide	O
,	,	O
administered	administered	O
twice	twice	O
daily	daily	O
for	for	O
one	one	O
month	month	O
to	to	O
hypertensive	hypertensive	B-Disease
patients	patients	O
.	.	O

Data	data	O
on	on	O
9,037	9,037	O
patients	patients	O
were	were	O
collected	collected	O
by	by	O
1,455	1,455	O
participating	participating	O
physicians	physicians	O
.	.	O

Mean	mean	O
systolic	systolic	O
blood	blood	O
pressure	pressure	O
decreased	decreased	O
25	25	O
mmHg	mmhg	O
and	and	O
mean	mean	O
diastolic	diastolic	O
blood	blood	O
pressure	pressure	O
declined	declined	O
15	15	O
mmHg	mmhg	O
after	after	O
one	one	O
month	month	O
of	of	O
timolol-hydrochlorothiazide	timolol-hydrochlorothiazide	O
therapy	therapy	O
(	(	O
P	p	O
less	less	O
than	than	O
0.01	0.01	O
,	,	O
both	both	O
comparisons	comparisons	O
)	)	O
.	.	O

Age	age	O
,	,	O
race	race	O
,	,	O
and	and	O
sex	sex	O
appeared	appeared	O
to	to	O
have	have	O
no	no	O
influence	influence	O
on	on	O
the	the	O
decrease	decrease	O
in	in	O
blood	blood	O
pressure	pressure	O
.	.	O

The	the	O
antihypertensive	antihypertensive	O
effect	effect	O
of	of	O
the	the	O
drug	drug	O
was	was	O
greater	greater	O
in	in	O
patients	patients	O
with	with	O
more	more	O
severe	severe	O
hypertension	hypertension	B-Disease
.	.	O

Overall	overall	O
,	,	O
1,453	1,453	O
patients	patients	O
experienced	experienced	O
a	a	O
total	total	O
of	of	O
2,658	2,658	O
adverse	adverse	O
events	events	O
,	,	O
the	the	O
most	most	O
common	common	O
being	being	O
fatigue	fatigue	B-Disease
,	,	O
dizziness	dizziness	B-Disease
,	,	O
and	and	O
weakness	weakness	B-Disease
.	.	O

Treatment	treatment	O
in	in	O
590	590	O
patients	patients	O
was	was	O
discontinued	discontinued	O
because	because	O
of	of	O
adverse	adverse	O
events	events	O
.	.	O

Salicylate	salicylate	O
nephropathy	nephropathy	B-Disease
in	in	O
the	the	O
Gunn	gunn	O
rat	rat	O
:	:	O
potential	potential	O
role	role	O
of	of	O
prostaglandins	prostaglandins	B-Chemical
.	.	O

We	we	O
examined	examined	O
the	the	O
potential	potential	O
role	role	O
of	of	O
prostaglandins	prostaglandins	B-Chemical
in	in	O
the	the	O
development	development	O
of	of	O
analgesic	analgesic	O
nephropathy	nephropathy	B-Disease
in	in	O
the	the	O
Gunn	gunn	O
strain	strain	O
of	of	O
rat	rat	O
.	.	O

The	the	O
homozygous	homozygous	O
Gunn	gunn	O
rats	rats	O
have	have	O
unconjugated	unconjugated	O
hyperbilirubinemia	hyperbilirubinemia	O
due	due	O
to	to	O
the	the	O
absence	absence	O
of	of	O
glucuronyl	glucuronyl	O
transferase	transferase	O
,	,	O
leading	leading	O
to	to	O
marked	marked	O
bilirubin	bilirubin	B-Chemical
deposition	deposition	O
in	in	O
renal	renal	O
medulla	medulla	O
and	and	O
papilla	papilla	O
.	.	O

These	these	O
rats	rats	O
are	are	O
also	also	O
highly	highly	O
susceptible	susceptible	O
to	to	O
develop	develop	O
papillary	papillary	O
necrosis	necrosis	B-Disease
with	with	O
analgesic	analgesic	O
administration	administration	O
.	.	O

We	we	O
used	used	O
homozygous	homozygous	O
(	(	O
jj	jj	O
)	)	O
and	and	O
phenotypically	phenotypically	O
normal	normal	O
heterozygous	heterozygous	O
(	(	O
jJ	jj	O
)	)	O
animals	animals	O
.	.	O

Four	four	O
groups	groups	O
of	of	O
rats	rats	O
(	(	O
n	n	O
=	=	O
7	7	O
)	)	O
were	were	O
studied	studied	O
:	:	O
jj	jj	O
and	and	O
jJ	jj	O
rats	rats	O
treated	treated	O
either	either	O
with	with	O
aspirin	aspirin	B-Chemical
300	300	O
mg/kg	mg/kg	O
every	every	O
other	other	O
day	day	O
or	or	O
sham-treated	sham-treated	O
.	.	O

After	after	O
one	one	O
week	week	O
,	,	O
slices	slices	O
of	of	O
cortex	cortex	O
,	,	O
outer	outer	O
and	and	O
inner	inner	O
medulla	medulla	O
from	from	O
one	one	O
kidney	kidney	O
were	were	O
incubated	incubated	O
in	in	O
buffer	buffer	O
and	and	O
prostaglandin	prostaglandin	O
synthesis	synthesis	O
was	was	O
determined	determined	O
by	by	O
radioimmunoassay	radioimmunoassay	O
.	.	O

The	the	O
other	other	O
kidney	kidney	O
was	was	O
examined	examined	O
histologically	histologically	O
.	.	O

A	a	O
marked	marked	O
corticomedullary	corticomedullary	O
gradient	gradient	O
of	of	O
prostaglandin	prostaglandin	O
synthesis	synthesis	O
was	was	O
observed	observed	O
in	in	O
all	all	O
groups	groups	O
.	.	O

PGE2	pge2	O
synthesis	synthesis	O
was	was	O
significantly	significantly	O
higher	higher	O
in	in	O
outer	outer	O
medulla	medulla	O
,	,	O
but	but	O
not	not	O
cortex	cortex	O
or	or	O
inner	inner	O
medulla	medulla	O
,	,	O
of	of	O
jj	jj	O
(	(	O
38	38	O
+	+	O
/-	/-	O
6	6	O
ng/mg	ng/mg	O
prot	prot	O
)	)	O
than	than	O
jJ	jj	O
rats	rats	O
(	(	O
15	15	O
+	+	O
/-	/-	O
3	3	O
)	)	O
(	(	O
p	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
.	.	O

Aspirin	aspirin	B-Chemical
treatment	treatment	O
reduced	reduced	O
PGE2	pge2	O
synthesis	synthesis	O
in	in	O
all	all	O
regions	regions	O
,	,	O
but	but	O
outer	outer	O
medullary	medullary	O
PGE2	pge2	O
remained	remained	O
higher	higher	O
in	in	O
jj	jj	O
(	(	O
18	18	O
+	+	O
/-	/-	O
3	3	O
)	)	O
than	than	O
jJ	jj	O
rats	rats	O
(	(	O
9	9	O
+	+	O
/-	/-	O
2	2	O
)	)	O
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

PGF2	pgf2	O
alpha	alpha	O
was	was	O
also	also	O
significantly	significantly	O
higher	higher	O
in	in	O
the	the	O
outer	outer	O
medulla	medulla	O
of	of	O
jj	jj	O
rats	rats	O
with	with	O
and	and	O
without	without	O
aspirin	aspirin	B-Chemical
administration	administration	O
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

The	the	O
changes	changes	O
in	in	O
renal	renal	O
prostaglandin	prostaglandin	O
synthesis	synthesis	O
were	were	O
accompanied	accompanied	O
by	by	O
evidence	evidence	O
of	of	O
renal	renal	B-Disease
damage	damage	I-Disease
in	in	O
aspirin-treated	aspirin-treated	O
jj	jj	O
but	but	O
not	not	O
jJ	jj	O
rats	rats	O
as	as	O
evidenced	evidenced	O
by	by	O
:	:	O
increased	increased	O
incidence	incidence	O
and	and	O
severity	severity	O
of	of	O
hematuria	hematuria	B-Disease
(	(	O
p	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
;	;	O
increased	increased	O
serum	serum	O
creatinine	creatinine	B-Chemical
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
;	;	O
and	and	O
increase	increase	O
in	in	O
outer	outer	O
medullary	medullary	O
histopathologic	histopathologic	O
lesions	lesions	O
(	(	O
p	p	O
less	less	O
than	than	O
0.005	0.005	O
compared	compared	O
to	to	O
either	either	O
sham-treated	sham-treated	O
jj	jj	O
or	or	O
aspirin-treated	aspirin-treated	O
jJ	jj	O
)	)	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
enhanced	enhanced	O
prostaglandin	prostaglandin	O
synthesis	synthesis	O
contributes	contributes	O
to	to	O
maintenance	maintenance	O
of	of	O
renal	renal	O
function	function	O
and	and	O
morphological	morphological	O
integrity	integrity	O
,	,	O
and	and	O
that	that	O
inhibition	inhibition	O
of	of	O
prostaglandin	prostaglandin	O
synthesis	synthesis	O
may	may	O
lead	lead	O
to	to	O
pathological	pathological	O
renal	renal	O
medullary	medullary	O
lesions	lesions	O
and	and	O
deterioration	deterioration	O
of	of	O
renal	renal	O
function	function	O
.	.	O

Prophylactic	prophylactic	O
lidocaine	lidocaine	B-Chemical
in	in	O
the	the	O
early	early	O
phase	phase	O
of	of	O
suspected	suspected	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

Four	four	O
hundred	hundred	O
two	two	O
patients	patients	O
with	with	O
suspected	suspected	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
seen	seen	O
within	within	O
6	6	O
hours	hours	O
of	of	O
the	the	O
onset	onset	O
of	of	O
symptoms	symptoms	O
entered	entered	O
a	a	O
double-blind	double-blind	O
randomized	randomized	O
trial	trial	O
of	of	O
lidocaine	lidocaine	B-Chemical
vs	vs	O
placebo	placebo	O
.	.	O

During	during	O
the	the	O
1	1	O
hour	hour	O
after	after	O
administration	administration	O
of	of	O
the	the	O
drug	drug	O
the	the	O
incidence	incidence	O
of	of	O
ventricular	ventricular	B-Disease
fibrillation	fibrillation	I-Disease
or	or	O
sustained	sustained	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
among	among	O
the	the	O
204	204	O
patients	patients	O
with	with	O
acute	acute	B-Disease
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
was	was	O
low	low	O
,	,	O
1.5	1.5	O
%	%	O
.	.	O

Lidocaine	lidocaine	B-Chemical
,	,	O
given	given	O
in	in	O
a	a	O
300	300	O
mg	mg	O
dose	dose	O
intramuscularly	intramuscularly	O
followed	followed	O
by	by	O
100	100	O
mg	mg	O
intravenously	intravenously	O
,	,	O
did	did	O
not	not	O
prevent	prevent	O
sustained	sustained	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
,	,	O
although	although	O
there	there	O
was	was	O
a	a	O
significant	significant	O
reduction	reduction	O
in	in	O
the	the	O
number	number	O
of	of	O
patients	patients	O
with	with	O
warning	warning	O
arrhythmias	arrhythmias	B-Disease
between	between	O
15	15	O
and	and	O
45	45	O
minutes	minutes	O
after	after	O
the	the	O
administration	administration	O
of	of	O
lidocaine	lidocaine	B-Chemical
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

The	the	O
average	average	O
plasma	plasma	O
lidocaine	lidocaine	B-Chemical
level	level	O
10	10	O
minutes	minutes	O
after	after	O
administration	administration	O
for	for	O
patients	patients	O
without	without	O
a	a	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
was	was	O
significantly	significantly	O
higher	higher	O
than	than	O
that	that	O
for	for	O
patients	patients	O
with	with	O
an	an	O
acute	acute	O
infarction	infarction	B-Disease
.	.	O

The	the	O
mean	mean	O
plasma	plasma	O
lidocaine	lidocaine	B-Chemical
level	level	O
of	of	O
patients	patients	O
on	on	O
beta-blocking	beta-blocking	O
agents	agents	O
was	was	O
no	no	O
different	different	O
from	from	O
that	that	O
in	in	O
patients	patients	O
not	not	O
on	on	O
beta	beta	O
blocking	blocking	O
agents	agents	O
.	.	O

During	during	O
the	the	O
1-hour	1-hour	O
study	study	O
period	period	O
,	,	O
the	the	O
incidence	incidence	O
of	of	O
central	central	O
nervous	nervous	O
system	system	O
side	side	O
effects	effects	O
was	was	O
significantly	significantly	O
greater	greater	O
in	in	O
the	the	O
lidocaine	lidocaine	B-Chemical
group	group	O
,	,	O
hypotension	hypotension	B-Disease
occurred	occurred	O
in	in	O
11	11	O
patients	patients	O
,	,	O
nine	nine	O
of	of	O
whom	whom	O
had	had	O
received	received	O
lidocaine	lidocaine	B-Chemical
,	,	O
and	and	O
four	four	O
patients	patients	O
died	died	O
from	from	O
asystole	asystole	B-Disease
,	,	O
three	three	O
of	of	O
whom	whom	O
had	had	O
had	had	O
lidocaine	lidocaine	B-Chemical
.	.	O

We	we	O
can	can	O
not	not	O
advocate	advocate	O
the	the	O
administration	administration	O
of	of	O
lidocaine	lidocaine	B-Chemical
prophylactically	prophylactically	O
in	in	O
the	the	O
early	early	O
hours	hours	O
of	of	O
suspected	suspected	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

Evidence	evidence	O
for	for	O
a	a	O
cholinergic	cholinergic	O
role	role	O
in	in	O
haloperidol-induced	haloperidol-induced	O
catalepsy	catalepsy	B-Disease
.	.	O

Experiments	experiments	O
in	in	O
mice	mice	O
tested	tested	O
previous	previous	O
evidence	evidence	O
that	that	O
activation	activation	O
of	of	O
cholinergic	cholinergic	O
systems	systems	O
promotes	promotes	O
catalepsy	catalepsy	B-Disease
and	and	O
that	that	O
cholinergic	cholinergic	O
mechanisms	mechanisms	O
need	need	O
to	to	O
be	be	O
intact	intact	O
for	for	O
full	full	O
expression	expression	O
of	of	O
neuroleptic-induced	neuroleptic-induced	O
catalepsy	catalepsy	B-Disease
.	.	O

Large	large	O
doses	doses	O
of	of	O
the	the	O
cholinomimetic	cholinomimetic	O
,	,	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
could	could	O
induce	induce	O
catalepsy	catalepsy	B-Disease
when	when	O
peripheral	peripheral	O
cholinergic	cholinergic	O
receptors	receptors	O
were	were	O
blocked	blocked	O
.	.	O

Low	low	O
doses	doses	O
of	of	O
pilocarpine	pilocarpine	B-Chemical
caused	caused	O
a	a	O
pronounced	pronounced	O
enhancement	enhancement	O
of	of	O
the	the	O
catalepsy	catalepsy	B-Disease
that	that	O
was	was	O
induced	induced	O
by	by	O
the	the	O
dopaminergic	dopaminergic	O
blocker	blocker	O
,	,	O
haloperidol	haloperidol	B-Chemical
.	.	O

A	a	O
muscarinic	muscarinic	O
receptor	receptor	O
blocker	blocker	O
,	,	O
atropine	atropine	B-Chemical
,	,	O
disrupted	disrupted	O
haloperidol-induced	haloperidol-induced	O
catalepsy	catalepsy	B-Disease
.	.	O

Intracranial	intracranial	O
injection	injection	O
of	of	O
an	an	O
acetylcholine-synthesis	acetylcholine-synthesis	O
inhibitor	inhibitor	O
,	,	O
hemicholinium	hemicholinium	O
,	,	O
prevented	prevented	O
the	the	O
catalepsy	catalepsy	B-Disease
that	that	O
is	is	O
usually	usually	O
induced	induced	O
by	by	O
haloperidol	haloperidol	B-Chemical
.	.	O

These	these	O
findings	findings	O
suggest	suggest	O
the	the	O
hypothesis	hypothesis	O
that	that	O
the	the	O
catalepsy	catalepsy	B-Disease
that	that	O
is	is	O
produced	produced	O
by	by	O
neuroleptics	neuroleptics	B-Chemical
such	such	O
as	as	O
haloperidol	haloperidol	B-Chemical
is	is	O
actually	actually	O
mediated	mediated	O
by	by	O
intrinsic	intrinsic	O
central	central	O
cholinergic	cholinergic	O
systems	systems	O
.	.	O

Alternatively	alternatively	O
,	,	O
activation	activation	O
of	of	O
central	central	O
cholinergic	cholinergic	O
systems	systems	O
could	could	O
promote	promote	O
catalepsy	catalepsy	B-Disease
by	by	O
suppression	suppression	O
of	of	O
dopaminergic	dopaminergic	O
systems	systems	O
.	.	O

Cardiovascular	cardiovascular	O
dysfunction	dysfunction	O
and	and	O
hypersensitivity	hypersensitivity	B-Disease
to	to	O
sodium	sodium	B-Chemical
pentobarbital	pentobarbital	B-Chemical
induced	induced	O
by	by	O
chronic	chronic	O
barium	barium	B-Chemical
chloride	chloride	I-Chemical
ingestion	ingestion	O
.	.	O

Barium-supplemented	barium-supplemented	O
Long-Evans	long-evans	O
hooded	hooded	O
rats	rats	O
were	were	O
characterized	characterized	O
by	by	O
a	a	O
persistent	persistent	O
hypertension	hypertension	B-Disease
that	that	O
was	was	O
evident	evident	O
after	after	O
1	1	O
month	month	O
of	of	O
barium	barium	O
(	(	O
100	100	O
micrograms/ml	micrograms/ml	O
mineral	mineral	O
fortified	fortified	O
water	water	O
)	)	O
treatment	treatment	O
.	.	O

Analysis	analysis	O
of	of	O
in	in	O
vivo	vivo	O
myocardial	myocardial	O
excitability	excitability	O
,	,	O
contractility	contractility	O
,	,	O
and	and	O
metabolic	metabolic	O
characteristics	characteristics	O
at	at	O
16	16	O
months	months	O
revealed	revealed	O
other	other	O
significant	significant	O
barium-induced	barium-induced	O
disturbances	disturbances	O
within	within	O
the	the	O
cardiovascular	cardiovascular	O
system	system	O
.	.	O

The	the	O
most	most	O
distinctive	distinctive	O
aspect	aspect	O
of	of	O
the	the	O
barium	barium	O
effect	effect	O
was	was	O
a	a	O
demonstrated	demonstrated	O
hypersensitivity	hypersensitivity	B-Disease
of	of	O
the	the	O
cardiovascular	cardiovascular	O
system	system	O
to	to	O
sodium	sodium	B-Chemical
pentobarbital	pentobarbital	B-Chemical
.	.	O

Under	under	O
barbiturate	barbiturate	O
anesthesia	anesthesia	O
,	,	O
virtually	virtually	O
all	all	O
of	of	O
the	the	O
myocardial	myocardial	O
contractile	contractile	O
indices	indices	O
were	were	O
depressed	depressed	B-Disease
significantly	significantly	O
in	in	O
barium-exposed	barium-exposed	O
rats	rats	O
relative	relative	O
to	to	O
the	the	O
corresponding	corresponding	O
control-fed	control-fed	O
rats	rats	O
.	.	O

The	the	O
lack	lack	O
of	of	O
a	a	O
similar	similar	O
response	response	O
to	to	O
ketamine	ketamine	B-Chemical
and	and	O
xylazine	xylazine	O
anesthesia	anesthesia	O
revealed	revealed	O
that	that	O
the	the	O
cardiovascular	cardiovascular	O
actions	actions	O
of	of	O
sodium	sodium	B-Chemical
pentobarbital	pentobarbital	B-Chemical
in	in	O
barium-treated	barium-treated	O
rats	rats	O
were	were	O
linked	linked	O
specifically	specifically	O
to	to	O
this	this	O
anesthetic	anesthetic	O
,	,	O
and	and	O
were	were	O
not	not	O
representative	representative	O
of	of	O
a	a	O
generalized	generalized	O
anesthetic	anesthetic	O
response	response	O
.	.	O

Other	other	O
myocardial	myocardial	O
pathophysiologic	pathophysiologic	O
and	and	O
metabolic	metabolic	O
changes	changes	O
induced	induced	O
by	by	O
barium	barium	O
were	were	O
manifest	manifest	O
,	,	O
irrespective	irrespective	O
of	of	O
the	the	O
anesthetic	anesthetic	O
employed	employed	O
.	.	O

The	the	O
contractile	contractile	O
element	element	O
shortening	shortening	O
velocity	velocity	O
of	of	O
the	the	O
cardiac	cardiac	O
muscle	muscle	O
fibers	fibers	O
was	was	O
significantly	significantly	O
slower	slower	O
in	in	O
both	both	O
groups	groups	O
of	of	O
barium-treated	barium-treated	O
rats	rats	O
relative	relative	O
to	to	O
the	the	O
control	control	O
groups	groups	O
,	,	O
irrespective	irrespective	O
of	of	O
the	the	O
anesthetic	anesthetic	O
regimen	regimen	O
.	.	O

Similarly	similarly	O
,	,	O
significant	significant	O
disturbances	disturbances	O
in	in	O
myocardial	myocardial	O
energy	energy	O
metabolism	metabolism	O
were	were	O
detected	detected	O
in	in	O
the	the	O
barium-exposed	barium-exposed	O
rats	rats	O
which	which	O
were	were	O
consistent	consistent	O
with	with	O
the	the	O
reduced	reduced	O
contractile	contractile	O
element	element	O
shortening	shortening	O
velocity	velocity	O
.	.	O

In	in	O
addition	addition	O
,	,	O
the	the	O
excitability	excitability	O
of	of	O
the	the	O
cardiac	cardiac	O
conduction	conduction	O
system	system	O
was	was	O
depressed	depressed	B-Disease
preferentially	preferentially	O
in	in	O
the	the	O
atrioventricular	atrioventricular	O
nodal	nodal	O
region	region	O
of	of	O
hearts	hearts	O
from	from	O
barium-exposed	barium-exposed	O
rats	rats	O
.	.	O

Overall	overall	O
,	,	O
the	the	O
altered	altered	O
cardiac	cardiac	O
contractility	contractility	O
and	and	O
excitability	excitability	O
characteristics	characteristics	O
,	,	O
the	the	O
myocardial	myocardial	O
metabolic	metabolic	O
disturbances	disturbances	O
,	,	O
and	and	O
the	the	O
hypersensitivity	hypersensitivity	B-Disease
of	of	O
the	the	O
cardiovascular	cardiovascular	O
system	system	O
to	to	O
sodium	sodium	B-Chemical
pentobarbital	pentobarbital	B-Chemical
suggest	suggest	O
the	the	O
existence	existence	O
of	of	O
a	a	O
heretofore	heretofore	O
undescribed	undescribed	O
cardiomyopathic	cardiomyopathic	O
disorder	disorder	O
induced	induced	O
by	by	O
chronic	chronic	O
barium	barium	O
exposure	exposure	O
.	.	O

These	these	O
experimental	experimental	O
findings	findings	O
represent	represent	O
the	the	O
first	first	O
indication	indication	O
that	that	O
life-long	life-long	O
barium	barium	O
ingestion	ingestion	O
may	may	O
have	have	O
significant	significant	O
adverse	adverse	O
effects	effects	O
on	on	O
the	the	O
mammalian	mammalian	O
cardiovascular	cardiovascular	O
system	system	O
.	.	O

Propranolol	propranolol	B-Chemical
antagonism	antagonism	O
of	of	O
phenylpropanolamine-induced	phenylpropanolamine-induced	O
hypertension	hypertension	B-Disease
.	.	O

Phenylpropanolamine	phenylpropanolamine	B-Chemical
(	(	O
PPA	ppa	B-Chemical
)	)	O
overdose	overdose	B-Disease
can	can	O
cause	cause	O
severe	severe	O
hypertension	hypertension	B-Disease
,	,	O
intracerebral	intracerebral	B-Disease
hemorrhage	hemorrhage	B-Disease
,	,	O
and	and	O
death	death	B-Disease
.	.	O

We	we	O
studied	studied	O
the	the	O
efficacy	efficacy	O
and	and	O
safety	safety	O
of	of	O
propranolol	propranolol	B-Chemical
in	in	O
the	the	O
treatment	treatment	O
of	of	O
PPA-induced	ppa-induced	O
hypertension	hypertension	B-Disease
.	.	O

Subjects	subjects	O
received	received	O
propranolol	propranolol	B-Chemical
either	either	O
by	by	O
mouth	mouth	O
for	for	O
48	48	O
hours	hours	O
before	before	O
PPA	ppa	B-Chemical
or	or	O
as	as	O
a	a	O
rapid	rapid	O
intravenous	intravenous	O
infusion	infusion	O
after	after	O
PPA	ppa	B-Chemical
.	.	O

PPA	ppa	B-Chemical
,	,	O
75	75	O
mg	mg	O
alone	alone	O
,	,	O
increased	increased	O
blood	blood	O
pressure	pressure	O
(	(	O
31	31	O
+	+	O
/-	/-	O
14	14	O
mm	mm	O
Hg	hg	O
systolic	systolic	O
,	,	O
20	20	O
+	+	O
/-	/-	O
5	5	O
mm	mm	O
Hg	hg	O
diastolic	diastolic	O
)	)	O
,	,	O
and	and	O
propranolol	propranolol	B-Chemical
pretreatment	pretreatment	O
antagonized	antagonized	O
this	this	O
increase	increase	O
(	(	O
12	12	O
+	+	O
/-	/-	O
10	10	O
mm	mm	O
Hg	hg	O
systolic	systolic	O
,	,	O
10	10	O
+	+	O
/-	/-	O
7	7	O
mm	mm	O
Hg	hg	O
diastolic	diastolic	O
)	)	O
.	.	O

Intravenous	intravenous	O
propranolol	propranolol	B-Chemical
after	after	O
PPA	ppa	B-Chemical
also	also	O
decreased	decreased	O
blood	blood	O
pressure	pressure	O
.	.	O

Left	left	O
ventricular	ventricular	O
function	function	O
(	(	O
assessed	assessed	O
by	by	O
echocardiography	echocardiography	O
)	)	O
showed	showed	O
that	that	O
PPA	ppa	B-Chemical
increased	increased	O
the	the	O
stroke	stroke	B-Disease
volume	volume	O
30	30	O
%	%	O
(	(	O
from	from	O
62.5	62.5	O
+	+	O
/-	/-	O
20.9	20.9	O
to	to	O
80.8	80.8	O
+	+	O
/-	/-	O
22.4	22.4	O
ml	ml	O
)	)	O
,	,	O
the	the	O
ejection	ejection	O
fraction	fraction	O
9	9	O
%	%	O
(	(	O
from	from	O
64	64	O
%	%	O
+	+	O
/-	/-	O
10	10	O
%	%	O
to	to	O
70	70	O
%	%	O
+	+	O
/-	/-	O
7	7	O
%	%	O
)	)	O
,	,	O
and	and	O
cardiac	cardiac	O
output	output	O
14	14	O
%	%	O
(	(	O
from	from	O
3.6	3.6	O
+	+	O
/-	/-	O
0.6	0.6	O
to	to	O
4.1	4.1	O
+	+	O
/-	/-	O
1.0	1.0	O
L/min	l/min	O
)	)	O
.	.	O

Intravenous	intravenous	O
propranolol	propranolol	B-Chemical
reversed	reversed	O
these	these	O
effects	effects	O
.	.	O

Systemic	systemic	O
vascular	vascular	O
resistance	resistance	O
was	was	O
increased	increased	O
by	by	O
PPA	ppa	B-Chemical
28	28	O
%	%	O
(	(	O
from	from	O
1710	1710	O
+	+	O
/-	/-	O
200	200	O
to	to	O
2190	2190	O
+	+	O
/-	/-	O
700	700	O
dyne	dyne	O
X	x	O
sec/cm5	sec/cm5	O
)	)	O
and	and	O
was	was	O
further	further	O
increased	increased	O
by	by	O
propranolol	propranolol	B-Chemical
22	22	O
%	%	O
(	(	O
to	to	O
2660	2660	O
+	+	O
/-	/-	O
1200	1200	O
dyne	dyne	O
X	x	O
sec/cm5	sec/cm5	O
)	)	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
PPA	ppa	B-Chemical
increases	increases	O
blood	blood	O
pressure	pressure	O
by	by	O
increasing	increasing	O
systemic	systemic	O
vascular	vascular	O
resistance	resistance	O
and	and	O
cardiac	cardiac	O
output	output	O
,	,	O
and	and	O
that	that	O
propranolol	propranolol	B-Chemical
antagonizes	antagonizes	O
this	this	O
increase	increase	O
by	by	O
reversing	reversing	O
the	the	O
effect	effect	O
of	of	O
PPA	ppa	B-Chemical
on	on	O
cardiac	cardiac	O
output	output	O
.	.	O

That	that	O
propranolol	propranolol	B-Chemical
antagonizes	antagonizes	O
the	the	O
pressor	pressor	O
effect	effect	O
of	of	O
PPA	ppa	B-Chemical
is	is	O
in	in	O
contrast	contrast	O
to	to	O
the	the	O
interaction	interaction	O
in	in	O
which	which	O
propranolol	propranolol	B-Chemical
enhances	enhances	O
the	the	O
pressor	pressor	O
effect	effect	O
of	of	O
norepinephrine	norepinephrine	B-Chemical
.	.	O

This	this	O
is	is	O
probably	probably	O
because	because	O
PPA	ppa	B-Chemical
has	has	O
less	less	O
beta	beta	O
2	2	O
activity	activity	O
than	than	O
does	does	O
norepinephrine	norepinephrine	B-Chemical
.	.	O

Mesangial	mesangial	O
function	function	O
and	and	O
glomerular	glomerular	B-Disease
sclerosis	sclerosis	I-Disease
in	in	O
rats	rats	O
with	with	O
aminonucleoside	aminonucleoside	B-Chemical
nephrosis	nephrosis	B-Disease
.	.	O

The	the	O
possible	possible	O
relationship	relationship	O
between	between	O
mesangial	mesangial	O
dysfunction	dysfunction	O
and	and	O
development	development	O
of	of	O
glomerular	glomerular	B-Disease
sclerosis	sclerosis	I-Disease
was	was	O
studied	studied	O
in	in	O
the	the	O
puromycin	puromycin	B-Chemical
aminonucleoside	aminonucleoside	B-Chemical
(	(	O
PAN	pan	B-Chemical
)	)	O
model	model	O
.	.	O

Five	five	O
male	male	O
Wistar	wistar	O
rats	rats	O
received	received	O
repeated	repeated	O
subcutaneous	subcutaneous	O
PAN	pan	B-Chemical
injections	injections	O
;	;	O
five	five	O
controls	controls	O
received	received	O
saline	saline	O
only	only	O
.	.	O

After	after	O
4	4	O
weeks	weeks	O
the	the	O
PAN	pan	B-Chemical
rats	rats	O
were	were	O
severely	severely	O
proteinuric	proteinuric	O
(	(	O
190	190	O
+	+	O
/-	/-	O
80	80	O
mg/24	mg/24	O
hr	hr	O
)	)	O
,	,	O
and	and	O
all	all	O
rats	rats	O
were	were	O
given	given	O
colloidal	colloidal	O
carbon	carbon	O
(	(	O
CC	cc	B-Chemical
)	)	O
intravenously	intravenously	O
.	.	O

At	at	O
5	5	O
months	months	O
glomerular	glomerular	B-Disease
sclerosis	sclerosis	I-Disease
was	was	O
found	found	O
in	in	O
7.6	7.6	O
+	+	O
/-	/-	O
3.4	3.4	O
%	%	O
of	of	O
the	the	O
glomeruli	glomeruli	O
of	of	O
PAN	pan	B-Chemical
rats	rats	O
;	;	O
glomeruli	glomeruli	O
of	of	O
the	the	O
controls	controls	O
were	were	O
normal	normal	O
.	.	O

Glomeruli	glomeruli	O
of	of	O
PAN	pan	B-Chemical
rats	rats	O
contained	contained	O
significantly	significantly	O
more	more	O
CC	cc	B-Chemical
than	than	O
glomeruli	glomeruli	O
of	of	O
controls	controls	O
.	.	O

Glomeruli	glomeruli	O
with	with	O
sclerosis	sclerosis	O
contained	contained	O
significantly	significantly	O
more	more	O
CC	cc	B-Chemical
than	than	O
non-sclerotic	non-sclerotic	O
glomeruli	glomeruli	O
in	in	O
the	the	O
same	same	O
kidneys	kidneys	O
.	.	O

CC	cc	B-Chemical
was	was	O
preferentially	preferentially	O
localized	localized	O
within	within	O
the	the	O
sclerotic	sclerotic	O
areas	areas	O
of	of	O
the	the	O
affected	affected	O
glomeruli	glomeruli	O
.	.	O

Since	since	O
mesangial	mesangial	O
CC	cc	B-Chemical
clearance	clearance	O
from	from	O
the	the	O
mesangium	mesangium	O
did	did	O
not	not	O
change	change	O
during	during	O
chronic	chronic	O
PAN	pan	B-Chemical
treatment	treatment	O
,	,	O
we	we	O
conclude	conclude	O
that	that	O
this	this	O
preferential	preferential	O
CC	cc	B-Chemical
localization	localization	O
within	within	O
the	the	O
lesions	lesions	O
is	is	O
caused	caused	O
by	by	O
an	an	O
increased	increased	O
CC	cc	B-Chemical
uptake	uptake	O
shortly	shortly	O
after	after	O
injection	injection	O
in	in	O
apparent	apparent	O
vulnerable	vulnerable	O
areas	areas	O
where	where	O
sclerosis	sclerosis	O
will	will	O
develop	develop	O
subsequently	subsequently	O
.	.	O

Cluster	cluster	O
analysis	analysis	O
showed	showed	O
a	a	O
random	random	O
distribution	distribution	O
of	of	O
lesions	lesions	O
in	in	O
the	the	O
PAN	pan	B-Chemical
glomeruli	glomeruli	O
in	in	O
concordance	concordance	O
with	with	O
the	the	O
random	random	O
localization	localization	O
of	of	O
mesangial	mesangial	O
areas	areas	O
with	with	O
dysfunction	dysfunction	O
in	in	O
this	this	O
model	model	O
.	.	O

Similar	similar	O
to	to	O
the	the	O
remnant	remnant	O
kidney	kidney	O
model	model	O
in	in	O
PAN	pan	B-Chemical
nephrosis	nephrosis	B-Disease
the	the	O
development	development	O
of	of	O
glomerular	glomerular	B-Disease
sclerosis	sclerosis	I-Disease
may	may	O
be	be	O
related	related	O
to	to	O
"	"	O
mesangial	mesangial	O
overloading	overloading	O
.	.	O
"	"	O

Relationship	relationship	O
between	between	O
nicotine-induced	nicotine-induced	O
seizures	seizures	B-Disease
and	and	O
hippocampal	hippocampal	O
nicotinic	nicotinic	O
receptors	receptors	O
.	.	O

A	a	O
controversy	controversy	O
has	has	O
existed	existed	O
for	for	O
several	several	O
years	years	O
concerning	concerning	O
the	the	O
physiological	physiological	O
relevance	relevance	O
of	of	O
the	the	O
nicotinic	nicotinic	O
receptor	receptor	O
measured	measured	O
by	by	O
alpha-bungarotoxin	alpha-bungarotoxin	O
binding	binding	O
.	.	O

Using	using	O
mice	mice	O
derived	derived	O
from	from	O
a	a	O
classical	classical	O
F2	f2	O
and	and	O
backcross	backcross	O
genetic	genetic	O
design	design	O
,	,	O
a	a	O
relationship	relationship	O
between	between	O
nicotine-induced	nicotine-induced	O
seizures	seizures	B-Disease
and	and	O
alpha-bungarotoxin	alpha-bungarotoxin	O
nicotinic	nicotinic	O
receptor	receptor	O
concentration	concentration	O
was	was	O
found	found	O
.	.	O

Mice	mice	O
sensitive	sensitive	O
to	to	O
the	the	O
convulsant	convulsant	O
effects	effects	O
of	of	O
nicotine	nicotine	B-Chemical
had	had	O
greater	greater	O
alpha-bungarotoxin	alpha-bungarotoxin	O
binding	binding	O
in	in	O
the	the	O
hippocampus	hippocampus	O
than	than	O
seizure	seizure	B-Disease
insensitive	insensitive	O
mice	mice	O
.	.	O

The	the	O
binding	binding	O
sites	sites	O
from	from	O
seizure	seizure	B-Disease
sensitive	sensitive	O
and	and	O
resistant	resistant	O
mice	mice	O
were	were	O
equally	equally	O
affected	affected	O
by	by	O
treatment	treatment	O
with	with	O
dithiothreitol	dithiothreitol	O
,	,	O
trypsin	trypsin	O
or	or	O
heat	heat	O
.	.	O

Thus	thus	O
it	it	O
appears	appears	O
that	that	O
the	the	O
difference	difference	O
between	between	O
seizure	seizure	B-Disease
sensitive	sensitive	O
and	and	O
insensitive	insensitive	O
animals	animals	O
may	may	O
be	be	O
due	due	O
to	to	O
a	a	O
difference	difference	O
in	in	O
hippocampal	hippocampal	O
nicotinic	nicotinic	O
receptor	receptor	O
concentration	concentration	O
as	as	O
measured	measured	O
with	with	O
alpha-bungarotoxin	alpha-bungarotoxin	O
binding	binding	O
.	.	O

The	the	O
role	role	O
of	of	O
p-aminophenol	p-aminophenol	O
in	in	O
acetaminophen-induced	acetaminophen-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
:	:	O
effect	effect	O
of	of	O
bis(p-nitrophenyl	bis(p-nitrophenyl	O
)	)	O
phosphate	phosphate	B-Chemical
on	on	O
acetaminophen	acetaminophen	B-Chemical
and	and	O
p-aminophenol	p-aminophenol	O
nephrotoxicity	nephrotoxicity	B-Disease
and	and	O
metabolism	metabolism	O
in	in	O
Fischer	fischer	O
344	344	O
rats	rats	O
.	.	O

Acetaminophen	acetaminophen	B-Chemical
(	(	O
APAP	apap	O
)	)	O
produces	produces	O
proximal	proximal	O
tubular	tubular	B-Disease
necrosis	necrosis	B-Disease
in	in	O
Fischer	fischer	O
344	344	O
(	(	O
F344	f344	O
)	)	O
rats	rats	O
.	.	O

Recently	recently	O
,	,	O
p-aminophenol	p-aminophenol	O
(	(	O
PAP	pap	O
)	)	O
,	,	O
a	a	O
known	known	O
potent	potent	O
nephrotoxicant	nephrotoxicant	O
,	,	O
was	was	O
identified	identified	O
as	as	O
a	a	O
metabolite	metabolite	O
of	of	O
APAP	apap	O
in	in	O
F344	f344	O
rats	rats	O
.	.	O

The	the	O
purpose	purpose	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
determine	determine	O
if	if	O
PAP	pap	O
formation	formation	O
is	is	O
a	a	O
requisite	requisite	O
step	step	O
in	in	O
APAP-induced	apap-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

Therefore	therefore	O
,	,	O
the	the	O
effect	effect	O
of	of	O
bis(p-nitrophenyl	bis(p-nitrophenyl	O
)	)	O
phosphate	phosphate	B-Chemical
(	(	O
BNPP	bnpp	O
)	)	O
,	,	O
an	an	O
acylamidase	acylamidase	O
inhibitor	inhibitor	O
,	,	O
on	on	O
APAP	apap	O
and	and	O
PAP	pap	O
nephrotoxicity	nephrotoxicity	B-Disease
and	and	O
metabolism	metabolism	O
was	was	O
determined	determined	O
.	.	O

BNPP	bnpp	O
(	(	O
1	1	O
to	to	O
8	8	O
mM	mm	O
)	)	O
reduced	reduced	O
APAP	apap	O
deacetylation	deacetylation	O
and	and	O
covalent	covalent	O
binding	binding	O
in	in	O
F344	f344	O
renal	renal	O
cortical	cortical	O
homogenates	homogenates	O
in	in	O
a	a	O
concentration-dependent	concentration-dependent	O
manner	manner	O
.	.	O

Pretreatment	pretreatment	O
of	of	O
animals	animals	O
with	with	O
BNPP	bnpp	O
prior	prior	O
to	to	O
APAP	apap	O
or	or	O
PAP	pap	O
administration	administration	O
resulted	resulted	O
in	in	O
marked	marked	O
reduction	reduction	O
of	of	O
APAP	apap	O
(	(	O
900	900	O
mg/kg	mg/kg	O
)	)	O
nephrotoxicity	nephrotoxicity	B-Disease
but	but	O
not	not	O
PAP	pap	O
nephrotoxicity	nephrotoxicity	B-Disease
.	.	O

This	this	O
result	result	O
was	was	O
not	not	O
due	due	O
to	to	O
altered	altered	O
disposition	disposition	O
of	of	O
either	either	O
APAP	apap	O
or	or	O
acetylated	acetylated	O
metabolites	metabolites	O
in	in	O
plasma	plasma	O
or	or	O
renal	renal	O
cortical	cortical	O
and	and	O
hepatic	hepatic	O
tissue	tissue	O
.	.	O

Rather	rather	O
,	,	O
BNPP	bnpp	O
pretreatment	pretreatment	O
reduced	reduced	O
the	the	O
fraction	fraction	O
of	of	O
APAP	apap	O
excreted	excreted	O
as	as	O
PAP	pap	O
by	by	O
64	64	O
and	and	O
75	75	O
%	%	O
after	after	O
APAP	apap	O
doses	doses	O
of	of	O
750	750	O
and	and	O
900	900	O
mg/kg	mg/kg	O
.	.	O

BNPP	bnpp	O
did	did	O
not	not	O
alter	alter	O
the	the	O
excretion	excretion	O
of	of	O
APAP	apap	O
or	or	O
any	any	O
of	of	O
its	its	O
non-deacetylated	non-deacetylated	O
metabolites	metabolites	O
nor	nor	O
did	did	O
BNPP	bnpp	O
alter	alter	O
excretion	excretion	O
of	of	O
PAP	pap	O
or	or	O
its	its	O
metabolites	metabolites	O
after	after	O
PAP	pap	O
doses	doses	O
of	of	O
150	150	O
and	and	O
300	300	O
mg/kg	mg/kg	O
.	.	O

Therefore	therefore	O
,	,	O
the	the	O
BNPP-induced	bnpp-induced	O
reduction	reduction	O
in	in	O
APAP-induced	apap-induced	O
nephrotoxicity	nephrotoxicity	B-Disease
appears	appears	O
to	to	O
be	be	O
due	due	O
to	to	O
inhibition	inhibition	O
of	of	O
APAP	apap	O
deacetylation	deacetylation	O
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
PAP	pap	O
formation	formation	O
,	,	O
in	in	O
vivo	vivo	O
,	,	O
accounts	accounts	O
,	,	O
at	at	O
least	least	O
in	in	O
part	part	O
,	,	O
for	for	O
APAP-induced	apap-induced	O
renal	renal	O
tubular	tubular	B-Disease
necrosis	necrosis	B-Disease
.	.	O

Morphine-induced	morphine-induced	O
seizures	seizures	B-Disease
in	in	O
newborn	newborn	O
infants	infants	O
.	.	O

Two	two	O
neonates	neonates	O
suffered	suffered	O
from	from	O
generalized	generalized	O
seizures	seizures	B-Disease
during	during	O
the	the	O
course	course	O
of	of	O
intravenous	intravenous	O
morphine	morphine	B-Chemical
sulfate	sulfate	O
for	for	O
post-operative	post-operative	O
analgesia	analgesia	O
.	.	O

They	they	O
received	received	O
morphine	morphine	B-Chemical
in	in	O
doses	doses	O
of	of	O
32	32	O
micrograms/kg/hr	micrograms/kg/hr	O
and	and	O
40	40	O
micrograms/kg/hr	micrograms/kg/hr	O
larger	larger	O
than	than	O
a	a	O
group	group	O
of	of	O
10	10	O
neonates	neonates	O
who	who	O
received	received	O
6	6	O
-	-	O
24	24	O
micrograms/kg/hr	micrograms/kg/hr	O
and	and	O
had	had	O
no	no	O
seizures	seizures	B-Disease
.	.	O

Plasma	plasma	O
concentrations	concentrations	O
of	of	O
morphine	morphine	B-Chemical
in	in	O
these	these	O
neonates	neonates	O
was	was	O
excessive	excessive	O
(	(	O
60	60	O
and	and	O
90	90	O
mg/ml	mg/ml	O
)	)	O
.	.	O

Other	other	O
known	known	O
reasons	reasons	O
for	for	O
seizures	seizures	B-Disease
were	were	O
ruled	ruled	O
out	out	O
and	and	O
the	the	O
convulsions	convulsions	B-Disease
stopped	stopped	O
a	a	O
few	few	O
hours	hours	O
after	after	O
cessation	cessation	O
of	of	O
morphine	morphine	B-Chemical
and	and	O
did	did	O
not	not	O
reoccur	reoccur	O
in	in	O
the	the	O
subsequent	subsequent	O
8	8	O
months	months	O
.	.	O

It	it	O
is	is	O
suggested	suggested	O
that	that	O
post-operative	post-operative	O
intravenous	intravenous	O
morphine	morphine	B-Chemical
should	should	O
not	not	O
exceed	exceed	O
20	20	O
micrograms/kg/ml	micrograms/kg/ml	O
in	in	O
neonates	neonates	O
.	.	O

Indomethacin	indomethacin	B-Chemical
induced	induced	O
hypotension	hypotension	B-Disease
in	in	O
sodium	sodium	B-Chemical
and	and	O
volume	volume	O
depleted	depleted	O
rats	rats	O
.	.	O

After	after	O
a	a	O
single	single	O
oral	oral	O
dose	dose	O
of	of	O
4	4	O
mg/kg	mg/kg	O
indomethacin	indomethacin	B-Chemical
(	(	O
IDM	idm	O
)	)	O
to	to	O
sodium	sodium	B-Chemical
and	and	O
volume	volume	O
depleted	depleted	O
rats	rats	O
plasma	plasma	O
renin	renin	O
activity	activity	O
(	(	O
PRA	pra	O
)	)	O
and	and	O
systolic	systolic	O
blood	blood	O
pressure	pressure	O
fell	fell	O
significantly	significantly	O
within	within	O
four	four	O
hours	hours	O
.	.	O

In	in	O
sodium	sodium	B-Chemical
repleted	repleted	O
animals	animals	O
indomethacin	indomethacin	B-Chemical
did	did	O
not	not	O
change	change	O
systolic	systolic	O
blood	blood	O
pressure	pressure	O
(	(	O
BP	bp	O
)	)	O
although	although	O
plasma	plasma	O
renin	renin	O
activity	activity	O
was	was	O
decreased	decreased	O
.	.	O

Thus	thus	O
,	,	O
indomethacin	indomethacin	B-Chemical
by	by	O
inhibition	inhibition	O
of	of	O
prostaglandin	prostaglandin	O
synthesis	synthesis	O
may	may	O
diminish	diminish	O
the	the	O
blood	blood	O
pressure	pressure	O
maintaining	maintaining	O
effect	effect	O
of	of	O
the	the	O
stimulated	stimulated	O
renin-angiotensin	renin-angiotensin	O
system	system	O
in	in	O
sodium	sodium	B-Chemical
and	and	O
volume	volume	O
depletion	depletion	O
.	.	O

On	on	O
the	the	O
antiarrhythmic	antiarrhythmic	O
activity	activity	O
of	of	O
one	one	O
N-substituted	n-substituted	O
piperazine	piperazine	O
derivative	derivative	O
of	of	O
trans-2-amino-3-hydroxy-1	trans-2-amino-3-hydroxy-1	O
,	,	O
2	2	O
,	,	O
3	3	O
,	,	O
4-tetrahydroanaphthalene	4-tetrahydroanaphthalene	O
.	.	O

The	the	O
antiarrhythmic	antiarrhythmic	O
activity	activity	O
of	of	O
the	the	O
compound	compound	O
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	n-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-n-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	O
hydrochloride	hydrochloride	O
,	,	O
referred	referred	O
to	to	O
as	as	O
P11	p11	O
,	,	O
is	is	O
studied	studied	O
on	on	O
anaesthesized	anaesthesized	O
cats	cats	O
and	and	O
Wistar	wistar	O
albino	albino	O
rats	rats	O
,	,	O
as	as	O
well	well	O
as	as	O
on	on	O
non-anaesthesized	non-anaesthesized	O
rabbits	rabbits	O
.	.	O

Four	four	O
types	types	O
of	of	O
experimental	experimental	O
arrhythmia	arrhythmia	B-Disease
are	are	O
used	used	O
--	--	O
with	with	O
BaCl2	bacl2	B-Chemical
,	,	O
with	with	O
chloroform-adrenaline	chloroform-adrenaline	O
,	,	O
with	with	O
strophantine	strophantine	O
G	g	O
and	and	O
with	with	O
aconitine	aconitine	O
.	.	O

The	the	O
compound	compound	O
P11	p11	O
is	is	O
introduced	introduced	O
in	in	O
doses	doses	O
of	of	O
0.25	0.25	O
and	and	O
0.50	0.50	O
mg/kg	mg/kg	O
intravenously	intravenously	O
and	and	O
10	10	O
mg/kg	mg/kg	O
orally	orally	O
.	.	O

The	the	O
compound	compound	O
manifests	manifests	O
antiarrhythmic	antiarrhythmic	O
activity	activity	O
in	in	O
all	all	O
models	models	O
of	of	O
experimental	experimental	O
arrhythmia	arrhythmia	B-Disease
used	used	O
,	,	O
causing	causing	O
greatest	greatest	O
inhibition	inhibition	O
on	on	O
the	the	O
arrhythmia	arrhythmia	B-Disease
induced	induced	O
by	by	O
chloroform-adrenaline	chloroform-adrenaline	O
(	(	O
in	in	O
90	90	O
per	per	O
cent	cent	O
)	)	O
and	and	O
with	with	O
BaCl2	bacl2	B-Chemical
(	(	O
in	in	O
84	84	O
per	per	O
cent	cent	O
)	)	O
.	.	O

The	the	O
results	results	O
obtained	obtained	O
are	are	O
associated	associated	O
with	with	O
the	the	O
beta-adrenoblocking	beta-adrenoblocking	O
and	and	O
with	with	O
the	the	O
membrane-stabilizing	membrane-stabilizing	O
action	action	O
of	of	O
the	the	O
compound	compound	O
.	.	O

Recurrent	recurrent	O
subarachnoid	subarachnoid	B-Disease
hemorrhage	hemorrhage	B-Disease
associated	associated	O
with	with	O
aminocaproic	aminocaproic	B-Chemical
acid	acid	I-Chemical
therapy	therapy	O
and	and	O
acute	acute	O
renal	renal	O
artery	artery	O
thrombosis	thrombosis	B-Disease
.	.	O

Case	case	O
report	report	O
.	.	O

Epsilon	epsilon	B-Chemical
aminocaproic	aminocaproic	B-Chemical
acid	acid	I-Chemical
(	(	O
EACA	eaca	O
)	)	O
has	has	O
been	been	O
used	used	O
to	to	O
prevent	prevent	O
rebleeding	rebleeding	O
in	in	O
patients	patients	O
with	with	O
subarachnoid	subarachnoid	B-Disease
hemorrhage	hemorrhage	B-Disease
(	(	O
SAH	sah	O
)	)	O
.	.	O

Although	although	O
this	this	O
agent	agent	O
does	does	O
decrease	decrease	O
the	the	O
frequency	frequency	O
of	of	O
rebleeding	rebleeding	O
,	,	O
several	several	O
reports	reports	O
have	have	O
described	described	O
thrombotic	thrombotic	B-Disease
complications	complications	O
of	of	O
EACA	eaca	O
therapy	therapy	O
.	.	O

These	these	O
complications	complications	O
have	have	O
included	included	O
clinical	clinical	B-Disease
deterioration	deterioration	I-Disease
and	and	O
intracranial	intracranial	O
vascular	vascular	O
thrombosis	thrombosis	B-Disease
in	in	O
patients	patients	O
with	with	O
SAH	sah	O
,	,	O
arteriolar	arteriolar	O
and	and	O
capillary	capillary	O
fibrin	fibrin	O
thrombi	thrombi	B-Disease
in	in	O
patients	patients	O
with	with	O
fibrinolytic	fibrinolytic	O
syndromes	syndromes	O
treated	treated	O
with	with	O
EACA	eaca	O
,	,	O
or	or	O
other	other	O
thromboembolic	thromboembolic	B-Disease
phenomena	phenomena	O
.	.	O

Since	since	O
intravascular	intravascular	O
fibrin	fibrin	O
thrombi	thrombi	B-Disease
are	are	O
often	often	O
observed	observed	O
in	in	O
patients	patients	O
with	with	O
fibrinolytic	fibrinolytic	O
disorders	disorders	O
,	,	O
EACA	eaca	O
should	should	O
not	not	O
be	be	O
implicated	implicated	O
in	in	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
fibrin	fibrin	O
thrombi	thrombi	B-Disease
in	in	O
patients	patients	O
with	with	O
disseminated	disseminated	B-Disease
intravascular	intravascular	I-Disease
coagulation	coagulation	I-Disease
or	or	O
other	other	O
"	"	O
consumption	consumption	B-Disease
coagulopathies	coagulopathies	I-Disease
.	.	O
"	"	O
This	this	O
report	report	O
describes	describes	O
subtotal	subtotal	O
infarction	infarction	B-Disease
of	of	O
the	the	O
kidney	kidney	O
due	due	O
to	to	O
thrombosis	thrombosis	B-Disease
of	of	O
a	a	O
normal	normal	O
renal	renal	O
artery	artery	O
.	.	O

This	this	O
occlusion	occlusion	O
occurred	occurred	O
after	after	O
EACA	eaca	O
therapy	therapy	O
in	in	O
a	a	O
patient	patient	O
with	with	O
SAH	sah	O
and	and	O
histopathological	histopathological	O
documentation	documentation	O
of	of	O
recurrent	recurrent	O
SAH	sah	O
.	.	O

The	the	O
corresponding	corresponding	O
clinical	clinical	O
event	event	O
was	was	O
characterized	characterized	O
by	by	O
marked	marked	O
hypertension	hypertension	B-Disease
and	and	O
abrupt	abrupt	O
neurological	neurological	O
deterioration	deterioration	O
.	.	O

Effect	effect	O
of	of	O
vincristine	vincristine	B-Chemical
sulfate	sulfate	O
on	on	O
Pseudomonas	pseudomonas	B-Disease
infections	infections	B-Disease
in	in	O
monkeys	monkeys	O
.	.	O

In	in	O
rhesus	rhesus	O
monkeys	monkeys	O
,	,	O
intravenous	intravenous	O
challenge	challenge	O
with	with	O
0.6	0.6	O
x	x	O
10(10	10(10	O
)	)	O
to	to	O
2.2	2.2	O
x	x	O
10(10)Pseudomonas	10(10)pseudomonas	O
aeruginosa	aeruginosa	O
organisms	organisms	O
caused	caused	O
acute	acute	O
illness	illness	O
of	of	O
4	4	O
to	to	O
5	5	O
days	days	O
'	'	O
duration	duration	O
with	with	O
spontaneous	spontaneous	O
recovery	recovery	O
in	in	O
13	13	O
of	of	O
15	15	O
monkeys	monkeys	O
;	;	O
blood	blood	O
cultures	cultures	O
became	became	O
negative	negative	O
3	3	O
to	to	O
17	17	O
days	days	O
after	after	O
challenge	challenge	O
.	.	O

Leukocytosis	leukocytosis	O
was	was	O
observed	observed	O
in	in	O
all	all	O
monkeys	monkeys	O
.	.	O

Intravenous	intravenous	O
or	or	O
intratracheal	intratracheal	O
inoculation	inoculation	O
of	of	O
2.0	2.0	O
to	to	O
2.5	2.5	O
mg	mg	O
of	of	O
vincristine	vincristine	B-Chemical
sulfate	sulfate	O
was	was	O
followed	followed	O
by	by	O
leukopenia	leukopenia	B-Disease
in	in	O
4	4	O
to	to	O
5	5	O
days	days	O
.	.	O

Intravenous	intravenous	O
inoculation	inoculation	O
of	of	O
4.2	4.2	O
x	x	O
10(10	10(10	O
)	)	O
to	to	O
7.8	7.8	O
x	x	O
10(10	10(10	O
)	)	O
pyocin	pyocin	O
type	type	O
6	6	O
Pseudomonas	pseudomonas	O
organisms	organisms	O
in	in	O
monkeys	monkeys	O
given	given	O
vincristine	vincristine	B-Chemical
sulfate	sulfate	O
4	4	O
days	days	O
previously	previously	O
resulted	resulted	O
in	in	O
fatal	fatal	O
infection	infection	B-Disease
in	in	O
11	11	O
of	of	O
14	14	O
monkeys	monkeys	O
,	,	O
whereas	whereas	O
none	none	O
of	of	O
four	four	O
receiving	receiving	O
Pseudomonas	pseudomonas	O
alone	alone	O
died	died	O
.	.	O

These	these	O
studies	studies	O
suggest	suggest	O
that	that	O
an	an	O
antimetabolite-induced	antimetabolite-induced	O
leukopenia	leukopenia	B-Disease
predisposes	predisposes	O
to	to	O
severe	severe	O
Pseudomonas	pseudomonas	O
sepsis	sepsis	B-Disease
and	and	O
that	that	O
such	such	O
monkeys	monkeys	O
may	may	O
serve	serve	O
as	as	O
a	a	O
biological	biological	O
model	model	O
for	for	O
study	study	O
of	of	O
comparative	comparative	O
efficacy	efficacy	O
of	of	O
antimicrobial	antimicrobial	O
agents	agents	O
.	.	O

Modification	modification	O
by	by	O
propranolol	propranolol	B-Chemical
of	of	O
cardiovascular	cardiovascular	O
effects	effects	O
of	of	O
induced	induced	O
hypoglycaemia	hypoglycaemia	O
.	.	O

The	the	O
cardiovascular	cardiovascular	O
effects	effects	O
of	of	O
hypoglycaemia	hypoglycaemia	O
,	,	O
with	with	O
and	and	O
without	without	O
beta-blockade	beta-blockade	O
,	,	O
were	were	O
compared	compared	O
in	in	O
fourteen	fourteen	O
healthy	healthy	O
men	men	O
.	.	O

Eight	eight	O
received	received	O
insulin	insulin	O
alone	alone	O
,	,	O
and	and	O
eight	eight	O
,	,	O
including	including	O
two	two	O
of	of	O
the	the	O
original	original	O
insulin-only	insulin-only	O
group	group	O
,	,	O
were	were	O
given	given	O
propranolol	propranolol	B-Chemical
and	and	O
insulin	insulin	O
.	.	O

In	in	O
the	the	O
insulin-group	insulin-group	O
the	the	O
period	period	O
of	of	O
hypoglycaemia	hypoglycaemia	O
was	was	O
associated	associated	O
with	with	O
an	an	O
increase	increase	O
in	in	O
heart-rate	heart-rate	O
and	and	O
a	a	O
fall	fall	O
in	in	O
diastolic	diastolic	O
blood-pressure	blood-pressure	O
.	.	O

In	in	O
the	the	O
propranolol-insulin	propranolol-insulin	O
group	group	O
there	there	O
was	was	O
a	a	O
significant	significant	O
fall	fall	O
in	in	O
heart-rate	heart-rate	O
in	in	O
most	most	O
subjects	subjects	O
and	and	O
an	an	O
increase	increase	O
in	in	O
diastolic	diastolic	O
pressure	pressure	O
.	.	O

Typical	typical	O
S-T/T	s-t/t	O
changes	changes	O
occurred	occurred	O
in	in	O
the	the	O
insulin-group	insulin-group	O
but	but	O
in	in	O
none	none	O
of	of	O
the	the	O
propranolol-insulin	propranolol-insulin	O
group	group	O
.	.	O

Hypertension	hypertension	B-Disease
in	in	O
diabetics	diabetics	O
prone	prone	O
to	to	O
hypoglycaemia	hypoglycaemia	O
attacks	attacks	O
should	should	O
not	not	O
be	be	O
treated	treated	O
with	with	O
beta-blockers	beta-blockers	O
because	because	O
these	these	O
drugs	drugs	O
may	may	O
cause	cause	O
a	a	O
sharp	sharp	O
rise	rise	O
in	in	O
blood-pressure	blood-pressure	O
in	in	O
such	such	O
patients	patients	O
.	.	O

Long-term	long-term	O
propranolol	propranolol	B-Chemical
therapy	therapy	O
in	in	O
pregnancy	pregnancy	O
:	:	O
maternal	maternal	O
and	and	O
fetal	fetal	O
outcome	outcome	O
.	.	O

Propranolol	propranolol	B-Chemical
,	,	O
a	a	O
beta-adrenergic	beta-adrenergic	O
blocking	blocking	O
agent	agent	O
,	,	O
has	has	O
found	found	O
an	an	O
important	important	O
position	position	O
in	in	O
the	the	O
practice	practice	O
of	of	O
medicine	medicine	O
.	.	O

Its	its	O
use	use	O
in	in	O
pregnancy	pregnancy	O
,	,	O
however	however	O
,	,	O
is	is	O
an	an	O
open	open	O
question	question	O
as	as	O
a	a	O
number	number	O
of	of	O
detrimental	detrimental	O
side	side	O
effects	effects	O
have	have	O
been	been	O
reported	reported	O
in	in	O
the	the	O
fetus	fetus	O
and	and	O
neonate	neonate	O
.	.	O

Ten	ten	O
patients	patients	O
and	and	O
12	12	O
pregnancies	pregnancies	O
are	are	O
reported	reported	O
where	where	O
chronic	chronic	O
propranolol	propranolol	B-Chemical
has	has	O
been	been	O
administered	administered	O
.	.	O

Five	five	O
patients	patients	O
with	with	O
serial	serial	O
pregnancies	pregnancies	O
with	with	O
and	and	O
without	without	O
propranolol	propranolol	B-Chemical
therapy	therapy	O
are	are	O
also	also	O
examined	examined	O
.	.	O

Maternal	maternal	O
,	,	O
fetal	fetal	O
,	,	O
and	and	O
neonatal	neonatal	O
complications	complications	O
are	are	O
examined	examined	O
.	.	O

An	an	O
attempt	attempt	O
is	is	O
made	made	O
to	to	O
differentiate	differentiate	O
drug-related	drug-related	O
complications	complications	O
from	from	O
maternal	maternal	O
disease	disease	O
--	--	O
related	related	O
complications	complications	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
previously	previously	O
reported	reported	O
hypoglycemia	hypoglycemia	O
,	,	O
hyperbilirubinemia	hyperbilirubinemia	O
,	,	O
polycythemia	polycythemia	O
,	,	O
neonatal	neonatal	O
apnea	apnea	B-Disease
,	,	O
and	and	O
bradycardia	bradycardia	B-Disease
are	are	O
not	not	O
invariable	invariable	O
and	and	O
can	can	O
not	not	O
be	be	O
statistically	statistically	O
correlated	correlated	O
with	with	O
chronic	chronic	O
propranolol	propranolol	B-Chemical
therapy	therapy	O
.	.	O

Growth	growth	O
retardation	retardation	O
,	,	O
however	however	O
,	,	O
appears	appears	O
to	to	O
be	be	O
significant	significant	O
in	in	O
both	both	O
of	of	O
our	our	O
series	series	O
.	.	O

Central	central	O
excitatory	excitatory	O
actions	actions	O
of	of	O
flurazepam	flurazepam	O
.	.	O

Toxic	toxic	B-Chemical
actions	actions	I-Chemical
of	of	O
flurazepam	flurazepam	O
(	(	O
FZP	fzp	O
)	)	O
were	were	O
studied	studied	O
in	in	O
cats	cats	O
,	,	O
mice	mice	O
and	and	O
rats	rats	O
.	.	O

High	high	O
doses	doses	O
caused	caused	O
an	an	O
apparent	apparent	O
central	central	O
excitation	excitation	O
,	,	O
most	most	O
clearly	clearly	O
seen	seen	O
as	as	O
clonic	clonic	O
convulsions	convulsions	B-Disease
,	,	O
superimposed	superimposed	O
on	on	O
general	general	O
depression	depression	B-Disease
.	.	O

Following	following	O
a	a	O
lethal	lethal	O
dose	dose	O
,	,	O
death	death	B-Disease
was	was	O
always	always	O
associated	associated	O
with	with	O
convulsions	convulsions	B-Disease
.	.	O

Comparing	comparing	O
the	the	O
relative	relative	O
sensitivity	sensitivity	O
to	to	O
central	central	O
depression	depression	B-Disease
and	and	O
excitation	excitation	O
revealed	revealed	O
that	that	O
rats	rats	O
were	were	O
least	least	O
likely	likely	O
to	to	O
have	have	O
convulsions	convulsions	B-Disease
at	at	O
doses	doses	O
that	that	O
did	did	O
not	not	O
first	first	O
cause	cause	O
loss	loss	O
of	of	O
consciousness	consciousness	O
,	,	O
while	while	O
cats	cats	O
most	most	O
clearly	clearly	O
showed	showed	O
marked	marked	O
central	central	O
excitatory	excitatory	O
actions	actions	O
.	.	O

Signs	signs	O
of	of	O
FZP	fzp	O
toxocity	toxocity	O
in	in	O
cats	cats	O
included	included	O
excessive	excessive	O
salivation	salivation	O
,	,	O
extreme	extreme	O
apprehensive	apprehensive	O
behavior	behavior	O
,	,	O
retching	retching	O
,	,	O
muscle	muscle	O
tremors	tremors	B-Disease
and	and	O
convulsions	convulsions	B-Disease
.	.	O

An	an	O
interaction	interaction	O
between	between	O
FZP	fzp	O
and	and	O
pentylenetetrazol	pentylenetetrazol	O
(	(	O
PTZ	ptz	B-Chemical
)	)	O
was	was	O
shown	shown	O
by	by	O
pretreating	pretreating	O
mice	mice	O
with	with	O
FZP	fzp	O
before	before	O
PTZ	ptz	B-Chemical
challenge	challenge	O
.	.	O

As	as	O
a	a	O
function	function	O
of	of	O
dose	dose	O
,	,	O
FZP	fzp	O
first	first	O
protected	protected	O
against	against	O
convulsions	convulsions	B-Disease
and	and	O
death	death	B-Disease
.	.	O

At	at	O
higher	higher	O
doses	doses	O
,	,	O
however	however	O
,	,	O
convulsions	convulsions	B-Disease
again	again	O
emerged	emerged	O
.	.	O

These	these	O
doses	doses	O
of	of	O
FZP	fzp	O
were	were	O
lower	lower	O
than	than	O
those	those	O
that	that	O
would	would	O
alone	alone	O
cause	cause	O
convulsions	convulsions	B-Disease
.	.	O

These	these	O
results	results	O
may	may	O
be	be	O
relevant	relevant	O
to	to	O
the	the	O
use	use	O
of	of	O
FZP	fzp	O
in	in	O
clinical	clinical	O
situations	situations	O
in	in	O
which	which	O
there	there	O
is	is	O
increased	increased	O
neural	neural	O
excitability	excitability	O
,	,	O
such	such	O
as	as	O
epilepsy	epilepsy	B-Disease
or	or	O
sedative-hypnotic	sedative-hypnotic	O
drug	drug	O
withdrawal	withdrawal	O
.	.	O

Use	use	O
of	of	O
propranolol	propranolol	B-Chemical
in	in	O
the	the	O
treatment	treatment	O
of	of	O
idiopathic	idiopathic	B-Disease
orthostatic	orthostatic	B-Disease
hypotension	hypotension	B-Disease
.	.	O

Five	five	O
patients	patients	O
with	with	O
idiopathic	idiopathic	B-Disease
orthostatic	orthostatic	B-Disease
hypotension	hypotension	B-Disease
who	who	O
had	had	O
physiologic	physiologic	O
and	and	O
biochemical	biochemical	O
evidence	evidence	O
of	of	O
severe	severe	O
autonomic	autonomic	O
dysfunction	dysfunction	O
were	were	O
included	included	O
in	in	O
the	the	O
study	study	O
.	.	O

They	they	O
all	all	O
exhibited	exhibited	O
markedly	markedly	O
reduced	reduced	O
plasma	plasma	O
catecholamines	catecholamines	B-Chemical
and	and	O
plasma	plasma	O
renin	renin	O
activity	activity	O
in	in	O
both	both	O
recumbent	recumbent	O
and	and	O
upright	upright	O
positions	positions	O
and	and	O
had	had	O
marked	marked	O
hypersensitivity	hypersensitivity	B-Disease
to	to	O
the	the	O
pressor	pressor	O
effects	effects	O
of	of	O
infused	infused	O
norepinephrine	norepinephrine	B-Chemical
.	.	O

Treatment	treatment	O
with	with	O
propanolol	propanolol	O
administered	administered	O
intravenously	intravenously	O
(	(	O
1	1	O
-	-	O
5	5	O
mg	mg	O
)	)	O
produced	produced	O
increases	increases	O
in	in	O
supine	supine	O
and	and	O
upright	upright	O
blood	blood	O
pressure	pressure	O
in	in	O
4	4	O
of	of	O
the	the	O
5	5	O
individuals	individuals	O
with	with	O
rises	rises	O
ranging	ranging	O
from	from	O
11/6	11/6	O
to	to	O
22/11	22/11	O
mmHg	mmhg	O
.	.	O

Chronic	chronic	O
oral	oral	O
administration	administration	O
of	of	O
propranolol	propranolol	B-Chemical
(	(	O
40	40	O
-	-	O
160	160	O
mg/day	mg/day	O
)	)	O
also	also	O
elevated	elevated	O
the	the	O
blood	blood	O
pressures	pressures	O
of	of	O
these	these	O
individuals	individuals	O
with	with	O
increases	increases	O
in	in	O
the	the	O
order	order	O
of	of	O
20	20	O
-	-	O
35/15	35/15	O
-	-	O
25	25	O
mmg	mmg	O
being	being	O
observed	observed	O
.	.	O

In	in	O
1	1	O
patient	patient	O
,	,	O
marked	marked	O
hypertension	hypertension	B-Disease
was	was	O
induced	induced	O
by	by	O
propranolol	propranolol	B-Chemical
and	and	O
the	the	O
drug	drug	O
had	had	O
to	to	O
be	be	O
withdrawn	withdrawn	O
.	.	O

It	it	O
otherwise	otherwise	O
was	was	O
well	well	O
tolerated	tolerated	O
and	and	O
no	no	O
important	important	O
side	side	O
effects	effects	O
were	were	O
observed	observed	O
.	.	O

Treatment	treatment	O
has	has	O
been	been	O
continued	continued	O
in	in	O
3	3	O
individuals	individuals	O
for	for	O
6	6	O
-	-	O
13	13	O
months	months	O
with	with	O
persistence	persistence	O
of	of	O
the	the	O
pressor	pressor	O
effect	effect	O
,	,	O
although	although	O
there	there	O
appears	appears	O
to	to	O
have	have	O
been	been	O
some	some	O
decrease	decrease	O
in	in	O
the	the	O
degree	degree	O
of	of	O
response	response	O
with	with	O
time	time	O
.	.	O

Hemodynamic	hemodynamic	O
measurements	measurements	O
in	in	O
1	1	O
of	of	O
the	the	O
patients	patients	O
demonstrated	demonstrated	O
an	an	O
increase	increase	O
in	in	O
total	total	O
peripheral	peripheral	O
resistance	resistance	O
and	and	O
essentially	essentially	O
no	no	O
change	change	O
in	in	O
cardiac	cardiac	O
output	output	O
following	following	O
propranolol	propranolol	B-Chemical
therapy	therapy	O
.	.	O

The	the	O
studies	studies	O
suggest	suggest	O
that	that	O
propranolol	propranolol	B-Chemical
is	is	O
a	a	O
useful	useful	O
drug	drug	O
in	in	O
selected	selected	O
patients	patients	O
with	with	O
severe	severe	O
idiopathic	idiopathic	B-Disease
orthostatic	orthostatic	B-Disease
hypotension	hypotension	B-Disease
.	.	O

Total	total	O
intravenous	intravenous	O
anesthesia	anesthesia	O
with	with	O
etomidate	etomidate	O
.	.	O

III	iii	O
.	.	O
Some	some	O
observations	observations	O
in	in	O
adults	adults	O
.	.	O

An	an	O
investigation	investigation	O
was	was	O
undertaken	undertaken	O
to	to	O
determine	determine	O
the	the	O
dosage	dosage	O
of	of	O
etomidate	etomidate	O
required	required	O
to	to	O
maintain	maintain	O
sleep	sleep	O
in	in	O
adults	adults	O
undergoing	undergoing	O
surgery	surgery	O
under	under	O
regional	regional	O
local	local	O
anesthesia	anesthesia	O
.	.	O

Premedication	premedication	O
of	of	O
diazepam	diazepam	B-Chemical
10	10	O
mg	mg	O
and	and	O
atropine	atropine	B-Chemical
0.5	0.5	O
mg	mg	O
was	was	O
given	given	O
,	,	O
and	and	O
sleep	sleep	O
was	was	O
induced	induced	O
and	and	O
maintained	maintained	O
by	by	O
intermittent	intermittent	O
intravenous	intravenous	O
injections	injections	O
of	of	O
etomidate	etomidate	O
0.1/mg/kg	0.1/mg/kg	O
,	,	O
given	given	O
whenever	whenever	O
the	the	O
patient	patient	O
would	would	O
open	open	O
his	his	O
eyes	eyes	O
on	on	O
request	request	O
.	.	O

A	a	O
mean	mean	O
overall	overall	O
dose	dose	O
of	of	O
etomidate	etomidate	O
17.4	17.4	O
microgram/kg/min	microgram/kg/min	O
.	.	O
was	was	O
required	required	O
to	to	O
maintain	maintain	O
sleep	sleep	O
,	,	O
but	but	O
great	great	O
individual	individual	O
variation	variation	O
occurred	occurred	O
,	,	O
with	with	O
older	older	O
patients	patients	O
requiring	requiring	O
less	less	O
drug	drug	O
.	.	O

The	the	O
investigation	investigation	O
was	was	O
discontinued	discontinued	O
after	after	O
18	18	O
patients	patients	O
because	because	O
of	of	O
the	the	O
frequency	frequency	O
and	and	O
intensity	intensity	O
of	of	O
side-effects	side-effects	O
,	,	O
particularly	particularly	O
pain	pain	B-Disease
and	and	O
myoclonia	myoclonia	O
,	,	O
which	which	O
caused	caused	O
the	the	O
technique	technique	O
to	to	O
be	be	O
abandoned	abandoned	O
in	in	O
two	two	O
cases	cases	O
.	.	O

It	it	O
is	is	O
considered	considered	O
unlikely	unlikely	O
that	that	O
etomidate	etomidate	O
will	will	O
prove	prove	O
to	to	O
be	be	O
the	the	O
hypnotic	hypnotic	O
of	of	O
choice	choice	O
for	for	O
a	a	O
totally	totally	O
intravenous	intravenous	O
anesthetic	anesthetic	O
technique	technique	O
in	in	O
adults	adults	O
because	because	O
of	of	O
the	the	O
high	high	O
incidence	incidence	O
of	of	O
myoclonia	myoclonia	O
after	after	O
prolonged	prolonged	O
administration	administration	O
.	.	O

In	in	O
several	several	O
patients	patients	O
uncontrollable	uncontrollable	O
muscle	muscle	O
movements	movements	O
persisted	persisted	O
for	for	O
many	many	O
minutes	minutes	O
after	after	O
complete	complete	O
recovery	recovery	O
of	of	O
consciousness	consciousness	O
.	.	O

Evidence	evidence	O
for	for	O
cardiac	cardiac	O
beta	beta	O
2-adrenoceptors	2-adrenoceptors	O
in	in	O
man	man	O
.	.	O

We	we	O
compared	compared	O
the	the	O
effects	effects	O
of	of	O
single	single	O
doses	doses	O
of	of	O
50	50	O
mg	mg	O
atenolol	atenolol	O
(	(	O
cardioselective	cardioselective	O
)	)	O
,	,	O
40	40	O
mg	mg	O
propranolol	propranolol	B-Chemical
(	(	O
nonselective	nonselective	O
)	)	O
,	,	O
and	and	O
placebo	placebo	O
on	on	O
both	both	O
exercise-	exercise-	O
and	and	O
isoproterenol-induced	isoproterenol-induced	O
tachycardia	tachycardia	B-Disease
in	in	O
two	two	O
experiments	experiments	O
involving	involving	O
nine	nine	O
normal	normal	O
subjects	subjects	O
.	.	O

Maximal	maximal	O
exercise	exercise	O
heart	heart	O
rate	rate	O
was	was	O
reduced	reduced	O
from	from	O
187	187	O
+	+	O
/-	/-	O
4(SEM	4(sem	O
)	)	O
after	after	O
placebo	placebo	O
to	to	O
146	146	O
+	+	O
/-	/-	O
7	7	O
bpm	bpm	O
after	after	O
atenolol	atenolol	O
and	and	O
138	138	O
+	+	O
/-	/-	O
6	6	O
bpm	bpm	O
after	after	O
propranolol	propranolol	B-Chemical
,	,	O
but	but	O
there	there	O
were	were	O
no	no	O
differences	differences	O
between	between	O
the	the	O
drugs	drugs	O
.	.	O

The	the	O
effects	effects	O
on	on	O
isoproterenol	isoproterenol	B-Chemical
tachycardia	tachycardia	B-Disease
were	were	O
determined	determined	O
before	before	O
and	and	O
after	after	O
atropine	atropine	B-Chemical
(	(	O
0.04	0.04	O
mg/kg	mg/kg	O
IV	iv	O
)	)	O
.	.	O

Isoproterenol	isoproterenol	B-Chemical
sensitivity	sensitivity	O
was	was	O
determined	determined	O
as	as	O
the	the	O
intravenous	intravenous	O
dose	dose	O
that	that	O
increased	increased	O
heart	heart	O
rate	rate	O
by	by	O
25	25	O
bpm	bpm	O
(	(	O
CD25	cd25	O
)	)	O
and	and	O
this	this	O
was	was	O
increased	increased	O
from	from	O
1.8	1.8	O
+	+	O
/-	/-	O
0.3	0.3	O
micrograms	micrograms	O
after	after	O
placebo	placebo	O
to	to	O
38.9	38.9	O
+	+	O
/-	/-	O
8.3	8.3	O
micrograms	micrograms	O
after	after	O
propranolol	propranolol	B-Chemical
and	and	O
8.3	8.3	O
+	+	O
/-	/-	O
1.7	1.7	O
micrograms	micrograms	O
after	after	O
atenolol	atenolol	O
.	.	O

The	the	O
difference	difference	O
in	in	O
the	the	O
effects	effects	O
of	of	O
the	the	O
two	two	O
was	was	O
significant	significant	O
.	.	O

After	after	O
atropine	atropine	B-Chemical
the	the	O
CD25	cd25	O
was	was	O
unchanged	unchanged	O
after	after	O
placebo	placebo	O
(	(	O
2.3	2.3	O
+	+	O
/-	/-	O
0.3	0.3	O
micrograms	micrograms	O
)	)	O
and	and	O
atenolol	atenolol	O
(	(	O
7.7	7.7	O
+	+	O
/-	/-	O
1.3	1.3	O
micrograms	micrograms	O
)	)	O
;	;	O
it	it	O
was	was	O
reduced	reduced	O
after	after	O
propranolol	propranolol	B-Chemical
(	(	O
24.8	24.8	O
+	+	O
/-	/-	O
5.0	5.0	O
micrograms	micrograms	O
)	)	O
,	,	O
but	but	O
remained	remained	O
different	different	O
from	from	O
atenolol	atenolol	O
.	.	O

This	this	O
change	change	O
with	with	O
propranolol	propranolol	B-Chemical
sensitivity	sensitivity	O
was	was	O
calculated	calculated	O
as	as	O
the	the	O
apparent	apparent	O
Ka	ka	O
,	,	O
this	this	O
was	was	O
unchanged	unchanged	O
by	by	O
atropine	atropine	B-Chemical
(	(	O
11.7	11.7	O
+	+	O
/-	/-	O
2.1	2.1	O
and	and	O
10.1	10.1	O
+	+	O
/-	/-	O
2.5	2.5	O
ml/ng	ml/ng	O
)	)	O
.	.	O

These	these	O
data	data	O
are	are	O
consistent	consistent	O
with	with	O
the	the	O
hypothesis	hypothesis	O
that	that	O
exercise-induced	exercise-induced	O
tachycardia	tachycardia	B-Disease
results	results	O
largely	largely	O
from	from	O
beta	beta	O
1-receptor	1-receptor	O
activation	activation	O
that	that	O
is	is	O
blocked	blocked	O
by	by	O
both	both	O
cardioselective	cardioselective	O
and	and	O
nonselective	nonselective	O
drugs	drugs	O
,	,	O
whereas	whereas	O
isoproterenol	isoproterenol	B-Chemical
activates	activates	O
both	both	O
beta	beta	O
1-	1-	O
and	and	O
beta	beta	O
2-receptors	2-receptors	O
so	so	O
that	that	O
after	after	O
cardioselective	cardioselective	O
blockade	blockade	O
there	there	O
remains	remains	O
a	a	O
beta	beta	O
2-component	2-component	O
that	that	O
can	can	O
be	be	O
blocked	blocked	O
with	with	O
a	a	O
nonselective	nonselective	O
drug	drug	O
.	.	O

While	while	O
there	there	O
appear	appear	O
to	to	O
be	be	O
beta	beta	O
2-receptors	2-receptors	O
in	in	O
the	the	O
human	human	O
heart	heart	O
,	,	O
their	their	O
physiologic	physiologic	O
or	or	O
pathologic	pathologic	O
roles	roles	O
remain	remain	O
to	to	O
be	be	O
defined	defined	O
.	.	O

Hormones	hormones	O
and	and	O
risk	risk	O
of	of	O
breast	breast	B-Disease
cancer	cancer	B-Disease
.	.	O

This	this	O
paper	paper	O
reports	reports	O
the	the	O
results	results	O
of	of	O
a	a	O
study	study	O
of	of	O
50	50	O
menopausal	menopausal	O
women	women	O
receiving	receiving	O
hormonal	hormonal	O
replacement	replacement	O
therapy	therapy	O
.	.	O

The	the	O
majority	majority	O
(	(	O
29	29	O
)	)	O
had	had	O
surgical	surgical	O
menopause	menopause	O
;	;	O
their	their	O
mean	mean	O
age	age	O
was	was	O
45.7	45.7	O
years	years	O
.	.	O

It	it	O
was	was	O
hypothesized	hypothesized	O
that	that	O
progestins	progestins	O
could	could	O
equilibrate	equilibrate	O
the	the	O
effects	effects	O
of	of	O
the	the	O
estrogenic	estrogenic	O
stimulation	stimulation	O
on	on	O
the	the	O
mammary	mammary	O
and	and	O
endometrial	endometrial	O
target	target	O
tissues	tissues	O
of	of	O
women	women	O
on	on	O
hormonal	hormonal	O
replacement	replacement	O
therapy	therapy	O
.	.	O

The	the	O
treatment	treatment	O
schedule	schedule	O
consisted	consisted	O
of	of	O
conjugated	conjugated	O
estrogens	estrogens	O
(	(	O
Premarin	premarin	O
)	)	O
1.25	1.25	O
mg/day	mg/day	O
for	for	O
21	21	O
days	days	O
and	and	O
Medroxyprogesterone	medroxyprogesterone	B-Chemical
acetate	acetate	I-Chemical
10	10	O
mg/day	mg/day	O
for	for	O
10	10	O
days	days	O
in	in	O
each	each	O
month	month	O
.	.	O

The	the	O
mean	mean	O
treatment	treatment	O
period	period	O
was	was	O
18	18	O
months	months	O
.	.	O

During	during	O
the	the	O
follow-up	follow-up	O
period	period	O
,	,	O
attention	attention	O
was	was	O
paid	paid	O
to	to	O
breast	breast	O
modifications	modifications	O
as	as	O
evidenced	evidenced	O
by	by	O
symptomatology	symptomatology	O
,	,	O
physical	physical	O
examination	examination	O
,	,	O
and	and	O
plate	plate	O
thermography	thermography	O
.	.	O

Mastodynia	mastodynia	O
was	was	O
reported	reported	O
by	by	O
21	21	O
patients	patients	O
,	,	O
and	and	O
physical	physical	O
examination	examination	O
revealed	revealed	O
a	a	O
light	light	O
increase	increase	O
in	in	O
breast	breast	O
firmness	firmness	O
in	in	O
12	12	O
women	women	O
and	and	O
a	a	O
moderate	moderate	O
increase	increase	O
in	in	O
breast	breast	O
nodularity	nodularity	O
in	in	O
2	2	O
women	women	O
.	.	O

Themography	themography	O
confirmed	confirmed	O
the	the	O
existence	existence	O
of	of	O
an	an	O
excessive	excessive	O
breast	breast	O
stimulation	stimulation	O
in	in	O
1	1	O
women	women	O
who	who	O
complained	complained	O
of	of	O
moderate	moderate	O
mastodynia	mastodynia	O
and	and	O
in	in	O
5	5	O
of	of	O
the	the	O
7	7	O
women	women	O
who	who	O
complained	complained	O
of	of	O
severe	severe	O
mastodynia	mastodynia	O
.	.	O

Normalization	normalization	O
was	was	O
obtained	obtained	O
by	by	O
halving	halving	O
the	the	O
estrogen	estrogen	B-Chemical
dose	dose	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
hormonal	hormonal	O
replacement	replacement	O
therapy	therapy	O
can	can	O
be	be	O
safely	safely	O
prescribed	prescribed	O
if	if	O
the	the	O
following	following	O
criteria	criteria	O
are	are	O
satisfied	satisfied	O
:	:	O
1	1	O
)	)	O
preliminary	preliminary	O
evaluation	evaluation	O
of	of	O
patients	patients	O
from	from	O
a	a	O
clinical	clinical	O
,	,	O
metabolic	metabolic	O
,	,	O
cytologic	cytologic	O
,	,	O
and	and	O
mammographic	mammographic	O
perspective	perspective	O
;	;	O
2	2	O
)	)	O
cyclic	cyclic	O
treatment	treatment	O
schedule	schedule	O
,	,	O
with	with	O
a	a	O
progestative	progestative	O
phase	phase	O
of	of	O
10	10	O
days	days	O
;	;	O
and	and	O
3	3	O
)	)	O
periodic	periodic	O
complete	complete	O
follow-up	follow-up	O
,	,	O
with	with	O
accurate	accurate	O
thermographic	thermographic	O
evaluation	evaluation	O
of	of	O
the	the	O
breast	breast	O
target	target	O
tissues	tissues	O
.	.	O

Early	early	O
infections	infections	B-Disease
in	in	O
kidney	kidney	O
,	,	O
heart	heart	O
,	,	O
and	and	O
liver	liver	O
transplant	transplant	O
recipients	recipients	O
on	on	O
cyclosporine	cyclosporine	B-Chemical
.	.	O

Eighty-one	eighty-one	O
renal	renal	O
,	,	O
seventeen	seventeen	O
heart	heart	O
,	,	O
and	and	O
twenty-four	twenty-four	O
liver	liver	O
transplant	transplant	O
patients	patients	O
were	were	O
followed	followed	O
for	for	O
infection	infection	B-Disease
.	.	O

Seventeen	seventeen	O
renal	renal	O
patients	patients	O
received	received	O
azathioprine	azathioprine	B-Chemical
(	(	O
Aza	aza	O
)	)	O
and	and	O
prednisone	prednisone	B-Chemical
as	as	O
part	part	O
of	of	O
a	a	O
randomized	randomized	O
trial	trial	O
of	of	O
immunosuppression	immunosuppression	O
with	with	O
21	21	O
cyclosporine-and-prednisone-treated	cyclosporine-and-prednisone-treated	O
renal	renal	O
transplant	transplant	O
patients	patients	O
.	.	O

All	all	O
others	others	O
received	received	O
cyclosporine	cyclosporine	B-Chemical
and	and	O
prednisone	prednisone	B-Chemical
.	.	O

The	the	O
randomized	randomized	O
Aza	aza	O
patients	patients	O
had	had	O
more	more	O
overall	overall	O
infections	infections	B-Disease
(	(	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
and	and	O
more	more	O
nonviral	nonviral	O
infections	infections	B-Disease
(	(	O
P	p	O
less	less	O
than	than	O
0.02	0.02	O
)	)	O
than	than	O
the	the	O
randomized	randomized	O
cyclosporine	cyclosporine	B-Chemical
patients	patients	O
.	.	O

Heart	heart	O
and	and	O
liver	liver	O
patients	patients	O
had	had	O
more	more	O
infections	infections	B-Disease
than	than	O
cyclosporine	cyclosporine	B-Chemical
renal	renal	O
patients	patients	O
but	but	O
fewer	fewer	O
infections	infections	B-Disease
than	than	O
the	the	O
Aza	aza	O
renal	renal	O
patients	patients	O
.	.	O

There	there	O
were	were	O
no	no	O
infectious	infectious	O
deaths	deaths	B-Disease
in	in	O
renal	renal	O
transplant	transplant	O
patients	patients	O
on	on	O
cyclosporine	cyclosporine	B-Chemical
or	or	O
Aza	aza	O
,	,	O
but	but	O
infection	infection	B-Disease
played	played	O
a	a	O
major	major	O
role	role	O
in	in	O
3	3	O
out	out	O
of	of	O
6	6	O
cardiac	cardiac	O
transplant	transplant	O
deaths	deaths	B-Disease
and	and	O
in	in	O
8	8	O
out	out	O
of	of	O
9	9	O
liver	liver	O
transplant	transplant	O
deaths	deaths	B-Disease
.	.	O

Renal	renal	O
patients	patients	O
on	on	O
cyclosporine	cyclosporine	B-Chemical
had	had	O
the	the	O
fewest	fewest	O
bacteremias	bacteremias	O
.	.	O

Analysis	analysis	O
of	of	O
site	site	O
of	of	O
infection	infection	B-Disease
showed	showed	O
a	a	O
preponderance	preponderance	O
of	of	O
abdominal	abdominal	O
infections	infections	B-Disease
in	in	O
liver	liver	O
patients	patients	O
,	,	O
intrathoracic	intrathoracic	O
infections	infections	B-Disease
in	in	O
heart	heart	O
patients	patients	O
,	,	O
and	and	O
urinary	urinary	B-Disease
tract	tract	I-Disease
infections	infections	B-Disease
in	in	O
renal	renal	O
patients	patients	O
.	.	O

Pulmonary	pulmonary	O
infections	infections	B-Disease
were	were	O
less	less	O
common	common	O
in	in	O
cyclosporine-treated	cyclosporine-treated	O
renal	renal	O
patients	patients	O
than	than	O
in	in	O
Aza-treated	aza-treated	O
patients	patients	O
(	(	O
P	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
.	.	O

Aza	aza	O
patients	patients	O
had	had	O
significantly	significantly	O
more	more	O
staphylococcal	staphylococcal	B-Disease
infections	infections	B-Disease
than	than	O
all	all	O
other	other	O
transplant	transplant	O
groups	groups	O
(	(	O
P	p	O
less	less	O
than	than	O
0.005	0.005	O
)	)	O
,	,	O
and	and	O
systemic	systemic	O
fungal	fungal	O
infections	infections	B-Disease
occurred	occurred	O
only	only	O
in	in	O
the	the	O
liver	liver	O
transplant	transplant	O
group	group	O
.	.	O

Cytomegalovirus	cytomegalovirus	O
(	(	O
CMV	cmv	O
)	)	O
shedding	shedding	O
or	or	O
serological	serological	O
rises	rises	O
in	in	O
antibody	antibody	O
titer	titer	O
,	,	O
or	or	O
both	both	O
occurred	occurred	O
in	in	O
78	78	O
%	%	O
of	of	O
cyclosporine	cyclosporine	B-Chemical
patients	patients	O
and	and	O
76	76	O
%	%	O
of	of	O
Aza	aza	O
patients	patients	O
.	.	O

Of	of	O
the	the	O
cyclosporine	cyclosporine	B-Chemical
patients	patients	O
,	,	O
15	15	O
%	%	O
had	had	O
symptoms	symptoms	O
related	related	O
to	to	O
CMV	cmv	O
infection	infection	B-Disease
.	.	O

Serological	serological	O
evidence	evidence	O
for	for	O
Epstein	epstein	O
Barr	barr	O
Virus	virus	O
infection	infection	B-Disease
was	was	O
found	found	O
in	in	O
20	20	O
%	%	O
of	of	O
65	65	O
cyclosporine	cyclosporine	B-Chemical
patients	patients	O
studied	studied	O
.	.	O

Three	three	O
had	had	O
associated	associated	O
symptoms	symptoms	O
,	,	O
and	and	O
one	one	O
developed	developed	O
a	a	O
lymphoma	lymphoma	O
.	.	O

Structure-activity	structure-activity	O
and	and	O
dose-effect	dose-effect	O
relationships	relationships	O
of	of	O
the	the	O
antagonism	antagonism	O
of	of	O
picrotoxin-induced	picrotoxin-induced	O
seizures	seizures	B-Disease
by	by	O
cholecystokinin	cholecystokinin	O
,	,	O
fragments	fragments	O
and	and	O
analogues	analogues	O
of	of	O
cholecystokinin	cholecystokinin	O
in	in	O
mice	mice	O
.	.	O

Intraperitoneal	intraperitoneal	O
administration	administration	O
of	of	O
cholecystokinin	cholecystokinin	O
octapeptide	octapeptide	O
sulphate	sulphate	O
ester	ester	O
(	(	O
CCK-8-SE	cck-8-se	O
)	)	O
and	and	O
nonsulphated	nonsulphated	O
cholecystokinin	cholecystokinin	O
octapeptide	octapeptide	O
(	(	O
CCK-8-NS	cck-8-ns	O
)	)	O
enhanced	enhanced	O
the	the	O
latency	latency	O
of	of	O
seizures	seizures	B-Disease
induced	induced	O
by	by	O
picrotoxin	picrotoxin	B-Chemical
in	in	O
mice	mice	O
.	.	O

Experiments	experiments	O
with	with	O
N-	n-	O
and	and	O
C-terminal	c-terminal	O
fragments	fragments	O
revealed	revealed	O
that	that	O
the	the	O
C-terminal	c-terminal	O
tetrapeptide	tetrapeptide	O
(	(	O
CCK-5	cck-5	O
-	-	O
8)	8)	O
was	was	O
the	the	O
active	active	O
centre	centre	O
of	of	O
the	the	O
CCK	cck	O
octapeptide	octapeptide	O
molecule	molecule	O
.	.	O

The	the	O
analogues	analogues	O
CCK-8-SE	cck-8-se	O
and	and	O
CCK-8-NS	cck-8-ns	O
(	(	O
dose	dose	O
range	range	O
0.2	0.2	O
-	-	O
6.4	6.4	O
mumol/kg	mumol/kg	O
)	)	O
and	and	O
caerulein	caerulein	O
dose	dose	O
range	range	O
0.1	0.1	O
-	-	O
0.8	0.8	O
mumol/kg	mumol/kg	O
)	)	O
showed	showed	O
bell-shaped	bell-shaped	O
dose-effect	dose-effect	O
curves	curves	O
,	,	O
with	with	O
the	the	O
greatest	greatest	O
maximum	maximum	O
inhibition	inhibition	O
for	for	O
CCK-8-NS	cck-8-ns	O
.	.	O

The	the	O
peptide	peptide	O
CCK-5	cck-5	O
-	-	O
8	8	O
had	had	O
weak	weak	O
anticonvulsant	anticonvulsant	O
activity	activity	O
in	in	O
comparison	comparison	O
to	to	O
the	the	O
octapeptides	octapeptides	O
,	,	O
3.2	3.2	O
mumol/kg	mumol/kg	O
and	and	O
larger	larger	O
doses	doses	O
of	of	O
the	the	O
reference	reference	O
drug	drug	O
,	,	O
diazepam	diazepam	B-Chemical
,	,	O
totally	totally	O
prevented	prevented	O
picrotoxin-induced	picrotoxin-induced	O
seizures	seizures	B-Disease
and	and	O
mortality	mortality	O
.	.	O

The	the	O
maximum	maximum	O
effect	effect	O
of	of	O
the	the	O
peptides	peptides	O
tested	tested	O
was	was	O
less	less	O
than	than	O
that	that	O
of	of	O
diazepam	diazepam	B-Chemical
.	.	O

Experiments	experiments	O
with	with	O
analogues	analogues	O
and	and	O
derivatives	derivatives	O
of	of	O
CCK-5	cck-5	O
-	-	O
8	8	O
demonstrated	demonstrated	O
that	that	O
the	the	O
effectiveness	effectiveness	O
of	of	O
the	the	O
beta-alanyl	beta-alanyl	O
derivatives	derivatives	O
of	of	O
CCK-5	cck-5	O
-	-	O
8	8	O
were	were	O
enhanced	enhanced	O
and	and	O
that	that	O
they	they	O
were	were	O
equipotent	equipotent	O
with	with	O
CCK-8-SE	cck-8-se	O
.	.	O

Of	of	O
the	the	O
CCK-2	cck-2	O
-	-	O
8	8	O
analogues	analogues	O
,	,	O
Ser(SO3H)7-Ac-CCK-2	ser(so3h)7-ac-cck-2	O
-	-	O
8-SE	8-se	O
and	and	O
Thr(SO3H)7-Ac-CCK-2	thr(so3h)7-ac-cck-2	O
-	-	O
8-SE	8-se	O
and	and	O
Hyp(SO3H)-Ac-CCK-2	hyp(so3h)-ac-cck-2	O
-	-	O
8-SE	8-se	O
were	were	O
slightly	slightly	O
more	more	O
active	active	O
than	than	O
CCK-8-SE	cck-8-se	O
.	.	O

Vasopressin	vasopressin	B-Chemical
as	as	O
a	a	O
possible	possible	O
contributor	contributor	O
to	to	O
hypertension	hypertension	B-Disease
.	.	O

The	the	O
role	role	O
of	of	O
vasopressin	vasopressin	B-Chemical
as	as	O
a	a	O
pressor	pressor	O
agent	agent	O
to	to	O
the	the	O
hypertensive	hypertensive	B-Disease
process	process	O
was	was	O
examined	examined	O
.	.	O

Vasopressin	vasopressin	B-Chemical
plays	plays	O
a	a	O
major	major	O
role	role	O
in	in	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
DOCA-salt	doca-salt	O
hypertension	hypertension	B-Disease
,	,	O
since	since	O
the	the	O
elevation	elevation	O
of	of	O
blood	blood	O
pressure	pressure	O
was	was	O
not	not	O
substantial	substantial	O
in	in	O
the	the	O
rats	rats	O
with	with	O
lithium-treated	lithium-treated	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
after	after	O
DOCA-salt	doca-salt	O
treatment	treatment	O
.	.	O

Administration	administration	O
of	of	O
DDAVP	ddavp	O
which	which	O
has	has	O
antidiuretic	antidiuretic	O
action	action	O
but	but	O
minimal	minimal	O
vasopressor	vasopressor	O
effect	effect	O
failed	failed	O
to	to	O
increase	increase	O
blood	blood	O
pressure	pressure	O
to	to	O
the	the	O
levels	levels	O
observed	observed	O
after	after	O
administration	administration	O
of	of	O
AVP	avp	B-Chemical
.	.	O

Furthermore	furthermore	O
,	,	O
the	the	O
pressor	pressor	O
action	action	O
of	of	O
vasopressin	vasopressin	B-Chemical
appears	appears	O
to	to	O
be	be	O
important	important	O
in	in	O
the	the	O
development	development	O
of	of	O
this	this	O
model	model	O
of	of	O
hypertension	hypertension	B-Disease
,	,	O
since	since	O
the	the	O
enhanced	enhanced	O
pressor	pressor	O
responsiveness	responsiveness	O
to	to	O
the	the	O
hormone	hormone	O
was	was	O
observed	observed	O
in	in	O
the	the	O
initial	initial	O
stage	stage	O
of	of	O
hypertension	hypertension	B-Disease
.	.	O

Increased	increased	O
secretion	secretion	O
of	of	O
vasopressin	vasopressin	B-Chemical
from	from	O
neurohypophysis	neurohypophysis	O
also	also	O
promotes	promotes	O
the	the	O
function	function	O
of	of	O
the	the	O
hormone	hormone	O
as	as	O
a	a	O
pathogenetic	pathogenetic	O
factor	factor	O
in	in	O
hypertension	hypertension	B-Disease
.	.	O

An	an	O
unproportional	unproportional	O
release	release	O
of	of	O
vasopressin	vasopressin	B-Chemical
compared	compared	O
to	to	O
plasma	plasma	O
osmolality	osmolality	O

may	may	O
be	be	O
induced	induced	O
by	by	O
the	the	O
absence	absence	O
of	of	O
an	an	O
adjusting	adjusting	O
control	control	O
of	of	O
angiotensin	angiotensin	B-Chemical
II	ii	I-Chemical
forming	forming	O
and	and	O
receptor	receptor	O
binding	binding	O
capacity	capacity	O
for	for	O
sodium	sodium	B-Chemical
balance	balance	O
in	in	O
the	the	O
brain	brain	O
.	.	O

However	however	O
,	,	O
the	the	O
role	role	O
of	of	O
vasopressin	vasopressin	B-Chemical
remains	remains	O
to	to	O
be	be	O
determined	determined	O
in	in	O
human	human	O
essential	essential	B-Disease
hypertension	hypertension	B-Disease
.	.	O

Toxic	toxic	O
hepatitis	hepatitis	B-Disease
induced	induced	O
by	by	O
disulfiram	disulfiram	B-Chemical
in	in	O
a	a	O
non-alcoholic	non-alcoholic	O
.	.	O

A	a	O
reversible	reversible	O
toxic	toxic	O
liver	liver	B-Disease
damage	damage	I-Disease
was	was	O
observed	observed	O
in	in	O
a	a	O
non-alcoholic	non-alcoholic	O
woman	woman	O
treated	treated	O
with	with	O
disulfiram	disulfiram	B-Chemical
.	.	O

The	the	O
causative	causative	O
relationship	relationship	O
was	was	O
proven	proven	O
by	by	O
challenge	challenge	O
.	.	O

Atrial	atrial	O
thrombosis	thrombosis	B-Disease
involving	involving	O
the	the	O
heart	heart	O
of	of	O
F-344	f-344	O
rats	rats	O
ingesting	ingesting	O
quinacrine	quinacrine	O
hydrochloride	hydrochloride	O
.	.	O

Quinacrine	quinacrine	O
hydrochloride	hydrochloride	O
is	is	O
toxic	toxic	O
for	for	O
the	the	O
heart	heart	O
of	of	O
F-344	f-344	O
rats	rats	O
.	.	O

Rats	rats	O
treated	treated	O
with	with	O
500	500	O
ppm	ppm	O
quinacrine	quinacrine	O
hydrochloride	hydrochloride	O
in	in	O
the	the	O
diet	diet	O
all	all	O
developed	developed	O
a	a	O
high	high	O
incidence	incidence	O
of	of	O
left	left	O
atrial	atrial	O
thrombosis	thrombosis	B-Disease
.	.	O

The	the	O
lesion	lesion	O
was	was	O
associated	associated	O
with	with	O
cardiac	cardiac	B-Disease
hypertrophy	hypertrophy	B-Disease
and	and	O
dilatation	dilatation	O
and	and	O
focal	focal	O
myocardial	myocardial	O
degeneration	degeneration	O
.	.	O

Rats	rats	O
died	died	O
from	from	O
cardiac	cardiac	B-Disease
hypertrophy	hypertrophy	B-Disease
with	with	O
severe	severe	O
acute	acute	O
and	and	O
chronic	chronic	O
congestion	congestion	O
of	of	O
the	the	O
lungs	lungs	O
,	,	O
liver	liver	O
,	,	O
and	and	O
other	other	O
organs	organs	O
.	.	O

Seventy	seventy	O
percent	percent	O
of	of	O
rats	rats	O
given	given	O
250	250	O
ppm	ppm	O
quinacrine	quinacrine	O
hydrochloride	hydrochloride	O
and	and	O
1,000	1,000	O
ppm	ppm	O
sodium	sodium	B-Chemical
nitrite	nitrite	I-Chemical
simultaneously	simultaneously	O
in	in	O
the	the	O
diet	diet	O
had	had	O
thrombosis	thrombosis	B-Disease
of	of	O
the	the	O
atria	atria	O
of	of	O
the	the	O
heart	heart	O
,	,	O
while	while	O
untreated	untreated	O
control	control	O
rats	rats	O
in	in	O
this	this	O
laboratory	laboratory	O
did	did	O
not	not	O
have	have	O
atrial	atrial	O
thrombosis	thrombosis	B-Disease
.	.	O

Sodium	sodium	B-Chemical
nitrite	nitrite	I-Chemical
in	in	O
combination	combination	O
with	with	O
quinacrine	quinacrine	O
hydrochloride	hydrochloride	O
appeared	appeared	O
to	to	O
have	have	O
no	no	O
additional	additional	O
effect	effect	O
.	.	O

Alternating	alternating	O
sinus	sinus	O
rhythm	rhythm	O
and	and	O
intermittent	intermittent	O
sinoatrial	sinoatrial	B-Disease
block	block	I-Disease
induced	induced	O
by	by	O
propranolol	propranolol	B-Chemical
.	.	O

Alternating	alternating	O
sinus	sinus	O
rhythm	rhythm	O
and	and	O
intermittent	intermittent	O
sinoatrial	sinoatrial	O
(	(	O
S-A	s-a	O
)	)	O
block	block	O
was	was	O
observed	observed	O
in	in	O
a	a	O
57-year-old	57-year-old	O
woman	woman	O
,	,	O
under	under	O
treatment	treatment	O
for	for	O
angina	angina	O
with	with	O
80	80	O
mg	mg	O
propranolol	propranolol	B-Chemical
daily	daily	O
.	.	O

The	the	O
electrocardiogram	electrocardiogram	O
showed	showed	O
alternation	alternation	O
of	of	O
long	long	O
and	and	O
short	short	O
P-P	p-p	O
intervals	intervals	O
and	and	O
occasional	occasional	O
pauses	pauses	O
.	.	O

These	these	O
pauses	pauses	O
were	were	O
always	always	O
preceded	preceded	O
by	by	O
the	the	O
short	short	O
P-P	p-p	O
intervals	intervals	O
and	and	O
were	were	O
usually	usually	O
followed	followed	O
by	by	O
one	one	O
or	or	O
two	two	O
P-P	p-p	O
intervals	intervals	O
of	of	O
0.92	0.92	O
-	-	O
0.95	0.95	O
s	s	O
representing	representing	O
the	the	O
basic	basic	O
sinus	sinus	O
cycle	cycle	O
.	.	O

Following	following	O
these	these	O
basic	basic	O
sinus	sinus	O
cycles	cycles	O
,	,	O
alternating	alternating	O
rhythm	rhythm	O
started	started	O
with	with	O
the	the	O
longer	longer	O
P-P	p-p	O
interval	interval	O
.	.	O

The	the	O
long	long	O
P-P	p-p	O
intervals	intervals	O
ranged	ranged	O
between	between	O
1.04	1.04	O
-	-	O
1.12	1.12	O
s	s	O
and	and	O
the	the	O
short	short	O
P-P	p-p	O
intervals	intervals	O
between	between	O
0.80	0.80	O
-	-	O
0.84	0.84	O
s	s	O
,	,	O
respectively	respectively	O
.	.	O

The	the	O
duration	duration	O
of	of	O
the	the	O
pauses	pauses	O
were	were	O
equal	equal	O
or	or	O
almost	almost	O
equal	equal	O
to	to	O
one	one	O
short	short	O
plus	plus	O
one	one	O
long	long	O
P-P	p-p	O
interval	interval	O
or	or	O
to	to	O
twice	twice	O
the	the	O
basic	basic	O
sinus	sinus	O
cycle	cycle	O
.	.	O

In	in	O
one	one	O
recording	recording	O
a	a	O
short	short	O
period	period	O
of	of	O
regular	regular	O
sinus	sinus	O
rhythm	rhythm	O
with	with	O
intermittent	intermittent	O
2/1	2/1	O
S-A	s-a	O
block	block	O
was	was	O
observed	observed	O
.	.	O

This	this	O
short	short	O
period	period	O
of	of	O
sinus	sinus	O
rhythm	rhythm	O
was	was	O
interrupted	interrupted	O
by	by	O
sudden	sudden	O
prolongation	prolongation	O
of	of	O
the	the	O
P-P	p-p	O
interval	interval	O
starting	starting	O
the	the	O
alternative	alternative	O
rhythm	rhythm	O
.	.	O

There	there	O
were	were	O
small	small	O
changes	changes	O
in	in	O
the	the	O
shape	shape	O
of	of	O
the	the	O
P	p	O
waves	waves	O
and	and	O
P-R	p-r	O
intervals	intervals	O
.	.	O

S-A	s-a	O
conduction	conduction	O
through	through	O
two	two	O
pathways	pathways	O
,	,	O
the	the	O
first	first	O
with	with	O
2/1	2/1	O
block	block	O
the	the	O
second	second	O
having	having	O
0.12	0.12	O
-	-	O
0.14	0.14	O
s	s	O
longer	longer	O
conduction	conduction	O
time	time	O
and	and	O
with	with	O
occasional	occasional	O
2/1	2/1	O
block	block	O
was	was	O
proposed	proposed	O
for	for	O
the	the	O
explanation	explanation	O
of	of	O
the	the	O
alternating	alternating	O
P-P	p-p	O
interval	interval	O
and	and	O
other	other	O
electrocardiographic	electrocardiographic	O
features	features	O
seen	seen	O
.	.	O

Atropine	atropine	B-Chemical
1	1	O
mg	mg	O
given	given	O
intravenously	intravenously	O
resulted	resulted	O
in	in	O
shortening	shortening	O
of	of	O
all	all	O
P-P	p-p	O
intervals	intervals	O
without	without	O
changing	changing	O
the	the	O
rhythm	rhythm	O
.	.	O

The	the	O
abnormal	abnormal	O
rhythm	rhythm	O
disappeared	disappeared	O
with	with	O
the	the	O
withdrawal	withdrawal	O
of	of	O
propranolol	propranolol	B-Chemical
and	and	O
when	when	O
the	the	O
drug	drug	O
was	was	O
restarted	restarted	O
a	a	O
2/1	2/1	O
S-A	s-a	O
block	block	O
was	was	O
seen	seen	O
.	.	O

This	this	O
was	was	O
accepted	accepted	O
as	as	O
evidence	evidence	O
for	for	O
propranolol	propranolol	B-Chemical
being	being	O
the	the	O
cause	cause	O
of	of	O
this	this	O
conduction	conduction	O
disorder	disorder	O
.	.	O

Antitumor	antitumor	O
effect	effect	O
,	,	O
cardiotoxicity	cardiotoxicity	B-Disease
,	,	O
and	and	O
nephrotoxicity	nephrotoxicity	B-Disease
of	of	O
doxorubicin	doxorubicin	B-Chemical
in	in	O
the	the	O
IgM	igm	O
solid	solid	O
immunocytoma-bearing	immunocytoma-bearing	O
LOU/M/WSL	lou/m/wsl	O
rat	rat	O
.	.	O

Antitumor	antitumor	O
activity	activity	O
,	,	O
cardiotoxicity	cardiotoxicity	B-Disease
,	,	O
and	and	O
nephrotoxicity	nephrotoxicity	B-Disease
induced	induced	O
by	by	O
doxorubicin	doxorubicin	B-Chemical
were	were	O
studied	studied	O
in	in	O
LOU/M/WSL	lou/m/wsl	O
inbred	inbred	O
rats	rats	O
each	each	O
bearing	bearing	O
a	a	O
transplantable	transplantable	O
solid	solid	O
IgM	igm	O
immunocytoma	immunocytoma	O
.	.	O

Animals	animals	O
with	with	O
a	a	O
tumor	tumor	B-Disease
(	(	O
diameter	diameter	O
,	,	O
15.8	15.8	O
+	+	O
/-	/-	O
3.3	3.3	O
mm	mm	O
)	)	O
were	were	O
treated	treated	O
with	with	O
iv	iv	O
injections	injections	O
of	of	O
doxorubicin	doxorubicin	B-Chemical
on	on	O
5	5	O
consecutive	consecutive	O
days	days	O
,	,	O
followed	followed	O
by	by	O
1	1	O
weekly	weekly	O
injection	injection	O
for	for	O
7	7	O
weeks	weeks	O
(	(	O
dose	dose	O
range	range	O
,	,	O
0.015	0.015	O
-	-	O
4.0	4.0	O
mg/kg	mg/kg	O
body	body	O
wt	wt	O
)	)	O
.	.	O

Tumor	tumor	B-Disease
regression	regression	O
was	was	O
observed	observed	O
with	with	O
0.5	0.5	O
mg	mg	O
doxorubicin/kg	doxorubicin/kg	O
.	.	O

Complete	complete	O
disappearance	disappearance	O
of	of	O
the	the	O
tumor	tumor	B-Disease
was	was	O
induced	induced	O
with	with	O
1.0	1.0	O
mg	mg	O
doxorubicin/kg	doxorubicin/kg	O
.	.	O

Histologic	histologic	O
evidence	evidence	O
of	of	O
cardiotoxicity	cardiotoxicity	B-Disease
scored	scored	O
as	as	O
grade	grade	O
III	iii	O
was	was	O
only	only	O
observed	observed	O
at	at	O
a	a	O
dose	dose	O
of	of	O
1.0	1.0	O
mg	mg	O
doxorubicin/kg	doxorubicin/kg	O
.	.	O

Light	light	O
microscopic	microscopic	O
evidence	evidence	O
of	of	O
renal	renal	B-Disease
damage	damage	I-Disease
was	was	O
seen	seen	O
above	above	O
a	a	O
dose	dose	O
of	of	O
0.5	0.5	O
mg	mg	O
doxorubicin/kg	doxorubicin/kg	O
,	,	O
which	which	O
resulted	resulted	O
in	in	O
albuminuria	albuminuria	B-Disease
and	and	O
very	very	O
low	low	O
serum	serum	B-Chemical
albumin	albumin	I-Chemical
levels	levels	O
.	.	O

In	in	O
the	the	O
group	group	O
that	that	O
received	received	O
1.0	1.0	O
mg	mg	O
doxorubicin/kg	doxorubicin/kg	O
,	,	O
the	the	O
serum	serum	B-Chemical
albumin	albumin	I-Chemical
level	level	O
decreased	decreased	O
from	from	O
33.6	33.6	O
+	+	O
/-	/-	O
4.1	4.1	O
to	to	O
1.5	1.5	O
+	+	O
/-	/-	O
0.5	0.5	O
g/liter	g/liter	O
.	.	O
Ascites	ascites	B-Disease
and	and	O
hydrothorax	hydrothorax	O
were	were	O
observed	observed	O
simultaneously	simultaneously	O
.	.	O

The	the	O
same	same	O
experiments	experiments	O
were	were	O
performed	performed	O
with	with	O
non-tumor-bearing	non-tumor-bearing	O
rats	rats	O
,	,	O
in	in	O
which	which	O
no	no	O
major	major	O
differences	differences	O
were	were	O
observed	observed	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
antitumor	antitumor	O
activity	activity	O
,	,	O
cardiotoxicity	cardiotoxicity	B-Disease
,	,	O
and	and	O
nephrotoxicity	nephrotoxicity	B-Disease
were	were	O
studied	studied	O
simultaneously	simultaneously	O
in	in	O
the	the	O
same	same	O
LOU/M/WSL	lou/m/wsl	O
rat	rat	O
.	.	O

Albuminuria	albuminuria	B-Disease
due	due	O
to	to	O
renal	renal	B-Disease
damage	damage	I-Disease
led	led	O
to	to	O
extremely	extremely	O
low	low	O
serum	serum	B-Chemical
albumin	albumin	I-Chemical
levels	levels	O
,	,	O
so	so	O
ascites	ascites	B-Disease
and	and	O
hydrothorax	hydrothorax	O
were	were	O
not	not	O
necessarily	necessarily	O
a	a	O
consequence	consequence	O
of	of	O
the	the	O
observed	observed	O
cardiomyopathy	cardiomyopathy	B-Disease
.	.	O

Intraoperative	intraoperative	O
bradycardia	bradycardia	B-Disease
and	and	O
hypotension	hypotension	B-Disease
associated	associated	O
with	with	O
timolol	timolol	B-Chemical
and	and	O
pilocarpine	pilocarpine	B-Chemical
eye	eye	O
drops	drops	O
.	.	O

A	a	O
69-yr-old	69-yr-old	O
man	man	O
,	,	O
who	who	O
was	was	O
concurrently	concurrently	O
being	being	O
treated	treated	O
with	with	O
pilocarpine	pilocarpine	B-Chemical
nitrate	nitrate	O
and	and	O
timolol	timolol	B-Chemical
maleate	maleate	O
eye	eye	O
drops	drops	O
,	,	O
developed	developed	O
a	a	O
bradycardia	bradycardia	B-Disease
and	and	O
became	became	O
hypotensive	hypotensive	B-Disease
during	during	O
halothane	halothane	B-Chemical
anaesthesia	anaesthesia	O
.	.	O

Both	both	O
timolol	timolol	B-Chemical
and	and	O
pilocarpine	pilocarpine	B-Chemical
were	were	O
subsequently	subsequently	O
identified	identified	O
in	in	O
a	a	O
24-h	24-h	O
collection	collection	O
of	of	O
urine	urine	O
.	.	O

Timolol	timolol	B-Chemical
(	(	O
but	but	O
not	not	O
pilocarpine	pilocarpine	B-Chemical
)	)	O
was	was	O
detected	detected	O
in	in	O
a	a	O
sample	sample	O
of	of	O
plasma	plasma	O
removed	removed	O
during	during	O
surgery	surgery	O
;	;	O
the	the	O
plasma	plasma	O
concentration	concentration	O
of	of	O
timolol	timolol	B-Chemical
(	(	O
2.6	2.6	O
ng	ng	O
ml-1	ml-1	O
)	)	O
was	was	O
consistent	consistent	O
with	with	O
partial	partial	O
beta-adrenoceptor	beta-adrenoceptor	O
blockade	blockade	O
.	.	O

It	it	O
is	is	O
postulated	postulated	O
that	that	O
this	this	O
action	action	O
may	may	O
have	have	O
been	been	O
enhanced	enhanced	O
during	during	O
halothane	halothane	B-Chemical
anaesthesia	anaesthesia	O
with	with	O
resultant	resultant	O
bradycardia	bradycardia	B-Disease
and	and	O
hypotension	hypotension	B-Disease
.	.	O

Pilocarpine	pilocarpine	B-Chemical
may	may	O
have	have	O
had	had	O
a	a	O
contributory	contributory	O
effect	effect	O
.	.	O

Succinylcholine	succinylcholine	B-Chemical
apnoea	apnoea	B-Disease
:	:	O
attempted	attempted	O
reversal	reversal	O
with	with	O
anticholinesterases	anticholinesterases	B-Chemical
.	.	O

Anticholinesterases	anticholinesterases	B-Chemical
were	were	O
administered	administered	O
in	in	O
an	an	O
attempt	attempt	O
to	to	O
antagonize	antagonize	O
prolonged	prolonged	O
neuromuscular	neuromuscular	O
blockade	blockade	O
following	following	O
the	the	O
administration	administration	O
of	of	O
succinylcholine	succinylcholine	B-Chemical
in	in	O
a	a	O
patient	patient	O
later	later	O
found	found	O
to	to	O
be	be	O
homozygous	homozygous	O
for	for	O
atypical	atypical	O
plasma	plasma	O
cholinesterase	cholinesterase	O
.	.	O

Edrophonium	edrophonium	O
10	10	O
mg	mg	O
,	,	O
given	given	O
74	74	O
min	min	O
after	after	O
succinylcholine	succinylcholine	B-Chemical
,	,	O
when	when	O
train-of-four	train-of-four	O
stimulation	stimulation	O
was	was	O
characteristic	characteristic	O
of	of	O
phase	phase	O
II	ii	O
block	block	O
,	,	O
produced	produced	O
partial	partial	O
antagonism	antagonism	O
which	which	O
was	was	O
not	not	O
sustained	sustained	O
.	.	O

Repeated	repeated	O
doses	doses	O
of	of	O
edrophonium	edrophonium	O
to	to	O
70	70	O
mg	mg	O
and	and	O
neostigmine	neostigmine	O
to	to	O
2.5	2.5	O
mg	mg	O
did	did	O
not	not	O
antagonize	antagonize	O
or	or	O
augment	augment	O
the	the	O
block	block	O
.	.	O

Spontaneous	spontaneous	O
respiration	respiration	O
recommenced	recommenced	O
200	200	O
min	min	O
after	after	O
succinylcholine	succinylcholine	B-Chemical
administration	administration	O
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
anticholinesterases	anticholinesterases	B-Chemical
are	are	O
only	only	O
partially	partially	O
effective	effective	O
in	in	O
restoring	restoring	O
neuromuscular	neuromuscular	O
function	function	O
in	in	O
succinylcholine	succinylcholine	B-Chemical
apnoea	apnoea	B-Disease
despite	despite	O
muscle	muscle	O
twitch	twitch	O
activity	activity	O
typical	typical	O
of	of	O
phase	phase	O
II	ii	O
block	block	O
.	.	O

Effect	effect	O
of	of	O
doxorubicin	doxorubicin	B-Chemical
on	on	O
[omega-I-131]heptadecanoic	[omega-i-131]heptadecanoic	O
acid	acid	O
myocardial	myocardial	O
scintigraphy	scintigraphy	O
and	and	O
echocardiography	echocardiography	O
in	in	O
dogs	dogs	O
.	.	O

The	the	O
effects	effects	O
of	of	O
serial	serial	O
treatment	treatment	O
with	with	O
doxorubicin	doxorubicin	B-Chemical
on	on	O
dynamic	dynamic	O
myocardial	myocardial	O
scintigraphy	scintigraphy	O
with	with	O
[omega-I-131]heptadecanoic	[omega-i-131]heptadecanoic	O
acid	acid	O
(	(	O
I-131	i-131	O
HA	ha	O
)	)	O
,	,	O
and	and	O
on	on	O
global	global	O
left-ventricular	left-ventricular	O
function	function	O
determined	determined	O
echocardiographically	echocardiographically	O
,	,	O
were	were	O
studied	studied	O
in	in	O
a	a	O
group	group	O
of	of	O
nine	nine	O
mongrel	mongrel	O
dogs	dogs	O
.	.	O

Total	total	O
extractable	extractable	O
myocardial	myocardial	O
lipid	lipid	O
was	was	O
compared	compared	O
postmortem	postmortem	O
between	between	O
a	a	O
group	group	O
of	of	O
control	control	O
dogs	dogs	O
and	and	O
doxorubicin-treated	doxorubicin-treated	O
dogs	dogs	O
.	.	O

A	a	O
significant	significant	O
and	and	O
then	then	O
progressive	progressive	O
fall	fall	O
in	in	O
global	global	O
LV	lv	O
function	function	O
was	was	O
observed	observed	O
at	at	O
a	a	O
cumulative	cumulative	O
doxorubicin	doxorubicin	B-Chemical
dose	dose	O
of	of	O
4	4	O
mg/kg	mg/kg	O
.	.	O

A	a	O
significant	significant	O
increase	increase	O
in	in	O
the	the	O
myocardial	myocardial	O
t1/2	t1/2	O
of	of	O
the	the	O
I-131	i-131	O
HA	ha	O
was	was	O
observed	observed	O
only	only	O
at	at	O
a	a	O
higher	higher	O
cumulative	cumulative	O
dose	dose	O
,	,	O
10	10	O
mg/kg	mg/kg	O
.	.	O

No	no	O
significant	significant	O
alteration	alteration	O
in	in	O
total	total	O
extractable	extractable	O
myocardial	myocardial	O
lipids	lipids	O
was	was	O
observed	observed	O
between	between	O
control	control	O
dogs	dogs	O
and	and	O
those	those	O
treated	treated	O
with	with	O
doxorubicin	doxorubicin	B-Chemical
.	.	O

Our	our	O
findings	findings	O
suggest	suggest	O
that	that	O
the	the	O
changes	changes	O
leading	leading	O
to	to	O
an	an	O
alteration	alteration	O
of	of	O
myocardial	myocardial	O
dynamic	dynamic	O
imaging	imaging	O
with	with	O
I-131	i-131	O
HA	ha	O
are	are	O
not	not	O
the	the	O
initiating	initiating	O
factor	factor	O
in	in	O
doxorubicin	doxorubicin	B-Chemical
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

Hemodynamics	hemodynamics	O
and	and	O
myocardial	myocardial	O
metabolism	metabolism	O
under	under	O
deliberate	deliberate	O
hypotension	hypotension	B-Disease
.	.	O

An	an	O
experimental	experimental	O
study	study	O
in	in	O
dogs	dogs	O
.	.	O

Coronary	coronary	O
blood	blood	O
flow	flow	O
,	,	O
cardiac	cardiac	O
work	work	O
and	and	O
metabolism	metabolism	O
were	were	O
studied	studied	O
in	in	O
dogs	dogs	O
under	under	O
sodium	sodium	B-Chemical
nitroprusside	nitroprusside	B-Chemical
(	(	O
SNP	snp	B-Chemical
)	)	O
and	and	O
trimetaphan	trimetaphan	O
(	(	O
TMP	tmp	B-Chemical
)	)	O
deliberate	deliberate	O
hypotension	hypotension	B-Disease
(	(	O
20	20	O
%	%	O
and	and	O
40	40	O
%	%	O
mean	mean	O
pressure	pressure	O
decrease	decrease	O
from	from	O
baseline	baseline	O
)	)	O
.	.	O

Regarding	regarding	O
the	the	O
effects	effects	O
of	of	O
drug-induced	drug-induced	O
hypotension	hypotension	B-Disease
on	on	O
coronary	coronary	O
blood	blood	O
flow	flow	O
,	,	O
aortic	aortic	O
and	and	O
coronary	coronary	O
sinus	sinus	O
metabolic	metabolic	O
data	data	O
(	(	O
pH	ph	O
,	,	O
pO2	po2	O
,	,	O
pCO2	pco2	O
)	)	O
we	we	O
could	could	O
confirm	confirm	O
that	that	O
nitroprusside	nitroprusside	B-Chemical
hypotension	hypotension	B-Disease
could	could	O
be	be	O
safely	safely	O
used	used	O
to	to	O
30	30	O
%	%	O
mean	mean	O
blood	blood	O
pressure	pressure	O
decrease	decrease	O
from	from	O
control	control	O
,	,	O
trimetaphan	trimetaphan	O
hypotension	hypotension	B-Disease
to	to	O
20	20	O
%	%	O
mean	mean	O
blood	blood	O
pressure	pressure	O
decrease	decrease	O
.	.	O

Cardiac	cardiac	O
work	work	O
was	was	O
significantly	significantly	O
reduced	reduced	O
during	during	O
SNP	snp	B-Chemical
hypotension	hypotension	B-Disease
.	.	O

Myocardial	myocardial	O
O2	o2	O
consumption	consumption	O
and	and	O
O2	o2	O
availability	availability	O
were	were	O
directly	directly	O
dependent	dependent	O
on	on	O
the	the	O
coronary	coronary	O
perfusion	perfusion	O
.	.	O

Careful	careful	O
invasive	invasive	O
monitoring	monitoring	O
of	of	O
the	the	O
blood	blood	O
pressure	pressure	O
,	,	O
blood	blood	O
gases	gases	O
and	and	O
of	of	O
the	the	O
ECG	ecg	O
ST-T	st-t	O
segment	segment	O
is	is	O
mandatory	mandatory	O
.	.	O

Evidence	evidence	O
for	for	O
a	a	O
selective	selective	O
brain	brain	O
noradrenergic	noradrenergic	O
involvement	involvement	O
in	in	O
the	the	O
locomotor	locomotor	O
stimulant	stimulant	O
effects	effects	O
of	of	O
amphetamine	amphetamine	B-Chemical
in	in	O
the	the	O
rat	rat	O
.	.	O

Male	male	O
rats	rats	O
received	received	O
the	the	O
noradrenaline	noradrenaline	B-Chemical
neurotoxin	neurotoxin	O
DSP4	dsp4	O
(	(	O
50	50	O
mg/kg	mg/kg	O
)	)	O
7	7	O
days	days	O
prior	prior	O
to	to	O
injection	injection	O
of	of	O
D-amphetamine	d-amphetamine	O
(	(	O
10	10	O
or	or	O
40	40	O
mumol/kg	mumol/kg	O
i.p	i.p	O
.	.	O
)	)	O
.	.	O

The	the	O
hyperactivity	hyperactivity	B-Disease
induced	induced	O
by	by	O
D-amphetamine	d-amphetamine	O
(	(	O
10	10	O
mumol/kg	mumol/kg	O
)	)	O
was	was	O
significantly	significantly	O
reduced	reduced	O
by	by	O
DSP4	dsp4	O
pretreatment	pretreatment	O
.	.	O

However	however	O
,	,	O
the	the	O
increased	increased	O
rearings	rearings	O
and	and	O
the	the	O
amphetamine-induced	amphetamine-induced	O
stereotypies	stereotypies	O
were	were	O
not	not	O
blocked	blocked	O
by	by	O
pretreatment	pretreatment	O
with	with	O
DSP4	dsp4	O
.	.	O

The	the	O
reduction	reduction	O
of	of	O
amphetamine	amphetamine	B-Chemical
hyperactivity	hyperactivity	B-Disease
induced	induced	O
by	by	O
DSP4	dsp4	O
was	was	O
blocked	blocked	O
by	by	O
pretreatment	pretreatment	O
with	with	O
the	the	O
noradrenaline-uptake	noradrenaline-uptake	O
blocking	blocking	O
agent	agent	O
,	,	O
desipramine	desipramine	B-Chemical
,	,	O
which	which	O
prevents	prevents	O
the	the	O
neurotoxic	neurotoxic	B-Disease
action	action	O
of	of	O
DSP4	dsp4	O
.	.	O

The	the	O
present	present	O
results	results	O
suggest	suggest	O
a	a	O
selective	selective	O
involvement	involvement	O
of	of	O
central	central	O
noradrenergic	noradrenergic	O
neurones	neurones	O
in	in	O
the	the	O
locomotor	locomotor	O
stimulant	stimulant	O
effect	effect	O
of	of	O
amphetamine	amphetamine	B-Chemical
in	in	O
the	the	O
rat	rat	O
.	.	O

Accelerated	accelerated	O
junctional	junctional	O
rhythms	rhythms	O
during	during	O
oral	oral	O
verapamil	verapamil	B-Chemical
therapy	therapy	O
.	.	O

This	this	O
study	study	O
examined	examined	O
the	the	O
frequency	frequency	O
of	of	O
atrioventricular	atrioventricular	O
(	(	O
AV	av	O
)	)	O
dissociation	dissociation	O
and	and	O
accelerated	accelerated	O
junctional	junctional	O
rhythms	rhythms	O
in	in	O
59	59	O
patients	patients	O
receiving	receiving	O
oral	oral	O
verapamil	verapamil	B-Chemical
.	.	O

Accelerated	accelerated	O
junctional	junctional	O
rhythms	rhythms	O
and	and	O
AV	av	O
dissociation	dissociation	O
were	were	O
frequent	frequent	O
in	in	O
patients	patients	O
with	with	O
supraventricular	supraventricular	O
tachyarrhythmias	tachyarrhythmias	O
,	,	O
particularly	particularly	O
AV	av	O
nodal	nodal	O
reentry	reentry	O
.	.	O

Verapamil	verapamil	B-Chemical
administration	administration	O
to	to	O
these	these	O
patients	patients	O
led	led	O
to	to	O
an	an	O
asymptomatic	asymptomatic	O
increase	increase	O
in	in	O
activity	activity	O
of	of	O
these	these	O
junctional	junctional	O
pacemakers	pacemakers	O
.	.	O

In	in	O
patients	patients	O
with	with	O
various	various	O
chest	chest	B-Disease
pain	pain	B-Disease
syndromes	syndromes	O
,	,	O
verapamil	verapamil	B-Chemical
neither	neither	O
increased	increased	O
the	the	O
frequency	frequency	O
of	of	O
junctional	junctional	O
rhythms	rhythms	O
nor	nor	O
suppressed	suppressed	O
their	their	O
role	role	O
as	as	O
escape	escape	O
rhythms	rhythms	O
under	under	O
physiologically	physiologically	O
appropriate	appropriate	O
circumstances	circumstances	O
.	.	O

Interstrain	interstrain	O
variation	variation	O
in	in	O
acute	acute	O
toxic	toxic	O
response	response	O
to	to	O
caffeine	caffeine	B-Chemical
among	among	O
inbred	inbred	O
mice	mice	O
.	.	O

Acute	acute	O
toxic	toxic	O
dosage-dependent	dosage-dependent	O
behavioral	behavioral	O
effects	effects	O
of	of	O
caffeine	caffeine	B-Chemical
were	were	O
compared	compared	O
in	in	O
adult	adult	O
males	males	O
from	from	O
seven	seven	O
inbred	inbred	O
mouse	mouse	O
strains	strains	O
(	(	O
A/J	a/j	O
,	,	O
BALB/cJ	balb/cj	O
,	,	O
CBA/J	cba/j	O
,	,	O
C3H/HeJ	c3h/hej	O
,	,	O
C57BL/6J	c57bl/6j	O
,	,	O
DBA/2J	dba/2j	O
,	,	O
SWR/J	swr/j	O
)	)	O
.	.	O

C57BL/6J	c57bl/6j	O
,	,	O
chosen	chosen	O
as	as	O
a	a	O
"	"	O
prototypic	prototypic	O
"	"	O
mouse	mouse	O
strain	strain	O
,	,	O
was	was	O
used	used	O
to	to	O
determine	determine	O
behavioral	behavioral	O
responses	responses	O
to	to	O
a	a	O
broad	broad	O
range	range	O
(	(	O
5	5	O
-	-	O
500	500	O
mg/kg	mg/kg	O
)	)	O
of	of	O
caffeine	caffeine	B-Chemical
doses	doses	O
.	.	O

Five	five	O
phenotypic	phenotypic	O
characteristics	characteristics	O
--	--	O
locomotor	locomotor	O
activity	activity	O
,	,	O
righting	righting	O
ability	ability	O
,	,	O
clonic	clonic	O
seizure	seizure	B-Disease
induction	induction	O
,	,	O
stress-induced	stress-induced	O
lethality	lethality	O
,	,	O
death	death	B-Disease
without	without	O
external	external	O
stress	stress	O
--	--	O
were	were	O
scored	scored	O
at	at	O
various	various	O
caffeine	caffeine	B-Chemical
doses	doses	O
in	in	O
drug-naive	drug-naive	O
animals	animals	O
under	under	O
empirically	empirically	O
optimized	optimized	O
,	,	O
rigidly	rigidly	O
constant	constant	O
experimental	experimental	O
conditions	conditions	O
.	.	O

Mice	mice	O
(	(	O
n	n	O
=	=	O
12	12	O
for	for	O
each	each	O
point	point	O
)	)	O
received	received	O
single	single	O
IP	ip	O
injections	injections	O
of	of	O
a	a	O
fixed	fixed	O
volume/g	volume/g	O
body	body	B-Disease
weight	weight	I-Disease
of	of	O
physiological	physiological	O
saline	saline	O
carrier	carrier	O
with	with	O
or	or	O
without	without	O
caffeine	caffeine	B-Chemical
in	in	O
doses	doses	O
ranging	ranging	O
from	from	O
125	125	O
-	-	O
500	500	O
mg/kg	mg/kg	O
.	.	O

Loss	loss	O
of	of	O
righting	righting	O
ability	ability	O
was	was	O
scored	scored	O
at	at	O
1	1	O
,	,	O
3	3	O
,	,	O
5	5	O
min	min	O
post	post	O
dosing	dosing	O
and	and	O
at	at	O
5	5	O
min	min	O
intervals	intervals	O
thereafter	thereafter	O
for	for	O
20	20	O
min	min	O
.	.	O

In	in	O
the	the	O
same	same	O
animals	animals	O
the	the	O
occurrence	occurrence	O
of	of	O
clonic	clonic	O
seizures	seizures	B-Disease
was	was	O
scored	scored	O
as	as	O
to	to	O
time	time	O
of	of	O
onset	onset	O
and	and	O
severity	severity	O
for	for	O
20	20	O
min	min	O
after	after	O
drug	drug	O
administration	administration	O
.	.	O

When	when	O
these	these	O
proceeded	proceeded	O
to	to	O
tonic	tonic	O
seizures	seizures	B-Disease
,	,	O
death	death	B-Disease
occurred	occurred	O
in	in	O
less	less	O
than	than	O
20	20	O
min	min	O
.	.	O

Animals	animals	O
surviving	surviving	O
for	for	O
20	20	O
min	min	O
were	were	O
immediately	immediately	O
stressed	stressed	O
by	by	O
a	a	O
swim	swim	O
test	test	O
in	in	O
25	25	O
degrees	degrees	O
C	c	O
water	water	O
,	,	O
and	and	O
death-producing	death-producing	O
tonic	tonic	O
seizures	seizures	B-Disease
were	were	O
scored	scored	O
for	for	O
2	2	O
min	min	O
.	.	O

In	in	O
other	other	O
animals	animals	O
locomotor	locomotor	O
activity	activity	O
was	was	O
measured	measured	O
15	15	O
or	or	O
60	60	O
min	min	O
after	after	O
caffeine	caffeine	B-Chemical
administration	administration	O
.	.	O

By	by	O
any	any	O
single	single	O
behavioral	behavioral	O
criterion	criterion	O
or	or	O
a	a	O
combination	combination	O
of	of	O
these	these	O
criteria	criteria	O
,	,	O
marked	marked	O
differences	differences	O
in	in	O
response	response	O
to	to	O
toxic	toxic	O
caffeine	caffeine	B-Chemical
doses	doses	O
were	were	O
observed	observed	O
between	between	O
strains	strains	O
.	.	O

These	these	O
results	results	O
indicate	indicate	O
that	that	O
behavioral	behavioral	O
toxicity	toxicity	B-Disease
testing	testing	O
of	of	O
alkylxanthines	alkylxanthines	O
in	in	O
a	a	O
single	single	O
mouse	mouse	O
strain	strain	O
may	may	O
be	be	O
misleading	misleading	O
and	and	O
suggest	suggest	O
that	that	O
toxic	toxic	O
responses	responses	O
of	of	O
the	the	O
central	central	O
nervous	nervous	O
system	system	O
to	to	O
this	this	O
class	class	O
of	of	O
compounds	compounds	O
are	are	O
genetically	genetically	O
influenced	influenced	O
in	in	O
mammals	mammals	O
.	.	O

Treatment	treatment	O
of	of	O
ovarian	ovarian	B-Disease
cancer	cancer	B-Disease
with	with	O
a	a	O
combination	combination	O
of	of	O
cis-platinum	cis-platinum	O
,	,	O
adriamycin	adriamycin	B-Chemical
,	,	O
cyclophosphamide	cyclophosphamide	B-Chemical
and	and	O
hexamethylmelamine	hexamethylmelamine	O
.	.	O

During	during	O
the	the	O
last	last	O
2	2	O
1/2	1/2	O
years	years	O
,	,	O
38	38	O
patients	patients	O
with	with	O
ovarian	ovarian	B-Disease
cancer	cancer	B-Disease
were	were	O
treated	treated	O
with	with	O
a	a	O
combination	combination	O
of	of	O
cisplatinum	cisplatinum	O
(	(	O
CPDD	cpdd	O
)	)	O
,	,	O
50	50	O
mg/m2	mg/m2	O
,	,	O
adriamycin	adriamycin	B-Chemical
,	,	O
30	30	O
mg/m2	mg/m2	O
,	,	O
cyclophosphamide	cyclophosphamide	B-Chemical
,	,	O
300	300	O
mg/m2	mg/m2	O
,	,	O
on	on	O
day	day	O
1	1	O
;	;	O
and	and	O
hexamethylmelamine	hexamethylmelamine	O
(	(	O
HMM	hmm	O
)	)	O
,	,	O
6	6	O
mg/kg	mg/kg	O
daily	daily	O
,	,	O
for	for	O
14	14	O
days	days	O
.	.	O

Each	each	O
course	course	O
was	was	O
repeated	repeated	O
monthly	monthly	O
.	.	O

2	2	O
patients	patients	O
had	had	O
stage	stage	O
II	ii	O
,	,	O
14	14	O
stage	stage	O
III	iii	O
and	and	O
22	22	O
stage	stage	O
IV	iv	O
disease	disease	O
.	.	O

14	14	O
of	of	O
the	the	O
38	38	O
patients	patients	O
were	were	O
previously	previously	O
treated	treated	O
with	with	O
chemotherapy	chemotherapy	O
,	,	O
1	1	O
with	with	O
radiation	radiation	O
,	,	O
6	6	O
with	with	O
both	both	O
chemotherapy	chemotherapy	O
and	and	O
radiation	radiation	O
,	,	O
and	and	O
17	17	O
did	did	O
not	not	O
have	have	O
any	any	O
treatment	treatment	O
before	before	O
CPDD	cpdd	O
combination	combination	O
.	.	O

31	31	O
of	of	O
the	the	O
38	38	O
cases	cases	O
(	(	O
81.5	81.5	O
%	%	O
)	)	O
demonstrated	demonstrated	O
objective	objective	O
responses	responses	O
lasting	lasting	O
for	for	O
2	2	O
months	months	O
or	or	O
more	more	O
.	.	O

These	these	O
responses	responses	O
were	were	O
partial	partial	O
in	in	O
19	19	O
and	and	O
complete	complete	O
in	in	O
12	12	O
cases	cases	O
.	.	O

Hematologic	hematologic	O
toxicity	toxicity	B-Disease
was	was	O
moderate	moderate	O
and	and	O
with	with	O
reversible	reversible	O
anemia	anemia	B-Disease
developing	developing	O
in	in	O
71	71	O
%	%	O
of	of	O
patients	patients	O
.	.	O

Gastrointestinal	gastrointestinal	O
side	side	O
effects	effects	O
from	from	O
CPDD	cpdd	O
were	were	O
universal	universal	O
.	.	O

HMM	hmm	O
gastrointestinal	gastrointestinal	O
toxicity	toxicity	B-Disease
necessitated	necessitated	O
discontinuation	discontinuation	O
of	of	O
the	the	O
drug	drug	O
in	in	O
5	5	O
patients	patients	O
.	.	O

Severe	severe	O
nephrotoxicity	nephrotoxicity	B-Disease
was	was	O
observed	observed	O
in	in	O
2	2	O
patients	patients	O
but	but	O
was	was	O
reversible	reversible	O
.	.	O

There	there	O
were	were	O
no	no	O
drug-related	drug-related	O
deaths	deaths	B-Disease
.	.	O

Nontraumatic	nontraumatic	O
dissecting	dissecting	O
aneurysm	aneurysm	B-Disease
of	of	O
the	the	O
basilar	basilar	O
artery	artery	O
.	.	O

A	a	O
case	case	O
of	of	O
nontraumatic	nontraumatic	O
dissecting	dissecting	O
aneurysm	aneurysm	B-Disease
of	of	O
the	the	O
basilar	basilar	O
artery	artery	O
in	in	O
association	association	O
with	with	O
hypertension	hypertension	B-Disease
,	,	O
smoke	smoke	O
,	,	O
and	and	O
oral	oral	B-Chemical
contraceptives	contraceptives	I-Chemical
is	is	O
reported	reported	O
in	in	O
a	a	O
young	young	O
female	female	O
patient	patient	O
with	with	O
a	a	O
locked-in	locked-in	O
syndrome	syndrome	O
.	.	O

A	a	O
method	method	O
for	for	O
the	the	O
measurement	measurement	O
of	of	O
tremor	tremor	B-Disease
,	,	O
and	and	O
a	a	O
comparison	comparison	O
of	of	O
the	the	O
effects	effects	O
of	of	O
tocolytic	tocolytic	O
beta-mimetics	beta-mimetics	O
.	.	O

A	a	O
method	method	O
permitting	permitting	O
measurement	measurement	O
of	of	O
finger	finger	O
tremor	tremor	B-Disease
as	as	O
a	a	O
displacement-time	displacement-time	O
curve	curve	O
is	is	O
described	described	O
,	,	O
using	using	O
a	a	O
test	test	O
system	system	O
with	with	O
simple	simple	O
amplitude	amplitude	O
calibration	calibration	O
.	.	O

The	the	O
coordinates	coordinates	O
of	of	O
the	the	O
inversion	inversion	O
points	points	O
of	of	O
the	the	O
displacement-time	displacement-time	O
curves	curves	O
were	were	O
transferred	transferred	O
through	through	O
graphical	graphical	O
input	input	O
equipment	equipment	O
to	to	O
punched	punched	O
tape	tape	O
.	.	O

By	by	O
means	means	O
of	of	O
a	a	O
computer	computer	O
program	program	O
,	,	O
periods	periods	O
and	and	O
amplitudes	amplitudes	O
of	of	O
tremor	tremor	B-Disease
oscillations	oscillations	O
were	were	O
calculated	calculated	O
and	and	O
classified	classified	O
.	.	O

The	the	O
event	event	O
frequency	frequency	O
for	for	O
each	each	O
class	class	O
of	of	O
periods	periods	O
and	and	O
amplitudes	amplitudes	O
was	was	O
determined	determined	O
.	.	O

The	the	O
actions	actions	O
of	of	O
fenoterol-hydrobromide	fenoterol-hydrobromide	O
,	,	O
ritodrin-HCl	ritodrin-hcl	O
and	and	O
placebo	placebo	O
given	given	O
to	to	O
10	10	O
healthy	healthy	O
subjects	subjects	O
by	by	O
intravenous	intravenous	O
infusion	infusion	O
in	in	O
a	a	O
double-blind	double-blind	O
crossover	crossover	O
study	study	O
were	were	O
tested	tested	O
by	by	O
this	this	O
method	method	O
.	.	O

At	at	O
therapeutic	therapeutic	O
doses	doses	O
both	both	O
substances	substances	O
raised	raised	O
the	the	O
mean	mean	O
tremor	tremor	B-Disease
amplitude	amplitude	O
to	to	O
about	about	O
three	three	O
times	times	O
the	the	O
control	control	O
level	level	O
.	.	O

At	at	O
the	the	O
same	same	O
time	time	O
,	,	O
the	the	O
mean	mean	O
period	period	O
within	within	O
each	each	O
class	class	O
of	of	O
amplitudes	amplitudes	O
shortened	shortened	O
by	by	O
10	10	O
-	-	O
-20	-20	O
ms	ms	B-Disease
,	,	O
whereas	whereas	O
the	the	O
mean	mean	O
periods	periods	O
calculated	calculated	O
from	from	O
all	all	O
oscillations	oscillations	O
together	together	O
did	did	O
not	not	O
change	change	O
significantly	significantly	O
.	.	O

After	after	O
the	the	O
end	end	O
of	of	O
fenoterol-hydrobromide	fenoterol-hydrobromide	O
infusion	infusion	O
,	,	O
tremor	tremor	B-Disease
amplitudes	amplitudes	O
decreased	decreased	O
significantly	significantly	O
faster	faster	O
than	than	O
those	those	O
following	following	O
ritodrin-HCl	ritodrin-hcl	O
infusion	infusion	O
.	.	O

Propylthiouracil-induced	propylthiouracil-induced	O
hepatic	hepatic	B-Disease
damage	damage	I-Disease
.	.	O

Two	two	O
cases	cases	O
of	of	O
propylthiouracil-induced	propylthiouracil-induced	O
liver	liver	B-Disease
damage	damage	I-Disease
have	have	O
been	been	O
observed	observed	O
.	.	O

The	the	O
first	first	O
case	case	O
is	is	O
of	of	O
an	an	O
acute	acute	O
type	type	O
of	of	O
damage	damage	O
,	,	O
proven	proven	O
by	by	O
rechallenge	rechallenge	O
;	;	O
the	the	O
second	second	O
presents	presents	O
a	a	O
clinical	clinical	O
and	and	O
histologic	histologic	O
picture	picture	O
resembling	resembling	O
chronic	chronic	O
active	active	O
hepatitis	hepatitis	B-Disease
,	,	O
with	with	O
spontaneous	spontaneous	O
remission	remission	O
.	.	O

Studies	studies	O
on	on	O
the	the	O
bradycardia	bradycardia	B-Disease
induced	induced	O
by	by	O
bepridil	bepridil	B-Chemical
.	.	O

Bepridil	bepridil	B-Chemical
,	,	O
a	a	O
novel	novel	O
active	active	O
compound	compound	O
for	for	O
prophylactic	prophylactic	O
treatment	treatment	O
of	of	O
anginal	anginal	O
attacks	attacks	O
,	,	O
induced	induced	O
persistent	persistent	O
bradycardia	bradycardia	B-Disease
and	and	O
a	a	O
non-specific	non-specific	O
anti-tachycardial	anti-tachycardial	O
effect	effect	O
,	,	O
the	the	O
mechanisms	mechanisms	O
of	of	O
which	which	O
were	were	O
investigated	investigated	O
in	in	O
vitro	vitro	O
and	and	O
in	in	O
vivo	vivo	O
.	.	O

In	in	O
vitro	vitro	O
perfusion	perfusion	O
of	of	O
bepridil	bepridil	B-Chemical
in	in	O
the	the	O
life-support	life-support	O
medium	medium	O
for	for	O
isolated	isolated	O
sino-atrial	sino-atrial	O
tissue	tissue	O
from	from	O
rabbit	rabbit	O
heart	heart	O
,	,	O
caused	caused	O
a	a	O
reduction	reduction	O
in	in	O
action	action	O
potential	potential	O
(	(	O
AP	ap	O
)	)	O
spike	spike	O
frequency	frequency	O
(	(	O
recorded	recorded	O
by	by	O
KCl	kcl	O
microelectrodes	microelectrodes	O
)	)	O
starting	starting	O
at	at	O
doses	doses	O
of	of	O
5	5	O
X	x	O
10(-6	10(-6	O
)	)	O
M.	m.	O
This	this	O
effect	effect	O
was	was	O
dose-dependent	dose-dependent	O
up	up	O
to	to	O
concentrations	concentrations	O
of	of	O
5	5	O
X	x	O
10(-5	10(-5	O
)	)	O
M	m	O
,	,	O
whereupon	whereupon	O
blockade	blockade	O
of	of	O
sinus	sinus	O
activity	activity	O
set	set	O
in	in	O
.	.	O

Bepridil	bepridil	B-Chemical
at	at	O
a	a	O
dose	dose	O
of	of	O
5	5	O
X	x	O
10(-6	10(-6	O
)	)	O
M	m	O
,	,	O
induced	induced	O
a	a	O
concomitant	concomitant	O
reduction	reduction	O
in	in	O
AP	ap	O
amplitude	amplitude	O
(	(	O
falling	falling	O
from	from	O
71	71	O
+	+	O
/-	/-	O
8	8	O
mV	mv	O
to	to	O
47	47	O
+	+	O
/-	/-	O
6	6	O
mV	mv	O
)	)	O
,	,	O
maximum	maximum	O
systolic	systolic	O
depolarization	depolarization	O
velocity	velocity	O
(	(	O
phase	phase	O
0	0	O
)	)	O
which	which	O
fell	fell	O
from	from	O
1.85	1.85	O
+	+	O
/-	/-	O
0.35	0.35	O
V/s	v/s	O
to	to	O
0.84	0.84	O
+	+	O
/-	/-	O
0.28	0.28	O
V/s	v/s	O
,	,	O
together	together	O
with	with	O
maximum	maximum	O
diastolic	diastolic	O
depolarization	depolarization	O
velocity	velocity	O
(	(	O
phase	phase	O
4	4	O
)	)	O
which	which	O
fell	fell	O
from	from	O
38	38	O
+	+	O
/-	/-	O
3	3	O
mV/s	mv/s	O
to	to	O
24	24	O
+	+	O
/-	/-	O
5	5	O
mV/s	mv/s	O
.	.	O

In	in	O
vivo	vivo	O
injection	injection	O
of	of	O
bepridil	bepridil	B-Chemical
at	at	O
a	a	O
dose	dose	O
of	of	O
5	5	O
mg/kg	mg/kg	O
(	(	O
i.v	i.v	O
.	.	O
)	)	O
into	into	O
6	6	O
anaesthetized	anaesthetized	O
dogs	dogs	O
which	which	O
had	had	O
undergone	undergone	O
ablation	ablation	O
of	of	O
all	all	O
the	the	O
extrinsic	extrinsic	O
cardiac	cardiac	O
afferent	afferent	O
nerve	nerve	O
supply	supply	O
,	,	O
together	together	O
with	with	O
a	a	O
bilateral	bilateral	O
medullo-adrenalectomy	medullo-adrenalectomy	O
,	,	O
caused	caused	O
a	a	O
marked	marked	O
reduction	reduction	O
in	in	O
heart	heart	O
rate	rate	O
which	which	O
fell	fell	O
from	from	O
98.7	98.7	O
+	+	O
/-	/-	O
4.2	4.2	O
beats/min	beats/min	O
to	to	O
76	76	O
+	+	O
/-	/-	O
5.3	5.3	O
beats/min	beats/min	O
sustained	sustained	O
for	for	O
more	more	O
than	than	O
45	45	O
min	min	O
.	.	O

It	it	O
is	is	O
concluded	concluded	O
that	that	O
bepridil	bepridil	B-Chemical
reduces	reduces	O
heart	heart	O
rate	rate	O
by	by	O
acting	acting	O
directly	directly	O
on	on	O
the	the	O
sinus	sinus	O
node	node	O
.	.	O

This	this	O
effect	effect	O
,	,	O
which	which	O
results	results	O
in	in	O
a	a	O
flattening	flattening	O
of	of	O
the	the	O
phase	phase	O
0	0	O
and	and	O
phase	phase	O
4	4	O
slope	slope	O
,	,	O
together	together	O
with	with	O
a	a	O
longer	longer	O
AP	ap	O
duration	duration	O
,	,	O
may	may	O
be	be	O
due	due	O
to	to	O
an	an	O
increase	increase	O
in	in	O
the	the	O
time	time	O
constants	constants	O
of	of	O
slow	slow	O
inward	inward	O
ionic	ionic	O
currents	currents	O
(	(	O
already	already	O
demonstrated	demonstrated	O
elsewhere	elsewhere	O
)	)	O
,	,	O
but	but	O
also	also	O
to	to	O
an	an	O
increased	increased	O
time	time	O
constant	constant	O
for	for	O
deactivation	deactivation	O
of	of	O
the	the	O
outward	outward	O
potassium	potassium	B-Chemical
current	current	O
(	(	O
Ip	ip	O
)	)	O
.	.	O

Hepatitis	hepatitis	B-Disease
and	and	O
renal	renal	O
tubular	tubular	O
acidosis	acidosis	B-Disease
after	after	O
anesthesia	anesthesia	O
with	with	O
methoxyflurane	methoxyflurane	O
.	.	O

A	a	O
69-year-old	69-year-old	O
man	man	O
operated	operated	O
for	for	O
acute	acute	O
cholecystitis	cholecystitis	O
under	under	O
methoxyflurane	methoxyflurane	O
anesthesia	anesthesia	O
developed	developed	O
postoperatively	postoperatively	O
a	a	O
hepatic	hepatic	B-Disease
insufficiency	insufficiency	I-Disease
syndrome	syndrome	O
and	and	O
renal	renal	O
tubular	tubular	O
acidosis	acidosis	B-Disease
.	.	O

Massive	massive	O
bleeding	bleeding	B-Disease
appeared	appeared	O
during	during	O
surgery	surgery	O
which	which	O
lasted	lasted	O
for	for	O
six	six	O
hours	hours	O
.	.	O

Postoperative	postoperative	O
evolution	evolution	O
under	under	O
supportive	supportive	O
therapy	therapy	O
was	was	O
favourable	favourable	O
.	.	O

Complete	complete	O
recovery	recovery	O
was	was	O
confirmed	confirmed	O
by	by	O
repeated	repeated	O
controls	controls	O
performed	performed	O
over	over	O
a	a	O
period	period	O
of	of	O
one	one	O
year	year	O
after	after	O
surgery	surgery	O
.	.	O

Pituitary	pituitary	O
response	response	O
to	to	O
luteinizing	luteinizing	O
hormone-releasing	hormone-releasing	O
hormone	hormone	O
during	during	O
haloperidol-induced	haloperidol-induced	O
hyperprolactinemia	hyperprolactinemia	B-Disease
.	.	O

The	the	O
effects	effects	O
of	of	O
a	a	O
6-hour	6-hour	O
infusion	infusion	O
with	with	O
haloperidol	haloperidol	B-Chemical
on	on	O
serum	serum	O
prolactin	prolactin	O
and	and	O
luteinizing	luteinizing	B-Chemical
hormone	hormone	I-Chemical
(	(	O
LH	lh	O
)	)	O
levels	levels	O
was	was	O
studied	studied	O
in	in	O
a	a	O
group	group	O
of	of	O
male	male	O
subjects	subjects	O
.	.	O

Five	five	O
hours	hours	O
after	after	O
starting	starting	O
the	the	O
infusions	infusions	O
,	,	O
a	a	O
study	study	O
of	of	O
the	the	O
pituitary	pituitary	O
responses	responses	O
to	to	O
LH-releasing	lh-releasing	O
hormone	hormone	O
(	(	O
LH-RH	lh-rh	O
)	)	O
was	was	O
carried	carried	O
out	out	O
.	.	O

Control	control	O
patients	patients	O
received	received	O
infusions	infusions	O
of	of	O
0.9	0.9	O
%	%	O
NaCl	nacl	B-Chemical
solution	solution	O
.	.	O

During	during	O
the	the	O
course	course	O
of	of	O
haloperidol	haloperidol	B-Chemical
infusions	infusions	O
,	,	O
significant	significant	O
hyperprolactinemia	hyperprolactinemia	B-Disease
was	was	O
found	found	O
,	,	O
together	together	O
with	with	O
an	an	O
abolished	abolished	O
pituitary	pituitary	O
response	response	O
to	to	O
LH-RH	lh-rh	O
,	,	O
as	as	O
compared	compared	O
with	with	O
responses	responses	O
of	of	O
control	control	O
subjects	subjects	O
.	.	O

Antirifampicin	antirifampicin	O
antibodies	antibodies	O
in	in	O
acute	acute	O
rifampicin-associated	rifampicin-associated	O
renal	renal	O
failure.5	failure.5	O
patients	patients	O
with	with	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
(	(	O
3	3	O
with	with	O
thrombopenia	thrombopenia	O
and	and	O
hemolysis	hemolysis	B-Disease
)	)	O
induced	induced	O
by	by	O
the	the	O
reintroduction	reintroduction	O
of	of	O
rifampicin	rifampicin	O
are	are	O
described	described	O
.	.	O

No	no	O
correlation	correlation	O
was	was	O
found	found	O
between	between	O
the	the	O
severity	severity	O
of	of	O
clinical	clinical	O
manifestations	manifestations	O
and	and	O
the	the	O
total	total	O
dose	dose	O
taken	taken	O
by	by	O
the	the	O
patients	patients	O
.	.	O

In	in	O
all	all	O
but	but	O
1	1	O
patient	patient	O
,	,	O
antirifampicin	antirifampicin	O
antibodies	antibodies	O
were	were	O
detected	detected	O
.	.	O

Antibodies	antibodies	O
suggested	suggested	O
to	to	O
be	be	O
of	of	O
the	the	O
IgM	igm	O
class	class	O
were	were	O
detected	detected	O
in	in	O
all	all	O
3	3	O
patients	patients	O
with	with	O
hematological	hematological	O
disorders	disorders	O
.	.	O

The	the	O
pattern	pattern	O
of	of	O
non-specific	non-specific	O
acute	acute	B-Disease
tubular	tubular	B-Disease
necrosis	necrosis	B-Disease
found	found	O
in	in	O
the	the	O
2	2	O
biopsied	biopsied	O
patients	patients	O
,	,	O
indistinguishable	indistinguishable	O
from	from	O
that	that	O
of	of	O
ischemic	ischemic	O
origin	origin	O
,	,	O
raised	raised	O
the	the	O
possibility	possibility	O
of	of	O
a	a	O
vascular-mediated	vascular-mediated	O
damage	damage	O
.	.	O

In	in	O
3	3	O
patients	patients	O
,	,	O
the	the	O
possibility	possibility	O
of	of	O
a	a	O
triggering	triggering	O
immunoallergic	immunoallergic	O
mechanism	mechanism	O
is	is	O
discussed	discussed	O
.	.	O

Cardiovascular	cardiovascular	O
effects	effects	O
of	of	O
hypotension	hypotension	B-Disease
induced	induced	O
by	by	O
adenosine	adenosine	B-Chemical
triphosphate	triphosphate	I-Chemical
and	and	O
sodium	sodium	B-Chemical
nitroprusside	nitroprusside	B-Chemical
on	on	O
dogs	dogs	O
with	with	O
denervated	denervated	O
hearts	hearts	O
.	.	O

Adenosine	adenosine	B-Chemical
triphosphate	triphosphate	I-Chemical
(	(	O
ATP	atp	B-Chemical
)	)	O
and	and	O
sodium	sodium	B-Chemical
nitroprusside	nitroprusside	B-Chemical
(	(	O
SNP	snp	B-Chemical
)	)	O
are	are	O
administered	administered	O
to	to	O
patients	patients	O
to	to	O
induce	induce	O
and	and	O
control	control	O
hypotension	hypotension	B-Disease
during	during	O
anesthesia	anesthesia	O
.	.	O

SNP	snp	B-Chemical
is	is	O
authorized	authorized	O
for	for	O
clinical	clinical	O
use	use	O
in	in	O
USA	usa	O
and	and	O
UK	uk	O
,	,	O
and	and	O
ATP	atp	B-Chemical
is	is	O
clinically	clinically	O
used	used	O
in	in	O
other	other	O
countries	countries	O
such	such	O
as	as	O
Japan	japan	O
.	.	O

We	we	O
investigated	investigated	O
how	how	O
these	these	O
two	two	O
drugs	drugs	O
act	act	O
on	on	O
the	the	O
cardiovascular	cardiovascular	O
systems	systems	O
of	of	O
20	20	O
dogs	dogs	O
whose	whose	O
hearts	hearts	O
had	had	O
been	been	O
denervated	denervated	O
by	by	O
a	a	O
procedure	procedure	O
we	we	O
had	had	O
devised	devised	O
.	.	O

ATP	atp	B-Chemical
(	(	O
10	10	O
dogs	dogs	O
)	)	O
or	or	O
SNP	snp	B-Chemical
(	(	O
10	10	O
dogs	dogs	O
)	)	O
was	was	O
administered	administered	O
to	to	O
reduce	reduce	O
mean	mean	O
arterial	arterial	O
pressure	pressure	O
by	by	O
30	30	O
%	%	O
to	to	O
70	70	O
%	%	O
of	of	O
control	control	O
.	.	O

Before	before	O
,	,	O
during	during	O
and	and	O
after	after	O
induced	induced	O
hypotension	hypotension	B-Disease
,	,	O
we	we	O
measured	measured	O
major	major	O
cardiovascular	cardiovascular	O
parameters	parameters	O
.	.	O

Hypotension	hypotension	B-Disease
induced	induced	O
by	by	O
ATP	atp	B-Chemical
was	was	O
accompanied	accompanied	O
by	by	O
significant	significant	O
decreases	decreases	O
in	in	O
mean	mean	O
pulmonary	pulmonary	O
arterial	arterial	O
pressure	pressure	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
central	central	O
venous	venous	O
pressure	pressure	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
left	left	O
ventricular	ventricular	O
end-diastolic	end-diastolic	O
pressure	pressure	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
total	total	O
peripheral	peripheral	O
resistance	resistance	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
rate	rate	O
pressure	pressure	O
product	product	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
total	total	O
body	body	O
oxygen	oxygen	B-Chemical
consumption	consumption	O
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
,	,	O
and	and	O
heart	heart	O
rate	rate	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
;	;	O
all	all	O
these	these	O
variables	variables	O
returned	returned	O
normal	normal	O
within	within	O
30	30	O
min	min	O
after	after	O
ATP	atp	B-Chemical
was	was	O
stopped	stopped	O
.	.	O

Cardiac	cardiac	O
output	output	O
did	did	O
not	not	O
change	change	O
.	.	O

During	during	O
hypotension	hypotension	B-Disease
produced	produced	O
by	by	O
SNP	snp	B-Chemical
similar	similar	O
decreases	decreases	O
were	were	O
observed	observed	O
in	in	O
mean	mean	O
pulmonary	pulmonary	O
arterial	arterial	O
pressure	pressure	O
(	(	O
p	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
,	,	O
central	central	O
venous	venous	O
pressure	pressure	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
left	left	O
ventricular	ventricular	O
end-diastolic	end-diastolic	O
pressure	pressure	O
(	(	O
p	p	O
less	less	O
than	than	O
0.01	0.01	O
)	)	O
,	,	O
total	total	O
peripheral	peripheral	O
resistance	resistance	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
rate	rate	O
pressure	pressure	O
product	product	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
,	,	O
and	and	O
oxygen	oxygen	B-Chemical
content	content	O
difference	difference	O
between	between	O
arterial	arterial	O
and	and	O
mixed	mixed	O
venous	venous	O
blood	blood	O
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
,	,	O
while	while	O
heart	heart	O
rate	rate	O
(	(	O
p	p	O
less	less	O
than	than	O
0.001	0.001	O
)	)	O
and	and	O
cardiac	cardiac	O
output	output	O
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
were	were	O
increased	increased	O
.	.	O

Recoveries	recoveries	O
of	of	O
heart	heart	O
rate	rate	O
and	and	O
left	left	O
ventricular	ventricular	O
end-diastolic	end-diastolic	O
pressure	pressure	O
were	were	O
not	not	O
shown	shown	O
within	within	O
60	60	O
min	min	O
after	after	O
SNP	snp	B-Chemical
had	had	O
been	been	O
stopped	stopped	O
.	.	O

Both	both	O
ATP	atp	B-Chemical
and	and	O
SNP	snp	B-Chemical
should	should	O
act	act	O
on	on	O
the	the	O
pacemaker	pacemaker	O
tissue	tissue	O
of	of	O
the	the	O
heart	heart	O
.	.	O

Comparative	comparative	O
study	study	O
:	:	O
Endografine	endografine	O
(	(	O
diatrizoate	diatrizoate	O
)	)	O
,	,	O
Vasurix	vasurix	O
polyvidone	polyvidone	O
(	(	O
acetrizoate	acetrizoate	O
)	)	O
,	,	O
Dimer-X	dimer-x	O
(	(	O
iocarmate	iocarmate	O
)	)	O
and	and	O
Hexabrix	hexabrix	O
(	(	O
ioxaglate	ioxaglate	O
)	)	O
in	in	O
hysterosalpingography	hysterosalpingography	O
.	.	O

Side	side	O
effects	effects	O
of	of	O
hysterosalpingography	hysterosalpingography	O
with	with	O
Dimer-X	dimer-x	O
,	,	O
Hexabrix	hexabrix	O
,	,	O
Vasurix	vasurix	O
polyvidone	polyvidone	O
and	and	O
Endografine	endografine	O
in	in	O
142	142	O
consecutive	consecutive	O
patients	patients	O
,	,	O
receiving	receiving	O
one	one	O
of	of	O
the	the	O
four	four	O
tested	tested	O
media	media	O
were	were	O
evaluated	evaluated	O
from	from	O
replies	replies	O
to	to	O
postal	postal	O
questionnaires	questionnaires	O
.	.	O

The	the	O
Dimer-X	dimer-x	O
group	group	O
had	had	O
a	a	O
higher	higher	O
incidence	incidence	O
of	of	O
nausea	nausea	B-Disease
and	and	O
dizziness	dizziness	B-Disease
.	.	O

The	the	O
Endografine	endografine	O
group	group	O
had	had	O
a	a	O
higher	higher	O
incidence	incidence	O
of	of	O
abdominal	abdominal	B-Disease
pain	pain	B-Disease
.	.	O

These	these	O
differences	differences	O
occur	occur	O
especially	especially	O
in	in	O
the	the	O
age	age	O
groups	groups	O
under	under	O
30	30	O
years	years	O
.	.	O

Hexabrix	hexabrix	O
and	and	O
Vasurix	vasurix	O
polyvidone	polyvidone	O
are	are	O
considered	considered	O
the	the	O
best	best	O
contrast	contrast	B-Chemical
media	media	I-Chemical
for	for	O
hysterosalpingography	hysterosalpingography	O
and	and	O
perhaps	perhaps	O
because	because	O
of	of	O
its	its	O
low	low	O
toxicity	toxicity	B-Disease
Hexabrix	hexabrix	O
should	should	O
be	be	O
preferred	preferred	O
.	.	O

Post-suxamethonium	post-suxamethonium	O
pains	pains	O
in	in	O
Nigerian	nigerian	O
surgical	surgical	O
patients	patients	O
.	.	O

Contrary	contrary	O
to	to	O
an	an	O
earlier	earlier	O
report	report	O
by	by	O
Coxon	coxon	O
,	,	O
scoline	scoline	O
pain	pain	B-Disease
occurs	occurs	O
in	in	O
African	african	O
negroes	negroes	O
.	.	O

Its	its	O
incidence	incidence	O
was	was	O
determined	determined	O
in	in	O
a	a	O
prospective	prospective	O
study	study	O
involving	involving	O
a	a	O
total	total	O
of	of	O
100	100	O
Nigerian	nigerian	O
patients	patients	O
(	(	O
50	50	O
out-patients	out-patients	O
and	and	O
50	50	O
in-patients	in-patients	O
)	)	O
.	.	O

About	about	O
62	62	O
%	%	O
of	of	O
the	the	O
out-patients	out-patients	O
developed	developed	O
scoline	scoline	O
pain	pain	B-Disease
as	as	O
compared	compared	O
with	with	O
about	about	O
26	26	O
%	%	O
among	among	O
the	the	O
in-patients	in-patients	O
.	.	O

The	the	O
abolition	abolition	O
of	of	O
muscle	muscle	O
fasciculations	fasciculations	O
(	(	O
by	by	O
0.075mg/kg	0.075mg/kg	O
dose	dose	O
of	of	O
Fazadinium	fazadinium	O
)	)	O
did	did	O
not	not	O
influence	influence	O
the	the	O
occurrence	occurrence	O
of	of	O
scoline	scoline	O
pain	pain	B-Disease
.	.	O

Neither	neither	O
the	the	O
type	type	O
of	of	O
induction	induction	O
agent	agent	O
(	(	O
Althesin	althesin	O
or	or	O
Thiopentone	thiopentone	B-Chemical
)	)	O
nor	nor	O
the	the	O
salt	salt	B-Chemical
preparation	preparation	O
of	of	O
suxamethonium	suxamethonium	B-Chemical
used	used	O
(	(	O
chloride	chloride	O
or	or	O
bromide	bromide	O
)	)	O
,	,	O
affected	affected	O
the	the	O
incidence	incidence	O
of	of	O
scoline	scoline	O
pain	pain	B-Disease
.	.	O

Invasive	invasive	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
renal	renal	O
pelvis	pelvis	O
following	following	O
cyclophosphamide	cyclophosphamide	B-Chemical
therapy	therapy	O
for	for	O
nonmalignant	nonmalignant	O
disease	disease	O
.	.	O

A	a	O
47-year-old	47-year-old	O
woman	woman	O
with	with	O
right	right	O
hydroureteronephrosis	hydroureteronephrosis	O
due	due	O
to	to	O
ureterovesical	ureterovesical	O
junction	junction	O
obstruction	obstruction	O
had	had	O
gross	gross	O
hematuria	hematuria	B-Disease
after	after	O
being	being	O
treated	treated	O
for	for	O
five	five	O
years	years	O
wtih	wtih	O
cyclophosphamide	cyclophosphamide	B-Chemical
for	for	O
cerebral	cerebral	O
vasculitis	vasculitis	B-Disease
.	.	O

A	a	O
right	right	O
nephroureterectomy	nephroureterectomy	O
was	was	O
required	required	O
for	for	O
control	control	O
of	of	O
bleeding	bleeding	B-Disease
.	.	O

The	the	O
pathology	pathology	O
specimen	specimen	O
contained	contained	O
clinically	clinically	O
occult	occult	O
invasive	invasive	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
renal	renal	O
pelvis	pelvis	O
.	.	O

Although	although	O
the	the	O
ability	ability	O
of	of	O
cyclophosphamide	cyclophosphamide	B-Chemical
to	to	O
cause	cause	O
hemorrhagic	hemorrhagic	B-Disease
cystitis	cystitis	B-Disease
and	and	O
urine	urine	O
cytologic	cytologic	O
abnormalities	abnormalities	O
indistinguishable	indistinguishable	O
from	from	O
high	high	O
grade	grade	O
carcinoma	carcinoma	B-Disease
is	is	O
well	well	O
known	known	O
,	,	O
it	it	O
is	is	O
less	less	O
widely	widely	O
appreciated	appreciated	O
that	that	O
it	it	O
is	is	O
also	also	O
associated	associated	O
with	with	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
urinary	urinary	O
tract	tract	O
.	.	O

Twenty	twenty	O
carcinomas	carcinomas	O
of	of	O
the	the	O
urinary	urinary	O
bladder	bladder	O
and	and	O
one	one	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
prostate	prostate	O
have	have	O
been	been	O
reported	reported	O
in	in	O
association	association	O
with	with	O
its	its	O
use	use	O
.	.	O

The	the	O
present	present	O
case	case	O
is	is	O
the	the	O
first	first	O
carcinoma	carcinoma	B-Disease
of	of	O
the	the	O
renal	renal	O
pelvis	pelvis	O
reported	reported	O
in	in	O
association	association	O
with	with	O
cyclophosphamide	cyclophosphamide	B-Chemical
treatment	treatment	O
.	.	O

It	it	O
is	is	O
the	the	O
third	third	O
urinary	urinary	O
tract	tract	O
cancer	cancer	B-Disease
reported	reported	O
in	in	O
association	association	O
with	with	O
cyclophosphamide	cyclophosphamide	B-Chemical
treatment	treatment	O
for	for	O
nonmalignant	nonmalignant	O
disease	disease	O
.	.	O

The	the	O
association	association	O
of	of	O
the	the	O
tumor	tumor	B-Disease
with	with	O
preexisting	preexisting	O
hydroureteronephrosis	hydroureteronephrosis	O
suggests	suggests	O
that	that	O
stasis	stasis	O
prolonged	prolonged	O
and	and	O
intensified	intensified	O
exposure	exposure	O
of	of	O
upper	upper	O
urinary	urinary	O
tract	tract	O
epithelium	epithelium	O
to	to	O
cyclophosphamide	cyclophosphamide	B-Chemical
.	.	O

Patients	patients	O
who	who	O
are	are	O
candidates	candidates	O
for	for	O
long-term	long-term	O
cyclophosphamide	cyclophosphamide	B-Chemical
treatment	treatment	O
should	should	O
be	be	O
routinely	routinely	O
evaluated	evaluated	O
for	for	O
obstructive	obstructive	O
uropathy	uropathy	O
.	.	O

Medial	medial	O
changes	changes	O
in	in	O
arterial	arterial	O
spasm	spasm	B-Disease
induced	induced	O
by	by	O
L-norepinephrine	l-norepinephrine	O
.	.	O

In	in	O
normal	normal	O
rats	rats	O
,	,	O
the	the	O
media	media	O
of	of	O
small	small	O
arteries	arteries	O
(	(	O
0.4	0.4	O
-	-	O
-0.2	-0.2	O
mm	mm	O
in	in	O
diameter	diameter	O
)	)	O
previously	previously	O
was	was	O
shown	shown	O
to	to	O
contain	contain	O
intracellular	intracellular	O
vacuoles	vacuoles	O
,	,	O
identified	identified	O
ultrastructurally	ultrastructurally	O
as	as	O
herniations	herniations	O
of	of	O
one	one	O
smooth	smooth	O
muscle	muscle	O
cell	cell	O
into	into	O
another	another	O
.	.	O

The	the	O
hypothesis	hypothesis	O
that	that	O
intense	intense	O
vasoconstriction	vasoconstriction	O
would	would	O
increase	increase	O
the	the	O
number	number	O
of	of	O
such	such	O
vacuoles	vacuoles	O
has	has	O
been	been	O
tested	tested	O
.	.	O

In	in	O
the	the	O
media	media	O
of	of	O
the	the	O
saphenous	saphenous	O
artery	artery	O
and	and	O
its	its	O
distal	distal	O
branch	branch	O
,	,	O
vasoconstriction	vasoconstriction	O
induced	induced	O
by	by	O
L-norepinephrine	l-norepinephrine	O
produced	produced	O
many	many	O
cell-to-cell	cell-to-cell	O
hernias	hernias	O
within	within	O
15	15	O
minutes	minutes	O
.	.	O

At	at	O
1	1	O
day	day	O
their	their	O
number	number	O
was	was	O
reduced	reduced	O
to	to	O
about	about	O
1/10	1/10	O
of	of	O
the	the	O
original	original	O
number	number	O
.	.	O

By	by	O
7	7	O
days	days	O
the	the	O
vessel	vessel	O
was	was	O
almost	almost	O
restored	restored	O
to	to	O
normal	normal	O
.	.	O

Triple	triple	O
stimulation	stimulation	O
over	over	O
1	1	O
day	day	O
induced	induced	O
more	more	O
severe	severe	O
changes	changes	O
in	in	O
the	the	O
media	media	O
.	.	O

These	these	O
findings	findings	O
suggest	suggest	O
that	that	O
smooth	smooth	O
muscle	muscle	O
cells	cells	O
are	are	O
susceptible	susceptible	O
to	to	O
damage	damage	O
in	in	O
the	the	O
course	course	O
of	of	O
their	their	O
specific	specific	O
function	function	O
.	.	O

The	the	O
experimental	experimental	O
data	data	O
are	are	O
discussed	discussed	O
in	in	O
relation	relation	O
to	to	O
medial	medial	O
changes	changes	O
observed	observed	O
in	in	O
other	other	O
instances	instances	O
of	of	O
arterial	arterial	O
spasm	spasm	B-Disease
.	.	O

Endothelial	endothelial	O
changes	changes	O
that	that	O
developed	developed	O
in	in	O
the	the	O
same	same	O
experimental	experimental	O
model	model	O
were	were	O
described	described	O
in	in	O
a	a	O
previous	previous	O
paper	paper	O
.	.	O

Bilateral	bilateral	O
retinal	retinal	O
artery	artery	O
and	and	O
choriocapillaris	choriocapillaris	O
occlusion	occlusion	O
following	following	O
the	the	O
injection	injection	O
of	of	O
long-acting	long-acting	O
corticosteroid	corticosteroid	O
suspensions	suspensions	O
in	in	O
combination	combination	O
with	with	O
other	other	O
drugs	drugs	O
:	:	O
I.	i.	O
Clinical	clinical	O
studies	studies	O
.	.	O

Two	two	O
well-documented	well-documented	O
cases	cases	O
of	of	O
bilateral	bilateral	O
retinal	retinal	O
artery	artery	O
and	and	O
choriocapillaris	choriocapillaris	O
occlusions	occlusions	O
with	with	O
blindness	blindness	O
following	following	O
head	head	O
and	and	O
neck	neck	O
soft-tissue	soft-tissue	O
injection	injection	O
with	with	O
methylprednisolone	methylprednisolone	B-Chemical
acetate	acetate	I-Chemical
in	in	O
combination	combination	O
with	with	O
lidocaine	lidocaine	B-Chemical
,	,	O
epinephrine	epinephrine	B-Chemical
,	,	O
or	or	O
penicillin	penicillin	B-Chemical
are	are	O
reported	reported	O
.	.	O

One	one	O
case	case	O
had	had	O
only	only	O
a	a	O
unilateral	unilateral	O
injection	injection	O
.	.	O

The	the	O
acute	acute	O
observations	observations	O
included	included	O
hazy	hazy	O
sensorium	sensorium	O
,	,	O
superior	superior	O
gaze	gaze	O
palsy	palsy	O
,	,	O
pupillary	pupillary	O
abnormalities	abnormalities	O
,	,	O
and	and	O
conjunctival	conjunctival	O
hemorrhages	hemorrhages	O
with	with	O
edema	edema	B-Disease
.	.	O

Follow-up	follow-up	O
changes	changes	O
showed	showed	O
marked	marked	O
visual	visual	B-Disease
loss	loss	I-Disease
,	,	O
constricted	constricted	O
visual	visual	O
fields	fields	O
,	,	O
optic	optic	O
nerve	nerve	O
pallor	pallor	O
,	,	O
vascular	vascular	O
attenuation	attenuation	O
,	,	O
and	and	O
chorioretinal	chorioretinal	O
atrophy	atrophy	B-Disease
.	.	O

The	the	O
literature	literature	O
is	is	O
reviewed	reviewed	O
,	,	O
and	and	O
possible	possible	O
causes	causes	O
are	are	O
discussed	discussed	O
.	.	O

Abnormalities	abnormalities	O
of	of	O
the	the	O
pupil	pupil	O
and	and	O
visual-evoked	visual-evoked	O
potential	potential	O
in	in	O
quinine	quinine	B-Chemical
amblyopia	amblyopia	O
.	.	O

Total	total	O
blindness	blindness	O
with	with	O
a	a	O
transient	transient	O
tonic	tonic	O
pupillary	pupillary	O
response	response	O
,	,	O
denervation	denervation	O
supersensitivity	supersensitivity	O
,	,	O
and	and	O
abnormal	abnormal	O
visual-evoked	visual-evoked	O
potentials	potentials	O
developed	developed	O
in	in	O
a	a	O
54-year-old	54-year-old	O
man	man	O
after	after	O
the	the	O
use	use	O
of	of	O
quinine	quinine	B-Chemical
sulfate	sulfate	O
for	for	O
leg	leg	O
cramps	cramps	O
.	.	O

He	he	O
later	later	O
recovered	recovered	O
normal	normal	O
visual	visual	O
acuity	acuity	O
.	.	O

A	a	O
transient	transient	O
tonic	tonic	O
pupillary	pupillary	O
response	response	O
,	,	O
denervation	denervation	O
supersensitivity	supersensitivity	O
,	,	O
and	and	O
abnormal	abnormal	O
visual-evoked	visual-evoked	O
potentials	potentials	O
in	in	O
quinine	quinine	B-Chemical
toxicity	toxicity	B-Disease
,	,	O
to	to	O
our	our	O
knowledge	knowledge	O
,	,	O
have	have	O
not	not	O
been	been	O
previously	previously	O
reported	reported	O
.	.	O

Suxamethonium-induced	suxamethonium-induced	O
jaw	jaw	O
stiffness	stiffness	O
and	and	O
myalgia	myalgia	B-Disease
associated	associated	O
with	with	O
atypical	atypical	O
cholinesterase	cholinesterase	O
:	:	O
case	case	O
report	report	O
.	.	O

An	an	O
11-year-old	11-year-old	O
boy	boy	O
was	was	O
given	given	O
halothane	halothane	B-Chemical
,	,	O
nitrous	nitrous	B-Chemical
oxide	oxide	I-Chemical
and	and	O
oxygen	oxygen	B-Chemical
,	,	O
pancuronium	pancuronium	O
0.4	0.4	O
mg	mg	O
and	and	O
suxamethonium	suxamethonium	B-Chemical
100	100	O
mg	mg	O
for	for	O
induction	induction	O
of	of	O
anaesthesia	anaesthesia	O
.	.	O

In	in	O
response	response	O
to	to	O
this	this	O
a	a	O
marked	marked	O
jaw	jaw	O
stiffness	stiffness	O
occurred	occurred	O
which	which	O
lasted	lasted	O
for	for	O
two	two	O
minutes	minutes	O
and	and	O
the	the	O
anaesthesia	anaesthesia	O
were	were	O
terminated	terminated	O
.	.	O

Four	four	O
hours	hours	O
of	of	O
apnoea	apnoea	B-Disease
ensued	ensued	O
and	and	O
he	he	O
suffered	suffered	O
generalized	generalized	O
severe	severe	O
myalgia	myalgia	B-Disease
lasting	lasting	O
for	for	O
one	one	O
week	week	O
.	.	O

He	he	O
was	was	O
found	found	O
to	to	O
have	have	O
atypical	atypical	O
plasma	plasma	O
cholinesterase	cholinesterase	O
with	with	O
a	a	O
dibucaine	dibucaine	O
number	number	O
of	of	O
12	12	O
,	,	O
indicating	indicating	O
homozygocity	homozygocity	O
.	.	O

This	this	O
was	was	O
verified	verified	O
by	by	O
study	study	O
of	of	O
the	the	O
family	family	O
.	.	O

The	the	O
case	case	O
shows	shows	O
that	that	O
prolonged	prolonged	O
jaw	jaw	O
rigidity	rigidity	B-Disease
and	and	O
myalgia	myalgia	B-Disease
may	may	O
occur	occur	O
after	after	O
suxamethonium	suxamethonium	B-Chemical
in	in	O
patients	patients	O
with	with	O
atypical	atypical	O
cholinesterase	cholinesterase	O
despite	despite	O
pretreatment	pretreatment	O
with	with	O
pancuronium	pancuronium	O
.	.	O

Indomethacin-induced	indomethacin-induced	O
hyperkalemia	hyperkalemia	B-Disease
in	in	O
three	three	O
patients	patients	O
with	with	O
gouty	gouty	O
arthritis	arthritis	B-Disease
.	.	O

We	we	O
describe	describe	O
three	three	O
patients	patients	O
in	in	O
whom	whom	O
severe	severe	O
,	,	O
life-threatening	life-threatening	O
hyperkalemia	hyperkalemia	B-Disease
and	and	O
renal	renal	B-Disease
insufficiency	insufficiency	I-Disease
developed	developed	O
after	after	O
treatment	treatment	O
of	of	O
acute	acute	O
gouty	gouty	O
arthritis	arthritis	B-Disease
with	with	O
indomethacin	indomethacin	B-Chemical
.	.	O

This	this	O
complication	complication	O
may	may	O
result	result	O
from	from	O
an	an	O
inhibition	inhibition	O
of	of	O
prostaglandin	prostaglandin	O
synthesis	synthesis	O
and	and	O
consequent	consequent	O
hyporeninemic	hyporeninemic	O
hypoaidosteronism	hypoaidosteronism	O
.	.	O

Careful	careful	O
attention	attention	O
to	to	O
renal	renal	O
function	function	O
and	and	O
potassium	potassium	B-Chemical
balance	balance	O
in	in	O
patients	patients	O
receiving	receiving	O
indomethacin	indomethacin	B-Chemical
or	or	O
other	other	O
nonsteroidal	nonsteroidal	O
anti-inflammatory	anti-inflammatory	O
agents	agents	O
,	,	O
particularly	particularly	O
in	in	O
those	those	O
patients	patients	O
with	with	O
diabetes	diabetes	B-Disease
mellitus	mellitus	I-Disease
or	or	O
preexisting	preexisting	O
renal	renal	O
disease	disease	O
,	,	O
will	will	O
help	help	O
prevent	prevent	O
this	this	O
potentially	potentially	O
serious	serious	O
complication	complication	O
.	.	O

Etomidate	etomidate	O
:	:	O
a	a	O
foreshortened	foreshortened	O
clinical	clinical	O
trial	trial	O
.	.	O

A	a	O
clinical	clinical	O
evaluation	evaluation	O
of	of	O
etomidate	etomidate	O
for	for	O
outpatient	outpatient	O
cystoscopy	cystoscopy	O
was	was	O
embarked	embarked	O
upon	upon	O
.	.	O

Unpremedicated	unpremedicated	O
patients	patients	O
were	were	O
given	given	O
fentanyl	fentanyl	B-Chemical
1	1	O
microgram/kg	microgram/kg	O
followed	followed	O
by	by	O
etomidate	etomidate	O
0.3	0.3	O
mg/kg	mg/kg	O
.	.	O

Anaesthesia	anaesthesia	O
was	was	O
maintained	maintained	O
with	with	O
intermittent	intermittent	O
etomidate	etomidate	O
in	in	O
2	2	O
-	-	O
4	4	O
mg	mg	O
doses	doses	O
.	.	O

Patients	patients	O
were	were	O
interviewed	interviewed	O
personally	personally	O
later	later	O
the	the	O
same	same	O
day	day	O
,	,	O
and	and	O
by	by	O
questionnaire	questionnaire	O
three	three	O
to	to	O
four	four	O
weeks	weeks	O
later	later	O
.	.	O

The	the	O
trial	trial	O
was	was	O
discontinued	discontinued	O
after	after	O
20	20	O
cases	cases	O
because	because	O
of	of	O
an	an	O
unacceptable	unacceptable	O
incidence	incidence	O
of	of	O
side	side	O
effects	effects	O
.	.	O

Venous	venous	O
pain	pain	B-Disease
occurred	occurred	O
in	in	O
68	68	O
%	%	O
of	of	O
patients	patients	O
and	and	O
50	50	O
%	%	O
had	had	O
redness	redness	O
,	,	O
pain	pain	B-Disease
or	or	O
swelling	swelling	O
related	related	O
to	to	O
the	the	O
injection	injection	O
site	site	O
,	,	O
in	in	O
some	some	O
cases	cases	O
lasting	lasting	O
up	up	O
to	to	O
three	three	O
weeks	weeks	O
after	after	O
anaesthesia	anaesthesia	O
.	.	O

Skeletal	skeletal	O
movements	movements	O
occurred	occurred	O
in	in	O
50	50	O
%	%	O
of	of	O
patients	patients	O
;	;	O
30	30	O
%	%	O
experienced	experienced	O
respiratory	respiratory	O
upset	upset	O
,	,	O
one	one	O
sufficiently	sufficiently	O
severe	severe	O
to	to	O
necessitate	necessitate	O
abandoning	abandoning	O
the	the	O
technique	technique	O
.	.	O

Nausea	nausea	B-Disease
and	and	O
vomiting	vomiting	B-Disease
occurred	occurred	O
in	in	O
40	40	O
%	%	O
and	and	O
25	25	O
%	%	O
had	had	O
disturbing	disturbing	O
emergence	emergence	O
psychoses	psychoses	B-Disease
.	.	O

Levodopa-induced	levodopa-induced	O
dyskinesias	dyskinesias	B-Disease
are	are	O
improved	improved	O
by	by	O
fluoxetine	fluoxetine	B-Chemical
.	.	O

We	we	O
evaluated	evaluated	O
the	the	O
severity	severity	O
of	of	O
motor	motor	B-Disease
disability	disability	I-Disease
and	and	O
dyskinesias	dyskinesias	B-Disease
in	in	O
seven	seven	O
levodopa-responsive	levodopa-responsive	O
patients	patients	O
with	with	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
after	after	O
an	an	O
acute	acute	O
challenge	challenge	O
with	with	O
the	the	O
mixed	mixed	O
dopamine	dopamine	B-Chemical
agonist	agonist	I-Chemical
,	,	O
apomorphine	apomorphine	B-Chemical
,	,	O
before	before	O
and	and	O
after	after	O
the	the	O
administration	administration	O
of	of	O
fluoxetine	fluoxetine	B-Chemical
(	(	O
20	20	O
mg	mg	O
twice	twice	O
per	per	O
day	day	O
)	)	O
for	for	O
11	11	O
+	+	O
/-	/-	O
1	1	O
days	days	O
.	.	O

After	after	O
fluoxetine	fluoxetine	B-Chemical
treatment	treatment	O
,	,	O
there	there	O
was	was	O
a	a	O
significant	significant	O
47	47	O
%	%	O
improvement	improvement	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
of	of	O
apomorphine-induced	apomorphine-induced	O
dyskinesias	dyskinesias	B-Disease
without	without	O
modification	modification	O
of	of	O
parkinsonian	parkinsonian	B-Disease
motor	motor	B-Disease
disability	disability	I-Disease
.	.	O

The	the	O
dyskinesias	dyskinesias	B-Disease
were	were	O
reduced	reduced	O
predominantly	predominantly	O
in	in	O
the	the	O
lower	lower	O
limbs	limbs	O
during	during	O
the	the	O
onset	onset	O
and	and	O
disappearance	disappearance	O
of	of	O
dystonic	dystonic	O
dyskinesias	dyskinesias	B-Disease
(	(	O
onset-	onset-	O
and	and	O
end-of-dose	end-of-dose	O
dyskinesias	dyskinesias	B-Disease
)	)	O
and	and	O
in	in	O
the	the	O
upper	upper	O
limbs	limbs	O
during	during	O
choreic	choreic	O
mid-dose	mid-dose	O
dyskinesias	dyskinesias	B-Disease
.	.	O

The	the	O
results	results	O
suggest	suggest	O
that	that	O
increased	increased	O
brain	brain	O
serotoninergic	serotoninergic	O
transmission	transmission	O
with	with	O
fluoxetine	fluoxetine	B-Chemical
may	may	O
reduce	reduce	O
levodopa-	levodopa-	O
or	or	O
dopamine	dopamine	B-Chemical
agonist-induced	agonist-induced	O
dyskinesias	dyskinesias	B-Disease
without	without	O
aggravating	aggravating	O
parkinsonian	parkinsonian	B-Disease
motor	motor	B-Disease
disability	disability	I-Disease
.	.	O

A	a	O
large	large	O
population-based	population-based	O
follow-up	follow-up	O
study	study	O
of	of	O
trimethoprim-sulfamethoxazole	trimethoprim-sulfamethoxazole	O
,	,	O
trimethoprim	trimethoprim	O
,	,	O
and	and	O
cephalexin	cephalexin	O
for	for	O
uncommon	uncommon	O
serious	serious	O
drug	drug	O
toxicity	toxicity	B-Disease
.	.	O

We	we	O
conducted	conducted	O
a	a	O
population-based	population-based	O
45-day	45-day	O
follow-up	follow-up	O
study	study	O
of	of	O
232,390	232,390	O
people	people	O
who	who	O
were	were	O
prescribed	prescribed	O
trimethoprim-sulfamethoxazole	trimethoprim-sulfamethoxazole	O
(	(	O
TMP-SMZ	tmp-smz	O
)	)	O
,	,	O
266,951	266,951	O
prescribed	prescribed	O
trimethoprim	trimethoprim	O
alone	alone	O
,	,	O
and	and	O
196,397	196,397	O
prescribed	prescribed	O
cephalexin	cephalexin	O
,	,	O
to	to	O
estimate	estimate	O
the	the	O
risk	risk	O
of	of	O
serious	serious	O
liver	liver	O
,	,	O
blood	blood	O
,	,	O
skin	skin	O
,	,	O
and	and	O
renal	renal	O
disorders	disorders	O
resulting	resulting	O
in	in	O
referral	referral	O
or	or	O
hospitalization	hospitalization	O
associated	associated	O
with	with	O
these	these	O
drugs	drugs	O
.	.	O

The	the	O
results	results	O
were	were	O
based	based	O
on	on	O
information	information	O
recorded	recorded	O
on	on	O
office	office	O
computers	computers	O
by	by	O
selected	selected	O
general	general	O
practitioners	practitioners	O
in	in	O
the	the	O
United	united	O
Kingdom	kingdom	O
,	,	O
together	together	O
with	with	O
a	a	O
review	review	O
of	of	O
clinical	clinical	O
records	records	O
.	.	O

The	the	O
risk	risk	O
of	of	O
clinically	clinically	O
important	important	O
idiopathic	idiopathic	O
liver	liver	B-Disease
disease	disease	I-Disease
was	was	O
similar	similar	O
for	for	O
persons	persons	O
prescribed	prescribed	O
TMP-SMZ	tmp-smz	O
(	(	O
5.2/100,000	5.2/100,000	O
)	)	O
and	and	O
those	those	O
prescribed	prescribed	O
trimethoprim	trimethoprim	O
alone	alone	O
(	(	O
3.8/100,000	3.8/100,000	O
)	)	O
.	.	O

The	the	O
risk	risk	O
for	for	O
those	those	O
prescribed	prescribed	O
cephalexin	cephalexin	O
was	was	O
somewhat	somewhat	O
lower	lower	O
(	(	O
2.0/100,000	2.0/100,000	O
)	)	O
.	.	O

Only	only	O
five	five	O
patients	patients	O
experienced	experienced	O
blood	blood	O
disorders	disorders	O
,	,	O
one	one	O
of	of	O
whom	whom	O
was	was	O
exposed	exposed	O
to	to	O
TMP-SMZ	tmp-smz	O
;	;	O
of	of	O
seven	seven	O
with	with	O
erythema	erythema	B-Disease
multiforme	multiforme	I-Disease
and	and	O
Stevens-Johnson	stevens-johnson	O
syndrome	syndrome	O
,	,	O
four	four	O
were	were	O
exposed	exposed	O
to	to	O
TMP-SMZ	tmp-smz	O
.	.	O

The	the	O
one	one	O
case	case	O
of	of	O
toxic	toxic	O
epidermal	epidermal	O
necrolysis	necrolysis	O
occurred	occurred	O
in	in	O
a	a	O
patient	patient	O
who	who	O
took	took	O
cephalexin	cephalexin	O
.	.	O

Finally	finally	O
,	,	O
only	only	O
five	five	O
cases	cases	O
of	of	O
acute	acute	O
parenchymal	parenchymal	O
renal	renal	O
disease	disease	O
occurred	occurred	O
,	,	O
none	none	O
likely	likely	O
to	to	O
be	be	O
caused	caused	O
by	by	O
a	a	O
study	study	O
drug	drug	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
the	the	O
risk	risk	O
of	of	O
the	the	O
serious	serious	O
diseases	diseases	O
studied	studied	O
is	is	O
small	small	O
for	for	O
the	the	O
three	three	O
agents	agents	O
,	,	O
and	and	O
compares	compares	O
reasonably	reasonably	O
with	with	O
the	the	O
risk	risk	O
for	for	O
many	many	O
other	other	O
antibiotics	antibiotics	O
.	.	O

Clinical	clinical	O
safety	safety	O
of	of	O
lidocaine	lidocaine	B-Chemical
in	in	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

STUDY	study	O
OBJECTIVE	objective	O
:	:	O
To	to	O
evaluate	evaluate	O
the	the	O
safety	safety	O
of	of	O
lidocaine	lidocaine	B-Chemical
in	in	O
the	the	O
setting	setting	O
of	of	O
cocaine-induced	cocaine-induced	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
(	(	O
MI	mi	O
)	)	O
.	.	O

DESIGN	design	O
:	:	O
A	a	O
retrospective	retrospective	O
,	,	O
multicenter	multicenter	O
study	study	O
.	.	O

SETTING	setting	O
:	:	O
Twenty-nine	twenty-nine	O
university	university	O
,	,	O
university-affiliated	university-affiliated	O
,	,	O
or	or	O
community	community	O
hospitals	hospitals	O
during	during	O
a	a	O
6-year	6-year	O
period	period	O
(	(	O
total	total	O
of	of	O
117	117	O
cumulative	cumulative	O
hospital-years	hospital-years	O
)	)	O
.	.	O

PARTICIPANTS	participants	O
:	:	O
Patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
MI	mi	O
who	who	O
received	received	O
lidocaine	lidocaine	B-Chemical
in	in	O
the	the	O
emergency	emergency	O
department	department	O
.	.	O

RESULTS	results	O
:	:	O
Of	of	O
29	29	O
patients	patients	O
who	who	O
received	received	O
lidocaine	lidocaine	B-Chemical
in	in	O
the	the	O
setting	setting	O
of	of	O
cocaine-associated	cocaine-associated	O
MI	mi	O
,	,	O
no	no	O
patient	patient	O
died	died	O
;	;	O
exhibited	exhibited	O
bradydysrhythmias	bradydysrhythmias	O
,	,	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
,	,	O
or	or	O
ventricular	ventricular	B-Disease
fibrillation	fibrillation	I-Disease
;	;	O
or	or	O
experienced	experienced	O
seizures	seizures	B-Disease
after	after	O
administration	administration	O
of	of	O
lidocaine	lidocaine	B-Chemical
(	(	O
95	95	O
%	%	O
confidence	confidence	O
interval	interval	O
,	,	O
0	0	O
%	%	O
to	to	O
11	11	O
%	%	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Despite	despite	O
theoretical	theoretical	O
concerns	concerns	O
that	that	O
lidocaine	lidocaine	B-Chemical
may	may	O
enhance	enhance	O
cocaine	cocaine	B-Chemical
toxicity	toxicity	B-Disease
,	,	O
the	the	O
use	use	O
of	of	O
lidocaine	lidocaine	B-Chemical
in	in	O
patients	patients	O
with	with	O
cocaine-associated	cocaine-associated	O
MI	mi	O
was	was	O
not	not	O
associated	associated	O
with	with	O
significant	significant	O
cardiovascular	cardiovascular	O
or	or	O
central	central	O
nervous	nervous	O
system	system	O
toxicity	toxicity	B-Disease
.	.	O

Experimental	experimental	O
progressive	progressive	O
muscular	muscular	O
dystrophy	dystrophy	O
and	and	O
its	its	O
treatment	treatment	O
with	with	O
high	high	O
doses	doses	O
anabolizing	anabolizing	O
agents	agents	O
.	.	O

We	we	O
are	are	O
still	still	O
a	a	O
long	long	O
way	way	O
from	from	O
discovering	discovering	O
an	an	O
unequivocal	unequivocal	O
pathogenetic	pathogenetic	O
interpretation	interpretation	O
of	of	O
progressive	progressive	O
muscular	muscular	O
dystrophy	dystrophy	O
in	in	O
man	man	O
.	.	O

Noteworthy	noteworthy	O
efforts	efforts	O
have	have	O
been	been	O
made	made	O
in	in	O
the	the	O
experimental	experimental	O
field	field	O
;	;	O
a	a	O
recessive	recessive	O
autosomic	autosomic	O
form	form	O
found	found	O
in	in	O
the	the	O
mouse	mouse	O
seems	seems	O
to	to	O
bear	bear	O
the	the	O
closest	closest	O
resemblance	resemblance	O
to	to	O
the	the	O
human	human	O
form	form	O
from	from	O
the	the	O
genetic	genetic	O
point	point	O
of	of	O
view	view	O
.	.	O

Myopathy	myopathy	B-Disease
due	due	O
to	to	O
lack	lack	O
of	of	O
vitamin	vitamin	B-Chemical
E	e	I-Chemical
and	and	O
myopathy	myopathy	B-Disease
induced	induced	O
by	by	O
certain	certain	O
viruses	viruses	O
have	have	O
much	much	O
in	in	O
common	common	O
anatomically	anatomically	O
and	and	O
pathologically	pathologically	O
with	with	O
the	the	O
human	human	O
form	form	O
.	.	O

The	the	O
authors	authors	O
induced	induced	O
myodystrophy	myodystrophy	O
in	in	O
the	the	O
rat	rat	O
by	by	O
giving	giving	O
it	it	O
a	a	O
diet	diet	O
lacking	lacking	O
in	in	O
vitamin	vitamin	O
E.	e.	O
The	the	O
pharmacological	pharmacological	O
characteristics	characteristics	O
of	of	O
vitamin	vitamin	B-Chemical
E	e	I-Chemical
and	and	O
the	the	O
degenerative	degenerative	O
changes	changes	O
brought	brought	O
about	about	O
by	by	O
its	its	O
deficiency	deficiency	O
,	,	O
especially	especially	O
in	in	O
the	the	O
muscles	muscles	O
,	,	O
are	are	O
illustrated	illustrated	O
.	.	O

It	it	O
is	is	O
thus	thus	O
confirmed	confirmed	O
that	that	O
the	the	O
histological	histological	O
characteristics	characteristics	O
of	of	O
myopathic	myopathic	O
rat	rat	O
muscle	muscle	O
induced	induced	O
experimentally	experimentally	O
are	are	O
extraordinarily	extraordinarily	O
similar	similar	O
to	to	O
those	those	O
of	of	O
human	human	O
myopathy	myopathy	B-Disease
as	as	O
confirmed	confirmed	O
during	during	O
biopsies	biopsies	O
performed	performed	O
at	at	O
the	the	O
Orthopaedic	orthopaedic	O
Traumatological	traumatological	O
Centre	centre	O
,	,	O
Florence	florence	O
.	.	O

The	the	O
encouraging	encouraging	O
results	results	O
obtained	obtained	O
in	in	O
various	various	O
authoratative	authoratative	O
departments	departments	O
in	in	O
myopathic	myopathic	O
patients	patients	O
by	by	O
using	using	O
anabolizing	anabolizing	O
steroids	steroids	B-Chemical
have	have	O
encouraged	encouraged	O
the	the	O
authors	authors	O
to	to	O
investigate	investigate	O
the	the	O
beneficial	beneficial	O
effects	effects	O
of	of	O
one	one	O
anabolizing	anabolizing	O
agent	agent	O
(	(	O
Dianabol	dianabol	O
,	,	O
CIBA	ciba	O
)	)	O
at	at	O
high	high	O
doses	doses	O
in	in	O
rats	rats	O
rendered	rendered	O
myopathic	myopathic	O
by	by	O
a	a	O
diet	diet	O
deficient	deficient	O
in	in	O
vitamin	vitamin	O
E.	e.	O
In	in	O
this	this	O
way	way	O
they	they	O
obtained	obtained	O
appreciable	appreciable	O
changes	changes	O
in	in	O
body	body	B-Disease
weight	weight	I-Disease
(	(	O
increased	increased	O
from	from	O
50	50	O
to	to	O
70	70	O
g	g	O
after	after	O
forty	forty	O
days	days	O
at	at	O
a	a	O
dose	dose	O
of	of	O
5	5	O
mg	mg	O
per	per	O
day	day	O
of	of	O
anabolizing	anabolizing	O
agent	agent	O
)	)	O
,	,	O
but	but	O
most	most	O
of	of	O
all	all	O
they	they	O
found	found	O
histological	histological	O
changes	changes	O
due	due	O
to	to	O
"	"	O
regenerative	regenerative	O
"	"	O
changes	changes	O
in	in	O
the	the	O
muscle	muscle	O
tissue	tissue	O
,	,	O
which	which	O
however	however	O
maintained	maintained	O
its	its	O
myopathic	myopathic	O
characteristics	characteristics	O
in	in	O
the	the	O
control	control	O
animals	animals	O
that	that	O
were	were	O
not	not	O
treated	treated	O
with	with	O
the	the	O
anabolizing	anabolizing	O
agent	agent	O
.	.	O

The	the	O
authors	authors	O
conclude	conclude	O
by	by	O
affirming	affirming	O
the	the	O
undoubted	undoubted	O
efficacy	efficacy	O
of	of	O
the	the	O
anabolizing	anabolizing	O
steroids	steroids	B-Chemical
in	in	O
experimental	experimental	O
myopathic	myopathic	O
disease	disease	O
,	,	O
but	but	O
they	they	O
have	have	O
reservations	reservations	O
as	as	O
to	to	O
the	the	O
transfer	transfer	O
of	of	O
the	the	O
results	results	O
into	into	O
the	the	O
human	human	O
field	field	O
,	,	O
where	where	O
high	high	O
dosage	dosage	O
can	can	O
not	not	O
be	be	O
carried	carried	O
out	out	O
continuously	continuously	O
because	because	O
of	of	O
the	the	O
effects	effects	O
of	of	O
the	the	O
drug	drug	O
on	on	O
virility	virility	O
;	;	O
because	because	O
the	the	O
tissue	tissue	O
injury	injury	O
too	too	O
often	often	O
occurs	occurs	O
at	at	O
an	an	O
irreversible	irreversible	O
stage	stage	O
vis-a-vis	vis-a-vis	O
the	the	O
"	"	O
regeneration	regeneration	O
"	"	O
of	of	O
the	the	O
muscle	muscle	O
tissue	tissue	O
;	;	O
and	and	O
finally	finally	O
because	because	O
the	the	O
dystrophic	dystrophic	O
injurious	injurious	O
agent	agent	O
is	is	O
certainly	certainly	O
not	not	O
the	the	O
lack	lack	O
of	of	O
vitamin	vitamin	B-Chemical
E	e	I-Chemical
but	but	O
something	something	O
as	as	O
yet	yet	O
unknown	unknown	O
.	.	O

Paclitaxel	paclitaxel	B-Chemical
3-hour	3-hour	O
infusion	infusion	O
given	given	O
alone	alone	O
and	and	O
combined	combined	O
with	with	O
carboplatin	carboplatin	B-Chemical
:	:	O
preliminary	preliminary	O
results	results	O
of	of	O
dose-escalation	dose-escalation	O
trials	trials	O
.	.	O

Paclitaxel	paclitaxel	B-Chemical
(	(	O
Taxol	taxol	B-Chemical
;	;	O
Bristol-Myers	bristol-myers	O
Squibb	squibb	O
Company	company	O
,	,	O
Princeton	princeton	O
,	,	O
NJ	nj	O
)	)	O
by	by	O
3-hour	3-hour	O
infusion	infusion	O
was	was	O
combined	combined	O
with	with	O
carboplatin	carboplatin	B-Chemical
in	in	O
a	a	O
phase	phase	O
I/II	i/ii	O
study	study	O
directed	directed	O
to	to	O
patients	patients	O
with	with	O
non-small	non-small	O
cell	cell	O
lung	lung	O
cancer	cancer	B-Disease
.	.	O

Carboplatin	carboplatin	B-Chemical
was	was	O
given	given	O
at	at	O
a	a	O
fixed	fixed	O
target	target	O
area	area	O
under	under	O
the	the	O
concentration-time	concentration-time	O
curve	curve	O
of	of	O
6.0	6.0	O
by	by	O
the	the	O
Calvert	calvert	O
formula	formula	O
,	,	O
whereas	whereas	O
paclitaxel	paclitaxel	B-Chemical
was	was	O
escalated	escalated	O
in	in	O
patient	patient	O
cohorts	cohorts	O
from	from	O
150	150	O
mg/m2	mg/m2	O
(	(	O
dose	dose	O
level	level	O
I	i	O
)	)	O
to	to	O
175	175	O
,	,	O
200	200	O
,	,	O
225	225	O
,	,	O
and	and	O
250	250	O
mg/m2	mg/m2	O
.	.	O

The	the	O
225	225	O
mg/m2	mg/m2	O
level	level	O
was	was	O
expanded	expanded	O
for	for	O
the	the	O
phase	phase	O
II	ii	O
study	study	O
since	since	O
the	the	O
highest	highest	O
level	level	O
achieved	achieved	O
(	(	O
250	250	O
mg/m2	mg/m2	O
)	)	O
required	required	O
modification	modification	O
because	because	O
of	of	O
nonhematologic	nonhematologic	O
toxicities	toxicities	B-Disease
(	(	O
arthralgia	arthralgia	O
and	and	O
sensory	sensory	O
neuropathy	neuropathy	B-Disease
)	)	O
.	.	O

Therapeutic	therapeutic	B-Chemical
effects	effects	I-Chemical
were	were	O
noted	noted	O
at	at	O
all	all	O
dose	dose	O
levels	levels	O
,	,	O
with	with	O
objective	objective	O
responses	responses	O
in	in	O
17	17	O
(	(	O
two	two	O
complete	complete	O
and	and	O
15	15	O
partial	partial	O
regressions	regressions	O
)	)	O
of	of	O
41	41	O
previously	previously	O
untreated	untreated	O
patients	patients	O
.	.	O

Toxicities	toxicities	B-Disease
were	were	O
compared	compared	O
with	with	O
a	a	O
cohort	cohort	O
of	of	O
patients	patients	O
in	in	O
a	a	O
phase	phase	O
I	i	O
trial	trial	O
of	of	O
paclitaxel	paclitaxel	B-Chemical
alone	alone	O
at	at	O
identical	identical	O
dose	dose	O
levels	levels	O
.	.	O

Carboplatin	carboplatin	B-Chemical
did	did	O
not	not	O
appear	appear	O
to	to	O
add	add	O
to	to	O
the	the	O
hematologic	hematologic	O
toxicities	toxicities	B-Disease
observed	observed	O
,	,	O
and	and	O
the	the	O
paclitaxel/carboplatin	paclitaxel/carboplatin	O
combination	combination	O
could	could	O
be	be	O
dosed	dosed	O
every	every	O
3	3	O
weeks	weeks	O
.	.	O

The	the	O
dose-dependent	dose-dependent	O
effect	effect	O
of	of	O
misoprostol	misoprostol	O
on	on	O
indomethacin-induced	indomethacin-induced	O
renal	renal	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
well	well	O
compensated	compensated	O
cirrhosis	cirrhosis	B-Disease
.	.	O

Misoprostol	misoprostol	O
(	(	O
200	200	O
micrograms	micrograms	O
)	)	O
has	has	O
been	been	O
shown	shown	O
to	to	O
acutely	acutely	O
counteract	counteract	O
the	the	O
indomethacin-induced	indomethacin-induced	O
renal	renal	B-Disease
dysfunction	dysfunction	I-Disease
in	in	O
well	well	O
compensated	compensated	O
cirrhotic	cirrhotic	O
patients	patients	O
.	.	O

The	the	O
aim	aim	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
determine	determine	O
if	if	O
the	the	O
prophylactic	prophylactic	O
value	value	O
of	of	O
misoprostol	misoprostol	O
was	was	O
dose-dependent	dose-dependent	O
.	.	O

Parameters	parameters	O
of	of	O
renal	renal	O
hemodynamics	hemodynamics	O
and	and	O
tubular	tubular	O
sodium	sodium	B-Chemical
and	and	O
water	water	O
handling	handling	O
were	were	O
assessed	assessed	O
by	by	O
clearance	clearance	O
techniques	techniques	O
in	in	O
26	26	O
well	well	O
compensated	compensated	O
cirrhotic	cirrhotic	O
patients	patients	O
before	before	O
and	and	O
after	after	O
an	an	O
oral	oral	O
combination	combination	O
of	of	O
50	50	O
mg	mg	O
of	of	O
indomethacin	indomethacin	B-Chemical
and	and	O
various	various	O
doses	doses	O
of	of	O
misoprostol	misoprostol	O
.	.	O

The	the	O
200-micrograms	200-micrograms	O
dose	dose	O
was	was	O
able	able	O
to	to	O
totally	totally	O
abolish	abolish	O
the	the	O
deleterious	deleterious	O
renal	renal	O
effects	effects	O
of	of	O
indomethacin	indomethacin	B-Chemical
,	,	O
whereas	whereas	O
the	the	O
800-micrograms	800-micrograms	O
dose	dose	O
resulted	resulted	O
in	in	O
significant	significant	O
worsening	worsening	O
of	of	O
renal	renal	O
hemodynamics	hemodynamics	O
and	and	O
sodium	sodium	B-Chemical
retention	retention	O
.	.	O

These	these	O
changes	changes	O
were	were	O
maximal	maximal	O
in	in	O
the	the	O
hour	hour	O
immediately	immediately	O
after	after	O
medications	medications	O
and	and	O
slowly	slowly	O
returned	returned	O
toward	toward	O
base-line	base-line	O
levels	levels	O
thereafter	thereafter	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
the	the	O
renal	renal	O
protective	protective	O
effects	effects	O
of	of	O
misoprostol	misoprostol	O
is	is	O
dose-dependent	dose-dependent	O
.	.	O

However	however	O
,	,	O
until	until	O
this	this	O
apparent	apparent	O
ability	ability	O
of	of	O
200	200	O
micrograms	micrograms	O
of	of	O
misoprostol	misoprostol	O
to	to	O
prevent	prevent	O
the	the	O
adverse	adverse	O
effects	effects	O
of	of	O
indomethacin	indomethacin	B-Chemical
on	on	O
renal	renal	O
function	function	O
is	is	O
confirmed	confirmed	O
with	with	O
chronic	chronic	O
frequent	frequent	O
dosing	dosing	O
,	,	O
it	it	O
would	would	O
be	be	O
prudent	prudent	O
to	to	O
avoid	avoid	O
nonsteroidal	nonsteroidal	O
anti-inflammatory	anti-inflammatory	O
therapy	therapy	O
in	in	O
patients	patients	O
with	with	O
cirrhosis	cirrhosis	B-Disease
.	.	O

Increased	increased	O
frequency	frequency	O
and	and	O
severity	severity	O
of	of	O
angio-oedema	angio-oedema	O
related	related	O
to	to	O
long-term	long-term	O
therapy	therapy	O
with	with	O
angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	O
inhibitor	inhibitor	O
in	in	O
two	two	O
patients	patients	O
.	.	O

Adverse	adverse	O
reactions	reactions	O
to	to	O
drugs	drugs	O
are	are	O
well	well	O
recognized	recognized	O
as	as	O
a	a	O
cause	cause	O
of	of	O
acute	acute	O
or	or	O
chronic	chronic	O
urticaria	urticaria	B-Disease
,	,	O
and	and	O
angio-oedema	angio-oedema	O
.	.	O

Angiotensin-converting	angiotensin-converting	O
enzyme	enzyme	O
(	(	O
ACE	ace	O
)	)	O
inhibitors	inhibitors	O
,	,	O
used	used	O
to	to	O
treat	treat	O
hypertension	hypertension	B-Disease
and	and	O
congestive	congestive	B-Disease
heart	heart	B-Disease
failure	failure	I-Disease
,	,	O
were	were	O
introduced	introduced	O
in	in	O
Europe	europe	O
in	in	O
the	the	O
middle	middle	O
of	of	O
the	the	O
eighties	eighties	O
,	,	O
and	and	O
the	the	O
use	use	O
of	of	O
these	these	O
drugs	drugs	O
has	has	O
increased	increased	O
progressively	progressively	O
.	.	O

Soon	soon	O
after	after	O
the	the	O
introduction	introduction	O
of	of	O
ACE	ace	O
inhibitors	inhibitors	O
,	,	O
acute	acute	O
bouts	bouts	O
of	of	O
angio-oedema	angio-oedema	O
were	were	O
reported	reported	O
in	in	O
association	association	O
with	with	O
the	the	O
use	use	O
of	of	O
these	these	O
drugs	drugs	O
.	.	O

We	we	O
wish	wish	O
to	to	O
draw	draw	O
attention	attention	O
to	to	O
the	the	O
possibility	possibility	O
of	of	O
adverse	adverse	O
reactions	reactions	O
to	to	O
ACE	ace	O
inhibitors	inhibitors	O
after	after	O
long-term	long-term	O
use	use	O
and	and	O
in	in	O
patients	patients	O
with	with	O
pre-existing	pre-existing	O
angio-oedema	angio-oedema	O
.	.	O

Myoclonus	myoclonus	B-Disease
associated	associated	O
with	with	O
lorazepam	lorazepam	O
therapy	therapy	O
in	in	O
very-low-birth-weight	very-low-birth-weight	O
infants	infants	O
.	.	O

Lorazepam	lorazepam	O
is	is	O
being	being	O
used	used	O
with	with	O
increasing	increasing	O
frequency	frequency	O
as	as	O
a	a	O
sedative	sedative	O
in	in	O
the	the	O
newborn	newborn	O
and	and	O
the	the	O
young	young	O
infant	infant	O
.	.	O

Concern	concern	O
has	has	O
been	been	O
raised	raised	O
with	with	O
regard	regard	O
to	to	O
the	the	O
safety	safety	O
of	of	O
lorazepam	lorazepam	O
in	in	O
this	this	O
age	age	O
group	group	O
,	,	O
especially	especially	O
in	in	O
very-low-birth-weight	very-low-birth-weight	O
(	(	O
VLBW	vlbw	O
;	;	O
<	<	O
1,500	1,500	O
g	g	O
)	)	O
infants	infants	O
.	.	O

Three	three	O
young	young	O
infants	infants	O
,	,	O
all	all	O
of	of	O
birth	birth	B-Disease
weight	weight	I-Disease
<	<	O
1,500	1,500	O
g	g	O
,	,	O
experienced	experienced	O
myoclonus	myoclonus	B-Disease
following	following	O
the	the	O
intravenous	intravenous	O
administration	administration	O
of	of	O
lorazepam	lorazepam	O
.	.	O

The	the	O
potential	potential	O
neurotoxic	neurotoxic	B-Disease
effects	effects	O
of	of	O
the	the	O
drug	drug	O
(	(	O
and	and	O
its	its	O
vehicle	vehicle	O
)	)	O
in	in	O
this	this	O
population	population	O
are	are	O
discussed	discussed	O
.	.	O

Injectable	injectable	O
lorazepam	lorazepam	O
should	should	O
be	be	O
used	used	O
with	with	O
caution	caution	O
in	in	O
VLBW	vlbw	O
infants	infants	O
.	.	O

Transvenous	transvenous	O
right	right	O
ventricular	ventricular	O
pacing	pacing	O
during	during	O
cardiopulmonary	cardiopulmonary	O
resuscitation	resuscitation	O
of	of	O
pediatric	pediatric	O
patients	patients	O
with	with	O
acute	acute	O
cardiomyopathy	cardiomyopathy	B-Disease
.	.	O

We	we	O
describe	describe	O
the	the	O
cardiopulmonary	cardiopulmonary	O
resuscitation	resuscitation	O
efforts	efforts	O
on	on	O
five	five	O
patients	patients	O
who	who	O
presented	presented	O
in	in	O
acute	acute	O
circulatory	circulatory	O
failure	failure	O
from	from	O
myocardial	myocardial	O
dysfunction	dysfunction	O
.	.	O

Three	three	O
patients	patients	O
had	had	O
acute	acute	O
viral	viral	O
myocarditis	myocarditis	B-Disease
,	,	O
one	one	O
had	had	O
a	a	O
carbamazepine-induced	carbamazepine-induced	O
acute	acute	O
eosinophilic	eosinophilic	O
myocarditis	myocarditis	B-Disease
,	,	O
and	and	O
one	one	O
had	had	O
cardiac	cardiac	O
hemosiderosis	hemosiderosis	O
resulting	resulting	O
in	in	O
acute	acute	O
cardiogenic	cardiogenic	O
shock	shock	B-Disease
.	.	O

All	all	O
patients	patients	O
were	were	O
continuously	continuously	O
monitored	monitored	O
with	with	O
central	central	O
venous	venous	O
and	and	O
arterial	arterial	O
catheters	catheters	O
in	in	O
addition	addition	O
to	to	O
routine	routine	O
noninvasive	noninvasive	O
monitoring	monitoring	O
.	.	O

An	an	O
introducer	introducer	O
sheath	sheath	O
,	,	O
a	a	O
pacemaker	pacemaker	O
,	,	O
and	and	O
sterile	sterile	O
pacing	pacing	O
wires	wires	O
were	were	O
made	made	O
readily	readily	O
available	available	O
for	for	O
the	the	O
patients	patients	O
,	,	O
should	should	O
the	the	O
need	need	O
arise	arise	O
to	to	O
terminate	terminate	O
resistant	resistant	O
cardiac	cardiac	O
dysrhythmias	dysrhythmias	O
.	.	O

All	all	O
patients	patients	O
developed	developed	O
cardiocirculatory	cardiocirculatory	O
arrest	arrest	O
associated	associated	O
with	with	O
extreme	extreme	O
hypotension	hypotension	B-Disease
and	and	O
dysrhythmias	dysrhythmias	O
within	within	O
the	the	O
first	first	O
48	48	O
hours	hours	O
of	of	O
their	their	O
admission	admission	O
to	to	O
the	the	O
pediatric	pediatric	O
intensive	intensive	O
care	care	O
unit	unit	O
(	(	O
PICU	picu	O
)	)	O
.	.	O

Right	right	O
ventricular	ventricular	O
pacemaker	pacemaker	O
wires	wires	O
were	were	O
inserted	inserted	O
in	in	O
all	all	O
of	of	O
them	them	O
during	during	O
cardiopulmonary	cardiopulmonary	O
resuscitation	resuscitation	O
(	(	O
CPR	cpr	O
)	)	O
.	.	O

In	in	O
four	four	O
patients	patients	O
,	,	O
cardiac	cardiac	O
pacing	pacing	O
was	was	O
used	used	O
,	,	O
resulting	resulting	O
in	in	O
a	a	O
temporary	temporary	O
captured	captured	O
rhythm	rhythm	O
and	and	O
restoration	restoration	O
of	of	O
their	their	O
cardiac	cardiac	O
output	output	O
.	.	O

These	these	O
patients	patients	O
had	had	O
a	a	O
second	second	O
event	event	O
of	of	O
cardiac	cardiac	B-Disease
arrest	arrest	I-Disease
,	,	O
resulting	resulting	O
in	in	O
death	death	B-Disease
,	,	O
within	within	O
10	10	O
to	to	O
60	60	O
minutes	minutes	O
.	.	O

In	in	O
one	one	O
patient	patient	O
,	,	O
cardiac	cardiac	O
pacing	pacing	O
was	was	O
not	not	O
used	used	O
,	,	O
because	because	O
he	he	O
converted	converted	O
to	to	O
normal	normal	O
sinus	sinus	O
rhythm	rhythm	O
by	by	O
electrical	electrical	O
defibrillation	defibrillation	O
within	within	O
three	three	O
minutes	minutes	O
of	of	O
initiating	initiating	O
CPR	cpr	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
cardiac	cardiac	O
pacing	pacing	O
during	during	O
resuscitative	resuscitative	O
efforts	efforts	O
in	in	O
pediatric	pediatric	O
patients	patients	O
suffering	suffering	O
from	from	O
acute	acute	O
myocardial	myocardial	O
dysfunction	dysfunction	O
may	may	O
not	not	O
have	have	O
long-term	long-term	O
value	value	O
in	in	O
and	and	O
of	of	O
itself	itself	O
;	;	O
however	however	O
,	,	O
if	if	O
temporary	temporary	O
hemodynamic	hemodynamic	O
stability	stability	O
is	is	O
achieved	achieved	O
by	by	O
this	this	O
procedure	procedure	O
,	,	O
it	it	O
may	may	O
provide	provide	O
additional	additional	O
time	time	O
needed	needed	O
to	to	O
institute	institute	O
other	other	O
therapeutic	therapeutic	O
modalities	modalities	O
.	.	O

Efficacy	efficacy	O
and	and	O
safety	safety	O
of	of	O
granisetron	granisetron	O
,	,	O
a	a	O
selective	selective	O
5-hydroxytryptamine-3	5-hydroxytryptamine-3	O
receptor	receptor	O
antagonist	antagonist	O
,	,	O
in	in	O
the	the	O
prevention	prevention	O
of	of	O
nausea	nausea	B-Disease
and	and	O
vomiting	vomiting	B-Disease
induced	induced	O
by	by	O
high-dose	high-dose	O
cisplatin	cisplatin	B-Chemical
.	.	O

PURPOSE	purpose	O
:	:	O
To	to	O
assess	assess	O
the	the	O
antiemetic	antiemetic	O
effects	effects	O
and	and	O
safety	safety	O
profile	profile	O
of	of	O
four	four	O
different	different	O
doses	doses	O
of	of	O
granisetron	granisetron	O
(	(	O
Kytril	kytril	O
;	;	O
SmithKline	smithkline	O
Beecham	beecham	O
Pharmaceuticals	pharmaceuticals	O
,	,	O
Philadelphia	philadelphia	O
,	,	O
PA	pa	O
)	)	O
when	when	O
administered	administered	O
as	as	O
a	a	O
single	single	O
intravenous	intravenous	O
(	(	O
IV	iv	O
)	)	O
dose	dose	O
for	for	O
prophylaxis	prophylaxis	O
of	of	O
cisplatin-induced	cisplatin-induced	O
nausea	nausea	B-Disease
and	and	O
vomiting	vomiting	B-Disease
.	.	O

PATIENTS	patients	O
AND	and	O
METHODS	methods	O
:	:	O
One	one	O
hundred	hundred	O
eighty-four	eighty-four	O
chemotherapy-naive	chemotherapy-naive	O
patients	patients	O
receiving	receiving	O
high-dose	high-dose	O
cisplatin	cisplatin	B-Chemical
(	(	O
81	81	O
to	to	O
120	120	O
mg/m2	mg/m2	O
)	)	O
were	were	O
randomized	randomized	O
to	to	O
receive	receive	O
one	one	O
of	of	O
four	four	O
granisetron	granisetron	O
doses	doses	O
(	(	O
5	5	O
,	,	O
10	10	O
,	,	O
20	20	O
,	,	O
or	or	O
40	40	O
micrograms/kg	micrograms/kg	O
)	)	O
administered	administered	O
before	before	O
chemotherapy	chemotherapy	O
.	.	O

Patients	patients	O
were	were	O
observed	observed	O
on	on	O
an	an	O
inpatient	inpatient	O
basis	basis	O
for	for	O
18	18	O
to	to	O
24	24	O
hours	hours	O
,	,	O
and	and	O
vital	vital	O
signs	signs	O
,	,	O
nausea	nausea	B-Disease
,	,	O
vomiting	vomiting	B-Disease
,	,	O
retching	retching	O
,	,	O
and	and	O
appetite	appetite	O
were	were	O
assessed	assessed	O
.	.	O

Safety	safety	O
analyses	analyses	O
included	included	O
incidence	incidence	O
of	of	O
adverse	adverse	O
experiences	experiences	O
and	and	O
laboratory	laboratory	O
parameter	parameter	O
changes	changes	O
.	.	O

RESULTS	results	O
:	:	O
After	after	O
granisetron	granisetron	O
doses	doses	O
of	of	O
5	5	O
,	,	O
10	10	O
,	,	O
20	20	O
,	,	O
and	and	O
40	40	O
micrograms/kg	micrograms/kg	O
,	,	O
a	a	O
major	major	O
response	response	O
(	(	O
<	<	O
or	or	O
=	=	O
two	two	O
vomiting	vomiting	B-Disease
or	or	O
retching	retching	O
episodes	episodes	O
,	,	O
and	and	O
no	no	O
antiemetic	antiemetic	O
rescue	rescue	O
)	)	O
was	was	O
recorded	recorded	O
in	in	O
23	23	O
%	%	O
,	,	O
57	57	O
%	%	O
,	,	O
58	58	O
%	%	O
,	,	O
and	and	O
60	60	O
%	%	O
of	of	O
patients	patients	O
,	,	O
respectively	respectively	O
,	,	O
and	and	O
a	a	O
complete	complete	O
response	response	O
(	(	O
no	no	O
vomiting	vomiting	B-Disease
or	or	O
retching	retching	O
,	,	O
and	and	O
no	no	O
antiemetic	antiemetic	O
rescue	rescue	O
)	)	O
in	in	O
18	18	O
%	%	O
,	,	O
41	41	O
%	%	O
,	,	O
40	40	O
%	%	O
,	,	O
and	and	O
47	47	O
%	%	O
of	of	O
patients	patients	O
,	,	O
respectively	respectively	O
.	.	O

There	there	O
was	was	O
a	a	O
statistically	statistically	O
longer	longer	O
time	time	O
to	to	O
first	first	O
episode	episode	O
of	of	O
nausea	nausea	B-Disease
(	(	O
P	p	O
=	=	O
.0015	.0015	O
)	)	O
and	and	O
vomiting	vomiting	B-Disease
(	(	O
P	p	O
=	=	O
.0001	.0001	O
)	)	O
,	,	O
and	and	O
fewer	fewer	O
patients	patients	O
were	were	O
administered	administered	O
additional	additional	O
antiemetic	antiemetic	O
medication	medication	O
in	in	O
the	the	O
10-micrograms/kg	10-micrograms/kg	O
dosing	dosing	O
groups	groups	O
than	than	O
in	in	O
the	the	O
5-micrograms/kg	5-micrograms/kg	O
dosing	dosing	O
group	group	O
.	.	O

As	as	O
granisetron	granisetron	O
dose	dose	O
increased	increased	O
,	,	O
appetite	appetite	O
return	return	O
increased	increased	O
(	(	O
P	p	O
=	=	O
.040	.040	O
)	)	O
.	.	O

Headache	headache	B-Disease
was	was	O
the	the	O
most	most	O
frequently	frequently	O
reported	reported	O
adverse	adverse	O
event	event	O
(	(	O
20	20	O
%	%	O
)	)	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
A	a	O
single	single	O
10-	10-	O
,	,	O
20-	20-	O
,	,	O
or	or	O
40-micrograms/kg	40-micrograms/kg	O
dose	dose	O
of	of	O
granisetron	granisetron	O
was	was	O
effective	effective	O
in	in	O
controlling	controlling	O
vomiting	vomiting	B-Disease
in	in	O
57	57	O
%	%	O
to	to	O
60	60	O
%	%	O
of	of	O
patients	patients	O
who	who	O
received	received	O
cisplatin	cisplatin	B-Chemical
at	at	O
doses	doses	O
greater	greater	O
than	than	O
81	81	O
mg/m2	mg/m2	O
and	and	O
totally	totally	O
prevented	prevented	O
vomiting	vomiting	B-Disease
in	in	O
40	40	O
%	%	O
to	to	O
47	47	O
%	%	O
of	of	O
patients	patients	O
.	.	O

There	there	O
were	were	O
no	no	O
statistically	statistically	O
significant	significant	O
differences	differences	O
in	in	O
efficacy	efficacy	O
between	between	O
the	the	O
10-micrograms/kg	10-micrograms/kg	O
dose	dose	O
and	and	O
the	the	O
20-	20-	O
and	and	O
40-micrograms/kg	40-micrograms/kg	O
doses	doses	O
.	.	O

Granisetron	granisetron	O
was	was	O
well	well	O
tolerated	tolerated	O
at	at	O
all	all	O
doses	doses	O
.	.	O

Adverse	adverse	O
interaction	interaction	O
between	between	O
clonidine	clonidine	B-Chemical
and	and	O
verapamil	verapamil	B-Chemical
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
report	report	O
two	two	O
cases	cases	O
of	of	O
a	a	O
possible	possible	O
adverse	adverse	O
interaction	interaction	O
between	between	O
clonidine	clonidine	B-Chemical
and	and	O
verapamil	verapamil	B-Chemical
resulting	resulting	O
in	in	O
atrioventricular	atrioventricular	O
(	(	O
AV	av	O
)	)	O
block	block	O
in	in	O
both	both	O
patients	patients	O
and	and	O
severe	severe	O
hypotension	hypotension	B-Disease
in	in	O
one	one	O
patient	patient	O
.	.	O

CASE	case	O
SUMMARIES	summaries	O
:	:	O
A	a	O
54-year-old	54-year-old	O
woman	woman	O
with	with	O
hyperaldosteronism	hyperaldosteronism	O
was	was	O
treated	treated	O
with	with	O
verapamil	verapamil	B-Chemical
480	480	O
mg/d	mg/d	O
and	and	O
spironolactone	spironolactone	B-Chemical
100	100	O
mg/d	mg/d	O
.	.	O

After	after	O
the	the	O
addition	addition	O
of	of	O
a	a	O
minimal	minimal	O
dose	dose	O
of	of	O
clonidine	clonidine	B-Chemical
(	(	O
0.15	0.15	O
mg	mg	O
bid	bid	O
)	)	O
,	,	O
she	she	O
developed	developed	O
complete	complete	O
AV	av	B-Disease
block	block	I-Disease
and	and	O
severe	severe	O
hypotension	hypotension	B-Disease
,	,	O
which	which	O
resolved	resolved	O
upon	upon	O
cessation	cessation	O
of	of	O
all	all	O
medications	medications	O
.	.	O

A	a	O
65-year-old	65-year-old	O
woman	woman	O
was	was	O
treated	treated	O
with	with	O
extended-release	extended-release	O
verapamil	verapamil	B-Chemical
240	240	O
mg/d	mg/d	O
.	.	O

After	after	O
the	the	O
addition	addition	O
of	of	O
clonidine	clonidine	B-Chemical
0.15	0.15	O
mg	mg	O
bid	bid	O
she	she	O
developed	developed	O
complete	complete	O
AV	av	B-Disease
block	block	I-Disease
,	,	O
which	which	O
resolved	resolved	O
after	after	O
all	all	O
therapy	therapy	O
was	was	O
stopped	stopped	O
.	.	O

DISCUSSION	discussion	O
:	:	O
An	an	O
adverse	adverse	O
interaction	interaction	O
between	between	O
clonidine	clonidine	B-Chemical
and	and	O
verapamil	verapamil	B-Chemical
has	has	O
not	not	O
been	been	O
reported	reported	O
previously	previously	O
.	.	O

We	we	O
describe	describe	O
two	two	O
such	such	O
cases	cases	O
and	and	O
discuss	discuss	O
the	the	O
various	various	O
mechanisms	mechanisms	O
that	that	O
might	might	O
cause	cause	O
such	such	O
an	an	O
interaction	interaction	O
.	.	O

Clinicians	clinicians	O
should	should	O
be	be	O
acquainted	acquainted	O
with	with	O
this	this	O
possibly	possibly	O
fatal	fatal	O
interaction	interaction	O
between	between	O
two	two	O
commonly	commonly	O
used	used	O
antihypertensive	antihypertensive	B-Chemical
drugs	drugs	I-Chemical
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
Caution	caution	O
is	is	O
recommended	recommended	O
in	in	O
combining	combining	O
clonidine	clonidine	B-Chemical
and	and	O
verapamil	verapamil	B-Chemical
therapy	therapy	O
,	,	O
even	even	O
in	in	O
patients	patients	O
who	who	O
do	do	O
not	not	O
have	have	O
sinus	sinus	O
or	or	O
AV	av	O
node	node	O
dysfunction	dysfunction	O
.	.	O

The	the	O
two	two	O
drugs	drugs	O
may	may	O
act	act	O
synergistically	synergistically	O
on	on	O
both	both	O
the	the	O
AV	av	O
node	node	O
and	and	O
the	the	O
peripheral	peripheral	O
circulation	circulation	O
.	.	O

Pharmacological	pharmacological	O
studies	studies	O
on	on	O
a	a	O
new	new	O
dihydrothienopyridine	dihydrothienopyridine	O
calcium	calcium	B-Chemical
antagonist	antagonist	O
,	,	O
S-312-d	s-312-d	O
.	.	O

5th	5th	O
communication	communication	O
:	:	O
anticonvulsant	anticonvulsant	O
effects	effects	O
in	in	O
mice	mice	O
.	.	O

S-312	s-312	O
,	,	O
S-312-d	s-312-d	O
,	,	O
but	but	O
not	not	O
S-312-l	s-312-l	O
,	,	O
L-type	l-type	O
calcium	calcium	B-Chemical
channel	channel	I-Chemical
antagonists	antagonists	I-Chemical
,	,	O
showed	showed	O
anticonvulsant	anticonvulsant	O
effects	effects	O
on	on	O
the	the	O
audiogenic	audiogenic	O
tonic	tonic	O
convulsions	convulsions	B-Disease
in	in	O
DBA/2	dba/2	O
mice	mice	O
;	;	O
and	and	O
their	their	O
ED50	ed50	O
values	values	O
were	were	O
18.4	18.4	O
(	(	O
12.8	12.8	O
-	-	O
27.1	27.1	O
)	)	O
mg/kg	mg/kg	O
,	,	O
p.o	p.o	O
.	.	O
and	and	O
15.0	15.0	O
(	(	O
10.2	10.2	O
-	-	O
23.7	23.7	O
)	)	O
mg/kg	mg/kg	O
,	,	O
p.o	p.o	O
.	.	O
,	,	O
respectively	respectively	O
,	,	O
while	while	O
that	that	O
of	of	O
flunarizine	flunarizine	O
was	was	O
34.0	34.0	O
(	(	O
26.0	26.0	O
-	-	O
44.8	44.8	O
)	)	O
mg/kg	mg/kg	O
,	,	O
p.o	p.o	O
.	.	O

Although	although	O
moderate	moderate	O
anticonvulsant	anticonvulsant	O
effects	effects	O
of	of	O
S-312-d	s-312-d	O
in	in	O
higher	higher	O
doses	doses	O
were	were	O
observed	observed	O
against	against	O
the	the	O
clonic	clonic	O
convulsions	convulsions	B-Disease
induced	induced	O
by	by	O
pentylenetetrazole	pentylenetetrazole	O
(	(	O
85	85	O
mg/kg	mg/kg	O
,	,	O
s.c	s.c	O
.	.	O
)	)	O
or	or	O
bemegride	bemegride	O
(	(	O
40	40	O
mg/kg	mg/kg	O
,	,	O
s.c	s.c	O
.	.	O
)	)	O
,	,	O
no	no	O
effects	effects	O
were	were	O
observed	observed	O
in	in	O
convulsions	convulsions	B-Disease
induced	induced	O
by	by	O
N-methyl-D-aspartate	n-methyl-d-aspartate	O
,	,	O
picrotoxin	picrotoxin	B-Chemical
,	,	O
or	or	O
electroshock	electroshock	O
in	in	O
Slc	slc	O
:	:	O
ddY	ddy	O
mice	mice	O
.	.	O

S-312-d	s-312-d	O
may	may	O
be	be	O
useful	useful	O
in	in	O
the	the	O
therapy	therapy	O
of	of	O
certain	certain	O
types	types	O
of	of	O
human	human	O
epilepsy	epilepsy	B-Disease
.	.	O

Transmural	transmural	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
with	with	O
sumatriptan	sumatriptan	B-Chemical
.	.	O

For	for	O
sumatriptan	sumatriptan	B-Chemical
,	,	O
tightness	tightness	O
in	in	O
the	the	O
chest	chest	O
caused	caused	O
by	by	O
an	an	O
unknown	unknown	O
mechanism	mechanism	O
has	has	O
been	been	O
reported	reported	O
in	in	O
3	3	O
-	-	O
5	5	O
%	%	O
of	of	O
users	users	O
.	.	O

We	we	O
describe	describe	O
a	a	O
47-year-old	47-year-old	O
woman	woman	O
with	with	O
an	an	O
acute	acute	B-Disease
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
after	after	O
administration	administration	O
of	of	O
sumatriptan	sumatriptan	B-Chemical
6	6	O
mg	mg	O
subcutaneously	subcutaneously	O
for	for	O
cluster	cluster	B-Disease
headache	headache	B-Disease
.	.	O

The	the	O
patient	patient	O
had	had	O
no	no	O
history	history	O
of	of	O
underlying	underlying	O
ischaemic	ischaemic	O
heart	heart	B-Disease
disease	disease	I-Disease
or	or	O
Prinzmetal	prinzmetal	O
's	's	O
angina	angina	O
.	.	O

She	she	O
recovered	recovered	O
without	without	O
complications	complications	O
.	.	O

Flumazenil	flumazenil	B-Chemical
induces	induces	O
seizures	seizures	B-Disease
and	and	O
death	death	B-Disease
in	in	O
mixed	mixed	O
cocaine-diazepam	cocaine-diazepam	O
intoxications	intoxications	O
.	.	O

STUDY	study	O
HYPOTHESIS	hypothesis	O
:	:	O
Administration	administration	O
of	of	O
the	the	O
benzodiazepine	benzodiazepine	B-Chemical
antagonist	antagonist	O
flumazenil	flumazenil	B-Chemical
may	may	O
unmask	unmask	O
seizures	seizures	B-Disease
in	in	O
mixed	mixed	O
cocaine-benzodiazepine	cocaine-benzodiazepine	O
intoxication	intoxication	O
.	.	O

DESIGN	design	O
:	:	O
Male	male	O
Sprague-Dawley	sprague-dawley	O
rats	rats	O
received	received	O
100	100	O
mg/kg	mg/kg	O
cocaine	cocaine	B-Chemical
IP	ip	O
alone	alone	O
,	,	O
5	5	O
mg/kg	mg/kg	O
diazepam	diazepam	B-Chemical
alone	alone	O
,	,	O
or	or	O
a	a	O
combination	combination	O
of	of	O
diazepam	diazepam	B-Chemical
and	and	O
cocaine	cocaine	B-Chemical
.	.	O

Three	three	O
minutes	minutes	O
later	later	O
,	,	O
groups	groups	O
were	were	O
challenged	challenged	O
with	with	O
vehicle	vehicle	O
or	or	O
flumazenil	flumazenil	B-Chemical
5	5	O
or	or	O
10	10	O
mg/kg	mg/kg	O
IP	ip	O
.	.	O

Animal	animal	O
behavior	behavior	O
,	,	O
seizures	seizures	B-Disease
(	(	O
time	time	O
to	to	O
and	and	O
incidence	incidence	O
)	)	O
,	,	O
death	death	B-Disease
(	(	O
time	time	O
to	to	O
and	and	O
incidence	incidence	O
)	)	O
,	,	O
and	and	O
cortical	cortical	O
EEG	eeg	O
tracings	tracings	O
were	were	O
recorded	recorded	O
.	.	O

INTERVENTIONS	interventions	O
:	:	O
Administration	administration	O
of	of	O
flumazenil	flumazenil	B-Chemical
to	to	O
animals	animals	O
after	after	O
they	they	O
had	had	O
received	received	O
a	a	O
combination	combination	O
dose	dose	O
of	of	O
cocaine	cocaine	B-Chemical
and	and	O
diazepam	diazepam	B-Chemical
.	.	O

RESULTS	results	O
:	:	O
In	in	O
group	group	O
1	1	O
,	,	O
animals	animals	O
received	received	O
cocaine	cocaine	B-Chemical
followed	followed	O
by	by	O
vehicle	vehicle	O
.	.	O

This	this	O
resulted	resulted	O
in	in	O
100	100	O
%	%	O
developing	developing	O
seizures	seizures	B-Disease
and	and	O
death	death	B-Disease
.	.	O

Group	group	O
2	2	O
received	received	O
diazepam	diazepam	B-Chemical
alone	alone	O
followed	followed	O
by	by	O
vehicle	vehicle	O
.	.	O

Animals	animals	O
became	became	O
somnolent	somnolent	O
and	and	O
none	none	O
died	died	O
.	.	O

Group	group	O
3	3	O
received	received	O
diazepam	diazepam	B-Chemical
followed	followed	O
by	by	O
5	5	O
mg/kg	mg/kg	O
flumazenil	flumazenil	B-Chemical
.	.	O

Animals	animals	O
became	became	O
somnolent	somnolent	O
after	after	O
diazepam	diazepam	B-Chemical
and	and	O
then	then	O
active	active	O
after	after	O
flumazenil	flumazenil	B-Chemical
administration	administration	O
.	.	O

In	in	O
group	group	O
4	4	O
,	,	O
a	a	O
combination	combination	O
of	of	O
cocaine	cocaine	B-Chemical
and	and	O
diazepam	diazepam	B-Chemical
was	was	O
administered	administered	O
simultaneously	simultaneously	O
.	.	O

This	this	O
resulted	resulted	O
in	in	O
no	no	O
overt	overt	O
or	or	O
EEG-detectable	eeg-detectable	O
seizures	seizures	B-Disease
and	and	O
a	a	O
50	50	O
%	%	O
incidence	incidence	O
of	of	O
death	death	B-Disease
.	.	O

Group	group	O
5	5	O
received	received	O
a	a	O
similar	similar	O
combination	combination	O
of	of	O
cocaine	cocaine	B-Chemical
and	and	O
diazepam	diazepam	B-Chemical
,	,	O
followed	followed	O
later	later	O
by	by	O
5	5	O
mg/kg	mg/kg	O
flumazenil	flumazenil	B-Chemical
.	.	O

This	this	O
resulted	resulted	O
in	in	O
an	an	O
increased	increased	O
incidence	incidence	O
of	of	O
seizures	seizures	B-Disease
,	,	O
90	90	O
%	%	O
(	(	O
P	p	O
<	<	O
.01	.01	O
)	)	O
,	,	O
and	and	O
death	death	B-Disease
,	,	O
100	100	O
%	%	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
.01	.01	O
)	)	O
,	,	O
compared	compared	O
with	with	O
group	group	O
4	4	O
.	.	O

Group	group	O
6	6	O
received	received	O
cocaine	cocaine	B-Chemical
and	and	O
diazepam	diazepam	B-Chemical
followed	followed	O
by	by	O
10	10	O
mg/kg	mg/kg	O
flumazenil	flumazenil	B-Chemical
.	.	O

This	this	O
also	also	O
resulted	resulted	O
in	in	O
an	an	O
increased	increased	O
incidence	incidence	O
of	of	O
seizures	seizures	B-Disease
,	,	O
90	90	O
%	%	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
.01	.01	O
)	)	O
,	,	O
and	and	O
death	death	B-Disease
,	,	O
90	90	O
%	%	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
.05	.05	O
)	)	O
,	,	O
compared	compared	O
with	with	O
group	group	O
4	4	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Flumazenil	flumazenil	B-Chemical
can	can	O
unmask	unmask	O
seizures	seizures	B-Disease
and	and	O
increase	increase	O
the	the	O
incidence	incidence	O
of	of	O
death	death	B-Disease
in	in	O
a	a	O
model	model	O
of	of	O
combined	combined	O
cocaine-diazepam	cocaine-diazepam	O
intoxications	intoxications	O
.	.	O

Mechanisms	mechanisms	O
for	for	O
protective	protective	O
effects	effects	O
of	of	O
free	free	B-Chemical
radical	radical	I-Chemical
scavengers	scavengers	I-Chemical
on	on	O
gentamicin-mediated	gentamicin-mediated	O
nephropathy	nephropathy	B-Disease
in	in	O
rats	rats	O
.	.	O

Studies	studies	O
were	were	O
performed	performed	O
to	to	O
examine	examine	O
the	the	O
mechanisms	mechanisms	O
for	for	O
the	the	O
protective	protective	O
effects	effects	O
of	of	O
free	free	B-Chemical
radical	radical	I-Chemical
scavengers	scavengers	I-Chemical
on	on	O
gentamicin	gentamicin	B-Chemical
(GM)-mediated	(gm)-mediated	O
nephropathy	nephropathy	B-Disease
.	.	O

Administration	administration	O
of	of	O
GM	gm	B-Chemical
at	at	O
40	40	O
mg/kg	mg/kg	O
sc	sc	O
for	for	O
13	13	O
days	days	O
to	to	O
rats	rats	O
induced	induced	O
a	a	O
significant	significant	O
reduction	reduction	O
in	in	O
renal	renal	O
blood	blood	O
flow	flow	O
(	(	O
RBF	rbf	O
)	)	O
and	and	O
inulin	inulin	O
clearance	clearance	O
(	(	O
CIn	cin	O
)	)	O
as	as	O
well	well	O
as	as	O
marked	marked	O
tubular	tubular	O
damage	damage	O
.	.	O

A	a	O
significant	significant	O
reduction	reduction	O
in	in	O
urinary	urinary	O
guanosine	guanosine	O
3',5'-cyclic	3',5'-cyclic	O
monophosphate	monophosphate	O
(	(	O
cGMP	cgmp	O
)	)	O
excretion	excretion	O
and	and	O
a	a	O
significant	significant	O
increase	increase	O
in	in	O
renal	renal	O
cortical	cortical	O
renin	renin	O
and	and	O
endothelin-1	endothelin-1	O
contents	contents	O
were	were	O
also	also	O
observed	observed	O
in	in	O
GM-mediated	gm-mediated	O
nephropathy	nephropathy	B-Disease
.	.	O

Superoxide	superoxide	B-Chemical
dismutase	dismutase	I-Chemical
(	(	O
SOD	sod	O
)	)	O
or	or	O
dimethylthiourea	dimethylthiourea	O
(	(	O
DMTU	dmtu	O
)	)	O
significantly	significantly	O
lessened	lessened	O
the	the	O
GM-induced	gm-induced	O
decrement	decrement	O
in	in	O
CIn	cin	O
.	.	O

The	the	O
SOD-induced	sod-induced	O
increase	increase	O
in	in	O
glomerular	glomerular	O
filtration	filtration	O
rate	rate	O
was	was	O
associated	associated	O
with	with	O
a	a	O
marked	marked	O
improvement	improvement	O
in	in	O
RBF	rbf	O
,	,	O
an	an	O
increase	increase	O
in	in	O
urinary	urinary	O
cGMP	cgmp	O
excretion	excretion	O
,	,	O
and	and	O
a	a	O
decrease	decrease	O
in	in	O
renal	renal	O
renin	renin	O
and	and	O
endothelin-1	endothelin-1	O
content	content	O
.	.	O

SOD	sod	O
did	did	O
not	not	O
attenuate	attenuate	O
the	the	O
tubular	tubular	O
damage	damage	O
.	.	O

In	in	O
contrast	contrast	O
,	,	O
DMTU	dmtu	O
significantly	significantly	O
reduced	reduced	O
the	the	O
tubular	tubular	O
damage	damage	O
and	and	O
lipid	lipid	O
peroxidation	peroxidation	O
,	,	O
but	but	O
it	it	O
did	did	O
not	not	O
affect	affect	O
renal	renal	O
hemodynamics	hemodynamics	O
and	and	O
vasoactive	vasoactive	O
substances	substances	O
.	.	O

Neither	neither	O
SOD	sod	O
nor	nor	O
DMTU	dmtu	O
affected	affected	O
the	the	O
renal	renal	O
cortical	cortical	O
GM	gm	B-Chemical
content	content	O
in	in	O
GM-treated	gm-treated	O
rats	rats	O
.	.	O

These	these	O
results	results	O
suggest	suggest	O
that	that	O
1	1	O
)	)	O
both	both	O
SOD	sod	O
and	and	O
DMTU	dmtu	O
have	have	O
protective	protective	O
effects	effects	O
on	on	O
GM-mediated	gm-mediated	O
nephropathy	nephropathy	B-Disease
,	,	O
2	2	O
)	)	O
the	the	O
mechanisms	mechanisms	O
for	for	O
the	the	O
protective	protective	O
effects	effects	O
differ	differ	O
for	for	O
SOD	sod	O
and	and	O
DMTU	dmtu	O
,	,	O
and	and	O
3	3	O
)	)	O
superoxide	superoxide	B-Chemical
anions	anions	O
play	play	O
a	a	O
critical	critical	O
role	role	O
in	in	O
GM-induced	gm-induced	O
renal	renal	O
vasoconstriction	vasoconstriction	O
.	.	O

Cephalothin-induced	cephalothin-induced	O
immune	immune	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
.	.	O

A	a	O
patient	patient	O
with	with	O
renal	renal	O
disease	disease	O
developed	developed	O
Coombs-positive	coombs-positive	O
hemolytic	hemolytic	B-Disease
anemia	anemia	B-Disease
while	while	O
receiving	receiving	O
cephalothin	cephalothin	B-Chemical
therapy	therapy	O
.	.	O

An	an	O
anti-cephalothin	anti-cephalothin	O
IgG	igg	O
antibody	antibody	O
was	was	O
detected	detected	O
in	in	O
the	the	O
patient	patient	O
's	's	O
serum	serum	O
and	and	O
in	in	O
the	the	O
eluates	eluates	O
from	from	O
her	her	O
erythrocytes	erythrocytes	O
.	.	O

In	in	O
addition	addition	O
,	,	O
nonimmunologic	nonimmunologic	O
binding	binding	O
of	of	O
normal	normal	O
and	and	O
patient	patient	O
's	's	O
serum	serum	O
proteins	proteins	O
to	to	O
her	her	O
own	own	O
and	and	O
cephalothin-coated	cephalothin-coated	O
normal	normal	O
red	red	O
cells	cells	O
was	was	O
demonstrated	demonstrated	O
.	.	O

Skin	skin	O
tests	tests	O
and	and	O
in	in	O
vitro	vitro	O
lymphocyte	lymphocyte	O
stimulation	stimulation	O
revealed	revealed	O
that	that	O
the	the	O
patient	patient	O
was	was	O
sensitized	sensitized	O
to	to	O
cephalothin	cephalothin	B-Chemical
and	and	O
also	also	O
to	to	O
ampicillin	ampicillin	B-Chemical
.	.	O

Careful	careful	O
investigation	investigation	O
of	of	O
drug-induced	drug-induced	O
hemolytic	hemolytic	O
anemias	anemias	O
reveals	reveals	O
the	the	O
complexity	complexity	O
of	of	O
the	the	O
immune	immune	O
mechanisms	mechanisms	O
involved	involved	O
.	.	O

Assessment	assessment	O
of	of	O
cardiomyocyte	cardiomyocyte	O
DNA	dna	O
synthesis	synthesis	O
during	during	O
hypertrophy	hypertrophy	B-Disease
in	in	O
adult	adult	O
mice	mice	O
.	.	O

The	the	O
ability	ability	O
of	of	O
cardiomyocytes	cardiomyocytes	O
to	to	O
synthesize	synthesize	O
DNA	dna	O
in	in	O
response	response	O
to	to	O
experimentally	experimentally	O
induced	induced	O
cardiac	cardiac	B-Disease
hypertrophy	hypertrophy	B-Disease
was	was	O
assessed	assessed	O
in	in	O
adult	adult	O
mice	mice	O
.	.	O

Isoproterenol	isoproterenol	B-Chemical
delivered	delivered	O
by	by	O
osmotic	osmotic	O
minipump	minipump	O
implantation	implantation	O
in	in	O
adult	adult	O
C3Heb/FeJ	c3heb/fej	O
mice	mice	O
resulted	resulted	O
in	in	O
a	a	O
46	46	O
%	%	O
increase	increase	O
in	in	O
heart	heart	O
weight	weight	O
and	and	O
a	a	O
19.3	19.3	O
%	%	O
increase	increase	O
in	in	O
cardiomyocyte	cardiomyocyte	O
area	area	O
.	.	O

No	no	O
DNA	dna	O
synthesis	synthesis	O
,	,	O
as	as	O
assessed	assessed	O
by	by	O
autoradiographic	autoradiographic	O
analysis	analysis	O
of	of	O
isolated	isolated	O
cardiomyocytes	cardiomyocytes	O
,	,	O
was	was	O
observed	observed	O
in	in	O
control	control	O
or	or	O
hypertrophic	hypertrophic	O
hearts	hearts	O
.	.	O

A	a	O
survey	survey	O
of	of	O
15	15	O
independent	independent	O
inbred	inbred	O
strains	strains	O
of	of	O
mice	mice	O
revealed	revealed	O
that	that	O
ventricular	ventricular	O
cardiomyocyte	cardiomyocyte	O
nuclear	nuclear	O
number	number	O
ranged	ranged	O
from	from	O
3	3	O
to	to	O
13	13	O
%	%	O
mononucleate	mononucleate	O
,	,	O
suggesting	suggesting	O
that	that	O
cardiomyocyte	cardiomyocyte	O
terminal	terminal	O
differentiation	differentiation	O
is	is	O
influenced	influenced	O
directly	directly	O
or	or	O
indirectly	indirectly	O
by	by	O
genetic	genetic	O
background	background	O
.	.	O

To	to	O
determine	determine	O
whether	whether	O
the	the	O
capacity	capacity	O
for	for	O
reactive	reactive	O
DNA	dna	O
synthesis	synthesis	O
was	was	O
also	also	O
subject	subject	O
to	to	O
genetic	genetic	O
regulation	regulation	O
,	,	O
cardiac	cardiac	B-Disease
hypertrophy	hypertrophy	B-Disease
was	was	O
induced	induced	O
in	in	O
the	the	O
strains	strains	O
of	of	O
mice	mice	O
comprising	comprising	O
the	the	O
extremes	extremes	O
of	of	O
the	the	O
nuclear	nuclear	O
number	number	O
survey	survey	O
.	.	O

These	these	O
data	data	O
indicate	indicate	O
that	that	O
adult	adult	O
mouse	mouse	O
atrial	atrial	O
and	and	O
ventricular	ventricular	O
cardiomyocytes	cardiomyocytes	O
do	do	O
not	not	O
synthesize	synthesize	O
DNA	dna	O
in	in	O
response	response	O
to	to	O
isoproterenol-induced	isoproterenol-induced	O
cardiac	cardiac	B-Disease
hypertrophy	hypertrophy	B-Disease
.	.	O

Central	central	O
cardiovascular	cardiovascular	O
effects	effects	O
of	of	O
AVP	avp	B-Chemical
and	and	O
ANP	anp	B-Chemical
in	in	O
normotensive	normotensive	O
and	and	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
rats	rats	O
.	.	O

The	the	O
purpose	purpose	O
of	of	O
the	the	O
present	present	O
study	study	O
was	was	O
to	to	O
compare	compare	O
influence	influence	O
of	of	O
central	central	O
arginine	arginine	B-Chemical
vasopressin	vasopressin	B-Chemical
(	(	O
AVP	avp	B-Chemical
)	)	O
and	and	O
of	of	O
atrial	atrial	O
natriuretic	natriuretic	O
peptide	peptide	O
(	(	O
ANP	anp	B-Chemical
)	)	O
on	on	O
control	control	O
of	of	O
arterial	arterial	O
blood	blood	O
pressure	pressure	O
(	(	O
MAP	map	O
)	)	O
and	and	O
heart	heart	O
rate	rate	O
(	(	O
HR	hr	O
)	)	O
in	in	O
normotensive	normotensive	O
(	(	O
WKY	wky	O
)	)	O
and	and	O
spontaneously	spontaneously	O
hypertensive	hypertensive	B-Disease
(	(	O
SHR	shr	O
)	)	O
rats	rats	O
.	.	O

Three	three	O
series	series	O
of	of	O
experiments	experiments	O
were	were	O
performed	performed	O
on	on	O
30	30	O
WKY	wky	O
and	and	O
30	30	O
SHR	shr	O
,	,	O
chronically	chronically	O
instrumented	instrumented	O
with	with	O
guide	guide	O
tubes	tubes	O
in	in	O
the	the	O
lateral	lateral	O
ventricle	ventricle	O
(	(	O
LV	lv	O
)	)	O
and	and	O
arterial	arterial	O
and	and	O
venous	venous	O
catheters	catheters	O
.	.	O

MAP	map	O
and	and	O
HR	hr	O
were	were	O
monitored	monitored	O
before	before	O
and	and	O
after	after	O
i.v	i.v	O
.	.	O

injections	injections	O
of	of	O
either	either	O
vehicle	vehicle	O
or	or	O
1	1	O
,	,	O
10	10	O
and	and	O
50	50	O
ng	ng	O
of	of	O
AVP	avp	B-Chemical
and	and	O
25	25	O
,	,	O
125	125	O
and	and	O
500	500	O
ng	ng	O
of	of	O
ANP	anp	B-Chemical
.	.	O

Sensitivity	sensitivity	O
of	of	O
cardiac	cardiac	O
component	component	O
of	of	O
baroreflex	baroreflex	O
(	(	O
CCB	ccb	O
)	)	O
,	,	O
expressed	expressed	O
as	as	O
a	a	O
slope	slope	O
of	of	O
the	the	O
regression	regression	O
line	line	O
was	was	O
determined	determined	O
from	from	O
relationships	relationships	O
between	between	O
systolic	systolic	O
arterial	arterial	O
pressure	pressure	O
(	(	O
SAP	sap	O
)	)	O
and	and	O
HR	hr	O
period	period	O
(	(	O
HRp	hrp	O
)	)	O
during	during	O
phenylephrine	phenylephrine	B-Chemical
(Phe)-induced	(phe)-induced	O
hypertension	hypertension	B-Disease
and	and	O
sodium	sodium	B-Chemical
nitroprusside	nitroprusside	B-Chemical
(SN)-induced	(sn)-induced	O
hypotension	hypotension	B-Disease
.	.	O

CCB	ccb	O
was	was	O
measured	measured	O
before	before	O
and	and	O
after	after	O
administration	administration	O
of	of	O
either	either	O
vehicle	vehicle	O
,	,	O
AVP	avp	B-Chemical
,	,	O
ANP	anp	B-Chemical
,	,	O
or	or	O
both	both	O
peptides	peptides	O
together	together	O
.	.	O

Increases	increases	O
of	of	O
MAP	map	O
occurred	occurred	O
after	after	O
LV	lv	O
administration	administration	O
of	of	O
1	1	O
,	,	O
10	10	O
and	and	O
50	50	O
ng	ng	O
of	of	O
AVP	avp	B-Chemical
in	in	O
WKY	wky	O
and	and	O
of	of	O
10	10	O
and	and	O
50	50	O
ng	ng	O
in	in	O
SHR	shr	O
.	.	O

ANP	anp	B-Chemical
did	did	O
not	not	O
cause	cause	O
significant	significant	O
changes	changes	O
in	in	O
MAP	map	O
in	in	O
both	both	O
strains	strains	O
as	as	O
compared	compared	O
to	to	O
vehicle	vehicle	O
,	,	O
but	but	O
it	it	O
abolished	abolished	O
AVP-induced	avp-induced	O
MAP	map	O
increase	increase	O
in	in	O
WKY	wky	O
and	and	O
SHR	shr	O
.	.	O

CCB	ccb	O
was	was	O
reduced	reduced	O
in	in	O
WKY	wky	O
and	and	O
SHR	shr	O
after	after	O
LV	lv	O
administration	administration	O
of	of	O
AVP	avp	B-Chemical
during	during	O
SN-induced	sn-induced	O
hypotension	hypotension	B-Disease
.	.	O

In	in	O
SHR	shr	O
but	but	O
not	not	O
in	in	O
WKY	wky	O
administration	administration	O
of	of	O
ANP	anp	B-Chemical
,	,	O
AVP	avp	B-Chemical
and	and	O
ANP	anp	B-Chemical
+	+	O
AVP	avp	B-Chemical
decreased	decreased	O
CCB	ccb	O
during	during	O
Phe-induced	phe-induced	O
MAP	map	O
elevation	elevation	O
.	.	O

The	the	O
results	results	O
indicate	indicate	O
that	that	O
centrally	centrally	O
applied	applied	O
AVP	avp	B-Chemical
and	and	O
ANP	anp	B-Chemical
exert	exert	O
differential	differential	O
effects	effects	O
on	on	O
blood	blood	O
pressure	pressure	O
and	and	O
baroreflex	baroreflex	O
control	control	O
of	of	O
heart	heart	O
rate	rate	O
in	in	O
WKY	wky	O
and	and	O
SHR	shr	O
and	and	O
suggest	suggest	O
interaction	interaction	O
of	of	O
these	these	O
two	two	O
peptides	peptides	O
in	in	O
blood	blood	O
pressure	pressure	O
regulation	regulation	O
at	at	O
the	the	O
level	level	O
of	of	O
central	central	O
nervous	nervous	O
system	system	O
.	.	O

Cutaneous	cutaneous	O
exposure	exposure	O
to	to	O
warfarin-like	warfarin-like	O
anticoagulant	anticoagulant	O
causing	causing	O
an	an	O
intracerebral	intracerebral	B-Disease
hemorrhage	hemorrhage	B-Disease
:	:	O
a	a	O
case	case	O
report	report	O
.	.	O

A	a	O
case	case	O
of	of	O
intercerebral	intercerebral	O
hematoma	hematoma	B-Disease
due	due	O
to	to	O
warfarin-induced	warfarin-induced	O
coagulopathy	coagulopathy	B-Disease
is	is	O
presented	presented	O
.	.	O

The	the	O
39-year-old	39-year-old	O
woman	woman	O
had	had	O
spread	spread	O
a	a	O
warfarin-type	warfarin-type	O
rat	rat	O
poison	poison	O
around	around	O
her	her	O
house	house	O
weekly	weekly	O
using	using	O
her	her	O
bare	bare	O
hands	hands	O
,	,	O
with	with	O
no	no	O
washing	washing	O
post	post	O
application	application	O
.	.	O

Percutaneous	percutaneous	O
absorption	absorption	O
of	of	O
warfarin	warfarin	B-Chemical
causing	causing	O
coagulopathy	coagulopathy	B-Disease
,	,	O
reported	reported	O
three	three	O
times	times	O
in	in	O
the	the	O
past	past	O
,	,	O
is	is	O
a	a	O
significant	significant	O
risk	risk	O
if	if	O
protective	protective	O
measures	measures	O
,	,	O
such	such	O
as	as	O
gloves	gloves	O
,	,	O
are	are	O
not	not	O
used	used	O
.	.	O

An	an	O
adverse	adverse	O
drug	drug	O
interaction	interaction	O
with	with	O
piroxicam	piroxicam	B-Chemical
,	,	O
which	which	O
she	she	O
took	took	O
occasionally	occasionally	O
,	,	O
may	may	O
have	have	O
exacerbated	exacerbated	O
the	the	O
coagulopathy	coagulopathy	B-Disease
.	.	O

Pediatric	pediatric	O
heart	heart	O
transplantation	transplantation	O
without	without	O
chronic	chronic	O
maintenance	maintenance	O
steroids	steroids	B-Chemical
.	.	O

From	from	O
1986	1986	O
to	to	O
February	february	O
1993	1993	O
,	,	O
40	40	O
children	children	O
aged	aged	O
2	2	O
months	months	O
to	to	O
18	18	O
years	years	O
(	(	O
average	average	O
age	age	O
10.4	10.4	O
+	+	O
/-	/-	O
5.8	5.8	O
years	years	O
)	)	O
underwent	underwent	O
heart	heart	O
transplantation	transplantation	O
.	.	O

Indications	indications	O
for	for	O
transplantation	transplantation	O
were	were	O
idiopathic	idiopathic	O
cardiomyopathy	cardiomyopathy	B-Disease
(	(	O
52	52	O
%	%	O
)	)	O
,	,	O
congenital	congenital	O
heart	heart	B-Disease
disease	disease	I-Disease
(	(	O
35	35	O
%	%	O
)	)	O
with	with	O
and	and	O
without	without	O
prior	prior	O
repair	repair	O
(	(	O
71	71	O
%	%	O
and	and	O
29	29	O
%	%	O
,	,	O
respectively	respectively	O
)	)	O
,	,	O
hypertrophic	hypertrophic	O
cardiomyopathy	cardiomyopathy	B-Disease
(	(	O
5	5	O
%	%	O
)	)	O
,	,	O
valvular	valvular	B-Disease
heart	heart	B-Disease
disease	disease	I-Disease
(	(	O
3	3	O
%	%	O
)	)	O
,	,	O
and	and	O
doxorubicin	doxorubicin	B-Chemical
cardiomyopathy	cardiomyopathy	B-Disease
(	(	O
5	5	O
%	%	O
)	)	O
.	.	O

Patients	patients	O
were	were	O
managed	managed	O
with	with	O
cyclosporine	cyclosporine	B-Chemical
and	and	O
azathioprine	azathioprine	B-Chemical
.	.	O

No	no	O
prophylaxis	prophylaxis	O
with	with	O
antilymphocyte	antilymphocyte	O
globulin	globulin	O
was	was	O
used	used	O
.	.	O

Steroids	steroids	B-Chemical
were	were	O
given	given	O
to	to	O
39	39	O
%	%	O
of	of	O
patients	patients	O
for	for	O
refractory	refractory	O
rejection	rejection	O
,	,	O
but	but	O
weaning	weaning	O
was	was	O
always	always	O
attempted	attempted	O
and	and	O
generally	generally	O
successful	successful	O
(	(	O
64	64	O
%	%	O
)	)	O
.	.	O

Five	five	O
patients	patients	O
(	(	O
14	14	O
%	%	O
)	)	O
received	received	O
maintenance	maintenance	O
steroids	steroids	B-Chemical
.	.	O

Four	four	O
patients	patients	O
died	died	O
in	in	O
the	the	O
perioperative	perioperative	O
period	period	O
and	and	O
one	one	O
died	died	O
4	4	O
months	months	O
later	later	O
.	.	O

There	there	O
have	have	O
been	been	O
no	no	O
deaths	deaths	B-Disease
related	related	O
to	to	O
rejection	rejection	O
or	or	O
infection	infection	B-Disease
.	.	O

Average	average	O
follow-up	follow-up	O
was	was	O
36	36	O
+	+	O
/-	/-	O
19	19	O
months	months	O
(	(	O
range	range	O
1	1	O
to	to	O
65	65	O
months	months	O
)	)	O
.	.	O

Cumulative	cumulative	O
survival	survival	O
is	is	O
88	88	O
%	%	O
at	at	O
5	5	O
years	years	O
.	.	O

In	in	O
patients	patients	O
less	less	O
than	than	O
7	7	O
years	years	O
of	of	O
age	age	O
,	,	O
rejection	rejection	O
was	was	O
monitored	monitored	O
noninvasively	noninvasively	O
.	.	O

In	in	O
the	the	O
first	first	O
postoperative	postoperative	O
month	month	O
,	,	O
89	89	O
%	%	O
of	of	O
patients	patients	O
were	were	O
treated	treated	O
for	for	O
rejection	rejection	O
.	.	O

Freedom	freedom	O
from	from	O
serious	serious	O
infections	infections	B-Disease
was	was	O
83	83	O
%	%	O
at	at	O
1	1	O
month	month	O
and	and	O
65	65	O
%	%	O
at	at	O
1	1	O
year	year	O
.	.	O

Cytomegalovirus	cytomegalovirus	B-Disease
infections	infections	B-Disease
were	were	O
treated	treated	O
successfully	successfully	O
with	with	O
ganciclovir	ganciclovir	O
in	in	O
11	11	O
patients	patients	O
.	.	O

No	no	O
impairment	impairment	O
of	of	O
growth	growth	O
was	was	O
observed	observed	O
in	in	O
children	children	O
who	who	O
underwent	underwent	O
transplantation	transplantation	O
compared	compared	O
with	with	O
a	a	O
control	control	O
population	population	O
.	.	O

Twenty-one	twenty-one	O
patients	patients	O
(	(	O
60	60	O
%	%	O
)	)	O
have	have	O
undergone	undergone	O
annual	annual	O
catheterizations	catheterizations	O
and	and	O
no	no	O
sign	sign	O
of	of	O
graft	graft	O
atherosclerosis	atherosclerosis	B-Disease
has	has	O
been	been	O
observed	observed	O
.	.	O

Seizures	seizures	B-Disease
occurred	occurred	O
in	in	O
five	five	O
patients	patients	O
(	(	O
14	14	O
%	%	O
)	)	O
and	and	O
hypertension	hypertension	B-Disease
was	was	O
treated	treated	O
in	in	O
10	10	O
patients	patients	O
(	(	O
28	28	O
%	%	O
)	)	O
.	.	O

No	no	O
patient	patient	O
was	was	O
disabled	disabled	O
and	and	O
no	no	O
lymphoproliferative	lymphoproliferative	O
disorder	disorder	O
was	was	O
observed.(ABSTRACT	observed.(abstract	O
TRUNCATED	truncated	O
AT	at	O
250	250	O
WORDS	words	O
)	)	O

Delirium	delirium	B-Disease
during	during	O
fluoxetine	fluoxetine	B-Chemical
treatment	treatment	O
.	.	O

A	a	O
case	case	O
report	report	O
.	.	O

The	the	O
correlation	correlation	O
between	between	O
high	high	O
serum	serum	O
tricyclic	tricyclic	O
antidepressant	antidepressant	B-Chemical
concentrations	concentrations	O
and	and	O
central	central	O
nervous	nervous	O
system	system	O
side	side	O
effects	effects	O
has	has	O
been	been	O
well	well	O
established	established	O
.	.	O

Only	only	O
a	a	O
few	few	O
reports	reports	O
exist	exist	O
,	,	O
however	however	O
,	,	O
on	on	O
the	the	O
relationship	relationship	O
between	between	O
the	the	O
serum	serum	O
concentrations	concentrations	O
of	of	O
selective	selective	O
serotonin	serotonin	B-Chemical
reuptake	reuptake	O
inhibitors	inhibitors	O
(	(	O
SSRIs	ssris	O
)	)	O
and	and	O
their	their	O
toxic	toxic	O
effects	effects	O
.	.	O

In	in	O
some	some	O
cases	cases	O
,	,	O
a	a	O
high	high	O
serum	serum	O
concentration	concentration	O
of	of	O
citalopram	citalopram	B-Chemical
(	(	O
>	>	O
600	600	O
nmol/L	nmol/l	O
)	)	O
in	in	O
elderly	elderly	O
patients	patients	O
has	has	O
been	been	O
associated	associated	O
with	with	O
increased	increased	O
somnolence	somnolence	B-Disease
and	and	O
movement	movement	O
difficulties	difficulties	O
.	.	O

Widespread	widespread	O
cognitive	cognitive	O
disorders	disorders	O
,	,	O
such	such	O
as	as	O
delirium	delirium	B-Disease
,	,	O
have	have	O
not	not	O
been	been	O
previously	previously	O
linked	linked	O
with	with	O
high	high	O
blood	blood	O
levels	levels	O
of	of	O
SSRIs	ssris	O
.	.	O

In	in	O
this	this	O
report	report	O
,	,	O
we	we	O
describe	describe	O
a	a	O
patient	patient	O
with	with	O
acute	acute	O
hyperkinetic	hyperkinetic	O
delirium	delirium	B-Disease
connected	connected	O
with	with	O
a	a	O
high	high	O
serum	serum	O
total	total	O
fluoxetine	fluoxetine	B-Chemical
(	(	O
fluoxetine	fluoxetine	B-Chemical
plus	plus	O
desmethylfluoxetine	desmethylfluoxetine	O
)	)	O
concentration	concentration	O
.	.	O

Pulmonary	pulmonary	B-Disease
edema	edema	B-Disease
and	and	O
shock	shock	B-Disease
after	after	O
high-dose	high-dose	O
aracytine-C	aracytine-c	O
for	for	O
lymphoma	lymphoma	O
;	;	O
possible	possible	O
role	role	O
of	of	O
TNF-alpha	tnf-alpha	O
and	and	O
PAF.Four	paf.four	O
out	out	O
of	of	O
23	23	O
consecutive	consecutive	O
patients	patients	O
treated	treated	O
with	with	O
high-dose	high-dose	O
Ara-C	ara-c	O
for	for	O
lymphomas	lymphomas	O
in	in	O
our	our	O
institution	institution	O
developed	developed	O
a	a	O
strikingly	strikingly	O
similar	similar	O
syndrome	syndrome	O
during	during	O
the	the	O
perfusion	perfusion	O
.	.	O

It	it	O
was	was	O
characterized	characterized	O
by	by	O
the	the	O
onset	onset	O
of	of	O
fever	fever	B-Disease
,	,	O
diarrhea	diarrhea	B-Disease
,	,	O
shock	shock	B-Disease
,	,	O
pulmonary	pulmonary	B-Disease
edema	edema	B-Disease
,	,	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
,	,	O
metabolic	metabolic	B-Disease
acidosis	acidosis	B-Disease
,	,	O
weight	weight	B-Disease
gain	gain	I-Disease
and	and	O
leukocytosis	leukocytosis	O
.	.	O

Thorough	thorough	O
bacteriological	bacteriological	O
screening	screening	O
failed	failed	O
to	to	O
provide	provide	O
evidence	evidence	O
of	of	O
infection	infection	B-Disease
.	.	O

Sequential	sequential	O
biological	biological	O
assays	assays	O
of	of	O
IL-1	il-1	O
,	,	O
IL-2	il-2	O
,	,	O
TNF	tnf	O
and	and	O
PAF	paf	O
were	were	O
performed	performed	O
during	during	O
Ara-C	ara-c	O
infusion	infusion	O
to	to	O
ten	ten	O
patients	patients	O
,	,	O
including	including	O
the	the	O
four	four	O
who	who	O
developed	developed	O
the	the	O
syndrome	syndrome	O
.	.	O

TNF	tnf	O
and	and	O
PAF	paf	O
activity	activity	O
was	was	O
found	found	O
in	in	O
the	the	O
serum	serum	O
of	of	O
respectively	respectively	O
two	two	O
and	and	O
four	four	O
of	of	O
the	the	O
cases	cases	O
,	,	O
but	but	O
not	not	O
in	in	O
the	the	O
six	six	O
controls	controls	O
.	.	O

As	as	O
TNF	tnf	O
and	and	O
PAF	paf	O
are	are	O
thought	thought	O
to	to	O
be	be	O
involved	involved	O
in	in	O
the	the	O
development	development	O
of	of	O
septic	septic	O
shock	shock	B-Disease
and	and	O
adult	adult	O
respiratory	respiratory	O
distress	distress	O
syndrome	syndrome	O
,	,	O
we	we	O
hypothesize	hypothesize	O
that	that	O
high-dose	high-dose	O
Ara-C	ara-c	O
may	may	O
be	be	O
associated	associated	O
with	with	O
cytokine	cytokine	O
release	release	O
.	.	O

Protective	protective	O
effect	effect	O
of	of	O
clentiazem	clentiazem	O
against	against	O
epinephrine-induced	epinephrine-induced	O
cardiac	cardiac	O
injury	injury	O
in	in	O
rats	rats	O
.	.	O

We	we	O
investigated	investigated	O
the	the	O
effects	effects	O
of	of	O
clentiazem	clentiazem	O
,	,	O
a	a	O
1,5-benzothiazepine	1,5-benzothiazepine	O
calcium	calcium	B-Chemical
antagonist	antagonist	O
,	,	O
on	on	O
epinephrine-induced	epinephrine-induced	O
cardiomyopathy	cardiomyopathy	B-Disease
in	in	O
rats	rats	O
.	.	O

With	with	O
2-week	2-week	O
chronic	chronic	O
epinephrine	epinephrine	B-Chemical
infusion	infusion	O
,	,	O
16	16	O
of	of	O
30	30	O
rats	rats	O
died	died	O
within	within	O
4	4	O
days	days	O
,	,	O
and	and	O
severe	severe	O
ischemic	ischemic	O
lesions	lesions	O
and	and	O
fibrosis	fibrosis	B-Disease
of	of	O
the	the	O
left	left	O
ventricles	ventricles	O
were	were	O
observed	observed	O
.	.	O

In	in	O
epinephrine-treated	epinephrine-treated	O
rats	rats	O
,	,	O
left	left	O
atrial	atrial	O
and	and	O
left	left	O
ventricular	ventricular	O
papillary	papillary	O
muscle	muscle	O
contractile	contractile	O
responses	responses	O
to	to	O
isoproterenol	isoproterenol	B-Chemical
were	were	O
reduced	reduced	O
,	,	O
but	but	O
responses	responses	O
to	to	O
calcium	calcium	B-Chemical
were	were	O
normal	normal	O
or	or	O
enhanced	enhanced	O
compared	compared	O
to	to	O
controls	controls	O
.	.	O

Left	left	O
ventricular	ventricular	O
alpha	alpha	O
and	and	O
beta	beta	O
adrenoceptor	adrenoceptor	O
densities	densities	O
were	were	O
also	also	O
reduced	reduced	O
compared	compared	O
to	to	O
controls	controls	O
.	.	O

Treatment	treatment	O
with	with	O
clentiazem	clentiazem	O
prevented	prevented	O
epinephrine-induced	epinephrine-induced	O
death	death	B-Disease
(	(	O
P	p	O
<	<	O
.05	.05	O
)	)	O
,	,	O
and	and	O
attenuated	attenuated	O
the	the	O
ventricular	ventricular	O
ischemic	ischemic	O
lesions	lesions	O
and	and	O
fibrosis	fibrosis	B-Disease
,	,	O
in	in	O
a	a	O
dose-dependent	dose-dependent	O
manner	manner	O
.	.	O

Left	left	O
atrial	atrial	O
and	and	O
left	left	O
ventricular	ventricular	O
papillary	papillary	O
muscle	muscle	O
contractile	contractile	O
responses	responses	O
to	to	O
isoproterenol	isoproterenol	B-Chemical
were	were	O
reduced	reduced	O
compared	compared	O
to	to	O
controls	controls	O
in	in	O
groups	groups	O
treated	treated	O
with	with	O
clentiazem	clentiazem	O
alone	alone	O
,	,	O
but	but	O
combined	combined	O
with	with	O
epinephrine	epinephrine	B-Chemical
,	,	O
clentiazem	clentiazem	O
restored	restored	O
left	left	O
atrial	atrial	O
responses	responses	O
and	and	O
enhanced	enhanced	O
left	left	O
ventricular	ventricular	O
papillary	papillary	O
responses	responses	O
to	to	O
isoproterenol	isoproterenol	B-Chemical
.	.	O

On	on	O
the	the	O
other	other	O
hand	hand	O
clentiazem	clentiazem	O
did	did	O
not	not	O
prevent	prevent	O
epinephrine-induced	epinephrine-induced	O
down-regulation	down-regulation	O
of	of	O
alpha	alpha	O
and	and	O
beta	beta	O
adrenoceptors	adrenoceptors	O
.	.	O

Interestingly	interestingly	O
,	,	O
clentiazem	clentiazem	O
,	,	O
infused	infused	O
alone	alone	O
,	,	O
resulted	resulted	O
in	in	O
decreased	decreased	O
adrenergic	adrenergic	O
receptor	receptor	O
densities	densities	O
in	in	O
the	the	O
left	left	O
ventricle	ventricle	O
.	.	O

Clentiazem	clentiazem	O
also	also	O
did	did	O
not	not	O
prevent	prevent	O
the	the	O
enhanced	enhanced	O
responses	responses	O
to	to	O
calcium	calcium	B-Chemical
seen	seen	O
in	in	O
the	the	O
epinephrine-treated	epinephrine-treated	O
animals	animals	O
,	,	O
although	although	O
the	the	O
high	high	O
dose	dose	O
of	of	O
clentiazem	clentiazem	O
partially	partially	O
attenuated	attenuated	O
the	the	O
maximal	maximal	O
response	response	O
to	to	O
calcium	calcium	B-Chemical
compared	compared	O
to	to	O
epinephrine-treated	epinephrine-treated	O
animals	animals	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
clentiazem	clentiazem	O
attenuated	attenuated	O
epinephrine-induced	epinephrine-induced	O
cardiac	cardiac	O
injury	injury	O
,	,	O
possibly	possibly	O
through	through	O
its	its	O
effect	effect	O
on	on	O
the	the	O
adrenergic	adrenergic	O
pathway	pathway	O
.	.	O

Kaliuretic	kaliuretic	O
effect	effect	O
of	of	O
L-dopa	l-dopa	O
treatment	treatment	O
in	in	O
parkinsonian	parkinsonian	B-Disease
patients	patients	O
.	.	O

Hypokalemia	hypokalemia	O
,	,	O
sometimes	sometimes	O
severe	severe	O
,	,	O
was	was	O
observed	observed	O
in	in	O
some	some	O
L-dopa-treated	l-dopa-treated	O
parkinsonian	parkinsonian	B-Disease
patients	patients	O
.	.	O

The	the	O
influence	influence	O
of	of	O
L-dopa	l-dopa	O
on	on	O
the	the	O
renal	renal	O
excretion	excretion	O
of	of	O
potassium	potassium	B-Chemical
was	was	O
studied	studied	O
in	in	O
3	3	O
patients	patients	O
with	with	O
hypokalemia	hypokalemia	O
and	and	O
in	in	O
5	5	O
normokalemic	normokalemic	O
patients	patients	O
by	by	O
determination	determination	O
of	of	O
renal	renal	O
plasma	plasma	O
flow	flow	O
,	,	O
glomerular	glomerular	O
filtration	filtration	O
rate	rate	O
,	,	O
plasma	plasma	O
concentration	concentration	O
of	of	O
potassium	potassium	B-Chemical
and	and	O
sodium	sodium	B-Chemical
as	as	O
well	well	O
as	as	O
urinary	urinary	O
excretion	excretion	O
of	of	O
potassium	potassium	B-Chemical
,	,	O
sodium	sodium	B-Chemical
and	and	O
aldosterone	aldosterone	B-Chemical
.	.	O

L-Dopa	l-dopa	O
intake	intake	O
was	was	O
found	found	O
to	to	O
cause	cause	O
an	an	O
increased	increased	O
excretion	excretion	O
of	of	O
potassium	potassium	B-Chemical
,	,	O
and	and	O
sometimes	sometimes	O
also	also	O
of	of	O
sodium	sodium	B-Chemical
,	,	O
in	in	O
the	the	O
hypokalemic	hypokalemic	O
but	but	O
not	not	O
in	in	O
the	the	O
normokalemic	normokalemic	O
patients	patients	O
.	.	O

This	this	O
effect	effect	O
on	on	O
the	the	O
renal	renal	O
function	function	O
could	could	O
be	be	O
prohibited	prohibited	O
by	by	O
the	the	O
administration	administration	O
of	of	O
a	a	O
peripheral	peripheral	O
dopa	dopa	O
decarbodylase	decarbodylase	O
inhibitor	inhibitor	O
.	.	O

It	it	O
is	is	O
not	not	O
known	known	O
why	why	O
this	this	O
effect	effect	O
occurred	occurred	O
in	in	O
some	some	O
individuals	individuals	O
but	but	O
not	not	O
in	in	O
others	others	O
,	,	O
but	but	O
our	our	O
results	results	O
indicate	indicate	O
a	a	O
correlation	correlation	O
between	between	O
aldosterone	aldosterone	B-Chemical
production	production	O
and	and	O
this	this	O
renal	renal	O
effect	effect	O
of	of	O
L-dopa	l-dopa	O
.	.	O

Cocaine	cocaine	B-Chemical
induced	induced	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
induced	induced	O
by	by	O
cocaine	cocaine	B-Chemical
.	.	O

The	the	O
ischemia	ischemia	B-Disease
probably	probably	O
induced	induced	O
by	by	O
coronary	coronary	O
artery	artery	O
spasm	spasm	B-Disease
was	was	O
reversed	reversed	O
by	by	O
nitroglycerin	nitroglycerin	B-Chemical
and	and	O
calcium	calcium	B-Chemical
blocking	blocking	O
agents	agents	O
.	.	O

Doxorubicin-induced	doxorubicin-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
monitored	monitored	O
by	by	O
ECG	ecg	O
in	in	O
freely	freely	O
moving	moving	O
mice	mice	O
.	.	O

A	a	O
new	new	O
model	model	O
to	to	O
test	test	O
potential	potential	O
protectors	protectors	O
.	.	O

In	in	O
laboratory	laboratory	O
animals	animals	O
,	,	O
histology	histology	O
is	is	O
most	most	O
commonly	commonly	O
used	used	O
to	to	O
study	study	O
doxorubicin-induced	doxorubicin-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
.	.	O

However	however	O
,	,	O
for	for	O
monitoring	monitoring	O
during	during	O
treatment	treatment	O
,	,	O
large	large	O
numbers	numbers	O
of	of	O
animals	animals	O
are	are	O
needed	needed	O
.	.	O

Recently	recently	O
we	we	O
developed	developed	O
a	a	O
new	new	O
method	method	O
to	to	O
measure	measure	O
ECG	ecg	O
values	values	O
in	in	O
freely	freely	O
moving	moving	O
mice	mice	O
by	by	O
telemetry	telemetry	O
.	.	O

With	with	O
this	this	O
model	model	O
we	we	O
investigated	investigated	O
the	the	O
effect	effect	O
of	of	O
chronic	chronic	O
doxorubicin	doxorubicin	B-Chemical
administration	administration	O
on	on	O
the	the	O
ECG	ecg	O
of	of	O
freely	freely	O
moving	moving	O
BALB/c	balb/c	O
mice	mice	O
and	and	O
the	the	O
efficacy	efficacy	O
of	of	O
ICRF-187	icrf-187	O
as	as	O
a	a	O
protective	protective	O
agent	agent	O
.	.	O

The	the	O
ST	st	O
interval	interval	O
significantly	significantly	O
widened	widened	O
from	from	O
15.0	15.0	O
+	+	O
/-	/-	O
1.5	1.5	O
to	to	O
56.8	56.8	O
+	+	O
/-	/-	O
11.8	11.8	O
ms	ms	B-Disease
in	in	O
week	week	O
10	10	O
(	(	O
7	7	O
weekly	weekly	O
doses	doses	O
of	of	O
4	4	O
mg/kg	mg/kg	O
doxorubicin	doxorubicin	B-Chemical
given	given	O
i.v	i.v	O
.	.	O
plus	plus	O
3	3	O
weeks	weeks	O
of	of	O
observation	observation	O
)	)	O
.	.	O

The	the	O
ECG	ecg	O
of	of	O
the	the	O
control	control	O
animals	animals	O
did	did	O
not	not	O
change	change	O
during	during	O
the	the	O
entire	entire	O
study	study	O
.	.	O

After	after	O
sacrifice	sacrifice	O
the	the	O
hearts	hearts	O
of	of	O
doxorubicin-treated	doxorubicin-treated	O
animals	animals	O
were	were	O
enlarged	enlarged	O
and	and	O
the	the	O
atria	atria	O
were	were	O
hypertrophic	hypertrophic	O
.	.	O

As	as	O
this	this	O
schedule	schedule	O
exerted	exerted	O
more	more	O
toxicity	toxicity	B-Disease
than	than	O
needed	needed	O
to	to	O
investigate	investigate	O
protective	protective	B-Chemical
agents	agents	I-Chemical
,	,	O
the	the	O
protection	protection	O
of	of	O
ICRF-187	icrf-187	O
was	was	O
determined	determined	O
using	using	O
a	a	O
dose	dose	O
schedule	schedule	O
with	with	O
lower	lower	O
general	general	O
toxicity	toxicity	B-Disease
(	(	O
6	6	O
weekly	weekly	O
doses	doses	O
of	of	O
4	4	O
mg/kg	mg/kg	O
doxorubicin	doxorubicin	B-Chemical
given	given	O
i.v	i.v	O
.	.	O
plus	plus	O
2	2	O
weeks	weeks	O
of	of	O
observation	observation	O
)	)	O
.	.	O

On	on	O
this	this	O
schedule	schedule	O
,	,	O
the	the	O
animals	animals	O
'	'	O
hearts	hearts	O
appeared	appeared	O
normal	normal	O
after	after	O
sacrifice	sacrifice	O
and	and	O
ICRF-187	icrf-187	O
(	(	O
50	50	O
mg/kg	mg/kg	O
given	given	O
i.p	i.p	O
.	.	O

1	1	O
h	h	B-Chemical
before	before	O
doxorubicin	doxorubicin	B-Chemical
)	)	O
provided	provided	O
almost	almost	O
full	full	O
protection	protection	O
.	.	O

These	these	O
data	data	O
were	were	O
confirmed	confirmed	O
by	by	O
histology	histology	O
.	.	O

The	the	O
results	results	O
indicate	indicate	O
that	that	O
this	this	O
new	new	O
model	model	O
is	is	O
very	very	O
sensitive	sensitive	O
and	and	O
enables	enables	O
monitoring	monitoring	O
of	of	O
the	the	O
development	development	O
of	of	O
cardiotoxicity	cardiotoxicity	B-Disease
with	with	O
time	time	O
.	.	O

These	these	O
findings	findings	O
result	result	O
in	in	O
a	a	O
model	model	O
that	that	O
allows	allows	O
the	the	O
testing	testing	O
of	of	O
protectors	protectors	O
against	against	O
doxorubicin-induced	doxorubicin-induced	O
cardiotoxicity	cardiotoxicity	B-Disease
as	as	O
demonstrated	demonstrated	O
by	by	O
the	the	O
protection	protection	O
provided	provided	O
by	by	O
ICRF-187	icrf-187	O
.	.	O

Epinephrine	epinephrine	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	O
is	is	O
not	not	O
enhanced	enhanced	O
by	by	O
subtoxic	subtoxic	O
bupivacaine	bupivacaine	B-Chemical
in	in	O
dogs	dogs	O
.	.	O

Since	since	O
bupivacaine	bupivacaine	B-Chemical
and	and	O
epinephrine	epinephrine	B-Chemical
may	may	O
both	both	O
precipitate	precipitate	O
dysrhythmias	dysrhythmias	O
,	,	O
circulating	circulating	O
bupivacaine	bupivacaine	B-Chemical
during	during	O
regional	regional	O
anesthesia	anesthesia	O
could	could	O
potentiate	potentiate	O
dysrhythmogenic	dysrhythmogenic	O
effects	effects	O
of	of	O
epinephrine	epinephrine	B-Chemical
.	.	O

We	we	O
therefore	therefore	O
examined	examined	O
whether	whether	O
bupivacaine	bupivacaine	B-Chemical
alters	alters	O
the	the	O
dysrhythmogenicity	dysrhythmogenicity	O
of	of	O
subsequent	subsequent	O
administration	administration	O
of	of	O
epinephrine	epinephrine	B-Chemical
in	in	O
conscious	conscious	O
,	,	O
healthy	healthy	O
dogs	dogs	O
and	and	O
in	in	O
anesthetized	anesthetized	O
dogs	dogs	O
with	with	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

Forty-one	forty-one	O
conscious	conscious	O
dogs	dogs	O
received	received	O
10	10	O
micrograms.kg-1.min-1	micrograms.kg-1.min-1	O
epinephrine	epinephrine	B-Chemical
.	.	O

Seventeen	seventeen	O
animals	animals	O
responded	responded	O
with	with	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
(	(	O
VT	vt	O
)	)	O
within	within	O
3	3	O
min	min	O
.	.	O

After	after	O
3	3	O
h	h	B-Chemical
,	,	O
these	these	O
responders	responders	O
randomly	randomly	O
received	received	O
1	1	O
or	or	O
2	2	O
mg/kg	mg/kg	O
bupivacaine	bupivacaine	B-Chemical
or	or	O
saline	saline	O
over	over	O
5	5	O
min	min	O
,	,	O
followed	followed	O
by	by	O
10	10	O
micrograms.kg-1.min-1	micrograms.kg-1.min-1	O
epinephrine	epinephrine	B-Chemical
.	.	O

In	in	O
the	the	O
bupivacaine	bupivacaine	B-Chemical
groups	groups	O
,	,	O
epinephrine	epinephrine	B-Chemical
caused	caused	O
fewer	fewer	O
prodysrhythmic	prodysrhythmic	O
effects	effects	O
than	than	O
without	without	O
bupivacaine	bupivacaine	B-Chemical
.	.	O

VT	vt	O
appeared	appeared	O
in	in	O
fewer	fewer	O
dogs	dogs	O
and	and	O
at	at	O
a	a	O
later	later	O
time	time	O
,	,	O
and	and	O
there	there	O
were	were	O
more	more	O
sinoatrial	sinoatrial	O
beats	beats	O
and	and	O
less	less	O
ectopies	ectopies	O
.	.	O

Epinephrine	epinephrine	B-Chemical
shortened	shortened	O
QT	qt	O
less	less	O
after	after	O
bupivacaine	bupivacaine	B-Chemical
than	than	O
in	in	O
control	control	O
animals	animals	O
.	.	O

One	one	O
day	day	O
after	after	O
experimental	experimental	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
,	,	O
six	six	O
additional	additional	O
halothane-anesthetized	halothane-anesthetized	O
dogs	dogs	O
received	received	O
4	4	O
micrograms.kg-1.min-1	micrograms.kg-1.min-1	O
epinephrine	epinephrine	B-Chemical
until	until	O
VT	vt	O
appeared	appeared	O
.	.	O

After	after	O
45	45	O
min	min	O
,	,	O
1	1	O
mg/kg	mg/kg	O
bupivacaine	bupivacaine	B-Chemical
was	was	O
injected	injected	O
over	over	O
5	5	O
min	min	O
,	,	O
again	again	O
followed	followed	O
by	by	O
4	4	O
micrograms.kg-1.min-1	micrograms.kg-1.min-1	O
epinephrine	epinephrine	B-Chemical
.	.	O

In	in	O
these	these	O
dogs	dogs	O
,	,	O
the	the	O
prodysrhythmic	prodysrhythmic	O
response	response	O
to	to	O
epinephrine	epinephrine	B-Chemical
was	was	O
also	also	O
mitigated	mitigated	O
by	by	O
preceding	preceding	O
bupivacaine	bupivacaine	B-Chemical
.	.	O

Bupivacaine	bupivacaine	B-Chemical
antagonizes	antagonizes	O
epinephrine	epinephrine	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	O
in	in	O
conscious	conscious	O
dogs	dogs	O
susceptible	susceptible	O
to	to	O
VT	vt	O
and	and	O
in	in	O
anesthetized	anesthetized	O
dogs	dogs	O
with	with	O
spontaneous	spontaneous	O
postinfarct	postinfarct	O
dysrhythmias	dysrhythmias	O
.	.	O

There	there	O
is	is	O
no	no	O
evidence	evidence	O
that	that	O
systemic	systemic	O
subtoxic	subtoxic	O
bupivacaine	bupivacaine	B-Chemical
administration	administration	O
enhances	enhances	O
the	the	O
dysrhythmogenicity	dysrhythmogenicity	O
of	of	O
subsequent	subsequent	O
epinephrine	epinephrine	B-Chemical
.	.	O

Milk-alkali	milk-alkali	O
syndrome	syndrome	O
induced	induced	O
by	by	O
1,25(OH)2D	1,25(oh)2d	O
in	in	O
a	a	O
patient	patient	O
with	with	O
hypoparathyroidism	hypoparathyroidism	O
.	.	O

Milk-alkali	milk-alkali	O
syndrome	syndrome	O
was	was	O
first	first	O
described	described	O
70	70	O
years	years	O
ago	ago	O
in	in	O
the	the	O
context	context	O
of	of	O
the	the	O
treatment	treatment	O
of	of	O
peptic	peptic	B-Disease
ulcer	ulcer	B-Disease
disease	disease	O
with	with	O
large	large	O
amounts	amounts	O
of	of	O
calcium	calcium	B-Chemical
and	and	O
alkali	alkali	O
.	.	O

Although	although	O
with	with	O
current	current	O
ulcer	ulcer	B-Disease
therapy	therapy	O
(	(	O
H-2	h-2	O
blockers	blockers	O
,	,	O
omeprazole	omeprazole	B-Chemical
,	,	O
and	and	O
sucralfate	sucralfate	O
)	)	O
,	,	O
the	the	O
frequency	frequency	O
of	of	O
milk-alkali	milk-alkali	O
syndrome	syndrome	O
has	has	O
decreased	decreased	O
significantly	significantly	O
,	,	O
the	the	O
classic	classic	O
triad	triad	O
of	of	O
hypercalcemia	hypercalcemia	B-Disease
,	,	O
alkalosis	alkalosis	O
,	,	O
and	and	O
renal	renal	O
impairment	impairment	O
remains	remains	O
the	the	O
hallmark	hallmark	O
of	of	O
the	the	O
syndrome	syndrome	O
.	.	O

Milk-alkali	milk-alkali	O
syndrome	syndrome	O
can	can	O
present	present	O
serious	serious	O
and	and	O
occasionally	occasionally	O
life-threatening	life-threatening	O
illness	illness	O
unless	unless	O
diagnosed	diagnosed	O
and	and	O
treated	treated	O
appropriately	appropriately	O
.	.	O

This	this	O
article	article	O
presents	presents	O
a	a	O
patient	patient	O
with	with	O
hypoparathyroidism	hypoparathyroidism	O
who	who	O
was	was	O
treated	treated	O
with	with	O
calcium	calcium	B-Chemical
carbonate	carbonate	I-Chemical
and	and	O
calcitriol	calcitriol	O
resulting	resulting	O
in	in	O
two	two	O
admissions	admissions	O
to	to	O
the	the	O
hospital	hospital	O
for	for	O
milk-alkali	milk-alkali	O
syndrome	syndrome	O
.	.	O

The	the	O
patient	patient	O
was	was	O
successfully	successfully	O
treated	treated	O
with	with	O
intravenous	intravenous	O
pamidronate	pamidronate	O
on	on	O
his	his	O
first	first	O
admission	admission	O
and	and	O
with	with	O
hydrocortisone	hydrocortisone	B-Chemical
on	on	O
the	the	O
second	second	O
.	.	O

This	this	O
illustrates	illustrates	O
intravenous	intravenous	O
pamidronate	pamidronate	O
as	as	O
a	a	O
valuable	valuable	O
therapeutic	therapeutic	O
tool	tool	O
when	when	O
milk-alkali	milk-alkali	O
syndrome	syndrome	O
presents	presents	O
as	as	O
hypercalcemic	hypercalcemic	O
emergency	emergency	O
.	.	O

Famotidine-associated	famotidine-associated	O
delirium	delirium	B-Disease
.	.	O

A	a	O
series	series	O
of	of	O
six	six	O
cases	cases	O
.	.	O

Famotidine	famotidine	O
is	is	O
a	a	O
histamine	histamine	B-Chemical
H2-receptor	h2-receptor	O
antagonist	antagonist	O
used	used	O
in	in	O
inpatient	inpatient	O
settings	settings	O
for	for	O
prevention	prevention	O
of	of	O
stress	stress	O
ulcers	ulcers	O
and	and	O
is	is	O
showing	showing	O
increasing	increasing	O
popularity	popularity	O
because	because	O
of	of	O
its	its	O
low	low	O
cost	cost	O
.	.	O

Although	although	O
all	all	O
of	of	O
the	the	O
currently	currently	O
available	available	O
H2-receptor	h2-receptor	O
antagonists	antagonists	O
have	have	O
shown	shown	O
the	the	O
propensity	propensity	O
to	to	O
cause	cause	O
delirium	delirium	B-Disease
,	,	O
only	only	O
two	two	O
previously	previously	O
reported	reported	O
cases	cases	O
have	have	O
been	been	O
associated	associated	O
with	with	O
famotidine	famotidine	O
.	.	O

The	the	O
authors	authors	O
report	report	O
on	on	O
six	six	O
cases	cases	O
of	of	O
famotidine-associated	famotidine-associated	O
delirium	delirium	B-Disease
in	in	O
hospitalized	hospitalized	O
patients	patients	O
who	who	O
cleared	cleared	O
completely	completely	O
upon	upon	O
removal	removal	O
of	of	O
famotidine	famotidine	O
.	.	O

The	the	O
pharmacokinetics	pharmacokinetics	O
of	of	O
famotidine	famotidine	O
are	are	O
reviewed	reviewed	O
,	,	O
with	with	O
no	no	O
change	change	O
in	in	O
its	its	O
metabolism	metabolism	O
in	in	O
the	the	O
elderly	elderly	O
population	population	O
seen	seen	O
.	.	O

The	the	O
implications	implications	O
of	of	O
using	using	O
famotidine	famotidine	O
in	in	O
elderly	elderly	O
persons	persons	O
are	are	O
discussed	discussed	O
.	.	O

Encephalopathy	encephalopathy	B-Disease
during	during	O
amitriptyline	amitriptyline	B-Chemical
therapy	therapy	O
:	:	O
are	are	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
and	and	O
serotonin	serotonin	B-Chemical
syndrome	syndrome	I-Disease
spectrum	spectrum	O
disorders?This	disorders?this	O
report	report	O
describes	describes	O
a	a	O
case	case	O
of	of	O
encephalopathy	encephalopathy	B-Disease
developed	developed	O
in	in	O
the	the	O
course	course	O
of	of	O
amitriptyline	amitriptyline	B-Chemical
therapy	therapy	O
,	,	O
during	during	O
a	a	O
remission	remission	O
of	of	O
unipolar	unipolar	B-Disease
depression	depression	B-Disease
.	.	O

This	this	O
patient	patient	O
could	could	O
have	have	O
been	been	O
diagnosed	diagnosed	O
as	as	O
having	having	O
either	either	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
(	(	O
NMS	nms	O
)	)	O
or	or	O
serotonin	serotonin	B-Chemical
syndrome	syndrome	I-Disease
(	(	O
SS	ss	O
)	)	O
.	.	O

The	the	O
major	major	O
determinant	determinant	O
of	of	O
the	the	O
symptoms	symptoms	O
may	may	O
have	have	O
been	been	O
dopamine/serotonin	dopamine/serotonin	O
imbalance	imbalance	O
in	in	O
the	the	O
central	central	O
nervous	nervous	O
system	system	O
.	.	O

The	the	O
NMS-like	nms-like	O
encephalopathy	encephalopathy	B-Disease
that	that	O
develops	develops	O
in	in	O
association	association	O
with	with	O
the	the	O
use	use	O
of	of	O
antidepressants	antidepressants	B-Chemical
indicates	indicates	O
that	that	O
NMS	nms	O
and	and	O
SS	ss	O
are	are	O
spectrum	spectrum	O
disorders	disorders	O
induced	induced	O
by	by	O
drugs	drugs	O
with	with	O
both	both	O
antidopaminergic	antidopaminergic	O
and	and	O
serotonergic	serotonergic	O
effects	effects	O
.	.	O

Genetic	genetic	O
separation	separation	O
of	of	O
tumor	tumor	B-Disease
growth	growth	O
and	and	O
hemorrhagic	hemorrhagic	B-Disease
phenotypes	phenotypes	O
in	in	O
an	an	O
estrogen-induced	estrogen-induced	O
tumor	tumor	B-Disease
.	.	O

Chronic	chronic	O
administration	administration	O
of	of	O
estrogen	estrogen	B-Chemical
to	to	O
the	the	O
Fischer	fischer	O
344	344	O
(	(	O
F344	f344	O
)	)	O
rat	rat	O
induces	induces	O
growth	growth	O
of	of	O
large	large	O
,	,	O
hemorrhagic	hemorrhagic	B-Disease
pituitary	pituitary	O
tumors	tumors	B-Disease
.	.	O

Ten	ten	O
weeks	weeks	O
of	of	O
diethylstilbestrol	diethylstilbestrol	B-Chemical
(	(	O
DES	des	B-Chemical
)	)	O
treatment	treatment	O
caused	caused	O
female	female	O
F344	f344	O
rat	rat	O
pituitaries	pituitaries	O
to	to	O
grow	grow	O
to	to	O
an	an	O
average	average	O
of	of	O
109.2	109.2	O
+	+	O
/-	/-	O
6.3	6.3	O
mg	mg	O
(	(	O
mean	mean	O
+	+	O
/-	/-	O
SE	se	B-Disease
)	)	O
versus	versus	O
11.3	11.3	O
+	+	O
/-	/-	O
1.4	1.4	O
mg	mg	O
for	for	O
untreated	untreated	O
rats	rats	O
,	,	O
and	and	O
to	to	O
become	become	O
highly	highly	O
hemorrhagic	hemorrhagic	B-Disease
.	.	O

The	the	O
same	same	O
DES	des	B-Chemical
treatment	treatment	O
produced	produced	O
no	no	O
significant	significant	O
growth	growth	O
(	(	O
8.9	8.9	O
+	+	O
/-	/-	O
0.5	0.5	O
mg	mg	O
for	for	O
treated	treated	O
females	females	O
versus	versus	O
8.7	8.7	O
+	+	O
/-	/-	O
1.1	1.1	O
for	for	O
untreated	untreated	O
females	females	O
)	)	O
or	or	O
morphological	morphological	O
changes	changes	O
in	in	O
Brown	brown	O
Norway	norway	O
(	(	O
BN	bn	O
)	)	O
rat	rat	O
pituitaries	pituitaries	O
.	.	O

An	an	O
F1	f1	O
hybrid	hybrid	O
of	of	O
F344	f344	O
and	and	O
BN	bn	O
exhibited	exhibited	O
significant	significant	O
pituitary	pituitary	O
growth	growth	O
after	after	O
10	10	O
weeks	weeks	O
of	of	O
DES	des	B-Chemical
treatment	treatment	O
with	with	O
an	an	O
average	average	O
mass	mass	O
of	of	O
26.3	26.3	O
+	+	O
/-	/-	O
0.7	0.7	O
mg	mg	O
compared	compared	O
with	with	O
8.6	8.6	O
+	+	O
/-	/-	O
0.9	0.9	O
mg	mg	O
for	for	O
untreated	untreated	O
rats	rats	O
.	.	O

Surprisingly	surprisingly	O
,	,	O
the	the	O
F1	f1	O
hybrid	hybrid	O
tumors	tumors	B-Disease
were	were	O
not	not	O
hemorrhagic	hemorrhagic	B-Disease
and	and	O
had	had	O
hemoglobin	hemoglobin	O
content	content	O
and	and	O
outward	outward	O
appearance	appearance	O
identical	identical	O
to	to	O
that	that	O
of	of	O
BN	bn	O
.	.	O

Expression	expression	O
of	of	O
both	both	O
growth	growth	O
and	and	O
morphological	morphological	O
changes	changes	O
is	is	O
due	due	O
to	to	O
multiple	multiple	O
genes	genes	O
.	.	O

However	however	O
,	,	O
while	while	O
DES-induced	des-induced	O
pituitary	pituitary	O
growth	growth	O
exhibited	exhibited	O
quantitative	quantitative	O
,	,	O
additive	additive	O
inheritance	inheritance	O
,	,	O
the	the	O
hemorrhagic	hemorrhagic	B-Disease
phenotype	phenotype	O
exhibited	exhibited	O
recessive	recessive	O
,	,	O
epistatic	epistatic	O
inheritance	inheritance	O
.	.	O

Only	only	O
5	5	O
of	of	O
the	the	O
160	160	O
F2	f2	O
pituitaries	pituitaries	O
exhibited	exhibited	O
the	the	O
hemorrhagic	hemorrhagic	B-Disease
phenotype	phenotype	O
;	;	O
36	36	O
of	of	O
the	the	O
160	160	O
F2	f2	O
pituitaries	pituitaries	O
were	were	O
in	in	O
the	the	O
F344	f344	O
range	range	O
of	of	O
mass	mass	O
,	,	O
but	but	O
31	31	O
of	of	O
these	these	O
were	were	O
not	not	O
hemorrhagic	hemorrhagic	B-Disease
,	,	O
indicating	indicating	O
that	that	O
the	the	O
hemorrhagic	hemorrhagic	B-Disease
phenotype	phenotype	O
is	is	O
not	not	O
merely	merely	O
a	a	O
consequence	consequence	O
of	of	O
extensive	extensive	O
growth	growth	O
.	.	O

The	the	O
hemorrhagic	hemorrhagic	B-Disease
F2	f2	O
pituitaries	pituitaries	O
were	were	O
all	all	O
among	among	O
the	the	O
most	most	O
massive	massive	O
,	,	O
indicating	indicating	O
that	that	O
some	some	O
of	of	O
the	the	O
genes	genes	O
regulate	regulate	O
both	both	O
phenotypes	phenotypes	O
.	.	O

Increased	increased	O
expression	expression	O
of	of	O
neuronal	neuronal	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
synthase	synthase	I-Chemical
in	in	O
bladder	bladder	O
afferent	afferent	O
pathways	pathways	O
following	following	O
chronic	chronic	O
bladder	bladder	O
irritation	irritation	O
.	.	O

Immunocytochemical	immunocytochemical	O
techniques	techniques	O
were	were	O
used	used	O
to	to	O
examine	examine	O
alterations	alterations	O
in	in	O
the	the	O
expression	expression	O
of	of	O
neuronal	neuronal	O
nitric	nitric	B-Chemical
oxide	oxide	I-Chemical
synthase	synthase	I-Chemical
(	(	O
NOS	nos	O
)	)	O
in	in	O
bladder	bladder	O
pathways	pathways	O
following	following	O
acute	acute	O
and	and	O
chronic	chronic	O
irritation	irritation	O
of	of	O
the	the	O
urinary	urinary	O
tract	tract	O
of	of	O
the	the	O
rat	rat	O
.	.	O

Chemical	chemical	O
cystitis	cystitis	B-Disease
was	was	O
induced	induced	O
by	by	O
cyclophosphamide	cyclophosphamide	B-Chemical
(	(	O
CYP	cyp	O
)	)	O
which	which	O
is	is	O
metabolized	metabolized	O
to	to	O
acrolein	acrolein	O
,	,	O
an	an	O
irritant	irritant	O
eliminated	eliminated	O
in	in	O
the	the	O
urine	urine	O
.	.	O

Injection	injection	O
of	of	O
CYP	cyp	O
(	(	O
n	n	O
=	=	O
10	10	O
,	,	O
75	75	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
)	)	O
2	2	O
hours	hours	O
prior	prior	O
to	to	O
perfusion	perfusion	O
(	(	O
acute	acute	O
treatment	treatment	O
)	)	O
of	of	O
the	the	O
animals	animals	O
increased	increased	O
Fos-immunoreactivity	fos-immunoreactivity	O
(	(	O
IR	ir	O
)	)	O
in	in	O
neurons	neurons	O
in	in	O
the	the	O
dorsal	dorsal	O
commissure	commissure	O
,	,	O
dorsal	dorsal	O
horn	horn	O
,	,	O
and	and	O
autonomic	autonomic	O
regions	regions	O
of	of	O
spinal	spinal	O
segments	segments	O
(	(	O
L1-L2	l1-l2	O
and	and	O
L6-S1	l6-s1	O
)	)	O
which	which	O
receive	receive	O
afferent	afferent	O
inputs	inputs	O
from	from	O
the	the	O
bladder	bladder	O
,	,	O
urethra	urethra	O
,	,	O
and	and	O
ureter	ureter	O
.	.	O

Fos-IR	fos-ir	O
in	in	O
the	the	O
spinal	spinal	O
cord	cord	O
was	was	O
not	not	O
changed	changed	O
in	in	O
rats	rats	O
receiving	receiving	O
chronic	chronic	O
CYP	cyp	O
treatment	treatment	O
(	(	O
n	n	O
=	=	O
15	15	O
,	,	O
75	75	O
mg/kg	mg/kg	O
,	,	O
i.p	i.p	O
.	.	O
,	,	O
every	every	O
3rd	3rd	O
day	day	O
for	for	O
2	2	O
weeks	weeks	O
)	)	O
.	.	O

In	in	O
control	control	O
animals	animals	O
and	and	O
in	in	O
animals	animals	O
treated	treated	O
acutely	acutely	O
with	with	O
CYP	cyp	O
,	,	O
only	only	O
small	small	O
numbers	numbers	O
of	of	O
NOS-IR	nos-ir	O
cells	cells	O
(	(	O
0.5	0.5	O
-	-	O
0.7	0.7	O
cell	cell	O
profiles/sections	profiles/sections	O
)	)	O
were	were	O
detected	detected	O
in	in	O
the	the	O
L6-S1	l6-s1	O
dorsal	dorsal	O
root	root	O
ganglia	ganglia	O
(	(	O
DRG	drg	O
)	)	O
.	.	O

Chronic	chronic	O
CYP	cyp	O
administration	administration	O
significantly	significantly	O
(	(	O
P	p	O
<	<	O
or	or	O
=	=	O
.002	.002	O
)	)	O
increased	increased	O
bladder	bladder	O
weight	weight	O
by	by	O
60	60	O
%	%	O
and	and	O
increased	increased	O
(	(	O
7-	7-	O
to	to	O
11-fold	11-fold	O
)	)	O
the	the	O
numbers	numbers	O
of	of	O
NOS-immunoreactive	nos-immunoreactive	O
(	(	O
IR	ir	O
)	)	O
afferent	afferent	O
neurons	neurons	O
in	in	O
the	the	O
L6-S1	l6-s1	O
DRG	drg	O
.	.	O

A	a	O
small	small	O
increase	increase	O
(	(	O
1.5-fold	1.5-fold	O
)	)	O
also	also	O
occurred	occurred	O
in	in	O
the	the	O
L1	l1	O
DRG	drg	O
,	,	O
but	but	O
no	no	O
change	change	O
was	was	O
detected	detected	O
in	in	O
the	the	O
L2	l2	O
and	and	O
L5	l5	O
DRG	drg	O
.	.	O

Bladder	bladder	O
afferent	afferent	O
cells	cells	O
in	in	O
the	the	O
L6-S1	l6-s1	O
DRG	drg	O
labeled	labeled	O
by	by	O
Fluorogold	fluorogold	O
(	(	O
40	40	O
microliters	microliters	O
)	)	O
injected	injected	O
into	into	O
the	the	O
bladder	bladder	O
wall	wall	O
did	did	O
not	not	O
exhibit	exhibit	O
NOS-IR	nos-ir	O
in	in	O
control	control	O
animals	animals	O
;	;	O
however	however	O
,	,	O
following	following	O
chronic	chronic	O
CYP	cyp	O
administration	administration	O
,	,	O
a	a	O
significant	significant	O
percentage	percentage	O
of	of	O
bladder	bladder	O
afferent	afferent	O
neurons	neurons	O
were	were	O
NOS-IR	nos-ir	O
:	:	O
L6	l6	O
(	(	O
19.8	19.8	O
+	+	O
/-	/-	O
4.6	4.6	O
%	%	O
)	)	O
and	and	O
S1	s1	O
(	(	O
25.3	25.3	O
+	+	O
/-	/-	O
2.9	2.9	O
%	%	O
)	)	O
.	.	O

These	these	O
results	results	O
indicate	indicate	O
that	that	O
neuronal	neuronal	O
gene	gene	O
expression	expression	O
in	in	O
visceral	visceral	O
sensory	sensory	O
pathways	pathways	O
can	can	O
be	be	O
upregulated	upregulated	O
by	by	O
chemical	chemical	O
irritation	irritation	O
of	of	O
afferent	afferent	O
receptors	receptors	O
in	in	O
the	the	O
urinary	urinary	O
tract	tract	O
and/or	and/or	O
that	that	O
pathological	pathological	O
changes	changes	O
in	in	O
the	the	O
urinary	urinary	O
tract	tract	O
can	can	O
initiate	initiate	O
chemical	chemical	O
signals	signals	O
that	that	O
alter	alter	O
the	the	O
chemical	chemical	O
properties	properties	O
of	of	O
visceral	visceral	O
afferent	afferent	O
neurons	neurons	O
.	.	O

Effects	effects	O
of	of	O
a	a	O
new	new	O
calcium	calcium	B-Chemical
antagonist	antagonist	O
,	,	O
CD-832	cd-832	O
,	,	O
on	on	O
isoproterenol-induced	isoproterenol-induced	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
in	in	O
dogs	dogs	O
with	with	O
partial	partial	O
coronary	coronary	B-Disease
stenosis	stenosis	I-Disease
.	.	O

Effects	effects	O
of	of	O
CD-832	cd-832	O
on	on	O
isoproterenol	isoproterenol	B-Chemical
(ISO)-induced	(iso)-induced	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
were	were	O
studied	studied	O
in	in	O
dogs	dogs	O
with	with	O
partial	partial	O
coronary	coronary	B-Disease
stenosis	stenosis	I-Disease
of	of	O
the	the	O
left	left	O
circumflex	circumflex	O
coronary	coronary	O
artery	artery	O
and	and	O
findings	findings	O
were	were	O
compared	compared	O
with	with	O
those	those	O
for	for	O
nifedipine	nifedipine	B-Chemical
or	or	O
diltiazem	diltiazem	B-Chemical
.	.	O

In	in	O
the	the	O
presence	presence	O
of	of	O
coronary	coronary	B-Disease
artery	artery	I-Disease
stenosis	stenosis	I-Disease
,	,	O
3-min	3-min	O
periods	periods	O
of	of	O
intracoronary	intracoronary	O
ISO	iso	B-Chemical
infusion	infusion	O
(	(	O
10	10	O
ng/kg/min	ng/kg/min	O
)	)	O
increased	increased	O
heart	heart	O
rate	rate	O
and	and	O
maximal	maximal	O
rate	rate	O
of	of	O
left	left	O
ventricular	ventricular	O
pressure	pressure	O
rise	rise	O
,	,	O
which	which	O
resulted	resulted	O
in	in	O
a	a	O
decrease	decrease	O
in	in	O
percentage	percentage	O
segmental	segmental	O
shortening	shortening	O
and	and	O
ST-segment	st-segment	O
elevation	elevation	O
of	of	O
the	the	O
epicardial	epicardial	O
electrocardiogram	electrocardiogram	O
.	.	O

After	after	O
the	the	O
control	control	O
ISO	iso	B-Chemical
infusion	infusion	O
with	with	O
stenosis	stenosis	O
was	was	O
performed	performed	O
,	,	O
equihypotensive	equihypotensive	O
doses	doses	O
of	of	O
CD-832	cd-832	O
(	(	O
3	3	O
and	and	O
10	10	O
micrograms/kg/min	micrograms/kg/min	O
,	,	O
n	n	O
=	=	O
7	7	O
)	)	O
,	,	O
nifedipine	nifedipine	B-Chemical
(	(	O
1	1	O
and	and	O
3	3	O
micrograms/kg/min	micrograms/kg/min	O
,	,	O
n	n	O
=	=	O
9	9	O
)	)	O
or	or	O
diltiazem	diltiazem	B-Chemical
(	(	O
10	10	O
and	and	O
30	30	O
micrograms/kg/min	micrograms/kg/min	O
,	,	O
n	n	O
=	=	O
7	7	O
)	)	O
were	were	O
infused	infused	O
5	5	O
min	min	O
before	before	O
and	and	O
during	during	O
the	the	O
second	second	O
and	and	O
third	third	O
ISO	iso	B-Chemical
infusion	infusion	O
.	.	O

Both	both	O
CD-832	cd-832	O
and	and	O
diltiazem	diltiazem	B-Chemical
,	,	O
but	but	O
not	not	O
nifedipine	nifedipine	B-Chemical
,	,	O
significantly	significantly	O
reduced	reduced	O
the	the	O
increase	increase	O
in	in	O
heart	heart	O
rate	rate	O
induced	induced	O
by	by	O
ISO	iso	B-Chemical
infusion	infusion	O
.	.	O

In	in	O
contrast	contrast	O
to	to	O
nifedipine	nifedipine	B-Chemical
,	,	O
CD-832	cd-832	O
(	(	O
10	10	O
micrograms/kg/min	micrograms/kg/min	O
)	)	O
prevented	prevented	O
the	the	O
decrease	decrease	O
in	in	O
percentage	percentage	O
segmental	segmental	O
shortening	shortening	O
from	from	O
32	32	O
+	+	O
/-	/-	O
12	12	O
%	%	O
to	to	O
115	115	O
+	+	O
/-	/-	O
26	26	O
%	%	O
of	of	O
the	the	O
control	control	O
value	value	O
(	(	O
P	p	O
<	<	O
.01	.01	O
)	)	O
and	and	O
ST-segment	st-segment	O
elevation	elevation	O
from	from	O
5.6	5.6	O
+	+	O
/-	/-	O
1.0	1.0	O
mV	mv	O
to	to	O
1.6	1.6	O
+	+	O
/-	/-	O
1.3	1.3	O
mV	mv	O
(	(	O
P	p	O
<	<	O
.01	.01	O
)	)	O
at	at	O
3	3	O
min	min	O
after	after	O
ISO	iso	B-Chemical
infusion	infusion	O
with	with	O
stenosis	stenosis	O
.	.	O

Diltiazem	diltiazem	B-Chemical
(	(	O
30	30	O
micrograms/kg/min	micrograms/kg/min	O
)	)	O
also	also	O
prevented	prevented	O
the	the	O
decrease	decrease	O
in	in	O
percentage	percentage	O
segmental	segmental	O
shortening	shortening	O
from	from	O
34	34	O
+	+	O
/-	/-	O
14	14	O
%	%	O
to	to	O
63	63	O
+	+	O
/-	/-	O
18	18	O
%	%	O
of	of	O
the	the	O
control	control	O
value	value	O
(	(	O
P	p	O
<	<	O
.05	.05	O
)	)	O
and	and	O
ST-segment	st-segment	O
elevation	elevation	O
from	from	O
4.7	4.7	O
+	+	O
/-	/-	O
0.7	0.7	O
mV	mv	O
to	to	O
2.1	2.1	O
+	+	O
/-	/-	O
0.7	0.7	O
mV	mv	O
(	(	O
P	p	O
<	<	O
.01	.01	O
)	)	O
at	at	O
3	3	O
min	min	O
after	after	O
ISO	iso	B-Chemical
infusion	infusion	O
with	with	O
stenosis	stenosis	O
.	.	O

These	these	O
data	data	O
show	show	O
that	that	O
CD-832	cd-832	O
improves	improves	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
during	during	O
ISO	iso	B-Chemical
infusion	infusion	O
with	with	O
stenosis	stenosis	O
and	and	O
suggest	suggest	O
that	that	O
the	the	O
negative	negative	O
chronotropic	chronotropic	O
property	property	O
of	of	O
CD-832	cd-832	O
plays	plays	O
a	a	O
major	major	O
role	role	O
in	in	O
the	the	O
beneficial	beneficial	O
effects	effects	O
of	of	O
CD-832	cd-832	O
.	.	O

The	the	O
effect	effect	O
of	of	O
recombinant	recombinant	O
human	human	O
insulin-like	insulin-like	O
growth	growth	O
factor-I	factor-i	O
on	on	O
chronic	chronic	O
puromycin	puromycin	B-Chemical
aminonucleoside	aminonucleoside	B-Chemical
nephropathy	nephropathy	B-Disease
in	in	O
rats	rats	O
.	.	O

We	we	O
recently	recently	O
demonstrated	demonstrated	O
that	that	O
recombinant	recombinant	O
hGH	hgh	O
exacerbates	exacerbates	O
renal	renal	O
functional	functional	O
and	and	O
structural	structural	O
injury	injury	O
in	in	O
chronic	chronic	O
puromycin	puromycin	B-Chemical
aminonucleoside	aminonucleoside	B-Chemical
(	(	O
PAN	pan	B-Chemical
)	)	O
nephropathy	nephropathy	B-Disease
,	,	O
an	an	O
experimental	experimental	O
model	model	O
of	of	O
glomerular	glomerular	O
disease	disease	O
.	.	O

Therefore	therefore	O
,	,	O
we	we	O
examined	examined	O
whether	whether	O
recombinant	recombinant	O
human	human	O
(	(	O
rh	rh	O
)	)	O
IGF-I	igf-i	O
is	is	O
a	a	O
safer	safer	O
alternative	alternative	O
for	for	O
the	the	O
treatment	treatment	O
of	of	O
growth	growth	O
failure	failure	O
in	in	O
rats	rats	O
with	with	O
chronic	chronic	O
PAN	pan	B-Chemical
nephropathy	nephropathy	B-Disease
.	.	O

The	the	O
glomerulopathy	glomerulopathy	O
was	was	O
induced	induced	O
by	by	O
seven	seven	O
serial	serial	O
injections	injections	O
of	of	O
PAN	pan	B-Chemical
over	over	O
12	12	O
wk	wk	O
.	.	O

Experimental	experimental	O
animals	animals	O
(	(	O
n	n	O
=	=	O
6	6	O
)	)	O
received	received	O
rhIGF-I	rhigf-i	O
,	,	O
400	400	O
micrograms/d	micrograms/d	O
,	,	O
whereas	whereas	O
control	control	O
rats	rats	O
(	(	O
n	n	O
=	=	O
6	6	O
)	)	O
received	received	O
the	the	O
vehicle	vehicle	O
.	.	O

rhIGF-I	rhigf-i	O
improved	improved	O
weight	weight	B-Disease
gain	gain	I-Disease
by	by	O
14	14	O
%	%	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
,	,	O
without	without	O
altering	altering	O
hematocrit	hematocrit	O
or	or	O
blood	blood	O
pressure	pressure	O
in	in	O
rats	rats	O
with	with	O
renal	renal	O
disease	disease	O
.	.	O

Urinary	urinary	O
protein	protein	O
excretion	excretion	O
was	was	O
unaltered	unaltered	O
by	by	O
rhIGF-I	rhigf-i	O
treatment	treatment	O
in	in	O
rats	rats	O
with	with	O
chronic	chronic	O
PAN	pan	B-Chemical
nephropathy	nephropathy	B-Disease
.	.	O

After	after	O
12	12	O
wk	wk	O
,	,	O
the	the	O
inulin	inulin	O
clearance	clearance	O
was	was	O
higher	higher	O
in	in	O
rhIGF-I-treated	rhigf-i-treated	O
rats	rats	O
,	,	O
0.48	0.48	O
+	+	O
/-	/-	O
0.08	0.08	O
versus	versus	O
0.24	0.24	O
+	+	O
/-	/-	O
0.06	0.06	O
mL/min/100	ml/min/100	O
g	g	O
of	of	O
body	body	B-Disease
weight	weight	I-Disease
in	in	O
untreated	untreated	O
PAN	pan	B-Chemical
nephropathy	nephropathy	B-Disease
animals	animals	O
,	,	O
p	p	O
<	<	O
0.05	0.05	O
.	.	O

The	the	O
improvement	improvement	O
in	in	O
GFR	gfr	O
was	was	O
not	not	O
associated	associated	O
with	with	O
enhanced	enhanced	O
glomerular	glomerular	O
hypertrophy	hypertrophy	B-Disease
or	or	O
increased	increased	O
segmental	segmental	B-Disease
glomerulosclerosis	glomerulosclerosis	B-Disease
,	,	O
tubulointerstitial	tubulointerstitial	O
injury	injury	O
,	,	O
or	or	O
renal	renal	O
cortical	cortical	O
malondialdehyde	malondialdehyde	B-Chemical
content	content	O
.	.	O

In	in	O
rats	rats	O
with	with	O
PAN	pan	B-Chemical
nephropathy	nephropathy	B-Disease
,	,	O
administration	administration	O
of	of	O
rhIGF-I	rhigf-i	O
increased	increased	O
IGF-I	igf-i	O
and	and	O
GH	gh	O
receptor	receptor	O
gene	gene	O
expression	expression	O
,	,	O
without	without	O
altering	altering	O
the	the	O
steady	steady	O
state	state	O
level	level	O
of	of	O
IGF-I	igf-i	O
receptor	receptor	O
mRNA	mrna	O
.	.	O

In	in	O
normal	normal	O
rats	rats	O
with	with	O
intact	intact	O
kidneys	kidneys	O
,	,	O
rhIGF-I	rhigf-i	O
administration	administration	O
(	(	O
n	n	O
=	=	O
4	4	O
)	)	O
did	did	O
not	not	O
alter	alter	O
weight	weight	B-Disease
gain	gain	I-Disease
,	,	O
blood	blood	O
pressure	pressure	O
,	,	O
proteinuria	proteinuria	B-Disease
,	,	O
GFR	gfr	O
,	,	O
glomerular	glomerular	O
planar	planar	O
area	area	O
,	,	O
renal	renal	O
cortical	cortical	O
malondialdehyde	malondialdehyde	B-Chemical
content	content	O
,	,	O
or	or	O
glomerular	glomerular	O
or	or	O
tubulointerstitial	tubulointerstitial	O
damage	damage	O
,	,	O
compared	compared	O
with	with	O
untreated	untreated	O
animals	animals	O
(	(	O
n	n	O
=	=	O
4	4	O
)	)	O
.	.	O

rhIGF-I	rhigf-i	O
treatment	treatment	O
reduced	reduced	O
the	the	O
steady	steady	O
state	state	O
renal	renal	O
IGF-I	igf-i	O
mRNA	mrna	O
level	level	O
but	but	O
did	did	O
not	not	O
modify	modify	O
gene	gene	O
expression	expression	O
of	of	O
the	the	O
IGF-I	igf-i	O
or	or	O
GH	gh	O
receptors	receptors	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
:	:	O
1	1	O
)	)	O
administration	administration	O
of	of	O
rhIGF-I	rhigf-i	O
improves	improves	O
growth	growth	O
and	and	O
GFR	gfr	O
in	in	O
rats	rats	O
with	with	O
chronic	chronic	O
PAN	pan	B-Chemical
nephropathy	nephropathy	B-Disease
and	and	O
2	2	O
)	)	O
unlike	unlike	O
rhGH	rhgh	O
,	,	O
long-term	long-term	O
use	use	O
of	of	O
rhIGF-I	rhigf-i	O
does	does	O
not	not	O
worsen	worsen	O
renal	renal	O
functional	functional	O
and	and	O
structural	structural	O
injury	injury	O
in	in	O
this	this	O
disease	disease	O
model	model	O
.	.	O

Nefiracetam	nefiracetam	O
(	(	O
DM-9384	dm-9384	O
)	)	O
reverses	reverses	O
apomorphine-induced	apomorphine-induced	O
amnesia	amnesia	B-Disease
of	of	O
a	a	O
passive	passive	O
avoidance	avoidance	O
response	response	O
:	:	O
delayed	delayed	O
emergence	emergence	O
of	of	O
the	the	O
memory	memory	O
retention	retention	O
effects	effects	O
.	.	O

Nefiracetam	nefiracetam	O
is	is	O
a	a	O
novel	novel	O
pyrrolidone	pyrrolidone	O
derivative	derivative	O
which	which	O
attenuates	attenuates	O
scopolamine-induced	scopolamine-induced	O
learning	learning	O
and	and	O
post-training	post-training	O
consolidation	consolidation	O
deficits	deficits	O
.	.	O

Given	given	O
that	that	O
apomorphine	apomorphine	B-Chemical
inhibits	inhibits	O
passive	passive	O
avoidance	avoidance	O
retention	retention	O
when	when	O
given	given	O
during	during	O
training	training	O
or	or	O
in	in	O
a	a	O
defined	defined	O
10	10	O
-	-	O
12h	12h	O
post-training	post-training	O
period	period	O
,	,	O
we	we	O
evaluated	evaluated	O
the	the	O
ability	ability	O
of	of	O
nefiracetam	nefiracetam	O
to	to	O
attenuate	attenuate	O
amnesia	amnesia	B-Disease
induced	induced	O
by	by	O
dopaminergic	dopaminergic	O
agonism	agonism	O
.	.	O

A	a	O
step-down	step-down	O
passive	passive	O
avoidance	avoidance	O
paradigm	paradigm	O
was	was	O
employed	employed	O
and	and	O
nefiracetam	nefiracetam	O
(	(	O
3	3	O
mg/kg	mg/kg	O
)	)	O
and	and	O
apomorphine	apomorphine	B-Chemical
(	(	O
0.5	0.5	O
mg/kg	mg/kg	O
)	)	O
were	were	O
given	given	O
alone	alone	O
or	or	O
in	in	O
combination	combination	O
during	during	O
training	training	O
and	and	O
at	at	O
the	the	O
10	10	O
-	-	O
12h	12h	O
post-training	post-training	O
period	period	O
of	of	O
consolidation	consolidation	O
.	.	O

Co-administration	co-administration	O
of	of	O
nefiracetam	nefiracetam	O
and	and	O
apomorphine	apomorphine	B-Chemical
during	during	O
training	training	O
or	or	O
10h	10h	O
thereafter	thereafter	O
produced	produced	O
no	no	O
significant	significant	O
anti-amnesic	anti-amnesic	O
effect	effect	O
.	.	O

However	however	O
,	,	O
administration	administration	O
of	of	O
nefiracetam	nefiracetam	O
during	during	O
training	training	O
completely	completely	O
reversed	reversed	O
the	the	O
amnesia	amnesia	B-Disease
induced	induced	O
by	by	O
apomorphine	apomorphine	B-Chemical
at	at	O
the	the	O
10h	10h	O
post-training	post-training	O
time	time	O
and	and	O
the	the	O
converse	converse	O
was	was	O
also	also	O
true	true	O
.	.	O

These	these	O
effects	effects	O
were	were	O
not	not	O
mediated	mediated	O
by	by	O
a	a	O
dopaminergic	dopaminergic	O
mechanism	mechanism	O
as	as	O
nefiracetam	nefiracetam	O
,	,	O
at	at	O
millimolar	millimolar	O
concentrations	concentrations	O
,	,	O
failed	failed	O
to	to	O
displace	displace	O
either	either	O
[3H]SCH	[3h]sch	O
23390	23390	O
or	or	O
[3H]spiperone	[3h]spiperone	O
binding	binding	O
from	from	O
D1	d1	O
or	or	O
D2	d2	O
dopamine	dopamine	B-Chemical
receptor	receptor	O
subtypes	subtypes	O
,	,	O
respectively	respectively	O
.	.	O

It	it	O
is	is	O
suggested	suggested	O
that	that	O
nefiracetam	nefiracetam	O
augments	augments	O
molecular	molecular	O
processes	processes	O
in	in	O
the	the	O
early	early	O
stages	stages	O
of	of	O
events	events	O
which	which	O
ultimately	ultimately	O
lead	lead	O
to	to	O
consolidation	consolidation	O
of	of	O
memory	memory	O
.	.	O

Phenytoin	phenytoin	B-Chemical
encephalopathy	encephalopathy	B-Disease
as	as	O
probable	probable	O
idiosyncratic	idiosyncratic	O
reaction	reaction	O
:	:	O
case	case	O
report	report	O
.	.	O

A	a	O
case	case	O
of	of	O
phenytoin	phenytoin	B-Chemical
(	(	O
DPH	dph	O
)	)	O
encephalopathy	encephalopathy	B-Disease
with	with	O
increasing	increasing	O
seizures	seizures	B-Disease
and	and	O
EEG	eeg	O
and	and	O
mental	mental	O
changes	changes	O
is	is	O
described	described	O
.	.	O

Despite	despite	O
adequate	adequate	O
oral	oral	O
dosage	dosage	O
of	of	O
DPH	dph	O
(	(	O
5	5	O
mg/kg/daily	mg/kg/daily	O
)	)	O
the	the	O
plasma	plasma	O
level	level	O
was	was	O
very	very	O
low	low	O
(	(	O
2.8	2.8	O
microgramg/ml	microgramg/ml	O
)	)	O
.	.	O

The	the	O
encephalopathy	encephalopathy	B-Disease
was	was	O
probably	probably	O
an	an	O
idiosyncratic	idiosyncratic	O
and	and	O
not	not	O
toxic	toxic	O
or	or	O
allergic	allergic	B-Disease
reaction	reaction	I-Disease
.	.	O

In	in	O
fact	fact	O
the	the	O
concentration	concentration	O
of	of	O
free	free	O
DPH	dph	O
was	was	O
normal	normal	O
,	,	O
the	the	O
patient	patient	O
presented	presented	O
a	a	O
retarded	retarded	O
morbilliform	morbilliform	O
rash	rash	B-Disease
during	during	O
DPH	dph	O
treatment	treatment	O
,	,	O
the	the	O
protidogram	protidogram	O
was	was	O
normal	normal	O
,	,	O
and	and	O
an	an	O
intradermic	intradermic	O
DPH	dph	O
injection	injection	O
had	had	O
no	no	O
local	local	O
effect	effect	O
.	.	O

The	the	O
authors	authors	O
conclude	conclude	O
that	that	O
in	in	O
a	a	O
patient	patient	O
starting	starting	O
DPH	dph	O
treatment	treatment	O
an	an	O
unexpected	unexpected	O
increase	increase	O
in	in	O
seizures	seizures	B-Disease
,	,	O
with	with	O
EEG	eeg	O
and	and	O
mental	mental	O
changes	changes	O
occurring	occurring	O
simultaneously	simultaneously	O
,	,	O
should	should	O
alert	alert	O
the	the	O
physician	physician	O
to	to	O
the	the	O
possible	possible	O
need	need	O
for	for	O
eliminating	eliminating	O
DPH	dph	O
from	from	O
the	the	O
therapeutic	therapeutic	O
regimen	regimen	O
,	,	O
even	even	O
if	if	O
plasma	plasma	O
concentrations	concentrations	O
are	are	O
low	low	O
.	.	O

Prevention	prevention	O
and	and	O
treatment	treatment	O
of	of	O
endometrial	endometrial	O
disease	disease	O
in	in	O
climacteric	climacteric	O
women	women	O
receiving	receiving	O
oestrogen	oestrogen	O
therapy	therapy	O
.	.	O

The	the	O
treatment	treatment	O
regimens	regimens	O
are	are	O
described	described	O
in	in	O
74	74	O
patients	patients	O
with	with	O
endometrial	endometrial	O
disease	disease	O
among	among	O
850	850	O
climacteric	climacteric	O
women	women	O
receiving	receiving	O
oestrogen	oestrogen	O
therapy	therapy	O
.	.	O

Cystic	cystic	O
hyperplasia	hyperplasia	O
was	was	O
associated	associated	O
with	with	O
unopposed	unopposed	O
oestrogen	oestrogen	O
therapy	therapy	O
without	without	O
progestagen	progestagen	O
.	.	O

Two	two	O
courses	courses	O
of	of	O
21	21	O
days	days	O
of	of	O
5	5	O
mg	mg	O
norethisterone	norethisterone	O
daily	daily	O
caused	caused	O
reversion	reversion	O
to	to	O
normal	normal	O
in	in	O
all	all	O
57	57	O
cases	cases	O
of	of	O
cystic	cystic	O
hyperplasia	hyperplasia	O
and	and	O
6	6	O
of	of	O
the	the	O
8	8	O
cases	cases	O
of	of	O
atypical	atypical	O
hyperplasia	hyperplasia	O
.	.	O

4	4	O
cases	cases	O
of	of	O
endometrial	endometrial	O
carcinoma	carcinoma	B-Disease
referred	referred	O
from	from	O
elsewhere	elsewhere	O
demonstrated	demonstrated	O
the	the	O
problems	problems	O
of	of	O
inappropriate	inappropriate	O
and	and	O
unsupervised	unsupervised	O
unopposed	unopposed	O
oestrogen	oestrogen	O
therapy	therapy	O
and	and	O
the	the	O
difficulty	difficulty	O
in	in	O
distinguishing	distinguishing	O
severe	severe	O
hyperplasia	hyperplasia	O
from	from	O
malignancy	malignancy	B-Disease
.	.	O

Cyclical	cyclical	O
low-dose	low-dose	O
oestrogen	oestrogen	O
therapy	therapy	O
with	with	O
7	7	O
-	-	O
-13	-13	O
days	days	O
of	of	O
progestagen	progestagen	O
does	does	O
not	not	O
seem	seem	O
to	to	O
increase	increase	O
the	the	O
risk	risk	O
of	of	O
endometrial	endometrial	B-Disease
hyperplasia	hyperplasia	I-Disease
or	or	O
carcinoma	carcinoma	B-Disease
.	.	O

Effects	effects	O
of	of	O
exercise	exercise	O
on	on	O
the	the	O
severity	severity	O
of	of	O
isoproterenol-induced	isoproterenol-induced	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
.	.	O

The	the	O
effect	effect	O
of	of	O
exercise	exercise	O
on	on	O
the	the	O
severity	severity	O
of	of	O
isoproterenol-induced	isoproterenol-induced	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
was	was	O
studied	studied	O
in	in	O
male	male	O
rats	rats	O
.	.	O

Ninety-three	ninety-three	O
rats	rats	O
were	were	O
randomly	randomly	O
divided	divided	O
into	into	O
three	three	O
groups	groups	O
.	.	O

The	the	O
exercise-isoproterenol	exercise-isoproterenol	O
(	(	O
E-1	e-1	O
)	)	O
and	and	O
exercise	exercise	O
control	control	O
(	(	O
EC	ec	O
)	)	O
groups	groups	O
exercised	exercised	O
daily	daily	O
for	for	O
thirty	thirty	O
days	days	O
on	on	O
a	a	O
treadmill	treadmill	O
at	at	O
1	1	O
mph	mph	O
,	,	O
2	2	O
%	%	O
grade	grade	O
while	while	O
animals	animals	O
of	of	O
the	the	O
sedentary-isoproterenol	sedentary-isoproterenol	O
(	(	O
S-I	s-i	O
)	)	O
group	group	O
remained	remained	O
sedentary	sedentary	O
.	.	O

Eight	eight	O
animals	animals	O
were	were	O
assigned	assigned	O
to	to	O
the	the	O
sedentary	sedentary	O
control	control	O
(	(	O
SC	sc	O
)	)	O
group	group	O
which	which	O
remained	remained	O
sedentary	sedentary	O
throughout	throughout	O
the	the	O
experimental	experimental	O
period	period	O
.	.	O

Forty-eight	forty-eight	O
hours	hours	O
after	after	O
the	the	O
final	final	O
exercise	exercise	O
period	period	O
,	,	O
S-I	s-i	O
and	and	O
E-I	e-i	O
animals	animals	O
received	received	O
a	a	O
single	single	O
subcutaneous	subcutaneous	O
injection	injection	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
(	(	O
250	250	O
mg/kg	mg/kg	O
body	body	B-Disease
weight	weight	I-Disease
)	)	O
.	.	O

Animals	animals	O
of	of	O
the	the	O
S-I	s-i	O
group	group	O
exhibited	exhibited	O
significantly	significantly	O
(	(	O
Pp	pp	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
greater	greater	O
mortality	mortality	O
from	from	O
the	the	O
effects	effects	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
than	than	O
animals	animals	O
of	of	O
the	the	O
E-I	e-i	O
group	group	O
.	.	O

Serum	serum	O
CPK	cpk	O
activity	activity	O
for	for	O
E-I	e-i	O
animals	animals	O
was	was	O
significantly	significantly	O
(	(	O
p	p	O
less	less	O
than	than	O
0.05	0.05	O
)	)	O
greater	greater	O
than	than	O
for	for	O
animals	animals	O
in	in	O
the	the	O
S-I	s-i	O
and	and	O
EC	ec	O
groups	groups	O
twenty	twenty	O
hours	hours	O
following	following	O
isoproterenol	isoproterenol	B-Chemical
injection	injection	O
.	.	O

No	no	O
statistically	statistically	O
significant	significant	O
differences	differences	O
were	were	O
observed	observed	O
between	between	O
the	the	O
two	two	O
isoproterenol	isoproterenol	B-Chemical
treated	treated	O
groups	groups	O
for	for	O
severity	severity	O
of	of	O
the	the	O
induced	induced	O
lesions	lesions	O
,	,	O
changes	changes	O
in	in	O
heart	heart	O
weight	weight	O
,	,	O
or	or	O
heart	heart	O
weight	weight	O
to	to	O
body	body	B-Disease
weight	weight	I-Disease
ratios	ratios	O
.	.	O

The	the	O
results	results	O
indicated	indicated	O
that	that	O
exercise	exercise	O
reduced	reduced	O
the	the	O
mortality	mortality	O
associated	associated	O
with	with	O
the	the	O
effects	effects	O
of	of	O
large	large	O
dosages	dosages	O
of	of	O
isoproterenol	isoproterenol	B-Chemical
but	but	O
had	had	O
little	little	O
on	on	O
the	the	O
severity	severity	O
of	of	O
the	the	O
infarction	infarction	B-Disease
.	.	O

Human	human	O
corticotropin-releasing	corticotropin-releasing	O
hormone	hormone	O
and	and	O
thyrotropin-releasing	thyrotropin-releasing	O
hormone	hormone	O
modulate	modulate	O
the	the	O
hypercapnic	hypercapnic	O
ventilatory	ventilatory	O
response	response	O
in	in	O
humans	humans	O
.	.	O

Human	human	O
corticotropin-releasing	corticotropin-releasing	O
hormone	hormone	O
(	(	O
hCRH	hcrh	O
)	)	O
and	and	O
thyrotropin-releasing	thyrotropin-releasing	O
hormone	hormone	O
(	(	O
TRH	trh	O
)	)	O
are	are	O
known	known	O
to	to	O
stimulate	stimulate	O
ventilation	ventilation	O
after	after	O
i.v	i.v	O
.	.	O

administration	administration	O
in	in	O
humans	humans	O
.	.	O

In	in	O
a	a	O
placebo-controlled	placebo-controlled	O
,	,	O
single-blind	single-blind	O
study	study	O
we	we	O
aimed	aimed	O
to	to	O
clarify	clarify	O
if	if	O
both	both	O
peptides	peptides	O
act	act	O
by	by	O
altering	altering	O
central	central	O
chemosensitivity	chemosensitivity	O
.	.	O

Two	two	O
subsequent	subsequent	O
CO2-rebreathing	co2-rebreathing	O
tests	tests	O
were	were	O
performed	performed	O
in	in	O
healthy	healthy	O
young	young	O
volunteers	volunteers	O
.	.	O

During	during	O
the	the	O
first	first	O
test	test	O
0.9	0.9	O
%	%	O
NaCl	nacl	B-Chemical
was	was	O
given	given	O
i.v	i.v	O
.	.	O
;	;	O
during	during	O
the	the	O
second	second	O
test	test	O
200	200	O
micrograms	micrograms	O
of	of	O
hCRH	hcrh	O
(	(	O
n	n	O
=	=	O
12	12	O
)	)	O
or	or	O
400	400	O
micrograms	micrograms	O
of	of	O
TRH	trh	O
(	(	O
n	n	O
=	=	O
6	6	O
)	)	O
was	was	O
administered	administered	O
i.v	i.v	O
.	.	O

Nine	nine	O
subjects	subjects	O
received	received	O
0.9	0.9	O
%	%	O
NaCl	nacl	B-Chemical
i.v	i.v	O
.	.	O
during	during	O
both	both	O
rebreathing	rebreathing	O
manoeuvres	manoeuvres	O
.	.	O

The	the	O
CO2-response	co2-response	O
curves	curves	O
for	for	O
the	the	O
two	two	O
tests	tests	O
were	were	O
compared	compared	O
within	within	O
the	the	O
same	same	O
subject	subject	O
.	.	O

In	in	O
the	the	O
hCRH	hcrh	O
group	group	O
a	a	O
marked	marked	O
parallel	parallel	O
shift	shift	O
of	of	O
the	the	O
CO2-response	co2-response	O
curve	curve	O
to	to	O
the	the	O
left	left	O
was	was	O
observed	observed	O
after	after	O
hCRH	hcrh	O
(	(	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
.	.	O

The	the	O
same	same	O
effect	effect	O
occurred	occurred	O
following	following	O
TRH	trh	O
but	but	O
was	was	O
less	less	O
striking	striking	O
(	(	O
P	p	O
=	=	O
0.05	0.05	O
)	)	O
.	.	O

hCRH	hcrh	O
and	and	O
TRH	trh	O
caused	caused	O
a	a	O
reduction	reduction	O
in	in	O
the	the	O
CO2	co2	B-Chemical
threshold	threshold	O
.	.	O

The	the	O
CO2-response	co2-response	O
curves	curves	O
in	in	O
the	the	O
control	control	O
group	group	O
were	were	O
nearly	nearly	O
identical	identical	O
.	.	O

The	the	O
results	results	O
indicate	indicate	O
an	an	O
additive	additive	O
effect	effect	O
of	of	O
both	both	O
releasing	releasing	O
hormones	hormones	O
on	on	O
the	the	O
hypercapnic	hypercapnic	O
ventilatory	ventilatory	O
response	response	O
in	in	O
humans	humans	O
,	,	O
presumably	presumably	O
independent	independent	O
of	of	O
central	central	O
chemosensitivity	chemosensitivity	O
.	.	O

Lamivudine	lamivudine	B-Chemical
is	is	O
effective	effective	O
in	in	O
suppressing	suppressing	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
virus	virus	O
DNA	dna	O
in	in	O
Chinese	chinese	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
surface	surface	O
antigen	antigen	O
carriers	carriers	O
:	:	O
a	a	O
placebo-controlled	placebo-controlled	O
trial	trial	O
.	.	O

Lamivudine	lamivudine	B-Chemical
is	is	O
a	a	O
novel	novel	O
2',3'-dideoxy	2',3'-dideoxy	O
cytosine	cytosine	O
analogue	analogue	O
that	that	O
has	has	O
potent	potent	O
inhibitory	inhibitory	O
effects	effects	O
on	on	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
virus	virus	O
replication	replication	O
in	in	O
vitro	vitro	O
and	and	O
in	in	O
vivo	vivo	O
.	.	O

We	we	O
performed	performed	O
a	a	O
single-blind	single-blind	O
,	,	O
placebo-controlled	placebo-controlled	O
study	study	O
to	to	O
assess	assess	O
its	its	O
effectiveness	effectiveness	O
and	and	O
safety	safety	O
in	in	O
Chinese	chinese	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
surface	surface	O
antigen	antigen	O
(	(	O
HBsAg	hbsag	B-Chemical
)	)	O
carriers	carriers	O
.	.	O

Forty-two	forty-two	O
Chinese	chinese	O
HBsAg	hbsag	B-Chemical
carriers	carriers	O
were	were	O
randomized	randomized	O
to	to	O
receive	receive	O
placebo	placebo	O
(	(	O
6	6	O
patients	patients	O
)	)	O
or	or	O
lamivudine	lamivudine	B-Chemical
orally	orally	O
in	in	O
dosages	dosages	O
of	of	O
25	25	O
mg	mg	O
,	,	O
100	100	O
mg	mg	O
,	,	O
or	or	O
300	300	O
mg	mg	O
daily	daily	O
(	(	O
12	12	O
patients	patients	O
for	for	O
each	each	O
dosage	dosage	O
)	)	O
.	.	O

The	the	O
drug	drug	O
was	was	O
given	given	O
for	for	O
4	4	O
weeks	weeks	O
.	.	O

The	the	O
patients	patients	O
were	were	O
closely	closely	O
monitored	monitored	O
clinically	clinically	O
,	,	O
biochemically	biochemically	O
,	,	O
and	and	O
serologically	serologically	O
up	up	O
to	to	O
4	4	O
weeks	weeks	O
after	after	O
drug	drug	O
treatment	treatment	O
.	.	O

All	all	O
36	36	O
patients	patients	O
receiving	receiving	O
lamivudine	lamivudine	B-Chemical
had	had	O
a	a	O
decrease	decrease	O
in	in	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
virus	virus	O
(	(	O
HBV	hbv	O
)	)	O
DNA	dna	O
values	values	O
of	of	O
>	>	O
90	90	O
%	%	O
(	(	O
P	p	O
<	<	O
.001	.001	O
compared	compared	O
with	with	O
placebo	placebo	O
)	)	O
.	.	O

Although	although	O
25	25	O
mg	mg	O
of	of	O
lamivudine	lamivudine	B-Chemical
was	was	O
slightly	slightly	O
less	less	O
effective	effective	O
than	than	O
100	100	O
mg	mg	O
(	(	O
P	p	O
=	=	O
.011	.011	O
)	)	O
and	and	O
300	300	O
mg	mg	O
(	(	O
P	p	O
=	=	O
.005	.005	O
)	)	O
,	,	O
it	it	O
still	still	O
induced	induced	O
94	94	O
%	%	O
suppression	suppression	O
of	of	O
HBV	hbv	O
DNA	dna	O
after	after	O
the	the	O
fourth	fourth	O
week	week	O
of	of	O
therapy	therapy	O
.	.	O

HBV	hbv	O
DNA	dna	O
values	values	O
returned	returned	O
to	to	O
pretreatment	pretreatment	O
levels	levels	O
within	within	O
4	4	O
weeks	weeks	O
of	of	O
cessation	cessation	O
of	of	O
therapy	therapy	O
.	.	O

There	there	O
was	was	O
no	no	O
change	change	O
in	in	O
the	the	O
hepatitis	hepatitis	B-Disease
B	b	I-Disease
e	e	O
antigen	antigen	O
status	status	O
or	or	O
in	in	O
aminotransferase	aminotransferase	O
levels	levels	O
.	.	O

No	no	O
serious	serious	O
adverse	adverse	O
events	events	O
were	were	O
observed	observed	O
.	.	O

In	in	O
conclusion	conclusion	O
,	,	O
a	a	O
4-week	4-week	O
course	course	O
of	of	O
lamivudine	lamivudine	B-Chemical
was	was	O
safe	safe	O
and	and	O
effective	effective	O
in	in	O
suppression	suppression	O
of	of	O
HBV	hbv	O
DNA	dna	O
in	in	O
Chinese	chinese	O
HBsAg	hbsag	B-Chemical
carriers	carriers	O
.	.	O

The	the	O
suppression	suppression	O
was	was	O
>	>	O
90	90	O
%	%	O
but	but	O
reversible	reversible	O
.	.	O

Studies	studies	O
with	with	O
long-term	long-term	O
lamivudine	lamivudine	B-Chemical
administration	administration	O
should	should	O
be	be	O
performed	performed	O
to	to	O
determine	determine	O
if	if	O
prolonged	prolonged	O
suppression	suppression	O
of	of	O
HBV	hbv	O
DNA	dna	O
can	can	O
be	be	O
achieved	achieved	O
.	.	O

Population-based	population-based	O
study	study	O
of	of	O
risk	risk	O
of	of	O
venous	venous	B-Disease
thromboembolism	thromboembolism	I-Disease
associated	associated	O
with	with	O
various	various	O
oral	oral	B-Chemical
contraceptives	contraceptives	I-Chemical
.	.	O

BACKGROUND	background	O
:	:	O
Four	four	O
studies	studies	O
published	published	O
since	since	O
December	december	O
,	,	O
1995	1995	O
,	,	O
reported	reported	O
that	that	O
the	the	O
incidence	incidence	O
of	of	O
venous	venous	B-Disease
thromboembolism	thromboembolism	I-Disease
(	(	O
VTE	vte	B-Disease
)	)	O
was	was	O
higher	higher	O
in	in	O
women	women	O
who	who	O
used	used	O
oral	oral	B-Chemical
contraceptives	contraceptives	I-Chemical
(	(	O
OCs	ocs	O
)	)	O
containing	containing	O
the	the	O
third-generation	third-generation	O
progestagens	progestagens	O
gestodene	gestodene	O
or	or	O
desogestrel	desogestrel	B-Chemical
than	than	O
in	in	O
users	users	O
of	of	O
OCs	ocs	O
containing	containing	O
second-generation	second-generation	O
progestagens	progestagens	O
.	.	O

However	however	O
,	,	O
confounding	confounding	O
and	and	O
bias	bias	O
in	in	O
the	the	O
design	design	O
of	of	O
these	these	O
studies	studies	O
may	may	O
have	have	O
affected	affected	O
the	the	O
findings	findings	O
.	.	O

The	the	O
aim	aim	O
of	of	O
our	our	O
study	study	O
was	was	O
to	to	O
re-examine	re-examine	O
the	the	O
association	association	O
between	between	O
risk	risk	O
of	of	O
VTE	vte	B-Disease
and	and	O
OC	oc	B-Chemical
use	use	O
with	with	O
a	a	O
different	different	O
study	study	O
design	design	O
and	and	O
analysis	analysis	O
to	to	O
avoid	avoid	O
some	some	O
of	of	O
the	the	O
bias	bias	O
and	and	O
confounding	confounding	O
of	of	O
the	the	O
earlier	earlier	O
studies	studies	O
.	.	O

METHODS	methods	O
:	:	O
We	we	O
used	used	O
computer	computer	O
records	records	O
of	of	O
patients	patients	O
from	from	O
143	143	O
general	general	O
practices	practices	O
in	in	O
the	the	O
UK	uk	O
.	.	O

The	the	O
study	study	O
was	was	O
based	based	O
on	on	O
the	the	O
medical	medical	O
records	records	O
of	of	O
about	about	O
540,000	540,000	O
women	women	O
born	born	O
between	between	O
1941	1941	O
and	and	O
1981	1981	O
.	.	O

All	all	O
women	women	O
who	who	O
had	had	O
a	a	O
recorded	recorded	O
diagnosis	diagnosis	O
of	of	O
deep-vein	deep-vein	O
thrombosis	thrombosis	B-Disease
,	,	O
venous	venous	B-Disease
thrombosis	thrombosis	B-Disease
not	not	O
otherwise	otherwise	O
specified	specified	O
,	,	O
or	or	O
pulmonary	pulmonary	O
embolus	embolus	O
during	during	O
the	the	O
study	study	O
period	period	O
,	,	O
and	and	O
who	who	O
had	had	O
been	been	O
treated	treated	O
with	with	O
an	an	O
anticoagulant	anticoagulant	O
were	were	O
identified	identified	O
as	as	O
potential	potential	O
cases	cases	O
of	of	O
VTE	vte	B-Disease
.	.	O

We	we	O
did	did	O
a	a	O
cohort	cohort	O
analysis	analysis	O
to	to	O
estimate	estimate	O
and	and	O
compare	compare	O
incidence	incidence	O
of	of	O
VTE	vte	B-Disease
in	in	O
users	users	O
of	of	O
the	the	O
main	main	O
OC	oc	B-Chemical
preparations	preparations	O
,	,	O
and	and	O
a	a	O
nested	nested	O
case-control	case-control	O
study	study	O
to	to	O
calculate	calculate	O
the	the	O
odds	odds	O
ratios	ratios	O
of	of	O
VTE	vte	B-Disease
associated	associated	O
with	with	O
use	use	O
of	of	O
different	different	O
types	types	O
of	of	O
OC	oc	B-Chemical
,	,	O
after	after	O
adjustment	adjustment	O
for	for	O
potential	potential	O
confounding	confounding	O
factors	factors	O
.	.	O

In	in	O
the	the	O
case-control	case-control	O
study	study	O
,	,	O
we	we	O
matched	matched	O
cases	cases	O
to	to	O
controls	controls	O
by	by	O
exact	exact	O
year	year	O
of	of	O
birth	birth	O
,	,	O
practice	practice	O
,	,	O
and	and	O
current	current	O
use	use	O
of	of	O
OCs	ocs	O
.	.	O

We	we	O
used	used	O
a	a	O
multiple	multiple	O
logistic	logistic	O
regression	regression	O
model	model	O
that	that	O
included	included	O
body-mass	body-mass	O
index	index	O
,	,	O
number	number	O
of	of	O
cycles	cycles	O
,	,	O
change	change	O
in	in	O
type	type	O
of	of	O
OC	oc	B-Chemical
prescribed	prescribed	O
within	within	O
3	3	O
months	months	O
of	of	O
the	the	O
event	event	O
,	,	O
previous	previous	O
pregnancy	pregnancy	O
,	,	O
and	and	O
concurrent	concurrent	O
disease	disease	O
.	.	O

FINDINGS	findings	O
:	:	O
85	85	O
women	women	O
met	met	O
the	the	O
inclusion	inclusion	O
criteria	criteria	O
for	for	O
VTE	vte	B-Disease
,	,	O
two	two	O
of	of	O
whom	whom	O
were	were	O
users	users	O
of	of	O
progestagen-only	progestagen-only	O
OCs	ocs	O
.	.	O

Of	of	O
the	the	O
83	83	O
cases	cases	O
of	of	O
VTE	vte	B-Disease
associated	associated	O
with	with	O
use	use	O
of	of	O
combined	combined	O
OCs	ocs	O
,	,	O
43	43	O
were	were	O
recorded	recorded	O
as	as	O
deep-vein	deep-vein	O
thrombosis	thrombosis	B-Disease
,	,	O
35	35	O
as	as	O
pulmonary	pulmonary	O
thrombosis	thrombosis	B-Disease
,	,	O
and	and	O
five	five	O
as	as	O
venous	venous	B-Disease
thrombosis	thrombosis	B-Disease
not	not	O
otherwise	otherwise	O
specified	specified	O
.	.	O

The	the	O
crude	crude	O
rate	rate	O
of	of	O
VTE	vte	B-Disease
per	per	O
10,000	10,000	O
woman-years	woman-years	O
was	was	O
4.10	4.10	O
in	in	O
current	current	O
users	users	O
of	of	O
any	any	O
OC	oc	B-Chemical
,	,	O
3.10	3.10	O
in	in	O
users	users	O
of	of	O
second-generation	second-generation	O
OCs	ocs	O
,	,	O
and	and	O
4.96	4.96	O
in	in	O
users	users	O
of	of	O
third-generation	third-generation	O
preparations	preparations	O
.	.	O

After	after	O
adjustment	adjustment	O
for	for	O
age	age	O
,	,	O
the	the	O
rate	rate	O
ratio	ratio	O
of	of	O
VTE	vte	B-Disease
in	in	O
users	users	O
of	of	O
third-generation	third-generation	O
relative	relative	O
to	to	O
second-generation	second-generation	O
OCs	ocs	O
was	was	O
1.68	1.68	O
(	(	O
95	95	O
%	%	O
CI	ci	O
1.04	1.04	O
-	-	O
2.75	2.75	O
)	)	O
.	.	O

Logistic	logistic	O
regression	regression	O
showed	showed	O
no	no	O
significant	significant	O
difference	difference	O
in	in	O
the	the	O
risk	risk	O
of	of	O
VTE	vte	B-Disease
between	between	O
users	users	O
of	of	O
third-generation	third-generation	O
and	and	O
second-generation	second-generation	O
OCs	ocs	O
.	.	O

Among	among	O
users	users	O
of	of	O
third-generation	third-generation	O
progestagens	progestagens	O
,	,	O
the	the	O
risk	risk	O
of	of	O
VTE	vte	B-Disease
was	was	O
higher	higher	O
in	in	O
users	users	O
of	of	O
desogestrel	desogestrel	B-Chemical
with	with	O
20	20	O
g	g	O
ethinyloestradiol	ethinyloestradiol	B-Chemical
than	than	O
in	in	O
users	users	O
of	of	O
gestodene	gestodene	O
or	or	O
desogestrel	desogestrel	B-Chemical
with	with	O
30	30	O
g	g	O
ethinyloestradiol	ethinyloestradiol	B-Chemical
.	.	O

With	with	O
all	all	O
second-generation	second-generation	O
OCs	ocs	O
as	as	O
the	the	O
reference	reference	O
,	,	O
the	the	O
odds	odds	O
ratios	ratios	O
for	for	O
VTE	vte	B-Disease
were	were	O
3.49	3.49	O
(	(	O
1.21	1.21	O
-	-	O
10.12	10.12	O
)	)	O
for	for	O
desogestrel	desogestrel	B-Chemical
plus	plus	O
20	20	O
g	g	O
ethinyloestradiol	ethinyloestradiol	B-Chemical
and	and	O
1.18	1.18	O
(	(	O
0.66	0.66	O
-	-	O
2.17	2.17	O
)	)	O
for	for	O
the	the	O
other	other	O
third-generation	third-generation	O
progestagens	progestagens	O
.	.	O

INTERPRETATION	interpretation	O
:	:	O
The	the	O
previously	previously	O
reported	reported	O
increase	increase	O
in	in	O
odds	odds	O
ratio	ratio	O
associated	associated	O
with	with	O
third-generation	third-generation	O
OCs	ocs	O
when	when	O
compared	compared	O
with	with	O
second-generation	second-generation	O
products	products	O
is	is	O
likely	likely	O
to	to	O
have	have	O
been	been	O
the	the	O
result	result	O
of	of	O
residual	residual	O
confounding	confounding	O
by	by	O
age	age	O
.	.	O

The	the	O
increased	increased	O
odds	odds	O
ratio	ratio	O
associated	associated	O
with	with	O
products	products	O
containing	containing	O
20	20	O
micrograms	micrograms	O
ethinyloestradiol	ethinyloestradiol	B-Chemical
and	and	O
desogestrel	desogestrel	B-Chemical
compared	compared	O
with	with	O
the	the	O
30	30	O
micrograms	micrograms	O
product	product	O
is	is	O
biologically	biologically	O
implausible	implausible	O
,	,	O
and	and	O
is	is	O
likely	likely	O
to	to	O
be	be	O
the	the	O
result	result	O
of	of	O
preferential	preferential	O
prescribing	prescribing	O
and	and	O
,	,	O
thus	thus	O
,	,	O
confounding	confounding	O
.	.	O

MK-801	mk-801	B-Chemical
augments	augments	O
pilocarpine-induced	pilocarpine-induced	O
electrographic	electrographic	O
seizure	seizure	B-Disease
but	but	O
protects	protects	O
against	against	O
brain	brain	B-Disease
damage	damage	I-Disease
in	in	O
rats.1	rats.1	O
.	.	O

The	the	O
authors	authors	O
examined	examined	O
the	the	O
anticonvulsant	anticonvulsant	O
effects	effects	O
of	of	O
MK-801	mk-801	B-Chemical
on	on	O
the	the	O
pilocarpine-induced	pilocarpine-induced	O
seizure	seizure	B-Disease
model	model	O
.	.	O

Intraperitoneal	intraperitoneal	O
injection	injection	O
of	of	O
pilocarpine	pilocarpine	B-Chemical
(	(	O
400	400	O
mg/kg	mg/kg	O
)	)	O
induced	induced	O
tonic	tonic	O
and	and	O
clonic	clonic	O
seizure	seizure	B-Disease
.	.	O

Scopolamine	scopolamine	B-Chemical
(	(	O
10	10	O
mg/kg	mg/kg	O
)	)	O
and	and	O
pentobarbital	pentobarbital	B-Chemical
(	(	O
5	5	O
mg/kg	mg/kg	O
)	)	O
prevented	prevented	O
development	development	O
of	of	O
pilocarpine-induced	pilocarpine-induced	O
behavioral	behavioral	O
seizure	seizure	B-Disease
but	but	O
MK-801	mk-801	B-Chemical
(	(	O
0.5	0.5	O
mg/kg	mg/kg	O
)	)	O
did	did	O
not	not	O
.	.	O

2	2	O
.	.	O
An	an	O
electrical	electrical	O
seizure	seizure	B-Disease
measured	measured	O
with	with	O
hippocampal	hippocampal	O
EEG	eeg	O
appeared	appeared	O
in	in	O
the	the	O
pilocarpine-treated	pilocarpine-treated	O
group	group	O
.	.	O

Scopolamine	scopolamine	B-Chemical
and	and	O
pentobarbital	pentobarbital	B-Chemical
blocked	blocked	O
the	the	O
pilocarpine-induced	pilocarpine-induced	O
electrographic	electrographic	O
seizure	seizure	B-Disease
,	,	O
MK-801	mk-801	B-Chemical
treatment	treatment	O
augmented	augmented	O
the	the	O
electrographic	electrographic	O
seizure	seizure	B-Disease
induced	induced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
.	.	O

3	3	O
.	.	O
Brain	brain	B-Disease
damage	damage	I-Disease
was	was	O
assessed	assessed	O
by	by	O
examining	examining	O
the	the	O
hippocampus	hippocampus	O
microscopically	microscopically	O
.	.	O

Pilocarpine	pilocarpine	B-Chemical
produced	produced	O
neuronal	neuronal	O
death	death	B-Disease
in	in	O
the	the	O
hippocampus	hippocampus	O
,	,	O
which	which	O
showed	showed	O
pyknotic	pyknotic	O
changes	changes	O
.	.	O

Pentobarbital	pentobarbital	B-Chemical
,	,	O
scopolamine	scopolamine	B-Chemical
and	and	O
MK-801	mk-801	B-Chemical
protected	protected	O
the	the	O
brain	brain	B-Disease
damage	damage	I-Disease
by	by	O
pilocarpine	pilocarpine	B-Chemical
,	,	O
though	though	O
in	in	O
the	the	O
MK-801-treated	mk-801-treated	O
group	group	O
,	,	O
the	the	O
pyramidal	pyramidal	O
cells	cells	O
of	of	O
hippocampus	hippocampus	O
appeared	appeared	O
darker	darker	O
than	than	O
normal	normal	O
.	.	O

In	in	O
all	all	O
treatments	treatments	O
,	,	O
granule	granule	O
cells	cells	O
of	of	O
the	the	O
dentate	dentate	O
gyrus	gyrus	O
were	were	O
not	not	O
affected	affected	O
.	.	O

4	4	O
.	.	O

These	these	O
results	results	O
indicate	indicate	O
that	that	O
status	status	B-Disease
epilepticus	epilepticus	I-Disease
induced	induced	O
by	by	O
pilocarpine	pilocarpine	B-Chemical
is	is	O
initiated	initiated	O
by	by	O
cholinergic	cholinergic	O
overstimulation	overstimulation	O
and	and	O
propagated	propagated	O
by	by	O
glutamatergic	glutamatergic	O
transmission	transmission	O
,	,	O
the	the	O
elevation	elevation	O
of	of	O
which	which	O
may	may	O
cause	cause	O
brain	brain	B-Disease
damage	damage	I-Disease
through	through	O
an	an	O
excitatory	excitatory	O
NMDA	nmda	B-Chemical
receptor-mediated	receptor-mediated	O
mechanism	mechanism	O
.	.	O

Paclitaxel	paclitaxel	B-Chemical
,	,	O
5-fluorouracil	5-fluorouracil	B-Chemical
,	,	O
and	and	O
folinic	folinic	B-Chemical
acid	acid	I-Chemical
in	in	O
metastatic	metastatic	O
breast	breast	B-Disease
cancer	cancer	B-Disease
:	:	O
BRE-26	bre-26	O
,	,	O
a	a	O
phase	phase	O
II	ii	O
trial.5-Fluorouracil	trial.5-fluorouracil	O
plus	plus	O
folinic	folinic	B-Chemical
acid	acid	I-Chemical
and	and	O
paclitaxel	paclitaxel	B-Chemical
(	(	O
Taxol	taxol	B-Chemical
;	;	O
Bristol-Myers	bristol-myers	O
Squibb	squibb	O
Company	company	O
,	,	O
Princeton	princeton	O
,	,	O
NJ	nj	O
)	)	O
are	are	O
effective	effective	O
salvage	salvage	O
therapies	therapies	O
for	for	O
metastatic	metastatic	O
breast	breast	B-Disease
cancer	cancer	B-Disease
patients	patients	O
.	.	O

Paclitaxel	paclitaxel	B-Chemical
and	and	O
5-fluorouracil	5-fluorouracil	B-Chemical
have	have	O
additive	additive	O
cytotoxicity	cytotoxicity	O
in	in	O
MCF-7	mcf-7	O
cell	cell	O
lines	lines	O
.	.	O

We	we	O
performed	performed	O
a	a	O
phase	phase	O
II	ii	O
trial	trial	O
of	of	O
paclitaxel	paclitaxel	B-Chemical
175	175	O
mg/m2	mg/m2	O
over	over	O
3	3	O
hours	hours	O
on	on	O
day	day	O
I	i	O
followed	followed	O
by	by	O
folinic	folinic	B-Chemical
acid	acid	I-Chemical
300	300	O
mg	mg	O
over	over	O
1	1	O
hour	hour	O
before	before	O
5-fluorouracil	5-fluorouracil	B-Chemical
350	350	O
mg/m2	mg/m2	O
on	on	O
days	days	O
1	1	O
to	to	O
3	3	O
every	every	O
28	28	O
days	days	O
(	(	O
TFL	tfl	O
)	)	O
in	in	O
women	women	O
with	with	O
metastatic	metastatic	O
breast	breast	B-Disease
cancer	cancer	B-Disease
.	.	O

Analysis	analysis	O
is	is	O
reported	reported	O
on	on	O
37	37	O
patients	patients	O
with	with	O
a	a	O
minimum	minimum	O
of	of	O
6	6	O
months	months	O
follow-up	follow-up	O
who	who	O
received	received	O
a	a	O
total	total	O
of	of	O
192	192	O
cycles	cycles	O
of	of	O
TFL	tfl	O
:	:	O
nine	nine	O
cycles	cycles	O
(	(	O
5	5	O
%	%	O
)	)	O
were	were	O
associated	associated	O
with	with	O
grade	grade	O
3/4	3/4	O
neutropenia	neutropenia	B-Disease
requiring	requiring	O
hospitalization	hospitalization	O
;	;	O
seven	seven	O
(	(	O
4	4	O
%	%	O
)	)	O
cycles	cycles	O
in	in	O
two	two	O
patients	patients	O
required	required	O
granulocyte	granulocyte	O
colony-stimulating	colony-stimulating	O
factor	factor	O
due	due	O
to	to	O
neutropenia	neutropenia	B-Disease
;	;	O
no	no	O
patient	patient	O
required	required	O
platelet	platelet	O
transfusions	transfusions	O
.	.	O

Grade	grade	O
3/4	3/4	O
nonhematologic	nonhematologic	O
toxicities	toxicities	B-Disease
were	were	O
uncommon	uncommon	O
.	.	O

Among	among	O
the	the	O
34	34	O
patients	patients	O
evaluable	evaluable	O
for	for	O
response	response	O
,	,	O
there	there	O
were	were	O
three	three	O
complete	complete	O
responses	responses	O
(	(	O
9	9	O
%	%	O
)	)	O
and	and	O
18	18	O
partial	partial	O
responses	responses	O
(	(	O
53	53	O
%	%	O
)	)	O
for	for	O
an	an	O
overall	overall	O
response	response	O
rate	rate	O
of	of	O
62	62	O
%	%	O
.	.	O

Of	of	O
the	the	O
19	19	O
evaluable	evaluable	O
patients	patients	O
with	with	O
prior	prior	O
doxorubicin	doxorubicin	B-Chemical
exposure	exposure	O
,	,	O
11	11	O
(	(	O
58	58	O
%	%	O
)	)	O
responded	responded	O
compared	compared	O
with	with	O
nine	nine	O
of	of	O
15	15	O
(	(	O
60	60	O
%	%	O
)	)	O
without	without	O
prior	prior	O
doxorubicin	doxorubicin	B-Chemical
.	.	O

Plasma	plasma	O
paclitaxel	paclitaxel	B-Chemical
concentrations	concentrations	O
were	were	O
measured	measured	O
at	at	O
the	the	O
completion	completion	O
of	of	O
paclitaxel	paclitaxel	B-Chemical
infusion	infusion	O
and	and	O
at	at	O
24	24	O
hours	hours	O
in	in	O
19	19	O
patients	patients	O
.	.	O

TFL	tfl	O
is	is	O
an	an	O
active	active	O
,	,	O
well-tolerated	well-tolerated	O
regimen	regimen	O
in	in	O
metastatic	metastatic	O
breast	breast	B-Disease
cancer	cancer	B-Disease
.	.	O

Efficacy	efficacy	O
and	and	O
proarrhythmia	proarrhythmia	O
with	with	O
the	the	O
use	use	O
of	of	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
for	for	O
sustained	sustained	O
ventricular	ventricular	O
tachyarrhythmias	tachyarrhythmias	O
.	.	O

This	this	O
study	study	O
prospectively	prospectively	O
evaluated	evaluated	O
the	the	O
clinical	clinical	O
efficacy	efficacy	O
,	,	O
the	the	O
incidence	incidence	O
of	of	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
,	,	O
and	and	O
the	the	O
presumable	presumable	O
risk	risk	O
factors	factors	O
for	for	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
in	in	O
patients	patients	O
treated	treated	O
with	with	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
for	for	O
sustained	sustained	O
ventricular	ventricular	O
tachyarrhythmias	tachyarrhythmias	O
.	.	O

Eighty-one	eighty-one	O
consecutive	consecutive	O
patients	patients	O
(	(	O
54	54	O
with	with	O
coronary	coronary	B-Disease
artery	artery	I-Disease
disease	disease	I-Disease
,	,	O
and	and	O
20	20	O
with	with	O
dilated	dilated	B-Disease
cardiomyopathy	cardiomyopathy	B-Disease
)	)	O
with	with	O
inducible	inducible	O
sustained	sustained	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
or	or	O
ventricular	ventricular	B-Disease
fibrillation	fibrillation	I-Disease
received	received	O
oral	oral	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
to	to	O
prevent	prevent	O
induction	induction	O
of	of	O
the	the	O
ventricular	ventricular	O
tachyarrhythmia	tachyarrhythmia	O
.	.	O

During	during	O
oral	oral	O
loading	loading	O
with	with	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
,	,	O
continuous	continuous	O
electrocardiographic	electrocardiographic	O
(	(	O
ECG	ecg	O
)	)	O
monitoring	monitoring	O
was	was	O
performed	performed	O
.	.	O

Those	those	O
patients	patients	O
in	in	O
whom	whom	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
prevented	prevented	O
induction	induction	O
of	of	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
or	or	O
ventricular	ventricular	B-Disease
fibrillation	fibrillation	I-Disease
were	were	O
discharged	discharged	O
with	with	O
the	the	O
drug	drug	O
and	and	O
followed	followed	O
up	up	O
on	on	O
an	an	O
outpatient	outpatient	O
basis	basis	O
for	for	O
21	21	O
+	+	O
/-	/-	O
18	18	O
months	months	O
.	.	O

Induction	induction	O
of	of	O
the	the	O
ventricular	ventricular	O
tachyarrhythmia	tachyarrhythmia	O
was	was	O
prevented	prevented	O
by	by	O
oral	oral	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
in	in	O
35	35	O
(	(	O
43	43	O
%	%	O
)	)	O
patients	patients	O
;	;	O
the	the	O
ventricular	ventricular	O
tachyarrhythmia	tachyarrhythmia	O
remained	remained	O
inducible	inducible	O
in	in	O
40	40	O
(	(	O
49	49	O
%	%	O
)	)	O
patients	patients	O
;	;	O
and	and	O
two	two	O
(	(	O
2.5	2.5	O
%	%	O
)	)	O
patients	patients	O
did	did	O
not	not	O
tolerate	tolerate	O
even	even	O
40	40	O
mg	mg	O
of	of	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
once	once	O
daily	daily	O
.	.	O

Four	four	O
(	(	O
5	5	O
%	%	O
)	)	O
patients	patients	O
had	had	O
from	from	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
during	during	O
the	the	O
initial	initial	O
oral	oral	O
treatment	treatment	O
with	with	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
.	.	O

Neither	neither	O
ECG	ecg	O
[	[	O
sinus-cycle	sinus-cycle	O
length	length	O
(	(	O
SCL	scl	O
)	)	O
,	,	O
QT	qt	O
or	or	O
QTc	qtc	O
interval	interval	O
,	,	O
or	or	O
U	u	O
wave	wave	O
]	]	O
nor	nor	O
clinical	clinical	O
parameters	parameters	O
identified	identified	O
patients	patients	O
at	at	O
risk	risk	O
for	for	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
.	.	O

However	however	O
,	,	O
the	the	O
oral	oral	O
dose	dose	O
of	of	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
was	was	O
significantly	significantly	O
lower	lower	O
in	in	O
patients	patients	O
with	with	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
(	(	O
200	200	O
+	+	O
/-	/-	O
46	46	O
vs.	vs.	O
328	328	O
+	+	O
/-	/-	O
53	53	O
mg/day	mg/day	O
;	;	O
p	p	O
=	=	O
0.0017	0.0017	O
)	)	O
.	.	O

Risk	risk	O
factors	factors	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
were	were	O
the	the	O
appearance	appearance	O
of	of	O
an	an	O
U	u	O
wave	wave	O
(	(	O
p	p	O
=	=	O
0.049	0.049	O
)	)	O
,	,	O
female	female	O
gender	gender	O
(	(	O
p	p	O
=	=	O
0.015	0.015	O
)	)	O
,	,	O
and	and	O
significant	significant	O
dose-corrected	dose-corrected	O
changes	changes	O
of	of	O
SCL	scl	O
,	,	O
QT	qt	O
interval	interval	O
,	,	O
and	and	O
QTc	qtc	O
interval	interval	O
(	(	O
p	p	O
<	<	O
0.05	0.05	O
)	)	O
.	.	O

During	during	O
follow-up	follow-up	O
,	,	O
seven	seven	O
(	(	O
20	20	O
%	%	O
)	)	O
patients	patients	O
had	had	O
a	a	O
nonfatal	nonfatal	O
ventricular	ventricular	B-Disease
tachycardia	tachycardia	B-Disease
recurrence	recurrence	O
,	,	O
and	and	O
two	two	O
(	(	O
6	6	O
%	%	O
)	)	O
patients	patients	O
died	died	O
suddenly	suddenly	O
.	.	O

One	one	O
female	female	O
patient	patient	O
with	with	O
stable	stable	O
cardiac	cardiac	B-Disease
disease	disease	I-Disease
had	had	O
recurrent	recurrent	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
after	after	O
2	2	O
years	years	O
of	of	O
successful	successful	O
treatment	treatment	O
with	with	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
.	.	O

Torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
occurred	occurred	O
early	early	O
during	during	O
treatment	treatment	O
even	even	O
with	with	O
low	low	O
doses	doses	O
of	of	O
oral	oral	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
.	.	O

Pronounced	pronounced	O
changes	changes	O
in	in	O
the	the	O
surface	surface	O
ECG	ecg	O
(	(	O
cycle	cycle	O
length	length	O
,	,	O
QT	qt	O
,	,	O
and	and	O
QTc	qtc	O
)	)	O
in	in	O
relation	relation	O
to	to	O
the	the	O
dose	dose	O
of	of	O
oral	oral	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
might	might	O
identify	identify	O
a	a	O
subgroup	subgroup	O
of	of	O
patients	patients	O
with	with	O
an	an	O
increased	increased	O
risk	risk	O
for	for	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
.	.	O

Other	other	O
ECG	ecg	O
parameters	parameters	O
before	before	O
the	the	O
application	application	O
of	of	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
did	did	O
not	not	O
identify	identify	O
patients	patients	O
at	at	O
increased	increased	O
risk	risk	O
for	for	O
torsades	torsades	B-Disease
de	de	I-Disease
pointes	pointes	I-Disease
.	.	O

Recurrence	recurrence	O
rates	rates	O
of	of	O
ventricular	ventricular	O
tachyarrhythmias	tachyarrhythmias	O
are	are	O
high	high	O
despite	despite	O
complete	complete	O
suppression	suppression	O
of	of	O
the	the	O
arrhythmia	arrhythmia	B-Disease
during	during	O
programmed	programmed	O
stimulation	stimulation	O
.	.	O

Therefore	therefore	O
programmed	programmed	O
electrical	electrical	O
stimulation	stimulation	O
in	in	O
the	the	O
case	case	O
of	of	O
d	d	O
,	,	O
l-sotalol	l-sotalol	O
seems	seems	O
to	to	O
be	be	O
of	of	O
limited	limited	O
prognostic	prognostic	O
value	value	O
.	.	O

Chronic	chronic	O
hyperprolactinemia	hyperprolactinemia	B-Disease
and	and	O
changes	changes	O
in	in	O
dopamine	dopamine	B-Chemical
neurons	neurons	O
.	.	O

The	the	O
tuberoinfundibular	tuberoinfundibular	O
dopaminergic	dopaminergic	O
(	(	O
TIDA	tida	O
)	)	O
system	system	O
is	is	O
known	known	O
to	to	O
inhibit	inhibit	O
prolactin	prolactin	O
(	(	O
PRL	prl	O
)	)	O
secretion	secretion	O
.	.	O

In	in	O
young	young	O
animals	animals	O
this	this	O
system	system	O
responds	responds	O
to	to	O
acute	acute	O
elevations	elevations	O
in	in	O
serum	serum	O
PRL	prl	O
by	by	O
increasing	increasing	O
its	its	O
activity	activity	O
.	.	O

However	however	O
,	,	O
this	this	O
responsiveness	responsiveness	O
is	is	O
lost	lost	O
in	in	O
aging	aging	O
rats	rats	O
with	with	O
chronically	chronically	O
high	high	O
serum	serum	O
PRL	prl	O
levels	levels	O
.	.	O

The	the	O
purpose	purpose	O
of	of	O
this	this	O
study	study	O
was	was	O
to	to	O
induce	induce	O
hyperprolactinemia	hyperprolactinemia	B-Disease
in	in	O
rats	rats	O
for	for	O
extended	extended	O
periods	periods	O
of	of	O
time	time	O
and	and	O
examine	examine	O
its	its	O
effects	effects	O
on	on	O
dopaminergic	dopaminergic	O
systems	systems	O
in	in	O
the	the	O
brain	brain	O
.	.	O

Hyperprolactinemia	hyperprolactinemia	B-Disease
was	was	O
induced	induced	O
by	by	O
treatment	treatment	O
with	with	O
haloperidol	haloperidol	B-Chemical
,	,	O
a	a	O
dopamine	dopamine	B-Chemical
receptor	receptor	O
antagonist	antagonist	O
,	,	O
and	and	O
Palkovits	palkovits	O
'	'	O
microdissection	microdissection	O
technique	technique	O
in	in	O
combination	combination	O
with	with	O
high-performance	high-performance	O
liquid	liquid	O
chromatography	chromatography	O
was	was	O
used	used	O
to	to	O
measure	measure	O
neurotransmitter	neurotransmitter	O
concentrations	concentrations	O
in	in	O
several	several	O
areas	areas	O
of	of	O
the	the	O
brain	brain	O
.	.	O

After	after	O
6	6	O
months	months	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
,	,	O
dopamine	dopamine	B-Chemical
(	(	O
DA	da	B-Chemical
)	)	O
concentrations	concentrations	O
in	in	O
the	the	O
median	median	O
eminence	eminence	O
(	(	O
ME	me	O
)	)	O
increased	increased	O
by	by	O
84	84	O
%	%	O
over	over	O
the	the	O
control	control	O
group	group	O
.	.	O

Nine	nine	O
months	months	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
produced	produced	O
a	a	O
50	50	O
%	%	O
increase	increase	O
in	in	O
DA	da	B-Chemical
concentrations	concentrations	O
in	in	O
the	the	O
ME	me	O
over	over	O
the	the	O
control	control	O
group	group	O
.	.	O

However	however	O
,	,	O
DA	da	B-Chemical
response	response	O
was	was	O
lost	lost	O
if	if	O
a	a	O
9-month	9-month	O
long	long	O
haloperidol-induced	haloperidol-induced	O
hyperprolactinemia	hyperprolactinemia	B-Disease
was	was	O
followed	followed	O
by	by	O
a	a	O
1	1	O
1/2	1/2	O
month-long	month-long	O
extremely	extremely	O
high	high	O
increase	increase	O
in	in	O
serum	serum	O
PRL	prl	O
levels	levels	O
produced	produced	O
by	by	O
implantation	implantation	O
of	of	O
MMQ	mmq	O
cells	cells	O
under	under	O
the	the	O
kidney	kidney	O
capsule	capsule	O
.	.	O

There	there	O
was	was	O
no	no	O
change	change	O
in	in	O
the	the	O
levels	levels	O
of	of	O
DA	da	B-Chemical
,	,	O
norepinephrine	norepinephrine	B-Chemical
(	(	O
NE	ne	O
)	)	O
,	,	O
serotonin	serotonin	B-Chemical
(	(	O
5-HT	5-ht	B-Chemical
)	)	O
,	,	O
or	or	O
their	their	O
metabolites	metabolites	O
in	in	O
the	the	O
arcuate	arcuate	O
nucleus	nucleus	O
(	(	O
AN	an	O
)	)	O
,	,	O
medial	medial	O
preoptic	preoptic	O
area	area	O
(	(	O
MPA	mpa	O
)	)	O
,	,	O
caudate	caudate	O
putamen	putamen	O
(	(	O
CP	cp	O
)	)	O
,	,	O
substantia	substantia	O
nigra	nigra	O
(	(	O
SN	sn	O
)	)	O
,	,	O
and	and	O
zona	zona	O
incerta	incerta	O
(	(	O
ZI	zi	O
)	)	O
,	,	O
except	except	O
for	for	O
a	a	O
decrease	decrease	O
in	in	O
5-hydroxyindoleacetic	5-hydroxyindoleacetic	O
acid	acid	O
(	(	O
5-HIAA	5-hiaa	O
)	)	O
in	in	O
the	the	O
AN	an	O
after	after	O
6-months	6-months	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
and	and	O
an	an	O
increase	increase	O
in	in	O
DA	da	B-Chemical
concentrations	concentrations	O
in	in	O
the	the	O
AN	an	O
after	after	O
9-months	9-months	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
.	.	O

These	these	O
results	results	O
demonstrate	demonstrate	O
that	that	O
hyperprolactinemia	hyperprolactinemia	B-Disease
specifically	specifically	O
affects	affects	O
TIDA	tida	O
neurons	neurons	O
and	and	O
these	these	O
effects	effects	O
vary	vary	O
,	,	O
depending	depending	O
on	on	O
the	the	O
duration	duration	O
and	and	O
intensity	intensity	O
of	of	O
hyperprolactinemia	hyperprolactinemia	B-Disease
.	.	O

The	the	O
age-related	age-related	O
decrease	decrease	O
in	in	O
hypothalamic	hypothalamic	O
dopamine	dopamine	B-Chemical
function	function	O
may	may	O
be	be	O
associated	associated	O
with	with	O
increases	increases	O
in	in	O
PRL	prl	O
secretion	secretion	O
.	.	O

Treatment-related	treatment-related	O
disseminated	disseminated	O
necrotizing	necrotizing	O
leukoencephalopathy	leukoencephalopathy	B-Disease
with	with	O
characteristic	characteristic	O
contrast	contrast	O
enhancement	enhancement	O
of	of	O
the	the	O
white	white	O
matter	matter	O
.	.	O

This	this	O
report	report	O
describes	describes	O
unique	unique	O
contrast	contrast	O
enhancement	enhancement	O
of	of	O
the	the	O
white	white	O
matter	matter	O
on	on	O
T1-weighted	t1-weighted	O
magnetic	magnetic	O
resonance	resonance	O
images	images	O
of	of	O
two	two	O
patients	patients	O
with	with	O
disseminated	disseminated	O
necrotizing	necrotizing	O
leukoencephalopathy	leukoencephalopathy	B-Disease
,	,	O
which	which	O
developed	developed	O
from	from	O
acute	acute	B-Disease
lymphoblastic	lymphoblastic	I-Disease
leukemia	leukemia	I-Disease
treated	treated	O
with	with	O
high-dose	high-dose	O
methotrexate	methotrexate	B-Chemical
.	.	O

In	in	O
both	both	O
patients	patients	O
,	,	O
the	the	O
enhancement	enhancement	O
was	was	O
more	more	O
pronounced	pronounced	O
near	near	O
the	the	O
base	base	O
of	of	O
the	the	O
brain	brain	O
than	than	O
at	at	O
the	the	O
vertex	vertex	O
.	.	O

Necropsy	necropsy	O
of	of	O
the	the	O
first	first	O
case	case	O
revealed	revealed	O
loss	loss	O
of	of	O
myelination	myelination	O
and	and	O
necrosis	necrosis	B-Disease
of	of	O
the	the	O
white	white	O
matter	matter	O
.	.	O

Possible	possible	O
mechanisms	mechanisms	O
causing	causing	O
such	such	O
a	a	O
leukoencephalopathy	leukoencephalopathy	B-Disease
are	are	O
discussed	discussed	O
.	.	O

Thrombotic	thrombotic	B-Disease
complications	complications	O
in	in	O
acute	acute	O
promyelocytic	promyelocytic	O
leukemia	leukemia	O
during	during	O
all-trans-retinoic	all-trans-retinoic	O
acid	acid	O
therapy	therapy	O
.	.	O

A	a	O
case	case	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
,	,	O
due	due	O
to	to	O
occlusion	occlusion	O
of	of	O
renal	renal	O
vessels	vessels	O
in	in	O
a	a	O
patient	patient	O
with	with	O
acute	acute	O
promyelocytic	promyelocytic	O
leukemia	leukemia	O
(	(	O
APL	apl	O
)	)	O
treated	treated	O
with	with	O
all-trans-retinoic	all-trans-retinoic	O
acid	acid	O
(	(	O
ATRA	atra	O
)	)	O
and	and	O
tranexamic	tranexamic	B-Chemical
acid	acid	I-Chemical
has	has	O
been	been	O
described	described	O
recently	recently	O
.	.	O

We	we	O
report	report	O
a	a	O
case	case	O
of	of	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
in	in	O
an	an	O
APL	apl	O
patient	patient	O
treated	treated	O
with	with	O
ATRA	atra	O
alone	alone	O
.	.	O

This	this	O
case	case	O
further	further	O
supports	supports	O
the	the	O
concern	concern	O
about	about	O
thromboembolic	thromboembolic	B-Disease
complications	complications	O
associated	associated	O
with	with	O
ATRA	atra	O
therapy	therapy	O
in	in	O
APL	apl	O
patients	patients	O
.	.	O

The	the	O
patients	patients	O
,	,	O
a	a	O
43-year-old	43-year-old	O
man	man	O
,	,	O
presented	presented	O
all	all	O
the	the	O
signs	signs	B-Disease
and	and	I-Disease
symptoms	symptoms	I-Disease
of	of	O
APL	apl	O
and	and	O
was	was	O
included	included	O
in	in	O
a	a	O
treatment	treatment	O
protocol	protocol	O
with	with	O
ATRA	atra	O
.	.	O

After	after	O
10	10	O
days	days	O
of	of	O
treatment	treatment	O
,	,	O
he	he	O
developed	developed	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
that	that	O
was	was	O
completely	completely	O
reversible	reversible	O
after	after	O
complete	complete	O
remission	remission	O
of	of	O
APL	apl	O
was	was	O
achieved	achieved	O
and	and	O
therapy	therapy	O
discontinued	discontinued	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
ATRA	atra	O
is	is	O
a	a	O
valid	valid	O
therapeutic	therapeutic	O
choice	choice	O
for	for	O
patients	patients	O
with	with	O
APL	apl	O
,	,	O
although	although	O
the	the	O
procoagulant	procoagulant	O
tendency	tendency	O
is	is	O
not	not	O
completely	completely	O
corrected	corrected	O
.	.	O

Thrombotic	thrombotic	B-Disease
events	events	O
,	,	O
however	however	O
,	,	O
could	could	O
be	be	O
avoided	avoided	O
by	by	O
using	using	O
low-dose	low-dose	O
heparin	heparin	B-Chemical
.	.	O

Pupillary	pupillary	O
changes	changes	O
associated	associated	O
with	with	O
the	the	O
development	development	O
of	of	O
stimulant-induced	stimulant-induced	O
mania	mania	B-Disease
:	:	O
a	a	O
case	case	O
report	report	O
.	.	O

A	a	O
30-year-old	30-year-old	O
cocaine-dependent	cocaine-dependent	O
man	man	O
who	who	O
was	was	O
a	a	O
subject	subject	O
in	in	O
a	a	O
study	study	O
evaluating	evaluating	O
the	the	O
anticraving	anticraving	O
efficacy	efficacy	O
of	of	O
the	the	O
stimulant	stimulant	O
medication	medication	O
diethylpropion	diethylpropion	O
(	(	O
DEP	dep	O
)	)	O
became	became	O
manic	manic	B-Disease
during	during	O
his	his	O
second	second	O
week	week	O
on	on	O
the	the	O
study	study	O
drug	drug	O
.	.	O

Pupillometric	pupillometric	O
changes	changes	O
while	while	O
on	on	O
DEP	dep	O
,	,	O
especially	especially	O
changes	changes	O
in	in	O
the	the	O
total	total	O
power	power	O
of	of	O
pupillary	pupillary	O
oscillation	oscillation	O
,	,	O
were	were	O
dramatically	dramatically	O
different	different	O
than	than	O
those	those	O
observed	observed	O
in	in	O
the	the	O
eight	eight	O
other	other	O
study	study	O
subjects	subjects	O
who	who	O
did	did	O
not	not	O
become	become	O
manic	manic	B-Disease
.	.	O

The	the	O
large	large	O
changes	changes	O
in	in	O
total	total	O
power	power	O
of	of	O
pupillary	pupillary	O
oscillation	oscillation	O
occurred	occurred	O
a	a	O
few	few	O
days	days	O
before	before	O
the	the	O
patient	patient	O
became	became	O
fully	fully	O
manic	manic	B-Disease
.	.	O

Such	such	O
medication-associated	medication-associated	O
changes	changes	O
in	in	O
the	the	O
total	total	O
power	power	O
of	of	O
pupillary	pupillary	O
oscillation	oscillation	O
might	might	O
be	be	O
of	of	O
utility	utility	O
in	in	O
identifying	identifying	O
persons	persons	O
at	at	O
risk	risk	O
for	for	O
manic-like	manic-like	O
adverse	adverse	O
effects	effects	O
during	during	O
the	the	O
medical	medical	O
use	use	O
of	of	O
psychomotor	psychomotor	O
stimulants	stimulants	O
or	or	O
sympathomimetic	sympathomimetic	O
agents	agents	O
.	.	O

Fetal	fetal	O
risks	risks	O
due	due	O
to	to	O
warfarin	warfarin	B-Chemical
therapy	therapy	O
during	during	O
pregnancy	pregnancy	O
.	.	O

Two	two	O
mothers	mothers	O
with	with	O
heart	heart	O
valve	valve	O
prosthesis	prosthesis	O
were	were	O
treated	treated	O
with	with	O
warfarin	warfarin	B-Chemical
during	during	O
pregnancy	pregnancy	O
.	.	O

In	in	O
the	the	O
first	first	O
case	case	O
a	a	O
caesarean	caesarean	O
section	section	O
was	was	O
done	done	O
one	one	O
week	week	O
after	after	O
replacement	replacement	O
of	of	O
warfarin	warfarin	B-Chemical
with	with	O
heparin	heparin	B-Chemical
.	.	O

The	the	O
baby	baby	O
died	died	O
of	of	O
cerebral	cerebral	O
and	and	O
pulmonary	pulmonary	O
hemorrhage	hemorrhage	B-Disease
.	.	O

The	the	O
second	second	O
mother	mother	O
had	had	O
a	a	O
male	male	O
infant	infant	O
by	by	O
caesarean	caesarean	O
section	section	O
.	.	O

The	the	O
baby	baby	O
showed	showed	O
warfarin-induced	warfarin-induced	O
embryopathy	embryopathy	O
with	with	O
nasal	nasal	O
hypoplasia	hypoplasia	O
and	and	O
stippled	stippled	B-Disease
epiphyses	epiphyses	I-Disease
(	(	O
chondrodysplasia	chondrodysplasia	B-Disease
punctata	punctata	I-Disease
)	)	O
.	.	O

Nasal	nasal	O
hypoplasia	hypoplasia	O
with	with	O
or	or	O
without	without	O
stippled	stippled	B-Disease
epiphyses	epiphyses	I-Disease
has	has	O
now	now	O
been	been	O
reported	reported	O
in	in	O
11	11	O
infants	infants	O
born	born	O
to	to	O
mothers	mothers	O
treated	treated	O
with	with	O
warfarin	warfarin	B-Chemical
during	during	O
the	the	O
first	first	O
trimester	trimester	O
,	,	O
and	and	O
a	a	O
causal	causal	O
association	association	O
is	is	O
probable	probable	O
.	.	O

In	in	O
view	view	O
of	of	O
the	the	O
risks	risks	O
to	to	O
both	both	O
mother	mother	O
and	and	O
fetus	fetus	O
in	in	O
women	women	O
with	with	O
prosthetic	prosthetic	O
cardiac	cardiac	O
valves	valves	O
it	it	O
is	is	O
recommended	recommended	O
that	that	O
therapeutic	therapeutic	O
abortion	abortion	O
be	be	O
advised	advised	O
as	as	O
the	the	O
first	first	O
alternative	alternative	O
.	.	O

The	the	O
negative	negative	O
mucosal	mucosal	O
potential	potential	O
:	:	O
separating	separating	O
central	central	O
and	and	O
peripheral	peripheral	O
effects	effects	O
of	of	O
NSAIDs	nsaids	O
in	in	O
man	man	O
.	.	O

OBJECTIVE	objective	O
:	:	O
We	we	O
wanted	wanted	O
to	to	O
test	test	O
whether	whether	O
assessment	assessment	O
of	of	O
both	both	O
a	a	O
central	central	O
pain-related	pain-related	O
signal	signal	O
(	(	O
chemo-somatosensory	chemo-somatosensory	O
evoked	evoked	O
potential	potential	O
,	,	O
CSSEP	cssep	O
)	)	O
and	and	O
a	a	O
concomitantly	concomitantly	O
recorded	recorded	O
peripheral	peripheral	O
signal	signal	O
(	(	O
negative	negative	O
mucosal	mucosal	O
potential	potential	O
,	,	O
NMP	nmp	O
)	)	O
allows	allows	O
for	for	O
separation	separation	O
of	of	O
central	central	O
and	and	O
peripheral	peripheral	O
effects	effects	O
of	of	O
NSAIDs	nsaids	O
.	.	O

For	for	O
this	this	O
purpose	purpose	O
,	,	O
experimental	experimental	O
conditions	conditions	O
were	were	O
created	created	O
in	in	O
which	which	O
NSAIDs	nsaids	O
had	had	O
previously	previously	O
been	been	O
observed	observed	O
to	to	O
produce	produce	O
effects	effects	O
on	on	O
phasic	phasic	O
and	and	O
tonic	tonic	O
pain	pain	B-Disease
by	by	O
either	either	O
central	central	O
or	or	O
peripheral	peripheral	O
mechanisms	mechanisms	O
.	.	O

METHODS	methods	O
:	:	O
According	according	O
to	to	O
a	a	O
double-blind	double-blind	O
,	,	O
randomised	randomised	O
,	,	O
controlled	controlled	O
,	,	O
threefold	threefold	O
cross-over	cross-over	O
design	design	O
,	,	O
18	18	O
healthy	healthy	O
subjects	subjects	O
(	(	O
11	11	O
males	males	O
,	,	O
7	7	O
females	females	O
;	;	O
mean	mean	O
age	age	O
26	26	O
years	years	O
)	)	O
received	received	O
either	either	O
placebo	placebo	O
,	,	O
400	400	O
mg	mg	O
ibuprofen	ibuprofen	B-Chemical
,	,	O
or	or	O
800	800	O
mg	mg	O
ibuprofen	ibuprofen	B-Chemical
.	.	O

Phasic	phasic	O
pain	pain	B-Disease
was	was	O
applied	applied	O
by	by	O
means	means	O
of	of	O
short	short	O
pulses	pulses	O
of	of	O
CO2	co2	B-Chemical
to	to	O
the	the	O
nasal	nasal	O
mucosa	mucosa	O
(	(	O
stimulus	stimulus	O
duration	duration	O
500	500	O
ms	ms	B-Disease
,	,	O
interval	interval	O
approximately	approximately	O
60	60	O
s	s	O
)	)	O
,	,	O
and	and	O
tonic	tonic	O
pain	pain	B-Disease
was	was	O
induced	induced	O
in	in	O
the	the	O
nasal	nasal	O
cavity	cavity	O
by	by	O
means	means	O
of	of	O
dry	dry	O
air	air	O
of	of	O
controlled	controlled	O
temperature	temperature	O
,	,	O
humidity	humidity	O
and	and	O
flow	flow	O
rate	rate	O
(	(	O
22	22	O
degrees	degrees	O
C	c	O
,	,	O
0	0	O
%	%	O
relative	relative	O
humidity	humidity	O
,	,	O
145	145	O
ml.s-1	ml.s-1	O
)	)	O
.	.	O

Both	both	O
CSSEPs	csseps	O
as	as	O
central	central	O
and	and	O
NMPs	nmps	O
as	as	O
peripheral	peripheral	O
correlates	correlates	O
of	of	O
pain	pain	B-Disease
were	were	O
obtained	obtained	O
in	in	O
response	response	O
to	to	O
the	the	O
CO2	co2	B-Chemical
stimuli	stimuli	O
.	.	O

Additionally	additionally	O
,	,	O
the	the	O
subjects	subjects	O
rated	rated	O
the	the	O
intensity	intensity	O
of	of	O
both	both	O
phasic	phasic	O
and	and	O
tonic	tonic	O
pain	pain	B-Disease
by	by	O
means	means	O
of	of	O
visual	visual	O
analogue	analogue	O
scales	scales	O
.	.	O

RESULTS	results	O
:	:	O
As	as	O
described	described	O
earlier	earlier	O
,	,	O
administration	administration	O
of	of	O
ibuprofen	ibuprofen	B-Chemical
was	was	O
followed	followed	O
by	by	O
a	a	O
decrease	decrease	O
in	in	O
tonic	tonic	O
pain	pain	B-Disease
but-relative	but-relative	O
to	to	O
placebo-an	placebo-an	O
increase	increase	O
in	in	O
correlates	correlates	O
of	of	O
phasic	phasic	O
pain	pain	B-Disease
,	,	O
indicating	indicating	O
a	a	O
specific	specific	O
effect	effect	O
of	of	O
ibuprofen	ibuprofen	B-Chemical
on	on	O
the	the	O
interaction	interaction	O
between	between	O
the	the	O
pain	pain	B-Disease
stimuli	stimuli	O
under	under	O
these	these	O
special	special	O
experimental	experimental	O
conditions	conditions	O
.	.	O

Based	based	O
on	on	O
the	the	O
similar	similar	O
behaviour	behaviour	O
of	of	O
CSSEP	cssep	O
and	and	O
NMP	nmp	O
,	,	O
it	it	O
was	was	O
concluded	concluded	O
that	that	O
the	the	O
pharmacological	pharmacological	O
process	process	O
underlying	underlying	O
this	this	O
phenomenon	phenomenon	O
was	was	O
localised	localised	O
in	in	O
the	the	O
periphery	periphery	O
.	.	O

By	by	O
means	means	O
of	of	O
the	the	O
simultaneous	simultaneous	O
recording	recording	O
of	of	O
interrelated	interrelated	O
peripheral	peripheral	O
and	and	O
central	central	O
electrophysiologic	electrophysiologic	O
correlates	correlates	O
of	of	O
nociception	nociception	O
,	,	O
it	it	O
was	was	O
possible	possible	O
to	to	O
separate	separate	O
central	central	O
and	and	O
peripheral	peripheral	O
effects	effects	O
of	of	O
an	an	O
NSAID	nsaid	O
.	.	O

The	the	O
major	major	O
advantage	advantage	O
of	of	O
this	this	O
pain	pain	B-Disease
model	model	O
is	is	O
the	the	O
possibility	possibility	O
of	of	O
obtaining	obtaining	O
peripheral	peripheral	O
pain-related	pain-related	O
activity	activity	O
directly	directly	O
using	using	O
a	a	O
non-invasive	non-invasive	O
technique	technique	O
in	in	O
humans	humans	O
.	.	O

Effect	effect	O
of	of	O
D-Glucarates	d-glucarates	O
on	on	O
basic	basic	O
antibiotic-induced	antibiotic-induced	O
renal	renal	B-Disease
damage	damage	I-Disease
in	in	O
rats	rats	O
.	.	O

Dehydrated	dehydrated	O
rats	rats	O
regularly	regularly	O
develop	develop	O
acute	acute	B-Disease
renal	renal	B-Disease
failure	failure	I-Disease
following	following	O
single	single	O
injection	injection	O
of	of	O
aminoglycoside	aminoglycoside	B-Chemical
antibiotics	antibiotics	O
combined	combined	O
with	with	O
dextran	dextran	B-Chemical
or	or	O
of	of	O
antibiotics	antibiotics	O
only	only	O
.	.	O

Oral	oral	O
administration	administration	O
of	of	O
2,5-di-O-acetyl-D-glucaro-1,4	2,5-di-o-acetyl-d-glucaro-1,4	O
-	-	O
6,3-dilactone	6,3-dilactone	O
protected	protected	O
rats	rats	O
against	against	O
renal	renal	B-Disease
failure	failure	I-Disease
induced	induced	O
by	by	O
kanamycin-dextran	kanamycin-dextran	O
.	.	O

The	the	O
protective	protective	O
effect	effect	O
was	was	O
prevalent	prevalent	O
among	among	O
D-glucarates	d-glucarates	O
,	,	O
and	and	O
also	also	O
to	to	O
other	other	O
saccharic	saccharic	B-Chemical
acid	acid	I-Chemical
,	,	O
hexauronic	hexauronic	O
acids	acids	O
and	and	O
hexaaldonic	hexaaldonic	O
acids	acids	O
,	,	O
although	although	O
to	to	O
a	a	O
lesser	lesser	O
degree	degree	O
,	,	O
but	but	O
not	not	O
to	to	O
a	a	O
hexaaldose	hexaaldose	O
,	,	O
sugar	sugar	B-Chemical
alcohols	alcohols	I-Chemical
,	,	O
substances	substances	O
inthe	inthe	O
TCA	tca	O
cycle	cycle	O
and	and	O
other	other	O
acidic	acidic	O
compounds	compounds	O
.	.	O

D-Glucarates	d-glucarates	O
were	were	O
effective	effective	O
against	against	O
renal	renal	B-Disease
damage	damage	I-Disease
induced	induced	O
by	by	O
peptide	peptide	O
antibiotics	antibiotics	O
as	as	O
well	well	O
as	as	O
various	various	O
aminoglycoside	aminoglycoside	B-Chemical
antibitocis	antibitocis	O
.	.	O

Dose-responses	dose-responses	O
were	were	O
observed	observed	O
in	in	O
the	the	O
protective	protective	O
effect	effect	O
of	of	O
D-Glucarates	d-glucarates	O
.	.	O

With	with	O
a	a	O
D-glucarate	d-glucarate	O
of	of	O
a	a	O
fixed	fixed	O
size	size	O
of	of	O
dose	dose	O
,	,	O
approximately	approximately	O
the	the	O
same	same	O
degree	degree	O
of	of	O
protection	protection	O
was	was	O
obtained	obtained	O
against	against	O
renal	renal	O
damages	damages	O
induced	induced	O
by	by	O
different	different	O
basic	basic	O
antibiotics	antibiotics	O
despite	despite	O
large	large	O
disparities	disparities	O
in	in	O
administration	administration	O
doses	doses	O
of	of	O
different	different	O
antibiotics	antibiotics	O
.	.	O

D-Glucarates	d-glucarates	O
had	had	O
the	the	O
ability	ability	O
to	to	O
prevent	prevent	O
renal	renal	B-Disease
damage	damage	I-Disease
but	but	O
not	not	O
to	to	O
cure	cure	O
it	it	O
.	.	O

Rats	rats	O
excreted	excreted	O
acidic	acidic	O
urine	urine	O
when	when	O
they	they	O
were	were	O
spared	spared	O
from	from	O
renal	renal	O
lesions	lesions	O
by	by	O
monosaccharides	monosaccharides	O
.	.	O

The	the	O
reduction	reduction	O
effect	effect	O
of	of	O
D-glucarates	d-glucarates	O
against	against	O
nephrotoxicity	nephrotoxicity	B-Disease
of	of	O
basic	basic	O
antibiotics	antibiotics	O
was	was	O
discussed	discussed	O
.	.	O

Acute	acute	O
severe	severe	O
depression	depression	B-Disease
following	following	O
peri-operative	peri-operative	O
ondansetron	ondansetron	O
.	.	O

A	a	O
41-year-old	41-year-old	O
woman	woman	O
with	with	O
a	a	O
strong	strong	O
history	history	O
of	of	O
postoperative	postoperative	B-Disease
nausea	nausea	B-Disease
and	and	I-Disease
vomiting	vomiting	B-Disease
presented	presented	O
for	for	O
abdominal	abdominal	O
hysterectomy	hysterectomy	O
3	3	O
months	months	O
after	after	O
a	a	O
previous	previous	O
anaesthetic	anaesthetic	O
where	where	O
ondansetron	ondansetron	O
prophylaxis	prophylaxis	O
had	had	O
been	been	O
used	used	O
.	.	O

She	she	O
had	had	O
developed	developed	O
a	a	O
severe	severe	O
acute	acute	O
major	major	B-Disease
depression	depression	B-Disease
disorder	disorder	O
almost	almost	O
immediately	immediately	O
thereafter	thereafter	O
,	,	O
possibly	possibly	O
related	related	O
to	to	O
the	the	O
use	use	O
of	of	O
a	a	O
serotonin	serotonin	B-Chemical
antagonist	antagonist	O
.	.	O

Nine	nine	O
years	years	O
before	before	O
she	she	O
had	had	O
experienced	experienced	O
a	a	O
self-limited	self-limited	O
puerperal	puerperal	O
depressive	depressive	B-Disease
episode	episode	O
.	.	O

Anaesthesia	anaesthesia	O
with	with	O
a	a	O
propofol	propofol	B-Chemical
infusion	infusion	O
and	and	O
avoidance	avoidance	O
of	of	O
serotonin	serotonin	B-Chemical
antagonists	antagonists	I-Chemical
provided	provided	O
a	a	O
nausea-free	nausea-free	O
postoperative	postoperative	O
course	course	O
without	without	O
exacerbation	exacerbation	O
of	of	O
the	the	O
depression	depression	B-Disease
disorder	disorder	O
.	.	O

Hypertensive	hypertensive	B-Disease
response	response	O
during	during	O
dobutamine	dobutamine	B-Chemical
stress	stress	O
echocardiography	echocardiography	O
.	.	O

Among	among	O
3,129	3,129	O
dobutamine	dobutamine	B-Chemical
stress	stress	O
echocardiographic	echocardiographic	O
studies	studies	O
,	,	O
a	a	O
hypertensive	hypertensive	B-Disease
response	response	O
,	,	O
defined	defined	O
as	as	O
systolic	systolic	O
blood	blood	O
pressure	pressure	O
(	(	O
BP	bp	O
)	)	O
>	>	O
or	or	O
=	=	O
220	220	O
mm	mm	O
Hg	hg	O
and/or	and/or	O
diastolic	diastolic	O
BP	bp	O
>	>	O
or	or	O
=	=	O
110	110	O
mm	mm	O
Hg	hg	O
,	,	O
occurred	occurred	O
in	in	O
30	30	O
patients	patients	O
(	(	O
1	1	O
%	%	O
)	)	O
.	.	O

Patients	patients	O
with	with	O
this	this	O
response	response	O
more	more	O
often	often	O
had	had	O
a	a	O
history	history	O
of	of	O
hypertension	hypertension	B-Disease
and	and	O
had	had	O
higher	higher	O
resting	resting	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
BP	bp	O
before	before	O
dobutamine	dobutamine	B-Chemical
infusion	infusion	O
.	.	O

Continuously	continuously	O
nebulized	nebulized	O
albuterol	albuterol	O
in	in	O
severe	severe	O
exacerbations	exacerbations	O
of	of	O
asthma	asthma	O
in	in	O
adults	adults	O
:	:	O
a	a	O
case-controlled	case-controlled	O
study	study	O
.	.	O

A	a	O
retrospective	retrospective	O
,	,	O
case-controlled	case-controlled	O
analysis	analysis	O
comparing	comparing	O
patients	patients	O
admitted	admitted	O
to	to	O
a	a	O
medical	medical	O
intensive	intensive	O
care	care	O
unit	unit	O
with	with	O
severe	severe	O
exacerbations	exacerbations	O
of	of	O
asthma	asthma	O
who	who	O
received	received	O
continuously	continuously	O
nebulized	nebulized	O
albuterol	albuterol	O
(	(	O
CNA	cna	O
)	)	O
versus	versus	O
intermittent	intermittent	O
albuterol	albuterol	O
(	(	O
INA	ina	O
)	)	O
treatments	treatments	O
is	is	O
reported	reported	O
.	.	O

Forty	forty	O
matched	matched	O
pairs	pairs	O
of	of	O
patients	patients	O
with	with	O
asthma	asthma	O
are	are	O
compared	compared	O
.	.	O

CNA	cna	O
was	was	O
administered	administered	O
for	for	O
a	a	O
mean	mean	O
of	of	O
11	11	O
+	+	O
/-	/-	O
10	10	O
hr	hr	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
cardiac	cardiac	O
dysrhythmias	dysrhythmias	O
was	was	O
similar	similar	O
between	between	O
groups	groups	O
.	.	O

Symptomatic	symptomatic	O
hypokalemia	hypokalemia	O
did	did	O
not	not	O
occur	occur	O
.	.	O

CNA	cna	O
patients	patients	O
had	had	O
higher	higher	O
heart	heart	O
rates	rates	O
during	during	O
treatment	treatment	O
,	,	O
which	which	O
may	may	O
reflect	reflect	O
severity	severity	O
of	of	O
illness	illness	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
intubation	intubation	O
was	was	O
similar	similar	O
.	.	O

We	we	O
conclude	conclude	O
that	that	O
CNA	cna	O
and	and	O
INA	ina	O
demonstrated	demonstrated	O
similar	similar	O
profiles	profiles	O
with	with	O
regard	regard	O
to	to	O
safety	safety	O
,	,	O
morbidity	morbidity	O
,	,	O
and	and	O
mortality	mortality	O
.	.	O

Paraplegia	paraplegia	O
following	following	O
intrathecal	intrathecal	O
methotrexate	methotrexate	B-Chemical
:	:	O
report	report	O
of	of	O
a	a	O
case	case	O
and	and	O
review	review	O
of	of	O
the	the	O
literature	literature	O
.	.	O

A	a	O
patient	patient	O
who	who	O
developed	developed	O
paraplegia	paraplegia	O
following	following	O
the	the	O
intrathecal	intrathecal	O
instillation	instillation	O
of	of	O
methotrexate	methotrexate	B-Chemical
is	is	O
discribed	discribed	O
.	.	O

The	the	O
ten	ten	O
previously	previously	O
reported	reported	O
cases	cases	O
of	of	O
this	this	O
unusual	unusual	O
complication	complication	O
are	are	O
reviewed	reviewed	O
.	.	O

The	the	O
following	following	O
factors	factors	O
appear	appear	O
to	to	O
predispose	predispose	O
to	to	O
the	the	O
development	development	O
of	of	O
this	this	O
complication	complication	O
:	:	O
abnormal	abnormal	O
cerebrospinal	cerebrospinal	O
dynamics	dynamics	O
related	related	O
to	to	O
the	the	O
presence	presence	O
of	of	O
central	central	O
nervous	nervous	O
system	system	O
leukemia	leukemia	O
,	,	O
and	and	O
epidural	epidural	O
cerebrospinal	cerebrospinal	O
leakage	leakage	O
;	;	O
elevated	elevated	O
cerebrospinal	cerebrospinal	O
fluid	fluid	O
methothexate	methothexate	O
concentration	concentration	O
related	related	O
to	to	O
abnormal	abnormal	O
cerebrospinal	cerebrospinal	O
fluid	fluid	O
dynamics	dynamics	O
and	and	O
to	to	O
inappropriately	inappropriately	O
high	high	O
methotrexate	methotrexate	B-Chemical
doses	doses	O
based	based	O
on	on	O
body	body	O
surface	surface	O
area	area	O
calculations	calculations	O
in	in	O
older	older	O
children	children	O
and	and	O
adults	adults	O
;	;	O
the	the	O
presence	presence	O
of	of	O
neurotoxic	neurotoxic	B-Disease
preservatives	preservatives	O
in	in	O
commercially	commercially	O
available	available	O
methotrexate	methotrexate	B-Chemical
preparations	preparations	O
and	and	O
diluents	diluents	O
;	;	O
and	and	O
the	the	O
use	use	O
of	of	O
methotrexate	methotrexate	B-Chemical
diluents	diluents	O
of	of	O
unphysiologic	unphysiologic	O
pH	ph	O
,	,	O
ionic	ionic	O
content	content	O
and	and	O
osmolarity	osmolarity	O
.	.	O

The	the	O
role	role	O
of	of	O
methotrexate	methotrexate	B-Chemical
contaminants	contaminants	O
,	,	O
local	local	O
folate	folate	B-Chemical
deficiency	deficiency	O
,	,	O
and	and	O
cranial	cranial	O
irradiation	irradiation	O
in	in	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
intrathecal	intrathecal	O
methotrexate	methotrexate	B-Chemical
toxicity	toxicity	B-Disease
is	is	O
unclear	unclear	O
.	.	O

The	the	O
incidence	incidence	O
of	of	O
neurotoxicity	neurotoxicity	B-Disease
may	may	O
be	be	O
reduced	reduced	O
by	by	O
employing	employing	O
lower	lower	O
doses	doses	O
of	of	O
methotrexate	methotrexate	B-Chemical
in	in	O
the	the	O
presence	presence	O
of	of	O
central	central	O
nervous	nervous	O
system	system	O
leukemia	leukemia	O
,	,	O
in	in	O
older	older	O
children	children	O
and	and	O
adults	adults	O
,	,	O
and	and	O
in	in	O
the	the	O
presence	presence	O
of	of	O
epidural	epidural	O
leakage	leakage	O
.	.	O

Only	only	O
preservative-free	preservative-free	O
methotrexate	methotrexate	B-Chemical
in	in	O
Elliott	elliott	O
's	's	O
B	b	O
Solution	solution	O
at	at	O
a	a	O
concentration	concentration	O
of	of	O
not	not	O
more	more	O
than	than	O
1	1	O
mg/ml	mg/ml	O
should	should	O
be	be	O
used	used	O
for	for	O
intrathecal	intrathecal	O
administration	administration	O
.	.	O

Periodic	periodic	O
monitoring	monitoring	O
of	of	O
cerebruspinal	cerebruspinal	O
fluid	fluid	O
methotrexate	methotrexate	B-Chemical
levels	levels	O
may	may	O
be	be	O
predictive	predictive	O
of	of	O
the	the	O
development	development	O
of	of	O
serious	serious	O
neurotoxicity	neurotoxicity	B-Disease
.	.	O

Hyperosmolar	hyperosmolar	O
nonketotic	nonketotic	O
coma	coma	B-Disease
precipitated	precipitated	O
by	by	O
lithium-induced	lithium-induced	O
nephrogenic	nephrogenic	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
.	.	O

A	a	O
45-year-old	45-year-old	O
man	man	O
,	,	O
with	with	O
a	a	O
10-year	10-year	O
history	history	O
of	of	O
manic	manic	B-Disease
depression	depression	B-Disease
treated	treated	O
with	with	O
lithium	lithium	B-Chemical
,	,	O
was	was	O
admitted	admitted	O
with	with	O
hyperosmolar	hyperosmolar	O
,	,	O
nonketotic	nonketotic	O
coma	coma	B-Disease
.	.	O

He	he	O
gave	gave	O
a	a	O
five-year	five-year	O
history	history	O
of	of	O
polyuria	polyuria	B-Disease
and	and	O
polydipsia	polydipsia	B-Disease
,	,	O
during	during	O
which	which	O
time	time	O
urinalysis	urinalysis	O
had	had	O
been	been	O
negative	negative	O
for	for	O
glucose	glucose	B-Chemical
.	.	O

After	after	O
recovery	recovery	O
from	from	O
hyperglycaemia	hyperglycaemia	O
,	,	O
he	he	O
remained	remained	O
polyuric	polyuric	O
despite	despite	O
normal	normal	O
blood	blood	B-Chemical
glucose	glucose	B-Chemical
concentrations	concentrations	O
;	;	O
water	water	O
deprivation	deprivation	O
testing	testing	O
indicated	indicated	O
nephrogenic	nephrogenic	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
,	,	O
likely	likely	O
to	to	O
be	be	O
lithium-induced	lithium-induced	O
.	.	O

We	we	O
hypothesize	hypothesize	O
that	that	O
when	when	O
this	this	O
man	man	O
developed	developed	O
type	type	O
2	2	O
diabetes	diabetes	B-Disease
,	,	O
chronic	chronic	O
polyuria	polyuria	B-Disease
due	due	O
to	to	O
nephrogenic	nephrogenic	O
diabetes	diabetes	B-Disease
insipidus	insipidus	I-Disease
was	was	O
sufficient	sufficient	O
to	to	O
precipitate	precipitate	O
hyperosmolar	hyperosmolar	O
dehydration	dehydration	B-Disease
.	.	O

Effects	effects	O
of	of	O
the	the	O
intracoronary	intracoronary	O
infusion	infusion	O
of	of	O
cocaine	cocaine	B-Chemical
on	on	O
left	left	O
ventricular	ventricular	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
function	function	O
in	in	O
humans	humans	O
.	.	O

BACKGROUND	background	O
:	:	O
In	in	O
dogs	dogs	O
,	,	O
a	a	O
large	large	O
amount	amount	O
of	of	O
intravenous	intravenous	O
cocaine	cocaine	B-Chemical
causes	causes	O
a	a	O
profound	profound	O
deterioration	deterioration	O
of	of	O
left	left	O
ventricular	ventricular	O
(	(	O
LV	lv	O
)	)	O
systolic	systolic	O
function	function	O
and	and	O
an	an	O
increase	increase	O
in	in	O
LV	lv	O
end-diastolic	end-diastolic	O
pressure	pressure	O
.	.	O

This	this	O
study	study	O
was	was	O
done	done	O
to	to	O
assess	assess	O
the	the	O
influence	influence	O
of	of	O
a	a	O
high	high	O
intracoronary	intracoronary	O
cocaine	cocaine	B-Chemical
concentration	concentration	O
on	on	O
LV	lv	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
function	function	O
in	in	O
humans	humans	O
.	.	O

METHODS	methods	O
AND	and	O
RESULTS	results	O
:	:	O
In	in	O
20	20	O
patients	patients	O
(	(	O
14	14	O
men	men	O
and	and	O
6	6	O
women	women	O
aged	aged	O
39	39	O
to	to	O
72	72	O
years	years	O
)	)	O
referred	referred	O
for	for	O
cardiac	cardiac	O
catheterization	catheterization	O
for	for	O
the	the	O
evaluation	evaluation	O
of	of	O
chest	chest	B-Disease
pain	pain	B-Disease
,	,	O
we	we	O
measured	measured	O
heart	heart	O
rate	rate	O
,	,	O
systemic	systemic	O
arterial	arterial	O
pressure	pressure	O
,	,	O
LV	lv	O
pressure	pressure	O
and	and	O
its	its	O
first	first	O
derivative	derivative	O
(	(	O
dP/dt	dp/dt	O
)	)	O
,	,	O
and	and	O
LV	lv	O
volumes	volumes	O
and	and	O
ejection	ejection	O
fraction	fraction	O
before	before	O
and	and	O
during	during	O
the	the	O
final	final	O
2	2	O
to	to	O
3	3	O
minutes	minutes	O
of	of	O
a	a	O
15-minute	15-minute	O
intracoronary	intracoronary	O
infusion	infusion	O
of	of	O
saline	saline	O
(	(	O
n=10	n=10	O
,	,	O
control	control	O
subjects	subjects	O
)	)	O
or	or	O
cocaine	cocaine	B-Chemical
hydrochloride	hydrochloride	O
1	1	O
mg/min	mg/min	O
(	(	O
n=10	n=10	O
)	)	O
.	.	O

No	no	O
variable	variable	O
changed	changed	O
with	with	O
saline	saline	O
.	.	O

With	with	O
cocaine	cocaine	B-Chemical
,	,	O
the	the	O
drug	drug	O
concentration	concentration	O
in	in	O
blood	blood	O
obtained	obtained	O
from	from	O
the	the	O
coronary	coronary	O
sinus	sinus	O
was	was	O
3.0+/-0.4	3.0+/-0.4	O
(	(	O
mean+/-SD	mean+/-sd	O
)	)	O
mg/L	mg/l	O
,	,	O
similar	similar	O
in	in	O
magnitude	magnitude	O
to	to	O
the	the	O
blood	blood	O
cocaine	cocaine	B-Chemical
concentration	concentration	O
reported	reported	O
in	in	O
abusers	abusers	O
dying	dying	O
of	of	O
cocaine	cocaine	B-Chemical
intoxication	intoxication	O
.	.	O

Cocaine	cocaine	B-Chemical
induced	induced	O
no	no	O
significant	significant	O
change	change	O
in	in	O
heart	heart	O
rate	rate	O
,	,	O
LV	lv	O
dP/dt	dp/dt	O
(	(	O
positive	positive	O
or	or	O
negative	negative	O
)	)	O
,	,	O
or	or	O
LV	lv	O
end-diastolic	end-diastolic	O
volume	volume	O
,	,	O
but	but	O
it	it	O
caused	caused	O
an	an	O
increase	increase	O
in	in	O
systolic	systolic	O
and	and	O
mean	mean	O
arterial	arterial	O
pressures	pressures	O
,	,	O
LV	lv	O
end-diastolic	end-diastolic	O
pressure	pressure	O
,	,	O
and	and	O
LV	lv	O
end-systolic	end-systolic	O
volume	volume	O
,	,	O
as	as	O
well	well	O
as	as	O
a	a	O
decrease	decrease	O
in	in	O
LV	lv	O
ejection	ejection	O
fraction	fraction	O
.	.	O

CONCLUSIONS	conclusions	O
:	:	O
In	in	O
humans	humans	O
,	,	O
the	the	O
intracoronary	intracoronary	O
infusion	infusion	O
of	of	O
cocaine	cocaine	B-Chemical
sufficient	sufficient	O
in	in	O
amount	amount	O
to	to	O
achieve	achieve	O
a	a	O
high	high	O
drug	drug	O
concentration	concentration	O
in	in	O
coronary	coronary	O
sinus	sinus	O
blood	blood	O
causes	causes	O
a	a	O
deterioration	deterioration	O
of	of	O
LV	lv	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
performance	performance	O
.	.	O

Ascending	ascending	O
dose	dose	O
tolerance	tolerance	O
study	study	O
of	of	O
intramuscular	intramuscular	O
carbetocin	carbetocin	O
administered	administered	O
after	after	O
normal	normal	O
vaginal	vaginal	O
birth	birth	O
.	.	O

OBJECTIVE	objective	O
:	:	O
To	to	O
determine	determine	O
the	the	O
maximum	maximum	O
tolerated	tolerated	O
dose	dose	O
(	(	O
MTD	mtd	O
)	)	O
of	of	O
carbetocin	carbetocin	O
(	(	O
a	a	O
long-acting	long-acting	O
synthetic	synthetic	O
analogue	analogue	O
of	of	O
oxytocin	oxytocin	B-Chemical
)	)	O
,	,	O
when	when	O
administered	administered	O
immediately	immediately	O
after	after	O
vaginal	vaginal	O
delivery	delivery	O
at	at	O
term	term	O
.	.	O

MATERIALS	materials	O
AND	and	O
METHODS	methods	O
:	:	O
Carbetocin	carbetocin	O
was	was	O
given	given	O
as	as	O
an	an	O
intramuscular	intramuscular	O
injection	injection	O
immediately	immediately	O
after	after	O
the	the	O
birth	birth	O
of	of	O
the	the	O
infant	infant	O
in	in	O
45	45	O
healthy	healthy	O
women	women	O
with	with	O
normal	normal	O
singleton	singleton	O
pregnancies	pregnancies	O
who	who	O
delivered	delivered	O
vaginally	vaginally	O
at	at	O
term	term	O
.	.	O

Dosage	dosage	O
groups	groups	O
of	of	O
15	15	O
,	,	O
30	30	O
,	,	O
50	50	O
,	,	O
75	75	O
,	,	O
100	100	O
,	,	O
125	125	O
,	,	O
150	150	O
,	,	O
175	175	O
or	or	O
200	200	O
microg	microg	O
carbetocin	carbetocin	O
were	were	O
assigned	assigned	O
to	to	O
blocks	blocks	O
of	of	O
three	three	O
women	women	O
according	according	O
to	to	O
the	the	O
continual	continual	O
reassessment	reassessment	O
method	method	O
(	(	O
CRM	crm	O
)	)	O
.	.	O

RESULTS	results	O
:	:	O
All	all	O
dosage	dosage	O
groups	groups	O
consisted	consisted	O
of	of	O
three	three	O
women	women	O
,	,	O
except	except	O
those	those	O
with	with	O
100	100	O
microg	microg	O
(	(	O
n=6	n=6	O
)	)	O
and	and	O
200	200	O
microg	microg	O
(	(	O
n=18	n=18	O
)	)	O
.	.	O

Recorded	recorded	O
were	were	O
dose-limiting	dose-limiting	O
adverse	adverse	O
events	events	O
:	:	O
hyper-	hyper-	O
or	or	O
hypotension	hypotension	B-Disease
(	(	O
three	three	O
)	)	O
,	,	O
severe	severe	O
abdominal	abdominal	B-Disease
pain	pain	B-Disease
(	(	O
0	0	O
)	)	O
,	,	O
vomiting	vomiting	B-Disease
(	(	O
0	0	O
)	)	O
and	and	O
retained	retained	O
placenta	placenta	O
(	(	O
four	four	O
)	)	O
.	.	O

Serious	serious	O
adverse	adverse	O
events	events	O
occurred	occurred	O
in	in	O
seven	seven	O
women	women	O
:	:	O
six	six	O
cases	cases	O
with	with	O
blood	blood	O
loss	loss	O
>	>	O
or	or	O
=	=	O
1000	1000	O
ml	ml	O
,	,	O
four	four	O
cases	cases	O
of	of	O
manual	manual	O
placenta	placenta	O
removal	removal	O
,	,	O
five	five	O
cases	cases	O
of	of	O
additional	additional	O
oxytocics	oxytocics	O
administration	administration	O
and	and	O
five	five	O
cases	cases	O
of	of	O
blood	blood	O
transfusion	transfusion	O
.	.	O

Maximum	maximum	O
blood	blood	O
loss	loss	O
was	was	O
greatest	greatest	O
at	at	O
the	the	O
upper	upper	O
and	and	O
lower	lower	O
dose	dose	O
levels	levels	O
,	,	O
and	and	O
lowest	lowest	O
in	in	O
the	the	O
70	70	O
-	-	O
125	125	O
microg	microg	O
dose	dose	O
range	range	O
.	.	O

Four	four	O
out	out	O
of	of	O
six	six	O
cases	cases	O
with	with	O
blood	blood	O
loss	loss	O
>	>	O
or	or	O
=	=	O
1000	1000	O
ml	ml	O
occurred	occurred	O
in	in	O
the	the	O
200	200	O
microg	microg	O
group	group	O
.	.	O

The	the	O
majority	majority	O
of	of	O
additional	additional	O
administration	administration	O
of	of	O
oxytocics	oxytocics	O
(	(	O
4/5	4/5	O
)	)	O
and	and	O
blood	blood	O
transfusion	transfusion	O
(	(	O
3/5	3/5	O
)	)	O
occurred	occurred	O
in	in	O
the	the	O
dose	dose	O
groups	groups	O
of	of	O
200	200	O
microg	microg	O
.	.	O

All	all	O
retained	retained	O
placentae	placentae	O
were	were	O
found	found	O
in	in	O
the	the	O
group	group	O
of	of	O
200	200	O
microg	microg	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
The	the	O
MTD	mtd	O
was	was	O
calculated	calculated	O
to	to	O
be	be	O
at	at	O
200	200	O
microg	microg	O
carbetocin	carbetocin	O
.	.	O

Heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
,	,	O
paradoxical	paradoxical	O
thromboembolism	thromboembolism	O
,	,	O
and	and	O
other	other	O
side	side	O
effects	effects	O
of	of	O
heparin	heparin	B-Chemical
therapy	therapy	O
.	.	O

Although	although	O
several	several	O
new	new	O
anticoagulant	anticoagulant	O
drugs	drugs	O
are	are	O
in	in	O
development	development	O
,	,	O
heparin	heparin	B-Chemical
remains	remains	O
the	the	O
drug	drug	O
of	of	O
choice	choice	O
for	for	O
most	most	O
anticoagulation	anticoagulation	O
needs	needs	O
.	.	O

The	the	O
clinical	clinical	O
effects	effects	O
of	of	O
heparin	heparin	B-Chemical
are	are	O
meritorious	meritorious	O
,	,	O
but	but	O
side	side	O
effects	effects	O
do	do	O
exist	exist	O
.	.	O

Important	important	O
untoward	untoward	O
effects	effects	O
of	of	O
heparin	heparin	B-Chemical
therapy	therapy	O
including	including	O
heparin-induced	heparin-induced	O
thrombocytopenia	thrombocytopenia	B-Disease
,	,	O
heparin-associated	heparin-associated	O
osteoporosis	osteoporosis	B-Disease
,	,	O
eosinophilia	eosinophilia	B-Disease
,	,	O
skin	skin	O
reactions	reactions	O
,	,	O
allergic	allergic	B-Disease
reactions	reactions	I-Disease
other	other	O
than	than	O
thrombocytopenia	thrombocytopenia	B-Disease
and	and	O
alopecia	alopecia	O
will	will	O
be	be	O
discussed	discussed	O
in	in	O
this	this	O
article	article	O
.	.	O

Nonopaque	nonopaque	O
crystal	crystal	O
deposition	deposition	O
causing	causing	O
ureteric	ureteric	O
obstruction	obstruction	O
in	in	O
patients	patients	O
with	with	O
HIV	hiv	O
undergoing	undergoing	O
indinavir	indinavir	B-Chemical
therapy	therapy	O
.	.	O

OBJECTIVE	objective	O
:	:	O
We	we	O
describe	describe	O
the	the	O
unique	unique	O
CT	ct	O
features	features	O
of	of	O
ureteric	ureteric	O
calculi	calculi	O
in	in	O
six	six	O
HIV-infected	hiv-infected	O
patients	patients	O
receiving	receiving	O
indinavir	indinavir	B-Chemical
,	,	O
the	the	O
most	most	O
commonly	commonly	O
used	used	O
HIV	hiv	B-Chemical
protease	protease	B-Chemical
inhibitor	inhibitor	I-Chemical
,	,	O
which	which	O
is	is	O
associated	associated	O
with	with	O
an	an	O
increased	increased	O
incidence	incidence	O
of	of	O
urolithiasis	urolithiasis	O
.	.	O

CONCLUSION	conclusion	O
:	:	O
Ureteric	ureteric	O
obstruction	obstruction	O
caused	caused	O
by	by	O
precipitated	precipitated	O
indinavir	indinavir	B-Chemical
crystals	crystals	O
may	may	O
be	be	O
difficult	difficult	O
to	to	O
diagnose	diagnose	O
with	with	O
unenhanced	unenhanced	O
CT	ct	O
.	.	O

The	the	O
calculi	calculi	O
are	are	O
not	not	O
opaque	opaque	O
,	,	O
and	and	O
secondary	secondary	O
signs	signs	O
of	of	O
obstruction	obstruction	O
may	may	O
be	be	O
absent	absent	O
or	or	O
minimal	minimal	O
and	and	O
should	should	O
be	be	O
sought	sought	O
carefully	carefully	O
.	.	O

Images	images	O
may	may	O
need	need	O
to	to	O
be	be	O
obtained	obtained	O
using	using	O
i.v	i.v	O
.	.	O

contrast	contrast	B-Chemical
material	material	I-Chemical
to	to	O
enable	enable	O
diagnosis	diagnosis	O
of	of	O
ureteric	ureteric	O
stones	stones	O
or	or	O
obstruction	obstruction	O
in	in	O
patients	patients	O
with	with	O
HIV	hiv	O
infection	infection	B-Disease
who	who	O
receive	receive	O
indinavir	indinavir	B-Chemical
therapy	therapy	O
.	.	O

Ischemic	ischemic	O
colitis	colitis	O
and	and	O
sumatriptan	sumatriptan	B-Chemical
use	use	O
.	.	O

Sumatriptan	sumatriptan	B-Chemical
succinate	succinate	O
,	,	O
a	a	O
serotonin-1	serotonin-1	O
(	(	O
5-hydroxytryptamine-1	5-hydroxytryptamine-1	O
)	)	O
receptor	receptor	O
agonist	agonist	O
,	,	O
is	is	O
an	an	O
antimigraine	antimigraine	O
drug	drug	O
that	that	O
is	is	O
reported	reported	O
to	to	O
act	act	O
by	by	O
selectively	selectively	O
constricting	constricting	O
intracranial	intracranial	O
arteries	arteries	O
.	.	O

Recently	recently	O
,	,	O
vasopressor	vasopressor	O
responses	responses	O
that	that	O
are	are	O
distinct	distinct	O
from	from	O
the	the	O
cranial	cranial	O
circulation	circulation	O
have	have	O
been	been	O
demonstrated	demonstrated	O
to	to	O
occur	occur	O
in	in	O
the	the	O
systemic	systemic	O
,	,	O
pulmonary	pulmonary	O
,	,	O
and	and	O
coronary	coronary	O
circulations	circulations	O
.	.	O

Cases	cases	O
have	have	O
been	been	O
published	published	O
of	of	O
coronary	coronary	B-Disease
vasospasm	vasospasm	B-Disease
,	,	O
myocardial	myocardial	B-Disease
ischemia	ischemia	B-Disease
,	,	O
and	and	O
myocardial	myocardial	B-Disease
infarction	infarction	B-Disease
occurring	occurring	O
after	after	O
sumatriptan	sumatriptan	B-Chemical
use	use	O
.	.	O

We	we	O
report	report	O
on	on	O
the	the	O
development	development	O
of	of	O
8	8	O
serious	serious	O
cases	cases	O
of	of	O
ischemic	ischemic	O
colitis	colitis	O
in	in	O
patients	patients	O
with	with	O
migraine	migraine	B-Disease
treated	treated	O
with	with	O
sumatriptan	sumatriptan	B-Chemical
.	.	O

Pallidotomy	pallidotomy	O
with	with	O
the	the	O
gamma	gamma	O
knife	knife	O
:	:	O
a	a	O
positive	positive	O
experience.51	experience.51	O
patients	patients	O
with	with	O
medically	medically	O
refractory	refractory	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
underwent	underwent	O
stereotactic	stereotactic	O
posteromedial	posteromedial	O
pallidotomy	pallidotomy	O
between	between	O
August	august	O
1993	1993	O
and	and	O
February	february	O
1997	1997	O
for	for	O
treatment	treatment	O
of	of	O
bradykinesia	bradykinesia	O
,	,	O
rigidity	rigidity	B-Disease
,	,	O
and	and	O
L-DOPA-induced	l-dopa-induced	O
dyskinesias	dyskinesias	B-Disease
.	.	O

In	in	O
29	29	O
patients	patients	O
,	,	O
the	the	O
pallidotomies	pallidotomies	O
were	were	O
performed	performed	O
with	with	O
the	the	O
Leksell	leksell	O
Gamma	gamma	O
Knife	knife	O
and	and	O
in	in	O
22	22	O
they	they	O
were	were	O
performed	performed	O
with	with	O
the	the	O
standard	standard	O
radiofrequency	radiofrequency	O
(	(	O
RF	rf	O
)	)	O
method	method	O
.	.	O

Clinical	clinical	O
assessment	assessment	O
as	as	O
well	well	O
as	as	O
blinded	blinded	O
ratings	ratings	O
of	of	O
Unified	unified	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
Disease	disease	I-Disease
Rating	rating	O
Scale	scale	O
(	(	O
UPDRS	updrs	O
)	)	O
scores	scores	O
were	were	O
carried	carried	O
out	out	O
pre-	pre-	O
and	and	O
postoperatively	postoperatively	O
.	.	O

Mean	mean	O
follow-up	follow-up	O
time	time	O
is	is	O
20.6	20.6	O
months	months	O
(	(	O
range	range	O
6	6	O
-	-	O
48	48	O
)	)	O
and	and	O
all	all	O
except	except	O
4	4	O
patients	patients	O
have	have	O
been	been	O
followed	followed	O
more	more	O
than	than	O
one	one	O
year	year	O
.	.	O

85	85	O
percent	percent	O
of	of	O
patients	patients	O
with	with	O
dyskinesias	dyskinesias	B-Disease
were	were	O
relieved	relieved	O
of	of	O
symptoms	symptoms	O
,	,	O
regardless	regardless	O
of	of	O
whether	whether	O
the	the	O
pallidotomies	pallidotomies	O
were	were	O
performed	performed	O
with	with	O
the	the	O
Gamma	gamma	O
Knife	knife	O
or	or	O
radiofrequency	radiofrequency	O
methods	methods	O
.	.	O

About	about	O
2/3	2/3	O
of	of	O
the	the	O
patients	patients	O
in	in	O
both	both	O
Gamma	gamma	O
Knife	knife	O
and	and	O
radiofrequency	radiofrequency	O
groups	groups	O
showed	showed	O
improvements	improvements	O
in	in	O
bradykinesia	bradykinesia	O
and	and	O
rigidity	rigidity	B-Disease
,	,	O
although	although	O
when	when	O
considered	considered	O
as	as	O
a	a	O
group	group	O
neither	neither	O
the	the	O
Gamma	gamma	O
Knife	knife	O
nor	nor	O
the	the	O
radiofrequency	radiofrequency	O
group	group	O
showed	showed	O
statistically	statistically	O
significant	significant	O
improvements	improvements	O
in	in	O
UPDRS	updrs	O
scores	scores	O
.	.	O

One	one	O
patient	patient	O
in	in	O
the	the	O
Gamma	gamma	O
Knife	knife	O
group	group	O
(	(	O
3.4	3.4	O
%	%	O
)	)	O
developed	developed	O
a	a	O
homonymous	homonymous	O
hemianopsia	hemianopsia	O
9	9	O
months	months	O
following	following	O
treatment	treatment	O
and	and	O
5	5	O
patients	patients	O
(	(	O
27.7	27.7	O
%	%	O
)	)	O
in	in	O
the	the	O
radiofrequency	radiofrequency	O
group	group	O
became	became	O
transiently	transiently	O
confused	confused	O
postoperatively	postoperatively	O
.	.	O

No	no	O
other	other	O
complications	complications	O
were	were	O
seen	seen	O
.	.	O

Gamma	gamma	O
Knife	knife	O
pallidotomy	pallidotomy	O
is	is	O
as	as	O
effective	effective	O
as	as	O
radiofrequency	radiofrequency	O
pallidotomy	pallidotomy	O
in	in	O
controlling	controlling	O
certain	certain	O
of	of	O
the	the	O
symptoms	symptoms	O
of	of	O
Parkinson	parkinson	B-Disease
's	's	I-Disease
disease	disease	I-Disease
.	.	O

It	it	O
may	may	O
be	be	O
the	the	O
only	only	O
practical	practical	O
technique	technique	O
available	available	O
in	in	O
certain	certain	O
patients	patients	O
,	,	O
such	such	O
as	as	O
those	those	O
who	who	O
take	take	O
anticoagulants	anticoagulants	O
,	,	O
have	have	O
bleeding	bleeding	B-Disease
diatheses	diatheses	O
or	or	O
serious	serious	O
systemic	systemic	O
medical	medical	O
illnesses	illnesses	O
.	.	O

It	it	O
is	is	O
a	a	O
viable	viable	O
option	option	O
for	for	O
other	other	O
patients	patients	O
as	as	O
well	well	O
.	.	O

Centrally	centrally	O
mediated	mediated	O
cardiovascular	cardiovascular	O
effects	effects	O
of	of	O
intracisternal	intracisternal	O
application	application	O
of	of	O
carbachol	carbachol	B-Chemical
in	in	O
anesthetized	anesthetized	O
rats	rats	O
.	.	O

The	the	O
pressor	pressor	O
response	response	O
to	to	O
the	the	O
intracisternal	intracisternal	O
(	(	O
i.c	i.c	O
.	.	O
)	)	O
injection	injection	O
of	of	O
carbachol	carbachol	B-Chemical
(	(	O
1	1	O
mug	mug	O
)	)	O
in	in	O
anesthetized	anesthetized	O
rats	rats	O
was	was	O
analyzed	analyzed	O
.	.	O

This	this	O
response	response	O
was	was	O
significantly	significantly	O
reduced	reduced	O
by	by	O
the	the	O
intravenous	intravenous	O
(	(	O
i.v	i.v	O
.	.	O
)	)	O
injection	injection	O
of	of	O
guanethidine	guanethidine	O
(	(	O
5	5	O
mg	mg	O
)	)	O
,	,	O
hexamethonium	hexamethonium	B-Chemical
(	(	O
10	10	O
mg	mg	O
)	)	O
or	or	O
phentolamine	phentolamine	O
(	(	O
5	5	O
mg	mg	O
)	)	O
,	,	O
and	and	O
conversely	conversely	O
,	,	O
potentiated	potentiated	O
by	by	O
i.v	i.v	O
.	.	O

desmethylimipramine	desmethylimipramine	O
(	(	O
0.3	0.3	O
mg	mg	O
)	)	O
,	,	O
while	while	O
propranolol	propranolol	B-Chemical
(	(	O
0.5	0.5	O
mg	mg	O
)	)	O
i.v	i.v	O
.	.	O
selectively	selectively	O
inhibited	inhibited	O
the	the	O
enlargement	enlargement	O
of	of	O
pulse	pulse	O
pressure	pressure	O
and	and	O
the	the	O
tachycardia	tachycardia	B-Disease
following	following	O
i.c	i.c	O
.	.	O

carbachol	carbachol	B-Chemical
(	(	O
1	1	O
mug	mug	O
)	)	O
.	.	O

On	on	O
the	the	O
other	other	O
hand	hand	O
,	,	O
the	the	O
pressor	pressor	O
response	response	O
to	to	O
i.c	i.c	O
.	.	O
carbachol	carbachol	B-Chemical
(	(	O
1	1	O
mug	mug	O
)	)	O
was	was	O
almost	almost	O
completely	completely	O
blocked	blocked	O
by	by	O
i.c	i.c	O
.	.	O

atropine	atropine	B-Chemical
(	(	O
3	3	O
mug	mug	O
)	)	O
or	or	O
hexamethonium	hexamethonium	B-Chemical
(	(	O
500	500	O
mug	mug	O
)	)	O
,	,	O
and	and	O
significantly	significantly	O
reduced	reduced	O
by	by	O
i.c	i.c	O
.	.	O

chlorpromazine	chlorpromazine	B-Chemical
(	(	O
50	50	O
mug	mug	O
)	)	O
but	but	O
significantly	significantly	O
potentiated	potentiated	O
by	by	O
i.c	i.c	O
.	.	O

desmethylimipramine	desmethylimipramine	O
(	(	O
30	30	O
mug	mug	O
)	)	O
.	.	O

The	the	O
pressor	pressor	O
response	response	O
to	to	O
i.c	i.c	O
.	.	O

carbachol	carbachol	B-Chemical
(	(	O
1	1	O
mug	mug	O
)	)	O
remained	remained	O
unchanged	unchanged	O
after	after	O
sectioning	sectioning	O
of	of	O
the	the	O
bilateral	bilateral	O
cervical	cervical	O
vagal	vagal	O
nerves	nerves	O
but	but	O
disappeared	disappeared	O
after	after	O
sectioning	sectioning	O
of	of	O
the	the	O
spinal	spinal	O
cord	cord	O
(	(	O
C7-C8	c7-c8	O
)	)	O
.	.	O

From	from	O
the	the	O
above	above	O
result	result	O
it	it	O
is	is	O
suggested	suggested	O
that	that	O
the	the	O
pressor	pressor	O
response	response	O
to	to	O
i.c	i.c	O
.	.	O
carbachol	carbachol	B-Chemical
ortral	ortral	O
and	and	O
peripheral	peripheral	O
adrenergic	adrenergic	O
mechanisms	mechanisms	O
,	,	O
and	and	O
that	that	O
the	the	O
sympathetic	sympathetic	O
trunk	trunk	O
is	is	O
the	the	O
main	main	O
pathway	pathway	O
.	.	O

Neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
and	and	O
methylphenidate	methylphenidate	B-Chemical
.	.	O

A	a	O
1-year-old	1-year-old	O
female	female	O
presented	presented	O
with	with	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
probably	probably	O
caused	caused	O
by	by	O
methylphenidate	methylphenidate	B-Chemical
.	.	O

She	she	O
had	had	O
defects	defects	O
in	in	O
the	the	O
supratentorial	supratentorial	O
brain	brain	O
including	including	O
the	the	O
basal	basal	O
ganglia	ganglia	O
and	and	O
the	the	O
striatum	striatum	O
(	(	O
multicystic	multicystic	O
encephalomalacia	encephalomalacia	O
)	)	O
due	due	O
to	to	O
severe	severe	O
perinatal	perinatal	O
hypoxic-ischemic	hypoxic-ischemic	O
encephalopathy	encephalopathy	B-Disease
,	,	O
which	which	O
was	was	O
considered	considered	O
to	to	O
be	be	O
a	a	O
possible	possible	O
predisposing	predisposing	O
factor	factor	O
causing	causing	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
.	.	O

A	a	O
dopaminergic	dopaminergic	O
blockade	blockade	O
mechanism	mechanism	O
generally	generally	O
is	is	O
accepted	accepted	O
as	as	O
the	the	O
pathogenesis	pathogenesis	O
of	of	O
this	this	O
syndrome	syndrome	O
.	.	O

However	however	O
,	,	O
methylphenidate	methylphenidate	B-Chemical
is	is	O
a	a	O
dopamine	dopamine	B-Chemical
agonist	agonist	I-Chemical
via	via	O
the	the	O
inhibition	inhibition	O
of	of	O
uptake	uptake	O
of	of	O
dopamine	dopamine	B-Chemical
,	,	O
and	and	O
therefore	therefore	O
dopaminergic	dopaminergic	O
systems	systems	O
in	in	O
the	the	O
brainstem	brainstem	O
(	(	O
mainly	mainly	O
the	the	O
midbrain	midbrain	O
)	)	O
and	and	O
the	the	O
spinal	spinal	O
cord	cord	O
were	were	O
unlikely	unlikely	O
to	to	O
participate	participate	O
in	in	O
the	the	O
onset	onset	O
of	of	O
this	this	O
syndrome	syndrome	O
.	.	O

A	a	O
relative	relative	O
gamma-aminobutyric	gamma-aminobutyric	O
acid-ergic	acid-ergic	O
deficiency	deficiency	O
might	might	O
occur	occur	O
because	because	O
diazepam	diazepam	B-Chemical
,	,	O
a	a	O
gamma-aminobutyric	gamma-aminobutyric	O
acid-mimetic	acid-mimetic	O
agent	agent	O
,	,	O
was	was	O
strikingly	strikingly	O
effective	effective	O
.	.	O

This	this	O
is	is	O
the	the	O
first	first	O
reported	reported	O
patient	patient	O
with	with	O
neuroleptic	neuroleptic	B-Disease
malignant	malignant	I-Disease
syndrome	syndrome	I-Disease
probably	probably	O
caused	caused	O
by	by	O
methylphenidate	methylphenidate	B-Chemical
.	.	O

Differential	differential	O
effects	effects	O
of	of	O
17alpha-ethinylestradiol	17alpha-ethinylestradiol	O
on	on	O
the	the	O
neutral	neutral	O
and	and	O
acidic	acidic	O
pathways	pathways	O
of	of	O
bile	bile	O
salt	salt	B-Chemical
synthesis	synthesis	O
in	in	O
the	the	O
rat	rat	O
.	.	O

Effects	effects	O
of	of	O
17alpha-ethinylestradiol	17alpha-ethinylestradiol	O
(	(	O
EE	ee	B-Chemical
)	)	O
on	on	O
the	the	O
neutral	neutral	O
and	and	O
acidic	acidic	O
biosynthetic	biosynthetic	O
pathways	pathways	O
of	of	O
bile	bile	O
salt	salt	B-Chemical
(	(	O
BS	bs	O
)	)	O
synthesis	synthesis	O
were	were	O
evaluated	evaluated	O
in	in	O
rats	rats	O
with	with	O
an	an	O
intact	intact	O
enterohepatic	enterohepatic	O
circulation	circulation	O
and	and	O
in	in	O
rats	rats	O
with	with	O
long-term	long-term	O
bile	bile	O
diversion	diversion	O
to	to	O
induce	induce	O
BS	bs	O
synthesis	synthesis	O
.	.	O

For	for	O
this	this	O
purpose	purpose	O
,	,	O
bile	bile	O
salt	salt	B-Chemical
pool	pool	O
composition	composition	O
,	,	O
synthesis	synthesis	O
of	of	O
individual	individual	O
BS	bs	O
in	in	O
vivo	vivo	O
,	,	O
hepatic	hepatic	O
activities	activities	O
,	,	O
and	and	O
expression	expression	O
levels	levels	O
of	of	O
cholesterol	cholesterol	B-Chemical
7alpha-hydroxylase	7alpha-hydroxylase	O
(	(	O
CYP7A	cyp7a	O
)	)	O
,	,	O
and	and	O
sterol	sterol	O
27-hydroxylase	27-hydroxylase	O
(	(	O
CYP27	cyp27	O
)	)	O
,	,	O
as	as	O
well	well	O
as	as	O
of	of	O
other	other	O
enzymes	enzymes	O
involved	involved	O
in	in	O
BS	bs	O
synthesis	synthesis	O
,	,	O
were	were	O
analyzed	analyzed	O
in	in	O
rats	rats	O
treated	treated	O
with	with	O
EE	ee	B-Chemical
(	(	O
5	5	O
mg/kg	mg/kg	O
,	,	O
3	3	O
days	days	O
)	)	O
or	or	O
its	its	O
vehicle	vehicle	O
.	.	O

BS	bs	O
pool	pool	O
size	size	O
was	was	O
decreased	decreased	O
by	by	O
27	27	O
%	%	O
but	but	O
total	total	O
BS	bs	O
synthesis	synthesis	O
was	was	O
not	not	O
affected	affected	O
by	by	O
EE	ee	B-Chemical
in	in	O
intact	intact	O
rats	rats	O
.	.	O

Synthesis	synthesis	O
of	of	O
cholate	cholate	O
was	was	O
reduced	reduced	O
by	by	O
68	68	O
%	%	O
in	in	O
EE-treated	ee-treated	O
rats	rats	O
,	,	O
while	while	O
that	that	O
of	of	O
chenodeoxycholate	chenodeoxycholate	O
was	was	O
increased	increased	O
by	by	O
60	60	O
%	%	O
.	.	O

The	the	O
recently	recently	O
identified	identified	O
Delta22-isomer	delta22-isomer	O
of	of	O
beta-muricholate	beta-muricholate	O
contributed	contributed	O
for	for	O
5.4	5.4	O
%	%	O
and	and	O
18.3	18.3	O
%	%	O
(	(	O
P	p	O
<	<	O
0.01	0.01	O
)	)	O
to	to	O
the	the	O
pool	pool	O
in	in	O
control	control	O
and	and	O
EE-treated	ee-treated	O
rats	rats	O
,	,	O
respectively	respectively	O
,	,	O
but	but	O
could	could	O
not	not	O
be	be	O
detected	detected	O
in	in	O
bile	bile	O
after	after	O
exhaustion	exhaustion	O
of	of	O
the	the	O
pool	pool	O
.	.	O

A	a	O
clear	clear	O
reduction	reduction	O
of	of	O
BS	bs	O
synthesis	synthesis	O
was	was	O
found	found	O
in	in	O
bile-diverted	bile-diverted	O
rats	rats	O
treated	treated	O
with	with	O
EE	ee	B-Chemical
,	,	O
yet	yet	O
biliary	biliary	O
BS	bs	O
composition	composition	O
was	was	O
only	only	O
minimally	minimally	O
affected	affected	O
.	.	O

Activity	activity	O
of	of	O
CYP7A	cyp7a	O
was	was	O
decreased	decreased	O
by	by	O
EE	ee	B-Chemical
in	in	O
both	both	O
intact	intact	O
and	and	O
bile-diverted	bile-diverted	O
rats	rats	O
,	,	O
whereas	whereas	O
the	the	O
activity	activity	O
of	of	O
the	the	O
CYP27	cyp27	O
was	was	O
not	not	O
affected	affected	O
.	.	O

Hepatic	hepatic	O
mRNA	mrna	O
levels	levels	O
of	of	O
CYP7A	cyp7a	O
were	were	O
significantly	significantly	O
reduced	reduced	O
by	by	O
EE	ee	B-Chemical
in	in	O
bile-diverted	bile-diverted	O
rats	rats	O
only	only	O
;	;	O
CYP27	cyp27	O
mRNA	mrna	O
levels	levels	O
were	were	O
not	not	O
affected	affected	O
by	by	O
EE	ee	B-Chemical
.	.	O

In	in	O
addition	addition	O
,	,	O
mRNA	mrna	O
levels	levels	O
of	of	O
sterol	sterol	O
12alpha-hydroxylase	12alpha-hydroxylase	O
and	and	O
lithocholate	lithocholate	O
6beta-hydroxylase	6beta-hydroxylase	O
were	were	O
increased	increased	O
by	by	O
bile	bile	O
diversion	diversion	O
and	and	O
suppressed	suppressed	O
by	by	O
EE	ee	B-Chemical
.	.	O

This	this	O
study	study	O
shows	shows	O
that	that	O
17alpha-ethinylestradiol	17alpha-ethinylestradiol	O
(EE)-induced	(ee)-induced	O
intrahepatic	intrahepatic	O
cholestasis	cholestasis	B-Disease
in	in	O
rats	rats	O
is	is	O
associated	associated	O
with	with	O
selective	selective	O
inhibition	inhibition	O
of	of	O
the	the	O
neutral	neutral	O
pathway	pathway	O
of	of	O
bile	bile	O
salt	salt	B-Chemical
(	(	O
BS	bs	O
)	)	O
synthesis	synthesis	O
.	.	O

Simultaneous	simultaneous	O
impairment	impairment	O
of	of	O
other	other	O
enzymes	enzymes	O
in	in	O
the	the	O
BS	bs	O
biosynthetic	biosynthetic	O
pathways	pathways	O
may	may	O
contribute	contribute	O
to	to	O
overall	overall	O
effects	effects	O
of	of	O
EE	ee	B-Chemical
on	on	O
BS	bs	O
synthesis	synthesis	O
.	.	O

Glibenclamide-sensitive	glibenclamide-sensitive	O
hypotension	hypotension	B-Disease
produced	produced	O
by	by	O
helodermin	helodermin	O
assessed	assessed	O
in	in	O
the	the	O
rat	rat	O
.	.	O

The	the	O
effects	effects	O
of	of	O
helodermin	helodermin	O
,	,	O
a	a	O
basic	basic	O
35-amino	35-amino	O
acid	acid	O
peptide	peptide	O
isolated	isolated	O
from	from	O
the	the	O
venom	venom	O
of	of	O
a	a	O
lizard	lizard	O
salivary	salivary	O
gland	gland	O
,	,	O
on	on	O
arterial	arterial	O
blood	blood	O
pressure	pressure	O
and	and	O
heart	heart	O
rate	rate	O
were	were	O
examined	examined	O
in	in	O
the	the	O
rat	rat	O
,	,	O
focusing	focusing	O
on	on	O
the	the	O
possibility	possibility	O
that	that	O
activation	activation	O
of	of	O
ATP	atp	B-Chemical
sensitive	sensitive	O
K+	k+	O
(	(	O
K(ATP	k(atp	O
)	)	O
)	)	O
channels	channels	O
is	is	O
involved	involved	O
in	in	O
the	the	O
responses	responses	O
.	.	O

The	the	O
results	results	O
were	were	O
also	also	O
compared	compared	O
with	with	O
those	those	O
of	of	O
vasoactive	vasoactive	O
intestinal	intestinal	O
polypeptide	polypeptide	O
(	(	O
VIP	vip	O
)	)	O
.	.	O

Helodermin	helodermin	O
produced	produced	O
hypotension	hypotension	B-Disease
in	in	O
a	a	O
dose-dependent	dose-dependent	O
manner	manner	O
with	with	O
approximately	approximately	O
similar	similar	O
potency	potency	O
and	and	O
duration	duration	O
to	to	O
VIP	vip	O
.	.	O

Hypotension	hypotension	B-Disease
induced	induced	O
by	by	O
both	both	O
peptides	peptides	O
was	was	O
significantly	significantly	O
attenuated	attenuated	O
by	by	O
glibenclamide	glibenclamide	O
,	,	O
which	which	O
abolished	abolished	O
a	a	O
levcromakalim-produced	levcromakalim-produced	O
decrease	decrease	O
in	in	O
arterial	arterial	O
blood	blood	O
pressure	pressure	O
.	.	O

Oxyhemoglobin	oxyhemoglobin	O
did	did	O
not	not	O
affect	affect	O
helodermin-induced	helodermin-induced	O
hypotension	hypotension	B-Disease
,	,	O
whereas	whereas	O
it	it	O
shortened	shortened	O
the	the	O
duration	duration	O
of	of	O
acetylcholine	acetylcholine	B-Chemical
(ACh)-produced	(ach)-produced	O
hypotension	hypotension	B-Disease
.	.	O

These	these	O
findings	findings	O
suggest	suggest	O
that	that	O
helodermin-produced	helodermin-produced	O
hypotension	hypotension	B-Disease
is	is	O
partly	partly	O
attributable	attributable	O
to	to	O
the	the	O
activation	activation	O
of	of	O
glibenclamide-sensitive	glibenclamide-sensitive	O
K+	k+	O
channels	channels	O
(	(	O
K(ATP	k(atp	O
)	)	O
channels	channels	O
)	)	O
,	,	O
which	which	O
presumably	presumably	O
exist	exist	O
on	on	O
arterial	arterial	O
smooth	smooth	O
muscle	muscle	O
cells	cells	O
.	.	O

EDRF	edrf	O
(	(	O
endothelium-derived	endothelium-derived	O
relaxing	relaxing	O
factor)/nitric	factor)/nitric	O
oxide	oxide	O
does	does	O
not	not	O
seem	seem	O
to	to	O
play	play	O
an	an	O
important	important	O
role	role	O
in	in	O
the	the	O
peptide-produced	peptide-produced	O
hypotension	hypotension	B-Disease
.	.	O

Long-term	long-term	O
efficacy	efficacy	O
and	and	O
adverse	adverse	O
event	event	O
of	of	O
nifedipine	nifedipine	B-Chemical
sustained-release	sustained-release	O
tablets	tablets	O
for	for	O
cyclosporin	cyclosporin	O
A-induced	a-induced	O
hypertension	hypertension	B-Disease
in	in	O
patients	patients	O
with	with	O
psoriasis	psoriasis	B-Disease
.	.	O

Thirteen	thirteen	O
psoriatic	psoriatic	O
patients	patients	O
with	with	O
hypertension	hypertension	B-Disease
during	during	O
the	the	O
course	course	O
of	of	O
cyclosporin	cyclosporin	B-Chemical
A	a	I-Chemical
therapy	therapy	O
were	were	O
treated	treated	O
for	for	O
25	25	O
months	months	O
with	with	O
a	a	O
calcium	calcium	B-Chemical
channel	channel	O
blocker	blocker	O
,	,	O
sustained-release	sustained-release	O
nifedipine	nifedipine	B-Chemical
,	,	O
to	to	O
study	study	O
the	the	O
clinical	clinical	O
antihypertensive	antihypertensive	O
effects	effects	O
and	and	O
adverse	adverse	O
events	events	O
during	during	O
treatment	treatment	O
with	with	O
both	both	O
drugs	drugs	O
.	.	O

Seven	seven	O
of	of	O
the	the	O
13	13	O
patients	patients	O
had	had	O
exhibited	exhibited	O
a	a	O
subclinical	subclinical	O
hypertensive	hypertensive	B-Disease
state	state	O
before	before	O
cyclosporin	cyclosporin	B-Chemical
A	a	I-Chemical
therapy	therapy	O
.	.	O

Both	both	O
systolic	systolic	O
and	and	O
diastolic	diastolic	O
blood	blood	O
pressures	pressures	O
of	of	O
these	these	O
13	13	O
patients	patients	O
were	were	O
decreased	decreased	O
significantly	significantly	O
after	after	O
4	4	O
weeks	weeks	O
of	of	O
nifedipine	nifedipine	B-Chemical
therapy	therapy	O
,	,	O
and	and	O
blood	blood	O
pressure	pressure	O
was	was	O
maintained	maintained	O
within	within	O
the	the	O
normal	normal	O
range	range	O
thereafter	thereafter	O
for	for	O
25	25	O
months	months	O
.	.	O

The	the	O
adverse	adverse	O
events	events	O
during	during	O
combined	combined	O
therapy	therapy	O
with	with	O
cyclosporin	cyclosporin	B-Chemical
A	a	I-Chemical
and	and	O
nifedipine	nifedipine	B-Chemical
included	included	O
an	an	O
increase	increase	O
in	in	O
blood	blood	B-Chemical
urea	urea	B-Chemical
nitrogen	nitrogen	I-Chemical
levels	levels	O
in	in	O
9	9	O
of	of	O
the	the	O
13	13	O
patients	patients	O
and	and	O
development	development	O
of	of	O
gingival	gingival	B-Disease
hyperplasia	hyperplasia	I-Disease
in	in	O
2	2	O
of	of	O
the	the	O
13	13	O
patients	patients	O
.	.	O

Our	our	O
findings	findings	O
indicate	indicate	O
that	that	O
sustained-release	sustained-release	O
nifedipine	nifedipine	B-Chemical
is	is	O
useful	useful	O
for	for	O
hypertensive	hypertensive	B-Disease
psoriatic	psoriatic	O
patients	patients	O
under	under	O
long-term	long-term	O
treatment	treatment	O
with	with	O
cyclosporin	cyclosporin	B-Chemical
A	a	I-Chemical
,	,	O
but	but	O
that	that	O
these	these	O
patients	patients	O
should	should	O
be	be	O
monitored	monitored	O
for	for	O
gingival	gingival	B-Disease
hyperplasia	hyperplasia	I-Disease
.	.	O

